Involvement	O
of	O
adenylate	O
cyclase	O
and	O
p70	B-Protein
(	I-Protein
S6	I-Protein
)	I-Protein
-	I-Protein
kinase	I-Protein
activation	O
in	O
IL	B-Protein
-	I-Protein
10	I-Protein
up	O
-	O
regulation	O
in	O
human	O
monocytes	O
by	O
gp41	B-Protein
envelope	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
results	B-X
show	B-X
that	B-X
recombinant	B-X
gp41	B-X
(	B-X
aa565-647	B-X
)	B-X
,	B-X
the	B-X
extracellular	B-X
domain	B-X
of	B-X
HIV-1	B-X
transmembrane	B-X
glycoprotein	B-X
,	B-X
stimulates	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
gp41-induced	B-X
IL-10	B-X
up-regulation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
previously	B-X
described	B-X
synergistic	B-X
activation	B-X
of	B-X
cAMP	B-X
and	B-X
NF-kappaB	B-X
pathways	B-X
.	B-X
gp41	B-X
induced	B-X
cAMP	B-X
accumulation	B-X
in	B-X
monocytes	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
and	B-X
the	B-X
adenylate	B-X
cyclase	B-X
inhibitor	B-X
SQ	B-X
22536	B-X
suppressed	B-X
gp41-induced	B-X
IL-10	B-X
production	B-X
in	B-X
monocytes	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
gp41	B-X
failed	B-X
to	B-X
stimulate	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
as	B-X
much	B-X
as	B-X
no	B-X
NF-kappaB	B-X
bound	B-X
to	B-X
the	B-X
main	B-X
NF-kappaB-binding	B-X
site	B-X
2	B-X
of	B-X
the	B-X
IL-10	B-X
promoter	B-X
after	B-X
addition	B-X
of	B-X
gp41	B-X
.	B-X
Specific	B-X
inhibitors	B-X
of	B-X
p70	B-X
(	B-X
S6	B-X
)	B-X
-kinase	B-X
(	B-X
rapamycin	B-X
)	B-X
,	B-X
and	B-X
Gi	B-X
protein	B-X
(	B-X
pertussis	B-X
toxin	B-X
)	B-X
,	B-X
prevented	B-X
induction	B-X
of	B-X
IL-10	B-X
production	B-X
by	B-X
gp41	B-X
in	B-X
monocytes	B-X
,	B-X
while	B-X
inhibitors	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI	B-X
3-kinase	B-X
)	B-X
(	B-X
wortmannin	B-X
)	B-X
and	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
pathway	B-X
(	B-X
PD	B-X
98059	B-X
)	B-X
did	B-X
not	B-X
.	B-X
Thus	B-X
HIV-1	B-X
gp41-induced	B-X
IL-10	B-X
up-regulation	B-X
in	B-X
monocytes	B-X
may	B-X
not	B-X
involve	B-X
NF-kappaB	B-X
,	B-X
MAPK	B-X
,	B-X
or	B-X
PI	B-X
3-kinase	B-X
activation	B-X
,	B-X
but	B-X
rather	B-X
may	B-X
operate	B-X
through	B-X
activation	B-X
of	B-X
adenylate	B-X
cyclase	B-X
and	B-X
pertussis-toxin-sensitive	B-X
Gi/Go	B-X
protein	B-X
to	B-X
effect	B-X
p70	B-X
(	B-X
S6	B-X
)	B-X
-kinase	B-X
activation	B-X
.	B-X

Our	O
previous	O
results	O
show	O
that	O
recombinant	O
gp41	B-Protein
(	O
aa565	O
-	O
647	O
)	O
,	O
the	O
extracellular	O
domain	O
of	O
HIV	O
-	O
1	O
transmembrane	O
glycoprotein	O
,	O
stimulates	O
interleukin	B-Protein
-	I-Protein
10	I-Protein
(	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
production	O
in	O
human	O
monocytes	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
results	B-X
show	B-X
that	B-X
recombinant	B-X
gp41	B-X
(	B-X
aa565-647	B-X
)	B-X
,	B-X
the	B-X
extracellular	B-X
domain	B-X
of	B-X
HIV-1	B-X
transmembrane	B-X
glycoprotein	B-X
,	B-X
stimulates	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
gp41-induced	B-X
IL-10	B-X
up-regulation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
previously	B-X
described	B-X
synergistic	B-X
activation	B-X
of	B-X
cAMP	B-X
and	B-X
NF-kappaB	B-X
pathways	B-X
.	B-X
gp41	B-X
induced	B-X
cAMP	B-X
accumulation	B-X
in	B-X
monocytes	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
and	B-X
the	B-X
adenylate	B-X
cyclase	B-X
inhibitor	B-X
SQ	B-X
22536	B-X
suppressed	B-X
gp41-induced	B-X
IL-10	B-X
production	B-X
in	B-X
monocytes	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
gp41	B-X
failed	B-X
to	B-X
stimulate	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
as	B-X
much	B-X
as	B-X
no	B-X
NF-kappaB	B-X
bound	B-X
to	B-X
the	B-X
main	B-X
NF-kappaB-binding	B-X
site	B-X
2	B-X
of	B-X
the	B-X
IL-10	B-X
promoter	B-X
after	B-X
addition	B-X
of	B-X
gp41	B-X
.	B-X
Specific	B-X
inhibitors	B-X
of	B-X
p70	B-X
(	B-X
S6	B-X
)	B-X
-kinase	B-X
(	B-X
rapamycin	B-X
)	B-X
,	B-X
and	B-X
Gi	B-X
protein	B-X
(	B-X
pertussis	B-X
toxin	B-X
)	B-X
,	B-X
prevented	B-X
induction	B-X
of	B-X
IL-10	B-X
production	B-X
by	B-X
gp41	B-X
in	B-X
monocytes	B-X
,	B-X
while	B-X
inhibitors	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI	B-X
3-kinase	B-X
)	B-X
(	B-X
wortmannin	B-X
)	B-X
and	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
pathway	B-X
(	B-X
PD	B-X
98059	B-X
)	B-X
did	B-X
not	B-X
.	B-X
Thus	B-X
HIV-1	B-X
gp41-induced	B-X
IL-10	B-X
up-regulation	B-X
in	B-X
monocytes	B-X
may	B-X
not	B-X
involve	B-X
NF-kappaB	B-X
,	B-X
MAPK	B-X
,	B-X
or	B-X
PI	B-X
3-kinase	B-X
activation	B-X
,	B-X
but	B-X
rather	B-X
may	B-X
operate	B-X
through	B-X
activation	B-X
of	B-X
adenylate	B-X
cyclase	B-X
and	B-X
pertussis-toxin-sensitive	B-X
Gi/Go	B-X
protein	B-X
to	B-X
effect	B-X
p70	B-X
(	B-X
S6	B-X
)	B-X
-kinase	B-X
activation	B-X
.	B-X

The	O
signal	O
cascade	O
transducing	O
this	O
effect	O
is	O
not	O
yet	O
clear	O
.	O
<EOS>	B-X
The	B-X
cGAS-STING	B-X
signalling	B-X
pathway	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
inflammation	B-X
in	B-X
the	B-X
settings	B-X
of	B-X
infection	B-X
,	B-X
cellular	B-X
stress	B-X
and	B-X
tissue	B-X
damage	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
outline	B-X
the	B-X
principal	B-X
elements	B-X
of	B-X
the	B-X
cGAS-STING	B-X
signalling	B-X
cascade	B-X
and	B-X
discuss	B-X
the	B-X
general	B-X
mechanisms	B-X
underlying	B-X
the	B-X
association	B-X
of	B-X
cGAS-STING	B-X
activity	B-X
with	B-X
various	B-X
autoinflammatory	B-X
,	B-X
autoimmune	B-X
and	B-X
degenerative	B-X
diseases	B-X
.	B-X
NOTCH1	B-X
,	B-X
NOTCH2	B-X
,	B-X
NOTCH3	B-X
and	B-X
NOTCH4	B-X
are	B-X
transmembrane	B-X
receptors	B-X
that	B-X
transduce	B-X
juxtacrine	B-X
signals	B-X
of	B-X
the	B-X
delta‑like	B-X
canonical	B-X
Notch	B-X
ligand	B-X
(	B-X
DLL	B-X
)	B-X
1	B-X
,	B-X
DLL3	B-X
,	B-X
DLL4	B-X
,	B-X
jagged	B-X
canonical	B-X
Notch	B-X
ligand	B-X
(	B-X
JAG	B-X
)	B-X
1	B-X
and	B-X
JAG2	B-X
.	B-X
Canonical	B-X
Notch	B-X
signaling	B-X
activates	B-X
the	B-X
transcription	B-X
of	B-X
BMI1	B-X
proto‑oncogene	B-X
polycomb	B-X
ring	B-X
finger	B-X
,	B-X
cyclin	B-X
D1	B-X
,	B-X
CD44	B-X
,	B-X
cyclin	B-X
dependent	B-X
kinase	B-X
inhibitor	B-X
1A	B-X
,	B-X
hes	B-X
family	B-X
bHLH	B-X
transcription	B-X
factor	B-X
1	B-X
,	B-X
hes	B-X
related	B-X
family	B-X
bHLH	B-X
transcription	B-X
factor	B-X
with	B-X
YRPW	B-X
motif	B-X
1	B-X
,	B-X
MYC	B-X
,	B-X
NOTCH3	B-X
,	B-X
RE1	B-X
silencing	B-X
transcription	B-X
factor	B-X
and	B-X
transcription	B-X
factor	B-X
7	B-X
in	B-X
a	B-X
cellular	B-X
context‑dependent	B-X
manner	B-X
,	B-X
while	B-X
non‑canonical	B-X
Notch	B-X
signaling	B-X
activates	B-X
NF‑κB	B-X
and	B-X
Rac	B-X
family	B-X
small	B-X
GTPase	B-X
1	B-X
.	B-X
Notch	B-X
signaling	B-X
is	B-X
aberrantly	B-X
activated	B-X
in	B-X
breast	B-X
cancer	B-X
,	B-X
non‑small‑cell	B-X
lung	B-X
cancer	B-X
and	B-X
hematological	B-X
malignancies	B-X
,	B-X
such	B-X
as	B-X
T‑cell	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
and	B-X
diffuse	B-X
large	B-X
B‑cell	B-X
lymphoma	B-X
.	B-X
However	B-X
,	B-X
Notch	B-X
signaling	B-X
is	B-X
inactivated	B-X
in	B-X
small‑cell	B-X
lung	B-X
cancer	B-X
and	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
.	B-X
Notch	B-X
signaling	B-X
cascades	B-X
crosstalk	B-X
with	B-X
fibroblast	B-X
growth	B-X
factor	B-X
and	B-X
WNT	B-X
signaling	B-X
cascades	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
to	B-X
maintain	B-X
cancer	B-X
stem	B-X
cells	B-X
and	B-X
remodel	B-X
the	B-X
tumor	B-X
microenvironment	B-X
.	B-X
The	B-X
Notch	B-X
signaling	B-X
network	B-X
exerts	B-X
oncogenic	B-X
and	B-X
tumor‑suppressive	B-X
effects	B-X
in	B-X
a	B-X
cancer	B-X
stage‑	B-X
or	B-X
(	B-X
sub	B-X
)	B-X
type‑dependent	B-X
manner	B-X
.	B-X
The	B-X
DLL3‑targeting	B-X
antibody‑drug	B-X
conjugate	B-X
(	B-X
ADC	B-X
)	B-X
Rova‑T	B-X
,	B-X
and	B-X
DLL3‑targeting	B-X
chimeric	B-X
antigen	B-X
receptor‑modified	B-X
T	B-X
cells	B-X
(	B-X
CAR‑Ts	B-X
)	B-X
,	B-X
AMG	B-X
119	B-X
,	B-X
are	B-X
promising	B-X
anti‑cancer	B-X
therapeutics	B-X
,	B-X
as	B-X
are	B-X
other	B-X
ADCs	B-X
or	B-X
CAR‑Ts	B-X
targeting	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
superfamily	B-X
member	B-X
17	B-X
,	B-X
CD19	B-X
,	B-X
CD22	B-X
,	B-X
CD30	B-X
,	B-X
CD79B	B-X
,	B-X
CD205	B-X
,	B-X
Claudin	B-X
18.2	B-X
,	B-X
fibroblast	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
FGFR	B-X
)	B-X
2	B-X
,	B-X
FGFR3	B-X
,	B-X
receptor‑type	B-X
tyrosine‑protein	B-X
kinase	B-X
FLT3	B-X
,	B-X
HER2	B-X
,	B-X
hepatocyte	B-X
growth	B-X
factor	B-X
receptor	B-X
,	B-X
NECTIN4	B-X
,	B-X
inactive	B-X
tyrosine‑protein	B-X
kinase	B-X
7	B-X
,	B-X
inactive	B-X
tyrosine‑protein	B-X
kinase	B-X
transmembrane	B-X
receptor	B-X
ROR1	B-X
and	B-X
tumor‑associated	B-X
calcium	B-X
signal	B-X
transducer	B-X
2	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
gp41	B-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
10	I-Protein
up	O
-	O
regulation	O
is	O
mediated	O
by	O
the	O
previously	O
described	O
synergistic	O
activation	O
of	O
cAMP	O
and	O
NF	O
-	O
kappaB	O
pathways	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
results	B-X
show	B-X
that	B-X
recombinant	B-X
gp41	B-X
(	B-X
aa565-647	B-X
)	B-X
,	B-X
the	B-X
extracellular	B-X
domain	B-X
of	B-X
HIV-1	B-X
transmembrane	B-X
glycoprotein	B-X
,	B-X
stimulates	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
gp41-induced	B-X
IL-10	B-X
up-regulation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
previously	B-X
described	B-X
synergistic	B-X
activation	B-X
of	B-X
cAMP	B-X
and	B-X
NF-kappaB	B-X
pathways	B-X
.	B-X
gp41	B-X
induced	B-X
cAMP	B-X
accumulation	B-X
in	B-X
monocytes	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
and	B-X
the	B-X
adenylate	B-X
cyclase	B-X
inhibitor	B-X
SQ	B-X
22536	B-X
suppressed	B-X
gp41-induced	B-X
IL-10	B-X
production	B-X
in	B-X
monocytes	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
gp41	B-X
failed	B-X
to	B-X
stimulate	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
as	B-X
much	B-X
as	B-X
no	B-X
NF-kappaB	B-X
bound	B-X
to	B-X
the	B-X
main	B-X
NF-kappaB-binding	B-X
site	B-X
2	B-X
of	B-X
the	B-X
IL-10	B-X
promoter	B-X
after	B-X
addition	B-X
of	B-X
gp41	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
involvement	B-X
of	B-X
other	B-X
signal	B-X
transduction	B-X
pathways	B-X
.	B-X
Specific	B-X
inhibitors	B-X
of	B-X
p70	B-X
(	B-X
S6	B-X
)	B-X
-kinase	B-X
(	B-X
rapamycin	B-X
)	B-X
,	B-X
and	B-X
Gi	B-X
protein	B-X
(	B-X
pertussis	B-X
toxin	B-X
)	B-X
,	B-X
prevented	B-X
induction	B-X
of	B-X
IL-10	B-X
production	B-X
by	B-X
gp41	B-X
in	B-X
monocytes	B-X
,	B-X
while	B-X
inhibitors	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI	B-X
3-kinase	B-X
)	B-X
(	B-X
wortmannin	B-X
)	B-X
and	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
pathway	B-X
(	B-X
PD	B-X
98059	B-X
)	B-X
did	B-X
not	B-X
.	B-X
Thus	B-X
HIV-1	B-X
gp41-induced	B-X
IL-10	B-X
up-regulation	B-X
in	B-X
monocytes	B-X
may	B-X
not	B-X
involve	B-X
NF-kappaB	B-X
,	B-X
MAPK	B-X
,	B-X
or	B-X
PI	B-X
3-kinase	B-X
activation	B-X
,	B-X
but	B-X
rather	B-X
may	B-X
operate	B-X
through	B-X
activation	B-X
of	B-X
adenylate	B-X
cyclase	B-X
and	B-X
pertussis-toxin-sensitive	B-X
Gi/Go	B-X
protein	B-X
to	B-X
effect	B-X
p70	B-X
(	B-X
S6	B-X
)	B-X
-kinase	B-X
activation	B-X
.	B-X

gp41	B-Protein
induced	O
cAMP	O
accumulation	O
in	O
monocytes	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
and	O
the	O
adenylate	O
cyclase	O
inhibitor	O
SQ	O
22536	O
suppressed	O
gp41	B-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
in	O
monocytes	O
.	O

In	O
contrast	O
,	O
gp41	B-Protein
failed	O
to	O
stimulate	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
as	O
much	O
as	O
no	O
NF	O
-	O
kappaB	O
bound	O
to	O
the	O
main	O
NF	O
-	O
kappaB	O
-	O
binding	O
site	O
2	O
of	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
promoter	O
after	O
addition	O
of	O
gp41	B-Protein
.	O

We	O
also	O
examined	O
the	O
involvement	O
of	O
other	O
signal	O
transduction	O
pathways	O
.	O
<EOS>	B-X
The	B-X
basic	B-X
mechanisms	B-X
of	B-X
cardiotoxicity	B-X
may	B-X
involve	B-X
direct	B-X
pathways	B-X
for	B-X
reactive	B-X
oxygen	B-X
species	B-X
generation	B-X
and	B-X
topoisomerase	B-X
2	B-X
as	B-X
well	B-X
as	B-X
other	B-X
indirect	B-X
pathways	B-X
.	B-X
Cardioprotective	B-X
treatments	B-X
are	B-X
few	B-X
and	B-X
those	B-X
that	B-X
have	B-X
been	B-X
examined	B-X
include	B-X
renin	B-X
angiotensin	B-X
system	B-X
blockade	B-X
,	B-X
beta	B-X
blockers	B-X
,	B-X
or	B-X
the	B-X
iron	B-X
chelator	B-X
dexrazoxane	B-X
.	B-X
New	B-X
treatments	B-X
exploiting	B-X
the	B-X
ErbB	B-X
or	B-X
other	B-X
novel	B-X
pro-survival	B-X
pathways	B-X
,	B-X
such	B-X
as	B-X
conditioning	B-X
,	B-X
are	B-X
on	B-X
the	B-X
cardioprotection	B-X
horizon	B-X
.	B-X
Researchers	B-X
have	B-X
explored	B-X
the	B-X
use	B-X
of	B-X
some	B-X
inhibitors	B-X
targeting	B-X
this	B-X
pathway	B-X
to	B-X
block	B-X
survival	B-X
pathways	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
roles	B-X
of	B-X
the	B-X
PI3K/Akt	B-X
pathway	B-X
in	B-X
various	B-X
cancer	B-X
phenotypes	B-X
,	B-X
review	B-X
the	B-X
current	B-X
statuses	B-X
of	B-X
different	B-X
PI3K/Akt	B-X
inhibitors	B-X
,	B-X
and	B-X
introduce	B-X
combination	B-X
therapies	B-X
consisting	B-X
of	B-X
signaling	B-X
inhibitors	B-X
and	B-X
conventional	B-X
cancer	B-X
therapies	B-X
.	B-X
The	B-X
information	B-X
presented	B-X
herein	B-X
suggests	B-X
that	B-X
cascading	B-X
inhibitors	B-X
of	B-X
the	B-X
PI3K/Akt	B-X
signaling	B-X
pathway	B-X
,	B-X
either	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
other	B-X
therapies	B-X
,	B-X
are	B-X
the	B-X
most	B-X
effective	B-X
treatment	B-X
strategy	B-X
for	B-X
cancer	B-X
.	B-X

Specific	O
inhibitors	O
of	O
p70	O
(	O
S6	O
)	O
-	O
kinase	O
(	O
rapamycin	O
)	O
,	O
and	O
Gi	O
protein	O
(	O
pertussis	O
toxin	O
)	O
,	O
prevented	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
gp41	B-Protein
in	O
monocytes	O
,	O
while	O
inhibitors	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI	O
3	O
-	O
kinase	O
)	O
(	O
wortmannin	O
)	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
(	O
PD	O
98059	O
)	O
did	O
not	O
.	O

Thus	O
HIV	O
-	O
1	O
gp41	B-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
10	I-Protein
up	O
-	O
regulation	O
in	O
monocytes	O
may	O
not	O
involve	O
NF	O
-	O
kappaB	O
,	O
MAPK	O
,	O
or	O
PI	O
3	O
-	O
kinase	O
activation	O
,	O
but	O
rather	O
may	O
operate	O
through	O
activation	O
of	O
adenylate	O
cyclase	O
and	O
pertussis	O
-	O
toxin	O
-	O
sensitive	O
Gi	O
/	O
Go	O
protein	O
to	O
effect	O
p70	O
(	O
S6	O
)	O
-	O
kinase	O
activation	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
results	B-X
show	B-X
that	B-X
recombinant	B-X
gp41	B-X
(	B-X
aa565-647	B-X
)	B-X
,	B-X
the	B-X
extracellular	B-X
domain	B-X
of	B-X
HIV-1	B-X
transmembrane	B-X
glycoprotein	B-X
,	B-X
stimulates	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
production	B-X
in	B-X
human	B-X
monocytes	B-X
.	B-X
The	B-X
signal	B-X
cascade	B-X
transducing	B-X
this	B-X
effect	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
gp41-induced	B-X
IL-10	B-X
up-regulation	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
previously	B-X
described	B-X
synergistic	B-X
activation	B-X
of	B-X
cAMP	B-X
and	B-X
NF-kappaB	B-X
pathways	B-X
.	B-X
gp41	B-X
induced	B-X
cAMP	B-X
accumulation	B-X
in	B-X
monocytes	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
and	B-X
the	B-X
adenylate	B-X
cyclase	B-X
inhibitor	B-X
SQ	B-X
22536	B-X
suppressed	B-X
gp41-induced	B-X
IL-10	B-X
production	B-X
in	B-X
monocytes	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
gp41	B-X
failed	B-X
to	B-X
stimulate	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
as	B-X
much	B-X
as	B-X
no	B-X
NF-kappaB	B-X
bound	B-X
to	B-X
the	B-X
main	B-X
NF-kappaB-binding	B-X
site	B-X
2	B-X
of	B-X
the	B-X
IL-10	B-X
promoter	B-X
after	B-X
addition	B-X
of	B-X
gp41	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
involvement	B-X
of	B-X
other	B-X
signal	B-X
transduction	B-X
pathways	B-X
.	B-X
Specific	B-X
inhibitors	B-X
of	B-X
p70	B-X
(	B-X
S6	B-X
)	B-X
-kinase	B-X
(	B-X
rapamycin	B-X
)	B-X
,	B-X
and	B-X
Gi	B-X
protein	B-X
(	B-X
pertussis	B-X
toxin	B-X
)	B-X
,	B-X
prevented	B-X
induction	B-X
of	B-X
IL-10	B-X
production	B-X
by	B-X
gp41	B-X
in	B-X
monocytes	B-X
,	B-X
while	B-X
inhibitors	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI	B-X
3-kinase	B-X
)	B-X
(	B-X
wortmannin	B-X
)	B-X
and	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
pathway	B-X
(	B-X
PD	B-X
98059	B-X
)	B-X
did	B-X
not	B-X
.	B-X
Thus	B-X
HIV-1	B-X
gp41-induced	B-X
IL-10	B-X
up-regulation	B-X
in	B-X
monocytes	B-X
may	B-X
not	B-X
involve	B-X
NF-kappaB	B-X
,	B-X
MAPK	B-X
,	B-X
or	B-X
PI	B-X
3-kinase	B-X
activation	B-X
,	B-X
but	B-X
rather	B-X
may	B-X
operate	B-X
through	B-X
activation	B-X
of	B-X
adenylate	B-X
cyclase	B-X
and	B-X
pertussis-toxin-sensitive	B-X
Gi/Go	B-X
protein	B-X
to	B-X
effect	B-X
p70	B-X
(	B-X
S6	B-X
)	B-X
-kinase	B-X
activation	B-X
.	B-X

Constitutive	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
adult	O
T	O
-	O
cell	O
leukemia	O
cells	O
.	O
<EOS>	B-X
Human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
is	B-X
an	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T-cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
.	B-X
The	B-X
viral	B-X
protein	B-X
Tax	B-X
induces	B-X
the	B-X
activation	B-X
and	B-X
nuclear	B-X
translocalization	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
which	B-X
is	B-X
proposed	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
HTLV-I	B-X
.	B-X
However	B-X
,	B-X
the	B-X
HTLV-I	B-X
genes	B-X
including	B-X
Tax	B-X
are	B-X
not	B-X
expressed	B-X
significantly	B-X
in	B-X
primary	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
basis	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
freshly	B-X
isolated	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
,	B-X
like	B-X
HTLV-I-infected	B-X
T-cell	B-X
lines	B-X
,	B-X
display	B-X
constitutive	B-X
NF-kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
increased	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
(	B-X
an	B-X
inhibitor	B-X
of	B-X
NF-kappaB	B-X
)	B-X
.	B-X
Whereas	B-X
the	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
Tax-expressing	B-X
T-cell	B-X
lines	B-X
consisted	B-X
mostly	B-X
of	B-X
p50/c-Rel	B-X
,	B-X
fresh	B-X
ATL	B-X
samples	B-X
contained	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
One	B-X
T-cell	B-X
line	B-X
derived	B-X
from	B-X
ATL	B-X
leukemic	B-X
cells	B-X
,	B-X
TL-Om1	B-X
,	B-X
displayed	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
,	B-X
as	B-X
well	B-X
as	B-X
enhanced	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
despite	B-X
the	B-X
lack	B-X
of	B-X
detectable	B-X
Tax	B-X
expression	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
NF-kappaB	B-X
in	B-X
TL-Om1	B-X
consists	B-X
of	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
like	B-X
that	B-X
in	B-X
fresh	B-X
primary	B-X
leukemic	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
a	B-X
Tax-independent	B-X
mechanism	B-X
in	B-X
leukemic	B-X
cells	B-X
of	B-X
ATL	B-X
patients	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
differential	B-X
NF-kappaB	B-X
subunit	B-X
activation	B-X
.	B-X

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O
<EOS>	B-X
Human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV-1	B-X
)	B-X
was	B-X
the	B-X
first	B-X
discovered	B-X
human	B-X
retrovirus	B-X
and	B-X
the	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T-cell	B-X
leukemia	B-X
and	B-X
HTLV-1-associated	B-X
myelopathy/tropical	B-X
spastic	B-X
paraparesis	B-X
.	B-X
Shortly	B-X
after	B-X
the	B-X
discovery	B-X
of	B-X
HTLV-1	B-X
,	B-X
human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
2	B-X
(	B-X
HTLV-2	B-X
)	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
hairy	B-X
cell	B-X
leukemia	B-X
.	B-X
Despite	B-X
possession	B-X
of	B-X
similar	B-X
structural	B-X
features	B-X
to	B-X
HTLV-1	B-X
,	B-X
HTLV-2	B-X
has	B-X
not	B-X
been	B-X
definitively	B-X
associated	B-X
with	B-X
lymphoproliferative	B-X
disease	B-X
.	B-X
Since	B-X
their	B-X
discovery	B-X
,	B-X
studies	B-X
have	B-X
been	B-X
performed	B-X
with	B-X
the	B-X
goal	B-X
of	B-X
highlighting	B-X
the	B-X
differences	B-X
between	B-X
HTLV-1	B-X
and	B-X
HTLV-2	B-X
.	B-X
A	B-X
better	B-X
understanding	B-X
of	B-X
these	B-X
differences	B-X
will	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
specific	B-X
pathogenic	B-X
mechanisms	B-X
of	B-X
HTLV-1	B-X
and	B-X
lead	B-X
to	B-X
novel	B-X
therapeutic	B-X
targets	B-X
.	B-X
This	B-X
review	B-X
will	B-X
compare	B-X
and	B-X
contrast	B-X
the	B-X
two	B-X
oldest	B-X
human	B-X
retroviruses	B-X
with	B-X
regards	B-X
to	B-X
epidemiology	B-X
,	B-X
genomic	B-X
structure	B-X
,	B-X
gene	B-X
products	B-X
,	B-X
and	B-X
pathobiology	B-X
.	B-X

The	O
viral	O
protein	O
Tax	B-Protein
induces	O
the	O
activation	O
and	O
nuclear	O
translocalization	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O
<EOS>	B-X
Human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
is	B-X
an	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T-cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
.	B-X
The	B-X
viral	B-X
protein	B-X
Tax	B-X
induces	B-X
the	B-X
activation	B-X
and	B-X
nuclear	B-X
translocalization	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
which	B-X
is	B-X
proposed	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
HTLV-I	B-X
.	B-X
However	B-X
,	B-X
the	B-X
HTLV-I	B-X
genes	B-X
including	B-X
Tax	B-X
are	B-X
not	B-X
expressed	B-X
significantly	B-X
in	B-X
primary	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
basis	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
freshly	B-X
isolated	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
,	B-X
like	B-X
HTLV-I-infected	B-X
T-cell	B-X
lines	B-X
,	B-X
display	B-X
constitutive	B-X
NF-kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
increased	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
(	B-X
an	B-X
inhibitor	B-X
of	B-X
NF-kappaB	B-X
)	B-X
.	B-X
Whereas	B-X
the	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
Tax-expressing	B-X
T-cell	B-X
lines	B-X
consisted	B-X
mostly	B-X
of	B-X
p50/c-Rel	B-X
,	B-X
fresh	B-X
ATL	B-X
samples	B-X
contained	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
One	B-X
T-cell	B-X
line	B-X
derived	B-X
from	B-X
ATL	B-X
leukemic	B-X
cells	B-X
,	B-X
TL-Om1	B-X
,	B-X
displayed	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
,	B-X
as	B-X
well	B-X
as	B-X
enhanced	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
despite	B-X
the	B-X
lack	B-X
of	B-X
detectable	B-X
Tax	B-X
expression	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
NF-kappaB	B-X
in	B-X
TL-Om1	B-X
consists	B-X
of	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
like	B-X
that	B-X
in	B-X
fresh	B-X
primary	B-X
leukemic	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
a	B-X
Tax-independent	B-X
mechanism	B-X
in	B-X
leukemic	B-X
cells	B-X
of	B-X
ATL	B-X
patients	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
differential	B-X
NF-kappaB	B-X
subunit	B-X
activation	B-X
.	B-X

However	O
,	O
the	O
HTLV	O
-	O
I	O
genes	O
including	O
Tax	B-Protein
are	O
not	O
expressed	O
significantly	O
in	O
primary	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O
<EOS>	B-X
Eukaryotic	B-X
cells	B-X
employ	B-X
a	B-X
broad	B-X
range	B-X
of	B-X
mechanisms	B-X
to	B-X
regulate	B-X
gene	B-X
expression	B-X
.	B-X
Although	B-X
retroviruses	B-X
may	B-X
exhibit	B-X
lymphocytic	B-X
infiltration	B-X
into	B-X
exocrine	B-X
glands	B-X
,	B-X
human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV-1	B-X
)	B-X
has	B-X
been	B-X
postulated	B-X
to	B-X
be	B-X
a	B-X
causative	B-X
agent	B-X
for	B-X
SS	B-X
.	B-X
Transgenic	B-X
mice	B-X
with	B-X
HTLV-1	B-X
genes	B-X
showed	B-X
sialadenitis	B-X
resembling	B-X
SS	B-X
,	B-X
but	B-X
their	B-X
phenotypic	B-X
symptoms	B-X
differed	B-X
based	B-X
on	B-X
the	B-X
adopted	B-X
region	B-X
of	B-X
HTLV-1	B-X
genes	B-X
.	B-X
HTLV-1-infection	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
diseases	B-X
including	B-X
adult	B-X
T-cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
and	B-X
non-neoplastic	B-X
inflammatory	B-X
diseases	B-X
.	B-X
The	B-X
latter	B-X
includes	B-X
HTLV-1-associated	B-X
myelopathy/tropical	B-X
spastic	B-X
paraparesis	B-X
(	B-X
HAM/TSP	B-X
)	B-X
and	B-X
HTLV-1	B-X
uveitis	B-X
(	B-X
HU	B-X
)	B-X
and	B-X
other	B-X
diseases	B-X
with	B-X
unestablished	B-X
associations	B-X
such	B-X
as	B-X
arthropathy	B-X
,	B-X
pneumopathy	B-X
,	B-X
dermatitis	B-X
,	B-X
exocrinopathy	B-X
and	B-X
myositis	B-X
.	B-X
ATL	B-X
is	B-X
defined	B-X
as	B-X
neoplastic	B-X
clonal	B-X
growth	B-X
of	B-X
HTLV-1-infected	B-X
T-cells	B-X
and	B-X
is	B-X
characterized	B-X
by	B-X
unique	B-X
clinical	B-X
features	B-X
including	B-X
hypercalcemia	B-X
and	B-X
severe	B-X
organ	B-X
infiltration	B-X
of	B-X
leukemic	B-X
cells	B-X
.	B-X
HAM/TSP	B-X
and	B-X
HU	B-X
are	B-X
characterized	B-X
by	B-X
infiltration	B-X
of	B-X
HTLV-1-infected	B-X
lymphocytes	B-X
and	B-X
dysregulated	B-X
production	B-X
of	B-X
cytokines	B-X
.	B-X
Four	B-X
major	B-X
subtypes	B-X
(	B-X
genotypes	B-X
)	B-X
of	B-X
HTLV-1	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
which	B-X
depend	B-X
more	B-X
on	B-X
geography	B-X
than	B-X
disease	B-X
.	B-X
A	B-X
viral	B-X
transcriptional	B-X
regulator	B-X
,	B-X
Tax	B-X
,	B-X
regulates	B-X
virus	B-X
and	B-X
cellular	B-X
gene	B-X
expression	B-X
through	B-X
binding	B-X
to	B-X
transcription	B-X
factors	B-X
or	B-X
other	B-X
cytoplasmic	B-X
cellular	B-X
molecules	B-X
.	B-X
Aberrant	B-X
expression	B-X
of	B-X
cellular	B-X
genes	B-X
will	B-X
affect	B-X
fundamental	B-X
cellular	B-X
functions	B-X
.	B-X
The	B-X
interaction	B-X
between	B-X
HTLV-1-infected	B-X
cells	B-X
and	B-X
different	B-X
kinds	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
host	B-X
appears	B-X
to	B-X
be	B-X
one	B-X
of	B-X
the	B-X
basic	B-X
mechanisms	B-X
underlying	B-X
the	B-X
development	B-X
of	B-X
HTLV-1-associated	B-X
diseases	B-X
.	B-X
Increased	B-X
provirus	B-X
load	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
HAM/TSP	B-X
and	B-X
HU	B-X
results	B-X
from	B-X
clonal	B-X
expansion	B-X
of	B-X
the	B-X
HTLV-1-infected	B-X
T-cells	B-X
,	B-X
which	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
HTLV-1-associated	B-X
diseases	B-X
.	B-X
Efforts	B-X
to	B-X
characterize	B-X
functions	B-X
of	B-X
the	B-X
viral	B-X
proteins	B-X
and	B-X
the	B-X
virus-infected	B-X
cells	B-X
and	B-X
to	B-X
understand	B-X
the	B-X
natural	B-X
history	B-X
of	B-X
the	B-X
HTLV-1-infection	B-X
are	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
mechanisms	B-X
of	B-X
HTLV-1	B-X
viral	B-X
pathogenesis	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
basis	O
for	O
NF	O
-	O
kappaB	O
activation	O
in	O
freshly	O
isolated	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O
<EOS>	B-X
Human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
is	B-X
an	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T-cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
.	B-X
The	B-X
viral	B-X
protein	B-X
Tax	B-X
induces	B-X
the	B-X
activation	B-X
and	B-X
nuclear	B-X
translocalization	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
which	B-X
is	B-X
proposed	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
HTLV-I	B-X
.	B-X
However	B-X
,	B-X
the	B-X
HTLV-I	B-X
genes	B-X
including	B-X
Tax	B-X
are	B-X
not	B-X
expressed	B-X
significantly	B-X
in	B-X
primary	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
basis	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
freshly	B-X
isolated	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
,	B-X
like	B-X
HTLV-I-infected	B-X
T-cell	B-X
lines	B-X
,	B-X
display	B-X
constitutive	B-X
NF-kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
increased	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
(	B-X
an	B-X
inhibitor	B-X
of	B-X
NF-kappaB	B-X
)	B-X
.	B-X
Whereas	B-X
the	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
Tax-expressing	B-X
T-cell	B-X
lines	B-X
consisted	B-X
mostly	B-X
of	B-X
p50/c-Rel	B-X
,	B-X
fresh	B-X
ATL	B-X
samples	B-X
contained	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
One	B-X
T-cell	B-X
line	B-X
derived	B-X
from	B-X
ATL	B-X
leukemic	B-X
cells	B-X
,	B-X
TL-Om1	B-X
,	B-X
displayed	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
,	B-X
as	B-X
well	B-X
as	B-X
enhanced	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
despite	B-X
the	B-X
lack	B-X
of	B-X
detectable	B-X
Tax	B-X
expression	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
NF-kappaB	B-X
in	B-X
TL-Om1	B-X
consists	B-X
of	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
like	B-X
that	B-X
in	B-X
fresh	B-X
primary	B-X
leukemic	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
a	B-X
Tax-independent	B-X
mechanism	B-X
in	B-X
leukemic	B-X
cells	B-X
of	B-X
ATL	B-X
patients	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
differential	B-X
NF-kappaB	B-X
subunit	B-X
activation	B-X
.	B-X

We	O
found	O
that	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
,	O
like	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
-	O
cell	O
lines	O
,	O
display	O
constitutive	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
and	O
increased	O
degradation	O
of	O
IkappaBalpha	B-Protein
(	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
)	O
.	O
<EOS>	B-X
Human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
is	B-X
an	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T-cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
.	B-X
The	B-X
viral	B-X
protein	B-X
Tax	B-X
induces	B-X
the	B-X
activation	B-X
and	B-X
nuclear	B-X
translocalization	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
which	B-X
is	B-X
proposed	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
HTLV-I	B-X
.	B-X
However	B-X
,	B-X
the	B-X
HTLV-I	B-X
genes	B-X
including	B-X
Tax	B-X
are	B-X
not	B-X
expressed	B-X
significantly	B-X
in	B-X
primary	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
basis	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
freshly	B-X
isolated	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
,	B-X
like	B-X
HTLV-I-infected	B-X
T-cell	B-X
lines	B-X
,	B-X
display	B-X
constitutive	B-X
NF-kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
increased	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
(	B-X
an	B-X
inhibitor	B-X
of	B-X
NF-kappaB	B-X
)	B-X
.	B-X
Whereas	B-X
the	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
Tax-expressing	B-X
T-cell	B-X
lines	B-X
consisted	B-X
mostly	B-X
of	B-X
p50/c-Rel	B-X
,	B-X
fresh	B-X
ATL	B-X
samples	B-X
contained	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
One	B-X
T-cell	B-X
line	B-X
derived	B-X
from	B-X
ATL	B-X
leukemic	B-X
cells	B-X
,	B-X
TL-Om1	B-X
,	B-X
displayed	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
,	B-X
as	B-X
well	B-X
as	B-X
enhanced	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
despite	B-X
the	B-X
lack	B-X
of	B-X
detectable	B-X
Tax	B-X
expression	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
NF-kappaB	B-X
in	B-X
TL-Om1	B-X
consists	B-X
of	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
like	B-X
that	B-X
in	B-X
fresh	B-X
primary	B-X
leukemic	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
a	B-X
Tax-independent	B-X
mechanism	B-X
in	B-X
leukemic	B-X
cells	B-X
of	B-X
ATL	B-X
patients	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
differential	B-X
NF-kappaB	B-X
subunit	B-X
activation	B-X
.	B-X

Whereas	O
the	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
Tax	B-Protein
-	O
expressing	O
T	O
-	O
cell	O
lines	O
consisted	O
mostly	O
of	O
p50	B-Protein
/	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
fresh	O
ATL	O
samples	O
contained	O
p50	B-Protein
/	O
p50	B-Protein
and	O
p50	B-Protein
/	O
p65	B-Protein
heterodimers	O
.	O
<EOS>	B-X
Human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
is	B-X
an	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T-cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
.	B-X
The	B-X
viral	B-X
protein	B-X
Tax	B-X
induces	B-X
the	B-X
activation	B-X
and	B-X
nuclear	B-X
translocalization	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
which	B-X
is	B-X
proposed	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
HTLV-I	B-X
.	B-X
However	B-X
,	B-X
the	B-X
HTLV-I	B-X
genes	B-X
including	B-X
Tax	B-X
are	B-X
not	B-X
expressed	B-X
significantly	B-X
in	B-X
primary	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
basis	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
freshly	B-X
isolated	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
,	B-X
like	B-X
HTLV-I-infected	B-X
T-cell	B-X
lines	B-X
,	B-X
display	B-X
constitutive	B-X
NF-kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
increased	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
(	B-X
an	B-X
inhibitor	B-X
of	B-X
NF-kappaB	B-X
)	B-X
.	B-X
Whereas	B-X
the	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
Tax-expressing	B-X
T-cell	B-X
lines	B-X
consisted	B-X
mostly	B-X
of	B-X
p50/c-Rel	B-X
,	B-X
fresh	B-X
ATL	B-X
samples	B-X
contained	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
One	B-X
T-cell	B-X
line	B-X
derived	B-X
from	B-X
ATL	B-X
leukemic	B-X
cells	B-X
,	B-X
TL-Om1	B-X
,	B-X
displayed	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
,	B-X
as	B-X
well	B-X
as	B-X
enhanced	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
despite	B-X
the	B-X
lack	B-X
of	B-X
detectable	B-X
Tax	B-X
expression	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
NF-kappaB	B-X
in	B-X
TL-Om1	B-X
consists	B-X
of	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
like	B-X
that	B-X
in	B-X
fresh	B-X
primary	B-X
leukemic	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
a	B-X
Tax-independent	B-X
mechanism	B-X
in	B-X
leukemic	B-X
cells	B-X
of	B-X
ATL	B-X
patients	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
differential	B-X
NF-kappaB	B-X
subunit	B-X
activation	B-X
.	B-X

One	O
T	O
-	O
cell	O
line	O
derived	O
from	O
ATL	O
leukemic	O
cells	O
,	O
TL	O
-	O
Om1	O
,	O
displayed	O
constitutive	O
NF	O
-	O
kappaB	O
activity	O
,	O
as	O
well	O
as	O
enhanced	O
degradation	O
of	O
IkappaBalpha	B-Protein
,	O
despite	O
the	O
lack	O
of	O
detectable	O
Tax	B-Protein
expression	O
.	O

Interestingly	O
,	O
the	O
NF	O
-	O
kappaB	O
in	O
TL	O
-	O
Om1	O
consists	O
of	O
p50	B-Protein
/	O
p50	B-Protein
and	O
p50	B-Protein
/	O
p65	B-Protein
like	O
that	O
in	O
fresh	O
primary	O
leukemic	O
cells	O
.	O
<EOS>	B-X
Human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
is	B-X
an	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T-cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
.	B-X
The	B-X
viral	B-X
protein	B-X
Tax	B-X
induces	B-X
the	B-X
activation	B-X
and	B-X
nuclear	B-X
translocalization	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
which	B-X
is	B-X
proposed	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
HTLV-I	B-X
.	B-X
However	B-X
,	B-X
the	B-X
HTLV-I	B-X
genes	B-X
including	B-X
Tax	B-X
are	B-X
not	B-X
expressed	B-X
significantly	B-X
in	B-X
primary	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
basis	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
freshly	B-X
isolated	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
,	B-X
like	B-X
HTLV-I-infected	B-X
T-cell	B-X
lines	B-X
,	B-X
display	B-X
constitutive	B-X
NF-kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
increased	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
(	B-X
an	B-X
inhibitor	B-X
of	B-X
NF-kappaB	B-X
)	B-X
.	B-X
Whereas	B-X
the	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
Tax-expressing	B-X
T-cell	B-X
lines	B-X
consisted	B-X
mostly	B-X
of	B-X
p50/c-Rel	B-X
,	B-X
fresh	B-X
ATL	B-X
samples	B-X
contained	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
One	B-X
T-cell	B-X
line	B-X
derived	B-X
from	B-X
ATL	B-X
leukemic	B-X
cells	B-X
,	B-X
TL-Om1	B-X
,	B-X
displayed	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
,	B-X
as	B-X
well	B-X
as	B-X
enhanced	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
despite	B-X
the	B-X
lack	B-X
of	B-X
detectable	B-X
Tax	B-X
expression	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
NF-kappaB	B-X
in	B-X
TL-Om1	B-X
consists	B-X
of	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
like	B-X
that	B-X
in	B-X
fresh	B-X
primary	B-X
leukemic	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
a	B-X
Tax-independent	B-X
mechanism	B-X
in	B-X
leukemic	B-X
cells	B-X
of	B-X
ATL	B-X
patients	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
differential	B-X
NF-kappaB	B-X
subunit	B-X
activation	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
through	O
a	O
Tax	B-Protein
-	O
independent	O
mechanism	O
in	O
leukemic	O
cells	O
of	O
ATL	O
patients	O
,	O
possibly	O
due	O
to	O
differential	O
NF	O
-	O
kappaB	O
subunit	O
activation	O
.	O
<EOS>	B-X
Human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
is	B-X
an	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T-cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
.	B-X
The	B-X
viral	B-X
protein	B-X
Tax	B-X
induces	B-X
the	B-X
activation	B-X
and	B-X
nuclear	B-X
translocalization	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
which	B-X
is	B-X
proposed	B-X
to	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
HTLV-I	B-X
.	B-X
However	B-X
,	B-X
the	B-X
HTLV-I	B-X
genes	B-X
including	B-X
Tax	B-X
are	B-X
not	B-X
expressed	B-X
significantly	B-X
in	B-X
primary	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
basis	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
freshly	B-X
isolated	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
.	B-X
We	B-X
found	B-X
that	B-X
leukemic	B-X
cells	B-X
from	B-X
ATL	B-X
patients	B-X
,	B-X
like	B-X
HTLV-I-infected	B-X
T-cell	B-X
lines	B-X
,	B-X
display	B-X
constitutive	B-X
NF-kappaB	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
increased	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
(	B-X
an	B-X
inhibitor	B-X
of	B-X
NF-kappaB	B-X
)	B-X
.	B-X
Whereas	B-X
the	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
Tax-expressing	B-X
T-cell	B-X
lines	B-X
consisted	B-X
mostly	B-X
of	B-X
p50/c-Rel	B-X
,	B-X
fresh	B-X
ATL	B-X
samples	B-X
contained	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
One	B-X
T-cell	B-X
line	B-X
derived	B-X
from	B-X
ATL	B-X
leukemic	B-X
cells	B-X
,	B-X
TL-Om1	B-X
,	B-X
displayed	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
,	B-X
as	B-X
well	B-X
as	B-X
enhanced	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
despite	B-X
the	B-X
lack	B-X
of	B-X
detectable	B-X
Tax	B-X
expression	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
NF-kappaB	B-X
in	B-X
TL-Om1	B-X
consists	B-X
of	B-X
p50/p50	B-X
and	B-X
p50/p65	B-X
like	B-X
that	B-X
in	B-X
fresh	B-X
primary	B-X
leukemic	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
a	B-X
Tax-independent	B-X
mechanism	B-X
in	B-X
leukemic	B-X
cells	B-X
of	B-X
ATL	B-X
patients	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
differential	B-X
NF-kappaB	B-X
subunit	B-X
activation	B-X
.	B-X

Apoptosis	O
-	O
resistant	O
T	O
cells	O
have	O
a	O
deficiency	O
in	O
NF	O
-	O
kappaB	O
-	O
mediated	O
induction	O
of	O
Fas	B-Protein
ligand	I-Protein
transcription	O
.	O
<EOS>	B-X
Apoptosis	B-X
induced	B-X
through	B-X
the	B-X
TCR	B-X
in	B-X
CD4+	B-X
T	B-X
cells	B-X
is	B-X
mostly	B-X
mediated	B-X
by	B-X
the	B-X
inducible	B-X
expression	B-X
of	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
as	B-X
a	B-X
primary	B-X
event	B-X
leading	B-X
to	B-X
the	B-X
commitment	B-X
to	B-X
death	B-X
.	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
transcriptional	B-X
events	B-X
that	B-X
regulate	B-X
this	B-X
expression	B-X
,	B-X
we	B-X
took	B-X
advantage	B-X
of	B-X
our	B-X
previously	B-X
described	B-X
mutant	B-X
Jurkat	B-X
cells	B-X
.	B-X
These	B-X
cells	B-X
are	B-X
deficient	B-X
in	B-X
FasL	B-X
expression	B-X
and	B-X
apoptosis	B-X
induced	B-X
upon	B-X
TCR	B-X
triggering	B-X
,	B-X
although	B-X
their	B-X
cytokine	B-X
(	B-X
IL-2	B-X
and	B-X
IFN-gamma	B-X
)	B-X
production	B-X
is	B-X
normal	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
both	B-X
a	B-X
FasL-	B-X
and	B-X
a	B-X
consensus	B-X
NF-kappaB-reporter	B-X
construct	B-X
are	B-X
inefficiently	B-X
induced	B-X
in	B-X
these	B-X
cells	B-X
compared	B-X
to	B-X
wild-type	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
inducible	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
FasL	B-X
reporter	B-X
is	B-X
abolished	B-X
by	B-X
specific	B-X
inhibitors	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
could	B-X
trace	B-X
the	B-X
deficit	B-X
of	B-X
the	B-X
mutant	B-X
cells	B-X
to	B-X
an	B-X
inefficient	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
evidencing	B-X
a	B-X
relevant	B-X
role	B-X
for	B-X
NF-kappaB	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
FasL	B-X
expression	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
induction	B-X
of	B-X
FasL	B-X
versus	B-X
cytokine	B-X
gene	B-X
expression	B-X
is	B-X
differentially	B-X
sensitive	B-X
to	B-X
NF-kappaB	B-X
deprivation	B-X
.	B-X

Apoptosis	O
induced	O
through	O
the	O
TCR	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
is	O
mostly	O
mediated	O
by	O
the	O
inducible	O
expression	O
of	O
Fas	B-Protein
ligand	I-Protein
(	O
FasL	B-Protein
)	O
as	O
a	O
primary	O
event	O
leading	O
to	O
the	O
commitment	O
to	O
death	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
transcriptional	O
events	O
that	O
regulate	O
this	O
expression	O
,	O
we	O
took	O
advantage	O
of	O
our	O
previously	O
described	O
mutant	O
Jurkat	O
cells	O
.	O

These	O
cells	O
are	O
deficient	O
in	O
FasL	B-Protein
expression	O
and	O
apoptosis	O
induced	O
upon	O
TCR	O
triggering	O
,	O
although	O
their	O
cytokine	O
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
production	O
is	O
normal	O
.	O
<EOS>	B-X
Apoptosis	B-X
induced	B-X
through	B-X
the	B-X
TCR	B-X
in	B-X
CD4+	B-X
T	B-X
cells	B-X
is	B-X
mostly	B-X
mediated	B-X
by	B-X
the	B-X
inducible	B-X
expression	B-X
of	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
as	B-X
a	B-X
primary	B-X
event	B-X
leading	B-X
to	B-X
the	B-X
commitment	B-X
to	B-X
death	B-X
.	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
transcriptional	B-X
events	B-X
that	B-X
regulate	B-X
this	B-X
expression	B-X
,	B-X
we	B-X
took	B-X
advantage	B-X
of	B-X
our	B-X
previously	B-X
described	B-X
mutant	B-X
Jurkat	B-X
cells	B-X
.	B-X
These	B-X
cells	B-X
are	B-X
deficient	B-X
in	B-X
FasL	B-X
expression	B-X
and	B-X
apoptosis	B-X
induced	B-X
upon	B-X
TCR	B-X
triggering	B-X
,	B-X
although	B-X
their	B-X
cytokine	B-X
(	B-X
IL-2	B-X
and	B-X
IFN-gamma	B-X
)	B-X
production	B-X
is	B-X
normal	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
both	B-X
a	B-X
FasL-	B-X
and	B-X
a	B-X
consensus	B-X
NF-kappaB-reporter	B-X
construct	B-X
are	B-X
inefficiently	B-X
induced	B-X
in	B-X
these	B-X
cells	B-X
compared	B-X
to	B-X
wild-type	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
inducible	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
FasL	B-X
reporter	B-X
is	B-X
abolished	B-X
by	B-X
specific	B-X
inhibitors	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
could	B-X
trace	B-X
the	B-X
deficit	B-X
of	B-X
the	B-X
mutant	B-X
cells	B-X
to	B-X
an	B-X
inefficient	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
evidencing	B-X
a	B-X
relevant	B-X
role	B-X
for	B-X
NF-kappaB	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
FasL	B-X
expression	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
induction	B-X
of	B-X
FasL	B-X
versus	B-X
cytokine	B-X
gene	B-X
expression	B-X
is	B-X
differentially	B-X
sensitive	B-X
to	B-X
NF-kappaB	B-X
deprivation	B-X
.	B-X

Here	O
we	O
show	O
that	O
both	O
a	O
FasL	B-Protein
-	O
and	O
a	O
consensus	O
NF	O
-	O
kappaB	O
-	O
reporter	O
construct	O
are	O
inefficiently	O
induced	O
in	O
these	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
cells	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
the	O
inducible	O
transcriptional	O
activity	O
of	O
the	O
FasL	B-Protein
reporter	O
is	O
abolished	O
by	O
specific	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
Apoptosis	B-X
induced	B-X
through	B-X
the	B-X
TCR	B-X
in	B-X
CD4+	B-X
T	B-X
cells	B-X
is	B-X
mostly	B-X
mediated	B-X
by	B-X
the	B-X
inducible	B-X
expression	B-X
of	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
as	B-X
a	B-X
primary	B-X
event	B-X
leading	B-X
to	B-X
the	B-X
commitment	B-X
to	B-X
death	B-X
.	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
transcriptional	B-X
events	B-X
that	B-X
regulate	B-X
this	B-X
expression	B-X
,	B-X
we	B-X
took	B-X
advantage	B-X
of	B-X
our	B-X
previously	B-X
described	B-X
mutant	B-X
Jurkat	B-X
cells	B-X
.	B-X
These	B-X
cells	B-X
are	B-X
deficient	B-X
in	B-X
FasL	B-X
expression	B-X
and	B-X
apoptosis	B-X
induced	B-X
upon	B-X
TCR	B-X
triggering	B-X
,	B-X
although	B-X
their	B-X
cytokine	B-X
(	B-X
IL-2	B-X
and	B-X
IFN-gamma	B-X
)	B-X
production	B-X
is	B-X
normal	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
both	B-X
a	B-X
FasL-	B-X
and	B-X
a	B-X
consensus	B-X
NF-kappaB-reporter	B-X
construct	B-X
are	B-X
inefficiently	B-X
induced	B-X
in	B-X
these	B-X
cells	B-X
compared	B-X
to	B-X
wild-type	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
inducible	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
FasL	B-X
reporter	B-X
is	B-X
abolished	B-X
by	B-X
specific	B-X
inhibitors	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
could	B-X
trace	B-X
the	B-X
deficit	B-X
of	B-X
the	B-X
mutant	B-X
cells	B-X
to	B-X
an	B-X
inefficient	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
evidencing	B-X
a	B-X
relevant	B-X
role	B-X
for	B-X
NF-kappaB	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
FasL	B-X
expression	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
induction	B-X
of	B-X
FasL	B-X
versus	B-X
cytokine	B-X
gene	B-X
expression	B-X
is	B-X
differentially	B-X
sensitive	B-X
to	B-X
NF-kappaB	B-X
deprivation	B-X
.	B-X

Thus	O
,	O
we	O
could	O
trace	O
the	O
deficit	O
of	O
the	O
mutant	O
cells	O
to	O
an	O
inefficient	O
NF	O
-	O
kappaB	O
activation	O
,	O
evidencing	O
a	O
relevant	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
the	O
regulation	O
of	O
FasL	B-Protein
expression	O
in	O
activated	O
T	O
cells	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
FasL	B-Protein
versus	O
cytokine	O
gene	O
expression	O
is	O
differentially	O
sensitive	O
to	O
NF	O
-	O
kappaB	O
deprivation	O
.	O
<EOS>	B-X
Apoptosis	B-X
induced	B-X
through	B-X
the	B-X
TCR	B-X
in	B-X
CD4+	B-X
T	B-X
cells	B-X
is	B-X
mostly	B-X
mediated	B-X
by	B-X
the	B-X
inducible	B-X
expression	B-X
of	B-X
Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
as	B-X
a	B-X
primary	B-X
event	B-X
leading	B-X
to	B-X
the	B-X
commitment	B-X
to	B-X
death	B-X
.	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
transcriptional	B-X
events	B-X
that	B-X
regulate	B-X
this	B-X
expression	B-X
,	B-X
we	B-X
took	B-X
advantage	B-X
of	B-X
our	B-X
previously	B-X
described	B-X
mutant	B-X
Jurkat	B-X
cells	B-X
.	B-X
These	B-X
cells	B-X
are	B-X
deficient	B-X
in	B-X
FasL	B-X
expression	B-X
and	B-X
apoptosis	B-X
induced	B-X
upon	B-X
TCR	B-X
triggering	B-X
,	B-X
although	B-X
their	B-X
cytokine	B-X
(	B-X
IL-2	B-X
and	B-X
IFN-gamma	B-X
)	B-X
production	B-X
is	B-X
normal	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
both	B-X
a	B-X
FasL-	B-X
and	B-X
a	B-X
consensus	B-X
NF-kappaB-reporter	B-X
construct	B-X
are	B-X
inefficiently	B-X
induced	B-X
in	B-X
these	B-X
cells	B-X
compared	B-X
to	B-X
wild-type	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
inducible	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
FasL	B-X
reporter	B-X
is	B-X
abolished	B-X
by	B-X
specific	B-X
inhibitors	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
could	B-X
trace	B-X
the	B-X
deficit	B-X
of	B-X
the	B-X
mutant	B-X
cells	B-X
to	B-X
an	B-X
inefficient	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
evidencing	B-X
a	B-X
relevant	B-X
role	B-X
for	B-X
NF-kappaB	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
FasL	B-X
expression	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
induction	B-X
of	B-X
FasL	B-X
versus	B-X
cytokine	B-X
gene	B-X
expression	B-X
is	B-X
differentially	B-X
sensitive	B-X
to	B-X
NF-kappaB	B-X
deprivation	B-X
.	B-X

NF	O
-	O
kappaB	O
regulates	O
Fas	B-Protein
/	O
APO	B-Protein
-	I-Protein
1	I-Protein
/	O
CD95	B-Protein
-	O
and	O
TCR	O
-	O
mediated	O
apoptosis	O
of	O
T	O
lymphocytes	O
.	O
<EOS>	B-X
The	B-X
maintenance	B-X
of	B-X
lymphocyte	B-X
homeostasis	B-X
by	B-X
apoptosis	B-X
is	B-X
a	B-X
critical	B-X
regulatory	B-X
mechanism	B-X
in	B-X
the	B-X
normal	B-X
immune	B-X
system	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
protecting	B-X
cells	B-X
against	B-X
death	B-X
mediated	B-X
by	B-X
TNF	B-X
We	B-X
show	B-X
here	B-X
that	B-X
NF-kappaB	B-X
also	B-X
has	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
Fas/APO-1/CD95-mediated	B-X
death	B-X
,	B-X
a	B-X
major	B-X
pathway	B-X
of	B-X
peripheral	B-X
T	B-X
cell	B-X
death	B-X
.	B-X
Transfection	B-X
of	B-X
Jurkat	B-X
cells	B-X
with	B-X
the	B-X
NF-kappaB	B-X
subunits	B-X
p50	B-X
and	B-X
p65	B-X
confers	B-X
resistance	B-X
against	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Reciprocally	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
or	B-X
a	B-X
dominant	B-X
form	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
,	B-X
IkappaB	B-X
,	B-X
makes	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
rendered	B-X
a	B-X
T	B-X
cell	B-X
hybridoma	B-X
more	B-X
susceptible	B-X
to	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
Correspondingly	B-X
,	B-X
transfection	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
provided	B-X
considerable	B-X
protection	B-X
from	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
observations	B-X
were	B-X
corroborated	B-X
by	B-X
studies	B-X
on	B-X
Fas-mediated	B-X
death	B-X
in	B-X
primary	B-X
T	B-X
cells	B-X
.	B-X
Concanavalin	B-X
A-activated	B-X
cycling	B-X
T	B-X
cell	B-X
blasts	B-X
from	B-X
mice	B-X
that	B-X
are	B-X
transgenic	B-X
for	B-X
the	B-X
dominant	B-X
IkappaB	B-X
molecule	B-X
have	B-X
increased	B-X
sensitivity	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
associated	B-X
with	B-X
a	B-X
down-regulation	B-X
of	B-X
NF-kappaB	B-X
complexes	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
blocking	B-X
TNF	B-X
,	B-X
itself	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
NF-kappaB	B-X
,	B-X
with	B-X
neutralizing	B-X
antibodies	B-X
renders	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
anti-Fas-mediated	B-X
apoptosis	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
compelling	B-X
evidence	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
against	B-X
Fas-mediated	B-X
death	B-X
and	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
T	B-X
cell	B-X
homeostasis	B-X
and	B-X
tolerance	B-X
.	B-X

The	O
maintenance	O
of	O
lymphocyte	O
homeostasis	O
by	O
apoptosis	O
is	O
a	O
critical	O
regulatory	O
mechanism	O
in	O
the	O
normal	O
immune	O
system	O
.	O
<EOS>	B-X
Maintenance	B-X
of	B-X
T-cell	B-X
homeostasis	B-X
is	B-X
critical	B-X
for	B-X
normal	B-X
functioning	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
Transient	B-X
disruption	B-X
of	B-X
homeostasis	B-X
occurs	B-X
when	B-X
naive	B-X
T	B-X
cells	B-X
undergo	B-X
antigen-driven	B-X
expansion	B-X
and	B-X
acquire	B-X
effector	B-X
functions	B-X
.	B-X
Effector	B-X
T	B-X
cells	B-X
then	B-X
either	B-X
undergo	B-X
apoptosis	B-X
(	B-X
i.e	B-X
.	B-X
This	B-X
apoptotic	B-X
process	B-X
is	B-X
crucial	B-X
:	B-X
it	B-X
resets	B-X
T-cell	B-X
homeostasis	B-X
,	B-X
promotes	B-X
protective	B-X
immunity	B-X
,	B-X
and	B-X
limits	B-X
autoimmunity	B-X
.	B-X
Although	B-X
initial	B-X
studies	B-X
using	B-X
in	B-X
vitro	B-X
models	B-X
supported	B-X
a	B-X
role	B-X
for	B-X
death	B-X
receptor	B-X
signaling	B-X
,	B-X
more	B-X
recent	B-X
in	B-X
vivo	B-X
studies	B-X
have	B-X
implicated	B-X
Bcl-2	B-X
family	B-X
members	B-X
as	B-X
being	B-X
critical	B-X
for	B-X
the	B-X
culling	B-X
of	B-X
T-cell	B-X
responses	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
progress	B-X
made	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
underlying	B-X
contraction	B-X
of	B-X
T-cell	B-X
responses	B-X
and	B-X
how	B-X
some	B-X
cells	B-X
avoid	B-X
this	B-X
cell	B-X
death	B-X
and	B-X
become	B-X
memory	B-X
T	B-X
cells	B-X
.	B-X

The	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
against	O
death	O
mediated	O
by	O
TNF	O
We	O
show	O
here	O
that	O
NF	O
-	O
kappaB	O
also	O
has	O
a	O
role	O
in	O
regulating	O
Fas	B-Protein
/	O
APO	B-Protein
-	I-Protein
1	I-Protein
/	O
CD95	B-Protein
-	O
mediated	O
death	O
,	O
a	O
major	O
pathway	O
of	O
peripheral	O
T	O
cell	O
death	O
.	O

Transfection	O
of	O
Jurkat	O
cells	O
with	O
the	O
NF	O
-	O
kappaB	O
subunits	O
p50	B-Protein
and	O
p65	B-Protein
confers	O
resistance	O
against	O
Fas	B-Protein
-	O
mediated	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
maintenance	B-X
of	B-X
lymphocyte	B-X
homeostasis	B-X
by	B-X
apoptosis	B-X
is	B-X
a	B-X
critical	B-X
regulatory	B-X
mechanism	B-X
in	B-X
the	B-X
normal	B-X
immune	B-X
system	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
protecting	B-X
cells	B-X
against	B-X
death	B-X
mediated	B-X
by	B-X
TNF	B-X
We	B-X
show	B-X
here	B-X
that	B-X
NF-kappaB	B-X
also	B-X
has	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
Fas/APO-1/CD95-mediated	B-X
death	B-X
,	B-X
a	B-X
major	B-X
pathway	B-X
of	B-X
peripheral	B-X
T	B-X
cell	B-X
death	B-X
.	B-X
Transfection	B-X
of	B-X
Jurkat	B-X
cells	B-X
with	B-X
the	B-X
NF-kappaB	B-X
subunits	B-X
p50	B-X
and	B-X
p65	B-X
confers	B-X
resistance	B-X
against	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Reciprocally	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
or	B-X
a	B-X
dominant	B-X
form	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
,	B-X
IkappaB	B-X
,	B-X
makes	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
rendered	B-X
a	B-X
T	B-X
cell	B-X
hybridoma	B-X
more	B-X
susceptible	B-X
to	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
Correspondingly	B-X
,	B-X
transfection	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
provided	B-X
considerable	B-X
protection	B-X
from	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
observations	B-X
were	B-X
corroborated	B-X
by	B-X
studies	B-X
on	B-X
Fas-mediated	B-X
death	B-X
in	B-X
primary	B-X
T	B-X
cells	B-X
.	B-X
Concanavalin	B-X
A-activated	B-X
cycling	B-X
T	B-X
cell	B-X
blasts	B-X
from	B-X
mice	B-X
that	B-X
are	B-X
transgenic	B-X
for	B-X
the	B-X
dominant	B-X
IkappaB	B-X
molecule	B-X
have	B-X
increased	B-X
sensitivity	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
associated	B-X
with	B-X
a	B-X
down-regulation	B-X
of	B-X
NF-kappaB	B-X
complexes	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
blocking	B-X
TNF	B-X
,	B-X
itself	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
NF-kappaB	B-X
,	B-X
with	B-X
neutralizing	B-X
antibodies	B-X
renders	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
anti-Fas-mediated	B-X
apoptosis	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
compelling	B-X
evidence	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
against	B-X
Fas-mediated	B-X
death	B-X
and	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
T	B-X
cell	B-X
homeostasis	B-X
and	B-X
tolerance	B-X
.	B-X

Reciprocally	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
or	O
a	O
dominant	O
form	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
IkappaB	O
,	O
makes	O
the	O
cells	O
more	O
susceptible	O
to	O
Fas	B-Protein
-	O
mediated	O
apoptosis	O
.	O
<EOS>	B-X
Transforming	B-X
growth	B-X
factor-β	B-X
(	B-X
TGF-β	B-X
)	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
in	B-X
the	B-X
development	B-X
of	B-X
diabetic	B-X
complications	B-X
.	B-X
It	B-X
is	B-X
well	B-X
known	B-X
that	B-X
TGF-β	B-X
exerts	B-X
its	B-X
biological	B-X
effects	B-X
by	B-X
activating	B-X
downstream	B-X
mediators	B-X
,	B-X
called	B-X
Smad2and	B-X
Smad3	B-X
,	B-X
which	B-X
is	B-X
negatively	B-X
regulated	B-X
by	B-X
an	B-X
inhibitory	B-X
Smad7	B-X
.	B-X
Recent	B-X
studies	B-X
also	B-X
demonstrated	B-X
that	B-X
under	B-X
disease	B-X
conditions	B-X
Smads	B-X
act	B-X
as	B-X
signal	B-X
integrators	B-X
and	B-X
interact	B-X
with	B-X
other	B-X
signaling	B-X
pathways	B-X
such	B-X
as	B-X
the	B-X
MAPK	B-X
and	B-X
NF-κB	B-X
pathways	B-X
.	B-X
Blocking	B-X
TGF-β	B-X
signaling	B-X
by	B-X
neutralizing	B-X
antibody	B-X
,	B-X
anti-sense	B-X
oligonucleotides	B-X
,	B-X
and	B-X
soluble	B-X
receptors	B-X
have	B-X
been	B-X
tested	B-X
,	B-X
but	B-X
effects	B-X
are	B-X
limited	B-X
.	B-X
Gene	B-X
transfer	B-X
of	B-X
Smad7	B-X
into	B-X
diseased	B-X
kidneys	B-X
demonstrates	B-X
a	B-X
prominent	B-X
inhibition	B-X
on	B-X
renal	B-X
fibrosis	B-X
and	B-X
amelioration	B-X
of	B-X
renal	B-X
impairment	B-X
.	B-X

Furthermore	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
rendered	O
a	O
T	O
cell	O
hybridoma	O
more	O
susceptible	O
to	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O

Correspondingly	O
,	O
transfection	O
of	O
p50	B-Protein
and	O
p65	B-Protein
provided	O
considerable	O
protection	O
from	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
maintenance	B-X
of	B-X
lymphocyte	B-X
homeostasis	B-X
by	B-X
apoptosis	B-X
is	B-X
a	B-X
critical	B-X
regulatory	B-X
mechanism	B-X
in	B-X
the	B-X
normal	B-X
immune	B-X
system	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
protecting	B-X
cells	B-X
against	B-X
death	B-X
mediated	B-X
by	B-X
TNF	B-X
We	B-X
show	B-X
here	B-X
that	B-X
NF-kappaB	B-X
also	B-X
has	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
Fas/APO-1/CD95-mediated	B-X
death	B-X
,	B-X
a	B-X
major	B-X
pathway	B-X
of	B-X
peripheral	B-X
T	B-X
cell	B-X
death	B-X
.	B-X
Transfection	B-X
of	B-X
Jurkat	B-X
cells	B-X
with	B-X
the	B-X
NF-kappaB	B-X
subunits	B-X
p50	B-X
and	B-X
p65	B-X
confers	B-X
resistance	B-X
against	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Reciprocally	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
or	B-X
a	B-X
dominant	B-X
form	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
,	B-X
IkappaB	B-X
,	B-X
makes	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
rendered	B-X
a	B-X
T	B-X
cell	B-X
hybridoma	B-X
more	B-X
susceptible	B-X
to	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
Correspondingly	B-X
,	B-X
transfection	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
provided	B-X
considerable	B-X
protection	B-X
from	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
observations	B-X
were	B-X
corroborated	B-X
by	B-X
studies	B-X
on	B-X
Fas-mediated	B-X
death	B-X
in	B-X
primary	B-X
T	B-X
cells	B-X
.	B-X
Concanavalin	B-X
A-activated	B-X
cycling	B-X
T	B-X
cell	B-X
blasts	B-X
from	B-X
mice	B-X
that	B-X
are	B-X
transgenic	B-X
for	B-X
the	B-X
dominant	B-X
IkappaB	B-X
molecule	B-X
have	B-X
increased	B-X
sensitivity	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
associated	B-X
with	B-X
a	B-X
down-regulation	B-X
of	B-X
NF-kappaB	B-X
complexes	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
blocking	B-X
TNF	B-X
,	B-X
itself	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
NF-kappaB	B-X
,	B-X
with	B-X
neutralizing	B-X
antibodies	B-X
renders	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
anti-Fas-mediated	B-X
apoptosis	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
compelling	B-X
evidence	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
against	B-X
Fas-mediated	B-X
death	B-X
and	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
T	B-X
cell	B-X
homeostasis	B-X
and	B-X
tolerance	B-X
.	B-X

These	O
observations	O
were	O
corroborated	O
by	O
studies	O
on	O
Fas	B-Protein
-	O
mediated	O
death	O
in	O
primary	O
T	O
cells	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
protecting	B-X
cells	B-X
against	B-X
death	B-X
mediated	B-X
by	B-X
TNF	B-X
We	B-X
show	B-X
here	B-X
that	B-X
NF-kappaB	B-X
also	B-X
has	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
Fas/APO-1/CD95-mediated	B-X
death	B-X
,	B-X
a	B-X
major	B-X
pathway	B-X
of	B-X
peripheral	B-X
T	B-X
cell	B-X
death	B-X
.	B-X
Transfection	B-X
of	B-X
Jurkat	B-X
cells	B-X
with	B-X
the	B-X
NF-kappaB	B-X
subunits	B-X
p50	B-X
and	B-X
p65	B-X
confers	B-X
resistance	B-X
against	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Reciprocally	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
or	B-X
a	B-X
dominant	B-X
form	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
,	B-X
IkappaB	B-X
,	B-X
makes	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
rendered	B-X
a	B-X
T	B-X
cell	B-X
hybridoma	B-X
more	B-X
susceptible	B-X
to	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
Correspondingly	B-X
,	B-X
transfection	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
provided	B-X
considerable	B-X
protection	B-X
from	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
observations	B-X
were	B-X
corroborated	B-X
by	B-X
studies	B-X
on	B-X
Fas-mediated	B-X
death	B-X
in	B-X
primary	B-X
T	B-X
cells	B-X
.	B-X
Concanavalin	B-X
A-activated	B-X
cycling	B-X
T	B-X
cell	B-X
blasts	B-X
from	B-X
mice	B-X
that	B-X
are	B-X
transgenic	B-X
for	B-X
the	B-X
dominant	B-X
IkappaB	B-X
molecule	B-X
have	B-X
increased	B-X
sensitivity	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
associated	B-X
with	B-X
a	B-X
down-regulation	B-X
of	B-X
NF-kappaB	B-X
complexes	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
blocking	B-X
TNF	B-X
,	B-X
itself	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
NF-kappaB	B-X
,	B-X
with	B-X
neutralizing	B-X
antibodies	B-X
renders	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
anti-Fas-mediated	B-X
apoptosis	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
compelling	B-X
evidence	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
against	B-X
Fas-mediated	B-X
death	B-X
and	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
T	B-X
cell	B-X
homeostasis	B-X
and	B-X
tolerance	B-X
.	B-X

Concanavalin	O
A	O
-	O
activated	O
cycling	O
T	O
cell	O
blasts	O
from	O
mice	O
that	O
are	O
transgenic	O
for	O
the	O
dominant	O
IkappaB	O
molecule	O
have	O
increased	O
sensitivity	O
to	O
Fas	B-Protein
-	O
mediated	O
apoptosis	O
,	O
associated	O
with	O
a	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
complexes	O
in	O
the	O
nucleus	O
.	O
<EOS>	B-X
The	B-X
maintenance	B-X
of	B-X
lymphocyte	B-X
homeostasis	B-X
by	B-X
apoptosis	B-X
is	B-X
a	B-X
critical	B-X
regulatory	B-X
mechanism	B-X
in	B-X
the	B-X
normal	B-X
immune	B-X
system	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
protecting	B-X
cells	B-X
against	B-X
death	B-X
mediated	B-X
by	B-X
TNF	B-X
We	B-X
show	B-X
here	B-X
that	B-X
NF-kappaB	B-X
also	B-X
has	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
Fas/APO-1/CD95-mediated	B-X
death	B-X
,	B-X
a	B-X
major	B-X
pathway	B-X
of	B-X
peripheral	B-X
T	B-X
cell	B-X
death	B-X
.	B-X
Transfection	B-X
of	B-X
Jurkat	B-X
cells	B-X
with	B-X
the	B-X
NF-kappaB	B-X
subunits	B-X
p50	B-X
and	B-X
p65	B-X
confers	B-X
resistance	B-X
against	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Reciprocally	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
or	B-X
a	B-X
dominant	B-X
form	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
,	B-X
IkappaB	B-X
,	B-X
makes	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
rendered	B-X
a	B-X
T	B-X
cell	B-X
hybridoma	B-X
more	B-X
susceptible	B-X
to	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
Correspondingly	B-X
,	B-X
transfection	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
provided	B-X
considerable	B-X
protection	B-X
from	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
observations	B-X
were	B-X
corroborated	B-X
by	B-X
studies	B-X
on	B-X
Fas-mediated	B-X
death	B-X
in	B-X
primary	B-X
T	B-X
cells	B-X
.	B-X
Concanavalin	B-X
A-activated	B-X
cycling	B-X
T	B-X
cell	B-X
blasts	B-X
from	B-X
mice	B-X
that	B-X
are	B-X
transgenic	B-X
for	B-X
the	B-X
dominant	B-X
IkappaB	B-X
molecule	B-X
have	B-X
increased	B-X
sensitivity	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
associated	B-X
with	B-X
a	B-X
down-regulation	B-X
of	B-X
NF-kappaB	B-X
complexes	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
blocking	B-X
TNF	B-X
,	B-X
itself	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
NF-kappaB	B-X
,	B-X
with	B-X
neutralizing	B-X
antibodies	B-X
renders	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
anti-Fas-mediated	B-X
apoptosis	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
compelling	B-X
evidence	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
against	B-X
Fas-mediated	B-X
death	B-X
and	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
T	B-X
cell	B-X
homeostasis	B-X
and	B-X
tolerance	B-X
.	B-X

In	O
addition	O
,	O
blocking	O
TNF	O
,	O
itself	O
a	O
positive	O
regulator	O
of	O
NF	O
-	O
kappaB	O
,	O
with	O
neutralizing	O
antibodies	O
renders	O
the	O
cells	O
more	O
susceptible	O
to	O
anti	O
-	O
Fas	B-Protein
-	O
mediated	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
maintenance	B-X
of	B-X
lymphocyte	B-X
homeostasis	B-X
by	B-X
apoptosis	B-X
is	B-X
a	B-X
critical	B-X
regulatory	B-X
mechanism	B-X
in	B-X
the	B-X
normal	B-X
immune	B-X
system	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
protecting	B-X
cells	B-X
against	B-X
death	B-X
mediated	B-X
by	B-X
TNF	B-X
We	B-X
show	B-X
here	B-X
that	B-X
NF-kappaB	B-X
also	B-X
has	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
Fas/APO-1/CD95-mediated	B-X
death	B-X
,	B-X
a	B-X
major	B-X
pathway	B-X
of	B-X
peripheral	B-X
T	B-X
cell	B-X
death	B-X
.	B-X
Transfection	B-X
of	B-X
Jurkat	B-X
cells	B-X
with	B-X
the	B-X
NF-kappaB	B-X
subunits	B-X
p50	B-X
and	B-X
p65	B-X
confers	B-X
resistance	B-X
against	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Reciprocally	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
or	B-X
a	B-X
dominant	B-X
form	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
,	B-X
IkappaB	B-X
,	B-X
makes	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
rendered	B-X
a	B-X
T	B-X
cell	B-X
hybridoma	B-X
more	B-X
susceptible	B-X
to	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
Correspondingly	B-X
,	B-X
transfection	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
provided	B-X
considerable	B-X
protection	B-X
from	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
observations	B-X
were	B-X
corroborated	B-X
by	B-X
studies	B-X
on	B-X
Fas-mediated	B-X
death	B-X
in	B-X
primary	B-X
T	B-X
cells	B-X
.	B-X
Concanavalin	B-X
A-activated	B-X
cycling	B-X
T	B-X
cell	B-X
blasts	B-X
from	B-X
mice	B-X
that	B-X
are	B-X
transgenic	B-X
for	B-X
the	B-X
dominant	B-X
IkappaB	B-X
molecule	B-X
have	B-X
increased	B-X
sensitivity	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
associated	B-X
with	B-X
a	B-X
down-regulation	B-X
of	B-X
NF-kappaB	B-X
complexes	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
blocking	B-X
TNF	B-X
,	B-X
itself	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
NF-kappaB	B-X
,	B-X
with	B-X
neutralizing	B-X
antibodies	B-X
renders	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
anti-Fas-mediated	B-X
apoptosis	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
compelling	B-X
evidence	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
against	B-X
Fas-mediated	B-X
death	B-X
and	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
T	B-X
cell	B-X
homeostasis	B-X
and	B-X
tolerance	B-X
.	B-X

In	O
summary	O
,	O
our	O
results	O
provide	O
compelling	O
evidence	O
that	O
NF	O
-	O
kappaB	O
protects	O
against	O
Fas	B-Protein
-	O
mediated	O
death	O
and	O
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
T	O
cell	O
homeostasis	O
and	O
tolerance	O
.	O
<EOS>	B-X
The	B-X
maintenance	B-X
of	B-X
lymphocyte	B-X
homeostasis	B-X
by	B-X
apoptosis	B-X
is	B-X
a	B-X
critical	B-X
regulatory	B-X
mechanism	B-X
in	B-X
the	B-X
normal	B-X
immune	B-X
system	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
protecting	B-X
cells	B-X
against	B-X
death	B-X
mediated	B-X
by	B-X
TNF	B-X
We	B-X
show	B-X
here	B-X
that	B-X
NF-kappaB	B-X
also	B-X
has	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
Fas/APO-1/CD95-mediated	B-X
death	B-X
,	B-X
a	B-X
major	B-X
pathway	B-X
of	B-X
peripheral	B-X
T	B-X
cell	B-X
death	B-X
.	B-X
Transfection	B-X
of	B-X
Jurkat	B-X
cells	B-X
with	B-X
the	B-X
NF-kappaB	B-X
subunits	B-X
p50	B-X
and	B-X
p65	B-X
confers	B-X
resistance	B-X
against	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Reciprocally	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
or	B-X
a	B-X
dominant	B-X
form	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
,	B-X
IkappaB	B-X
,	B-X
makes	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
Furthermore	B-X
,	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
soluble	B-X
peptide	B-X
inhibitor	B-X
rendered	B-X
a	B-X
T	B-X
cell	B-X
hybridoma	B-X
more	B-X
susceptible	B-X
to	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
Correspondingly	B-X
,	B-X
transfection	B-X
of	B-X
p50	B-X
and	B-X
p65	B-X
provided	B-X
considerable	B-X
protection	B-X
from	B-X
TCR-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
observations	B-X
were	B-X
corroborated	B-X
by	B-X
studies	B-X
on	B-X
Fas-mediated	B-X
death	B-X
in	B-X
primary	B-X
T	B-X
cells	B-X
.	B-X
Concanavalin	B-X
A-activated	B-X
cycling	B-X
T	B-X
cell	B-X
blasts	B-X
from	B-X
mice	B-X
that	B-X
are	B-X
transgenic	B-X
for	B-X
the	B-X
dominant	B-X
IkappaB	B-X
molecule	B-X
have	B-X
increased	B-X
sensitivity	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
associated	B-X
with	B-X
a	B-X
down-regulation	B-X
of	B-X
NF-kappaB	B-X
complexes	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
blocking	B-X
TNF	B-X
,	B-X
itself	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
NF-kappaB	B-X
,	B-X
with	B-X
neutralizing	B-X
antibodies	B-X
renders	B-X
the	B-X
cells	B-X
more	B-X
susceptible	B-X
to	B-X
anti-Fas-mediated	B-X
apoptosis	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
compelling	B-X
evidence	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
against	B-X
Fas-mediated	B-X
death	B-X
and	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
T	B-X
cell	B-X
homeostasis	B-X
and	B-X
tolerance	B-X
.	B-X

Evidence	O
for	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
CD34	B-Protein
+	O
progenitor	O
to	O
dendritic	O
cell	O
differentiation	O
from	O
a	O
human	O
cell	O
line	O
model	O
.	O
<EOS>	B-X
Intracellular	B-X
signals	B-X
that	B-X
mediate	B-X
differentiation	B-X
of	B-X
pluripotent	B-X
hemopoietic	B-X
progenitors	B-X
to	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
are	B-X
largely	B-X
undefined	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activation	B-X
(	B-X
with	B-X
phorbol	B-X
ester	B-X
(	B-X
PMA	B-X
)	B-X
alone	B-X
)	B-X
specifically	B-X
induces	B-X
differentiation	B-X
of	B-X
primary	B-X
human	B-X
CD34+	B-X
hemopoietic	B-X
progenitor	B-X
cells	B-X
(	B-X
HPC	B-X
)	B-X
to	B-X
mature	B-X
DC	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
cytokine-driven	B-X
(	B-X
granulocyte-macrophage	B-X
CSF	B-X
and	B-X
TNF-alpha	B-X
)	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
is	B-X
preferentially	B-X
blocked	B-X
by	B-X
inhibitors	B-X
of	B-X
PKC	B-X
activation	B-X
.	B-X
To	B-X
further	B-X
identify	B-X
intracellular	B-X
signals	B-X
and	B-X
downstream	B-X
events	B-X
important	B-X
in	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
we	B-X
have	B-X
characterized	B-X
a	B-X
human	B-X
leukemic	B-X
cell	B-X
line	B-X
model	B-X
of	B-X
this	B-X
process	B-X
.	B-X
The	B-X
CD34+	B-X
myelomonocytic	B-X
cell	B-X
line	B-X
KG1	B-X
differentiates	B-X
into	B-X
dendritic-like	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
granulocyte-macrophage	B-X
CSF	B-X
plus	B-X
TNF-alpha	B-X
,	B-X
or	B-X
PMA	B-X
(	B-X
with	B-X
or	B-X
without	B-X
the	B-X
calcium	B-X
ionophore	B-X
ionomycin	B-X
,	B-X
or	B-X
TNF-alpha	B-X
)	B-X
,	B-X
with	B-X
different	B-X
stimuli	B-X
mediating	B-X
different	B-X
aspects	B-X
of	B-X
the	B-X
process	B-X
.	B-X
Phenotypic	B-X
DC	B-X
characteristics	B-X
of	B-X
KG1	B-X
dendritic-like	B-X
cells	B-X
include	B-X
morphology	B-X
(	B-X
loosely	B-X
adherent	B-X
cells	B-X
with	B-X
long	B-X
neurite	B-X
processes	B-X
)	B-X
,	B-X
MHC	B-X
I+/MHC	B-X
IIbright/CD83+/CD86+/CD14-	B-X
surface	B-X
Ag	B-X
expression	B-X
,	B-X
and	B-X
RelB	B-X
and	B-X
DC-CK1	B-X
gene	B-X
expression	B-X
.	B-X
Functional	B-X
DC	B-X
characteristics	B-X
include	B-X
fluid	B-X
phase	B-X
macromolecule	B-X
uptake	B-X
(	B-X
FITC-dextran	B-X
)	B-X
and	B-X
activation	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
.	B-X
Comparison	B-X
of	B-X
KG1	B-X
to	B-X
the	B-X
PMA-unresponsive	B-X
subline	B-X
KG1a	B-X
reveals	B-X
differences	B-X
in	B-X
expression	B-X
of	B-X
TNF	B-X
receptors	B-X
1	B-X
and	B-X
2	B-X
;	B-X
PKC	B-X
isoforms	B-X
alpha	B-X
,	B-X
beta	B-X
I	B-X
,	B-X
beta	B-X
II	B-X
,	B-X
and	B-X
mu	B-X
;	B-X
and	B-X
RelB	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
components/pathways	B-X
are	B-X
important	B-X
for	B-X
DC	B-X
differentiation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
cytokine	B-X
or	B-X
phorbol	B-X
ester	B-X
stimulation	B-X
of	B-X
KG1	B-X
is	B-X
a	B-X
model	B-X
of	B-X
human	B-X
CD34+	B-X
HPC	B-X
to	B-X
DC	B-X
differentiation	B-X
and	B-X
suggest	B-X
that	B-X
specific	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
mediate	B-X
specific	B-X
events	B-X
in	B-X
DC	B-X
lineage	B-X
commitment	B-X
.	B-X

Intracellular	O
signals	O
that	O
mediate	O
differentiation	O
of	O
pluripotent	O
hemopoietic	O
progenitors	O
to	O
dendritic	O
cells	O
(	O
DC	O
)	O
are	O
largely	O
undefined	O
.	O
<EOS>	B-X
The	B-X
intracellular	B-X
signals	B-X
that	B-X
mediate	B-X
the	B-X
differentiation	B-X
of	B-X
pluripotent	B-X
hemopoietic	B-X
progenitors	B-X
to	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
are	B-X
largely	B-X
undefined	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
the	B-X
phorbol	B-X
ester	B-X
PMA	B-X
by	B-X
itself	B-X
induced	B-X
47	B-X
%	B-X
+/-	B-X
8.7	B-X
%	B-X
of	B-X
input	B-X
human	B-X
CD34+	B-X
hemopoietic	B-X
progenitors	B-X
to	B-X
differentiate	B-X
into	B-X
cells	B-X
with	B-X
morphology	B-X
and	B-X
surface	B-X
Ag	B-X
phenotype	B-X
characteristic	B-X
of	B-X
DC	B-X
by	B-X
day	B-X
7	B-X
of	B-X
culture	B-X
.	B-X
Functionally	B-X
,	B-X
PMA-generated	B-X
DC	B-X
processed	B-X
and	B-X
presented	B-X
whole	B-X
soluble	B-X
Ag	B-X
and	B-X
also	B-X
induced	B-X
resting	B-X
T	B-X
cell	B-X
proliferation	B-X
and	B-X
Ag-specific	B-X
CTL	B-X
effector	B-X
function	B-X
.	B-X
Unlike	B-X
cytokine-driven	B-X
DC	B-X
differentiation	B-X
,	B-X
PMA	B-X
suppressed	B-X
proliferation	B-X
and	B-X
induced	B-X
cell	B-X
death	B-X
(	B-X
in	B-X
part	B-X
via	B-X
apoptosis	B-X
)	B-X
in	B-X
cells	B-X
that	B-X
did	B-X
not	B-X
differentiate	B-X
to	B-X
DC	B-X
.	B-X
PMA-mediated	B-X
signaling	B-X
also	B-X
induced	B-X
expression	B-X
of	B-X
the	B-X
RelB	B-X
transcription	B-X
factor	B-X
,	B-X
an	B-X
NF-kappaB	B-X
family	B-X
member	B-X
implicated	B-X
in	B-X
DC	B-X
differentiation	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
phorbol	B-X
esters	B-X
activate	B-X
protein	B-X
kinase	B-X
C	B-X
,	B-X
which	B-X
then	B-X
initiates	B-X
the	B-X
terminal	B-X
component	B-X
of	B-X
an	B-X
intracellular	B-X
signaling	B-X
pathway	B-X
(	B-X
s	B-X
)	B-X
involved	B-X
in	B-X
the	B-X
DC	B-X
differentiation	B-X
of	B-X
CD34+	B-X
hemopoietic	B-X
progenitors	B-X
.	B-X

We	O
have	O
previously	O
shown	O
that	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
(	O
with	O
phorbol	O
ester	O
(	O
PMA	O
)	O
alone	O
)	O
specifically	O
induces	O
differentiation	O
of	O
primary	O
human	O
CD34	B-Protein
+	O
hemopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
to	O
mature	O
DC	O
.	O
<EOS>	B-X
Intracellular	B-X
signals	B-X
that	B-X
mediate	B-X
differentiation	B-X
of	B-X
pluripotent	B-X
hemopoietic	B-X
progenitors	B-X
to	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
are	B-X
largely	B-X
undefined	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activation	B-X
(	B-X
with	B-X
phorbol	B-X
ester	B-X
(	B-X
PMA	B-X
)	B-X
alone	B-X
)	B-X
specifically	B-X
induces	B-X
differentiation	B-X
of	B-X
primary	B-X
human	B-X
CD34+	B-X
hemopoietic	B-X
progenitor	B-X
cells	B-X
(	B-X
HPC	B-X
)	B-X
to	B-X
mature	B-X
DC	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
cytokine-driven	B-X
(	B-X
granulocyte-macrophage	B-X
CSF	B-X
and	B-X
TNF-alpha	B-X
)	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
is	B-X
preferentially	B-X
blocked	B-X
by	B-X
inhibitors	B-X
of	B-X
PKC	B-X
activation	B-X
.	B-X
To	B-X
further	B-X
identify	B-X
intracellular	B-X
signals	B-X
and	B-X
downstream	B-X
events	B-X
important	B-X
in	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
we	B-X
have	B-X
characterized	B-X
a	B-X
human	B-X
leukemic	B-X
cell	B-X
line	B-X
model	B-X
of	B-X
this	B-X
process	B-X
.	B-X
The	B-X
CD34+	B-X
myelomonocytic	B-X
cell	B-X
line	B-X
KG1	B-X
differentiates	B-X
into	B-X
dendritic-like	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
granulocyte-macrophage	B-X
CSF	B-X
plus	B-X
TNF-alpha	B-X
,	B-X
or	B-X
PMA	B-X
(	B-X
with	B-X
or	B-X
without	B-X
the	B-X
calcium	B-X
ionophore	B-X
ionomycin	B-X
,	B-X
or	B-X
TNF-alpha	B-X
)	B-X
,	B-X
with	B-X
different	B-X
stimuli	B-X
mediating	B-X
different	B-X
aspects	B-X
of	B-X
the	B-X
process	B-X
.	B-X
Phenotypic	B-X
DC	B-X
characteristics	B-X
of	B-X
KG1	B-X
dendritic-like	B-X
cells	B-X
include	B-X
morphology	B-X
(	B-X
loosely	B-X
adherent	B-X
cells	B-X
with	B-X
long	B-X
neurite	B-X
processes	B-X
)	B-X
,	B-X
MHC	B-X
I+/MHC	B-X
IIbright/CD83+/CD86+/CD14-	B-X
surface	B-X
Ag	B-X
expression	B-X
,	B-X
and	B-X
RelB	B-X
and	B-X
DC-CK1	B-X
gene	B-X
expression	B-X
.	B-X
Functional	B-X
DC	B-X
characteristics	B-X
include	B-X
fluid	B-X
phase	B-X
macromolecule	B-X
uptake	B-X
(	B-X
FITC-dextran	B-X
)	B-X
and	B-X
activation	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
.	B-X
Comparison	B-X
of	B-X
KG1	B-X
to	B-X
the	B-X
PMA-unresponsive	B-X
subline	B-X
KG1a	B-X
reveals	B-X
differences	B-X
in	B-X
expression	B-X
of	B-X
TNF	B-X
receptors	B-X
1	B-X
and	B-X
2	B-X
;	B-X
PKC	B-X
isoforms	B-X
alpha	B-X
,	B-X
beta	B-X
I	B-X
,	B-X
beta	B-X
II	B-X
,	B-X
and	B-X
mu	B-X
;	B-X
and	B-X
RelB	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
components/pathways	B-X
are	B-X
important	B-X
for	B-X
DC	B-X
differentiation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
cytokine	B-X
or	B-X
phorbol	B-X
ester	B-X
stimulation	B-X
of	B-X
KG1	B-X
is	B-X
a	B-X
model	B-X
of	B-X
human	B-X
CD34+	B-X
HPC	B-X
to	B-X
DC	B-X
differentiation	B-X
and	B-X
suggest	B-X
that	B-X
specific	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
mediate	B-X
specific	B-X
events	B-X
in	B-X
DC	B-X
lineage	B-X
commitment	B-X
.	B-X

We	O
now	O
find	O
that	O
cytokine	O
-	O
driven	O
(	O
granulocyte	O
-	O
macrophage	O
CSF	O
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
CD34	B-Protein
+	O
HPC	O
-	O
-	O
>	O
DC	O
differentiation	O
is	O
preferentially	O
blocked	O
by	O
inhibitors	O
of	O
PKC	O
activation	O
.	O
<EOS>	B-X
Intracellular	B-X
signals	B-X
that	B-X
mediate	B-X
differentiation	B-X
of	B-X
pluripotent	B-X
hemopoietic	B-X
progenitors	B-X
to	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
are	B-X
largely	B-X
undefined	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activation	B-X
(	B-X
with	B-X
phorbol	B-X
ester	B-X
(	B-X
PMA	B-X
)	B-X
alone	B-X
)	B-X
specifically	B-X
induces	B-X
differentiation	B-X
of	B-X
primary	B-X
human	B-X
CD34+	B-X
hemopoietic	B-X
progenitor	B-X
cells	B-X
(	B-X
HPC	B-X
)	B-X
to	B-X
mature	B-X
DC	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
cytokine-driven	B-X
(	B-X
granulocyte-macrophage	B-X
CSF	B-X
and	B-X
TNF-alpha	B-X
)	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
is	B-X
preferentially	B-X
blocked	B-X
by	B-X
inhibitors	B-X
of	B-X
PKC	B-X
activation	B-X
.	B-X
To	B-X
further	B-X
identify	B-X
intracellular	B-X
signals	B-X
and	B-X
downstream	B-X
events	B-X
important	B-X
in	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
we	B-X
have	B-X
characterized	B-X
a	B-X
human	B-X
leukemic	B-X
cell	B-X
line	B-X
model	B-X
of	B-X
this	B-X
process	B-X
.	B-X
The	B-X
CD34+	B-X
myelomonocytic	B-X
cell	B-X
line	B-X
KG1	B-X
differentiates	B-X
into	B-X
dendritic-like	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
granulocyte-macrophage	B-X
CSF	B-X
plus	B-X
TNF-alpha	B-X
,	B-X
or	B-X
PMA	B-X
(	B-X
with	B-X
or	B-X
without	B-X
the	B-X
calcium	B-X
ionophore	B-X
ionomycin	B-X
,	B-X
or	B-X
TNF-alpha	B-X
)	B-X
,	B-X
with	B-X
different	B-X
stimuli	B-X
mediating	B-X
different	B-X
aspects	B-X
of	B-X
the	B-X
process	B-X
.	B-X
Phenotypic	B-X
DC	B-X
characteristics	B-X
of	B-X
KG1	B-X
dendritic-like	B-X
cells	B-X
include	B-X
morphology	B-X
(	B-X
loosely	B-X
adherent	B-X
cells	B-X
with	B-X
long	B-X
neurite	B-X
processes	B-X
)	B-X
,	B-X
MHC	B-X
I+/MHC	B-X
IIbright/CD83+/CD86+/CD14-	B-X
surface	B-X
Ag	B-X
expression	B-X
,	B-X
and	B-X
RelB	B-X
and	B-X
DC-CK1	B-X
gene	B-X
expression	B-X
.	B-X
Functional	B-X
DC	B-X
characteristics	B-X
include	B-X
fluid	B-X
phase	B-X
macromolecule	B-X
uptake	B-X
(	B-X
FITC-dextran	B-X
)	B-X
and	B-X
activation	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
.	B-X
Comparison	B-X
of	B-X
KG1	B-X
to	B-X
the	B-X
PMA-unresponsive	B-X
subline	B-X
KG1a	B-X
reveals	B-X
differences	B-X
in	B-X
expression	B-X
of	B-X
TNF	B-X
receptors	B-X
1	B-X
and	B-X
2	B-X
;	B-X
PKC	B-X
isoforms	B-X
alpha	B-X
,	B-X
beta	B-X
I	B-X
,	B-X
beta	B-X
II	B-X
,	B-X
and	B-X
mu	B-X
;	B-X
and	B-X
RelB	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
components/pathways	B-X
are	B-X
important	B-X
for	B-X
DC	B-X
differentiation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
cytokine	B-X
or	B-X
phorbol	B-X
ester	B-X
stimulation	B-X
of	B-X
KG1	B-X
is	B-X
a	B-X
model	B-X
of	B-X
human	B-X
CD34+	B-X
HPC	B-X
to	B-X
DC	B-X
differentiation	B-X
and	B-X
suggest	B-X
that	B-X
specific	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
mediate	B-X
specific	B-X
events	B-X
in	B-X
DC	B-X
lineage	B-X
commitment	B-X
.	B-X

To	O
further	O
identify	O
intracellular	O
signals	O
and	O
downstream	O
events	O
important	O
in	O
CD34	B-Protein
+	O
HPC	O
-	O
-	O
>	O
DC	O
differentiation	O
we	O
have	O
characterized	O
a	O
human	O
leukemic	O
cell	O
line	O
model	O
of	O
this	O
process	O
.	O
<EOS>	B-X
Intracellular	B-X
signals	B-X
that	B-X
mediate	B-X
differentiation	B-X
of	B-X
pluripotent	B-X
hemopoietic	B-X
progenitors	B-X
to	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
are	B-X
largely	B-X
undefined	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activation	B-X
(	B-X
with	B-X
phorbol	B-X
ester	B-X
(	B-X
PMA	B-X
)	B-X
alone	B-X
)	B-X
specifically	B-X
induces	B-X
differentiation	B-X
of	B-X
primary	B-X
human	B-X
CD34+	B-X
hemopoietic	B-X
progenitor	B-X
cells	B-X
(	B-X
HPC	B-X
)	B-X
to	B-X
mature	B-X
DC	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
cytokine-driven	B-X
(	B-X
granulocyte-macrophage	B-X
CSF	B-X
and	B-X
TNF-alpha	B-X
)	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
is	B-X
preferentially	B-X
blocked	B-X
by	B-X
inhibitors	B-X
of	B-X
PKC	B-X
activation	B-X
.	B-X
To	B-X
further	B-X
identify	B-X
intracellular	B-X
signals	B-X
and	B-X
downstream	B-X
events	B-X
important	B-X
in	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
we	B-X
have	B-X
characterized	B-X
a	B-X
human	B-X
leukemic	B-X
cell	B-X
line	B-X
model	B-X
of	B-X
this	B-X
process	B-X
.	B-X
The	B-X
CD34+	B-X
myelomonocytic	B-X
cell	B-X
line	B-X
KG1	B-X
differentiates	B-X
into	B-X
dendritic-like	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
granulocyte-macrophage	B-X
CSF	B-X
plus	B-X
TNF-alpha	B-X
,	B-X
or	B-X
PMA	B-X
(	B-X
with	B-X
or	B-X
without	B-X
the	B-X
calcium	B-X
ionophore	B-X
ionomycin	B-X
,	B-X
or	B-X
TNF-alpha	B-X
)	B-X
,	B-X
with	B-X
different	B-X
stimuli	B-X
mediating	B-X
different	B-X
aspects	B-X
of	B-X
the	B-X
process	B-X
.	B-X
Phenotypic	B-X
DC	B-X
characteristics	B-X
of	B-X
KG1	B-X
dendritic-like	B-X
cells	B-X
include	B-X
morphology	B-X
(	B-X
loosely	B-X
adherent	B-X
cells	B-X
with	B-X
long	B-X
neurite	B-X
processes	B-X
)	B-X
,	B-X
MHC	B-X
I+/MHC	B-X
IIbright/CD83+/CD86+/CD14-	B-X
surface	B-X
Ag	B-X
expression	B-X
,	B-X
and	B-X
RelB	B-X
and	B-X
DC-CK1	B-X
gene	B-X
expression	B-X
.	B-X
Functional	B-X
DC	B-X
characteristics	B-X
include	B-X
fluid	B-X
phase	B-X
macromolecule	B-X
uptake	B-X
(	B-X
FITC-dextran	B-X
)	B-X
and	B-X
activation	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
.	B-X
Comparison	B-X
of	B-X
KG1	B-X
to	B-X
the	B-X
PMA-unresponsive	B-X
subline	B-X
KG1a	B-X
reveals	B-X
differences	B-X
in	B-X
expression	B-X
of	B-X
TNF	B-X
receptors	B-X
1	B-X
and	B-X
2	B-X
;	B-X
PKC	B-X
isoforms	B-X
alpha	B-X
,	B-X
beta	B-X
I	B-X
,	B-X
beta	B-X
II	B-X
,	B-X
and	B-X
mu	B-X
;	B-X
and	B-X
RelB	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
components/pathways	B-X
are	B-X
important	B-X
for	B-X
DC	B-X
differentiation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
cytokine	B-X
or	B-X
phorbol	B-X
ester	B-X
stimulation	B-X
of	B-X
KG1	B-X
is	B-X
a	B-X
model	B-X
of	B-X
human	B-X
CD34+	B-X
HPC	B-X
to	B-X
DC	B-X
differentiation	B-X
and	B-X
suggest	B-X
that	B-X
specific	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
mediate	B-X
specific	B-X
events	B-X
in	B-X
DC	B-X
lineage	B-X
commitment	B-X
.	B-X

The	O
CD34	B-Protein
+	O
myelomonocytic	O
cell	O
line	O
KG1	O
differentiates	O
into	O
dendritic	O
-	O
like	O
cells	O
in	O
response	O
to	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
CSF	I-Protein
plus	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
or	O
PMA	O
(	O
with	O
or	O
without	O
the	O
calcium	O
ionophore	O
ionomycin	O
,	O
or	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
,	O
with	O
different	O
stimuli	O
mediating	O
different	O
aspects	O
of	O
the	O
process	O
.	O
<EOS>	B-X
Intracellular	B-X
signals	B-X
that	B-X
mediate	B-X
differentiation	B-X
of	B-X
pluripotent	B-X
hemopoietic	B-X
progenitors	B-X
to	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
are	B-X
largely	B-X
undefined	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activation	B-X
(	B-X
with	B-X
phorbol	B-X
ester	B-X
(	B-X
PMA	B-X
)	B-X
alone	B-X
)	B-X
specifically	B-X
induces	B-X
differentiation	B-X
of	B-X
primary	B-X
human	B-X
CD34+	B-X
hemopoietic	B-X
progenitor	B-X
cells	B-X
(	B-X
HPC	B-X
)	B-X
to	B-X
mature	B-X
DC	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
cytokine-driven	B-X
(	B-X
granulocyte-macrophage	B-X
CSF	B-X
and	B-X
TNF-alpha	B-X
)	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
is	B-X
preferentially	B-X
blocked	B-X
by	B-X
inhibitors	B-X
of	B-X
PKC	B-X
activation	B-X
.	B-X
To	B-X
further	B-X
identify	B-X
intracellular	B-X
signals	B-X
and	B-X
downstream	B-X
events	B-X
important	B-X
in	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
we	B-X
have	B-X
characterized	B-X
a	B-X
human	B-X
leukemic	B-X
cell	B-X
line	B-X
model	B-X
of	B-X
this	B-X
process	B-X
.	B-X
The	B-X
CD34+	B-X
myelomonocytic	B-X
cell	B-X
line	B-X
KG1	B-X
differentiates	B-X
into	B-X
dendritic-like	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
granulocyte-macrophage	B-X
CSF	B-X
plus	B-X
TNF-alpha	B-X
,	B-X
or	B-X
PMA	B-X
(	B-X
with	B-X
or	B-X
without	B-X
the	B-X
calcium	B-X
ionophore	B-X
ionomycin	B-X
,	B-X
or	B-X
TNF-alpha	B-X
)	B-X
,	B-X
with	B-X
different	B-X
stimuli	B-X
mediating	B-X
different	B-X
aspects	B-X
of	B-X
the	B-X
process	B-X
.	B-X
Phenotypic	B-X
DC	B-X
characteristics	B-X
of	B-X
KG1	B-X
dendritic-like	B-X
cells	B-X
include	B-X
morphology	B-X
(	B-X
loosely	B-X
adherent	B-X
cells	B-X
with	B-X
long	B-X
neurite	B-X
processes	B-X
)	B-X
,	B-X
MHC	B-X
I+/MHC	B-X
IIbright/CD83+/CD86+/CD14-	B-X
surface	B-X
Ag	B-X
expression	B-X
,	B-X
and	B-X
RelB	B-X
and	B-X
DC-CK1	B-X
gene	B-X
expression	B-X
.	B-X
Functional	B-X
DC	B-X
characteristics	B-X
include	B-X
fluid	B-X
phase	B-X
macromolecule	B-X
uptake	B-X
(	B-X
FITC-dextran	B-X
)	B-X
and	B-X
activation	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
.	B-X
Comparison	B-X
of	B-X
KG1	B-X
to	B-X
the	B-X
PMA-unresponsive	B-X
subline	B-X
KG1a	B-X
reveals	B-X
differences	B-X
in	B-X
expression	B-X
of	B-X
TNF	B-X
receptors	B-X
1	B-X
and	B-X
2	B-X
;	B-X
PKC	B-X
isoforms	B-X
alpha	B-X
,	B-X
beta	B-X
I	B-X
,	B-X
beta	B-X
II	B-X
,	B-X
and	B-X
mu	B-X
;	B-X
and	B-X
RelB	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
components/pathways	B-X
are	B-X
important	B-X
for	B-X
DC	B-X
differentiation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
cytokine	B-X
or	B-X
phorbol	B-X
ester	B-X
stimulation	B-X
of	B-X
KG1	B-X
is	B-X
a	B-X
model	B-X
of	B-X
human	B-X
CD34+	B-X
HPC	B-X
to	B-X
DC	B-X
differentiation	B-X
and	B-X
suggest	B-X
that	B-X
specific	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
mediate	B-X
specific	B-X
events	B-X
in	B-X
DC	B-X
lineage	B-X
commitment	B-X
.	B-X

Phenotypic	O
DC	O
characteristics	O
of	O
KG1	O
dendritic	O
-	O
like	O
cells	O
include	O
morphology	O
(	O
loosely	O
adherent	O
cells	O
with	O
long	O
neurite	O
processes	O
)	O
,	O
MHC	O
I	O
+	O
/	O
MHC	O
IIbright	O
/	O
CD83	B-Protein
+	O
/	O
CD86	B-Protein
+	O
/	O
CD14	B-Protein
-	O
surface	O
Ag	O
expression	O
,	O
and	O
RelB	B-Protein
and	O
DC	B-Protein
-	I-Protein
CK1	I-Protein
gene	O
expression	O
.	O
<EOS>	B-X
Intracellular	B-X
signals	B-X
that	B-X
mediate	B-X
differentiation	B-X
of	B-X
pluripotent	B-X
hemopoietic	B-X
progenitors	B-X
to	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
are	B-X
largely	B-X
undefined	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activation	B-X
(	B-X
with	B-X
phorbol	B-X
ester	B-X
(	B-X
PMA	B-X
)	B-X
alone	B-X
)	B-X
specifically	B-X
induces	B-X
differentiation	B-X
of	B-X
primary	B-X
human	B-X
CD34+	B-X
hemopoietic	B-X
progenitor	B-X
cells	B-X
(	B-X
HPC	B-X
)	B-X
to	B-X
mature	B-X
DC	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
cytokine-driven	B-X
(	B-X
granulocyte-macrophage	B-X
CSF	B-X
and	B-X
TNF-alpha	B-X
)	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
is	B-X
preferentially	B-X
blocked	B-X
by	B-X
inhibitors	B-X
of	B-X
PKC	B-X
activation	B-X
.	B-X
To	B-X
further	B-X
identify	B-X
intracellular	B-X
signals	B-X
and	B-X
downstream	B-X
events	B-X
important	B-X
in	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
we	B-X
have	B-X
characterized	B-X
a	B-X
human	B-X
leukemic	B-X
cell	B-X
line	B-X
model	B-X
of	B-X
this	B-X
process	B-X
.	B-X
The	B-X
CD34+	B-X
myelomonocytic	B-X
cell	B-X
line	B-X
KG1	B-X
differentiates	B-X
into	B-X
dendritic-like	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
granulocyte-macrophage	B-X
CSF	B-X
plus	B-X
TNF-alpha	B-X
,	B-X
or	B-X
PMA	B-X
(	B-X
with	B-X
or	B-X
without	B-X
the	B-X
calcium	B-X
ionophore	B-X
ionomycin	B-X
,	B-X
or	B-X
TNF-alpha	B-X
)	B-X
,	B-X
with	B-X
different	B-X
stimuli	B-X
mediating	B-X
different	B-X
aspects	B-X
of	B-X
the	B-X
process	B-X
.	B-X
Phenotypic	B-X
DC	B-X
characteristics	B-X
of	B-X
KG1	B-X
dendritic-like	B-X
cells	B-X
include	B-X
morphology	B-X
(	B-X
loosely	B-X
adherent	B-X
cells	B-X
with	B-X
long	B-X
neurite	B-X
processes	B-X
)	B-X
,	B-X
MHC	B-X
I+/MHC	B-X
IIbright/CD83+/CD86+/CD14-	B-X
surface	B-X
Ag	B-X
expression	B-X
,	B-X
and	B-X
RelB	B-X
and	B-X
DC-CK1	B-X
gene	B-X
expression	B-X
.	B-X
Functional	B-X
DC	B-X
characteristics	B-X
include	B-X
fluid	B-X
phase	B-X
macromolecule	B-X
uptake	B-X
(	B-X
FITC-dextran	B-X
)	B-X
and	B-X
activation	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
.	B-X
Comparison	B-X
of	B-X
KG1	B-X
to	B-X
the	B-X
PMA-unresponsive	B-X
subline	B-X
KG1a	B-X
reveals	B-X
differences	B-X
in	B-X
expression	B-X
of	B-X
TNF	B-X
receptors	B-X
1	B-X
and	B-X
2	B-X
;	B-X
PKC	B-X
isoforms	B-X
alpha	B-X
,	B-X
beta	B-X
I	B-X
,	B-X
beta	B-X
II	B-X
,	B-X
and	B-X
mu	B-X
;	B-X
and	B-X
RelB	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
components/pathways	B-X
are	B-X
important	B-X
for	B-X
DC	B-X
differentiation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
cytokine	B-X
or	B-X
phorbol	B-X
ester	B-X
stimulation	B-X
of	B-X
KG1	B-X
is	B-X
a	B-X
model	B-X
of	B-X
human	B-X
CD34+	B-X
HPC	B-X
to	B-X
DC	B-X
differentiation	B-X
and	B-X
suggest	B-X
that	B-X
specific	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
mediate	B-X
specific	B-X
events	B-X
in	B-X
DC	B-X
lineage	B-X
commitment	B-X
.	B-X

Functional	O
DC	O
characteristics	O
include	O
fluid	O
phase	O
macromolecule	O
uptake	O
(	O
FITC	O
-	O
dextran	O
)	O
and	O
activation	O
of	O
resting	O
T	O
cells	O
.	O
<EOS>	B-X
Intracellular	B-X
signals	B-X
that	B-X
mediate	B-X
differentiation	B-X
of	B-X
pluripotent	B-X
hemopoietic	B-X
progenitors	B-X
to	B-X
dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
are	B-X
largely	B-X
undefined	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
activation	B-X
(	B-X
with	B-X
phorbol	B-X
ester	B-X
(	B-X
PMA	B-X
)	B-X
alone	B-X
)	B-X
specifically	B-X
induces	B-X
differentiation	B-X
of	B-X
primary	B-X
human	B-X
CD34+	B-X
hemopoietic	B-X
progenitor	B-X
cells	B-X
(	B-X
HPC	B-X
)	B-X
to	B-X
mature	B-X
DC	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
cytokine-driven	B-X
(	B-X
granulocyte-macrophage	B-X
CSF	B-X
and	B-X
TNF-alpha	B-X
)	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
is	B-X
preferentially	B-X
blocked	B-X
by	B-X
inhibitors	B-X
of	B-X
PKC	B-X
activation	B-X
.	B-X
To	B-X
further	B-X
identify	B-X
intracellular	B-X
signals	B-X
and	B-X
downstream	B-X
events	B-X
important	B-X
in	B-X
CD34+	B-X
HPC	B-X
--	B-X
>	B-X
DC	B-X
differentiation	B-X
we	B-X
have	B-X
characterized	B-X
a	B-X
human	B-X
leukemic	B-X
cell	B-X
line	B-X
model	B-X
of	B-X
this	B-X
process	B-X
.	B-X
The	B-X
CD34+	B-X
myelomonocytic	B-X
cell	B-X
line	B-X
KG1	B-X
differentiates	B-X
into	B-X
dendritic-like	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
granulocyte-macrophage	B-X
CSF	B-X
plus	B-X
TNF-alpha	B-X
,	B-X
or	B-X
PMA	B-X
(	B-X
with	B-X
or	B-X
without	B-X
the	B-X
calcium	B-X
ionophore	B-X
ionomycin	B-X
,	B-X
or	B-X
TNF-alpha	B-X
)	B-X
,	B-X
with	B-X
different	B-X
stimuli	B-X
mediating	B-X
different	B-X
aspects	B-X
of	B-X
the	B-X
process	B-X
.	B-X
Phenotypic	B-X
DC	B-X
characteristics	B-X
of	B-X
KG1	B-X
dendritic-like	B-X
cells	B-X
include	B-X
morphology	B-X
(	B-X
loosely	B-X
adherent	B-X
cells	B-X
with	B-X
long	B-X
neurite	B-X
processes	B-X
)	B-X
,	B-X
MHC	B-X
I+/MHC	B-X
IIbright/CD83+/CD86+/CD14-	B-X
surface	B-X
Ag	B-X
expression	B-X
,	B-X
and	B-X
RelB	B-X
and	B-X
DC-CK1	B-X
gene	B-X
expression	B-X
.	B-X
Functional	B-X
DC	B-X
characteristics	B-X
include	B-X
fluid	B-X
phase	B-X
macromolecule	B-X
uptake	B-X
(	B-X
FITC-dextran	B-X
)	B-X
and	B-X
activation	B-X
of	B-X
resting	B-X
T	B-X
cells	B-X
.	B-X
Comparison	B-X
of	B-X
KG1	B-X
to	B-X
the	B-X
PMA-unresponsive	B-X
subline	B-X
KG1a	B-X
reveals	B-X
differences	B-X
in	B-X
expression	B-X
of	B-X
TNF	B-X
receptors	B-X
1	B-X
and	B-X
2	B-X
;	B-X
PKC	B-X
isoforms	B-X
alpha	B-X
,	B-X
beta	B-X
I	B-X
,	B-X
beta	B-X
II	B-X
,	B-X
and	B-X
mu	B-X
;	B-X
and	B-X
RelB	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
components/pathways	B-X
are	B-X
important	B-X
for	B-X
DC	B-X
differentiation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
demonstrate	B-X
that	B-X
cytokine	B-X
or	B-X
phorbol	B-X
ester	B-X
stimulation	B-X
of	B-X
KG1	B-X
is	B-X
a	B-X
model	B-X
of	B-X
human	B-X
CD34+	B-X
HPC	B-X
to	B-X
DC	B-X
differentiation	B-X
and	B-X
suggest	B-X
that	B-X
specific	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
mediate	B-X
specific	B-X
events	B-X
in	B-X
DC	B-X
lineage	B-X
commitment	B-X
.	B-X

Comparison	O
of	O
KG1	O
to	O
the	O
PMA	O
-	O
unresponsive	O
subline	O
KG1a	O
reveals	O
differences	O
in	O
expression	O
of	O
TNF	B-Protein
receptors	I-Protein
1	I-Protein
and	O
2	B-Protein
;	O
PKC	B-Protein
isoforms	I-Protein
alpha	I-Protein
,	O
beta	B-Protein
I	I-Protein
,	O
beta	B-Protein
II	I-Protein
,	O
and	O
mu	B-Protein
;	O
and	O
RelB	B-Protein
,	O
suggesting	O
that	O
these	O
components	O
/	O
pathways	O
are	O
important	O
for	O
DC	O
differentiation	O
.	O

Together	O
,	O
these	O
findings	O
demonstrate	O
that	O
cytokine	O
or	O
phorbol	O
ester	O
stimulation	O
of	O
KG1	O
is	O
a	O
model	O
of	O
human	O
CD34	B-Protein
+	O
HPC	O
to	O
DC	O
differentiation	O
and	O
suggest	O
that	O
specific	O
intracellular	O
signaling	O
pathways	O
mediate	O
specific	O
events	O
in	O
DC	O
lineage	O
commitment	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
using	B-X
single-cell	B-X
RNA	B-X
sequencing	B-X
of	B-X
human	B-X
diabetic	B-X
wounds	B-X
,	B-X
we	B-X
identified	B-X
increased	B-X
JMJD3	B-X
in	B-X
diabetic	B-X
wound	B-X
macrophages	B-X
,	B-X
resulting	B-X
in	B-X
increased	B-X
inflammatory	B-X
gene	B-X
expression	B-X
.	B-X
Mechanistically	B-X
,	B-X
we	B-X
report	B-X
that	B-X
in	B-X
wound	B-X
healing	B-X
,	B-X
JMJD3	B-X
directs	B-X
early	B-X
macrophage-mediated	B-X
inflammation	B-X
via	B-X
JAK1,3/STAT3	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
in	B-X
the	B-X
diabetic	B-X
state	B-X
,	B-X
we	B-X
found	B-X
that	B-X
IL-6	B-X
,	B-X
a	B-X
cytokine	B-X
increased	B-X
in	B-X
diabetic	B-X
wound	B-X
tissue	B-X
at	B-X
later	B-X
time	B-X
points	B-X
post-injury	B-X
,	B-X
regulates	B-X
JMJD3	B-X
expression	B-X
in	B-X
diabetic	B-X
wound	B-X
macrophages	B-X
via	B-X
the	B-X
JAK1,3/STAT3	B-X
pathway	B-X
and	B-X
that	B-X
this	B-X
late	B-X
increase	B-X
in	B-X
JMJD3	B-X
induces	B-X
NFκB-mediated	B-X
inflammatory	B-X
gene	B-X
transcription	B-X
in	B-X
wound	B-X
macrophages	B-X
via	B-X
an	B-X
H3K27me3	B-X
mechanism	B-X
.	B-X
Data	B-X
to	B-X
date	B-X
suggest	B-X
a	B-X
bidirectional	B-X
relationship	B-X
between	B-X
inflammation	B-X
and	B-X
depression	B-X
wherein	B-X
one	B-X
process	B-X
can	B-X
drive	B-X
the	B-X
other	B-X
.	B-X
A	B-X
wealth	B-X
of	B-X
animal	B-X
and	B-X
clinical	B-X
studies	B-X
have	B-X
demonstrated	B-X
an	B-X
association	B-X
between	B-X
concentrations	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
-	B-X
specifically	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1β	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-α	B-X
-	B-X
and	B-X
depressive	B-X
symptoms	B-X
.	B-X
Mounting	B-X
evidence	B-X
has	B-X
shown	B-X
a	B-X
concomitant	B-X
reduction	B-X
in	B-X
both	B-X
depressive	B-X
symptoms	B-X
and	B-X
pro-inflammatory	B-X
cytokine	B-X
concentrations	B-X
following	B-X
treatment	B-X
with	B-X
pharmacological	B-X
anti-inflammatory	B-X
interventions	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
reviewed	B-X
preclinical	B-X
and	B-X
clinical	B-X
findings	B-X
may	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
distinct	B-X
inflammatory	B-X
subtype	B-X
of	B-X
depression	B-X
in	B-X
which	B-X
these	B-X
patients	B-X
exhibit	B-X
unique	B-X
biochemical	B-X
and	B-X
clinical	B-X
features	B-X
and	B-X
may	B-X
potentially	B-X
experience	B-X
improved	B-X
clinical	B-X
outcomes	B-X
with	B-X
inflammation-targeted	B-X
pharmacotherapy	B-X
.	B-X

IL	B-Protein
-	I-Protein
2	I-Protein
-	O
mediated	O
cell	O
cycle	O
progression	O
and	O
inhibition	O
of	O
apoptosis	O
does	O
not	O
require	O
NF	O
-	O
kappa	O
B	O
or	O
activating	O
protein	O
-	O
1	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
.	O
<EOS>	B-X
Activation-induced	B-X
cell	B-X
death	B-X
of	B-X
peripheral	B-X
T	B-X
cells	B-X
results	B-X
from	B-X
the	B-X
interaction	B-X
between	B-X
Fas	B-X
and	B-X
Fas	B-X
ligand	B-X
.	B-X
Resting	B-X
peripheral	B-X
T	B-X
cells	B-X
are	B-X
resistant	B-X
to	B-X
Fas-induced	B-X
apoptosis	B-X
and	B-X
become	B-X
susceptible	B-X
only	B-X
after	B-X
their	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
molecular	B-X
mechanism	B-X
mediating	B-X
the	B-X
sensitization	B-X
of	B-X
resting	B-X
peripheral	B-X
T	B-X
cells	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
following	B-X
TCR	B-X
stimulation	B-X
.	B-X
TCR	B-X
activation	B-X
decreases	B-X
the	B-X
steady	B-X
state	B-X
protein	B-X
levels	B-X
of	B-X
FLIP	B-X
(	B-X
FLICE-like	B-X
inhibitory	B-X
protein	B-X
)	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
Fas	B-X
signaling	B-X
pathway	B-X
.	B-X
Reconstitution	B-X
of	B-X
intracellular	B-X
FLIP	B-X
levels	B-X
by	B-X
the	B-X
addition	B-X
of	B-X
a	B-X
soluble	B-X
HIV	B-X
transactivator	B-X
protein-FLIP	B-X
chimera	B-X
completely	B-X
restores	B-X
resistance	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
in	B-X
TCR	B-X
primary	B-X
T	B-X
cells	B-X
.	B-X
Inhibition	B-X
of	B-X
IL-2	B-X
production	B-X
by	B-X
cyclosporin	B-X
A	B-X
,	B-X
or	B-X
inhibition	B-X
of	B-X
IL-2	B-X
signaling	B-X
by	B-X
rapamycin	B-X
or	B-X
anti-IL-2	B-X
neutralizing	B-X
Abs	B-X
prevents	B-X
the	B-X
decrease	B-X
in	B-X
FLIP	B-X
levels	B-X
and	B-X
confers	B-X
resistance	B-X
to	B-X
Fas-mediated	B-X
apoptosis	B-X
following	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
Using	B-X
cell	B-X
cycle-blocking	B-X
agents	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
activated	B-X
T	B-X
cells	B-X
arrested	B-X
in	B-X
G1	B-X
phase	B-X
contain	B-X
high	B-X
levels	B-X
of	B-X
FLIP	B-X
protein	B-X
,	B-X
whereas	B-X
activated	B-X
T	B-X
cells	B-X
arrested	B-X
in	B-X
S	B-X
phase	B-X
have	B-X
decreased	B-X
FLIP	B-X
protein	B-X
levels	B-X
.	B-X
These	B-X
findings	B-X
link	B-X
regulation	B-X
of	B-X
FLIP	B-X
protein	B-X
levels	B-X
with	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
provide	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
increase	B-X
in	B-X
TCR-induced	B-X
apoptosis	B-X
observed	B-X
during	B-X
the	B-X
S	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X

The	O
IL	B-Protein
-	I-Protein
2	I-Protein
growth	O
hormone	O
is	O
the	O
major	O
growth	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
during	O
a	O
developing	O
immune	O
response	O
.	O
<EOS>	B-X
The	B-X
IL-2	B-X
growth	B-X
hormone	B-X
is	B-X
the	B-X
major	B-X
growth	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
lymphocytes	B-X
during	B-X
a	B-X
developing	B-X
immune	B-X
response	B-X
.	B-X
IL-2	B-X
is	B-X
required	B-X
not	B-X
only	B-X
for	B-X
cell	B-X
cycle	B-X
progression	B-X
but	B-X
also	B-X
to	B-X
protect	B-X
Ag-activated	B-X
T	B-X
cells	B-X
from	B-X
programmed	B-X
cell	B-X
death	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
either	B-X
or	B-X
both	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
are	B-X
involved	B-X
in	B-X
cell	B-X
survival	B-X
or	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
response	B-X
to	B-X
IL-2	B-X
,	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
responsive	B-X
to	B-X
the	B-X
growth	B-X
factor	B-X
were	B-X
analyzed	B-X
for	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
activation	B-X
.	B-X
The	B-X
current	B-X
study	B-X
clearly	B-X
demonstrates	B-X
that	B-X
IL-2	B-X
does	B-X
not	B-X
induce	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
degradation	B-X
or	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
that	B-X
respond	B-X
to	B-X
IL-2	B-X
by	B-X
entering	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
avoiding	B-X
apoptosis	B-X
.	B-X
Similarly	B-X
,	B-X
IL-2	B-X
neither	B-X
activates	B-X
JNK	B-X
nor	B-X
increases	B-X
AP-1	B-X
binding	B-X
activity	B-X
to	B-X
a	B-X
consensus	B-X
o-tetradecanoylphorbol	B-X
13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
response	B-X
element	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
growth	B-X
factor	B-X
does	B-X
induce	B-X
the	B-X
activation	B-X
of	B-X
STAT3	B-X
and	B-X
STAT5	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
as	B-X
has	B-X
been	B-X
previously	B-X
demonstrated	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
neither	B-X
NF-kappa	B-X
B	B-X
nor	B-X
AP-1	B-X
activation	B-X
is	B-X
required	B-X
for	B-X
IL-2-mediated	B-X
survival	B-X
or	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
activated	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
.	B-X

IL	B-Protein
-	I-Protein
2	I-Protein
is	O
required	O
not	O
only	O
for	O
cell	O
cycle	O
progression	O
but	O
also	O
to	O
protect	O
Ag	O
-	O
activated	O
T	O
cells	O
from	O
programmed	O
cell	O
death	O
.	O
<EOS>	B-X
Regulatory	B-X
T	B-X
cells	B-X
(	B-X
Treg	B-X
)	B-X
are	B-X
crucial	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
peripheral	B-X
tolerance	B-X
and	B-X
for	B-X
the	B-X
control	B-X
of	B-X
ongoing	B-X
inflammation	B-X
and	B-X
autoimmunity	B-X
.	B-X
The	B-X
cytokine	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
is	B-X
essentially	B-X
required	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
survival	B-X
of	B-X
Treg	B-X
in	B-X
the	B-X
peripheral	B-X
lymphatic	B-X
tissues	B-X
and	B-X
thus	B-X
plays	B-X
a	B-X
vital	B-X
role	B-X
in	B-X
the	B-X
biology	B-X
of	B-X
Treg	B-X
.	B-X
Most	B-X
autoimmune	B-X
and	B-X
rheumatic	B-X
diseases	B-X
exhibit	B-X
disturbances	B-X
in	B-X
Treg	B-X
biology	B-X
either	B-X
at	B-X
a	B-X
numerical	B-X
or	B-X
functional	B-X
level	B-X
resulting	B-X
in	B-X
an	B-X
imbalance	B-X
between	B-X
protective	B-X
and	B-X
pathogenic	B-X
immune	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
in	B-X
some	B-X
autoimmune	B-X
diseases	B-X
,	B-X
a	B-X
relative	B-X
deficiency	B-X
of	B-X
IL-2	B-X
develops	B-X
during	B-X
disease	B-X
pathogenesis	B-X
leading	B-X
to	B-X
a	B-X
disturbance	B-X
of	B-X
Treg	B-X
homeostasis	B-X
,	B-X
which	B-X
further	B-X
amplifies	B-X
the	B-X
vicious	B-X
cycle	B-X
of	B-X
tolerance	B-X
breach	B-X
and	B-X
chronic	B-X
inflammation	B-X
.	B-X
Low-dose	B-X
IL-2	B-X
therapy	B-X
aims	B-X
either	B-X
to	B-X
compensate	B-X
for	B-X
this	B-X
IL-2	B-X
deficiency	B-X
to	B-X
restore	B-X
a	B-X
physiological	B-X
state	B-X
or	B-X
to	B-X
strengthen	B-X
the	B-X
Treg	B-X
population	B-X
in	B-X
order	B-X
to	B-X
be	B-X
more	B-X
effective	B-X
in	B-X
counter-regulating	B-X
inflammation	B-X
while	B-X
avoiding	B-X
global	B-X
immunosuppression	B-X
.	B-X
Here	B-X
we	B-X
highlight	B-X
key	B-X
findings	B-X
and	B-X
summarize	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
clinical	B-X
translation	B-X
of	B-X
low-dose	B-X
IL-2	B-X
therapy	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
autoimmune	B-X
and	B-X
rheumatic	B-X
diseases	B-X
.	B-X

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
/	O
or	O
activating	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
has	B-X
attracted	B-X
widespread	B-X
attention	B-X
among	B-X
researchers	B-X
in	B-X
many	B-X
fields	B-X
based	B-X
on	B-X
the	B-X
following	B-X
:	B-X
its	B-X
unusual	B-X
and	B-X
rapid	B-X
regulation	B-X
,	B-X
the	B-X
wide	B-X
range	B-X
of	B-X
genes	B-X
that	B-X
it	B-X
controls	B-X
,	B-X
its	B-X
central	B-X
role	B-X
in	B-X
immunological	B-X
processes	B-X
,	B-X
the	B-X
complexity	B-X
of	B-X
its	B-X
subunits	B-X
,	B-X
and	B-X
its	B-X
apparent	B-X
involvement	B-X
in	B-X
several	B-X
diseases	B-X
.	B-X
A	B-X
primary	B-X
level	B-X
of	B-X
control	B-X
for	B-X
NF-kappa	B-X
B	B-X
is	B-X
through	B-X
interactions	B-X
with	B-X
an	B-X
inhibitor	B-X
protein	B-X
called	B-X
I	B-X
kappa	B-X
B	B-X
.	B-X
Recent	B-X
evidence	B-X
confirms	B-X
the	B-X
existence	B-X
of	B-X
multiple	B-X
forms	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
that	B-X
appear	B-X
to	B-X
regulate	B-X
NF-kappa	B-X
B	B-X
by	B-X
distinct	B-X
mechanisms	B-X
.	B-X
NF-kappa	B-X
B	B-X
can	B-X
be	B-X
activated	B-X
by	B-X
exposure	B-X
of	B-X
cells	B-X
to	B-X
LPS	B-X
or	B-X
inflammatory	B-X
cytokines	B-X
such	B-X
as	B-X
TNF	B-X
or	B-X
IL-1	B-X
,	B-X
viral	B-X
infection	B-X
or	B-X
expression	B-X
of	B-X
certain	B-X
viral	B-X
gene	B-X
products	B-X
,	B-X
UV	B-X
irradiation	B-X
,	B-X
B	B-X
or	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
and	B-X
by	B-X
other	B-X
physiological	B-X
and	B-X
nonphysiological	B-X
stimuli	B-X
.	B-X
Activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
to	B-X
move	B-X
into	B-X
the	B-X
nucleus	B-X
is	B-X
controlled	B-X
by	B-X
the	B-X
targeted	B-X
phosphorylation	B-X
and	B-X
subsequent	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
.	B-X
Exciting	B-X
new	B-X
research	B-X
has	B-X
elaborated	B-X
several	B-X
important	B-X
and	B-X
unexpected	B-X
findings	B-X
that	B-X
explain	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
In	B-X
the	B-X
nucleus	B-X
,	B-X
NF-kappa	B-X
B	B-X
dimers	B-X
bind	B-X
to	B-X
target	B-X
DNA	B-X
elements	B-X
and	B-X
activate	B-X
transcription	B-X
of	B-X
genes	B-X
encoding	B-X
proteins	B-X
involved	B-X
with	B-X
immune	B-X
or	B-X
inflammation	B-X
responses	B-X
and	B-X
with	B-X
cell	B-X
growth	B-X
control	B-X
.	B-X
Recent	B-X
data	B-X
provide	B-X
evidence	B-X
that	B-X
NF-kappa	B-X
B	B-X
is	B-X
constitutively	B-X
active	B-X
in	B-X
several	B-X
cell	B-X
types	B-X
,	B-X
potentially	B-X
playing	B-X
unexpected	B-X
roles	B-X
in	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
advances	B-X
in	B-X
describing	B-X
the	B-X
mechanisms	B-X
of	B-X
NF-kappa	B-X
B	B-X
activation	B-X
,	B-X
excitement	B-X
in	B-X
NF-kappa	B-X
B	B-X
research	B-X
has	B-X
been	B-X
generated	B-X
by	B-X
the	B-X
first	B-X
report	B-X
of	B-X
a	B-X
crystal	B-X
structure	B-X
for	B-X
one	B-X
form	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
the	B-X
first	B-X
gene	B-X
knockout	B-X
studies	B-X
for	B-X
different	B-X
forms	B-X
of	B-X
NF-kB	B-X
and	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
and	B-X
the	B-X
implications	B-X
for	B-X
therapies	B-X
of	B-X
diseases	B-X
thought	B-X
to	B-X
involve	B-X
the	B-X
inappropriate	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X

To	O
determine	O
whether	O
either	O
or	O
both	O
of	O
these	O
transcription	O
factors	O
are	O
involved	O
in	O
cell	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
primary	O
human	O
T	O
cells	O
responsive	O
to	O
the	O
growth	O
factor	O
were	O
analyzed	O
for	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
activation	O
.	O
<EOS>	B-X
Regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
are	B-X
engaged	B-X
in	B-X
maintaining	B-X
immune	B-X
homeostasis	B-X
and	B-X
preventing	B-X
autoimmunity	B-X
.	B-X
Treg	B-X
cells	B-X
include	B-X
thymic	B-X
Treg	B-X
cells	B-X
and	B-X
peripheral	B-X
Treg	B-X
cells	B-X
,	B-X
both	B-X
of	B-X
which	B-X
can	B-X
suppress	B-X
the	B-X
immune	B-X
response	B-X
via	B-X
multiple	B-X
distinct	B-X
mechanisms	B-X
.	B-X
The	B-X
differentiation	B-X
,	B-X
proliferation	B-X
,	B-X
suppressive	B-X
function	B-X
and	B-X
survival	B-X
of	B-X
Treg	B-X
cells	B-X
are	B-X
affected	B-X
by	B-X
distinct	B-X
energy	B-X
metabolic	B-X
programs	B-X
.	B-X
Tissue-resident	B-X
Treg	B-X
cells	B-X
hold	B-X
unique	B-X
features	B-X
in	B-X
comparison	B-X
with	B-X
the	B-X
lymphoid	B-X
organ	B-X
Treg	B-X
cells	B-X
.	B-X
Foxp3	B-X
transcription	B-X
factor	B-X
is	B-X
a	B-X
lineage	B-X
master	B-X
regulator	B-X
for	B-X
Treg	B-X
cell	B-X
development	B-X
and	B-X
suppressive	B-X
activity	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
define	B-X
features	B-X
of	B-X
Treg	B-X
cells	B-X
and	B-X
roles	B-X
of	B-X
Foxp3	B-X
in	B-X
Treg	B-X
biology	B-X
,	B-X
and	B-X
summarize	B-X
current	B-X
research	B-X
in	B-X
PTMs	B-X
of	B-X
Foxp3	B-X
protein	B-X
involved	B-X
in	B-X
modulating	B-X
Treg	B-X
function	B-X
.	B-X

The	O
current	O
study	O
clearly	O
demonstrates	O
that	O
IL	B-Protein
-	I-Protein
2	I-Protein
does	O
not	O
induce	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
degradation	O
or	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
that	O
respond	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
by	O
entering	O
the	O
cell	O
cycle	O
and	O
avoiding	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
T	B-X
cell	B-X
receptor	B-X
for	B-X
antigen	B-X
(	B-X
TCR	B-X
)	B-X
is	B-X
a	B-X
multichain	B-X
complex	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
T	B-X
lymphocytes	B-X
which	B-X
binds	B-X
peptide	B-X
antigen	B-X
and	B-X
transduces	B-X
a	B-X
transmembrane	B-X
signal	B-X
leading	B-X
to	B-X
IL-2	B-X
secretion	B-X
.	B-X
Engagement	B-X
of	B-X
the	B-X
TCR	B-X
leads	B-X
to	B-X
activation	B-X
of	B-X
a	B-X
tyrosine	B-X
phosphorylation	B-X
pathway	B-X
and	B-X
a	B-X
phospholipase	B-X
C	B-X
(	B-X
PLC	B-X
)	B-X
pathway	B-X
leading	B-X
to	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PCK	B-X
)	B-X
.	B-X
Currently	B-X
available	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
primary	B-X
event	B-X
in	B-X
signal	B-X
transduction	B-X
is	B-X
tyrosine	B-X
kinase	B-X
activation	B-X
,	B-X
since	B-X
when	B-X
this	B-X
pathway	B-X
is	B-X
inhibited	B-X
,	B-X
PLC	B-X
activation	B-X
is	B-X
blocked	B-X
and	B-X
there	B-X
is	B-X
no	B-X
production	B-X
of	B-X
IL-2	B-X
.	B-X
The	B-X
nature	B-X
of	B-X
the	B-X
tyrosine	B-X
kinase	B-X
which	B-X
initiates	B-X
the	B-X
signaling	B-X
cascade	B-X
is	B-X
currently	B-X
unknown	B-X
.	B-X
The	B-X
CD4/CD8	B-X
associated	B-X
kinase	B-X
p56lck	B-X
clearly	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
but	B-X
it	B-X
is	B-X
clearly	B-X
not	B-X
the	B-X
only	B-X
tyrosine	B-X
kinase	B-X
involved	B-X
.	B-X
The	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
CD45	B-X
also	B-X
plays	B-X
a	B-X
critical	B-X
early	B-X
role	B-X
in	B-X
signal	B-X
transduction	B-X
since	B-X
in	B-X
cells	B-X
where	B-X
it	B-X
is	B-X
deficient	B-X
,	B-X
neither	B-X
tyrosine	B-X
kinase	B-X
activation	B-X
nor	B-X
later	B-X
signaling	B-X
events	B-X
are	B-X
seen	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
the	B-X
PLC/PKC	B-X
pathway	B-X
is	B-X
illustrated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
activation	B-X
of	B-X
this	B-X
pathway	B-X
alone	B-X
may	B-X
lead	B-X
to	B-X
IL-2	B-X
production	B-X
.	B-X
However	B-X
,	B-X
there	B-X
may	B-X
also	B-X
be	B-X
other	B-X
mechanisms	B-X
which	B-X
can	B-X
generate	B-X
an	B-X
IL-2	B-X
response	B-X
.	B-X
Two	B-X
proteins	B-X
known	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
growth	B-X
regulation	B-X
--	B-X
p21ras	B-X
and	B-X
c-raf	B-X
--	B-X
have	B-X
now	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
downstream	B-X
targets	B-X
of	B-X
the	B-X
PLC/PKC	B-X
pathway	B-X
.	B-X

Similarly	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
neither	O
activates	O
JNK	O
nor	O
increases	O
AP	O
-	O
1	O
binding	O
activity	O
to	O
a	O
consensus	O
o	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
response	O
element	O
.	O
<EOS>	B-X
The	B-X
IL-2	B-X
growth	B-X
hormone	B-X
is	B-X
the	B-X
major	B-X
growth	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
lymphocytes	B-X
during	B-X
a	B-X
developing	B-X
immune	B-X
response	B-X
.	B-X
IL-2	B-X
is	B-X
required	B-X
not	B-X
only	B-X
for	B-X
cell	B-X
cycle	B-X
progression	B-X
but	B-X
also	B-X
to	B-X
protect	B-X
Ag-activated	B-X
T	B-X
cells	B-X
from	B-X
programmed	B-X
cell	B-X
death	B-X
.	B-X
In	B-X
several	B-X
cell	B-X
types	B-X
,	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
and/or	B-X
activating	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
be	B-X
extremely	B-X
important	B-X
in	B-X
blocking	B-X
apoptosis	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
either	B-X
or	B-X
both	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
are	B-X
involved	B-X
in	B-X
cell	B-X
survival	B-X
or	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
response	B-X
to	B-X
IL-2	B-X
,	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
responsive	B-X
to	B-X
the	B-X
growth	B-X
factor	B-X
were	B-X
analyzed	B-X
for	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
activation	B-X
.	B-X
The	B-X
current	B-X
study	B-X
clearly	B-X
demonstrates	B-X
that	B-X
IL-2	B-X
does	B-X
not	B-X
induce	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
degradation	B-X
or	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
that	B-X
respond	B-X
to	B-X
IL-2	B-X
by	B-X
entering	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
avoiding	B-X
apoptosis	B-X
.	B-X
Similarly	B-X
,	B-X
IL-2	B-X
neither	B-X
activates	B-X
JNK	B-X
nor	B-X
increases	B-X
AP-1	B-X
binding	B-X
activity	B-X
to	B-X
a	B-X
consensus	B-X
o-tetradecanoylphorbol	B-X
13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
response	B-X
element	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
neither	B-X
NF-kappa	B-X
B	B-X
nor	B-X
AP-1	B-X
activation	B-X
is	B-X
required	B-X
for	B-X
IL-2-mediated	B-X
survival	B-X
or	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
activated	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
.	B-X

On	O
the	O
other	O
hand	O
,	O
the	O
growth	O
factor	O
does	O
induce	O
the	O
activation	O
of	O
STAT3	B-Protein
and	O
STAT5	O
in	O
these	O
cells	O
,	O
as	O
has	O
been	O
previously	O
demonstrated	O
.	O
<EOS>	B-X
The	B-X
IL-2	B-X
growth	B-X
hormone	B-X
is	B-X
the	B-X
major	B-X
growth	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
lymphocytes	B-X
during	B-X
a	B-X
developing	B-X
immune	B-X
response	B-X
.	B-X
IL-2	B-X
is	B-X
required	B-X
not	B-X
only	B-X
for	B-X
cell	B-X
cycle	B-X
progression	B-X
but	B-X
also	B-X
to	B-X
protect	B-X
Ag-activated	B-X
T	B-X
cells	B-X
from	B-X
programmed	B-X
cell	B-X
death	B-X
.	B-X
In	B-X
several	B-X
cell	B-X
types	B-X
,	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
and/or	B-X
activating	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
be	B-X
extremely	B-X
important	B-X
in	B-X
blocking	B-X
apoptosis	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
either	B-X
or	B-X
both	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
are	B-X
involved	B-X
in	B-X
cell	B-X
survival	B-X
or	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
response	B-X
to	B-X
IL-2	B-X
,	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
responsive	B-X
to	B-X
the	B-X
growth	B-X
factor	B-X
were	B-X
analyzed	B-X
for	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
activation	B-X
.	B-X
The	B-X
current	B-X
study	B-X
clearly	B-X
demonstrates	B-X
that	B-X
IL-2	B-X
does	B-X
not	B-X
induce	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
degradation	B-X
or	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
that	B-X
respond	B-X
to	B-X
IL-2	B-X
by	B-X
entering	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
avoiding	B-X
apoptosis	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
growth	B-X
factor	B-X
does	B-X
induce	B-X
the	B-X
activation	B-X
of	B-X
STAT3	B-X
and	B-X
STAT5	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
as	B-X
has	B-X
been	B-X
previously	B-X
demonstrated	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
neither	B-X
NF-kappa	B-X
B	B-X
nor	B-X
AP-1	B-X
activation	B-X
is	B-X
required	B-X
for	B-X
IL-2-mediated	B-X
survival	B-X
or	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
activated	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
.	B-X

These	O
data	O
show	O
that	O
neither	O
NF	O
-	O
kappa	O
B	O
nor	O
AP	O
-	O
1	O
activation	O
is	O
required	O
for	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
mediated	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
activated	O
primary	O
human	O
T	O
cells	O
.	O
<EOS>	B-X
The	B-X
IL-2	B-X
growth	B-X
hormone	B-X
is	B-X
the	B-X
major	B-X
growth	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
lymphocytes	B-X
during	B-X
a	B-X
developing	B-X
immune	B-X
response	B-X
.	B-X
IL-2	B-X
is	B-X
required	B-X
not	B-X
only	B-X
for	B-X
cell	B-X
cycle	B-X
progression	B-X
but	B-X
also	B-X
to	B-X
protect	B-X
Ag-activated	B-X
T	B-X
cells	B-X
from	B-X
programmed	B-X
cell	B-X
death	B-X
.	B-X
In	B-X
several	B-X
cell	B-X
types	B-X
,	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
and/or	B-X
activating	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
be	B-X
extremely	B-X
important	B-X
in	B-X
blocking	B-X
apoptosis	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
either	B-X
or	B-X
both	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
are	B-X
involved	B-X
in	B-X
cell	B-X
survival	B-X
or	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
response	B-X
to	B-X
IL-2	B-X
,	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
responsive	B-X
to	B-X
the	B-X
growth	B-X
factor	B-X
were	B-X
analyzed	B-X
for	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
activation	B-X
.	B-X
The	B-X
current	B-X
study	B-X
clearly	B-X
demonstrates	B-X
that	B-X
IL-2	B-X
does	B-X
not	B-X
induce	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
degradation	B-X
or	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
that	B-X
respond	B-X
to	B-X
IL-2	B-X
by	B-X
entering	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
avoiding	B-X
apoptosis	B-X
.	B-X
Similarly	B-X
,	B-X
IL-2	B-X
neither	B-X
activates	B-X
JNK	B-X
nor	B-X
increases	B-X
AP-1	B-X
binding	B-X
activity	B-X
to	B-X
a	B-X
consensus	B-X
o-tetradecanoylphorbol	B-X
13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
response	B-X
element	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
growth	B-X
factor	B-X
does	B-X
induce	B-X
the	B-X
activation	B-X
of	B-X
STAT3	B-X
and	B-X
STAT5	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
as	B-X
has	B-X
been	B-X
previously	B-X
demonstrated	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
neither	B-X
NF-kappa	B-X
B	B-X
nor	B-X
AP-1	B-X
activation	B-X
is	B-X
required	B-X
for	B-X
IL-2-mediated	B-X
survival	B-X
or	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
activated	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
.	B-X

Impaired	O
fetal	O
thymocyte	O
development	O
after	O
efficient	O
adenovirus	O
-	O
mediated	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O
<EOS>	B-X
We	B-X
introduce	B-X
a	B-X
new	B-X
experimental	B-X
system	B-X
combining	B-X
adenovirus-mediated	B-X
gene	B-X
transfer	B-X
and	B-X
fetal	B-X
thymic	B-X
organ	B-X
culture	B-X
(	B-X
FTOC	B-X
)	B-X
.	B-X
This	B-X
system	B-X
allowed	B-X
us	B-X
to	B-X
efficiently	B-X
express	B-X
in	B-X
developing	B-X
thymocytes	B-X
a	B-X
mutant	B-X
form	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
(	B-X
mut-I	B-X
kappa	B-X
B	B-X
)	B-X
and	B-X
to	B-X
study	B-X
the	B-X
maturation	B-X
defects	B-X
occurring	B-X
when	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
inhibited	B-X
during	B-X
fetal	B-X
development	B-X
.	B-X
Fetal	B-X
thymocytes	B-X
infected	B-X
with	B-X
adenovirus	B-X
containing	B-X
mut-I	B-X
kappa	B-X
B	B-X
were	B-X
found	B-X
to	B-X
develop	B-X
normally	B-X
until	B-X
the	B-X
CD44-CD25+	B-X
,	B-X
CD4-CD8-	B-X
double-negative	B-X
stage	B-X
,	B-X
while	B-X
production	B-X
of	B-X
more	B-X
mature	B-X
double-positive	B-X
and	B-X
single-positive	B-X
populations	B-X
was	B-X
strongly	B-X
decreased	B-X
.	B-X
However	B-X
,	B-X
apoptosis	B-X
was	B-X
much	B-X
higher	B-X
in	B-X
FTOC	B-X
infected	B-X
with	B-X
adenovirus	B-X
containing	B-X
mut-I	B-X
kappa	B-X
B	B-X
than	B-X
in	B-X
FTOC	B-X
infected	B-X
with	B-X
a	B-X
control	B-X
virus	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
NF-kappa	B-X
B	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
ensuring	B-X
the	B-X
differentiation	B-X
and	B-X
survival	B-X
of	B-X
thymocytes	B-X
in	B-X
the	B-X
early	B-X
stages	B-X
of	B-X
their	B-X
development	B-X
.	B-X

We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus	O
-	O
mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O
<EOS>	B-X
We	B-X
introduce	B-X
a	B-X
new	B-X
experimental	B-X
system	B-X
combining	B-X
adenovirus-mediated	B-X
gene	B-X
transfer	B-X
and	B-X
fetal	B-X
thymic	B-X
organ	B-X
culture	B-X
(	B-X
FTOC	B-X
)	B-X
.	B-X
This	B-X
system	B-X
allowed	B-X
us	B-X
to	B-X
efficiently	B-X
express	B-X
in	B-X
developing	B-X
thymocytes	B-X
a	B-X
mutant	B-X
form	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
(	B-X
mut-I	B-X
kappa	B-X
B	B-X
)	B-X
and	B-X
to	B-X
study	B-X
the	B-X
maturation	B-X
defects	B-X
occurring	B-X
when	B-X
NF-kappa	B-X
B	B-X
activation	B-X
is	B-X
inhibited	B-X
during	B-X
fetal	B-X
development	B-X
.	B-X
Fetal	B-X
thymocytes	B-X
infected	B-X
with	B-X
adenovirus	B-X
containing	B-X
mut-I	B-X
kappa	B-X
B	B-X
were	B-X
found	B-X
to	B-X
develop	B-X
normally	B-X
until	B-X
the	B-X
CD44-CD25+	B-X
,	B-X
CD4-CD8-	B-X
double-negative	B-X
stage	B-X
,	B-X
while	B-X
production	B-X
of	B-X
more	B-X
mature	B-X
double-positive	B-X
and	B-X
single-positive	B-X
populations	B-X
was	B-X
strongly	B-X
decreased	B-X
.	B-X
However	B-X
,	B-X
apoptosis	B-X
was	B-X
much	B-X
higher	B-X
in	B-X
FTOC	B-X
infected	B-X
with	B-X
adenovirus	B-X
containing	B-X
mut-I	B-X
kappa	B-X
B	B-X
than	B-X
in	B-X
FTOC	B-X
infected	B-X
with	B-X
a	B-X
control	B-X
virus	B-X
.	B-X

This	O
system	O
allowed	O
us	O
to	O
efficiently	O
express	O
in	O
developing	O
thymocytes	O
a	O
mutant	O
form	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
(	O
mut	B-Protein
-	I-Protein
I	I-Protein
kappa	I-Protein
B	I-Protein
)	O
and	O
to	O
study	O
the	O
maturation	O
defects	O
occurring	O
when	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
inhibited	O
during	O
fetal	O
development	O
.	O

Fetal	O
thymocytes	O
infected	O
with	O
adenovirus	O
containing	O
mut	O
-	O
I	O
kappa	O
B	O
were	O
found	O
to	O
develop	O
normally	O
until	O
the	O
CD44	B-Protein
-	O
CD25	B-Protein
+	O
,	O
CD4	B-Protein
-	O
CD8	O
-	O
double	O
-	O
negative	O
stage	O
,	O
while	O
production	O
of	O
more	O
mature	O
double	O
-	O
positive	O
and	O
single	O
-	O
positive	O
populations	O
was	O
strongly	O
decreased	O
.	O

Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	O
normal	O
,	O
as	O
did	O
rearrangement	O
and	O
expression	O
of	O
the	O
TCR	B-Protein
beta	I-Protein
-	I-Protein
chain	I-Protein
.	O
<EOS>	B-X
Fetal	B-X
thymocytes	B-X
infected	B-X
with	B-X
adenovirus	B-X
containing	B-X
mut-I	B-X
kappa	B-X
B	B-X
were	B-X
found	B-X
to	B-X
develop	B-X
normally	B-X
until	B-X
the	B-X
CD44-CD25+	B-X
,	B-X
CD4-CD8-	B-X
double-negative	B-X
stage	B-X
,	B-X
while	B-X
production	B-X
of	B-X
more	B-X
mature	B-X
double-positive	B-X
and	B-X
single-positive	B-X
populations	B-X
was	B-X
strongly	B-X
decreased	B-X
.	B-X
Proliferation	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
the	B-X
percentage	B-X
of	B-X
cells	B-X
in	B-X
cycle	B-X
appeared	B-X
normal	B-X
,	B-X
as	B-X
did	B-X
rearrangement	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
TCR	B-X
beta-chain	B-X
.	B-X

However	O
,	O
apoptosis	O
was	O
much	O
higher	O
in	O
FTOC	O
infected	O
with	O
adenovirus	O
containing	O
mut	O
-	O
I	O
kappa	O
B	O
than	O
in	O
FTOC	O
infected	O
with	O
a	O
control	O
virus	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
a	O
crucial	O
role	O
in	O
ensuring	O
the	O
differentiation	O
and	O
survival	O
of	O
thymocytes	O
in	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O

Differential	O
regulation	O
of	O
4E	B-Protein
-	I-Protein
BP1	I-Protein
and	O
4E	B-Protein
-	I-Protein
BP2	I-Protein
,	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
.	O
<EOS>	B-X
Human	B-X
myeloid	B-X
differentiation	B-X
is	B-X
accompanied	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
cell	B-X
proliferation	B-X
.	B-X
Because	B-X
the	B-X
translation	B-X
rate	B-X
is	B-X
an	B-X
important	B-X
determinant	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
translation	B-X
initiation	B-X
during	B-X
human	B-X
myeloid	B-X
cell	B-X
differentiation	B-X
using	B-X
the	B-X
HL-60	B-X
promyelocytic	B-X
leukemia	B-X
cell	B-X
line	B-X
and	B-X
the	B-X
U-937	B-X
monoblastic	B-X
cell	B-X
line	B-X
.	B-X
A	B-X
decrease	B-X
in	B-X
the	B-X
translation	B-X
rate	B-X
is	B-X
observed	B-X
when	B-X
the	B-X
cells	B-X
are	B-X
induced	B-X
to	B-X
differentiate	B-X
along	B-X
the	B-X
monocytic/macrophage	B-X
pathway	B-X
or	B-X
along	B-X
the	B-X
granulocytic	B-X
pathway	B-X
.	B-X
The	B-X
inhibition	B-X
in	B-X
protein	B-X
synthesis	B-X
correlates	B-X
with	B-X
specific	B-X
regulation	B-X
of	B-X
two	B-X
repressors	B-X
of	B-X
translation	B-X
initiation	B-X
,	B-X
4E-BP1	B-X
and	B-X
4E-BP2	B-X
.	B-X
Induction	B-X
of	B-X
HL-60	B-X
and	B-X
U-937	B-X
cell	B-X
differentiation	B-X
into	B-X
monocytes/macrophages	B-X
by	B-X
IFN-gamma	B-X
or	B-X
PMA	B-X
results	B-X
in	B-X
a	B-X
dephosphorylation	B-X
and	B-X
consequent	B-X
activation	B-X
of	B-X
4E-BP1	B-X
.	B-X
Dephosphorylation	B-X
of	B-X
4E-BP1	B-X
was	B-X
also	B-X
observed	B-X
when	B-X
U-937	B-X
cells	B-X
were	B-X
induced	B-X
to	B-X
differentiate	B-X
into	B-X
monocytes/macrophages	B-X
following	B-X
treatment	B-X
with	B-X
retinoic	B-X
acid	B-X
or	B-X
DMSO	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
treatment	B-X
of	B-X
HL-60	B-X
cells	B-X
with	B-X
retinoic	B-X
acid	B-X
or	B-X
DMSO	B-X
,	B-X
which	B-X
results	B-X
in	B-X
a	B-X
granulocytic	B-X
differentiation	B-X
of	B-X
these	B-X
cells	B-X
,	B-X
decreases	B-X
4E-BP1	B-X
amount	B-X
without	B-X
affecting	B-X
its	B-X
phosphorylation	B-X
and	B-X
strongly	B-X
increases	B-X
4E-BP2	B-X
amount	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
provide	B-X
evidence	B-X
for	B-X
differential	B-X
regulation	B-X
of	B-X
the	B-X
translational	B-X
machinery	B-X
during	B-X
human	B-X
myeloid	B-X
differentiation	B-X
,	B-X
specific	B-X
to	B-X
the	B-X
monocytic/macrophage	B-X
pathway	B-X
or	B-X
to	B-X
the	B-X
granulocytic	B-X
pathway	B-X
.	B-X

Human	O
myeloid	O
differentiation	O
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
cell	O
proliferation	O
.	O
<EOS>	B-X
Differentiation	B-X
of	B-X
myeloid	B-X
progenitor	B-X
cells	B-X
into	B-X
macrophages	B-X
is	B-X
accompanied	B-X
by	B-X
increased	B-X
PU.1	B-X
concentration	B-X
and	B-X
increasing	B-X
cell	B-X
cycle	B-X
length	B-X
,	B-X
culminating	B-X
in	B-X
cell	B-X
cycle	B-X
arrest	B-X
.	B-X
Induction	B-X
of	B-X
PU.1	B-X
expression	B-X
in	B-X
a	B-X
cultured	B-X
myeloid	B-X
cell	B-X
line	B-X
expressing	B-X
low	B-X
PU.1	B-X
concentration	B-X
results	B-X
in	B-X
decreased	B-X
levels	B-X
of	B-X
mRNA	B-X
encoding	B-X
ATP-Citrate	B-X
Lyase	B-X
(	B-X
ACL	B-X
)	B-X
and	B-X
cell	B-X
cycle	B-X
arrest	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
ACL	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
cell	B-X
cycle	B-X
regulation	B-X
in	B-X
the	B-X
myeloid	B-X
lineage	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
acetyl-CoA	B-X
or	B-X
acetate	B-X
supplementation	B-X
was	B-X
sufficient	B-X
to	B-X
rescue	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
cultured	B-X
BN	B-X
cells	B-X
treated	B-X
with	B-X
an	B-X
ACL	B-X
inhibitor	B-X
or	B-X
induced	B-X
for	B-X
PU.1	B-X
expression	B-X
.	B-X
Acetyl-CoA	B-X
supplementation	B-X
was	B-X
also	B-X
sufficient	B-X
to	B-X
rescue	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
BN	B-X
cells	B-X
treated	B-X
with	B-X
a	B-X
fatty	B-X
acid	B-X
synthase	B-X
(	B-X
FASN	B-X
)	B-X
inhibitor	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
acetyl-CoA	B-X
was	B-X
utilized	B-X
in	B-X
both	B-X
fatty	B-X
acid	B-X
synthesis	B-X
and	B-X
histone	B-X
acetylation	B-X
pathways	B-X
to	B-X
promote	B-X
proliferation	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
found	B-X
that	B-X
Acly	B-X
mRNA	B-X
transcript	B-X
levels	B-X
decrease	B-X
during	B-X
normal	B-X
macrophage	B-X
differentiation	B-X
from	B-X
bone	B-X
marrow	B-X
precursors	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
regulation	B-X
of	B-X
ACL	B-X
activity	B-X
is	B-X
a	B-X
potentially	B-X
important	B-X
point	B-X
of	B-X
control	B-X
for	B-X
cell	B-X
cycle	B-X
regulation	B-X
in	B-X
the	B-X
myeloid	B-X
lineage	B-X
.	B-X

Because	O
the	O
translation	O
rate	O
is	O
an	O
important	O
determinant	O
of	O
cell	O
proliferation	O
,	O
we	O
have	O
investigated	O
translation	O
initiation	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
using	O
the	O
HL	O
-	O
60	O
promyelocytic	O
leukemia	O
cell	O
line	O
and	O
the	O
U	O
-	O
937	O
monoblastic	O
cell	O
line	O
.	O

A	O
decrease	O
in	O
the	O
translation	O
rate	O
is	O
observed	O
when	O
the	O
cells	O
are	O
induced	O
to	O
differentiate	O
along	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
or	O
along	O
the	O
granulocytic	O
pathway	O
.	O
<EOS>	B-X
Acute	B-X
reactions	B-X
to	B-X
foods	B-X
are	B-X
triggered	B-X
by	B-X
the	B-X
activation	B-X
of	B-X
mast	B-X
cells	B-X
and	B-X
basophils	B-X
,	B-X
both	B-X
of	B-X
which	B-X
release	B-X
inflammatory	B-X
mediators	B-X
that	B-X
lead	B-X
to	B-X
a	B-X
range	B-X
of	B-X
clinical	B-X
manifestations	B-X
,	B-X
including	B-X
gastrointestinal	B-X
,	B-X
cutaneous	B-X
,	B-X
and	B-X
respiratory	B-X
reactions	B-X
as	B-X
well	B-X
as	B-X
systemic	B-X
anaphylaxis	B-X
.	B-X
These	B-X
cells	B-X
also	B-X
express	B-X
inhibitory	B-X
receptors	B-X
,	B-X
including	B-X
the	B-X
IgG	B-X
Fc	B-X
receptor	B-X
,	B-X
FcγRIIb	B-X
,	B-X
that	B-X
suppress	B-X
their	B-X
IgE-mediated	B-X
activation	B-X
.	B-X
Consequently	B-X
,	B-X
these	B-X
cells	B-X
have	B-X
received	B-X
little	B-X
attention	B-X
as	B-X
potential	B-X
cancer	B-X
immunotherapeutic	B-X
agents	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
mouse	B-X
models	B-X
that	B-X
neutrophils	B-X
can	B-X
be	B-X
harnessed	B-X
to	B-X
induce	B-X
eradication	B-X
of	B-X
tumors	B-X
and	B-X
reduce	B-X
metastatic	B-X
seeding	B-X
through	B-X
the	B-X
combined	B-X
actions	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
,	B-X
CD40	B-X
agonist	B-X
,	B-X
and	B-X
tumor-binding	B-X
antibody	B-X
.	B-X
The	B-X
same	B-X
combination	B-X
activates	B-X
human	B-X
neutrophils	B-X
in	B-X
vitro	B-X
,	B-X
enabling	B-X
their	B-X
lysis	B-X
of	B-X
human	B-X
tumor	B-X
cells	B-X
.	B-X
Mechanistically	B-X
,	B-X
this	B-X
therapy	B-X
induces	B-X
rapid	B-X
mobilization	B-X
and	B-X
tumor	B-X
infiltration	B-X
of	B-X
neutrophils	B-X
along	B-X
with	B-X
complement	B-X
activation	B-X
in	B-X
tumors	B-X
.	B-X

The	O
inhibition	O
in	O
protein	O
synthesis	O
correlates	O
with	O
specific	O
regulation	O
of	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
4E	B-Protein
-	I-Protein
BP1	I-Protein
and	O
4E	B-Protein
-	I-Protein
BP2	I-Protein
.	O
<EOS>	B-X
Because	B-X
the	B-X
translation	B-X
rate	B-X
is	B-X
an	B-X
important	B-X
determinant	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
translation	B-X
initiation	B-X
during	B-X
human	B-X
myeloid	B-X
cell	B-X
differentiation	B-X
using	B-X
the	B-X
HL-60	B-X
promyelocytic	B-X
leukemia	B-X
cell	B-X
line	B-X
and	B-X
the	B-X
U-937	B-X
monoblastic	B-X
cell	B-X
line	B-X
.	B-X
A	B-X
decrease	B-X
in	B-X
the	B-X
translation	B-X
rate	B-X
is	B-X
observed	B-X
when	B-X
the	B-X
cells	B-X
are	B-X
induced	B-X
to	B-X
differentiate	B-X
along	B-X
the	B-X
monocytic/macrophage	B-X
pathway	B-X
or	B-X
along	B-X
the	B-X
granulocytic	B-X
pathway	B-X
.	B-X
The	B-X
inhibition	B-X
in	B-X
protein	B-X
synthesis	B-X
correlates	B-X
with	B-X
specific	B-X
regulation	B-X
of	B-X
two	B-X
repressors	B-X
of	B-X
translation	B-X
initiation	B-X
,	B-X
4E-BP1	B-X
and	B-X
4E-BP2	B-X
.	B-X
Induction	B-X
of	B-X
HL-60	B-X
and	B-X
U-937	B-X
cell	B-X
differentiation	B-X
into	B-X
monocytes/macrophages	B-X
by	B-X
IFN-gamma	B-X
or	B-X
PMA	B-X
results	B-X
in	B-X
a	B-X
dephosphorylation	B-X
and	B-X
consequent	B-X
activation	B-X
of	B-X
4E-BP1	B-X
.	B-X
Dephosphorylation	B-X
of	B-X
4E-BP1	B-X
was	B-X
also	B-X
observed	B-X
when	B-X
U-937	B-X
cells	B-X
were	B-X
induced	B-X
to	B-X
differentiate	B-X
into	B-X
monocytes/macrophages	B-X
following	B-X
treatment	B-X
with	B-X
retinoic	B-X
acid	B-X
or	B-X
DMSO	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
treatment	B-X
of	B-X
HL-60	B-X
cells	B-X
with	B-X
retinoic	B-X
acid	B-X
or	B-X
DMSO	B-X
,	B-X
which	B-X
results	B-X
in	B-X
a	B-X
granulocytic	B-X
differentiation	B-X
of	B-X
these	B-X
cells	B-X
,	B-X
decreases	B-X
4E-BP1	B-X
amount	B-X
without	B-X
affecting	B-X
its	B-X
phosphorylation	B-X
and	B-X
strongly	B-X
increases	B-X
4E-BP2	B-X
amount	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
provide	B-X
evidence	B-X
for	B-X
differential	B-X
regulation	B-X
of	B-X
the	B-X
translational	B-X
machinery	B-X
during	B-X
human	B-X
myeloid	B-X
differentiation	B-X
,	B-X
specific	B-X
to	B-X
the	B-X
monocytic/macrophage	B-X
pathway	B-X
or	B-X
to	B-X
the	B-X
granulocytic	B-X
pathway	B-X
.	B-X

Induction	O
of	O
HL	O
-	O
60	O
and	O
U	O
-	O
937	O
cell	O
differentiation	O
into	O
monocytes	O
/	O
macrophages	O
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
or	O
PMA	O
results	O
in	O
a	O
dephosphorylation	O
and	O
consequent	O
activation	O
of	O
4E	B-Protein
-	I-Protein
BP1	I-Protein
.	O
<EOS>	B-X
Human	B-X
myeloid	B-X
differentiation	B-X
is	B-X
accompanied	B-X
by	B-X
a	B-X
decrease	B-X
in	B-X
cell	B-X
proliferation	B-X
.	B-X
Because	B-X
the	B-X
translation	B-X
rate	B-X
is	B-X
an	B-X
important	B-X
determinant	B-X
of	B-X
cell	B-X
proliferation	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
translation	B-X
initiation	B-X
during	B-X
human	B-X
myeloid	B-X
cell	B-X
differentiation	B-X
using	B-X
the	B-X
HL-60	B-X
promyelocytic	B-X
leukemia	B-X
cell	B-X
line	B-X
and	B-X
the	B-X
U-937	B-X
monoblastic	B-X
cell	B-X
line	B-X
.	B-X
A	B-X
decrease	B-X
in	B-X
the	B-X
translation	B-X
rate	B-X
is	B-X
observed	B-X
when	B-X
the	B-X
cells	B-X
are	B-X
induced	B-X
to	B-X
differentiate	B-X
along	B-X
the	B-X
monocytic/macrophage	B-X
pathway	B-X
or	B-X
along	B-X
the	B-X
granulocytic	B-X
pathway	B-X
.	B-X
The	B-X
inhibition	B-X
in	B-X
protein	B-X
synthesis	B-X
correlates	B-X
with	B-X
specific	B-X
regulation	B-X
of	B-X
two	B-X
repressors	B-X
of	B-X
translation	B-X
initiation	B-X
,	B-X
4E-BP1	B-X
and	B-X
4E-BP2	B-X
.	B-X
Induction	B-X
of	B-X
HL-60	B-X
and	B-X
U-937	B-X
cell	B-X
differentiation	B-X
into	B-X
monocytes/macrophages	B-X
by	B-X
IFN-gamma	B-X
or	B-X
PMA	B-X
results	B-X
in	B-X
a	B-X
dephosphorylation	B-X
and	B-X
consequent	B-X
activation	B-X
of	B-X
4E-BP1	B-X
.	B-X
Dephosphorylation	B-X
of	B-X
4E-BP1	B-X
was	B-X
also	B-X
observed	B-X
when	B-X
U-937	B-X
cells	B-X
were	B-X
induced	B-X
to	B-X
differentiate	B-X
into	B-X
monocytes/macrophages	B-X
following	B-X
treatment	B-X
with	B-X
retinoic	B-X
acid	B-X
or	B-X
DMSO	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
treatment	B-X
of	B-X
HL-60	B-X
cells	B-X
with	B-X
retinoic	B-X
acid	B-X
or	B-X
DMSO	B-X
,	B-X
which	B-X
results	B-X
in	B-X
a	B-X
granulocytic	B-X
differentiation	B-X
of	B-X
these	B-X
cells	B-X
,	B-X
decreases	B-X
4E-BP1	B-X
amount	B-X
without	B-X
affecting	B-X
its	B-X
phosphorylation	B-X
and	B-X
strongly	B-X
increases	B-X
4E-BP2	B-X
amount	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
provide	B-X
evidence	B-X
for	B-X
differential	B-X
regulation	B-X
of	B-X
the	B-X
translational	B-X
machinery	B-X
during	B-X
human	B-X
myeloid	B-X
differentiation	B-X
,	B-X
specific	B-X
to	B-X
the	B-X
monocytic/macrophage	B-X
pathway	B-X
or	B-X
to	B-X
the	B-X
granulocytic	B-X
pathway	B-X
.	B-X

Dephosphorylation	O
of	O
4E	B-Protein
-	I-Protein
BP1	I-Protein
was	O
also	O
observed	O
when	O
U	O
-	O
937	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
monocytes	O
/	O
macrophages	O
following	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
.	O
<EOS>	B-X
Dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
is	B-X
a	B-X
very	B-X
simple	B-X
compound	B-X
that	B-X
has	B-X
stimulated	B-X
much	B-X
controversy	B-X
in	B-X
the	B-X
scientific	B-X
and	B-X
popular	B-X
literature	B-X
.	B-X
Therapeutic	B-X
and	B-X
toxic	B-X
agents	B-X
that	B-X
are	B-X
not	B-X
soluble	B-X
in	B-X
water	B-X
are	B-X
often	B-X
soluble	B-X
in	B-X
DMSO	B-X
.	B-X
DMSO	B-X
has	B-X
a	B-X
very	B-X
strong	B-X
affinity	B-X
for	B-X
water	B-X
;	B-X
on	B-X
exposure	B-X
to	B-X
air	B-X
,	B-X
pure	B-X
DMSO	B-X
is	B-X
rapidly	B-X
diluted	B-X
.	B-X
DMSO	B-X
's	B-X
physiologic	B-X
and	B-X
pharmacologic	B-X
properties	B-X
and	B-X
effects	B-X
are	B-X
incompletely	B-X
understood	B-X
.	B-X
Properties	B-X
that	B-X
are	B-X
considered	B-X
to	B-X
be	B-X
particularly	B-X
important	B-X
to	B-X
its	B-X
therapeutic	B-X
and	B-X
toxic	B-X
effects	B-X
include	B-X
:	B-X
its	B-X
own	B-X
rapid	B-X
penetration	B-X
and	B-X
enhanced	B-X
penetration	B-X
of	B-X
other	B-X
substances	B-X
across	B-X
biologic	B-X
membranes	B-X
;	B-X
free	B-X
radical	B-X
scavenging	B-X
;	B-X
effects	B-X
on	B-X
coagulation	B-X
;	B-X
anticholinesterase	B-X
activity	B-X
;	B-X
and	B-X
DMSO-induced	B-X
histamine	B-X
release	B-X
by	B-X
mast	B-X
cells	B-X
.	B-X
DMSO	B-X
's	B-X
systemic	B-X
toxicity	B-X
is	B-X
considered	B-X
to	B-X
be	B-X
low	B-X
.	B-X
Combinations	B-X
of	B-X
DMSO	B-X
with	B-X
other	B-X
toxic	B-X
agents	B-X
probably	B-X
constitute	B-X
its	B-X
greatest	B-X
toxic	B-X
potential	B-X
.	B-X
The	B-X
scientific	B-X
literature	B-X
is	B-X
reviewed	B-X
with	B-X
particular	B-X
attention	B-X
to	B-X
mechanisms	B-X
underlying	B-X
DMSO	B-X
's	B-X
reported	B-X
therapeutic	B-X
and	B-X
toxic	B-X
effects	B-X
.	B-X
Currently	B-X
approved	B-X
,	B-X
veterinary	B-X
applications	B-X
of	B-X
DMSO	B-X
are	B-X
limited	B-X
.	B-X
DMSO	B-X
's	B-X
potential	B-X
value	B-X
in	B-X
specific	B-X
,	B-X
approved	B-X
and	B-X
unapproved	B-X
veterinary	B-X
applications	B-X
is	B-X
discussed	B-X
.	B-X

In	O
contrast	O
,	O
treatment	O
of	O
HL	O
-	O
60	O
cells	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
,	O
which	O
results	O
in	O
a	O
granulocytic	O
differentiation	O
of	O
these	O
cells	O
,	O
decreases	O
4E	B-Protein
-	I-Protein
BP1	I-Protein
amount	O
without	O
affecting	O
its	O
phosphorylation	O
and	O
strongly	O
increases	O
4E	B-Protein
-	I-Protein
BP2	I-Protein
amount	O
.	O
<EOS>	B-X
They	B-X
could	B-X
be	B-X
important	B-X
in	B-X
neutrophils	B-X
for	B-X
handling	B-X
the	B-X
large	B-X
amount	B-X
of	B-X
oxidants	B-X
that	B-X
these	B-X
cells	B-X
produce	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
redox	B-X
state	B-X
of	B-X
Prx1	B-X
and	B-X
Prx2	B-X
in	B-X
HL-60	B-X
promyelocytic	B-X
cells	B-X
differentiated	B-X
to	B-X
neutrophil-like	B-X
cells	B-X
(	B-X
dHL-60	B-X
)	B-X
and	B-X
in	B-X
human	B-X
neutrophils	B-X
.	B-X
HL-60	B-X
cell	B-X
differentiation	B-X
with	B-X
dimethyl	B-X
sulfoxide	B-X
caused	B-X
a	B-X
large	B-X
decrease	B-X
in	B-X
expression	B-X
of	B-X
both	B-X
Prxs	B-X
,	B-X
and	B-X
all-trans	B-X
retinoic	B-X
acid	B-X
also	B-X
decreased	B-X
Prx1	B-X
expression	B-X
.	B-X
Prx1	B-X
was	B-X
mostly	B-X
reduced	B-X
in	B-X
dHL-60	B-X
cells	B-X
.	B-X
The	B-X
NADPH	B-X
oxidase	B-X
inhibitor	B-X
,	B-X
diphenyleneiodonium	B-X
,	B-X
prevented	B-X
Prx1	B-X
dimerization	B-X
in	B-X
stimulated	B-X
dHL-60	B-X
cells	B-X
,	B-X
and	B-X
decreased	B-X
the	B-X
extent	B-X
of	B-X
oxidation	B-X
under	B-X
resting	B-X
conditions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Prx1	B-X
and	B-X
Prx2	B-X
were	B-X
present	B-X
in	B-X
neutrophils	B-X
from	B-X
human	B-X
blood	B-X
as	B-X
disulfides	B-X
,	B-X
and	B-X
PMA	B-X
or	B-X
S.	B-X
aureus	B-X
caused	B-X
no	B-X
further	B-X
oxidation	B-X
.	B-X
Although	B-X
this	B-X
suggests	B-X
that	B-X
Prx	B-X
redox	B-X
cycling	B-X
could	B-X
be	B-X
deficient	B-X
in	B-X
neutrophils	B-X
,	B-X
thioredoxin	B-X
expression	B-X
and	B-X
thioredoxin	B-X
reductase	B-X
activity	B-X
were	B-X
similar	B-X
in	B-X
neutrophils	B-X
and	B-X
dHL-60	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
although	B-X
the	B-X
Prxs	B-X
respond	B-X
to	B-X
oxidant	B-X
generation	B-X
in	B-X
dHL-60	B-X
cells	B-X
,	B-X
in	B-X
neutrophils	B-X
they	B-X
appear	B-X
``	B-X
locked	B-X
''	B-X
as	B-X
disulfides	B-X
.	B-X

Taken	O
together	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
translational	O
machinery	O
during	O
human	O
myeloid	O
differentiation	O
,	O
specific	O
to	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
or	O
to	O
the	O
granulocytic	O
pathway	O
.	O

Stimulation	O
of	O
CD40	B-Protein
on	O
immunogenic	O
human	O
malignant	O
melanomas	O
augments	O
their	O
cytotoxic	O
T	O
lymphocyte	O
-	O
mediated	O
lysis	O
and	O
induces	O
apoptosis	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
functional	B-X
expression	B-X
of	B-X
CD40	B-X
on	B-X
human	B-X
malignant	B-X
melanomas	B-X
(	B-X
MMs	B-X
)	B-X
.	B-X
Comparison	B-X
of	B-X
tumor	B-X
specimen	B-X
from	B-X
MM	B-X
precursor	B-X
lesions	B-X
,	B-X
primary	B-X
tumors	B-X
,	B-X
and	B-X
metastases	B-X
revealed	B-X
that	B-X
CD40	B-X
surface	B-X
expression	B-X
is	B-X
down-regulated	B-X
during	B-X
tumor	B-X
progression	B-X
.	B-X
CD40	B-X
expression	B-X
was	B-X
confirmed	B-X
in	B-X
7	B-X
human	B-X
MM	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
immunogenic	B-X
primary	B-X
tumors	B-X
or	B-X
metastases	B-X
,	B-X
whereas	B-X
11	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
advanced	B-X
stages	B-X
were	B-X
CD40	B-X
negative	B-X
.	B-X
CD40	B-X
expression	B-X
could	B-X
be	B-X
enhanced	B-X
in	B-X
CD40-positive	B-X
MM	B-X
by	B-X
stimulation	B-X
with	B-X
IFN-gamma	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
but	B-X
not	B-X
by	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1beta	B-X
or	B-X
CD40	B-X
triggering	B-X
.	B-X
CD40	B-X
ligation	B-X
on	B-X
MM	B-X
by	B-X
CD40L-transfected	B-X
murine	B-X
L-cells	B-X
or	B-X
by	B-X
a	B-X
soluble	B-X
CD40L	B-X
fusion	B-X
protein	B-X
up-regulated	B-X
their	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
and	B-X
MHC	B-X
class	B-X
I	B-X
and	B-X
class	B-X
II	B-X
molecules	B-X
and	B-X
their	B-X
secretion	B-X
of	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-a	B-X
,	B-X
and	B-X
granulocyte	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
and	B-X
also	B-X
induced	B-X
a	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
CD40	B-X
ligation	B-X
of	B-X
a	B-X
HLA-A2+	B-X
,	B-X
MelanA/MART1+	B-X
MM	B-X
cell	B-X
line	B-X
enhanced	B-X
its	B-X
susceptibility	B-X
to	B-X
specific	B-X
lysis	B-X
by	B-X
a	B-X
HLA-A2-restricted	B-X
,	B-X
MelanA/MART-1-specific	B-X
CTL	B-X
clone	B-X
.	B-X
Finally	B-X
,	B-X
CD40	B-X
ligation	B-X
induced	B-X
growth	B-X
inhibition	B-X
and	B-X
apoptosis	B-X
in	B-X
MM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
CD40-CD40L	B-X
interactions	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
augmenting	B-X
antitumor	B-X
immunity	B-X
and	B-X
inducing	B-X
apoptosis	B-X
in	B-X
some	B-X
CD40-positive	B-X
immunogenic	B-X
human	B-X
MMs	B-X
.	B-X

Here	O
,	O
we	O
report	O
the	O
functional	O
expression	O
of	O
CD40	B-Protein
on	O
human	O
malignant	O
melanomas	O
(	O
MMs	O
)	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
functional	B-X
expression	B-X
of	B-X
CD40	B-X
on	B-X
human	B-X
malignant	B-X
melanomas	B-X
(	B-X
MMs	B-X
)	B-X
.	B-X
Comparison	B-X
of	B-X
tumor	B-X
specimen	B-X
from	B-X
MM	B-X
precursor	B-X
lesions	B-X
,	B-X
primary	B-X
tumors	B-X
,	B-X
and	B-X
metastases	B-X
revealed	B-X
that	B-X
CD40	B-X
surface	B-X
expression	B-X
is	B-X
down-regulated	B-X
during	B-X
tumor	B-X
progression	B-X
.	B-X
CD40	B-X
expression	B-X
was	B-X
confirmed	B-X
in	B-X
7	B-X
human	B-X
MM	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
immunogenic	B-X
primary	B-X
tumors	B-X
or	B-X
metastases	B-X
,	B-X
whereas	B-X
11	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
advanced	B-X
stages	B-X
were	B-X
CD40	B-X
negative	B-X
.	B-X
CD40	B-X
expression	B-X
could	B-X
be	B-X
enhanced	B-X
in	B-X
CD40-positive	B-X
MM	B-X
by	B-X
stimulation	B-X
with	B-X
IFN-gamma	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
but	B-X
not	B-X
by	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1beta	B-X
or	B-X
CD40	B-X
triggering	B-X
.	B-X
CD40	B-X
ligation	B-X
on	B-X
MM	B-X
by	B-X
CD40L-transfected	B-X
murine	B-X
L-cells	B-X
or	B-X
by	B-X
a	B-X
soluble	B-X
CD40L	B-X
fusion	B-X
protein	B-X
up-regulated	B-X
their	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
and	B-X
MHC	B-X
class	B-X
I	B-X
and	B-X
class	B-X
II	B-X
molecules	B-X
and	B-X
their	B-X
secretion	B-X
of	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-a	B-X
,	B-X
and	B-X
granulocyte	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
and	B-X
also	B-X
induced	B-X
a	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
CD40	B-X
ligation	B-X
of	B-X
a	B-X
HLA-A2+	B-X
,	B-X
MelanA/MART1+	B-X
MM	B-X
cell	B-X
line	B-X
enhanced	B-X
its	B-X
susceptibility	B-X
to	B-X
specific	B-X
lysis	B-X
by	B-X
a	B-X
HLA-A2-restricted	B-X
,	B-X
MelanA/MART-1-specific	B-X
CTL	B-X
clone	B-X
.	B-X
Finally	B-X
,	B-X
CD40	B-X
ligation	B-X
induced	B-X
growth	B-X
inhibition	B-X
and	B-X
apoptosis	B-X
in	B-X
MM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
CD40-CD40L	B-X
interactions	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
augmenting	B-X
antitumor	B-X
immunity	B-X
and	B-X
inducing	B-X
apoptosis	B-X
in	B-X
some	B-X
CD40-positive	B-X
immunogenic	B-X
human	B-X
MMs	B-X
.	B-X

Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	B-Protein
surface	O
expression	O
is	O
down	O
-	O
regulated	O
during	O
tumor	O
progression	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
functional	B-X
expression	B-X
of	B-X
CD40	B-X
on	B-X
human	B-X
malignant	B-X
melanomas	B-X
(	B-X
MMs	B-X
)	B-X
.	B-X
Comparison	B-X
of	B-X
tumor	B-X
specimen	B-X
from	B-X
MM	B-X
precursor	B-X
lesions	B-X
,	B-X
primary	B-X
tumors	B-X
,	B-X
and	B-X
metastases	B-X
revealed	B-X
that	B-X
CD40	B-X
surface	B-X
expression	B-X
is	B-X
down-regulated	B-X
during	B-X
tumor	B-X
progression	B-X
.	B-X
CD40	B-X
expression	B-X
was	B-X
confirmed	B-X
in	B-X
7	B-X
human	B-X
MM	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
immunogenic	B-X
primary	B-X
tumors	B-X
or	B-X
metastases	B-X
,	B-X
whereas	B-X
11	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
advanced	B-X
stages	B-X
were	B-X
CD40	B-X
negative	B-X
.	B-X
CD40	B-X
expression	B-X
could	B-X
be	B-X
enhanced	B-X
in	B-X
CD40-positive	B-X
MM	B-X
by	B-X
stimulation	B-X
with	B-X
IFN-gamma	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
but	B-X
not	B-X
by	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1beta	B-X
or	B-X
CD40	B-X
triggering	B-X
.	B-X
CD40	B-X
ligation	B-X
on	B-X
MM	B-X
by	B-X
CD40L-transfected	B-X
murine	B-X
L-cells	B-X
or	B-X
by	B-X
a	B-X
soluble	B-X
CD40L	B-X
fusion	B-X
protein	B-X
up-regulated	B-X
their	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
and	B-X
MHC	B-X
class	B-X
I	B-X
and	B-X
class	B-X
II	B-X
molecules	B-X
and	B-X
their	B-X
secretion	B-X
of	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-a	B-X
,	B-X
and	B-X
granulocyte	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
and	B-X
also	B-X
induced	B-X
a	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
CD40	B-X
ligation	B-X
of	B-X
a	B-X
HLA-A2+	B-X
,	B-X
MelanA/MART1+	B-X
MM	B-X
cell	B-X
line	B-X
enhanced	B-X
its	B-X
susceptibility	B-X
to	B-X
specific	B-X
lysis	B-X
by	B-X
a	B-X
HLA-A2-restricted	B-X
,	B-X
MelanA/MART-1-specific	B-X
CTL	B-X
clone	B-X
.	B-X
Finally	B-X
,	B-X
CD40	B-X
ligation	B-X
induced	B-X
growth	B-X
inhibition	B-X
and	B-X
apoptosis	B-X
in	B-X
MM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
CD40-CD40L	B-X
interactions	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
augmenting	B-X
antitumor	B-X
immunity	B-X
and	B-X
inducing	B-X
apoptosis	B-X
in	B-X
some	B-X
CD40-positive	B-X
immunogenic	B-X
human	B-X
MMs	B-X
.	B-X

CD40	B-Protein
expression	O
was	O
confirmed	O
in	O
7	O
human	O
MM	O
cell	O
lines	O
established	O
from	O
immunogenic	O
primary	O
tumors	O
or	O
metastases	O
,	O
whereas	O
11	O
cell	O
lines	O
established	O
from	O
advanced	O
stages	O
were	O
CD40	B-Protein
negative	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
functional	B-X
expression	B-X
of	B-X
CD40	B-X
on	B-X
human	B-X
malignant	B-X
melanomas	B-X
(	B-X
MMs	B-X
)	B-X
.	B-X
Comparison	B-X
of	B-X
tumor	B-X
specimen	B-X
from	B-X
MM	B-X
precursor	B-X
lesions	B-X
,	B-X
primary	B-X
tumors	B-X
,	B-X
and	B-X
metastases	B-X
revealed	B-X
that	B-X
CD40	B-X
surface	B-X
expression	B-X
is	B-X
down-regulated	B-X
during	B-X
tumor	B-X
progression	B-X
.	B-X
CD40	B-X
expression	B-X
was	B-X
confirmed	B-X
in	B-X
7	B-X
human	B-X
MM	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
immunogenic	B-X
primary	B-X
tumors	B-X
or	B-X
metastases	B-X
,	B-X
whereas	B-X
11	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
advanced	B-X
stages	B-X
were	B-X
CD40	B-X
negative	B-X
.	B-X
CD40	B-X
expression	B-X
could	B-X
be	B-X
enhanced	B-X
in	B-X
CD40-positive	B-X
MM	B-X
by	B-X
stimulation	B-X
with	B-X
IFN-gamma	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
but	B-X
not	B-X
by	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1beta	B-X
or	B-X
CD40	B-X
triggering	B-X
.	B-X
CD40	B-X
ligation	B-X
on	B-X
MM	B-X
by	B-X
CD40L-transfected	B-X
murine	B-X
L-cells	B-X
or	B-X
by	B-X
a	B-X
soluble	B-X
CD40L	B-X
fusion	B-X
protein	B-X
up-regulated	B-X
their	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
and	B-X
MHC	B-X
class	B-X
I	B-X
and	B-X
class	B-X
II	B-X
molecules	B-X
and	B-X
their	B-X
secretion	B-X
of	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-a	B-X
,	B-X
and	B-X
granulocyte	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
and	B-X
also	B-X
induced	B-X
a	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
CD40	B-X
ligation	B-X
of	B-X
a	B-X
HLA-A2+	B-X
,	B-X
MelanA/MART1+	B-X
MM	B-X
cell	B-X
line	B-X
enhanced	B-X
its	B-X
susceptibility	B-X
to	B-X
specific	B-X
lysis	B-X
by	B-X
a	B-X
HLA-A2-restricted	B-X
,	B-X
MelanA/MART-1-specific	B-X
CTL	B-X
clone	B-X
.	B-X
Finally	B-X
,	B-X
CD40	B-X
ligation	B-X
induced	B-X
growth	B-X
inhibition	B-X
and	B-X
apoptosis	B-X
in	B-X
MM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
CD40-CD40L	B-X
interactions	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
augmenting	B-X
antitumor	B-X
immunity	B-X
and	B-X
inducing	B-X
apoptosis	B-X
in	B-X
some	B-X
CD40-positive	B-X
immunogenic	B-X
human	B-X
MMs	B-X
.	B-X

CD40	B-Protein
expression	O
could	O
be	O
enhanced	O
in	O
CD40	B-Protein
-	O
positive	O
MM	O
by	O
stimulation	O
with	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
but	O
not	O
by	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
1beta	I-Protein
or	O
CD40	B-Protein
triggering	O
.	O
<EOS>	B-X
CD40	B-X
is	B-X
a	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
member	B-X
expressed	B-X
on	B-X
both	B-X
immune	B-X
and	B-X
non-immune	B-X
cells	B-X
.	B-X
Interactions	B-X
between	B-X
B	B-X
cell-expressed	B-X
CD40	B-X
and	B-X
its	B-X
binding	B-X
partner	B-X
,	B-X
CD40L	B-X
,	B-X
predominantly	B-X
expressed	B-X
on	B-X
activated	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
promoting	B-X
germinal	B-X
center	B-X
formation	B-X
and	B-X
the	B-X
production	B-X
of	B-X
class-switched	B-X
antibodies	B-X
.	B-X
Non-hematopoietic	B-X
cells	B-X
expressing	B-X
CD40	B-X
can	B-X
also	B-X
engage	B-X
CD40L	B-X
and	B-X
trigger	B-X
a	B-X
pro-inflammatory	B-X
response	B-X
.	B-X
This	B-X
article	B-X
will	B-X
highlight	B-X
what	B-X
is	B-X
known	B-X
about	B-X
the	B-X
biology	B-X
of	B-X
the	B-X
CD40-CD40L	B-X
axis	B-X
in	B-X
humans	B-X
and	B-X
describe	B-X
the	B-X
potential	B-X
contribution	B-X
of	B-X
CD40	B-X
signaling	B-X
on	B-X
both	B-X
hematopoietic	B-X
and	B-X
non-hematopoietic	B-X
cells	B-X
to	B-X
autoimmune	B-X
disease	B-X
pathogenesis	B-X
.	B-X

CD40	B-Protein
ligation	O
on	O
MM	O
by	O
CD40L	B-Protein
-	O
transfected	O
murine	O
L	O
-	O
cells	O
or	O
by	O
a	O
soluble	O
CD40L	B-Protein
fusion	O
protein	O
up	O
-	O
regulated	O
their	O
expression	O
of	O
intercellular	B-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	I-Protein
and	O
MHC	O
class	O
I	O
and	O
class	O
II	O
molecules	O
and	O
their	O
secretion	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
a	I-Protein
,	O
and	O
granulocyte	B-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
and	O
also	O
induced	O
a	O
rapid	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappaB	O
.	O
<EOS>	B-X
While	B-X
CD40-CD40	B-X
ligand	B-X
interactions	B-X
are	B-X
known	B-X
to	B-X
regulate	B-X
B	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
,	B-X
much	B-X
less	B-X
is	B-X
known	B-X
about	B-X
the	B-X
role	B-X
this	B-X
receptor	B-X
plays	B-X
on	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
especially	B-X
those	B-X
of	B-X
nonhemopoietic	B-X
origin	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
CD40	B-X
is	B-X
expressed	B-X
in	B-X
normal	B-X
human	B-X
epidermis	B-X
in	B-X
situ	B-X
,	B-X
especially	B-X
on	B-X
the	B-X
basal	B-X
cell	B-X
layer	B-X
,	B-X
and	B-X
that	B-X
it	B-X
is	B-X
maintained	B-X
on	B-X
cultured	B-X
epidermal	B-X
basal	B-X
cells	B-X
.	B-X
Immunoprecipitation	B-X
and	B-X
SDS-PAGE	B-X
analysis	B-X
confirms	B-X
that	B-X
CD40	B-X
expressed	B-X
by	B-X
epidermal	B-X
basal	B-X
cells	B-X
is	B-X
immunologically	B-X
related	B-X
to	B-X
the	B-X
B	B-X
cell	B-X
CD40	B-X
.	B-X
IFN-gamma	B-X
up-regulates	B-X
CD40	B-X
expression	B-X
on	B-X
cultured	B-X
keratinocytes	B-X
,	B-X
whereas	B-X
other	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
such	B-X
as	B-X
IL-1	B-X
or	B-X
TNF-alpha	B-X
,	B-X
have	B-X
little	B-X
effects	B-X
.	B-X
Using	B-X
CD40-ligand-transfected	B-X
L	B-X
cells	B-X
(	B-X
CD40Lc	B-X
)	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
CD40	B-X
triggering	B-X
results	B-X
in	B-X
an	B-X
enhanced	B-X
secretion	B-X
of	B-X
both	B-X
IL-8	B-X
and	B-X
TNF-alpha	B-X
by	B-X
cultured	B-X
epidermal	B-X
basal	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
CD40-CD40L	B-X
interactions	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
amplifying	B-X
the	B-X
cutaneous	B-X
inflammatory	B-X
reactions	B-X
.	B-X
More	B-X
importantly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
keratinocyte	B-X
proliferation	B-X
was	B-X
significantly	B-X
inhibited	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
grown	B-X
on	B-X
CD40Lc	B-X
,	B-X
as	B-X
compared	B-X
with	B-X
CD32-transfected	B-X
,	B-X
or	B-X
nontransfected	B-X
,	B-X
L	B-X
cells	B-X
.	B-X
This	B-X
inhibitory	B-X
effect	B-X
can	B-X
be	B-X
reversed	B-X
substantially	B-X
by	B-X
pretreatment	B-X
of	B-X
keratinocytes	B-X
with	B-X
anti-CD40	B-X
mAb	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
inhibition	B-X
of	B-X
proliferation	B-X
could	B-X
be	B-X
obtained	B-X
by	B-X
adding	B-X
a	B-X
soluble	B-X
form	B-X
of	B-X
CD40	B-X
ligand	B-X
to	B-X
the	B-X
keratinocyte	B-X
cultures	B-X
.	B-X
Interestingly	B-X
,	B-X
inhibition	B-X
of	B-X
keratinocyte	B-X
proliferation	B-X
on	B-X
CD40Lc	B-X
correlates	B-X
with	B-X
differentiation	B-X
of	B-X
the	B-X
cells	B-X
,	B-X
as	B-X
assessed	B-X
by	B-X
morphologic	B-X
analysis	B-X
and	B-X
increased	B-X
profilaggrin	B-X
content	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
demonstrate	B-X
that	B-X
CD40	B-X
is	B-X
expressed	B-X
and	B-X
functional	B-X
on	B-X
human	B-X
epidermal	B-X
basal	B-X
cells	B-X
and	B-X
that	B-X
,	B-X
on	B-X
these	B-X
cells	B-X
,	B-X
CD40	B-X
ligation	B-X
may	B-X
be	B-X
a	B-X
signal	B-X
for	B-X
limitation	B-X
of	B-X
cell	B-X
growth	B-X
and	B-X
induction	B-X
of	B-X
differentiation	B-X
.	B-X

Furthermore	O
,	O
CD40	B-Protein
ligation	O
of	O
a	O
HLA	B-Protein
-	I-Protein
A2	I-Protein
+	O
,	O
MelanA	B-Protein
/	O
MART1	B-Protein
+	O
MM	O
cell	O
line	O
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA	B-Protein
-	I-Protein
A2	I-Protein
-	O
restricted	O
,	O
MelanA	B-Protein
/	O
MART	B-Protein
-	I-Protein
1	I-Protein
-	O
specific	O
CTL	O
clone	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
functional	B-X
expression	B-X
of	B-X
CD40	B-X
on	B-X
human	B-X
malignant	B-X
melanomas	B-X
(	B-X
MMs	B-X
)	B-X
.	B-X
Comparison	B-X
of	B-X
tumor	B-X
specimen	B-X
from	B-X
MM	B-X
precursor	B-X
lesions	B-X
,	B-X
primary	B-X
tumors	B-X
,	B-X
and	B-X
metastases	B-X
revealed	B-X
that	B-X
CD40	B-X
surface	B-X
expression	B-X
is	B-X
down-regulated	B-X
during	B-X
tumor	B-X
progression	B-X
.	B-X
CD40	B-X
expression	B-X
was	B-X
confirmed	B-X
in	B-X
7	B-X
human	B-X
MM	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
immunogenic	B-X
primary	B-X
tumors	B-X
or	B-X
metastases	B-X
,	B-X
whereas	B-X
11	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
advanced	B-X
stages	B-X
were	B-X
CD40	B-X
negative	B-X
.	B-X
CD40	B-X
expression	B-X
could	B-X
be	B-X
enhanced	B-X
in	B-X
CD40-positive	B-X
MM	B-X
by	B-X
stimulation	B-X
with	B-X
IFN-gamma	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
but	B-X
not	B-X
by	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1beta	B-X
or	B-X
CD40	B-X
triggering	B-X
.	B-X
CD40	B-X
ligation	B-X
on	B-X
MM	B-X
by	B-X
CD40L-transfected	B-X
murine	B-X
L-cells	B-X
or	B-X
by	B-X
a	B-X
soluble	B-X
CD40L	B-X
fusion	B-X
protein	B-X
up-regulated	B-X
their	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
and	B-X
MHC	B-X
class	B-X
I	B-X
and	B-X
class	B-X
II	B-X
molecules	B-X
and	B-X
their	B-X
secretion	B-X
of	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-a	B-X
,	B-X
and	B-X
granulocyte	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
and	B-X
also	B-X
induced	B-X
a	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
CD40	B-X
ligation	B-X
of	B-X
a	B-X
HLA-A2+	B-X
,	B-X
MelanA/MART1+	B-X
MM	B-X
cell	B-X
line	B-X
enhanced	B-X
its	B-X
susceptibility	B-X
to	B-X
specific	B-X
lysis	B-X
by	B-X
a	B-X
HLA-A2-restricted	B-X
,	B-X
MelanA/MART-1-specific	B-X
CTL	B-X
clone	B-X
.	B-X
Finally	B-X
,	B-X
CD40	B-X
ligation	B-X
induced	B-X
growth	B-X
inhibition	B-X
and	B-X
apoptosis	B-X
in	B-X
MM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
CD40-CD40L	B-X
interactions	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
augmenting	B-X
antitumor	B-X
immunity	B-X
and	B-X
inducing	B-X
apoptosis	B-X
in	B-X
some	B-X
CD40-positive	B-X
immunogenic	B-X
human	B-X
MMs	B-X
.	B-X

Finally	O
,	O
CD40	B-Protein
ligation	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
MM	O
.	O
<EOS>	B-X
B	B-X
cells	B-X
are	B-X
induced	B-X
to	B-X
enter	B-X
the	B-X
cell	B-X
cycle	B-X
by	B-X
stimuli	B-X
including	B-X
ligation	B-X
of	B-X
the	B-X
B-cell	B-X
receptor	B-X
(	B-X
BCR	B-X
)	B-X
complex	B-X
and	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
agonists	B-X
.	B-X
The	B-X
adapter	B-X
molecule	B-X
Bam32	B-X
(	B-X
B-lymphocyte	B-X
adapter	B-X
of	B-X
32	B-X
kDa	B-X
)	B-X
helps	B-X
promote	B-X
BCR-induced	B-X
cell	B-X
cycle	B-X
entry	B-X
,	B-X
while	B-X
the	B-X
secondary	B-X
messenger	B-X
superoxide	B-X
has	B-X
the	B-X
opposite	B-X
effect	B-X
.	B-X
Bam32	B-X
and	B-X
superoxide	B-X
may	B-X
fine	B-X
tune	B-X
BCR-induced	B-X
activation	B-X
by	B-X
competing	B-X
for	B-X
the	B-X
same	B-X
limited	B-X
resources	B-X
,	B-X
namely	B-X
Rac1	B-X
and	B-X
the	B-X
plasma	B-X
membrane	B-X
phospholipid	B-X
PI	B-X
(	B-X
3,4	B-X
)	B-X
P	B-X
(	B-X
2	B-X
)	B-X
.	B-X
The	B-X
co-receptor	B-X
CD22	B-X
can	B-X
inhibit	B-X
BCR-induced	B-X
proliferation	B-X
by	B-X
binding	B-X
to	B-X
novel	B-X
CD22	B-X
ligands	B-X
.	B-X
Finally	B-X
,	B-X
regulators	B-X
of	B-X
B-cell	B-X
survival	B-X
and	B-X
death	B-X
also	B-X
play	B-X
roles	B-X
in	B-X
B-cell	B-X
transit	B-X
through	B-X
the	B-X
cell	B-X
cycle	B-X
.	B-X
Caspase	B-X
6	B-X
negatively	B-X
regulates	B-X
CD40-	B-X
and	B-X
TLR-dependent	B-X
G	B-X
(	B-X
1	B-X
)	B-X
entry	B-X
,	B-X
while	B-X
acting	B-X
later	B-X
in	B-X
the	B-X
cell	B-X
cycle	B-X
to	B-X
promote	B-X
S-phase	B-X
entry	B-X
.	B-X

These	O
results	O
indicate	O
that	O
CD40	B-Protein
-	O
CD40L	B-Protein
interactions	O
may	O
play	O
an	O
important	O
role	O
in	O
augmenting	O
antitumor	O
immunity	O
and	O
inducing	O
apoptosis	O
in	O
some	O
CD40	B-Protein
-	O
positive	O
immunogenic	O
human	O
MMs	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
the	B-X
functional	B-X
expression	B-X
of	B-X
CD40	B-X
on	B-X
human	B-X
malignant	B-X
melanomas	B-X
(	B-X
MMs	B-X
)	B-X
.	B-X
Comparison	B-X
of	B-X
tumor	B-X
specimen	B-X
from	B-X
MM	B-X
precursor	B-X
lesions	B-X
,	B-X
primary	B-X
tumors	B-X
,	B-X
and	B-X
metastases	B-X
revealed	B-X
that	B-X
CD40	B-X
surface	B-X
expression	B-X
is	B-X
down-regulated	B-X
during	B-X
tumor	B-X
progression	B-X
.	B-X
CD40	B-X
expression	B-X
was	B-X
confirmed	B-X
in	B-X
7	B-X
human	B-X
MM	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
immunogenic	B-X
primary	B-X
tumors	B-X
or	B-X
metastases	B-X
,	B-X
whereas	B-X
11	B-X
cell	B-X
lines	B-X
established	B-X
from	B-X
advanced	B-X
stages	B-X
were	B-X
CD40	B-X
negative	B-X
.	B-X
CD40	B-X
expression	B-X
could	B-X
be	B-X
enhanced	B-X
in	B-X
CD40-positive	B-X
MM	B-X
by	B-X
stimulation	B-X
with	B-X
IFN-gamma	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
but	B-X
not	B-X
by	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1beta	B-X
or	B-X
CD40	B-X
triggering	B-X
.	B-X
CD40	B-X
ligation	B-X
on	B-X
MM	B-X
by	B-X
CD40L-transfected	B-X
murine	B-X
L-cells	B-X
or	B-X
by	B-X
a	B-X
soluble	B-X
CD40L	B-X
fusion	B-X
protein	B-X
up-regulated	B-X
their	B-X
expression	B-X
of	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
and	B-X
MHC	B-X
class	B-X
I	B-X
and	B-X
class	B-X
II	B-X
molecules	B-X
and	B-X
their	B-X
secretion	B-X
of	B-X
IL-6	B-X
,	B-X
IL-8	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-a	B-X
,	B-X
and	B-X
granulocyte	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
and	B-X
also	B-X
induced	B-X
a	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
CD40	B-X
ligation	B-X
of	B-X
a	B-X
HLA-A2+	B-X
,	B-X
MelanA/MART1+	B-X
MM	B-X
cell	B-X
line	B-X
enhanced	B-X
its	B-X
susceptibility	B-X
to	B-X
specific	B-X
lysis	B-X
by	B-X
a	B-X
HLA-A2-restricted	B-X
,	B-X
MelanA/MART-1-specific	B-X
CTL	B-X
clone	B-X
.	B-X
Finally	B-X
,	B-X
CD40	B-X
ligation	B-X
induced	B-X
growth	B-X
inhibition	B-X
and	B-X
apoptosis	B-X
in	B-X
MM	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
CD40-CD40L	B-X
interactions	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
augmenting	B-X
antitumor	B-X
immunity	B-X
and	B-X
inducing	B-X
apoptosis	B-X
in	B-X
some	B-X
CD40-positive	B-X
immunogenic	B-X
human	B-X
MMs	B-X
.	B-X

Essential	O
role	O
of	O
alveolar	O
macrophages	O
in	O
intrapulmonary	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
Acute	B-X
inflammatory	B-X
injury	B-X
in	B-X
rat	B-X
lung	B-X
induced	B-X
by	B-X
deposition	B-X
of	B-X
immunoglobulin	B-X
G	B-X
immune	B-X
complexes	B-X
requires	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
chemokines	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
.	B-X
There	B-X
is	B-X
little	B-X
direct	B-X
evidence	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
alveolar	B-X
macrophages	B-X
in	B-X
these	B-X
activation	B-X
events	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
rat	B-X
lungs	B-X
were	B-X
depleted	B-X
of	B-X
alveolar	B-X
macrophages	B-X
by	B-X
airway	B-X
instillation	B-X
of	B-X
liposome-encapsulated	B-X
dichloromethylene	B-X
diphosphonate	B-X
.	B-X
These	B-X
procedures	B-X
,	B-X
which	B-X
greatly	B-X
reduced	B-X
the	B-X
number	B-X
of	B-X
retrievable	B-X
alveolar	B-X
macrophages	B-X
,	B-X
suppressed	B-X
activation	B-X
of	B-X
lung	B-X
NF-kappaB	B-X
in	B-X
the	B-X
inflammatory	B-X
model	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
bronchoalveolar	B-X
lavage	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
the	B-X
CXC	B-X
chemokine	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
,	B-X
were	B-X
substantially	B-X
reduced	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
upregulation	B-X
of	B-X
the	B-X
lung	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
,	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
,	B-X
was	B-X
greatly	B-X
reduced	B-X
by	B-X
intrapulmonary	B-X
instillation	B-X
of	B-X
phosphonate-containing	B-X
liposomes	B-X
.	B-X
Lung	B-X
instillation	B-X
of	B-X
TNF-alpha	B-X
in	B-X
alveolar	B-X
macrophage-depleted	B-X
rats	B-X
restored	B-X
the	B-X
NF-kappaB	B-X
activation	B-X
response	B-X
in	B-X
whole	B-X
lung	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
this	B-X
inflammatory	B-X
model	B-X
,	B-X
initial	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
in	B-X
alveolar	B-X
macrophages	B-X
and	B-X
the	B-X
ensuing	B-X
production	B-X
of	B-X
TNF-alpha	B-X
may	B-X
propagate	B-X
NF-kappaB	B-X
activation	B-X
to	B-X
other	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

Acute	O
inflammatory	O
injury	O
in	O
rat	O
lung	O
induced	O
by	O
deposition	O
of	O
immunoglobulin	O
G	O
immune	O
complexes	O
requires	O
expression	O
of	O
cytokines	O
and	O
chemokines	O
as	O
well	O
as	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
.	O
<EOS>	B-X
Acute	B-X
inflammatory	B-X
injury	B-X
in	B-X
rat	B-X
lung	B-X
induced	B-X
by	B-X
deposition	B-X
of	B-X
immunoglobulin	B-X
G	B-X
immune	B-X
complexes	B-X
requires	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
chemokines	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
.	B-X
There	B-X
is	B-X
little	B-X
direct	B-X
evidence	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
alveolar	B-X
macrophages	B-X
in	B-X
these	B-X
activation	B-X
events	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
rat	B-X
lungs	B-X
were	B-X
depleted	B-X
of	B-X
alveolar	B-X
macrophages	B-X
by	B-X
airway	B-X
instillation	B-X
of	B-X
liposome-encapsulated	B-X
dichloromethylene	B-X
diphosphonate	B-X
.	B-X
These	B-X
procedures	B-X
,	B-X
which	B-X
greatly	B-X
reduced	B-X
the	B-X
number	B-X
of	B-X
retrievable	B-X
alveolar	B-X
macrophages	B-X
,	B-X
suppressed	B-X
activation	B-X
of	B-X
lung	B-X
NF-kappaB	B-X
in	B-X
the	B-X
inflammatory	B-X
model	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
bronchoalveolar	B-X
lavage	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
the	B-X
CXC	B-X
chemokine	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
,	B-X
were	B-X
substantially	B-X
reduced	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
upregulation	B-X
of	B-X
the	B-X
lung	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
,	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
,	B-X
was	B-X
greatly	B-X
reduced	B-X
by	B-X
intrapulmonary	B-X
instillation	B-X
of	B-X
phosphonate-containing	B-X
liposomes	B-X
.	B-X
Neutrophil	B-X
accumulation	B-X
and	B-X
development	B-X
of	B-X
lung	B-X
injury	B-X
were	B-X
also	B-X
substantially	B-X
diminished	B-X
.	B-X
Lung	B-X
instillation	B-X
of	B-X
TNF-alpha	B-X
in	B-X
alveolar	B-X
macrophage-depleted	B-X
rats	B-X
restored	B-X
the	B-X
NF-kappaB	B-X
activation	B-X
response	B-X
in	B-X
whole	B-X
lung	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
this	B-X
inflammatory	B-X
model	B-X
,	B-X
initial	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
in	B-X
alveolar	B-X
macrophages	B-X
and	B-X
the	B-X
ensuing	B-X
production	B-X
of	B-X
TNF-alpha	B-X
may	B-X
propagate	B-X
NF-kappaB	B-X
activation	B-X
to	B-X
other	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

There	O
is	O
little	O
direct	O
evidence	O
regarding	O
the	O
role	O
of	O
alveolar	O
macrophages	O
in	O
these	O
activation	O
events	O
.	O
<EOS>	B-X
Acute	B-X
inflammatory	B-X
injury	B-X
in	B-X
rat	B-X
lung	B-X
induced	B-X
by	B-X
deposition	B-X
of	B-X
immunoglobulin	B-X
G	B-X
immune	B-X
complexes	B-X
requires	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
chemokines	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
.	B-X
There	B-X
is	B-X
little	B-X
direct	B-X
evidence	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
alveolar	B-X
macrophages	B-X
in	B-X
these	B-X
activation	B-X
events	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
rat	B-X
lungs	B-X
were	B-X
depleted	B-X
of	B-X
alveolar	B-X
macrophages	B-X
by	B-X
airway	B-X
instillation	B-X
of	B-X
liposome-encapsulated	B-X
dichloromethylene	B-X
diphosphonate	B-X
.	B-X
These	B-X
procedures	B-X
,	B-X
which	B-X
greatly	B-X
reduced	B-X
the	B-X
number	B-X
of	B-X
retrievable	B-X
alveolar	B-X
macrophages	B-X
,	B-X
suppressed	B-X
activation	B-X
of	B-X
lung	B-X
NF-kappaB	B-X
in	B-X
the	B-X
inflammatory	B-X
model	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
bronchoalveolar	B-X
lavage	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
the	B-X
CXC	B-X
chemokine	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
,	B-X
were	B-X
substantially	B-X
reduced	B-X
.	B-X
Lung	B-X
instillation	B-X
of	B-X
TNF-alpha	B-X
in	B-X
alveolar	B-X
macrophage-depleted	B-X
rats	B-X
restored	B-X
the	B-X
NF-kappaB	B-X
activation	B-X
response	B-X
in	B-X
whole	B-X
lung	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
this	B-X
inflammatory	B-X
model	B-X
,	B-X
initial	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
in	B-X
alveolar	B-X
macrophages	B-X
and	B-X
the	B-X
ensuing	B-X
production	B-X
of	B-X
TNF-alpha	B-X
may	B-X
propagate	B-X
NF-kappaB	B-X
activation	B-X
to	B-X
other	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

In	O
the	O
present	O
studies	O
,	O
rat	O
lungs	O
were	O
depleted	O
of	O
alveolar	O
macrophages	O
by	O
airway	O
instillation	O
of	O
liposome	O
-	O
encapsulated	O
dichloromethylene	O
diphosphonate	O
.	O
<EOS>	B-X
Acute	B-X
inflammatory	B-X
injury	B-X
in	B-X
rat	B-X
lung	B-X
induced	B-X
by	B-X
deposition	B-X
of	B-X
immunoglobulin	B-X
G	B-X
immune	B-X
complexes	B-X
requires	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
chemokines	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
.	B-X
There	B-X
is	B-X
little	B-X
direct	B-X
evidence	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
alveolar	B-X
macrophages	B-X
in	B-X
these	B-X
activation	B-X
events	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
rat	B-X
lungs	B-X
were	B-X
depleted	B-X
of	B-X
alveolar	B-X
macrophages	B-X
by	B-X
airway	B-X
instillation	B-X
of	B-X
liposome-encapsulated	B-X
dichloromethylene	B-X
diphosphonate	B-X
.	B-X
These	B-X
procedures	B-X
,	B-X
which	B-X
greatly	B-X
reduced	B-X
the	B-X
number	B-X
of	B-X
retrievable	B-X
alveolar	B-X
macrophages	B-X
,	B-X
suppressed	B-X
activation	B-X
of	B-X
lung	B-X
NF-kappaB	B-X
in	B-X
the	B-X
inflammatory	B-X
model	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
bronchoalveolar	B-X
lavage	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
the	B-X
CXC	B-X
chemokine	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
,	B-X
were	B-X
substantially	B-X
reduced	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
upregulation	B-X
of	B-X
the	B-X
lung	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
,	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
,	B-X
was	B-X
greatly	B-X
reduced	B-X
by	B-X
intrapulmonary	B-X
instillation	B-X
of	B-X
phosphonate-containing	B-X
liposomes	B-X
.	B-X
Lung	B-X
instillation	B-X
of	B-X
TNF-alpha	B-X
in	B-X
alveolar	B-X
macrophage-depleted	B-X
rats	B-X
restored	B-X
the	B-X
NF-kappaB	B-X
activation	B-X
response	B-X
in	B-X
whole	B-X
lung	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
this	B-X
inflammatory	B-X
model	B-X
,	B-X
initial	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
in	B-X
alveolar	B-X
macrophages	B-X
and	B-X
the	B-X
ensuing	B-X
production	B-X
of	B-X
TNF-alpha	B-X
may	B-X
propagate	B-X
NF-kappaB	B-X
activation	B-X
to	B-X
other	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

These	O
procedures	O
,	O
which	O
greatly	O
reduced	O
the	O
number	O
of	O
retrievable	O
alveolar	O
macrophages	O
,	O
suppressed	O
activation	O
of	O
lung	O
NF	O
-	O
kappaB	O
in	O
the	O
inflammatory	O
model	O
.	O
<EOS>	B-X
Acute	B-X
inflammatory	B-X
injury	B-X
in	B-X
rat	B-X
lung	B-X
induced	B-X
by	B-X
deposition	B-X
of	B-X
immunoglobulin	B-X
G	B-X
immune	B-X
complexes	B-X
requires	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
chemokines	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
.	B-X
There	B-X
is	B-X
little	B-X
direct	B-X
evidence	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
alveolar	B-X
macrophages	B-X
in	B-X
these	B-X
activation	B-X
events	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
rat	B-X
lungs	B-X
were	B-X
depleted	B-X
of	B-X
alveolar	B-X
macrophages	B-X
by	B-X
airway	B-X
instillation	B-X
of	B-X
liposome-encapsulated	B-X
dichloromethylene	B-X
diphosphonate	B-X
.	B-X
These	B-X
procedures	B-X
,	B-X
which	B-X
greatly	B-X
reduced	B-X
the	B-X
number	B-X
of	B-X
retrievable	B-X
alveolar	B-X
macrophages	B-X
,	B-X
suppressed	B-X
activation	B-X
of	B-X
lung	B-X
NF-kappaB	B-X
in	B-X
the	B-X
inflammatory	B-X
model	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
bronchoalveolar	B-X
lavage	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
the	B-X
CXC	B-X
chemokine	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
,	B-X
were	B-X
substantially	B-X
reduced	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
upregulation	B-X
of	B-X
the	B-X
lung	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
,	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
,	B-X
was	B-X
greatly	B-X
reduced	B-X
by	B-X
intrapulmonary	B-X
instillation	B-X
of	B-X
phosphonate-containing	B-X
liposomes	B-X
.	B-X
Neutrophil	B-X
accumulation	B-X
and	B-X
development	B-X
of	B-X
lung	B-X
injury	B-X
were	B-X
also	B-X
substantially	B-X
diminished	B-X
.	B-X
Lung	B-X
instillation	B-X
of	B-X
TNF-alpha	B-X
in	B-X
alveolar	B-X
macrophage-depleted	B-X
rats	B-X
restored	B-X
the	B-X
NF-kappaB	B-X
activation	B-X
response	B-X
in	B-X
whole	B-X
lung	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
this	B-X
inflammatory	B-X
model	B-X
,	B-X
initial	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
in	B-X
alveolar	B-X
macrophages	B-X
and	B-X
the	B-X
ensuing	B-X
production	B-X
of	B-X
TNF-alpha	B-X
may	B-X
propagate	B-X
NF-kappaB	B-X
activation	B-X
to	B-X
other	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

In	O
addition	O
,	O
bronchoalveolar	O
lavage	O
levels	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
and	O
the	O
CXC	O
chemokine	O
,	O
macrophage	B-Protein
inflammatory	I-Protein
protein	I-Protein
-	I-Protein
2	I-Protein
,	O
were	O
substantially	O
reduced	O
.	O
<EOS>	B-X
Acute	B-X
inflammatory	B-X
injury	B-X
in	B-X
rat	B-X
lung	B-X
induced	B-X
by	B-X
deposition	B-X
of	B-X
immunoglobulin	B-X
G	B-X
immune	B-X
complexes	B-X
requires	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
chemokines	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
.	B-X
There	B-X
is	B-X
little	B-X
direct	B-X
evidence	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
alveolar	B-X
macrophages	B-X
in	B-X
these	B-X
activation	B-X
events	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
rat	B-X
lungs	B-X
were	B-X
depleted	B-X
of	B-X
alveolar	B-X
macrophages	B-X
by	B-X
airway	B-X
instillation	B-X
of	B-X
liposome-encapsulated	B-X
dichloromethylene	B-X
diphosphonate	B-X
.	B-X
These	B-X
procedures	B-X
,	B-X
which	B-X
greatly	B-X
reduced	B-X
the	B-X
number	B-X
of	B-X
retrievable	B-X
alveolar	B-X
macrophages	B-X
,	B-X
suppressed	B-X
activation	B-X
of	B-X
lung	B-X
NF-kappaB	B-X
in	B-X
the	B-X
inflammatory	B-X
model	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
bronchoalveolar	B-X
lavage	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
the	B-X
CXC	B-X
chemokine	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
,	B-X
were	B-X
substantially	B-X
reduced	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
upregulation	B-X
of	B-X
the	B-X
lung	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
,	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
,	B-X
was	B-X
greatly	B-X
reduced	B-X
by	B-X
intrapulmonary	B-X
instillation	B-X
of	B-X
phosphonate-containing	B-X
liposomes	B-X
.	B-X
Neutrophil	B-X
accumulation	B-X
and	B-X
development	B-X
of	B-X
lung	B-X
injury	B-X
were	B-X
also	B-X
substantially	B-X
diminished	B-X
.	B-X
Lung	B-X
instillation	B-X
of	B-X
TNF-alpha	B-X
in	B-X
alveolar	B-X
macrophage-depleted	B-X
rats	B-X
restored	B-X
the	B-X
NF-kappaB	B-X
activation	B-X
response	B-X
in	B-X
whole	B-X
lung	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
this	B-X
inflammatory	B-X
model	B-X
,	B-X
initial	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
in	B-X
alveolar	B-X
macrophages	B-X
and	B-X
the	B-X
ensuing	B-X
production	B-X
of	B-X
TNF-alpha	B-X
may	B-X
propagate	B-X
NF-kappaB	B-X
activation	B-X
to	B-X
other	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

In	O
parallel	O
,	O
upregulation	O
of	O
the	O
lung	O
vascular	O
adhesion	O
molecule	O
,	O
intercellular	B-Protein
adhesion	I-Protein
molecule	I-Protein
-	I-Protein
1	I-Protein
,	O
was	O
greatly	O
reduced	O
by	O
intrapulmonary	O
instillation	O
of	O
phosphonate	O
-	O
containing	O
liposomes	O
.	O
<EOS>	B-X
Acute	B-X
inflammatory	B-X
injury	B-X
in	B-X
rat	B-X
lung	B-X
induced	B-X
by	B-X
deposition	B-X
of	B-X
immunoglobulin	B-X
G	B-X
immune	B-X
complexes	B-X
requires	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
chemokines	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
rat	B-X
lungs	B-X
were	B-X
depleted	B-X
of	B-X
alveolar	B-X
macrophages	B-X
by	B-X
airway	B-X
instillation	B-X
of	B-X
liposome-encapsulated	B-X
dichloromethylene	B-X
diphosphonate	B-X
.	B-X
These	B-X
procedures	B-X
,	B-X
which	B-X
greatly	B-X
reduced	B-X
the	B-X
number	B-X
of	B-X
retrievable	B-X
alveolar	B-X
macrophages	B-X
,	B-X
suppressed	B-X
activation	B-X
of	B-X
lung	B-X
NF-kappaB	B-X
in	B-X
the	B-X
inflammatory	B-X
model	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
bronchoalveolar	B-X
lavage	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
the	B-X
CXC	B-X
chemokine	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
,	B-X
were	B-X
substantially	B-X
reduced	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
upregulation	B-X
of	B-X
the	B-X
lung	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
,	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
,	B-X
was	B-X
greatly	B-X
reduced	B-X
by	B-X
intrapulmonary	B-X
instillation	B-X
of	B-X
phosphonate-containing	B-X
liposomes	B-X
.	B-X
Neutrophil	B-X
accumulation	B-X
and	B-X
development	B-X
of	B-X
lung	B-X
injury	B-X
were	B-X
also	B-X
substantially	B-X
diminished	B-X
.	B-X
Lung	B-X
instillation	B-X
of	B-X
TNF-alpha	B-X
in	B-X
alveolar	B-X
macrophage-depleted	B-X
rats	B-X
restored	B-X
the	B-X
NF-kappaB	B-X
activation	B-X
response	B-X
in	B-X
whole	B-X
lung	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
this	B-X
inflammatory	B-X
model	B-X
,	B-X
initial	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
in	B-X
alveolar	B-X
macrophages	B-X
and	B-X
the	B-X
ensuing	B-X
production	B-X
of	B-X
TNF-alpha	B-X
may	B-X
propagate	B-X
NF-kappaB	B-X
activation	B-X
to	B-X
other	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

Neutrophil	O
accumulation	O
and	O
development	O
of	O
lung	O
injury	O
were	O
also	O
substantially	O
diminished	O
.	O
<EOS>	B-X
Airway	B-X
instillation	B-X
into	B-X
rats	B-X
of	B-X
2-chloroethyl	B-X
ethyl	B-X
sulfide	B-X
(	B-X
CEES	B-X
)	B-X
,	B-X
the	B-X
half	B-X
molecule	B-X
of	B-X
sulfur	B-X
mustard	B-X
compound	B-X
,	B-X
results	B-X
in	B-X
acute	B-X
lung	B-X
injury	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
the	B-X
leak	B-X
of	B-X
plasma	B-X
albumin	B-X
into	B-X
the	B-X
lung	B-X
.	B-X
Morphologically	B-X
,	B-X
early	B-X
changes	B-X
in	B-X
the	B-X
lung	B-X
include	B-X
alveolar	B-X
hemorrhage	B-X
and	B-X
fibrin	B-X
deposition	B-X
and	B-X
the	B-X
influx	B-X
of	B-X
neutrophils	B-X
.	B-X
Following	B-X
lung	B-X
contact	B-X
with	B-X
CEES	B-X
,	B-X
progressive	B-X
accumulation	B-X
of	B-X
collagen	B-X
occurred	B-X
in	B-X
the	B-X
lung	B-X
,	B-X
followed	B-X
by	B-X
parenchymal	B-X
collapse	B-X
.	B-X
The	B-X
co-instillation	B-X
with	B-X
CEES	B-X
of	B-X
liposomes	B-X
containing	B-X
pegylated	B-X
(	B-X
PEG	B-X
)	B-X
-catalase	B-X
(	B-X
CAT	B-X
)	B-X
,	B-X
PEG-superoxide	B-X
dismutase	B-X
(	B-X
SOD	B-X
)	B-X
,	B-X
or	B-X
the	B-X
combination	B-X
,	B-X
greatly	B-X
attenuated	B-X
the	B-X
development	B-X
of	B-X
lung	B-X
injury	B-X
.	B-X
Likewise	B-X
,	B-X
the	B-X
co-instillation	B-X
of	B-X
liposomes	B-X
containing	B-X
the	B-X
reducing	B-X
agents	B-X
,	B-X
N-acetylcysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
,	B-X
or	B-X
resveratrol	B-X
(	B-X
RES	B-X
)	B-X
,	B-X
significantly	B-X
reduced	B-X
acute	B-X
lung	B-X
injury	B-X
.	B-X
The	B-X
combination	B-X
of	B-X
complement	B-X
depletion	B-X
and	B-X
airway	B-X
instillation	B-X
of	B-X
liposomes	B-X
containing	B-X
anti-oxidant	B-X
compounds	B-X
maximally	B-X
attenuated	B-X
CEES-induced	B-X
lung	B-X
injury	B-X
by	B-X
nearly	B-X
80	B-X
%	B-X
.	B-X
Delayed	B-X
airway	B-X
instillation	B-X
of	B-X
anti-oxidant-containing	B-X
liposomes	B-X
(	B-X
containing	B-X
NAC	B-X
or	B-X
GSH	B-X
,	B-X
or	B-X
the	B-X
combination	B-X
)	B-X
significantly	B-X
diminished	B-X
lung	B-X
injury	B-X
even	B-X
when	B-X
instillation	B-X
was	B-X
delayed	B-X
as	B-X
long	B-X
as	B-X
1	B-X
h	B-X
after	B-X
lung	B-X
exposure	B-X
to	B-X
CEES	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
CEES-induced	B-X
injury	B-X
of	B-X
rat	B-X
lungs	B-X
can	B-X
be	B-X
substantially	B-X
diminished	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
reducing	B-X
agents	B-X
or	B-X
anti-oxidant	B-X
enzymes	B-X
delivered	B-X
via	B-X
liposomes	B-X
.	B-X

Lung	O
instillation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
in	O
alveolar	O
macrophage	O
-	O
depleted	O
rats	O
restored	O
the	O
NF	O
-	O
kappaB	O
activation	O
response	O
in	O
whole	O
lung	O
.	O
<EOS>	B-X
Acute	B-X
inflammatory	B-X
injury	B-X
in	B-X
rat	B-X
lung	B-X
induced	B-X
by	B-X
deposition	B-X
of	B-X
immunoglobulin	B-X
G	B-X
immune	B-X
complexes	B-X
requires	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
chemokines	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
.	B-X
There	B-X
is	B-X
little	B-X
direct	B-X
evidence	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
alveolar	B-X
macrophages	B-X
in	B-X
these	B-X
activation	B-X
events	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
rat	B-X
lungs	B-X
were	B-X
depleted	B-X
of	B-X
alveolar	B-X
macrophages	B-X
by	B-X
airway	B-X
instillation	B-X
of	B-X
liposome-encapsulated	B-X
dichloromethylene	B-X
diphosphonate	B-X
.	B-X
These	B-X
procedures	B-X
,	B-X
which	B-X
greatly	B-X
reduced	B-X
the	B-X
number	B-X
of	B-X
retrievable	B-X
alveolar	B-X
macrophages	B-X
,	B-X
suppressed	B-X
activation	B-X
of	B-X
lung	B-X
NF-kappaB	B-X
in	B-X
the	B-X
inflammatory	B-X
model	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
bronchoalveolar	B-X
lavage	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
the	B-X
CXC	B-X
chemokine	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
,	B-X
were	B-X
substantially	B-X
reduced	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
upregulation	B-X
of	B-X
the	B-X
lung	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
,	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
,	B-X
was	B-X
greatly	B-X
reduced	B-X
by	B-X
intrapulmonary	B-X
instillation	B-X
of	B-X
phosphonate-containing	B-X
liposomes	B-X
.	B-X
Neutrophil	B-X
accumulation	B-X
and	B-X
development	B-X
of	B-X
lung	B-X
injury	B-X
were	B-X
also	B-X
substantially	B-X
diminished	B-X
.	B-X
Lung	B-X
instillation	B-X
of	B-X
TNF-alpha	B-X
in	B-X
alveolar	B-X
macrophage-depleted	B-X
rats	B-X
restored	B-X
the	B-X
NF-kappaB	B-X
activation	B-X
response	B-X
in	B-X
whole	B-X
lung	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
this	B-X
inflammatory	B-X
model	B-X
,	B-X
initial	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
in	B-X
alveolar	B-X
macrophages	B-X
and	B-X
the	B-X
ensuing	B-X
production	B-X
of	B-X
TNF-alpha	B-X
may	B-X
propagate	B-X
NF-kappaB	B-X
activation	B-X
to	B-X
other	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

These	O
data	O
suggest	O
that	O
,	O
in	O
this	O
inflammatory	O
model	O
,	O
initial	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
in	O
alveolar	O
macrophages	O
and	O
the	O
ensuing	O
production	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
may	O
propagate	O
NF	O
-	O
kappaB	O
activation	O
to	O
other	O
cell	O
types	O
in	O
the	O
lung	O
.	O
<EOS>	B-X
Acute	B-X
inflammatory	B-X
injury	B-X
in	B-X
rat	B-X
lung	B-X
induced	B-X
by	B-X
deposition	B-X
of	B-X
immunoglobulin	B-X
G	B-X
immune	B-X
complexes	B-X
requires	B-X
expression	B-X
of	B-X
cytokines	B-X
and	B-X
chemokines	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
.	B-X
There	B-X
is	B-X
little	B-X
direct	B-X
evidence	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
alveolar	B-X
macrophages	B-X
in	B-X
these	B-X
activation	B-X
events	B-X
.	B-X
In	B-X
the	B-X
present	B-X
studies	B-X
,	B-X
rat	B-X
lungs	B-X
were	B-X
depleted	B-X
of	B-X
alveolar	B-X
macrophages	B-X
by	B-X
airway	B-X
instillation	B-X
of	B-X
liposome-encapsulated	B-X
dichloromethylene	B-X
diphosphonate	B-X
.	B-X
These	B-X
procedures	B-X
,	B-X
which	B-X
greatly	B-X
reduced	B-X
the	B-X
number	B-X
of	B-X
retrievable	B-X
alveolar	B-X
macrophages	B-X
,	B-X
suppressed	B-X
activation	B-X
of	B-X
lung	B-X
NF-kappaB	B-X
in	B-X
the	B-X
inflammatory	B-X
model	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
bronchoalveolar	B-X
lavage	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
the	B-X
CXC	B-X
chemokine	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
,	B-X
were	B-X
substantially	B-X
reduced	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
upregulation	B-X
of	B-X
the	B-X
lung	B-X
vascular	B-X
adhesion	B-X
molecule	B-X
,	B-X
intercellular	B-X
adhesion	B-X
molecule-1	B-X
,	B-X
was	B-X
greatly	B-X
reduced	B-X
by	B-X
intrapulmonary	B-X
instillation	B-X
of	B-X
phosphonate-containing	B-X
liposomes	B-X
.	B-X
Neutrophil	B-X
accumulation	B-X
and	B-X
development	B-X
of	B-X
lung	B-X
injury	B-X
were	B-X
also	B-X
substantially	B-X
diminished	B-X
.	B-X
Lung	B-X
instillation	B-X
of	B-X
TNF-alpha	B-X
in	B-X
alveolar	B-X
macrophage-depleted	B-X
rats	B-X
restored	B-X
the	B-X
NF-kappaB	B-X
activation	B-X
response	B-X
in	B-X
whole	B-X
lung	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
this	B-X
inflammatory	B-X
model	B-X
,	B-X
initial	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
in	B-X
alveolar	B-X
macrophages	B-X
and	B-X
the	B-X
ensuing	B-X
production	B-X
of	B-X
TNF-alpha	B-X
may	B-X
propagate	B-X
NF-kappaB	B-X
activation	B-X
to	B-X
other	B-X
cell	B-X
types	B-X
in	B-X
the	B-X
lung	B-X
.	B-X

Role	O
of	O
cellular	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
in	O
NF	O
-	O
kappaB	O
activation	O
and	O
lymphocyte	O
transformation	O
by	O
herpesvirus	O
Saimiri	O
STP	O
.	O
<EOS>	B-X
The	B-X
STP	B-X
oncoproteins	B-X
of	B-X
the	B-X
herpesvirus	B-X
saimiri	B-X
(	B-X
HVS	B-X
)	B-X
subgroup	B-X
A	B-X
strain	B-X
11	B-X
and	B-X
subgroup	B-X
C	B-X
strain	B-X
488	B-X
are	B-X
now	B-X
found	B-X
to	B-X
be	B-X
stably	B-X
associated	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
or	B-X
3	B-X
.	B-X
Mutational	B-X
analyses	B-X
identified	B-X
residues	B-X
of	B-X
PXQXT/S	B-X
in	B-X
STP-A11	B-X
as	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
somewhat	B-X
divergent	B-X
region	B-X
of	B-X
STP-C488	B-X
is	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
Mutational	B-X
analysis	B-X
also	B-X
revealed	B-X
that	B-X
STP-C488	B-X
induced	B-X
NF-kappaB	B-X
activation	B-X
that	B-X
was	B-X
correlated	B-X
with	B-X
its	B-X
ability	B-X
to	B-X
associate	B-X
with	B-X
TRAFs	B-X
.	B-X
The	B-X
HVS	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
deficient	B-X
in	B-X
human	B-X
T-lymphocyte	B-X
transformation	B-X
to	B-X
interleukin-2-independent	B-X
growth	B-X
but	B-X
showed	B-X
wild-type	B-X
phenotype	B-X
for	B-X
marmoset	B-X
T-lymphocyte	B-X
transformation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
also	B-X
defective	B-X
in	B-X
Rat-1	B-X
fibroblast	B-X
transformation	B-X
,	B-X
and	B-X
fibroblast	B-X
cell	B-X
transformation	B-X
was	B-X
blocked	B-X
by	B-X
a	B-X
TRAF2	B-X
dominant-negative	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
implicate	B-X
TRAFs	B-X
in	B-X
STP-C488-mediated	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X
Other	B-X
factors	B-X
are	B-X
implicated	B-X
in	B-X
immortalization	B-X
of	B-X
common	B-X
marmoset	B-X
T	B-X
lymphocytes	B-X
and	B-X
may	B-X
also	B-X
be	B-X
critical	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X

The	O
STP	O
oncoproteins	O
of	O
the	O
herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
subgroup	O
A	O
strain	O
11	O
and	O
subgroup	O
C	O
strain	O
488	O
are	O
now	O
found	O
to	O
be	O
stably	O
associated	O
with	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
(	I-Protein
TRAF	I-Protein
)	I-Protein
1	I-Protein
,	O
2	B-Protein
,	O
or	O
3	B-Protein
.	O
<EOS>	B-X
Metal	B-X
substitutions	B-X
incarbonic	B-X
anhydrase	B-X
:	B-X
a	B-X
halide	B-X
ion	B-X
probe	B-X
study	B-X
.	B-X

Mutational	O
analyses	O
identified	O
residues	O
of	O
PXQXT	O
/	O
S	O
in	O
STP	B-Protein
-	I-Protein
A11	I-Protein
as	O
critical	O
for	O
TRAF	O
association	O
.	O
<EOS>	B-X
The	B-X
STP	B-X
oncoproteins	B-X
of	B-X
the	B-X
herpesvirus	B-X
saimiri	B-X
(	B-X
HVS	B-X
)	B-X
subgroup	B-X
A	B-X
strain	B-X
11	B-X
and	B-X
subgroup	B-X
C	B-X
strain	B-X
488	B-X
are	B-X
now	B-X
found	B-X
to	B-X
be	B-X
stably	B-X
associated	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
or	B-X
3	B-X
.	B-X
Mutational	B-X
analyses	B-X
identified	B-X
residues	B-X
of	B-X
PXQXT/S	B-X
in	B-X
STP-A11	B-X
as	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
somewhat	B-X
divergent	B-X
region	B-X
of	B-X
STP-C488	B-X
is	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
Mutational	B-X
analysis	B-X
also	B-X
revealed	B-X
that	B-X
STP-C488	B-X
induced	B-X
NF-kappaB	B-X
activation	B-X
that	B-X
was	B-X
correlated	B-X
with	B-X
its	B-X
ability	B-X
to	B-X
associate	B-X
with	B-X
TRAFs	B-X
.	B-X
The	B-X
HVS	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
deficient	B-X
in	B-X
human	B-X
T-lymphocyte	B-X
transformation	B-X
to	B-X
interleukin-2-independent	B-X
growth	B-X
but	B-X
showed	B-X
wild-type	B-X
phenotype	B-X
for	B-X
marmoset	B-X
T-lymphocyte	B-X
transformation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
also	B-X
defective	B-X
in	B-X
Rat-1	B-X
fibroblast	B-X
transformation	B-X
,	B-X
and	B-X
fibroblast	B-X
cell	B-X
transformation	B-X
was	B-X
blocked	B-X
by	B-X
a	B-X
TRAF2	B-X
dominant-negative	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
implicate	B-X
TRAFs	B-X
in	B-X
STP-C488-mediated	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X
Other	B-X
factors	B-X
are	B-X
implicated	B-X
in	B-X
immortalization	B-X
of	B-X
common	B-X
marmoset	B-X
T	B-X
lymphocytes	B-X
and	B-X
may	B-X
also	B-X
be	B-X
critical	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X

In	O
addition	O
,	O
a	O
somewhat	O
divergent	O
region	O
of	O
STP	B-Protein
-	I-Protein
C488	I-Protein
is	O
critical	O
for	O
TRAF	O
association	O
.	O
<EOS>	B-X
The	B-X
STP	B-X
oncoproteins	B-X
of	B-X
the	B-X
herpesvirus	B-X
saimiri	B-X
(	B-X
HVS	B-X
)	B-X
subgroup	B-X
A	B-X
strain	B-X
11	B-X
and	B-X
subgroup	B-X
C	B-X
strain	B-X
488	B-X
are	B-X
now	B-X
found	B-X
to	B-X
be	B-X
stably	B-X
associated	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
or	B-X
3	B-X
.	B-X
Mutational	B-X
analyses	B-X
identified	B-X
residues	B-X
of	B-X
PXQXT/S	B-X
in	B-X
STP-A11	B-X
as	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
somewhat	B-X
divergent	B-X
region	B-X
of	B-X
STP-C488	B-X
is	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
Mutational	B-X
analysis	B-X
also	B-X
revealed	B-X
that	B-X
STP-C488	B-X
induced	B-X
NF-kappaB	B-X
activation	B-X
that	B-X
was	B-X
correlated	B-X
with	B-X
its	B-X
ability	B-X
to	B-X
associate	B-X
with	B-X
TRAFs	B-X
.	B-X
The	B-X
HVS	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
deficient	B-X
in	B-X
human	B-X
T-lymphocyte	B-X
transformation	B-X
to	B-X
interleukin-2-independent	B-X
growth	B-X
but	B-X
showed	B-X
wild-type	B-X
phenotype	B-X
for	B-X
marmoset	B-X
T-lymphocyte	B-X
transformation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
also	B-X
defective	B-X
in	B-X
Rat-1	B-X
fibroblast	B-X
transformation	B-X
,	B-X
and	B-X
fibroblast	B-X
cell	B-X
transformation	B-X
was	B-X
blocked	B-X
by	B-X
a	B-X
TRAF2	B-X
dominant-negative	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
implicate	B-X
TRAFs	B-X
in	B-X
STP-C488-mediated	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X
Other	B-X
factors	B-X
are	B-X
implicated	B-X
in	B-X
immortalization	B-X
of	B-X
common	B-X
marmoset	B-X
T	B-X
lymphocytes	B-X
and	B-X
may	B-X
also	B-X
be	B-X
critical	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X

Mutational	O
analysis	O
also	O
revealed	O
that	O
STP	B-Protein
-	I-Protein
C488	I-Protein
induced	O
NF	O
-	O
kappaB	O
activation	O
that	O
was	O
correlated	O
with	O
its	O
ability	O
to	O
associate	O
with	O
TRAFs	O
.	O
<EOS>	B-X
The	B-X
STP	B-X
oncoproteins	B-X
of	B-X
the	B-X
herpesvirus	B-X
saimiri	B-X
(	B-X
HVS	B-X
)	B-X
subgroup	B-X
A	B-X
strain	B-X
11	B-X
and	B-X
subgroup	B-X
C	B-X
strain	B-X
488	B-X
are	B-X
now	B-X
found	B-X
to	B-X
be	B-X
stably	B-X
associated	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
or	B-X
3	B-X
.	B-X
Mutational	B-X
analyses	B-X
identified	B-X
residues	B-X
of	B-X
PXQXT/S	B-X
in	B-X
STP-A11	B-X
as	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
somewhat	B-X
divergent	B-X
region	B-X
of	B-X
STP-C488	B-X
is	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
Mutational	B-X
analysis	B-X
also	B-X
revealed	B-X
that	B-X
STP-C488	B-X
induced	B-X
NF-kappaB	B-X
activation	B-X
that	B-X
was	B-X
correlated	B-X
with	B-X
its	B-X
ability	B-X
to	B-X
associate	B-X
with	B-X
TRAFs	B-X
.	B-X
The	B-X
HVS	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
deficient	B-X
in	B-X
human	B-X
T-lymphocyte	B-X
transformation	B-X
to	B-X
interleukin-2-independent	B-X
growth	B-X
but	B-X
showed	B-X
wild-type	B-X
phenotype	B-X
for	B-X
marmoset	B-X
T-lymphocyte	B-X
transformation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
also	B-X
defective	B-X
in	B-X
Rat-1	B-X
fibroblast	B-X
transformation	B-X
,	B-X
and	B-X
fibroblast	B-X
cell	B-X
transformation	B-X
was	B-X
blocked	B-X
by	B-X
a	B-X
TRAF2	B-X
dominant-negative	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
implicate	B-X
TRAFs	B-X
in	B-X
STP-C488-mediated	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X
Other	B-X
factors	B-X
are	B-X
implicated	B-X
in	B-X
immortalization	B-X
of	B-X
common	B-X
marmoset	B-X
T	B-X
lymphocytes	B-X
and	B-X
may	B-X
also	B-X
be	B-X
critical	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X

The	O
HVS	O
STP	B-Protein
-	I-Protein
C488	I-Protein
P10	O
-	O
-	O
>	O
R	O
mutant	O
was	O
deficient	O
in	O
human	O
T	O
-	O
lymphocyte	O
transformation	O
to	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
growth	O
but	O
showed	O
wild	O
-	O
type	O
phenotype	O
for	O
marmoset	O
T	O
-	O
lymphocyte	O
transformation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
STP	B-Protein
-	I-Protein
C488	I-Protein
P10	O
-	O
-	O
>	O
R	O
mutant	O
was	O
also	O
defective	O
in	O
Rat	O
-	O
1	O
fibroblast	O
transformation	O
,	O
and	O
fibroblast	O
cell	O
transformation	O
was	O
blocked	O
by	O
a	O
TRAF2	B-Protein
dominant	O
-	O
negative	O
mutant	O
.	O
<EOS>	B-X
The	B-X
STP	B-X
oncoproteins	B-X
of	B-X
the	B-X
herpesvirus	B-X
saimiri	B-X
(	B-X
HVS	B-X
)	B-X
subgroup	B-X
A	B-X
strain	B-X
11	B-X
and	B-X
subgroup	B-X
C	B-X
strain	B-X
488	B-X
are	B-X
now	B-X
found	B-X
to	B-X
be	B-X
stably	B-X
associated	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
or	B-X
3	B-X
.	B-X
Mutational	B-X
analyses	B-X
identified	B-X
residues	B-X
of	B-X
PXQXT/S	B-X
in	B-X
STP-A11	B-X
as	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
somewhat	B-X
divergent	B-X
region	B-X
of	B-X
STP-C488	B-X
is	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
Mutational	B-X
analysis	B-X
also	B-X
revealed	B-X
that	B-X
STP-C488	B-X
induced	B-X
NF-kappaB	B-X
activation	B-X
that	B-X
was	B-X
correlated	B-X
with	B-X
its	B-X
ability	B-X
to	B-X
associate	B-X
with	B-X
TRAFs	B-X
.	B-X
The	B-X
HVS	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
deficient	B-X
in	B-X
human	B-X
T-lymphocyte	B-X
transformation	B-X
to	B-X
interleukin-2-independent	B-X
growth	B-X
but	B-X
showed	B-X
wild-type	B-X
phenotype	B-X
for	B-X
marmoset	B-X
T-lymphocyte	B-X
transformation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
also	B-X
defective	B-X
in	B-X
Rat-1	B-X
fibroblast	B-X
transformation	B-X
,	B-X
and	B-X
fibroblast	B-X
cell	B-X
transformation	B-X
was	B-X
blocked	B-X
by	B-X
a	B-X
TRAF2	B-X
dominant-negative	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
implicate	B-X
TRAFs	B-X
in	B-X
STP-C488-mediated	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X
Other	B-X
factors	B-X
are	B-X
implicated	B-X
in	B-X
immortalization	B-X
of	B-X
common	B-X
marmoset	B-X
T	B-X
lymphocytes	B-X
and	B-X
may	B-X
also	B-X
be	B-X
critical	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X

These	O
data	O
implicate	O
TRAFs	O
in	O
STP	B-Protein
-	I-Protein
C488	I-Protein
-	O
mediated	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O
<EOS>	B-X
The	B-X
STP	B-X
oncoproteins	B-X
of	B-X
the	B-X
herpesvirus	B-X
saimiri	B-X
(	B-X
HVS	B-X
)	B-X
subgroup	B-X
A	B-X
strain	B-X
11	B-X
and	B-X
subgroup	B-X
C	B-X
strain	B-X
488	B-X
are	B-X
now	B-X
found	B-X
to	B-X
be	B-X
stably	B-X
associated	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
or	B-X
3	B-X
.	B-X
Mutational	B-X
analyses	B-X
identified	B-X
residues	B-X
of	B-X
PXQXT/S	B-X
in	B-X
STP-A11	B-X
as	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
somewhat	B-X
divergent	B-X
region	B-X
of	B-X
STP-C488	B-X
is	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
Mutational	B-X
analysis	B-X
also	B-X
revealed	B-X
that	B-X
STP-C488	B-X
induced	B-X
NF-kappaB	B-X
activation	B-X
that	B-X
was	B-X
correlated	B-X
with	B-X
its	B-X
ability	B-X
to	B-X
associate	B-X
with	B-X
TRAFs	B-X
.	B-X
The	B-X
HVS	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
deficient	B-X
in	B-X
human	B-X
T-lymphocyte	B-X
transformation	B-X
to	B-X
interleukin-2-independent	B-X
growth	B-X
but	B-X
showed	B-X
wild-type	B-X
phenotype	B-X
for	B-X
marmoset	B-X
T-lymphocyte	B-X
transformation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
also	B-X
defective	B-X
in	B-X
Rat-1	B-X
fibroblast	B-X
transformation	B-X
,	B-X
and	B-X
fibroblast	B-X
cell	B-X
transformation	B-X
was	B-X
blocked	B-X
by	B-X
a	B-X
TRAF2	B-X
dominant-negative	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
implicate	B-X
TRAFs	B-X
in	B-X
STP-C488-mediated	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X
Other	B-X
factors	B-X
are	B-X
implicated	B-X
in	B-X
immortalization	B-X
of	B-X
common	B-X
marmoset	B-X
T	B-X
lymphocytes	B-X
and	B-X
may	B-X
also	B-X
be	B-X
critical	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X

Other	O
factors	O
are	O
implicated	O
in	O
immortalization	O
of	O
common	O
marmoset	O
T	O
lymphocytes	O
and	O
may	O
also	O
be	O
critical	O
in	O
the	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O
<EOS>	B-X
Mutational	B-X
analyses	B-X
identified	B-X
residues	B-X
of	B-X
PXQXT/S	B-X
in	B-X
STP-A11	B-X
as	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
somewhat	B-X
divergent	B-X
region	B-X
of	B-X
STP-C488	B-X
is	B-X
critical	B-X
for	B-X
TRAF	B-X
association	B-X
.	B-X
Mutational	B-X
analysis	B-X
also	B-X
revealed	B-X
that	B-X
STP-C488	B-X
induced	B-X
NF-kappaB	B-X
activation	B-X
that	B-X
was	B-X
correlated	B-X
with	B-X
its	B-X
ability	B-X
to	B-X
associate	B-X
with	B-X
TRAFs	B-X
.	B-X
The	B-X
HVS	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
deficient	B-X
in	B-X
human	B-X
T-lymphocyte	B-X
transformation	B-X
to	B-X
interleukin-2-independent	B-X
growth	B-X
but	B-X
showed	B-X
wild-type	B-X
phenotype	B-X
for	B-X
marmoset	B-X
T-lymphocyte	B-X
transformation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
STP-C488	B-X
P10	B-X
--	B-X
>	B-X
R	B-X
mutant	B-X
was	B-X
also	B-X
defective	B-X
in	B-X
Rat-1	B-X
fibroblast	B-X
transformation	B-X
,	B-X
and	B-X
fibroblast	B-X
cell	B-X
transformation	B-X
was	B-X
blocked	B-X
by	B-X
a	B-X
TRAF2	B-X
dominant-negative	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
implicate	B-X
TRAFs	B-X
in	B-X
STP-C488-mediated	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X
Other	B-X
factors	B-X
are	B-X
implicated	B-X
in	B-X
immortalization	B-X
of	B-X
common	B-X
marmoset	B-X
T	B-X
lymphocytes	B-X
and	B-X
may	B-X
also	B-X
be	B-X
critical	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
human	B-X
lymphocytes	B-X
and	B-X
rodent	B-X
fibroblasts	B-X
.	B-X

Regulation	O
of	O
Fas	B-Protein
ligand	I-Protein
expression	O
and	O
cell	O
death	O
by	O
apoptosis	B-Protein
-	I-Protein
linked	I-Protein
gene	I-Protein
4	I-Protein
.	O
<EOS>	B-X
Environmental	B-X
contaminants	B-X
exposure	B-X
may	B-X
lead	B-X
to	B-X
detrimental	B-X
changes	B-X
to	B-X
the	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
expression	B-X
resulting	B-X
in	B-X
several	B-X
health	B-X
effects	B-X
.	B-X
miRNAs	B-X
,	B-X
small	B-X
non-coding	B-X
RNAs	B-X
that	B-X
regulate	B-X
gene	B-X
expression	B-X
,	B-X
have	B-X
multiple	B-X
transcript	B-X
targets	B-X
and	B-X
thereby	B-X
regulate	B-X
several	B-X
signalling	B-X
molecules	B-X
.	B-X
Even	B-X
a	B-X
minor	B-X
alteration	B-X
in	B-X
the	B-X
abundance	B-X
of	B-X
one	B-X
miRNA	B-X
can	B-X
have	B-X
deep	B-X
effects	B-X
on	B-X
global	B-X
gene	B-X
expression	B-X
.	B-X
Altered	B-X
patterns	B-X
of	B-X
miRNAs	B-X
can	B-X
be	B-X
responsible	B-X
for	B-X
changes	B-X
linked	B-X
to	B-X
various	B-X
health	B-X
outcomes	B-X
,	B-X
suggesting	B-X
that	B-X
specific	B-X
miRNAs	B-X
are	B-X
activated	B-X
in	B-X
pathophysiological	B-X
processes	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
studies	B-X
investigating	B-X
the	B-X
impact	B-X
of	B-X
air	B-X
pollution	B-X
,	B-X
organic	B-X
chemicals	B-X
,	B-X
and	B-X
heavy	B-X
metals	B-X
on	B-X
miRNA	B-X
expression	B-X
and	B-X
the	B-X
potential	B-X
biologic	B-X
effects	B-X
on	B-X
humans	B-X
.	B-X

Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O
<EOS>	B-X
The	B-X
balance	B-X
between	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
is	B-X
critical	B-X
for	B-X
normal	B-X
development	B-X
and	B-X
for	B-X
the	B-X
maintenance	B-X
of	B-X
homeostasis	B-X
in	B-X
adult	B-X
organisms	B-X
.	B-X
Disruption	B-X
of	B-X
this	B-X
balance	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
a	B-X
large	B-X
number	B-X
of	B-X
disease	B-X
processes	B-X
,	B-X
ranging	B-X
from	B-X
autoimmunity	B-X
and	B-X
neurodegenerative	B-X
disorders	B-X
to	B-X
cancer	B-X
.	B-X
The	B-X
ubiquitin-proteasome	B-X
pathway	B-X
,	B-X
responsible	B-X
for	B-X
mediating	B-X
the	B-X
majority	B-X
of	B-X
intracellular	B-X
proteolysis	B-X
,	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
many	B-X
normal	B-X
cellular	B-X
processes	B-X
,	B-X
including	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
differentiation	B-X
and	B-X
apoptosis	B-X
.	B-X
Apoptosis	B-X
in	B-X
cancer	B-X
cells	B-X
is	B-X
closely	B-X
connected	B-X
with	B-X
the	B-X
activity	B-X
of	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
The	B-X
peptide-aldehyde	B-X
proteasome	B-X
inhibitor	B-X
MG132	B-X
(	B-X
carbobenzoxyl-L-leucyl-L-leucyl-L-leucine	B-X
)	B-X
induces	B-X
the	B-X
apoptosis	B-X
of	B-X
cells	B-X
by	B-X
a	B-X
different	B-X
intermediary	B-X
pathway	B-X
.	B-X
There	B-X
are	B-X
many	B-X
cancer-related	B-X
molecules	B-X
in	B-X
which	B-X
the	B-X
protein	B-X
levels	B-X
present	B-X
in	B-X
cells	B-X
are	B-X
regulated	B-X
by	B-X
a	B-X
proteasomal	B-X
pathway	B-X
;	B-X
for	B-X
example	B-X
,	B-X
tumor	B-X
inhibitors	B-X
(	B-X
P53	B-X
,	B-X
E2A	B-X
,	B-X
c-Myc	B-X
,	B-X
c-Jun	B-X
,	B-X
c-Fos	B-X
)	B-X
,	B-X
transcription	B-X
factors	B-X
(	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
,	B-X
IκBα	B-X
,	B-X
HIFI	B-X
,	B-X
YYI	B-X
,	B-X
ICER	B-X
)	B-X
,	B-X
cell	B-X
cycle	B-X
proteins	B-X
(	B-X
cyclin	B-X
A	B-X
and	B-X
B	B-X
,	B-X
P27	B-X
,	B-X
P21	B-X
,	B-X
IAP1/3	B-X
)	B-X
,	B-X
MG132	B-X
induces	B-X
cell	B-X
apoptosis	B-X
through	B-X
formation	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
or	B-X
the	B-X
upregulation	B-X
and	B-X
downregulation	B-X
of	B-X
these	B-X
factors	B-X
,	B-X
which	B-X
is	B-X
ultimately	B-X
dependent	B-X
upon	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
caspase	B-X
family	B-X
of	B-X
cysteine	B-X
proteases	B-X
.	B-X
In	B-X
this	B-X
article	B-X
we	B-X
review	B-X
the	B-X
mechanism	B-X
of	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
order	B-X
to	B-X
provide	B-X
information	B-X
required	B-X
for	B-X
research	B-X
.	B-X

One	O
of	O
the	O
best	O
understood	O
apoptotic	O
pathways	O
occurs	O
in	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
Fas	B-Protein
/	O
Fas	B-Protein
ligand	I-Protein
(	O
FasL	B-Protein
)	O
interaction	O
.	O

During	O
studies	O
of	O
apoptosis	O
induced	O
by	O
T	O
cell	O
-	O
receptor	O
engagement	O
,	O
we	O
identified	O
ALG	O
-	O
4F	O
,	O
a	O
truncated	O
transcript	O
that	O
prevents	O
T	O
cell	O
-	O
receptor	O
-	O
induced	O
FasL	B-Protein
upregulation	O
and	O
cell	O
death	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
ALG	B-Protein
-	I-Protein
4	I-Protein
induced	O
transcription	O
of	O
FasL	B-Protein
and	O
,	O
consequently	O
,	O
apoptosis	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
best	B-X
understood	B-X
apoptotic	B-X
pathways	B-X
occurs	B-X
in	B-X
T	B-X
lymphocytes	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
Fas/Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
interaction	B-X
.	B-X
During	B-X
studies	B-X
of	B-X
apoptosis	B-X
induced	B-X
by	B-X
T	B-X
cell-receptor	B-X
engagement	B-X
,	B-X
we	B-X
identified	B-X
ALG-4F	B-X
,	B-X
a	B-X
truncated	B-X
transcript	B-X
that	B-X
prevents	B-X
T	B-X
cell-receptor-induced	B-X
FasL	B-X
upregulation	B-X
and	B-X
cell	B-X
death	B-X
.	B-X
Overexpression	B-X
of	B-X
full-length	B-X
ALG-4	B-X
induced	B-X
transcription	B-X
of	B-X
FasL	B-X
and	B-X
,	B-X
consequently	B-X
,	B-X
apoptosis	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
ALG-4	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
FasL	B-X
expression	B-X
.	B-X
Fas/FasL	B-X
interaction	B-X
initiates	B-X
cell	B-X
death	B-X
in	B-X
many	B-X
other	B-X
systems	B-X
,	B-X
and	B-X
its	B-X
dysregulation	B-X
is	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
several	B-X
pathologic	B-X
conditions	B-X
arise	B-X
.	B-X
Understanding	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
FasL	B-X
regulation	B-X
could	B-X
be	B-X
very	B-X
useful	B-X
in	B-X
elucidating	B-X
how	B-X
these	B-X
diseases	B-X
develop	B-X
and	B-X
in	B-X
identifying	B-X
potential	B-X
therapeutic	B-X
targets	B-X
.	B-X

These	O
results	O
indicate	O
that	O
ALG	B-Protein
-	I-Protein
4	I-Protein
is	O
necessary	O
and	O
sufficient	O
for	O
FasL	B-Protein
expression	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
best	B-X
understood	B-X
apoptotic	B-X
pathways	B-X
occurs	B-X
in	B-X
T	B-X
lymphocytes	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
Fas/Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
interaction	B-X
.	B-X
During	B-X
studies	B-X
of	B-X
apoptosis	B-X
induced	B-X
by	B-X
T	B-X
cell-receptor	B-X
engagement	B-X
,	B-X
we	B-X
identified	B-X
ALG-4F	B-X
,	B-X
a	B-X
truncated	B-X
transcript	B-X
that	B-X
prevents	B-X
T	B-X
cell-receptor-induced	B-X
FasL	B-X
upregulation	B-X
and	B-X
cell	B-X
death	B-X
.	B-X
Overexpression	B-X
of	B-X
full-length	B-X
ALG-4	B-X
induced	B-X
transcription	B-X
of	B-X
FasL	B-X
and	B-X
,	B-X
consequently	B-X
,	B-X
apoptosis	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
ALG-4	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
FasL	B-X
expression	B-X
.	B-X
Fas/FasL	B-X
interaction	B-X
initiates	B-X
cell	B-X
death	B-X
in	B-X
many	B-X
other	B-X
systems	B-X
,	B-X
and	B-X
its	B-X
dysregulation	B-X
is	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
several	B-X
pathologic	B-X
conditions	B-X
arise	B-X
.	B-X
Understanding	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
FasL	B-X
regulation	B-X
could	B-X
be	B-X
very	B-X
useful	B-X
in	B-X
elucidating	B-X
how	B-X
these	B-X
diseases	B-X
develop	B-X
and	B-X
in	B-X
identifying	B-X
potential	B-X
therapeutic	B-X
targets	B-X
.	B-X

Fas	B-Protein
/	O
FasL	B-Protein
interaction	O
initiates	O
cell	O
death	O
in	O
many	O
other	O
systems	O
,	O
and	O
its	O
dysregulation	O
is	O
a	O
mechanism	O
by	O
which	O
several	O
pathologic	O
conditions	O
arise	O
.	O
<EOS>	B-X
Programmed	B-X
cell	B-X
death	B-X
is	B-X
a	B-X
process	B-X
required	B-X
for	B-X
the	B-X
normal	B-X
development	B-X
of	B-X
an	B-X
organism	B-X
.	B-X
One	B-X
of	B-X
the	B-X
best	B-X
understood	B-X
apoptotic	B-X
pathways	B-X
occurs	B-X
in	B-X
T	B-X
lymphocytes	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
Fas/Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
interaction	B-X
.	B-X
During	B-X
studies	B-X
of	B-X
apoptosis	B-X
induced	B-X
by	B-X
T	B-X
cell-receptor	B-X
engagement	B-X
,	B-X
we	B-X
identified	B-X
ALG-4F	B-X
,	B-X
a	B-X
truncated	B-X
transcript	B-X
that	B-X
prevents	B-X
T	B-X
cell-receptor-induced	B-X
FasL	B-X
upregulation	B-X
and	B-X
cell	B-X
death	B-X
.	B-X
Overexpression	B-X
of	B-X
full-length	B-X
ALG-4	B-X
induced	B-X
transcription	B-X
of	B-X
FasL	B-X
and	B-X
,	B-X
consequently	B-X
,	B-X
apoptosis	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
ALG-4	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
FasL	B-X
expression	B-X
.	B-X
Fas/FasL	B-X
interaction	B-X
initiates	B-X
cell	B-X
death	B-X
in	B-X
many	B-X
other	B-X
systems	B-X
,	B-X
and	B-X
its	B-X
dysregulation	B-X
is	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
several	B-X
pathologic	B-X
conditions	B-X
arise	B-X
.	B-X
Understanding	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
FasL	B-X
regulation	B-X
could	B-X
be	B-X
very	B-X
useful	B-X
in	B-X
elucidating	B-X
how	B-X
these	B-X
diseases	B-X
develop	B-X
and	B-X
in	B-X
identifying	B-X
potential	B-X
therapeutic	B-X
targets	B-X
.	B-X

Understanding	O
the	O
molecular	O
mechanisms	O
of	O
FasL	B-Protein
regulation	O
could	O
be	O
very	O
useful	O
in	O
elucidating	O
how	O
these	O
diseases	O
develop	O
and	O
in	O
identifying	O
potential	O
therapeutic	O
targets	O
.	O
<EOS>	B-X
Programmed	B-X
cell	B-X
death	B-X
is	B-X
a	B-X
process	B-X
required	B-X
for	B-X
the	B-X
normal	B-X
development	B-X
of	B-X
an	B-X
organism	B-X
.	B-X
One	B-X
of	B-X
the	B-X
best	B-X
understood	B-X
apoptotic	B-X
pathways	B-X
occurs	B-X
in	B-X
T	B-X
lymphocytes	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
Fas/Fas	B-X
ligand	B-X
(	B-X
FasL	B-X
)	B-X
interaction	B-X
.	B-X
During	B-X
studies	B-X
of	B-X
apoptosis	B-X
induced	B-X
by	B-X
T	B-X
cell-receptor	B-X
engagement	B-X
,	B-X
we	B-X
identified	B-X
ALG-4F	B-X
,	B-X
a	B-X
truncated	B-X
transcript	B-X
that	B-X
prevents	B-X
T	B-X
cell-receptor-induced	B-X
FasL	B-X
upregulation	B-X
and	B-X
cell	B-X
death	B-X
.	B-X
Overexpression	B-X
of	B-X
full-length	B-X
ALG-4	B-X
induced	B-X
transcription	B-X
of	B-X
FasL	B-X
and	B-X
,	B-X
consequently	B-X
,	B-X
apoptosis	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
ALG-4	B-X
is	B-X
necessary	B-X
and	B-X
sufficient	B-X
for	B-X
FasL	B-X
expression	B-X
.	B-X
Fas/FasL	B-X
interaction	B-X
initiates	B-X
cell	B-X
death	B-X
in	B-X
many	B-X
other	B-X
systems	B-X
,	B-X
and	B-X
its	B-X
dysregulation	B-X
is	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
several	B-X
pathologic	B-X
conditions	B-X
arise	B-X
.	B-X
Understanding	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
FasL	B-X
regulation	B-X
could	B-X
be	B-X
very	B-X
useful	B-X
in	B-X
elucidating	B-X
how	B-X
these	B-X
diseases	B-X
develop	B-X
and	B-X
in	B-X
identifying	B-X
potential	B-X
therapeutic	B-X
targets	B-X
.	B-X

High	O
molecular	O
weight	O
dextran	O
sulfate	O
increases	O
the	O
activity	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O
<EOS>	B-X
It	B-X
is	B-X
known	B-X
that	B-X
sulfated	B-X
polysaccharides	B-X
can	B-X
mimic	B-X
the	B-X
action	B-X
of	B-X
common	B-X
T-cell	B-X
mitogens	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
mitogenic	B-X
effect	B-X
of	B-X
high	B-X
molecular	B-X
weight	B-X
dextran	B-X
sulfate	B-X
(	B-X
HMDS	B-X
)	B-X
,	B-X
monocyte-derived	B-X
macrophages	B-X
were	B-X
transfected	B-X
with	B-X
recombinant	B-X
plasmid	B-X
containing	B-X
chloramphenicol	B-X
acetyl	B-X
transferase	B-X
(	B-X
CAT	B-X
)	B-X
reporter	B-X
gene	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
promoter	B-X
,	B-X
which	B-X
is	B-X
regulated	B-X
by	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
HMDS	B-X
,	B-X
similar	B-X
to	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
increases	B-X
the	B-X
expression	B-X
of	B-X
CAT	B-X
reporter	B-X
gene	B-X
suggesting	B-X
increased	B-X
activity	B-X
of	B-X
NF-kappaB	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
correlated	B-X
with	B-X
the	B-X
increased	B-X
expression	B-X
of	B-X
B7.1	B-X
molecules	B-X
.	B-X
It	B-X
was	B-X
postulated	B-X
that	B-X
this	B-X
NF-kappaB-regulated	B-X
promoter	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
accessory	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
the	B-X
rate	B-X
of	B-X
replication	B-X
of	B-X
HIV-1	B-X
in	B-X
monocyte-derived	B-X
macrophages	B-X
.	B-X

It	O
is	O
known	O
that	O
sulfated	O
polysaccharides	O
can	O
mimic	O
the	O
action	O
of	O
common	O
T	O
-	O
cell	O
mitogens	O
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
of	O
the	O
mitogenic	O
effect	O
of	O
high	O
molecular	O
weight	O
dextran	O
sulfate	O
(	O
HMDS	O
)	O
,	O
monocyte	O
-	O
derived	O
macrophages	O
were	O
transfected	O
with	O
recombinant	O
plasmid	O
containing	O
chloramphenicol	B-Protein
acetyl	I-Protein
transferase	I-Protein
(	O
CAT	B-Protein
)	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
,	O
which	O
is	O
regulated	O
by	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

We	O
observed	O
that	O
HMDS	O
,	O
similar	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
increases	O
the	O
expression	O
of	O
CAT	B-Protein
reporter	O
gene	O
suggesting	O
increased	O
activity	O
of	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
mitogenic	B-X
effect	B-X
of	B-X
high	B-X
molecular	B-X
weight	B-X
dextran	B-X
sulfate	B-X
(	B-X
HMDS	B-X
)	B-X
,	B-X
monocyte-derived	B-X
macrophages	B-X
were	B-X
transfected	B-X
with	B-X
recombinant	B-X
plasmid	B-X
containing	B-X
chloramphenicol	B-X
acetyl	B-X
transferase	B-X
(	B-X
CAT	B-X
)	B-X
reporter	B-X
gene	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
promoter	B-X
,	B-X
which	B-X
is	B-X
regulated	B-X
by	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
HMDS	B-X
,	B-X
similar	B-X
to	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
increases	B-X
the	B-X
expression	B-X
of	B-X
CAT	B-X
reporter	B-X
gene	B-X
suggesting	B-X
increased	B-X
activity	B-X
of	B-X
NF-kappaB	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
correlated	B-X
with	B-X
the	B-X
increased	B-X
expression	B-X
of	B-X
B7.1	B-X
molecules	B-X
.	B-X
It	B-X
was	B-X
postulated	B-X
that	B-X
this	B-X
NF-kappaB-regulated	B-X
promoter	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
accessory	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
the	B-X
rate	B-X
of	B-X
replication	B-X
of	B-X
HIV-1	B-X
in	B-X
monocyte-derived	B-X
macrophages	B-X
.	B-X

The	O
activation	O
of	O
NF	O
-	O
kappaB	O
correlated	O
with	O
the	O
increased	O
expression	O
of	O
B7	B-Protein
.	I-Protein
1	I-Protein
molecules	O
.	O
<EOS>	B-X
T-cells	B-X
are	B-X
key	B-X
players	B-X
in	B-X
fighting	B-X
the	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
.	B-X
The	B-X
checkpoint	B-X
molecule	B-X
B7-H4	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
B7	B-X
family	B-X
,	B-X
can	B-X
inhibit	B-X
T-cell	B-X
activation	B-X
and	B-X
proliferation	B-X
by	B-X
inhibiting	B-X
NF-kb	B-X
expression	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
elucidate	B-X
the	B-X
immunological	B-X
role	B-X
of	B-X
soluble	B-X
B7-H4	B-X
(	B-X
sB7-H4	B-X
)	B-X
and	B-X
B7-H4	B-X
in	B-X
pregnant	B-X
women	B-X
suffered	B-X
from	B-X
an	B-X
acute	B-X
Sars-Cov2	B-X
infection	B-X
.	B-X
Costimulatory	B-X
molecules	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
immune-regulatory	B-X
networks	B-X
.	B-X
Although	B-X
B7	B-X
family	B-X
costimulatory	B-X
molecules	B-X
were	B-X
previously	B-X
discovered	B-X
in	B-X
human	B-X
salivary	B-X
gland	B-X
epithelial	B-X
(	B-X
HSGE	B-X
)	B-X
cells	B-X
in	B-X
pSS	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
B7	B-X
family	B-X
member	B-X
B7-H3	B-X
(	B-X
CD276	B-X
)	B-X
have	B-X
not	B-X
been	B-X
well	B-X
elucidated	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
and	B-X
mechanism	B-X
of	B-X
B7-H3	B-X
in	B-X
HSGE	B-X
cells	B-X
in	B-X
pSS	B-X
.	B-X

It	O
was	O
postulated	O
that	O
this	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
might	O
play	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
accessory	O
cells	O
as	O
well	O
as	O
the	O
rate	O
of	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
mitogenic	B-X
effect	B-X
of	B-X
high	B-X
molecular	B-X
weight	B-X
dextran	B-X
sulfate	B-X
(	B-X
HMDS	B-X
)	B-X
,	B-X
monocyte-derived	B-X
macrophages	B-X
were	B-X
transfected	B-X
with	B-X
recombinant	B-X
plasmid	B-X
containing	B-X
chloramphenicol	B-X
acetyl	B-X
transferase	B-X
(	B-X
CAT	B-X
)	B-X
reporter	B-X
gene	B-X
under	B-X
the	B-X
control	B-X
of	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
promoter	B-X
,	B-X
which	B-X
is	B-X
regulated	B-X
by	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
HMDS	B-X
,	B-X
similar	B-X
to	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
increases	B-X
the	B-X
expression	B-X
of	B-X
CAT	B-X
reporter	B-X
gene	B-X
suggesting	B-X
increased	B-X
activity	B-X
of	B-X
NF-kappaB	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
correlated	B-X
with	B-X
the	B-X
increased	B-X
expression	B-X
of	B-X
B7.1	B-X
molecules	B-X
.	B-X
It	B-X
was	B-X
postulated	B-X
that	B-X
this	B-X
NF-kappaB-regulated	B-X
promoter	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
accessory	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
the	B-X
rate	B-X
of	B-X
replication	B-X
of	B-X
HIV-1	B-X
in	B-X
monocyte-derived	B-X
macrophages	B-X
.	B-X

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
human	O
T	O
lymphocytes	O
induces	O
caspase	O
-	O
dependent	O
apoptosis	O
without	O
detectable	O
activation	O
of	O
caspase	O
-	O
1	O
and	O
-	O
3	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
involved	O
in	O
the	O
transcriptional	O
control	O
of	O
various	O
genes	O
that	O
act	O
as	O
extrinsic	O
and	O
intrinsic	O
survival	O
factors	O
for	O
T	O
cells	O
.	O

Our	O
findings	O
show	O
that	O
suppression	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
with	O
cell	O
-	O
permeable	O
SN50	O
peptide	O
,	O
which	O
masks	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF	O
-	O
kappa	O
B1	O
dimers	O
and	O
prevents	O
their	O
nuclear	O
localization	O
,	O
induces	O
apoptosis	O
in	O
resting	O
normal	O
human	O
PBL	O
.	O
<EOS>	B-X
NF-kappa	B-X
B	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
transcriptional	B-X
control	B-X
of	B-X
various	B-X
genes	B-X
that	B-X
act	B-X
as	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
survival	B-X
factors	B-X
for	B-X
T	B-X
cells	B-X
.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
suppression	B-X
of	B-X
NF-kappa	B-X
B	B-X
activity	B-X
with	B-X
cell-permeable	B-X
SN50	B-X
peptide	B-X
,	B-X
which	B-X
masks	B-X
the	B-X
nuclear	B-X
localization	B-X
sequence	B-X
of	B-X
NF-kappa	B-X
B1	B-X
dimers	B-X
and	B-X
prevents	B-X
their	B-X
nuclear	B-X
localization	B-X
,	B-X
induces	B-X
apoptosis	B-X
in	B-X
resting	B-X
normal	B-X
human	B-X
PBL	B-X
.	B-X
Inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
resulted	B-X
in	B-X
the	B-X
externalization	B-X
of	B-X
phosphatidylserine	B-X
,	B-X
induction	B-X
of	B-X
DNA	B-X
breaks	B-X
,	B-X
and	B-X
morphological	B-X
changes	B-X
consistent	B-X
with	B-X
apoptosis	B-X
.	B-X
DNA	B-X
fragmentation	B-X
was	B-X
efficiently	B-X
blocked	B-X
by	B-X
the	B-X
caspase	B-X
inhibitor	B-X
Z-VAD-fmk	B-X
and	B-X
partially	B-X
blocked	B-X
by	B-X
Ac-DEVD-fmk	B-X
,	B-X
suggesting	B-X
that	B-X
SN50-mediated	B-X
apoptosis	B-X
is	B-X
caspase-dependent	B-X
.	B-X
Interestingly	B-X
,	B-X
apoptosis	B-X
induced	B-X
by	B-X
NF-kappa	B-X
B	B-X
suppression	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
induced	B-X
by	B-X
TPEN	B-X
(	B-X
N	B-X
,	B-X
N	B-X
,	B-X
N	B-X
'	B-X
,	B-X
N'-tetrakis	B-X
[	B-X
2-pyridylmethyl	B-X
]	B-X
ethylenediamine	B-X
)	B-X
or	B-X
soluble	B-X
Fas	B-X
ligand	B-X
(	B-X
CD95	B-X
)	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
active	B-X
death	B-X
effector	B-X
proteases	B-X
caspase-1-like	B-X
(	B-X
IL-1	B-X
converting	B-X
enzyme	B-X
)	B-X
,	B-X
caspase-3-like	B-X
(	B-X
CPP32/Yama/apopain	B-X
)	B-X
,	B-X
and	B-X
caspase-6-like	B-X
and	B-X
without	B-X
cleavage	B-X
of	B-X
caspase-3	B-X
substrates	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
and	B-X
DNA	B-X
fragmentation	B-X
factor-45	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
either	B-X
low	B-X
level	B-X
of	B-X
activation	B-X
is	B-X
required	B-X
or	B-X
that	B-X
different	B-X
caspases	B-X
are	B-X
involved	B-X
.	B-X
Preactivation	B-X
of	B-X
T	B-X
cells	B-X
resulting	B-X
in	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
translocation	B-X
protected	B-X
cells	B-X
from	B-X
SN50-induced	B-X
apoptosis	B-X
.	B-X
Our	B-X
findings	B-X
demonstrate	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
survival	B-X
of	B-X
naive	B-X
PBL	B-X
.	B-X

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
resulted	O
in	O
the	O
externalization	O
of	O
phosphatidylserine	O
,	O
induction	O
of	O
DNA	O
breaks	O
,	O
and	O
morphological	O
changes	O
consistent	O
with	O
apoptosis	O
.	O
<EOS>	B-X
NF-kappa	B-X
B	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
transcriptional	B-X
control	B-X
of	B-X
various	B-X
genes	B-X
that	B-X
act	B-X
as	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
survival	B-X
factors	B-X
for	B-X
T	B-X
cells	B-X
.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
suppression	B-X
of	B-X
NF-kappa	B-X
B	B-X
activity	B-X
with	B-X
cell-permeable	B-X
SN50	B-X
peptide	B-X
,	B-X
which	B-X
masks	B-X
the	B-X
nuclear	B-X
localization	B-X
sequence	B-X
of	B-X
NF-kappa	B-X
B1	B-X
dimers	B-X
and	B-X
prevents	B-X
their	B-X
nuclear	B-X
localization	B-X
,	B-X
induces	B-X
apoptosis	B-X
in	B-X
resting	B-X
normal	B-X
human	B-X
PBL	B-X
.	B-X
Inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
resulted	B-X
in	B-X
the	B-X
externalization	B-X
of	B-X
phosphatidylserine	B-X
,	B-X
induction	B-X
of	B-X
DNA	B-X
breaks	B-X
,	B-X
and	B-X
morphological	B-X
changes	B-X
consistent	B-X
with	B-X
apoptosis	B-X
.	B-X
DNA	B-X
fragmentation	B-X
was	B-X
efficiently	B-X
blocked	B-X
by	B-X
the	B-X
caspase	B-X
inhibitor	B-X
Z-VAD-fmk	B-X
and	B-X
partially	B-X
blocked	B-X
by	B-X
Ac-DEVD-fmk	B-X
,	B-X
suggesting	B-X
that	B-X
SN50-mediated	B-X
apoptosis	B-X
is	B-X
caspase-dependent	B-X
.	B-X
Interestingly	B-X
,	B-X
apoptosis	B-X
induced	B-X
by	B-X
NF-kappa	B-X
B	B-X
suppression	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
induced	B-X
by	B-X
TPEN	B-X
(	B-X
N	B-X
,	B-X
N	B-X
,	B-X
N	B-X
'	B-X
,	B-X
N'-tetrakis	B-X
[	B-X
2-pyridylmethyl	B-X
]	B-X
ethylenediamine	B-X
)	B-X
or	B-X
soluble	B-X
Fas	B-X
ligand	B-X
(	B-X
CD95	B-X
)	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
active	B-X
death	B-X
effector	B-X
proteases	B-X
caspase-1-like	B-X
(	B-X
IL-1	B-X
converting	B-X
enzyme	B-X
)	B-X
,	B-X
caspase-3-like	B-X
(	B-X
CPP32/Yama/apopain	B-X
)	B-X
,	B-X
and	B-X
caspase-6-like	B-X
and	B-X
without	B-X
cleavage	B-X
of	B-X
caspase-3	B-X
substrates	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
and	B-X
DNA	B-X
fragmentation	B-X
factor-45	B-X
.	B-X
Preactivation	B-X
of	B-X
T	B-X
cells	B-X
resulting	B-X
in	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
translocation	B-X
protected	B-X
cells	B-X
from	B-X
SN50-induced	B-X
apoptosis	B-X
.	B-X
Our	B-X
findings	B-X
demonstrate	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
survival	B-X
of	B-X
naive	B-X
PBL	B-X
.	B-X

DNA	O
fragmentation	O
was	O
efficiently	O
blocked	O
by	O
the	O
caspase	O
inhibitor	O
Z	O
-	O
VAD	O
-	O
fmk	O
and	O
partially	O
blocked	O
by	O
Ac	O
-	O
DEVD	O
-	O
fmk	O
,	O
suggesting	O
that	O
SN50	O
-	O
mediated	O
apoptosis	O
is	O
caspase	O
-	O
dependent	O
.	O
<EOS>	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
suppression	B-X
of	B-X
NF-kappa	B-X
B	B-X
activity	B-X
with	B-X
cell-permeable	B-X
SN50	B-X
peptide	B-X
,	B-X
which	B-X
masks	B-X
the	B-X
nuclear	B-X
localization	B-X
sequence	B-X
of	B-X
NF-kappa	B-X
B1	B-X
dimers	B-X
and	B-X
prevents	B-X
their	B-X
nuclear	B-X
localization	B-X
,	B-X
induces	B-X
apoptosis	B-X
in	B-X
resting	B-X
normal	B-X
human	B-X
PBL	B-X
.	B-X
Inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
resulted	B-X
in	B-X
the	B-X
externalization	B-X
of	B-X
phosphatidylserine	B-X
,	B-X
induction	B-X
of	B-X
DNA	B-X
breaks	B-X
,	B-X
and	B-X
morphological	B-X
changes	B-X
consistent	B-X
with	B-X
apoptosis	B-X
.	B-X
DNA	B-X
fragmentation	B-X
was	B-X
efficiently	B-X
blocked	B-X
by	B-X
the	B-X
caspase	B-X
inhibitor	B-X
Z-VAD-fmk	B-X
and	B-X
partially	B-X
blocked	B-X
by	B-X
Ac-DEVD-fmk	B-X
,	B-X
suggesting	B-X
that	B-X
SN50-mediated	B-X
apoptosis	B-X
is	B-X
caspase-dependent	B-X
.	B-X
Interestingly	B-X
,	B-X
apoptosis	B-X
induced	B-X
by	B-X
NF-kappa	B-X
B	B-X
suppression	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
induced	B-X
by	B-X
TPEN	B-X
(	B-X
N	B-X
,	B-X
N	B-X
,	B-X
N	B-X
'	B-X
,	B-X
N'-tetrakis	B-X
[	B-X
2-pyridylmethyl	B-X
]	B-X
ethylenediamine	B-X
)	B-X
or	B-X
soluble	B-X
Fas	B-X
ligand	B-X
(	B-X
CD95	B-X
)	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
active	B-X
death	B-X
effector	B-X
proteases	B-X
caspase-1-like	B-X
(	B-X
IL-1	B-X
converting	B-X
enzyme	B-X
)	B-X
,	B-X
caspase-3-like	B-X
(	B-X
CPP32/Yama/apopain	B-X
)	B-X
,	B-X
and	B-X
caspase-6-like	B-X
and	B-X
without	B-X
cleavage	B-X
of	B-X
caspase-3	B-X
substrates	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
and	B-X
DNA	B-X
fragmentation	B-X
factor-45	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
either	B-X
low	B-X
level	B-X
of	B-X
activation	B-X
is	B-X
required	B-X
or	B-X
that	B-X
different	B-X
caspases	B-X
are	B-X
involved	B-X
.	B-X
Preactivation	B-X
of	B-X
T	B-X
cells	B-X
resulting	B-X
in	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
translocation	B-X
protected	B-X
cells	B-X
from	B-X
SN50-induced	B-X
apoptosis	B-X
.	B-X

Interestingly	O
,	O
apoptosis	O
induced	O
by	O
NF	O
-	O
kappa	O
B	O
suppression	O
,	O
in	O
contrast	O
to	O
that	O
induced	O
by	O
TPEN	O
(	O
N	O
,	O
N	O
,	O
N	O
'	O
,	O
N	O
'	O
-	O
tetrakis	O
[	O
2	O
-	O
pyridylmethyl	O
]	O
ethylenediamine	O
)	O
or	O
soluble	O
Fas	B-Protein
ligand	I-Protein
(	O
CD95	B-Protein
)	O
,	O
was	O
observed	O
in	O
the	O
absence	O
of	O
active	O
death	O
effector	O
proteases	O
caspase	B-Protein
-	I-Protein
1	I-Protein
-	O
like	O
(	O
IL	O
-	O
1	O
converting	O
enzyme	O
)	O
,	O
caspase	B-Protein
-	I-Protein
3	I-Protein
-	O
like	O
(	O
CPP32	B-Protein
/	O
Yama	B-Protein
/	O
apopain	B-Protein
)	O
,	O
and	O
caspase	B-Protein
-	I-Protein
6	I-Protein
-	O
like	O
and	O
without	O
cleavage	O
of	O
caspase	B-Protein
-	I-Protein
3	I-Protein
substrates	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
and	O
DNA	B-Protein
fragmentation	I-Protein
factor	I-Protein
-	I-Protein
45	I-Protein
.	O
<EOS>	B-X
NF-kappa	B-X
B	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
transcriptional	B-X
control	B-X
of	B-X
various	B-X
genes	B-X
that	B-X
act	B-X
as	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
survival	B-X
factors	B-X
for	B-X
T	B-X
cells	B-X
.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
suppression	B-X
of	B-X
NF-kappa	B-X
B	B-X
activity	B-X
with	B-X
cell-permeable	B-X
SN50	B-X
peptide	B-X
,	B-X
which	B-X
masks	B-X
the	B-X
nuclear	B-X
localization	B-X
sequence	B-X
of	B-X
NF-kappa	B-X
B1	B-X
dimers	B-X
and	B-X
prevents	B-X
their	B-X
nuclear	B-X
localization	B-X
,	B-X
induces	B-X
apoptosis	B-X
in	B-X
resting	B-X
normal	B-X
human	B-X
PBL	B-X
.	B-X
Inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
resulted	B-X
in	B-X
the	B-X
externalization	B-X
of	B-X
phosphatidylserine	B-X
,	B-X
induction	B-X
of	B-X
DNA	B-X
breaks	B-X
,	B-X
and	B-X
morphological	B-X
changes	B-X
consistent	B-X
with	B-X
apoptosis	B-X
.	B-X
DNA	B-X
fragmentation	B-X
was	B-X
efficiently	B-X
blocked	B-X
by	B-X
the	B-X
caspase	B-X
inhibitor	B-X
Z-VAD-fmk	B-X
and	B-X
partially	B-X
blocked	B-X
by	B-X
Ac-DEVD-fmk	B-X
,	B-X
suggesting	B-X
that	B-X
SN50-mediated	B-X
apoptosis	B-X
is	B-X
caspase-dependent	B-X
.	B-X
Interestingly	B-X
,	B-X
apoptosis	B-X
induced	B-X
by	B-X
NF-kappa	B-X
B	B-X
suppression	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
induced	B-X
by	B-X
TPEN	B-X
(	B-X
N	B-X
,	B-X
N	B-X
,	B-X
N	B-X
'	B-X
,	B-X
N'-tetrakis	B-X
[	B-X
2-pyridylmethyl	B-X
]	B-X
ethylenediamine	B-X
)	B-X
or	B-X
soluble	B-X
Fas	B-X
ligand	B-X
(	B-X
CD95	B-X
)	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
active	B-X
death	B-X
effector	B-X
proteases	B-X
caspase-1-like	B-X
(	B-X
IL-1	B-X
converting	B-X
enzyme	B-X
)	B-X
,	B-X
caspase-3-like	B-X
(	B-X
CPP32/Yama/apopain	B-X
)	B-X
,	B-X
and	B-X
caspase-6-like	B-X
and	B-X
without	B-X
cleavage	B-X
of	B-X
caspase-3	B-X
substrates	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
and	B-X
DNA	B-X
fragmentation	B-X
factor-45	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
either	B-X
low	B-X
level	B-X
of	B-X
activation	B-X
is	B-X
required	B-X
or	B-X
that	B-X
different	B-X
caspases	B-X
are	B-X
involved	B-X
.	B-X
Preactivation	B-X
of	B-X
T	B-X
cells	B-X
resulting	B-X
in	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
translocation	B-X
protected	B-X
cells	B-X
from	B-X
SN50-induced	B-X
apoptosis	B-X
.	B-X
Our	B-X
findings	B-X
demonstrate	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
survival	B-X
of	B-X
naive	B-X
PBL	B-X
.	B-X

These	O
findings	O
suggest	O
either	O
low	O
level	O
of	O
activation	O
is	O
required	O
or	O
that	O
different	O
caspases	O
are	O
involved	O
.	O
<EOS>	B-X
Apoptotic	B-X
signalling	B-X
downstream	B-X
of	B-X
MOMP	B-X
involves	B-X
cytochrome	B-X
c	B-X
release	B-X
from	B-X
mitochondria	B-X
and	B-X
subsequent	B-X
caspase	B-X
activation	B-X
.	B-X
As	B-X
such	B-X
,	B-X
targeting	B-X
MOMP	B-X
in	B-X
order	B-X
to	B-X
manipulate	B-X
cell	B-X
death	B-X
holds	B-X
tremendous	B-X
therapeutic	B-X
potential	B-X
across	B-X
different	B-X
diseases	B-X
,	B-X
including	B-X
neurodegenerative	B-X
diseases	B-X
,	B-X
autoimmune	B-X
disorders	B-X
and	B-X
cancer	B-X
.	B-X
Surprisingly	B-X
,	B-X
recent	B-X
data	B-X
demonstrate	B-X
that	B-X
besides	B-X
eliciting	B-X
caspase	B-X
activation	B-X
,	B-X
MOMP	B-X
engages	B-X
various	B-X
pro-inflammatory	B-X
signalling	B-X
functions	B-X
.	B-X
As	B-X
we	B-X
highlight	B-X
,	B-X
together	B-X
with	B-X
new	B-X
findings	B-X
demonstrating	B-X
cell	B-X
survival	B-X
following	B-X
MOMP	B-X
,	B-X
this	B-X
pro-inflammatory	B-X
role	B-X
suggests	B-X
that	B-X
mitochondria-derived	B-X
signalling	B-X
downstream	B-X
of	B-X
pro-apoptotic	B-X
cues	B-X
may	B-X
also	B-X
have	B-X
non-lethal	B-X
functions	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
new	B-X
findings	B-X
offer	B-X
exciting	B-X
,	B-X
unexplored	B-X
opportunities	B-X
to	B-X
target	B-X
mitochondrial	B-X
regulation	B-X
of	B-X
cell	B-X
death	B-X
for	B-X
clinical	B-X
benefit	B-X
.	B-X

Preactivation	O
of	O
T	O
cells	O
resulting	O
in	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
protected	O
cells	O
from	O
SN50	O
-	O
induced	O
apoptosis	O
.	O
<EOS>	B-X
NF-kappa	B-X
B	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
transcriptional	B-X
control	B-X
of	B-X
various	B-X
genes	B-X
that	B-X
act	B-X
as	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
survival	B-X
factors	B-X
for	B-X
T	B-X
cells	B-X
.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
suppression	B-X
of	B-X
NF-kappa	B-X
B	B-X
activity	B-X
with	B-X
cell-permeable	B-X
SN50	B-X
peptide	B-X
,	B-X
which	B-X
masks	B-X
the	B-X
nuclear	B-X
localization	B-X
sequence	B-X
of	B-X
NF-kappa	B-X
B1	B-X
dimers	B-X
and	B-X
prevents	B-X
their	B-X
nuclear	B-X
localization	B-X
,	B-X
induces	B-X
apoptosis	B-X
in	B-X
resting	B-X
normal	B-X
human	B-X
PBL	B-X
.	B-X
Inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
resulted	B-X
in	B-X
the	B-X
externalization	B-X
of	B-X
phosphatidylserine	B-X
,	B-X
induction	B-X
of	B-X
DNA	B-X
breaks	B-X
,	B-X
and	B-X
morphological	B-X
changes	B-X
consistent	B-X
with	B-X
apoptosis	B-X
.	B-X
DNA	B-X
fragmentation	B-X
was	B-X
efficiently	B-X
blocked	B-X
by	B-X
the	B-X
caspase	B-X
inhibitor	B-X
Z-VAD-fmk	B-X
and	B-X
partially	B-X
blocked	B-X
by	B-X
Ac-DEVD-fmk	B-X
,	B-X
suggesting	B-X
that	B-X
SN50-mediated	B-X
apoptosis	B-X
is	B-X
caspase-dependent	B-X
.	B-X
Interestingly	B-X
,	B-X
apoptosis	B-X
induced	B-X
by	B-X
NF-kappa	B-X
B	B-X
suppression	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
induced	B-X
by	B-X
TPEN	B-X
(	B-X
N	B-X
,	B-X
N	B-X
,	B-X
N	B-X
'	B-X
,	B-X
N'-tetrakis	B-X
[	B-X
2-pyridylmethyl	B-X
]	B-X
ethylenediamine	B-X
)	B-X
or	B-X
soluble	B-X
Fas	B-X
ligand	B-X
(	B-X
CD95	B-X
)	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
active	B-X
death	B-X
effector	B-X
proteases	B-X
caspase-1-like	B-X
(	B-X
IL-1	B-X
converting	B-X
enzyme	B-X
)	B-X
,	B-X
caspase-3-like	B-X
(	B-X
CPP32/Yama/apopain	B-X
)	B-X
,	B-X
and	B-X
caspase-6-like	B-X
and	B-X
without	B-X
cleavage	B-X
of	B-X
caspase-3	B-X
substrates	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
and	B-X
DNA	B-X
fragmentation	B-X
factor-45	B-X
.	B-X
Preactivation	B-X
of	B-X
T	B-X
cells	B-X
resulting	B-X
in	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
translocation	B-X
protected	B-X
cells	B-X
from	B-X
SN50-induced	B-X
apoptosis	B-X
.	B-X
Our	B-X
findings	B-X
demonstrate	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
survival	B-X
of	B-X
naive	B-X
PBL	B-X
.	B-X

Our	O
findings	O
demonstrate	O
an	O
essential	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
survival	O
of	O
naive	O
PBL	O
.	O
<EOS>	B-X
NF-kappa	B-X
B	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
transcriptional	B-X
control	B-X
of	B-X
various	B-X
genes	B-X
that	B-X
act	B-X
as	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
survival	B-X
factors	B-X
for	B-X
T	B-X
cells	B-X
.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
suppression	B-X
of	B-X
NF-kappa	B-X
B	B-X
activity	B-X
with	B-X
cell-permeable	B-X
SN50	B-X
peptide	B-X
,	B-X
which	B-X
masks	B-X
the	B-X
nuclear	B-X
localization	B-X
sequence	B-X
of	B-X
NF-kappa	B-X
B1	B-X
dimers	B-X
and	B-X
prevents	B-X
their	B-X
nuclear	B-X
localization	B-X
,	B-X
induces	B-X
apoptosis	B-X
in	B-X
resting	B-X
normal	B-X
human	B-X
PBL	B-X
.	B-X
Inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
resulted	B-X
in	B-X
the	B-X
externalization	B-X
of	B-X
phosphatidylserine	B-X
,	B-X
induction	B-X
of	B-X
DNA	B-X
breaks	B-X
,	B-X
and	B-X
morphological	B-X
changes	B-X
consistent	B-X
with	B-X
apoptosis	B-X
.	B-X
Interestingly	B-X
,	B-X
apoptosis	B-X
induced	B-X
by	B-X
NF-kappa	B-X
B	B-X
suppression	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
that	B-X
induced	B-X
by	B-X
TPEN	B-X
(	B-X
N	B-X
,	B-X
N	B-X
,	B-X
N	B-X
'	B-X
,	B-X
N'-tetrakis	B-X
[	B-X
2-pyridylmethyl	B-X
]	B-X
ethylenediamine	B-X
)	B-X
or	B-X
soluble	B-X
Fas	B-X
ligand	B-X
(	B-X
CD95	B-X
)	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
active	B-X
death	B-X
effector	B-X
proteases	B-X
caspase-1-like	B-X
(	B-X
IL-1	B-X
converting	B-X
enzyme	B-X
)	B-X
,	B-X
caspase-3-like	B-X
(	B-X
CPP32/Yama/apopain	B-X
)	B-X
,	B-X
and	B-X
caspase-6-like	B-X
and	B-X
without	B-X
cleavage	B-X
of	B-X
caspase-3	B-X
substrates	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
polymerase	B-X
and	B-X
DNA	B-X
fragmentation	B-X
factor-45	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
either	B-X
low	B-X
level	B-X
of	B-X
activation	B-X
is	B-X
required	B-X
or	B-X
that	B-X
different	B-X
caspases	B-X
are	B-X
involved	B-X
.	B-X
Preactivation	B-X
of	B-X
T	B-X
cells	B-X
resulting	B-X
in	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
translocation	B-X
protected	B-X
cells	B-X
from	B-X
SN50-induced	B-X
apoptosis	B-X
.	B-X
Our	B-X
findings	B-X
demonstrate	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
survival	B-X
of	B-X
naive	B-X
PBL	B-X
.	B-X

Signaling	O
events	O
induced	O
by	O
lipopolysaccharide	O
-	O
activated	O
toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
2	I-Protein
.	O
<EOS>	B-X
Human	B-X
Toll-like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
is	B-X
a	B-X
signaling	B-X
receptor	B-X
that	B-X
responds	B-X
to	B-X
LPS	B-X
and	B-X
activates	B-X
NF-kappaB	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
further	B-X
the	B-X
events	B-X
triggered	B-X
by	B-X
TLR2	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X
We	B-X
show	B-X
that	B-X
TLR2	B-X
associates	B-X
with	B-X
the	B-X
high-affinity	B-X
LPS	B-X
binding	B-X
protein	B-X
membrane	B-X
CD14	B-X
to	B-X
serve	B-X
as	B-X
an	B-X
LPS	B-X
receptor	B-X
complex	B-X
,	B-X
and	B-X
that	B-X
LPS	B-X
treatment	B-X
enhances	B-X
the	B-X
oligomerization	B-X
of	B-X
TLR2	B-X
.	B-X
Concomitant	B-X
with	B-X
receptor	B-X
oligomerization	B-X
,	B-X
the	B-X
IL-1R-associated	B-X
kinase	B-X
(	B-X
IRAK	B-X
)	B-X
is	B-X
recruited	B-X
to	B-X
the	B-X
TLR2	B-X
complex	B-X
.	B-X
Intracellular	B-X
deletion	B-X
variants	B-X
of	B-X
TLR2	B-X
lacking	B-X
C-terminal	B-X
13	B-X
or	B-X
141	B-X
aa	B-X
fail	B-X
to	B-X
recruit	B-X
IRAK	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
inability	B-X
of	B-X
these	B-X
mutants	B-X
to	B-X
transmit	B-X
LPS	B-X
cellular	B-X
signaling	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
deletion	B-X
mutants	B-X
could	B-X
still	B-X
form	B-X
complexes	B-X
with	B-X
wild-type	B-X
TLR2	B-X
and	B-X
act	B-X
in	B-X
a	B-X
dominant-negative	B-X
(	B-X
DN	B-X
)	B-X
fashion	B-X
to	B-X
block	B-X
TLR2-mediated	B-X
signal	B-X
transduction	B-X
.	B-X
DN	B-X
constructs	B-X
of	B-X
myeloid	B-X
differentiation	B-X
protein	B-X
,	B-X
IRAK	B-X
,	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
6	B-X
,	B-X
and	B-X
NF-kappaB-inducing	B-X
kinase	B-X
,	B-X
when	B-X
coexpressed	B-X
with	B-X
TLR2	B-X
,	B-X
abrogate	B-X
TLR2-mediated	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
conserved	B-X
signaling	B-X
pathway	B-X
for	B-X
TLR2	B-X
and	B-X
IL-1Rs	B-X
and	B-X
suggest	B-X
a	B-X
molecular	B-X
mechanism	B-X
for	B-X
the	B-X
inhibition	B-X
of	B-X
TLR2	B-X
by	B-X
DN	B-X
variants	B-X
.	B-X

Human	O
Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
2	I-Protein
(	O
TLR2	B-Protein
)	O
is	O
a	O
signaling	O
receptor	O
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
A	B-X
missense	B-X
mutation	B-X
in	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
the	B-X
Toll-like	B-X
receptor-4	B-X
(	B-X
TLR-4	B-X
)	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
defect	B-X
responsible	B-X
for	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
hyporesponsiveness	B-X
in	B-X
C3H/HeJ	B-X
mice	B-X
.	B-X
TLR-4	B-X
and	B-X
TLR-2	B-X
have	B-X
recently	B-X
been	B-X
implicated	B-X
in	B-X
LPS	B-X
signaling	B-X
in	B-X
studies	B-X
where	B-X
these	B-X
receptors	B-X
were	B-X
overexpressed	B-X
in	B-X
LPS	B-X
non-responsive	B-X
293	B-X
human	B-X
embryonic	B-X
kidney	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signaling	B-X
role	B-X
of	B-X
TLR-4	B-X
or	B-X
TLR-2	B-X
in	B-X
human	B-X
cells	B-X
with	B-X
natural	B-X
LPS	B-X
response	B-X
remains	B-X
largely	B-X
undefined	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
human	B-X
dermal	B-X
microvessel	B-X
endothelial	B-X
cells	B-X
(	B-X
HMEC	B-X
)	B-X
and	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
express	B-X
predominantly	B-X
TLR-4	B-X
but	B-X
very	B-X
weak	B-X
TLR-2	B-X
and	B-X
respond	B-X
vigorously	B-X
to	B-X
LPS	B-X
but	B-X
not	B-X
to	B-X
Mycobacterium	B-X
tuberculosis	B-X
19-kDa	B-X
lipoprotein	B-X
.	B-X
Transient	B-X
transfection	B-X
of	B-X
non-signaling	B-X
mutant	B-X
forms	B-X
of	B-X
TLR-4	B-X
and	B-X
anti-TLR-4	B-X
monoclonal	B-X
antibody	B-X
inhibited	B-X
LPS-induced	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
HMEC	B-X
,	B-X
while	B-X
a	B-X
monoclonal	B-X
antibody	B-X
against	B-X
TLR-2	B-X
was	B-X
ineffective	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
LPS	B-X
responsiveness	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
HMEC	B-X
to	B-X
respond	B-X
to	B-X
19-kDa	B-X
lipoprotein	B-X
correlated	B-X
with	B-X
the	B-X
expression	B-X
of	B-X
TLR-2	B-X
.	B-X
Transfection	B-X
of	B-X
TLR-2	B-X
into	B-X
HMEC	B-X
conferred	B-X
responsiveness	B-X
to	B-X
19-kDa	B-X
lipoprotein	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
TLR-4	B-X
is	B-X
the	B-X
LPS	B-X
signaling	B-X
receptor	B-X
in	B-X
HMEC	B-X
and	B-X
that	B-X
human	B-X
endothelial	B-X
cells	B-X
(	B-X
EC	B-X
)	B-X
express	B-X
predominantly	B-X
TLR-4	B-X
and	B-X
weak	B-X
TLR-2	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
why	B-X
they	B-X
do	B-X
not	B-X
respond	B-X
to	B-X
19-kDa	B-X
lipoprotein	B-X
.	B-X

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	B-Protein
in	O
response	O
to	O
LPS	O
.	O
<EOS>	B-X
Although	B-X
previous	B-X
reports	B-X
investigated	B-X
TLR	B-X
signaling	B-X
in	B-X
response	B-X
to	B-X
intact	B-X
H.	B-X
pylori	B-X
,	B-X
the	B-X
specific	B-X
contribution	B-X
of	B-X
H.	B-X
pylori	B-X
LPS	B-X
with	B-X
regard	B-X
to	B-X
functional	B-X
genomics	B-X
and	B-X
cell-signaling	B-X
events	B-X
has	B-X
not	B-X
been	B-X
defined	B-X
.	B-X
This	B-X
study	B-X
set	B-X
out	B-X
to	B-X
define	B-X
downstream	B-X
signaling	B-X
components	B-X
and	B-X
altered	B-X
gene	B-X
expression	B-X
triggered	B-X
by	B-X
H.	B-X
pylori	B-X
LPS	B-X
and	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
signaling	B-X
protein	B-X
tribbles	B-X
3	B-X
(	B-X
TRIB3	B-X
)	B-X
during	B-X
the	B-X
TLR-mediated	B-X
response	B-X
to	B-X
H.	B-X
pylori	B-X
LPS	B-X
.	B-X
Cotransfections	B-X
using	B-X
small	B-X
interfering	B-X
RNA	B-X
and	B-X
dominant-negative	B-X
constructs	B-X
demonstrated	B-X
that	B-X
H.	B-X
pylori	B-X
LPS	B-X
functions	B-X
as	B-X
a	B-X
classic	B-X
TLR2	B-X
ligand	B-X
by	B-X
signaling	B-X
through	B-X
pathways	B-X
involving	B-X
the	B-X
key	B-X
TLR	B-X
signaling	B-X
components	B-X
MyD88	B-X
adaptor-like	B-X
,	B-X
MyD88	B-X
,	B-X
IRAK1	B-X
,	B-X
IRAK4	B-X
,	B-X
TNFR-associated	B-X
factor	B-X
6	B-X
,	B-X
IκB	B-X
kinase	B-X
β	B-X
,	B-X
and	B-X
IκBα	B-X
.	B-X
Microarray	B-X
analysis	B-X
,	B-X
real-time	B-X
PCR	B-X
,	B-X
and	B-X
ELISA	B-X
revealed	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
discrete	B-X
pattern	B-X
of	B-X
chemokines	B-X
as	B-X
a	B-X
direct	B-X
effect	B-X
of	B-X
LPS	B-X
:	B-X
TLR2	B-X
signaling	B-X
.	B-X
Furthermore	B-X
,	B-X
knockdown	B-X
of	B-X
TRIB3	B-X
and	B-X
C/EBP	B-X
homologous	B-X
protein	B-X
enhanced	B-X
TLR2-mediated	B-X
NF-κB	B-X
activation	B-X
and	B-X
chemokine	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
H.	B-X
pylori	B-X
LPS	B-X
.	B-X

We	O
show	O
that	O
TLR2	B-Protein
associates	O
with	O
the	O
high	O
-	O
affinity	O
LPS	O
binding	O
protein	O
membrane	O
CD14	B-Protein
to	O
serve	O
as	O
an	O
LPS	O
receptor	O
complex	O
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	B-Protein
.	O
<EOS>	B-X
Human	B-X
Toll-like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
is	B-X
a	B-X
signaling	B-X
receptor	B-X
that	B-X
responds	B-X
to	B-X
LPS	B-X
and	B-X
activates	B-X
NF-kappaB	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
further	B-X
the	B-X
events	B-X
triggered	B-X
by	B-X
TLR2	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X
We	B-X
show	B-X
that	B-X
TLR2	B-X
associates	B-X
with	B-X
the	B-X
high-affinity	B-X
LPS	B-X
binding	B-X
protein	B-X
membrane	B-X
CD14	B-X
to	B-X
serve	B-X
as	B-X
an	B-X
LPS	B-X
receptor	B-X
complex	B-X
,	B-X
and	B-X
that	B-X
LPS	B-X
treatment	B-X
enhances	B-X
the	B-X
oligomerization	B-X
of	B-X
TLR2	B-X
.	B-X
Concomitant	B-X
with	B-X
receptor	B-X
oligomerization	B-X
,	B-X
the	B-X
IL-1R-associated	B-X
kinase	B-X
(	B-X
IRAK	B-X
)	B-X
is	B-X
recruited	B-X
to	B-X
the	B-X
TLR2	B-X
complex	B-X
.	B-X
Intracellular	B-X
deletion	B-X
variants	B-X
of	B-X
TLR2	B-X
lacking	B-X
C-terminal	B-X
13	B-X
or	B-X
141	B-X
aa	B-X
fail	B-X
to	B-X
recruit	B-X
IRAK	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
inability	B-X
of	B-X
these	B-X
mutants	B-X
to	B-X
transmit	B-X
LPS	B-X
cellular	B-X
signaling	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
deletion	B-X
mutants	B-X
could	B-X
still	B-X
form	B-X
complexes	B-X
with	B-X
wild-type	B-X
TLR2	B-X
and	B-X
act	B-X
in	B-X
a	B-X
dominant-negative	B-X
(	B-X
DN	B-X
)	B-X
fashion	B-X
to	B-X
block	B-X
TLR2-mediated	B-X
signal	B-X
transduction	B-X
.	B-X
DN	B-X
constructs	B-X
of	B-X
myeloid	B-X
differentiation	B-X
protein	B-X
,	B-X
IRAK	B-X
,	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
6	B-X
,	B-X
and	B-X
NF-kappaB-inducing	B-X
kinase	B-X
,	B-X
when	B-X
coexpressed	B-X
with	B-X
TLR2	B-X
,	B-X
abrogate	B-X
TLR2-mediated	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
conserved	B-X
signaling	B-X
pathway	B-X
for	B-X
TLR2	B-X
and	B-X
IL-1Rs	B-X
and	B-X
suggest	B-X
a	B-X
molecular	B-X
mechanism	B-X
for	B-X
the	B-X
inhibition	B-X
of	B-X
TLR2	B-X
by	B-X
DN	B-X
variants	B-X
.	B-X

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL	O
-	O
1R	O
-	O
associated	O
kinase	O
(	O
IRAK	O
)	O
is	O
recruited	O
to	O
the	O
TLR2	B-Protein
complex	O
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	B-Protein
lacking	O
C	O
-	O
terminal	O
13	O
or	O
141	O
aa	O
fail	O
to	O
recruit	O
IRAK	O
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O
<EOS>	B-X
Human	B-X
Toll-like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
is	B-X
a	B-X
signaling	B-X
receptor	B-X
that	B-X
responds	B-X
to	B-X
LPS	B-X
and	B-X
activates	B-X
NF-kappaB	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
further	B-X
the	B-X
events	B-X
triggered	B-X
by	B-X
TLR2	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X
We	B-X
show	B-X
that	B-X
TLR2	B-X
associates	B-X
with	B-X
the	B-X
high-affinity	B-X
LPS	B-X
binding	B-X
protein	B-X
membrane	B-X
CD14	B-X
to	B-X
serve	B-X
as	B-X
an	B-X
LPS	B-X
receptor	B-X
complex	B-X
,	B-X
and	B-X
that	B-X
LPS	B-X
treatment	B-X
enhances	B-X
the	B-X
oligomerization	B-X
of	B-X
TLR2	B-X
.	B-X
Concomitant	B-X
with	B-X
receptor	B-X
oligomerization	B-X
,	B-X
the	B-X
IL-1R-associated	B-X
kinase	B-X
(	B-X
IRAK	B-X
)	B-X
is	B-X
recruited	B-X
to	B-X
the	B-X
TLR2	B-X
complex	B-X
.	B-X
Intracellular	B-X
deletion	B-X
variants	B-X
of	B-X
TLR2	B-X
lacking	B-X
C-terminal	B-X
13	B-X
or	B-X
141	B-X
aa	B-X
fail	B-X
to	B-X
recruit	B-X
IRAK	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
inability	B-X
of	B-X
these	B-X
mutants	B-X
to	B-X
transmit	B-X
LPS	B-X
cellular	B-X
signaling	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
deletion	B-X
mutants	B-X
could	B-X
still	B-X
form	B-X
complexes	B-X
with	B-X
wild-type	B-X
TLR2	B-X
and	B-X
act	B-X
in	B-X
a	B-X
dominant-negative	B-X
(	B-X
DN	B-X
)	B-X
fashion	B-X
to	B-X
block	B-X
TLR2-mediated	B-X
signal	B-X
transduction	B-X
.	B-X
DN	B-X
constructs	B-X
of	B-X
myeloid	B-X
differentiation	B-X
protein	B-X
,	B-X
IRAK	B-X
,	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
6	B-X
,	B-X
and	B-X
NF-kappaB-inducing	B-X
kinase	B-X
,	B-X
when	B-X
coexpressed	B-X
with	B-X
TLR2	B-X
,	B-X
abrogate	B-X
TLR2-mediated	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
conserved	B-X
signaling	B-X
pathway	B-X
for	B-X
TLR2	B-X
and	B-X
IL-1Rs	B-X
and	B-X
suggest	B-X
a	B-X
molecular	B-X
mechanism	B-X
for	B-X
the	B-X
inhibition	B-X
of	B-X
TLR2	B-X
by	B-X
DN	B-X
variants	B-X
.	B-X

Moreover	O
,	O
both	O
deletion	O
mutants	O
could	O
still	O
form	O
complexes	O
with	O
wild	O
-	O
type	O
TLR2	B-Protein
and	O
act	O
in	O
a	O
dominant	O
-	O
negative	O
(	O
DN	O
)	O
fashion	O
to	O
block	O
TLR2	B-Protein
-	O
mediated	O
signal	O
transduction	O
.	O

DN	O
constructs	O
of	O
myeloid	O
differentiation	O
protein	O
,	O
IRAK	O
,	O
TNF	B-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
6	I-Protein
,	O
and	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
-	I-Protein
inducing	I-Protein
kinase	I-Protein
,	O
when	O
coexpressed	O
with	O
TLR2	B-Protein
,	O
abrogate	O
TLR2	B-Protein
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
Human	B-X
Toll-like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
is	B-X
a	B-X
signaling	B-X
receptor	B-X
that	B-X
responds	B-X
to	B-X
LPS	B-X
and	B-X
activates	B-X
NF-kappaB	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
further	B-X
the	B-X
events	B-X
triggered	B-X
by	B-X
TLR2	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X
We	B-X
show	B-X
that	B-X
TLR2	B-X
associates	B-X
with	B-X
the	B-X
high-affinity	B-X
LPS	B-X
binding	B-X
protein	B-X
membrane	B-X
CD14	B-X
to	B-X
serve	B-X
as	B-X
an	B-X
LPS	B-X
receptor	B-X
complex	B-X
,	B-X
and	B-X
that	B-X
LPS	B-X
treatment	B-X
enhances	B-X
the	B-X
oligomerization	B-X
of	B-X
TLR2	B-X
.	B-X
Concomitant	B-X
with	B-X
receptor	B-X
oligomerization	B-X
,	B-X
the	B-X
IL-1R-associated	B-X
kinase	B-X
(	B-X
IRAK	B-X
)	B-X
is	B-X
recruited	B-X
to	B-X
the	B-X
TLR2	B-X
complex	B-X
.	B-X
Intracellular	B-X
deletion	B-X
variants	B-X
of	B-X
TLR2	B-X
lacking	B-X
C-terminal	B-X
13	B-X
or	B-X
141	B-X
aa	B-X
fail	B-X
to	B-X
recruit	B-X
IRAK	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
inability	B-X
of	B-X
these	B-X
mutants	B-X
to	B-X
transmit	B-X
LPS	B-X
cellular	B-X
signaling	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
deletion	B-X
mutants	B-X
could	B-X
still	B-X
form	B-X
complexes	B-X
with	B-X
wild-type	B-X
TLR2	B-X
and	B-X
act	B-X
in	B-X
a	B-X
dominant-negative	B-X
(	B-X
DN	B-X
)	B-X
fashion	B-X
to	B-X
block	B-X
TLR2-mediated	B-X
signal	B-X
transduction	B-X
.	B-X
DN	B-X
constructs	B-X
of	B-X
myeloid	B-X
differentiation	B-X
protein	B-X
,	B-X
IRAK	B-X
,	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
6	B-X
,	B-X
and	B-X
NF-kappaB-inducing	B-X
kinase	B-X
,	B-X
when	B-X
coexpressed	B-X
with	B-X
TLR2	B-X
,	B-X
abrogate	B-X
TLR2-mediated	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
conserved	B-X
signaling	B-X
pathway	B-X
for	B-X
TLR2	B-X
and	B-X
IL-1Rs	B-X
and	B-X
suggest	B-X
a	B-X
molecular	B-X
mechanism	B-X
for	B-X
the	B-X
inhibition	B-X
of	B-X
TLR2	B-X
by	B-X
DN	B-X
variants	B-X
.	B-X

These	O
results	O
reveal	O
a	O
conserved	O
signaling	O
pathway	O
for	O
TLR2	B-Protein
and	O
IL	O
-	O
1Rs	O
and	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
inhibition	O
of	O
TLR2	B-Protein
by	O
DN	O
variants	O
.	O
<EOS>	B-X
Human	B-X
Toll-like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
is	B-X
a	B-X
signaling	B-X
receptor	B-X
that	B-X
responds	B-X
to	B-X
LPS	B-X
and	B-X
activates	B-X
NF-kappaB	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
further	B-X
the	B-X
events	B-X
triggered	B-X
by	B-X
TLR2	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X
We	B-X
show	B-X
that	B-X
TLR2	B-X
associates	B-X
with	B-X
the	B-X
high-affinity	B-X
LPS	B-X
binding	B-X
protein	B-X
membrane	B-X
CD14	B-X
to	B-X
serve	B-X
as	B-X
an	B-X
LPS	B-X
receptor	B-X
complex	B-X
,	B-X
and	B-X
that	B-X
LPS	B-X
treatment	B-X
enhances	B-X
the	B-X
oligomerization	B-X
of	B-X
TLR2	B-X
.	B-X
Concomitant	B-X
with	B-X
receptor	B-X
oligomerization	B-X
,	B-X
the	B-X
IL-1R-associated	B-X
kinase	B-X
(	B-X
IRAK	B-X
)	B-X
is	B-X
recruited	B-X
to	B-X
the	B-X
TLR2	B-X
complex	B-X
.	B-X
Intracellular	B-X
deletion	B-X
variants	B-X
of	B-X
TLR2	B-X
lacking	B-X
C-terminal	B-X
13	B-X
or	B-X
141	B-X
aa	B-X
fail	B-X
to	B-X
recruit	B-X
IRAK	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
inability	B-X
of	B-X
these	B-X
mutants	B-X
to	B-X
transmit	B-X
LPS	B-X
cellular	B-X
signaling	B-X
.	B-X
Moreover	B-X
,	B-X
both	B-X
deletion	B-X
mutants	B-X
could	B-X
still	B-X
form	B-X
complexes	B-X
with	B-X
wild-type	B-X
TLR2	B-X
and	B-X
act	B-X
in	B-X
a	B-X
dominant-negative	B-X
(	B-X
DN	B-X
)	B-X
fashion	B-X
to	B-X
block	B-X
TLR2-mediated	B-X
signal	B-X
transduction	B-X
.	B-X
DN	B-X
constructs	B-X
of	B-X
myeloid	B-X
differentiation	B-X
protein	B-X
,	B-X
IRAK	B-X
,	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
6	B-X
,	B-X
and	B-X
NF-kappaB-inducing	B-X
kinase	B-X
,	B-X
when	B-X
coexpressed	B-X
with	B-X
TLR2	B-X
,	B-X
abrogate	B-X
TLR2-mediated	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
a	B-X
conserved	B-X
signaling	B-X
pathway	B-X
for	B-X
TLR2	B-X
and	B-X
IL-1Rs	B-X
and	B-X
suggest	B-X
a	B-X
molecular	B-X
mechanism	B-X
for	B-X
the	B-X
inhibition	B-X
of	B-X
TLR2	B-X
by	B-X
DN	B-X
variants	B-X
.	B-X

Activation	O
of	O
the	O
Janus	B-Protein
kinase	I-Protein
3	I-Protein
-	O
STAT5a	B-Protein
pathway	O
after	O
CD40	B-Protein
triggering	O
of	O
human	O
monocytes	O
but	O
not	O
of	O
resting	O
B	O
cells	O
.	O

CD40	B-Protein
/	O
CD40	B-Protein
ligand	I-Protein
interactions	O
play	O
a	O
key	O
role	O
in	O
the	O
immune	O
responses	O
of	O
B	O
lymphocytes	O
,	O
monocytes	O
,	O
and	O
dendritic	O
cells	O
.	O
<EOS>	B-X
CD40/CD40	B-X
ligand	B-X
interactions	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
responses	B-X
of	B-X
B	B-X
lymphocytes	B-X
,	B-X
monocytes	B-X
,	B-X
and	B-X
dendritic	B-X
cells	B-X
.	B-X
The	B-X
signal	B-X
transduction	B-X
events	B-X
triggered	B-X
by	B-X
cross-linking	B-X
of	B-X
the	B-X
CD40	B-X
receptor	B-X
have	B-X
been	B-X
widely	B-X
studied	B-X
in	B-X
B	B-X
cell	B-X
lines	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
signaling	B-X
following	B-X
CD40	B-X
stimulation	B-X
of	B-X
monocytes	B-X
and	B-X
resting	B-X
tonsillar	B-X
B	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
CD40	B-X
pathway	B-X
in	B-X
highly	B-X
purified	B-X
human	B-X
monocytes	B-X
and	B-X
resting	B-X
B	B-X
cells	B-X
.	B-X
After	B-X
CD40	B-X
triggering	B-X
,	B-X
a	B-X
similar	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
(	B-X
but	B-X
not	B-X
of	B-X
the	B-X
AP-1	B-X
)	B-X
transcription	B-X
factor	B-X
complex	B-X
occurred	B-X
in	B-X
both	B-X
cell	B-X
preparations	B-X
.	B-X
However	B-X
,	B-X
the	B-X
components	B-X
of	B-X
the	B-X
NF-kappaB	B-X
complexes	B-X
were	B-X
different	B-X
in	B-X
monocytes	B-X
and	B-X
B	B-X
cells	B-X
,	B-X
because	B-X
p50	B-X
is	B-X
part	B-X
of	B-X
the	B-X
NF-kappaB	B-X
complex	B-X
induced	B-X
by	B-X
CD40	B-X
triggering	B-X
in	B-X
both	B-X
monocytes	B-X
and	B-X
B	B-X
cells	B-X
,	B-X
whereas	B-X
p65	B-X
was	B-X
only	B-X
induced	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
although	B-X
the	B-X
Janus	B-X
kinase	B-X
3	B-X
tyrosine	B-X
kinase	B-X
was	B-X
associated	B-X
with	B-X
CD40	B-X
molecules	B-X
in	B-X
both	B-X
monocytes	B-X
and	B-X
resting	B-X
B	B-X
cells	B-X
,	B-X
Janus	B-X
kinase	B-X
3	B-X
phosphorylation	B-X
induction	B-X
was	B-X
observed	B-X
only	B-X
in	B-X
CD40-activated	B-X
monocytes	B-X
,	B-X
with	B-X
subsequent	B-X
induction	B-X
of	B-X
STAT5a	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
activation	B-X
signals	B-X
in	B-X
human	B-X
B	B-X
cells	B-X
and	B-X
monocytes	B-X
differ	B-X
following	B-X
CD40	B-X
stimulation	B-X
.	B-X
This	B-X
observation	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
detection	B-X
of	B-X
normal	B-X
CD40-induced	B-X
monocyte	B-X
activation	B-X
in	B-X
patients	B-X
with	B-X
CD40	B-X
ligand+	B-X
hyper	B-X
IgM	B-X
syndrome	B-X
in	B-X
whom	B-X
a	B-X
defect	B-X
in	B-X
CD40-induced	B-X
B	B-X
cell	B-X
activation	B-X
has	B-X
been	B-X
reported	B-X
.	B-X

The	O
signal	O
transduction	O
events	O
triggered	O
by	O
cross	O
-	O
linking	O
of	O
the	O
CD40	B-Protein
receptor	O
have	O
been	O
widely	O
studied	O
in	O
B	O
cell	O
lines	O
,	O
but	O
little	O
is	O
known	O
about	O
signaling	O
following	O
CD40	B-Protein
stimulation	O
of	O
monocytes	O
and	O
resting	O
tonsillar	O
B	O
cells	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
CD40	B-Protein
pathway	O
in	O
highly	O
purified	O
human	O
monocytes	O
and	O
resting	O
B	O
cells	O
.	O
<EOS>	B-X
CD40/CD40	B-X
ligand	B-X
interactions	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
responses	B-X
of	B-X
B	B-X
lymphocytes	B-X
,	B-X
monocytes	B-X
,	B-X
and	B-X
dendritic	B-X
cells	B-X
.	B-X
The	B-X
signal	B-X
transduction	B-X
events	B-X
triggered	B-X
by	B-X
cross-linking	B-X
of	B-X
the	B-X
CD40	B-X
receptor	B-X
have	B-X
been	B-X
widely	B-X
studied	B-X
in	B-X
B	B-X
cell	B-X
lines	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
signaling	B-X
following	B-X
CD40	B-X
stimulation	B-X
of	B-X
monocytes	B-X
and	B-X
resting	B-X
tonsillar	B-X
B	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
CD40	B-X
pathway	B-X
in	B-X
highly	B-X
purified	B-X
human	B-X
monocytes	B-X
and	B-X
resting	B-X
B	B-X
cells	B-X
.	B-X
After	B-X
CD40	B-X
triggering	B-X
,	B-X
a	B-X
similar	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
(	B-X
but	B-X
not	B-X
of	B-X
the	B-X
AP-1	B-X
)	B-X
transcription	B-X
factor	B-X
complex	B-X
occurred	B-X
in	B-X
both	B-X
cell	B-X
preparations	B-X
.	B-X
However	B-X
,	B-X
the	B-X
components	B-X
of	B-X
the	B-X
NF-kappaB	B-X
complexes	B-X
were	B-X
different	B-X
in	B-X
monocytes	B-X
and	B-X
B	B-X
cells	B-X
,	B-X
because	B-X
p50	B-X
is	B-X
part	B-X
of	B-X
the	B-X
NF-kappaB	B-X
complex	B-X
induced	B-X
by	B-X
CD40	B-X
triggering	B-X
in	B-X
both	B-X
monocytes	B-X
and	B-X
B	B-X
cells	B-X
,	B-X
whereas	B-X
p65	B-X
was	B-X
only	B-X
induced	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
although	B-X
the	B-X
Janus	B-X
kinase	B-X
3	B-X
tyrosine	B-X
kinase	B-X
was	B-X
associated	B-X
with	B-X
CD40	B-X
molecules	B-X
in	B-X
both	B-X
monocytes	B-X
and	B-X
resting	B-X
B	B-X
cells	B-X
,	B-X
Janus	B-X
kinase	B-X
3	B-X
phosphorylation	B-X
induction	B-X
was	B-X
observed	B-X
only	B-X
in	B-X
CD40-activated	B-X
monocytes	B-X
,	B-X
with	B-X
subsequent	B-X
induction	B-X
of	B-X
STAT5a	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
activation	B-X
signals	B-X
in	B-X
human	B-X
B	B-X
cells	B-X
and	B-X
monocytes	B-X
differ	B-X
following	B-X
CD40	B-X
stimulation	B-X
.	B-X
This	B-X
observation	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
detection	B-X
of	B-X
normal	B-X
CD40-induced	B-X
monocyte	B-X
activation	B-X
in	B-X
patients	B-X
with	B-X
CD40	B-X
ligand+	B-X
hyper	B-X
IgM	B-X
syndrome	B-X
in	B-X
whom	B-X
a	B-X
defect	B-X
in	B-X
CD40-induced	B-X
B	B-X
cell	B-X
activation	B-X
has	B-X
been	B-X
reported	B-X
.	B-X

After	O
CD40	B-Protein
triggering	O
,	O
a	O
similar	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
(	O
but	O
not	O
of	O
the	O
AP	O
-	O
1	O
)	O
transcription	O
factor	O
complex	O
occurred	O
in	O
both	O
cell	O
preparations	O
.	O
<EOS>	B-X
CD40/CD40	B-X
ligand	B-X
interactions	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
responses	B-X
of	B-X
B	B-X
lymphocytes	B-X
,	B-X
monocytes	B-X
,	B-X
and	B-X
dendritic	B-X
cells	B-X
.	B-X
The	B-X
signal	B-X
transduction	B-X
events	B-X
triggered	B-X
by	B-X
cross-linking	B-X
of	B-X
the	B-X
CD40	B-X
receptor	B-X
have	B-X
been	B-X
widely	B-X
studied	B-X
in	B-X
B	B-X
cell	B-X
lines	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
signaling	B-X
following	B-X
CD40	B-X
stimulation	B-X
of	B-X
monocytes	B-X
and	B-X
resting	B-X
tonsillar	B-X
B	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
CD40	B-X
pathway	B-X
in	B-X
highly	B-X
purified	B-X
human	B-X
monocytes	B-X
and	B-X
resting	B-X
B	B-X
cells	B-X
.	B-X
After	B-X
CD40	B-X
triggering	B-X
,	B-X
a	B-X
similar	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
(	B-X
but	B-X
not	B-X
of	B-X
the	B-X
AP-1	B-X
)	B-X
transcription	B-X
factor	B-X
complex	B-X
occurred	B-X
in	B-X
both	B-X
cell	B-X
preparations	B-X
.	B-X
However	B-X
,	B-X
the	B-X
components	B-X
of	B-X
the	B-X
NF-kappaB	B-X
complexes	B-X
were	B-X
different	B-X
in	B-X
monocytes	B-X
and	B-X
B	B-X
cells	B-X
,	B-X
because	B-X
p50	B-X
is	B-X
part	B-X
of	B-X
the	B-X
NF-kappaB	B-X
complex	B-X
induced	B-X
by	B-X
CD40	B-X
triggering	B-X
in	B-X
both	B-X
monocytes	B-X
and	B-X
B	B-X
cells	B-X
,	B-X
whereas	B-X
p65	B-X
was	B-X
only	B-X
induced	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
although	B-X
the	B-X
Janus	B-X
kinase	B-X
3	B-X
tyrosine	B-X
kinase	B-X
was	B-X
associated	B-X
with	B-X
CD40	B-X
molecules	B-X
in	B-X
both	B-X
monocytes	B-X
and	B-X
resting	B-X
B	B-X
cells	B-X
,	B-X
Janus	B-X
kinase	B-X
3	B-X
phosphorylation	B-X
induction	B-X
was	B-X
observed	B-X
only	B-X
in	B-X
CD40-activated	B-X
monocytes	B-X
,	B-X
with	B-X
subsequent	B-X
induction	B-X
of	B-X
STAT5a	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
activation	B-X
signals	B-X
in	B-X
human	B-X
B	B-X
cells	B-X
and	B-X
monocytes	B-X
differ	B-X
following	B-X
CD40	B-X
stimulation	B-X
.	B-X
This	B-X
observation	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
detection	B-X
of	B-X
normal	B-X
CD40-induced	B-X
monocyte	B-X
activation	B-X
in	B-X
patients	B-X
with	B-X
CD40	B-X
ligand+	B-X
hyper	B-X
IgM	B-X
syndrome	B-X
in	B-X
whom	B-X
a	B-X
defect	B-X
in	B-X
CD40-induced	B-X
B	B-X
cell	B-X
activation	B-X
has	B-X
been	B-X
reported	B-X
.	B-X

However	O
,	O
the	O
components	O
of	O
the	O
NF	O
-	O
kappaB	O
complexes	O
were	O
different	O
in	O
monocytes	O
and	O
B	O
cells	O
,	O
because	O
p50	B-Protein
is	O
part	O
of	O
the	O
NF	O
-	O
kappaB	O
complex	O
induced	O
by	O
CD40	B-Protein
triggering	O
in	O
both	O
monocytes	O
and	O
B	O
cells	O
,	O
whereas	O
p65	B-Protein
was	O
only	O
induced	O
in	O
B	O
cells	O
.	O

In	O
contrast	O
,	O
although	O
the	O
Janus	B-Protein
kinase	I-Protein
3	I-Protein
tyrosine	O
kinase	O
was	O
associated	O
with	O
CD40	B-Protein
molecules	O
in	O
both	O
monocytes	O
and	O
resting	O
B	O
cells	O
,	O
Janus	B-Protein
kinase	I-Protein
3	I-Protein
phosphorylation	O
induction	O
was	O
observed	O
only	O
in	O
CD40	B-Protein
-	O
activated	O
monocytes	O
,	O
with	O
subsequent	O
induction	O
of	O
STAT5a	B-Protein
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O
<EOS>	B-X
CD40/CD40	B-X
ligand	B-X
interactions	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
responses	B-X
of	B-X
B	B-X
lymphocytes	B-X
,	B-X
monocytes	B-X
,	B-X
and	B-X
dendritic	B-X
cells	B-X
.	B-X
The	B-X
signal	B-X
transduction	B-X
events	B-X
triggered	B-X
by	B-X
cross-linking	B-X
of	B-X
the	B-X
CD40	B-X
receptor	B-X
have	B-X
been	B-X
widely	B-X
studied	B-X
in	B-X
B	B-X
cell	B-X
lines	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
signaling	B-X
following	B-X
CD40	B-X
stimulation	B-X
of	B-X
monocytes	B-X
and	B-X
resting	B-X
tonsillar	B-X
B	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
CD40	B-X
pathway	B-X
in	B-X
highly	B-X
purified	B-X
human	B-X
monocytes	B-X
and	B-X
resting	B-X
B	B-X
cells	B-X
.	B-X
After	B-X
CD40	B-X
triggering	B-X
,	B-X
a	B-X
similar	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
(	B-X
but	B-X
not	B-X
of	B-X
the	B-X
AP-1	B-X
)	B-X
transcription	B-X
factor	B-X
complex	B-X
occurred	B-X
in	B-X
both	B-X
cell	B-X
preparations	B-X
.	B-X
However	B-X
,	B-X
the	B-X
components	B-X
of	B-X
the	B-X
NF-kappaB	B-X
complexes	B-X
were	B-X
different	B-X
in	B-X
monocytes	B-X
and	B-X
B	B-X
cells	B-X
,	B-X
because	B-X
p50	B-X
is	B-X
part	B-X
of	B-X
the	B-X
NF-kappaB	B-X
complex	B-X
induced	B-X
by	B-X
CD40	B-X
triggering	B-X
in	B-X
both	B-X
monocytes	B-X
and	B-X
B	B-X
cells	B-X
,	B-X
whereas	B-X
p65	B-X
was	B-X
only	B-X
induced	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
although	B-X
the	B-X
Janus	B-X
kinase	B-X
3	B-X
tyrosine	B-X
kinase	B-X
was	B-X
associated	B-X
with	B-X
CD40	B-X
molecules	B-X
in	B-X
both	B-X
monocytes	B-X
and	B-X
resting	B-X
B	B-X
cells	B-X
,	B-X
Janus	B-X
kinase	B-X
3	B-X
phosphorylation	B-X
induction	B-X
was	B-X
observed	B-X
only	B-X
in	B-X
CD40-activated	B-X
monocytes	B-X
,	B-X
with	B-X
subsequent	B-X
induction	B-X
of	B-X
STAT5a	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
activation	B-X
signals	B-X
in	B-X
human	B-X
B	B-X
cells	B-X
and	B-X
monocytes	B-X
differ	B-X
following	B-X
CD40	B-X
stimulation	B-X
.	B-X
This	B-X
observation	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
detection	B-X
of	B-X
normal	B-X
CD40-induced	B-X
monocyte	B-X
activation	B-X
in	B-X
patients	B-X
with	B-X
CD40	B-X
ligand+	B-X
hyper	B-X
IgM	B-X
syndrome	B-X
in	B-X
whom	B-X
a	B-X
defect	B-X
in	B-X
CD40-induced	B-X
B	B-X
cell	B-X
activation	B-X
has	B-X
been	B-X
reported	B-X
.	B-X

These	O
results	O
suggest	O
that	O
the	O
activation	O
signals	O
in	O
human	O
B	O
cells	O
and	O
monocytes	O
differ	O
following	O
CD40	B-Protein
stimulation	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
detection	O
of	O
normal	O
CD40	B-Protein
-	O
induced	O
monocyte	O
activation	O
in	O
patients	O
with	O
CD40	B-Protein
ligand	O
+	O
hyper	O
IgM	O
syndrome	O
in	O
whom	O
a	O
defect	O
in	O
CD40	B-Protein
-	O
induced	O
B	O
cell	O
activation	O
has	O
been	O
reported	O
.	O
<EOS>	B-X
CD40/CD40	B-X
ligand	B-X
interactions	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
responses	B-X
of	B-X
B	B-X
lymphocytes	B-X
,	B-X
monocytes	B-X
,	B-X
and	B-X
dendritic	B-X
cells	B-X
.	B-X
The	B-X
signal	B-X
transduction	B-X
events	B-X
triggered	B-X
by	B-X
cross-linking	B-X
of	B-X
the	B-X
CD40	B-X
receptor	B-X
have	B-X
been	B-X
widely	B-X
studied	B-X
in	B-X
B	B-X
cell	B-X
lines	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
signaling	B-X
following	B-X
CD40	B-X
stimulation	B-X
of	B-X
monocytes	B-X
and	B-X
resting	B-X
tonsillar	B-X
B	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
CD40	B-X
pathway	B-X
in	B-X
highly	B-X
purified	B-X
human	B-X
monocytes	B-X
and	B-X
resting	B-X
B	B-X
cells	B-X
.	B-X
After	B-X
CD40	B-X
triggering	B-X
,	B-X
a	B-X
similar	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
(	B-X
but	B-X
not	B-X
of	B-X
the	B-X
AP-1	B-X
)	B-X
transcription	B-X
factor	B-X
complex	B-X
occurred	B-X
in	B-X
both	B-X
cell	B-X
preparations	B-X
.	B-X
However	B-X
,	B-X
the	B-X
components	B-X
of	B-X
the	B-X
NF-kappaB	B-X
complexes	B-X
were	B-X
different	B-X
in	B-X
monocytes	B-X
and	B-X
B	B-X
cells	B-X
,	B-X
because	B-X
p50	B-X
is	B-X
part	B-X
of	B-X
the	B-X
NF-kappaB	B-X
complex	B-X
induced	B-X
by	B-X
CD40	B-X
triggering	B-X
in	B-X
both	B-X
monocytes	B-X
and	B-X
B	B-X
cells	B-X
,	B-X
whereas	B-X
p65	B-X
was	B-X
only	B-X
induced	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
although	B-X
the	B-X
Janus	B-X
kinase	B-X
3	B-X
tyrosine	B-X
kinase	B-X
was	B-X
associated	B-X
with	B-X
CD40	B-X
molecules	B-X
in	B-X
both	B-X
monocytes	B-X
and	B-X
resting	B-X
B	B-X
cells	B-X
,	B-X
Janus	B-X
kinase	B-X
3	B-X
phosphorylation	B-X
induction	B-X
was	B-X
observed	B-X
only	B-X
in	B-X
CD40-activated	B-X
monocytes	B-X
,	B-X
with	B-X
subsequent	B-X
induction	B-X
of	B-X
STAT5a	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
activation	B-X
signals	B-X
in	B-X
human	B-X
B	B-X
cells	B-X
and	B-X
monocytes	B-X
differ	B-X
following	B-X
CD40	B-X
stimulation	B-X
.	B-X
This	B-X
observation	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
detection	B-X
of	B-X
normal	B-X
CD40-induced	B-X
monocyte	B-X
activation	B-X
in	B-X
patients	B-X
with	B-X
CD40	B-X
ligand+	B-X
hyper	B-X
IgM	B-X
syndrome	B-X
in	B-X
whom	B-X
a	B-X
defect	B-X
in	B-X
CD40-induced	B-X
B	B-X
cell	B-X
activation	B-X
has	B-X
been	B-X
reported	B-X
.	B-X

Suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
normal	O
T	O
cells	O
by	O
supernatant	O
fluid	O
from	O
human	O
renal	O
cell	O
carcinomas	O
.	O
<EOS>	B-X
T	B-X
lymphocytes	B-X
from	B-X
patients	B-X
with	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
show	B-X
reduced	B-X
immune	B-X
function	B-X
and	B-X
impaired	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
,	B-X
NF-kappaB	B-X
.	B-X
We	B-X
determined	B-X
the	B-X
mechanism	B-X
of	B-X
NF-kappaB	B-X
suppression	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
RCC	B-X
patient	B-X
and	B-X
determined	B-X
whether	B-X
supernatant	B-X
fluid	B-X
from	B-X
RCC	B-X
explants	B-X
(	B-X
RCC-S	B-X
)	B-X
induced	B-X
the	B-X
same	B-X
phenotype	B-X
of	B-X
NF-kappaB	B-X
suppression	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
that	B-X
is	B-X
observed	B-X
in	B-X
patient	B-X
T	B-X
cells	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
kappaB-binding	B-X
activity	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
RCC	B-X
patient	B-X
was	B-X
altered	B-X
as	B-X
compared	B-X
to	B-X
that	B-X
seen	B-X
in	B-X
T	B-X
cells	B-X
obtained	B-X
from	B-X
normal	B-X
volunteers	B-X
.	B-X
In	B-X
some	B-X
patients	B-X
,	B-X
no	B-X
activation	B-X
of	B-X
RelA/NFkappaB1-binding	B-X
activity	B-X
was	B-X
detectable	B-X
,	B-X
while	B-X
in	B-X
others	B-X
kappaB-binding	B-X
activity	B-X
was	B-X
modestly	B-X
induced	B-X
but	B-X
the	B-X
duration	B-X
was	B-X
reduced	B-X
.	B-X
IkappaBalpha	B-X
was	B-X
degraded	B-X
normally	B-X
following	B-X
stimulation	B-X
in	B-X
both	B-X
normal	B-X
controls	B-X
and	B-X
T	B-X
cells	B-X
from	B-X
RCC	B-X
patients	B-X
.	B-X
RCC-S	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
cytoplasmic	B-X
levels	B-X
of	B-X
RelA	B-X
and	B-X
NF-kappaB1	B-X
but	B-X
did	B-X
suppress	B-X
their	B-X
nuclear	B-X
localization	B-X
and	B-X
inhibited	B-X
the	B-X
activation	B-X
of	B-X
RelA/NF-kappaB1	B-X
binding	B-X
complexes	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
RCC-S	B-X
can	B-X
induce	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
the	B-X
same	B-X
phenotype	B-X
of	B-X
impaired	B-X
NF-kappaB	B-X
activation	B-X
that	B-X
is	B-X
detected	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
RCC	B-X
patient	B-X
.	B-X
It	B-X
also	B-X
appears	B-X
that	B-X
NF-kappaB	B-X
suppression	B-X
by	B-X
RCC-S	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
immunosuppression	B-X
of	B-X
host	B-X
immunity	B-X
.	B-X

T	O
lymphocytes	O
from	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
show	O
reduced	O
immune	O
function	O
and	O
impaired	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
T	B-X
lymphocytes	B-X
from	B-X
patients	B-X
with	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
show	B-X
reduced	B-X
immune	B-X
function	B-X
and	B-X
impaired	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
,	B-X
NF-kappaB	B-X
.	B-X
We	B-X
determined	B-X
the	B-X
mechanism	B-X
of	B-X
NF-kappaB	B-X
suppression	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
RCC	B-X
patient	B-X
and	B-X
determined	B-X
whether	B-X
supernatant	B-X
fluid	B-X
from	B-X
RCC	B-X
explants	B-X
(	B-X
RCC-S	B-X
)	B-X
induced	B-X
the	B-X
same	B-X
phenotype	B-X
of	B-X
NF-kappaB	B-X
suppression	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
that	B-X
is	B-X
observed	B-X
in	B-X
patient	B-X
T	B-X
cells	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
kappaB-binding	B-X
activity	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
RCC	B-X
patient	B-X
was	B-X
altered	B-X
as	B-X
compared	B-X
to	B-X
that	B-X
seen	B-X
in	B-X
T	B-X
cells	B-X
obtained	B-X
from	B-X
normal	B-X
volunteers	B-X
.	B-X
In	B-X
some	B-X
patients	B-X
,	B-X
no	B-X
activation	B-X
of	B-X
RelA/NFkappaB1-binding	B-X
activity	B-X
was	B-X
detectable	B-X
,	B-X
while	B-X
in	B-X
others	B-X
kappaB-binding	B-X
activity	B-X
was	B-X
modestly	B-X
induced	B-X
but	B-X
the	B-X
duration	B-X
was	B-X
reduced	B-X
.	B-X
IkappaBalpha	B-X
was	B-X
degraded	B-X
normally	B-X
following	B-X
stimulation	B-X
in	B-X
both	B-X
normal	B-X
controls	B-X
and	B-X
T	B-X
cells	B-X
from	B-X
RCC	B-X
patients	B-X
.	B-X
RCC-S	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
cytoplasmic	B-X
levels	B-X
of	B-X
RelA	B-X
and	B-X
NF-kappaB1	B-X
but	B-X
did	B-X
suppress	B-X
their	B-X
nuclear	B-X
localization	B-X
and	B-X
inhibited	B-X
the	B-X
activation	B-X
of	B-X
RelA/NF-kappaB1	B-X
binding	B-X
complexes	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
RCC-S	B-X
can	B-X
induce	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
the	B-X
same	B-X
phenotype	B-X
of	B-X
impaired	B-X
NF-kappaB	B-X
activation	B-X
that	B-X
is	B-X
detected	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
RCC	B-X
patient	B-X
.	B-X
It	B-X
also	B-X
appears	B-X
that	B-X
NF-kappaB	B-X
suppression	B-X
by	B-X
RCC-S	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
immunosuppression	B-X
of	B-X
host	B-X
immunity	B-X
.	B-X

We	O
determined	O
the	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
suppression	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
and	O
determined	O
whether	O
supernatant	O
fluid	O
from	O
RCC	O
explants	O
(	O
RCC	O
-	O
S	O
)	O
induced	O
the	O
same	O
phenotype	O
of	O
NF	O
-	O
kappaB	O
suppression	O
in	O
normal	O
T	O
cells	O
that	O
is	O
observed	O
in	O
patient	O
T	O
cells	O
.	O

The	O
pattern	O
of	O
kappaB	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
was	O
altered	O
as	O
compared	O
to	O
that	O
seen	O
in	O
T	O
cells	O
obtained	O
from	O
normal	O
volunteers	O
.	O

In	O
some	O
patients	O
,	O
no	O
activation	O
of	O
RelA	B-Protein
/	O
NFkappaB1	B-Protein
-	O
binding	O
activity	O
was	O
detectable	O
,	O
while	O
in	O
others	O
kappaB	O
-	O
binding	O
activity	O
was	O
modestly	O
induced	O
but	O
the	O
duration	O
was	O
reduced	O
.	O
<EOS>	B-X
T	B-X
lymphocytes	B-X
from	B-X
patients	B-X
with	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
show	B-X
reduced	B-X
immune	B-X
function	B-X
and	B-X
impaired	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
,	B-X
NF-kappaB	B-X
.	B-X
We	B-X
determined	B-X
the	B-X
mechanism	B-X
of	B-X
NF-kappaB	B-X
suppression	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
RCC	B-X
patient	B-X
and	B-X
determined	B-X
whether	B-X
supernatant	B-X
fluid	B-X
from	B-X
RCC	B-X
explants	B-X
(	B-X
RCC-S	B-X
)	B-X
induced	B-X
the	B-X
same	B-X
phenotype	B-X
of	B-X
NF-kappaB	B-X
suppression	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
that	B-X
is	B-X
observed	B-X
in	B-X
patient	B-X
T	B-X
cells	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
kappaB-binding	B-X
activity	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
RCC	B-X
patient	B-X
was	B-X
altered	B-X
as	B-X
compared	B-X
to	B-X
that	B-X
seen	B-X
in	B-X
T	B-X
cells	B-X
obtained	B-X
from	B-X
normal	B-X
volunteers	B-X
.	B-X
In	B-X
some	B-X
patients	B-X
,	B-X
no	B-X
activation	B-X
of	B-X
RelA/NFkappaB1-binding	B-X
activity	B-X
was	B-X
detectable	B-X
,	B-X
while	B-X
in	B-X
others	B-X
kappaB-binding	B-X
activity	B-X
was	B-X
modestly	B-X
induced	B-X
but	B-X
the	B-X
duration	B-X
was	B-X
reduced	B-X
.	B-X
IkappaBalpha	B-X
was	B-X
degraded	B-X
normally	B-X
following	B-X
stimulation	B-X
in	B-X
both	B-X
normal	B-X
controls	B-X
and	B-X
T	B-X
cells	B-X
from	B-X
RCC	B-X
patients	B-X
.	B-X
RCC-S	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
cytoplasmic	B-X
levels	B-X
of	B-X
RelA	B-X
and	B-X
NF-kappaB1	B-X
but	B-X
did	B-X
suppress	B-X
their	B-X
nuclear	B-X
localization	B-X
and	B-X
inhibited	B-X
the	B-X
activation	B-X
of	B-X
RelA/NF-kappaB1	B-X
binding	B-X
complexes	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
RCC-S	B-X
can	B-X
induce	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
the	B-X
same	B-X
phenotype	B-X
of	B-X
impaired	B-X
NF-kappaB	B-X
activation	B-X
that	B-X
is	B-X
detected	B-X
in	B-X
T	B-X
cells	B-X
of	B-X
RCC	B-X
patient	B-X
.	B-X
It	B-X
also	B-X
appears	B-X
that	B-X
NF-kappaB	B-X
suppression	B-X
by	B-X
RCC-S	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
immunosuppression	B-X
of	B-X
host	B-X
immunity	B-X
.	B-X

IkappaBalpha	B-Protein
was	O
degraded	O
normally	O
following	O
stimulation	O
in	O
both	O
normal	O
controls	O
and	O
T	O
cells	O
from	O
RCC	O
patients	O
.	O

RCC	O
-	O
S	O
did	O
not	O
alter	O
the	O
cytoplasmic	O
levels	O
of	O
RelA	B-Protein
and	O
NF	B-Protein
-	I-Protein
kappaB1	I-Protein
but	O
did	O
suppress	O
their	O
nuclear	O
localization	O
and	O
inhibited	O
the	O
activation	O
of	O
RelA	B-Protein
/	O
NF	B-Protein
-	I-Protein
kappaB1	I-Protein
binding	O
complexes	O
.	O
<EOS>	B-X
Renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
denotes	B-X
cancer	B-X
originated	B-X
from	B-X
the	B-X
renal	B-X
epithelium	B-X
and	B-X
accounts	B-X
for	B-X
>	B-X
90	B-X
%	B-X
of	B-X
cancers	B-X
in	B-X
the	B-X
kidney	B-X
.	B-X
The	B-X
disease	B-X
encompasses	B-X
>	B-X
10	B-X
histological	B-X
and	B-X
molecular	B-X
subtypes	B-X
,	B-X
of	B-X
which	B-X
clear	B-X
cell	B-X
RCC	B-X
(	B-X
ccRCC	B-X
)	B-X
is	B-X
most	B-X
common	B-X
and	B-X
accounts	B-X
for	B-X
most	B-X
cancer-related	B-X
deaths	B-X
.	B-X
Localized	B-X
RCC	B-X
can	B-X
be	B-X
successfully	B-X
managed	B-X
with	B-X
surgery	B-X
,	B-X
whereas	B-X
metastatic	B-X
RCC	B-X
is	B-X
refractory	B-X
to	B-X
conventional	B-X
chemotherapy	B-X
.	B-X
However	B-X
,	B-X
over	B-X
the	B-X
past	B-X
decade	B-X
,	B-X
marked	B-X
advances	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
metastatic	B-X
RCC	B-X
have	B-X
been	B-X
made	B-X
,	B-X
with	B-X
targeted	B-X
agents	B-X
including	B-X
sorafenib	B-X
,	B-X
sunitinib	B-X
,	B-X
bevacizumab	B-X
,	B-X
pazopanib	B-X
and	B-X
axitinib	B-X
,	B-X
which	B-X
inhibit	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
its	B-X
receptor	B-X
(	B-X
VEGFR	B-X
)	B-X
,	B-X
and	B-X
everolimus	B-X
and	B-X
temsirolimus	B-X
,	B-X
which	B-X
inhibit	B-X
mechanistic	B-X
target	B-X
of	B-X
rapamycin	B-X
complex	B-X
1	B-X
(	B-X
mTORC1	B-X
)	B-X
,	B-X
being	B-X
approved	B-X
.	B-X
Since	B-X
2015	B-X
,	B-X
agents	B-X
with	B-X
additional	B-X
targets	B-X
aside	B-X
from	B-X
VEGFR	B-X
have	B-X
been	B-X
approved	B-X
,	B-X
such	B-X
as	B-X
cabozantinib	B-X
and	B-X
lenvatinib	B-X
;	B-X
immunotherapies	B-X
,	B-X
such	B-X
as	B-X
nivolumab	B-X
,	B-X
have	B-X
also	B-X
been	B-X
added	B-X
to	B-X
the	B-X
armamentarium	B-X
for	B-X
metastatic	B-X
RCC	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
biology	B-X
of	B-X
RCC	B-X
,	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
ccRCC	B-X
,	B-X
as	B-X
well	B-X
as	B-X
updates	B-X
to	B-X
complement	B-X
the	B-X
current	B-X
clinical	B-X
guidelines	B-X
and	B-X
an	B-X
outline	B-X
of	B-X
potential	B-X
future	B-X
directions	B-X
for	B-X
RCC	B-X
research	B-X
and	B-X
therapy	B-X
.	B-X

These	O
results	O
show	O
that	O
RCC	O
-	O
S	O
can	O
induce	O
in	O
normal	O
T	O
cells	O
the	O
same	O
phenotype	O
of	O
impaired	O
NF	O
-	O
kappaB	O
activation	O
that	O
is	O
detected	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
.	O

It	O
also	O
appears	O
that	O
NF	O
-	O
kappaB	O
suppression	O
by	O
RCC	O
-	O
S	O
may	O
contribute	O
to	O
the	O
immunosuppression	O
of	O
host	O
immunity	O
.	O

Monoclonal	O
anti	O
-	O
endothelial	O
cell	O
antibodies	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
activate	O
endothelial	O
cells	O
from	O
large	O
vessels	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

OBJECTIVE	O
:	O
To	O
create	O
monoclonal	O
anti	O
-	O
endothelial	O
cell	O
antibodies	O
(	O
mAECA	O
)	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
to	O
evaluate	O
their	O
ability	O
to	O
activate	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
and	O
to	O
characterize	O
the	O
mechanism	O
of	O
EC	O
activation	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

METHODS	O
:	O
A	O
panel	O
of	O
mAECA	O
was	O
generated	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
,	O
using	O
Epstein	O
-	O
Barr	O
virus	O
transformation	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

Activity	O
against	O
macrovascular	O
EC	O
(	O
HUVEC	O
)	O
and	O
microvascular	O
EC	O
(	O
human	O
bone	O
marrow	O
EC	O
immortalized	O
by	O
SV40	O
)	O
antigens	O
was	O
detected	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

Inhibition	O
studies	O
were	O
used	O
to	O
select	O
the	O
monoclonal	O
antibodies	O
(	O
mAECA	O
)	O
which	O
share	O
the	O
same	O
EC	O
epitope	O
binding	O
specificity	O
as	O
the	O
total	O
IgG	B-Protein
-	O
AECA	O
from	O
the	O
Takayasu	O
arteritis	O
patient	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

The	O
binding	O
of	O
the	O
mAECA	O
to	O
human	O
aortic	O
EC	O
was	O
studied	O
by	O
immunohistochemistry	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

The	O
secretion	O
levels	O
of	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
)	O
and	O
von	B-Protein
Willebrand	I-Protein
factor	I-Protein
(	O
vWF	B-Protein
)	O
were	O
determined	O
,	O
to	O
serve	O
as	O
markers	O
for	O
EC	O
activation	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

The	O
activated	O
EC	O
were	O
examined	O
for	O
the	O
adherence	O
of	O
a	O
monocytic	O
cell	O
line	O
(	O
U937	O
)	O
,	O
as	O
well	O
as	O
for	O
expression	O
of	O
vascular	B-Protein
cell	I-Protein
adhesion	I-Protein
molecule	I-Protein
1	I-Protein
,	O
intercellular	B-Protein
adhesion	I-Protein
molecule	I-Protein
1	I-Protein
,	O
and	O
E	B-Protein
-	I-Protein
selectin	I-Protein
.	O

In	O
addition	O
,	O
nuclear	O
extracts	O
of	O
the	O
mAECA	O
-	O
treated	O
EC	O
were	O
analyzed	O
for	O
the	O
induction	O
of	O
translocation	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
using	O
a	O
specific	O
NF	O
-	O
kappaB	O
oligoprobe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
Six	O
mAECA	O
were	O
selected	O
,	O
the	O
mixture	O
of	O
which	O
produced	O
100	O
%	O
inhibition	O
of	O
binding	O
of	O
the	O
original	O
IgG	O
(	O
from	O
the	O
patient	O
with	O
Takayasu	O
arteritis	O
)	O
to	O
HUVEC	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

All	O
mAECA	O
possessed	O
high	O
activity	O
against	O
macrovascular	O
EC	O
,	O
but	O
none	O
had	O
significant	O
antimicrovascular	O
EC	O
activity	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

The	O
mAECA	O
,	O
but	O
not	O
normal	O
human	O
IgG	B-Protein
,	O
had	O
anti	O
-	O
human	O
aortic	O
EC	O
activity	O
.	O
<EOS>	B-X
A	B-X
family	B-X
of	B-X
amphiphilic	B-X
copolymers	B-X
containing	B-X
hydrophobic	B-X
cholate	B-X
pendants	B-X
has	B-X
been	B-X
prepared	B-X
by	B-X
copolymerization	B-X
of	B-X
cholic	B-X
acid-based	B-X
monomer	B-X
2-	B-X
(	B-X
methacryloxy	B-X
)	B-X
-ethyl	B-X
cholate	B-X
(	B-X
MAECA	B-X
)	B-X
with	B-X
polyethylene	B-X
glycol	B-X
methyl	B-X
ether	B-X
methacrylate	B-X
(	B-X
PEGMA	B-X
)	B-X
.	B-X
The	B-X
polymers	B-X
differ	B-X
for	B-X
the	B-X
content	B-X
of	B-X
MAECA	B-X
that	B-X
increases	B-X
from	B-X
0	B-X
to	B-X
35	B-X
%	B-X
.	B-X
The	B-X
copolymers	B-X
partition	B-X
within	B-X
liposomes	B-X
and	B-X
display	B-X
potent	B-X
ionophoric	B-X
activity	B-X
forming	B-X
large	B-X
pores	B-X
in	B-X
the	B-X
membrane	B-X
and	B-X
allowing	B-X
the	B-X
leakage	B-X
of	B-X
small	B-X
inorganic	B-X
ions	B-X
(	B-X
H	B-X

Four	O
of	O
the	O
6	O
mAECA	O
activated	O
EC	O
,	O
manifested	O
by	O
increased	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
vWF	B-Protein
secretion	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

The	O
4	O
mAECA	O
induced	O
EC	O
expression	O
of	O
adhesion	O
molecules	O
and	O
increased	O
adhesion	O
of	O
U937	O
monocytic	O
cells	O
to	O
EC	O
.	O

In	O
addition	O
,	O
these	O
mAECA	O
stimulated	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
AECA	O
may	O
directly	O
stimulate	O
EC	O
in	O
Takayasu	O
arteritis	O
through	O
elevation	O
of	O
adhesion	O
molecule	O
expression	O
associated	O
with	O
NF	O
-	O
kappaB	O
activation	O
and	O
adhesion	O
of	O
monocytes	O
,	O
and	O
may	O
therefore	O
play	O
a	O
pathogenic	O
role	O
in	O
the	O
development	O
of	O
the	O
vasculopathy	O
in	O
Takayasu	O
arteritis	O
.	O
<EOS>	B-X
To	B-X
create	B-X
monoclonal	B-X
anti-endothelial	B-X
cell	B-X
antibodies	B-X
(	B-X
mAECA	B-X
)	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
Takayasu	B-X
arteritis	B-X
to	B-X
evaluate	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVEC	B-X
)	B-X
,	B-X
and	B-X
to	B-X
characterize	B-X
the	B-X
mechanism	B-X
of	B-X
EC	B-X
activation	B-X
.	B-X

The	O
Epstein	O
-	O
Barr	O
virus	O
oncoprotein	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
proteins	O
TRADD	B-Protein
and	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
but	O
does	O
not	O
induce	O
apoptosis	O
or	O
require	O
RIP	O
for	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
signaling	B-X
is	B-X
triggered	B-X
by	B-X
pathogen-associated	B-X
molecular	B-X
patterns	B-X
that	B-X
mediate	B-X
well	B-X
established	B-X
cytokine-driven	B-X
pathways	B-X
,	B-X
activating	B-X
NF-κB	B-X
together	B-X
with	B-X
IRF3/IRF7	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
TLR3	B-X
drives	B-X
caspase	B-X
8-regulated	B-X
programmed	B-X
cell	B-X
death	B-X
pathways	B-X
reminiscent	B-X
of	B-X
TNF	B-X
family	B-X
death	B-X
receptor	B-X
signaling	B-X
.	B-X
We	B-X
find	B-X
that	B-X
inhibition	B-X
or	B-X
elimination	B-X
of	B-X
caspase	B-X
8	B-X
during	B-X
stimulation	B-X
of	B-X
TLR2	B-X
,	B-X
TLR3	B-X
,	B-X
TLR4	B-X
,	B-X
TLR5	B-X
,	B-X
or	B-X
TLR9	B-X
results	B-X
in	B-X
receptor	B-X
interacting	B-X
protein	B-X
(	B-X
RIP	B-X
)	B-X
3	B-X
kinase-dependent	B-X
programmed	B-X
necrosis	B-X
that	B-X
occurs	B-X
through	B-X
either	B-X
TIR	B-X
domain-containing	B-X
adapter-inducing	B-X
interferon-β	B-X
(	B-X
TRIF	B-X
)	B-X
or	B-X
MyD88	B-X
signal	B-X
transduction	B-X
.	B-X
TLR3	B-X
or	B-X
TLR4	B-X
directly	B-X
activates	B-X
programmed	B-X
necrosis	B-X
through	B-X
a	B-X
RIP	B-X
homotypic	B-X
interaction	B-X
motif-dependent	B-X
association	B-X
of	B-X
TRIF	B-X
with	B-X
RIP3	B-X
kinase	B-X
(	B-X
also	B-X
called	B-X
RIPK3	B-X
)	B-X
.	B-X
In	B-X
fibroblasts	B-X
,	B-X
this	B-X
pathway	B-X
proceeds	B-X
independent	B-X
of	B-X
RIP1	B-X
or	B-X
its	B-X
kinase	B-X
activity	B-X
,	B-X
but	B-X
it	B-X
remains	B-X
dependent	B-X
on	B-X
mixed	B-X
lineage	B-X
kinase	B-X
domain-like	B-X
protein	B-X
(	B-X
MLKL	B-X
)	B-X
downstream	B-X
of	B-X
RIP3	B-X
kinase	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
two	B-X
small	B-X
molecule	B-X
RIP3	B-X
kinase	B-X
inhibitors	B-X
and	B-X
employ	B-X
them	B-X
to	B-X
demonstrate	B-X
the	B-X
common	B-X
requirement	B-X
for	B-X
RIP3	B-X
kinase	B-X
in	B-X
programmed	B-X
necrosis	B-X
induced	B-X
by	B-X
RIP1-RIP3	B-X
,	B-X
DAI-RIP3	B-X
,	B-X
and	B-X
TRIF-RIP3	B-X
complexes	B-X
.	B-X
Cell	B-X
fate	B-X
decisions	B-X
following	B-X
TLR	B-X
signaling	B-X
parallel	B-X
death	B-X
receptor	B-X
signaling	B-X
and	B-X
rely	B-X
on	B-X
caspase	B-X
8	B-X
to	B-X
suppress	B-X
RIP3-dependent	B-X
programmed	B-X
necrosis	B-X
whether	B-X
initiated	B-X
directly	B-X
by	B-X
a	B-X
TRIF-RIP3-MLKL	B-X
pathway	B-X
or	B-X
indirectly	B-X
via	B-X
TNF	B-X
activation	B-X
and	B-X
the	B-X
RIP1-RIP3-MLKL	B-X
necroptosis	B-X
pathway	B-X
.	B-X

A	O
site	O
in	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
transforming	O
protein	O
LMP1	B-Protein
that	O
constitutively	O
associates	O
with	O
the	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
1	I-Protein
(	I-Protein
TNFR1	I-Protein
)	I-Protein
-	I-Protein
associated	I-Protein
death	I-Protein
domain	I-Protein
protein	I-Protein
TRADD	B-Protein
to	O
mediate	O
NF	O
-	O
kappaB	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
activation	O
is	O
critical	O
for	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
proliferation	O
.	O

We	O
now	O
find	O
that	O
LMP1	B-Protein
signaling	O
through	O
TRADD	B-Protein
differs	O
from	O
TNFR1	B-Protein
signaling	O
through	O
TRADD	B-Protein
.	O
<EOS>	B-X
A	B-X
site	B-X
in	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
transforming	B-X
protein	B-X
LMP1	B-X
that	B-X
constitutively	B-X
associates	B-X
with	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
TNFR1	B-X
)	B-X
-associated	B-X
death	B-X
domain	B-X
protein	B-X
TRADD	B-X
to	B-X
mediate	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
activation	B-X
is	B-X
critical	B-X
for	B-X
long-term	B-X
lymphoblastoid	B-X
cell	B-X
proliferation	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
LMP1	B-X
signaling	B-X
through	B-X
TRADD	B-X
differs	B-X
from	B-X
TNFR1	B-X
signaling	B-X
through	B-X
TRADD	B-X
.	B-X
LMP1	B-X
needs	B-X
only	B-X
11	B-X
amino	B-X
acids	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
or	B-X
synergize	B-X
with	B-X
TRADD	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
while	B-X
TNFR1	B-X
requires	B-X
approximately	B-X
70	B-X
residues	B-X
.	B-X
Further	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
require	B-X
TRADD	B-X
residues	B-X
294	B-X
to	B-X
312	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
while	B-X
TNFR1	B-X
requires	B-X
TRADD	B-X
residues	B-X
296	B-X
to	B-X
302	B-X
.	B-X
LMP1	B-X
is	B-X
partially	B-X
blocked	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
TRADD	B-X
mutant	B-X
consisting	B-X
of	B-X
residues	B-X
122	B-X
to	B-X
293	B-X
.	B-X
Unlike	B-X
TNFR1	B-X
,	B-X
LMP1	B-X
can	B-X
interact	B-X
directly	B-X
with	B-X
receptor-interacting	B-X
protein	B-X
(	B-X
RIP	B-X
)	B-X
and	B-X
stably	B-X
associates	B-X
with	B-X
RIP	B-X
in	B-X
EBV-transformed	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
.	B-X
Surprisingly	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
require	B-X
RIP	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Despite	B-X
constitutive	B-X
association	B-X
with	B-X
TRADD	B-X
or	B-X
RIP	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
induce	B-X
apoptosis	B-X
in	B-X
EBV-negative	B-X
Burkitt	B-X
lymphoma	B-X
or	B-X
human	B-X
embryonic	B-X
kidney	B-X
293	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
add	B-X
a	B-X
different	B-X
perspective	B-X
to	B-X
the	B-X
molecular	B-X
interactions	B-X
through	B-X
which	B-X
LMP1	B-X
,	B-X
TRADD	B-X
,	B-X
and	B-X
RIP	B-X
participate	B-X
in	B-X
B-lymphocyte	B-X
activation	B-X
and	B-X
growth	B-X
.	B-X

LMP1	B-Protein
needs	O
only	O
11	O
amino	O
acids	O
to	O
activate	O
NF	O
-	O
kappaB	O
or	O
synergize	O
with	O
TRADD	B-Protein
in	O
NF	O
-	O
kappaB	O
activation	O
,	O
while	O
TNFR1	B-Protein
requires	O
approximately	O
70	O
residues	O
.	O
<EOS>	B-X
A	B-X
site	B-X
in	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
transforming	B-X
protein	B-X
LMP1	B-X
that	B-X
constitutively	B-X
associates	B-X
with	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
TNFR1	B-X
)	B-X
-associated	B-X
death	B-X
domain	B-X
protein	B-X
TRADD	B-X
to	B-X
mediate	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
activation	B-X
is	B-X
critical	B-X
for	B-X
long-term	B-X
lymphoblastoid	B-X
cell	B-X
proliferation	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
LMP1	B-X
signaling	B-X
through	B-X
TRADD	B-X
differs	B-X
from	B-X
TNFR1	B-X
signaling	B-X
through	B-X
TRADD	B-X
.	B-X
LMP1	B-X
needs	B-X
only	B-X
11	B-X
amino	B-X
acids	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
or	B-X
synergize	B-X
with	B-X
TRADD	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
while	B-X
TNFR1	B-X
requires	B-X
approximately	B-X
70	B-X
residues	B-X
.	B-X
Further	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
require	B-X
TRADD	B-X
residues	B-X
294	B-X
to	B-X
312	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
while	B-X
TNFR1	B-X
requires	B-X
TRADD	B-X
residues	B-X
296	B-X
to	B-X
302	B-X
.	B-X
LMP1	B-X
is	B-X
partially	B-X
blocked	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
TRADD	B-X
mutant	B-X
consisting	B-X
of	B-X
residues	B-X
122	B-X
to	B-X
293	B-X
.	B-X
Unlike	B-X
TNFR1	B-X
,	B-X
LMP1	B-X
can	B-X
interact	B-X
directly	B-X
with	B-X
receptor-interacting	B-X
protein	B-X
(	B-X
RIP	B-X
)	B-X
and	B-X
stably	B-X
associates	B-X
with	B-X
RIP	B-X
in	B-X
EBV-transformed	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
.	B-X
Surprisingly	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
require	B-X
RIP	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Despite	B-X
constitutive	B-X
association	B-X
with	B-X
TRADD	B-X
or	B-X
RIP	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
induce	B-X
apoptosis	B-X
in	B-X
EBV-negative	B-X
Burkitt	B-X
lymphoma	B-X
or	B-X
human	B-X
embryonic	B-X
kidney	B-X
293	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
add	B-X
a	B-X
different	B-X
perspective	B-X
to	B-X
the	B-X
molecular	B-X
interactions	B-X
through	B-X
which	B-X
LMP1	B-X
,	B-X
TRADD	B-X
,	B-X
and	B-X
RIP	B-X
participate	B-X
in	B-X
B-lymphocyte	B-X
activation	B-X
and	B-X
growth	B-X
.	B-X

Further	O
,	O
LMP1	B-Protein
does	O
not	O
require	O
TRADD	B-Protein
residues	O
294	O
to	O
312	O
for	O
NF	O
-	O
kappaB	O
activation	O
,	O
while	O
TNFR1	B-Protein
requires	O
TRADD	B-Protein
residues	O
296	O
to	O
302	O
.	O
<EOS>	B-X
The	B-X
Epstein-Barr	B-X
Virus	B-X
(	B-X
EBV	B-X
)	B-X
principal	B-X
oncoprotein	B-X
Latent	B-X
Membrane	B-X
Protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Tumor	B-X
Necrosis	B-X
Factor	B-X
Receptor	B-X
(	B-X
TNFR	B-X
)	B-X
superfamily	B-X
with	B-X
constitutive	B-X
activity	B-X
.	B-X
LMP1	B-X
shares	B-X
many	B-X
features	B-X
with	B-X
Pathogen	B-X
Recognition	B-X
Receptors	B-X
(	B-X
PRRs	B-X
)	B-X
,	B-X
including	B-X
the	B-X
use	B-X
of	B-X
TRAFs	B-X
,	B-X
adaptors	B-X
,	B-X
and	B-X
kinase	B-X
cascades	B-X
,	B-X
for	B-X
signal	B-X
transduction	B-X
leading	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
NFκB	B-X
,	B-X
AP1	B-X
,	B-X
and	B-X
Akt	B-X
,	B-X
as	B-X
well	B-X
as	B-X
a	B-X
subset	B-X
of	B-X
IRFs	B-X
and	B-X
likely	B-X
the	B-X
master	B-X
antioxidative	B-X
transcription	B-X
factor	B-X
NRF2	B-X
,	B-X
which	B-X
we	B-X
have	B-X
gradually	B-X
added	B-X
to	B-X
the	B-X
list	B-X
.	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
we	B-X
have	B-X
discovered	B-X
the	B-X
Linear	B-X
UBiquitin	B-X
Assembly	B-X
Complex	B-X
(	B-X
LUBAC	B-X
)	B-X
,	B-X
the	B-X
adaptor	B-X
protein	B-X
LIMD1	B-X
,	B-X
and	B-X
the	B-X
ubiquitin	B-X
sensor	B-X
and	B-X
signaling	B-X
hub	B-X
p62	B-X
,	B-X
as	B-X
novel	B-X
components	B-X
of	B-X
LMP1	B-X
signalosome	B-X
.	B-X
Functionally	B-X
,	B-X
LMP1	B-X
is	B-X
a	B-X
pleiotropic	B-X
factor	B-X
that	B-X
reprograms	B-X
,	B-X
balances	B-X
,	B-X
and	B-X
perturbs	B-X
a	B-X
large	B-X
spectrum	B-X
of	B-X
cellular	B-X
mechanisms	B-X
,	B-X
including	B-X
the	B-X
ubiquitin	B-X
machinery	B-X
,	B-X
metabolism	B-X
,	B-X
epigenetics	B-X
,	B-X
DNA	B-X
damage	B-X
response	B-X
,	B-X
extracellular	B-X
vehicles	B-X
,	B-X
immune	B-X
defenses	B-X
,	B-X
and	B-X
telomere	B-X
elongation	B-X
,	B-X
to	B-X
promote	B-X
oncogenic	B-X
transformation	B-X
,	B-X
cell	B-X
proliferation	B-X
and	B-X
survival	B-X
,	B-X
anchorage-independent	B-X
cell	B-X
growth	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
metastasis	B-X
and	B-X
invasion	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
development	B-X
of	B-X
the	B-X
tumor	B-X
microenvironment	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
LMP1	B-X
induces	B-X
p62-mediated	B-X
selective	B-X
autophagy	B-X
in	B-X
EBV	B-X
latency	B-X
,	B-X
at	B-X
least	B-X
by	B-X
contributing	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
p62	B-X
expression	B-X
,	B-X
and	B-X
Reactive	B-X
Oxygen	B-X
Species	B-X
(	B-X
ROS	B-X
)	B-X
production	B-X
.	B-X
We	B-X
have	B-X
also	B-X
been	B-X
collecting	B-X
evidence	B-X
supporting	B-X
the	B-X
hypothesis	B-X
that	B-X
LMP1	B-X
activates	B-X
the	B-X
Keap1-NRF2	B-X
pathway	B-X
,	B-X
which	B-X
serves	B-X
as	B-X
the	B-X
key	B-X
antioxidative	B-X
defense	B-X
mechanism	B-X
.	B-X
Last	B-X
but	B-X
not	B-X
least	B-X
,	B-X
our	B-X
preliminary	B-X
data	B-X
shows	B-X
that	B-X
LMP1	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
deregulation	B-X
of	B-X
cGAS-STING	B-X
DNA	B-X
sensing	B-X
pathway	B-X
in	B-X
EBV	B-X
latency	B-X
.	B-X
A	B-X
comprehensive	B-X
understanding	B-X
of	B-X
the	B-X
LMP1	B-X
signaling	B-X
landscape	B-X
is	B-X
essential	B-X
for	B-X
identifying	B-X
potential	B-X
targets	B-X
for	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
strategies	B-X
towards	B-X
targeted	B-X
therapeutic	B-X
applications	B-X
.	B-X

LMP1	B-Protein
is	O
partially	O
blocked	O
for	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
TRADD	B-Protein
mutant	O
consisting	O
of	O
residues	O
122	O
to	O
293	O
.	O
<EOS>	B-X
A	B-X
site	B-X
in	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
transforming	B-X
protein	B-X
LMP1	B-X
that	B-X
constitutively	B-X
associates	B-X
with	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
TNFR1	B-X
)	B-X
-associated	B-X
death	B-X
domain	B-X
protein	B-X
TRADD	B-X
to	B-X
mediate	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
activation	B-X
is	B-X
critical	B-X
for	B-X
long-term	B-X
lymphoblastoid	B-X
cell	B-X
proliferation	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
LMP1	B-X
signaling	B-X
through	B-X
TRADD	B-X
differs	B-X
from	B-X
TNFR1	B-X
signaling	B-X
through	B-X
TRADD	B-X
.	B-X
LMP1	B-X
needs	B-X
only	B-X
11	B-X
amino	B-X
acids	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
or	B-X
synergize	B-X
with	B-X
TRADD	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
while	B-X
TNFR1	B-X
requires	B-X
approximately	B-X
70	B-X
residues	B-X
.	B-X
Further	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
require	B-X
TRADD	B-X
residues	B-X
294	B-X
to	B-X
312	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
while	B-X
TNFR1	B-X
requires	B-X
TRADD	B-X
residues	B-X
296	B-X
to	B-X
302	B-X
.	B-X
LMP1	B-X
is	B-X
partially	B-X
blocked	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
TRADD	B-X
mutant	B-X
consisting	B-X
of	B-X
residues	B-X
122	B-X
to	B-X
293	B-X
.	B-X
Unlike	B-X
TNFR1	B-X
,	B-X
LMP1	B-X
can	B-X
interact	B-X
directly	B-X
with	B-X
receptor-interacting	B-X
protein	B-X
(	B-X
RIP	B-X
)	B-X
and	B-X
stably	B-X
associates	B-X
with	B-X
RIP	B-X
in	B-X
EBV-transformed	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
.	B-X
Surprisingly	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
require	B-X
RIP	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Despite	B-X
constitutive	B-X
association	B-X
with	B-X
TRADD	B-X
or	B-X
RIP	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
induce	B-X
apoptosis	B-X
in	B-X
EBV-negative	B-X
Burkitt	B-X
lymphoma	B-X
or	B-X
human	B-X
embryonic	B-X
kidney	B-X
293	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
add	B-X
a	B-X
different	B-X
perspective	B-X
to	B-X
the	B-X
molecular	B-X
interactions	B-X
through	B-X
which	B-X
LMP1	B-X
,	B-X
TRADD	B-X
,	B-X
and	B-X
RIP	B-X
participate	B-X
in	B-X
B-lymphocyte	B-X
activation	B-X
and	B-X
growth	B-X
.	B-X

Unlike	O
TNFR1	B-Protein
,	O
LMP1	B-Protein
can	O
interact	O
directly	O
with	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
and	O
stably	O
associates	O
with	O
RIP	O
in	O
EBV	O
-	O
transformed	O
lymphoblastoid	O
cell	O
lines	O
.	O
<EOS>	B-X
A	B-X
site	B-X
in	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
transforming	B-X
protein	B-X
LMP1	B-X
that	B-X
constitutively	B-X
associates	B-X
with	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
TNFR1	B-X
)	B-X
-associated	B-X
death	B-X
domain	B-X
protein	B-X
TRADD	B-X
to	B-X
mediate	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
activation	B-X
is	B-X
critical	B-X
for	B-X
long-term	B-X
lymphoblastoid	B-X
cell	B-X
proliferation	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
LMP1	B-X
signaling	B-X
through	B-X
TRADD	B-X
differs	B-X
from	B-X
TNFR1	B-X
signaling	B-X
through	B-X
TRADD	B-X
.	B-X
LMP1	B-X
needs	B-X
only	B-X
11	B-X
amino	B-X
acids	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
or	B-X
synergize	B-X
with	B-X
TRADD	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
while	B-X
TNFR1	B-X
requires	B-X
approximately	B-X
70	B-X
residues	B-X
.	B-X
Further	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
require	B-X
TRADD	B-X
residues	B-X
294	B-X
to	B-X
312	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
while	B-X
TNFR1	B-X
requires	B-X
TRADD	B-X
residues	B-X
296	B-X
to	B-X
302	B-X
.	B-X
LMP1	B-X
is	B-X
partially	B-X
blocked	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
a	B-X
TRADD	B-X
mutant	B-X
consisting	B-X
of	B-X
residues	B-X
122	B-X
to	B-X
293	B-X
.	B-X
Unlike	B-X
TNFR1	B-X
,	B-X
LMP1	B-X
can	B-X
interact	B-X
directly	B-X
with	B-X
receptor-interacting	B-X
protein	B-X
(	B-X
RIP	B-X
)	B-X
and	B-X
stably	B-X
associates	B-X
with	B-X
RIP	B-X
in	B-X
EBV-transformed	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
.	B-X
Surprisingly	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
require	B-X
RIP	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Despite	B-X
constitutive	B-X
association	B-X
with	B-X
TRADD	B-X
or	B-X
RIP	B-X
,	B-X
LMP1	B-X
does	B-X
not	B-X
induce	B-X
apoptosis	B-X
in	B-X
EBV-negative	B-X
Burkitt	B-X
lymphoma	B-X
or	B-X
human	B-X
embryonic	B-X
kidney	B-X
293	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
add	B-X
a	B-X
different	B-X
perspective	B-X
to	B-X
the	B-X
molecular	B-X
interactions	B-X
through	B-X
which	B-X
LMP1	B-X
,	B-X
TRADD	B-X
,	B-X
and	B-X
RIP	B-X
participate	B-X
in	B-X
B-lymphocyte	B-X
activation	B-X
and	B-X
growth	B-X
.	B-X

Surprisingly	O
,	O
LMP1	B-Protein
does	O
not	O
require	O
RIP	O
for	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
The	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
transforming	B-X
protein	B-X
LMP1	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
constitutively	B-X
activated	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR	B-X
)	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
an	B-X
intrinsic	B-X
ability	B-X
to	B-X
aggregate	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
an	B-X
association	B-X
of	B-X
its	B-X
cytoplasmic	B-X
carboxyl	B-X
terminus	B-X
(	B-X
CT	B-X
)	B-X
with	B-X
TNFR-associated	B-X
factors	B-X
(	B-X
TRAFs	B-X
)	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
in	B-X
EBV-transformed	B-X
B	B-X
lymphocytes	B-X
most	B-X
of	B-X
TRAF1	B-X
or	B-X
TRAF3	B-X
and	B-X
5	B-X
%	B-X
of	B-X
TRAF2	B-X
are	B-X
associated	B-X
with	B-X
LMP1	B-X
and	B-X
that	B-X
most	B-X
of	B-X
LMP1	B-X
is	B-X
associated	B-X
with	B-X
TRAF1	B-X
or	B-X
TRAF3	B-X
.	B-X
TRAF1	B-X
,	B-X
TRAF2	B-X
,	B-X
and	B-X
TRAF3	B-X
bind	B-X
to	B-X
a	B-X
single	B-X
site	B-X
in	B-X
the	B-X
LMP1	B-X
CT	B-X
corresponding	B-X
to	B-X
amino	B-X
acids	B-X
(	B-X
aa	B-X
)	B-X
199	B-X
to	B-X
214	B-X
,	B-X
within	B-X
a	B-X
domain	B-X
which	B-X
is	B-X
important	B-X
for	B-X
B-lymphocyte	B-X
growth	B-X
transformation	B-X
(	B-X
aa	B-X
187	B-X
to	B-X
231	B-X
)	B-X
.	B-X
Further	B-X
deletional	B-X
and	B-X
alanine	B-X
mutagenesis	B-X
analyses	B-X
and	B-X
comparison	B-X
with	B-X
TRAF	B-X
binding	B-X
sequences	B-X
in	B-X
CD40	B-X
,	B-X
in	B-X
CD30	B-X
,	B-X
and	B-X
in	B-X
the	B-X
LMP1	B-X
of	B-X
other	B-X
lymphycryptoviruses	B-X
provide	B-X
the	B-X
first	B-X
evidence	B-X
that	B-X
PXQXT/S	B-X
is	B-X
a	B-X
core	B-X
TRAF	B-X
binding	B-X
motif	B-X
.	B-X
The	B-X
negative	B-X
effects	B-X
of	B-X
point	B-X
mutations	B-X
in	B-X
the	B-X
LMP1	B-X
(	B-X
1-231	B-X
)	B-X
core	B-X
TRAF	B-X
binding	B-X
motif	B-X
on	B-X
TRAF	B-X
binding	B-X
and	B-X
NF-kappaB	B-X
activation	B-X
genetically	B-X
link	B-X
the	B-X
TRAFs	B-X
to	B-X
LMP1	B-X
(	B-X
1-231	B-X
)	B-X
-mediated	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
LMP1	B-X
(	B-X
1-231	B-X
)	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
TRAF1/TRAF2	B-X
heteroaggregates	B-X
since	B-X
TRAF1	B-X
is	B-X
unique	B-X
among	B-X
the	B-X
TRAFs	B-X
in	B-X
coactivating	B-X
NF-kappaB	B-X
with	B-X
LMP1	B-X
(	B-X
1-231	B-X
)	B-X
,	B-X
a	B-X
TRAF2	B-X
dominant-negative	B-X
mutant	B-X
can	B-X
block	B-X
LMP1	B-X
(	B-X
1-231	B-X
)	B-X
-mediated	B-X
NF-kappaB	B-X
activation	B-X
as	B-X
well	B-X
as	B-X
TRAF1	B-X
coactivation	B-X
,	B-X
and	B-X
30	B-X
%	B-X
of	B-X
TRAF2	B-X
is	B-X
associated	B-X
with	B-X
TRAF1	B-X
in	B-X
EBV-transformed	B-X
B	B-X
cells	B-X
.	B-X
TRAF3	B-X
is	B-X
a	B-X
negative	B-X
modulator	B-X
of	B-X
LMP1	B-X
(	B-X
1-231	B-X
)	B-X
-mediated	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Surprisingly	B-X
,	B-X
TRAF1	B-X
,	B-X
-2	B-X
,	B-X
or	B-X
-3	B-X
does	B-X
not	B-X
interact	B-X
with	B-X
the	B-X
terminal	B-X
LMP1	B-X
CT	B-X
aa	B-X
333	B-X
to	B-X
386	B-X
which	B-X
can	B-X
independently	B-X
mediate	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
The	B-X
constitutive	B-X
association	B-X
of	B-X
TRAFs	B-X
with	B-X
LMP1	B-X
through	B-X
the	B-X
aa	B-X
187	B-X
to	B-X
231	B-X
domain	B-X
which	B-X
is	B-X
important	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
and	B-X
primary	B-X
B-lymphocyte	B-X
growth	B-X
transformation	B-X
implicates	B-X
TRAF	B-X
aggregation	B-X
in	B-X
LMP1	B-X
signaling	B-X
.	B-X

Despite	O
constitutive	O
association	O
with	O
TRADD	B-Protein
or	O
RIP	O
,	O
LMP1	B-Protein
does	O
not	O
induce	O
apoptosis	O
in	O
EBV	O
-	O
negative	O
Burkitt	O
lymphoma	O
or	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O
<EOS>	B-X
In	B-X
fact	B-X
,	B-X
this	B-X
method	B-X
has	B-X
become	B-X
so	B-X
ingrained	B-X
in	B-X
certain	B-X
areas	B-X
of	B-X
research	B-X
that	B-X
reports	B-X
often	B-X
simply	B-X
state	B-X
that	B-X
cells	B-X
were	B-X
serum	B-X
starved	B-X
without	B-X
providing	B-X
any	B-X
factual	B-X
details	B-X
as	B-X
to	B-X
how	B-X
the	B-X
procedure	B-X
was	B-X
carried	B-X
out	B-X
.	B-X
Although	B-X
it	B-X
is	B-X
frequently	B-X
assumed	B-X
that	B-X
serum	B-X
starvation	B-X
reduces	B-X
basal	B-X
activity	B-X
of	B-X
cells	B-X
,	B-X
available	B-X
experimental	B-X
data	B-X
do	B-X
not	B-X
entirely	B-X
support	B-X
this	B-X
notion	B-X
.	B-X
To	B-X
address	B-X
this	B-X
important	B-X
issue	B-X
,	B-X
we	B-X
studied	B-X
primary	B-X
human	B-X
myotubes	B-X
,	B-X
rat	B-X
L6	B-X
myotubes	B-X
and	B-X
human	B-X
embryonic	B-X
kidney	B-X
(	B-X
HEK	B-X
)	B-X
293	B-X
cells	B-X
under	B-X
different	B-X
serum	B-X
starvation	B-X
conditions	B-X
and	B-X
followed	B-X
time-dependent	B-X
changes	B-X
in	B-X
important	B-X
signaling	B-X
pathways	B-X
such	B-X
as	B-X
the	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
,	B-X
the	B-X
AMP-activated	B-X
protein	B-X
kinase	B-X
,	B-X
and	B-X
the	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
.	B-X
Serum	B-X
starvation	B-X
induced	B-X
a	B-X
swift	B-X
and	B-X
dynamic	B-X
response	B-X
,	B-X
which	B-X
displayed	B-X
obvious	B-X
qualitative	B-X
and	B-X
quantitative	B-X
differences	B-X
across	B-X
different	B-X
cell	B-X
types	B-X
and	B-X
experimental	B-X
conditions	B-X
despite	B-X
certain	B-X
unifying	B-X
features	B-X
.	B-X

These	O
results	O
add	O
a	O
different	O
perspective	O
to	O
the	O
molecular	O
interactions	O
through	O
which	O
LMP1	B-Protein
,	O
TRADD	B-Protein
,	O
and	O
RIP	O
participate	O
in	O
B	O
-	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Regulatory	O
effects	O
of	O
interleukin	B-Protein
-	I-Protein
11	I-Protein
during	O
acute	O
lung	O
inflammatory	O
injury	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
interleukin-11	B-X
(	B-X
IL-11	B-X
)	B-X
was	B-X
evaluated	B-X
in	B-X
the	B-X
IgG	B-X
immune	B-X
complex	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
injury	B-X
in	B-X
rats	B-X
.	B-X
IL-11	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
both	B-X
up-regulated	B-X
during	B-X
the	B-X
course	B-X
of	B-X
this	B-X
inflammatory	B-X
response	B-X
.	B-X
Exogenously	B-X
administered	B-X
IL-11	B-X
substantially	B-X
reduced	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
,	B-X
the	B-X
intrapulmonary	B-X
accumulation	B-X
of	B-X
neutrophils	B-X
and	B-X
the	B-X
lung	B-X
vascular	B-X
leak	B-X
of	B-X
albumin	B-X
.	B-X
These	B-X
in	B-X
vivo	B-X
anti-inflammatory	B-X
effects	B-X
of	B-X
IL-11	B-X
were	B-X
associated	B-X
with	B-X
reduced	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
lung	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluids	B-X
,	B-X
and	B-X
diminished	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
that	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
BAL	B-X
fluid	B-X
content	B-X
of	B-X
the	B-X
CXC	B-X
chemokines	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
(	B-X
MIP-2	B-X
)	B-X
and	B-X
cytokine-inducible	B-X
neutrophil	B-X
chemoattractant	B-X
(	B-X
CINC	B-X
)	B-X
;	B-X
the	B-X
presence	B-X
of	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
these	B-X
chemokines	B-X
.	B-X
However	B-X
,	B-X
BAL	B-X
content	B-X
of	B-X
C5a	B-X
was	B-X
reduced	B-X
by	B-X
IL-11	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
IL-11	B-X
is	B-X
a	B-X
regulatory	B-X
cytokine	B-X
in	B-X
the	B-X
lung	B-X
and	B-X
that	B-X
,	B-X
like	B-X
other	B-X
members	B-X
of	B-X
this	B-X
family	B-X
,	B-X
its	B-X
anti-inflammatory	B-X
properties	B-X
appear	B-X
to	B-X
be	B-X
linked	B-X
to	B-X
its	B-X
suppression	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
diminished	B-X
production	B-X
of	B-X
TNF-alpha	B-X
,	B-X
and	B-X
reduced	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X

The	O
role	O
of	O
interleukin	B-Protein
-	I-Protein
11	I-Protein
(	O
IL	B-Protein
-	I-Protein
11	I-Protein
)	O
was	O
evaluated	O
in	O
the	O
IgG	O
immune	O
complex	O
model	O
of	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
interleukin-11	B-X
(	B-X
IL-11	B-X
)	B-X
was	B-X
evaluated	B-X
in	B-X
the	B-X
IgG	B-X
immune	B-X
complex	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
injury	B-X
in	B-X
rats	B-X
.	B-X
IL-11	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
both	B-X
up-regulated	B-X
during	B-X
the	B-X
course	B-X
of	B-X
this	B-X
inflammatory	B-X
response	B-X
.	B-X
Exogenously	B-X
administered	B-X
IL-11	B-X
substantially	B-X
reduced	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
,	B-X
the	B-X
intrapulmonary	B-X
accumulation	B-X
of	B-X
neutrophils	B-X
and	B-X
the	B-X
lung	B-X
vascular	B-X
leak	B-X
of	B-X
albumin	B-X
.	B-X
These	B-X
in	B-X
vivo	B-X
anti-inflammatory	B-X
effects	B-X
of	B-X
IL-11	B-X
were	B-X
associated	B-X
with	B-X
reduced	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
lung	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluids	B-X
,	B-X
and	B-X
diminished	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
that	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
BAL	B-X
fluid	B-X
content	B-X
of	B-X
the	B-X
CXC	B-X
chemokines	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
(	B-X
MIP-2	B-X
)	B-X
and	B-X
cytokine-inducible	B-X
neutrophil	B-X
chemoattractant	B-X
(	B-X
CINC	B-X
)	B-X
;	B-X
the	B-X
presence	B-X
of	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
these	B-X
chemokines	B-X
.	B-X
However	B-X
,	B-X
BAL	B-X
content	B-X
of	B-X
C5a	B-X
was	B-X
reduced	B-X
by	B-X
IL-11	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
IL-11	B-X
is	B-X
a	B-X
regulatory	B-X
cytokine	B-X
in	B-X
the	B-X
lung	B-X
and	B-X
that	B-X
,	B-X
like	B-X
other	B-X
members	B-X
of	B-X
this	B-X
family	B-X
,	B-X
its	B-X
anti-inflammatory	B-X
properties	B-X
appear	B-X
to	B-X
be	B-X
linked	B-X
to	B-X
its	B-X
suppression	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
diminished	B-X
production	B-X
of	B-X
TNF-alpha	B-X
,	B-X
and	B-X
reduced	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X

IL	B-Protein
-	I-Protein
11	I-Protein
mRNA	O
and	O
protein	O
were	O
both	O
up	O
-	O
regulated	O
during	O
the	O
course	O
of	O
this	O
inflammatory	O
response	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
interleukin-11	B-X
(	B-X
IL-11	B-X
)	B-X
was	B-X
evaluated	B-X
in	B-X
the	B-X
IgG	B-X
immune	B-X
complex	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
injury	B-X
in	B-X
rats	B-X
.	B-X
IL-11	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
both	B-X
up-regulated	B-X
during	B-X
the	B-X
course	B-X
of	B-X
this	B-X
inflammatory	B-X
response	B-X
.	B-X
Exogenously	B-X
administered	B-X
IL-11	B-X
substantially	B-X
reduced	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
,	B-X
the	B-X
intrapulmonary	B-X
accumulation	B-X
of	B-X
neutrophils	B-X
and	B-X
the	B-X
lung	B-X
vascular	B-X
leak	B-X
of	B-X
albumin	B-X
.	B-X
These	B-X
in	B-X
vivo	B-X
anti-inflammatory	B-X
effects	B-X
of	B-X
IL-11	B-X
were	B-X
associated	B-X
with	B-X
reduced	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
lung	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluids	B-X
,	B-X
and	B-X
diminished	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
that	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
BAL	B-X
fluid	B-X
content	B-X
of	B-X
the	B-X
CXC	B-X
chemokines	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
(	B-X
MIP-2	B-X
)	B-X
and	B-X
cytokine-inducible	B-X
neutrophil	B-X
chemoattractant	B-X
(	B-X
CINC	B-X
)	B-X
;	B-X
the	B-X
presence	B-X
of	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
these	B-X
chemokines	B-X
.	B-X
However	B-X
,	B-X
BAL	B-X
content	B-X
of	B-X
C5a	B-X
was	B-X
reduced	B-X
by	B-X
IL-11	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
IL-11	B-X
is	B-X
a	B-X
regulatory	B-X
cytokine	B-X
in	B-X
the	B-X
lung	B-X
and	B-X
that	B-X
,	B-X
like	B-X
other	B-X
members	B-X
of	B-X
this	B-X
family	B-X
,	B-X
its	B-X
anti-inflammatory	B-X
properties	B-X
appear	B-X
to	B-X
be	B-X
linked	B-X
to	B-X
its	B-X
suppression	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
diminished	B-X
production	B-X
of	B-X
TNF-alpha	B-X
,	B-X
and	B-X
reduced	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X

Exogenously	O
administered	O
IL	B-Protein
-	I-Protein
11	I-Protein
substantially	O
reduced	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
the	O
intrapulmonary	O
accumulation	O
of	O
neutrophils	O
and	O
the	O
lung	O
vascular	O
leak	O
of	O
albumin	O
.	O

These	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
effects	O
of	O
IL	B-Protein
-	I-Protein
11	I-Protein
were	O
associated	O
with	O
reduced	O
NF	O
-	O
kappaB	O
activation	O
in	O
lung	O
,	O
reduced	O
levels	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
diminished	O
up	O
-	O
regulation	O
of	O
lung	O
vascular	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
interleukin-11	B-X
(	B-X
IL-11	B-X
)	B-X
was	B-X
evaluated	B-X
in	B-X
the	B-X
IgG	B-X
immune	B-X
complex	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
injury	B-X
in	B-X
rats	B-X
.	B-X
IL-11	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
both	B-X
up-regulated	B-X
during	B-X
the	B-X
course	B-X
of	B-X
this	B-X
inflammatory	B-X
response	B-X
.	B-X
Exogenously	B-X
administered	B-X
IL-11	B-X
substantially	B-X
reduced	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
,	B-X
the	B-X
intrapulmonary	B-X
accumulation	B-X
of	B-X
neutrophils	B-X
and	B-X
the	B-X
lung	B-X
vascular	B-X
leak	B-X
of	B-X
albumin	B-X
.	B-X
These	B-X
in	B-X
vivo	B-X
anti-inflammatory	B-X
effects	B-X
of	B-X
IL-11	B-X
were	B-X
associated	B-X
with	B-X
reduced	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
lung	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluids	B-X
,	B-X
and	B-X
diminished	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
that	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
BAL	B-X
fluid	B-X
content	B-X
of	B-X
the	B-X
CXC	B-X
chemokines	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
(	B-X
MIP-2	B-X
)	B-X
and	B-X
cytokine-inducible	B-X
neutrophil	B-X
chemoattractant	B-X
(	B-X
CINC	B-X
)	B-X
;	B-X
the	B-X
presence	B-X
of	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
these	B-X
chemokines	B-X
.	B-X
However	B-X
,	B-X
BAL	B-X
content	B-X
of	B-X
C5a	B-X
was	B-X
reduced	B-X
by	B-X
IL-11	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
IL-11	B-X
is	B-X
a	B-X
regulatory	B-X
cytokine	B-X
in	B-X
the	B-X
lung	B-X
and	B-X
that	B-X
,	B-X
like	B-X
other	B-X
members	B-X
of	B-X
this	B-X
family	B-X
,	B-X
its	B-X
anti-inflammatory	B-X
properties	B-X
appear	B-X
to	B-X
be	B-X
linked	B-X
to	B-X
its	B-X
suppression	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
diminished	B-X
production	B-X
of	B-X
TNF-alpha	B-X
,	B-X
and	B-X
reduced	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X

It	O
is	O
interesting	O
that	O
IL	B-Protein
-	I-Protein
11	I-Protein
did	O
not	O
affect	O
BAL	O
fluid	O
content	O
of	O
the	O
CXC	O
chemokines	O
,	O
macrophage	B-Protein
inflammatory	I-Protein
protein	I-Protein
-	I-Protein
2	I-Protein
(	O
MIP	B-Protein
-	I-Protein
2	I-Protein
)	O
and	O
cytokine	O
-	O
inducible	O
neutrophil	O
chemoattractant	O
(	O
CINC	O
)	O
;	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
11	I-Protein
did	O
not	O
affect	O
these	O
chemokines	O
.	O

However	O
,	O
BAL	O
content	O
of	O
C5a	O
was	O
reduced	O
by	O
IL	B-Protein
-	I-Protein
11	I-Protein
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
interleukin-11	B-X
(	B-X
IL-11	B-X
)	B-X
was	B-X
evaluated	B-X
in	B-X
the	B-X
IgG	B-X
immune	B-X
complex	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
injury	B-X
in	B-X
rats	B-X
.	B-X
IL-11	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
both	B-X
up-regulated	B-X
during	B-X
the	B-X
course	B-X
of	B-X
this	B-X
inflammatory	B-X
response	B-X
.	B-X
Exogenously	B-X
administered	B-X
IL-11	B-X
substantially	B-X
reduced	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
,	B-X
the	B-X
intrapulmonary	B-X
accumulation	B-X
of	B-X
neutrophils	B-X
and	B-X
the	B-X
lung	B-X
vascular	B-X
leak	B-X
of	B-X
albumin	B-X
.	B-X
These	B-X
in	B-X
vivo	B-X
anti-inflammatory	B-X
effects	B-X
of	B-X
IL-11	B-X
were	B-X
associated	B-X
with	B-X
reduced	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
lung	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluids	B-X
,	B-X
and	B-X
diminished	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
that	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
BAL	B-X
fluid	B-X
content	B-X
of	B-X
the	B-X
CXC	B-X
chemokines	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
(	B-X
MIP-2	B-X
)	B-X
and	B-X
cytokine-inducible	B-X
neutrophil	B-X
chemoattractant	B-X
(	B-X
CINC	B-X
)	B-X
;	B-X
the	B-X
presence	B-X
of	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
these	B-X
chemokines	B-X
.	B-X
However	B-X
,	B-X
BAL	B-X
content	B-X
of	B-X
C5a	B-X
was	B-X
reduced	B-X
by	B-X
IL-11	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
IL-11	B-X
is	B-X
a	B-X
regulatory	B-X
cytokine	B-X
in	B-X
the	B-X
lung	B-X
and	B-X
that	B-X
,	B-X
like	B-X
other	B-X
members	B-X
of	B-X
this	B-X
family	B-X
,	B-X
its	B-X
anti-inflammatory	B-X
properties	B-X
appear	B-X
to	B-X
be	B-X
linked	B-X
to	B-X
its	B-X
suppression	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
diminished	B-X
production	B-X
of	B-X
TNF-alpha	B-X
,	B-X
and	B-X
reduced	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X

These	O
data	O
indicate	O
that	O
IL	B-Protein
-	I-Protein
11	I-Protein
is	O
a	O
regulatory	O
cytokine	O
in	O
the	O
lung	O
and	O
that	O
,	O
like	O
other	O
members	O
of	O
this	O
family	O
,	O
its	O
anti	O
-	O
inflammatory	O
properties	O
appear	O
to	O
be	O
linked	O
to	O
its	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
diminished	O
production	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
and	O
reduced	O
up	O
-	O
regulation	O
of	O
lung	O
vascular	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
interleukin-11	B-X
(	B-X
IL-11	B-X
)	B-X
was	B-X
evaluated	B-X
in	B-X
the	B-X
IgG	B-X
immune	B-X
complex	B-X
model	B-X
of	B-X
acute	B-X
lung	B-X
injury	B-X
in	B-X
rats	B-X
.	B-X
IL-11	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
both	B-X
up-regulated	B-X
during	B-X
the	B-X
course	B-X
of	B-X
this	B-X
inflammatory	B-X
response	B-X
.	B-X
Exogenously	B-X
administered	B-X
IL-11	B-X
substantially	B-X
reduced	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
,	B-X
the	B-X
intrapulmonary	B-X
accumulation	B-X
of	B-X
neutrophils	B-X
and	B-X
the	B-X
lung	B-X
vascular	B-X
leak	B-X
of	B-X
albumin	B-X
.	B-X
These	B-X
in	B-X
vivo	B-X
anti-inflammatory	B-X
effects	B-X
of	B-X
IL-11	B-X
were	B-X
associated	B-X
with	B-X
reduced	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
lung	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluids	B-X
,	B-X
and	B-X
diminished	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
that	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
BAL	B-X
fluid	B-X
content	B-X
of	B-X
the	B-X
CXC	B-X
chemokines	B-X
,	B-X
macrophage	B-X
inflammatory	B-X
protein-2	B-X
(	B-X
MIP-2	B-X
)	B-X
and	B-X
cytokine-inducible	B-X
neutrophil	B-X
chemoattractant	B-X
(	B-X
CINC	B-X
)	B-X
;	B-X
the	B-X
presence	B-X
of	B-X
IL-11	B-X
did	B-X
not	B-X
affect	B-X
these	B-X
chemokines	B-X
.	B-X
However	B-X
,	B-X
BAL	B-X
content	B-X
of	B-X
C5a	B-X
was	B-X
reduced	B-X
by	B-X
IL-11	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
IL-11	B-X
is	B-X
a	B-X
regulatory	B-X
cytokine	B-X
in	B-X
the	B-X
lung	B-X
and	B-X
that	B-X
,	B-X
like	B-X
other	B-X
members	B-X
of	B-X
this	B-X
family	B-X
,	B-X
its	B-X
anti-inflammatory	B-X
properties	B-X
appear	B-X
to	B-X
be	B-X
linked	B-X
to	B-X
its	B-X
suppression	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
diminished	B-X
production	B-X
of	B-X
TNF-alpha	B-X
,	B-X
and	B-X
reduced	B-X
up-regulation	B-X
of	B-X
lung	B-X
vascular	B-X
ICAM-1	B-X
.	B-X

ETS	O
transcription	O
factors	O
regulate	O
an	O
enhancer	O
activity	O
in	O
the	O
third	O
intron	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
.	O
<EOS>	B-X
We	B-X
describe	B-X
an	B-X
enhancer	B-X
site	B-X
in	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
.	B-X
A	B-X
reporter	B-X
construct	B-X
containing	B-X
the	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
mouse	B-X
TNF-alpha	B-X
gene	B-X
displayed	B-X
weak	B-X
activity	B-X
when	B-X
transfected	B-X
into	B-X
RAW264.7	B-X
macrophage-like	B-X
cells	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
TNF-alpha	B-X
to	B-X
this	B-X
construct	B-X
resulted	B-X
in	B-X
an	B-X
enhancement	B-X
of	B-X
CAT	B-X
protein	B-X
.	B-X
This	B-X
enhancement	B-X
was	B-X
eliminated	B-X
if	B-X
a	B-X
conserved	B-X
20-bp	B-X
sequence	B-X
was	B-X
removed	B-X
from	B-X
the	B-X
intron	B-X
or	B-X
if	B-X
a	B-X
dominant-negative	B-X
ets-binding	B-X
factor	B-X
was	B-X
co-transfected	B-X
with	B-X
the	B-X
reporter	B-X
gene	B-X
.	B-X
Mutations	B-X
of	B-X
this	B-X
site	B-X
that	B-X
destroyed	B-X
potential	B-X
ets	B-X
transcription	B-X
factor	B-X
binding	B-X
sites	B-X
had	B-X
reduced	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
major	B-X
transcription	B-X
factor	B-X
that	B-X
bound	B-X
to	B-X
the	B-X
oligonucleotide	B-X
was	B-X
confirmed	B-X
to	B-X
be	B-X
GABP	B-X
by	B-X
supershift	B-X
and	B-X
competition	B-X
analysis	B-X
.	B-X
In	B-X
RAW264.7	B-X
cells	B-X
,	B-X
the	B-X
binding	B-X
was	B-X
constitutive	B-X
,	B-X
however	B-X
,	B-X
in	B-X
bone	B-X
marrow-derived	B-X
macrophages	B-X
binding	B-X
activity	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
interferon-gamma	B-X
inducible	B-X
.	B-X
This	B-X
may	B-X
imply	B-X
a	B-X
role	B-X
for	B-X
ets	B-X
transcription	B-X
factors	B-X
in	B-X
the	B-X
production	B-X
of	B-X
TNF-alpha	B-X
.	B-X

We	O
describe	O
an	O
enhancer	O
site	O
in	O
the	O
third	O
intron	O
of	O
tumor	O
necrosis	B-Protein
factor	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
an	B-X
enhancer	B-X
site	B-X
in	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
.	B-X
A	B-X
reporter	B-X
construct	B-X
containing	B-X
the	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
mouse	B-X
TNF-alpha	B-X
gene	B-X
displayed	B-X
weak	B-X
activity	B-X
when	B-X
transfected	B-X
into	B-X
RAW264.7	B-X
macrophage-like	B-X
cells	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
TNF-alpha	B-X
to	B-X
this	B-X
construct	B-X
resulted	B-X
in	B-X
an	B-X
enhancement	B-X
of	B-X
CAT	B-X
protein	B-X
.	B-X
This	B-X
enhancement	B-X
was	B-X
eliminated	B-X
if	B-X
a	B-X
conserved	B-X
20-bp	B-X
sequence	B-X
was	B-X
removed	B-X
from	B-X
the	B-X
intron	B-X
or	B-X
if	B-X
a	B-X
dominant-negative	B-X
ets-binding	B-X
factor	B-X
was	B-X
co-transfected	B-X
with	B-X
the	B-X
reporter	B-X
gene	B-X
.	B-X
Mutations	B-X
of	B-X
this	B-X
site	B-X
that	B-X
destroyed	B-X
potential	B-X
ets	B-X
transcription	B-X
factor	B-X
binding	B-X
sites	B-X
had	B-X
reduced	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
major	B-X
transcription	B-X
factor	B-X
that	B-X
bound	B-X
to	B-X
the	B-X
oligonucleotide	B-X
was	B-X
confirmed	B-X
to	B-X
be	B-X
GABP	B-X
by	B-X
supershift	B-X
and	B-X
competition	B-X
analysis	B-X
.	B-X
This	B-X
may	B-X
imply	B-X
a	B-X
role	B-X
for	B-X
ets	B-X
transcription	B-X
factors	B-X
in	B-X
the	B-X
production	B-X
of	B-X
TNF-alpha	B-X
.	B-X

A	O
reporter	O
construct	O
containing	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
mouse	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
displayed	O
weak	O
activity	O
when	O
transfected	O
into	O
RAW264	O
.	O
7	O
macrophage	O
-	O
like	O
cells	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
an	B-X
enhancer	B-X
site	B-X
in	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
.	B-X
A	B-X
reporter	B-X
construct	B-X
containing	B-X
the	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
mouse	B-X
TNF-alpha	B-X
gene	B-X
displayed	B-X
weak	B-X
activity	B-X
when	B-X
transfected	B-X
into	B-X
RAW264.7	B-X
macrophage-like	B-X
cells	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
TNF-alpha	B-X
to	B-X
this	B-X
construct	B-X
resulted	B-X
in	B-X
an	B-X
enhancement	B-X
of	B-X
CAT	B-X
protein	B-X
.	B-X
This	B-X
enhancement	B-X
was	B-X
eliminated	B-X
if	B-X
a	B-X
conserved	B-X
20-bp	B-X
sequence	B-X
was	B-X
removed	B-X
from	B-X
the	B-X
intron	B-X
or	B-X
if	B-X
a	B-X
dominant-negative	B-X
ets-binding	B-X
factor	B-X
was	B-X
co-transfected	B-X
with	B-X
the	B-X
reporter	B-X
gene	B-X
.	B-X
Mutations	B-X
of	B-X
this	B-X
site	B-X
that	B-X
destroyed	B-X
potential	B-X
ets	B-X
transcription	B-X
factor	B-X
binding	B-X
sites	B-X
had	B-X
reduced	B-X
transcriptional	B-X
activity	B-X
.	B-X
In	B-X
RAW264.7	B-X
cells	B-X
,	B-X
the	B-X
binding	B-X
was	B-X
constitutive	B-X
,	B-X
however	B-X
,	B-X
in	B-X
bone	B-X
marrow-derived	B-X
macrophages	B-X
binding	B-X
activity	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
interferon-gamma	B-X
inducible	B-X
.	B-X
This	B-X
may	B-X
imply	B-X
a	B-X
role	B-X
for	B-X
ets	B-X
transcription	B-X
factors	B-X
in	B-X
the	B-X
production	B-X
of	B-X
TNF-alpha	B-X
.	B-X

The	O
addition	O
of	O
the	O
third	O
intron	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
to	O
this	O
construct	O
resulted	O
in	O
an	O
enhancement	O
of	O
CAT	B-Protein
protein	O
.	O

This	O
enhancement	O
was	O
eliminated	O
if	O
a	O
conserved	O
20	O
-	O
bp	O
sequence	O
was	O
removed	O
from	O
the	O
intron	O
or	O
if	O
a	O
dominant	O
-	O
negative	O
ets	O
-	O
binding	O
factor	O
was	O
co	O
-	O
transfected	O
with	O
the	O
reporter	O
gene	O
.	O

Mutations	O
of	O
this	O
site	O
that	O
destroyed	O
potential	O
ets	O
transcription	O
factor	O
binding	O
sites	O
had	O
reduced	O
transcriptional	O
activity	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
an	B-X
enhancer	B-X
site	B-X
in	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
.	B-X
A	B-X
reporter	B-X
construct	B-X
containing	B-X
the	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
mouse	B-X
TNF-alpha	B-X
gene	B-X
displayed	B-X
weak	B-X
activity	B-X
when	B-X
transfected	B-X
into	B-X
RAW264.7	B-X
macrophage-like	B-X
cells	B-X
.	B-X
This	B-X
enhancement	B-X
was	B-X
eliminated	B-X
if	B-X
a	B-X
conserved	B-X
20-bp	B-X
sequence	B-X
was	B-X
removed	B-X
from	B-X
the	B-X
intron	B-X
or	B-X
if	B-X
a	B-X
dominant-negative	B-X
ets-binding	B-X
factor	B-X
was	B-X
co-transfected	B-X
with	B-X
the	B-X
reporter	B-X
gene	B-X
.	B-X
Mutations	B-X
of	B-X
this	B-X
site	B-X
that	B-X
destroyed	B-X
potential	B-X
ets	B-X
transcription	B-X
factor	B-X
binding	B-X
sites	B-X
had	B-X
reduced	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
major	B-X
transcription	B-X
factor	B-X
that	B-X
bound	B-X
to	B-X
the	B-X
oligonucleotide	B-X
was	B-X
confirmed	B-X
to	B-X
be	B-X
GABP	B-X
by	B-X
supershift	B-X
and	B-X
competition	B-X
analysis	B-X
.	B-X
In	B-X
RAW264.7	B-X
cells	B-X
,	B-X
the	B-X
binding	B-X
was	B-X
constitutive	B-X
,	B-X
however	B-X
,	B-X
in	B-X
bone	B-X
marrow-derived	B-X
macrophages	B-X
binding	B-X
activity	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
interferon-gamma	B-X
inducible	B-X
.	B-X
This	B-X
may	B-X
imply	B-X
a	B-X
role	B-X
for	B-X
ets	B-X
transcription	B-X
factors	B-X
in	B-X
the	B-X
production	B-X
of	B-X
TNF-alpha	B-X
.	B-X

The	O
major	O
transcription	O
factor	O
that	O
bound	O
to	O
the	O
oligonucleotide	O
was	O
confirmed	O
to	O
be	O
GABP	B-Protein
by	O
supershift	O
and	O
competition	O
analysis	O
.	O

In	O
RAW264	O
.	O
7	O
cells	O
,	O
the	O
binding	O
was	O
constitutive	O
,	O
however	O
,	O
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
binding	O
activity	O
was	O
shown	O
to	O
be	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
inducible	O
.	O
<EOS>	B-X
A	B-X
reporter	B-X
construct	B-X
containing	B-X
the	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
mouse	B-X
TNF-alpha	B-X
gene	B-X
displayed	B-X
weak	B-X
activity	B-X
when	B-X
transfected	B-X
into	B-X
RAW264.7	B-X
macrophage-like	B-X
cells	B-X
.	B-X
This	B-X
enhancement	B-X
was	B-X
eliminated	B-X
if	B-X
a	B-X
conserved	B-X
20-bp	B-X
sequence	B-X
was	B-X
removed	B-X
from	B-X
the	B-X
intron	B-X
or	B-X
if	B-X
a	B-X
dominant-negative	B-X
ets-binding	B-X
factor	B-X
was	B-X
co-transfected	B-X
with	B-X
the	B-X
reporter	B-X
gene	B-X
.	B-X
Mutations	B-X
of	B-X
this	B-X
site	B-X
that	B-X
destroyed	B-X
potential	B-X
ets	B-X
transcription	B-X
factor	B-X
binding	B-X
sites	B-X
had	B-X
reduced	B-X
transcriptional	B-X
activity	B-X
.	B-X
In	B-X
RAW264.7	B-X
cells	B-X
,	B-X
the	B-X
binding	B-X
was	B-X
constitutive	B-X
,	B-X
however	B-X
,	B-X
in	B-X
bone	B-X
marrow-derived	B-X
macrophages	B-X
binding	B-X
activity	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
interferon-gamma	B-X
inducible	B-X
.	B-X

This	O
may	O
imply	O
a	O
role	O
for	O
ets	O
transcription	O
factors	O
in	O
the	O
production	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
.	O
<EOS>	B-X
We	B-X
describe	B-X
an	B-X
enhancer	B-X
site	B-X
in	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
.	B-X
A	B-X
reporter	B-X
construct	B-X
containing	B-X
the	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
mouse	B-X
TNF-alpha	B-X
gene	B-X
displayed	B-X
weak	B-X
activity	B-X
when	B-X
transfected	B-X
into	B-X
RAW264.7	B-X
macrophage-like	B-X
cells	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
TNF-alpha	B-X
to	B-X
this	B-X
construct	B-X
resulted	B-X
in	B-X
an	B-X
enhancement	B-X
of	B-X
CAT	B-X
protein	B-X
.	B-X
This	B-X
enhancement	B-X
was	B-X
eliminated	B-X
if	B-X
a	B-X
conserved	B-X
20-bp	B-X
sequence	B-X
was	B-X
removed	B-X
from	B-X
the	B-X
intron	B-X
or	B-X
if	B-X
a	B-X
dominant-negative	B-X
ets-binding	B-X
factor	B-X
was	B-X
co-transfected	B-X
with	B-X
the	B-X
reporter	B-X
gene	B-X
.	B-X
Mutations	B-X
of	B-X
this	B-X
site	B-X
that	B-X
destroyed	B-X
potential	B-X
ets	B-X
transcription	B-X
factor	B-X
binding	B-X
sites	B-X
had	B-X
reduced	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
major	B-X
transcription	B-X
factor	B-X
that	B-X
bound	B-X
to	B-X
the	B-X
oligonucleotide	B-X
was	B-X
confirmed	B-X
to	B-X
be	B-X
GABP	B-X
by	B-X
supershift	B-X
and	B-X
competition	B-X
analysis	B-X
.	B-X
This	B-X
may	B-X
imply	B-X
a	B-X
role	B-X
for	B-X
ets	B-X
transcription	B-X
factors	B-X
in	B-X
the	B-X
production	B-X
of	B-X
TNF-alpha	B-X
.	B-X

Abnormal	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
is	O
associated	O
with	O
decreased	O
p65	B-Protein
-	O
RelA	B-Protein
protein	O
expression	O
.	O

Numerous	O
cellular	O
and	O
biochemical	O
abnormalities	O
in	O
immune	O
regulation	O
have	O
been	O
described	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
including	O
surface	O
Ag	O
receptor	O
-	O
initiated	O
signaling	O
events	O
and	O
lymphokine	O
production	O
.	O
<EOS>	B-X
Numerous	B-X
cellular	B-X
and	B-X
biochemical	B-X
abnormalities	B-X
in	B-X
immune	B-X
regulation	B-X
have	B-X
been	B-X
described	B-X
in	B-X
patients	B-X
with	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
,	B-X
including	B-X
surface	B-X
Ag	B-X
receptor-initiated	B-X
signaling	B-X
events	B-X
and	B-X
lymphokine	B-X
production	B-X
.	B-X
Because	B-X
NF-kappa	B-X
B	B-X
contributes	B-X
to	B-X
the	B-X
transcription	B-X
of	B-X
numerous	B-X
inflammatory	B-X
genes	B-X
and	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
molecular	B-X
target	B-X
of	B-X
antiinflammatory	B-X
drugs	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
characterize	B-X
the	B-X
functional	B-X
role	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
protein	B-X
complex	B-X
in	B-X
lupus	B-X
T	B-X
cells	B-X
.	B-X
Freshly	B-X
isolated	B-X
T	B-X
cells	B-X
from	B-X
lupus	B-X
patients	B-X
,	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
patients	B-X
,	B-X
and	B-X
normal	B-X
individuals	B-X
were	B-X
activated	B-X
physiologically	B-X
via	B-X
the	B-X
TCR	B-X
with	B-X
anti-CD3	B-X
and	B-X
anti-CD28	B-X
Abs	B-X
to	B-X
assess	B-X
proximal	B-X
membrane	B-X
signaling	B-X
,	B-X
and	B-X
with	B-X
PMA	B-X
and	B-X
a	B-X
calcium	B-X
ionophore	B-X
(	B-X
A23187	B-X
)	B-X
to	B-X
bypass	B-X
membrane-mediated	B-X
signaling	B-X
events	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
normal	B-X
cells	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
activity	B-X
in	B-X
SLE	B-X
patients	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
SLE	B-X
,	B-X
but	B-X
not	B-X
in	B-X
RA	B-X
,	B-X
patients	B-X
.	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
absent	B-X
in	B-X
several	B-X
SLE	B-X
patients	B-X
who	B-X
were	B-X
not	B-X
receiving	B-X
any	B-X
medication	B-X
,	B-X
including	B-X
corticosteroids	B-X
.	B-X
In	B-X
supershift	B-X
experiments	B-X
using	B-X
specific	B-X
Abs	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
group	B-X
of	B-X
SLE	B-X
patients	B-X
who	B-X
displayed	B-X
undetectable	B-X
NF-kappa	B-X
B	B-X
activity	B-X
,	B-X
p65	B-X
complexes	B-X
were	B-X
not	B-X
formed	B-X
.	B-X
As	B-X
p65	B-X
complexes	B-X
are	B-X
transcriptionally	B-X
active	B-X
in	B-X
comparison	B-X
to	B-X
the	B-X
p50	B-X
homodimer	B-X
,	B-X
this	B-X
novel	B-X
finding	B-X
may	B-X
provide	B-X
insight	B-X
on	B-X
the	B-X
origin	B-X
of	B-X
abnormal	B-X
cytokine	B-X
or	B-X
other	B-X
gene	B-X
transcription	B-X
in	B-X
SLE	B-X
patients	B-X
.	B-X

Because	O
NF	O
-	O
kappa	O
B	O
contributes	O
to	O
the	O
transcription	O
of	O
numerous	O
inflammatory	O
genes	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
molecular	O
target	O
of	O
antiinflammatory	O
drugs	O
,	O
we	O
sought	O
to	O
characterize	O
the	O
functional	O
role	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
protein	O
complex	O
in	O
lupus	O
T	O
cells	O
.	O

Freshly	O
isolated	O
T	O
cells	O
from	O
lupus	O
patients	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
and	O
normal	O
individuals	O
were	O
activated	O
physiologically	O
via	O
the	O
TCR	O
with	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	B-Protein
Abs	O
to	O
assess	O
proximal	O
membrane	O
signaling	O
,	O
and	O
with	O
PMA	O
and	O
a	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
to	O
bypass	O
membrane	O
-	O
mediated	O
signaling	O
events	O
.	O

We	O
measured	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
by	O
gel	O
shift	O
analysis	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
this	B-X
response	B-X
often	B-X
involves	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF	B-X
kappa	B-X
B	B-X
.	B-X
The	B-X
current	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
determine	B-X
whether	B-X
monocyte	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
in	B-X
response	B-X
to	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
is	B-X
affected	B-X
by	B-X
pretreatment	B-X
with	B-X
metal	B-X
ions	B-X
.	B-X
Parallel	B-X
cultures	B-X
were	B-X
treated	B-X
with	B-X
10	B-X
microg/mL	B-X
Escherichia	B-X
coli	B-X
LPS	B-X
,	B-X
and	B-X
all	B-X
samples	B-X
were	B-X
cultured	B-X
an	B-X
additional	B-X
2	B-X
h.	B-X
Nuclear	B-X
proteins	B-X
were	B-X
extracted	B-X
and	B-X
normalized	B-X
amounts	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
(	B-X
32	B-X
)	B-X
P	B-X
]	B-X
-end-labeled	B-X
NF	B-X
kappa	B-X
B	B-X
consensus	B-X
oligonucleotide	B-X
.	B-X
NF	B-X
kappa	B-X
B-DNA	B-X
complexes	B-X
were	B-X
identified	B-X
and	B-X
quantified	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
analysis	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
NF	B-X
kappa	B-X
B-DNA	B-X
complex	B-X
formation	B-X
after	B-X
metal	B-X
ion	B-X
pretreatment	B-X
with	B-X
or	B-X
without	B-X
LPS	B-X
induction	B-X
was	B-X
compared	B-X
to	B-X
no	B-X
treatment	B-X
or	B-X
LPS-only	B-X
treated	B-X
controls	B-X
.	B-X
Finally	B-X
,	B-X
LPS-induced	B-X
IL1	B-X
beta	B-X
secretion	B-X
was	B-X
measured	B-X
from	B-X
palladium-treated	B-X
and	B-X
control	B-X
cells	B-X
.	B-X
LPS	B-X
exposure	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
cell	B-X
number	B-X
with	B-X
or	B-X
without	B-X
metal	B-X
ions	B-X
after	B-X
2	B-X
h.	B-X
When	B-X
metal	B-X
treatment	B-X
alone	B-X
was	B-X
assessed	B-X
,	B-X
none	B-X
of	B-X
the	B-X
metal	B-X
ions	B-X
had	B-X
a	B-X
significant	B-X
effect	B-X
on	B-X
NF	B-X
kappa	B-X
B-DNA	B-X
binding	B-X
.	B-X
However	B-X
,	B-X
pretreatment	B-X
with	B-X
Co	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ni	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
Ag	B-X
(	B-X
1+	B-X
)	B-X
,	B-X
Hg	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
and	B-X
Pd	B-X
(	B-X
2+	B-X
)	B-X
significantly	B-X
decreased	B-X
NF	B-X
kappa	B-X
B-DNA	B-X
binding	B-X
by	B-X
40-70	B-X
%	B-X
versus	B-X
LPS	B-X
alone	B-X
.	B-X
Only	B-X
Cu	B-X
(	B-X
2+	B-X
)	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
LPS-induced	B-X
NF	B-X
kappa	B-X
B-DNA	B-X
complex	B-X
formation	B-X
.	B-X
Pd	B-X
(	B-X
2+	B-X
)	B-X
lowered	B-X
,	B-X
but	B-X
did	B-X
not	B-X
abolish	B-X
,	B-X
IL1	B-X
beta	B-X
secretion	B-X
at	B-X
concentrations	B-X
comparable	B-X
to	B-X
those	B-X
that	B-X
altered	B-X
NF	B-X
kappa	B-X
B-DNA	B-X
binding	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
many	B-X
commonly	B-X
used	B-X
metals	B-X
alter	B-X
monocyte	B-X
function	B-X
at	B-X
concentrations	B-X
that	B-X
are	B-X
not	B-X
overtly	B-X
toxic	B-X
,	B-X
and	B-X
that	B-X
protein	B-X
levels	B-X
controlled	B-X
in	B-X
part	B-X
by	B-X
NF	B-X
kappa	B-X
B	B-X
also	B-X
may	B-X
be	B-X
altered	B-X
.	B-X

When	O
compared	O
with	O
normal	O
cells	O
,	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
SLE	O
patients	O
was	O
significantly	O
decreased	O
in	O
SLE	O
,	O
but	O
not	O
in	O
RA	O
,	O
patients	O
.	O
<EOS>	B-X
Auto-reactive	B-X
B	B-X
lymphocytes	B-X
and	B-X
its	B-X
abnormal	B-X
CD40	B-X
signaling	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
analyzed	B-X
CD40	B-X
expression	B-X
and	B-X
CD40/CD154	B-X
induced	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
in	B-X
B	B-X
cells	B-X
from	B-X
SLE	B-X
patients	B-X
.	B-X
B	B-X
cells	B-X
from	B-X
healthy	B-X
volunteers	B-X
and	B-X
tonsilar	B-X
B	B-X
cells	B-X
from	B-X
chronic	B-X
tonsillitis	B-X
were	B-X
used	B-X
as	B-X
negative	B-X
and	B-X
positive	B-X
controls	B-X
.	B-X
Results	B-X
showed	B-X
CD40-induced	B-X
NF-κB	B-X
signaling	B-X
was	B-X
constitutively	B-X
activated	B-X
in	B-X
B	B-X
cells	B-X
from	B-X
active	B-X
lupus	B-X
patients	B-X
,	B-X
including	B-X
decreased	B-X
CD40	B-X
in	B-X
raft	B-X
portion	B-X
,	B-X
increased	B-X
phosphorylation	B-X
and	B-X
degradation	B-X
of	B-X
IκBα	B-X
,	B-X
phosphorylation	B-X
of	B-X
P65	B-X
,	B-X
as	B-X
well	B-X
as	B-X
increased	B-X
nuclear	B-X
translocation	B-X
of	B-X
P65	B-X
,	B-X
P50	B-X
,	B-X
c-Rel	B-X
,	B-X
which	B-X
could	B-X
be	B-X
blocked	B-X
by	B-X
anti-CD154	B-X
.	B-X
CD154	B-X
stimulation	B-X
could	B-X
induce	B-X
further	B-X
phosphorylation	B-X
and	B-X
degradation	B-X
of	B-X
IκBα	B-X
,	B-X
as	B-X
well	B-X
as	B-X
phosphorylation	B-X
of	B-X
P65	B-X
and	B-X
nuclear	B-X
translocation	B-X
of	B-X
P65	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
CD40-induced	B-X
kinase	B-X
activities	B-X
in	B-X
B	B-X
cells	B-X
from	B-X
lupus	B-X
patients	B-X
mimicked	B-X
that	B-X
of	B-X
tonsil	B-X
B	B-X
cells	B-X
,	B-X
in	B-X
that	B-X
IKKα/β	B-X
were	B-X
more	B-X
activated	B-X
compared	B-X
to	B-X
normal	B-X
B	B-X
cells	B-X
.	B-X
CD40-induced	B-X
NF-κB	B-X
activity	B-X
was	B-X
blocked	B-X
by	B-X
both	B-X
IκB	B-X
phosphorylation	B-X
and	B-X
proteosome	B-X
degradation	B-X
inhibitors	B-X
in	B-X
both	B-X
lupus	B-X
and	B-X
normal	B-X
B	B-X
cells	B-X
.	B-X
All	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
revealed	B-X
that	B-X
canonical	B-X
NF-κB	B-X
signaling	B-X
is	B-X
constitutively	B-X
activated	B-X
in	B-X
active	B-X
lupus	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
CD154/CD40	B-X
.	B-X
CD40	B-X
induced	B-X
NF-κB	B-X
activation	B-X
is	B-X
different	B-X
in	B-X
human	B-X
lupus	B-X
B	B-X
lymphocytes	B-X
compared	B-X
with	B-X
normal	B-X
B	B-X
cells	B-X
.	B-X

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
was	O
absent	O
in	O
several	O
SLE	O
patients	O
who	O
were	O
not	O
receiving	O
any	O
medication	O
,	O
including	O
corticosteroids	O
.	O

Also	O
,	O
NF	O
-	O
kappa	O
B	O
activity	O
remained	O
absent	O
in	O
follow	O
-	O
up	O
studies	O
.	O
<EOS>	B-X
Because	B-X
NF-kappa	B-X
B	B-X
contributes	B-X
to	B-X
the	B-X
transcription	B-X
of	B-X
numerous	B-X
inflammatory	B-X
genes	B-X
and	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
molecular	B-X
target	B-X
of	B-X
antiinflammatory	B-X
drugs	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
characterize	B-X
the	B-X
functional	B-X
role	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
protein	B-X
complex	B-X
in	B-X
lupus	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
measured	B-X
the	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
nuclear	B-X
extracts	B-X
by	B-X
gel	B-X
shift	B-X
analysis	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
normal	B-X
cells	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
activity	B-X
in	B-X
SLE	B-X
patients	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
SLE	B-X
,	B-X
but	B-X
not	B-X
in	B-X
RA	B-X
,	B-X
patients	B-X
.	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
absent	B-X
in	B-X
several	B-X
SLE	B-X
patients	B-X
who	B-X
were	B-X
not	B-X
receiving	B-X
any	B-X
medication	B-X
,	B-X
including	B-X
corticosteroids	B-X
.	B-X
Also	B-X
,	B-X
NF-kappa	B-X
B	B-X
activity	B-X
remained	B-X
absent	B-X
in	B-X
follow-up	B-X
studies	B-X
.	B-X
In	B-X
supershift	B-X
experiments	B-X
using	B-X
specific	B-X
Abs	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
,	B-X
in	B-X
the	B-X
group	B-X
of	B-X
SLE	B-X
patients	B-X
who	B-X
displayed	B-X
undetectable	B-X
NF-kappa	B-X
B	B-X
activity	B-X
,	B-X
p65	B-X
complexes	B-X
were	B-X
not	B-X
formed	B-X
.	B-X
Finally	B-X
,	B-X
immunoblot	B-X
analysis	B-X
of	B-X
nuclear	B-X
extracts	B-X
showed	B-X
decreased	B-X
or	B-X
absent	B-X
p65	B-X
protein	B-X
levels	B-X
.	B-X

In	O
supershift	O
experiments	O
using	O
specific	O
Abs	O
,	O
we	O
showed	O
that	O
,	O
in	O
the	O
group	O
of	O
SLE	O
patients	O
who	O
displayed	O
undetectable	O
NF	O
-	O
kappa	O
B	O
activity	O
,	O
p65	B-Protein
complexes	O
were	O
not	O
formed	O
.	O

Finally	O
,	O
immunoblot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
decreased	O
or	O
absent	O
p65	B-Protein
protein	O
levels	O
.	O
<EOS>	B-X
To	B-X
address	B-X
this	B-X
,	B-X
we	B-X
compared	B-X
NF-κB	B-X
activity	B-X
in	B-X
cultures	B-X
of	B-X
primary	B-X
neocortical	B-X
neurons	B-X
,	B-X
mixed	B-X
brain	B-X
cells	B-X
,	B-X
and	B-X
liver	B-X
cells	B-X
,	B-X
employing	B-X
Western	B-X
blot	B-X
of	B-X
NF-κB	B-X
subunits	B-X
,	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
of	B-X
nuclear	B-X
κB	B-X
DNA	B-X
binding	B-X
,	B-X
reporter	B-X
assay	B-X
of	B-X
κB	B-X
DNA	B-X
binding	B-X
,	B-X
immunofluorescence	B-X
of	B-X
the	B-X
NF-κB	B-X
subunit	B-X
protein	B-X
p65	B-X
,	B-X
quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
of	B-X
NF-κB-regulated	B-X
gene	B-X
expression	B-X
,	B-X
and	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
of	B-X
produced	B-X
proteins	B-X
.	B-X
Assay	B-X
of	B-X
p65	B-X
showed	B-X
its	B-X
constitutive	B-X
presence	B-X
in	B-X
cytoplasm	B-X
and	B-X
nucleus	B-X
of	B-X
neurons	B-X
at	B-X
levels	B-X
significantly	B-X
lower	B-X
than	B-X
in	B-X
mixed	B-X
brain	B-X
or	B-X
liver	B-X
cells	B-X
.	B-X
EMSA	B-X
and	B-X
reporter	B-X
assays	B-X
showed	B-X
that	B-X
constitutive	B-X
NF-κB	B-X
activity	B-X
was	B-X
nearly	B-X
absent	B-X
in	B-X
neurons	B-X
.	B-X
Induced	B-X
activity	B-X
was	B-X
minimal	B-X
--	B-X
many	B-X
fold	B-X
lower	B-X
than	B-X
in	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
phosphorylation	B-X
and	B-X
degradation	B-X
of	B-X
the	B-X
inhibitor	B-X
IκBα	B-X
,	B-X
nuclear	B-X
accumulation	B-X
of	B-X
p65	B-X
,	B-X
binding	B-X
to	B-X
κB	B-X
DNA	B-X
consensus	B-X
sites	B-X
,	B-X
NF-κB	B-X
reporting	B-X
,	B-X
or	B-X
induction	B-X
of	B-X
NF-κB-responsive	B-X
genes	B-X
.	B-X

As	O
p65	B-Protein
complexes	O
are	O
transcriptionally	O
active	O
in	O
comparison	O
to	O
the	O
p50	B-Protein
homodimer	O
,	O
this	O
novel	O
finding	O
may	O
provide	O
insight	O
on	O
the	O
origin	O
of	O
abnormal	O
cytokine	O
or	O
other	O
gene	O
transcription	O
in	O
SLE	O
patients	O
.	O
<EOS>	B-X
Rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
,	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
and	B-X
primary	B-X
Sjögren	B-X
's	B-X
syndrome	B-X
(	B-X
pSS	B-X
)	B-X
share	B-X
many	B-X
clinical	B-X
manifestations	B-X
and	B-X
serological	B-X
features	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
identify	B-X
the	B-X
common	B-X
transcriptional	B-X
profiling	B-X
and	B-X
composition	B-X
of	B-X
immune	B-X
cells	B-X
in	B-X
peripheral	B-X
blood	B-X
in	B-X
these	B-X
autoimmune	B-X
diseases	B-X
(	B-X
ADs	B-X
)	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
IRF5	B-X
has	B-X
been	B-X
implicated	B-X
as	B-X
a	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
autoimmune	B-X
disease	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
SLE	B-X
patients	B-X
in	B-X
both	B-X
the	B-X
active	B-X
and	B-X
remission	B-X
phase	B-X
have	B-X
aberrant	B-X
activation	B-X
of	B-X
IRF5	B-X
and	B-X
interferon-stimulated	B-X
genes	B-X
.	B-X
Partial	B-X
inhibition	B-X
of	B-X
IRF5	B-X
is	B-X
superior	B-X
to	B-X
full	B-X
inhibition	B-X
of	B-X
type	B-X
I	B-X
interferon	B-X
signaling	B-X
in	B-X
suppressing	B-X
disease	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
SLE	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
the	B-X
function	B-X
of	B-X
IRF5	B-X
in	B-X
oxidative	B-X
phosphorylation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
IRF5	B-X
inhibition	B-X
might	B-X
overcome	B-X
the	B-X
limitations	B-X
of	B-X
current	B-X
SLE	B-X
therapies	B-X
,	B-X
thus	B-X
promoting	B-X
drug	B-X
discovery	B-X
research	B-X
on	B-X
IRF5	B-X
inhibitors	B-X
.	B-X

Possible	O
differences	O
in	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
different	O
glucocorticoid	O
hormone	O
compounds	O
.	O
<EOS>	B-X
Various	B-X
therapeutic	B-X
compounds	B-X
have	B-X
been	B-X
investigated	B-X
and	B-X
applied	B-X
to	B-X
mitigate	B-X
the	B-X
symptoms	B-X
in	B-X
COVID-19	B-X
patients	B-X
and	B-X
cure	B-X
the	B-X
disease	B-X
.	B-X
However	B-X
,	B-X
the	B-X
studies	B-X
and	B-X
clinical	B-X
trials	B-X
have	B-X
documented	B-X
diverging	B-X
findings	B-X
,	B-X
which	B-X
seem	B-X
to	B-X
be	B-X
due	B-X
to	B-X
the	B-X
differences	B-X
in	B-X
these	B-X
drugs	B-X
'	B-X
possible	B-X
mechanisms	B-X
of	B-X
action	B-X
.	B-X
These	B-X
drugs	B-X
'	B-X
mechanism	B-X
of	B-X
action	B-X
generally	B-X
includes	B-X
suppressing	B-X
or	B-X
modulating	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
preventing	B-X
the	B-X
development	B-X
of	B-X
cytokine	B-X
storm	B-X
via	B-X
various	B-X
signaling	B-X
pathways	B-X
,	B-X
and	B-X
enhancing	B-X
the	B-X
blood	B-X
vessels	B-X
'	B-X
diameter	B-X
in	B-X
the	B-X
lungs	B-X
.	B-X
In	B-X
this	B-X
review	B-X
article	B-X
,	B-X
multiple	B-X
medications	B-X
from	B-X
different	B-X
drug	B-X
families	B-X
are	B-X
discussed	B-X
,	B-X
and	B-X
their	B-X
possible	B-X
mechanisms	B-X
of	B-X
action	B-X
are	B-X
also	B-X
described	B-X
.	B-X

Different	O
glucocorticoid	O
hormones	O
(	O
GCH	O
)	O
show	O
differences	O
in	O
the	O
intensity	O
and	O
in	O
the	O
kinetics	O
of	O
their	O
immunomodulating	O
activity	O
.	O
<EOS>	B-X
Different	B-X
glucocorticoid	B-X
hormones	B-X
(	B-X
GCH	B-X
)	B-X
show	B-X
differences	B-X
in	B-X
the	B-X
intensity	B-X
and	B-X
in	B-X
the	B-X
kinetics	B-X
of	B-X
their	B-X
immunomodulating	B-X
activity	B-X
.	B-X
The	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
of	B-X
action	B-X
of	B-X
GCH	B-X
is	B-X
under	B-X
investigation	B-X
,	B-X
but	B-X
is	B-X
has	B-X
been	B-X
noted	B-X
that	B-X
they	B-X
exert	B-X
immune	B-X
activity	B-X
via	B-X
the	B-X
genomic	B-X
pathway	B-X
.	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
prednisone	B-X
(	B-X
PDN	B-X
)	B-X
,	B-X
deflazacort	B-X
(	B-X
DFC	B-X
)	B-X
,	B-X
and	B-X
dexamethasone	B-X
(	B-X
DXM	B-X
)	B-X
on	B-X
the	B-X
production	B-X
of	B-X
cytokines	B-X
(	B-X
IL-2	B-X
,	B-X
IL-6	B-X
,	B-X
TNF-alpha	B-X
,	B-X
IL-10	B-X
)	B-X
by	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
,	B-X
and	B-X
the	B-X
effects	B-X
on	B-X
the	B-X
inhibition	B-X
of	B-X
NF-kB	B-X
DNA	B-X
binding	B-X
activity	B-X
by	B-X
activated	B-X
Jurkat	B-X
cell	B-X
line	B-X
.	B-X
The	B-X
data	B-X
obtained	B-X
show	B-X
that	B-X
the	B-X
three	B-X
GCH	B-X
molecules	B-X
exert	B-X
an	B-X
immunosuppression	B-X
on	B-X
cytokine	B-X
production	B-X
by	B-X
T	B-X
lymphocytes	B-X
and	B-X
a	B-X
strong	B-X
decrease	B-X
in	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kB	B-X
in	B-X
Jurkat	B-X
cells	B-X
;	B-X
moreover	B-X
,	B-X
(	B-X
a	B-X
)	B-X
not	B-X
all	B-X
the	B-X
cytokines	B-X
investigated	B-X
were	B-X
affected	B-X
,	B-X
and	B-X
not	B-X
with	B-X
the	B-X
same	B-X
intensity	B-X
,	B-X
by	B-X
the	B-X
three	B-X
GCH	B-X
and	B-X
(	B-X
b	B-X
)	B-X
DXM	B-X
inhibited	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
NF-kB	B-X
less	B-X
than	B-X
that	B-X
of	B-X
DFC	B-X
and	B-X
PDN	B-X
.	B-X
These	B-X
data	B-X
are	B-X
in	B-X
agreement	B-X
with	B-X
the	B-X
concept	B-X
that	B-X
different	B-X
GCH	B-X
compounds	B-X
might	B-X
differ	B-X
in	B-X
their	B-X
binding	B-X
and	B-X
affinity	B-X
properties	B-X
,	B-X
tissue-specific	B-X
metabolism	B-X
,	B-X
and	B-X
interaction	B-X
with	B-X
transcription	B-X
factor	B-X
.	B-X

The	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
GCH	O
is	O
under	O
investigation	O
,	O
but	O
is	O
has	O
been	O
noted	O
that	O
they	O
exert	O
immune	O
activity	O
via	O
the	O
genomic	O
pathway	O
.	O
<EOS>	B-X
Different	B-X
glucocorticoid	B-X
hormones	B-X
(	B-X
GCH	B-X
)	B-X
show	B-X
differences	B-X
in	B-X
the	B-X
intensity	B-X
and	B-X
in	B-X
the	B-X
kinetics	B-X
of	B-X
their	B-X
immunomodulating	B-X
activity	B-X
.	B-X
The	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
of	B-X
action	B-X
of	B-X
GCH	B-X
is	B-X
under	B-X
investigation	B-X
,	B-X
but	B-X
is	B-X
has	B-X
been	B-X
noted	B-X
that	B-X
they	B-X
exert	B-X
immune	B-X
activity	B-X
via	B-X
the	B-X
genomic	B-X
pathway	B-X
.	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
prednisone	B-X
(	B-X
PDN	B-X
)	B-X
,	B-X
deflazacort	B-X
(	B-X
DFC	B-X
)	B-X
,	B-X
and	B-X
dexamethasone	B-X
(	B-X
DXM	B-X
)	B-X
on	B-X
the	B-X
production	B-X
of	B-X
cytokines	B-X
(	B-X
IL-2	B-X
,	B-X
IL-6	B-X
,	B-X
TNF-alpha	B-X
,	B-X
IL-10	B-X
)	B-X
by	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
,	B-X
and	B-X
the	B-X
effects	B-X
on	B-X
the	B-X
inhibition	B-X
of	B-X
NF-kB	B-X
DNA	B-X
binding	B-X
activity	B-X
by	B-X
activated	B-X
Jurkat	B-X
cell	B-X
line	B-X
.	B-X
The	B-X
data	B-X
obtained	B-X
show	B-X
that	B-X
the	B-X
three	B-X
GCH	B-X
molecules	B-X
exert	B-X
an	B-X
immunosuppression	B-X
on	B-X
cytokine	B-X
production	B-X
by	B-X
T	B-X
lymphocytes	B-X
and	B-X
a	B-X
strong	B-X
decrease	B-X
in	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kB	B-X
in	B-X
Jurkat	B-X
cells	B-X
;	B-X
moreover	B-X
,	B-X
(	B-X
a	B-X
)	B-X
not	B-X
all	B-X
the	B-X
cytokines	B-X
investigated	B-X
were	B-X
affected	B-X
,	B-X
and	B-X
not	B-X
with	B-X
the	B-X
same	B-X
intensity	B-X
,	B-X
by	B-X
the	B-X
three	B-X
GCH	B-X
and	B-X
(	B-X
b	B-X
)	B-X
DXM	B-X
inhibited	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
NF-kB	B-X
less	B-X
than	B-X
that	B-X
of	B-X
DFC	B-X
and	B-X
PDN	B-X
.	B-X
These	B-X
data	B-X
are	B-X
in	B-X
agreement	B-X
with	B-X
the	B-X
concept	B-X
that	B-X
different	B-X
GCH	B-X
compounds	B-X
might	B-X
differ	B-X
in	B-X
their	B-X
binding	B-X
and	B-X
affinity	B-X
properties	B-X
,	B-X
tissue-specific	B-X
metabolism	B-X
,	B-X
and	B-X
interaction	B-X
with	B-X
transcription	B-X
factor	B-X
.	B-X

We	O
have	O
studied	O
the	O
effects	O
of	O
prednisone	O
(	O
PDN	O
)	O
,	O
deflazacort	O
(	O
DFC	O
)	O
,	O
and	O
dexamethasone	O
(	O
DXM	O
)	O
on	O
the	O
production	O
of	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
by	O
peripheral	O
T	O
lymphocytes	O
,	O
and	O
the	O
effects	O
on	O
the	O
inhibition	O
of	O
NF	O
-	O
kB	O
DNA	O
binding	O
activity	O
by	O
activated	O
Jurkat	O
cell	O
line	O
.	O
<EOS>	B-X
Different	B-X
glucocorticoid	B-X
hormones	B-X
(	B-X
GCH	B-X
)	B-X
show	B-X
differences	B-X
in	B-X
the	B-X
intensity	B-X
and	B-X
in	B-X
the	B-X
kinetics	B-X
of	B-X
their	B-X
immunomodulating	B-X
activity	B-X
.	B-X
The	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
of	B-X
action	B-X
of	B-X
GCH	B-X
is	B-X
under	B-X
investigation	B-X
,	B-X
but	B-X
is	B-X
has	B-X
been	B-X
noted	B-X
that	B-X
they	B-X
exert	B-X
immune	B-X
activity	B-X
via	B-X
the	B-X
genomic	B-X
pathway	B-X
.	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
prednisone	B-X
(	B-X
PDN	B-X
)	B-X
,	B-X
deflazacort	B-X
(	B-X
DFC	B-X
)	B-X
,	B-X
and	B-X
dexamethasone	B-X
(	B-X
DXM	B-X
)	B-X
on	B-X
the	B-X
production	B-X
of	B-X
cytokines	B-X
(	B-X
IL-2	B-X
,	B-X
IL-6	B-X
,	B-X
TNF-alpha	B-X
,	B-X
IL-10	B-X
)	B-X
by	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
,	B-X
and	B-X
the	B-X
effects	B-X
on	B-X
the	B-X
inhibition	B-X
of	B-X
NF-kB	B-X
DNA	B-X
binding	B-X
activity	B-X
by	B-X
activated	B-X
Jurkat	B-X
cell	B-X
line	B-X
.	B-X
The	B-X
data	B-X
obtained	B-X
show	B-X
that	B-X
the	B-X
three	B-X
GCH	B-X
molecules	B-X
exert	B-X
an	B-X
immunosuppression	B-X
on	B-X
cytokine	B-X
production	B-X
by	B-X
T	B-X
lymphocytes	B-X
and	B-X
a	B-X
strong	B-X
decrease	B-X
in	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kB	B-X
in	B-X
Jurkat	B-X
cells	B-X
;	B-X
moreover	B-X
,	B-X
(	B-X
a	B-X
)	B-X
not	B-X
all	B-X
the	B-X
cytokines	B-X
investigated	B-X
were	B-X
affected	B-X
,	B-X
and	B-X
not	B-X
with	B-X
the	B-X
same	B-X
intensity	B-X
,	B-X
by	B-X
the	B-X
three	B-X
GCH	B-X
and	B-X
(	B-X
b	B-X
)	B-X
DXM	B-X
inhibited	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
NF-kB	B-X
less	B-X
than	B-X
that	B-X
of	B-X
DFC	B-X
and	B-X
PDN	B-X
.	B-X
These	B-X
data	B-X
are	B-X
in	B-X
agreement	B-X
with	B-X
the	B-X
concept	B-X
that	B-X
different	B-X
GCH	B-X
compounds	B-X
might	B-X
differ	B-X
in	B-X
their	B-X
binding	B-X
and	B-X
affinity	B-X
properties	B-X
,	B-X
tissue-specific	B-X
metabolism	B-X
,	B-X
and	B-X
interaction	B-X
with	B-X
transcription	B-X
factor	B-X
.	B-X

The	O
data	O
obtained	O
show	O
that	O
the	O
three	O
GCH	O
molecules	O
exert	O
an	O
immunosuppression	O
on	O
cytokine	O
production	O
by	O
T	O
lymphocytes	O
and	O
a	O
strong	O
decrease	O
in	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kB	O
in	O
Jurkat	O
cells	O
;	O
moreover	O
,	O
(	O
a	O
)	O
not	O
all	O
the	O
cytokines	O
investigated	O
were	O
affected	O
,	O
and	O
not	O
with	O
the	O
same	O
intensity	O
,	O
by	O
the	O
three	O
GCH	O
and	O
(	O
b	O
)	O
DXM	O
inhibited	O
the	O
binding	O
activity	O
of	O
NF	O
-	O
kB	O
less	O
than	O
that	O
of	O
DFC	O
and	O
PDN	O
.	O

These	O
data	O
are	O
in	O
agreement	O
with	O
the	O
concept	O
that	O
different	O
GCH	O
compounds	O
might	O
differ	O
in	O
their	O
binding	O
and	O
affinity	O
properties	O
,	O
tissue	O
-	O
specific	O
metabolism	O
,	O
and	O
interaction	O
with	O
transcription	O
factor	O
.	O
<EOS>	B-X
Different	B-X
glucocorticoid	B-X
hormones	B-X
(	B-X
GCH	B-X
)	B-X
show	B-X
differences	B-X
in	B-X
the	B-X
intensity	B-X
and	B-X
in	B-X
the	B-X
kinetics	B-X
of	B-X
their	B-X
immunomodulating	B-X
activity	B-X
.	B-X
The	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
of	B-X
action	B-X
of	B-X
GCH	B-X
is	B-X
under	B-X
investigation	B-X
,	B-X
but	B-X
is	B-X
has	B-X
been	B-X
noted	B-X
that	B-X
they	B-X
exert	B-X
immune	B-X
activity	B-X
via	B-X
the	B-X
genomic	B-X
pathway	B-X
.	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
prednisone	B-X
(	B-X
PDN	B-X
)	B-X
,	B-X
deflazacort	B-X
(	B-X
DFC	B-X
)	B-X
,	B-X
and	B-X
dexamethasone	B-X
(	B-X
DXM	B-X
)	B-X
on	B-X
the	B-X
production	B-X
of	B-X
cytokines	B-X
(	B-X
IL-2	B-X
,	B-X
IL-6	B-X
,	B-X
TNF-alpha	B-X
,	B-X
IL-10	B-X
)	B-X
by	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
,	B-X
and	B-X
the	B-X
effects	B-X
on	B-X
the	B-X
inhibition	B-X
of	B-X
NF-kB	B-X
DNA	B-X
binding	B-X
activity	B-X
by	B-X
activated	B-X
Jurkat	B-X
cell	B-X
line	B-X
.	B-X
The	B-X
data	B-X
obtained	B-X
show	B-X
that	B-X
the	B-X
three	B-X
GCH	B-X
molecules	B-X
exert	B-X
an	B-X
immunosuppression	B-X
on	B-X
cytokine	B-X
production	B-X
by	B-X
T	B-X
lymphocytes	B-X
and	B-X
a	B-X
strong	B-X
decrease	B-X
in	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kB	B-X
in	B-X
Jurkat	B-X
cells	B-X
;	B-X
moreover	B-X
,	B-X
(	B-X
a	B-X
)	B-X
not	B-X
all	B-X
the	B-X
cytokines	B-X
investigated	B-X
were	B-X
affected	B-X
,	B-X
and	B-X
not	B-X
with	B-X
the	B-X
same	B-X
intensity	B-X
,	B-X
by	B-X
the	B-X
three	B-X
GCH	B-X
and	B-X
(	B-X
b	B-X
)	B-X
DXM	B-X
inhibited	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
NF-kB	B-X
less	B-X
than	B-X
that	B-X
of	B-X
DFC	B-X
and	B-X
PDN	B-X
.	B-X
These	B-X
data	B-X
are	B-X
in	B-X
agreement	B-X
with	B-X
the	B-X
concept	B-X
that	B-X
different	B-X
GCH	B-X
compounds	B-X
might	B-X
differ	B-X
in	B-X
their	B-X
binding	B-X
and	B-X
affinity	B-X
properties	B-X
,	B-X
tissue-specific	B-X
metabolism	B-X
,	B-X
and	B-X
interaction	B-X
with	B-X
transcription	B-X
factor	B-X
.	B-X

The	O
p53	B-Protein
paradox	O
in	O
the	O
pathogenesis	O
of	O
tumor	O
progression	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
we	B-X
studied	B-X
the	B-X
functional	B-X
consequences	B-X
of	B-X
SQLE	B-X
reduction	B-X
in	B-X
CRC	B-X
progression	B-X
.	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
the	B-X
p53	B-X
molecule	B-X
appears	B-X
in	B-X
two	B-X
different	B-X
forms	B-X
:	B-X
the	B-X
mutant	B-X
p53	B-X
that	B-X
stimulates	B-X
tumor	B-X
progression	B-X
,	B-X
and	B-X
wild	B-X
type	B-X
p53	B-X
that	B-X
inhibits	B-X
tumor	B-X
progression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
it	B-X
has	B-X
been	B-X
established	B-X
that	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
can	B-X
activate	B-X
the	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
p53	B-X
in	B-X
concert	B-X
with	B-X
the	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
NF-kappa	B-X
B	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
shall	B-X
advance	B-X
the	B-X
hypothesis	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
TNF-alpha	B-X
indirectly	B-X
controls	B-X
immune	B-X
surveillance	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
TNF-alpha	B-X
controls	B-X
DNA	B-X
repair	B-X
and	B-X
tumor	B-X
suppression	B-X
through	B-X
the	B-X
regulation	B-X
of	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
hypothesized	B-X
that	B-X
elevated	B-X
TNF-alpha	B-X
is	B-X
primarily	B-X
responsible	B-X
for	B-X
promoting	B-X
tumor	B-X
progression	B-X
.	B-X

Recent	O
evidence	O
suggests	O
that	O
the	O
p53	B-Protein
molecule	O
appears	O
in	O
two	O
different	O
forms	O
:	O
the	O
mutant	O
p53	B-Protein
that	O
stimulates	O
tumor	O
progression	O
,	O
and	O
wild	O
type	O
p53	B-Protein
that	O
inhibits	O
tumor	O
progression	O
.	O
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
the	B-X
p53	B-X
molecule	B-X
appears	B-X
in	B-X
two	B-X
different	B-X
forms	B-X
:	B-X
the	B-X
mutant	B-X
p53	B-X
that	B-X
stimulates	B-X
tumor	B-X
progression	B-X
,	B-X
and	B-X
wild	B-X
type	B-X
p53	B-X
that	B-X
inhibits	B-X
tumor	B-X
progression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
it	B-X
has	B-X
been	B-X
established	B-X
that	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
can	B-X
activate	B-X
the	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
p53	B-X
in	B-X
concert	B-X
with	B-X
the	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
NF-kappa	B-X
B	B-X
.	B-X
Both	B-X
TNF-alpha	B-X
and	B-X
NF-kappa	B-X
B	B-X
are	B-X
also	B-X
involved	B-X
in	B-X
the	B-X
stimulation	B-X
of	B-X
the	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
expression	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
class	B-X
I	B-X
molecules	B-X
and	B-X
,	B-X
hence	B-X
,	B-X
antigen	B-X
presentation	B-X
to	B-X
the	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
shall	B-X
advance	B-X
the	B-X
hypothesis	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
TNF-alpha	B-X
indirectly	B-X
controls	B-X
immune	B-X
surveillance	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
TNF-alpha	B-X
controls	B-X
DNA	B-X
repair	B-X
and	B-X
tumor	B-X
suppression	B-X
through	B-X
the	B-X
regulation	B-X
of	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
hypothesized	B-X
that	B-X
elevated	B-X
TNF-alpha	B-X
is	B-X
primarily	B-X
responsible	B-X
for	B-X
promoting	B-X
tumor	B-X
progression	B-X
.	B-X

In	O
addition	O
,	O
it	O
has	O
been	O
established	O
that	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
can	O
activate	O
the	O
expression	O
of	O
wild	O
type	O
p53	B-Protein
in	O
concert	O
with	O
the	O
nuclear	O
transcription	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
the	B-X
p53	B-X
molecule	B-X
appears	B-X
in	B-X
two	B-X
different	B-X
forms	B-X
:	B-X
the	B-X
mutant	B-X
p53	B-X
that	B-X
stimulates	B-X
tumor	B-X
progression	B-X
,	B-X
and	B-X
wild	B-X
type	B-X
p53	B-X
that	B-X
inhibits	B-X
tumor	B-X
progression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
it	B-X
has	B-X
been	B-X
established	B-X
that	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
can	B-X
activate	B-X
the	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
p53	B-X
in	B-X
concert	B-X
with	B-X
the	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
NF-kappa	B-X
B	B-X
.	B-X
Both	B-X
TNF-alpha	B-X
and	B-X
NF-kappa	B-X
B	B-X
are	B-X
also	B-X
involved	B-X
in	B-X
the	B-X
stimulation	B-X
of	B-X
the	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
expression	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
class	B-X
I	B-X
molecules	B-X
and	B-X
,	B-X
hence	B-X
,	B-X
antigen	B-X
presentation	B-X
to	B-X
the	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
shall	B-X
advance	B-X
the	B-X
hypothesis	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
TNF-alpha	B-X
indirectly	B-X
controls	B-X
immune	B-X
surveillance	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
TNF-alpha	B-X
controls	B-X
DNA	B-X
repair	B-X
and	B-X
tumor	B-X
suppression	B-X
through	B-X
the	B-X
regulation	B-X
of	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
hypothesized	B-X
that	B-X
elevated	B-X
TNF-alpha	B-X
is	B-X
primarily	B-X
responsible	B-X
for	B-X
promoting	B-X
tumor	B-X
progression	B-X
.	B-X

Both	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
NF	O
-	O
kappa	O
B	O
are	O
also	O
involved	O
in	O
the	O
stimulation	O
of	O
the	O
pathway	O
that	O
leads	O
to	O
the	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
and	O
,	O
hence	O
,	O
antigen	O
presentation	O
to	O
the	O
T	O
cells	O
.	O

In	O
this	O
paper	O
we	O
shall	O
advance	O
the	O
hypothesis	O
that	O
:	O
(	O
i	O
)	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
indirectly	O
controls	O
immune	O
surveillance	O
;	O
and	O
(	O
ii	O
)	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
controls	O
DNA	O
repair	O
and	O
tumor	O
suppression	O
through	O
the	O
regulation	O
of	O
wild	O
type	O
p53	B-Protein
.	O
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
the	B-X
p53	B-X
molecule	B-X
appears	B-X
in	B-X
two	B-X
different	B-X
forms	B-X
:	B-X
the	B-X
mutant	B-X
p53	B-X
that	B-X
stimulates	B-X
tumor	B-X
progression	B-X
,	B-X
and	B-X
wild	B-X
type	B-X
p53	B-X
that	B-X
inhibits	B-X
tumor	B-X
progression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
it	B-X
has	B-X
been	B-X
established	B-X
that	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
can	B-X
activate	B-X
the	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
p53	B-X
in	B-X
concert	B-X
with	B-X
the	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
NF-kappa	B-X
B	B-X
.	B-X
Both	B-X
TNF-alpha	B-X
and	B-X
NF-kappa	B-X
B	B-X
are	B-X
also	B-X
involved	B-X
in	B-X
the	B-X
stimulation	B-X
of	B-X
the	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
expression	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
class	B-X
I	B-X
molecules	B-X
and	B-X
,	B-X
hence	B-X
,	B-X
antigen	B-X
presentation	B-X
to	B-X
the	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
shall	B-X
advance	B-X
the	B-X
hypothesis	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
TNF-alpha	B-X
indirectly	B-X
controls	B-X
immune	B-X
surveillance	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
TNF-alpha	B-X
controls	B-X
DNA	B-X
repair	B-X
and	B-X
tumor	B-X
suppression	B-X
through	B-X
the	B-X
regulation	B-X
of	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
hypothesized	B-X
that	B-X
elevated	B-X
TNF-alpha	B-X
is	B-X
primarily	B-X
responsible	B-X
for	B-X
promoting	B-X
tumor	B-X
progression	B-X
.	B-X

Thus	O
,	O
it	O
is	O
hypothesized	O
that	O
elevated	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
is	O
primarily	O
responsible	O
for	O
promoting	O
tumor	O
progression	O
.	O
<EOS>	B-X
Recent	B-X
evidence	B-X
suggests	B-X
that	B-X
the	B-X
p53	B-X
molecule	B-X
appears	B-X
in	B-X
two	B-X
different	B-X
forms	B-X
:	B-X
the	B-X
mutant	B-X
p53	B-X
that	B-X
stimulates	B-X
tumor	B-X
progression	B-X
,	B-X
and	B-X
wild	B-X
type	B-X
p53	B-X
that	B-X
inhibits	B-X
tumor	B-X
progression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
it	B-X
has	B-X
been	B-X
established	B-X
that	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
can	B-X
activate	B-X
the	B-X
expression	B-X
of	B-X
wild	B-X
type	B-X
p53	B-X
in	B-X
concert	B-X
with	B-X
the	B-X
nuclear	B-X
transcription	B-X
factor	B-X
,	B-X
NF-kappa	B-X
B	B-X
.	B-X
Both	B-X
TNF-alpha	B-X
and	B-X
NF-kappa	B-X
B	B-X
are	B-X
also	B-X
involved	B-X
in	B-X
the	B-X
stimulation	B-X
of	B-X
the	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
expression	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
class	B-X
I	B-X
molecules	B-X
and	B-X
,	B-X
hence	B-X
,	B-X
antigen	B-X
presentation	B-X
to	B-X
the	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
shall	B-X
advance	B-X
the	B-X
hypothesis	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
TNF-alpha	B-X
indirectly	B-X
controls	B-X
immune	B-X
surveillance	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
TNF-alpha	B-X
controls	B-X
DNA	B-X
repair	B-X
and	B-X
tumor	B-X
suppression	B-X
through	B-X
the	B-X
regulation	B-X
of	B-X
wild	B-X
type	B-X
p53	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
hypothesized	B-X
that	B-X
elevated	B-X
TNF-alpha	B-X
is	B-X
primarily	B-X
responsible	B-X
for	B-X
promoting	B-X
tumor	B-X
progression	B-X
.	B-X

Differential	O
effects	O
of	O
lipopolysaccharide	O
and	O
tumor	O
necrosis	O
factor	O
on	O
monocytic	O
IkappaB	O
kinase	O
signalsome	O
activation	O
and	O
IkappaB	O
proteolysis	O
.	O
<EOS>	B-X
The	B-X
inflammatory	B-X
mediators	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
are	B-X
potent	B-X
activators	B-X
of	B-X
NF-kappaB	B-X
.	B-X
This	B-X
study	B-X
compared	B-X
the	B-X
effect	B-X
of	B-X
these	B-X
stimuli	B-X
on	B-X
endogenous	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
signalsome	B-X
activation	B-X
and	B-X
IkappaB	B-X
phosphorylation/proteolysis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
and	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
signalsome	B-X
proteins	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
NF-kappaB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
,	B-X
IKK-gamma	B-X
(	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
)	B-X
,	B-X
and	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
.	B-X
The	B-X
endogenous	B-X
levels	B-X
of	B-X
the	B-X
signalsome	B-X
components	B-X
were	B-X
unaffected	B-X
by	B-X
stimulation	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
studies	B-X
showed	B-X
association	B-X
of	B-X
the	B-X
IKK-alpha/beta	B-X
heterodimer	B-X
with	B-X
NIK	B-X
,	B-X
IkappaB-alpha	B-X
and	B-X
-epsilon	B-X
in	B-X
unstimulated	B-X
cells	B-X
.	B-X
Exposure	B-X
to	B-X
LPS	B-X
or	B-X
TNF	B-X
led	B-X
to	B-X
differential	B-X
patterns	B-X
of	B-X
IkappaB-alpha	B-X
and	B-X
IkappaB-epsilon	B-X
disappearance	B-X
from	B-X
and	B-X
reassembly	B-X
with	B-X
the	B-X
signalsome	B-X
,	B-X
whereas	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
and	B-X
NIK	B-X
remained	B-X
complex-associated	B-X
.	B-X
NIK	B-X
can	B-X
not	B-X
phosphorylate	B-X
IkappaB-alpha	B-X
directly	B-X
,	B-X
but	B-X
it	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
functionally	B-X
important	B-X
subunit	B-X
,	B-X
because	B-X
mutated	B-X
NIK	B-X
inhibited	B-X
stimulus-induced	B-X
kappaB-dependent	B-X
transcription	B-X
more	B-X
effectively	B-X
than	B-X
mutated	B-X
IKK-alpha	B-X
or	B-X
-beta	B-X
.	B-X

The	O
inflammatory	O
mediators	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
are	O
potent	O
activators	O
of	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
The	B-X
initiation	B-X
and	B-X
development	B-X
of	B-X
major	B-X
inflammatory	B-X
diseases	B-X
,	B-X
Triptolide	B-X
obtained	B-X
from	B-X
Tripterygium	B-X
wilfordii	B-X
Hook	B-X
F	B-X
possesses	B-X
potent	B-X
anti-inflammatory	B-X
and	B-X
immunosuppressive	B-X
effects	B-X
.	B-X
Probiotics	B-X
are	B-X
able	B-X
to	B-X
reduce	B-X
inflammatory	B-X
responses	B-X
in	B-X
intestinal	B-X
epithelial	B-X
cells	B-X
(	B-X
IECs	B-X
)	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
investigate	B-X
the	B-X
anti-inflammatory	B-X
effects	B-X
and	B-X
mechanisms	B-X
of	B-X
single	B-X
and	B-X
combined	B-X
probiotics	B-X
.	B-X
HT-29	B-X
cells	B-X
were	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
,	B-X
treated	B-X
with	B-X

This	O
study	O
compared	O
the	O
effect	O
of	O
these	O
stimuli	O
on	O
endogenous	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
signalsome	O
activation	O
and	O
IkappaB	O
phosphorylation	O
/	O
proteolysis	O
in	O
human	O
monocytic	O
cells	O
and	O
investigated	O
the	O
role	O
of	O
the	O
signalsome	O
proteins	O
IKK	B-Protein
-	I-Protein
alpha	I-Protein
,	O
IKK	B-Protein
-	I-Protein
beta	I-Protein
,	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
-	I-Protein
inducing	I-Protein
kinase	I-Protein
(	O
NIK	B-Protein
)	O
,	O
IKK	B-Protein
-	I-Protein
gamma	I-Protein
(	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
)	O
,	O
and	O
IKK	B-Protein
complex	I-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
.	O
<EOS>	B-X
The	B-X
inflammatory	B-X
mediators	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
are	B-X
potent	B-X
activators	B-X
of	B-X
NF-kappaB	B-X
.	B-X
This	B-X
study	B-X
compared	B-X
the	B-X
effect	B-X
of	B-X
these	B-X
stimuli	B-X
on	B-X
endogenous	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
signalsome	B-X
activation	B-X
and	B-X
IkappaB	B-X
phosphorylation/proteolysis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
and	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
signalsome	B-X
proteins	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
NF-kappaB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
,	B-X
IKK-gamma	B-X
(	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
)	B-X
,	B-X
and	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
.	B-X
Kinase	B-X
assays	B-X
showed	B-X
that	B-X
TNF	B-X
elicited	B-X
a	B-X
rapid	B-X
but	B-X
short-lived	B-X
induction	B-X
of	B-X
IKK	B-X
activity	B-X
with	B-X
a	B-X
3-fold	B-X
greater	B-X
effect	B-X
on	B-X
IKK-alpha	B-X
than	B-X
on	B-X
IKK-beta	B-X
,	B-X
peaking	B-X
at	B-X
5	B-X
min	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
LPS	B-X
predominantly	B-X
stimulated	B-X
IKK-beta	B-X
activity	B-X
,	B-X
which	B-X
slowly	B-X
increased	B-X
,	B-X
peaking	B-X
at	B-X
30	B-X
min	B-X
.	B-X
A	B-X
second	B-X
peak	B-X
was	B-X
observed	B-X
at	B-X
a	B-X
later	B-X
time	B-X
point	B-X
following	B-X
LPS	B-X
stimulation	B-X
,	B-X
which	B-X
consisted	B-X
of	B-X
both	B-X
IKK-alpha	B-X
and	B-X
-beta	B-X
activity	B-X
.	B-X
The	B-X
endogenous	B-X
levels	B-X
of	B-X
the	B-X
signalsome	B-X
components	B-X
were	B-X
unaffected	B-X
by	B-X
stimulation	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
studies	B-X
showed	B-X
association	B-X
of	B-X
the	B-X
IKK-alpha/beta	B-X
heterodimer	B-X
with	B-X
NIK	B-X
,	B-X
IkappaB-alpha	B-X
and	B-X
-epsilon	B-X
in	B-X
unstimulated	B-X
cells	B-X
.	B-X
Exposure	B-X
to	B-X
LPS	B-X
or	B-X
TNF	B-X
led	B-X
to	B-X
differential	B-X
patterns	B-X
of	B-X
IkappaB-alpha	B-X
and	B-X
IkappaB-epsilon	B-X
disappearance	B-X
from	B-X
and	B-X
reassembly	B-X
with	B-X
the	B-X
signalsome	B-X
,	B-X
whereas	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
and	B-X
NIK	B-X
remained	B-X
complex-associated	B-X
.	B-X
NIK	B-X
can	B-X
not	B-X
phosphorylate	B-X
IkappaB-alpha	B-X
directly	B-X
,	B-X
but	B-X
it	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
functionally	B-X
important	B-X
subunit	B-X
,	B-X
because	B-X
mutated	B-X
NIK	B-X
inhibited	B-X
stimulus-induced	B-X
kappaB-dependent	B-X
transcription	B-X
more	B-X
effectively	B-X
than	B-X
mutated	B-X
IKK-alpha	B-X
or	B-X
-beta	B-X
.	B-X
Overexpression	B-X
of	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
inhibited	B-X
stimulus-mediated	B-X
transcription	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
understanding	B-X
of	B-X
LPS-	B-X
and	B-X
TNF-induced	B-X
signaling	B-X
may	B-X
allow	B-X
the	B-X
development	B-X
of	B-X
specific	B-X
strategies	B-X
to	B-X
treat	B-X
sepsis-associated	B-X
disease	B-X
.	B-X

Kinase	O
assays	O
showed	O
that	O
TNF	O
elicited	O
a	O
rapid	O
but	O
short	O
-	O
lived	O
induction	O
of	O
IKK	O
activity	O
with	O
a	O
3	O
-	O
fold	O
greater	O
effect	O
on	O
IKK	B-Protein
-	I-Protein
alpha	I-Protein
than	O
on	O
IKK	B-Protein
-	I-Protein
beta	I-Protein
,	O
peaking	O
at	O
5	O
min	O
.	O
<EOS>	B-X
The	B-X
inflammatory	B-X
mediators	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
are	B-X
potent	B-X
activators	B-X
of	B-X
NF-kappaB	B-X
.	B-X
This	B-X
study	B-X
compared	B-X
the	B-X
effect	B-X
of	B-X
these	B-X
stimuli	B-X
on	B-X
endogenous	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
signalsome	B-X
activation	B-X
and	B-X
IkappaB	B-X
phosphorylation/proteolysis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
and	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
signalsome	B-X
proteins	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
NF-kappaB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
,	B-X
IKK-gamma	B-X
(	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
)	B-X
,	B-X
and	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
.	B-X
Kinase	B-X
assays	B-X
showed	B-X
that	B-X
TNF	B-X
elicited	B-X
a	B-X
rapid	B-X
but	B-X
short-lived	B-X
induction	B-X
of	B-X
IKK	B-X
activity	B-X
with	B-X
a	B-X
3-fold	B-X
greater	B-X
effect	B-X
on	B-X
IKK-alpha	B-X
than	B-X
on	B-X
IKK-beta	B-X
,	B-X
peaking	B-X
at	B-X
5	B-X
min	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
LPS	B-X
predominantly	B-X
stimulated	B-X
IKK-beta	B-X
activity	B-X
,	B-X
which	B-X
slowly	B-X
increased	B-X
,	B-X
peaking	B-X
at	B-X
30	B-X
min	B-X
.	B-X
A	B-X
second	B-X
peak	B-X
was	B-X
observed	B-X
at	B-X
a	B-X
later	B-X
time	B-X
point	B-X
following	B-X
LPS	B-X
stimulation	B-X
,	B-X
which	B-X
consisted	B-X
of	B-X
both	B-X
IKK-alpha	B-X
and	B-X
-beta	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
studies	B-X
showed	B-X
association	B-X
of	B-X
the	B-X
IKK-alpha/beta	B-X
heterodimer	B-X
with	B-X
NIK	B-X
,	B-X
IkappaB-alpha	B-X
and	B-X
-epsilon	B-X
in	B-X
unstimulated	B-X
cells	B-X
.	B-X
Exposure	B-X
to	B-X
LPS	B-X
or	B-X
TNF	B-X
led	B-X
to	B-X
differential	B-X
patterns	B-X
of	B-X
IkappaB-alpha	B-X
and	B-X
IkappaB-epsilon	B-X
disappearance	B-X
from	B-X
and	B-X
reassembly	B-X
with	B-X
the	B-X
signalsome	B-X
,	B-X
whereas	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
and	B-X
NIK	B-X
remained	B-X
complex-associated	B-X
.	B-X
NIK	B-X
can	B-X
not	B-X
phosphorylate	B-X
IkappaB-alpha	B-X
directly	B-X
,	B-X
but	B-X
it	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
functionally	B-X
important	B-X
subunit	B-X
,	B-X
because	B-X
mutated	B-X
NIK	B-X
inhibited	B-X
stimulus-induced	B-X
kappaB-dependent	B-X
transcription	B-X
more	B-X
effectively	B-X
than	B-X
mutated	B-X
IKK-alpha	B-X
or	B-X
-beta	B-X
.	B-X
Overexpression	B-X
of	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
inhibited	B-X
stimulus-mediated	B-X
transcription	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
understanding	B-X
of	B-X
LPS-	B-X
and	B-X
TNF-induced	B-X
signaling	B-X
may	B-X
allow	B-X
the	B-X
development	B-X
of	B-X
specific	B-X
strategies	B-X
to	B-X
treat	B-X
sepsis-associated	B-X
disease	B-X
.	B-X

In	O
contrast	O
,	O
LPS	O
predominantly	O
stimulated	O
IKK	B-Protein
-	I-Protein
beta	I-Protein
activity	O
,	O
which	O
slowly	O
increased	O
,	O
peaking	O
at	O
30	O
min	O
.	O
<EOS>	B-X
The	B-X
inflammatory	B-X
mediators	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
are	B-X
potent	B-X
activators	B-X
of	B-X
NF-kappaB	B-X
.	B-X
This	B-X
study	B-X
compared	B-X
the	B-X
effect	B-X
of	B-X
these	B-X
stimuli	B-X
on	B-X
endogenous	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
signalsome	B-X
activation	B-X
and	B-X
IkappaB	B-X
phosphorylation/proteolysis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
and	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
signalsome	B-X
proteins	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
NF-kappaB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
,	B-X
IKK-gamma	B-X
(	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
)	B-X
,	B-X
and	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
.	B-X
Kinase	B-X
assays	B-X
showed	B-X
that	B-X
TNF	B-X
elicited	B-X
a	B-X
rapid	B-X
but	B-X
short-lived	B-X
induction	B-X
of	B-X
IKK	B-X
activity	B-X
with	B-X
a	B-X
3-fold	B-X
greater	B-X
effect	B-X
on	B-X
IKK-alpha	B-X
than	B-X
on	B-X
IKK-beta	B-X
,	B-X
peaking	B-X
at	B-X
5	B-X
min	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
LPS	B-X
predominantly	B-X
stimulated	B-X
IKK-beta	B-X
activity	B-X
,	B-X
which	B-X
slowly	B-X
increased	B-X
,	B-X
peaking	B-X
at	B-X
30	B-X
min	B-X
.	B-X
A	B-X
second	B-X
peak	B-X
was	B-X
observed	B-X
at	B-X
a	B-X
later	B-X
time	B-X
point	B-X
following	B-X
LPS	B-X
stimulation	B-X
,	B-X
which	B-X
consisted	B-X
of	B-X
both	B-X
IKK-alpha	B-X
and	B-X
-beta	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
studies	B-X
showed	B-X
association	B-X
of	B-X
the	B-X
IKK-alpha/beta	B-X
heterodimer	B-X
with	B-X
NIK	B-X
,	B-X
IkappaB-alpha	B-X
and	B-X
-epsilon	B-X
in	B-X
unstimulated	B-X
cells	B-X
.	B-X
Exposure	B-X
to	B-X
LPS	B-X
or	B-X
TNF	B-X
led	B-X
to	B-X
differential	B-X
patterns	B-X
of	B-X
IkappaB-alpha	B-X
and	B-X
IkappaB-epsilon	B-X
disappearance	B-X
from	B-X
and	B-X
reassembly	B-X
with	B-X
the	B-X
signalsome	B-X
,	B-X
whereas	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
and	B-X
NIK	B-X
remained	B-X
complex-associated	B-X
.	B-X
NIK	B-X
can	B-X
not	B-X
phosphorylate	B-X
IkappaB-alpha	B-X
directly	B-X
,	B-X
but	B-X
it	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
functionally	B-X
important	B-X
subunit	B-X
,	B-X
because	B-X
mutated	B-X
NIK	B-X
inhibited	B-X
stimulus-induced	B-X
kappaB-dependent	B-X
transcription	B-X
more	B-X
effectively	B-X
than	B-X
mutated	B-X
IKK-alpha	B-X
or	B-X
-beta	B-X
.	B-X
Overexpression	B-X
of	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
inhibited	B-X
stimulus-mediated	B-X
transcription	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
understanding	B-X
of	B-X
LPS-	B-X
and	B-X
TNF-induced	B-X
signaling	B-X
may	B-X
allow	B-X
the	B-X
development	B-X
of	B-X
specific	B-X
strategies	B-X
to	B-X
treat	B-X
sepsis-associated	B-X
disease	B-X
.	B-X

A	O
second	O
peak	O
was	O
observed	O
at	O
a	O
later	O
time	O
point	O
following	O
LPS	O
stimulation	O
,	O
which	O
consisted	O
of	O
both	O
IKK	B-Protein
-	I-Protein
alpha	I-Protein
and	O
-	B-Protein
beta	I-Protein
activity	O
.	O

The	O
endogenous	O
levels	O
of	O
the	O
signalsome	O
components	O
were	O
unaffected	O
by	O
stimulation	O
.	O
<EOS>	B-X
This	B-X
study	B-X
compared	B-X
the	B-X
effect	B-X
of	B-X
these	B-X
stimuli	B-X
on	B-X
endogenous	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
signalsome	B-X
activation	B-X
and	B-X
IkappaB	B-X
phosphorylation/proteolysis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
and	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
signalsome	B-X
proteins	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
NF-kappaB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
,	B-X
IKK-gamma	B-X
(	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
)	B-X
,	B-X
and	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
.	B-X
A	B-X
second	B-X
peak	B-X
was	B-X
observed	B-X
at	B-X
a	B-X
later	B-X
time	B-X
point	B-X
following	B-X
LPS	B-X
stimulation	B-X
,	B-X
which	B-X
consisted	B-X
of	B-X
both	B-X
IKK-alpha	B-X
and	B-X
-beta	B-X
activity	B-X
.	B-X
The	B-X
endogenous	B-X
levels	B-X
of	B-X
the	B-X
signalsome	B-X
components	B-X
were	B-X
unaffected	B-X
by	B-X
stimulation	B-X
.	B-X
Exposure	B-X
to	B-X
LPS	B-X
or	B-X
TNF	B-X
led	B-X
to	B-X
differential	B-X
patterns	B-X
of	B-X
IkappaB-alpha	B-X
and	B-X
IkappaB-epsilon	B-X
disappearance	B-X
from	B-X
and	B-X
reassembly	B-X
with	B-X
the	B-X
signalsome	B-X
,	B-X
whereas	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
and	B-X
NIK	B-X
remained	B-X
complex-associated	B-X
.	B-X

Furthermore	O
,	O
our	O
studies	O
showed	O
association	O
of	O
the	O
IKK	O
-	O
alpha	O
/	O
beta	O
heterodimer	O
with	O
NIK	B-Protein
,	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
-	B-Protein
epsilon	I-Protein
in	O
unstimulated	O
cells	O
.	O
<EOS>	B-X
This	B-X
study	B-X
compared	B-X
the	B-X
effect	B-X
of	B-X
these	B-X
stimuli	B-X
on	B-X
endogenous	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
signalsome	B-X
activation	B-X
and	B-X
IkappaB	B-X
phosphorylation/proteolysis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
and	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
signalsome	B-X
proteins	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
NF-kappaB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
,	B-X
IKK-gamma	B-X
(	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
)	B-X
,	B-X
and	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
.	B-X
Kinase	B-X
assays	B-X
showed	B-X
that	B-X
TNF	B-X
elicited	B-X
a	B-X
rapid	B-X
but	B-X
short-lived	B-X
induction	B-X
of	B-X
IKK	B-X
activity	B-X
with	B-X
a	B-X
3-fold	B-X
greater	B-X
effect	B-X
on	B-X
IKK-alpha	B-X
than	B-X
on	B-X
IKK-beta	B-X
,	B-X
peaking	B-X
at	B-X
5	B-X
min	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
LPS	B-X
predominantly	B-X
stimulated	B-X
IKK-beta	B-X
activity	B-X
,	B-X
which	B-X
slowly	B-X
increased	B-X
,	B-X
peaking	B-X
at	B-X
30	B-X
min	B-X
.	B-X
A	B-X
second	B-X
peak	B-X
was	B-X
observed	B-X
at	B-X
a	B-X
later	B-X
time	B-X
point	B-X
following	B-X
LPS	B-X
stimulation	B-X
,	B-X
which	B-X
consisted	B-X
of	B-X
both	B-X
IKK-alpha	B-X
and	B-X
-beta	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
studies	B-X
showed	B-X
association	B-X
of	B-X
the	B-X
IKK-alpha/beta	B-X
heterodimer	B-X
with	B-X
NIK	B-X
,	B-X
IkappaB-alpha	B-X
and	B-X
-epsilon	B-X
in	B-X
unstimulated	B-X
cells	B-X
.	B-X
Exposure	B-X
to	B-X
LPS	B-X
or	B-X
TNF	B-X
led	B-X
to	B-X
differential	B-X
patterns	B-X
of	B-X
IkappaB-alpha	B-X
and	B-X
IkappaB-epsilon	B-X
disappearance	B-X
from	B-X
and	B-X
reassembly	B-X
with	B-X
the	B-X
signalsome	B-X
,	B-X
whereas	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
and	B-X
NIK	B-X
remained	B-X
complex-associated	B-X
.	B-X
NIK	B-X
can	B-X
not	B-X
phosphorylate	B-X
IkappaB-alpha	B-X
directly	B-X
,	B-X
but	B-X
it	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
functionally	B-X
important	B-X
subunit	B-X
,	B-X
because	B-X
mutated	B-X
NIK	B-X
inhibited	B-X
stimulus-induced	B-X
kappaB-dependent	B-X
transcription	B-X
more	B-X
effectively	B-X
than	B-X
mutated	B-X
IKK-alpha	B-X
or	B-X
-beta	B-X
.	B-X
Overexpression	B-X
of	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
inhibited	B-X
stimulus-mediated	B-X
transcription	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
enhanced	B-X
it	B-X
.	B-X

Exposure	O
to	O
LPS	O
or	O
TNF	O
led	O
to	O
differential	O
patterns	O
of	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
and	O
IkappaB	B-Protein
-	I-Protein
epsilon	I-Protein
disappearance	O
from	O
and	O
reassembly	O
with	O
the	O
signalsome	O
,	O
whereas	O
IKK	B-Protein
-	I-Protein
alpha	I-Protein
,	O
IKK	B-Protein
-	I-Protein
beta	I-Protein
,	O
and	O
NIK	B-Protein
remained	O
complex	O
-	O
associated	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
their	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
exposures	B-X
arose	B-X
primarily	B-X
from	B-X
Bacteroides	B-X
rather	B-X
than	B-X
from	B-X
Escherichia	B-X
coli	B-X
,	B-X
which	B-X
is	B-X
a	B-X
potent	B-X
innate	B-X
immune	B-X
activator	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Bacteroides	B-X
LPS	B-X
is	B-X
structurally	B-X
distinct	B-X
from	B-X
E.	B-X
coli	B-X
LPS	B-X
and	B-X
inhibits	B-X
innate	B-X
immune	B-X
signaling	B-X
and	B-X
endotoxin	B-X
tolerance	B-X
;	B-X
furthermore	B-X
,	B-X
unlike	B-X
LPS	B-X
from	B-X
E.	B-X
coli	B-X
,	B-X
B.	B-X
dorei	B-X
LPS	B-X
does	B-X
not	B-X
decrease	B-X
incidence	B-X
of	B-X
autoimmune	B-X
diabetes	B-X
in	B-X
non-obese	B-X
diabetic	B-X
mice	B-X
.	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
can	B-X
trigger	B-X
the	B-X
inflammation	B-X
burden	B-X
of	B-X
various	B-X
tissues	B-X
.	B-X
Whether	B-X
PSNPs	B-X
deteriorate	B-X
LPS-induced	B-X
intestinal	B-X
damage	B-X
via	B-X
ROS	B-X
drived-NF-κB/NLRP3	B-X
pathway	B-X
is	B-X
remains	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
PSNPs	B-X
exposure/PSNPs	B-X
and	B-X
LPS	B-X
co-exposure	B-X
mice	B-X
model	B-X
were	B-X
duplicated	B-X
by	B-X
intraperitoneal	B-X
injection	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
exposure	B-X
to	B-X
PSNPs/LPS	B-X
caused	B-X
duodenal	B-X
inflammation	B-X
and	B-X
increased	B-X
permeability	B-X
.	B-X
We	B-X
found	B-X
that	B-X
PSNPs/LPS	B-X
could	B-X
aggravate	B-X
the	B-X
production	B-X
of	B-X
ROS	B-X
and	B-X
oxidative	B-X
stress	B-X
in	B-X
cells	B-X
,	B-X
activate	B-X
NF-κB/NLRP3	B-X
pathway	B-X
,	B-X
decrease	B-X
the	B-X
expression	B-X
tight	B-X
junction	B-X
proteins	B-X
(	B-X
ZO-1	B-X
,	B-X
Claudin	B-X
1	B-X
,	B-X
and	B-X
Occludin	B-X
)	B-X
levels	B-X
,	B-X
promote	B-X
inflammatory	B-X
factors	B-X
(	B-X
TNF-α	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
IFN-γ	B-X
)	B-X
expressions	B-X
.	B-X
Duodenal	B-X
oxidative	B-X
stress	B-X
and	B-X
inflammation	B-X
in	B-X
PS	B-X
+	B-X
LPS	B-X
group	B-X
were	B-X
more	B-X
serious	B-X
than	B-X
those	B-X
in	B-X
single	B-X
exposure	B-X
group	B-X
,	B-X
which	B-X
could	B-X
be	B-X
alleviated	B-X
by	B-X
NF-kB	B-X
inhibitor	B-X
QNZ	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
results	B-X
verified	B-X
that	B-X
PSNPs	B-X
deteriorated	B-X
LPS-induced	B-X
inflammation	B-X
and	B-X
increasing	B-X
permeability	B-X
in	B-X
mice	B-X
duodenum	B-X
via	B-X
ROS	B-X
drived-NF-κB/NLRP3	B-X
pathway	B-X
.	B-X

NIK	B-Protein
cannot	O
phosphorylate	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
directly	O
,	O
but	O
it	O
appears	O
to	O
be	O
a	O
functionally	O
important	O
subunit	O
,	O
because	O
mutated	O
NIK	B-Protein
inhibited	O
stimulus	O
-	O
induced	O
kappaB	O
-	O
dependent	O
transcription	O
more	O
effectively	O
than	O
mutated	O
IKK	B-Protein
-	I-Protein
alpha	I-Protein
or	O
-	B-Protein
beta	I-Protein
.	O
<EOS>	B-X
The	B-X
drug	B-X
appears	B-X
safe	B-X
in	B-X
trials	B-X
,	B-X
and	B-X
no	B-X
patient	B-X
left	B-X
the	B-X
trials	B-X
due	B-X
to	B-X
side	B-X
effects	B-X
.	B-X
Protease	B-X
inhibitor	B-X
drugs	B-X
need	B-X
to	B-X
be	B-X
taken	B-X
in	B-X
adherence	B-X
to	B-X
a	B-X
strict	B-X
schedule	B-X
in	B-X
order	B-X
for	B-X
them	B-X
to	B-X
work	B-X
effectively	B-X
,	B-X
and	B-X
there	B-X
is	B-X
great	B-X
potential	B-X
for	B-X
interaction	B-X
between	B-X
these	B-X
drugs	B-X
and	B-X
others	B-X
,	B-X
including	B-X
others	B-X
in	B-X
the	B-X
same	B-X
class	B-X
.	B-X
As	B-X
public	B-X
health	B-X
and	B-X
media	B-X
attention	B-X
increasingly	B-X
focus	B-X
on	B-X
serosorting	B-X
as	B-X
a	B-X
form	B-X
of	B-X
risk	B-X
reduction	B-X
for	B-X
both	B-X
HIV	B-X
positive	B-X
and	B-X
HIV	B-X
negative	B-X
individuals	B-X
,	B-X
it	B-X
has	B-X
become	B-X
increasingly	B-X
important	B-X
to	B-X
understand	B-X
this	B-X
phenomenon	B-X
.	B-X
Two	B-X
types	B-X
of	B-X
super-secondary	B-X
structure	B-X
,	B-X
coiled	B-X
beta-beta-hairpins	B-X
and	B-X
beta-beta-corners	B-X
,	B-X
are	B-X
considered	B-X
in	B-X
this	B-X
paper	B-X
.	B-X
A	B-X
beta-beta-corner	B-X
can	B-X
be	B-X
represented	B-X
as	B-X
a	B-X
long	B-X
beta-beta-hairpin	B-X
folded	B-X
orthogonally	B-X
on	B-X
itself	B-X
so	B-X
that	B-X
the	B-X
strands	B-X
,	B-X
when	B-X
passing	B-X
from	B-X
one	B-X
layer	B-X
to	B-X
the	B-X
other	B-X
,	B-X
rotate	B-X
in	B-X
a	B-X
right-handed	B-X
direction	B-X
about	B-X
an	B-X
imaginary	B-X
axis	B-X
.	B-X
It	B-X
is	B-X
shown	B-X
that	B-X
a	B-X
beta-beta-hairpin	B-X
,	B-X
forming	B-X
a	B-X
coiled	B-X
coil	B-X
structure	B-X
or	B-X
a	B-X
beta-beta-corner	B-X
,	B-X
is	B-X
right-handed	B-X
when	B-X
viewed	B-X
from	B-X
the	B-X
concave	B-X
side	B-X
.	B-X
These	B-X
unique	B-X
arrangements	B-X
of	B-X
beta-strands	B-X
in	B-X
the	B-X
coiled	B-X
beta-beta-hairpins	B-X
and	B-X
beta-beta-corners	B-X
are	B-X
of	B-X
particular	B-X
value	B-X
in	B-X
protein	B-X
modelling	B-X
and	B-X
prediction	B-X
.	B-X

Overexpression	O
of	O
IKK	O
complex	O
-	O
associated	O
protein	O
inhibited	O
stimulus	O
-	O
mediated	O
transcription	O
,	O
whereas	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
enhanced	O
it	O
.	O
<EOS>	B-X
The	B-X
inflammatory	B-X
mediators	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
are	B-X
potent	B-X
activators	B-X
of	B-X
NF-kappaB	B-X
.	B-X
This	B-X
study	B-X
compared	B-X
the	B-X
effect	B-X
of	B-X
these	B-X
stimuli	B-X
on	B-X
endogenous	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
signalsome	B-X
activation	B-X
and	B-X
IkappaB	B-X
phosphorylation/proteolysis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
and	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
signalsome	B-X
proteins	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
NF-kappaB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
,	B-X
IKK-gamma	B-X
(	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
)	B-X
,	B-X
and	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
.	B-X
Kinase	B-X
assays	B-X
showed	B-X
that	B-X
TNF	B-X
elicited	B-X
a	B-X
rapid	B-X
but	B-X
short-lived	B-X
induction	B-X
of	B-X
IKK	B-X
activity	B-X
with	B-X
a	B-X
3-fold	B-X
greater	B-X
effect	B-X
on	B-X
IKK-alpha	B-X
than	B-X
on	B-X
IKK-beta	B-X
,	B-X
peaking	B-X
at	B-X
5	B-X
min	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
LPS	B-X
predominantly	B-X
stimulated	B-X
IKK-beta	B-X
activity	B-X
,	B-X
which	B-X
slowly	B-X
increased	B-X
,	B-X
peaking	B-X
at	B-X
30	B-X
min	B-X
.	B-X
A	B-X
second	B-X
peak	B-X
was	B-X
observed	B-X
at	B-X
a	B-X
later	B-X
time	B-X
point	B-X
following	B-X
LPS	B-X
stimulation	B-X
,	B-X
which	B-X
consisted	B-X
of	B-X
both	B-X
IKK-alpha	B-X
and	B-X
-beta	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
studies	B-X
showed	B-X
association	B-X
of	B-X
the	B-X
IKK-alpha/beta	B-X
heterodimer	B-X
with	B-X
NIK	B-X
,	B-X
IkappaB-alpha	B-X
and	B-X
-epsilon	B-X
in	B-X
unstimulated	B-X
cells	B-X
.	B-X
Exposure	B-X
to	B-X
LPS	B-X
or	B-X
TNF	B-X
led	B-X
to	B-X
differential	B-X
patterns	B-X
of	B-X
IkappaB-alpha	B-X
and	B-X
IkappaB-epsilon	B-X
disappearance	B-X
from	B-X
and	B-X
reassembly	B-X
with	B-X
the	B-X
signalsome	B-X
,	B-X
whereas	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
and	B-X
NIK	B-X
remained	B-X
complex-associated	B-X
.	B-X
NIK	B-X
can	B-X
not	B-X
phosphorylate	B-X
IkappaB-alpha	B-X
directly	B-X
,	B-X
but	B-X
it	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
functionally	B-X
important	B-X
subunit	B-X
,	B-X
because	B-X
mutated	B-X
NIK	B-X
inhibited	B-X
stimulus-induced	B-X
kappaB-dependent	B-X
transcription	B-X
more	B-X
effectively	B-X
than	B-X
mutated	B-X
IKK-alpha	B-X
or	B-X
-beta	B-X
.	B-X
Overexpression	B-X
of	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
inhibited	B-X
stimulus-mediated	B-X
transcription	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
understanding	B-X
of	B-X
LPS-	B-X
and	B-X
TNF-induced	B-X
signaling	B-X
may	B-X
allow	B-X
the	B-X
development	B-X
of	B-X
specific	B-X
strategies	B-X
to	B-X
treat	B-X
sepsis-associated	B-X
disease	B-X
.	B-X

The	O
understanding	O
of	O
LPS	O
-	O
and	O
TNF	O
-	O
induced	O
signaling	O
may	O
allow	O
the	O
development	O
of	O
specific	O
strategies	O
to	O
treat	O
sepsis	O
-	O
associated	O
disease	O
.	O
<EOS>	B-X
The	B-X
inflammatory	B-X
mediators	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
are	B-X
potent	B-X
activators	B-X
of	B-X
NF-kappaB	B-X
.	B-X
This	B-X
study	B-X
compared	B-X
the	B-X
effect	B-X
of	B-X
these	B-X
stimuli	B-X
on	B-X
endogenous	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
signalsome	B-X
activation	B-X
and	B-X
IkappaB	B-X
phosphorylation/proteolysis	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
and	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
the	B-X
signalsome	B-X
proteins	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
NF-kappaB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
)	B-X
,	B-X
IKK-gamma	B-X
(	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
)	B-X
,	B-X
and	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
.	B-X
Kinase	B-X
assays	B-X
showed	B-X
that	B-X
TNF	B-X
elicited	B-X
a	B-X
rapid	B-X
but	B-X
short-lived	B-X
induction	B-X
of	B-X
IKK	B-X
activity	B-X
with	B-X
a	B-X
3-fold	B-X
greater	B-X
effect	B-X
on	B-X
IKK-alpha	B-X
than	B-X
on	B-X
IKK-beta	B-X
,	B-X
peaking	B-X
at	B-X
5	B-X
min	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
LPS	B-X
predominantly	B-X
stimulated	B-X
IKK-beta	B-X
activity	B-X
,	B-X
which	B-X
slowly	B-X
increased	B-X
,	B-X
peaking	B-X
at	B-X
30	B-X
min	B-X
.	B-X
A	B-X
second	B-X
peak	B-X
was	B-X
observed	B-X
at	B-X
a	B-X
later	B-X
time	B-X
point	B-X
following	B-X
LPS	B-X
stimulation	B-X
,	B-X
which	B-X
consisted	B-X
of	B-X
both	B-X
IKK-alpha	B-X
and	B-X
-beta	B-X
activity	B-X
.	B-X
Exposure	B-X
to	B-X
LPS	B-X
or	B-X
TNF	B-X
led	B-X
to	B-X
differential	B-X
patterns	B-X
of	B-X
IkappaB-alpha	B-X
and	B-X
IkappaB-epsilon	B-X
disappearance	B-X
from	B-X
and	B-X
reassembly	B-X
with	B-X
the	B-X
signalsome	B-X
,	B-X
whereas	B-X
IKK-alpha	B-X
,	B-X
IKK-beta	B-X
,	B-X
and	B-X
NIK	B-X
remained	B-X
complex-associated	B-X
.	B-X
NIK	B-X
can	B-X
not	B-X
phosphorylate	B-X
IkappaB-alpha	B-X
directly	B-X
,	B-X
but	B-X
it	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
functionally	B-X
important	B-X
subunit	B-X
,	B-X
because	B-X
mutated	B-X
NIK	B-X
inhibited	B-X
stimulus-induced	B-X
kappaB-dependent	B-X
transcription	B-X
more	B-X
effectively	B-X
than	B-X
mutated	B-X
IKK-alpha	B-X
or	B-X
-beta	B-X
.	B-X
Overexpression	B-X
of	B-X
IKK	B-X
complex-associated	B-X
protein	B-X
inhibited	B-X
stimulus-mediated	B-X
transcription	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
essential	B-X
modulator	B-X
enhanced	B-X
it	B-X
.	B-X
The	B-X
understanding	B-X
of	B-X
LPS-	B-X
and	B-X
TNF-induced	B-X
signaling	B-X
may	B-X
allow	B-X
the	B-X
development	B-X
of	B-X
specific	B-X
strategies	B-X
to	B-X
treat	B-X
sepsis-associated	B-X
disease	B-X
.	B-X

Activation	O
of	O
protein	O
kinase	O
C	O
and	O
elevation	O
of	O
cAMP	O
interact	O
synergistically	O
to	O
raise	O
c	B-Protein
-	I-Protein
Fos	I-Protein
and	O
AP	O
-	O
1	O
activity	O
in	O
Jurkat	O
cells	O
.	O
<EOS>	B-X
We	B-X
have	B-X
earlier	B-X
found	B-X
that	B-X
in	B-X
Jurkat	B-X
cells	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
enhances	B-X
the	B-X
cyclic	B-X
adenosine	B-X
monophosphate	B-X
(	B-X
cAMP	B-X
)	B-X
accumulation	B-X
induced	B-X
by	B-X
adenosine	B-X
receptor	B-X
stimulation	B-X
or	B-X
activation	B-X
of	B-X
Gs	B-X
.	B-X
Here	B-X
we	B-X
have	B-X
therefore	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
phorbol	B-X
ester	B-X
PMA	B-X
(	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
)	B-X
which	B-X
stimulates	B-X
PKC	B-X
and	B-X
a	B-X
combination	B-X
of	B-X
the	B-X
adenosine	B-X
receptor	B-X
agonist	B-X
NECA	B-X
(	B-X
5'-	B-X
(	B-X
N-ethyl	B-X
)	B-X
-carboxamido	B-X
adenosine	B-X
)	B-X
and	B-X
forskolin	B-X
to	B-X
raise	B-X
cAMP	B-X
,	B-X
on	B-X
the	B-X
levels	B-X
of	B-X
c-Fos	B-X
and	B-X
Jun	B-X
and	B-X
on	B-X
the	B-X
binding	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
,	B-X
activator	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
.	B-X
PMA	B-X
treatment	B-X
caused	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
increase	B-X
in	B-X
both	B-X
c-Fos	B-X
and	B-X
Jun	B-X
immunoreactivity	B-X
in	B-X
contrast	B-X
to	B-X
cAMP	B-X
elevation	B-X
that	B-X
had	B-X
only	B-X
a	B-X
slight	B-X
effect	B-X
.	B-X
Both	B-X
PMA	B-X
and	B-X
the	B-X
combination	B-X
of	B-X
NECA	B-X
and	B-X
forskolin	B-X
acted	B-X
together	B-X
either	B-X
to	B-X
increase	B-X
(	B-X
c-Fos	B-X
)	B-X
or	B-X
decrease	B-X
(	B-X
Jun	B-X
)	B-X
protein	B-X
levels	B-X
as	B-X
well	B-X
as	B-X
increasing	B-X
AP-1	B-X
binding	B-X
,	B-X
as	B-X
judged	B-X
by	B-X
gel-shift	B-X
assay	B-X
,	B-X
and	B-X
AP-1	B-X
transcriptional	B-X
activity	B-X
.	B-X
Furthermore	B-X
there	B-X
was	B-X
a	B-X
clear-cut	B-X
synergy	B-X
between	B-X
the	B-X
PKC	B-X
stimulator	B-X
and	B-X
the	B-X
cAMP	B-X
elevating	B-X
agents	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
simultaneous	B-X
activation	B-X
of	B-X
PKC	B-X
and	B-X
elevation	B-X
of	B-X
cAMP	B-X
leads	B-X
to	B-X
an	B-X
enhanced	B-X
AP-1	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
T-leukemia	B-X
cell	B-X
line	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
previously	B-X
observed	B-X
interaction	B-X
between	B-X
the	B-X
parallel	B-X
signal	B-X
transduction	B-X
pathways	B-X
may	B-X
have	B-X
functional	B-X
consequences	B-X
at	B-X
the	B-X
level	B-X
of	B-X
gene	B-X
transcription	B-X
.	B-X

We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	O
.	O
<EOS>	B-X
We	B-X
conducted	B-X
a	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
to	B-X
clarify	B-X
the	B-X
effects	B-X
of	B-X
different	B-X
exercise	B-X
modes	B-X
(	B-X
resistance	B-X
training	B-X
[	B-X
RT	B-X
]	B-X
,	B-X
whole	B-X
body	B-X
vibration	B-X
training	B-X
[	B-X
WBVT	B-X
]	B-X
,	B-X
and	B-X
mixed	B-X
training	B-X
[	B-X
MT	B-X
,	B-X
resistance	B-X
training	B-X
combined	B-X
with	B-X
other	B-X
exercises	B-X
such	B-X
as	B-X
balance	B-X
,	B-X
endurance	B-X
and	B-X
aerobic	B-X
training	B-X
]	B-X
)	B-X
on	B-X
muscle	B-X
strength	B-X
(	B-X
knee	B-X
extension	B-X
strength	B-X
[	B-X
KES	B-X
]	B-X
)	B-X
and	B-X
physical	B-X
performance	B-X
(	B-X
Timed	B-X
Up	B-X
and	B-X
Go	B-X
[	B-X
TUG	B-X
]	B-X
,	B-X
gait	B-X
speed	B-X
[	B-X
GS	B-X
]	B-X
and	B-X
the	B-X
Chair	B-X
Stand	B-X
[	B-X
CS	B-X
]	B-X
)	B-X
in	B-X
older	B-X
people	B-X
with	B-X
sarcopenia	B-X
.	B-X
Breast	B-X
cancer-related	B-X
lymphedema	B-X
(	B-X
BCRL	B-X
)	B-X
is	B-X
a	B-X
negative	B-X
sequela	B-X
of	B-X
breast	B-X
cancer	B-X
treatment	B-X
,	B-X
and	B-X
well-established	B-X
risk	B-X
factors	B-X
include	B-X
axillary	B-X
lymph	B-X
node	B-X
dissection	B-X
(	B-X
ALND	B-X
)	B-X
and	B-X
regional	B-X
lymph	B-X
node	B-X
radiation	B-X
(	B-X
RLNR	B-X
)	B-X
.	B-X
BCRL	B-X
affects	B-X
approximately	B-X
1	B-X
in	B-X
5	B-X
patients	B-X
treated	B-X
for	B-X
breast	B-X
cancer	B-X
,	B-X
and	B-X
it	B-X
has	B-X
a	B-X
significant	B-X
negative	B-X
impact	B-X
on	B-X
patients	B-X
'	B-X
quality	B-X
of	B-X
life	B-X
after	B-X
breast	B-X
cancer	B-X
treatment	B-X
,	B-X
serving	B-X
as	B-X
a	B-X
reminder	B-X
of	B-X
previous	B-X
illness	B-X
.	B-X
This	B-X
paper	B-X
is	B-X
a	B-X
comprehensive	B-X
review	B-X
of	B-X
the	B-X
current	B-X
evidence	B-X
regarding	B-X
BCRL	B-X
risk	B-X
factors	B-X
,	B-X
precautionary	B-X
guidelines	B-X
,	B-X
prospective	B-X
screening	B-X
,	B-X
early	B-X
intervention	B-X
,	B-X
and	B-X
surgical	B-X
and	B-X
non-surgical	B-X
treatment	B-X
techniques	B-X
.	B-X
Through	B-X
establishing	B-X
evidence-based	B-X
BCRL	B-X
risk	B-X
factors	B-X
,	B-X
researchers	B-X
and	B-X
clinicians	B-X
are	B-X
better	B-X
able	B-X
to	B-X
prevent	B-X
,	B-X
anticipate	B-X
,	B-X
and	B-X
provide	B-X
early	B-X
intervention	B-X
for	B-X
BCRL	B-X
.	B-X
Clinicians	B-X
can	B-X
identify	B-X
patients	B-X
at	B-X
high	B-X
risk	B-X
and	B-X
utilize	B-X
prospective	B-X
screening	B-X
programs	B-X
,	B-X
which	B-X
incorporate	B-X
objective	B-X
measurements	B-X
,	B-X
patient	B-X
reported	B-X
outcome	B-X
measures	B-X
(	B-X
PROM	B-X
)	B-X
,	B-X
and	B-X
clinical	B-X
examination	B-X
,	B-X
thereby	B-X
creating	B-X
opportunities	B-X
for	B-X
early	B-X
intervention	B-X
and	B-X
,	B-X
accordingly	B-X
,	B-X
improving	B-X
BCRL	B-X
prognosis	B-X
.	B-X
Innovative	B-X
surgical	B-X
techniques	B-X
that	B-X
minimize	B-X
and/or	B-X
prophylactically	B-X
correct	B-X
lymphatic	B-X
disruption	B-X
,	B-X
such	B-X
as	B-X
axillary	B-X
reverse	B-X
mapping	B-X
(	B-X
ARM	B-X
)	B-X
and	B-X
lymphatic-venous	B-X
anastomoses	B-X
(	B-X
LVAs	B-X
)	B-X
,	B-X
are	B-X
promising	B-X
avenues	B-X
for	B-X
reducing	B-X
BCRL	B-X
incidence	B-X
.	B-X
Nonetheless	B-X
,	B-X
for	B-X
those	B-X
patients	B-X
with	B-X
BCRL	B-X
who	B-X
remain	B-X
unresponsive	B-X
to	B-X
conservative	B-X
methods	B-X
like	B-X
complete	B-X
decongestive	B-X
therapy	B-X
(	B-X
CDT	B-X
)	B-X
,	B-X
surgical	B-X
treatment	B-X
options	B-X
aiming	B-X
to	B-X
reduce	B-X
limb	B-X
volume	B-X
or	B-X
restore	B-X
lymphatic	B-X
flow	B-X
may	B-X
prove	B-X
to	B-X
be	B-X
palliative	B-X
or	B-X
corrective	B-X
.	B-X
It	B-X
is	B-X
only	B-X
through	B-X
a	B-X
strong	B-X
team-based	B-X
approach	B-X
that	B-X
such	B-X
a	B-X
continuum	B-X
of	B-X
care	B-X
can	B-X
exist	B-X
,	B-X
and	B-X
a	B-X
multidisciplinary	B-X
approach	B-X
to	B-X
BCRL	B-X
screening	B-X
,	B-X
intervention	B-X
,	B-X
and	B-X
research	B-X
is	B-X
therefore	B-X
strongly	B-X
encouraged	B-X
.	B-X

Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
)	O
which	O
stimulates	O
PKC	B-Protein
and	O
a	O
combination	O
of	O
the	O
adenosine	O
receptor	O
agonist	O
NECA	O
(	O
5	O
'	O
-	O
(	O
N	O
-	O
ethyl	O
)	O
-	O
carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	O
of	O
c	B-Protein
-	I-Protein
Fos	I-Protein
and	O
Jun	B-Protein
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	O
factor	O
,	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
.	O

PMA	O
treatment	O
caused	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
increase	O
in	O
both	O
c	B-Protein
-	I-Protein
Fos	I-Protein
and	O
Jun	B-Protein
immunoreactivity	O
in	O
contrast	O
to	O
cAMP	O
elevation	O
that	O
had	O
only	O
a	O
slight	O
effect	O
.	O

Both	O
PMA	O
and	O
the	O
combination	O
of	O
NECA	O
and	O
forskolin	O
acted	O
together	O
either	O
to	O
increase	O
(	O
c	B-Protein
-	I-Protein
Fos	I-Protein
)	O
or	O
decrease	O
(	O
Jun	B-Protein
)	O
protein	O
levels	O
as	O
well	O
as	O
increasing	O
AP	O
-	O
1	O
binding	O
,	O
as	O
judged	O
by	O
gel	O
-	O
shift	O
assay	O
,	O
and	O
AP	O
-	O
1	O
transcriptional	O
activity	O
.	O
<EOS>	B-X
We	B-X
have	B-X
earlier	B-X
found	B-X
that	B-X
in	B-X
Jurkat	B-X
cells	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
enhances	B-X
the	B-X
cyclic	B-X
adenosine	B-X
monophosphate	B-X
(	B-X
cAMP	B-X
)	B-X
accumulation	B-X
induced	B-X
by	B-X
adenosine	B-X
receptor	B-X
stimulation	B-X
or	B-X
activation	B-X
of	B-X
Gs	B-X
.	B-X
Here	B-X
we	B-X
have	B-X
therefore	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
phorbol	B-X
ester	B-X
PMA	B-X
(	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
)	B-X
which	B-X
stimulates	B-X
PKC	B-X
and	B-X
a	B-X
combination	B-X
of	B-X
the	B-X
adenosine	B-X
receptor	B-X
agonist	B-X
NECA	B-X
(	B-X
5'-	B-X
(	B-X
N-ethyl	B-X
)	B-X
-carboxamido	B-X
adenosine	B-X
)	B-X
and	B-X
forskolin	B-X
to	B-X
raise	B-X
cAMP	B-X
,	B-X
on	B-X
the	B-X
levels	B-X
of	B-X
c-Fos	B-X
and	B-X
Jun	B-X
and	B-X
on	B-X
the	B-X
binding	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
,	B-X
activator	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
.	B-X
PMA	B-X
treatment	B-X
caused	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
increase	B-X
in	B-X
both	B-X
c-Fos	B-X
and	B-X
Jun	B-X
immunoreactivity	B-X
in	B-X
contrast	B-X
to	B-X
cAMP	B-X
elevation	B-X
that	B-X
had	B-X
only	B-X
a	B-X
slight	B-X
effect	B-X
.	B-X
Both	B-X
PMA	B-X
and	B-X
the	B-X
combination	B-X
of	B-X
NECA	B-X
and	B-X
forskolin	B-X
acted	B-X
together	B-X
either	B-X
to	B-X
increase	B-X
(	B-X
c-Fos	B-X
)	B-X
or	B-X
decrease	B-X
(	B-X
Jun	B-X
)	B-X
protein	B-X
levels	B-X
as	B-X
well	B-X
as	B-X
increasing	B-X
AP-1	B-X
binding	B-X
,	B-X
as	B-X
judged	B-X
by	B-X
gel-shift	B-X
assay	B-X
,	B-X
and	B-X
AP-1	B-X
transcriptional	B-X
activity	B-X
.	B-X
Furthermore	B-X
there	B-X
was	B-X
a	B-X
clear-cut	B-X
synergy	B-X
between	B-X
the	B-X
PKC	B-X
stimulator	B-X
and	B-X
the	B-X
cAMP	B-X
elevating	B-X
agents	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
simultaneous	B-X
activation	B-X
of	B-X
PKC	B-X
and	B-X
elevation	B-X
of	B-X
cAMP	B-X
leads	B-X
to	B-X
an	B-X
enhanced	B-X
AP-1	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
T-leukemia	B-X
cell	B-X
line	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
previously	B-X
observed	B-X
interaction	B-X
between	B-X
the	B-X
parallel	B-X
signal	B-X
transduction	B-X
pathways	B-X
may	B-X
have	B-X
functional	B-X
consequences	B-X
at	B-X
the	B-X
level	B-X
of	B-X
gene	B-X
transcription	B-X
.	B-X

Furthermore	O
there	O
was	O
a	O
clear	O
-	O
cut	O
synergy	O
between	O
the	O
PKC	B-Protein
stimulator	O
and	O
the	O
cAMP	O
elevating	O
agents	O
.	O
<EOS>	B-X
We	B-X
have	B-X
earlier	B-X
found	B-X
that	B-X
in	B-X
Jurkat	B-X
cells	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
enhances	B-X
the	B-X
cyclic	B-X
adenosine	B-X
monophosphate	B-X
(	B-X
cAMP	B-X
)	B-X
accumulation	B-X
induced	B-X
by	B-X
adenosine	B-X
receptor	B-X
stimulation	B-X
or	B-X
activation	B-X
of	B-X
Gs	B-X
.	B-X
Here	B-X
we	B-X
have	B-X
therefore	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
phorbol	B-X
ester	B-X
PMA	B-X
(	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
)	B-X
which	B-X
stimulates	B-X
PKC	B-X
and	B-X
a	B-X
combination	B-X
of	B-X
the	B-X
adenosine	B-X
receptor	B-X
agonist	B-X
NECA	B-X
(	B-X
5'-	B-X
(	B-X
N-ethyl	B-X
)	B-X
-carboxamido	B-X
adenosine	B-X
)	B-X
and	B-X
forskolin	B-X
to	B-X
raise	B-X
cAMP	B-X
,	B-X
on	B-X
the	B-X
levels	B-X
of	B-X
c-Fos	B-X
and	B-X
Jun	B-X
and	B-X
on	B-X
the	B-X
binding	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
,	B-X
activator	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
.	B-X
PMA	B-X
treatment	B-X
caused	B-X
a	B-X
concentration-	B-X
and	B-X
time-dependent	B-X
increase	B-X
in	B-X
both	B-X
c-Fos	B-X
and	B-X
Jun	B-X
immunoreactivity	B-X
in	B-X
contrast	B-X
to	B-X
cAMP	B-X
elevation	B-X
that	B-X
had	B-X
only	B-X
a	B-X
slight	B-X
effect	B-X
.	B-X
Furthermore	B-X
there	B-X
was	B-X
a	B-X
clear-cut	B-X
synergy	B-X
between	B-X
the	B-X
PKC	B-X
stimulator	B-X
and	B-X
the	B-X
cAMP	B-X
elevating	B-X
agents	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
simultaneous	B-X
activation	B-X
of	B-X
PKC	B-X
and	B-X
elevation	B-X
of	B-X
cAMP	B-X
leads	B-X
to	B-X
an	B-X
enhanced	B-X
AP-1	B-X
transcriptional	B-X
activity	B-X
in	B-X
a	B-X
T-leukemia	B-X
cell	B-X
line	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
previously	B-X
observed	B-X
interaction	B-X
between	B-X
the	B-X
parallel	B-X
signal	B-X
transduction	B-X
pathways	B-X
may	B-X
have	B-X
functional	B-X
consequences	B-X
at	B-X
the	B-X
level	B-X
of	B-X
gene	B-X
transcription	B-X
.	B-X

The	O
results	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
PKC	B-Protein
and	O
elevation	O
of	O
cAMP	O
leads	O
to	O
an	O
enhanced	O
AP	O
-	O
1	O
transcriptional	O
activity	O
in	O
a	O
T	O
-	O
leukemia	O
cell	O
line	O
,	O
suggesting	O
that	O
the	O
previously	O
observed	O
interaction	O
between	O
the	O
parallel	O
signal	O
transduction	O
pathways	O
may	O
have	O
functional	O
consequences	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Functional	O
interaction	O
between	O
the	O
two	O
zinc	O
finger	O
domains	O
of	O
the	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	I-Protein
oncoprotein	O
.	O

The	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	I-Protein
oncogene	O
of	O
avian	O
erythroblastosis	O
virus	O
is	O
a	O
mutated	O
and	O
virally	O
transduced	O
copy	O
of	O
a	O
host	O
cell	O
gene	O
encoding	O
a	O
thyroid	O
hormone	O
receptor	O
.	O

The	O
protein	O
expressed	O
by	O
the	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	I-Protein
oncogene	O
binds	O
to	O
DNA	O
and	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
both	O
the	O
thyroid	O
hormone	O
receptor	O
and	O
the	O
closely	O
related	O
retinoic	B-Protein
acid	I-Protein
receptor	I-Protein
.	O

The	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	I-Protein
protein	O
has	O
sustained	O
two	O
amino	O
acid	O
alterations	O
within	O
its	O
DNA	O
-	O
binding	O
domain	O
relative	O
to	O
that	O
of	O
c	B-Protein
-	I-Protein
erb	I-Protein
A	I-Protein
,	O
one	O
of	O
which	O
,	O
at	O
serine	O
61	O
,	O
is	O
known	O
to	O
be	O
important	O
for	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	I-Protein
function	O
in	O
the	O
neoplastic	O
cell	O
.	O

We	O
report	O
here	O
that	O
the	O
second	O
alteration	O
,	O
at	O
threonine	O
78	O
,	O
also	O
plays	O
an	O
important	O
,	O
although	O
more	O
indirect	O
,	O
role	O
:	O
alteration	O
of	O
the	O
sequence	O
at	O
threonine	O
78	O
such	O
that	O
it	O
resembles	O
that	O
of	O
c	B-Protein
-	I-Protein
erb	I-Protein
A	I-Protein
can	O
act	O
as	O
an	O
intragenic	O
suppressor	O
and	O
can	O
partially	O
restore	O
function	O
to	O
a	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	I-Protein
protein	O
rendered	O
defective	O
due	O
to	O
a	O
mutation	O
at	O
position	O
61	O
.	O

Threonine	O
78	O
lies	O
within	O
the	O
D	O
-	O
box	O
of	O
the	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	I-Protein
protein	O
,	O
a	O
region	O
thought	O
to	O
mediate	O
receptor	O
-	O
receptor	O
dimerizations	O
,	O
and	O
is	O
not	O
in	O
physical	O
proximity	O
to	O
the	O
serine	O
at	O
position	O
61	O
.	O

It	O
therefore	O
appears	O
that	O
an	O
indirect	O
interaction	O
occurs	O
between	O
these	O
two	O
sites	O
and	O
that	O
this	O
interaction	O
is	O
crucial	O
for	O
v	B-Protein
-	I-Protein
erb	I-Protein
A	I-Protein
function	O
.	O

Inhibition	O
of	O
transcription	O
factors	O
belonging	O
to	O
the	O
rel	O
/	O
NF	O
-	O
kappa	O
B	O
family	O
by	O
a	O
transdominant	O
negative	O
mutant	O
.	O

The	O
KBF1	B-Protein
factor	O
,	O
which	O
binds	O
to	O
the	O
enhancer	O
A	O
located	O
in	O
the	O
promoter	O
of	O
the	O
mouse	O
MHC	O
class	O
I	O
gene	O
H	B-Protein
-	I-Protein
2Kb	I-Protein
,	O
is	O
indistinguishable	O
from	O
the	O
p50	B-Protein
DNA	O
binding	O
subunit	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
KBF1	B-Protein
/	O
p50	B-Protein
factor	O
binds	O
as	O
a	O
homodimer	O
but	O
can	O
also	O
form	O
heterodimers	O
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c	B-Protein
-	I-Protein
rel	I-Protein
and	O
v	B-Protein
-	I-Protein
rel	I-Protein
(	O
proto	O
)	O
oncogenes	O
.	O

The	O
dimerization	O
domain	O
of	O
KBF1	B-Protein
/	O
p50	B-Protein
is	O
contained	O
between	O
amino	O
acids	O
201	O
and	O
367	O
.	O
<EOS>	B-X
The	B-X
KBF1	B-X
factor	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
the	B-X
enhancer	B-X
A	B-X
located	B-X
in	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
mouse	B-X
MHC	B-X
class	B-X
I	B-X
gene	B-X
H-2Kb	B-X
,	B-X
is	B-X
indistinguishable	B-X
from	B-X
the	B-X
p50	B-X
DNA	B-X
binding	B-X
subunit	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
regulates	B-X
a	B-X
series	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
.	B-X
The	B-X
KBF1/p50	B-X
factor	B-X
binds	B-X
as	B-X
a	B-X
homodimer	B-X
but	B-X
can	B-X
also	B-X
form	B-X
heterodimers	B-X
with	B-X
the	B-X
products	B-X
of	B-X
other	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
,	B-X
like	B-X
the	B-X
c-rel	B-X
and	B-X
v-rel	B-X
(	B-X
proto	B-X
)	B-X
oncogenes	B-X
.	B-X
The	B-X
dimerization	B-X
domain	B-X
of	B-X
KBF1/p50	B-X
is	B-X
contained	B-X
between	B-X
amino	B-X
acids	B-X
201	B-X
and	B-X
367	B-X
.	B-X
A	B-X
mutant	B-X
of	B-X
KBF1/p50	B-X
(	B-X
delta	B-X
SP	B-X
)	B-X
,	B-X
unable	B-X
to	B-X
bind	B-X
to	B-X
DNA	B-X
but	B-X
able	B-X
to	B-X
form	B-X
homo-	B-X
or	B-X
heterodimers	B-X
,	B-X
has	B-X
been	B-X
constructed	B-X
.	B-X
This	B-X
protein	B-X
reduces	B-X
or	B-X
abolishes	B-X
in	B-X
vitro	B-X
the	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
wild-type	B-X
proteins	B-X
of	B-X
the	B-X
same	B-X
family	B-X
(	B-X
KBF1/p50	B-X
,	B-X
c-	B-X
and	B-X
v-rel	B-X
)	B-X
.	B-X

A	O
mutant	O
of	O
KBF1	B-Protein
/	O
p50	B-Protein
(	O
delta	O
SP	O
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo	O
-	O
or	O
heterodimers	O
,	O
has	O
been	O
constructed	O
.	O
<EOS>	B-X
While	B-X
growth	B-X
factors	B-X
,	B-X
neurotransmitters	B-X
,	B-X
and	B-X
peptide	B-X
hormones	B-X
bind	B-X
to	B-X
membrane	B-X
receptors	B-X
,	B-X
thereby	B-X
inducing	B-X
the	B-X
activity	B-X
of	B-X
intracellular	B-X
kinase	B-X
cascades	B-X
or	B-X
the	B-X
JAK-STAT	B-X
signaling	B-X
pathways	B-X
,	B-X
other	B-X
small	B-X
signaling	B-X
compounds	B-X
such	B-X
as	B-X
steroid	B-X
hormones	B-X
,	B-X
certain	B-X
vitamins	B-X
,	B-X
and	B-X
metabolic	B-X
intermediates	B-X
enter	B-X
,	B-X
or	B-X
are	B-X
generated	B-X
,	B-X
within	B-X
the	B-X
target	B-X
cells	B-X
and	B-X
bind	B-X
to	B-X
members	B-X
of	B-X
a	B-X
large	B-X
family	B-X
of	B-X
nuclear	B-X
receptors	B-X
(	B-X
NRs	B-X
)	B-X
.	B-X
NR-NR	B-X
interactions	B-X
are	B-X
of	B-X
major	B-X
importance	B-X
in	B-X
these	B-X
regulatory	B-X
processes	B-X
,	B-X
as	B-X
NRs	B-X
regulate	B-X
their	B-X
target	B-X
genes	B-X
by	B-X
binding	B-X
to	B-X
cognate	B-X
DNA	B-X
response	B-X
elements	B-X
essentially	B-X
as	B-X
homo-	B-X
or	B-X
heterodimers	B-X
.	B-X
A	B-X
number	B-X
of	B-X
structural	B-X
and	B-X
functional	B-X
studies	B-X
have	B-X
provided	B-X
significant	B-X
insights	B-X
as	B-X
to	B-X
how	B-X
combinatorial	B-X
NRs	B-X
rely	B-X
on	B-X
protein-protein	B-X
contacts	B-X
that	B-X
discriminate	B-X
geometric	B-X
features	B-X
of	B-X
their	B-X
DNA	B-X
response	B-X
elements	B-X
,	B-X
thereby	B-X
allowing	B-X
both	B-X
binding	B-X
site	B-X
diversity	B-X
and	B-X
physiological	B-X
specificity	B-X
.	B-X
The	B-X
gamma/delta	B-X
TCR	B-X
is	B-X
found	B-X
on	B-X
a	B-X
minor	B-X
population	B-X
of	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
its	B-X
functional	B-X
significance	B-X
needs	B-X
further	B-X
characterization	B-X
.	B-X
With	B-X
respect	B-X
to	B-X
dermatology	B-X
,	B-X
the	B-X
knowledge	B-X
of	B-X
TCR	B-X
genetics	B-X
,	B-X
along	B-X
with	B-X
the	B-X
application	B-X
of	B-X
recombinant	B-X
DNA	B-X
methodology	B-X
,	B-X
has	B-X
provided	B-X
a	B-X
major	B-X
improvement	B-X
in	B-X
the	B-X
diagnosis	B-X
and	B-X
management	B-X
of	B-X
mycosis	B-X
fungoides	B-X
.	B-X

This	O
protein	O
reduces	O
or	O
abolishes	O
in	O
vitro	O
the	O
DNA	O
binding	O
activity	O
of	O
wild	O
-	O
type	O
proteins	O
of	O
the	O
same	O
family	O
(	O
KBF1	B-Protein
/	O
p50	B-Protein
,	O
c	B-Protein
-	I-Protein
and	O
v	B-Protein
-	I-Protein
rel	I-Protein
)	O
.	O
<EOS>	B-X
Thrombophilia	B-X
that	B-X
is	B-X
common	B-X
among	B-X
Caucasians	B-X
is	B-X
caused	B-X
by	B-X
genetic	B-X
polymorphisms	B-X
of	B-X
coagulation	B-X
factor	B-X
V	B-X
Leiden	B-X
(	B-X
R506Q	B-X
)	B-X
and	B-X
prothrombin	B-X
G20210A	B-X
.	B-X
Unlike	B-X
that	B-X
in	B-X
Caucasians	B-X
,	B-X
thrombophilia	B-X
that	B-X
is	B-X
common	B-X
in	B-X
the	B-X
Japanese	B-X
and	B-X
Chinese	B-X
involve	B-X
dysfunction	B-X
of	B-X
the	B-X
activated	B-X
protein	B-X
C	B-X
(	B-X
APC	B-X
)	B-X
anticoagulant	B-X
system	B-X
caused	B-X
by	B-X
abnormal	B-X
protein	B-X
S	B-X
and	B-X
protein	B-X
C	B-X
molecules	B-X
.	B-X
Approximately	B-X
50	B-X
%	B-X
of	B-X
Japanese	B-X
and	B-X
Chinese	B-X
individuals	B-X
who	B-X
develop	B-X
venous	B-X
thrombosis	B-X
have	B-X
reduced	B-X
activities	B-X
of	B-X
protein	B-X
S.	B-X
The	B-X
abnormal	B-X
sites	B-X
causing	B-X
the	B-X
protein	B-X
S	B-X
molecule	B-X
abnormalities	B-X
are	B-X
distributed	B-X
throughout	B-X
the	B-X
protein	B-X
S	B-X
gene	B-X
,	B-X
PROS1	B-X
.	B-X
One	B-X
of	B-X
the	B-X
most	B-X
common	B-X
abnormalities	B-X
is	B-X
protein	B-X
S	B-X
Tokushima	B-X
(	B-X
K155E	B-X
)	B-X
,	B-X
which	B-X
accounts	B-X
for	B-X
about	B-X
30	B-X
%	B-X
of	B-X
the	B-X
protein	B-X
S	B-X
molecule	B-X
abnormalities	B-X
in	B-X
the	B-X
Japanese	B-X
.	B-X
Whether	B-X
APC	B-X
dysfunction	B-X
occurs	B-X
in	B-X
other	B-X
Asian	B-X
countries	B-X
is	B-X
an	B-X
important	B-X
aspect	B-X
of	B-X
mapping	B-X
thrombophilia	B-X
among	B-X
Asians	B-X
.	B-X
International	B-X
surveys	B-X
using	B-X
an	B-X
accurate	B-X
assay	B-X
system	B-X
are	B-X
needed	B-X
to	B-X
determine	B-X
this	B-X
.	B-X

This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans	O
-	O
acting	O
dominant	O
negative	O
regulator	O
:	O
the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
which	O
contains	O
two	O
potential	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co	O
-	O
transfected	O
into	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
the	O
delta	O
SP	O
mutant	O
.	O

Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	O
or	O
IL1	O
-	O
induced	O
activity	O
of	O
the	O
MHC	O
class	O
I	O
H	B-Protein
-	I-Protein
2Kb	I-Protein
promoter	O
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	O
lines	O
.	O
<EOS>	B-X
Basal	B-X
nuclear	B-X
factor	B-X
κB	B-X
(	B-X
NF-κB	B-X
)	B-X
activation	B-X
is	B-X
required	B-X
for	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
(	B-X
HSC	B-X
)	B-X
homeostasis	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
inflammation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
upstream	B-X
mediators	B-X
of	B-X
basal	B-X
NF-κB	B-X
signaling	B-X
are	B-X
less	B-X
well	B-X
understood	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
TRAF6	B-X
as	B-X
an	B-X
essential	B-X
regulator	B-X
of	B-X
HSC	B-X
homeostasis	B-X
through	B-X
basal	B-X
activation	B-X
of	B-X
NF-κB	B-X
.	B-X
Hematopoietic-specific	B-X
deletion	B-X
of	B-X
Traf6	B-X
resulted	B-X
in	B-X
impaired	B-X
HSC	B-X
self-renewal	B-X
and	B-X
fitness	B-X
.	B-X
Gene	B-X
expression	B-X
,	B-X
RNA	B-X
splicing	B-X
,	B-X
and	B-X
molecular	B-X
analyses	B-X
of	B-X
Traf6-deficient	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
(	B-X
HSPCs	B-X
)	B-X
revealed	B-X
changes	B-X
in	B-X
adaptive	B-X
immune	B-X
signaling	B-X
,	B-X
innate	B-X
immune	B-X
signaling	B-X
,	B-X
and	B-X
NF-κB	B-X
signaling	B-X
,	B-X
indicating	B-X
that	B-X
signaling	B-X
via	B-X
TRAF6	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
cytokine	B-X
stimulation	B-X
and/or	B-X
infection	B-X
is	B-X
required	B-X
for	B-X
HSC	B-X
function	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
established	B-X
that	B-X
loss	B-X
of	B-X
IκB	B-X
kinase	B-X
beta	B-X
(	B-X
IKKβ	B-X
)	B-X
-mediated	B-X
NF-κB	B-X
activation	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
major	B-X
hematopoietic	B-X
defects	B-X
observed	B-X
in	B-X
Traf6-deficient	B-X
HSPC	B-X
as	B-X
deletion	B-X
of	B-X
IKKβ	B-X
similarly	B-X
resulted	B-X
in	B-X
impaired	B-X
HSC	B-X
self-renewal	B-X
and	B-X
fitness	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
TRAF6	B-X
is	B-X
required	B-X
for	B-X
HSC	B-X
homeostasis	B-X
by	B-X
maintaining	B-X
a	B-X
minimal	B-X
threshold	B-X
level	B-X
of	B-X
IKKβ/NF-κB	B-X
signaling	B-X
.	B-X

These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel	O
/	O
NF	O
-	O
kappa	O
B	O
family	O
.	O
<EOS>	B-X
The	B-X
KBF1	B-X
factor	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
the	B-X
enhancer	B-X
A	B-X
located	B-X
in	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
mouse	B-X
MHC	B-X
class	B-X
I	B-X
gene	B-X
H-2Kb	B-X
,	B-X
is	B-X
indistinguishable	B-X
from	B-X
the	B-X
p50	B-X
DNA	B-X
binding	B-X
subunit	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
regulates	B-X
a	B-X
series	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
.	B-X
The	B-X
KBF1/p50	B-X
factor	B-X
binds	B-X
as	B-X
a	B-X
homodimer	B-X
but	B-X
can	B-X
also	B-X
form	B-X
heterodimers	B-X
with	B-X
the	B-X
products	B-X
of	B-X
other	B-X
members	B-X
of	B-X
the	B-X
same	B-X
family	B-X
,	B-X
like	B-X
the	B-X
c-rel	B-X
and	B-X
v-rel	B-X
(	B-X
proto	B-X
)	B-X
oncogenes	B-X
.	B-X
The	B-X
dimerization	B-X
domain	B-X
of	B-X
KBF1/p50	B-X
is	B-X
contained	B-X
between	B-X
amino	B-X
acids	B-X
201	B-X
and	B-X
367	B-X
.	B-X
A	B-X
mutant	B-X
of	B-X
KBF1/p50	B-X
(	B-X
delta	B-X
SP	B-X
)	B-X
,	B-X
unable	B-X
to	B-X
bind	B-X
to	B-X
DNA	B-X
but	B-X
able	B-X
to	B-X
form	B-X
homo-	B-X
or	B-X
heterodimers	B-X
,	B-X
has	B-X
been	B-X
constructed	B-X
.	B-X
This	B-X
protein	B-X
reduces	B-X
or	B-X
abolishes	B-X
in	B-X
vitro	B-X
the	B-X
DNA	B-X
binding	B-X
activity	B-X
of	B-X
wild-type	B-X
proteins	B-X
of	B-X
the	B-X
same	B-X
family	B-X
(	B-X
KBF1/p50	B-X
,	B-X
c-	B-X
and	B-X
v-rel	B-X
)	B-X
.	B-X
This	B-X
mutant	B-X
also	B-X
functions	B-X
in	B-X
vivo	B-X
as	B-X
a	B-X
trans-acting	B-X
dominant	B-X
negative	B-X
regulator	B-X
:	B-X
the	B-X
transcriptional	B-X
inducibility	B-X
of	B-X
the	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
which	B-X
contains	B-X
two	B-X
potential	B-X
NF-kappa	B-X
B	B-X
binding	B-X
sites	B-X
)	B-X
by	B-X
phorbol	B-X
ester	B-X
(	B-X
PMA	B-X
)	B-X
is	B-X
inhibited	B-X
when	B-X
it	B-X
is	B-X
co-transfected	B-X
into	B-X
CD4+	B-X
T	B-X
cells	B-X
with	B-X
the	B-X
delta	B-X
SP	B-X
mutant	B-X
.	B-X
Similarly	B-X
the	B-X
basal	B-X
as	B-X
well	B-X
as	B-X
TNF	B-X
or	B-X
IL1-induced	B-X
activity	B-X
of	B-X
the	B-X
MHC	B-X
class	B-X
I	B-X
H-2Kb	B-X
promoter	B-X
can	B-X
be	B-X
inhibited	B-X
by	B-X
this	B-X
mutant	B-X
in	B-X
two	B-X
different	B-X
cell	B-X
lines	B-X
.	B-X
These	B-X
results	B-X
constitute	B-X
the	B-X
first	B-X
formal	B-X
demonstration	B-X
that	B-X
these	B-X
genes	B-X
are	B-X
regulated	B-X
by	B-X
members	B-X
of	B-X
the	B-X
rel/NF-kappa	B-X
B	B-X
family	B-X
.	B-X

NF	O
-	O
kappa	O
B	O
activity	O
in	O
T	O
cells	O
stably	O
expressing	O
the	O
Tax	B-Protein
protein	O
of	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
.	O

The	O
effect	O
of	O
constitutive	O
Tax	B-Protein
expression	O
on	O
the	O
interaction	O
of	O
NF	O
-	O
kappa	O
B	O
with	O
its	O
recognition	O
sequence	O
and	O
on	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	O
lymphoid	O
Jurkat	O
cell	O
lines	O
(	O
19D	O
and	O
9J	O
)	O
stably	O
transformed	O
with	O
a	O
Tax	B-Protein
expression	O
vector	O
.	O

Tax	B-Protein
expressing	O
T	O
cell	O
lines	O
contained	O
a	O
constitutive	O
level	O
of	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
,	O
detectable	O
by	O
mobility	O
shift	O
assay	O
and	O
uv	O
cross	O
-	O
linking	O
using	O
a	O
palindromic	O
NF	O
-	O
kappa	O
B	O
probe	O
homologous	O
to	O
the	O
interferon	B-Protein
beta	I-Protein
PRDII	O
site	O
.	O

In	O
Jurkat	O
and	O
NC2	O
.	O
10	O
induction	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	O
binding	O
proteins	O
of	O
85	O
,	O
75	O
,	O
and	O
54	O
kDa	O
,	O
whereas	O
in	O
Tax	B-Protein
expressing	O
cells	O
the	O
85	O
-	O
kDa	O
protein	O
and	O
a	O
92	O
-	O
kDa	O
DNA	O
binding	O
protein	O
were	O
constitutively	O
induced	O
.	O

Expression	O
of	O
Tax	B-Protein
protein	O
in	O
19D	O
and	O
9J	O
resulted	O
in	O
transcription	O
of	O
the	O
endogenous	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
stimulating	I-Protein
factor	I-Protein
gene	O
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
promoters	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
constitutive	B-X
Tax	B-X
expression	B-X
on	B-X
the	B-X
interaction	B-X
of	B-X
NF-kappa	B-X
B	B-X
with	B-X
its	B-X
recognition	B-X
sequence	B-X
and	B-X
on	B-X
NF-kappa	B-X
B-dependent	B-X
gene	B-X
expression	B-X
was	B-X
examined	B-X
in	B-X
T	B-X
lymphoid	B-X
Jurkat	B-X
cell	B-X
lines	B-X
(	B-X
19D	B-X
and	B-X
9J	B-X
)	B-X
stably	B-X
transformed	B-X
with	B-X
a	B-X
Tax	B-X
expression	B-X
vector	B-X
.	B-X
Tax	B-X
expressing	B-X
T	B-X
cell	B-X
lines	B-X
contained	B-X
a	B-X
constitutive	B-X
level	B-X
of	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
,	B-X
detectable	B-X
by	B-X
mobility	B-X
shift	B-X
assay	B-X
and	B-X
uv	B-X
cross-linking	B-X
using	B-X
a	B-X
palindromic	B-X
NF-kappa	B-X
B	B-X
probe	B-X
homologous	B-X
to	B-X
the	B-X
interferon	B-X
beta	B-X
PRDII	B-X
site	B-X
.	B-X
In	B-X
Jurkat	B-X
and	B-X
NC2.10	B-X
induction	B-X
with	B-X
phorbol	B-X
esters	B-X
resulted	B-X
in	B-X
the	B-X
appearance	B-X
of	B-X
new	B-X
DNA	B-X
binding	B-X
proteins	B-X
of	B-X
85	B-X
,	B-X
75	B-X
,	B-X
and	B-X
54	B-X
kDa	B-X
,	B-X
whereas	B-X
in	B-X
Tax	B-X
expressing	B-X
cells	B-X
the	B-X
85-kDa	B-X
protein	B-X
and	B-X
a	B-X
92-kDa	B-X
DNA	B-X
binding	B-X
protein	B-X
were	B-X
constitutively	B-X
induced	B-X
.	B-X
Expression	B-X
of	B-X
Tax	B-X
protein	B-X
in	B-X
19D	B-X
and	B-X
9J	B-X
resulted	B-X
in	B-X
transcription	B-X
of	B-X
the	B-X
endogenous	B-X
NF-kappa	B-X
B-dependent	B-X
granulocyte-macrophage	B-X
colony	B-X
stimulating	B-X
factor	B-X
gene	B-X
and	B-X
increased	B-X
basal	B-X
level	B-X
expression	B-X
of	B-X
transfected	B-X
NF-kappa	B-X
B-regulated	B-X
promoters	B-X
.	B-X
Nonetheless	B-X
transcription	B-X
of	B-X
both	B-X
the	B-X
endogenous	B-X
and	B-X
the	B-X
transfected	B-X
gene	B-X
was	B-X
inducible	B-X
by	B-X
PMA	B-X
treatment	B-X
.	B-X
Tax	B-X
expression	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
may	B-X
alter	B-X
the	B-X
stoichiometry	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
proteins	B-X
and	B-X
thus	B-X
change	B-X
the	B-X
expression	B-X
of	B-X
NF-kappa	B-X
B-regulated	B-X
promoters	B-X
.	B-X

Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	O
treatment	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
constitutive	B-X
Tax	B-X
expression	B-X
on	B-X
the	B-X
interaction	B-X
of	B-X
NF-kappa	B-X
B	B-X
with	B-X
its	B-X
recognition	B-X
sequence	B-X
and	B-X
on	B-X
NF-kappa	B-X
B-dependent	B-X
gene	B-X
expression	B-X
was	B-X
examined	B-X
in	B-X
T	B-X
lymphoid	B-X
Jurkat	B-X
cell	B-X
lines	B-X
(	B-X
19D	B-X
and	B-X
9J	B-X
)	B-X
stably	B-X
transformed	B-X
with	B-X
a	B-X
Tax	B-X
expression	B-X
vector	B-X
.	B-X
Expression	B-X
of	B-X
Tax	B-X
protein	B-X
in	B-X
19D	B-X
and	B-X
9J	B-X
resulted	B-X
in	B-X
transcription	B-X
of	B-X
the	B-X
endogenous	B-X
NF-kappa	B-X
B-dependent	B-X
granulocyte-macrophage	B-X
colony	B-X
stimulating	B-X
factor	B-X
gene	B-X
and	B-X
increased	B-X
basal	B-X
level	B-X
expression	B-X
of	B-X
transfected	B-X
NF-kappa	B-X
B-regulated	B-X
promoters	B-X
.	B-X
Nonetheless	B-X
transcription	B-X
of	B-X
both	B-X
the	B-X
endogenous	B-X
and	B-X
the	B-X
transfected	B-X
gene	B-X
was	B-X
inducible	B-X
by	B-X
PMA	B-X
treatment	B-X
.	B-X

Tax	B-Protein
expression	O
in	O
Jurkat	O
T	O
cells	O
may	O
alter	O
the	O
stoichiometry	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
proteins	O
and	O
thus	O
change	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
promoters	O
.	O

Anti	O
-	O
CD2	B-Protein
receptor	O
antibodies	O
activate	O
the	O
HIV	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O

The	O
CD2	B-Protein
T	O
lymphocyte	O
glycoprotein	O
surface	O
molecule	O
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O

Treatment	O
of	O
chronically	O
HIV	O
-	O
infected	O
PBMC	O
with	O
anti	O
-	O
CD2	B-Protein
mAb	O
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O
<EOS>	B-X
The	B-X
CD2	B-X
T	B-X
lymphocyte	B-X
glycoprotein	B-X
surface	B-X
molecule	B-X
mediates	B-X
both	B-X
cell	B-X
to	B-X
cell	B-X
adhesion	B-X
and	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
two	B-X
processes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
spread	B-X
of	B-X
HIV	B-X
infection	B-X
.	B-X
Treatment	B-X
of	B-X
chronically	B-X
HIV-infected	B-X
PBMC	B-X
with	B-X
anti-CD2	B-X
mAb	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
induce	B-X
the	B-X
expression	B-X
of	B-X
infectious	B-X
virus	B-X
from	B-X
these	B-X
cultures	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
mechanisms	B-X
whereby	B-X
anti-CD2	B-X
antibodies	B-X
stimulate	B-X
viral	B-X
production	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
treatment	B-X
of	B-X
transiently	B-X
transfected	B-X
T	B-X
lymphocytes	B-X
with	B-X
anti-CD2	B-X
antibodies	B-X
results	B-X
in	B-X
activation	B-X
of	B-X
the	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat	B-X
.	B-X
Furthermore	B-X
,	B-X
CAT	B-X
assays	B-X
using	B-X
mutated	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat-CAT	B-X
constructs	B-X
and	B-X
gel	B-X
shift	B-X
assays	B-X
demonstrate	B-X
that	B-X
this	B-X
activation	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
NF-kappa	B-X
B	B-X
enhancer	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
interaction	B-X
of	B-X
CD2	B-X
with	B-X
its	B-X
natural	B-X
ligand	B-X
,	B-X
LFA-3	B-X
,	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulation	B-X
of	B-X
HIV	B-X
expression	B-X
.	B-X

In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti	O
-	O
CD2	B-Protein
antibodies	O
stimulate	O
viral	O
production	O
.	O
<EOS>	B-X
The	B-X
CD2	B-X
T	B-X
lymphocyte	B-X
glycoprotein	B-X
surface	B-X
molecule	B-X
mediates	B-X
both	B-X
cell	B-X
to	B-X
cell	B-X
adhesion	B-X
and	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
two	B-X
processes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
spread	B-X
of	B-X
HIV	B-X
infection	B-X
.	B-X
Treatment	B-X
of	B-X
chronically	B-X
HIV-infected	B-X
PBMC	B-X
with	B-X
anti-CD2	B-X
mAb	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
induce	B-X
the	B-X
expression	B-X
of	B-X
infectious	B-X
virus	B-X
from	B-X
these	B-X
cultures	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
mechanisms	B-X
whereby	B-X
anti-CD2	B-X
antibodies	B-X
stimulate	B-X
viral	B-X
production	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
treatment	B-X
of	B-X
transiently	B-X
transfected	B-X
T	B-X
lymphocytes	B-X
with	B-X
anti-CD2	B-X
antibodies	B-X
results	B-X
in	B-X
activation	B-X
of	B-X
the	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
interaction	B-X
of	B-X
CD2	B-X
with	B-X
its	B-X
natural	B-X
ligand	B-X
,	B-X
LFA-3	B-X
,	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulation	B-X
of	B-X
HIV	B-X
expression	B-X
.	B-X

We	O
demonstrate	O
that	O
treatment	O
of	O
transiently	O
transfected	O
T	O
lymphocytes	O
with	O
anti	O
-	O
CD2	B-Protein
antibodies	O
results	O
in	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

Furthermore	O
,	O
CAT	B-Protein
assays	O
using	O
mutated	O
HIV	O
long	O
terminal	O
repeat	O
-	O
CAT	B-Protein
constructs	O
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
enhancer	O
.	O
<EOS>	B-X
The	B-X
CD2	B-X
T	B-X
lymphocyte	B-X
glycoprotein	B-X
surface	B-X
molecule	B-X
mediates	B-X
both	B-X
cell	B-X
to	B-X
cell	B-X
adhesion	B-X
and	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
two	B-X
processes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
spread	B-X
of	B-X
HIV	B-X
infection	B-X
.	B-X
Treatment	B-X
of	B-X
chronically	B-X
HIV-infected	B-X
PBMC	B-X
with	B-X
anti-CD2	B-X
mAb	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
induce	B-X
the	B-X
expression	B-X
of	B-X
infectious	B-X
virus	B-X
from	B-X
these	B-X
cultures	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
treatment	B-X
of	B-X
transiently	B-X
transfected	B-X
T	B-X
lymphocytes	B-X
with	B-X
anti-CD2	B-X
antibodies	B-X
results	B-X
in	B-X
activation	B-X
of	B-X
the	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat	B-X
.	B-X
Furthermore	B-X
,	B-X
CAT	B-X
assays	B-X
using	B-X
mutated	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat-CAT	B-X
constructs	B-X
and	B-X
gel	B-X
shift	B-X
assays	B-X
demonstrate	B-X
that	B-X
this	B-X
activation	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
NF-kappa	B-X
B	B-X
enhancer	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
interaction	B-X
of	B-X
CD2	B-X
with	B-X
its	B-X
natural	B-X
ligand	B-X
,	B-X
LFA-3	B-X
,	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulation	B-X
of	B-X
HIV	B-X
expression	B-X
.	B-X

These	O
studies	O
suggest	O
that	O
interaction	O
of	O
CD2	B-Protein
with	O
its	O
natural	O
ligand	O
,	O
LFA	B-Protein
-	I-Protein
3	I-Protein
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O
<EOS>	B-X
The	B-X
CD2	B-X
T	B-X
lymphocyte	B-X
glycoprotein	B-X
surface	B-X
molecule	B-X
mediates	B-X
both	B-X
cell	B-X
to	B-X
cell	B-X
adhesion	B-X
and	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
two	B-X
processes	B-X
that	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
spread	B-X
of	B-X
HIV	B-X
infection	B-X
.	B-X
Treatment	B-X
of	B-X
chronically	B-X
HIV-infected	B-X
PBMC	B-X
with	B-X
anti-CD2	B-X
mAb	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
induce	B-X
the	B-X
expression	B-X
of	B-X
infectious	B-X
virus	B-X
from	B-X
these	B-X
cultures	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
mechanisms	B-X
whereby	B-X
anti-CD2	B-X
antibodies	B-X
stimulate	B-X
viral	B-X
production	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
treatment	B-X
of	B-X
transiently	B-X
transfected	B-X
T	B-X
lymphocytes	B-X
with	B-X
anti-CD2	B-X
antibodies	B-X
results	B-X
in	B-X
activation	B-X
of	B-X
the	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat	B-X
.	B-X
Furthermore	B-X
,	B-X
CAT	B-X
assays	B-X
using	B-X
mutated	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat-CAT	B-X
constructs	B-X
and	B-X
gel	B-X
shift	B-X
assays	B-X
demonstrate	B-X
that	B-X
this	B-X
activation	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
NF-kappa	B-X
B	B-X
enhancer	B-X
.	B-X
These	B-X
studies	B-X
suggest	B-X
that	B-X
interaction	B-X
of	B-X
CD2	B-X
with	B-X
its	B-X
natural	B-X
ligand	B-X
,	B-X
LFA-3	B-X
,	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulation	B-X
of	B-X
HIV	B-X
expression	B-X
.	B-X

v	B-Protein
-	I-Protein
erbA	I-Protein
overexpression	O
is	O
required	O
to	O
extinguish	O
c	B-Protein
-	I-Protein
erbA	I-Protein
function	O
in	O
erythroid	O
cell	O
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	O
target	O
gene	O
CAII	B-Protein
.	O
<EOS>	B-X
The	B-X
v-erbA	B-X
oncoprotein	B-X
represents	B-X
a	B-X
retrovirus-transduced	B-X
oncogenic	B-X
version	B-X
of	B-X
the	B-X
thyroid	B-X
hormone	B-X
(	B-X
T3/T4	B-X
)	B-X
receptor	B-X
c-erbA	B-X
(	B-X
type	B-X
alpha	B-X
)	B-X
.	B-X
It	B-X
contributes	B-X
to	B-X
virus-induced	B-X
erythroleukemia	B-X
by	B-X
efficiently	B-X
arresting	B-X
differentiation	B-X
of	B-X
red	B-X
cell	B-X
progenitors	B-X
and	B-X
by	B-X
suppressing	B-X
transcription	B-X
of	B-X
erythrocyte-specific	B-X
genes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
v-erbA	B-X
and	B-X
c-erbA	B-X
bind	B-X
directly	B-X
to	B-X
sequences	B-X
within	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
erythrocyte-specific	B-X
carbonic	B-X
anhydrase	B-X
II	B-X
(	B-X
CAII	B-X
)	B-X
,	B-X
a	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
efficiently	B-X
suppressed	B-X
by	B-X
v-erbA	B-X
.	B-X
This	B-X
erbA-binding	B-X
site	B-X
confers	B-X
thyroid	B-X
hormone	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
in	B-X
transient	B-X
expression	B-X
experiments	B-X
and	B-X
is	B-X
a	B-X
target	B-X
for	B-X
efficient	B-X
down-regulation	B-X
of	B-X
CAII	B-X
transcription	B-X
by	B-X
the	B-X
v-erbA	B-X
oncoprotein	B-X
.	B-X
In	B-X
stably	B-X
transformed	B-X
erythroblasts	B-X
coexpressing	B-X
the	B-X
v-erbA	B-X
oncoprotein	B-X
and	B-X
the	B-X
c-erbA/T3	B-X
receptor	B-X
at	B-X
an	B-X
approximately	B-X
equimolar	B-X
ratio	B-X
,	B-X
c-erbA	B-X
activity	B-X
is	B-X
dominant	B-X
over	B-X
v-erbA	B-X
.	B-X
T3	B-X
efficiently	B-X
induced	B-X
erythroid	B-X
differentiation	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
thus	B-X
overcoming	B-X
the	B-X
v-erbA-mediated	B-X
differentiation	B-X
arrest	B-X
.	B-X
Likewise	B-X
,	B-X
T3	B-X
activated	B-X
CAII	B-X
transcription	B-X
as	B-X
well	B-X
as	B-X
transient	B-X
expression	B-X
of	B-X
a	B-X
T3-responsive	B-X
reporter	B-X
gene	B-X
containing	B-X
the	B-X
CAII-specific	B-X
erbA-binding	B-X
site	B-X
.	B-X
The	B-X
c-erbA-dependent	B-X
activation	B-X
of	B-X
this	B-X
CAII	B-X
reporter	B-X
construct	B-X
could	B-X
only	B-X
be	B-X
suppressed	B-X
by	B-X
very	B-X
high	B-X
amounts	B-X
of	B-X
v-erbA	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
overexpression	B-X
of	B-X
v-erbA	B-X
is	B-X
required	B-X
for	B-X
its	B-X
function	B-X
as	B-X
an	B-X
oncoprotein	B-X
.	B-X

The	O
v	B-Protein
-	I-Protein
erbA	I-Protein
oncoprotein	O
represents	O
a	O
retrovirus	O
-	O
transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	O
hormone	O
(	O
T3	O
/	O
T4	O
)	O
receptor	O
c	B-Protein
-	I-Protein
erbA	I-Protein
(	O
type	O
alpha	O
)	O
.	O

It	O
contributes	O
to	O
virus	O
-	O
induced	O
erythroleukemia	O
by	O
efficiently	O
arresting	O
differentiation	O
of	O
red	O
cell	O
progenitors	O
and	O
by	O
suppressing	O
transcription	O
of	O
erythrocyte	O
-	O
specific	O
genes	O
.	O
<EOS>	B-X
The	B-X
v-erbA	B-X
oncoprotein	B-X
represents	B-X
a	B-X
retrovirus-transduced	B-X
oncogenic	B-X
version	B-X
of	B-X
the	B-X
thyroid	B-X
hormone	B-X
(	B-X
T3/T4	B-X
)	B-X
receptor	B-X
c-erbA	B-X
(	B-X
type	B-X
alpha	B-X
)	B-X
.	B-X
It	B-X
contributes	B-X
to	B-X
virus-induced	B-X
erythroleukemia	B-X
by	B-X
efficiently	B-X
arresting	B-X
differentiation	B-X
of	B-X
red	B-X
cell	B-X
progenitors	B-X
and	B-X
by	B-X
suppressing	B-X
transcription	B-X
of	B-X
erythrocyte-specific	B-X
genes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
v-erbA	B-X
and	B-X
c-erbA	B-X
bind	B-X
directly	B-X
to	B-X
sequences	B-X
within	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
erythrocyte-specific	B-X
carbonic	B-X
anhydrase	B-X
II	B-X
(	B-X
CAII	B-X
)	B-X
,	B-X
a	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
efficiently	B-X
suppressed	B-X
by	B-X
v-erbA	B-X
.	B-X
This	B-X
erbA-binding	B-X
site	B-X
confers	B-X
thyroid	B-X
hormone	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
in	B-X
transient	B-X
expression	B-X
experiments	B-X
and	B-X
is	B-X
a	B-X
target	B-X
for	B-X
efficient	B-X
down-regulation	B-X
of	B-X
CAII	B-X
transcription	B-X
by	B-X
the	B-X
v-erbA	B-X
oncoprotein	B-X
.	B-X
T3	B-X
efficiently	B-X
induced	B-X
erythroid	B-X
differentiation	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
thus	B-X
overcoming	B-X
the	B-X
v-erbA-mediated	B-X
differentiation	B-X
arrest	B-X
.	B-X
Likewise	B-X
,	B-X
T3	B-X
activated	B-X
CAII	B-X
transcription	B-X
as	B-X
well	B-X
as	B-X
transient	B-X
expression	B-X
of	B-X
a	B-X
T3-responsive	B-X
reporter	B-X
gene	B-X
containing	B-X
the	B-X
CAII-specific	B-X
erbA-binding	B-X
site	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
overexpression	B-X
of	B-X
v-erbA	B-X
is	B-X
required	B-X
for	B-X
its	B-X
function	B-X
as	B-X
an	B-X
oncoprotein	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
v	B-Protein
-	I-Protein
erbA	I-Protein
and	O
c	B-Protein
-	I-Protein
erbA	I-Protein
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	O
of	O
the	O
erythrocyte	O
-	O
specific	O
carbonic	B-Protein
anhydrase	I-Protein
II	I-Protein
(	O
CAII	B-Protein
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v	B-Protein
-	I-Protein
erbA	I-Protein
.	O

This	O
erbA	O
-	O
binding	O
site	O
confers	O
thyroid	O
hormone	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	O
for	O
efficient	O
down	O
-	O
regulation	O
of	O
CAII	B-Protein
transcription	O
by	O
the	O
v	B-Protein
-	I-Protein
erbA	I-Protein
oncoprotein	O
.	O

In	O
stably	O
transformed	O
erythroblasts	O
coexpressing	O
the	O
v	B-Protein
-	I-Protein
erbA	I-Protein
oncoprotein	O
and	O
the	O
c	B-Protein
-	I-Protein
erbA	I-Protein
/	O
T3	O
receptor	O
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c	B-Protein
-	I-Protein
erbA	I-Protein
activity	O
is	O
dominant	O
over	O
v	B-Protein
-	I-Protein
erbA	I-Protein
.	O

T3	O
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v	B-Protein
-	I-Protein
erbA	I-Protein
-	O
mediated	O
differentiation	O
arrest	O
.	O

Likewise	O
,	O
T3	O
activated	O
CAII	B-Protein
transcription	O
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3	O
-	O
responsive	O
reporter	O
gene	O
containing	O
the	O
CAII	B-Protein
-	O
specific	O
erbA	O
-	O
binding	O
site	O
.	O
<EOS>	B-X
The	B-X
v-erbA	B-X
oncoprotein	B-X
represents	B-X
a	B-X
retrovirus-transduced	B-X
oncogenic	B-X
version	B-X
of	B-X
the	B-X
thyroid	B-X
hormone	B-X
(	B-X
T3/T4	B-X
)	B-X
receptor	B-X
c-erbA	B-X
(	B-X
type	B-X
alpha	B-X
)	B-X
.	B-X
It	B-X
contributes	B-X
to	B-X
virus-induced	B-X
erythroleukemia	B-X
by	B-X
efficiently	B-X
arresting	B-X
differentiation	B-X
of	B-X
red	B-X
cell	B-X
progenitors	B-X
and	B-X
by	B-X
suppressing	B-X
transcription	B-X
of	B-X
erythrocyte-specific	B-X
genes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
v-erbA	B-X
and	B-X
c-erbA	B-X
bind	B-X
directly	B-X
to	B-X
sequences	B-X
within	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
erythrocyte-specific	B-X
carbonic	B-X
anhydrase	B-X
II	B-X
(	B-X
CAII	B-X
)	B-X
,	B-X
a	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
efficiently	B-X
suppressed	B-X
by	B-X
v-erbA	B-X
.	B-X
This	B-X
erbA-binding	B-X
site	B-X
confers	B-X
thyroid	B-X
hormone	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
in	B-X
transient	B-X
expression	B-X
experiments	B-X
and	B-X
is	B-X
a	B-X
target	B-X
for	B-X
efficient	B-X
down-regulation	B-X
of	B-X
CAII	B-X
transcription	B-X
by	B-X
the	B-X
v-erbA	B-X
oncoprotein	B-X
.	B-X
In	B-X
stably	B-X
transformed	B-X
erythroblasts	B-X
coexpressing	B-X
the	B-X
v-erbA	B-X
oncoprotein	B-X
and	B-X
the	B-X
c-erbA/T3	B-X
receptor	B-X
at	B-X
an	B-X
approximately	B-X
equimolar	B-X
ratio	B-X
,	B-X
c-erbA	B-X
activity	B-X
is	B-X
dominant	B-X
over	B-X
v-erbA	B-X
.	B-X
T3	B-X
efficiently	B-X
induced	B-X
erythroid	B-X
differentiation	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
thus	B-X
overcoming	B-X
the	B-X
v-erbA-mediated	B-X
differentiation	B-X
arrest	B-X
.	B-X
Likewise	B-X
,	B-X
T3	B-X
activated	B-X
CAII	B-X
transcription	B-X
as	B-X
well	B-X
as	B-X
transient	B-X
expression	B-X
of	B-X
a	B-X
T3-responsive	B-X
reporter	B-X
gene	B-X
containing	B-X
the	B-X
CAII-specific	B-X
erbA-binding	B-X
site	B-X
.	B-X
The	B-X
c-erbA-dependent	B-X
activation	B-X
of	B-X
this	B-X
CAII	B-X
reporter	B-X
construct	B-X
could	B-X
only	B-X
be	B-X
suppressed	B-X
by	B-X
very	B-X
high	B-X
amounts	B-X
of	B-X
v-erbA	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
overexpression	B-X
of	B-X
v-erbA	B-X
is	B-X
required	B-X
for	B-X
its	B-X
function	B-X
as	B-X
an	B-X
oncoprotein	B-X
.	B-X

The	O
c	B-Protein
-	I-Protein
erbA	I-Protein
-	O
dependent	O
activation	O
of	O
this	O
CAII	B-Protein
reporter	O
construct	O
could	O
only	O
be	O
suppressed	O
by	O
very	O
high	O
amounts	O
of	O
v	B-Protein
-	I-Protein
erbA	I-Protein
.	O

Our	O
results	O
suggest	O
that	O
overexpression	O
of	O
v	B-Protein
-	I-Protein
erbA	I-Protein
is	O
required	O
for	O
its	O
function	O
as	O
an	O
oncoprotein	O
.	O
<EOS>	B-X
The	B-X
v-erbA	B-X
oncoprotein	B-X
represents	B-X
a	B-X
retrovirus-transduced	B-X
oncogenic	B-X
version	B-X
of	B-X
the	B-X
thyroid	B-X
hormone	B-X
(	B-X
T3/T4	B-X
)	B-X
receptor	B-X
c-erbA	B-X
(	B-X
type	B-X
alpha	B-X
)	B-X
.	B-X
It	B-X
contributes	B-X
to	B-X
virus-induced	B-X
erythroleukemia	B-X
by	B-X
efficiently	B-X
arresting	B-X
differentiation	B-X
of	B-X
red	B-X
cell	B-X
progenitors	B-X
and	B-X
by	B-X
suppressing	B-X
transcription	B-X
of	B-X
erythrocyte-specific	B-X
genes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
v-erbA	B-X
and	B-X
c-erbA	B-X
bind	B-X
directly	B-X
to	B-X
sequences	B-X
within	B-X
the	B-X
promoter	B-X
of	B-X
the	B-X
erythrocyte-specific	B-X
carbonic	B-X
anhydrase	B-X
II	B-X
(	B-X
CAII	B-X
)	B-X
,	B-X
a	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
efficiently	B-X
suppressed	B-X
by	B-X
v-erbA	B-X
.	B-X
This	B-X
erbA-binding	B-X
site	B-X
confers	B-X
thyroid	B-X
hormone	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
in	B-X
transient	B-X
expression	B-X
experiments	B-X
and	B-X
is	B-X
a	B-X
target	B-X
for	B-X
efficient	B-X
down-regulation	B-X
of	B-X
CAII	B-X
transcription	B-X
by	B-X
the	B-X
v-erbA	B-X
oncoprotein	B-X
.	B-X
In	B-X
stably	B-X
transformed	B-X
erythroblasts	B-X
coexpressing	B-X
the	B-X
v-erbA	B-X
oncoprotein	B-X
and	B-X
the	B-X
c-erbA/T3	B-X
receptor	B-X
at	B-X
an	B-X
approximately	B-X
equimolar	B-X
ratio	B-X
,	B-X
c-erbA	B-X
activity	B-X
is	B-X
dominant	B-X
over	B-X
v-erbA	B-X
.	B-X
T3	B-X
efficiently	B-X
induced	B-X
erythroid	B-X
differentiation	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
thus	B-X
overcoming	B-X
the	B-X
v-erbA-mediated	B-X
differentiation	B-X
arrest	B-X
.	B-X
Likewise	B-X
,	B-X
T3	B-X
activated	B-X
CAII	B-X
transcription	B-X
as	B-X
well	B-X
as	B-X
transient	B-X
expression	B-X
of	B-X
a	B-X
T3-responsive	B-X
reporter	B-X
gene	B-X
containing	B-X
the	B-X
CAII-specific	B-X
erbA-binding	B-X
site	B-X
.	B-X
The	B-X
c-erbA-dependent	B-X
activation	B-X
of	B-X
this	B-X
CAII	B-X
reporter	B-X
construct	B-X
could	B-X
only	B-X
be	B-X
suppressed	B-X
by	B-X
very	B-X
high	B-X
amounts	B-X
of	B-X
v-erbA	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
overexpression	B-X
of	B-X
v-erbA	B-X
is	B-X
required	B-X
for	B-X
its	B-X
function	B-X
as	B-X
an	B-X
oncoprotein	B-X
.	B-X

NF	O
-	O
X2	O
that	O
binds	O
to	O
the	O
DRA	O
X2	O
-	O
box	O
is	O
activator	O
protein	O
1	O
.	O

Expression	O
cloning	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
.	O
<EOS>	B-X
Hemocyanin	B-X
(	B-X
HMC	B-X
)	B-X
is	B-X
a	B-X
respiratory	B-X
glycoprotein	B-X
,	B-X
which	B-X
also	B-X
plays	B-X
multifunctional	B-X
non-specific	B-X
innate	B-X
immune	B-X
defense	B-X
functions	B-X
in	B-X
shrimp	B-X
.	B-X
However	B-X
,	B-X
the	B-X
transcriptional	B-X
regulatory	B-X
mechanisms	B-X
of	B-X
the	B-X
hemocyanin	B-X
gene	B-X
expression	B-X
have	B-X
not	B-X
been	B-X
reported	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
cloned	B-X
a	B-X
4324	B-X
bp	B-X
fragment	B-X
of	B-X
small	B-X
subunit	B-X
hemocyanin	B-X
(	B-X
HMCs	B-X
)	B-X
gene	B-X
of	B-X
Litopenaeus	B-X
vannamei	B-X
including	B-X
the	B-X
5'-flanking	B-X
region	B-X
,	B-X
from	B-X
upstream	B-X
2475	B-X
bp	B-X
to	B-X
downstream	B-X
1849	B-X
bp	B-X
(	B-X
exon	B-X
1-intron	B-X
1-exon	B-X
2	B-X
)	B-X
by	B-X
genome	B-X
walking	B-X
method	B-X
.	B-X
Four	B-X
deletion	B-X
constructs	B-X
were	B-X
then	B-X
generated	B-X
and	B-X
their	B-X
promoter	B-X
activity	B-X
assessed	B-X
using	B-X
the	B-X
luciferase	B-X
reporter	B-X
system	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
identified	B-X
an	B-X
alternative	B-X
promoter	B-X
(	B-X
+1516/+1849	B-X
bp	B-X
)	B-X
located	B-X
in	B-X
exon	B-X
2	B-X
,	B-X
which	B-X
has	B-X
stronger	B-X
promoter	B-X
activity	B-X
than	B-X
the	B-X
full-length	B-X
or	B-X
the	B-X
other	B-X
constructs	B-X
.	B-X
Bioinformatics	B-X
analyses	B-X
revealed	B-X
that	B-X
the	B-X
alternative	B-X
promoter	B-X
region	B-X
contains	B-X
two	B-X
conserved	B-X
binding	B-X
sites	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
c-Jun	B-X
.	B-X
Mutational	B-X
analysis	B-X
and	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
showed	B-X
that	B-X
Litopenaeus	B-X
vannamei	B-X
c-Jun	B-X
(	B-X
Lvc-Jun	B-X
)	B-X
binds	B-X
to	B-X
the	B-X
region	B-X
+1582/+1589	B-X
bp	B-X
and	B-X
+1831/+1837	B-X
bp	B-X
of	B-X
the	B-X
alternative	B-X
promoter	B-X
.	B-X
Furthermore	B-X
,	B-X
overexpression	B-X
of	B-X
Lvc-Jun	B-X
significantly	B-X
increased	B-X
the	B-X
alternative	B-X
promoter	B-X
activity	B-X
,	B-X
while	B-X
co-transfection	B-X
with	B-X
dsRNA-Lvc-Jun	B-X
significantly	B-X
reduced	B-X
the	B-X
alternative	B-X
promoter	B-X
activity	B-X
of	B-X
HMCs	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
present	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
transcription	B-X
factor	B-X
Lvc-Jun	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
HMCs	B-X
gene	B-X
expression	B-X
.	B-X

Human	O
class	O
II	O
MHC	O
Ag	O
are	O
a	O
family	O
of	O
cell	O
surface	O
glycoproteins	O
.	O
<EOS>	B-X
The	B-X
Major	B-X
Histocompatibility	B-X
Complex	B-X
(	B-X
MHC	B-X
)	B-X
locus	B-X
encodes	B-X
classical	B-X
MHC	B-X
class	B-X
I	B-X
and	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
and	B-X
nonclassical	B-X
MHC-I	B-X
molecules	B-X
.	B-X
The	B-X
architecture	B-X
of	B-X
these	B-X
molecules	B-X
is	B-X
ideally	B-X
suited	B-X
to	B-X
capture	B-X
and	B-X
present	B-X
an	B-X
array	B-X
of	B-X
peptide	B-X
antigens	B-X
(	B-X
Ags	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
CD1	B-X
family	B-X
members	B-X
and	B-X
MR1	B-X
are	B-X
MHC	B-X
class	B-X
I-like	B-X
molecules	B-X
that	B-X
bind	B-X
lipid-based	B-X
Ags	B-X
and	B-X
vitamin	B-X
B	B-X
precursors	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
Ag-bound	B-X
molecules	B-X
are	B-X
subsequently	B-X
recognized	B-X
by	B-X
T	B-X
cell	B-X
antigen	B-X
receptors	B-X
(	B-X
TCRs	B-X
)	B-X
expressed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
T	B-X
lymphocytes	B-X
.	B-X
Structural	B-X
and	B-X
associated	B-X
functional	B-X
studies	B-X
have	B-X
been	B-X
highly	B-X
informative	B-X
in	B-X
providing	B-X
insight	B-X
into	B-X
these	B-X
interactions	B-X
,	B-X
which	B-X
are	B-X
crucial	B-X
to	B-X
immunity	B-X
,	B-X
and	B-X
how	B-X
they	B-X
can	B-X
lead	B-X
to	B-X
aberrant	B-X
T	B-X
cell	B-X
reactivity	B-X
.	B-X
Investigators	B-X
have	B-X
determined	B-X
over	B-X
thirty	B-X
unique	B-X
TCR-peptide-MHC-I	B-X
complex	B-X
structures	B-X
and	B-X
twenty	B-X
unique	B-X
TCR-peptide-MHC-II	B-X
complex	B-X
structures	B-X
.	B-X
These	B-X
investigations	B-X
have	B-X
shown	B-X
a	B-X
broad	B-X
consensus	B-X
in	B-X
docking	B-X
geometry	B-X
and	B-X
provided	B-X
insight	B-X
into	B-X
MHC	B-X
restriction	B-X
.	B-X
Structural	B-X
studies	B-X
on	B-X
TCR-mediated	B-X
recognition	B-X
of	B-X
lipid	B-X
and	B-X
metabolite	B-X
Ags	B-X
have	B-X
been	B-X
mostly	B-X
confined	B-X
to	B-X
TCRs	B-X
from	B-X
innate-like	B-X
natural	B-X
killer	B-X
T	B-X
cells	B-X
and	B-X
mucosal-associated	B-X
invariant	B-X
T	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
studies	B-X
revealed	B-X
clear	B-X
differences	B-X
between	B-X
TCR-lipid-CD1	B-X
,	B-X
TCR-metabolite-MR1	B-X
,	B-X
and	B-X
TCR-peptide-MHC	B-X
recognition	B-X
.	B-X
Accordingly	B-X
,	B-X
TCRs	B-X
show	B-X
remarkable	B-X
structural	B-X
and	B-X
biological	B-X
versatility	B-X
in	B-X
engaging	B-X
different	B-X
classes	B-X
of	B-X
Ag	B-X
that	B-X
are	B-X
presented	B-X
by	B-X
polymorphic	B-X
and	B-X
monomorphic	B-X
Ag-presenting	B-X
molecules	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
.	B-X

Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	O
lymphocytes	O
and	O
thymic	O
epithelial	O
cells	O
.	O

In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
.	O
<EOS>	B-X
A	B-X
key	B-X
player	B-X
in	B-X
driving	B-X
cellular	B-X
immunity	B-X
,	B-X
IFN-γ	B-X
is	B-X
capable	B-X
of	B-X
orchestrating	B-X
numerous	B-X
protective	B-X
functions	B-X
to	B-X
heighten	B-X
immune	B-X
responses	B-X
in	B-X
infections	B-X
and	B-X
cancers	B-X
.	B-X
A	B-X
complex	B-X
interplay	B-X
between	B-X
immune	B-X
cell	B-X
activity	B-X
and	B-X
IFN-γ	B-X
through	B-X
coordinated	B-X
integration	B-X
of	B-X
signals	B-X
from	B-X
other	B-X
pathways	B-X
involving	B-X
cytokines	B-X
and	B-X
Pattern	B-X
Recognition	B-X
Receptors	B-X
(	B-X
PRRs	B-X
)	B-X
such	B-X
as	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
,	B-X
TNF-α	B-X
,	B-X
Lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
Type-I	B-X
Interferons	B-X
(	B-X
IFNS	B-X
)	B-X
etc	B-X
.	B-X
Microarray	B-X
data	B-X
has	B-X
unraveled	B-X
numerous	B-X
genes	B-X
whose	B-X
transcriptional	B-X
regulation	B-X
is	B-X
influenced	B-X
by	B-X
IFN-γ	B-X
.	B-X
Consequently	B-X
,	B-X
IFN-γ	B-X
stimulated	B-X
cells	B-X
display	B-X
altered	B-X
expression	B-X
of	B-X
many	B-X
such	B-X
target	B-X
genes	B-X
which	B-X
mediate	B-X
its	B-X
downstream	B-X
effector	B-X
functions	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
IFN-γ	B-X
is	B-X
further	B-X
reinforced	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
mice	B-X
possessing	B-X
disruptions	B-X
in	B-X
the	B-X
IFN-γ	B-X
gene	B-X
or	B-X
its	B-X
receptor	B-X
develop	B-X
extreme	B-X
susceptibility	B-X
to	B-X
infectious	B-X
diseases	B-X
and	B-X
rapidly	B-X
succumb	B-X
to	B-X
them	B-X
.	B-X
As	B-X
a	B-X
counter	B-X
strategy	B-X
,	B-X
many	B-X
virulent	B-X
pathogenic	B-X
species	B-X
have	B-X
devised	B-X
ways	B-X
to	B-X
thwart	B-X
IFN-γ	B-X
endowed	B-X
immune-protection	B-X
.	B-X
Thus	B-X
,	B-X
IFN-γ	B-X
mediated	B-X
host-pathogen	B-X
interactions	B-X
are	B-X
critical	B-X
for	B-X
our	B-X
understanding	B-X
of	B-X
disease	B-X
mechanisms	B-X
and	B-X
these	B-X
aspects	B-X
also	B-X
manifest	B-X
enormous	B-X
therapeutic	B-X
importance	B-X
for	B-X
the	B-X
annulment	B-X
of	B-X
various	B-X
infections	B-X
and	B-X
autoimmune	B-X
conditions	B-X
.	B-X

Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue	O
-	O
specific	O
expression	O
of	O
class	O
II	O
genes	O
.	O
<EOS>	B-X
Class	B-X
II	B-X
major	B-X
histocompatibility	B-X
genes	B-X
contain	B-X
a	B-X
conserved	B-X
upstream	B-X
sequence	B-X
(	B-X
CUS	B-X
)	B-X
that	B-X
is	B-X
important	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
these	B-X
elements	B-X
to	B-X
mediate	B-X
transcription	B-X
of	B-X
a	B-X
heterologous	B-X
promoter	B-X
was	B-X
assayed	B-X
upon	B-X
transfection	B-X
into	B-X
a	B-X
B-cell	B-X
line	B-X
(	B-X
Raji	B-X
)	B-X
,	B-X
a	B-X
class	B-X
II-specific	B-X
trans-acting	B-X
factor-deficient	B-X
B-cell	B-X
line	B-X
(	B-X
RJ2.2.5	B-X
cells	B-X
)	B-X
,	B-X
and	B-X
a	B-X
T-cell	B-X
line	B-X
(	B-X
Jurkat	B-X
)	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
X	B-X
box	B-X
element	B-X
was	B-X
responsible	B-X
for	B-X
directing	B-X
tissue-specific	B-X
expression	B-X
when	B-X
Raji	B-X
cells	B-X
were	B-X
compared	B-X
to	B-X
Jurkat	B-X
cells	B-X
.	B-X
The	B-X
X	B-X
box	B-X
could	B-X
not	B-X
direct	B-X
expression	B-X
of	B-X
the	B-X
heterologous	B-X
promoter	B-X
in	B-X
the	B-X
trans-acting	B-X
factor-deficient	B-X
cell	B-X
line	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
X	B-X
box	B-X
is	B-X
an	B-X
ultimate	B-X
target	B-X
of	B-X
the	B-X
missing	B-X
or	B-X
defective	B-X
factor	B-X
in	B-X
the	B-X
RJ2.2.5	B-X
cell	B-X
line	B-X
.	B-X
The	B-X
Y	B-X
box	B-X
directed	B-X
an	B-X
equal	B-X
but	B-X
extremely	B-X
low	B-X
level	B-X
of	B-X
transcription	B-X
in	B-X
this	B-X
system	B-X
in	B-X
both	B-X
the	B-X
mutant	B-X
and	B-X
wild-type	B-X
B-cell	B-X
lines	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
element	B-X
is	B-X
not	B-X
involved	B-X
in	B-X
B-cell	B-X
expression	B-X
or	B-X
as	B-X
a	B-X
target	B-X
of	B-X
the	B-X
mutant	B-X
factor	B-X
.	B-X

In	O
the	O
DRA	O
promoter	O
,	O
one	O
of	O
these	O
cis	O
-	O
acting	O
regulatory	O
motifs	O
is	O
the	O
X2	O
-	O
box	O
to	O
which	O
nuclear	O
factor	O
X2	O
(	O
NF	O
-	O
X2	O
)	O
binds	O
.	O
<EOS>	B-X
Conserved	B-X
upstream	B-X
promoter	B-X
sequences	B-X
regulate	B-X
this	B-X
tissue-specific	B-X
expression	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
.	B-X
In	B-X
the	B-X
DRA	B-X
promoter	B-X
,	B-X
one	B-X
of	B-X
these	B-X
cis-acting	B-X
regulatory	B-X
motifs	B-X
is	B-X
the	B-X
X2-box	B-X
to	B-X
which	B-X
nuclear	B-X
factor	B-X
X2	B-X
(	B-X
NF-X2	B-X
)	B-X
binds	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
present	B-X
the	B-X
isolation	B-X
and	B-X
characterization	B-X
of	B-X
the	B-X
full-length	B-X
cDNA	B-X
clone	B-X
encoding	B-X
NF-X2	B-X
.	B-X
This	B-X
cDNA	B-X
clone	B-X
was	B-X
isolated	B-X
by	B-X
expression	B-X
cDNA	B-X
cloning	B-X
,	B-X
and	B-X
encodes	B-X
the	B-X
human	B-X
c-Jun	B-X
protein	B-X
,	B-X
which	B-X
together	B-X
with	B-X
c-Fos	B-X
forms	B-X
the	B-X
heterodimeric	B-X
activator	B-X
protein-1	B-X
transcription	B-X
complex	B-X
.	B-X
Whereas	B-X
c-Fos/c-Jun	B-X
heterodimers	B-X
do	B-X
not	B-X
exist	B-X
in	B-X
B	B-X
cells	B-X
,	B-X
they	B-X
form	B-X
and	B-X
bind	B-X
to	B-X
the	B-X
X2-box	B-X
in	B-X
class	B-X
II	B-X
nonexpressing	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
c-Fos/c-Jun	B-X
heterodimers	B-X
might	B-X
contribute	B-X
to	B-X
the	B-X
repression	B-X
of	B-X
DRA	B-X
gene	B-X
expression	B-X
.	B-X

Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full	O
-	O
length	O
cDNA	O
clone	O
encoding	O
NF	O
-	O
X2	O
.	O
<EOS>	B-X
In	B-X
the	B-X
DRA	B-X
promoter	B-X
,	B-X
one	B-X
of	B-X
these	B-X
cis-acting	B-X
regulatory	B-X
motifs	B-X
is	B-X
the	B-X
X2-box	B-X
to	B-X
which	B-X
nuclear	B-X
factor	B-X
X2	B-X
(	B-X
NF-X2	B-X
)	B-X
binds	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
present	B-X
the	B-X
isolation	B-X
and	B-X
characterization	B-X
of	B-X
the	B-X
full-length	B-X
cDNA	B-X
clone	B-X
encoding	B-X
NF-X2	B-X
.	B-X
This	B-X
cDNA	B-X
clone	B-X
was	B-X
isolated	B-X
by	B-X
expression	B-X
cDNA	B-X
cloning	B-X
,	B-X
and	B-X
encodes	B-X
the	B-X
human	B-X
c-Jun	B-X
protein	B-X
,	B-X
which	B-X
together	B-X
with	B-X
c-Fos	B-X
forms	B-X
the	B-X
heterodimeric	B-X
activator	B-X
protein-1	B-X
transcription	B-X
complex	B-X
.	B-X
Whereas	B-X
c-Fos/c-Jun	B-X
heterodimers	B-X
do	B-X
not	B-X
exist	B-X
in	B-X
B	B-X
cells	B-X
,	B-X
they	B-X
form	B-X
and	B-X
bind	B-X
to	B-X
the	B-X
X2-box	B-X
in	B-X
class	B-X
II	B-X
nonexpressing	B-X
cells	B-X
.	B-X

This	O
cDNA	O
clone	O
was	O
isolated	O
by	O
expression	O
cDNA	O
cloning	O
,	O
and	O
encodes	O
the	O
human	O
c	B-Protein
-	I-Protein
Jun	I-Protein
protein	O
,	O
which	O
together	O
with	O
c	B-Protein
-	I-Protein
Fos	I-Protein
forms	O
the	O
heterodimeric	O
activator	O
protein	O
-	O
1	O
transcription	O
complex	O
.	O

Whereas	O
c	B-Protein
-	I-Protein
Fos	I-Protein
/	O
c	B-Protein
-	I-Protein
Jun	I-Protein
heterodimers	O
do	O
not	O
exist	O
in	O
B	O
cells	O
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2	O
-	O
box	O
in	O
class	O
II	O
nonexpressing	O
cells	O
.	O
<EOS>	B-X
Recent	B-X
progress	B-X
in	B-X
the	B-X
analysis	B-X
of	B-X
transcriptional	B-X
regulation	B-X
has	B-X
revealed	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
exquisite	B-X
functional	B-X
network	B-X
comprising	B-X
the	B-X
Maf	B-X
and	B-X
Cap	B-X
'n	B-X
'	B-X
collar	B-X
(	B-X
CNC	B-X
)	B-X
families	B-X
of	B-X
regulatory	B-X
proteins	B-X
,	B-X
many	B-X
of	B-X
which	B-X
have	B-X
been	B-X
isolated	B-X
.	B-X
Among	B-X
Maf	B-X
factors	B-X
,	B-X
large	B-X
Maf	B-X
proteins	B-X
are	B-X
important	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
embryonic	B-X
development	B-X
and	B-X
cell	B-X
differentiation	B-X
,	B-X
whereas	B-X
small	B-X
Maf	B-X
proteins	B-X
serve	B-X
as	B-X
obligatory	B-X
heterodimeric	B-X
partner	B-X
molecules	B-X
for	B-X
members	B-X
of	B-X
the	B-X
CNC	B-X
family	B-X
.	B-X
Both	B-X
Maf	B-X
homodimers	B-X
and	B-X
CNC-small	B-X
Maf	B-X
heterodimers	B-X
bind	B-X
to	B-X
the	B-X
Maf	B-X
recognition	B-X
element	B-X
(	B-X
MARE	B-X
)	B-X
.	B-X
Since	B-X
the	B-X
MARE	B-X
contains	B-X
a	B-X
consensus	B-X
TRE	B-X
sequence	B-X
recognized	B-X
by	B-X
AP-1	B-X
,	B-X
Jun	B-X
and	B-X
Fos	B-X
family	B-X
members	B-X
may	B-X
act	B-X
to	B-X
compete	B-X
or	B-X
interfere	B-X
with	B-X
the	B-X
function	B-X
of	B-X
CNC-small	B-X
Maf	B-X
heterodimers	B-X
.	B-X
Overall	B-X
then	B-X
,	B-X
the	B-X
quantitative	B-X
balance	B-X
of	B-X
transcription	B-X
factors	B-X
interacting	B-X
with	B-X
the	B-X
MARE	B-X
determines	B-X
its	B-X
transcriptional	B-X
activity	B-X
.	B-X
Many	B-X
putative	B-X
MARE-dependent	B-X
target	B-X
genes	B-X
such	B-X
as	B-X
those	B-X
induced	B-X
by	B-X
antioxidants	B-X
and	B-X
oxidative	B-X
stress	B-X
are	B-X
under	B-X
concerted	B-X
regulation	B-X
by	B-X
the	B-X
CNC	B-X
family	B-X
member	B-X
Nrf2	B-X
,	B-X
as	B-X
clearly	B-X
proven	B-X
by	B-X
mouse	B-X
germline	B-X
mutagenesis	B-X
.	B-X
Since	B-X
these	B-X
genes	B-X
represent	B-X
a	B-X
vital	B-X
aspect	B-X
of	B-X
the	B-X
cellular	B-X
defense	B-X
mechanism	B-X
against	B-X
oxidative	B-X
stress	B-X
,	B-X
Nrf2-null	B-X
mutant	B-X
mice	B-X
are	B-X
highly	B-X
sensitive	B-X
to	B-X
xenobiotic	B-X
and	B-X
oxidative	B-X
insults	B-X
.	B-X
Deciphering	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
regulatory	B-X
network	B-X
composed	B-X
of	B-X
Maf	B-X
and	B-X
CNC	B-X
families	B-X
of	B-X
transcription	B-X
factors	B-X
will	B-X
undoubtedly	B-X
lead	B-X
to	B-X
a	B-X
new	B-X
paradigm	B-X
for	B-X
the	B-X
cooperative	B-X
function	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X

Thus	O
,	O
c	B-Protein
-	I-Protein
Fos	I-Protein
/	O
c	B-Protein
-	I-Protein
Jun	I-Protein
heterodimers	O
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	B-Protein
gene	O
expression	O
.	O

Regulation	O
of	O
jun	B-Protein
and	O
fos	B-Protein
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
.	O
<EOS>	B-X
The	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
is	B-X
required	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
differentiation	B-X
of	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
M-CSF	B-X
on	B-X
potential	B-X
signaling	B-X
pathways	B-X
involving	B-X
expression	B-X
of	B-X
the	B-X
jun	B-X
and	B-X
fos	B-X
early	B-X
response	B-X
genes	B-X
.	B-X
Low	B-X
levels	B-X
of	B-X
c-jun	B-X
transcripts	B-X
were	B-X
detectable	B-X
in	B-X
resting	B-X
human	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
.	B-X
Treatment	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
10	B-X
(	B-X
3	B-X
)	B-X
units/ml	B-X
human	B-X
recombinant	B-X
M-CSF	B-X
was	B-X
associated	B-X
with	B-X
rapid	B-X
and	B-X
transient	B-X
increases	B-X
in	B-X
c-jun	B-X
mRNA	B-X
levels	B-X
.	B-X
Nuclear	B-X
run-on	B-X
assays	B-X
and	B-X
mRNA	B-X
stability	B-X
studies	B-X
demonstrated	B-X
that	B-X
M-CSF	B-X
regulates	B-X
c-jun	B-X
expression	B-X
by	B-X
both	B-X
an	B-X
increase	B-X
in	B-X
transcription	B-X
rate	B-X
and	B-X
a	B-X
prolongation	B-X
in	B-X
the	B-X
half-life	B-X
of	B-X
c-jun	B-X
transcripts	B-X
.	B-X
M-CSF	B-X
treatment	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
a	B-X
rapid	B-X
induction	B-X
of	B-X
the	B-X
jun-B	B-X
gene	B-X
,	B-X
although	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
was	B-X
prolonged	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
c-jun	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
increases	B-X
c-fos	B-X
mRNA	B-X
levels	B-X
in	B-X
human	B-X
monocytes	B-X
through	B-X
control	B-X
at	B-X
both	B-X
the	B-X
transcriptional	B-X
and	B-X
posttranscriptional	B-X
levels	B-X
.	B-X
Maximal	B-X
induction	B-X
of	B-X
the	B-X
c-fos	B-X
gene	B-X
was	B-X
followed	B-X
by	B-X
that	B-X
for	B-X
the	B-X
fos-B	B-X
gene	B-X
.	B-X
Moreover	B-X
,	B-X
M-CSF-induced	B-X
expression	B-X
of	B-X
the	B-X
fos-related	B-X
gene	B-X
,	B-X
fra-1	B-X
,	B-X
was	B-X
delayed	B-X
compared	B-X
to	B-X
that	B-X
for	B-X
both	B-X
c-fos	B-X
and	B-X
fos-B	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
that	B-X
M-CSF	B-X
treatment	B-X
is	B-X
associated	B-X
with	B-X
differential	B-X
activation	B-X
of	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
jun/fos	B-X
family	B-X
and	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
could	B-X
contribute	B-X
to	B-X
nuclear	B-X
signaling	B-X
mechanisms	B-X
that	B-X
regulate	B-X
a	B-X
specific	B-X
program	B-X
of	B-X
monocyte	B-X
differentiation	B-X
.	B-X

The	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
is	O
required	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
mononuclear	O
phagocytes	O
.	O
<EOS>	B-X
The	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
,	B-X
CSF-1	B-X
(	B-X
M-CSF	B-X
)	B-X
,	B-X
is	B-X
a	B-X
homodimeric	B-X
glycoprotein	B-X
required	B-X
for	B-X
the	B-X
lineage-specific	B-X
growth	B-X
of	B-X
cells	B-X
of	B-X
the	B-X
mononuclear	B-X
phagocyte	B-X
series	B-X
.	B-X
Apart	B-X
from	B-X
its	B-X
role	B-X
in	B-X
stimulating	B-X
the	B-X
proliferation	B-X
of	B-X
bone	B-X
marrow-derived	B-X
precursors	B-X
of	B-X
monocytes	B-X
and	B-X
macrophages	B-X
,	B-X
CSF-1	B-X
acts	B-X
as	B-X
a	B-X
survival	B-X
factor	B-X
and	B-X
primes	B-X
mature	B-X
macrophages	B-X
to	B-X
carry	B-X
out	B-X
differentiated	B-X
functions	B-X
.	B-X
Each	B-X
of	B-X
the	B-X
actions	B-X
of	B-X
CSF-1	B-X
are	B-X
mediated	B-X
through	B-X
its	B-X
binding	B-X
to	B-X
a	B-X
single	B-X
class	B-X
of	B-X
high-affinity	B-X
receptors	B-X
expressed	B-X
on	B-X
monocytes	B-X
,	B-X
macrophages	B-X
,	B-X
and	B-X
their	B-X
committed	B-X
progenitors	B-X
.	B-X
The	B-X
CSF-1	B-X
receptor	B-X
(	B-X
CSF-1R	B-X
)	B-X
is	B-X
encoded	B-X
by	B-X
the	B-X
c-fms	B-X
proto-oncogene	B-X
,	B-X
and	B-X
is	B-X
one	B-X
of	B-X
a	B-X
family	B-X
of	B-X
growth	B-X
factor	B-X
receptors	B-X
that	B-X
exhibits	B-X
an	B-X
intrinsic	B-X
tyrosine-specific	B-X
protein	B-X
kinase	B-X
activity	B-X
.	B-X
Transduction	B-X
of	B-X
c-fms	B-X
sequences	B-X
as	B-X
a	B-X
viral	B-X
oncogene	B-X
(	B-X
v-fms	B-X
)	B-X
in	B-X
the	B-X
McDonough	B-X
(	B-X
SM	B-X
)	B-X
and	B-X
HZ-5	B-X
strains	B-X
of	B-X
feline	B-X
sarcoma	B-X
virus	B-X
has	B-X
resulted	B-X
in	B-X
alterations	B-X
in	B-X
receptor	B-X
coding	B-X
sequences	B-X
that	B-X
affect	B-X
its	B-X
activity	B-X
as	B-X
a	B-X
tyrosine	B-X
kinase	B-X
and	B-X
provide	B-X
persistent	B-X
signals	B-X
for	B-X
cell	B-X
growth	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
its	B-X
ligand	B-X
.	B-X
The	B-X
genetic	B-X
alterations	B-X
in	B-X
the	B-X
c-fms	B-X
gene	B-X
that	B-X
unmask	B-X
its	B-X
latent	B-X
transforming	B-X
potential	B-X
abrogate	B-X
its	B-X
lineage-specific	B-X
activity	B-X
and	B-X
enable	B-X
v-fms	B-X
to	B-X
transform	B-X
a	B-X
variety	B-X
of	B-X
cells	B-X
that	B-X
do	B-X
not	B-X
normally	B-X
express	B-X
CSF-1	B-X
receptors	B-X
.	B-X

However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O
<EOS>	B-X
Besides	B-X
the	B-X
two	B-X
main	B-X
classical	B-X
features	B-X
of	B-X
amyloid	B-X
beta	B-X
aggregation	B-X
and	B-X
tau-containing	B-X
neurofibrillary	B-X
tangle	B-X
deposition	B-X
,	B-X
neuroinflammation	B-X
plays	B-X
an	B-X
important	B-X
yet	B-X
unclear	B-X
role	B-X
in	B-X
the	B-X
pathophysiology	B-X
of	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
.	B-X
Microglia	B-X
are	B-X
believed	B-X
to	B-X
be	B-X
key	B-X
mediators	B-X
of	B-X
neuroinflammation	B-X
during	B-X
AD	B-X
and	B-X
responsible	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
brain	B-X
homeostasis	B-X
by	B-X
balancing	B-X
neurotoxicity	B-X
and	B-X
neuroprotective	B-X
events	B-X
.	B-X
HEV	B-X
infection	B-X
is	B-X
the	B-X
most	B-X
common	B-X
cause	B-X
of	B-X
liver	B-X
inflammation	B-X
,	B-X
but	B-X
the	B-X
pathogenic	B-X
mechanisms	B-X
remain	B-X
largely	B-X
unclear	B-X
.	B-X
However	B-X
,	B-X
between	B-X
1999	B-X
and	B-X
2018	B-X
,	B-X
over	B-X
400,000	B-X
people	B-X
in	B-X
the	B-X
United	B-X
States	B-X
died	B-X
from	B-X
opioid	B-X
overdose	B-X
.	B-X
This	B-X
rationale	B-X
stems	B-X
from	B-X
a	B-X
study	B-X
suggesting	B-X
that	B-X
MOR-induced	B-X
ß-arrestin	B-X
2	B-X
dependent	B-X
signaling	B-X
is	B-X
responsible	B-X
for	B-X
opioid	B-X
respiratory	B-X
depression	B-X
,	B-X
whereas	B-X
adenylyl	B-X
cyclase	B-X
inhibition	B-X
produces	B-X
analgesia	B-X
.	B-X

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M	O
-	O
CSF	O
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	B-Protein
and	O
fos	B-Protein
early	O
response	O
genes	O
.	O
<EOS>	B-X
The	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
is	B-X
required	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
differentiation	B-X
of	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signaling	B-X
events	B-X
responsible	B-X
for	B-X
these	B-X
effects	B-X
remain	B-X
unclear	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
M-CSF	B-X
on	B-X
potential	B-X
signaling	B-X
pathways	B-X
involving	B-X
expression	B-X
of	B-X
the	B-X
jun	B-X
and	B-X
fos	B-X
early	B-X
response	B-X
genes	B-X
.	B-X
Low	B-X
levels	B-X
of	B-X
c-jun	B-X
transcripts	B-X
were	B-X
detectable	B-X
in	B-X
resting	B-X
human	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
.	B-X
Treatment	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
10	B-X
(	B-X
3	B-X
)	B-X
units/ml	B-X
human	B-X
recombinant	B-X
M-CSF	B-X
was	B-X
associated	B-X
with	B-X
rapid	B-X
and	B-X
transient	B-X
increases	B-X
in	B-X
c-jun	B-X
mRNA	B-X
levels	B-X
.	B-X
Nuclear	B-X
run-on	B-X
assays	B-X
and	B-X
mRNA	B-X
stability	B-X
studies	B-X
demonstrated	B-X
that	B-X
M-CSF	B-X
regulates	B-X
c-jun	B-X
expression	B-X
by	B-X
both	B-X
an	B-X
increase	B-X
in	B-X
transcription	B-X
rate	B-X
and	B-X
a	B-X
prolongation	B-X
in	B-X
the	B-X
half-life	B-X
of	B-X
c-jun	B-X
transcripts	B-X
.	B-X
M-CSF	B-X
treatment	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
a	B-X
rapid	B-X
induction	B-X
of	B-X
the	B-X
jun-B	B-X
gene	B-X
,	B-X
although	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
was	B-X
prolonged	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
c-jun	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
increases	B-X
c-fos	B-X
mRNA	B-X
levels	B-X
in	B-X
human	B-X
monocytes	B-X
through	B-X
control	B-X
at	B-X
both	B-X
the	B-X
transcriptional	B-X
and	B-X
posttranscriptional	B-X
levels	B-X
.	B-X
Maximal	B-X
induction	B-X
of	B-X
the	B-X
c-fos	B-X
gene	B-X
was	B-X
followed	B-X
by	B-X
that	B-X
for	B-X
the	B-X
fos-B	B-X
gene	B-X
.	B-X
Moreover	B-X
,	B-X
M-CSF-induced	B-X
expression	B-X
of	B-X
the	B-X
fos-related	B-X
gene	B-X
,	B-X
fra-1	B-X
,	B-X
was	B-X
delayed	B-X
compared	B-X
to	B-X
that	B-X
for	B-X
both	B-X
c-fos	B-X
and	B-X
fos-B	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
that	B-X
M-CSF	B-X
treatment	B-X
is	B-X
associated	B-X
with	B-X
differential	B-X
activation	B-X
of	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
jun/fos	B-X
family	B-X
and	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
could	B-X
contribute	B-X
to	B-X
nuclear	B-X
signaling	B-X
mechanisms	B-X
that	B-X
regulate	B-X
a	B-X
specific	B-X
program	B-X
of	B-X
monocyte	B-X
differentiation	B-X
.	B-X

Low	O
levels	O
of	O
c	B-Protein
-	I-Protein
jun	I-Protein
transcripts	O
were	O
detectable	O
in	O
resting	O
human	O
peripheral	O
blood	O
monocytes	O
.	O
<EOS>	B-X
The	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
is	B-X
required	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
differentiation	B-X
of	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signaling	B-X
events	B-X
responsible	B-X
for	B-X
these	B-X
effects	B-X
remain	B-X
unclear	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
M-CSF	B-X
on	B-X
potential	B-X
signaling	B-X
pathways	B-X
involving	B-X
expression	B-X
of	B-X
the	B-X
jun	B-X
and	B-X
fos	B-X
early	B-X
response	B-X
genes	B-X
.	B-X
Low	B-X
levels	B-X
of	B-X
c-jun	B-X
transcripts	B-X
were	B-X
detectable	B-X
in	B-X
resting	B-X
human	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
.	B-X
Treatment	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
10	B-X
(	B-X
3	B-X
)	B-X
units/ml	B-X
human	B-X
recombinant	B-X
M-CSF	B-X
was	B-X
associated	B-X
with	B-X
rapid	B-X
and	B-X
transient	B-X
increases	B-X
in	B-X
c-jun	B-X
mRNA	B-X
levels	B-X
.	B-X
Nuclear	B-X
run-on	B-X
assays	B-X
and	B-X
mRNA	B-X
stability	B-X
studies	B-X
demonstrated	B-X
that	B-X
M-CSF	B-X
regulates	B-X
c-jun	B-X
expression	B-X
by	B-X
both	B-X
an	B-X
increase	B-X
in	B-X
transcription	B-X
rate	B-X
and	B-X
a	B-X
prolongation	B-X
in	B-X
the	B-X
half-life	B-X
of	B-X
c-jun	B-X
transcripts	B-X
.	B-X
M-CSF	B-X
treatment	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
a	B-X
rapid	B-X
induction	B-X
of	B-X
the	B-X
jun-B	B-X
gene	B-X
,	B-X
although	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
was	B-X
prolonged	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
c-jun	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
increases	B-X
c-fos	B-X
mRNA	B-X
levels	B-X
in	B-X
human	B-X
monocytes	B-X
through	B-X
control	B-X
at	B-X
both	B-X
the	B-X
transcriptional	B-X
and	B-X
posttranscriptional	B-X
levels	B-X
.	B-X
Maximal	B-X
induction	B-X
of	B-X
the	B-X
c-fos	B-X
gene	B-X
was	B-X
followed	B-X
by	B-X
that	B-X
for	B-X
the	B-X
fos-B	B-X
gene	B-X
.	B-X
Moreover	B-X
,	B-X
M-CSF-induced	B-X
expression	B-X
of	B-X
the	B-X
fos-related	B-X
gene	B-X
,	B-X
fra-1	B-X
,	B-X
was	B-X
delayed	B-X
compared	B-X
to	B-X
that	B-X
for	B-X
both	B-X
c-fos	B-X
and	B-X
fos-B	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
that	B-X
M-CSF	B-X
treatment	B-X
is	B-X
associated	B-X
with	B-X
differential	B-X
activation	B-X
of	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
jun/fos	B-X
family	B-X
and	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
could	B-X
contribute	B-X
to	B-X
nuclear	B-X
signaling	B-X
mechanisms	B-X
that	B-X
regulate	B-X
a	B-X
specific	B-X
program	B-X
of	B-X
monocyte	B-X
differentiation	B-X
.	B-X

Treatment	O
of	O
these	O
cells	O
with	O
10	O
(	O
3	O
)	O
units	O
/	O
ml	O
human	O
recombinant	O
M	O
-	O
CSF	O
was	O
associated	O
with	O
rapid	O
and	O
transient	O
increases	O
in	O
c	B-Protein
-	I-Protein
jun	I-Protein
mRNA	O
levels	O
.	O

Nuclear	O
run	O
-	O
on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M	O
-	O
CSF	O
regulates	O
c	B-Protein
-	I-Protein
jun	I-Protein
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
c	B-Protein
-	I-Protein
jun	I-Protein
transcripts	O
.	O

M	O
-	O
CSF	O
treatment	O
was	O
also	O
associated	O
with	O
a	O
rapid	O
induction	O
of	O
the	O
jun	B-Protein
-	I-Protein
B	I-Protein
gene	O
,	O
although	O
expression	O
of	O
this	O
gene	O
was	O
prolonged	O
compared	O
to	O
that	O
of	O
c	B-Protein
-	I-Protein
jun	I-Protein
.	O

We	O
further	O
demonstrate	O
that	O
M	O
-	O
CSF	O
increases	O
c	B-Protein
-	I-Protein
fos	I-Protein
mRNA	O
levels	O
in	O
human	O
monocytes	O
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O
<EOS>	B-X
The	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
is	B-X
required	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
differentiation	B-X
of	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signaling	B-X
events	B-X
responsible	B-X
for	B-X
these	B-X
effects	B-X
remain	B-X
unclear	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
M-CSF	B-X
on	B-X
potential	B-X
signaling	B-X
pathways	B-X
involving	B-X
expression	B-X
of	B-X
the	B-X
jun	B-X
and	B-X
fos	B-X
early	B-X
response	B-X
genes	B-X
.	B-X
Low	B-X
levels	B-X
of	B-X
c-jun	B-X
transcripts	B-X
were	B-X
detectable	B-X
in	B-X
resting	B-X
human	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
.	B-X
Treatment	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
10	B-X
(	B-X
3	B-X
)	B-X
units/ml	B-X
human	B-X
recombinant	B-X
M-CSF	B-X
was	B-X
associated	B-X
with	B-X
rapid	B-X
and	B-X
transient	B-X
increases	B-X
in	B-X
c-jun	B-X
mRNA	B-X
levels	B-X
.	B-X
Nuclear	B-X
run-on	B-X
assays	B-X
and	B-X
mRNA	B-X
stability	B-X
studies	B-X
demonstrated	B-X
that	B-X
M-CSF	B-X
regulates	B-X
c-jun	B-X
expression	B-X
by	B-X
both	B-X
an	B-X
increase	B-X
in	B-X
transcription	B-X
rate	B-X
and	B-X
a	B-X
prolongation	B-X
in	B-X
the	B-X
half-life	B-X
of	B-X
c-jun	B-X
transcripts	B-X
.	B-X
M-CSF	B-X
treatment	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
a	B-X
rapid	B-X
induction	B-X
of	B-X
the	B-X
jun-B	B-X
gene	B-X
,	B-X
although	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
was	B-X
prolonged	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
c-jun	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
increases	B-X
c-fos	B-X
mRNA	B-X
levels	B-X
in	B-X
human	B-X
monocytes	B-X
through	B-X
control	B-X
at	B-X
both	B-X
the	B-X
transcriptional	B-X
and	B-X
posttranscriptional	B-X
levels	B-X
.	B-X
Maximal	B-X
induction	B-X
of	B-X
the	B-X
c-fos	B-X
gene	B-X
was	B-X
followed	B-X
by	B-X
that	B-X
for	B-X
the	B-X
fos-B	B-X
gene	B-X
.	B-X
Moreover	B-X
,	B-X
M-CSF-induced	B-X
expression	B-X
of	B-X
the	B-X
fos-related	B-X
gene	B-X
,	B-X
fra-1	B-X
,	B-X
was	B-X
delayed	B-X
compared	B-X
to	B-X
that	B-X
for	B-X
both	B-X
c-fos	B-X
and	B-X
fos-B	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
that	B-X
M-CSF	B-X
treatment	B-X
is	B-X
associated	B-X
with	B-X
differential	B-X
activation	B-X
of	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
jun/fos	B-X
family	B-X
and	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
could	B-X
contribute	B-X
to	B-X
nuclear	B-X
signaling	B-X
mechanisms	B-X
that	B-X
regulate	B-X
a	B-X
specific	B-X
program	B-X
of	B-X
monocyte	B-X
differentiation	B-X
.	B-X

Maximal	O
induction	O
of	O
the	O
c	B-Protein
-	I-Protein
fos	I-Protein
gene	O
was	O
followed	O
by	O
that	O
for	O
the	O
fos	B-Protein
-	I-Protein
B	I-Protein
gene	O
.	O

Moreover	O
,	O
M	O
-	O
CSF	O
-	O
induced	O
expression	O
of	O
the	O
fos	O
-	O
related	O
gene	O
,	O
fra	B-Protein
-	I-Protein
1	I-Protein
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c	B-Protein
-	I-Protein
fos	I-Protein
and	O
fos	B-Protein
-	I-Protein
B	I-Protein
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
M	O
-	O
CSF	O
treatment	O
is	O
associated	O
with	O
differential	O
activation	O
of	O
multiple	O
members	O
of	O
the	O
jun	O
/	O
fos	O
family	O
and	O
that	O
expression	O
of	O
these	O
genes	O
could	O
contribute	O
to	O
nuclear	O
signaling	O
mechanisms	O
that	O
regulate	O
a	O
specific	O
program	O
of	O
monocyte	O
differentiation	O
.	O
<EOS>	B-X
The	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
is	B-X
required	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
differentiation	B-X
of	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signaling	B-X
events	B-X
responsible	B-X
for	B-X
these	B-X
effects	B-X
remain	B-X
unclear	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
M-CSF	B-X
on	B-X
potential	B-X
signaling	B-X
pathways	B-X
involving	B-X
expression	B-X
of	B-X
the	B-X
jun	B-X
and	B-X
fos	B-X
early	B-X
response	B-X
genes	B-X
.	B-X
Low	B-X
levels	B-X
of	B-X
c-jun	B-X
transcripts	B-X
were	B-X
detectable	B-X
in	B-X
resting	B-X
human	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
.	B-X
Treatment	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
10	B-X
(	B-X
3	B-X
)	B-X
units/ml	B-X
human	B-X
recombinant	B-X
M-CSF	B-X
was	B-X
associated	B-X
with	B-X
rapid	B-X
and	B-X
transient	B-X
increases	B-X
in	B-X
c-jun	B-X
mRNA	B-X
levels	B-X
.	B-X
Nuclear	B-X
run-on	B-X
assays	B-X
and	B-X
mRNA	B-X
stability	B-X
studies	B-X
demonstrated	B-X
that	B-X
M-CSF	B-X
regulates	B-X
c-jun	B-X
expression	B-X
by	B-X
both	B-X
an	B-X
increase	B-X
in	B-X
transcription	B-X
rate	B-X
and	B-X
a	B-X
prolongation	B-X
in	B-X
the	B-X
half-life	B-X
of	B-X
c-jun	B-X
transcripts	B-X
.	B-X
M-CSF	B-X
treatment	B-X
was	B-X
also	B-X
associated	B-X
with	B-X
a	B-X
rapid	B-X
induction	B-X
of	B-X
the	B-X
jun-B	B-X
gene	B-X
,	B-X
although	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
was	B-X
prolonged	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
c-jun	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
increases	B-X
c-fos	B-X
mRNA	B-X
levels	B-X
in	B-X
human	B-X
monocytes	B-X
through	B-X
control	B-X
at	B-X
both	B-X
the	B-X
transcriptional	B-X
and	B-X
posttranscriptional	B-X
levels	B-X
.	B-X
Maximal	B-X
induction	B-X
of	B-X
the	B-X
c-fos	B-X
gene	B-X
was	B-X
followed	B-X
by	B-X
that	B-X
for	B-X
the	B-X
fos-B	B-X
gene	B-X
.	B-X
Moreover	B-X
,	B-X
M-CSF-induced	B-X
expression	B-X
of	B-X
the	B-X
fos-related	B-X
gene	B-X
,	B-X
fra-1	B-X
,	B-X
was	B-X
delayed	B-X
compared	B-X
to	B-X
that	B-X
for	B-X
both	B-X
c-fos	B-X
and	B-X
fos-B	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
indicate	B-X
that	B-X
M-CSF	B-X
treatment	B-X
is	B-X
associated	B-X
with	B-X
differential	B-X
activation	B-X
of	B-X
multiple	B-X
members	B-X
of	B-X
the	B-X
jun/fos	B-X
family	B-X
and	B-X
that	B-X
expression	B-X
of	B-X
these	B-X
genes	B-X
could	B-X
contribute	B-X
to	B-X
nuclear	B-X
signaling	B-X
mechanisms	B-X
that	B-X
regulate	B-X
a	B-X
specific	B-X
program	B-X
of	B-X
monocyte	B-X
differentiation	B-X
.	B-X

cAMP	O
-	O
dependent	O
regulation	O
of	O
proenkephalin	O
by	O
JunD	B-Protein
and	O
JunB	B-Protein
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP	O
-	O
1	O
proteins	O
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
JunD	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
AP-1	B-X
transcription	B-X
factor	B-X
complex	B-X
,	B-X
activates	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
proenkephalin	B-X
gene	B-X
in	B-X
a	B-X
fashion	B-X
that	B-X
is	B-X
completely	B-X
dependent	B-X
upon	B-X
the	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
,	B-X
protein	B-X
kinase	B-X
A.	B-X
Activation	B-X
of	B-X
proenkephalin	B-X
transcription	B-X
by	B-X
JunD	B-X
is	B-X
dependent	B-X
upon	B-X
a	B-X
previously	B-X
characterized	B-X
cAMP-	B-X
,	B-X
phorbol	B-X
ester-	B-X
,	B-X
and	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-inducible	B-X
enhancer	B-X
,	B-X
and	B-X
JunD	B-X
is	B-X
shown	B-X
to	B-X
bind	B-X
the	B-X
enhancer	B-X
as	B-X
a	B-X
homodimer	B-X
.	B-X
Another	B-X
component	B-X
of	B-X
the	B-X
AP-1	B-X
transcription	B-X
complex	B-X
,	B-X
JunB	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
inhibit	B-X
activation	B-X
mediated	B-X
by	B-X
JunD	B-X
.	B-X
As	B-X
a	B-X
homodimer	B-X
JunB	B-X
is	B-X
unable	B-X
to	B-X
bind	B-X
the	B-X
enhancer	B-X
;	B-X
however	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
c-Fos	B-X
,	B-X
high-affinity	B-X
binding	B-X
is	B-X
observed	B-X
.	B-X
Furthermore	B-X
,	B-X
JunD	B-X
is	B-X
shown	B-X
to	B-X
activate	B-X
transcription	B-X
of	B-X
genes	B-X
linked	B-X
to	B-X
both	B-X
cAMP	B-X
and	B-X
phorbol	B-X
ester	B-X
response	B-X
elements	B-X
in	B-X
a	B-X
protein	B-X
kinase	B-X
A-dependent	B-X
fashion	B-X
,	B-X
further	B-X
blurring	B-X
the	B-X
distinction	B-X
between	B-X
these	B-X
response	B-X
elements	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
an	B-X
AP-1-related	B-X
protein	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
cAMP-dependent	B-X
second-messenger	B-X
pathway	B-X
and	B-X
suggest	B-X
that	B-X
JunD	B-X
and	B-X
other	B-X
AP-1-related	B-X
proteins	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
by	B-X
cAMP-dependent	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
.	B-X

We	O
demonstrate	O
that	O
JunD	B-Protein
,	O
a	O
component	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
factor	O
complex	O
,	O
activates	O
transcription	O
of	O
the	O
human	O
proenkephalin	O
gene	O
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
,	O
protein	O
kinase	O
A	O
.	O

Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	B-Protein
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP	O
-	O
,	O
phorbol	O
ester	O
-	O
,	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-	O
inducible	O
enhancer	O
,	O
and	O
JunD	B-Protein
is	O
shown	O
to	O
bind	O
the	O
enhancer	O
as	O
a	O
homodimer	O
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
JunD	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
AP-1	B-X
transcription	B-X
factor	B-X
complex	B-X
,	B-X
activates	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
proenkephalin	B-X
gene	B-X
in	B-X
a	B-X
fashion	B-X
that	B-X
is	B-X
completely	B-X
dependent	B-X
upon	B-X
the	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
,	B-X
protein	B-X
kinase	B-X
A.	B-X
Activation	B-X
of	B-X
proenkephalin	B-X
transcription	B-X
by	B-X
JunD	B-X
is	B-X
dependent	B-X
upon	B-X
a	B-X
previously	B-X
characterized	B-X
cAMP-	B-X
,	B-X
phorbol	B-X
ester-	B-X
,	B-X
and	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-inducible	B-X
enhancer	B-X
,	B-X
and	B-X
JunD	B-X
is	B-X
shown	B-X
to	B-X
bind	B-X
the	B-X
enhancer	B-X
as	B-X
a	B-X
homodimer	B-X
.	B-X
Another	B-X
component	B-X
of	B-X
the	B-X
AP-1	B-X
transcription	B-X
complex	B-X
,	B-X
JunB	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
inhibit	B-X
activation	B-X
mediated	B-X
by	B-X
JunD	B-X
.	B-X
As	B-X
a	B-X
homodimer	B-X
JunB	B-X
is	B-X
unable	B-X
to	B-X
bind	B-X
the	B-X
enhancer	B-X
;	B-X
however	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
c-Fos	B-X
,	B-X
high-affinity	B-X
binding	B-X
is	B-X
observed	B-X
.	B-X
Furthermore	B-X
,	B-X
JunD	B-X
is	B-X
shown	B-X
to	B-X
activate	B-X
transcription	B-X
of	B-X
genes	B-X
linked	B-X
to	B-X
both	B-X
cAMP	B-X
and	B-X
phorbol	B-X
ester	B-X
response	B-X
elements	B-X
in	B-X
a	B-X
protein	B-X
kinase	B-X
A-dependent	B-X
fashion	B-X
,	B-X
further	B-X
blurring	B-X
the	B-X
distinction	B-X
between	B-X
these	B-X
response	B-X
elements	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
an	B-X
AP-1-related	B-X
protein	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
cAMP-dependent	B-X
second-messenger	B-X
pathway	B-X
and	B-X
suggest	B-X
that	B-X
JunD	B-X
and	B-X
other	B-X
AP-1-related	B-X
proteins	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
by	B-X
cAMP-dependent	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
.	B-X

Another	O
component	O
of	O
the	O
AP	O
-	O
1	O
transcription	O
complex	O
,	O
JunB	B-Protein
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	B-Protein
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
JunD	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
AP-1	B-X
transcription	B-X
factor	B-X
complex	B-X
,	B-X
activates	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
proenkephalin	B-X
gene	B-X
in	B-X
a	B-X
fashion	B-X
that	B-X
is	B-X
completely	B-X
dependent	B-X
upon	B-X
the	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
,	B-X
protein	B-X
kinase	B-X
A.	B-X
Activation	B-X
of	B-X
proenkephalin	B-X
transcription	B-X
by	B-X
JunD	B-X
is	B-X
dependent	B-X
upon	B-X
a	B-X
previously	B-X
characterized	B-X
cAMP-	B-X
,	B-X
phorbol	B-X
ester-	B-X
,	B-X
and	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-inducible	B-X
enhancer	B-X
,	B-X
and	B-X
JunD	B-X
is	B-X
shown	B-X
to	B-X
bind	B-X
the	B-X
enhancer	B-X
as	B-X
a	B-X
homodimer	B-X
.	B-X
Another	B-X
component	B-X
of	B-X
the	B-X
AP-1	B-X
transcription	B-X
complex	B-X
,	B-X
JunB	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
inhibit	B-X
activation	B-X
mediated	B-X
by	B-X
JunD	B-X
.	B-X
As	B-X
a	B-X
homodimer	B-X
JunB	B-X
is	B-X
unable	B-X
to	B-X
bind	B-X
the	B-X
enhancer	B-X
;	B-X
however	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
c-Fos	B-X
,	B-X
high-affinity	B-X
binding	B-X
is	B-X
observed	B-X
.	B-X
Furthermore	B-X
,	B-X
JunD	B-X
is	B-X
shown	B-X
to	B-X
activate	B-X
transcription	B-X
of	B-X
genes	B-X
linked	B-X
to	B-X
both	B-X
cAMP	B-X
and	B-X
phorbol	B-X
ester	B-X
response	B-X
elements	B-X
in	B-X
a	B-X
protein	B-X
kinase	B-X
A-dependent	B-X
fashion	B-X
,	B-X
further	B-X
blurring	B-X
the	B-X
distinction	B-X
between	B-X
these	B-X
response	B-X
elements	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
an	B-X
AP-1-related	B-X
protein	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
cAMP-dependent	B-X
second-messenger	B-X
pathway	B-X
and	B-X
suggest	B-X
that	B-X
JunD	B-X
and	B-X
other	B-X
AP-1-related	B-X
proteins	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
by	B-X
cAMP-dependent	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
.	B-X

As	O
a	O
homodimer	O
JunB	B-Protein
is	O
unable	O
to	O
bind	O
the	O
enhancer	O
;	O
however	O
in	O
the	O
presence	O
of	O
c	B-Protein
-	I-Protein
Fos	I-Protein
,	O
high	O
-	O
affinity	O
binding	O
is	O
observed	O
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
JunD	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
AP-1	B-X
transcription	B-X
factor	B-X
complex	B-X
,	B-X
activates	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
proenkephalin	B-X
gene	B-X
in	B-X
a	B-X
fashion	B-X
that	B-X
is	B-X
completely	B-X
dependent	B-X
upon	B-X
the	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
,	B-X
protein	B-X
kinase	B-X
A.	B-X
Activation	B-X
of	B-X
proenkephalin	B-X
transcription	B-X
by	B-X
JunD	B-X
is	B-X
dependent	B-X
upon	B-X
a	B-X
previously	B-X
characterized	B-X
cAMP-	B-X
,	B-X
phorbol	B-X
ester-	B-X
,	B-X
and	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-inducible	B-X
enhancer	B-X
,	B-X
and	B-X
JunD	B-X
is	B-X
shown	B-X
to	B-X
bind	B-X
the	B-X
enhancer	B-X
as	B-X
a	B-X
homodimer	B-X
.	B-X
Another	B-X
component	B-X
of	B-X
the	B-X
AP-1	B-X
transcription	B-X
complex	B-X
,	B-X
JunB	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
inhibit	B-X
activation	B-X
mediated	B-X
by	B-X
JunD	B-X
.	B-X
As	B-X
a	B-X
homodimer	B-X
JunB	B-X
is	B-X
unable	B-X
to	B-X
bind	B-X
the	B-X
enhancer	B-X
;	B-X
however	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
c-Fos	B-X
,	B-X
high-affinity	B-X
binding	B-X
is	B-X
observed	B-X
.	B-X
Furthermore	B-X
,	B-X
JunD	B-X
is	B-X
shown	B-X
to	B-X
activate	B-X
transcription	B-X
of	B-X
genes	B-X
linked	B-X
to	B-X
both	B-X
cAMP	B-X
and	B-X
phorbol	B-X
ester	B-X
response	B-X
elements	B-X
in	B-X
a	B-X
protein	B-X
kinase	B-X
A-dependent	B-X
fashion	B-X
,	B-X
further	B-X
blurring	B-X
the	B-X
distinction	B-X
between	B-X
these	B-X
response	B-X
elements	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
an	B-X
AP-1-related	B-X
protein	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
cAMP-dependent	B-X
second-messenger	B-X
pathway	B-X
and	B-X
suggest	B-X
that	B-X
JunD	B-X
and	B-X
other	B-X
AP-1-related	B-X
proteins	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
by	B-X
cAMP-dependent	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
.	B-X

Furthermore	O
,	O
JunD	B-Protein
is	O
shown	O
to	O
activate	O
transcription	O
of	O
genes	O
linked	O
to	O
both	O
cAMP	O
and	O
phorbol	O
ester	O
response	O
elements	O
in	O
a	O
protein	O
kinase	O
A	O
-	O
dependent	O
fashion	O
,	O
further	O
blurring	O
the	O
distinction	O
between	O
these	O
response	O
elements	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP	O
-	O
1	O
-	O
related	O
protein	O
is	O
regulated	O
by	O
the	O
cAMP	O
-	O
dependent	O
second	O
-	O
messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	B-Protein
and	O
other	O
AP	O
-	O
1	O
-	O
related	O
proteins	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP	O
-	O
dependent	O
intracellular	O
signaling	O
pathways	O
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
JunD	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
AP-1	B-X
transcription	B-X
factor	B-X
complex	B-X
,	B-X
activates	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
proenkephalin	B-X
gene	B-X
in	B-X
a	B-X
fashion	B-X
that	B-X
is	B-X
completely	B-X
dependent	B-X
upon	B-X
the	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
,	B-X
protein	B-X
kinase	B-X
A.	B-X
Activation	B-X
of	B-X
proenkephalin	B-X
transcription	B-X
by	B-X
JunD	B-X
is	B-X
dependent	B-X
upon	B-X
a	B-X
previously	B-X
characterized	B-X
cAMP-	B-X
,	B-X
phorbol	B-X
ester-	B-X
,	B-X
and	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-inducible	B-X
enhancer	B-X
,	B-X
and	B-X
JunD	B-X
is	B-X
shown	B-X
to	B-X
bind	B-X
the	B-X
enhancer	B-X
as	B-X
a	B-X
homodimer	B-X
.	B-X
Another	B-X
component	B-X
of	B-X
the	B-X
AP-1	B-X
transcription	B-X
complex	B-X
,	B-X
JunB	B-X
,	B-X
is	B-X
shown	B-X
to	B-X
inhibit	B-X
activation	B-X
mediated	B-X
by	B-X
JunD	B-X
.	B-X
Furthermore	B-X
,	B-X
JunD	B-X
is	B-X
shown	B-X
to	B-X
activate	B-X
transcription	B-X
of	B-X
genes	B-X
linked	B-X
to	B-X
both	B-X
cAMP	B-X
and	B-X
phorbol	B-X
ester	B-X
response	B-X
elements	B-X
in	B-X
a	B-X
protein	B-X
kinase	B-X
A-dependent	B-X
fashion	B-X
,	B-X
further	B-X
blurring	B-X
the	B-X
distinction	B-X
between	B-X
these	B-X
response	B-X
elements	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
an	B-X
AP-1-related	B-X
protein	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
cAMP-dependent	B-X
second-messenger	B-X
pathway	B-X
and	B-X
suggest	B-X
that	B-X
JunD	B-X
and	B-X
other	B-X
AP-1-related	B-X
proteins	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
by	B-X
cAMP-dependent	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
.	B-X

Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
on	B-X
cellular	B-X
differentiation	B-X
and	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
have	B-X
been	B-X
investigated	B-X
in	B-X
a	B-X
new	B-X
model	B-X
of	B-X
myeloid	B-X
differentiation	B-X
.	B-X
PLB-985	B-X
cells	B-X
represent	B-X
a	B-X
bipotential	B-X
myelomonoblastic	B-X
cell	B-X
population	B-X
capable	B-X
of	B-X
either	B-X
granulocytic	B-X
or	B-X
monocytic	B-X
differentiation	B-X
after	B-X
induction	B-X
with	B-X
appropriate	B-X
inducers	B-X
.	B-X
By	B-X
virtue	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
CD4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
PLB-985	B-X
cells	B-X
were	B-X
chronically	B-X
infected	B-X
with	B-X
HIV-1	B-X
strain	B-X
IIIB	B-X
.	B-X
PLB-IIIB	B-X
cells	B-X
clearly	B-X
possessed	B-X
a	B-X
more	B-X
monocytic	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
myeloblasts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
differential	B-X
staining	B-X
,	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
myeloid-specific	B-X
surface	B-X
markers	B-X
,	B-X
and	B-X
transcription	B-X
of	B-X
the	B-X
c-fms	B-X
proto-oncogene	B-X
.	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
inducible	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
in	B-X
PLB-985	B-X
.	B-X
However	B-X
,	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
,	B-X
constitutive	B-X
expression	B-X
of	B-X
a	B-X
novel	B-X
NF-kappa	B-X
B	B-X
complex	B-X
was	B-X
detected	B-X
,	B-X
composed	B-X
of	B-X
proteins	B-X
ranging	B-X
between	B-X
70	B-X
and	B-X
110	B-X
kD	B-X
.	B-X
These	B-X
proteins	B-X
interacted	B-X
specifically	B-X
with	B-X
the	B-X
symmetric	B-X
NF-kappa	B-X
B	B-X
site	B-X
from	B-X
the	B-X
interferon	B-X
beta	B-X
(	B-X
IFN-beta	B-X
)	B-X
promoter	B-X
.	B-X
Mutations	B-X
affecting	B-X
the	B-X
5	B-X
'	B-X
guanine	B-X
residues	B-X
of	B-X
the	B-X
kappa	B-X
B	B-X
site	B-X
were	B-X
unable	B-X
to	B-X
compete	B-X
for	B-X
these	B-X
NF-kappa	B-X
B-related	B-X
proteins	B-X
.	B-X
Inducibility	B-X
of	B-X
endogenous	B-X
IFN-beta	B-X
and	B-X
IFN-alpha	B-X
RNA	B-X
was	B-X
also	B-X
increased	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
HIV-1	B-X
infection	B-X
of	B-X
myelomonoblastic	B-X
cells	B-X
may	B-X
select	B-X
for	B-X
a	B-X
more	B-X
mature	B-X
monocytic	B-X
phenotype	B-X
and	B-X
that	B-X
unique	B-X
subunit	B-X
associations	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
proteins	B-X
may	B-X
contribute	B-X
to	B-X
differential	B-X
NF-kappa	B-X
B-mediated	B-X
gene	B-X
expression	B-X
.	B-X

The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O

PLB	O
-	O
985	O
cells	O
represent	O
a	O
bipotential	O
myelomonoblastic	O
cell	O
population	O
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
on	B-X
cellular	B-X
differentiation	B-X
and	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
have	B-X
been	B-X
investigated	B-X
in	B-X
a	B-X
new	B-X
model	B-X
of	B-X
myeloid	B-X
differentiation	B-X
.	B-X
PLB-985	B-X
cells	B-X
represent	B-X
a	B-X
bipotential	B-X
myelomonoblastic	B-X
cell	B-X
population	B-X
capable	B-X
of	B-X
either	B-X
granulocytic	B-X
or	B-X
monocytic	B-X
differentiation	B-X
after	B-X
induction	B-X
with	B-X
appropriate	B-X
inducers	B-X
.	B-X
By	B-X
virtue	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
CD4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
PLB-985	B-X
cells	B-X
were	B-X
chronically	B-X
infected	B-X
with	B-X
HIV-1	B-X
strain	B-X
IIIB	B-X
.	B-X
PLB-IIIB	B-X
cells	B-X
clearly	B-X
possessed	B-X
a	B-X
more	B-X
monocytic	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
myeloblasts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
differential	B-X
staining	B-X
,	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
myeloid-specific	B-X
surface	B-X
markers	B-X
,	B-X
and	B-X
transcription	B-X
of	B-X
the	B-X
c-fms	B-X
proto-oncogene	B-X
.	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
inducible	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
in	B-X
PLB-985	B-X
.	B-X
However	B-X
,	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
,	B-X
constitutive	B-X
expression	B-X
of	B-X
a	B-X
novel	B-X
NF-kappa	B-X
B	B-X
complex	B-X
was	B-X
detected	B-X
,	B-X
composed	B-X
of	B-X
proteins	B-X
ranging	B-X
between	B-X
70	B-X
and	B-X
110	B-X
kD	B-X
.	B-X
Inducibility	B-X
of	B-X
endogenous	B-X
IFN-beta	B-X
and	B-X
IFN-alpha	B-X
RNA	B-X
was	B-X
also	B-X
increased	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
HIV-1	B-X
infection	B-X
of	B-X
myelomonoblastic	B-X
cells	B-X
may	B-X
select	B-X
for	B-X
a	B-X
more	B-X
mature	B-X
monocytic	B-X
phenotype	B-X
and	B-X
that	B-X
unique	B-X
subunit	B-X
associations	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
proteins	B-X
may	B-X
contribute	B-X
to	B-X
differential	B-X
NF-kappa	B-X
B-mediated	B-X
gene	B-X
expression	B-X
.	B-X

By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	B-Protein
on	O
the	O
cell	O
surface	O
,	O
PLB	O
-	O
985	O
cells	O
were	O
chronically	O
infected	O
with	O
HIV	O
-	O
1	O
strain	O
IIIB	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
on	B-X
cellular	B-X
differentiation	B-X
and	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
have	B-X
been	B-X
investigated	B-X
in	B-X
a	B-X
new	B-X
model	B-X
of	B-X
myeloid	B-X
differentiation	B-X
.	B-X
PLB-985	B-X
cells	B-X
represent	B-X
a	B-X
bipotential	B-X
myelomonoblastic	B-X
cell	B-X
population	B-X
capable	B-X
of	B-X
either	B-X
granulocytic	B-X
or	B-X
monocytic	B-X
differentiation	B-X
after	B-X
induction	B-X
with	B-X
appropriate	B-X
inducers	B-X
.	B-X
By	B-X
virtue	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
CD4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
PLB-985	B-X
cells	B-X
were	B-X
chronically	B-X
infected	B-X
with	B-X
HIV-1	B-X
strain	B-X
IIIB	B-X
.	B-X
PLB-IIIB	B-X
cells	B-X
clearly	B-X
possessed	B-X
a	B-X
more	B-X
monocytic	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
myeloblasts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
differential	B-X
staining	B-X
,	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
myeloid-specific	B-X
surface	B-X
markers	B-X
,	B-X
and	B-X
transcription	B-X
of	B-X
the	B-X
c-fms	B-X
proto-oncogene	B-X
.	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
inducible	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
in	B-X
PLB-985	B-X
.	B-X
However	B-X
,	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
,	B-X
constitutive	B-X
expression	B-X
of	B-X
a	B-X
novel	B-X
NF-kappa	B-X
B	B-X
complex	B-X
was	B-X
detected	B-X
,	B-X
composed	B-X
of	B-X
proteins	B-X
ranging	B-X
between	B-X
70	B-X
and	B-X
110	B-X
kD	B-X
.	B-X
Inducibility	B-X
of	B-X
endogenous	B-X
IFN-beta	B-X
and	B-X
IFN-alpha	B-X
RNA	B-X
was	B-X
also	B-X
increased	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
HIV-1	B-X
infection	B-X
of	B-X
myelomonoblastic	B-X
cells	B-X
may	B-X
select	B-X
for	B-X
a	B-X
more	B-X
mature	B-X
monocytic	B-X
phenotype	B-X
and	B-X
that	B-X
unique	B-X
subunit	B-X
associations	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
proteins	B-X
may	B-X
contribute	B-X
to	B-X
differential	B-X
NF-kappa	B-X
B-mediated	B-X
gene	B-X
expression	B-X
.	B-X

PLB	O
-	O
IIIB	O
cells	O
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	O
myeloblasts	O
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid	O
-	O
specific	O
surface	O
markers	O
,	O
and	O
transcription	O
of	O
the	O
c	B-Protein
-	I-Protein
fms	I-Protein
proto	O
-	O
oncogene	O
.	O

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
was	O
inducible	O
by	O
tumor	O
necrosis	O
factor	O
and	O
phorbol	O
myristate	O
acetate	O
in	O
PLB	O
-	O
985	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
on	B-X
cellular	B-X
differentiation	B-X
and	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
have	B-X
been	B-X
investigated	B-X
in	B-X
a	B-X
new	B-X
model	B-X
of	B-X
myeloid	B-X
differentiation	B-X
.	B-X
PLB-985	B-X
cells	B-X
represent	B-X
a	B-X
bipotential	B-X
myelomonoblastic	B-X
cell	B-X
population	B-X
capable	B-X
of	B-X
either	B-X
granulocytic	B-X
or	B-X
monocytic	B-X
differentiation	B-X
after	B-X
induction	B-X
with	B-X
appropriate	B-X
inducers	B-X
.	B-X
By	B-X
virtue	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
CD4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
PLB-985	B-X
cells	B-X
were	B-X
chronically	B-X
infected	B-X
with	B-X
HIV-1	B-X
strain	B-X
IIIB	B-X
.	B-X
PLB-IIIB	B-X
cells	B-X
clearly	B-X
possessed	B-X
a	B-X
more	B-X
monocytic	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
myeloblasts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
differential	B-X
staining	B-X
,	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
myeloid-specific	B-X
surface	B-X
markers	B-X
,	B-X
and	B-X
transcription	B-X
of	B-X
the	B-X
c-fms	B-X
proto-oncogene	B-X
.	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
inducible	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
in	B-X
PLB-985	B-X
.	B-X
However	B-X
,	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
,	B-X
constitutive	B-X
expression	B-X
of	B-X
a	B-X
novel	B-X
NF-kappa	B-X
B	B-X
complex	B-X
was	B-X
detected	B-X
,	B-X
composed	B-X
of	B-X
proteins	B-X
ranging	B-X
between	B-X
70	B-X
and	B-X
110	B-X
kD	B-X
.	B-X
These	B-X
proteins	B-X
interacted	B-X
specifically	B-X
with	B-X
the	B-X
symmetric	B-X
NF-kappa	B-X
B	B-X
site	B-X
from	B-X
the	B-X
interferon	B-X
beta	B-X
(	B-X
IFN-beta	B-X
)	B-X
promoter	B-X
.	B-X
Mutations	B-X
affecting	B-X
the	B-X
5	B-X
'	B-X
guanine	B-X
residues	B-X
of	B-X
the	B-X
kappa	B-X
B	B-X
site	B-X
were	B-X
unable	B-X
to	B-X
compete	B-X
for	B-X
these	B-X
NF-kappa	B-X
B-related	B-X
proteins	B-X
.	B-X
Inducibility	B-X
of	B-X
endogenous	B-X
IFN-beta	B-X
and	B-X
IFN-alpha	B-X
RNA	B-X
was	B-X
also	B-X
increased	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
HIV-1	B-X
infection	B-X
of	B-X
myelomonoblastic	B-X
cells	B-X
may	B-X
select	B-X
for	B-X
a	B-X
more	B-X
mature	B-X
monocytic	B-X
phenotype	B-X
and	B-X
that	B-X
unique	B-X
subunit	B-X
associations	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
proteins	B-X
may	B-X
contribute	B-X
to	B-X
differential	B-X
NF-kappa	B-X
B-mediated	B-X
gene	B-X
expression	B-X
.	B-X

However	O
,	O
in	O
PLB	O
-	O
IIIB	O
cells	O
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF	O
-	O
kappa	O
B	O
complex	O
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
on	B-X
cellular	B-X
differentiation	B-X
and	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
have	B-X
been	B-X
investigated	B-X
in	B-X
a	B-X
new	B-X
model	B-X
of	B-X
myeloid	B-X
differentiation	B-X
.	B-X
PLB-985	B-X
cells	B-X
represent	B-X
a	B-X
bipotential	B-X
myelomonoblastic	B-X
cell	B-X
population	B-X
capable	B-X
of	B-X
either	B-X
granulocytic	B-X
or	B-X
monocytic	B-X
differentiation	B-X
after	B-X
induction	B-X
with	B-X
appropriate	B-X
inducers	B-X
.	B-X
By	B-X
virtue	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
CD4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
PLB-985	B-X
cells	B-X
were	B-X
chronically	B-X
infected	B-X
with	B-X
HIV-1	B-X
strain	B-X
IIIB	B-X
.	B-X
PLB-IIIB	B-X
cells	B-X
clearly	B-X
possessed	B-X
a	B-X
more	B-X
monocytic	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
myeloblasts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
differential	B-X
staining	B-X
,	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
myeloid-specific	B-X
surface	B-X
markers	B-X
,	B-X
and	B-X
transcription	B-X
of	B-X
the	B-X
c-fms	B-X
proto-oncogene	B-X
.	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
inducible	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
in	B-X
PLB-985	B-X
.	B-X
However	B-X
,	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
,	B-X
constitutive	B-X
expression	B-X
of	B-X
a	B-X
novel	B-X
NF-kappa	B-X
B	B-X
complex	B-X
was	B-X
detected	B-X
,	B-X
composed	B-X
of	B-X
proteins	B-X
ranging	B-X
between	B-X
70	B-X
and	B-X
110	B-X
kD	B-X
.	B-X
These	B-X
proteins	B-X
interacted	B-X
specifically	B-X
with	B-X
the	B-X
symmetric	B-X
NF-kappa	B-X
B	B-X
site	B-X
from	B-X
the	B-X
interferon	B-X
beta	B-X
(	B-X
IFN-beta	B-X
)	B-X
promoter	B-X
.	B-X
Mutations	B-X
affecting	B-X
the	B-X
5	B-X
'	B-X
guanine	B-X
residues	B-X
of	B-X
the	B-X
kappa	B-X
B	B-X
site	B-X
were	B-X
unable	B-X
to	B-X
compete	B-X
for	B-X
these	B-X
NF-kappa	B-X
B-related	B-X
proteins	B-X
.	B-X
Inducibility	B-X
of	B-X
endogenous	B-X
IFN-beta	B-X
and	B-X
IFN-alpha	B-X
RNA	B-X
was	B-X
also	B-X
increased	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
HIV-1	B-X
infection	B-X
of	B-X
myelomonoblastic	B-X
cells	B-X
may	B-X
select	B-X
for	B-X
a	B-X
more	B-X
mature	B-X
monocytic	B-X
phenotype	B-X
and	B-X
that	B-X
unique	B-X
subunit	B-X
associations	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
proteins	B-X
may	B-X
contribute	B-X
to	B-X
differential	B-X
NF-kappa	B-X
B-mediated	B-X
gene	B-X
expression	B-X
.	B-X

These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	O
NF	O
-	O
kappa	O
B	O
site	O
from	O
the	O
interferon	B-Protein
beta	I-Protein
(	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
)	O
promoter	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
on	B-X
cellular	B-X
differentiation	B-X
and	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
have	B-X
been	B-X
investigated	B-X
in	B-X
a	B-X
new	B-X
model	B-X
of	B-X
myeloid	B-X
differentiation	B-X
.	B-X
PLB-985	B-X
cells	B-X
represent	B-X
a	B-X
bipotential	B-X
myelomonoblastic	B-X
cell	B-X
population	B-X
capable	B-X
of	B-X
either	B-X
granulocytic	B-X
or	B-X
monocytic	B-X
differentiation	B-X
after	B-X
induction	B-X
with	B-X
appropriate	B-X
inducers	B-X
.	B-X
By	B-X
virtue	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
CD4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
PLB-985	B-X
cells	B-X
were	B-X
chronically	B-X
infected	B-X
with	B-X
HIV-1	B-X
strain	B-X
IIIB	B-X
.	B-X
PLB-IIIB	B-X
cells	B-X
clearly	B-X
possessed	B-X
a	B-X
more	B-X
monocytic	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
myeloblasts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
differential	B-X
staining	B-X
,	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
myeloid-specific	B-X
surface	B-X
markers	B-X
,	B-X
and	B-X
transcription	B-X
of	B-X
the	B-X
c-fms	B-X
proto-oncogene	B-X
.	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
inducible	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
in	B-X
PLB-985	B-X
.	B-X
However	B-X
,	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
,	B-X
constitutive	B-X
expression	B-X
of	B-X
a	B-X
novel	B-X
NF-kappa	B-X
B	B-X
complex	B-X
was	B-X
detected	B-X
,	B-X
composed	B-X
of	B-X
proteins	B-X
ranging	B-X
between	B-X
70	B-X
and	B-X
110	B-X
kD	B-X
.	B-X
These	B-X
proteins	B-X
interacted	B-X
specifically	B-X
with	B-X
the	B-X
symmetric	B-X
NF-kappa	B-X
B	B-X
site	B-X
from	B-X
the	B-X
interferon	B-X
beta	B-X
(	B-X
IFN-beta	B-X
)	B-X
promoter	B-X
.	B-X
Mutations	B-X
affecting	B-X
the	B-X
5	B-X
'	B-X
guanine	B-X
residues	B-X
of	B-X
the	B-X
kappa	B-X
B	B-X
site	B-X
were	B-X
unable	B-X
to	B-X
compete	B-X
for	B-X
these	B-X
NF-kappa	B-X
B-related	B-X
proteins	B-X
.	B-X
Inducibility	B-X
of	B-X
endogenous	B-X
IFN-beta	B-X
and	B-X
IFN-alpha	B-X
RNA	B-X
was	B-X
also	B-X
increased	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
HIV-1	B-X
infection	B-X
of	B-X
myelomonoblastic	B-X
cells	B-X
may	B-X
select	B-X
for	B-X
a	B-X
more	B-X
mature	B-X
monocytic	B-X
phenotype	B-X
and	B-X
that	B-X
unique	B-X
subunit	B-X
associations	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
proteins	B-X
may	B-X
contribute	B-X
to	B-X
differential	B-X
NF-kappa	B-X
B-mediated	B-X
gene	B-X
expression	B-X
.	B-X

Mutations	O
affecting	O
the	O
5	O
'	O
guanine	O
residues	O
of	O
the	O
kappa	O
B	O
site	O
were	O
unable	O
to	O
compete	O
for	O
these	O
NF	O
-	O
kappa	O
B	O
-	O
related	O
proteins	O
.	O
<EOS>	B-X
The	B-X
effects	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
infection	B-X
on	B-X
cellular	B-X
differentiation	B-X
and	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
have	B-X
been	B-X
investigated	B-X
in	B-X
a	B-X
new	B-X
model	B-X
of	B-X
myeloid	B-X
differentiation	B-X
.	B-X
PLB-985	B-X
cells	B-X
represent	B-X
a	B-X
bipotential	B-X
myelomonoblastic	B-X
cell	B-X
population	B-X
capable	B-X
of	B-X
either	B-X
granulocytic	B-X
or	B-X
monocytic	B-X
differentiation	B-X
after	B-X
induction	B-X
with	B-X
appropriate	B-X
inducers	B-X
.	B-X
By	B-X
virtue	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
CD4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
PLB-985	B-X
cells	B-X
were	B-X
chronically	B-X
infected	B-X
with	B-X
HIV-1	B-X
strain	B-X
IIIB	B-X
.	B-X
PLB-IIIB	B-X
cells	B-X
clearly	B-X
possessed	B-X
a	B-X
more	B-X
monocytic	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
myeloblasts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
differential	B-X
staining	B-X
,	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
myeloid-specific	B-X
surface	B-X
markers	B-X
,	B-X
and	B-X
transcription	B-X
of	B-X
the	B-X
c-fms	B-X
proto-oncogene	B-X
.	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
inducible	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
in	B-X
PLB-985	B-X
.	B-X
However	B-X
,	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
,	B-X
constitutive	B-X
expression	B-X
of	B-X
a	B-X
novel	B-X
NF-kappa	B-X
B	B-X
complex	B-X
was	B-X
detected	B-X
,	B-X
composed	B-X
of	B-X
proteins	B-X
ranging	B-X
between	B-X
70	B-X
and	B-X
110	B-X
kD	B-X
.	B-X
These	B-X
proteins	B-X
interacted	B-X
specifically	B-X
with	B-X
the	B-X
symmetric	B-X
NF-kappa	B-X
B	B-X
site	B-X
from	B-X
the	B-X
interferon	B-X
beta	B-X
(	B-X
IFN-beta	B-X
)	B-X
promoter	B-X
.	B-X
Mutations	B-X
affecting	B-X
the	B-X
5	B-X
'	B-X
guanine	B-X
residues	B-X
of	B-X
the	B-X
kappa	B-X
B	B-X
site	B-X
were	B-X
unable	B-X
to	B-X
compete	B-X
for	B-X
these	B-X
NF-kappa	B-X
B-related	B-X
proteins	B-X
.	B-X
Inducibility	B-X
of	B-X
endogenous	B-X
IFN-beta	B-X
and	B-X
IFN-alpha	B-X
RNA	B-X
was	B-X
also	B-X
increased	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
HIV-1	B-X
infection	B-X
of	B-X
myelomonoblastic	B-X
cells	B-X
may	B-X
select	B-X
for	B-X
a	B-X
more	B-X
mature	B-X
monocytic	B-X
phenotype	B-X
and	B-X
that	B-X
unique	B-X
subunit	B-X
associations	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
proteins	B-X
may	B-X
contribute	B-X
to	B-X
differential	B-X
NF-kappa	B-X
B-mediated	B-X
gene	B-X
expression	B-X
.	B-X

Inducibility	O
of	O
endogenous	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
and	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
RNA	O
was	O
also	O
increased	O
in	O
PLB	O
-	O
IIIB	O
cells	O
.	O
<EOS>	B-X
PLB-985	B-X
cells	B-X
represent	B-X
a	B-X
bipotential	B-X
myelomonoblastic	B-X
cell	B-X
population	B-X
capable	B-X
of	B-X
either	B-X
granulocytic	B-X
or	B-X
monocytic	B-X
differentiation	B-X
after	B-X
induction	B-X
with	B-X
appropriate	B-X
inducers	B-X
.	B-X
By	B-X
virtue	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
CD4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
PLB-985	B-X
cells	B-X
were	B-X
chronically	B-X
infected	B-X
with	B-X
HIV-1	B-X
strain	B-X
IIIB	B-X
.	B-X
PLB-IIIB	B-X
cells	B-X
clearly	B-X
possessed	B-X
a	B-X
more	B-X
monocytic	B-X
phenotype	B-X
than	B-X
the	B-X
parental	B-X
myeloblasts	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
differential	B-X
staining	B-X
,	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
myeloid-specific	B-X
surface	B-X
markers	B-X
,	B-X
and	B-X
transcription	B-X
of	B-X
the	B-X
c-fms	B-X
proto-oncogene	B-X
.	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
was	B-X
inducible	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
in	B-X
PLB-985	B-X
.	B-X
However	B-X
,	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
,	B-X
constitutive	B-X
expression	B-X
of	B-X
a	B-X
novel	B-X
NF-kappa	B-X
B	B-X
complex	B-X
was	B-X
detected	B-X
,	B-X
composed	B-X
of	B-X
proteins	B-X
ranging	B-X
between	B-X
70	B-X
and	B-X
110	B-X
kD	B-X
.	B-X
These	B-X
proteins	B-X
interacted	B-X
specifically	B-X
with	B-X
the	B-X
symmetric	B-X
NF-kappa	B-X
B	B-X
site	B-X
from	B-X
the	B-X
interferon	B-X
beta	B-X
(	B-X
IFN-beta	B-X
)	B-X
promoter	B-X
.	B-X
Inducibility	B-X
of	B-X
endogenous	B-X
IFN-beta	B-X
and	B-X
IFN-alpha	B-X
RNA	B-X
was	B-X
also	B-X
increased	B-X
in	B-X
PLB-IIIB	B-X
cells	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
HIV-1	B-X
infection	B-X
of	B-X
myelomonoblastic	B-X
cells	B-X
may	B-X
select	B-X
for	B-X
a	B-X
more	B-X
mature	B-X
monocytic	B-X
phenotype	B-X
and	B-X
that	B-X
unique	B-X
subunit	B-X
associations	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
proteins	B-X
may	B-X
contribute	B-X
to	B-X
differential	B-X
NF-kappa	B-X
B-mediated	B-X
gene	B-X
expression	B-X
.	B-X

These	O
studies	O
indicate	O
that	O
HIV	O
-	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
may	O
select	O
for	O
a	O
more	O
mature	O
monocytic	O
phenotype	O
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
proteins	O
may	O
contribute	O
to	O
differential	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
expression	O
.	O

The	O
AP	O
-	O
1	O
site	O
at	O
-	O
150	O
bp	O
,	O
but	O
not	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
,	O
is	O
likely	O
to	O
represent	O
the	O
major	O
target	O
of	O
protein	O
kinase	O
C	O
in	O
the	O
interleukin	B-Protein
2	I-Protein
promoter	O
.	O
<EOS>	B-X
The	B-X
regulation	B-X
of	B-X
steroidogenic	B-X
acute	B-X
regulatory	B-X
protein	B-X
(	B-X
StAR	B-X
)	B-X
gene	B-X
transcription	B-X
by	B-X
cAMP-dependent	B-X
mechanisms	B-X
occurs	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
consensus	B-X
cAMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
,	B-X
TGACGTGA	B-X
)	B-X
.	B-X
This	B-X
regulation	B-X
is	B-X
coordinated	B-X
by	B-X
multiple	B-X
transcription	B-X
factors	B-X
that	B-X
bind	B-X
to	B-X
sequence-specific	B-X
elements	B-X
located	B-X
approximately	B-X
150	B-X
bp	B-X
upstream	B-X
of	B-X
the	B-X
transcription	B-X
start	B-X
site	B-X
.	B-X
Among	B-X
the	B-X
proteins	B-X
that	B-X
bind	B-X
within	B-X
this	B-X
region	B-X
,	B-X
the	B-X
basic	B-X
leucine	B-X
zipper	B-X
(	B-X
bZIP	B-X
)	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
,	B-X
i.e	B-X
.	B-X
CRE	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
/CRE	B-X
modulator	B-X
(	B-X
CREM	B-X
)	B-X
/activating	B-X
transcription	B-X
factor	B-X
(	B-X
ATF	B-X
)	B-X
,	B-X
activator	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
;	B-X
Fos/Jun	B-X
)	B-X
,	B-X
and	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
protein	B-X
beta	B-X
(	B-X
C/EBPbeta	B-X
)	B-X
,	B-X
interact	B-X
with	B-X
an	B-X
overlapping	B-X
region	B-X
(	B-X
-81/-72	B-X
bp	B-X
)	B-X
in	B-X
the	B-X
StAR	B-X
promoter	B-X
,	B-X
mediate	B-X
stimulus-transcription	B-X
coupling	B-X
of	B-X
cAMP	B-X
signaling	B-X
and	B-X
play	B-X
integral	B-X
roles	B-X
in	B-X
regulating	B-X
StAR	B-X
gene	B-X
expression	B-X
.	B-X
These	B-X
bZIP	B-X
proteins	B-X
are	B-X
structurally	B-X
similar	B-X
and	B-X
bind	B-X
to	B-X
DNA	B-X
sequences	B-X
as	B-X
dimers	B-X
;	B-X
however	B-X
,	B-X
they	B-X
exhibit	B-X
discrete	B-X
transcriptional	B-X
activities	B-X
,	B-X
interact	B-X
with	B-X
several	B-X
transcription	B-X
factors	B-X
and	B-X
other	B-X
properties	B-X
that	B-X
contribute	B-X
in	B-X
their	B-X
regulatory	B-X
functions	B-X
.	B-X
The	B-X
5'-flanking	B-X
-81/-72	B-X
bp	B-X
region	B-X
of	B-X
the	B-X
StAR	B-X
gene	B-X
appears	B-X
to	B-X
function	B-X
as	B-X
a	B-X
key	B-X
element	B-X
within	B-X
a	B-X
complex	B-X
cAMP	B-X
response	B-X
unit	B-X
by	B-X
binding	B-X
to	B-X
different	B-X
bZIP	B-X
members	B-X
,	B-X
and	B-X
the	B-X
StAR	B-X
promoter	B-X
displays	B-X
variable	B-X
states	B-X
of	B-X
cAMP	B-X
responsivity	B-X
contingent	B-X
upon	B-X
the	B-X
occupancy	B-X
of	B-X
these	B-X
cis-elements	B-X
with	B-X
these	B-X
transcription	B-X
factors	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activities	B-X
of	B-X
CREB/CREM/ATF	B-X
,	B-X
Fos/Jun	B-X
and	B-X
C/EBPbeta	B-X
have	B-X
been	B-X
demonstrated	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
a	B-X
plethora	B-X
of	B-X
extracellular	B-X
signals	B-X
,	B-X
and	B-X
the	B-X
phosphorylation	B-X
of	B-X
these	B-X
proteins	B-X
at	B-X
several	B-X
Ser	B-X
and	B-X
Thr	B-X
residues	B-X
allows	B-X
recruitment	B-X
of	B-X
the	B-X
transcriptional	B-X
coactivator	B-X
CREB	B-X
binding	B-X
protein	B-X
(	B-X
CBP	B-X
)	B-X
or	B-X
its	B-X
functional	B-X
homolog	B-X
p300	B-X
to	B-X
the	B-X
StAR	B-X
promoter	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
the	B-X
current	B-X
level	B-X
of	B-X
understanding	B-X
of	B-X
the	B-X
roles	B-X
of	B-X
selective	B-X
bZIP	B-X
family	B-X
proteins	B-X
within	B-X
the	B-X
complex	B-X
series	B-X
of	B-X
processes	B-X
involved	B-X
in	B-X
regulating	B-X
StAR	B-X
gene	B-X
transcription	B-X
.	B-X

Stimulation	O
of	O
T	O
cells	O
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	O
,	O
including	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
that	O
may	O
mediate	O
the	O
later	O
induction	O
of	O
activation	O
-	O
related	O
genes	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
antigen	B-X
results	B-X
in	B-X
activation	B-X
of	B-X
several	B-X
kinases	B-X
,	B-X
including	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
that	B-X
may	B-X
mediate	B-X
the	B-X
later	B-X
induction	B-X
of	B-X
activation-related	B-X
genes	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
PKC	B-X
in	B-X
induction	B-X
of	B-X
the	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
gene	B-X
in	B-X
T	B-X
cells	B-X
stimulated	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor/CD3	B-X
complex	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
prolonged	B-X
treatment	B-X
of	B-X
the	B-X
untransformed	B-X
T	B-X
cell	B-X
clone	B-X
Ar-5	B-X
with	B-X
phorbol	B-X
esters	B-X
results	B-X
in	B-X
downmodulation	B-X
of	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
isozymes	B-X
of	B-X
PKC	B-X
,	B-X
and	B-X
abrogates	B-X
induction	B-X
of	B-X
IL-2	B-X
mRNA	B-X
and	B-X
protein	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
phorbol	B-X
ester	B-X
treatment	B-X
also	B-X
abolishes	B-X
induction	B-X
of	B-X
chloramphenicol	B-X
acetyltransferase	B-X
activity	B-X
in	B-X
Ar-5	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
containing	B-X
the	B-X
IL-2	B-X
promoter	B-X
linked	B-X
to	B-X
this	B-X
reporter	B-X
gene	B-X
.	B-X
The	B-X
IL-2	B-X
promoter	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
nuclear	B-X
factors	B-X
including	B-X
NFAT-1	B-X
,	B-X
Oct	B-X
,	B-X
NF-kappa	B-X
B	B-X
,	B-X
and	B-X
AP-1	B-X
,	B-X
which	B-X
are	B-X
all	B-X
potentially	B-X
sensitive	B-X
to	B-X
activation	B-X
of	B-X
PKC	B-X
.	B-X
We	B-X
show	B-X
that	B-X
induction	B-X
of	B-X
a	B-X
trimer	B-X
of	B-X
the	B-X
NFAT	B-X
and	B-X
Oct	B-X
sites	B-X
is	B-X
not	B-X
sensitive	B-X
to	B-X
phorbol	B-X
ester	B-X
treatment	B-X
,	B-X
and	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
NF-kappa	B-X
B	B-X
site	B-X
have	B-X
no	B-X
effect	B-X
on	B-X
inducibility	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
mutations	B-X
in	B-X
the	B-X
AP-1	B-X
site	B-X
located	B-X
at	B-X
-150	B-X
bp	B-X
almost	B-X
completely	B-X
abrogate	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
,	B-X
and	B-X
appearance	B-X
of	B-X
an	B-X
inducible	B-X
nuclear	B-X
factor	B-X
binding	B-X
to	B-X
this	B-X
site	B-X
is	B-X
sensitive	B-X
to	B-X
PKC	B-X
depletion	B-X
.	B-X
Moreover	B-X
,	B-X
cotransfections	B-X
with	B-X
c-fos	B-X
and	B-X
c-jun	B-X
expression	B-X
plasmids	B-X
markedly	B-X
enhance	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
in	B-X
minimally	B-X
stimulated	B-X
T	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
AP-1	B-X
site	B-X
at	B-X
-150	B-X
bp	B-X
represents	B-X
a	B-X
major	B-X
,	B-X
if	B-X
not	B-X
the	B-X
only	B-X
,	B-X
site	B-X
of	B-X
PKC	B-X
responsiveness	B-X
in	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X

We	O
have	O
examined	O
the	O
potential	O
role	O
of	O
PKC	O
in	O
induction	O
of	O
the	O
interleukin	B-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
gene	O
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T	O
cell	O
receptor	O
/	O
CD3	O
complex	O
.	O

We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	O
cell	O
clone	O
Ar	O
-	O
5	O
with	O
phorbol	O
esters	O
results	O
in	O
downmodulation	O
of	O
the	O
alpha	O
and	O
beta	O
isozymes	O
of	O
PKC	O
,	O
and	O
abrogates	O
induction	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
mRNA	O
and	O
protein	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
antigen	B-X
results	B-X
in	B-X
activation	B-X
of	B-X
several	B-X
kinases	B-X
,	B-X
including	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
that	B-X
may	B-X
mediate	B-X
the	B-X
later	B-X
induction	B-X
of	B-X
activation-related	B-X
genes	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
PKC	B-X
in	B-X
induction	B-X
of	B-X
the	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
gene	B-X
in	B-X
T	B-X
cells	B-X
stimulated	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor/CD3	B-X
complex	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
prolonged	B-X
treatment	B-X
of	B-X
the	B-X
untransformed	B-X
T	B-X
cell	B-X
clone	B-X
Ar-5	B-X
with	B-X
phorbol	B-X
esters	B-X
results	B-X
in	B-X
downmodulation	B-X
of	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
isozymes	B-X
of	B-X
PKC	B-X
,	B-X
and	B-X
abrogates	B-X
induction	B-X
of	B-X
IL-2	B-X
mRNA	B-X
and	B-X
protein	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
phorbol	B-X
ester	B-X
treatment	B-X
also	B-X
abolishes	B-X
induction	B-X
of	B-X
chloramphenicol	B-X
acetyltransferase	B-X
activity	B-X
in	B-X
Ar-5	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
containing	B-X
the	B-X
IL-2	B-X
promoter	B-X
linked	B-X
to	B-X
this	B-X
reporter	B-X
gene	B-X
.	B-X
The	B-X
IL-2	B-X
promoter	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
nuclear	B-X
factors	B-X
including	B-X
NFAT-1	B-X
,	B-X
Oct	B-X
,	B-X
NF-kappa	B-X
B	B-X
,	B-X
and	B-X
AP-1	B-X
,	B-X
which	B-X
are	B-X
all	B-X
potentially	B-X
sensitive	B-X
to	B-X
activation	B-X
of	B-X
PKC	B-X
.	B-X
We	B-X
show	B-X
that	B-X
induction	B-X
of	B-X
a	B-X
trimer	B-X
of	B-X
the	B-X
NFAT	B-X
and	B-X
Oct	B-X
sites	B-X
is	B-X
not	B-X
sensitive	B-X
to	B-X
phorbol	B-X
ester	B-X
treatment	B-X
,	B-X
and	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
NF-kappa	B-X
B	B-X
site	B-X
have	B-X
no	B-X
effect	B-X
on	B-X
inducibility	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
mutations	B-X
in	B-X
the	B-X
AP-1	B-X
site	B-X
located	B-X
at	B-X
-150	B-X
bp	B-X
almost	B-X
completely	B-X
abrogate	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
,	B-X
and	B-X
appearance	B-X
of	B-X
an	B-X
inducible	B-X
nuclear	B-X
factor	B-X
binding	B-X
to	B-X
this	B-X
site	B-X
is	B-X
sensitive	B-X
to	B-X
PKC	B-X
depletion	B-X
.	B-X
Moreover	B-X
,	B-X
cotransfections	B-X
with	B-X
c-fos	B-X
and	B-X
c-jun	B-X
expression	B-X
plasmids	B-X
markedly	B-X
enhance	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
in	B-X
minimally	B-X
stimulated	B-X
T	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
AP-1	B-X
site	B-X
at	B-X
-150	B-X
bp	B-X
represents	B-X
a	B-X
major	B-X
,	B-X
if	B-X
not	B-X
the	B-X
only	B-X
,	B-X
site	B-X
of	B-X
PKC	B-X
responsiveness	B-X
in	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X

Here	O
we	O
show	O
that	O
phorbol	O
ester	O
treatment	O
also	O
abolishes	O
induction	O
of	O
chloramphenicol	B-Protein
acetyltransferase	I-Protein
activity	O
in	O
Ar	O
-	O
5	O
cells	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
linked	O
to	O
this	O
reporter	O
gene	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
antigen	B-X
results	B-X
in	B-X
activation	B-X
of	B-X
several	B-X
kinases	B-X
,	B-X
including	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
that	B-X
may	B-X
mediate	B-X
the	B-X
later	B-X
induction	B-X
of	B-X
activation-related	B-X
genes	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
PKC	B-X
in	B-X
induction	B-X
of	B-X
the	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
gene	B-X
in	B-X
T	B-X
cells	B-X
stimulated	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor/CD3	B-X
complex	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
prolonged	B-X
treatment	B-X
of	B-X
the	B-X
untransformed	B-X
T	B-X
cell	B-X
clone	B-X
Ar-5	B-X
with	B-X
phorbol	B-X
esters	B-X
results	B-X
in	B-X
downmodulation	B-X
of	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
isozymes	B-X
of	B-X
PKC	B-X
,	B-X
and	B-X
abrogates	B-X
induction	B-X
of	B-X
IL-2	B-X
mRNA	B-X
and	B-X
protein	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
phorbol	B-X
ester	B-X
treatment	B-X
also	B-X
abolishes	B-X
induction	B-X
of	B-X
chloramphenicol	B-X
acetyltransferase	B-X
activity	B-X
in	B-X
Ar-5	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
containing	B-X
the	B-X
IL-2	B-X
promoter	B-X
linked	B-X
to	B-X
this	B-X
reporter	B-X
gene	B-X
.	B-X
The	B-X
IL-2	B-X
promoter	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
nuclear	B-X
factors	B-X
including	B-X
NFAT-1	B-X
,	B-X
Oct	B-X
,	B-X
NF-kappa	B-X
B	B-X
,	B-X
and	B-X
AP-1	B-X
,	B-X
which	B-X
are	B-X
all	B-X
potentially	B-X
sensitive	B-X
to	B-X
activation	B-X
of	B-X
PKC	B-X
.	B-X
We	B-X
show	B-X
that	B-X
induction	B-X
of	B-X
a	B-X
trimer	B-X
of	B-X
the	B-X
NFAT	B-X
and	B-X
Oct	B-X
sites	B-X
is	B-X
not	B-X
sensitive	B-X
to	B-X
phorbol	B-X
ester	B-X
treatment	B-X
,	B-X
and	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
NF-kappa	B-X
B	B-X
site	B-X
have	B-X
no	B-X
effect	B-X
on	B-X
inducibility	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
mutations	B-X
in	B-X
the	B-X
AP-1	B-X
site	B-X
located	B-X
at	B-X
-150	B-X
bp	B-X
almost	B-X
completely	B-X
abrogate	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
,	B-X
and	B-X
appearance	B-X
of	B-X
an	B-X
inducible	B-X
nuclear	B-X
factor	B-X
binding	B-X
to	B-X
this	B-X
site	B-X
is	B-X
sensitive	B-X
to	B-X
PKC	B-X
depletion	B-X
.	B-X
Moreover	B-X
,	B-X
cotransfections	B-X
with	B-X
c-fos	B-X
and	B-X
c-jun	B-X
expression	B-X
plasmids	B-X
markedly	B-X
enhance	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
in	B-X
minimally	B-X
stimulated	B-X
T	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
AP-1	B-X
site	B-X
at	B-X
-150	B-X
bp	B-X
represents	B-X
a	B-X
major	B-X
,	B-X
if	B-X
not	B-X
the	B-X
only	B-X
,	B-X
site	B-X
of	B-X
PKC	B-X
responsiveness	B-X
in	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X

The	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factors	O
including	O
NFAT	B-Protein
-	I-Protein
1	I-Protein
,	O
Oct	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
AP	O
-	O
1	O
,	O
which	O
are	O
all	O
potentially	O
sensitive	O
to	O
activation	O
of	O
PKC	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
antigen	B-X
results	B-X
in	B-X
activation	B-X
of	B-X
several	B-X
kinases	B-X
,	B-X
including	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
that	B-X
may	B-X
mediate	B-X
the	B-X
later	B-X
induction	B-X
of	B-X
activation-related	B-X
genes	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
PKC	B-X
in	B-X
induction	B-X
of	B-X
the	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
gene	B-X
in	B-X
T	B-X
cells	B-X
stimulated	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor/CD3	B-X
complex	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
prolonged	B-X
treatment	B-X
of	B-X
the	B-X
untransformed	B-X
T	B-X
cell	B-X
clone	B-X
Ar-5	B-X
with	B-X
phorbol	B-X
esters	B-X
results	B-X
in	B-X
downmodulation	B-X
of	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
isozymes	B-X
of	B-X
PKC	B-X
,	B-X
and	B-X
abrogates	B-X
induction	B-X
of	B-X
IL-2	B-X
mRNA	B-X
and	B-X
protein	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
phorbol	B-X
ester	B-X
treatment	B-X
also	B-X
abolishes	B-X
induction	B-X
of	B-X
chloramphenicol	B-X
acetyltransferase	B-X
activity	B-X
in	B-X
Ar-5	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
containing	B-X
the	B-X
IL-2	B-X
promoter	B-X
linked	B-X
to	B-X
this	B-X
reporter	B-X
gene	B-X
.	B-X
The	B-X
IL-2	B-X
promoter	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
nuclear	B-X
factors	B-X
including	B-X
NFAT-1	B-X
,	B-X
Oct	B-X
,	B-X
NF-kappa	B-X
B	B-X
,	B-X
and	B-X
AP-1	B-X
,	B-X
which	B-X
are	B-X
all	B-X
potentially	B-X
sensitive	B-X
to	B-X
activation	B-X
of	B-X
PKC	B-X
.	B-X
We	B-X
show	B-X
that	B-X
induction	B-X
of	B-X
a	B-X
trimer	B-X
of	B-X
the	B-X
NFAT	B-X
and	B-X
Oct	B-X
sites	B-X
is	B-X
not	B-X
sensitive	B-X
to	B-X
phorbol	B-X
ester	B-X
treatment	B-X
,	B-X
and	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
NF-kappa	B-X
B	B-X
site	B-X
have	B-X
no	B-X
effect	B-X
on	B-X
inducibility	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
mutations	B-X
in	B-X
the	B-X
AP-1	B-X
site	B-X
located	B-X
at	B-X
-150	B-X
bp	B-X
almost	B-X
completely	B-X
abrogate	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
,	B-X
and	B-X
appearance	B-X
of	B-X
an	B-X
inducible	B-X
nuclear	B-X
factor	B-X
binding	B-X
to	B-X
this	B-X
site	B-X
is	B-X
sensitive	B-X
to	B-X
PKC	B-X
depletion	B-X
.	B-X
Moreover	B-X
,	B-X
cotransfections	B-X
with	B-X
c-fos	B-X
and	B-X
c-jun	B-X
expression	B-X
plasmids	B-X
markedly	B-X
enhance	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
in	B-X
minimally	B-X
stimulated	B-X
T	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
AP-1	B-X
site	B-X
at	B-X
-150	B-X
bp	B-X
represents	B-X
a	B-X
major	B-X
,	B-X
if	B-X
not	B-X
the	B-X
only	B-X
,	B-X
site	B-X
of	B-X
PKC	B-X
responsiveness	B-X
in	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X

We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	O
and	O
Oct	O
sites	O
is	O
not	O
sensitive	O
to	O
phorbol	O
ester	O
treatment	O
,	O
and	O
that	O
mutations	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
have	O
no	O
effect	O
on	O
inducibility	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
.	O

In	O
contrast	O
,	O
mutations	O
in	O
the	O
AP	O
-	O
1	O
site	O
located	O
at	O
-	O
150	O
bp	O
almost	O
completely	O
abrogate	O
induction	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
,	O
and	O
appearance	O
of	O
an	O
inducible	O
nuclear	O
factor	O
binding	O
to	O
this	O
site	O
is	O
sensitive	O
to	O
PKC	O
depletion	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
antigen	B-X
results	B-X
in	B-X
activation	B-X
of	B-X
several	B-X
kinases	B-X
,	B-X
including	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
that	B-X
may	B-X
mediate	B-X
the	B-X
later	B-X
induction	B-X
of	B-X
activation-related	B-X
genes	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
PKC	B-X
in	B-X
induction	B-X
of	B-X
the	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
gene	B-X
in	B-X
T	B-X
cells	B-X
stimulated	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor/CD3	B-X
complex	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
prolonged	B-X
treatment	B-X
of	B-X
the	B-X
untransformed	B-X
T	B-X
cell	B-X
clone	B-X
Ar-5	B-X
with	B-X
phorbol	B-X
esters	B-X
results	B-X
in	B-X
downmodulation	B-X
of	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
isozymes	B-X
of	B-X
PKC	B-X
,	B-X
and	B-X
abrogates	B-X
induction	B-X
of	B-X
IL-2	B-X
mRNA	B-X
and	B-X
protein	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
phorbol	B-X
ester	B-X
treatment	B-X
also	B-X
abolishes	B-X
induction	B-X
of	B-X
chloramphenicol	B-X
acetyltransferase	B-X
activity	B-X
in	B-X
Ar-5	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
containing	B-X
the	B-X
IL-2	B-X
promoter	B-X
linked	B-X
to	B-X
this	B-X
reporter	B-X
gene	B-X
.	B-X
The	B-X
IL-2	B-X
promoter	B-X
contains	B-X
binding	B-X
sites	B-X
for	B-X
nuclear	B-X
factors	B-X
including	B-X
NFAT-1	B-X
,	B-X
Oct	B-X
,	B-X
NF-kappa	B-X
B	B-X
,	B-X
and	B-X
AP-1	B-X
,	B-X
which	B-X
are	B-X
all	B-X
potentially	B-X
sensitive	B-X
to	B-X
activation	B-X
of	B-X
PKC	B-X
.	B-X
We	B-X
show	B-X
that	B-X
induction	B-X
of	B-X
a	B-X
trimer	B-X
of	B-X
the	B-X
NFAT	B-X
and	B-X
Oct	B-X
sites	B-X
is	B-X
not	B-X
sensitive	B-X
to	B-X
phorbol	B-X
ester	B-X
treatment	B-X
,	B-X
and	B-X
that	B-X
mutations	B-X
in	B-X
the	B-X
NF-kappa	B-X
B	B-X
site	B-X
have	B-X
no	B-X
effect	B-X
on	B-X
inducibility	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
mutations	B-X
in	B-X
the	B-X
AP-1	B-X
site	B-X
located	B-X
at	B-X
-150	B-X
bp	B-X
almost	B-X
completely	B-X
abrogate	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
,	B-X
and	B-X
appearance	B-X
of	B-X
an	B-X
inducible	B-X
nuclear	B-X
factor	B-X
binding	B-X
to	B-X
this	B-X
site	B-X
is	B-X
sensitive	B-X
to	B-X
PKC	B-X
depletion	B-X
.	B-X
Moreover	B-X
,	B-X
cotransfections	B-X
with	B-X
c-fos	B-X
and	B-X
c-jun	B-X
expression	B-X
plasmids	B-X
markedly	B-X
enhance	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
in	B-X
minimally	B-X
stimulated	B-X
T	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
AP-1	B-X
site	B-X
at	B-X
-150	B-X
bp	B-X
represents	B-X
a	B-X
major	B-X
,	B-X
if	B-X
not	B-X
the	B-X
only	B-X
,	B-X
site	B-X
of	B-X
PKC	B-X
responsiveness	B-X
in	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X

Moreover	O
,	O
cotransfections	O
with	O
c	B-Protein
-	I-Protein
fos	I-Protein
and	O
c	B-Protein
-	I-Protein
jun	I-Protein
expression	O
plasmids	O
markedly	O
enhance	O
induction	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
in	O
minimally	O
stimulated	O
T	O
cells	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
AP	O
-	O
1	O
site	O
at	O
-	O
150	O
bp	O
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	O
responsiveness	O
in	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
.	O

The	O
role	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
in	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O
<EOS>	B-X
Terminal	B-X
differentiation	B-X
of	B-X
the	B-X
leukemic	B-X
cell	B-X
lines	B-X
U-937	B-X
and	B-X
HL-60	B-X
by	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
is	B-X
accompanied	B-X
by	B-X
marked	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
family	B-X
members	B-X
is	B-X
induced	B-X
with	B-X
variable	B-X
kinetics	B-X
during	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
induced	B-X
differentiation	B-X
,	B-X
with	B-X
c-jun	B-X
expression	B-X
best	B-X
paralleling	B-X
differentiation	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
AP-1	B-X
complexes	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
DNA	B-X
binding	B-X
activity	B-X
,	B-X
closely	B-X
parallels	B-X
morphological	B-X
differentiation	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
complexes	B-X
to	B-X
regulate	B-X
gene	B-X
expression	B-X
is	B-X
demonstrated	B-X
by	B-X
increased	B-X
transcription	B-X
from	B-X
an	B-X
AP-1	B-X
driven	B-X
reporter	B-X
construct	B-X
and	B-X
marked	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
AP-1	B-X
regulated	B-X
genes	B-X
.	B-X
Differentiation	B-X
assays	B-X
using	B-X
water	B-X
soluble	B-X
phorbol	B-X
esters	B-X
reveal	B-X
that	B-X
differentiation	B-X
becomes	B-X
irreversible	B-X
soon	B-X
after	B-X
AP-1	B-X
appears	B-X
.	B-X
This	B-X
tight	B-X
correlation	B-X
between	B-X
c-jun	B-X
expression	B-X
,	B-X
the	B-X
generation	B-X
of	B-X
AP-1	B-X
activity	B-X
,	B-X
and	B-X
differentiation	B-X
suggests	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
this	B-X
gene	B-X
and	B-X
transcriptional	B-X
complex	B-X
during	B-X
this	B-X
process	B-X
.	B-X

Terminal	O
differentiation	O
of	O
the	O
leukemic	O
cell	O
lines	O
U	O
-	O
937	O
and	O
HL	O
-	O
60	O
by	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O
<EOS>	B-X
Terminal	B-X
differentiation	B-X
of	B-X
the	B-X
leukemic	B-X
cell	B-X
lines	B-X
U-937	B-X
and	B-X
HL-60	B-X
by	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
is	B-X
accompanied	B-X
by	B-X
marked	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
family	B-X
members	B-X
is	B-X
induced	B-X
with	B-X
variable	B-X
kinetics	B-X
during	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
induced	B-X
differentiation	B-X
,	B-X
with	B-X
c-jun	B-X
expression	B-X
best	B-X
paralleling	B-X
differentiation	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
AP-1	B-X
complexes	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
DNA	B-X
binding	B-X
activity	B-X
,	B-X
closely	B-X
parallels	B-X
morphological	B-X
differentiation	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
complexes	B-X
to	B-X
regulate	B-X
gene	B-X
expression	B-X
is	B-X
demonstrated	B-X
by	B-X
increased	B-X
transcription	B-X
from	B-X
an	B-X
AP-1	B-X
driven	B-X
reporter	B-X
construct	B-X
and	B-X
marked	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
AP-1	B-X
regulated	B-X
genes	B-X
.	B-X
Differentiation	B-X
assays	B-X
using	B-X
water	B-X
soluble	B-X
phorbol	B-X
esters	B-X
reveal	B-X
that	B-X
differentiation	B-X
becomes	B-X
irreversible	B-X
soon	B-X
after	B-X
AP-1	B-X
appears	B-X
.	B-X
This	B-X
tight	B-X
correlation	B-X
between	B-X
c-jun	B-X
expression	B-X
,	B-X
the	B-X
generation	B-X
of	B-X
AP-1	B-X
activity	B-X
,	B-X
and	B-X
differentiation	B-X
suggests	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
this	B-X
gene	B-X
and	B-X
transcriptional	B-X
complex	B-X
during	B-X
this	B-X
process	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
is	O
induced	O
with	O
variable	O
kinetics	O
during	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
induced	O
differentiation	O
,	O
with	O
c	B-Protein
-	I-Protein
jun	I-Protein
expression	O
best	O
paralleling	O
differentiation	O
.	O

The	O
generation	O
of	O
AP	O
-	O
1	O
complexes	O
,	O
as	O
measured	O
by	O
DNA	O
binding	O
activity	O
,	O
closely	O
parallels	O
morphological	O
differentiation	O
.	O
<EOS>	B-X
Terminal	B-X
differentiation	B-X
of	B-X
the	B-X
leukemic	B-X
cell	B-X
lines	B-X
U-937	B-X
and	B-X
HL-60	B-X
by	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
is	B-X
accompanied	B-X
by	B-X
marked	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
family	B-X
members	B-X
is	B-X
induced	B-X
with	B-X
variable	B-X
kinetics	B-X
during	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
induced	B-X
differentiation	B-X
,	B-X
with	B-X
c-jun	B-X
expression	B-X
best	B-X
paralleling	B-X
differentiation	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
AP-1	B-X
complexes	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
DNA	B-X
binding	B-X
activity	B-X
,	B-X
closely	B-X
parallels	B-X
morphological	B-X
differentiation	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
complexes	B-X
to	B-X
regulate	B-X
gene	B-X
expression	B-X
is	B-X
demonstrated	B-X
by	B-X
increased	B-X
transcription	B-X
from	B-X
an	B-X
AP-1	B-X
driven	B-X
reporter	B-X
construct	B-X
and	B-X
marked	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
AP-1	B-X
regulated	B-X
genes	B-X
.	B-X
Differentiation	B-X
assays	B-X
using	B-X
water	B-X
soluble	B-X
phorbol	B-X
esters	B-X
reveal	B-X
that	B-X
differentiation	B-X
becomes	B-X
irreversible	B-X
soon	B-X
after	B-X
AP-1	B-X
appears	B-X
.	B-X
This	B-X
tight	B-X
correlation	B-X
between	B-X
c-jun	B-X
expression	B-X
,	B-X
the	B-X
generation	B-X
of	B-X
AP-1	B-X
activity	B-X
,	B-X
and	B-X
differentiation	B-X
suggests	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
this	B-X
gene	B-X
and	B-X
transcriptional	B-X
complex	B-X
during	B-X
this	B-X
process	B-X
.	B-X

Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP	O
-	O
1	O
driven	O
reporter	O
construct	O
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	O
AP	O
-	O
1	O
regulated	O
genes	O
.	O
<EOS>	B-X
Terminal	B-X
differentiation	B-X
of	B-X
the	B-X
leukemic	B-X
cell	B-X
lines	B-X
U-937	B-X
and	B-X
HL-60	B-X
by	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
is	B-X
accompanied	B-X
by	B-X
marked	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
family	B-X
members	B-X
is	B-X
induced	B-X
with	B-X
variable	B-X
kinetics	B-X
during	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
induced	B-X
differentiation	B-X
,	B-X
with	B-X
c-jun	B-X
expression	B-X
best	B-X
paralleling	B-X
differentiation	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
AP-1	B-X
complexes	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
DNA	B-X
binding	B-X
activity	B-X
,	B-X
closely	B-X
parallels	B-X
morphological	B-X
differentiation	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
complexes	B-X
to	B-X
regulate	B-X
gene	B-X
expression	B-X
is	B-X
demonstrated	B-X
by	B-X
increased	B-X
transcription	B-X
from	B-X
an	B-X
AP-1	B-X
driven	B-X
reporter	B-X
construct	B-X
and	B-X
marked	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
AP-1	B-X
regulated	B-X
genes	B-X
.	B-X
Differentiation	B-X
assays	B-X
using	B-X
water	B-X
soluble	B-X
phorbol	B-X
esters	B-X
reveal	B-X
that	B-X
differentiation	B-X
becomes	B-X
irreversible	B-X
soon	B-X
after	B-X
AP-1	B-X
appears	B-X
.	B-X
This	B-X
tight	B-X
correlation	B-X
between	B-X
c-jun	B-X
expression	B-X
,	B-X
the	B-X
generation	B-X
of	B-X
AP-1	B-X
activity	B-X
,	B-X
and	B-X
differentiation	B-X
suggests	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
this	B-X
gene	B-X
and	B-X
transcriptional	B-X
complex	B-X
during	B-X
this	B-X
process	B-X
.	B-X

Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP	O
-	O
1	O
appears	O
.	O
<EOS>	B-X
Terminal	B-X
differentiation	B-X
of	B-X
the	B-X
leukemic	B-X
cell	B-X
lines	B-X
U-937	B-X
and	B-X
HL-60	B-X
by	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
is	B-X
accompanied	B-X
by	B-X
marked	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
family	B-X
members	B-X
is	B-X
induced	B-X
with	B-X
variable	B-X
kinetics	B-X
during	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
induced	B-X
differentiation	B-X
,	B-X
with	B-X
c-jun	B-X
expression	B-X
best	B-X
paralleling	B-X
differentiation	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
AP-1	B-X
complexes	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
DNA	B-X
binding	B-X
activity	B-X
,	B-X
closely	B-X
parallels	B-X
morphological	B-X
differentiation	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
complexes	B-X
to	B-X
regulate	B-X
gene	B-X
expression	B-X
is	B-X
demonstrated	B-X
by	B-X
increased	B-X
transcription	B-X
from	B-X
an	B-X
AP-1	B-X
driven	B-X
reporter	B-X
construct	B-X
and	B-X
marked	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
AP-1	B-X
regulated	B-X
genes	B-X
.	B-X
Differentiation	B-X
assays	B-X
using	B-X
water	B-X
soluble	B-X
phorbol	B-X
esters	B-X
reveal	B-X
that	B-X
differentiation	B-X
becomes	B-X
irreversible	B-X
soon	B-X
after	B-X
AP-1	B-X
appears	B-X
.	B-X
This	B-X
tight	B-X
correlation	B-X
between	B-X
c-jun	B-X
expression	B-X
,	B-X
the	B-X
generation	B-X
of	B-X
AP-1	B-X
activity	B-X
,	B-X
and	B-X
differentiation	B-X
suggests	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
this	B-X
gene	B-X
and	B-X
transcriptional	B-X
complex	B-X
during	B-X
this	B-X
process	B-X
.	B-X

This	O
tight	O
correlation	O
between	O
c	B-Protein
-	I-Protein
jun	I-Protein
expression	O
,	O
the	O
generation	O
of	O
AP	O
-	O
1	O
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	O
complex	O
during	O
this	O
process	O
.	O
<EOS>	B-X
Terminal	B-X
differentiation	B-X
of	B-X
the	B-X
leukemic	B-X
cell	B-X
lines	B-X
U-937	B-X
and	B-X
HL-60	B-X
by	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
is	B-X
accompanied	B-X
by	B-X
marked	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
family	B-X
members	B-X
is	B-X
induced	B-X
with	B-X
variable	B-X
kinetics	B-X
during	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
induced	B-X
differentiation	B-X
,	B-X
with	B-X
c-jun	B-X
expression	B-X
best	B-X
paralleling	B-X
differentiation	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
AP-1	B-X
complexes	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
DNA	B-X
binding	B-X
activity	B-X
,	B-X
closely	B-X
parallels	B-X
morphological	B-X
differentiation	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
complexes	B-X
to	B-X
regulate	B-X
gene	B-X
expression	B-X
is	B-X
demonstrated	B-X
by	B-X
increased	B-X
transcription	B-X
from	B-X
an	B-X
AP-1	B-X
driven	B-X
reporter	B-X
construct	B-X
and	B-X
marked	B-X
increases	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
endogenous	B-X
AP-1	B-X
regulated	B-X
genes	B-X
.	B-X
Differentiation	B-X
assays	B-X
using	B-X
water	B-X
soluble	B-X
phorbol	B-X
esters	B-X
reveal	B-X
that	B-X
differentiation	B-X
becomes	B-X
irreversible	B-X
soon	B-X
after	B-X
AP-1	B-X
appears	B-X
.	B-X
This	B-X
tight	B-X
correlation	B-X
between	B-X
c-jun	B-X
expression	B-X
,	B-X
the	B-X
generation	B-X
of	B-X
AP-1	B-X
activity	B-X
,	B-X
and	B-X
differentiation	B-X
suggests	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
this	B-X
gene	B-X
and	B-X
transcriptional	B-X
complex	B-X
during	B-X
this	B-X
process	B-X
.	B-X

Characterization	O
of	O
a	O
cofactor	O
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	O
homeodomain	O
protein	O
.	O
<EOS>	B-X
Hepatocyte	B-X
nuclear	B-X
factor-1	B-X
alpha	B-X
(	B-X
HNF-1	B-X
alpha	B-X
)	B-X
is	B-X
a	B-X
homeodomain-containing	B-X
protein	B-X
that	B-X
functions	B-X
as	B-X
a	B-X
dimer	B-X
.	B-X
A	B-X
dimerization	B-X
cofactor	B-X
of	B-X
HNF-1	B-X
alpha	B-X
(	B-X
DCoH	B-X
)	B-X
was	B-X
identified	B-X
that	B-X
displayed	B-X
a	B-X
restricted	B-X
tissue	B-X
distribution	B-X
and	B-X
did	B-X
not	B-X
bind	B-X
to	B-X
DNA	B-X
,	B-X
but	B-X
,	B-X
rather	B-X
,	B-X
selectively	B-X
stabilized	B-X
HNF-1	B-X
alpha	B-X
dimers	B-X
.	B-X
The	B-X
formation	B-X
of	B-X
a	B-X
stable	B-X
tetrameric	B-X
DCoH-HNF-1	B-X
alpha	B-X
complex	B-X
,	B-X
which	B-X
required	B-X
the	B-X
dimerization	B-X
domain	B-X
of	B-X
HNF-1	B-X
alpha	B-X
,	B-X
did	B-X
not	B-X
change	B-X
the	B-X
DNA	B-X
binding	B-X
characteristics	B-X
of	B-X
HNF-1	B-X
alpha	B-X
,	B-X
but	B-X
enhanced	B-X
its	B-X
transcriptional	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
DCoH	B-X
regulates	B-X
formation	B-X
of	B-X
transcriptionally	B-X
active	B-X
tetrameric	B-X
complexes	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
developmental	B-X
specificity	B-X
of	B-X
the	B-X
complex	B-X
.	B-X

Dimerization	O
among	O
transcription	O
factors	O
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O
<EOS>	B-X
Dimerization	B-X
among	B-X
transcription	B-X
factors	B-X
has	B-X
become	B-X
a	B-X
recurrent	B-X
theme	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
eukaryotic	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
formation	B-X
of	B-X
a	B-X
stable	B-X
tetrameric	B-X
DCoH-HNF-1	B-X
alpha	B-X
complex	B-X
,	B-X
which	B-X
required	B-X
the	B-X
dimerization	B-X
domain	B-X
of	B-X
HNF-1	B-X
alpha	B-X
,	B-X
did	B-X
not	B-X
change	B-X
the	B-X
DNA	B-X
binding	B-X
characteristics	B-X
of	B-X
HNF-1	B-X
alpha	B-X
,	B-X
but	B-X
enhanced	B-X
its	B-X
transcriptional	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
DCoH	B-X
did	B-X
not	B-X
confer	B-X
transcriptional	B-X
activation	B-X
to	B-X
the	B-X
GAL4	B-X
DNA	B-X
binding	B-X
domain	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
DCoH	B-X
regulates	B-X
formation	B-X
of	B-X
transcriptionally	B-X
active	B-X
tetrameric	B-X
complexes	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
developmental	B-X
specificity	B-X
of	B-X
the	B-X
complex	B-X
.	B-X

Hepatocyte	B-Protein
nuclear	I-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
(	O
HNF	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
)	O
is	O
a	O
homeodomain	O
-	O
containing	O
protein	O
that	O
functions	O
as	O
a	O
dimer	O
.	O
<EOS>	B-X
Hepatocyte	B-X
nuclear	B-X
factors	B-X
1	B-X
alpha	B-X
and	B-X
1	B-X
beta	B-X
(	B-X
HNF-1	B-X
alpha	B-X
and	B-X
HNF-1	B-X
beta	B-X
)	B-X
are	B-X
homologous	B-X
homeodomain-containing	B-X
transcription	B-X
factors	B-X
that	B-X
form	B-X
homodimers	B-X
or	B-X
heterodimers	B-X
that	B-X
bind	B-X
the	B-X
same	B-X
consensus	B-X
sequence	B-X
in	B-X
the	B-X
promoters	B-X
of	B-X
several	B-X
genes	B-X
expressed	B-X
in	B-X
liver	B-X
.	B-X
Many	B-X
of	B-X
these	B-X
genes	B-X
,	B-X
including	B-X
the	B-X
mouse	B-X
alpha-fetoprotein	B-X
(	B-X
AFP	B-X
)	B-X
gene	B-X
,	B-X
are	B-X
also	B-X
expressed	B-X
in	B-X
the	B-X
intestinal	B-X
epithelium	B-X
.	B-X
AFP	B-X
expression	B-X
is	B-X
restricted	B-X
to	B-X
the	B-X
enteroendocrine	B-X
cell	B-X
lineage	B-X
in	B-X
the	B-X
adult	B-X
small	B-X
intestine	B-X
,	B-X
and	B-X
we	B-X
have	B-X
investigated	B-X
the	B-X
distribution	B-X
of	B-X
HNF-1	B-X
alpha	B-X
and	B-X
HNF-1	B-X
beta	B-X
mRNA	B-X
in	B-X
the	B-X
mouse	B-X
intestine	B-X
to	B-X
determine	B-X
whether	B-X
expression	B-X
of	B-X
either	B-X
of	B-X
these	B-X
regulatory	B-X
factors	B-X
colocalizes	B-X
with	B-X
AFP	B-X
.	B-X
We	B-X
found	B-X
that	B-X
transcripts	B-X
encoding	B-X
both	B-X
factors	B-X
are	B-X
expressed	B-X
at	B-X
the	B-X
highest	B-X
levels	B-X
in	B-X
crypts	B-X
of	B-X
small	B-X
and	B-X
large	B-X
intestine	B-X
.	B-X
Quantitation	B-X
shows	B-X
that	B-X
the	B-X
relative	B-X
ratio	B-X
of	B-X
HNF-1	B-X
alpha	B-X
to	B-X
HNF-1	B-X
beta	B-X
mRNAs	B-X
appears	B-X
lower	B-X
in	B-X
the	B-X
colon	B-X
,	B-X
where	B-X
AFP	B-X
is	B-X
not	B-X
expressed	B-X
.	B-X
Alterations	B-X
in	B-X
the	B-X
ratio	B-X
of	B-X
HNF-1	B-X
alpha	B-X
to	B-X
HNF-1	B-X
beta	B-X
along	B-X
the	B-X
length	B-X
of	B-X
the	B-X
intestine	B-X
may	B-X
influence	B-X
HNF-1	B-X
dimer	B-X
formation	B-X
and	B-X
expression	B-X
of	B-X
target	B-X
genes	B-X
.	B-X
Although	B-X
HNF-1	B-X
is	B-X
necessary	B-X
for	B-X
transcription	B-X
of	B-X
the	B-X
AFP	B-X
gene	B-X
,	B-X
other	B-X
factors	B-X
must	B-X
be	B-X
involved	B-X
in	B-X
eliciting	B-X
the	B-X
cell	B-X
type-specific	B-X
pattern	B-X
of	B-X
AFP	B-X
expression	B-X
in	B-X
the	B-X
intestine	B-X
.	B-X

A	O
dimerization	B-Protein
cofactor	I-Protein
of	I-Protein
HNF	I-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
(	O
DCoH	B-Protein
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	O
bind	O
to	O
DNA	O
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
dimers	O
.	O

The	O
formation	O
of	O
a	O
stable	O
tetrameric	O
DCoH	B-Protein
-	O
HNF	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
complex	O
,	O
which	O
required	O
the	O
dimerization	O
domain	O
of	O
HNF	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
,	O
did	O
not	O
change	O
the	O
DNA	O
binding	O
characteristics	O
of	O
HNF	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O

However	O
,	O
DCoH	B-Protein
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
.	O
<EOS>	B-X
The	B-X
bifunctional	B-X
protein	B-X
PCD/DCoH	B-X
is	B-X
both	B-X
an	B-X
enzyme	B-X
involved	B-X
in	B-X
the	B-X
phenylalanine	B-X
hydroxylation	B-X
system	B-X
and	B-X
a	B-X
transcription	B-X
coactivator	B-X
forming	B-X
a	B-X
2:2	B-X
heterotetrameric	B-X
complex	B-X
with	B-X
the	B-X
nuclear	B-X
transcription	B-X
factor	B-X
HNF1	B-X
.	B-X
The	B-X
crystal	B-X
structures	B-X
of	B-X
the	B-X
tetrameric	B-X
rat	B-X
and	B-X
the	B-X
dimeric	B-X
bacterial	B-X
PCD/DCoH	B-X
have	B-X
led	B-X
to	B-X
the	B-X
proposal	B-X
of	B-X
substrate	B-X
and	B-X
HNF1	B-X
binding	B-X
sites	B-X
.	B-X
The	B-X
saddle-shaped	B-X
beta-sheet	B-X
surfaces	B-X
of	B-X
the	B-X
DCoH	B-X
dimers	B-X
likely	B-X
represent	B-X
binding	B-X
sites	B-X
for	B-X
as	B-X
yet	B-X
unknown	B-X
macromolecular	B-X
interaction	B-X
partners	B-X
.	B-X
Possible	B-X
mechanisms	B-X
for	B-X
DCoH-induced	B-X
transcriptional	B-X
regulation	B-X
are	B-X
discussed	B-X
in	B-X
the	B-X
light	B-X
of	B-X
the	B-X
three-dimensional	B-X
structures	B-X
.	B-X

These	O
results	O
indicate	O
that	O
DCoH	B-Protein
regulates	O
formation	O
of	O
transcriptionally	O
active	O
tetrameric	O
complexes	O
and	O
may	O
contribute	O
to	O
the	O
developmental	O
specificity	O
of	O
the	O
complex	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
activates	O
proenkephalin	B-Protein
transcription	O
in	O
T	O
lymphocytes	O
.	O

Upon	O
activation	O
,	O
T	O
lymphocytes	O
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	B-Protein
mRNA	O
in	O
the	O
cells	O
.	O
<EOS>	B-X
Upon	B-X
activation	B-X
,	B-X
T	B-X
lymphocytes	B-X
accumulate	B-X
high	B-X
levels	B-X
of	B-X
the	B-X
neuropeptide	B-X
enkephalin	B-X
which	B-X
correlate	B-X
with	B-X
high	B-X
levels	B-X
of	B-X
proenkephalin	B-X
mRNA	B-X
in	B-X
the	B-X
cells	B-X
.	B-X
The	B-X
proenkephalin	B-X
promoter	B-X
contains	B-X
a	B-X
sequence	B-X
GGGGACGTCCCC	B-X
,	B-X
named	B-X
B2	B-X
,	B-X
which	B-X
is	B-X
similar	B-X
to	B-X
the	B-X
kappa	B-X
B	B-X
sequence	B-X
GGGGACTTTCC	B-X
,	B-X
the	B-X
binding	B-X
site	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B.	B-X
Activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
induces	B-X
an	B-X
NF-kappa	B-X
B-like	B-X
binding	B-X
activity	B-X
to	B-X
the	B-X
B2	B-X
site	B-X
,	B-X
concomitant	B-X
with	B-X
activation	B-X
of	B-X
the	B-X
proenkephalin	B-X
promoter	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
B2	B-X
site	B-X
abolish	B-X
this	B-X
transcriptional	B-X
activation	B-X
.	B-X
The	B-X
purified	B-X
homodimer	B-X
(	B-X
two	B-X
p50s	B-X
)	B-X
of	B-X
the	B-X
DNA-binding	B-X
subunit	B-X
of	B-X
NF-kappa	B-X
B	B-X
binds	B-X
the	B-X
B2	B-X
site	B-X
of	B-X
proenkephalin	B-X
relatively	B-X
better	B-X
than	B-X
does	B-X
the	B-X
heterotetramer	B-X
(	B-X
two	B-X
p65s	B-X
plus	B-X
two	B-X
p50s	B-X
)	B-X
form	B-X
of	B-X
the	B-X
factor	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
the	B-X
T-cell-specific	B-X
activation	B-X
of	B-X
the	B-X
proenkephalin	B-X
promoter	B-X
is	B-X
mediated	B-X
by	B-X
NF-kappa	B-X
B	B-X
.	B-X
However	B-X
,	B-X
as	B-X
NF-kappa	B-X
B	B-X
is	B-X
ubiquitous	B-X
and	B-X
the	B-X
transcriptional	B-X
activation	B-X
through	B-X
the	B-X
B2	B-X
site	B-X
is	B-X
T	B-X
cell	B-X
specific	B-X
,	B-X
yet	B-X
another	B-X
T-cell-specific	B-X
factor	B-X
which	B-X
synergizes	B-X
with	B-X
NF-kappa	B-X
B	B-X
should	B-X
be	B-X
considered	B-X
.	B-X

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O
<EOS>	B-X
After	B-X
synthesizing	B-X
key	B-X
evidence	B-X
from	B-X
the	B-X
literature	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
intrinsic	B-X
host	B-X
factors	B-X
,	B-X
such	B-X
as	B-X
changes	B-X
in	B-X
the	B-X
amount	B-X
or	B-X
composition	B-X
of	B-X
sebum	B-X
and/or	B-X
defective	B-X
epidermal	B-X
barrier	B-X
,	B-X
rather	B-X
than	B-X
Malassezia	B-X
,	B-X
may	B-X
form	B-X
the	B-X
basis	B-X
of	B-X
SD	B-X
pathobiology	B-X
.	B-X
We	B-X
argue	B-X
that	B-X
these	B-X
intrinsic	B-X
changes	B-X
provide	B-X
favourable	B-X
conditions	B-X
for	B-X
the	B-X
commensal	B-X
Malassezia	B-X
to	B-X
over-colonize	B-X
and	B-X
elicit	B-X
host	B-X
inflammatory	B-X
response	B-X
.	B-X
Because	B-X
the	B-X
heterogeneous	B-X
transcriptome	B-X
responses	B-X
to	B-X
catabolism	B-X
in	B-X
different	B-X
types	B-X
of	B-X
muscle	B-X
cells	B-X
are	B-X
not	B-X
fully	B-X
characterized	B-X
,	B-X
we	B-X
applied	B-X
single-nucleus	B-X
RNA	B-X
sequencing	B-X
(	B-X
snRNA-seq	B-X
)	B-X
to	B-X
unveil	B-X
muscle	B-X
atrophy	B-X
related	B-X
transcriptional	B-X
changes	B-X
at	B-X
single	B-X
nucleus	B-X
resolution	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
landscape	B-X
of	B-X
IPF	B-X
patients	B-X
'	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
transcription	B-X
and	B-X
translation	B-X
phases	B-X
and	B-X
investigated	B-X
the	B-X
expression	B-X
and	B-X
functions	B-X
of	B-X
two	B-X
new	B-X
potential	B-X
biomarkers	B-X
.	B-X
On	B-X
this	B-X
basis	B-X
,	B-X
we	B-X
identified	B-X
thirteen	B-X
potential	B-X
marker	B-X
genes	B-X
.	B-X
Among	B-X
them	B-X
,	B-X
we	B-X
validated	B-X
the	B-X
expression	B-X
changes	B-X
of	B-X
butyrophilin-like	B-X
9	B-X
(	B-X
BTNL9	B-X
)	B-X
and	B-X
plasmolipin	B-X
(	B-X
PLLP	B-X
)	B-X
and	B-X
investigated	B-X
their	B-X
functional	B-X
pathways	B-X
in	B-X
the	B-X
IPF	B-X
mechanism	B-X
.	B-X

The	O
proenkephalin	B-Protein
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	O
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	O
B	O
sequence	O
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
binding	O
activity	O
to	O
the	O
B2	O
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	B-Protein
promoter	O
.	O

Mutations	O
at	O
the	O
B2	O
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O
<EOS>	B-X
Upon	B-X
activation	B-X
,	B-X
T	B-X
lymphocytes	B-X
accumulate	B-X
high	B-X
levels	B-X
of	B-X
the	B-X
neuropeptide	B-X
enkephalin	B-X
which	B-X
correlate	B-X
with	B-X
high	B-X
levels	B-X
of	B-X
proenkephalin	B-X
mRNA	B-X
in	B-X
the	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
investigated	B-X
the	B-X
transcriptional	B-X
basis	B-X
for	B-X
these	B-X
changes	B-X
.	B-X
The	B-X
proenkephalin	B-X
promoter	B-X
contains	B-X
a	B-X
sequence	B-X
GGGGACGTCCCC	B-X
,	B-X
named	B-X
B2	B-X
,	B-X
which	B-X
is	B-X
similar	B-X
to	B-X
the	B-X
kappa	B-X
B	B-X
sequence	B-X
GGGGACTTTCC	B-X
,	B-X
the	B-X
binding	B-X
site	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B.	B-X
Activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
induces	B-X
an	B-X
NF-kappa	B-X
B-like	B-X
binding	B-X
activity	B-X
to	B-X
the	B-X
B2	B-X
site	B-X
,	B-X
concomitant	B-X
with	B-X
activation	B-X
of	B-X
the	B-X
proenkephalin	B-X
promoter	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
B2	B-X
site	B-X
abolish	B-X
this	B-X
transcriptional	B-X
activation	B-X
.	B-X
The	B-X
purified	B-X
homodimer	B-X
(	B-X
two	B-X
p50s	B-X
)	B-X
of	B-X
the	B-X
DNA-binding	B-X
subunit	B-X
of	B-X
NF-kappa	B-X
B	B-X
binds	B-X
the	B-X
B2	B-X
site	B-X
of	B-X
proenkephalin	B-X
relatively	B-X
better	B-X
than	B-X
does	B-X
the	B-X
heterotetramer	B-X
(	B-X
two	B-X
p65s	B-X
plus	B-X
two	B-X
p50s	B-X
)	B-X
form	B-X
of	B-X
the	B-X
factor	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
the	B-X
T-cell-specific	B-X
activation	B-X
of	B-X
the	B-X
proenkephalin	B-X
promoter	B-X
is	B-X
mediated	B-X
by	B-X
NF-kappa	B-X
B	B-X
.	B-X
However	B-X
,	B-X
as	B-X
NF-kappa	B-X
B	B-X
is	B-X
ubiquitous	B-X
and	B-X
the	B-X
transcriptional	B-X
activation	B-X
through	B-X
the	B-X
B2	B-X
site	B-X
is	B-X
T	B-X
cell	B-X
specific	B-X
,	B-X
yet	B-X
another	B-X
T-cell-specific	B-X
factor	B-X
which	B-X
synergizes	B-X
with	B-X
NF-kappa	B-X
B	B-X
should	B-X
be	B-X
considered	B-X
.	B-X

The	O
purified	O
homodimer	O
(	O
two	O
p50s	B-Protein
)	O
of	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
binds	O
the	O
B2	O
site	O
of	O
proenkephalin	B-Protein
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	O
(	O
two	O
p65s	B-Protein
plus	O
two	O
p50s	B-Protein
)	O
form	O
of	O
the	O
factor	O
.	O
<EOS>	B-X
Upon	B-X
activation	B-X
,	B-X
T	B-X
lymphocytes	B-X
accumulate	B-X
high	B-X
levels	B-X
of	B-X
the	B-X
neuropeptide	B-X
enkephalin	B-X
which	B-X
correlate	B-X
with	B-X
high	B-X
levels	B-X
of	B-X
proenkephalin	B-X
mRNA	B-X
in	B-X
the	B-X
cells	B-X
.	B-X
The	B-X
proenkephalin	B-X
promoter	B-X
contains	B-X
a	B-X
sequence	B-X
GGGGACGTCCCC	B-X
,	B-X
named	B-X
B2	B-X
,	B-X
which	B-X
is	B-X
similar	B-X
to	B-X
the	B-X
kappa	B-X
B	B-X
sequence	B-X
GGGGACTTTCC	B-X
,	B-X
the	B-X
binding	B-X
site	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B.	B-X
Activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
induces	B-X
an	B-X
NF-kappa	B-X
B-like	B-X
binding	B-X
activity	B-X
to	B-X
the	B-X
B2	B-X
site	B-X
,	B-X
concomitant	B-X
with	B-X
activation	B-X
of	B-X
the	B-X
proenkephalin	B-X
promoter	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
B2	B-X
site	B-X
abolish	B-X
this	B-X
transcriptional	B-X
activation	B-X
.	B-X
The	B-X
purified	B-X
homodimer	B-X
(	B-X
two	B-X
p50s	B-X
)	B-X
of	B-X
the	B-X
DNA-binding	B-X
subunit	B-X
of	B-X
NF-kappa	B-X
B	B-X
binds	B-X
the	B-X
B2	B-X
site	B-X
of	B-X
proenkephalin	B-X
relatively	B-X
better	B-X
than	B-X
does	B-X
the	B-X
heterotetramer	B-X
(	B-X
two	B-X
p65s	B-X
plus	B-X
two	B-X
p50s	B-X
)	B-X
form	B-X
of	B-X
the	B-X
factor	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
the	B-X
T-cell-specific	B-X
activation	B-X
of	B-X
the	B-X
proenkephalin	B-X
promoter	B-X
is	B-X
mediated	B-X
by	B-X
NF-kappa	B-X
B	B-X
.	B-X
However	B-X
,	B-X
as	B-X
NF-kappa	B-X
B	B-X
is	B-X
ubiquitous	B-X
and	B-X
the	B-X
transcriptional	B-X
activation	B-X
through	B-X
the	B-X
B2	B-X
site	B-X
is	B-X
T	B-X
cell	B-X
specific	B-X
,	B-X
yet	B-X
another	B-X
T-cell-specific	B-X
factor	B-X
which	B-X
synergizes	B-X
with	B-X
NF-kappa	B-X
B	B-X
should	B-X
be	B-X
considered	B-X
.	B-X

Thus	O
,	O
it	O
appears	O
that	O
the	O
T	O
-	O
cell	O
-	O
specific	O
activation	O
of	O
the	O
proenkephalin	B-Protein
promoter	O
is	O
mediated	O
by	O
NF	O
-	O
kappa	O
B	O
.	O

However	O
,	O
as	O
NF	O
-	O
kappa	O
B	O
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	O
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
which	O
synergizes	O
with	O
NF	O
-	O
kappa	O
B	O
should	O
be	O
considered	O
.	O

ETS1	B-Protein
transactivates	O
the	O
human	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Activation	O
of	O
T	O
helper	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	O
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
T	B-X
helper	B-X
cells	B-X
results	B-X
in	B-X
coordinate	B-X
expression	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cytokines	B-X
involved	B-X
in	B-X
differentiation	B-X
,	B-X
proliferation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
haematopoietic	B-X
system	B-X
.	B-X
Granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
is	B-X
one	B-X
such	B-X
cytokine	B-X
whose	B-X
increased	B-X
expression	B-X
results	B-X
partly	B-X
from	B-X
increases	B-X
in	B-X
transcription	B-X
.	B-X
A	B-X
number	B-X
of	B-X
the	B-X
ETS	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
including	B-X
ETS1	B-X
and	B-X
ELF1	B-X
.	B-X
Other	B-X
unidentified	B-X
ETS-like	B-X
factors	B-X
present	B-X
in	B-X
Jurkat	B-X
cells	B-X
are	B-X
also	B-X
capable	B-X
of	B-X
binding	B-X
GM5	B-X
.	B-X
The	B-X
GM-CSF	B-X
promoter	B-X
,	B-X
modified	B-X
in	B-X
this	B-X
way	B-X
to	B-X
be	B-X
ETS1	B-X
specific	B-X
,	B-X
is	B-X
fully	B-X
responsive	B-X
to	B-X
PMA/ionomycin	B-X
induction	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
ETS1	B-X
transactivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PMA	B-X
and	B-X
ionomycin	B-X
.	B-X
Together	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
ETS1	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
mediating	B-X
the	B-X
increased	B-X
GM-CSF	B-X
production	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

Granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
is	O
one	O
such	O
cytokine	O
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
T	B-X
helper	B-X
cells	B-X
results	B-X
in	B-X
coordinate	B-X
expression	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cytokines	B-X
involved	B-X
in	B-X
differentiation	B-X
,	B-X
proliferation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
haematopoietic	B-X
system	B-X
.	B-X
Granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
is	B-X
one	B-X
such	B-X
cytokine	B-X
whose	B-X
increased	B-X
expression	B-X
results	B-X
partly	B-X
from	B-X
increases	B-X
in	B-X
transcription	B-X
.	B-X
Cis-acting	B-X
elements	B-X
with	B-X
NF	B-X
kappa	B-X
B	B-X
,	B-X
AP-1	B-X
and	B-X
ETS-like	B-X
motifs	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
,	B-X
which	B-X
are	B-X
important	B-X
for	B-X
transcriptional	B-X
activity	B-X
following	B-X
PMA	B-X
and	B-X
ionomycin	B-X
stimulation	B-X
.	B-X
A	B-X
number	B-X
of	B-X
the	B-X
ETS	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
including	B-X
ETS1	B-X
and	B-X
ELF1	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
factors	B-X
to	B-X
interact	B-X
with	B-X
a	B-X
site	B-X
(	B-X
GM5	B-X
)	B-X
,	B-X
located	B-X
within	B-X
the	B-X
CLE0	B-X
element	B-X
,	B-X
-47	B-X
to	B-X
-40	B-X
upstream	B-X
of	B-X
the	B-X
GM-CSF	B-X
transcription	B-X
initiation	B-X
site	B-X
.	B-X
Exogenous	B-X
ETS1	B-X
,	B-X
but	B-X
not	B-X
ELF1	B-X
,	B-X
can	B-X
transactivate	B-X
GM-CSF	B-X
,	B-X
through	B-X
the	B-X
GM5	B-X
site	B-X
,	B-X
in	B-X
a	B-X
PMA/ionomycin	B-X
dependent	B-X
manner	B-X
.	B-X
Other	B-X
unidentified	B-X
ETS-like	B-X
factors	B-X
present	B-X
in	B-X
Jurkat	B-X
cells	B-X
are	B-X
also	B-X
capable	B-X
of	B-X
binding	B-X
GM5	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
core	B-X
ETS	B-X
binding	B-X
site	B-X
from	B-X
-GGAA-	B-X
to	B-X
-GGAT-	B-X
prevents	B-X
the	B-X
binding	B-X
of	B-X
ETS-like	B-X
factors	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
ETS1	B-X
.	B-X
The	B-X
GM-CSF	B-X
promoter	B-X
,	B-X
modified	B-X
in	B-X
this	B-X
way	B-X
to	B-X
be	B-X
ETS1	B-X
specific	B-X
,	B-X
is	B-X
fully	B-X
responsive	B-X
to	B-X
PMA/ionomycin	B-X
induction	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
ETS1	B-X
transactivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PMA	B-X
and	B-X
ionomycin	B-X
.	B-X
Together	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
ETS1	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
mediating	B-X
the	B-X
increased	B-X
GM-CSF	B-X
production	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

Cis	O
-	O
acting	O
elements	O
with	O
NF	O
kappa	O
B	O
,	O
AP	O
-	O
1	O
and	O
ETS	O
-	O
like	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
gene	O
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O
<EOS>	B-X
Granulocyte-macrophage	B-X
colony	B-X
stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
is	B-X
one	B-X
such	B-X
cytokine	B-X
,	B-X
whose	B-X
increased	B-X
expression	B-X
results	B-X
mostly	B-X
from	B-X
increases	B-X
in	B-X
transcription	B-X
.	B-X
Cis-acting	B-X
elements	B-X
with	B-X
NFkappaB	B-X
,	B-X
AP1	B-X
and	B-X
ETS-like	B-X
binding	B-X
motifs	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
,	B-X
and	B-X
are	B-X
important	B-X
or	B-X
essential	B-X
for	B-X
transcriptional	B-X
activity	B-X
following	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
ETS1	B-X
is	B-X
a	B-X
transcription	B-X
factor	B-X
of	B-X
the	B-X
ETS	B-X
family	B-X
that	B-X
is	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
ETS1	B-X
can	B-X
transactivate	B-X
GM-CSF	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
only	B-X
after	B-X
the	B-X
cells	B-X
have	B-X
been	B-X
stimulated	B-X
by	B-X
treatment	B-X
with	B-X
PMA	B-X
and	B-X
ionomycin	B-X
,	B-X
agents	B-X
that	B-X
mimic	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
Thus	B-X
we	B-X
proposed	B-X
that	B-X
ETS1	B-X
,	B-X
which	B-X
is	B-X
expressed	B-X
constitutively	B-X
in	B-X
Jurkat	B-X
cells	B-X
,	B-X
may	B-X
act	B-X
in	B-X
concert	B-X
with	B-X
PMA/ionomycin	B-X
inducible	B-X
factors	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
ETS1	B-X
can	B-X
transactivate	B-X
a	B-X
GM-CSF	B-X
reporter	B-X
construct	B-X
in	B-X
unstimulated	B-X
Jurkat	B-X
cells	B-X
,	B-X
providing	B-X
that	B-X
either	B-X
NFkappaB	B-X
or	B-X
AP1	B-X
transcription	B-X
factors	B-X
are	B-X
supplied	B-X
by	B-X
co-transfection	B-X
.	B-X
We	B-X
confirm	B-X
that	B-X
binding	B-X
of	B-X
endogenous	B-X
NFkappaB	B-X
and	B-X
AP1	B-X
is	B-X
induced	B-X
following	B-X
PMA/ionomycin	B-X
treatment	B-X
of	B-X
T	B-X
cells	B-X
.	B-X
Transactivation	B-X
by	B-X
ETS1	B-X
,	B-X
NFkappaB	B-X
and	B-X
AP1	B-X
is	B-X
synergistic	B-X
,	B-X
and	B-X
mutation	B-X
of	B-X
the	B-X
individual	B-X
binding	B-X
sites	B-X
reveals	B-X
that	B-X
the	B-X
transcriptional	B-X
activities	B-X
of	B-X
these	B-X
factors	B-X
are	B-X
interdependent	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
constitutive	B-X
ETS1	B-X
,	B-X
and	B-X
inducible	B-X
NFkappaB	B-X
and	B-X
AP1	B-X
,	B-X
cooperate	B-X
as	B-X
part	B-X
of	B-X
a	B-X
higher	B-X
order	B-X
transcriptional	B-X
complex	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X

A	O
number	O
of	O
the	O
ETS	O
family	O
of	O
transcription	O
factors	O
are	O
expressed	O
in	O
T	O
cells	O
,	O
including	O
ETS1	B-Protein
and	O
ELF1	B-Protein
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	O
)	O
,	O
located	O
within	O
the	O
CLE0	O
element	O
,	O
-	O
47	O
to	O
-	O
40	O
upstream	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
transcription	O
initiation	O
site	O
.	O
<EOS>	B-X
Granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
is	B-X
one	B-X
such	B-X
cytokine	B-X
whose	B-X
increased	B-X
expression	B-X
results	B-X
partly	B-X
from	B-X
increases	B-X
in	B-X
transcription	B-X
.	B-X
Cis-acting	B-X
elements	B-X
with	B-X
NF	B-X
kappa	B-X
B	B-X
,	B-X
AP-1	B-X
and	B-X
ETS-like	B-X
motifs	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
,	B-X
which	B-X
are	B-X
important	B-X
for	B-X
transcriptional	B-X
activity	B-X
following	B-X
PMA	B-X
and	B-X
ionomycin	B-X
stimulation	B-X
.	B-X
A	B-X
number	B-X
of	B-X
the	B-X
ETS	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
including	B-X
ETS1	B-X
and	B-X
ELF1	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
factors	B-X
to	B-X
interact	B-X
with	B-X
a	B-X
site	B-X
(	B-X
GM5	B-X
)	B-X
,	B-X
located	B-X
within	B-X
the	B-X
CLE0	B-X
element	B-X
,	B-X
-47	B-X
to	B-X
-40	B-X
upstream	B-X
of	B-X
the	B-X
GM-CSF	B-X
transcription	B-X
initiation	B-X
site	B-X
.	B-X
Exogenous	B-X
ETS1	B-X
,	B-X
but	B-X
not	B-X
ELF1	B-X
,	B-X
can	B-X
transactivate	B-X
GM-CSF	B-X
,	B-X
through	B-X
the	B-X
GM5	B-X
site	B-X
,	B-X
in	B-X
a	B-X
PMA/ionomycin	B-X
dependent	B-X
manner	B-X
.	B-X
Other	B-X
unidentified	B-X
ETS-like	B-X
factors	B-X
present	B-X
in	B-X
Jurkat	B-X
cells	B-X
are	B-X
also	B-X
capable	B-X
of	B-X
binding	B-X
GM5	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
core	B-X
ETS	B-X
binding	B-X
site	B-X
from	B-X
-GGAA-	B-X
to	B-X
-GGAT-	B-X
prevents	B-X
the	B-X
binding	B-X
of	B-X
ETS-like	B-X
factors	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
ETS1	B-X
.	B-X
The	B-X
GM-CSF	B-X
promoter	B-X
,	B-X
modified	B-X
in	B-X
this	B-X
way	B-X
to	B-X
be	B-X
ETS1	B-X
specific	B-X
,	B-X
is	B-X
fully	B-X
responsive	B-X
to	B-X
PMA/ionomycin	B-X
induction	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
ETS1	B-X
transactivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PMA	B-X
and	B-X
ionomycin	B-X
.	B-X
Together	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
ETS1	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
mediating	B-X
the	B-X
increased	B-X
GM-CSF	B-X
production	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

Exogenous	O
ETS1	B-Protein
,	O
but	O
not	O
ELF1	B-Protein
,	O
can	O
transactivate	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
,	O
through	O
the	O
GM5	O
site	O
,	O
in	O
a	O
PMA	O
/	O
ionomycin	O
dependent	O
manner	O
.	O
<EOS>	B-X
Granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
is	B-X
one	B-X
such	B-X
cytokine	B-X
whose	B-X
increased	B-X
expression	B-X
results	B-X
partly	B-X
from	B-X
increases	B-X
in	B-X
transcription	B-X
.	B-X
Cis-acting	B-X
elements	B-X
with	B-X
NF	B-X
kappa	B-X
B	B-X
,	B-X
AP-1	B-X
and	B-X
ETS-like	B-X
motifs	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
,	B-X
which	B-X
are	B-X
important	B-X
for	B-X
transcriptional	B-X
activity	B-X
following	B-X
PMA	B-X
and	B-X
ionomycin	B-X
stimulation	B-X
.	B-X
A	B-X
number	B-X
of	B-X
the	B-X
ETS	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
including	B-X
ETS1	B-X
and	B-X
ELF1	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
factors	B-X
to	B-X
interact	B-X
with	B-X
a	B-X
site	B-X
(	B-X
GM5	B-X
)	B-X
,	B-X
located	B-X
within	B-X
the	B-X
CLE0	B-X
element	B-X
,	B-X
-47	B-X
to	B-X
-40	B-X
upstream	B-X
of	B-X
the	B-X
GM-CSF	B-X
transcription	B-X
initiation	B-X
site	B-X
.	B-X
Exogenous	B-X
ETS1	B-X
,	B-X
but	B-X
not	B-X
ELF1	B-X
,	B-X
can	B-X
transactivate	B-X
GM-CSF	B-X
,	B-X
through	B-X
the	B-X
GM5	B-X
site	B-X
,	B-X
in	B-X
a	B-X
PMA/ionomycin	B-X
dependent	B-X
manner	B-X
.	B-X
Other	B-X
unidentified	B-X
ETS-like	B-X
factors	B-X
present	B-X
in	B-X
Jurkat	B-X
cells	B-X
are	B-X
also	B-X
capable	B-X
of	B-X
binding	B-X
GM5	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
core	B-X
ETS	B-X
binding	B-X
site	B-X
from	B-X
-GGAA-	B-X
to	B-X
-GGAT-	B-X
prevents	B-X
the	B-X
binding	B-X
of	B-X
ETS-like	B-X
factors	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
ETS1	B-X
.	B-X
The	B-X
GM-CSF	B-X
promoter	B-X
,	B-X
modified	B-X
in	B-X
this	B-X
way	B-X
to	B-X
be	B-X
ETS1	B-X
specific	B-X
,	B-X
is	B-X
fully	B-X
responsive	B-X
to	B-X
PMA/ionomycin	B-X
induction	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
ETS1	B-X
transactivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PMA	B-X
and	B-X
ionomycin	B-X
.	B-X
Together	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
ETS1	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
mediating	B-X
the	B-X
increased	B-X
GM-CSF	B-X
production	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

Other	O
unidentified	O
ETS	O
-	O
like	O
factors	O
present	O
in	O
Jurkat	O
cells	O
are	O
also	O
capable	O
of	O
binding	O
GM5	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
T	B-X
helper	B-X
cells	B-X
results	B-X
in	B-X
coordinate	B-X
expression	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cytokines	B-X
involved	B-X
in	B-X
differentiation	B-X
,	B-X
proliferation	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
haematopoietic	B-X
system	B-X
.	B-X
Cis-acting	B-X
elements	B-X
with	B-X
NF	B-X
kappa	B-X
B	B-X
,	B-X
AP-1	B-X
and	B-X
ETS-like	B-X
motifs	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
,	B-X
which	B-X
are	B-X
important	B-X
for	B-X
transcriptional	B-X
activity	B-X
following	B-X
PMA	B-X
and	B-X
ionomycin	B-X
stimulation	B-X
.	B-X
A	B-X
number	B-X
of	B-X
the	B-X
ETS	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
including	B-X
ETS1	B-X
and	B-X
ELF1	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
factors	B-X
to	B-X
interact	B-X
with	B-X
a	B-X
site	B-X
(	B-X
GM5	B-X
)	B-X
,	B-X
located	B-X
within	B-X
the	B-X
CLE0	B-X
element	B-X
,	B-X
-47	B-X
to	B-X
-40	B-X
upstream	B-X
of	B-X
the	B-X
GM-CSF	B-X
transcription	B-X
initiation	B-X
site	B-X
.	B-X
Exogenous	B-X
ETS1	B-X
,	B-X
but	B-X
not	B-X
ELF1	B-X
,	B-X
can	B-X
transactivate	B-X
GM-CSF	B-X
,	B-X
through	B-X
the	B-X
GM5	B-X
site	B-X
,	B-X
in	B-X
a	B-X
PMA/ionomycin	B-X
dependent	B-X
manner	B-X
.	B-X
Other	B-X
unidentified	B-X
ETS-like	B-X
factors	B-X
present	B-X
in	B-X
Jurkat	B-X
cells	B-X
are	B-X
also	B-X
capable	B-X
of	B-X
binding	B-X
GM5	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
core	B-X
ETS	B-X
binding	B-X
site	B-X
from	B-X
-GGAA-	B-X
to	B-X
-GGAT-	B-X
prevents	B-X
the	B-X
binding	B-X
of	B-X
ETS-like	B-X
factors	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
ETS1	B-X
.	B-X
The	B-X
GM-CSF	B-X
promoter	B-X
,	B-X
modified	B-X
in	B-X
this	B-X
way	B-X
to	B-X
be	B-X
ETS1	B-X
specific	B-X
,	B-X
is	B-X
fully	B-X
responsive	B-X
to	B-X
PMA/ionomycin	B-X
induction	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
ETS1	B-X
transactivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PMA	B-X
and	B-X
ionomycin	B-X
.	B-X
Together	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
ETS1	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
mediating	B-X
the	B-X
increased	B-X
GM-CSF	B-X
production	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

Mutation	O
of	O
the	O
core	O
ETS	O
binding	O
site	O
from	O
-	O
GGAA	O
-	O
to	O
-	O
GGAT	O
-	O
prevents	O
the	O
binding	O
of	O
ETS	O
-	O
like	O
factors	O
with	O
the	O
exception	O
of	O
ETS1	B-Protein
.	O
<EOS>	B-X
Cis-acting	B-X
elements	B-X
with	B-X
NF	B-X
kappa	B-X
B	B-X
,	B-X
AP-1	B-X
and	B-X
ETS-like	B-X
motifs	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
,	B-X
which	B-X
are	B-X
important	B-X
for	B-X
transcriptional	B-X
activity	B-X
following	B-X
PMA	B-X
and	B-X
ionomycin	B-X
stimulation	B-X
.	B-X
A	B-X
number	B-X
of	B-X
the	B-X
ETS	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
including	B-X
ETS1	B-X
and	B-X
ELF1	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
factors	B-X
to	B-X
interact	B-X
with	B-X
a	B-X
site	B-X
(	B-X
GM5	B-X
)	B-X
,	B-X
located	B-X
within	B-X
the	B-X
CLE0	B-X
element	B-X
,	B-X
-47	B-X
to	B-X
-40	B-X
upstream	B-X
of	B-X
the	B-X
GM-CSF	B-X
transcription	B-X
initiation	B-X
site	B-X
.	B-X
Exogenous	B-X
ETS1	B-X
,	B-X
but	B-X
not	B-X
ELF1	B-X
,	B-X
can	B-X
transactivate	B-X
GM-CSF	B-X
,	B-X
through	B-X
the	B-X
GM5	B-X
site	B-X
,	B-X
in	B-X
a	B-X
PMA/ionomycin	B-X
dependent	B-X
manner	B-X
.	B-X
Other	B-X
unidentified	B-X
ETS-like	B-X
factors	B-X
present	B-X
in	B-X
Jurkat	B-X
cells	B-X
are	B-X
also	B-X
capable	B-X
of	B-X
binding	B-X
GM5	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
core	B-X
ETS	B-X
binding	B-X
site	B-X
from	B-X
-GGAA-	B-X
to	B-X
-GGAT-	B-X
prevents	B-X
the	B-X
binding	B-X
of	B-X
ETS-like	B-X
factors	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
ETS1	B-X
.	B-X
The	B-X
GM-CSF	B-X
promoter	B-X
,	B-X
modified	B-X
in	B-X
this	B-X
way	B-X
to	B-X
be	B-X
ETS1	B-X
specific	B-X
,	B-X
is	B-X
fully	B-X
responsive	B-X
to	B-X
PMA/ionomycin	B-X
induction	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
ETS1	B-X
transactivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PMA	B-X
and	B-X
ionomycin	B-X
.	B-X
Together	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
ETS1	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
mediating	B-X
the	B-X
increased	B-X
GM-CSF	B-X
production	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

The	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	B-Protein
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA	O
/	O
ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	B-Protein
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O
<EOS>	B-X
Granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
is	B-X
one	B-X
such	B-X
cytokine	B-X
whose	B-X
increased	B-X
expression	B-X
results	B-X
partly	B-X
from	B-X
increases	B-X
in	B-X
transcription	B-X
.	B-X
Cis-acting	B-X
elements	B-X
with	B-X
NF	B-X
kappa	B-X
B	B-X
,	B-X
AP-1	B-X
and	B-X
ETS-like	B-X
motifs	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
,	B-X
which	B-X
are	B-X
important	B-X
for	B-X
transcriptional	B-X
activity	B-X
following	B-X
PMA	B-X
and	B-X
ionomycin	B-X
stimulation	B-X
.	B-X
A	B-X
number	B-X
of	B-X
the	B-X
ETS	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
are	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
including	B-X
ETS1	B-X
and	B-X
ELF1	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
the	B-X
ability	B-X
of	B-X
these	B-X
factors	B-X
to	B-X
interact	B-X
with	B-X
a	B-X
site	B-X
(	B-X
GM5	B-X
)	B-X
,	B-X
located	B-X
within	B-X
the	B-X
CLE0	B-X
element	B-X
,	B-X
-47	B-X
to	B-X
-40	B-X
upstream	B-X
of	B-X
the	B-X
GM-CSF	B-X
transcription	B-X
initiation	B-X
site	B-X
.	B-X
Exogenous	B-X
ETS1	B-X
,	B-X
but	B-X
not	B-X
ELF1	B-X
,	B-X
can	B-X
transactivate	B-X
GM-CSF	B-X
,	B-X
through	B-X
the	B-X
GM5	B-X
site	B-X
,	B-X
in	B-X
a	B-X
PMA/ionomycin	B-X
dependent	B-X
manner	B-X
.	B-X
Other	B-X
unidentified	B-X
ETS-like	B-X
factors	B-X
present	B-X
in	B-X
Jurkat	B-X
cells	B-X
are	B-X
also	B-X
capable	B-X
of	B-X
binding	B-X
GM5	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
core	B-X
ETS	B-X
binding	B-X
site	B-X
from	B-X
-GGAA-	B-X
to	B-X
-GGAT-	B-X
prevents	B-X
the	B-X
binding	B-X
of	B-X
ETS-like	B-X
factors	B-X
with	B-X
the	B-X
exception	B-X
of	B-X
ETS1	B-X
.	B-X
The	B-X
GM-CSF	B-X
promoter	B-X
,	B-X
modified	B-X
in	B-X
this	B-X
way	B-X
to	B-X
be	B-X
ETS1	B-X
specific	B-X
,	B-X
is	B-X
fully	B-X
responsive	B-X
to	B-X
PMA/ionomycin	B-X
induction	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
ETS1	B-X
transactivation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PMA	B-X
and	B-X
ionomycin	B-X
.	B-X
Together	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
ETS1	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
mediating	B-X
the	B-X
increased	B-X
GM-CSF	B-X
production	B-X
associated	B-X
with	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

Together	O
these	O
data	O
suggest	O
that	O
ETS1	B-Protein
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
production	O
associated	O
with	O
T	O
cell	O
activation	O
.	O

Tissue	O
-	O
specific	O
regulation	O
of	O
the	O
rabbit	O
15	B-Protein
-	I-Protein
lipoxygenase	I-Protein
gene	O
in	O
erythroid	O
cells	O
by	O
a	O
transcriptional	O
silencer	O
.	O
<EOS>	B-X
The	B-X
15-lipoxygenase	B-X
(	B-X
lox	B-X
)	B-X
gene	B-X
is	B-X
expressed	B-X
in	B-X
a	B-X
tissue-specific	B-X
manner	B-X
,	B-X
predominantly	B-X
in	B-X
erythroid	B-X
cells	B-X
but	B-X
also	B-X
in	B-X
airway	B-X
epithelial	B-X
cells	B-X
and	B-X
eosinophils	B-X
.	B-X
We	B-X
demonstrate	B-X
in	B-X
this	B-X
report	B-X
that	B-X
the	B-X
5	B-X
'	B-X
flanking	B-X
DNA	B-X
of	B-X
the	B-X
15-lox	B-X
gene	B-X
contains	B-X
sequences	B-X
which	B-X
down-regulate	B-X
its	B-X
activity	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
non-erythroid	B-X
cell	B-X
lines	B-X
but	B-X
not	B-X
in	B-X
two	B-X
erythroid	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
element	B-X
has	B-X
characteristics	B-X
of	B-X
a	B-X
transcriptional	B-X
'silencer	B-X
'	B-X
since	B-X
it	B-X
functions	B-X
in	B-X
both	B-X
orientations	B-X
.	B-X
The	B-X
main	B-X
activity	B-X
of	B-X
the	B-X
silencer	B-X
has	B-X
been	B-X
mapped	B-X
to	B-X
the	B-X
first	B-X
900	B-X
bp	B-X
of	B-X
5	B-X
'	B-X
flanking	B-X
DNA	B-X
,	B-X
which	B-X
contains	B-X
nine	B-X
binding	B-X
sites	B-X
for	B-X
a	B-X
nuclear	B-X
factor	B-X
present	B-X
in	B-X
non-erythroid	B-X
cells	B-X
but	B-X
not	B-X
in	B-X
erythroid	B-X
cells	B-X
.	B-X
These	B-X
binding	B-X
sites	B-X
have	B-X
similar	B-X
sequences	B-X
and	B-X
multiple	B-X
copies	B-X
of	B-X
the	B-X
binding	B-X
sites	B-X
confer	B-X
tissue-specific	B-X
down-regulation	B-X
when	B-X
attached	B-X
to	B-X
a	B-X
minimal	B-X
lox	B-X
promoter	B-X
fragment	B-X
.	B-X

The	O
15	B-Protein
-	I-Protein
lipoxygenase	I-Protein
(	O
lox	B-Protein
)	O
gene	O
is	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	O
cells	O
but	O
also	O
in	O
airway	O
epithelial	O
cells	O
and	O
eosinophils	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	O
'	O
flanking	O
DNA	O
of	O
the	O
15	B-Protein
-	I-Protein
lox	I-Protein
gene	O
contains	O
sequences	O
which	O
down	O
-	O
regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non	O
-	O
erythroid	O
cell	O
lines	O
but	O
not	O
in	O
two	O
erythroid	O
cell	O
lines	O
.	O

The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	O
'	O
silencer	O
'	O
since	O
it	O
functions	O
in	O
both	O
orientations	O
.	O
<EOS>	B-X
By	B-X
using	B-X
the	B-X
recombinant	B-X
virus	B-X
as	B-X
a	B-X
backbone	B-X
,	B-X
the	B-X
EC	B-X
cell-specific	B-X
repressor-binding	B-X
site	B-X
(	B-X
RBS	B-X
)	B-X
element	B-X
has	B-X
been	B-X
mapped	B-X
to	B-X
M-MuLV	B-X
nucleotides	B-X
147	B-X
to	B-X
174	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
the	B-X
RBS	B-X
element	B-X
can	B-X
repress	B-X
heterologous	B-X
promoters	B-X
from	B-X
an	B-X
upstream	B-X
position	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
RBS	B-X
acts	B-X
as	B-X
a	B-X
silencer	B-X
that	B-X
its	B-X
inhibitory	B-X
effect	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
trans-acting	B-X
factor	B-X
,	B-X
and	B-X
that	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
is	B-X
probably	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
.	B-X
The	B-X
binding	B-X
characteristics	B-X
of	B-X
factor	B-X
A	B-X
suggest	B-X
that	B-X
it	B-X
is	B-X
a	B-X
stem	B-X
cell	B-X
repressor	B-X
which	B-X
acts	B-X
at	B-X
the	B-X
M-MuLV	B-X
RBS	B-X
.	B-X

The	O
main	O
activity	O
of	O
the	O
silencer	O
has	O
been	O
mapped	O
to	O
the	O
first	O
900	O
bp	O
of	O
5	O
'	O
flanking	O
DNA	O
,	O
which	O
contains	O
nine	O
binding	O
sites	O
for	O
a	O
nuclear	O
factor	O
present	O
in	O
non	O
-	O
erythroid	O
cells	O
but	O
not	O
in	O
erythroid	O
cells	O
.	O

These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	O
sites	O
confer	O
tissue	O
-	O
specific	O
down	O
-	O
regulation	O
when	O
attached	O
to	O
a	O
minimal	O
lox	B-Protein
promoter	O
fragment	O
.	O
<EOS>	B-X
The	B-X
15-lipoxygenase	B-X
(	B-X
lox	B-X
)	B-X
gene	B-X
is	B-X
expressed	B-X
in	B-X
a	B-X
tissue-specific	B-X
manner	B-X
,	B-X
predominantly	B-X
in	B-X
erythroid	B-X
cells	B-X
but	B-X
also	B-X
in	B-X
airway	B-X
epithelial	B-X
cells	B-X
and	B-X
eosinophils	B-X
.	B-X
We	B-X
demonstrate	B-X
in	B-X
this	B-X
report	B-X
that	B-X
the	B-X
5	B-X
'	B-X
flanking	B-X
DNA	B-X
of	B-X
the	B-X
15-lox	B-X
gene	B-X
contains	B-X
sequences	B-X
which	B-X
down-regulate	B-X
its	B-X
activity	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
non-erythroid	B-X
cell	B-X
lines	B-X
but	B-X
not	B-X
in	B-X
two	B-X
erythroid	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
main	B-X
activity	B-X
of	B-X
the	B-X
silencer	B-X
has	B-X
been	B-X
mapped	B-X
to	B-X
the	B-X
first	B-X
900	B-X
bp	B-X
of	B-X
5	B-X
'	B-X
flanking	B-X
DNA	B-X
,	B-X
which	B-X
contains	B-X
nine	B-X
binding	B-X
sites	B-X
for	B-X
a	B-X
nuclear	B-X
factor	B-X
present	B-X
in	B-X
non-erythroid	B-X
cells	B-X
but	B-X
not	B-X
in	B-X
erythroid	B-X
cells	B-X
.	B-X
These	B-X
binding	B-X
sites	B-X
have	B-X
similar	B-X
sequences	B-X
and	B-X
multiple	B-X
copies	B-X
of	B-X
the	B-X
binding	B-X
sites	B-X
confer	B-X
tissue-specific	B-X
down-regulation	B-X
when	B-X
attached	B-X
to	B-X
a	B-X
minimal	B-X
lox	B-X
promoter	B-X
fragment	B-X
.	B-X
The	B-X
5	B-X
'	B-X
flanking	B-X
DNA	B-X
also	B-X
contains	B-X
a	B-X
cluster	B-X
of	B-X
three	B-X
binding	B-X
sites	B-X
for	B-X
the	B-X
GATA	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X

The	O
5	O
'	O
flanking	O
DNA	O
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	O
sites	O
for	O
the	O
GATA	O
family	O
of	O
transcription	O
factors	O
.	O
<EOS>	B-X
The	B-X
15-lipoxygenase	B-X
(	B-X
lox	B-X
)	B-X
gene	B-X
is	B-X
expressed	B-X
in	B-X
a	B-X
tissue-specific	B-X
manner	B-X
,	B-X
predominantly	B-X
in	B-X
erythroid	B-X
cells	B-X
but	B-X
also	B-X
in	B-X
airway	B-X
epithelial	B-X
cells	B-X
and	B-X
eosinophils	B-X
.	B-X
We	B-X
demonstrate	B-X
in	B-X
this	B-X
report	B-X
that	B-X
the	B-X
5	B-X
'	B-X
flanking	B-X
DNA	B-X
of	B-X
the	B-X
15-lox	B-X
gene	B-X
contains	B-X
sequences	B-X
which	B-X
down-regulate	B-X
its	B-X
activity	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
non-erythroid	B-X
cell	B-X
lines	B-X
but	B-X
not	B-X
in	B-X
two	B-X
erythroid	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
element	B-X
has	B-X
characteristics	B-X
of	B-X
a	B-X
transcriptional	B-X
'silencer	B-X
'	B-X
since	B-X
it	B-X
functions	B-X
in	B-X
both	B-X
orientations	B-X
.	B-X
The	B-X
main	B-X
activity	B-X
of	B-X
the	B-X
silencer	B-X
has	B-X
been	B-X
mapped	B-X
to	B-X
the	B-X
first	B-X
900	B-X
bp	B-X
of	B-X
5	B-X
'	B-X
flanking	B-X
DNA	B-X
,	B-X
which	B-X
contains	B-X
nine	B-X
binding	B-X
sites	B-X
for	B-X
a	B-X
nuclear	B-X
factor	B-X
present	B-X
in	B-X
non-erythroid	B-X
cells	B-X
but	B-X
not	B-X
in	B-X
erythroid	B-X
cells	B-X
.	B-X
These	B-X
binding	B-X
sites	B-X
have	B-X
similar	B-X
sequences	B-X
and	B-X
multiple	B-X
copies	B-X
of	B-X
the	B-X
binding	B-X
sites	B-X
confer	B-X
tissue-specific	B-X
down-regulation	B-X
when	B-X
attached	B-X
to	B-X
a	B-X
minimal	B-X
lox	B-X
promoter	B-X
fragment	B-X
.	B-X
The	B-X
5	B-X
'	B-X
flanking	B-X
DNA	B-X
also	B-X
contains	B-X
a	B-X
cluster	B-X
of	B-X
three	B-X
binding	B-X
sites	B-X
for	B-X
the	B-X
GATA	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X

Coexpression	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
and	O
Sp1	B-Protein
transcription	O
factors	O
in	O
human	O
immunodeficiency	O
virus	O
1	O
-	O
induced	O
,	O
dendritic	O
cell	O
-	O
T	O
-	O
cell	O
syncytia	O
.	O
<EOS>	B-X
Productive	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
typically	B-X
requires	B-X
that	B-X
the	B-X
T	B-X
cells	B-X
be	B-X
stimulated	B-X
with	B-X
antigens	B-X
or	B-X
mitogens	B-X
.	B-X
This	B-X
requirement	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
synergizes	B-X
with	B-X
the	B-X
constitutive	B-X
transcription	B-X
factor	B-X
Sp1	B-X
to	B-X
drive	B-X
the	B-X
HIV-1	B-X
promoter	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
vigorous	B-X
replication	B-X
of	B-X
HIV-1	B-X
takes	B-X
place	B-X
in	B-X
nonactivated	B-X
memory	B-X
T	B-X
cells	B-X
after	B-X
syncytium	B-X
formation	B-X
with	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
.	B-X
These	B-X
syncytia	B-X
lack	B-X
activated	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
an	B-X
absence	B-X
of	B-X
staining	B-X
for	B-X
Ki-67	B-X
cell	B-X
cycle	B-X
antigen	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
were	B-X
,	B-X
therefore	B-X
,	B-X
analyzed	B-X
in	B-X
isolated	B-X
T	B-X
cells	B-X
and	B-X
DCs	B-X
from	B-X
humans	B-X
and	B-X
mice	B-X
.	B-X
T	B-X
cells	B-X
lack	B-X
active	B-X
NF-kappa	B-X
B	B-X
but	B-X
express	B-X
Sp1	B-X
as	B-X
expected	B-X
.	B-X
DCs	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
all	B-X
known	B-X
NF-kappa	B-X
B	B-X
and	B-X
Rel	B-X
proteins	B-X
,	B-X
with	B-X
activity	B-X
residing	B-X
primarily	B-X
within	B-X
RelB	B-X
,	B-X
p50	B-X
,	B-X
and	B-X
p65	B-X
.	B-X
However	B-X
,	B-X
DCs	B-X
lack	B-X
Sp1	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
the	B-X
failure	B-X
of	B-X
HIV-1	B-X
to	B-X
replicate	B-X
in	B-X
purified	B-X
DCs	B-X
.	B-X
Coexpression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
occurs	B-X
in	B-X
the	B-X
heterologous	B-X
DC-T-cell	B-X
syncytia	B-X
that	B-X
are	B-X
induced	B-X
by	B-X
HIV-1	B-X
.	B-X
Therefore	B-X
,	B-X
HIV-1-induced	B-X
cell	B-X
fusion	B-X
brings	B-X
together	B-X
factors	B-X
that	B-X
upregulate	B-X
virus	B-X
transcription	B-X
.	B-X
Since	B-X
DCs	B-X
and	B-X
memory	B-X
T	B-X
cells	B-X
frequently	B-X
traffic	B-X
together	B-X
in	B-X
situ	B-X
,	B-X
these	B-X
unusual	B-X
heterologous	B-X
syncytia	B-X
could	B-X
develop	B-X
in	B-X
infected	B-X
individuals	B-X
and	B-X
lead	B-X
to	B-X
chronic	B-X
HIV-1	B-X
replication	B-X
without	B-X
ostensible	B-X
immune	B-X
stimulation	B-X
.	B-X

Productive	O
infection	O
of	O
T	O
cells	O
with	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV	O
-	O
1	O
)	O
typically	O
requires	O
that	O
the	O
T	O
cells	O
be	O
stimulated	O
with	O
antigens	O
or	O
mitogens	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
perspective	B-X
of	B-X
a	B-X
'paradoxical	B-X
intervention	B-X
'	B-X
in	B-X
cancer	B-X
therapy	B-X
:	B-X
rather	B-X
than	B-X
attempting	B-X
to	B-X
inhibit	B-X
oncogenic	B-X
signaling	B-X
,	B-X
the	B-X
proposed	B-X
therapy	B-X
would	B-X
further	B-X
activate	B-X
mitogenic	B-X
signaling	B-X
to	B-X
disrupt	B-X
the	B-X
labile	B-X
homeostasis	B-X
of	B-X
cancer	B-X
cells	B-X
and	B-X
overload	B-X
stress	B-X
response	B-X
pathways	B-X
.	B-X
Such	B-X
overactivation	B-X
can	B-X
potentially	B-X
be	B-X
combined	B-X
with	B-X
stress-targeted	B-X
drugs	B-X
to	B-X
kill	B-X
overstressed	B-X
cancer	B-X
cells	B-X
.	B-X
Although	B-X
counter-intuitive	B-X
,	B-X
such	B-X
an	B-X
approach	B-X
exploits	B-X
intrinsic	B-X
and	B-X
ubiquitous	B-X
differences	B-X
between	B-X
normal	B-X
and	B-X
cancer	B-X
cells	B-X
.	B-X
The	B-X
cells	B-X
of	B-X
Nocardia	B-X
opaca	B-X
are	B-X
a	B-X
source	B-X
of	B-X
potent	B-X
immunostimulating	B-X
substances	B-X
,	B-X
differing	B-X
in	B-X
solubility	B-X
and	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
peptidoglycan	B-X
.	B-X
Three	B-X
classes	B-X
of	B-X
N.	B-X
opaca	B-X
fractions	B-X
have	B-X
been	B-X
investigated	B-X
:	B-X
(	B-X
1	B-X
)	B-X
NDCM	B-X
(	B-X
Nocardia	B-X
delipidated	B-X
cell	B-X
mitogen	B-X
)	B-X
,	B-X
the	B-X
starting	B-X
fraction	B-X
;	B-X
(	B-X
2	B-X
)	B-X
PG	B-X
(	B-X
peptidoglycan	B-X
)	B-X
-containing	B-X
fractions	B-X
:	B-X
CW	B-X
(	B-X
cell	B-X
walls	B-X
)	B-X
,	B-X
PG	B-X
,	B-X
and	B-X
fractions	B-X
containing	B-X
soluble	B-X
PG	B-X
derivatives	B-X
such	B-X
as	B-X
NWSM	B-X
(	B-X
Nocardia	B-X
water	B-X
soluble	B-X
mitogen	B-X
)	B-X
and	B-X
NSPD	B-X
(	B-X
Nocardia	B-X
soluble	B-X
peptidoglycan	B-X
derivative	B-X
)	B-X
;	B-X
and	B-X
(	B-X
3	B-X
)	B-X
soluble	B-X
fractions	B-X
devoid	B-X
of	B-X
PG	B-X
,	B-X
such	B-X
as	B-X
NWSMP	B-X
(	B-X
NWSP-pellet	B-X
)	B-X
and	B-X
CyI	B-X
(	B-X
cytoplasmic	B-X
membrane	B-X
)	B-X
.	B-X
This	B-X
report	B-X
summarizes	B-X
our	B-X
results	B-X
on	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
structure	B-X
of	B-X
N.	B-X
opaca	B-X
fractions	B-X
and	B-X
their	B-X
stimulatory	B-X
activities	B-X
on	B-X
mouse	B-X
,	B-X
rabbit	B-X
,	B-X
germ-free	B-X
piglet	B-X
and	B-X
human	B-X
lymphocytes	B-X
and	B-X
monocytes/macrophages	B-X
.	B-X

This	O
requirement	O
has	O
been	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
synergizes	O
with	O
the	O
constitutive	O
transcription	O
factor	O
Sp1	B-Protein
to	O
drive	O
the	O
HIV	O
-	O
1	O
promoter	O
.	O

Recently	O
,	O
we	O
have	O
found	O
that	O
vigorous	O
replication	O
of	O
HIV	O
-	O
1	O
takes	O
place	O
in	O
nonactivated	O
memory	O
T	O
cells	O
after	O
syncytium	O
formation	O
with	O
dendritic	O
cells	O
(	O
DCs	O
)	O
.	O
<EOS>	B-X
Productive	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
typically	B-X
requires	B-X
that	B-X
the	B-X
T	B-X
cells	B-X
be	B-X
stimulated	B-X
with	B-X
antigens	B-X
or	B-X
mitogens	B-X
.	B-X
This	B-X
requirement	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
synergizes	B-X
with	B-X
the	B-X
constitutive	B-X
transcription	B-X
factor	B-X
Sp1	B-X
to	B-X
drive	B-X
the	B-X
HIV-1	B-X
promoter	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
vigorous	B-X
replication	B-X
of	B-X
HIV-1	B-X
takes	B-X
place	B-X
in	B-X
nonactivated	B-X
memory	B-X
T	B-X
cells	B-X
after	B-X
syncytium	B-X
formation	B-X
with	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
.	B-X
These	B-X
syncytia	B-X
lack	B-X
activated	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
an	B-X
absence	B-X
of	B-X
staining	B-X
for	B-X
Ki-67	B-X
cell	B-X
cycle	B-X
antigen	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
were	B-X
,	B-X
therefore	B-X
,	B-X
analyzed	B-X
in	B-X
isolated	B-X
T	B-X
cells	B-X
and	B-X
DCs	B-X
from	B-X
humans	B-X
and	B-X
mice	B-X
.	B-X
T	B-X
cells	B-X
lack	B-X
active	B-X
NF-kappa	B-X
B	B-X
but	B-X
express	B-X
Sp1	B-X
as	B-X
expected	B-X
.	B-X
DCs	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
all	B-X
known	B-X
NF-kappa	B-X
B	B-X
and	B-X
Rel	B-X
proteins	B-X
,	B-X
with	B-X
activity	B-X
residing	B-X
primarily	B-X
within	B-X
RelB	B-X
,	B-X
p50	B-X
,	B-X
and	B-X
p65	B-X
.	B-X
However	B-X
,	B-X
DCs	B-X
lack	B-X
Sp1	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
the	B-X
failure	B-X
of	B-X
HIV-1	B-X
to	B-X
replicate	B-X
in	B-X
purified	B-X
DCs	B-X
.	B-X
Coexpression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
occurs	B-X
in	B-X
the	B-X
heterologous	B-X
DC-T-cell	B-X
syncytia	B-X
that	B-X
are	B-X
induced	B-X
by	B-X
HIV-1	B-X
.	B-X
Therefore	B-X
,	B-X
HIV-1-induced	B-X
cell	B-X
fusion	B-X
brings	B-X
together	B-X
factors	B-X
that	B-X
upregulate	B-X
virus	B-X
transcription	B-X
.	B-X
Since	B-X
DCs	B-X
and	B-X
memory	B-X
T	B-X
cells	B-X
frequently	B-X
traffic	B-X
together	B-X
in	B-X
situ	B-X
,	B-X
these	B-X
unusual	B-X
heterologous	B-X
syncytia	B-X
could	B-X
develop	B-X
in	B-X
infected	B-X
individuals	B-X
and	B-X
lead	B-X
to	B-X
chronic	B-X
HIV-1	B-X
replication	B-X
without	B-X
ostensible	B-X
immune	B-X
stimulation	B-X
.	B-X

These	O
syncytia	O
lack	O
activated	O
cells	O
as	O
determined	O
by	O
an	O
absence	O
of	O
staining	O
for	O
Ki	O
-	O
67	O
cell	O
cycle	O
antigen	O
.	O
<EOS>	B-X
Productive	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
typically	B-X
requires	B-X
that	B-X
the	B-X
T	B-X
cells	B-X
be	B-X
stimulated	B-X
with	B-X
antigens	B-X
or	B-X
mitogens	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
vigorous	B-X
replication	B-X
of	B-X
HIV-1	B-X
takes	B-X
place	B-X
in	B-X
nonactivated	B-X
memory	B-X
T	B-X
cells	B-X
after	B-X
syncytium	B-X
formation	B-X
with	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
.	B-X
These	B-X
syncytia	B-X
lack	B-X
activated	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
an	B-X
absence	B-X
of	B-X
staining	B-X
for	B-X
Ki-67	B-X
cell	B-X
cycle	B-X
antigen	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
were	B-X
,	B-X
therefore	B-X
,	B-X
analyzed	B-X
in	B-X
isolated	B-X
T	B-X
cells	B-X
and	B-X
DCs	B-X
from	B-X
humans	B-X
and	B-X
mice	B-X
.	B-X
T	B-X
cells	B-X
lack	B-X
active	B-X
NF-kappa	B-X
B	B-X
but	B-X
express	B-X
Sp1	B-X
as	B-X
expected	B-X
.	B-X
However	B-X
,	B-X
DCs	B-X
lack	B-X
Sp1	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
the	B-X
failure	B-X
of	B-X
HIV-1	B-X
to	B-X
replicate	B-X
in	B-X
purified	B-X
DCs	B-X
.	B-X
Coexpression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
occurs	B-X
in	B-X
the	B-X
heterologous	B-X
DC-T-cell	B-X
syncytia	B-X
that	B-X
are	B-X
induced	B-X
by	B-X
HIV-1	B-X
.	B-X
Therefore	B-X
,	B-X
HIV-1-induced	B-X
cell	B-X
fusion	B-X
brings	B-X
together	B-X
factors	B-X
that	B-X
upregulate	B-X
virus	B-X
transcription	B-X
.	B-X
Since	B-X
DCs	B-X
and	B-X
memory	B-X
T	B-X
cells	B-X
frequently	B-X
traffic	B-X
together	B-X
in	B-X
situ	B-X
,	B-X
these	B-X
unusual	B-X
heterologous	B-X
syncytia	B-X
could	B-X
develop	B-X
in	B-X
infected	B-X
individuals	B-X
and	B-X
lead	B-X
to	B-X
chronic	B-X
HIV-1	B-X
replication	B-X
without	B-X
ostensible	B-X
immune	B-X
stimulation	B-X
.	B-X

The	O
expression	O
and	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	B-Protein
were	O
,	O
therefore	O
,	O
analyzed	O
in	O
isolated	O
T	O
cells	O
and	O
DCs	O
from	O
humans	O
and	O
mice	O
.	O
<EOS>	B-X
Productive	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
typically	B-X
requires	B-X
that	B-X
the	B-X
T	B-X
cells	B-X
be	B-X
stimulated	B-X
with	B-X
antigens	B-X
or	B-X
mitogens	B-X
.	B-X
This	B-X
requirement	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
synergizes	B-X
with	B-X
the	B-X
constitutive	B-X
transcription	B-X
factor	B-X
Sp1	B-X
to	B-X
drive	B-X
the	B-X
HIV-1	B-X
promoter	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
vigorous	B-X
replication	B-X
of	B-X
HIV-1	B-X
takes	B-X
place	B-X
in	B-X
nonactivated	B-X
memory	B-X
T	B-X
cells	B-X
after	B-X
syncytium	B-X
formation	B-X
with	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
.	B-X
These	B-X
syncytia	B-X
lack	B-X
activated	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
an	B-X
absence	B-X
of	B-X
staining	B-X
for	B-X
Ki-67	B-X
cell	B-X
cycle	B-X
antigen	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
were	B-X
,	B-X
therefore	B-X
,	B-X
analyzed	B-X
in	B-X
isolated	B-X
T	B-X
cells	B-X
and	B-X
DCs	B-X
from	B-X
humans	B-X
and	B-X
mice	B-X
.	B-X
T	B-X
cells	B-X
lack	B-X
active	B-X
NF-kappa	B-X
B	B-X
but	B-X
express	B-X
Sp1	B-X
as	B-X
expected	B-X
.	B-X
DCs	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
all	B-X
known	B-X
NF-kappa	B-X
B	B-X
and	B-X
Rel	B-X
proteins	B-X
,	B-X
with	B-X
activity	B-X
residing	B-X
primarily	B-X
within	B-X
RelB	B-X
,	B-X
p50	B-X
,	B-X
and	B-X
p65	B-X
.	B-X
However	B-X
,	B-X
DCs	B-X
lack	B-X
Sp1	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
the	B-X
failure	B-X
of	B-X
HIV-1	B-X
to	B-X
replicate	B-X
in	B-X
purified	B-X
DCs	B-X
.	B-X
Coexpression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
occurs	B-X
in	B-X
the	B-X
heterologous	B-X
DC-T-cell	B-X
syncytia	B-X
that	B-X
are	B-X
induced	B-X
by	B-X
HIV-1	B-X
.	B-X
Since	B-X
DCs	B-X
and	B-X
memory	B-X
T	B-X
cells	B-X
frequently	B-X
traffic	B-X
together	B-X
in	B-X
situ	B-X
,	B-X
these	B-X
unusual	B-X
heterologous	B-X
syncytia	B-X
could	B-X
develop	B-X
in	B-X
infected	B-X
individuals	B-X
and	B-X
lead	B-X
to	B-X
chronic	B-X
HIV-1	B-X
replication	B-X
without	B-X
ostensible	B-X
immune	B-X
stimulation	B-X
.	B-X

We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O
<EOS>	B-X
We	B-X
have	B-X
used	B-X
immunolabeling	B-X
,	B-X
Western	B-X
blot	B-X
analysis	B-X
,	B-X
and	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
and	B-X
supershift	B-X
assays	B-X
.	B-X

T	O
cells	O
lack	O
active	O
NF	O
-	O
kappa	O
B	O
but	O
express	O
Sp1	B-Protein
as	O
expected	O
.	O
<EOS>	B-X
Productive	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
typically	B-X
requires	B-X
that	B-X
the	B-X
T	B-X
cells	B-X
be	B-X
stimulated	B-X
with	B-X
antigens	B-X
or	B-X
mitogens	B-X
.	B-X
This	B-X
requirement	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
synergizes	B-X
with	B-X
the	B-X
constitutive	B-X
transcription	B-X
factor	B-X
Sp1	B-X
to	B-X
drive	B-X
the	B-X
HIV-1	B-X
promoter	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
vigorous	B-X
replication	B-X
of	B-X
HIV-1	B-X
takes	B-X
place	B-X
in	B-X
nonactivated	B-X
memory	B-X
T	B-X
cells	B-X
after	B-X
syncytium	B-X
formation	B-X
with	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
.	B-X
These	B-X
syncytia	B-X
lack	B-X
activated	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
an	B-X
absence	B-X
of	B-X
staining	B-X
for	B-X
Ki-67	B-X
cell	B-X
cycle	B-X
antigen	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
were	B-X
,	B-X
therefore	B-X
,	B-X
analyzed	B-X
in	B-X
isolated	B-X
T	B-X
cells	B-X
and	B-X
DCs	B-X
from	B-X
humans	B-X
and	B-X
mice	B-X
.	B-X
T	B-X
cells	B-X
lack	B-X
active	B-X
NF-kappa	B-X
B	B-X
but	B-X
express	B-X
Sp1	B-X
as	B-X
expected	B-X
.	B-X
DCs	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
all	B-X
known	B-X
NF-kappa	B-X
B	B-X
and	B-X
Rel	B-X
proteins	B-X
,	B-X
with	B-X
activity	B-X
residing	B-X
primarily	B-X
within	B-X
RelB	B-X
,	B-X
p50	B-X
,	B-X
and	B-X
p65	B-X
.	B-X
However	B-X
,	B-X
DCs	B-X
lack	B-X
Sp1	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
the	B-X
failure	B-X
of	B-X
HIV-1	B-X
to	B-X
replicate	B-X
in	B-X
purified	B-X
DCs	B-X
.	B-X
Coexpression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
occurs	B-X
in	B-X
the	B-X
heterologous	B-X
DC-T-cell	B-X
syncytia	B-X
that	B-X
are	B-X
induced	B-X
by	B-X
HIV-1	B-X
.	B-X
Since	B-X
DCs	B-X
and	B-X
memory	B-X
T	B-X
cells	B-X
frequently	B-X
traffic	B-X
together	B-X
in	B-X
situ	B-X
,	B-X
these	B-X
unusual	B-X
heterologous	B-X
syncytia	B-X
could	B-X
develop	B-X
in	B-X
infected	B-X
individuals	B-X
and	B-X
lead	B-X
to	B-X
chronic	B-X
HIV-1	B-X
replication	B-X
without	B-X
ostensible	B-X
immune	B-X
stimulation	B-X
.	B-X

DCs	O
express	O
high	O
levels	O
of	O
all	O
known	O
NF	O
-	O
kappa	O
B	O
and	O
Rel	O
proteins	O
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	B-Protein
,	O
p50	B-Protein
,	O
and	O
p65	B-Protein
.	O
<EOS>	B-X
This	B-X
requirement	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
synergizes	B-X
with	B-X
the	B-X
constitutive	B-X
transcription	B-X
factor	B-X
Sp1	B-X
to	B-X
drive	B-X
the	B-X
HIV-1	B-X
promoter	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
vigorous	B-X
replication	B-X
of	B-X
HIV-1	B-X
takes	B-X
place	B-X
in	B-X
nonactivated	B-X
memory	B-X
T	B-X
cells	B-X
after	B-X
syncytium	B-X
formation	B-X
with	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
were	B-X
,	B-X
therefore	B-X
,	B-X
analyzed	B-X
in	B-X
isolated	B-X
T	B-X
cells	B-X
and	B-X
DCs	B-X
from	B-X
humans	B-X
and	B-X
mice	B-X
.	B-X
T	B-X
cells	B-X
lack	B-X
active	B-X
NF-kappa	B-X
B	B-X
but	B-X
express	B-X
Sp1	B-X
as	B-X
expected	B-X
.	B-X
DCs	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
all	B-X
known	B-X
NF-kappa	B-X
B	B-X
and	B-X
Rel	B-X
proteins	B-X
,	B-X
with	B-X
activity	B-X
residing	B-X
primarily	B-X
within	B-X
RelB	B-X
,	B-X
p50	B-X
,	B-X
and	B-X
p65	B-X
.	B-X
However	B-X
,	B-X
DCs	B-X
lack	B-X
Sp1	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
the	B-X
failure	B-X
of	B-X
HIV-1	B-X
to	B-X
replicate	B-X
in	B-X
purified	B-X
DCs	B-X
.	B-X
Coexpression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
occurs	B-X
in	B-X
the	B-X
heterologous	B-X
DC-T-cell	B-X
syncytia	B-X
that	B-X
are	B-X
induced	B-X
by	B-X
HIV-1	B-X
.	B-X
Since	B-X
DCs	B-X
and	B-X
memory	B-X
T	B-X
cells	B-X
frequently	B-X
traffic	B-X
together	B-X
in	B-X
situ	B-X
,	B-X
these	B-X
unusual	B-X
heterologous	B-X
syncytia	B-X
could	B-X
develop	B-X
in	B-X
infected	B-X
individuals	B-X
and	B-X
lead	B-X
to	B-X
chronic	B-X
HIV-1	B-X
replication	B-X
without	B-X
ostensible	B-X
immune	B-X
stimulation	B-X
.	B-X

However	O
,	O
DCs	O
lack	O
Sp1	B-Protein
,	O
which	O
may	O
explain	O
the	O
failure	O
of	O
HIV	O
-	O
1	O
to	O
replicate	O
in	O
purified	O
DCs	O
.	O
<EOS>	B-X
Productive	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
typically	B-X
requires	B-X
that	B-X
the	B-X
T	B-X
cells	B-X
be	B-X
stimulated	B-X
with	B-X
antigens	B-X
or	B-X
mitogens	B-X
.	B-X
This	B-X
requirement	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
synergizes	B-X
with	B-X
the	B-X
constitutive	B-X
transcription	B-X
factor	B-X
Sp1	B-X
to	B-X
drive	B-X
the	B-X
HIV-1	B-X
promoter	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
vigorous	B-X
replication	B-X
of	B-X
HIV-1	B-X
takes	B-X
place	B-X
in	B-X
nonactivated	B-X
memory	B-X
T	B-X
cells	B-X
after	B-X
syncytium	B-X
formation	B-X
with	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
.	B-X
These	B-X
syncytia	B-X
lack	B-X
activated	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
an	B-X
absence	B-X
of	B-X
staining	B-X
for	B-X
Ki-67	B-X
cell	B-X
cycle	B-X
antigen	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
were	B-X
,	B-X
therefore	B-X
,	B-X
analyzed	B-X
in	B-X
isolated	B-X
T	B-X
cells	B-X
and	B-X
DCs	B-X
from	B-X
humans	B-X
and	B-X
mice	B-X
.	B-X
T	B-X
cells	B-X
lack	B-X
active	B-X
NF-kappa	B-X
B	B-X
but	B-X
express	B-X
Sp1	B-X
as	B-X
expected	B-X
.	B-X
DCs	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
all	B-X
known	B-X
NF-kappa	B-X
B	B-X
and	B-X
Rel	B-X
proteins	B-X
,	B-X
with	B-X
activity	B-X
residing	B-X
primarily	B-X
within	B-X
RelB	B-X
,	B-X
p50	B-X
,	B-X
and	B-X
p65	B-X
.	B-X
However	B-X
,	B-X
DCs	B-X
lack	B-X
Sp1	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
the	B-X
failure	B-X
of	B-X
HIV-1	B-X
to	B-X
replicate	B-X
in	B-X
purified	B-X
DCs	B-X
.	B-X
Coexpression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
occurs	B-X
in	B-X
the	B-X
heterologous	B-X
DC-T-cell	B-X
syncytia	B-X
that	B-X
are	B-X
induced	B-X
by	B-X
HIV-1	B-X
.	B-X
Therefore	B-X
,	B-X
HIV-1-induced	B-X
cell	B-X
fusion	B-X
brings	B-X
together	B-X
factors	B-X
that	B-X
upregulate	B-X
virus	B-X
transcription	B-X
.	B-X
Since	B-X
DCs	B-X
and	B-X
memory	B-X
T	B-X
cells	B-X
frequently	B-X
traffic	B-X
together	B-X
in	B-X
situ	B-X
,	B-X
these	B-X
unusual	B-X
heterologous	B-X
syncytia	B-X
could	B-X
develop	B-X
in	B-X
infected	B-X
individuals	B-X
and	B-X
lead	B-X
to	B-X
chronic	B-X
HIV-1	B-X
replication	B-X
without	B-X
ostensible	B-X
immune	B-X
stimulation	B-X
.	B-X

Coexpression	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	B-Protein
occurs	O
in	O
the	O
heterologous	O
DC	O
-	O
T	O
-	O
cell	O
syncytia	O
that	O
are	O
induced	O
by	O
HIV	O
-	O
1	O
.	O
<EOS>	B-X
Productive	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
typically	B-X
requires	B-X
that	B-X
the	B-X
T	B-X
cells	B-X
be	B-X
stimulated	B-X
with	B-X
antigens	B-X
or	B-X
mitogens	B-X
.	B-X
This	B-X
requirement	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
synergizes	B-X
with	B-X
the	B-X
constitutive	B-X
transcription	B-X
factor	B-X
Sp1	B-X
to	B-X
drive	B-X
the	B-X
HIV-1	B-X
promoter	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
vigorous	B-X
replication	B-X
of	B-X
HIV-1	B-X
takes	B-X
place	B-X
in	B-X
nonactivated	B-X
memory	B-X
T	B-X
cells	B-X
after	B-X
syncytium	B-X
formation	B-X
with	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
.	B-X
These	B-X
syncytia	B-X
lack	B-X
activated	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
an	B-X
absence	B-X
of	B-X
staining	B-X
for	B-X
Ki-67	B-X
cell	B-X
cycle	B-X
antigen	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
were	B-X
,	B-X
therefore	B-X
,	B-X
analyzed	B-X
in	B-X
isolated	B-X
T	B-X
cells	B-X
and	B-X
DCs	B-X
from	B-X
humans	B-X
and	B-X
mice	B-X
.	B-X
T	B-X
cells	B-X
lack	B-X
active	B-X
NF-kappa	B-X
B	B-X
but	B-X
express	B-X
Sp1	B-X
as	B-X
expected	B-X
.	B-X
DCs	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
all	B-X
known	B-X
NF-kappa	B-X
B	B-X
and	B-X
Rel	B-X
proteins	B-X
,	B-X
with	B-X
activity	B-X
residing	B-X
primarily	B-X
within	B-X
RelB	B-X
,	B-X
p50	B-X
,	B-X
and	B-X
p65	B-X
.	B-X
However	B-X
,	B-X
DCs	B-X
lack	B-X
Sp1	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
the	B-X
failure	B-X
of	B-X
HIV-1	B-X
to	B-X
replicate	B-X
in	B-X
purified	B-X
DCs	B-X
.	B-X
Coexpression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
occurs	B-X
in	B-X
the	B-X
heterologous	B-X
DC-T-cell	B-X
syncytia	B-X
that	B-X
are	B-X
induced	B-X
by	B-X
HIV-1	B-X
.	B-X
Therefore	B-X
,	B-X
HIV-1-induced	B-X
cell	B-X
fusion	B-X
brings	B-X
together	B-X
factors	B-X
that	B-X
upregulate	B-X
virus	B-X
transcription	B-X
.	B-X
Since	B-X
DCs	B-X
and	B-X
memory	B-X
T	B-X
cells	B-X
frequently	B-X
traffic	B-X
together	B-X
in	B-X
situ	B-X
,	B-X
these	B-X
unusual	B-X
heterologous	B-X
syncytia	B-X
could	B-X
develop	B-X
in	B-X
infected	B-X
individuals	B-X
and	B-X
lead	B-X
to	B-X
chronic	B-X
HIV-1	B-X
replication	B-X
without	B-X
ostensible	B-X
immune	B-X
stimulation	B-X
.	B-X

Therefore	O
,	O
HIV	O
-	O
1	O
-	O
induced	O
cell	O
fusion	O
brings	O
together	O
factors	O
that	O
upregulate	O
virus	O
transcription	O
.	O
<EOS>	B-X
Productive	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
typically	B-X
requires	B-X
that	B-X
the	B-X
T	B-X
cells	B-X
be	B-X
stimulated	B-X
with	B-X
antigens	B-X
or	B-X
mitogens	B-X
.	B-X
This	B-X
requirement	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
synergizes	B-X
with	B-X
the	B-X
constitutive	B-X
transcription	B-X
factor	B-X
Sp1	B-X
to	B-X
drive	B-X
the	B-X
HIV-1	B-X
promoter	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
vigorous	B-X
replication	B-X
of	B-X
HIV-1	B-X
takes	B-X
place	B-X
in	B-X
nonactivated	B-X
memory	B-X
T	B-X
cells	B-X
after	B-X
syncytium	B-X
formation	B-X
with	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
.	B-X
These	B-X
syncytia	B-X
lack	B-X
activated	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
an	B-X
absence	B-X
of	B-X
staining	B-X
for	B-X
Ki-67	B-X
cell	B-X
cycle	B-X
antigen	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
were	B-X
,	B-X
therefore	B-X
,	B-X
analyzed	B-X
in	B-X
isolated	B-X
T	B-X
cells	B-X
and	B-X
DCs	B-X
from	B-X
humans	B-X
and	B-X
mice	B-X
.	B-X
T	B-X
cells	B-X
lack	B-X
active	B-X
NF-kappa	B-X
B	B-X
but	B-X
express	B-X
Sp1	B-X
as	B-X
expected	B-X
.	B-X
However	B-X
,	B-X
DCs	B-X
lack	B-X
Sp1	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
the	B-X
failure	B-X
of	B-X
HIV-1	B-X
to	B-X
replicate	B-X
in	B-X
purified	B-X
DCs	B-X
.	B-X
Coexpression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
occurs	B-X
in	B-X
the	B-X
heterologous	B-X
DC-T-cell	B-X
syncytia	B-X
that	B-X
are	B-X
induced	B-X
by	B-X
HIV-1	B-X
.	B-X
Therefore	B-X
,	B-X
HIV-1-induced	B-X
cell	B-X
fusion	B-X
brings	B-X
together	B-X
factors	B-X
that	B-X
upregulate	B-X
virus	B-X
transcription	B-X
.	B-X
Since	B-X
DCs	B-X
and	B-X
memory	B-X
T	B-X
cells	B-X
frequently	B-X
traffic	B-X
together	B-X
in	B-X
situ	B-X
,	B-X
these	B-X
unusual	B-X
heterologous	B-X
syncytia	B-X
could	B-X
develop	B-X
in	B-X
infected	B-X
individuals	B-X
and	B-X
lead	B-X
to	B-X
chronic	B-X
HIV-1	B-X
replication	B-X
without	B-X
ostensible	B-X
immune	B-X
stimulation	B-X
.	B-X

Since	O
DCs	O
and	O
memory	O
T	O
cells	O
frequently	O
traffic	O
together	O
in	O
situ	O
,	O
these	O
unusual	O
heterologous	O
syncytia	O
could	O
develop	O
in	O
infected	O
individuals	O
and	O
lead	O
to	O
chronic	O
HIV	O
-	O
1	O
replication	O
without	O
ostensible	O
immune	O
stimulation	O
.	O
<EOS>	B-X
Productive	B-X
infection	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
typically	B-X
requires	B-X
that	B-X
the	B-X
T	B-X
cells	B-X
be	B-X
stimulated	B-X
with	B-X
antigens	B-X
or	B-X
mitogens	B-X
.	B-X
This	B-X
requirement	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
synergizes	B-X
with	B-X
the	B-X
constitutive	B-X
transcription	B-X
factor	B-X
Sp1	B-X
to	B-X
drive	B-X
the	B-X
HIV-1	B-X
promoter	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
found	B-X
that	B-X
vigorous	B-X
replication	B-X
of	B-X
HIV-1	B-X
takes	B-X
place	B-X
in	B-X
nonactivated	B-X
memory	B-X
T	B-X
cells	B-X
after	B-X
syncytium	B-X
formation	B-X
with	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
.	B-X
These	B-X
syncytia	B-X
lack	B-X
activated	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
an	B-X
absence	B-X
of	B-X
staining	B-X
for	B-X
Ki-67	B-X
cell	B-X
cycle	B-X
antigen	B-X
.	B-X
The	B-X
expression	B-X
and	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
were	B-X
,	B-X
therefore	B-X
,	B-X
analyzed	B-X
in	B-X
isolated	B-X
T	B-X
cells	B-X
and	B-X
DCs	B-X
from	B-X
humans	B-X
and	B-X
mice	B-X
.	B-X
T	B-X
cells	B-X
lack	B-X
active	B-X
NF-kappa	B-X
B	B-X
but	B-X
express	B-X
Sp1	B-X
as	B-X
expected	B-X
.	B-X
DCs	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
all	B-X
known	B-X
NF-kappa	B-X
B	B-X
and	B-X
Rel	B-X
proteins	B-X
,	B-X
with	B-X
activity	B-X
residing	B-X
primarily	B-X
within	B-X
RelB	B-X
,	B-X
p50	B-X
,	B-X
and	B-X
p65	B-X
.	B-X
However	B-X
,	B-X
DCs	B-X
lack	B-X
Sp1	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
the	B-X
failure	B-X
of	B-X
HIV-1	B-X
to	B-X
replicate	B-X
in	B-X
purified	B-X
DCs	B-X
.	B-X
Coexpression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
Sp1	B-X
occurs	B-X
in	B-X
the	B-X
heterologous	B-X
DC-T-cell	B-X
syncytia	B-X
that	B-X
are	B-X
induced	B-X
by	B-X
HIV-1	B-X
.	B-X
Therefore	B-X
,	B-X
HIV-1-induced	B-X
cell	B-X
fusion	B-X
brings	B-X
together	B-X
factors	B-X
that	B-X
upregulate	B-X
virus	B-X
transcription	B-X
.	B-X
Since	B-X
DCs	B-X
and	B-X
memory	B-X
T	B-X
cells	B-X
frequently	B-X
traffic	B-X
together	B-X
in	B-X
situ	B-X
,	B-X
these	B-X
unusual	B-X
heterologous	B-X
syncytia	B-X
could	B-X
develop	B-X
in	B-X
infected	B-X
individuals	B-X
and	B-X
lead	B-X
to	B-X
chronic	B-X
HIV-1	B-X
replication	B-X
without	B-X
ostensible	B-X
immune	B-X
stimulation	B-X
.	B-X

Costimulation	O
requirement	O
for	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
activation	O
in	O
T	O
cells	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
requires	O
T	O
-	O
cell	O
costimulation	O
delivered	O
by	O
the	O
TCR	O
and	O
the	O
auxiliary	O
receptor	O
CD28	B-Protein
.	O
<EOS>	B-X
The	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
requires	B-X
T-cell	B-X
costimulation	B-X
delivered	B-X
by	B-X
the	B-X
TCR	B-X
and	B-X
the	B-X
auxiliary	B-X
receptor	B-X
CD28	B-X
.	B-X
Several	B-X
transcription	B-X
factors	B-X
participate	B-X
in	B-X
IL-2	B-X
promoter	B-X
activation	B-X
,	B-X
among	B-X
which	B-X
are	B-X
AP-1-like	B-X
factors	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
Protein	B-X
phosphorylation	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
these	B-X
two	B-X
factors	B-X
:	B-X
(	B-X
1	B-X
)	B-X
it	B-X
induces	B-X
the	B-X
transactivating	B-X
capacity	B-X
of	B-X
the	B-X
AP-1	B-X
protein	B-X
c-Jun	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
release	B-X
of	B-X
the	B-X
cytoplasmic	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
from	B-X
NF-kappa	B-X
B	B-X
,	B-X
allowing	B-X
translocation	B-X
of	B-X
the	B-X
latter	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
both	B-X
phosphorylation	B-X
processes	B-X
require	B-X
T-cell	B-X
costimulation	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
kinetics	B-X
of	B-X
the	B-X
two	B-X
phosphorylation	B-X
events	B-X
are	B-X
essentially	B-X
similar	B-X
.	B-X
Whereas	B-X
TPCK	B-X
inhibits	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
and	B-X
,	B-X
consequently	B-X
,	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
it	B-X
markedly	B-X
enhances	B-X
the	B-X
activity	B-X
of	B-X
JNK	B-X
,	B-X
the	B-X
MAP	B-X
kinase-related	B-X
kinase	B-X
that	B-X
phosphorylates	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
c-Jun	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
propose	B-X
the	B-X
activation	B-X
scheme	B-X
presented	B-X
in	B-X
FIGURE	B-X
3	B-X
for	B-X
T-cell	B-X
costimulation	B-X
.	B-X
Integration	B-X
of	B-X
the	B-X
signals	B-X
generated	B-X
by	B-X
TCR	B-X
and	B-X
CD28	B-X
engagement	B-X
occurs	B-X
along	B-X
this	B-X
pathway	B-X
,	B-X
which	B-X
then	B-X
bifurcates	B-X
to	B-X
induce	B-X
I	B-X
kappa	B-X
B	B-X
phosphorylation	B-X
and	B-X
NF-kappa	B-X
B	B-X
activation	B-X
on	B-X
the	B-X
one	B-X
hand	B-X
,	B-X
and	B-X
JNK	B-X
activation	B-X
and	B-X
c-Jun	B-X
phosphorylation	B-X
on	B-X
the	B-X
other	B-X
.	B-X

Several	O
transcription	O
factors	O
participate	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
activation	O
,	O
among	O
which	O
are	O
AP	O
-	O
1	O
-	O
like	O
factors	O
and	O
NF	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
The	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
requires	B-X
T-cell	B-X
costimulation	B-X
delivered	B-X
by	B-X
the	B-X
TCR	B-X
and	B-X
the	B-X
auxiliary	B-X
receptor	B-X
CD28	B-X
.	B-X
Several	B-X
transcription	B-X
factors	B-X
participate	B-X
in	B-X
IL-2	B-X
promoter	B-X
activation	B-X
,	B-X
among	B-X
which	B-X
are	B-X
AP-1-like	B-X
factors	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
Protein	B-X
phosphorylation	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
these	B-X
two	B-X
factors	B-X
:	B-X
(	B-X
1	B-X
)	B-X
it	B-X
induces	B-X
the	B-X
transactivating	B-X
capacity	B-X
of	B-X
the	B-X
AP-1	B-X
protein	B-X
c-Jun	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
release	B-X
of	B-X
the	B-X
cytoplasmic	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
from	B-X
NF-kappa	B-X
B	B-X
,	B-X
allowing	B-X
translocation	B-X
of	B-X
the	B-X
latter	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
Whereas	B-X
TPCK	B-X
inhibits	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
and	B-X
,	B-X
consequently	B-X
,	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
it	B-X
markedly	B-X
enhances	B-X
the	B-X
activity	B-X
of	B-X
JNK	B-X
,	B-X
the	B-X
MAP	B-X
kinase-related	B-X
kinase	B-X
that	B-X
phosphorylates	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
c-Jun	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
propose	B-X
the	B-X
activation	B-X
scheme	B-X
presented	B-X
in	B-X
FIGURE	B-X
3	B-X
for	B-X
T-cell	B-X
costimulation	B-X
.	B-X
Costimulation	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
signaling	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
simultaneous	B-X
induction	B-X
of	B-X
the	B-X
two	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
Integration	B-X
of	B-X
the	B-X
signals	B-X
generated	B-X
by	B-X
TCR	B-X
and	B-X
CD28	B-X
engagement	B-X
occurs	B-X
along	B-X
this	B-X
pathway	B-X
,	B-X
which	B-X
then	B-X
bifurcates	B-X
to	B-X
induce	B-X
I	B-X
kappa	B-X
B	B-X
phosphorylation	B-X
and	B-X
NF-kappa	B-X
B	B-X
activation	B-X
on	B-X
the	B-X
one	B-X
hand	B-X
,	B-X
and	B-X
JNK	B-X
activation	B-X
and	B-X
c-Jun	B-X
phosphorylation	B-X
on	B-X
the	B-X
other	B-X
.	B-X
We	B-X
are	B-X
currently	B-X
engaged	B-X
in	B-X
defining	B-X
where	B-X
the	B-X
two	B-X
signals	B-X
integrate	B-X
along	B-X
the	B-X
AP-1/NF-kappa	B-X
B	B-X
pathway	B-X
.	B-X

Protein	O
phosphorylation	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors	O
:	O
(	O
1	O
)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP	O
-	O
1	O
protein	O
c	B-Protein
-	I-Protein
Jun	I-Protein
;	O
and	O
(	O
2	O
)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	O
inhibitor	O
,	O
I	O
kappa	O
B	O
,	O
from	O
NF	O
-	O
kappa	O
B	O
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O
<EOS>	B-X
The	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
requires	B-X
T-cell	B-X
costimulation	B-X
delivered	B-X
by	B-X
the	B-X
TCR	B-X
and	B-X
the	B-X
auxiliary	B-X
receptor	B-X
CD28	B-X
.	B-X
Several	B-X
transcription	B-X
factors	B-X
participate	B-X
in	B-X
IL-2	B-X
promoter	B-X
activation	B-X
,	B-X
among	B-X
which	B-X
are	B-X
AP-1-like	B-X
factors	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
Protein	B-X
phosphorylation	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
these	B-X
two	B-X
factors	B-X
:	B-X
(	B-X
1	B-X
)	B-X
it	B-X
induces	B-X
the	B-X
transactivating	B-X
capacity	B-X
of	B-X
the	B-X
AP-1	B-X
protein	B-X
c-Jun	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
release	B-X
of	B-X
the	B-X
cytoplasmic	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
from	B-X
NF-kappa	B-X
B	B-X
,	B-X
allowing	B-X
translocation	B-X
of	B-X
the	B-X
latter	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
both	B-X
phosphorylation	B-X
processes	B-X
require	B-X
T-cell	B-X
costimulation	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
kinetics	B-X
of	B-X
the	B-X
two	B-X
phosphorylation	B-X
events	B-X
are	B-X
essentially	B-X
similar	B-X
.	B-X
According	B-X
to	B-X
our	B-X
results	B-X
,	B-X
however	B-X
,	B-X
the	B-X
kinases	B-X
responsible	B-X
for	B-X
the	B-X
two	B-X
processes	B-X
are	B-X
distinct	B-X
entities	B-X
.	B-X
Whereas	B-X
TPCK	B-X
inhibits	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
and	B-X
,	B-X
consequently	B-X
,	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
it	B-X
markedly	B-X
enhances	B-X
the	B-X
activity	B-X
of	B-X
JNK	B-X
,	B-X
the	B-X
MAP	B-X
kinase-related	B-X
kinase	B-X
that	B-X
phosphorylates	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
c-Jun	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
propose	B-X
the	B-X
activation	B-X
scheme	B-X
presented	B-X
in	B-X
FIGURE	B-X
3	B-X
for	B-X
T-cell	B-X
costimulation	B-X
.	B-X
Costimulation	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
signaling	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
simultaneous	B-X
induction	B-X
of	B-X
the	B-X
two	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
Integration	B-X
of	B-X
the	B-X
signals	B-X
generated	B-X
by	B-X
TCR	B-X
and	B-X
CD28	B-X
engagement	B-X
occurs	B-X
along	B-X
this	B-X
pathway	B-X
,	B-X
which	B-X
then	B-X
bifurcates	B-X
to	B-X
induce	B-X
I	B-X
kappa	B-X
B	B-X
phosphorylation	B-X
and	B-X
NF-kappa	B-X
B	B-X
activation	B-X
on	B-X
the	B-X
one	B-X
hand	B-X
,	B-X
and	B-X
JNK	B-X
activation	B-X
and	B-X
c-Jun	B-X
phosphorylation	B-X
on	B-X
the	B-X
other	B-X
.	B-X
We	B-X
are	B-X
currently	B-X
engaged	B-X
in	B-X
defining	B-X
where	B-X
the	B-X
two	B-X
signals	B-X
integrate	B-X
along	B-X
the	B-X
AP-1/NF-kappa	B-X
B	B-X
pathway	B-X
.	B-X

We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T	O
-	O
cell	O
costimulation	O
.	O
<EOS>	B-X
Which	B-X
can	B-X
either	B-X
be	B-X
direct	B-X
where	B-X
donor	B-X
antigens	B-X
of	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
expressed	B-X
on	B-X
the	B-X
donor	B-X
cells	B-X
(	B-X
passenger	B-X
leukocytes	B-X
)	B-X
or	B-X
tissues	B-X
are	B-X
recognised	B-X
by	B-X
the	B-X
host	B-X
immune	B-X
system	B-X
.	B-X
Alternatively	B-X
processed	B-X
donor	B-X
MHC	B-X
peptides	B-X
presented	B-X
by	B-X
the	B-X
recipient	B-X
antigen	B-X
presenting	B-X
cells	B-X
(	B-X
APC	B-X
)	B-X
initiate	B-X
the	B-X
indirect	B-X
pathway	B-X
of	B-X
immune	B-X
response	B-X
,	B-X
which	B-X
is	B-X
as	B-X
important	B-X
as	B-X
the	B-X
direct	B-X
recognition	B-X
especially	B-X
in	B-X
chronic	B-X
rejection	B-X
.	B-X
Recognition	B-X
is	B-X
followed	B-X
by	B-X
the	B-X
ligation	B-X
of	B-X
a	B-X
series	B-X
of	B-X
adhesion	B-X
molecules	B-X
starting	B-X
with	B-X
an	B-X
antigen	B-X
to	B-X
its	B-X
specific	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
/cluster	B-X
of	B-X
differentiation	B-X
(	B-X
CD	B-X
)	B-X
complex	B-X
,	B-X
expressed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
.	B-X
In	B-X
order	B-X
for	B-X
the	B-X
activation	B-X
to	B-X
precede	B-X
additional	B-X
costimulatory	B-X
signals	B-X
,	B-X
such	B-X
as	B-X
ligation	B-X
of	B-X
the	B-X
CD28/B7	B-X
,	B-X
CD4/HLA	B-X
class	B-X
II	B-X
and	B-X
CD/HLA	B-X
class	B-X
I	B-X
antigens	B-X
are	B-X
required	B-X
.	B-X
The	B-X
activation	B-X
process	B-X
is	B-X
accompanied	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
cytokines	B-X
production	B-X
such	B-X
as	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
,	B-X
IL-12	B-X
,	B-X
interferon	B-X
(	B-X
INF	B-X
)	B-X
and	B-X
tumour	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
by	B-X
the	B-X
primed	B-X
T	B-X
cell	B-X
.	B-X
Rapamycin	B-X
,	B-X
which	B-X
is	B-X
similar	B-X
to	B-X
Tacrolimus	B-X
,	B-X
inhibits	B-X
graft	B-X
rejection	B-X
by	B-X
blocking	B-X
IL-2	B-X
activation	B-X
and	B-X
phosphorylation	B-X
of	B-X
70	B-X
S6	B-X
kinase	B-X
thus	B-X
inhibiting	B-X
the	B-X
progression	B-X
of	B-X
T-cell	B-X
from	B-X
G	B-X
to	B-X
S	B-X
phase	B-X
.	B-X
While	B-X
Cellcept	B-X
(	B-X
MMF	B-X
)	B-X
reduce	B-X
the	B-X
proliferation	B-X
of	B-X
T	B-X
cell	B-X
by	B-X
inhibiting	B-X
purine	B-X
synthesis	B-X
and	B-X
by	B-X
its	B-X
action	B-X
on	B-X
ionosine	B-X
monophosphate	B-X
dehydrogenase	B-X
.	B-X
Anti-lymphocyte	B-X
antibodies	B-X
(	B-X
ATG	B-X
)	B-X
deplete	B-X
circulating	B-X
lymphocytes	B-X
while	B-X
selective	B-X
monoclonal	B-X
antibodies	B-X
are	B-X
directed	B-X
against	B-X
IL-2	B-X
receptor	B-X
thus	B-X
reducing	B-X
the	B-X
rate	B-X
of	B-X
proliferation	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X
Recently	B-X
,	B-X
antibodies	B-X
to	B-X
the	B-X
CD40/CD40	B-X
ligand	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
induce	B-X
long-term	B-X
graft	B-X
survival	B-X
with	B-X
the	B-X
inhibition	B-X
of	B-X
the	B-X
Th1	B-X
cytokines	B-X
(	B-X
INF	B-X
)	B-X
,	B-X
IL-2	B-X
and	B-X
IL-12	B-X
and	B-X
upregulating	B-X
the	B-X
Th2	B-X
cytokines	B-X
IL-4	B-X
and	B-X
IL-10	B-X
.	B-X
Lastly	B-X
graft	B-X
rejection	B-X
can	B-X
be	B-X
reduced	B-X
by	B-X
blockade	B-X
of	B-X
the	B-X
B7/CD28	B-X
costimulation	B-X
pathway	B-X
with	B-X
the	B-X
fusion	B-X
protein	B-X
CTLA-4Ig	B-X
.	B-X

Furthermore	O
,	O
in	O
activated	O
T	O
cells	O
,	O
the	O
kinetics	O
of	O
the	O
two	O
phosphorylation	O
events	O
are	O
essentially	O
similar	O
.	O
<EOS>	B-X
Protein	B-X
phosphorylation	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
these	B-X
two	B-X
factors	B-X
:	B-X
(	B-X
1	B-X
)	B-X
it	B-X
induces	B-X
the	B-X
transactivating	B-X
capacity	B-X
of	B-X
the	B-X
AP-1	B-X
protein	B-X
c-Jun	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
release	B-X
of	B-X
the	B-X
cytoplasmic	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
from	B-X
NF-kappa	B-X
B	B-X
,	B-X
allowing	B-X
translocation	B-X
of	B-X
the	B-X
latter	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
both	B-X
phosphorylation	B-X
processes	B-X
require	B-X
T-cell	B-X
costimulation	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
kinetics	B-X
of	B-X
the	B-X
two	B-X
phosphorylation	B-X
events	B-X
are	B-X
essentially	B-X
similar	B-X
.	B-X
According	B-X
to	B-X
our	B-X
results	B-X
,	B-X
however	B-X
,	B-X
the	B-X
kinases	B-X
responsible	B-X
for	B-X
the	B-X
two	B-X
processes	B-X
are	B-X
distinct	B-X
entities	B-X
.	B-X
Whereas	B-X
TPCK	B-X
inhibits	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
and	B-X
,	B-X
consequently	B-X
,	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
it	B-X
markedly	B-X
enhances	B-X
the	B-X
activity	B-X
of	B-X
JNK	B-X
,	B-X
the	B-X
MAP	B-X
kinase-related	B-X
kinase	B-X
that	B-X
phosphorylates	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
c-Jun	B-X
.	B-X
Costimulation	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
signaling	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
simultaneous	B-X
induction	B-X
of	B-X
the	B-X
two	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
Integration	B-X
of	B-X
the	B-X
signals	B-X
generated	B-X
by	B-X
TCR	B-X
and	B-X
CD28	B-X
engagement	B-X
occurs	B-X
along	B-X
this	B-X
pathway	B-X
,	B-X
which	B-X
then	B-X
bifurcates	B-X
to	B-X
induce	B-X
I	B-X
kappa	B-X
B	B-X
phosphorylation	B-X
and	B-X
NF-kappa	B-X
B	B-X
activation	B-X
on	B-X
the	B-X
one	B-X
hand	B-X
,	B-X
and	B-X
JNK	B-X
activation	B-X
and	B-X
c-Jun	B-X
phosphorylation	B-X
on	B-X
the	B-X
other	B-X
.	B-X
We	B-X
are	B-X
currently	B-X
engaged	B-X
in	B-X
defining	B-X
where	B-X
the	B-X
two	B-X
signals	B-X
integrate	B-X
along	B-X
the	B-X
AP-1/NF-kappa	B-X
B	B-X
pathway	B-X
.	B-X

According	O
to	O
our	O
results	O
,	O
however	O
,	O
the	O
kinases	O
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O
entities	O
.	O
<EOS>	B-X
Protein	B-X
phosphorylation	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
these	B-X
two	B-X
factors	B-X
:	B-X
(	B-X
1	B-X
)	B-X
it	B-X
induces	B-X
the	B-X
transactivating	B-X
capacity	B-X
of	B-X
the	B-X
AP-1	B-X
protein	B-X
c-Jun	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
release	B-X
of	B-X
the	B-X
cytoplasmic	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
from	B-X
NF-kappa	B-X
B	B-X
,	B-X
allowing	B-X
translocation	B-X
of	B-X
the	B-X
latter	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
both	B-X
phosphorylation	B-X
processes	B-X
require	B-X
T-cell	B-X
costimulation	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
kinetics	B-X
of	B-X
the	B-X
two	B-X
phosphorylation	B-X
events	B-X
are	B-X
essentially	B-X
similar	B-X
.	B-X
According	B-X
to	B-X
our	B-X
results	B-X
,	B-X
however	B-X
,	B-X
the	B-X
kinases	B-X
responsible	B-X
for	B-X
the	B-X
two	B-X
processes	B-X
are	B-X
distinct	B-X
entities	B-X
.	B-X
Costimulation	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
signaling	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
simultaneous	B-X
induction	B-X
of	B-X
the	B-X
two	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
We	B-X
are	B-X
currently	B-X
engaged	B-X
in	B-X
defining	B-X
where	B-X
the	B-X
two	B-X
signals	B-X
integrate	B-X
along	B-X
the	B-X
AP-1/NF-kappa	B-X
B	B-X
pathway	B-X
.	B-X

Whereas	O
TPCK	O
inhibits	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
and	O
,	O
consequently	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	O
,	O
the	O
MAP	O
kinase	O
-	O
related	O
kinase	O
that	O
phosphorylates	O
the	O
transactivation	O
domain	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
.	O
<EOS>	B-X
The	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
requires	B-X
T-cell	B-X
costimulation	B-X
delivered	B-X
by	B-X
the	B-X
TCR	B-X
and	B-X
the	B-X
auxiliary	B-X
receptor	B-X
CD28	B-X
.	B-X
Several	B-X
transcription	B-X
factors	B-X
participate	B-X
in	B-X
IL-2	B-X
promoter	B-X
activation	B-X
,	B-X
among	B-X
which	B-X
are	B-X
AP-1-like	B-X
factors	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
Protein	B-X
phosphorylation	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
these	B-X
two	B-X
factors	B-X
:	B-X
(	B-X
1	B-X
)	B-X
it	B-X
induces	B-X
the	B-X
transactivating	B-X
capacity	B-X
of	B-X
the	B-X
AP-1	B-X
protein	B-X
c-Jun	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
release	B-X
of	B-X
the	B-X
cytoplasmic	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
from	B-X
NF-kappa	B-X
B	B-X
,	B-X
allowing	B-X
translocation	B-X
of	B-X
the	B-X
latter	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
both	B-X
phosphorylation	B-X
processes	B-X
require	B-X
T-cell	B-X
costimulation	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
kinetics	B-X
of	B-X
the	B-X
two	B-X
phosphorylation	B-X
events	B-X
are	B-X
essentially	B-X
similar	B-X
.	B-X
According	B-X
to	B-X
our	B-X
results	B-X
,	B-X
however	B-X
,	B-X
the	B-X
kinases	B-X
responsible	B-X
for	B-X
the	B-X
two	B-X
processes	B-X
are	B-X
distinct	B-X
entities	B-X
.	B-X
Whereas	B-X
TPCK	B-X
inhibits	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
and	B-X
,	B-X
consequently	B-X
,	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
it	B-X
markedly	B-X
enhances	B-X
the	B-X
activity	B-X
of	B-X
JNK	B-X
,	B-X
the	B-X
MAP	B-X
kinase-related	B-X
kinase	B-X
that	B-X
phosphorylates	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
c-Jun	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
propose	B-X
the	B-X
activation	B-X
scheme	B-X
presented	B-X
in	B-X
FIGURE	B-X
3	B-X
for	B-X
T-cell	B-X
costimulation	B-X
.	B-X
Costimulation	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
signaling	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
simultaneous	B-X
induction	B-X
of	B-X
the	B-X
two	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
Integration	B-X
of	B-X
the	B-X
signals	B-X
generated	B-X
by	B-X
TCR	B-X
and	B-X
CD28	B-X
engagement	B-X
occurs	B-X
along	B-X
this	B-X
pathway	B-X
,	B-X
which	B-X
then	B-X
bifurcates	B-X
to	B-X
induce	B-X
I	B-X
kappa	B-X
B	B-X
phosphorylation	B-X
and	B-X
NF-kappa	B-X
B	B-X
activation	B-X
on	B-X
the	B-X
one	B-X
hand	B-X
,	B-X
and	B-X
JNK	B-X
activation	B-X
and	B-X
c-Jun	B-X
phosphorylation	B-X
on	B-X
the	B-X
other	B-X
.	B-X
We	B-X
are	B-X
currently	B-X
engaged	B-X
in	B-X
defining	B-X
where	B-X
the	B-X
two	B-X
signals	B-X
integrate	B-X
along	B-X
the	B-X
AP-1/NF-kappa	B-X
B	B-X
pathway	B-X
.	B-X

We	O
,	O
therefore	O
,	O
propose	O
the	O
activation	O
scheme	O
presented	O
in	O
FIGURE	O
3	O
for	O
T	O
-	O
cell	O
costimulation	O
.	O

Costimulation	O
results	O
in	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
that	O
leads	O
to	O
the	O
simultaneous	O
induction	O
of	O
the	O
two	O
transcription	O
factors	O
,	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	O
and	O
CD28	B-Protein
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	O
kappa	O
B	O
phosphorylation	O
and	O
NF	O
-	O
kappa	O
B	O
activation	O
on	O
the	O
one	O
hand	O
,	O
and	O
JNK	O
activation	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
phosphorylation	O
on	O
the	O
other	O
.	O

We	O
are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP	O
-	O
1	O
/	O
NF	O
-	O
kappa	O
B	O
pathway	O
.	O
<EOS>	B-X
Several	B-X
transcription	B-X
factors	B-X
participate	B-X
in	B-X
IL-2	B-X
promoter	B-X
activation	B-X
,	B-X
among	B-X
which	B-X
are	B-X
AP-1-like	B-X
factors	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
Protein	B-X
phosphorylation	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
these	B-X
two	B-X
factors	B-X
:	B-X
(	B-X
1	B-X
)	B-X
it	B-X
induces	B-X
the	B-X
transactivating	B-X
capacity	B-X
of	B-X
the	B-X
AP-1	B-X
protein	B-X
c-Jun	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
it	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
release	B-X
of	B-X
the	B-X
cytoplasmic	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
from	B-X
NF-kappa	B-X
B	B-X
,	B-X
allowing	B-X
translocation	B-X
of	B-X
the	B-X
latter	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
Furthermore	B-X
,	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
,	B-X
the	B-X
kinetics	B-X
of	B-X
the	B-X
two	B-X
phosphorylation	B-X
events	B-X
are	B-X
essentially	B-X
similar	B-X
.	B-X
According	B-X
to	B-X
our	B-X
results	B-X
,	B-X
however	B-X
,	B-X
the	B-X
kinases	B-X
responsible	B-X
for	B-X
the	B-X
two	B-X
processes	B-X
are	B-X
distinct	B-X
entities	B-X
.	B-X
Whereas	B-X
TPCK	B-X
inhibits	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
and	B-X
,	B-X
consequently	B-X
,	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
it	B-X
markedly	B-X
enhances	B-X
the	B-X
activity	B-X
of	B-X
JNK	B-X
,	B-X
the	B-X
MAP	B-X
kinase-related	B-X
kinase	B-X
that	B-X
phosphorylates	B-X
the	B-X
transactivation	B-X
domain	B-X
of	B-X
c-Jun	B-X
.	B-X
Costimulation	B-X
results	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
a	B-X
signaling	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
simultaneous	B-X
induction	B-X
of	B-X
the	B-X
two	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
Integration	B-X
of	B-X
the	B-X
signals	B-X
generated	B-X
by	B-X
TCR	B-X
and	B-X
CD28	B-X
engagement	B-X
occurs	B-X
along	B-X
this	B-X
pathway	B-X
,	B-X
which	B-X
then	B-X
bifurcates	B-X
to	B-X
induce	B-X
I	B-X
kappa	B-X
B	B-X
phosphorylation	B-X
and	B-X
NF-kappa	B-X
B	B-X
activation	B-X
on	B-X
the	B-X
one	B-X
hand	B-X
,	B-X
and	B-X
JNK	B-X
activation	B-X
and	B-X
c-Jun	B-X
phosphorylation	B-X
on	B-X
the	B-X
other	B-X
.	B-X
We	B-X
are	B-X
currently	B-X
engaged	B-X
in	B-X
defining	B-X
where	B-X
the	B-X
two	B-X
signals	B-X
integrate	B-X
along	B-X
the	B-X
AP-1/NF-kappa	B-X
B	B-X
pathway	B-X
.	B-X

Cupric	O
ion	O
blocks	O
NF	O
kappa	O
B	O
activation	O
through	O
inhibiting	O
the	O
signal	O
-	O
induced	O
phosphorylation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
.	O
<EOS>	B-X
A	B-X
transcription	B-X
factor	B-X
NF	B-X
kappa	B-X
B	B-X
,	B-X
which	B-X
regulates	B-X
expression	B-X
of	B-X
various	B-X
cellular	B-X
genes	B-X
involved	B-X
in	B-X
immune	B-X
responses	B-X
and	B-X
viral	B-X
genes	B-X
including	B-X
HIV	B-X
,	B-X
is	B-X
sequestered	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
a	B-X
complex	B-X
with	B-X
an	B-X
inhibitory	B-X
protein	B-X
I	B-X
kappa	B-X
B	B-X
.	B-X
Various	B-X
extracellular	B-X
signals	B-X
induce	B-X
phosphorylation	B-X
and	B-X
rapid	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
to	B-X
release	B-X
NF	B-X
kappa	B-X
B.	B-X
Cu2+	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
induced	B-X
by	B-X
TNF-alpha	B-X
,	B-X
TPA	B-X
,	B-X
or	B-X
H2O2	B-X
.	B-X
Deoxycholate	B-X
treatment	B-X
of	B-X
the	B-X
cytoplasmic	B-X
extract	B-X
prepared	B-X
from	B-X
cells	B-X
stimulated	B-X
by	B-X
TNF-alpha	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Cu2+	B-X
resulted	B-X
in	B-X
the	B-X
release	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
from	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
indicating	B-X
that	B-X
Cu2+	B-X
interferes	B-X
with	B-X
the	B-X
dissociation	B-X
of	B-X
the	B-X
NF	B-X
kappa	B-X
B-I	B-X
kappa	B-X
B	B-X
complex	B-X
.	B-X
Neither	B-X
phosphorylation	B-X
nor	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
was	B-X
observed	B-X
upon	B-X
TNF-alpha	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Cu2+	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Cu2+	B-X
inhibits	B-X
the	B-X
release	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
by	B-X
blockade	B-X
of	B-X
a	B-X
signal	B-X
leading	B-X
to	B-X
the	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X

A	O
transcription	O
factor	O
NF	O
kappa	O
B	O
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	O
genes	O
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	B-Protein
protein	I-Protein
I	I-Protein
kappa	I-Protein
B	I-Protein
.	O
<EOS>	B-X
A	B-X
transcription	B-X
factor	B-X
NF	B-X
kappa	B-X
B	B-X
,	B-X
which	B-X
regulates	B-X
expression	B-X
of	B-X
various	B-X
cellular	B-X
genes	B-X
involved	B-X
in	B-X
immune	B-X
responses	B-X
and	B-X
viral	B-X
genes	B-X
including	B-X
HIV	B-X
,	B-X
is	B-X
sequestered	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
a	B-X
complex	B-X
with	B-X
an	B-X
inhibitory	B-X
protein	B-X
I	B-X
kappa	B-X
B	B-X
.	B-X
Various	B-X
extracellular	B-X
signals	B-X
induce	B-X
phosphorylation	B-X
and	B-X
rapid	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
to	B-X
release	B-X
NF	B-X
kappa	B-X
B.	B-X
Cu2+	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
induced	B-X
by	B-X
TNF-alpha	B-X
,	B-X
TPA	B-X
,	B-X
or	B-X
H2O2	B-X
.	B-X
Deoxycholate	B-X
treatment	B-X
of	B-X
the	B-X
cytoplasmic	B-X
extract	B-X
prepared	B-X
from	B-X
cells	B-X
stimulated	B-X
by	B-X
TNF-alpha	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Cu2+	B-X
resulted	B-X
in	B-X
the	B-X
release	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
from	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
indicating	B-X
that	B-X
Cu2+	B-X
interferes	B-X
with	B-X
the	B-X
dissociation	B-X
of	B-X
the	B-X
NF	B-X
kappa	B-X
B-I	B-X
kappa	B-X
B	B-X
complex	B-X
.	B-X
Neither	B-X
phosphorylation	B-X
nor	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
was	B-X
observed	B-X
upon	B-X
TNF-alpha	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Cu2+	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Cu2+	B-X
inhibits	B-X
the	B-X
release	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
by	B-X
blockade	B-X
of	B-X
a	B-X
signal	B-X
leading	B-X
to	B-X
the	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X

Various	O
extracellular	O
signals	O
induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
to	O
release	O
NF	O
kappa	O
B	O
.	O
<EOS>	B-X
NF-kappa	B-X
B	B-X
is	B-X
an	B-X
important	B-X
activator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
response	B-X
genes	B-X
.	B-X
NF-kappa	B-X
B	B-X
is	B-X
sequestered	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
nonstimulated	B-X
cells	B-X
through	B-X
interaction	B-X
with	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
inhibitors	B-X
.	B-X
These	B-X
inactive	B-X
complexes	B-X
are	B-X
dissociated	B-X
in	B-X
response	B-X
to	B-X
a	B-X
variety	B-X
of	B-X
extracellular	B-X
signals	B-X
,	B-X
thereby	B-X
allowing	B-X
free	B-X
NF-kappa	B-X
B	B-X
dimers	B-X
to	B-X
translocate	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
active	B-X
transcription	B-X
of	B-X
specific	B-X
target	B-X
genes	B-X
.	B-X
The	B-X
current	B-X
dogma	B-X
is	B-X
that	B-X
phosphorylation	B-X
of	B-X
the	B-X
I	B-X
kappa	B-X
Bs	B-X
is	B-X
responsible	B-X
for	B-X
dissociation	B-X
of	B-X
the	B-X
inactive	B-X
complexes	B-X
,	B-X
an	B-X
event	B-X
that	B-X
is	B-X
rendered	B-X
irreversible	B-X
by	B-X
rapid	B-X
I	B-X
kappa	B-X
B	B-X
degradation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
inducers	B-X
of	B-X
NF-kappa	B-X
B	B-X
activity	B-X
stimulate	B-X
the	B-X
hyperphosphorylation	B-X
of	B-X
one	B-X
of	B-X
the	B-X
I	B-X
kappa	B-X
Bs	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
However	B-X
,	B-X
contrary	B-X
to	B-X
the	B-X
present	B-X
dogma	B-X
the	B-X
hyperphosphorylated	B-X
form	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
remains	B-X
associated	B-X
with	B-X
NF-kappa	B-X
B	B-X
components	B-X
such	B-X
as	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
is	B-X
not	B-X
sufficient	B-X
to	B-X
cause	B-X
dissociation	B-X
of	B-X
the	B-X
inactive	B-X
NF-kappa	B-X
B	B-X
:	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
complex	B-X
.	B-X
However	B-X
,	B-X
that	B-X
complex	B-X
is	B-X
disrupted	B-X
through	B-X
the	B-X
selective	B-X
degradation	B-X
of	B-X
phosphorylated	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
response	B-X
to	B-X
extracellular	B-X
signals	B-X
.	B-X
Using	B-X
a	B-X
variety	B-X
of	B-X
protease	B-X
inhibitors	B-X
,	B-X
some	B-X
of	B-X
which	B-X
have	B-X
specificity	B-X
towards	B-X
the	B-X
multicatalytic	B-X
proteinase	B-X
complex	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
is	B-X
required	B-X
for	B-X
NF-kappa	B-X
B	B-X
activation	B-X
.	B-X
The	B-X
results	B-X
of	B-X
these	B-X
experiments	B-X
are	B-X
more	B-X
consistent	B-X
with	B-X
a	B-X
new	B-X
model	B-X
according	B-X
to	B-X
which	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
associated	B-X
with	B-X
NF-kappa	B-X
B	B-X
marks	B-X
it	B-X
for	B-X
proteolytic	B-X
degradation	B-X
.	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
is	B-X
degraded	B-X
while	B-X
bound	B-X
to	B-X
NF-kappa	B-X
B	B-X
.	B-X
The	B-X
selective	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
releases	B-X
active	B-X
NF-kappa	B-X
B	B-X
dimers	B-X
which	B-X
can	B-X
translocate	B-X
to	B-X
the	B-X
nucleus	B-X
to	B-X
activate	B-X
specific	B-X
target	B-X
genes	B-X
.	B-X

Cu2	O
+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	O
kappa	O
B	O
induced	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
TPA	O
,	O
or	O
H2O2	O
.	O
<EOS>	B-X
Hydrogen	B-X
peroxide	B-X
(	B-X
H₂O₂	B-X
)	B-X
is	B-X
generated	B-X
in	B-X
mitochondria	B-X
in	B-X
aerobic	B-X
cells	B-X
as	B-X
a	B-X
minor	B-X
product	B-X
of	B-X
electron	B-X
transport	B-X
,	B-X
is	B-X
inhibited	B-X
selectively	B-X
by	B-X
phenolic	B-X
acids	B-X
(	B-X
in	B-X
animals	B-X
)	B-X
or	B-X
salicylhydroxamate	B-X
(	B-X
in	B-X
plants	B-X
)	B-X
and	B-X
is	B-X
regulated	B-X
by	B-X
hormones	B-X
and	B-X
environmental	B-X
conditions	B-X
.	B-X
Failure	B-X
to	B-X
detect	B-X
this	B-X
activity	B-X
is	B-X
due	B-X
to	B-X
presence	B-X
of	B-X
H₂O₂-consuming	B-X
reactions	B-X
or	B-X
inhibitors	B-X
present	B-X
in	B-X
the	B-X
reaction	B-X
mixture	B-X
.	B-X
DPV	B-X
was	B-X
found	B-X
to	B-X
substitute	B-X
for	B-X
H₂O₂	B-X
at	B-X
concentrations	B-X
orders	B-X
of	B-X
magnitude	B-X
lower	B-X
,	B-X
and	B-X
in	B-X
presence	B-X
of	B-X
catalase	B-X
,	B-X
as	B-X
a	B-X
substrate	B-X
for	B-X
user	B-X
reaction	B-X
,	B-X
horseradish	B-X
peroxidase	B-X
(	B-X
HRP	B-X
)	B-X
,	B-X
and	B-X
in	B-X
inactivating	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
.	B-X
superoxide	B-X
dismutase	B-X
(	B-X
SOD	B-X
)	B-X
-sensitive	B-X
oxidation	B-X
of	B-X
NADH	B-X
was	B-X
found	B-X
to	B-X
operate	B-X
as	B-X
peroxovanadate	B-X
cycle	B-X
using	B-X
traces	B-X
of	B-X
DPV	B-X
and	B-X
decameric	B-X
vanadate	B-X
(	B-X
V₁₀	B-X
)	B-X
and	B-X
reduces	B-X
O₂	B-X
to	B-X
peroxide	B-X
(	B-X
DPV	B-X
in	B-X
presence	B-X
of	B-X
free	B-X
vanadate	B-X
)	B-X
.	B-X
Diperoxovanadate	B-X
reproduces	B-X
several	B-X
actions	B-X
of	B-X
H₂O₂	B-X
at	B-X
low	B-X
concentrations	B-X
:	B-X
enhances	B-X
protein	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
activates	B-X
phospholipase	B-X
D	B-X
,	B-X
produces	B-X
smooth	B-X
muscle	B-X
contraction	B-X
,	B-X
and	B-X
accelerates	B-X
stress	B-X
induced	B-X
premature	B-X
senescence	B-X
(	B-X
SIPS	B-X
)	B-X
and	B-X
rounding	B-X
in	B-X
fibroblasts	B-X
.	B-X

Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
in	O
the	O
presence	O
of	O
Cu2	O
+	O
resulted	O
in	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
from	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
,	O
indicating	O
that	O
Cu2	O
+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	O
kappa	O
B	O
-	O
I	B-Protein
kappa	I-Protein
B	I-Protein
complex	O
.	O

Neither	O
phosphorylation	O
nor	O
degradation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
was	O
observed	O
upon	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
stimulation	O
in	O
the	O
presence	O
of	O
Cu2	O
+	O
.	O
<EOS>	B-X
A	B-X
transcription	B-X
factor	B-X
NF	B-X
kappa	B-X
B	B-X
,	B-X
which	B-X
regulates	B-X
expression	B-X
of	B-X
various	B-X
cellular	B-X
genes	B-X
involved	B-X
in	B-X
immune	B-X
responses	B-X
and	B-X
viral	B-X
genes	B-X
including	B-X
HIV	B-X
,	B-X
is	B-X
sequestered	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
a	B-X
complex	B-X
with	B-X
an	B-X
inhibitory	B-X
protein	B-X
I	B-X
kappa	B-X
B	B-X
.	B-X
Various	B-X
extracellular	B-X
signals	B-X
induce	B-X
phosphorylation	B-X
and	B-X
rapid	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
to	B-X
release	B-X
NF	B-X
kappa	B-X
B.	B-X
Cu2+	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
activation	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
induced	B-X
by	B-X
TNF-alpha	B-X
,	B-X
TPA	B-X
,	B-X
or	B-X
H2O2	B-X
.	B-X
Deoxycholate	B-X
treatment	B-X
of	B-X
the	B-X
cytoplasmic	B-X
extract	B-X
prepared	B-X
from	B-X
cells	B-X
stimulated	B-X
by	B-X
TNF-alpha	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Cu2+	B-X
resulted	B-X
in	B-X
the	B-X
release	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
from	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
indicating	B-X
that	B-X
Cu2+	B-X
interferes	B-X
with	B-X
the	B-X
dissociation	B-X
of	B-X
the	B-X
NF	B-X
kappa	B-X
B-I	B-X
kappa	B-X
B	B-X
complex	B-X
.	B-X
Neither	B-X
phosphorylation	B-X
nor	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
was	B-X
observed	B-X
upon	B-X
TNF-alpha	B-X
stimulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Cu2+	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
Cu2+	B-X
inhibits	B-X
the	B-X
release	B-X
of	B-X
NF	B-X
kappa	B-X
B	B-X
by	B-X
blockade	B-X
of	B-X
a	B-X
signal	B-X
leading	B-X
to	B-X
the	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X

These	O
results	O
indicate	O
that	O
Cu2	O
+	O
inhibits	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O
the	O
phosphorylation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
.	O

Salicylates	O
inhibit	O
lipopolysaccharide	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O
<EOS>	B-X
Binding	B-X
of	B-X
plasma	B-X
Factor	B-X
VII/VIIa	B-X
to	B-X
the	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
receptor	B-X
initiates	B-X
the	B-X
coagulation	B-X
protease	B-X
cascades	B-X
.	B-X
Transcriptional	B-X
activation	B-X
of	B-X
the	B-X
human	B-X
TF	B-X
gene	B-X
in	B-X
monocytic	B-X
cells	B-X
exposed	B-X
to	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
is	B-X
mediated	B-X
by	B-X
binding	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
to	B-X
a	B-X
kappa	B-X
B	B-X
site	B-X
in	B-X
the	B-X
TF	B-X
promoter	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
family	B-X
of	B-X
anti-inflammatory	B-X
agents	B-X
,	B-X
known	B-X
as	B-X
the	B-X
salicylates	B-X
,	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
activity	B-X
and	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
.	B-X
Furthermore	B-X
,	B-X
sodium	B-X
salicylate	B-X
blocked	B-X
the	B-X
LPS-induced	B-X
proteolytic	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
which	B-X
prevented	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
two	B-X
other	B-X
nonsteroidal	B-X
anti-inflammatory	B-X
drugs	B-X
,	B-X
ibuprofen	B-X
and	B-X
indomethacin	B-X
,	B-X
did	B-X
not	B-X
inhibit	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TF	B-X
gene	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
salicylates	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
preventing	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
The	B-X
clinical	B-X
benefits	B-X
of	B-X
salicylates	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
several	B-X
diseases	B-X
,	B-X
including	B-X
atherosclerosis	B-X
and	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
may	B-X
be	B-X
related	B-X
to	B-X
their	B-X
ability	B-X
to	B-X
reduce	B-X
monocyte	B-X
gene	B-X
expression	B-X
.	B-X

Binding	O
of	O
plasma	O
Factor	B-Protein
VII	I-Protein
/	I-Protein
VIIa	I-Protein
to	O
the	O
tissue	B-Protein
factor	I-Protein
(	I-Protein
TF	I-Protein
)	I-Protein
receptor	I-Protein
initiates	O
the	O
coagulation	O
protease	O
cascades	O
.	O

TF	B-Protein
expression	O
by	O
circulating	O
monocytes	O
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	O
TF	B-Protein
gene	O
in	O
monocytic	O
cells	O
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
/	O
p65	B-Protein
heterodimers	O
to	O
a	O
kappa	O
B	O
site	O
in	O
the	O
TF	B-Protein
promoter	O
.	O
<EOS>	B-X
Tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
is	B-X
expressed	B-X
rapidly	B-X
by	B-X
human	B-X
monocytes	B-X
exposed	B-X
to	B-X
bacterial	B-X
endotoxin	B-X
(	B-X
lipopolysaccharide	B-X
,	B-X
or	B-X
LPS	B-X
)	B-X
.	B-X
Transcriptional	B-X
regulation	B-X
is	B-X
mediated	B-X
by	B-X
binding	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
to	B-X
a	B-X
kappa	B-X
B-like	B-X
site	B-X
in	B-X
the	B-X
TF	B-X
promoter	B-X
.	B-X
Nuclear	B-X
translocation	B-X
of	B-X
cytosolic	B-X
c-Rel/p65	B-X
heterodimers	B-X
and	B-X
other	B-X
members	B-X
of	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
family	B-X
requires	B-X
dissociation	B-X
and	B-X
proteolytic	B-X
degradation	B-X
of	B-X
the	B-X
inhibitor	B-X
protein	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
The	B-X
protease	B-X
inhibitors	B-X
N	B-X
alpha-tosylphenylalanyl	B-X
chloromethyl	B-X
ketone	B-X
(	B-X
TPCK	B-X
)	B-X
and	B-X
N	B-X
alpha-tosyl-L-lysine	B-X
chloromethyl	B-X
ketone	B-X
(	B-X
TLCK	B-X
)	B-X
block	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
proteins	B-X
by	B-X
preventing	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
To	B-X
determine	B-X
if	B-X
TPCK	B-X
and	B-X
TLCK	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
expression	B-X
,	B-X
freshly	B-X
isolated	B-X
human	B-X
monocytes	B-X
and	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
were	B-X
pretreated	B-X
with	B-X
these	B-X
inhibitors	B-X
for	B-X
30	B-X
min	B-X
before	B-X
LPS	B-X
stimulation	B-X
.	B-X
Both	B-X
TPCK	B-X
and	B-X
TLCK	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
protein	B-X
,	B-X
TF	B-X
mRNA	B-X
and	B-X
TF	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
These	B-X
inhibitors	B-X
specifically	B-X
prevented	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
TPCK	B-X
and	B-X
TLCK	B-X
did	B-X
not	B-X
block	B-X
induction	B-X
of	B-X
an	B-X
immediate-early	B-X
gene	B-X
encoding	B-X
the	B-X
transcription	B-X
factor	B-X
,	B-X
Egr-1	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
indicated	B-X
that	B-X
inhibiting	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
prevented	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
.	B-X

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti	O
-	O
inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-Protein
activity	O
and	O
TF	B-Protein
gene	O
transcription	O
in	O
human	O
monocytes	O
and	O
monocytic	O
THP	O
-	O
1	O
cells	O
at	O
clinically	O
relevant	O
doses	O
.	O
<EOS>	B-X
Binding	B-X
of	B-X
plasma	B-X
Factor	B-X
VII/VIIa	B-X
to	B-X
the	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
receptor	B-X
initiates	B-X
the	B-X
coagulation	B-X
protease	B-X
cascades	B-X
.	B-X
TF	B-X
expression	B-X
by	B-X
circulating	B-X
monocytes	B-X
is	B-X
associated	B-X
with	B-X
thrombotic	B-X
and	B-X
inflammatory	B-X
complications	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
diseases	B-X
.	B-X
Transcriptional	B-X
activation	B-X
of	B-X
the	B-X
human	B-X
TF	B-X
gene	B-X
in	B-X
monocytic	B-X
cells	B-X
exposed	B-X
to	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
is	B-X
mediated	B-X
by	B-X
binding	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
to	B-X
a	B-X
kappa	B-X
B	B-X
site	B-X
in	B-X
the	B-X
TF	B-X
promoter	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
family	B-X
of	B-X
anti-inflammatory	B-X
agents	B-X
,	B-X
known	B-X
as	B-X
the	B-X
salicylates	B-X
,	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
activity	B-X
and	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
.	B-X
Furthermore	B-X
,	B-X
sodium	B-X
salicylate	B-X
blocked	B-X
the	B-X
LPS-induced	B-X
proteolytic	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
which	B-X
prevented	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
two	B-X
other	B-X
nonsteroidal	B-X
anti-inflammatory	B-X
drugs	B-X
,	B-X
ibuprofen	B-X
and	B-X
indomethacin	B-X
,	B-X
did	B-X
not	B-X
inhibit	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TF	B-X
gene	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
salicylates	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
preventing	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
The	B-X
clinical	B-X
benefits	B-X
of	B-X
salicylates	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
several	B-X
diseases	B-X
,	B-X
including	B-X
atherosclerosis	B-X
and	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
may	B-X
be	B-X
related	B-X
to	B-X
their	B-X
ability	B-X
to	B-X
reduce	B-X
monocyte	B-X
gene	B-X
expression	B-X
.	B-X

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS	O
-	O
induced	O
proteolytic	O
degradation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
/	O
p65	B-Protein
heterodimers	O
.	O
<EOS>	B-X
Binding	B-X
of	B-X
plasma	B-X
Factor	B-X
VII/VIIa	B-X
to	B-X
the	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
receptor	B-X
initiates	B-X
the	B-X
coagulation	B-X
protease	B-X
cascades	B-X
.	B-X
TF	B-X
expression	B-X
by	B-X
circulating	B-X
monocytes	B-X
is	B-X
associated	B-X
with	B-X
thrombotic	B-X
and	B-X
inflammatory	B-X
complications	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
diseases	B-X
.	B-X
Transcriptional	B-X
activation	B-X
of	B-X
the	B-X
human	B-X
TF	B-X
gene	B-X
in	B-X
monocytic	B-X
cells	B-X
exposed	B-X
to	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
is	B-X
mediated	B-X
by	B-X
binding	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
to	B-X
a	B-X
kappa	B-X
B	B-X
site	B-X
in	B-X
the	B-X
TF	B-X
promoter	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
family	B-X
of	B-X
anti-inflammatory	B-X
agents	B-X
,	B-X
known	B-X
as	B-X
the	B-X
salicylates	B-X
,	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
activity	B-X
and	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
.	B-X
Furthermore	B-X
,	B-X
sodium	B-X
salicylate	B-X
blocked	B-X
the	B-X
LPS-induced	B-X
proteolytic	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
which	B-X
prevented	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
two	B-X
other	B-X
nonsteroidal	B-X
anti-inflammatory	B-X
drugs	B-X
,	B-X
ibuprofen	B-X
and	B-X
indomethacin	B-X
,	B-X
did	B-X
not	B-X
inhibit	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TF	B-X
gene	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
salicylates	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
preventing	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
The	B-X
clinical	B-X
benefits	B-X
of	B-X
salicylates	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
several	B-X
diseases	B-X
,	B-X
including	B-X
atherosclerosis	B-X
and	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
may	B-X
be	B-X
related	B-X
to	B-X
their	B-X
ability	B-X
to	B-X
reduce	B-X
monocyte	B-X
gene	B-X
expression	B-X
.	B-X

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	B-Protein
gene	O
.	O
<EOS>	B-X
Non-steroidal	B-X
anti-inflammatory	B-X
drugs	B-X
,	B-X
which	B-X
inhibit	B-X
prostaglandin	B-X
synthesis	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
effective	B-X
in	B-X
reducing	B-X
menstrual	B-X
bleeding	B-X
and	B-X
pain	B-X
in	B-X
women	B-X
without	B-X
IUDs	B-X
.	B-X
There	B-X
are	B-X
two	B-X
isozymes	B-X
of	B-X
prostaglandin	B-X
endoperoxide	B-X
(	B-X
PGH	B-X
)	B-X
synthase	B-X
(	B-X
cyclooxygenase	B-X
)	B-X
called	B-X
PGH	B-X
synthase-1	B-X
and	B-X
-2	B-X
or	B-X
COX	B-X
I	B-X
and	B-X
II	B-X
.	B-X
Both	B-X
isozymes	B-X
catalyze	B-X
the	B-X
same	B-X
two	B-X
reactions	B-X
:	B-X
oxygenation	B-X
of	B-X
arachidonate	B-X
to	B-X
yield	B-X
PGG2	B-X
and	B-X
reduction	B-X
of	B-X
PGG2	B-X
to	B-X
PGH2	B-X
.	B-X
PGH	B-X
synthase-1	B-X
(	B-X
PGHS-1	B-X
)	B-X
has	B-X
been	B-X
presumed	B-X
to	B-X
be	B-X
the	B-X
site	B-X
of	B-X
action	B-X
of	B-X
nonsteroidal	B-X
antiinflammatory	B-X
drugs	B-X
(	B-X
NSAIDs	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
discovery	B-X
of	B-X
the	B-X
second	B-X
isozyme	B-X
,	B-X
PGH	B-X
synthase-2	B-X
(	B-X
PGHS-2	B-X
)	B-X
,	B-X
and	B-X
its	B-X
association	B-X
with	B-X
inflammation	B-X
has	B-X
suggested	B-X
that	B-X
this	B-X
latter	B-X
enzyme	B-X
may	B-X
be	B-X
the	B-X
therapeutic	B-X
target	B-X
of	B-X
NSAIDs	B-X
functioning	B-X
in	B-X
their	B-X
antiinflammatory	B-X
capacities	B-X
.	B-X
We	B-X
have	B-X
cloned	B-X
cDNAs	B-X
for	B-X
murine	B-X
PGHS-1	B-X
and	B-X
PGHS-2	B-X
,	B-X
expressed	B-X
these	B-X
enzymes	B-X
in	B-X
cos-1	B-X
cells	B-X
,	B-X
and	B-X
compared	B-X
the	B-X
relative	B-X
sensitivities	B-X
of	B-X
the	B-X
two	B-X
isozymes	B-X
to	B-X
some	B-X
common	B-X
NSAIDs	B-X
.	B-X
Indomethacin	B-X
,	B-X
piroxicam	B-X
,	B-X
and	B-X
sulindac	B-X
sulfide	B-X
were	B-X
found	B-X
to	B-X
preferentially	B-X
inhibit	B-X
PGHS-1	B-X
.	B-X
Ibuprofen	B-X
and	B-X
meclofenamate	B-X
inhibit	B-X
both	B-X
enzymes	B-X
with	B-X
comparable	B-X
potencies	B-X
.	B-X
6-Methoxy-2-naphthylacetic	B-X
acid	B-X
,	B-X
the	B-X
active	B-X
metabolite	B-X
of	B-X
Relafen	B-X
,	B-X
inhibits	B-X
murine	B-X
PGHS-2	B-X
preferentially	B-X
.	B-X
Aspirin	B-X
irreversibly	B-X
inhibits	B-X
PGHS-1	B-X
,	B-X
preventing	B-X
this	B-X
isozyme	B-X
from	B-X
forming	B-X
PGH2	B-X
or	B-X
any	B-X
other	B-X
oxygenated	B-X
product	B-X
;	B-X
in	B-X
contrast	B-X
,	B-X
aspirin	B-X
treatment	B-X
of	B-X
PGHS-2	B-X
causes	B-X
this	B-X
enzyme	B-X
to	B-X
form	B-X
15-hydroxy-5c,8c,11c,13t-eicosatetraenoic	B-X
acid	B-X
(	B-X
15-HETE	B-X
)	B-X
instead	B-X
of	B-X
PGH2	B-X
.	B-X
PGHS-2	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
stomach	B-X
but	B-X
is	B-X
increased	B-X
by	B-X
inflammatory	B-X
cytokines	B-X
in	B-X
cells	B-X
such	B-X
as	B-X
macrophages	B-X
.	B-X
Thus	B-X
,	B-X
a	B-X
selective	B-X
inhibitor	B-X
of	B-X
PGHS-2	B-X
could	B-X
be	B-X
an	B-X
antiinflammatory	B-X
agent	B-X
but	B-X
without	B-X
being	B-X
ulcerogenic	B-X
.	B-X

These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-Protein
gene	O
transcription	O
in	O
monocytic	O
cells	O
by	O
preventing	O
nuclear	O
translocation	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
/	O
p65	B-Protein
heterodimers	O
.	O
<EOS>	B-X
Binding	B-X
of	B-X
plasma	B-X
Factor	B-X
VII/VIIa	B-X
to	B-X
the	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
receptor	B-X
initiates	B-X
the	B-X
coagulation	B-X
protease	B-X
cascades	B-X
.	B-X
TF	B-X
expression	B-X
by	B-X
circulating	B-X
monocytes	B-X
is	B-X
associated	B-X
with	B-X
thrombotic	B-X
and	B-X
inflammatory	B-X
complications	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
diseases	B-X
.	B-X
Transcriptional	B-X
activation	B-X
of	B-X
the	B-X
human	B-X
TF	B-X
gene	B-X
in	B-X
monocytic	B-X
cells	B-X
exposed	B-X
to	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
is	B-X
mediated	B-X
by	B-X
binding	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
to	B-X
a	B-X
kappa	B-X
B	B-X
site	B-X
in	B-X
the	B-X
TF	B-X
promoter	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
family	B-X
of	B-X
anti-inflammatory	B-X
agents	B-X
,	B-X
known	B-X
as	B-X
the	B-X
salicylates	B-X
,	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
activity	B-X
and	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
.	B-X
Furthermore	B-X
,	B-X
sodium	B-X
salicylate	B-X
blocked	B-X
the	B-X
LPS-induced	B-X
proteolytic	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
which	B-X
prevented	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
two	B-X
other	B-X
nonsteroidal	B-X
anti-inflammatory	B-X
drugs	B-X
,	B-X
ibuprofen	B-X
and	B-X
indomethacin	B-X
,	B-X
did	B-X
not	B-X
inhibit	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TF	B-X
gene	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
salicylates	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
preventing	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
The	B-X
clinical	B-X
benefits	B-X
of	B-X
salicylates	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
several	B-X
diseases	B-X
,	B-X
including	B-X
atherosclerosis	B-X
and	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
may	B-X
be	B-X
related	B-X
to	B-X
their	B-X
ability	B-X
to	B-X
reduce	B-X
monocyte	B-X
gene	B-X
expression	B-X
.	B-X

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O
<EOS>	B-X
TF	B-X
expression	B-X
by	B-X
circulating	B-X
monocytes	B-X
is	B-X
associated	B-X
with	B-X
thrombotic	B-X
and	B-X
inflammatory	B-X
complications	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
diseases	B-X
.	B-X
Transcriptional	B-X
activation	B-X
of	B-X
the	B-X
human	B-X
TF	B-X
gene	B-X
in	B-X
monocytic	B-X
cells	B-X
exposed	B-X
to	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
is	B-X
mediated	B-X
by	B-X
binding	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
to	B-X
a	B-X
kappa	B-X
B	B-X
site	B-X
in	B-X
the	B-X
TF	B-X
promoter	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
family	B-X
of	B-X
anti-inflammatory	B-X
agents	B-X
,	B-X
known	B-X
as	B-X
the	B-X
salicylates	B-X
,	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
activity	B-X
and	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
two	B-X
other	B-X
nonsteroidal	B-X
anti-inflammatory	B-X
drugs	B-X
,	B-X
ibuprofen	B-X
and	B-X
indomethacin	B-X
,	B-X
did	B-X
not	B-X
inhibit	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TF	B-X
gene	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
salicylates	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
preventing	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
The	B-X
clinical	B-X
benefits	B-X
of	B-X
salicylates	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
several	B-X
diseases	B-X
,	B-X
including	B-X
atherosclerosis	B-X
and	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
may	B-X
be	B-X
related	B-X
to	B-X
their	B-X
ability	B-X
to	B-X
reduce	B-X
monocyte	B-X
gene	B-X
expression	B-X
.	B-X

CIITA	B-Protein
activates	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
.	O

It	O
has	O
long	O
been	O
a	O
puzzle	O
that	O
MHC	O
class	O
II	O
molecules	O
are	O
expressed	O
in	O
human	O
T	O
cells	O
after	O
activation	O
but	O
not	O
in	O
mouse	O
T	O
cells	O
;	O
this	O
expression	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
cell	O
mediated	O
immune	O
response	O
.	O

Recently	O
the	O
MHC	B-Protein
class	I-Protein
II	I-Protein
transactivator	I-Protein
(	O
CIITA	B-Protein
)	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	O
regulatory	O
factor	O
for	O
both	O
the	O
constitutive	O
and	O
IFN	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

Here	O
we	O
show	O
that	O
human	O
T	O
cells	O
expressing	O
MHC	O
class	O
II	O
have	O
CIITA	B-Protein
transcripts	O
while	O
MHC	O
class	O
II	O
-	O
negative	O
human	O
T	O
cells	O
and	O
mouse	O
T	O
cells	O
do	O
not	O
.	O

The	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
can	O
be	O
reconstituted	O
upon	O
transfection	O
with	O
the	O
human	O
CIITA	B-Protein
cDNA	O
.	O

These	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
CIITA	B-Protein
explains	O
the	O
expression	O
or	O
lack	O
of	O
expression	O
of	O
MHC	O
class	O
II	O
in	O
human	O
and	O
mouse	O
T	O
cells	O
respectively	O
.	O
<EOS>	B-X
It	B-X
has	B-X
long	B-X
been	B-X
a	B-X
puzzle	B-X
that	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
are	B-X
expressed	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
after	B-X
activation	B-X
but	B-X
not	B-X
in	B-X
mouse	B-X
T	B-X
cells	B-X
;	B-X
this	B-X
expression	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
cell	B-X
mediated	B-X
immune	B-X
response	B-X
.	B-X
Recently	B-X
the	B-X
MHC	B-X
class	B-X
II	B-X
transactivator	B-X
(	B-X
CIITA	B-X
)	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
a	B-X
major	B-X
regulatory	B-X
factor	B-X
for	B-X
both	B-X
the	B-X
constitutive	B-X
and	B-X
IFN	B-X
inducible	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
human	B-X
T	B-X
cells	B-X
expressing	B-X
MHC	B-X
class	B-X
II	B-X
have	B-X
CIITA	B-X
transcripts	B-X
while	B-X
MHC	B-X
class	B-X
II-negative	B-X
human	B-X
T	B-X
cells	B-X
and	B-X
mouse	B-X
T	B-X
cells	B-X
do	B-X
not	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
in	B-X
mouse	B-X
T	B-X
cells	B-X
can	B-X
be	B-X
reconstituted	B-X
upon	B-X
transfection	B-X
with	B-X
the	B-X
human	B-X
CIITA	B-X
cDNA	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
CIITA	B-X
explains	B-X
the	B-X
expression	B-X
or	B-X
lack	B-X
of	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
in	B-X
human	B-X
and	B-X
mouse	B-X
T	B-X
cells	B-X
respectively	B-X
.	B-X

Identification	O
of	O
an	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
-	O
associated	O
protein	O
kinase	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
and	O
determination	O
of	O
its	O
phosphorylation	O
sites	O
on	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
stored	O
in	O
the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	O
kappa	O
B	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
is	B-X
stored	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
an	B-X
inactive	B-X
form	B-X
through	B-X
interaction	B-X
with	B-X
I	B-X
kappa	B-X
B.	B-X
Stimulation	B-X
of	B-X
cells	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
which	B-X
is	B-X
presumed	B-X
to	B-X
be	B-X
important	B-X
for	B-X
the	B-X
subsequent	B-X
degradation	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
reported	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-dependent	B-X
cell-free	B-X
activation	B-X
system	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
association	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
phosphorylation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
kinase	B-X
in	B-X
cell	B-X
extracts	B-X
from	B-X
the	B-X
LPS-stimulated	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
,	B-X
THP-1	B-X
,	B-X
that	B-X
specifically	B-X
binds	B-X
and	B-X
phosphorylates	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
LPS	B-X
stimulation	B-X
transiently	B-X
enhanced	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha-bound	B-X
kinase	B-X
activity	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Mutational	B-X
analyses	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
competition	B-X
experiments	B-X
with	B-X
the	B-X
synthetic	B-X
peptides	B-X
identified	B-X
major	B-X
phosphorylation	B-X
sites	B-X
by	B-X
the	B-X
bound	B-X
kinase	B-X
as	B-X
Ser	B-X
and	B-X
Thr	B-X
residues	B-X
in	B-X
the	B-X
C-terminal	B-X
acidic	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
peptide	B-X
,	B-X
corresponding	B-X
to	B-X
the	B-X
C-terminal	B-X
acidic	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
blocked	B-X
the	B-X
LPS-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
as	B-X
well	B-X
as	B-X
inducible	B-X
phosphorylation	B-X
of	B-X
endogenous	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
using	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
bound	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
of	B-X
LPS	B-X
by	B-X
inducing	B-X
the	B-X
phosphorylation	B-X
of	B-X
the	B-X
C-terminal	B-X
region	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
subsequent	B-X
dissociation	B-X
of	B-X
the	B-X
NF-kappa	B-X
B.I	B-X
kappa	B-X
B	B-X
alpha	B-X
complex	B-X
.	B-X

Stimulation	O
of	O
cells	O
leads	O
to	O
a	O
rapid	O
phosphorylation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
,	O
which	O
is	O
presumed	O
to	O
be	O
important	O
for	O
the	O
subsequent	O
degradation	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
is	B-X
stored	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
an	B-X
inactive	B-X
form	B-X
through	B-X
interaction	B-X
with	B-X
I	B-X
kappa	B-X
B.	B-X
Stimulation	B-X
of	B-X
cells	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
which	B-X
is	B-X
presumed	B-X
to	B-X
be	B-X
important	B-X
for	B-X
the	B-X
subsequent	B-X
degradation	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
reported	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-dependent	B-X
cell-free	B-X
activation	B-X
system	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
association	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
phosphorylation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
kinase	B-X
in	B-X
cell	B-X
extracts	B-X
from	B-X
the	B-X
LPS-stimulated	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
,	B-X
THP-1	B-X
,	B-X
that	B-X
specifically	B-X
binds	B-X
and	B-X
phosphorylates	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
LPS	B-X
stimulation	B-X
transiently	B-X
enhanced	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha-bound	B-X
kinase	B-X
activity	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Mutational	B-X
analyses	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
competition	B-X
experiments	B-X
with	B-X
the	B-X
synthetic	B-X
peptides	B-X
identified	B-X
major	B-X
phosphorylation	B-X
sites	B-X
by	B-X
the	B-X
bound	B-X
kinase	B-X
as	B-X
Ser	B-X
and	B-X
Thr	B-X
residues	B-X
in	B-X
the	B-X
C-terminal	B-X
acidic	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
peptide	B-X
,	B-X
corresponding	B-X
to	B-X
the	B-X
C-terminal	B-X
acidic	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
blocked	B-X
the	B-X
LPS-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
as	B-X
well	B-X
as	B-X
inducible	B-X
phosphorylation	B-X
of	B-X
endogenous	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
using	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
bound	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
of	B-X
LPS	B-X
by	B-X
inducing	B-X
the	B-X
phosphorylation	B-X
of	B-X
the	B-X
C-terminal	B-X
region	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
subsequent	B-X
dissociation	B-X
of	B-X
the	B-X
NF-kappa	B-X
B.I	B-X
kappa	B-X
B	B-X
alpha	B-X
complex	B-X
.	B-X

We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
dependent	O
cell	O
-	O
free	O
activation	O
system	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
association	O
with	O
the	O
induction	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
phosphorylation	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
is	B-X
stored	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
an	B-X
inactive	B-X
form	B-X
through	B-X
interaction	B-X
with	B-X
I	B-X
kappa	B-X
B.	B-X
Stimulation	B-X
of	B-X
cells	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
which	B-X
is	B-X
presumed	B-X
to	B-X
be	B-X
important	B-X
for	B-X
the	B-X
subsequent	B-X
degradation	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
reported	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-dependent	B-X
cell-free	B-X
activation	B-X
system	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
association	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
phosphorylation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
kinase	B-X
in	B-X
cell	B-X
extracts	B-X
from	B-X
the	B-X
LPS-stimulated	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
,	B-X
THP-1	B-X
,	B-X
that	B-X
specifically	B-X
binds	B-X
and	B-X
phosphorylates	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
LPS	B-X
stimulation	B-X
transiently	B-X
enhanced	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha-bound	B-X
kinase	B-X
activity	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Mutational	B-X
analyses	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
competition	B-X
experiments	B-X
with	B-X
the	B-X
synthetic	B-X
peptides	B-X
identified	B-X
major	B-X
phosphorylation	B-X
sites	B-X
by	B-X
the	B-X
bound	B-X
kinase	B-X
as	B-X
Ser	B-X
and	B-X
Thr	B-X
residues	B-X
in	B-X
the	B-X
C-terminal	B-X
acidic	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
peptide	B-X
,	B-X
corresponding	B-X
to	B-X
the	B-X
C-terminal	B-X
acidic	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
blocked	B-X
the	B-X
LPS-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
as	B-X
well	B-X
as	B-X
inducible	B-X
phosphorylation	B-X
of	B-X
endogenous	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
using	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
bound	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
of	B-X
LPS	B-X
by	B-X
inducing	B-X
the	B-X
phosphorylation	B-X
of	B-X
the	B-X
C-terminal	B-X
region	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
subsequent	B-X
dissociation	B-X
of	B-X
the	B-X
NF-kappa	B-X
B.I	B-X
kappa	B-X
B	B-X
alpha	B-X
complex	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
kinase	O
in	O
cell	O
extracts	O
from	O
the	O
LPS	O
-	O
stimulated	O
human	O
monocytic	O
cell	O
line	O
,	O
THP	O
-	O
1	O
,	O
that	O
specifically	O
binds	O
and	O
phosphorylates	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
is	B-X
stored	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
an	B-X
inactive	B-X
form	B-X
through	B-X
interaction	B-X
with	B-X
I	B-X
kappa	B-X
B.	B-X
Stimulation	B-X
of	B-X
cells	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
which	B-X
is	B-X
presumed	B-X
to	B-X
be	B-X
important	B-X
for	B-X
the	B-X
subsequent	B-X
degradation	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
reported	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-dependent	B-X
cell-free	B-X
activation	B-X
system	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
association	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
phosphorylation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
kinase	B-X
in	B-X
cell	B-X
extracts	B-X
from	B-X
the	B-X
LPS-stimulated	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
,	B-X
THP-1	B-X
,	B-X
that	B-X
specifically	B-X
binds	B-X
and	B-X
phosphorylates	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
LPS	B-X
stimulation	B-X
transiently	B-X
enhanced	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha-bound	B-X
kinase	B-X
activity	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Mutational	B-X
analyses	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
competition	B-X
experiments	B-X
with	B-X
the	B-X
synthetic	B-X
peptides	B-X
identified	B-X
major	B-X
phosphorylation	B-X
sites	B-X
by	B-X
the	B-X
bound	B-X
kinase	B-X
as	B-X
Ser	B-X
and	B-X
Thr	B-X
residues	B-X
in	B-X
the	B-X
C-terminal	B-X
acidic	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
peptide	B-X
,	B-X
corresponding	B-X
to	B-X
the	B-X
C-terminal	B-X
acidic	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
blocked	B-X
the	B-X
LPS-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
as	B-X
well	B-X
as	B-X
inducible	B-X
phosphorylation	B-X
of	B-X
endogenous	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
using	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
bound	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
of	B-X
LPS	B-X
by	B-X
inducing	B-X
the	B-X
phosphorylation	B-X
of	B-X
the	B-X
C-terminal	B-X
region	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
subsequent	B-X
dissociation	B-X
of	B-X
the	B-X
NF-kappa	B-X
B.I	B-X
kappa	B-X
B	B-X
alpha	B-X
complex	B-X
.	B-X

LPS	O
stimulation	O
transiently	O
enhanced	O
the	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
-	O
bound	O
kinase	O
activity	O
in	O
THP	O
-	O
1	O
cells	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
is	B-X
stored	B-X
in	B-X
the	B-X
cytoplasm	B-X
as	B-X
an	B-X
inactive	B-X
form	B-X
through	B-X
interaction	B-X
with	B-X
I	B-X
kappa	B-X
B.	B-X
Stimulation	B-X
of	B-X
cells	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
which	B-X
is	B-X
presumed	B-X
to	B-X
be	B-X
important	B-X
for	B-X
the	B-X
subsequent	B-X
degradation	B-X
.	B-X
We	B-X
have	B-X
recently	B-X
reported	B-X
the	B-X
establishment	B-X
of	B-X
a	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-dependent	B-X
cell-free	B-X
activation	B-X
system	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
association	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
phosphorylation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
kinase	B-X
in	B-X
cell	B-X
extracts	B-X
from	B-X
the	B-X
LPS-stimulated	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
,	B-X
THP-1	B-X
,	B-X
that	B-X
specifically	B-X
binds	B-X
and	B-X
phosphorylates	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
LPS	B-X
stimulation	B-X
transiently	B-X
enhanced	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha-bound	B-X
kinase	B-X
activity	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Mutational	B-X
analyses	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
competition	B-X
experiments	B-X
with	B-X
the	B-X
synthetic	B-X
peptides	B-X
identified	B-X
major	B-X
phosphorylation	B-X
sites	B-X
by	B-X
the	B-X
bound	B-X
kinase	B-X
as	B-X
Ser	B-X
and	B-X
Thr	B-X
residues	B-X
in	B-X
the	B-X
C-terminal	B-X
acidic	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
peptide	B-X
,	B-X
corresponding	B-X
to	B-X
the	B-X
C-terminal	B-X
acidic	B-X
domain	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
blocked	B-X
the	B-X
LPS-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
as	B-X
well	B-X
as	B-X
inducible	B-X
phosphorylation	B-X
of	B-X
endogenous	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
a	B-X
cell-free	B-X
system	B-X
using	B-X
THP-1	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
bound	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
of	B-X
LPS	B-X
by	B-X
inducing	B-X
the	B-X
phosphorylation	B-X
of	B-X
the	B-X
C-terminal	B-X
region	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
subsequent	B-X
dissociation	B-X
of	B-X
the	B-X
NF-kappa	B-X
B.I	B-X
kappa	B-X
B	B-X
alpha	B-X
complex	B-X
.	B-X

Mutational	O
analyses	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O
phosphorylation	O
sites	O
by	O
the	O
bound	O
kinase	O
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C	O
-	O
terminal	O
acidic	O
domain	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
.	O

Moreover	O
,	O
we	O
show	O
that	O
the	O
peptide	O
,	O
corresponding	O
to	O
the	O
C	O
-	O
terminal	O
acidic	O
domain	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
,	O
blocked	O
the	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
as	O
well	O
as	O
inducible	O
phosphorylation	O
of	O
endogenous	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
in	O
a	O
cell	O
-	O
free	O
system	O
using	O
THP	O
-	O
1	O
cells	O
.	O

These	O
results	O
suggested	O
that	O
the	O
bound	O
kinase	O
is	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
LPS	O
by	O
inducing	O
the	O
phosphorylation	O
of	O
the	O
C	O
-	O
terminal	O
region	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
and	O
subsequent	O
dissociation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
.	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
complex	O
.	O

Triggering	O
of	O
the	O
human	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
gene	O
by	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
in	O
monocytic	O
cells	O
involves	O
cooperation	O
between	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
,	O
NF	O
kappa	O
B	O
,	O
and	O
Sp1	B-Protein
transcription	O
factors	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
synergistic	B-X
induction	B-X
by	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
/tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
of	B-X
human	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
gene	B-X
in	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
,	B-X
and	B-X
compared	B-X
it	B-X
with	B-X
the	B-X
basis	B-X
of	B-X
this	B-X
induction	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
Functional	B-X
studies	B-X
with	B-X
IL-6	B-X
promoter	B-X
demonstrated	B-X
that	B-X
three	B-X
regions	B-X
are	B-X
the	B-X
targets	B-X
of	B-X
the	B-X
IFN-gamma	B-X
and/or	B-X
TNF-alpha	B-X
action	B-X
,	B-X
whereas	B-X
only	B-X
one	B-X
of	B-X
these	B-X
regions	B-X
seemed	B-X
to	B-X
be	B-X
implicated	B-X
in	B-X
LPS	B-X
activation	B-X
.	B-X
The	B-X
three	B-X
regions	B-X
concerned	B-X
are	B-X
:	B-X
1	B-X
)	B-X
a	B-X
region	B-X
between	B-X
-73	B-X
and	B-X
-36	B-X
,	B-X
which	B-X
is	B-X
the	B-X
minimal	B-X
element	B-X
inducible	B-X
by	B-X
LPS	B-X
or	B-X
TNF-alpha	B-X
;	B-X
2	B-X
)	B-X
an	B-X
element	B-X
located	B-X
between	B-X
-181	B-X
and	B-X
-73	B-X
,	B-X
which	B-X
appeared	B-X
to	B-X
regulate	B-X
the	B-X
response	B-X
to	B-X
IFN-gamma	B-X
and	B-X
TNF-alpha	B-X
negatively	B-X
;	B-X
and	B-X
3	B-X
)	B-X
a	B-X
distal	B-X
element	B-X
upstream	B-X
of	B-X
-224	B-X
,	B-X
which	B-X
was	B-X
inducible	B-X
by	B-X
IFN-gamma	B-X
alone	B-X
.	B-X
LPS	B-X
signaling	B-X
was	B-X
found	B-X
to	B-X
involve	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
by	B-X
the	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
Synergistic	B-X
induction	B-X
of	B-X
the	B-X
IL-6	B-X
gene	B-X
by	B-X
IFN-gamma	B-X
and	B-X
TNF-alpha	B-X
,	B-X
in	B-X
monocytic	B-X
cells	B-X
,	B-X
involved	B-X
cooperation	B-X
between	B-X
the	B-X
IRF-1	B-X
and	B-X
NF	B-X
kappa	B-X
B	B-X
p65	B-X
homodimers	B-X
with	B-X
concomitant	B-X
removal	B-X
of	B-X
the	B-X
negative	B-X
effect	B-X
of	B-X
the	B-X
retinoblastoma	B-X
control	B-X
element	B-X
present	B-X
in	B-X
the	B-X
IL-6	B-X
promoter	B-X
.	B-X
This	B-X
removal	B-X
occurred	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
constitutive	B-X
Sp1	B-X
factor	B-X
,	B-X
whose	B-X
increased	B-X
binding	B-X
activity	B-X
and	B-X
phosphorylation	B-X
were	B-X
mediated	B-X
by	B-X
IFN-gamma	B-X
.	B-X

We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
synergistic	O
induction	O
by	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
/	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
of	O
human	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
)	O
gene	O
in	O
THP	O
-	O
1	O
monocytic	O
cells	O
,	O
and	O
compared	O
it	O
with	O
the	O
basis	O
of	O
this	O
induction	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
synergistic	B-X
induction	B-X
by	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
/tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
of	B-X
human	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
gene	B-X
in	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
,	B-X
and	B-X
compared	B-X
it	B-X
with	B-X
the	B-X
basis	B-X
of	B-X
this	B-X
induction	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
Functional	B-X
studies	B-X
with	B-X
IL-6	B-X
promoter	B-X
demonstrated	B-X
that	B-X
three	B-X
regions	B-X
are	B-X
the	B-X
targets	B-X
of	B-X
the	B-X
IFN-gamma	B-X
and/or	B-X
TNF-alpha	B-X
action	B-X
,	B-X
whereas	B-X
only	B-X
one	B-X
of	B-X
these	B-X
regions	B-X
seemed	B-X
to	B-X
be	B-X
implicated	B-X
in	B-X
LPS	B-X
activation	B-X
.	B-X
The	B-X
three	B-X
regions	B-X
concerned	B-X
are	B-X
:	B-X
1	B-X
)	B-X
a	B-X
region	B-X
between	B-X
-73	B-X
and	B-X
-36	B-X
,	B-X
which	B-X
is	B-X
the	B-X
minimal	B-X
element	B-X
inducible	B-X
by	B-X
LPS	B-X
or	B-X
TNF-alpha	B-X
;	B-X
2	B-X
)	B-X
an	B-X
element	B-X
located	B-X
between	B-X
-181	B-X
and	B-X
-73	B-X
,	B-X
which	B-X
appeared	B-X
to	B-X
regulate	B-X
the	B-X
response	B-X
to	B-X
IFN-gamma	B-X
and	B-X
TNF-alpha	B-X
negatively	B-X
;	B-X
and	B-X
3	B-X
)	B-X
a	B-X
distal	B-X
element	B-X
upstream	B-X
of	B-X
-224	B-X
,	B-X
which	B-X
was	B-X
inducible	B-X
by	B-X
IFN-gamma	B-X
alone	B-X
.	B-X
LPS	B-X
signaling	B-X
was	B-X
found	B-X
to	B-X
involve	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
by	B-X
the	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
Synergistic	B-X
induction	B-X
of	B-X
the	B-X
IL-6	B-X
gene	B-X
by	B-X
IFN-gamma	B-X
and	B-X
TNF-alpha	B-X
,	B-X
in	B-X
monocytic	B-X
cells	B-X
,	B-X
involved	B-X
cooperation	B-X
between	B-X
the	B-X
IRF-1	B-X
and	B-X
NF	B-X
kappa	B-X
B	B-X
p65	B-X
homodimers	B-X
with	B-X
concomitant	B-X
removal	B-X
of	B-X
the	B-X
negative	B-X
effect	B-X
of	B-X
the	B-X
retinoblastoma	B-X
control	B-X
element	B-X
present	B-X
in	B-X
the	B-X
IL-6	B-X
promoter	B-X
.	B-X
This	B-X
removal	B-X
occurred	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
constitutive	B-X
Sp1	B-X
factor	B-X
,	B-X
whose	B-X
increased	B-X
binding	B-X
activity	B-X
and	B-X
phosphorylation	B-X
were	B-X
mediated	B-X
by	B-X
IFN-gamma	B-X
.	B-X

Functional	O
studies	O
with	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
demonstrated	O
that	O
three	O
regions	O
are	O
the	O
targets	O
of	O
the	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
/	O
or	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
action	O
,	O
whereas	O
only	O
one	O
of	O
these	O
regions	O
seemed	O
to	O
be	O
implicated	O
in	O
LPS	O
activation	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
synergistic	B-X
induction	B-X
by	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
/tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
of	B-X
human	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
gene	B-X
in	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
,	B-X
and	B-X
compared	B-X
it	B-X
with	B-X
the	B-X
basis	B-X
of	B-X
this	B-X
induction	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
Functional	B-X
studies	B-X
with	B-X
IL-6	B-X
promoter	B-X
demonstrated	B-X
that	B-X
three	B-X
regions	B-X
are	B-X
the	B-X
targets	B-X
of	B-X
the	B-X
IFN-gamma	B-X
and/or	B-X
TNF-alpha	B-X
action	B-X
,	B-X
whereas	B-X
only	B-X
one	B-X
of	B-X
these	B-X
regions	B-X
seemed	B-X
to	B-X
be	B-X
implicated	B-X
in	B-X
LPS	B-X
activation	B-X
.	B-X
The	B-X
three	B-X
regions	B-X
concerned	B-X
are	B-X
:	B-X
1	B-X
)	B-X
a	B-X
region	B-X
between	B-X
-73	B-X
and	B-X
-36	B-X
,	B-X
which	B-X
is	B-X
the	B-X
minimal	B-X
element	B-X
inducible	B-X
by	B-X
LPS	B-X
or	B-X
TNF-alpha	B-X
;	B-X
2	B-X
)	B-X
an	B-X
element	B-X
located	B-X
between	B-X
-181	B-X
and	B-X
-73	B-X
,	B-X
which	B-X
appeared	B-X
to	B-X
regulate	B-X
the	B-X
response	B-X
to	B-X
IFN-gamma	B-X
and	B-X
TNF-alpha	B-X
negatively	B-X
;	B-X
and	B-X
3	B-X
)	B-X
a	B-X
distal	B-X
element	B-X
upstream	B-X
of	B-X
-224	B-X
,	B-X
which	B-X
was	B-X
inducible	B-X
by	B-X
IFN-gamma	B-X
alone	B-X
.	B-X
LPS	B-X
signaling	B-X
was	B-X
found	B-X
to	B-X
involve	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
by	B-X
the	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
Synergistic	B-X
induction	B-X
of	B-X
the	B-X
IL-6	B-X
gene	B-X
by	B-X
IFN-gamma	B-X
and	B-X
TNF-alpha	B-X
,	B-X
in	B-X
monocytic	B-X
cells	B-X
,	B-X
involved	B-X
cooperation	B-X
between	B-X
the	B-X
IRF-1	B-X
and	B-X
NF	B-X
kappa	B-X
B	B-X
p65	B-X
homodimers	B-X
with	B-X
concomitant	B-X
removal	B-X
of	B-X
the	B-X
negative	B-X
effect	B-X
of	B-X
the	B-X
retinoblastoma	B-X
control	B-X
element	B-X
present	B-X
in	B-X
the	B-X
IL-6	B-X
promoter	B-X
.	B-X
This	B-X
removal	B-X
occurred	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
constitutive	B-X
Sp1	B-X
factor	B-X
,	B-X
whose	B-X
increased	B-X
binding	B-X
activity	B-X
and	B-X
phosphorylation	B-X
were	B-X
mediated	B-X
by	B-X
IFN-gamma	B-X
.	B-X

The	O
three	O
regions	O
concerned	O
are	O
:	O
1	O
)	O
a	O
region	O
between	O
-	O
73	O
and	O
-	O
36	O
,	O
which	O
is	O
the	O
minimal	O
element	O
inducible	O
by	O
LPS	O
or	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
;	O
2	O
)	O
an	O
element	O
located	O
between	O
-	O
181	O
and	O
-	O
73	O
,	O
which	O
appeared	O
to	O
regulate	O
the	O
response	O
to	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
negatively	O
;	O
and	O
3	O
)	O
a	O
distal	O
element	O
upstream	O
of	O
-	O
224	O
,	O
which	O
was	O
inducible	O
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
alone	O
.	O
<EOS>	B-X
Tumour	B-X
Necrosis	B-X
Factor	B-X
alpha	B-X
(	B-X
TNF	B-X
alpha	B-X
)	B-X
,	B-X
is	B-X
an	B-X
inflammatory	B-X
cytokine	B-X
produced	B-X
by	B-X
macrophages/monocytes	B-X
during	B-X
acute	B-X
inflammation	B-X
and	B-X
is	B-X
responsible	B-X
for	B-X
a	B-X
diverse	B-X
range	B-X
of	B-X
signalling	B-X
events	B-X
within	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
necrosis	B-X
or	B-X
apoptosis	B-X
.	B-X
TNF	B-X
alpha	B-X
exerts	B-X
many	B-X
of	B-X
its	B-X
effects	B-X
by	B-X
binding	B-X
,	B-X
as	B-X
a	B-X
trimer	B-X
,	B-X
to	B-X
either	B-X
a	B-X
55	B-X
kDa	B-X
cell	B-X
membrane	B-X
receptor	B-X
termed	B-X
TNFR-1	B-X
or	B-X
a	B-X
75	B-X
kDa	B-X
cell	B-X
membrane	B-X
receptor	B-X
termed	B-X
TNFR-2	B-X
.	B-X
Both	B-X
these	B-X
receptors	B-X
belong	B-X
to	B-X
the	B-X
so-called	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
.	B-X
The	B-X
superfamily	B-X
includes	B-X
FAS	B-X
,	B-X
CD40	B-X
,	B-X
CD27	B-X
,	B-X
and	B-X
RANK	B-X
.	B-X
Additionally	B-X
,	B-X
a	B-X
number	B-X
of	B-X
structurally	B-X
related	B-X
``	B-X
decoy	B-X
receptors	B-X
''	B-X
exist	B-X
that	B-X
act	B-X
to	B-X
sequester	B-X
TNF	B-X
molecules	B-X
,	B-X
thereby	B-X
rescuing	B-X
cells	B-X
from	B-X
apoptosis	B-X
.	B-X
The	B-X
crystal	B-X
structures	B-X
of	B-X
TNF	B-X
alpha	B-X
,	B-X
TNF	B-X
beta	B-X
,	B-X
the	B-X
extracellular	B-X
domain	B-X
of	B-X
TNFR-1	B-X
(	B-X
denoted	B-X
sTNFR-1	B-X
)	B-X
,	B-X
and	B-X
the	B-X
TNF	B-X
beta	B-X
sTNFR-1	B-X
complex	B-X
have	B-X
been	B-X
defined	B-X
by	B-X
crystallography	B-X
.	B-X
This	B-X
article	B-X
will	B-X
review	B-X
the	B-X
structure/function	B-X
relationships	B-X
of	B-X
the	B-X
TNF	B-X
alpha	B-X
and	B-X
the	B-X
TNF	B-X
receptor	B-X
superfamily	B-X
.	B-X
It	B-X
will	B-X
also	B-X
discuss	B-X
insights	B-X
as	B-X
to	B-X
how	B-X
structural	B-X
features	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
pleiotropic	B-X
effects	B-X
of	B-X
TNF	B-X
alpha	B-X
.	B-X

LPS	O
signaling	O
was	O
found	O
to	O
involve	O
NF	O
kappa	O
B	O
activation	O
by	O
the	O
p50	B-Protein
/	O
p65	B-Protein
heterodimers	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
the	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
Mono	B-X
Mac	B-X
6	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
leads	B-X
to	B-X
rapid	B-X
and	B-X
transient	B-X
expression	B-X
of	B-X
cytokines	B-X
like	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
.	B-X
When	B-X
such	B-X
cells	B-X
are	B-X
precultured	B-X
for	B-X
2	B-X
days	B-X
with	B-X
a	B-X
low	B-X
dose	B-X
of	B-X
LPS	B-X
(	B-X
20	B-X
ng/ml	B-X
)	B-X
followed	B-X
by	B-X
stimulation	B-X
with	B-X
a	B-X
high	B-X
dose	B-X
of	B-X
LPS	B-X
(	B-X
1	B-X
microgram/ml	B-X
)	B-X
,	B-X
expression	B-X
of	B-X
the	B-X
TNF	B-X
gene	B-X
is	B-X
minimal	B-X
,	B-X
i.e	B-X
.	B-X
The	B-X
CD14	B-X
LPS	B-X
receptor	B-X
is	B-X
,	B-X
however	B-X
,	B-X
up-regulated	B-X
(	B-X
not	B-X
down-regulated	B-X
)	B-X
in	B-X
tolerant	B-X
cells	B-X
,	B-X
and	B-X
LPS	B-X
can	B-X
,	B-X
in	B-X
fact	B-X
,	B-X
still	B-X
lead	B-X
to	B-X
activation	B-X
of	B-X
tolerant	B-X
cells	B-X
as	B-X
evidenced	B-X
by	B-X
mobilization	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
.	B-X
Resolution	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
complex	B-X
in	B-X
gel	B-X
shift	B-X
analysis	B-X
shows	B-X
that	B-X
the	B-X
binding	B-X
protein	B-X
,	B-X
mobilized	B-X
in	B-X
naive	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
,	B-X
consists	B-X
mainly	B-X
of	B-X
p50-p65	B-X
heterodimers	B-X
,	B-X
while	B-X
in	B-X
tolerant	B-X
cells	B-X
,	B-X
the	B-X
p50	B-X
homodimer	B-X
is	B-X
predominant	B-X
.	B-X
This	B-X
increase	B-X
in	B-X
p50	B-X
homodimers	B-X
coincides	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
p105	B-X
mRNA	B-X
,	B-X
suggestive	B-X
of	B-X
a	B-X
transcriptional	B-X
up-regulation	B-X
of	B-X
p50	B-X
.	B-X
Reporter	B-X
gene	B-X
analysis	B-X
reveals	B-X
that	B-X
the	B-X
NF-kappa	B-X
B	B-X
complex	B-X
mobilized	B-X
in	B-X
tolerant	B-X
cells	B-X
is	B-X
functionally	B-X
inactive	B-X
in	B-X
that	B-X
NF-kappa	B-X
B-dependent	B-X
luciferase	B-X
constructs	B-X
containing	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
long	B-X
terminal	B-X
repeat	B-X
or	B-X
the	B-X
TNF	B-X
5'-region	B-X
show	B-X
only	B-X
minimal	B-X
transactivation	B-X
after	B-X
LPS	B-X
stimulation	B-X
.	B-X
Similar	B-X
to	B-X
Mono	B-X
Mac	B-X
6	B-X
cells	B-X
,	B-X
primary	B-X
blood	B-X
monocytes	B-X
,	B-X
when	B-X
precultured	B-X
with	B-X
a	B-X
low	B-X
dose	B-X
of	B-X
LPS	B-X
,	B-X
also	B-X
become	B-X
tolerant	B-X
and	B-X
produce	B-X
little	B-X
TNF	B-X
after	B-X
LPS	B-X
stimulation	B-X
.	B-X
The	B-X
tolerant	B-X
blood	B-X
monocytes	B-X
also	B-X
up-regulate	B-X
CD14	B-X
,	B-X
and	B-X
they	B-X
mobilize	B-X
NF-kappa	B-X
B	B-X
with	B-X
a	B-X
predominance	B-X
of	B-X
p50	B-X
homodimers	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
demonstrate	B-X
that	B-X
tolerance	B-X
to	B-X
LPS	B-X
is	B-X
determined	B-X
by	B-X
post-receptor	B-X
mechanisms	B-X
that	B-X
involve	B-X
an	B-X
altered	B-X
composition	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
complex	B-X
.	B-X

Synergistic	O
induction	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
gene	O
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
in	O
monocytic	O
cells	O
,	O
involved	O
cooperation	O
between	O
the	O
IRF	B-Protein
-	I-Protein
1	I-Protein
and	O
NF	O
kappa	O
B	O
p65	B-Protein
homodimers	O
with	O
concomitant	O
removal	O
of	O
the	O
negative	O
effect	O
of	O
the	O
retinoblastoma	O
control	O
element	O
present	O
in	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
synergistic	B-X
induction	B-X
by	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
/tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
of	B-X
human	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
gene	B-X
in	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
,	B-X
and	B-X
compared	B-X
it	B-X
with	B-X
the	B-X
basis	B-X
of	B-X
this	B-X
induction	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
Functional	B-X
studies	B-X
with	B-X
IL-6	B-X
promoter	B-X
demonstrated	B-X
that	B-X
three	B-X
regions	B-X
are	B-X
the	B-X
targets	B-X
of	B-X
the	B-X
IFN-gamma	B-X
and/or	B-X
TNF-alpha	B-X
action	B-X
,	B-X
whereas	B-X
only	B-X
one	B-X
of	B-X
these	B-X
regions	B-X
seemed	B-X
to	B-X
be	B-X
implicated	B-X
in	B-X
LPS	B-X
activation	B-X
.	B-X
The	B-X
three	B-X
regions	B-X
concerned	B-X
are	B-X
:	B-X
1	B-X
)	B-X
a	B-X
region	B-X
between	B-X
-73	B-X
and	B-X
-36	B-X
,	B-X
which	B-X
is	B-X
the	B-X
minimal	B-X
element	B-X
inducible	B-X
by	B-X
LPS	B-X
or	B-X
TNF-alpha	B-X
;	B-X
2	B-X
)	B-X
an	B-X
element	B-X
located	B-X
between	B-X
-181	B-X
and	B-X
-73	B-X
,	B-X
which	B-X
appeared	B-X
to	B-X
regulate	B-X
the	B-X
response	B-X
to	B-X
IFN-gamma	B-X
and	B-X
TNF-alpha	B-X
negatively	B-X
;	B-X
and	B-X
3	B-X
)	B-X
a	B-X
distal	B-X
element	B-X
upstream	B-X
of	B-X
-224	B-X
,	B-X
which	B-X
was	B-X
inducible	B-X
by	B-X
IFN-gamma	B-X
alone	B-X
.	B-X
LPS	B-X
signaling	B-X
was	B-X
found	B-X
to	B-X
involve	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
by	B-X
the	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
Synergistic	B-X
induction	B-X
of	B-X
the	B-X
IL-6	B-X
gene	B-X
by	B-X
IFN-gamma	B-X
and	B-X
TNF-alpha	B-X
,	B-X
in	B-X
monocytic	B-X
cells	B-X
,	B-X
involved	B-X
cooperation	B-X
between	B-X
the	B-X
IRF-1	B-X
and	B-X
NF	B-X
kappa	B-X
B	B-X
p65	B-X
homodimers	B-X
with	B-X
concomitant	B-X
removal	B-X
of	B-X
the	B-X
negative	B-X
effect	B-X
of	B-X
the	B-X
retinoblastoma	B-X
control	B-X
element	B-X
present	B-X
in	B-X
the	B-X
IL-6	B-X
promoter	B-X
.	B-X
This	B-X
removal	B-X
occurred	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
constitutive	B-X
Sp1	B-X
factor	B-X
,	B-X
whose	B-X
increased	B-X
binding	B-X
activity	B-X
and	B-X
phosphorylation	B-X
were	B-X
mediated	B-X
by	B-X
IFN-gamma	B-X
.	B-X

This	O
removal	O
occurred	O
by	O
activation	O
of	O
the	O
constitutive	O
Sp1	B-Protein
factor	O
,	O
whose	O
increased	O
binding	O
activity	O
and	O
phosphorylation	O
were	O
mediated	O
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
synergistic	B-X
induction	B-X
by	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
/tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
of	B-X
human	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
gene	B-X
in	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
,	B-X
and	B-X
compared	B-X
it	B-X
with	B-X
the	B-X
basis	B-X
of	B-X
this	B-X
induction	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
Functional	B-X
studies	B-X
with	B-X
IL-6	B-X
promoter	B-X
demonstrated	B-X
that	B-X
three	B-X
regions	B-X
are	B-X
the	B-X
targets	B-X
of	B-X
the	B-X
IFN-gamma	B-X
and/or	B-X
TNF-alpha	B-X
action	B-X
,	B-X
whereas	B-X
only	B-X
one	B-X
of	B-X
these	B-X
regions	B-X
seemed	B-X
to	B-X
be	B-X
implicated	B-X
in	B-X
LPS	B-X
activation	B-X
.	B-X
The	B-X
three	B-X
regions	B-X
concerned	B-X
are	B-X
:	B-X
1	B-X
)	B-X
a	B-X
region	B-X
between	B-X
-73	B-X
and	B-X
-36	B-X
,	B-X
which	B-X
is	B-X
the	B-X
minimal	B-X
element	B-X
inducible	B-X
by	B-X
LPS	B-X
or	B-X
TNF-alpha	B-X
;	B-X
2	B-X
)	B-X
an	B-X
element	B-X
located	B-X
between	B-X
-181	B-X
and	B-X
-73	B-X
,	B-X
which	B-X
appeared	B-X
to	B-X
regulate	B-X
the	B-X
response	B-X
to	B-X
IFN-gamma	B-X
and	B-X
TNF-alpha	B-X
negatively	B-X
;	B-X
and	B-X
3	B-X
)	B-X
a	B-X
distal	B-X
element	B-X
upstream	B-X
of	B-X
-224	B-X
,	B-X
which	B-X
was	B-X
inducible	B-X
by	B-X
IFN-gamma	B-X
alone	B-X
.	B-X
LPS	B-X
signaling	B-X
was	B-X
found	B-X
to	B-X
involve	B-X
NF	B-X
kappa	B-X
B	B-X
activation	B-X
by	B-X
the	B-X
p50/p65	B-X
heterodimers	B-X
.	B-X
Synergistic	B-X
induction	B-X
of	B-X
the	B-X
IL-6	B-X
gene	B-X
by	B-X
IFN-gamma	B-X
and	B-X
TNF-alpha	B-X
,	B-X
in	B-X
monocytic	B-X
cells	B-X
,	B-X
involved	B-X
cooperation	B-X
between	B-X
the	B-X
IRF-1	B-X
and	B-X
NF	B-X
kappa	B-X
B	B-X
p65	B-X
homodimers	B-X
with	B-X
concomitant	B-X
removal	B-X
of	B-X
the	B-X
negative	B-X
effect	B-X
of	B-X
the	B-X
retinoblastoma	B-X
control	B-X
element	B-X
present	B-X
in	B-X
the	B-X
IL-6	B-X
promoter	B-X
.	B-X
This	B-X
removal	B-X
occurred	B-X
by	B-X
activation	B-X
of	B-X
the	B-X
constitutive	B-X
Sp1	B-X
factor	B-X
,	B-X
whose	B-X
increased	B-X
binding	B-X
activity	B-X
and	B-X
phosphorylation	B-X
were	B-X
mediated	B-X
by	B-X
IFN-gamma	B-X
.	B-X

The	O
lymphotoxin	O
promoter	O
is	O
stimulated	O
by	O
HTLV	O
-	O
I	O
tax	B-Protein
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
T	O
-	O
cell	O
lines	O
.	O

The	O
HTLV	O
-	O
I	O
transcriptional	O
activator	O
tax	B-Protein
was	O
used	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
lymphotoxin	O
(	O
LT	O
;	O
TNF	B-Protein
-	I-Protein
beta	I-Protein
)	O
gene	O
induction	O
.	O
<EOS>	B-X
The	B-X
HTLV-I	B-X
transcriptional	B-X
activator	B-X
tax	B-X
was	B-X
used	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
lymphotoxin	B-X
(	B-X
LT	B-X
;	B-X
TNF-beta	B-X
)	B-X
gene	B-X
induction	B-X
.	B-X
Tax-expressing	B-X
cell	B-X
lines	B-X
produce	B-X
LT	B-X
biologic	B-X
activity	B-X
.	B-X
An	B-X
LT	B-X
promoter	B-X
(	B-X
LT-293	B-X
)	B-X
CAT	B-X
construct	B-X
that	B-X
contained	B-X
an	B-X
NF-kappa	B-X
B	B-X
site	B-X
was	B-X
active	B-X
in	B-X
the	B-X
LT-producing	B-X
C81-66-45	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
contains	B-X
defective	B-X
HTLV-I	B-X
but	B-X
expresses	B-X
tax	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
a	B-X
mutated	B-X
LT-kappa	B-X
B	B-X
construct	B-X
(	B-X
M1-CAT	B-X
)	B-X
was	B-X
inactive	B-X
in	B-X
C81-66-45	B-X
,	B-X
confirmed	B-X
the	B-X
importance	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
LT	B-X
gene	B-X
expression	B-X
.	B-X
Tax	B-X
was	B-X
transfected	B-X
into	B-X
HTLV-I-negative	B-X
human	B-X
T-cell	B-X
lines	B-X
.	B-X
Jurkat	B-X
T	B-X
cells	B-X
stably	B-X
expressing	B-X
tax	B-X
contained	B-X
elevated	B-X
levels	B-X
of	B-X
NF-kappa	B-X
B	B-X
that	B-X
directly	B-X
bound	B-X
to	B-X
the	B-X
LT-kappa	B-X
B	B-X
site	B-X
.	B-X
Tax	B-X
co-transfected	B-X
with	B-X
reporter	B-X
constructs	B-X
into	B-X
Jurkat	B-X
cells	B-X
maximally	B-X
activated	B-X
HTLV-I-LTR-CAT	B-X
and	B-X
kappa	B-X
B-fos-CAT	B-X
and	B-X
also	B-X
activated	B-X
LT-293	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
.	B-X
In	B-X
JM	B-X
T	B-X
cells	B-X
,	B-X
tax	B-X
induced	B-X
LT-293	B-X
activity	B-X
by	B-X
two-	B-X
to	B-X
four-fold	B-X
,	B-X
though	B-X
there	B-X
was	B-X
no	B-X
induction	B-X
of	B-X
M1-CAT	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
LT-293	B-X
CAT	B-X
activity	B-X
mirrored	B-X
the	B-X
increase	B-X
in	B-X
LT	B-X
biologic	B-X
activity	B-X
seen	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
These	B-X
studies	B-X
,	B-X
the	B-X
first	B-X
to	B-X
demonstrate	B-X
induction	B-X
of	B-X
LT	B-X
promoter	B-X
activity	B-X
over	B-X
basal	B-X
levels	B-X
,	B-X
indicate	B-X
that	B-X
HTLV-I	B-X
tax	B-X
causes	B-X
low-level	B-X
activation	B-X
of	B-X
both	B-X
endogenous	B-X
LT	B-X
and	B-X
the	B-X
LT	B-X
promoter	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
through	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X

Tax	O
-	O
expressing	O
cell	O
lines	O
produce	O
LT	O
biologic	O
activity	O
.	O
<EOS>	B-X
Human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
-infected	B-X
T-cell	B-X
lines	B-X
constitutively	B-X
produce	B-X
high	B-X
levels	B-X
of	B-X
biologically	B-X
active	B-X
lymphotoxin	B-X
(	B-X
LT	B-X
;	B-X
tumor	B-X
necrosis	B-X
factor-beta	B-X
)	B-X
protein	B-X
and	B-X
LT	B-X
mRNA	B-X
.	B-X
To	B-X
understand	B-X
the	B-X
regulation	B-X
of	B-X
LT	B-X
transcription	B-X
by	B-X
HTLV-I	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
ability	B-X
of	B-X
a	B-X
series	B-X
of	B-X
deletions	B-X
of	B-X
the	B-X
LT	B-X
promoter	B-X
to	B-X
drive	B-X
the	B-X
chloramphenicol	B-X
acetyltransferase	B-X
(	B-X
CAT	B-X
)	B-X
reporter	B-X
gene	B-X
in	B-X
HTLV-I-positive	B-X
MT-2	B-X
cells	B-X
.	B-X
The	B-X
smallest	B-X
LT	B-X
promoter	B-X
fragment	B-X
(	B-X
-140	B-X
to	B-X
+77	B-X
)	B-X
that	B-X
was	B-X
able	B-X
to	B-X
drive	B-X
CAT	B-X
activity	B-X
contained	B-X
a	B-X
site	B-X
that	B-X
was	B-X
similar	B-X
to	B-X
the	B-X
immunoglobulin	B-X
kappa-chain	B-X
NF-kappa	B-X
B-binding	B-X
site	B-X
.	B-X
Since	B-X
the	B-X
HTLV-I	B-X
tax	B-X
gene	B-X
activates	B-X
the	B-X
nuclear	B-X
form	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
this	B-X
finding	B-X
suggested	B-X
a	B-X
possible	B-X
means	B-X
of	B-X
HTLV-I	B-X
activation	B-X
of	B-X
LT	B-X
production	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
LT	B-X
kappa	B-X
B-like	B-X
site	B-X
specifically	B-X
formed	B-X
a	B-X
complex	B-X
with	B-X
NF-kappa	B-X
B-containing	B-X
nuclear	B-X
extract	B-X
from	B-X
MT-2	B-X
,	B-X
C81-66-45	B-X
,	B-X
and	B-X
other	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
LT	B-X
kappa	B-X
B	B-X
site	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
LT	B-X
promoter	B-X
(	B-X
-293	B-X
to	B-X
+77	B-X
)	B-X
(	B-X
mutant	B-X
M1	B-X
)	B-X
reduced	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
promoter	B-X
to	B-X
drive	B-X
the	B-X
CAT	B-X
gene	B-X
in	B-X
HTLV-I-infected	B-X
and	B-X
noninfected	B-X
human	B-X
T-cell	B-X
lines	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
general	B-X
role	B-X
for	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
LT	B-X
gene	B-X
transcription	B-X
.	B-X
Activation	B-X
of	B-X
LT	B-X
in	B-X
HTLV-I-infected	B-X
cells	B-X
may	B-X
explain	B-X
the	B-X
pathology	B-X
associated	B-X
with	B-X
HTLV-I	B-X
infection	B-X
,	B-X
including	B-X
the	B-X
hypercalcemia	B-X
that	B-X
is	B-X
prevalent	B-X
in	B-X
adult	B-X
T-cell	B-X
leukemia	B-X
.	B-X

An	O
LT	O
promoter	O
(	O
LT	O
-	O
293	O
)	O
CAT	B-Protein
construct	O
that	O
contained	O
an	O
NF	O
-	O
kappa	O
B	O
site	O
was	O
active	O
in	O
the	O
LT	O
-	O
producing	O
C81	O
-	O
66	O
-	O
45	O
cell	O
line	O
,	O
which	O
contains	O
defective	O
HTLV	O
-	O
I	O
but	O
expresses	O
tax	B-Protein
.	O

The	O
observation	O
that	O
a	O
mutated	O
LT	O
-	O
kappa	O
B	O
construct	O
(	O
M1	O
-	O
CAT	B-Protein
)	O
was	O
inactive	O
in	O
C81	O
-	O
66	O
-	O
45	O
,	O
confirmed	O
the	O
importance	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
LT	O
gene	O
expression	O
.	O
<EOS>	B-X
The	B-X
HTLV-I	B-X
transcriptional	B-X
activator	B-X
tax	B-X
was	B-X
used	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
lymphotoxin	B-X
(	B-X
LT	B-X
;	B-X
TNF-beta	B-X
)	B-X
gene	B-X
induction	B-X
.	B-X
Tax-expressing	B-X
cell	B-X
lines	B-X
produce	B-X
LT	B-X
biologic	B-X
activity	B-X
.	B-X
An	B-X
LT	B-X
promoter	B-X
(	B-X
LT-293	B-X
)	B-X
CAT	B-X
construct	B-X
that	B-X
contained	B-X
an	B-X
NF-kappa	B-X
B	B-X
site	B-X
was	B-X
active	B-X
in	B-X
the	B-X
LT-producing	B-X
C81-66-45	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
contains	B-X
defective	B-X
HTLV-I	B-X
but	B-X
expresses	B-X
tax	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
a	B-X
mutated	B-X
LT-kappa	B-X
B	B-X
construct	B-X
(	B-X
M1-CAT	B-X
)	B-X
was	B-X
inactive	B-X
in	B-X
C81-66-45	B-X
,	B-X
confirmed	B-X
the	B-X
importance	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
LT	B-X
gene	B-X
expression	B-X
.	B-X
Jurkat	B-X
T	B-X
cells	B-X
stably	B-X
expressing	B-X
tax	B-X
contained	B-X
elevated	B-X
levels	B-X
of	B-X
NF-kappa	B-X
B	B-X
that	B-X
directly	B-X
bound	B-X
to	B-X
the	B-X
LT-kappa	B-X
B	B-X
site	B-X
.	B-X
Tax	B-X
co-transfected	B-X
with	B-X
reporter	B-X
constructs	B-X
into	B-X
Jurkat	B-X
cells	B-X
maximally	B-X
activated	B-X
HTLV-I-LTR-CAT	B-X
and	B-X
kappa	B-X
B-fos-CAT	B-X
and	B-X
also	B-X
activated	B-X
LT-293	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
.	B-X
In	B-X
JM	B-X
T	B-X
cells	B-X
,	B-X
tax	B-X
induced	B-X
LT-293	B-X
activity	B-X
by	B-X
two-	B-X
to	B-X
four-fold	B-X
,	B-X
though	B-X
there	B-X
was	B-X
no	B-X
induction	B-X
of	B-X
M1-CAT	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
LT-293	B-X
CAT	B-X
activity	B-X
mirrored	B-X
the	B-X
increase	B-X
in	B-X
LT	B-X
biologic	B-X
activity	B-X
seen	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
These	B-X
studies	B-X
,	B-X
the	B-X
first	B-X
to	B-X
demonstrate	B-X
induction	B-X
of	B-X
LT	B-X
promoter	B-X
activity	B-X
over	B-X
basal	B-X
levels	B-X
,	B-X
indicate	B-X
that	B-X
HTLV-I	B-X
tax	B-X
causes	B-X
low-level	B-X
activation	B-X
of	B-X
both	B-X
endogenous	B-X
LT	B-X
and	B-X
the	B-X
LT	B-X
promoter	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
through	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X

Tax	B-Protein
was	O
transfected	O
into	O
HTLV	O
-	O
I	O
-	O
negative	O
human	O
T	O
-	O
cell	O
lines	O
.	O

Jurkat	O
T	O
cells	O
stably	O
expressing	O
tax	B-Protein
contained	O
elevated	O
levels	O
of	O
NF	O
-	O
kappa	O
B	O
that	O
directly	O
bound	O
to	O
the	O
LT	O
-	O
kappa	O
B	O
site	O
.	O

Tax	B-Protein
co	O
-	O
transfected	O
with	O
reporter	O
constructs	O
into	O
Jurkat	O
cells	O
maximally	O
activated	O
HTLV	O
-	O
I	O
-	O
LTR	O
-	O
CAT	B-Protein
and	O
kappa	O
B	O
-	O
fos	B-Protein
-	O
CAT	B-Protein
and	O
also	O
activated	O
LT	O
-	O
293	O
to	O
a	O
lesser	O
extent	O
.	O

In	O
JM	O
T	O
cells	O
,	O
tax	B-Protein
induced	O
LT	O
-	O
293	O
activity	O
by	O
two	O
-	O
to	O
four	O
-	O
fold	O
,	O
though	O
there	O
was	O
no	O
induction	O
of	O
M1	O
-	O
CAT	B-Protein
.	O
<EOS>	B-X
The	B-X
HTLV-I	B-X
transcriptional	B-X
activator	B-X
tax	B-X
was	B-X
used	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
lymphotoxin	B-X
(	B-X
LT	B-X
;	B-X
TNF-beta	B-X
)	B-X
gene	B-X
induction	B-X
.	B-X
Tax-expressing	B-X
cell	B-X
lines	B-X
produce	B-X
LT	B-X
biologic	B-X
activity	B-X
.	B-X
An	B-X
LT	B-X
promoter	B-X
(	B-X
LT-293	B-X
)	B-X
CAT	B-X
construct	B-X
that	B-X
contained	B-X
an	B-X
NF-kappa	B-X
B	B-X
site	B-X
was	B-X
active	B-X
in	B-X
the	B-X
LT-producing	B-X
C81-66-45	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
contains	B-X
defective	B-X
HTLV-I	B-X
but	B-X
expresses	B-X
tax	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
a	B-X
mutated	B-X
LT-kappa	B-X
B	B-X
construct	B-X
(	B-X
M1-CAT	B-X
)	B-X
was	B-X
inactive	B-X
in	B-X
C81-66-45	B-X
,	B-X
confirmed	B-X
the	B-X
importance	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
LT	B-X
gene	B-X
expression	B-X
.	B-X
Jurkat	B-X
T	B-X
cells	B-X
stably	B-X
expressing	B-X
tax	B-X
contained	B-X
elevated	B-X
levels	B-X
of	B-X
NF-kappa	B-X
B	B-X
that	B-X
directly	B-X
bound	B-X
to	B-X
the	B-X
LT-kappa	B-X
B	B-X
site	B-X
.	B-X
Tax	B-X
co-transfected	B-X
with	B-X
reporter	B-X
constructs	B-X
into	B-X
Jurkat	B-X
cells	B-X
maximally	B-X
activated	B-X
HTLV-I-LTR-CAT	B-X
and	B-X
kappa	B-X
B-fos-CAT	B-X
and	B-X
also	B-X
activated	B-X
LT-293	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
.	B-X
In	B-X
JM	B-X
T	B-X
cells	B-X
,	B-X
tax	B-X
induced	B-X
LT-293	B-X
activity	B-X
by	B-X
two-	B-X
to	B-X
four-fold	B-X
,	B-X
though	B-X
there	B-X
was	B-X
no	B-X
induction	B-X
of	B-X
M1-CAT	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
LT-293	B-X
CAT	B-X
activity	B-X
mirrored	B-X
the	B-X
increase	B-X
in	B-X
LT	B-X
biologic	B-X
activity	B-X
seen	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
These	B-X
studies	B-X
,	B-X
the	B-X
first	B-X
to	B-X
demonstrate	B-X
induction	B-X
of	B-X
LT	B-X
promoter	B-X
activity	B-X
over	B-X
basal	B-X
levels	B-X
,	B-X
indicate	B-X
that	B-X
HTLV-I	B-X
tax	B-X
causes	B-X
low-level	B-X
activation	B-X
of	B-X
both	B-X
endogenous	B-X
LT	B-X
and	B-X
the	B-X
LT	B-X
promoter	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
through	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X

The	O
increase	O
in	O
LT	O
-	O
293	O
CAT	B-Protein
activity	O
mirrored	O
the	O
increase	O
in	O
LT	O
biologic	O
activity	O
seen	O
under	O
these	O
conditions	O
.	O
<EOS>	B-X
The	B-X
HTLV-I	B-X
transcriptional	B-X
activator	B-X
tax	B-X
was	B-X
used	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
lymphotoxin	B-X
(	B-X
LT	B-X
;	B-X
TNF-beta	B-X
)	B-X
gene	B-X
induction	B-X
.	B-X
Tax-expressing	B-X
cell	B-X
lines	B-X
produce	B-X
LT	B-X
biologic	B-X
activity	B-X
.	B-X
An	B-X
LT	B-X
promoter	B-X
(	B-X
LT-293	B-X
)	B-X
CAT	B-X
construct	B-X
that	B-X
contained	B-X
an	B-X
NF-kappa	B-X
B	B-X
site	B-X
was	B-X
active	B-X
in	B-X
the	B-X
LT-producing	B-X
C81-66-45	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
contains	B-X
defective	B-X
HTLV-I	B-X
but	B-X
expresses	B-X
tax	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
a	B-X
mutated	B-X
LT-kappa	B-X
B	B-X
construct	B-X
(	B-X
M1-CAT	B-X
)	B-X
was	B-X
inactive	B-X
in	B-X
C81-66-45	B-X
,	B-X
confirmed	B-X
the	B-X
importance	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
LT	B-X
gene	B-X
expression	B-X
.	B-X
Jurkat	B-X
T	B-X
cells	B-X
stably	B-X
expressing	B-X
tax	B-X
contained	B-X
elevated	B-X
levels	B-X
of	B-X
NF-kappa	B-X
B	B-X
that	B-X
directly	B-X
bound	B-X
to	B-X
the	B-X
LT-kappa	B-X
B	B-X
site	B-X
.	B-X
Tax	B-X
co-transfected	B-X
with	B-X
reporter	B-X
constructs	B-X
into	B-X
Jurkat	B-X
cells	B-X
maximally	B-X
activated	B-X
HTLV-I-LTR-CAT	B-X
and	B-X
kappa	B-X
B-fos-CAT	B-X
and	B-X
also	B-X
activated	B-X
LT-293	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
.	B-X
In	B-X
JM	B-X
T	B-X
cells	B-X
,	B-X
tax	B-X
induced	B-X
LT-293	B-X
activity	B-X
by	B-X
two-	B-X
to	B-X
four-fold	B-X
,	B-X
though	B-X
there	B-X
was	B-X
no	B-X
induction	B-X
of	B-X
M1-CAT	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
LT-293	B-X
CAT	B-X
activity	B-X
mirrored	B-X
the	B-X
increase	B-X
in	B-X
LT	B-X
biologic	B-X
activity	B-X
seen	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
These	B-X
studies	B-X
,	B-X
the	B-X
first	B-X
to	B-X
demonstrate	B-X
induction	B-X
of	B-X
LT	B-X
promoter	B-X
activity	B-X
over	B-X
basal	B-X
levels	B-X
,	B-X
indicate	B-X
that	B-X
HTLV-I	B-X
tax	B-X
causes	B-X
low-level	B-X
activation	B-X
of	B-X
both	B-X
endogenous	B-X
LT	B-X
and	B-X
the	B-X
LT	B-X
promoter	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
through	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X

These	O
studies	O
,	O
the	O
first	O
to	O
demonstrate	O
induction	O
of	O
LT	O
promoter	O
activity	O
over	O
basal	O
levels	O
,	O
indicate	O
that	O
HTLV	O
-	O
I	O
tax	B-Protein
causes	O
low	O
-	O
level	O
activation	O
of	O
both	O
endogenous	O
LT	O
and	O
the	O
LT	O
promoter	O
,	O
at	O
least	O
in	O
part	O
through	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
The	B-X
HTLV-I	B-X
transcriptional	B-X
activator	B-X
tax	B-X
was	B-X
used	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
lymphotoxin	B-X
(	B-X
LT	B-X
;	B-X
TNF-beta	B-X
)	B-X
gene	B-X
induction	B-X
.	B-X
Tax-expressing	B-X
cell	B-X
lines	B-X
produce	B-X
LT	B-X
biologic	B-X
activity	B-X
.	B-X
An	B-X
LT	B-X
promoter	B-X
(	B-X
LT-293	B-X
)	B-X
CAT	B-X
construct	B-X
that	B-X
contained	B-X
an	B-X
NF-kappa	B-X
B	B-X
site	B-X
was	B-X
active	B-X
in	B-X
the	B-X
LT-producing	B-X
C81-66-45	B-X
cell	B-X
line	B-X
,	B-X
which	B-X
contains	B-X
defective	B-X
HTLV-I	B-X
but	B-X
expresses	B-X
tax	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
a	B-X
mutated	B-X
LT-kappa	B-X
B	B-X
construct	B-X
(	B-X
M1-CAT	B-X
)	B-X
was	B-X
inactive	B-X
in	B-X
C81-66-45	B-X
,	B-X
confirmed	B-X
the	B-X
importance	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
LT	B-X
gene	B-X
expression	B-X
.	B-X
Tax	B-X
was	B-X
transfected	B-X
into	B-X
HTLV-I-negative	B-X
human	B-X
T-cell	B-X
lines	B-X
.	B-X
Jurkat	B-X
T	B-X
cells	B-X
stably	B-X
expressing	B-X
tax	B-X
contained	B-X
elevated	B-X
levels	B-X
of	B-X
NF-kappa	B-X
B	B-X
that	B-X
directly	B-X
bound	B-X
to	B-X
the	B-X
LT-kappa	B-X
B	B-X
site	B-X
.	B-X
Tax	B-X
co-transfected	B-X
with	B-X
reporter	B-X
constructs	B-X
into	B-X
Jurkat	B-X
cells	B-X
maximally	B-X
activated	B-X
HTLV-I-LTR-CAT	B-X
and	B-X
kappa	B-X
B-fos-CAT	B-X
and	B-X
also	B-X
activated	B-X
LT-293	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
.	B-X
In	B-X
JM	B-X
T	B-X
cells	B-X
,	B-X
tax	B-X
induced	B-X
LT-293	B-X
activity	B-X
by	B-X
two-	B-X
to	B-X
four-fold	B-X
,	B-X
though	B-X
there	B-X
was	B-X
no	B-X
induction	B-X
of	B-X
M1-CAT	B-X
.	B-X
The	B-X
increase	B-X
in	B-X
LT-293	B-X
CAT	B-X
activity	B-X
mirrored	B-X
the	B-X
increase	B-X
in	B-X
LT	B-X
biologic	B-X
activity	B-X
seen	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
These	B-X
studies	B-X
,	B-X
the	B-X
first	B-X
to	B-X
demonstrate	B-X
induction	B-X
of	B-X
LT	B-X
promoter	B-X
activity	B-X
over	B-X
basal	B-X
levels	B-X
,	B-X
indicate	B-X
that	B-X
HTLV-I	B-X
tax	B-X
causes	B-X
low-level	B-X
activation	B-X
of	B-X
both	B-X
endogenous	B-X
LT	B-X
and	B-X
the	B-X
LT	B-X
promoter	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
through	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X

Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T	O
-	O
cell	O
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	O
tyrosine	O
phosphatases	O
.	O

Rapid	O
tyrosine	O
phosphorylation	O
of	O
key	O
cellular	O
proteins	O
is	O
a	O
crucial	O
event	O
in	O
the	O
transduction	O
of	O
activation	O
signals	O
to	O
T	O
-	O
lymphocytes	O
.	O

The	O
regulatory	O
role	O
of	O
protein	O
tyrosine	O
phosphatases	O
(	O
PTPases	O
)	O
in	O
this	O
process	O
was	O
explored	O
by	O
studying	O
the	O
effects	O
of	O
a	O
powerful	O
PTPase	O
inhibitor	O
,	O
vanadate	O
peroxide	O
(	O
pervanadate	O
)	O
,	O
on	O
the	O
activation	O
cascade	O
of	O
Jurkat	O
human	O
leukaemic	O
T	O
-	O
cells	O
.	O
<EOS>	B-X
Rapid	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
key	B-X
cellular	B-X
proteins	B-X
is	B-X
a	B-X
crucial	B-X
event	B-X
in	B-X
the	B-X
transduction	B-X
of	B-X
activation	B-X
signals	B-X
to	B-X
T-lymphocytes	B-X
.	B-X
The	B-X
regulatory	B-X
role	B-X
of	B-X
protein	B-X
tyrosine	B-X
phosphatases	B-X
(	B-X
PTPases	B-X
)	B-X
in	B-X
this	B-X
process	B-X
was	B-X
explored	B-X
by	B-X
studying	B-X
the	B-X
effects	B-X
of	B-X
a	B-X
powerful	B-X
PTPase	B-X
inhibitor	B-X
,	B-X
vanadate	B-X
peroxide	B-X
(	B-X
pervanadate	B-X
)	B-X
,	B-X
on	B-X
the	B-X
activation	B-X
cascade	B-X
of	B-X
Jurkat	B-X
human	B-X
leukaemic	B-X
T-cells	B-X
.	B-X
Pervanadate	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
tyrosine	B-X
kinases	B-X
lck	B-X
and	B-X
fyn	B-X
(	B-X
4-	B-X
and	B-X
3-fold	B-X
respectively	B-X
)	B-X
and	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
notably	B-X
phospholipase	B-X
C	B-X
gamma	B-X
1	B-X
.	B-X
This	B-X
effect	B-X
required	B-X
surface	B-X
expression	B-X
of	B-X
the	B-X
CD45	B-X
PTPase	B-X
and	B-X
was	B-X
not	B-X
observed	B-X
in	B-X
CD45-deficient	B-X
variants	B-X
of	B-X
Jurkat	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
CD45-negative	B-X
variant	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
pervanadate	B-X
on	B-X
tyrosine	B-X
phosphorylation	B-X
was	B-X
globally	B-X
decreased	B-X
and	B-X
some	B-X
phosphorylated	B-X
substrates	B-X
were	B-X
specifically	B-X
missing	B-X
.	B-X
Pervanadate	B-X
also	B-X
stimulated	B-X
transcription	B-X
of	B-X
the	B-X
c-fos	B-X
gene	B-X
and	B-X
accumulation	B-X
of	B-X
its	B-X
mRNA	B-X
as	B-X
well	B-X
as	B-X
several	B-X
other	B-X
hallmarks	B-X
of	B-X
T-lymphocyte	B-X
activation	B-X
such	B-X
as	B-X
surface	B-X
expression	B-X
of	B-X
the	B-X
CD69	B-X
antigen	B-X
and	B-X
the	B-X
interleukin	B-X
2	B-X
receptor	B-X
alpha-chain	B-X
(	B-X
CD25	B-X
)	B-X
.	B-X
Pervanadate	B-X
synergized	B-X
with	B-X
signals	B-X
delivered	B-X
by	B-X
T-cell	B-X
antigen	B-X
receptor	B-X
engagement	B-X
or	B-X
by	B-X
a	B-X
phorbol	B-X
ester	B-X
to	B-X
induce	B-X
interleukin	B-X
2	B-X
production	B-X
.	B-X
Pervanadate	B-X
activated	B-X
NF-kappa	B-X
B	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
DNA-binding	B-X
activity	B-X
of	B-X
this	B-X
transcription	B-X
factor	B-X
.	B-X
We	B-X
thus	B-X
conclude	B-X
that	B-X
PTPases	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
signal	B-X
transduction	B-X
culminating	B-X
in	B-X
T-lymphocyte	B-X
activation	B-X
.	B-X
Moreover	B-X
,	B-X
induction	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
appears	B-X
sufficient	B-X
per	B-X
se	B-X
to	B-X
initiate	B-X
a	B-X
complete	B-X
activation	B-X
programme	B-X
.	B-X

Pervanadate	O
induced	O
activation	O
of	O
the	O
tyrosine	O
kinases	O
lck	B-Protein
and	O
fyn	B-Protein
(	O
4	O
-	O
and	O
3	O
-	O
fold	O
respectively	O
)	O
and	O
a	O
dramatic	O
increase	O
in	O
tyrosine	O
phosphorylation	O
of	O
cellular	O
proteins	O
,	O
notably	O
phospholipase	B-Protein
C	I-Protein
gamma	I-Protein
1	I-Protein
.	O

After	O
this	O
event	O
,	O
we	O
observed	O
a	O
rise	O
in	O
intracellular	O
Ca2	O
+	O
concentration	O
,	O
corresponding	O
to	O
an	O
influx	O
.	O

This	O
effect	O
required	O
surface	O
expression	O
of	O
the	O
CD45	B-Protein
PTPase	O
and	O
was	O
not	O
observed	O
in	O
CD45	B-Protein
-	O
deficient	O
variants	O
of	O
Jurkat	O
cells	O
.	O
<EOS>	B-X
The	B-X
first	B-X
step	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
response	B-X
involves	B-X
the	B-X
interaction	B-X
of	B-X
T	B-X
cells	B-X
that	B-X
express	B-X
T-cell	B-X
receptors	B-X
(	B-X
TCRs	B-X
)	B-X
with	B-X
peptide-loaded	B-X
major	B-X
histocompatibility	B-X
complexes	B-X
expressed	B-X
by	B-X
antigen-presenting	B-X
cells	B-X
(	B-X
APCs	B-X
)	B-X
.	B-X
Recent	B-X
findings	B-X
suggest	B-X
that	B-X
one	B-X
of	B-X
the	B-X
key	B-X
events	B-X
is	B-X
the	B-X
exclusion	B-X
of	B-X
the	B-X
large	B-X
receptor-type	B-X
tyrosine	B-X
phosphatase	B-X
CD45	B-X
,	B-X
from	B-X
close	B-X
contacts	B-X
formed	B-X
at	B-X
sites	B-X
of	B-X
T-cell/APC	B-X
interaction	B-X
.	B-X
If	B-X
this	B-X
is	B-X
true	B-X
,	B-X
a	B-X
full	B-X
understanding	B-X
of	B-X
how	B-X
close	B-X
contact	B-X
formation	B-X
leads	B-X
to	B-X
signaling	B-X
would	B-X
require	B-X
insights	B-X
into	B-X
the	B-X
structures	B-X
of	B-X
,	B-X
and	B-X
interactions	B-X
between	B-X
,	B-X
large	B-X
membrane	B-X
proteins	B-X
like	B-X
CD45	B-X
and	B-X
other	B-X
proteins	B-X
forming	B-X
the	B-X
glycocalyx	B-X
,	B-X
such	B-X
as	B-X
CD43	B-X
.	B-X
Structural	B-X
insights	B-X
into	B-X
the	B-X
overall	B-X
dimensions	B-X
of	B-X
these	B-X
proteins	B-X
using	B-X
crystallographic	B-X
methods	B-X
are	B-X
hard	B-X
to	B-X
obtain	B-X
,	B-X
and	B-X
their	B-X
conformations	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
are	B-X
also	B-X
unknown	B-X
.	B-X
Several	B-X
imaging-based	B-X
optical	B-X
microscopy	B-X
techniques	B-X
have	B-X
however	B-X
been	B-X
developed	B-X
for	B-X
analyzing	B-X
protein	B-X
dimensions	B-X
and	B-X
orientation	B-X
on	B-X
model	B-X
cell	B-X
surfaces	B-X
with	B-X
nanometer	B-X
precision	B-X
.	B-X
Important	B-X
insights	B-X
that	B-X
have	B-X
been	B-X
obtained	B-X
include	B-X
(	B-X
i	B-X
)	B-X
how	B-X
protein	B-X
flexibility	B-X
and	B-X
coverage	B-X
might	B-X
affect	B-X
the	B-X
effective	B-X
heights	B-X
of	B-X
these	B-X
molecules	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
the	B-X
height	B-X
of	B-X
proteins	B-X
on	B-X
the	B-X
membrane	B-X
as	B-X
a	B-X
key	B-X
parameter	B-X
determining	B-X
how	B-X
they	B-X
will	B-X
distribute	B-X
in	B-X
cell-cell	B-X
contacts	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
how	B-X
repulsive	B-X
interactions	B-X
between	B-X
the	B-X
extracellular	B-X
parts	B-X
of	B-X
the	B-X
proteins	B-X
influences	B-X
protein	B-X
aggregation	B-X
and	B-X
distribution	B-X
.	B-X

In	O
the	O
CD45	B-Protein
-	O
negative	O
variant	O
,	O
the	O
effect	O
of	O
pervanadate	O
on	O
tyrosine	O
phosphorylation	O
was	O
globally	O
decreased	O
and	O
some	O
phosphorylated	O
substrates	O
were	O
specifically	O
missing	O
.	O
<EOS>	B-X
Rapid	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
key	B-X
cellular	B-X
proteins	B-X
is	B-X
a	B-X
crucial	B-X
event	B-X
in	B-X
the	B-X
transduction	B-X
of	B-X
activation	B-X
signals	B-X
to	B-X
T-lymphocytes	B-X
.	B-X
The	B-X
regulatory	B-X
role	B-X
of	B-X
protein	B-X
tyrosine	B-X
phosphatases	B-X
(	B-X
PTPases	B-X
)	B-X
in	B-X
this	B-X
process	B-X
was	B-X
explored	B-X
by	B-X
studying	B-X
the	B-X
effects	B-X
of	B-X
a	B-X
powerful	B-X
PTPase	B-X
inhibitor	B-X
,	B-X
vanadate	B-X
peroxide	B-X
(	B-X
pervanadate	B-X
)	B-X
,	B-X
on	B-X
the	B-X
activation	B-X
cascade	B-X
of	B-X
Jurkat	B-X
human	B-X
leukaemic	B-X
T-cells	B-X
.	B-X
Pervanadate	B-X
induced	B-X
activation	B-X
of	B-X
the	B-X
tyrosine	B-X
kinases	B-X
lck	B-X
and	B-X
fyn	B-X
(	B-X
4-	B-X
and	B-X
3-fold	B-X
respectively	B-X
)	B-X
and	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
notably	B-X
phospholipase	B-X
C	B-X
gamma	B-X
1	B-X
.	B-X
This	B-X
effect	B-X
required	B-X
surface	B-X
expression	B-X
of	B-X
the	B-X
CD45	B-X
PTPase	B-X
and	B-X
was	B-X
not	B-X
observed	B-X
in	B-X
CD45-deficient	B-X
variants	B-X
of	B-X
Jurkat	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
CD45-negative	B-X
variant	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
pervanadate	B-X
on	B-X
tyrosine	B-X
phosphorylation	B-X
was	B-X
globally	B-X
decreased	B-X
and	B-X
some	B-X
phosphorylated	B-X
substrates	B-X
were	B-X
specifically	B-X
missing	B-X
.	B-X
We	B-X
thus	B-X
conclude	B-X
that	B-X
PTPases	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
signal	B-X
transduction	B-X
culminating	B-X
in	B-X
T-lymphocyte	B-X
activation	B-X
.	B-X
Moreover	B-X
,	B-X
induction	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
appears	B-X
sufficient	B-X
per	B-X
se	B-X
to	B-X
initiate	B-X
a	B-X
complete	B-X
activation	B-X
programme	B-X
.	B-X

Pervanadate	O
also	O
stimulated	O
transcription	O
of	O
the	O
c	B-Protein
-	I-Protein
fos	I-Protein
gene	O
and	O
accumulation	O
of	O
its	O
mRNA	O
as	O
well	O
as	O
several	O
other	O
hallmarks	O
of	O
T	O
-	O
lymphocyte	O
activation	O
such	O
as	O
surface	O
expression	O
of	O
the	O
CD69	B-Protein
antigen	O
and	O
the	O
interleukin	B-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
-	I-Protein
chain	I-Protein
(	O
CD25	B-Protein
)	O
.	O

Pervanadate	O
synergized	O
with	O
signals	O
delivered	O
by	O
T	O
-	O
cell	O
antigen	O
receptor	O
engagement	O
or	O
by	O
a	O
phorbol	O
ester	O
to	O
induce	O
interleukin	B-Protein
2	I-Protein
production	O
.	O
<EOS>	B-X
The	B-X
CD3	B-X
subunits	B-X
of	B-X
the	B-X
T-cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
regulation	B-X
of	B-X
surface	B-X
TCR	B-X
expression	B-X
levels	B-X
.	B-X
Using	B-X
a	B-X
transient	B-X
transfection	B-X
assay	B-X
,	B-X
we	B-X
have	B-X
defined	B-X
the	B-X
sequences	B-X
required	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
signals	B-X
from	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
.	B-X
To	B-X
do	B-X
so	B-X
we	B-X
have	B-X
transfected	B-X
the	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
Jurkat	B-X
with	B-X
hybrid	B-X
DNA	B-X
constructs	B-X
in	B-X
which	B-X
fragments	B-X
from	B-X
the	B-X
IL-2	B-X
gene	B-X
are	B-X
linked	B-X
to	B-X
an	B-X
indicator	B-X
gene	B-X
.	B-X
The	B-X
indicator	B-X
gene	B-X
product	B-X
,	B-X
as	B-X
well	B-X
as	B-X
IL-2	B-X
production	B-X
from	B-X
the	B-X
endogenous	B-X
IL-2	B-X
gene	B-X
were	B-X
assayed	B-X
after	B-X
activation	B-X
of	B-X
the	B-X
transfected	B-X
Jurkat	B-X
cells	B-X
by	B-X
various	B-X
stimuli	B-X
.	B-X
We	B-X
have	B-X
demonstrated	B-X
that	B-X
a	B-X
275	B-X
bp	B-X
fragment	B-X
stretching	B-X
from	B-X
52	B-X
to	B-X
326	B-X
bp	B-X
upstream	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
transcription	B-X
initiation	B-X
site	B-X
is	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
the	B-X
linked	B-X
indicator	B-X
gene	B-X
.	B-X
This	B-X
IL-2	B-X
gene	B-X
fragment	B-X
has	B-X
several	B-X
of	B-X
the	B-X
characteristics	B-X
of	B-X
a	B-X
transcriptional	B-X
enhancer	B-X
element	B-X
,	B-X
in	B-X
that	B-X
it	B-X
functions	B-X
in	B-X
both	B-X
orientations	B-X
and	B-X
will	B-X
enhance	B-X
the	B-X
expression	B-X
from	B-X
the	B-X
promoter	B-X
of	B-X
an	B-X
unrelated	B-X
gene	B-X
.	B-X
Such	B-X
enhancement	B-X
occurred	B-X
only	B-X
after	B-X
activation	B-X
of	B-X
Jurkat	B-X
cells	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
.	B-X
More	B-X
specifically	B-X
,	B-X
this	B-X
275	B-X
bp	B-X
fragment	B-X
activated	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
linked	B-X
gene	B-X
after	B-X
binding	B-X
of	B-X
a	B-X
monoclonal	B-X
antibody	B-X
to	B-X
the	B-X
Jurkat	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PMA	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
calcium	B-X
ionophore	B-X
,	B-X
which	B-X
circumvents	B-X
antigen	B-X
receptor	B-X
binding	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
linked	B-X
gene	B-X
through	B-X
this	B-X
275	B-X
bp	B-X
sequence	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
PMA	B-X
.	B-X
Finally	B-X
,	B-X
in	B-X
a	B-X
mutant	B-X
Jurkat	B-X
cell	B-X
line	B-X
lacking	B-X
T3/antigen	B-X
receptor	B-X
complexes	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
no	B-X
expression	B-X
due	B-X
to	B-X
the	B-X
IL-2	B-X
5	B-X
'	B-X
flanking	B-X
region	B-X
was	B-X
seen	B-X
after	B-X
exposure	B-X
to	B-X
antibody	B-X
to	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
plus	B-X
PMA	B-X
or	B-X
to	B-X
PHA	B-X
plus	B-X
PMA	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
calcium	B-X
ionophore	B-X
plus	B-X
PMA	B-X
did	B-X
induce	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
linked	B-X
gene	B-X
through	B-X
the	B-X
IL-2	B-X
5	B-X
'	B-X
flanking	B-X
region	B-X
in	B-X
the	B-X
mutant	B-X
Jurkat	B-X
cell	B-X
line	B-X
.	B-X
The	B-X
responsiveness	B-X
of	B-X
the	B-X
transfected	B-X
hybrid	B-X
genes	B-X
containing	B-X
the	B-X
IL-2	B-X
regulatory	B-X
region	B-X
paralleled	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
endogenous	B-X
IL-2	B-X
gene	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
IL-2	B-X
bioassays	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
275	B-X
bp	B-X
IL-2	B-X
sequence	B-X
(	B-X
-326	B-X
to	B-X
-52	B-X
bp	B-X
)	B-X
is	B-X
a	B-X
target	B-X
for	B-X
the	B-X
signal	B-X
pathway	B-X
originating	B-X
at	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
.	B-X
Definition	B-X
of	B-X
this	B-X
275	B-X
bp	B-X
target	B-X
sequence	B-X
should	B-X
now	B-X
permit	B-X
the	B-X
isolation	B-X
of	B-X
the	B-X
molecules	B-X
that	B-X
bind	B-X
to	B-X
and	B-X
activate	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X

Pervanadate	O
activated	O
NF	O
-	O
kappa	O
B	O
,	O
as	O
shown	O
by	O
an	O
increase	O
in	O
DNA	O
-	O
binding	O
activity	O
of	O
this	O
transcription	O
factor	O
.	O
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
and	B-X
phosphorylation	B-X
events	B-X
mediated	B-X
by	B-X
tyrosine	B-X
kinase	B-X
are	B-X
involved	B-X
in	B-X
silica-induced	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappaB	B-X
)	B-X
activation	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
PTPase	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
and	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
silica-stimulated	B-X
macrophages	B-X
,	B-X
and	B-X
the	B-X
involvement	B-X
of	B-X
ROS	B-X
in	B-X
these	B-X
responses	B-X
.	B-X
Treatment	B-X
of	B-X
mouse	B-X
peritoneal	B-X
macrophages	B-X
(	B-X
RAW264.7	B-X
cells	B-X
)	B-X
with	B-X
a	B-X
PTPase	B-X
inhibitor	B-X
,	B-X
pervanadate	B-X
,	B-X
markedly	B-X
enhanced	B-X
the	B-X
DNA-binding	B-X
activity	B-X
of	B-X
NF-kappaB	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
silica	B-X
.	B-X
The	B-X
stimulatory	B-X
effect	B-X
of	B-X
pervanadate	B-X
on	B-X
NF-kappaB	B-X
activation	B-X
was	B-X
also	B-X
demonstrated	B-X
in	B-X
LPS-stimulated	B-X
macrophages	B-X
.	B-X
A	B-X
specific	B-X
inhibitor	B-X
of	B-X
protein	B-X
tyrosine	B-X
kinase	B-X
(	B-X
PTK	B-X
)	B-X
,	B-X
genistein	B-X
,	B-X
prevented	B-X
the	B-X
NF-kappaB	B-X
activation	B-X
induced	B-X
by	B-X
pervanadate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
silica	B-X
while	B-X
inhibitors	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
or	B-X
C	B-X
,	B-X
such	B-X
as	B-X
staurosporine	B-X
or	B-X
H7	B-X
,	B-X
had	B-X
no	B-X
inhibitory	B-X
effect	B-X
on	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
antioxidants	B-X
,	B-X
such	B-X
as	B-X
catalase	B-X
,	B-X
superoxide	B-X
dismutase	B-X
,	B-X
N-acetyl	B-X
cysteine	B-X
(	B-X
NAC	B-X
)	B-X
,	B-X
and	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
inhibited	B-X
NF-kappaB	B-X
activation	B-X
induced	B-X
by	B-X
pervanadate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
silica	B-X
.	B-X
Treatment	B-X
of	B-X
macrophages	B-X
with	B-X
NAC	B-X
abolished	B-X
the	B-X
increase	B-X
in	B-X
tyrosine	B-X
phosphorylation	B-X
in	B-X
cells	B-X
stimulated	B-X
with	B-X
the	B-X
combination	B-X
of	B-X
pervanadate	B-X
and	B-X
either	B-X
silica	B-X
or	B-X
LPS	B-X
or	B-X
with	B-X
silica	B-X
alone	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
PTPase	B-X
may	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
negative	B-X
regulation	B-X
of	B-X
silica-signaling	B-X
pathways	B-X
leading	B-X
to	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
macrophages	B-X
.	B-X
Furthermore	B-X
,	B-X
ROS	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
downstream	B-X
signaling	B-X
between	B-X
PTPase	B-X
inhibition	B-X
and	B-X
NF-kappaB	B-X
activation	B-X
.	B-X

We	O
thus	O
conclude	O
that	O
PTPases	O
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T	O
-	O
lymphocyte	O
activation	O
.	O

Moreover	O
,	O
induction	O
of	O
tyrosine	O
phosphorylation	O
appears	O
sufficient	O
per	O
se	O
to	O
initiate	O
a	O
complete	O
activation	O
programme	O
.	O

The	O
interleukin	B-Protein
-	I-Protein
8	I-Protein
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
genetic	O
end	O
targets	O
of	O
FK506	O
-	O
sensitive	O
pathway	O
accompanied	O
by	O
calcium	O
mobilization	O
.	O
<EOS>	B-X
FK506	B-X
,	B-X
an	B-X
immunosuppressant	B-X
,	B-X
inhibits	B-X
the	B-X
production	B-X
of	B-X
several	B-X
cytokines	B-X
in	B-X
T	B-X
lymphocytes	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
FK506	B-X
suppressed	B-X
the	B-X
transcription	B-X
of	B-X
a	B-X
chemotactic	B-X
cytokine	B-X
,	B-X
interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
in	B-X
a	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
,	B-X
Jurkat	B-X
cells	B-X
,	B-X
activated	B-X
by	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
calcium	B-X
(	B-X
Ca2+	B-X
)	B-X
ionophore	B-X
(	B-X
ionomycin	B-X
)	B-X
.	B-X
By	B-X
deleted	B-X
and	B-X
mutated	B-X
analysis	B-X
of	B-X
the	B-X
IL-8	B-X
promoters	B-X
,	B-X
the	B-X
AP-1	B-X
and	B-X
kappa	B-X
B-like	B-X
sites	B-X
were	B-X
identified	B-X
as	B-X
the	B-X
responsive	B-X
elements	B-X
for	B-X
PMA	B-X
and	B-X
ionomycin	B-X
.	B-X
FK506	B-X
suppressed	B-X
the	B-X
transcriptions	B-X
through	B-X
the	B-X
AP-1	B-X
or	B-X
kappa	B-X
B-like	B-X
sites	B-X
induced	B-X
by	B-X
PMA	B-X
plus	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-mobilizing	B-X
agents	B-X
,	B-X
but	B-X
not	B-X
those	B-X
induced	B-X
by	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-independent	B-X
stimuli	B-X
.	B-X
In	B-X
gel	B-X
retardation	B-X
analysis	B-X
,	B-X
FK506	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
binding	B-X
to	B-X
the	B-X
AP-1	B-X
site	B-X
of	B-X
PMA/ionomycin-induced	B-X
nuclear	B-X
factors	B-X
,	B-X
which	B-X
were	B-X
recognized	B-X
with	B-X
anti-JunD	B-X
or	B-X
c-Fos	B-X
antibody	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
FK506	B-X
or	B-X
EGTA	B-X
(	B-X
Ca2+	B-X
chelator	B-X
)	B-X
similarly	B-X
affected	B-X
the	B-X
formation	B-X
of	B-X
kappa	B-X
B-like	B-X
site	B-X
binding	B-X
complexes	B-X
,	B-X
which	B-X
were	B-X
not	B-X
recognized	B-X
by	B-X
any	B-X
antibodies	B-X
against	B-X
the	B-X
human	B-X
Rel	B-X
family	B-X
proteins	B-X
(	B-X
c-Rel	B-X
,	B-X
p65	B-X
,	B-X
p50	B-X
,	B-X
and	B-X
p49	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
confirmed	B-X
the	B-X
previous	B-X
report	B-X
that	B-X
FK506	B-X
suppressed	B-X
the	B-X
PMA/ionomycin-induced	B-X
activation	B-X
through	B-X
authentic	B-X
kappa	B-X
B	B-X
site	B-X
of	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
gene	B-X
,	B-X
to	B-X
which	B-X
NF-kappa	B-X
B	B-X
binding	B-X
was	B-X
also	B-X
decreased	B-X
by	B-X
FK506	B-X
,	B-X
indicating	B-X
that	B-X
both	B-X
IL-8	B-X
kappa	B-X
B-like	B-X
site	B-X
and	B-X
Ig	B-X
kappa	B-X
B	B-X
site	B-X
are	B-X
FK506-sensitive	B-X
in	B-X
spite	B-X
of	B-X
the	B-X
difference	B-X
of	B-X
binding	B-X
factors	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
not	B-X
only	B-X
the	B-X
reported	B-X
IL-2	B-X
NF-AT	B-X
and	B-X
NFIL-2A	B-X
sites	B-X
and	B-X
Ig	B-X
kappa	B-X
B	B-X
site	B-X
,	B-X
but	B-X
also	B-X
the	B-X
IL-8	B-X
AP-1	B-X
and	B-X
kappa	B-X
B-like	B-X
sites	B-X
are	B-X
terminals	B-X
of	B-X
FK506-sensitive	B-X
pathway	B-X
involving	B-X
Ca2+	B-X
mobilization	B-X
.	B-X

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	O
in	O
T	O
lymphocytes	O
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	O
cytokine	O
,	O
interleukin	B-Protein
-	I-Protein
8	I-Protein
(	O
IL	B-Protein
-	I-Protein
8	I-Protein
)	O
in	O
a	O
human	O
T	O
cell	O
line	O
,	O
Jurkat	O
cells	O
,	O
activated	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2	O
+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
promoters	O
,	O
the	O
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O
<EOS>	B-X
We	B-X
observed	B-X
that	B-X
FK506	B-X
suppressed	B-X
the	B-X
transcription	B-X
of	B-X
a	B-X
chemotactic	B-X
cytokine	B-X
,	B-X
interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
in	B-X
a	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
,	B-X
Jurkat	B-X
cells	B-X
,	B-X
activated	B-X
by	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
calcium	B-X
(	B-X
Ca2+	B-X
)	B-X
ionophore	B-X
(	B-X
ionomycin	B-X
)	B-X
.	B-X
By	B-X
deleted	B-X
and	B-X
mutated	B-X
analysis	B-X
of	B-X
the	B-X
IL-8	B-X
promoters	B-X
,	B-X
the	B-X
AP-1	B-X
and	B-X
kappa	B-X
B-like	B-X
sites	B-X
were	B-X
identified	B-X
as	B-X
the	B-X
responsive	B-X
elements	B-X
for	B-X
PMA	B-X
and	B-X
ionomycin	B-X
.	B-X
FK506	B-X
suppressed	B-X
the	B-X
transcriptions	B-X
through	B-X
the	B-X
AP-1	B-X
or	B-X
kappa	B-X
B-like	B-X
sites	B-X
induced	B-X
by	B-X
PMA	B-X
plus	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-mobilizing	B-X
agents	B-X
,	B-X
but	B-X
not	B-X
those	B-X
induced	B-X
by	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-independent	B-X
stimuli	B-X
.	B-X
In	B-X
gel	B-X
retardation	B-X
analysis	B-X
,	B-X
FK506	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
binding	B-X
to	B-X
the	B-X
AP-1	B-X
site	B-X
of	B-X
PMA/ionomycin-induced	B-X
nuclear	B-X
factors	B-X
,	B-X
which	B-X
were	B-X
recognized	B-X
with	B-X
anti-JunD	B-X
or	B-X
c-Fos	B-X
antibody	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
FK506	B-X
or	B-X
EGTA	B-X
(	B-X
Ca2+	B-X
chelator	B-X
)	B-X
similarly	B-X
affected	B-X
the	B-X
formation	B-X
of	B-X
kappa	B-X
B-like	B-X
site	B-X
binding	B-X
complexes	B-X
,	B-X
which	B-X
were	B-X
not	B-X
recognized	B-X
by	B-X
any	B-X
antibodies	B-X
against	B-X
the	B-X
human	B-X
Rel	B-X
family	B-X
proteins	B-X
(	B-X
c-Rel	B-X
,	B-X
p65	B-X
,	B-X
p50	B-X
,	B-X
and	B-X
p49	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
confirmed	B-X
the	B-X
previous	B-X
report	B-X
that	B-X
FK506	B-X
suppressed	B-X
the	B-X
PMA/ionomycin-induced	B-X
activation	B-X
through	B-X
authentic	B-X
kappa	B-X
B	B-X
site	B-X
of	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
gene	B-X
,	B-X
to	B-X
which	B-X
NF-kappa	B-X
B	B-X
binding	B-X
was	B-X
also	B-X
decreased	B-X
by	B-X
FK506	B-X
,	B-X
indicating	B-X
that	B-X
both	B-X
IL-8	B-X
kappa	B-X
B-like	B-X
site	B-X
and	B-X
Ig	B-X
kappa	B-X
B	B-X
site	B-X
are	B-X
FK506-sensitive	B-X
in	B-X
spite	B-X
of	B-X
the	B-X
difference	B-X
of	B-X
binding	B-X
factors	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
not	B-X
only	B-X
the	B-X
reported	B-X
IL-2	B-X
NF-AT	B-X
and	B-X
NFIL-2A	B-X
sites	B-X
and	B-X
Ig	B-X
kappa	B-X
B	B-X
site	B-X
,	B-X
but	B-X
also	B-X
the	B-X
IL-8	B-X
AP-1	B-X
and	B-X
kappa	B-X
B-like	B-X
sites	B-X
are	B-X
terminals	B-X
of	B-X
FK506-sensitive	B-X
pathway	B-X
involving	B-X
Ca2+	B-X
mobilization	B-X
.	B-X

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP	O
-	O
1	O
or	O
kappa	O
B	O
-	O
like	O
sites	O
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2	O
+	O
)	O
-	O
mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	O
by	O
Ca	O
(	O
2	O
+	O
)	O
-	O
independent	O
stimuli	O
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP	O
-	O
1	O
site	O
of	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	O
with	O
anti	O
-	O
JunD	B-Protein
or	O
c	B-Protein
-	I-Protein
Fos	I-Protein
antibody	O
.	O
<EOS>	B-X
Psoriasis	B-X
is	B-X
a	B-X
common	B-X
chronic	B-X
skin	B-X
disorder	B-X
characterized	B-X
by	B-X
keratinocyte	B-X
hyperproliferation	B-X
with	B-X
altered	B-X
differentiation	B-X
accompanied	B-X
by	B-X
inflammation	B-X
and	B-X
increased	B-X
angiogenesis	B-X
.	B-X
It	B-X
remains	B-X
unclear	B-X
whether	B-X
the	B-X
first	B-X
events	B-X
that	B-X
initiate	B-X
psoriasis	B-X
development	B-X
occur	B-X
in	B-X
keratinocytes	B-X
or	B-X
inflammatory	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
using	B-X
different	B-X
psoriasis	B-X
mouse	B-X
models	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
conditional	B-X
deletion	B-X
of	B-X
The	B-X
induction	B-X
of	B-X
c-fos	B-X
mRNA	B-X
was	B-X
assessed	B-X
using	B-X
Northern	B-X
blots	B-X
and	B-X
in	B-X
situ	B-X
hybridization	B-X
in	B-X
adult	B-X
rats	B-X
administered	B-X
hypertonic	B-X
saline	B-X
(	B-X
HS	B-X
)	B-X
and	B-X
isotonic	B-X
saline	B-X
(	B-X
IS	B-X
)	B-X
.	B-X
HS	B-X
induced	B-X
c-fos	B-X
mRNA	B-X
in	B-X
magnocellular	B-X
paraventricular	B-X
nucleus	B-X
(	B-X
PVNm	B-X
)	B-X
,	B-X
parvocellular	B-X
paraventricular	B-X
nucleus	B-X
(	B-X
PVNp	B-X
)	B-X
,	B-X
supraoptic	B-X
nucleus	B-X
(	B-X
SON	B-X
)	B-X
,	B-X
and	B-X
lamina	B-X
terminalis	B-X
(	B-X
LMT	B-X
)	B-X
.	B-X
This	B-X
occurred	B-X
within	B-X
5	B-X
min	B-X
,	B-X
peaked	B-X
at	B-X
30-60	B-X
min	B-X
,	B-X
and	B-X
disappeared	B-X
by	B-X
180	B-X
min	B-X
.	B-X
Fos	B-X
protein	B-X
,	B-X
detected	B-X
using	B-X
a	B-X
specific	B-X
monoclonal	B-X
antibody	B-X
,	B-X
was	B-X
maximal	B-X
at	B-X
1-2	B-X
hr	B-X
and	B-X
disappeared	B-X
4-8	B-X
hr	B-X
after	B-X
HS	B-X
administration	B-X
.	B-X
This	B-X
confirms	B-X
observations	B-X
showing	B-X
that	B-X
the	B-X
c-fos	B-X
gene	B-X
response	B-X
is	B-X
transient	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
continuing	B-X
stimulus	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Fos-like	B-X
immunoreactivity	B-X
(	B-X
FLI	B-X
)	B-X
,	B-X
detected	B-X
using	B-X
two	B-X
polyclonal	B-X
antisera	B-X
,	B-X
was	B-X
observed	B-X
in	B-X
PVNm	B-X
,	B-X
PVNp	B-X
,	B-X
SON	B-X
,	B-X
and	B-X
LMT	B-X
for	B-X
1-24	B-X
hr	B-X
during	B-X
continuous	B-X
osmotic	B-X
stimulation	B-X
.	B-X
Moreover	B-X
,	B-X
FLI	B-X
was	B-X
observable	B-X
in	B-X
these	B-X
structures	B-X
for	B-X
7	B-X
d	B-X
in	B-X
rats	B-X
administered	B-X
HS	B-X
and	B-X
allowed	B-X
to	B-X
drink	B-X
water	B-X
ad	B-X
libitum	B-X
beginning	B-X
24	B-X
hr	B-X
later	B-X
.	B-X
At	B-X
times	B-X
greater	B-X
than	B-X
8	B-X
hr	B-X
,	B-X
FLI	B-X
presumably	B-X
represents	B-X
Fos-related	B-X
antigens	B-X
(	B-X
FRA	B-X
)	B-X
,	B-X
proteins	B-X
immunologically	B-X
and	B-X
functionally	B-X
related	B-X
to	B-X
Fos	B-X
,	B-X
whose	B-X
expression	B-X
is	B-X
much	B-X
more	B-X
prolonged	B-X
than	B-X
authentic	B-X
Fos	B-X
following	B-X
the	B-X
osmotic	B-X
stimulus	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
induction	B-X
of	B-X
c-fos	B-X
expression	B-X
in	B-X
regions	B-X
specifically	B-X
involved	B-X
in	B-X
osmotic	B-X
regulation	B-X
,	B-X
HS	B-X
injections	B-X
also	B-X
induced	B-X
c-fos	B-X
in	B-X
many	B-X
other	B-X
forebrain	B-X
regions	B-X
.	B-X
In	B-X
order	B-X
to	B-X
assess	B-X
the	B-X
induction	B-X
of	B-X
c-fos	B-X
mRNA	B-X
due	B-X
to	B-X
the	B-X
``	B-X
stress	B-X
''	B-X
of	B-X
the	B-X
injections	B-X
,	B-X
rats	B-X
injected	B-X
with	B-X
isotonic	B-X
saline	B-X
were	B-X
compared	B-X
to	B-X
uninjected	B-X
controls	B-X
.	B-X
Isotonic	B-X
saline	B-X
injections	B-X
induced	B-X
c-fos	B-X
mRNA	B-X
in	B-X
the	B-X
PVNp	B-X
,	B-X
anterior	B-X
hypothalamus	B-X
,	B-X
suprachiasmatic	B-X
nucleus	B-X
,	B-X
cingulate	B-X
gyrus	B-X
,	B-X
neocortex	B-X
,	B-X
ventral	B-X
lateral	B-X
septal	B-X
nucleus	B-X
,	B-X
piriform	B-X
cortex	B-X
,	B-X
hippocampal	B-X
pyramidal	B-X
and	B-X
dentate	B-X
granule	B-X
neurons	B-X
,	B-X
paraventricular	B-X
and	B-X
intralaminar	B-X
thalamic	B-X
nuclei	B-X
,	B-X
bed	B-X
nuclei	B-X
of	B-X
stria	B-X
terminalis	B-X
,	B-X
cortical	B-X
and	B-X
medial	B-X
amygdaloid	B-X
nuclei	B-X
,	B-X
and	B-X
other	B-X
structures	B-X
.	B-X
In	B-X
accord	B-X
with	B-X
other	B-X
work	B-X
,	B-X
we	B-X
interpret	B-X
this	B-X
pattern	B-X
of	B-X
c-fos	B-X
expression	B-X
to	B-X
result	B-X
from	B-X
the	B-X
stress	B-X
of	B-X
handling	B-X
and	B-X
injections	B-X
.	B-X
Since	B-X
Fos	B-X
and	B-X
FRA	B-X
probably	B-X
bind	B-X
to	B-X
the	B-X
promoters	B-X
of	B-X
target	B-X
genes	B-X
and	B-X
regulate	B-X
their	B-X
expression	B-X
,	B-X
they	B-X
likely	B-X
mediate	B-X
biochemical	B-X
changes	B-X
in	B-X
the	B-X
cells	B-X
activated	B-X
by	B-X
the	B-X
osmotic	B-X
and	B-X
stressful	B-X
stimuli	B-X
.	B-X
Whereas	B-X
the	B-X
Fos	B-X
signal	B-X
is	B-X
transient	B-X
,	B-X
FRA	B-X
may	B-X
act	B-X
on	B-X
target	B-X
genes	B-X
for	B-X
the	B-X
duration	B-X
of	B-X
the	B-X
stimulus	B-X
or	B-X
longer	B-X
.	B-X

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2	O
+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	O
B	O
-	O
like	O
site	O
binding	O
complexes	O
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	O
against	O
the	O
human	O
Rel	O
family	O
proteins	O
(	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
p65	B-Protein
,	O
p50	B-Protein
,	O
and	O
p49	B-Protein
)	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
activation	O
through	O
authentic	O
kappa	O
B	O
site	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
gene	O
,	O
to	O
which	O
NF	O
-	O
kappa	O
B	O
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL	B-Protein
-	I-Protein
8	I-Protein
kappa	O
B	O
-	O
like	O
site	O
and	O
Ig	B-Protein
kappa	I-Protein
B	I-Protein
site	O
are	O
FK506	O
-	O
sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	O
factors	O
.	O
<EOS>	B-X
FK506	B-X
,	B-X
an	B-X
immunosuppressant	B-X
,	B-X
inhibits	B-X
the	B-X
production	B-X
of	B-X
several	B-X
cytokines	B-X
in	B-X
T	B-X
lymphocytes	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
FK506	B-X
suppressed	B-X
the	B-X
transcription	B-X
of	B-X
a	B-X
chemotactic	B-X
cytokine	B-X
,	B-X
interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
in	B-X
a	B-X
human	B-X
T	B-X
cell	B-X
line	B-X
,	B-X
Jurkat	B-X
cells	B-X
,	B-X
activated	B-X
by	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
calcium	B-X
(	B-X
Ca2+	B-X
)	B-X
ionophore	B-X
(	B-X
ionomycin	B-X
)	B-X
.	B-X
By	B-X
deleted	B-X
and	B-X
mutated	B-X
analysis	B-X
of	B-X
the	B-X
IL-8	B-X
promoters	B-X
,	B-X
the	B-X
AP-1	B-X
and	B-X
kappa	B-X
B-like	B-X
sites	B-X
were	B-X
identified	B-X
as	B-X
the	B-X
responsive	B-X
elements	B-X
for	B-X
PMA	B-X
and	B-X
ionomycin	B-X
.	B-X
FK506	B-X
suppressed	B-X
the	B-X
transcriptions	B-X
through	B-X
the	B-X
AP-1	B-X
or	B-X
kappa	B-X
B-like	B-X
sites	B-X
induced	B-X
by	B-X
PMA	B-X
plus	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-mobilizing	B-X
agents	B-X
,	B-X
but	B-X
not	B-X
those	B-X
induced	B-X
by	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-independent	B-X
stimuli	B-X
.	B-X
In	B-X
gel	B-X
retardation	B-X
analysis	B-X
,	B-X
FK506	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
the	B-X
binding	B-X
to	B-X
the	B-X
AP-1	B-X
site	B-X
of	B-X
PMA/ionomycin-induced	B-X
nuclear	B-X
factors	B-X
,	B-X
which	B-X
were	B-X
recognized	B-X
with	B-X
anti-JunD	B-X
or	B-X
c-Fos	B-X
antibody	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
FK506	B-X
or	B-X
EGTA	B-X
(	B-X
Ca2+	B-X
chelator	B-X
)	B-X
similarly	B-X
affected	B-X
the	B-X
formation	B-X
of	B-X
kappa	B-X
B-like	B-X
site	B-X
binding	B-X
complexes	B-X
,	B-X
which	B-X
were	B-X
not	B-X
recognized	B-X
by	B-X
any	B-X
antibodies	B-X
against	B-X
the	B-X
human	B-X
Rel	B-X
family	B-X
proteins	B-X
(	B-X
c-Rel	B-X
,	B-X
p65	B-X
,	B-X
p50	B-X
,	B-X
and	B-X
p49	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
confirmed	B-X
the	B-X
previous	B-X
report	B-X
that	B-X
FK506	B-X
suppressed	B-X
the	B-X
PMA/ionomycin-induced	B-X
activation	B-X
through	B-X
authentic	B-X
kappa	B-X
B	B-X
site	B-X
of	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
gene	B-X
,	B-X
to	B-X
which	B-X
NF-kappa	B-X
B	B-X
binding	B-X
was	B-X
also	B-X
decreased	B-X
by	B-X
FK506	B-X
,	B-X
indicating	B-X
that	B-X
both	B-X
IL-8	B-X
kappa	B-X
B-like	B-X
site	B-X
and	B-X
Ig	B-X
kappa	B-X
B	B-X
site	B-X
are	B-X
FK506-sensitive	B-X
in	B-X
spite	B-X
of	B-X
the	B-X
difference	B-X
of	B-X
binding	B-X
factors	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
not	B-X
only	B-X
the	B-X
reported	B-X
IL-2	B-X
NF-AT	B-X
and	B-X
NFIL-2A	B-X
sites	B-X
and	B-X
Ig	B-X
kappa	B-X
B	B-X
site	B-X
,	B-X
but	B-X
also	B-X
the	B-X
IL-8	B-X
AP-1	B-X
and	B-X
kappa	B-X
B-like	B-X
sites	B-X
are	B-X
terminals	B-X
of	B-X
FK506-sensitive	B-X
pathway	B-X
involving	B-X
Ca2+	B-X
mobilization	B-X
.	B-X

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL	B-Protein
-	I-Protein
2	I-Protein
NF	B-Protein
-	I-Protein
AT	I-Protein
and	O
NFIL	B-Protein
-	I-Protein
2A	I-Protein
sites	O
and	O
Ig	B-Protein
kappa	I-Protein
B	I-Protein
site	O
,	O
but	O
also	O
the	O
IL	B-Protein
-	I-Protein
8	I-Protein
AP	O
-	O
1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
terminals	O
of	O
FK506	O
-	O
sensitive	O
pathway	O
involving	O
Ca2	O
+	O
mobilization	O
.	O
<EOS>	B-X
PrestoBlue	B-X
is	B-X
a	B-X
new	B-X
resazurin	B-X
based	B-X
reagent	B-X
to	B-X
assess	B-X
cell	B-X
viability	B-X
and	B-X
cytotoxicity	B-X
.	B-X
It	B-X
is	B-X
claimed	B-X
to	B-X
be	B-X
a	B-X
fast	B-X
and	B-X
highly	B-X
sensitive	B-X
assay	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
compared	B-X
PrestoBlue	B-X
,	B-X
alamarBlue	B-X
,	B-X
and	B-X
3-	B-X
[	B-X
4,5-dimethylthiazol-2-yl	B-X
]	B-X
-2,5-diphenyl	B-X
tetrazonium	B-X
bromide	B-X
(	B-X
MTT	B-X
)	B-X
in	B-X
assessing	B-X
cell	B-X
viability	B-X
of	B-X
human	B-X
corneal	B-X
epithelial	B-X
cells	B-X
(	B-X
HCEC	B-X
)	B-X
,	B-X
and	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
plate	B-X
color	B-X
,	B-X
reading	B-X
mode	B-X
,	B-X
and	B-X
plate	B-X
storage	B-X
on	B-X
the	B-X
performance	B-X
of	B-X
PrestoBlue	B-X
assay	B-X
.	B-X
A	B-X
tristimulus	B-X
colorimeter	B-X
was	B-X
used	B-X
to	B-X
measure	B-X
CIELAB	B-X
color	B-X
values	B-X
.	B-X
Color	B-X
indicator	B-X
for	B-X
heat	B-X
detection	B-X
can	B-X
be	B-X
utilized	B-X
to	B-X
test	B-X
if	B-X
the	B-X
heat-sensitive	B-X
API	B-X
would	B-X
go	B-X
through	B-X
physical	B-X
changes	B-X
during	B-X
the	B-X
pharmaceutical	B-X
drying	B-X
process	B-X
.	B-X
Both	B-X
the	B-X
prepared	B-X
granules	B-X
and	B-X
pellets	B-X
can	B-X
be	B-X
used	B-X
as	B-X
heat	B-X
indicator	B-X
in	B-X
fluid	B-X
bed	B-X
drying	B-X
process	B-X
.	B-X

Monocyte	O
tethering	O
by	O
P	B-Protein
-	I-Protein
selectin	I-Protein
regulates	O
monocyte	B-Protein
chemotactic	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
secretion	O
.	O
<EOS>	B-X
Adhesion	B-X
of	B-X
human	B-X
monocytes	B-X
to	B-X
P-selectin	B-X
,	B-X
the	B-X
most	B-X
rapidly	B-X
expressed	B-X
endothelial	B-X
tethering	B-X
factor	B-X
,	B-X
increased	B-X
the	B-X
secretion	B-X
of	B-X
monocyte	B-X
chemotactic	B-X
protein-1	B-X
(	B-X
MCP-1	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
by	B-X
the	B-X
leukocytes	B-X
when	B-X
they	B-X
were	B-X
stimulated	B-X
with	B-X
platelet-activating	B-X
factor	B-X
.	B-X
Increased	B-X
cytokine	B-X
secretion	B-X
was	B-X
specifically	B-X
inhibited	B-X
by	B-X
G1	B-X
,	B-X
an	B-X
anti-P-selectin	B-X
mAb	B-X
that	B-X
prevents	B-X
P-selectin	B-X
from	B-X
binding	B-X
to	B-X
its	B-X
ligand	B-X
(	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
)	B-X
on	B-X
myeloid	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
tethering	B-X
by	B-X
P-selectin	B-X
specifically	B-X
enhanced	B-X
nuclear	B-X
translocation	B-X
of	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
MCP-1	B-X
,	B-X
TNF-alpha	B-X
,	B-X
and	B-X
other	B-X
immediate-early	B-X
genes	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
P-selectin	B-X
,	B-X
through	B-X
its	B-X
ligands	B-X
on	B-X
monocytes	B-X
,	B-X
may	B-X
locally	B-X
regulate	B-X
cytokine	B-X
secretion	B-X
in	B-X
inflamed	B-X
tissues	B-X
.	B-X

Signal	O
integration	O
and	O
NF	O
-	O
kappa	O
B	O
translocation	O
[	O
see	O
comments	O
]	O
<EOS>	B-X
NF-kappaB	B-X
(	B-X
nuclear	B-X
factor-kappaB	B-X
)	B-X
is	B-X
a	B-X
collective	B-X
name	B-X
for	B-X
inducible	B-X
dimeric	B-X
transcription	B-X
factors	B-X
composed	B-X
of	B-X
members	B-X
of	B-X
the	B-X
Rel	B-X
family	B-X
of	B-X
DNA-binding	B-X
proteins	B-X
that	B-X
recognize	B-X
a	B-X
common	B-X
sequence	B-X
motif	B-X
.	B-X
NF-kappaB	B-X
is	B-X
found	B-X
in	B-X
essentially	B-X
all	B-X
cell	B-X
types	B-X
and	B-X
is	B-X
involved	B-X
in	B-X
activation	B-X
of	B-X
an	B-X
exceptionally	B-X
large	B-X
number	B-X
of	B-X
genes	B-X
in	B-X
response	B-X
to	B-X
infections	B-X
,	B-X
inflammation	B-X
,	B-X
and	B-X
other	B-X
stressful	B-X
situations	B-X
requiring	B-X
rapid	B-X
reprogramming	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
NF-kappaB	B-X
is	B-X
normally	B-X
sequestered	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
nonstimulated	B-X
cells	B-X
and	B-X
consequently	B-X
must	B-X
be	B-X
translocated	B-X
into	B-X
the	B-X
nucleus	B-X
to	B-X
function	B-X
.	B-X
The	B-X
subcellular	B-X
location	B-X
of	B-X
NF-kappaB	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
family	B-X
of	B-X
inhibitory	B-X
proteins	B-X
,	B-X
IkappaBs	B-X
,	B-X
which	B-X
bind	B-X
NF-kappaB	B-X
and	B-X
mask	B-X
its	B-X
nuclear	B-X
localization	B-X
signal	B-X
,	B-X
thereby	B-X
preventing	B-X
nuclear	B-X
uptake	B-X
.	B-X
Exposure	B-X
of	B-X
cells	B-X
to	B-X
a	B-X
variety	B-X
of	B-X
extracellular	B-X
stimuli	B-X
leads	B-X
to	B-X
the	B-X
rapid	B-X
phosphorylation	B-X
,	B-X
ubiquitination	B-X
,	B-X
and	B-X
ultimately	B-X
proteolytic	B-X
degradation	B-X
of	B-X
IkappaB	B-X
,	B-X
which	B-X
frees	B-X
NF-kappaB	B-X
to	B-X
translocate	B-X
to	B-X
the	B-X
nucleus	B-X
where	B-X
it	B-X
regulates	B-X
gene	B-X
transcription	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
represents	B-X
a	B-X
paradigm	B-X
for	B-X
controlling	B-X
the	B-X
function	B-X
of	B-X
a	B-X
regulatory	B-X
protein	B-X
via	B-X
ubiquitination-dependent	B-X
proteolysis	B-X
,	B-X
as	B-X
an	B-X
integral	B-X
part	B-X
of	B-X
a	B-X
phosphorylationbased	B-X
signaling	B-X
cascade	B-X
.	B-X
Recently	B-X
,	B-X
considerable	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
in	B-X
understanding	B-X
the	B-X
details	B-X
of	B-X
the	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
NF-kappaB	B-X
activity	B-X
,	B-X
particularly	B-X
those	B-X
responding	B-X
to	B-X
the	B-X
proinflammatory	B-X
cytokines	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
and	B-X
interleukin-1	B-X
.	B-X
The	B-X
multisubunit	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
responsible	B-X
for	B-X
inducible	B-X
IkappaB	B-X
phosphorylation	B-X
is	B-X
the	B-X
point	B-X
of	B-X
convergence	B-X
for	B-X
most	B-X
NF-kappaB-activating	B-X
stimuli	B-X
.	B-X
IKK	B-X
contains	B-X
two	B-X
catalytic	B-X
subunits	B-X
,	B-X
IKKalpha	B-X
and	B-X
IKKbeta	B-X
,	B-X
both	B-X
of	B-X
which	B-X
are	B-X
able	B-X
to	B-X
correctly	B-X
phosphorylate	B-X
IkappaB	B-X
.	B-X
After	B-X
phosphorylation	B-X
,	B-X
the	B-X
IKK	B-X
phosphoacceptor	B-X
sites	B-X
on	B-X
IkappaB	B-X
serve	B-X
as	B-X
an	B-X
essential	B-X
part	B-X
of	B-X
a	B-X
specific	B-X
recognition	B-X
site	B-X
for	B-X
E3RS	B-X
(	B-X
IkappaB/beta-TrCP	B-X
)	B-X
,	B-X
an	B-X
SCF-type	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
thereby	B-X
explaining	B-X
how	B-X
IKK	B-X
controls	B-X
IkappaB	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
other	B-X
signaling	B-X
events	B-X
,	B-X
including	B-X
phosphorylation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
hyperphosphorylation	B-X
of	B-X
IKK	B-X
,	B-X
induction	B-X
of	B-X
IkappaB	B-X
synthesis	B-X
,	B-X
and	B-X
the	B-X
processing	B-X
of	B-X
NF-kappaB	B-X
precursors	B-X
,	B-X
provide	B-X
additional	B-X
mechanisms	B-X
that	B-X
modulate	B-X
the	B-X
level	B-X
and	B-X
duration	B-X
of	B-X
NF-kappaB	B-X
activity	B-X
.	B-X

Adhesion	O
molecules	O
that	O
tether	O
circulating	O
leukocytes	O
to	O
endothelial	O
cells	O
may	O
also	O
transduce	O
or	O
modulate	O
outside	O
-	O
in	O
signals	O
for	O
cellular	O
activation	O
,	O
providing	O
an	O
initial	O
regulatory	O
point	O
in	O
the	O
inflammatory	O
response	O
.	O
<EOS>	B-X
Adhesion	B-X
molecules	B-X
that	B-X
tether	B-X
circulating	B-X
leukocytes	B-X
to	B-X
endothelial	B-X
cells	B-X
may	B-X
also	B-X
transduce	B-X
or	B-X
modulate	B-X
outside-in	B-X
signals	B-X
for	B-X
cellular	B-X
activation	B-X
,	B-X
providing	B-X
an	B-X
initial	B-X
regulatory	B-X
point	B-X
in	B-X
the	B-X
inflammatory	B-X
response	B-X
.	B-X
Adhesion	B-X
of	B-X
human	B-X
monocytes	B-X
to	B-X
P-selectin	B-X
,	B-X
the	B-X
most	B-X
rapidly	B-X
expressed	B-X
endothelial	B-X
tethering	B-X
factor	B-X
,	B-X
increased	B-X
the	B-X
secretion	B-X
of	B-X
monocyte	B-X
chemotactic	B-X
protein-1	B-X
(	B-X
MCP-1	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
by	B-X
the	B-X
leukocytes	B-X
when	B-X
they	B-X
were	B-X
stimulated	B-X
with	B-X
platelet-activating	B-X
factor	B-X
.	B-X
Increased	B-X
cytokine	B-X
secretion	B-X
was	B-X
specifically	B-X
inhibited	B-X
by	B-X
G1	B-X
,	B-X
an	B-X
anti-P-selectin	B-X
mAb	B-X
that	B-X
prevents	B-X
P-selectin	B-X
from	B-X
binding	B-X
to	B-X
its	B-X
ligand	B-X
(	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
)	B-X
on	B-X
myeloid	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
tethering	B-X
by	B-X
P-selectin	B-X
specifically	B-X
enhanced	B-X
nuclear	B-X
translocation	B-X
of	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
MCP-1	B-X
,	B-X
TNF-alpha	B-X
,	B-X
and	B-X
other	B-X
immediate-early	B-X
genes	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
P-selectin	B-X
,	B-X
through	B-X
its	B-X
ligands	B-X
on	B-X
monocytes	B-X
,	B-X
may	B-X
locally	B-X
regulate	B-X
cytokine	B-X
secretion	B-X
in	B-X
inflamed	B-X
tissues	B-X
.	B-X

Adhesion	O
of	O
human	O
monocytes	O
to	O
P	B-Protein
-	I-Protein
selectin	I-Protein
,	O
the	O
most	O
rapidly	O
expressed	O
endothelial	O
tethering	O
factor	O
,	O
increased	O
the	O
secretion	O
of	O
monocyte	B-Protein
chemotactic	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
MCP	B-Protein
-	I-Protein
1	I-Protein
)	O
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
by	O
the	O
leukocytes	O
when	O
they	O
were	O
stimulated	O
with	O
platelet	O
-	O
activating	O
factor	O
.	O

Increased	O
cytokine	O
secretion	O
was	O
specifically	O
inhibited	O
by	O
G1	O
,	O
an	O
anti	O
-	O
P	B-Protein
-	I-Protein
selectin	I-Protein
mAb	O
that	O
prevents	O
P	B-Protein
-	I-Protein
selectin	I-Protein
from	O
binding	O
to	O
its	O
ligand	O
(	O
P	B-Protein
-	I-Protein
selectin	I-Protein
glycoprotein	I-Protein
ligand	I-Protein
-	I-Protein
1	I-Protein
)	O
on	O
myeloid	O
cells	O
.	O

Moreover	O
,	O
tethering	O
by	O
P	B-Protein
-	I-Protein
selectin	I-Protein
specifically	O
enhanced	O
nuclear	O
translocation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
required	O
for	O
expression	O
of	O
MCP	B-Protein
-	I-Protein
1	I-Protein
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
and	O
other	O
immediate	O
-	O
early	O
genes	O
.	O
<EOS>	B-X
Adhesion	B-X
of	B-X
human	B-X
monocytes	B-X
to	B-X
P-selectin	B-X
,	B-X
the	B-X
most	B-X
rapidly	B-X
expressed	B-X
endothelial	B-X
tethering	B-X
factor	B-X
,	B-X
increased	B-X
the	B-X
secretion	B-X
of	B-X
monocyte	B-X
chemotactic	B-X
protein-1	B-X
(	B-X
MCP-1	B-X
)	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
by	B-X
the	B-X
leukocytes	B-X
when	B-X
they	B-X
were	B-X
stimulated	B-X
with	B-X
platelet-activating	B-X
factor	B-X
.	B-X
Increased	B-X
cytokine	B-X
secretion	B-X
was	B-X
specifically	B-X
inhibited	B-X
by	B-X
G1	B-X
,	B-X
an	B-X
anti-P-selectin	B-X
mAb	B-X
that	B-X
prevents	B-X
P-selectin	B-X
from	B-X
binding	B-X
to	B-X
its	B-X
ligand	B-X
(	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
)	B-X
on	B-X
myeloid	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
tethering	B-X
by	B-X
P-selectin	B-X
specifically	B-X
enhanced	B-X
nuclear	B-X
translocation	B-X
of	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
MCP-1	B-X
,	B-X
TNF-alpha	B-X
,	B-X
and	B-X
other	B-X
immediate-early	B-X
genes	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
P-selectin	B-X
,	B-X
through	B-X
its	B-X
ligands	B-X
on	B-X
monocytes	B-X
,	B-X
may	B-X
locally	B-X
regulate	B-X
cytokine	B-X
secretion	B-X
in	B-X
inflamed	B-X
tissues	B-X
.	B-X

These	O
results	O
demonstrate	O
that	O
P	B-Protein
-	I-Protein
selectin	I-Protein
,	O
through	O
its	O
ligands	O
on	O
monocytes	O
,	O
may	O
locally	O
regulate	O
cytokine	O
secretion	O
in	O
inflamed	O
tissues	O
.	O

HMG	B-Protein
-	I-Protein
I	I-Protein
binds	O
to	O
GATA	O
motifs	O
:	O
implications	O
for	O
an	O
HPFH	O
syndrome	O
.	O
<EOS>	B-X
We	B-X
have	B-X
examined	B-X
binding	B-X
of	B-X
the	B-X
nuclear	B-X
protein	B-X
HMG-I	B-X
to	B-X
the	B-X
human	B-X
gamma-globin	B-X
promoter	B-X
.	B-X
We	B-X
find	B-X
that	B-X
HMG-I	B-X
binds	B-X
preferentially	B-X
to	B-X
the	B-X
more	B-X
3	B-X
'	B-X
of	B-X
a	B-X
pair	B-X
of	B-X
GATA	B-X
motifs	B-X
in	B-X
the	B-X
gamma-globin	B-X
promoter	B-X
;	B-X
this	B-X
paired	B-X
motif	B-X
is	B-X
bound	B-X
by	B-X
the	B-X
erythroid	B-X
factor	B-X
GATA-1	B-X
.	B-X
A	B-X
naturally	B-X
occurring	B-X
mutation	B-X
(	B-X
-175	B-X
T-C	B-X
)	B-X
in	B-X
the	B-X
area	B-X
bound	B-X
by	B-X
HMG-I	B-X
results	B-X
in	B-X
overexpression	B-X
of	B-X
gamma-globin	B-X
in	B-X
adult	B-X
red	B-X
blood	B-X
cells	B-X
(	B-X
HPFH	B-X
)	B-X
and	B-X
up-regulation	B-X
of	B-X
the	B-X
gamma-globin	B-X
promoter	B-X
in	B-X
in	B-X
vitro	B-X
expression	B-X
assays	B-X
;	B-X
HMG-I	B-X
does	B-X
not	B-X
bind	B-X
to	B-X
this	B-X
mutant	B-X
sequence	B-X
.	B-X
A	B-X
survey	B-X
of	B-X
GATA	B-X
motifs	B-X
from	B-X
other	B-X
globin	B-X
cis-elements	B-X
demonstrates	B-X
HMG-I	B-X
binding	B-X
to	B-X
most	B-X
of	B-X
them	B-X
.	B-X
These	B-X
findings	B-X
implicate	B-X
HMG-I	B-X
in	B-X
the	B-X
HPFH	B-X
phenotype	B-X
;	B-X
we	B-X
speculate	B-X
that	B-X
it	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
multiprotein	B-X
complexes	B-X
that	B-X
regulate	B-X
globin	B-X
gene	B-X
expression	B-X
.	B-X

We	O
have	O
examined	O
binding	O
of	O
the	O
nuclear	O
protein	O
HMG	B-Protein
-	I-Protein
I	I-Protein
to	O
the	O
human	O
gamma	O
-	O
globin	O
promoter	O
.	O

We	O
find	O
that	O
HMG	B-Protein
-	I-Protein
I	I-Protein
binds	O
preferentially	O
to	O
the	O
more	O
3	O
'	O
of	O
a	O
pair	O
of	O
GATA	O
motifs	O
in	O
the	O
gamma	O
-	O
globin	O
promoter	O
;	O
this	O
paired	O
motif	O
is	O
bound	O
by	O
the	O
erythroid	O
factor	O
GATA	B-Protein
-	I-Protein
1	I-Protein
.	O

A	O
naturally	O
occurring	O
mutation	O
(	O
-	O
175	O
T	O
-	O
C	O
)	O
in	O
the	O
area	O
bound	O
by	O
HMG	B-Protein
-	I-Protein
I	I-Protein
results	O
in	O
overexpression	O
of	O
gamma	O
-	O
globin	O
in	O
adult	O
red	O
blood	O
cells	O
(	O
HPFH	O
)	O
and	O
up	O
-	O
regulation	O
of	O
the	O
gamma	O
-	O
globin	O
promoter	O
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG	B-Protein
-	I-Protein
I	I-Protein
does	O
not	O
bind	O
to	O
this	O
mutant	O
sequence	O
.	O

A	O
survey	O
of	O
GATA	O
motifs	O
from	O
other	O
globin	O
cis	O
-	O
elements	O
demonstrates	O
HMG	B-Protein
-	I-Protein
I	I-Protein
binding	O
to	O
most	O
of	O
them	O
.	O
<EOS>	B-X
We	B-X
have	B-X
examined	B-X
binding	B-X
of	B-X
the	B-X
nuclear	B-X
protein	B-X
HMG-I	B-X
to	B-X
the	B-X
human	B-X
gamma-globin	B-X
promoter	B-X
.	B-X
We	B-X
find	B-X
that	B-X
HMG-I	B-X
binds	B-X
preferentially	B-X
to	B-X
the	B-X
more	B-X
3	B-X
'	B-X
of	B-X
a	B-X
pair	B-X
of	B-X
GATA	B-X
motifs	B-X
in	B-X
the	B-X
gamma-globin	B-X
promoter	B-X
;	B-X
this	B-X
paired	B-X
motif	B-X
is	B-X
bound	B-X
by	B-X
the	B-X
erythroid	B-X
factor	B-X
GATA-1	B-X
.	B-X
A	B-X
naturally	B-X
occurring	B-X
mutation	B-X
(	B-X
-175	B-X
T-C	B-X
)	B-X
in	B-X
the	B-X
area	B-X
bound	B-X
by	B-X
HMG-I	B-X
results	B-X
in	B-X
overexpression	B-X
of	B-X
gamma-globin	B-X
in	B-X
adult	B-X
red	B-X
blood	B-X
cells	B-X
(	B-X
HPFH	B-X
)	B-X
and	B-X
up-regulation	B-X
of	B-X
the	B-X
gamma-globin	B-X
promoter	B-X
in	B-X
in	B-X
vitro	B-X
expression	B-X
assays	B-X
;	B-X
HMG-I	B-X
does	B-X
not	B-X
bind	B-X
to	B-X
this	B-X
mutant	B-X
sequence	B-X
.	B-X
A	B-X
survey	B-X
of	B-X
GATA	B-X
motifs	B-X
from	B-X
other	B-X
globin	B-X
cis-elements	B-X
demonstrates	B-X
HMG-I	B-X
binding	B-X
to	B-X
most	B-X
of	B-X
them	B-X
.	B-X
These	B-X
findings	B-X
implicate	B-X
HMG-I	B-X
in	B-X
the	B-X
HPFH	B-X
phenotype	B-X
;	B-X
we	B-X
speculate	B-X
that	B-X
it	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
multiprotein	B-X
complexes	B-X
that	B-X
regulate	B-X
globin	B-X
gene	B-X
expression	B-X
.	B-X

These	O
findings	O
implicate	O
HMG	B-Protein
-	I-Protein
I	I-Protein
in	O
the	O
HPFH	O
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	O
complexes	O
that	O
regulate	O
globin	O
gene	O
expression	O
.	O
<EOS>	B-X
We	B-X
have	B-X
examined	B-X
binding	B-X
of	B-X
the	B-X
nuclear	B-X
protein	B-X
HMG-I	B-X
to	B-X
the	B-X
human	B-X
gamma-globin	B-X
promoter	B-X
.	B-X
We	B-X
find	B-X
that	B-X
HMG-I	B-X
binds	B-X
preferentially	B-X
to	B-X
the	B-X
more	B-X
3	B-X
'	B-X
of	B-X
a	B-X
pair	B-X
of	B-X
GATA	B-X
motifs	B-X
in	B-X
the	B-X
gamma-globin	B-X
promoter	B-X
;	B-X
this	B-X
paired	B-X
motif	B-X
is	B-X
bound	B-X
by	B-X
the	B-X
erythroid	B-X
factor	B-X
GATA-1	B-X
.	B-X
A	B-X
naturally	B-X
occurring	B-X
mutation	B-X
(	B-X
-175	B-X
T-C	B-X
)	B-X
in	B-X
the	B-X
area	B-X
bound	B-X
by	B-X
HMG-I	B-X
results	B-X
in	B-X
overexpression	B-X
of	B-X
gamma-globin	B-X
in	B-X
adult	B-X
red	B-X
blood	B-X
cells	B-X
(	B-X
HPFH	B-X
)	B-X
and	B-X
up-regulation	B-X
of	B-X
the	B-X
gamma-globin	B-X
promoter	B-X
in	B-X
in	B-X
vitro	B-X
expression	B-X
assays	B-X
;	B-X
HMG-I	B-X
does	B-X
not	B-X
bind	B-X
to	B-X
this	B-X
mutant	B-X
sequence	B-X
.	B-X
A	B-X
survey	B-X
of	B-X
GATA	B-X
motifs	B-X
from	B-X
other	B-X
globin	B-X
cis-elements	B-X
demonstrates	B-X
HMG-I	B-X
binding	B-X
to	B-X
most	B-X
of	B-X
them	B-X
.	B-X
These	B-X
findings	B-X
implicate	B-X
HMG-I	B-X
in	B-X
the	B-X
HPFH	B-X
phenotype	B-X
;	B-X
we	B-X
speculate	B-X
that	B-X
it	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
multiprotein	B-X
complexes	B-X
that	B-X
regulate	B-X
globin	B-X
gene	B-X
expression	B-X
.	B-X

Positive	O
and	O
negative	O
regulation	O
of	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
promoter	O
activity	O
by	O
AML1	O
-	O
related	O
transcription	O
factor	O
,	O
PEBP2	O
.	O
<EOS>	B-X
The	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
gene	B-X
promoter	B-X
contains	B-X
a	B-X
consensus	B-X
sequence	B-X
for	B-X
the	B-X
polyomavirus	B-X
enhancer	B-X
binding-protein	B-X
2	B-X
(	B-X
PEBP2	B-X
)	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
consists	B-X
of	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
.	B-X
alpha	B-X
B	B-X
is	B-X
the	B-X
mouse	B-X
homologue	B-X
of	B-X
human	B-X
AML1	B-X
gene	B-X
detected	B-X
at	B-X
the	B-X
breakpoints	B-X
of	B-X
t	B-X
(	B-X
8	B-X
;	B-X
21	B-X
)	B-X
and	B-X
t	B-X
(	B-X
3	B-X
;	B-X
21	B-X
)	B-X
myeloid	B-X
leukemias	B-X
.	B-X
We	B-X
examined	B-X
alpha	B-X
A1	B-X
(	B-X
an	B-X
alpha	B-X
A-gene	B-X
product	B-X
)	B-X
and	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
(	B-X
two	B-X
alpha	B-X
B-encoded	B-X
isomers	B-X
)	B-X
for	B-X
their	B-X
effects	B-X
on	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
,	B-X
alpha	B-X
B1	B-X
,	B-X
and	B-X
alpha	B-X
B2	B-X
proteins	B-X
bound	B-X
the	B-X
PEBP2	B-X
site	B-X
within	B-X
the	B-X
mouse	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
and	B-X
alpha	B-X
B1	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
GM-CSF	B-X
promoter-driven	B-X
reporter	B-X
plasmid	B-X
in	B-X
unstimulated	B-X
and	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate/phytohemagglutinin-stimulated	B-X
human	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
promoter	B-X
activity	B-X
was	B-X
suppressed	B-X
by	B-X
alpha	B-X
B2	B-X
.	B-X
Coexpression	B-X
of	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
showed	B-X
that	B-X
the	B-X
promoter	B-X
activity	B-X
could	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
alpha	B-X
B1/alpha	B-X
B2	B-X
ratio	B-X
.	B-X
Jurkat	B-X
cell	B-X
extract	B-X
contained	B-X
PEBP2	B-X
site-binding	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
that	B-X
cross-reacted	B-X
with	B-X
antimouse	B-X
alpha	B-X
A1	B-X
antibodies	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
indicated	B-X
the	B-X
expression	B-X
of	B-X
human	B-X
PEBP2	B-X
alpha	B-X
A	B-X
,	B-X
alpha	B-X
B	B-X
(	B-X
AML1	B-X
)	B-X
,	B-X
and	B-X
beta	B-X
genes	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Although	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
precise	B-X
role	B-X
of	B-X
PEBP2	B-X
in	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
activity	B-X
,	B-X
the	B-X
present	B-X
findings	B-X
suggested	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
relative	B-X
ratio	B-X
of	B-X
different	B-X
PEBP2	B-X
isoforms	B-X
in	B-X
regulating	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
promoter	B-X
activity	B-X
.	B-X

The	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
gene	O
promoter	O
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	O
enhancer	O
binding	O
-	O
protein	O
2	O
(	O
PEBP2	O
)	O
transcription	O
factor	O
,	O
which	O
consists	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O
<EOS>	B-X
The	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
gene	B-X
promoter	B-X
contains	B-X
a	B-X
consensus	B-X
sequence	B-X
for	B-X
the	B-X
polyomavirus	B-X
enhancer	B-X
binding-protein	B-X
2	B-X
(	B-X
PEBP2	B-X
)	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
consists	B-X
of	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
.	B-X
There	B-X
are	B-X
at	B-X
least	B-X
two	B-X
genes	B-X
,	B-X
alpha	B-X
A	B-X
and	B-X
alpha	B-X
B	B-X
,	B-X
encoding	B-X
the	B-X
alpha	B-X
subunit	B-X
.	B-X
alpha	B-X
B	B-X
is	B-X
the	B-X
mouse	B-X
homologue	B-X
of	B-X
human	B-X
AML1	B-X
gene	B-X
detected	B-X
at	B-X
the	B-X
breakpoints	B-X
of	B-X
t	B-X
(	B-X
8	B-X
;	B-X
21	B-X
)	B-X
and	B-X
t	B-X
(	B-X
3	B-X
;	B-X
21	B-X
)	B-X
myeloid	B-X
leukemias	B-X
.	B-X
We	B-X
examined	B-X
alpha	B-X
A1	B-X
(	B-X
an	B-X
alpha	B-X
A-gene	B-X
product	B-X
)	B-X
and	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
(	B-X
two	B-X
alpha	B-X
B-encoded	B-X
isomers	B-X
)	B-X
for	B-X
their	B-X
effects	B-X
on	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
,	B-X
alpha	B-X
B1	B-X
,	B-X
and	B-X
alpha	B-X
B2	B-X
proteins	B-X
bound	B-X
the	B-X
PEBP2	B-X
site	B-X
within	B-X
the	B-X
mouse	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
and	B-X
alpha	B-X
B1	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
GM-CSF	B-X
promoter-driven	B-X
reporter	B-X
plasmid	B-X
in	B-X
unstimulated	B-X
and	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate/phytohemagglutinin-stimulated	B-X
human	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
promoter	B-X
activity	B-X
was	B-X
suppressed	B-X
by	B-X
alpha	B-X
B2	B-X
.	B-X
Coexpression	B-X
of	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
showed	B-X
that	B-X
the	B-X
promoter	B-X
activity	B-X
could	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
alpha	B-X
B1/alpha	B-X
B2	B-X
ratio	B-X
.	B-X
Jurkat	B-X
cell	B-X
extract	B-X
contained	B-X
PEBP2	B-X
site-binding	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
that	B-X
cross-reacted	B-X
with	B-X
antimouse	B-X
alpha	B-X
A1	B-X
antibodies	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
indicated	B-X
the	B-X
expression	B-X
of	B-X
human	B-X
PEBP2	B-X
alpha	B-X
A	B-X
,	B-X
alpha	B-X
B	B-X
(	B-X
AML1	B-X
)	B-X
,	B-X
and	B-X
beta	B-X
genes	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Although	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
precise	B-X
role	B-X
of	B-X
PEBP2	B-X
in	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
activity	B-X
,	B-X
the	B-X
present	B-X
findings	B-X
suggested	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
relative	B-X
ratio	B-X
of	B-X
different	B-X
PEBP2	B-X
isoforms	B-X
in	B-X
regulating	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
promoter	B-X
activity	B-X
.	B-X

There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	O
A	O
and	O
alpha	O
B	O
,	O
encoding	O
the	O
alpha	O
subunit	O
.	O
alpha	O
B	O
is	O
the	O
mouse	O
homologue	O
of	O
human	O
AML1	B-Protein
gene	O
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O

We	O
examined	O
alpha	B-Protein
A1	I-Protein
(	O
an	O
alpha	O
A	O
-	O
gene	O
product	O
)	O
and	O
alpha	B-Protein
B1	I-Protein
and	O
alpha	B-Protein
B2	I-Protein
(	O
two	O
alpha	O
B	O
-	O
encoded	O
isomers	O
)	O
for	O
their	O
effects	O
on	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
.	O

PEBP2	B-Protein
alpha	I-Protein
A1	I-Protein
,	O
alpha	B-Protein
B1	I-Protein
,	O
and	O
alpha	B-Protein
B2	I-Protein
proteins	O
bound	O
the	O
PEBP2	O
site	O
within	O
the	O
mouse	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
.	O
<EOS>	B-X
The	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
gene	B-X
promoter	B-X
contains	B-X
a	B-X
consensus	B-X
sequence	B-X
for	B-X
the	B-X
polyomavirus	B-X
enhancer	B-X
binding-protein	B-X
2	B-X
(	B-X
PEBP2	B-X
)	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
consists	B-X
of	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
.	B-X
There	B-X
are	B-X
at	B-X
least	B-X
two	B-X
genes	B-X
,	B-X
alpha	B-X
A	B-X
and	B-X
alpha	B-X
B	B-X
,	B-X
encoding	B-X
the	B-X
alpha	B-X
subunit	B-X
.	B-X
alpha	B-X
B	B-X
is	B-X
the	B-X
mouse	B-X
homologue	B-X
of	B-X
human	B-X
AML1	B-X
gene	B-X
detected	B-X
at	B-X
the	B-X
breakpoints	B-X
of	B-X
t	B-X
(	B-X
8	B-X
;	B-X
21	B-X
)	B-X
and	B-X
t	B-X
(	B-X
3	B-X
;	B-X
21	B-X
)	B-X
myeloid	B-X
leukemias	B-X
.	B-X
We	B-X
examined	B-X
alpha	B-X
A1	B-X
(	B-X
an	B-X
alpha	B-X
A-gene	B-X
product	B-X
)	B-X
and	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
(	B-X
two	B-X
alpha	B-X
B-encoded	B-X
isomers	B-X
)	B-X
for	B-X
their	B-X
effects	B-X
on	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
,	B-X
alpha	B-X
B1	B-X
,	B-X
and	B-X
alpha	B-X
B2	B-X
proteins	B-X
bound	B-X
the	B-X
PEBP2	B-X
site	B-X
within	B-X
the	B-X
mouse	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
and	B-X
alpha	B-X
B1	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
GM-CSF	B-X
promoter-driven	B-X
reporter	B-X
plasmid	B-X
in	B-X
unstimulated	B-X
and	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate/phytohemagglutinin-stimulated	B-X
human	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
promoter	B-X
activity	B-X
was	B-X
suppressed	B-X
by	B-X
alpha	B-X
B2	B-X
.	B-X
Coexpression	B-X
of	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
showed	B-X
that	B-X
the	B-X
promoter	B-X
activity	B-X
could	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
alpha	B-X
B1/alpha	B-X
B2	B-X
ratio	B-X
.	B-X
Jurkat	B-X
cell	B-X
extract	B-X
contained	B-X
PEBP2	B-X
site-binding	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
that	B-X
cross-reacted	B-X
with	B-X
antimouse	B-X
alpha	B-X
A1	B-X
antibodies	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
indicated	B-X
the	B-X
expression	B-X
of	B-X
human	B-X
PEBP2	B-X
alpha	B-X
A	B-X
,	B-X
alpha	B-X
B	B-X
(	B-X
AML1	B-X
)	B-X
,	B-X
and	B-X
beta	B-X
genes	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Although	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
precise	B-X
role	B-X
of	B-X
PEBP2	B-X
in	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
activity	B-X
,	B-X
the	B-X
present	B-X
findings	B-X
suggested	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
relative	B-X
ratio	B-X
of	B-X
different	B-X
PEBP2	B-X
isoforms	B-X
in	B-X
regulating	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
promoter	B-X
activity	B-X
.	B-X

PEBP2	B-Protein
alpha	I-Protein
A1	I-Protein
and	O
alpha	B-Protein
B1	I-Protein
enhanced	O
the	O
expression	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
-	O
driven	O
reporter	O
plasmid	O
in	O
unstimulated	O
and	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
/	O
phytohemagglutinin	B-Protein
-	O
stimulated	O
human	O
Jurkat	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
promoter	O
activity	O
was	O
suppressed	O
by	O
alpha	B-Protein
B2	I-Protein
.	O
<EOS>	B-X
The	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
gene	B-X
promoter	B-X
contains	B-X
a	B-X
consensus	B-X
sequence	B-X
for	B-X
the	B-X
polyomavirus	B-X
enhancer	B-X
binding-protein	B-X
2	B-X
(	B-X
PEBP2	B-X
)	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
consists	B-X
of	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
.	B-X
There	B-X
are	B-X
at	B-X
least	B-X
two	B-X
genes	B-X
,	B-X
alpha	B-X
A	B-X
and	B-X
alpha	B-X
B	B-X
,	B-X
encoding	B-X
the	B-X
alpha	B-X
subunit	B-X
.	B-X
alpha	B-X
B	B-X
is	B-X
the	B-X
mouse	B-X
homologue	B-X
of	B-X
human	B-X
AML1	B-X
gene	B-X
detected	B-X
at	B-X
the	B-X
breakpoints	B-X
of	B-X
t	B-X
(	B-X
8	B-X
;	B-X
21	B-X
)	B-X
and	B-X
t	B-X
(	B-X
3	B-X
;	B-X
21	B-X
)	B-X
myeloid	B-X
leukemias	B-X
.	B-X
We	B-X
examined	B-X
alpha	B-X
A1	B-X
(	B-X
an	B-X
alpha	B-X
A-gene	B-X
product	B-X
)	B-X
and	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
(	B-X
two	B-X
alpha	B-X
B-encoded	B-X
isomers	B-X
)	B-X
for	B-X
their	B-X
effects	B-X
on	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
,	B-X
alpha	B-X
B1	B-X
,	B-X
and	B-X
alpha	B-X
B2	B-X
proteins	B-X
bound	B-X
the	B-X
PEBP2	B-X
site	B-X
within	B-X
the	B-X
mouse	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
and	B-X
alpha	B-X
B1	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
GM-CSF	B-X
promoter-driven	B-X
reporter	B-X
plasmid	B-X
in	B-X
unstimulated	B-X
and	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate/phytohemagglutinin-stimulated	B-X
human	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
promoter	B-X
activity	B-X
was	B-X
suppressed	B-X
by	B-X
alpha	B-X
B2	B-X
.	B-X
Coexpression	B-X
of	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
showed	B-X
that	B-X
the	B-X
promoter	B-X
activity	B-X
could	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
alpha	B-X
B1/alpha	B-X
B2	B-X
ratio	B-X
.	B-X
Jurkat	B-X
cell	B-X
extract	B-X
contained	B-X
PEBP2	B-X
site-binding	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
that	B-X
cross-reacted	B-X
with	B-X
antimouse	B-X
alpha	B-X
A1	B-X
antibodies	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
indicated	B-X
the	B-X
expression	B-X
of	B-X
human	B-X
PEBP2	B-X
alpha	B-X
A	B-X
,	B-X
alpha	B-X
B	B-X
(	B-X
AML1	B-X
)	B-X
,	B-X
and	B-X
beta	B-X
genes	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Although	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
precise	B-X
role	B-X
of	B-X
PEBP2	B-X
in	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
activity	B-X
,	B-X
the	B-X
present	B-X
findings	B-X
suggested	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
relative	B-X
ratio	B-X
of	B-X
different	B-X
PEBP2	B-X
isoforms	B-X
in	B-X
regulating	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
promoter	B-X
activity	B-X
.	B-X

Coexpression	O
of	O
alpha	B-Protein
B1	I-Protein
and	O
alpha	B-Protein
B2	I-Protein
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	B-Protein
B1	I-Protein
/	O
alpha	B-Protein
B2	I-Protein
ratio	O
.	O
<EOS>	B-X
The	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
gene	B-X
promoter	B-X
contains	B-X
a	B-X
consensus	B-X
sequence	B-X
for	B-X
the	B-X
polyomavirus	B-X
enhancer	B-X
binding-protein	B-X
2	B-X
(	B-X
PEBP2	B-X
)	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
consists	B-X
of	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
.	B-X
There	B-X
are	B-X
at	B-X
least	B-X
two	B-X
genes	B-X
,	B-X
alpha	B-X
A	B-X
and	B-X
alpha	B-X
B	B-X
,	B-X
encoding	B-X
the	B-X
alpha	B-X
subunit	B-X
.	B-X
alpha	B-X
B	B-X
is	B-X
the	B-X
mouse	B-X
homologue	B-X
of	B-X
human	B-X
AML1	B-X
gene	B-X
detected	B-X
at	B-X
the	B-X
breakpoints	B-X
of	B-X
t	B-X
(	B-X
8	B-X
;	B-X
21	B-X
)	B-X
and	B-X
t	B-X
(	B-X
3	B-X
;	B-X
21	B-X
)	B-X
myeloid	B-X
leukemias	B-X
.	B-X
We	B-X
examined	B-X
alpha	B-X
A1	B-X
(	B-X
an	B-X
alpha	B-X
A-gene	B-X
product	B-X
)	B-X
and	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
(	B-X
two	B-X
alpha	B-X
B-encoded	B-X
isomers	B-X
)	B-X
for	B-X
their	B-X
effects	B-X
on	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
,	B-X
alpha	B-X
B1	B-X
,	B-X
and	B-X
alpha	B-X
B2	B-X
proteins	B-X
bound	B-X
the	B-X
PEBP2	B-X
site	B-X
within	B-X
the	B-X
mouse	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
and	B-X
alpha	B-X
B1	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
GM-CSF	B-X
promoter-driven	B-X
reporter	B-X
plasmid	B-X
in	B-X
unstimulated	B-X
and	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate/phytohemagglutinin-stimulated	B-X
human	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
promoter	B-X
activity	B-X
was	B-X
suppressed	B-X
by	B-X
alpha	B-X
B2	B-X
.	B-X
Coexpression	B-X
of	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
showed	B-X
that	B-X
the	B-X
promoter	B-X
activity	B-X
could	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
alpha	B-X
B1/alpha	B-X
B2	B-X
ratio	B-X
.	B-X
Jurkat	B-X
cell	B-X
extract	B-X
contained	B-X
PEBP2	B-X
site-binding	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
that	B-X
cross-reacted	B-X
with	B-X
antimouse	B-X
alpha	B-X
A1	B-X
antibodies	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
indicated	B-X
the	B-X
expression	B-X
of	B-X
human	B-X
PEBP2	B-X
alpha	B-X
A	B-X
,	B-X
alpha	B-X
B	B-X
(	B-X
AML1	B-X
)	B-X
,	B-X
and	B-X
beta	B-X
genes	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Although	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
precise	B-X
role	B-X
of	B-X
PEBP2	B-X
in	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
activity	B-X
,	B-X
the	B-X
present	B-X
findings	B-X
suggested	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
relative	B-X
ratio	B-X
of	B-X
different	B-X
PEBP2	B-X
isoforms	B-X
in	B-X
regulating	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
promoter	B-X
activity	B-X
.	B-X

Jurkat	O
cell	O
extract	O
contained	O
PEBP2	O
site	O
-	O
binding	O
protein	O
(	O
s	O
)	O
that	O
cross	O
-	O
reacted	O
with	O
antimouse	O
alpha	B-Protein
A1	I-Protein
antibodies	O
.	O
<EOS>	B-X
The	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
gene	B-X
promoter	B-X
contains	B-X
a	B-X
consensus	B-X
sequence	B-X
for	B-X
the	B-X
polyomavirus	B-X
enhancer	B-X
binding-protein	B-X
2	B-X
(	B-X
PEBP2	B-X
)	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
consists	B-X
of	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
.	B-X
There	B-X
are	B-X
at	B-X
least	B-X
two	B-X
genes	B-X
,	B-X
alpha	B-X
A	B-X
and	B-X
alpha	B-X
B	B-X
,	B-X
encoding	B-X
the	B-X
alpha	B-X
subunit	B-X
.	B-X
alpha	B-X
B	B-X
is	B-X
the	B-X
mouse	B-X
homologue	B-X
of	B-X
human	B-X
AML1	B-X
gene	B-X
detected	B-X
at	B-X
the	B-X
breakpoints	B-X
of	B-X
t	B-X
(	B-X
8	B-X
;	B-X
21	B-X
)	B-X
and	B-X
t	B-X
(	B-X
3	B-X
;	B-X
21	B-X
)	B-X
myeloid	B-X
leukemias	B-X
.	B-X
We	B-X
examined	B-X
alpha	B-X
A1	B-X
(	B-X
an	B-X
alpha	B-X
A-gene	B-X
product	B-X
)	B-X
and	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
(	B-X
two	B-X
alpha	B-X
B-encoded	B-X
isomers	B-X
)	B-X
for	B-X
their	B-X
effects	B-X
on	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
,	B-X
alpha	B-X
B1	B-X
,	B-X
and	B-X
alpha	B-X
B2	B-X
proteins	B-X
bound	B-X
the	B-X
PEBP2	B-X
site	B-X
within	B-X
the	B-X
mouse	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
and	B-X
alpha	B-X
B1	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
GM-CSF	B-X
promoter-driven	B-X
reporter	B-X
plasmid	B-X
in	B-X
unstimulated	B-X
and	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate/phytohemagglutinin-stimulated	B-X
human	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
promoter	B-X
activity	B-X
was	B-X
suppressed	B-X
by	B-X
alpha	B-X
B2	B-X
.	B-X
Coexpression	B-X
of	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
showed	B-X
that	B-X
the	B-X
promoter	B-X
activity	B-X
could	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
alpha	B-X
B1/alpha	B-X
B2	B-X
ratio	B-X
.	B-X
Jurkat	B-X
cell	B-X
extract	B-X
contained	B-X
PEBP2	B-X
site-binding	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
that	B-X
cross-reacted	B-X
with	B-X
antimouse	B-X
alpha	B-X
A1	B-X
antibodies	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
indicated	B-X
the	B-X
expression	B-X
of	B-X
human	B-X
PEBP2	B-X
alpha	B-X
A	B-X
,	B-X
alpha	B-X
B	B-X
(	B-X
AML1	B-X
)	B-X
,	B-X
and	B-X
beta	B-X
genes	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Although	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
precise	B-X
role	B-X
of	B-X
PEBP2	B-X
in	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
activity	B-X
,	B-X
the	B-X
present	B-X
findings	B-X
suggested	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
relative	B-X
ratio	B-X
of	B-X
different	B-X
PEBP2	B-X
isoforms	B-X
in	B-X
regulating	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
promoter	B-X
activity	B-X
.	B-X

Northern	O
blot	O
analysis	O
indicated	O
the	O
expression	O
of	O
human	O
PEBP2	O
alpha	O
A	O
,	O
alpha	O
B	O
(	B-Protein
AML1	I-Protein
)	I-Protein
,	O
and	O
beta	O
genes	O
in	O
Jurkat	O
cells	O
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	O
in	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	O
isoforms	O
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O
<EOS>	B-X
The	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
gene	B-X
promoter	B-X
contains	B-X
a	B-X
consensus	B-X
sequence	B-X
for	B-X
the	B-X
polyomavirus	B-X
enhancer	B-X
binding-protein	B-X
2	B-X
(	B-X
PEBP2	B-X
)	B-X
transcription	B-X
factor	B-X
,	B-X
which	B-X
consists	B-X
of	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
.	B-X
We	B-X
examined	B-X
alpha	B-X
A1	B-X
(	B-X
an	B-X
alpha	B-X
A-gene	B-X
product	B-X
)	B-X
and	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
(	B-X
two	B-X
alpha	B-X
B-encoded	B-X
isomers	B-X
)	B-X
for	B-X
their	B-X
effects	B-X
on	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
,	B-X
alpha	B-X
B1	B-X
,	B-X
and	B-X
alpha	B-X
B2	B-X
proteins	B-X
bound	B-X
the	B-X
PEBP2	B-X
site	B-X
within	B-X
the	B-X
mouse	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
PEBP2	B-X
alpha	B-X
A1	B-X
and	B-X
alpha	B-X
B1	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
GM-CSF	B-X
promoter-driven	B-X
reporter	B-X
plasmid	B-X
in	B-X
unstimulated	B-X
and	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate/phytohemagglutinin-stimulated	B-X
human	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
promoter	B-X
activity	B-X
was	B-X
suppressed	B-X
by	B-X
alpha	B-X
B2	B-X
.	B-X
Coexpression	B-X
of	B-X
alpha	B-X
B1	B-X
and	B-X
alpha	B-X
B2	B-X
showed	B-X
that	B-X
the	B-X
promoter	B-X
activity	B-X
could	B-X
be	B-X
determined	B-X
by	B-X
the	B-X
alpha	B-X
B1/alpha	B-X
B2	B-X
ratio	B-X
.	B-X
Jurkat	B-X
cell	B-X
extract	B-X
contained	B-X
PEBP2	B-X
site-binding	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
that	B-X
cross-reacted	B-X
with	B-X
antimouse	B-X
alpha	B-X
A1	B-X
antibodies	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
indicated	B-X
the	B-X
expression	B-X
of	B-X
human	B-X
PEBP2	B-X
alpha	B-X
A	B-X
,	B-X
alpha	B-X
B	B-X
(	B-X
AML1	B-X
)	B-X
,	B-X
and	B-X
beta	B-X
genes	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Although	B-X
further	B-X
studies	B-X
are	B-X
required	B-X
to	B-X
determine	B-X
the	B-X
precise	B-X
role	B-X
of	B-X
PEBP2	B-X
in	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
activity	B-X
,	B-X
the	B-X
present	B-X
findings	B-X
suggested	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
relative	B-X
ratio	B-X
of	B-X
different	B-X
PEBP2	B-X
isoforms	B-X
in	B-X
regulating	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
promoter	B-X
activity	B-X
.	B-X

Differential	O
induction	O
of	O
the	O
NF	O
-	O
AT	O
complex	O
during	O
restimulation	O
and	O
the	O
induction	O
of	O
T	O
-	O
cell	O
anergy	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
human	B-X
CD4+	B-X
T-cell	B-X
clones	B-X
through	B-X
the	B-X
T-cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
by	B-X
high	B-X
doses	B-X
of	B-X
specific	B-X
peptide	B-X
results	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
long-lived	B-X
state	B-X
of	B-X
nonresponsiveness	B-X
that	B-X
has	B-X
been	B-X
called	B-X
anergy	B-X
.	B-X
During	B-X
the	B-X
induction	B-X
of	B-X
anergy	B-X
,	B-X
T	B-X
cells	B-X
are	B-X
phenotypically	B-X
similar	B-X
to	B-X
cells	B-X
responding	B-X
to	B-X
an	B-X
immunogenic	B-X
stimulus	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
TcR	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
is	B-X
downmodulated	B-X
,	B-X
whereas	B-X
the	B-X
CD2	B-X
and	B-X
CD25	B-X
receptors	B-X
are	B-X
increased	B-X
.	B-X
When	B-X
restimulated	B-X
,	B-X
however	B-X
,	B-X
anergic	B-X
T	B-X
cells	B-X
fail	B-X
to	B-X
up-regulate	B-X
transcription	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
and	B-X
in	B-X
consequence	B-X
do	B-X
not	B-X
produce	B-X
IL-2	B-X
.	B-X
Factors	B-X
were	B-X
isolated	B-X
from	B-X
the	B-X
nuclei	B-X
of	B-X
T	B-X
cells	B-X
that	B-X
were	B-X
in	B-X
the	B-X
induction	B-X
phase	B-X
of	B-X
anergy	B-X
or	B-X
were	B-X
undergoing	B-X
activation	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
binding	B-X
activity	B-X
in	B-X
restimulated	B-X
T	B-X
cells	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
pattern	B-X
that	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
T-cell-specific	B-X
expression	B-X
of	B-X
the	B-X
IL-2	B-X
and	B-X
the	B-X
beta	B-X
chain	B-X
of	B-X
the	B-X
TcR	B-X
genes	B-X
.	B-X
The	B-X
measured	B-X
binding	B-X
to	B-X
a	B-X
TCF-1	B-X
site	B-X
is	B-X
the	B-X
same	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
resting	B-X
,	B-X
activated	B-X
,	B-X
and	B-X
anergized	B-X
cells	B-X
.	B-X
The	B-X
inducible	B-X
factors	B-X
NK-kappa	B-X
B	B-X
,	B-X
beta	B-X
E2	B-X
,	B-X
CD28RC	B-X
,	B-X
and	B-X
AP-1	B-X
are	B-X
not	B-X
expressed	B-X
in	B-X
resting	B-X
cells	B-X
and	B-X
are	B-X
twofold	B-X
lower	B-X
in	B-X
anergized	B-X
as	B-X
compared	B-X
with	B-X
activated	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
anergic	B-X
T	B-X
cells	B-X
express	B-X
approximately	B-X
eightfold	B-X
lower	B-X
amounts	B-X
of	B-X
NF-AT	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
class	B-X
of	B-X
inducible	B-X
factors	B-X
that	B-X
regulates	B-X
IL-2	B-X
gene	B-X
transcription	B-X
.	B-X

Stimulation	O
of	O
human	O
CD4	B-Protein
+	O
T	O
-	O
cell	O
clones	O
through	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
by	O
high	O
doses	O
of	O
specific	O
peptide	O
results	O
in	O
the	O
induction	O
of	O
a	O
long	O
-	O
lived	O
state	O
of	O
nonresponsiveness	O
that	O
has	O
been	O
called	O
anergy	O
.	O

During	O
the	O
induction	O
of	O
anergy	O
,	O
T	O
cells	O
are	O
phenotypically	O
similar	O
to	O
cells	O
responding	O
to	O
an	O
immunogenic	O
stimulus	O
.	O

The	O
amount	O
of	O
TcR	O
at	O
the	O
cell	O
surface	O
is	O
downmodulated	O
,	O
whereas	O
the	O
CD2	O
and	O
CD25	O
receptors	O
are	O
increased	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
human	B-X
CD4+	B-X
T-cell	B-X
clones	B-X
through	B-X
the	B-X
T-cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
by	B-X
high	B-X
doses	B-X
of	B-X
specific	B-X
peptide	B-X
results	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
long-lived	B-X
state	B-X
of	B-X
nonresponsiveness	B-X
that	B-X
has	B-X
been	B-X
called	B-X
anergy	B-X
.	B-X
During	B-X
the	B-X
induction	B-X
of	B-X
anergy	B-X
,	B-X
T	B-X
cells	B-X
are	B-X
phenotypically	B-X
similar	B-X
to	B-X
cells	B-X
responding	B-X
to	B-X
an	B-X
immunogenic	B-X
stimulus	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
TcR	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
is	B-X
downmodulated	B-X
,	B-X
whereas	B-X
the	B-X
CD2	B-X
and	B-X
CD25	B-X
receptors	B-X
are	B-X
increased	B-X
.	B-X
When	B-X
restimulated	B-X
,	B-X
however	B-X
,	B-X
anergic	B-X
T	B-X
cells	B-X
fail	B-X
to	B-X
up-regulate	B-X
transcription	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
and	B-X
in	B-X
consequence	B-X
do	B-X
not	B-X
produce	B-X
IL-2	B-X
.	B-X
Factors	B-X
were	B-X
isolated	B-X
from	B-X
the	B-X
nuclei	B-X
of	B-X
T	B-X
cells	B-X
that	B-X
were	B-X
in	B-X
the	B-X
induction	B-X
phase	B-X
of	B-X
anergy	B-X
or	B-X
were	B-X
undergoing	B-X
activation	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
binding	B-X
activity	B-X
in	B-X
restimulated	B-X
T	B-X
cells	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
pattern	B-X
that	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
T-cell-specific	B-X
expression	B-X
of	B-X
the	B-X
IL-2	B-X
and	B-X
the	B-X
beta	B-X
chain	B-X
of	B-X
the	B-X
TcR	B-X
genes	B-X
.	B-X
The	B-X
measured	B-X
binding	B-X
to	B-X
a	B-X
TCF-1	B-X
site	B-X
is	B-X
the	B-X
same	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
resting	B-X
,	B-X
activated	B-X
,	B-X
and	B-X
anergized	B-X
cells	B-X
.	B-X
The	B-X
inducible	B-X
factors	B-X
NK-kappa	B-X
B	B-X
,	B-X
beta	B-X
E2	B-X
,	B-X
CD28RC	B-X
,	B-X
and	B-X
AP-1	B-X
are	B-X
not	B-X
expressed	B-X
in	B-X
resting	B-X
cells	B-X
and	B-X
are	B-X
twofold	B-X
lower	B-X
in	B-X
anergized	B-X
as	B-X
compared	B-X
with	B-X
activated	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
anergic	B-X
T	B-X
cells	B-X
express	B-X
approximately	B-X
eightfold	B-X
lower	B-X
amounts	B-X
of	B-X
NF-AT	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
class	B-X
of	B-X
inducible	B-X
factors	B-X
that	B-X
regulates	B-X
IL-2	B-X
gene	B-X
transcription	B-X
.	B-X

When	O
restimulated	O
,	O
however	O
,	O
anergic	O
T	O
cells	O
fail	O
to	O
up	O
-	O
regulate	O
transcription	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
and	O
in	O
consequence	O
do	O
not	O
produce	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

In	O
this	O
study	O
,	O
we	O
have	O
compared	O
the	O
ability	O
of	O
various	O
transcription	O
factors	O
to	O
bind	O
to	O
their	O
appropriate	O
site	O
on	O
DNA	O
.	O
<EOS>	B-X
When	B-X
restimulated	B-X
,	B-X
however	B-X
,	B-X
anergic	B-X
T	B-X
cells	B-X
fail	B-X
to	B-X
up-regulate	B-X
transcription	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
and	B-X
in	B-X
consequence	B-X
do	B-X
not	B-X
produce	B-X
IL-2	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
compared	B-X
the	B-X
ability	B-X
of	B-X
various	B-X
transcription	B-X
factors	B-X
to	B-X
bind	B-X
to	B-X
their	B-X
appropriate	B-X
site	B-X
on	B-X
DNA	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
binding	B-X
activity	B-X
in	B-X
restimulated	B-X
T	B-X
cells	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
pattern	B-X
that	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
T-cell-specific	B-X
expression	B-X
of	B-X
the	B-X
IL-2	B-X
and	B-X
the	B-X
beta	B-X
chain	B-X
of	B-X
the	B-X
TcR	B-X
genes	B-X
.	B-X
The	B-X
measured	B-X
binding	B-X
to	B-X
a	B-X
TCF-1	B-X
site	B-X
is	B-X
the	B-X
same	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
resting	B-X
,	B-X
activated	B-X
,	B-X
and	B-X
anergized	B-X
cells	B-X
.	B-X
The	B-X
inducible	B-X
factors	B-X
NK-kappa	B-X
B	B-X
,	B-X
beta	B-X
E2	B-X
,	B-X
CD28RC	B-X
,	B-X
and	B-X
AP-1	B-X
are	B-X
not	B-X
expressed	B-X
in	B-X
resting	B-X
cells	B-X
and	B-X
are	B-X
twofold	B-X
lower	B-X
in	B-X
anergized	B-X
as	B-X
compared	B-X
with	B-X
activated	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
anergic	B-X
T	B-X
cells	B-X
express	B-X
approximately	B-X
eightfold	B-X
lower	B-X
amounts	B-X
of	B-X
NF-AT	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
class	B-X
of	B-X
inducible	B-X
factors	B-X
that	B-X
regulates	B-X
IL-2	B-X
gene	B-X
transcription	B-X
.	B-X

Factors	O
were	O
isolated	O
from	O
the	O
nuclei	O
of	O
T	O
cells	O
that	O
were	O
in	O
the	O
induction	O
phase	O
of	O
anergy	O
or	O
were	O
undergoing	O
activation	O
.	O
<EOS>	B-X
Women	B-X
undergoing	B-X
surgery	B-X
for	B-X
pelvic	B-X
organ	B-X
prolapse	B-X
are	B-X
more	B-X
likely	B-X
to	B-X
report	B-X
a	B-X
history	B-X
of	B-X
heavy	B-X
work	B-X
than	B-X
controls	B-X
;	B-X
however	B-X
,	B-X
women	B-X
recruited	B-X
from	B-X
the	B-X
community	B-X
with	B-X
pelvic	B-X
organ	B-X
prolapse	B-X
on	B-X
examination	B-X
report	B-X
similar	B-X
lifetime	B-X
levels	B-X
of	B-X
strenuous	B-X
activity	B-X
as	B-X
women	B-X
without	B-X
this	B-X
examination	B-X
finding	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
preclinical	B-X
data	B-X
,	B-X
the	B-X
available	B-X
studies	B-X
in	B-X
patients	B-X
with	B-X
Becker	B-X
's	B-X
muscular	B-X
dystrophy	B-X
undergoing	B-X
workout	B-X
on	B-X
a	B-X
cycle	B-X
ergometer	B-X
or	B-X
on	B-X
a	B-X
treadmill	B-X
,	B-X
at	B-X
a	B-X
heart	B-X
rate	B-X
≤65	B-X
%	B-X
of	B-X
their	B-X
maximal	B-X
oxygen	B-X
uptake	B-X
,	B-X
showed	B-X
that	B-X
aerobic	B-X
exercise	B-X
counteracts	B-X
physical	B-X
deterioration	B-X
and	B-X
loss	B-X
of	B-X
functional	B-X
abilities	B-X
.	B-X
In	B-X
the	B-X
capacitation	B-X
process	B-X
,	B-X
the	B-X
EGFR	B-X
is	B-X
partially	B-X
activated	B-X
by	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
,	B-X
resulting	B-X
in	B-X
phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
activation	B-X
and	B-X
actin	B-X
polymerization	B-X
.	B-X
Protein	B-X
kinase	B-X
C	B-X
alpha	B-X
(	B-X
PKCα	B-X
)	B-X
,	B-X
which	B-X
is	B-X
already	B-X
activated	B-X
at	B-X
the	B-X
beginning	B-X
of	B-X
the	B-X
capacitation	B-X
,	B-X
also	B-X
participates	B-X
in	B-X
PLD	B-X
activation	B-X
.	B-X
Further	B-X
activation	B-X
of	B-X
the	B-X
EGFR	B-X
at	B-X
the	B-X
end	B-X
of	B-X
the	B-X
capacitation	B-X
enhances	B-X
intracellular	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
concentration	B-X
leading	B-X
to	B-X
F-actin	B-X
breakdown	B-X
and	B-X
allows	B-X
the	B-X
AR	B-X
to	B-X
take	B-X
place	B-X
.	B-X
Under	B-X
in	B-X
vivo	B-X
conditions	B-X
,	B-X
the	B-X
EGFR	B-X
can	B-X
be	B-X
directly	B-X
activated	B-X
by	B-X
its	B-X
known	B-X
ligand	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
,	B-X
and	B-X
indirectly	B-X
by	B-X
activating	B-X
PKA	B-X
or	B-X
by	B-X
transactivation	B-X
mediated	B-X
by	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
(	B-X
GPCRs	B-X
)	B-X
activation	B-X
or	B-X
by	B-X
ouabain	B-X
.	B-X

The	O
pattern	O
of	O
binding	O
activity	O
in	O
restimulated	O
T	O
cells	O
is	O
consistent	O
with	O
the	O
pattern	O
that	O
has	O
previously	O
been	O
shown	O
to	O
regulate	O
T	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
the	O
beta	O
chain	O
of	O
the	O
TcR	O
genes	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
human	B-X
CD4+	B-X
T-cell	B-X
clones	B-X
through	B-X
the	B-X
T-cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
by	B-X
high	B-X
doses	B-X
of	B-X
specific	B-X
peptide	B-X
results	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
long-lived	B-X
state	B-X
of	B-X
nonresponsiveness	B-X
that	B-X
has	B-X
been	B-X
called	B-X
anergy	B-X
.	B-X
During	B-X
the	B-X
induction	B-X
of	B-X
anergy	B-X
,	B-X
T	B-X
cells	B-X
are	B-X
phenotypically	B-X
similar	B-X
to	B-X
cells	B-X
responding	B-X
to	B-X
an	B-X
immunogenic	B-X
stimulus	B-X
.	B-X
The	B-X
amount	B-X
of	B-X
TcR	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
is	B-X
downmodulated	B-X
,	B-X
whereas	B-X
the	B-X
CD2	B-X
and	B-X
CD25	B-X
receptors	B-X
are	B-X
increased	B-X
.	B-X
When	B-X
restimulated	B-X
,	B-X
however	B-X
,	B-X
anergic	B-X
T	B-X
cells	B-X
fail	B-X
to	B-X
up-regulate	B-X
transcription	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
and	B-X
in	B-X
consequence	B-X
do	B-X
not	B-X
produce	B-X
IL-2	B-X
.	B-X
Factors	B-X
were	B-X
isolated	B-X
from	B-X
the	B-X
nuclei	B-X
of	B-X
T	B-X
cells	B-X
that	B-X
were	B-X
in	B-X
the	B-X
induction	B-X
phase	B-X
of	B-X
anergy	B-X
or	B-X
were	B-X
undergoing	B-X
activation	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
binding	B-X
activity	B-X
in	B-X
restimulated	B-X
T	B-X
cells	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
pattern	B-X
that	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
T-cell-specific	B-X
expression	B-X
of	B-X
the	B-X
IL-2	B-X
and	B-X
the	B-X
beta	B-X
chain	B-X
of	B-X
the	B-X
TcR	B-X
genes	B-X
.	B-X
The	B-X
measured	B-X
binding	B-X
to	B-X
a	B-X
TCF-1	B-X
site	B-X
is	B-X
the	B-X
same	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
resting	B-X
,	B-X
activated	B-X
,	B-X
and	B-X
anergized	B-X
cells	B-X
.	B-X
The	B-X
inducible	B-X
factors	B-X
NK-kappa	B-X
B	B-X
,	B-X
beta	B-X
E2	B-X
,	B-X
CD28RC	B-X
,	B-X
and	B-X
AP-1	B-X
are	B-X
not	B-X
expressed	B-X
in	B-X
resting	B-X
cells	B-X
and	B-X
are	B-X
twofold	B-X
lower	B-X
in	B-X
anergized	B-X
as	B-X
compared	B-X
with	B-X
activated	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
anergic	B-X
T	B-X
cells	B-X
express	B-X
approximately	B-X
eightfold	B-X
lower	B-X
amounts	B-X
of	B-X
NF-AT	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
class	B-X
of	B-X
inducible	B-X
factors	B-X
that	B-X
regulates	B-X
IL-2	B-X
gene	B-X
transcription	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

The	O
measured	O
binding	O
to	O
a	O
TCF	B-Protein
-	I-Protein
1	I-Protein
site	O
is	O
the	O
same	O
in	O
the	O
nuclei	O
of	O
resting	O
,	O
activated	O
,	O
and	O
anergized	O
cells	O
.	O
<EOS>	B-X
During	B-X
the	B-X
induction	B-X
of	B-X
anergy	B-X
,	B-X
T	B-X
cells	B-X
are	B-X
phenotypically	B-X
similar	B-X
to	B-X
cells	B-X
responding	B-X
to	B-X
an	B-X
immunogenic	B-X
stimulus	B-X
.	B-X
When	B-X
restimulated	B-X
,	B-X
however	B-X
,	B-X
anergic	B-X
T	B-X
cells	B-X
fail	B-X
to	B-X
up-regulate	B-X
transcription	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
and	B-X
in	B-X
consequence	B-X
do	B-X
not	B-X
produce	B-X
IL-2	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
compared	B-X
the	B-X
ability	B-X
of	B-X
various	B-X
transcription	B-X
factors	B-X
to	B-X
bind	B-X
to	B-X
their	B-X
appropriate	B-X
site	B-X
on	B-X
DNA	B-X
.	B-X
Factors	B-X
were	B-X
isolated	B-X
from	B-X
the	B-X
nuclei	B-X
of	B-X
T	B-X
cells	B-X
that	B-X
were	B-X
in	B-X
the	B-X
induction	B-X
phase	B-X
of	B-X
anergy	B-X
or	B-X
were	B-X
undergoing	B-X
activation	B-X
.	B-X
The	B-X
pattern	B-X
of	B-X
binding	B-X
activity	B-X
in	B-X
restimulated	B-X
T	B-X
cells	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
pattern	B-X
that	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
T-cell-specific	B-X
expression	B-X
of	B-X
the	B-X
IL-2	B-X
and	B-X
the	B-X
beta	B-X
chain	B-X
of	B-X
the	B-X
TcR	B-X
genes	B-X
.	B-X
The	B-X
measured	B-X
binding	B-X
to	B-X
a	B-X
TCF-1	B-X
site	B-X
is	B-X
the	B-X
same	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
resting	B-X
,	B-X
activated	B-X
,	B-X
and	B-X
anergized	B-X
cells	B-X
.	B-X
The	B-X
inducible	B-X
factors	B-X
NK-kappa	B-X
B	B-X
,	B-X
beta	B-X
E2	B-X
,	B-X
CD28RC	B-X
,	B-X
and	B-X
AP-1	B-X
are	B-X
not	B-X
expressed	B-X
in	B-X
resting	B-X
cells	B-X
and	B-X
are	B-X
twofold	B-X
lower	B-X
in	B-X
anergized	B-X
as	B-X
compared	B-X
with	B-X
activated	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
anergic	B-X
T	B-X
cells	B-X
express	B-X
approximately	B-X
eightfold	B-X
lower	B-X
amounts	B-X
of	B-X
NF-AT	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
class	B-X
of	B-X
inducible	B-X
factors	B-X
that	B-X
regulates	B-X
IL-2	B-X
gene	B-X
transcription	B-X
.	B-X

The	O
inducible	O
factors	O
NK	O
-	O
kappa	O
B	O
,	O
beta	O
E2	O
,	O
CD28RC	B-Protein
,	O
and	O
AP	O
-	O
1	O
are	O
not	O
expressed	O
in	O
resting	O
cells	O
and	O
are	O
twofold	O
lower	O
in	O
anergized	O
as	O
compared	O
with	O
activated	O
cells	O
.	O

In	O
contrast	O
,	O
anergic	O
T	O
cells	O
express	O
approximately	O
eightfold	O
lower	O
amounts	O
of	O
NF	O
-	O
AT	O
,	O
a	O
member	O
of	O
the	O
class	O
of	O
inducible	O
factors	O
that	O
regulates	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
transcription	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
<EOS>	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

The	O
retinoblastoma	O
gene	O
product	O
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	O
cytomegalovirus	O
IE2	B-Protein
protein	O
.	O
<EOS>	B-X
The	B-X
IE2	B-X
gene	B-X
product	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
HCMV	B-X
)	B-X
is	B-X
one	B-X
of	B-X
a	B-X
few	B-X
viral	B-X
regulatory	B-X
proteins	B-X
expressed	B-X
immediately	B-X
upon	B-X
infection	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
.	B-X
It	B-X
is	B-X
a	B-X
potent	B-X
transcriptional	B-X
activator	B-X
of	B-X
many	B-X
viral	B-X
and	B-X
cellular	B-X
promoters	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
retinoblastoma	B-X
susceptibility	B-X
gene	B-X
product	B-X
(	B-X
Rb	B-X
)	B-X
dramatically	B-X
suppressed	B-X
this	B-X
IE2	B-X
transactivation	B-X
of	B-X
various	B-X
promoters	B-X
.	B-X
However	B-X
,	B-X
unlike	B-X
another	B-X
tumor	B-X
suppressor	B-X
protein	B-X
,	B-X
p53	B-X
,	B-X
Rb	B-X
did	B-X
not	B-X
have	B-X
any	B-X
significant	B-X
effect	B-X
on	B-X
basal	B-X
levels	B-X
of	B-X
transcription	B-X
,	B-X
suggesting	B-X
that	B-X
Rb	B-X
specifically	B-X
interacts	B-X
with	B-X
IE2	B-X
rather	B-X
than	B-X
other	B-X
cellular	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
general	B-X
transcription	B-X
machinery	B-X
.	B-X
We	B-X
found	B-X
by	B-X
protein-affinity	B-X
chromatography	B-X
that	B-X
Rb	B-X
in	B-X
nuclear	B-X
extracts	B-X
or	B-X
produced	B-X
by	B-X
in	B-X
vitro	B-X
translation	B-X
directly	B-X
bound	B-X
to	B-X
IE2	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
Rb	B-X
may	B-X
regulate	B-X
the	B-X
life	B-X
cycle	B-X
of	B-X
HCMV	B-X
,	B-X
which	B-X
is	B-X
endemic	B-X
in	B-X
the	B-X
human	B-X
population	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
may	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
slow	B-X
rate	B-X
of	B-X
HCMV	B-X
DNA	B-X
replication	B-X
in	B-X
cells	B-X
and	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
HCMV	B-X
in	B-X
tumorigenesis	B-X
.	B-X

The	O
IE2	B-Protein
gene	O
product	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	O
regulatory	O
proteins	O
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	O
cell	O
.	O
<EOS>	B-X
The	B-X
IE2	B-X
gene	B-X
product	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
HCMV	B-X
)	B-X
is	B-X
one	B-X
of	B-X
a	B-X
few	B-X
viral	B-X
regulatory	B-X
proteins	B-X
expressed	B-X
immediately	B-X
upon	B-X
infection	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
.	B-X
It	B-X
is	B-X
a	B-X
potent	B-X
transcriptional	B-X
activator	B-X
of	B-X
many	B-X
viral	B-X
and	B-X
cellular	B-X
promoters	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
retinoblastoma	B-X
susceptibility	B-X
gene	B-X
product	B-X
(	B-X
Rb	B-X
)	B-X
dramatically	B-X
suppressed	B-X
this	B-X
IE2	B-X
transactivation	B-X
of	B-X
various	B-X
promoters	B-X
.	B-X
However	B-X
,	B-X
unlike	B-X
another	B-X
tumor	B-X
suppressor	B-X
protein	B-X
,	B-X
p53	B-X
,	B-X
Rb	B-X
did	B-X
not	B-X
have	B-X
any	B-X
significant	B-X
effect	B-X
on	B-X
basal	B-X
levels	B-X
of	B-X
transcription	B-X
,	B-X
suggesting	B-X
that	B-X
Rb	B-X
specifically	B-X
interacts	B-X
with	B-X
IE2	B-X
rather	B-X
than	B-X
other	B-X
cellular	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
general	B-X
transcription	B-X
machinery	B-X
.	B-X
We	B-X
found	B-X
by	B-X
protein-affinity	B-X
chromatography	B-X
that	B-X
Rb	B-X
in	B-X
nuclear	B-X
extracts	B-X
or	B-X
produced	B-X
by	B-X
in	B-X
vitro	B-X
translation	B-X
directly	B-X
bound	B-X
to	B-X
IE2	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
Rb	B-X
may	B-X
regulate	B-X
the	B-X
life	B-X
cycle	B-X
of	B-X
HCMV	B-X
,	B-X
which	B-X
is	B-X
endemic	B-X
in	B-X
the	B-X
human	B-X
population	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
may	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
slow	B-X
rate	B-X
of	B-X
HCMV	B-X
DNA	B-X
replication	B-X
in	B-X
cells	B-X
and	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
HCMV	B-X
in	B-X
tumorigenesis	B-X
.	B-X

It	O
is	O
a	O
potent	O
transcriptional	O
activator	O
of	O
many	O
viral	O
and	O
cellular	O
promoters	O
.	O
<EOS>	B-X
The	B-X
tumour-associated	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
has	B-X
potent	B-X
B-cell	B-X
transforming	B-X
ability	B-X
and	B-X
manipulates	B-X
RUNX3	B-X
and	B-X
RUNX1	B-X
transcription	B-X
through	B-X
novel	B-X
mechanisms	B-X
to	B-X
control	B-X
B	B-X
cell	B-X
growth	B-X
.	B-X
Therefore	B-X
in	B-X
addition	B-X
to	B-X
B-cell	B-X
growth	B-X
manipulation	B-X
through	B-X
the	B-X
long-range	B-X
control	B-X
of	B-X
RUNX	B-X
transcription	B-X
,	B-X
EBV	B-X
may	B-X
also	B-X
use	B-X
RUNX	B-X
proteins	B-X
as	B-X
co-factors	B-X
to	B-X
deregulate	B-X
the	B-X
transcription	B-X
of	B-X
many	B-X
B	B-X
cell	B-X
genes	B-X
during	B-X
immortalisation	B-X
.	B-X
Interferons	B-X
(	B-X
IFN	B-X
)	B-X
are	B-X
potent	B-X
components	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
to	B-X
microbial	B-X
infection	B-X
.	B-X
The	B-X
genes	B-X
for	B-X
type	B-X
I	B-X
IFN	B-X
(	B-X
IFN-alpha	B-X
and	B-X
IFN-beta	B-X
)	B-X
are	B-X
rapidly	B-X
induced	B-X
in	B-X
response	B-X
to	B-X
viral	B-X
infection	B-X
through	B-X
a	B-X
mechanism	B-X
that	B-X
involves	B-X
latent	B-X
cellular	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
activated	B-X
in	B-X
response	B-X
to	B-X
innate	B-X
recognition	B-X
of	B-X
viral	B-X
components	B-X
.	B-X
Early	B-X
response	B-X
to	B-X
virus	B-X
causes	B-X
secretion	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
IFN	B-X
genes	B-X
through	B-X
the	B-X
action	B-X
of	B-X
IRF-3	B-X
in	B-X
conjunction	B-X
with	B-X
additional	B-X
transcription	B-X
factors	B-X
,	B-X
such	B-X
as	B-X
NF-kappaB	B-X
and	B-X
activator	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
(	B-X
c-jun/ATF	B-X
)	B-X
.	B-X
This	B-X
early	B-X
IFN	B-X
acts	B-X
in	B-X
an	B-X
autocrine	B-X
manner	B-X
to	B-X
stimulate	B-X
production	B-X
of	B-X
IRF-7	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
capable	B-X
of	B-X
activating	B-X
the	B-X
many	B-X
additional	B-X
members	B-X
of	B-X
the	B-X
IFN-alpha	B-X
gene	B-X
family	B-X
.	B-X
Characterization	B-X
of	B-X
the	B-X
cellular	B-X
components	B-X
involved	B-X
in	B-X
viral	B-X
detection	B-X
and	B-X
IRF	B-X
activation	B-X
will	B-X
further	B-X
delineate	B-X
this	B-X
vital	B-X
mechanism	B-X
of	B-X
innate	B-X
immune	B-X
response	B-X
.	B-X

We	O
found	O
that	O
the	O
retinoblastoma	O
susceptibility	O
gene	O
product	O
(	O
Rb	B-Protein
)	O
dramatically	O
suppressed	O
this	O
IE2	B-Protein
transactivation	O
of	O
various	O
promoters	O
.	O
<EOS>	B-X
The	B-X
IE2	B-X
gene	B-X
product	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
HCMV	B-X
)	B-X
is	B-X
one	B-X
of	B-X
a	B-X
few	B-X
viral	B-X
regulatory	B-X
proteins	B-X
expressed	B-X
immediately	B-X
upon	B-X
infection	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
.	B-X
It	B-X
is	B-X
a	B-X
potent	B-X
transcriptional	B-X
activator	B-X
of	B-X
many	B-X
viral	B-X
and	B-X
cellular	B-X
promoters	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
retinoblastoma	B-X
susceptibility	B-X
gene	B-X
product	B-X
(	B-X
Rb	B-X
)	B-X
dramatically	B-X
suppressed	B-X
this	B-X
IE2	B-X
transactivation	B-X
of	B-X
various	B-X
promoters	B-X
.	B-X
However	B-X
,	B-X
unlike	B-X
another	B-X
tumor	B-X
suppressor	B-X
protein	B-X
,	B-X
p53	B-X
,	B-X
Rb	B-X
did	B-X
not	B-X
have	B-X
any	B-X
significant	B-X
effect	B-X
on	B-X
basal	B-X
levels	B-X
of	B-X
transcription	B-X
,	B-X
suggesting	B-X
that	B-X
Rb	B-X
specifically	B-X
interacts	B-X
with	B-X
IE2	B-X
rather	B-X
than	B-X
other	B-X
cellular	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
general	B-X
transcription	B-X
machinery	B-X
.	B-X
We	B-X
found	B-X
by	B-X
protein-affinity	B-X
chromatography	B-X
that	B-X
Rb	B-X
in	B-X
nuclear	B-X
extracts	B-X
or	B-X
produced	B-X
by	B-X
in	B-X
vitro	B-X
translation	B-X
directly	B-X
bound	B-X
to	B-X
IE2	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
Rb	B-X
may	B-X
regulate	B-X
the	B-X
life	B-X
cycle	B-X
of	B-X
HCMV	B-X
,	B-X
which	B-X
is	B-X
endemic	B-X
in	B-X
the	B-X
human	B-X
population	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
may	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
slow	B-X
rate	B-X
of	B-X
HCMV	B-X
DNA	B-X
replication	B-X
in	B-X
cells	B-X
and	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
HCMV	B-X
in	B-X
tumorigenesis	B-X
.	B-X

However	O
,	O
unlike	O
another	O
tumor	O
suppressor	O
protein	O
,	O
p53	B-Protein
,	O
Rb	B-Protein
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	B-Protein
specifically	O
interacts	O
with	O
IE2	B-Protein
rather	O
than	O
other	O
cellular	O
factors	O
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
reported	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
RB	B-X
activity	B-X
,	B-X
a	B-X
retinoma	B-X
is	B-X
generated	B-X
,	B-X
and	B-X
the	B-X
onset	B-X
of	B-X
retina	B-X
cancer	B-X
occurs	B-X
until	B-X
the	B-X
p53	B-X
pathway	B-X
is	B-X
altered	B-X
.	B-X
Unlike	B-X
other	B-X
types	B-X
of	B-X
cancer	B-X
,	B-X
in	B-X
retinoblastoma	B-X
the	B-X
p53	B-X
tumour	B-X
suppressor	B-X
is	B-X
mostly	B-X
wild	B-X
type	B-X
,	B-X
although	B-X
its	B-X
two	B-X
primary	B-X
regulators	B-X
,	B-X
MDMX	B-X
and	B-X
MDM2	B-X
,	B-X
are	B-X
commonly	B-X
dysregulated	B-X
.	B-X
Here	B-X
we	B-X
investigated	B-X
the	B-X
mRNA	B-X
levels	B-X
of	B-X
RB	B-X
,	B-X
p53	B-X
,	B-X
MDMX	B-X
and	B-X
MDM2	B-X
in	B-X
peripheral	B-X
blood	B-X
samples	B-X
of	B-X
retinoblastoma	B-X
patients	B-X
to	B-X
monitor	B-X
the	B-X
pathway	B-X
status	B-X
of	B-X
p53	B-X
in	B-X
somatic	B-X
cells	B-X
.	B-X
It	B-X
is	B-X
widely	B-X
accepted	B-X
that	B-X
small	B-X
DNA	B-X
tumor	B-X
viruses	B-X
,	B-X
such	B-X
as	B-X
adenovirus	B-X
,	B-X
simian	B-X
virus	B-X
40	B-X
and	B-X
papillomavirus	B-X
,	B-X
push	B-X
infected	B-X
cells	B-X
into	B-X
S-phase	B-X
to	B-X
facilitate	B-X
the	B-X
replication	B-X
of	B-X
their	B-X
genome	B-X
.	B-X
However	B-X
,	B-X
studies	B-X
over	B-X
the	B-X
last	B-X
6-8	B-X
years	B-X
have	B-X
uncovered	B-X
striking	B-X
parallels	B-X
(	B-X
and	B-X
differences	B-X
)	B-X
between	B-X
the	B-X
functions	B-X
of	B-X
the	B-X
major	B-X
immediate	B-X
early	B-X
(	B-X
IE	B-X
)	B-X
proteins	B-X
of	B-X
at	B-X
least	B-X
one	B-X
herpesvirus	B-X
,	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
HCMV	B-X
)	B-X
and	B-X
IE	B-X
equivalents	B-X
encoded	B-X
by	B-X
small	B-X
DNA	B-X
tumor	B-X
viruses	B-X
,	B-X
such	B-X
as	B-X
adenovirus	B-X
.	B-X
Similarities	B-X
between	B-X
the	B-X
HCMV	B-X
major	B-X
IE	B-X
proteins	B-X
and	B-X
adenovirus	B-X
IE	B-X
proteins	B-X
include	B-X
targeting	B-X
of	B-X
members	B-X
of	B-X
the	B-X
RB	B-X
and	B-X
p53	B-X
families	B-X
and	B-X
an	B-X
ability	B-X
of	B-X
these	B-X
viral	B-X
factors	B-X
to	B-X
induce	B-X
S-phase	B-X
in	B-X
quiescent	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
unlike	B-X
the	B-X
small	B-X
DNA	B-X
tumor	B-X
virus	B-X
proteins	B-X
,	B-X
individual	B-X
HCMV	B-X
IE	B-X
proteins	B-X
target	B-X
different	B-X
RB	B-X
family	B-X
members	B-X
.	B-X
HCMV	B-X
also	B-X
encodes	B-X
several	B-X
other	B-X
IE	B-X
gene	B-X
products	B-X
as	B-X
well	B-X
as	B-X
virion	B-X
tegument	B-X
proteins	B-X
that	B-X
act	B-X
early	B-X
during	B-X
infection	B-X
to	B-X
prevent	B-X
an	B-X
infected	B-X
cell	B-X
from	B-X
replicating	B-X
its	B-X
host	B-X
genome	B-X
and	B-X
from	B-X
undergoing	B-X
apoptosis	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
specifics	B-X
of	B-X
several	B-X
HCMV	B-X
IE	B-X
proteins	B-X
,	B-X
two	B-X
virion	B-X
components	B-X
,	B-X
and	B-X
their	B-X
functions	B-X
in	B-X
relation	B-X
to	B-X
cell	B-X
growth	B-X
control	B-X
.	B-X

We	O
found	O
by	O
protein	O
-	O
affinity	O
chromatography	O
that	O
Rb	B-Protein
in	O
nuclear	O
extracts	O
or	O
produced	O
by	O
in	O
vitro	O
translation	O
directly	O
bound	O
to	O
IE2	B-Protein
.	O
<EOS>	B-X
To	B-X
determine	B-X
how	B-X
CMV	B-X
infection	B-X
transactivates	B-X
the	B-X
TGF-beta1	B-X
promoter	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
cotransfected	B-X
IE2	B-X
regulatory	B-X
protein	B-X
of	B-X
human	B-X
CMV	B-X
on	B-X
5'-deleted	B-X
TGF-beta1	B-X
promoter-CAT	B-X
reporter	B-X
genes	B-X
in	B-X
transient	B-X
DNA	B-X
transfection	B-X
assays	B-X
.	B-X
Two	B-X
upstream	B-X
TGF-beta1	B-X
promoter	B-X
regions	B-X
each	B-X
containing	B-X
an	B-X
Egr-1	B-X
consensus	B-X
site	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
important	B-X
for	B-X
IE2-induced	B-X
transactivation	B-X
in	B-X
a	B-X
cell	B-X
type	B-X
that	B-X
displayed	B-X
greatly	B-X
reduced	B-X
nonspecific	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
transfer	B-X
of	B-X
an	B-X
Egr-l	B-X
site	B-X
from	B-X
between	B-X
positions	B-X
-125	B-X
and	B-X
-98	B-X
,	B-X
but	B-X
not	B-X
point	B-X
mutant	B-X
versions	B-X
of	B-X
this	B-X
site	B-X
,	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
also	B-X
conveyed	B-X
IE2	B-X
responsiveness	B-X
.	B-X
Addition	B-X
of	B-X
an	B-X
IE2	B-X
expression	B-X
vector	B-X
or	B-X
use	B-X
of	B-X
the	B-X
U373	B-X
A45	B-X
astrocytoma	B-X
cell	B-X
line	B-X
expressing	B-X
IE2	B-X
also	B-X
produced	B-X
synergistic	B-X
stimulation	B-X
of	B-X
GAL4-Egr-l-mediated	B-X
activation	B-X
of	B-X
a	B-X
target	B-X
promoter	B-X
containing	B-X
GAL4	B-X
binding	B-X
sites	B-X
.	B-X
The	B-X
80-kDa	B-X
IE2	B-X
protein	B-X
present	B-X
in	B-X
A45	B-X
cells	B-X
proved	B-X
to	B-X
selectively	B-X
bind	B-X
to	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-Egr-1	B-X
beads	B-X
.	B-X
The	B-X
results	B-X
of	B-X
in	B-X
vitro	B-X
protein	B-X
binding	B-X
assays	B-X
also	B-X
revealed	B-X
that	B-X
an	B-X
intact	B-X
in	B-X
vitro-translated	B-X
IE2	B-X
protein	B-X
bound	B-X
directly	B-X
to	B-X
the	B-X
GST-Egr-1	B-X
fusion	B-X
protein	B-X
through	B-X
the	B-X
zinc	B-X
finger	B-X
domain	B-X
of	B-X
the	B-X
Egr-1	B-X
protein	B-X
and	B-X
that	B-X
this	B-X
binding	B-X
activity	B-X
was	B-X
abolished	B-X
by	B-X
deletion	B-X
of	B-X
parts	B-X
of	B-X
the	B-X
zinc	B-X
finger	B-X
DNA-binding	B-X
domain	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
Egr-1	B-X
protein	B-X
was	B-X
found	B-X
to	B-X
associate	B-X
preferentially	B-X
with	B-X
a	B-X
small	B-X
region	B-X
within	B-X
the	B-X
C-terminal	B-X
half	B-X
of	B-X
the	B-X
IE2	B-X
protein	B-X
adjacent	B-X
to	B-X
the	B-X
DNA-binding	B-X
and	B-X
dimerization	B-X
domains	B-X
that	B-X
are	B-X
important	B-X
for	B-X
both	B-X
transactivation	B-X
and	B-X
downregulation	B-X
.	B-X
We	B-X
conclude	B-X
from	B-X
these	B-X
observations	B-X
that	B-X
IE2	B-X
may	B-X
regulate	B-X
transcription	B-X
of	B-X
the	B-X
TGF-beta1	B-X
gene	B-X
as	B-X
well	B-X
as	B-X
other	B-X
potential	B-X
cellular	B-X
targets	B-X
by	B-X
virtue	B-X
of	B-X
its	B-X
ability	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
Egr-1	B-X
DNA-binding	B-X
protein	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
Rb	B-Protein
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O
<EOS>	B-X
The	B-X
IE2	B-X
gene	B-X
product	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
HCMV	B-X
)	B-X
is	B-X
one	B-X
of	B-X
a	B-X
few	B-X
viral	B-X
regulatory	B-X
proteins	B-X
expressed	B-X
immediately	B-X
upon	B-X
infection	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
retinoblastoma	B-X
susceptibility	B-X
gene	B-X
product	B-X
(	B-X
Rb	B-X
)	B-X
dramatically	B-X
suppressed	B-X
this	B-X
IE2	B-X
transactivation	B-X
of	B-X
various	B-X
promoters	B-X
.	B-X
However	B-X
,	B-X
unlike	B-X
another	B-X
tumor	B-X
suppressor	B-X
protein	B-X
,	B-X
p53	B-X
,	B-X
Rb	B-X
did	B-X
not	B-X
have	B-X
any	B-X
significant	B-X
effect	B-X
on	B-X
basal	B-X
levels	B-X
of	B-X
transcription	B-X
,	B-X
suggesting	B-X
that	B-X
Rb	B-X
specifically	B-X
interacts	B-X
with	B-X
IE2	B-X
rather	B-X
than	B-X
other	B-X
cellular	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
general	B-X
transcription	B-X
machinery	B-X
.	B-X
We	B-X
found	B-X
by	B-X
protein-affinity	B-X
chromatography	B-X
that	B-X
Rb	B-X
in	B-X
nuclear	B-X
extracts	B-X
or	B-X
produced	B-X
by	B-X
in	B-X
vitro	B-X
translation	B-X
directly	B-X
bound	B-X
to	B-X
IE2	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
Rb	B-X
may	B-X
regulate	B-X
the	B-X
life	B-X
cycle	B-X
of	B-X
HCMV	B-X
,	B-X
which	B-X
is	B-X
endemic	B-X
in	B-X
the	B-X
human	B-X
population	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
may	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
slow	B-X
rate	B-X
of	B-X
HCMV	B-X
DNA	B-X
replication	B-X
in	B-X
cells	B-X
and	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
HCMV	B-X
in	B-X
tumorigenesis	B-X
.	B-X

Furthermore	O
,	O
these	O
data	O
may	O
provide	O
new	O
insights	O
into	O
the	O
slow	O
rate	O
of	O
HCMV	O
DNA	O
replication	O
in	O
cells	O
and	O
the	O
possible	O
involvement	O
of	O
HCMV	O
in	O
tumorigenesis	O
.	O
<EOS>	B-X
The	B-X
IE2	B-X
gene	B-X
product	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
HCMV	B-X
)	B-X
is	B-X
one	B-X
of	B-X
a	B-X
few	B-X
viral	B-X
regulatory	B-X
proteins	B-X
expressed	B-X
immediately	B-X
upon	B-X
infection	B-X
of	B-X
the	B-X
host	B-X
cell	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
Rb	B-X
may	B-X
regulate	B-X
the	B-X
life	B-X
cycle	B-X
of	B-X
HCMV	B-X
,	B-X
which	B-X
is	B-X
endemic	B-X
in	B-X
the	B-X
human	B-X
population	B-X
.	B-X
Furthermore	B-X
,	B-X
these	B-X
data	B-X
may	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
slow	B-X
rate	B-X
of	B-X
HCMV	B-X
DNA	B-X
replication	B-X
in	B-X
cells	B-X
and	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
HCMV	B-X
in	B-X
tumorigenesis	B-X
.	B-X

Epstein	O
-	O
Barr	O
virus	O
replicative	O
gene	O
transcription	O
during	O
de	O
novo	O
infection	O
of	O
human	O
thymocytes	O
:	O
simultaneous	O
early	O
expression	O
of	O
BZLF	B-Protein
-	I-Protein
1	I-Protein
and	O
its	O
repressor	O
RAZ	B-Protein
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
known	B-X
to	B-X
infect	B-X
B	B-X
cells	B-X
and	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
and	B-X
others	B-X
have	B-X
shown	B-X
that	B-X
EBV	B-X
can	B-X
also	B-X
infect	B-X
a	B-X
subset	B-X
of	B-X
thymocytes	B-X
.	B-X
Infection	B-X
of	B-X
thymocytes	B-X
was	B-X
accompanied	B-X
by	B-X
the	B-X
appearance	B-X
of	B-X
linear	B-X
EBV	B-X
genome	B-X
within	B-X
8	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
Circularization	B-X
of	B-X
the	B-X
EBV	B-X
genome	B-X
was	B-X
not	B-X
detected	B-X
.	B-X
This	B-X
is	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
infection	B-X
in	B-X
B	B-X
cells	B-X
where	B-X
the	B-X
genome	B-X
can	B-X
circularize	B-X
within	B-X
24	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
the	B-X
BamHI	B-X
ZLF-1	B-X
gene	B-X
product	B-X
,	B-X
ZEBRA	B-X
,	B-X
by	B-X
RT-PCR	B-X
,	B-X
was	B-X
observed	B-X
within	B-X
8	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
a	B-X
novel	B-X
fusion	B-X
transcript	B-X
(	B-X
RAZ	B-X
)	B-X
,	B-X
which	B-X
comprised	B-X
regions	B-X
of	B-X
the	B-X
BZLF-1	B-X
locus	B-X
and	B-X
the	B-X
adjacent	B-X
BRLF-1	B-X
locus	B-X
,	B-X
was	B-X
detected	B-X
by	B-X
RT-PCR	B-X
.	B-X
ZEBRA	B-X
protein	B-X
was	B-X
also	B-X
identified	B-X
in	B-X
infected	B-X
thymocytes	B-X
by	B-X
immunoprecipitation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
EBNA-1	B-X
gene	B-X
in	B-X
infected	B-X
thymocytes	B-X
was	B-X
transcribed	B-X
from	B-X
the	B-X
Fp	B-X
promoter	B-X
,	B-X
rather	B-X
than	B-X
from	B-X
the	B-X
Cp/Wp	B-X
promoter	B-X
which	B-X
is	B-X
used	B-X
in	B-X
latently	B-X
infected	B-X
B	B-X
cells	B-X
.	B-X
Transcripts	B-X
encoding	B-X
gp350/220	B-X
,	B-X
the	B-X
major	B-X
coat	B-X
protein	B-X
of	B-X
EBV	B-X
,	B-X
were	B-X
identified	B-X
,	B-X
but	B-X
we	B-X
did	B-X
not	B-X
find	B-X
any	B-X
evidence	B-X
of	B-X
transcription	B-X
from	B-X
the	B-X
LMP-2A	B-X
or	B-X
EBER-1	B-X
loci	B-X
in	B-X
infected	B-X
thymocytes	B-X
.	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
de	B-X
novo	B-X
EBV	B-X
infection	B-X
of	B-X
thymocytes	B-X
differs	B-X
from	B-X
infection	B-X
of	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
main	B-X
difference	B-X
is	B-X
that	B-X
with	B-X
thymocytes	B-X
,	B-X
no	B-X
evidence	B-X
could	B-X
be	B-X
found	B-X
that	B-X
the	B-X
virus	B-X
ever	B-X
circularizes	B-X
.	B-X
Rather	B-X
,	B-X
EBV	B-X
remains	B-X
in	B-X
a	B-X
linear	B-X
configuration	B-X
from	B-X
which	B-X
replicative	B-X
genes	B-X
are	B-X
transcribed	B-X
.	B-X

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	O
cells	O
and	O
epithelial	O
cells	O
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
,	B-X
also	B-X
known	B-X
as	B-X
human	B-X
herpesvirus	B-X
4	B-X
,	B-X
is	B-X
a	B-X
double-stranded	B-X
DNA	B-X
virus	B-X
that	B-X
is	B-X
ubiquitous	B-X
in	B-X
90-95	B-X
%	B-X
of	B-X
the	B-X
population	B-X
as	B-X
a	B-X
gamma	B-X
herpesvirus	B-X
.	B-X
It	B-X
exists	B-X
in	B-X
two	B-X
main	B-X
states	B-X
,	B-X
latent	B-X
infection	B-X
and	B-X
lytic	B-X
replication	B-X
,	B-X
each	B-X
encoding	B-X
viral	B-X
proteins	B-X
with	B-X
different	B-X
functions	B-X
.	B-X
Human	B-X
B-lymphocytes	B-X
and	B-X
epithelial	B-X
cells	B-X
are	B-X
EBV-susceptible	B-X
host	B-X
cells	B-X
.	B-X
EBV	B-X
latently	B-X
infects	B-X
B	B-X
cells	B-X
and	B-X
nasopharyngeal	B-X
epithelial	B-X
cells	B-X
throughout	B-X
life	B-X
in	B-X
most	B-X
immunologically	B-X
active	B-X
individuals	B-X
.	B-X
EBV-infected	B-X
cells	B-X
,	B-X
free	B-X
viruses	B-X
,	B-X
their	B-X
gene	B-X
products	B-X
,	B-X
and	B-X
abnormally	B-X
elevated	B-X
EBV	B-X
titers	B-X
are	B-X
observed	B-X
in	B-X
the	B-X
cerebrospinal	B-X
fluid	B-X
.	B-X
Studies	B-X
have	B-X
shown	B-X
that	B-X
EBV	B-X
can	B-X
infect	B-X
neurons	B-X
directly	B-X
or	B-X
indirectly	B-X

We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	O
.	O
<EOS>	B-X
In	B-X
an	B-X
effort	B-X
to	B-X
ascertain	B-X
whether	B-X
T	B-X
cells	B-X
are	B-X
susceptible	B-X
to	B-X
EBV	B-X
infection	B-X
,	B-X
we	B-X
and	B-X
others	B-X
have	B-X
detected	B-X
the	B-X
EBV	B-X
receptor	B-X
,	B-X
CD21	B-X
on	B-X
a	B-X
population	B-X
of	B-X
immature	B-X
thymocytes	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
EBV	B-X
is	B-X
a	B-X
cofactor	B-X
in	B-X
stimulating	B-X
proliferation	B-X
of	B-X
thymocytes	B-X
.	B-X
This	B-X
proliferation	B-X
may	B-X
be	B-X
a	B-X
relevant	B-X
factor	B-X
in	B-X
EBV-associated	B-X
T-cell	B-X
malignancies	B-X
as	B-X
well	B-X
as	B-X
EBV	B-X
causation	B-X
of	B-X
acute	B-X
infectious	B-X
mononucleosis	B-X
(	B-X
AIM	B-X
)	B-X
.	B-X
We	B-X
have	B-X
further	B-X
identified	B-X
a	B-X
subset	B-X
of	B-X
thymocytes	B-X
that	B-X
is	B-X
infectable	B-X
by	B-X
EBV	B-X
in	B-X
which	B-X
the	B-X
genome	B-X
remains	B-X
linear	B-X
in	B-X
the	B-X
first	B-X
weeks	B-X
after	B-X
infection	B-X
.	B-X
We	B-X
hypothesise	B-X
that	B-X
EBV	B-X
may	B-X
be	B-X
a	B-X
cofactor	B-X
in	B-X
oncogenesis	B-X
in	B-X
T	B-X
cells	B-X
through	B-X
several	B-X
different	B-X
pathways	B-X
.	B-X

Infection	O
of	O
thymocytes	O
was	O
accompanied	O
by	O
the	O
appearance	O
of	O
linear	O
EBV	O
genome	O
within	O
8	O
hr	O
of	O
infection	O
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
known	B-X
to	B-X
infect	B-X
B	B-X
cells	B-X
and	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
and	B-X
others	B-X
have	B-X
shown	B-X
that	B-X
EBV	B-X
can	B-X
also	B-X
infect	B-X
a	B-X
subset	B-X
of	B-X
thymocytes	B-X
.	B-X
Infection	B-X
of	B-X
thymocytes	B-X
was	B-X
accompanied	B-X
by	B-X
the	B-X
appearance	B-X
of	B-X
linear	B-X
EBV	B-X
genome	B-X
within	B-X
8	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
Circularization	B-X
of	B-X
the	B-X
EBV	B-X
genome	B-X
was	B-X
not	B-X
detected	B-X
.	B-X
This	B-X
is	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
infection	B-X
in	B-X
B	B-X
cells	B-X
where	B-X
the	B-X
genome	B-X
can	B-X
circularize	B-X
within	B-X
24	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
the	B-X
BamHI	B-X
ZLF-1	B-X
gene	B-X
product	B-X
,	B-X
ZEBRA	B-X
,	B-X
by	B-X
RT-PCR	B-X
,	B-X
was	B-X
observed	B-X
within	B-X
8	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
a	B-X
novel	B-X
fusion	B-X
transcript	B-X
(	B-X
RAZ	B-X
)	B-X
,	B-X
which	B-X
comprised	B-X
regions	B-X
of	B-X
the	B-X
BZLF-1	B-X
locus	B-X
and	B-X
the	B-X
adjacent	B-X
BRLF-1	B-X
locus	B-X
,	B-X
was	B-X
detected	B-X
by	B-X
RT-PCR	B-X
.	B-X
ZEBRA	B-X
protein	B-X
was	B-X
also	B-X
identified	B-X
in	B-X
infected	B-X
thymocytes	B-X
by	B-X
immunoprecipitation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
EBNA-1	B-X
gene	B-X
in	B-X
infected	B-X
thymocytes	B-X
was	B-X
transcribed	B-X
from	B-X
the	B-X
Fp	B-X
promoter	B-X
,	B-X
rather	B-X
than	B-X
from	B-X
the	B-X
Cp/Wp	B-X
promoter	B-X
which	B-X
is	B-X
used	B-X
in	B-X
latently	B-X
infected	B-X
B	B-X
cells	B-X
.	B-X
Transcripts	B-X
encoding	B-X
gp350/220	B-X
,	B-X
the	B-X
major	B-X
coat	B-X
protein	B-X
of	B-X
EBV	B-X
,	B-X
were	B-X
identified	B-X
,	B-X
but	B-X
we	B-X
did	B-X
not	B-X
find	B-X
any	B-X
evidence	B-X
of	B-X
transcription	B-X
from	B-X
the	B-X
LMP-2A	B-X
or	B-X
EBER-1	B-X
loci	B-X
in	B-X
infected	B-X
thymocytes	B-X
.	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
de	B-X
novo	B-X
EBV	B-X
infection	B-X
of	B-X
thymocytes	B-X
differs	B-X
from	B-X
infection	B-X
of	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
main	B-X
difference	B-X
is	B-X
that	B-X
with	B-X
thymocytes	B-X
,	B-X
no	B-X
evidence	B-X
could	B-X
be	B-X
found	B-X
that	B-X
the	B-X
virus	B-X
ever	B-X
circularizes	B-X
.	B-X
Rather	B-X
,	B-X
EBV	B-X
remains	B-X
in	B-X
a	B-X
linear	B-X
configuration	B-X
from	B-X
which	B-X
replicative	B-X
genes	B-X
are	B-X
transcribed	B-X
.	B-X

Circularization	O
of	O
the	O
EBV	O
genome	O
was	O
not	O
detected	O
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
infection	B-X
is	B-X
an	B-X
established	B-X
cause	B-X
of	B-X
nasopharyngeal	B-X
carcinoma	B-X
(	B-X
NPC	B-X
)	B-X
and	B-X
is	B-X
involved	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
malignant	B-X
phenotypes	B-X
,	B-X
including	B-X
tumor	B-X
immune	B-X
escape	B-X
.	B-X
EBV	B-X
can	B-X
encode	B-X
a	B-X
variety	B-X
of	B-X
circular	B-X
RNAs	B-X
(	B-X
circRNA	B-X
)	B-X
,	B-X
however	B-X
,	B-X
little	B-X
is	B-X
known	B-X
regarding	B-X
the	B-X
biological	B-X
functions	B-X
of	B-X
these	B-X
circRNAs	B-X
in	B-X
NPC	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
EBV-encoded	B-X
The	B-X
tumor	B-X
viruses	B-X
human	B-X
T-lymphotropic	B-X
virus	B-X
1	B-X
(	B-X
HTLV-1	B-X
)	B-X
,	B-X
hepatitis	B-X
C	B-X
virus	B-X
(	B-X
HCV	B-X
)	B-X
,	B-X
Merkel	B-X
cell	B-X
polyomavirus	B-X
(	B-X
MCPyV	B-X
)	B-X
,	B-X
high-risk	B-X
human	B-X
papillomaviruses	B-X
(	B-X
HR-HPVs	B-X
)	B-X
,	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
,	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpes	B-X
virus	B-X
(	B-X
KSHV	B-X
)	B-X
and	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
account	B-X
for	B-X
approximately	B-X
15	B-X
%	B-X
of	B-X
all	B-X
human	B-X
cancers	B-X
.	B-X

This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	O
cells	O
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
the	O
BamHI	B-Protein
ZLF	I-Protein
-	I-Protein
1	I-Protein
gene	O
product	O
,	O
ZEBRA	B-Protein
,	O
by	O
RT	O
-	O
PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
a	O
novel	O
fusion	O
transcript	O
(	O
RAZ	B-Protein
)	O
,	O
which	O
comprised	O
regions	O
of	O
the	O
BZLF	B-Protein
-	I-Protein
1	I-Protein
locus	O
and	O
the	O
adjacent	O
BRLF	B-Protein
-	I-Protein
1	I-Protein
locus	O
,	O
was	O
detected	O
by	O
RT	O
-	O
PCR	O
.	O

ZEBRA	B-Protein
protein	O
was	O
also	O
identified	O
in	O
infected	O
thymocytes	O
by	O
immunoprecipitation	O
.	O
<EOS>	B-X
We	B-X
and	B-X
others	B-X
have	B-X
shown	B-X
that	B-X
EBV	B-X
can	B-X
also	B-X
infect	B-X
a	B-X
subset	B-X
of	B-X
thymocytes	B-X
.	B-X
Infection	B-X
of	B-X
thymocytes	B-X
was	B-X
accompanied	B-X
by	B-X
the	B-X
appearance	B-X
of	B-X
linear	B-X
EBV	B-X
genome	B-X
within	B-X
8	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
the	B-X
BamHI	B-X
ZLF-1	B-X
gene	B-X
product	B-X
,	B-X
ZEBRA	B-X
,	B-X
by	B-X
RT-PCR	B-X
,	B-X
was	B-X
observed	B-X
within	B-X
8	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
ZEBRA	B-X
protein	B-X
was	B-X
also	B-X
identified	B-X
in	B-X
infected	B-X
thymocytes	B-X
by	B-X
immunoprecipitation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
EBNA-1	B-X
gene	B-X
in	B-X
infected	B-X
thymocytes	B-X
was	B-X
transcribed	B-X
from	B-X
the	B-X
Fp	B-X
promoter	B-X
,	B-X
rather	B-X
than	B-X
from	B-X
the	B-X
Cp/Wp	B-X
promoter	B-X
which	B-X
is	B-X
used	B-X
in	B-X
latently	B-X
infected	B-X
B	B-X
cells	B-X
.	B-X
Transcripts	B-X
encoding	B-X
gp350/220	B-X
,	B-X
the	B-X
major	B-X
coat	B-X
protein	B-X
of	B-X
EBV	B-X
,	B-X
were	B-X
identified	B-X
,	B-X
but	B-X
we	B-X
did	B-X
not	B-X
find	B-X
any	B-X
evidence	B-X
of	B-X
transcription	B-X
from	B-X
the	B-X
LMP-2A	B-X
or	B-X
EBER-1	B-X
loci	B-X
in	B-X
infected	B-X
thymocytes	B-X
.	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
de	B-X
novo	B-X
EBV	B-X
infection	B-X
of	B-X
thymocytes	B-X
differs	B-X
from	B-X
infection	B-X
of	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
main	B-X
difference	B-X
is	B-X
that	B-X
with	B-X
thymocytes	B-X
,	B-X
no	B-X
evidence	B-X
could	B-X
be	B-X
found	B-X
that	B-X
the	B-X
virus	B-X
ever	B-X
circularizes	B-X
.	B-X

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA	B-Protein
-	I-Protein
1	I-Protein
gene	O
in	O
infected	O
thymocytes	O
was	O
transcribed	O
from	O
the	O
Fp	O
promoter	O
,	O
rather	O
than	O
from	O
the	O
Cp	O
/	O
Wp	O
promoter	O
which	O
is	O
used	O
in	O
latently	O
infected	O
B	O
cells	O
.	O

Transcripts	O
encoding	O
gp350	B-Protein
/	I-Protein
220	I-Protein
,	O
the	O
major	O
coat	O
protein	O
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP	B-Protein
-	I-Protein
2A	I-Protein
or	O
EBER	B-Protein
-	I-Protein
1	I-Protein
loci	O
in	O
infected	O
thymocytes	O
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
known	B-X
to	B-X
infect	B-X
B	B-X
cells	B-X
and	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
and	B-X
others	B-X
have	B-X
shown	B-X
that	B-X
EBV	B-X
can	B-X
also	B-X
infect	B-X
a	B-X
subset	B-X
of	B-X
thymocytes	B-X
.	B-X
Infection	B-X
of	B-X
thymocytes	B-X
was	B-X
accompanied	B-X
by	B-X
the	B-X
appearance	B-X
of	B-X
linear	B-X
EBV	B-X
genome	B-X
within	B-X
8	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
Circularization	B-X
of	B-X
the	B-X
EBV	B-X
genome	B-X
was	B-X
not	B-X
detected	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
the	B-X
BamHI	B-X
ZLF-1	B-X
gene	B-X
product	B-X
,	B-X
ZEBRA	B-X
,	B-X
by	B-X
RT-PCR	B-X
,	B-X
was	B-X
observed	B-X
within	B-X
8	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
a	B-X
novel	B-X
fusion	B-X
transcript	B-X
(	B-X
RAZ	B-X
)	B-X
,	B-X
which	B-X
comprised	B-X
regions	B-X
of	B-X
the	B-X
BZLF-1	B-X
locus	B-X
and	B-X
the	B-X
adjacent	B-X
BRLF-1	B-X
locus	B-X
,	B-X
was	B-X
detected	B-X
by	B-X
RT-PCR	B-X
.	B-X
ZEBRA	B-X
protein	B-X
was	B-X
also	B-X
identified	B-X
in	B-X
infected	B-X
thymocytes	B-X
by	B-X
immunoprecipitation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
EBNA-1	B-X
gene	B-X
in	B-X
infected	B-X
thymocytes	B-X
was	B-X
transcribed	B-X
from	B-X
the	B-X
Fp	B-X
promoter	B-X
,	B-X
rather	B-X
than	B-X
from	B-X
the	B-X
Cp/Wp	B-X
promoter	B-X
which	B-X
is	B-X
used	B-X
in	B-X
latently	B-X
infected	B-X
B	B-X
cells	B-X
.	B-X
Transcripts	B-X
encoding	B-X
gp350/220	B-X
,	B-X
the	B-X
major	B-X
coat	B-X
protein	B-X
of	B-X
EBV	B-X
,	B-X
were	B-X
identified	B-X
,	B-X
but	B-X
we	B-X
did	B-X
not	B-X
find	B-X
any	B-X
evidence	B-X
of	B-X
transcription	B-X
from	B-X
the	B-X
LMP-2A	B-X
or	B-X
EBER-1	B-X
loci	B-X
in	B-X
infected	B-X
thymocytes	B-X
.	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
de	B-X
novo	B-X
EBV	B-X
infection	B-X
of	B-X
thymocytes	B-X
differs	B-X
from	B-X
infection	B-X
of	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
main	B-X
difference	B-X
is	B-X
that	B-X
with	B-X
thymocytes	B-X
,	B-X
no	B-X
evidence	B-X
could	B-X
be	B-X
found	B-X
that	B-X
the	B-X
virus	B-X
ever	B-X
circularizes	B-X
.	B-X
Rather	B-X
,	B-X
EBV	B-X
remains	B-X
in	B-X
a	B-X
linear	B-X
configuration	B-X
from	B-X
which	B-X
replicative	B-X
genes	B-X
are	B-X
transcribed	B-X
.	B-X

These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	O
differs	O
from	O
infection	O
of	O
B	O
cells	O
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
known	B-X
to	B-X
infect	B-X
B	B-X
cells	B-X
and	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
and	B-X
others	B-X
have	B-X
shown	B-X
that	B-X
EBV	B-X
can	B-X
also	B-X
infect	B-X
a	B-X
subset	B-X
of	B-X
thymocytes	B-X
.	B-X
Infection	B-X
of	B-X
thymocytes	B-X
was	B-X
accompanied	B-X
by	B-X
the	B-X
appearance	B-X
of	B-X
linear	B-X
EBV	B-X
genome	B-X
within	B-X
8	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
Circularization	B-X
of	B-X
the	B-X
EBV	B-X
genome	B-X
was	B-X
not	B-X
detected	B-X
.	B-X
This	B-X
is	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
infection	B-X
in	B-X
B	B-X
cells	B-X
where	B-X
the	B-X
genome	B-X
can	B-X
circularize	B-X
within	B-X
24	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
the	B-X
BamHI	B-X
ZLF-1	B-X
gene	B-X
product	B-X
,	B-X
ZEBRA	B-X
,	B-X
by	B-X
RT-PCR	B-X
,	B-X
was	B-X
observed	B-X
within	B-X
8	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
a	B-X
novel	B-X
fusion	B-X
transcript	B-X
(	B-X
RAZ	B-X
)	B-X
,	B-X
which	B-X
comprised	B-X
regions	B-X
of	B-X
the	B-X
BZLF-1	B-X
locus	B-X
and	B-X
the	B-X
adjacent	B-X
BRLF-1	B-X
locus	B-X
,	B-X
was	B-X
detected	B-X
by	B-X
RT-PCR	B-X
.	B-X
ZEBRA	B-X
protein	B-X
was	B-X
also	B-X
identified	B-X
in	B-X
infected	B-X
thymocytes	B-X
by	B-X
immunoprecipitation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
EBNA-1	B-X
gene	B-X
in	B-X
infected	B-X
thymocytes	B-X
was	B-X
transcribed	B-X
from	B-X
the	B-X
Fp	B-X
promoter	B-X
,	B-X
rather	B-X
than	B-X
from	B-X
the	B-X
Cp/Wp	B-X
promoter	B-X
which	B-X
is	B-X
used	B-X
in	B-X
latently	B-X
infected	B-X
B	B-X
cells	B-X
.	B-X
Transcripts	B-X
encoding	B-X
gp350/220	B-X
,	B-X
the	B-X
major	B-X
coat	B-X
protein	B-X
of	B-X
EBV	B-X
,	B-X
were	B-X
identified	B-X
,	B-X
but	B-X
we	B-X
did	B-X
not	B-X
find	B-X
any	B-X
evidence	B-X
of	B-X
transcription	B-X
from	B-X
the	B-X
LMP-2A	B-X
or	B-X
EBER-1	B-X
loci	B-X
in	B-X
infected	B-X
thymocytes	B-X
.	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
de	B-X
novo	B-X
EBV	B-X
infection	B-X
of	B-X
thymocytes	B-X
differs	B-X
from	B-X
infection	B-X
of	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
main	B-X
difference	B-X
is	B-X
that	B-X
with	B-X
thymocytes	B-X
,	B-X
no	B-X
evidence	B-X
could	B-X
be	B-X
found	B-X
that	B-X
the	B-X
virus	B-X
ever	B-X
circularizes	B-X
.	B-X
Rather	B-X
,	B-X
EBV	B-X
remains	B-X
in	B-X
a	B-X
linear	B-X
configuration	B-X
from	B-X
which	B-X
replicative	B-X
genes	B-X
are	B-X
transcribed	B-X
.	B-X

The	O
main	O
difference	O
is	O
that	O
with	O
thymocytes	O
,	O
no	O
evidence	O
could	O
be	O
found	O
that	O
the	O
virus	O
ever	O
circularizes	O
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
known	B-X
to	B-X
infect	B-X
B	B-X
cells	B-X
and	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
and	B-X
others	B-X
have	B-X
shown	B-X
that	B-X
EBV	B-X
can	B-X
also	B-X
infect	B-X
a	B-X
subset	B-X
of	B-X
thymocytes	B-X
.	B-X
Infection	B-X
of	B-X
thymocytes	B-X
was	B-X
accompanied	B-X
by	B-X
the	B-X
appearance	B-X
of	B-X
linear	B-X
EBV	B-X
genome	B-X
within	B-X
8	B-X
hr	B-X
of	B-X
infection	B-X
.	B-X
ZEBRA	B-X
protein	B-X
was	B-X
also	B-X
identified	B-X
in	B-X
infected	B-X
thymocytes	B-X
by	B-X
immunoprecipitation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
EBNA-1	B-X
gene	B-X
in	B-X
infected	B-X
thymocytes	B-X
was	B-X
transcribed	B-X
from	B-X
the	B-X
Fp	B-X
promoter	B-X
,	B-X
rather	B-X
than	B-X
from	B-X
the	B-X
Cp/Wp	B-X
promoter	B-X
which	B-X
is	B-X
used	B-X
in	B-X
latently	B-X
infected	B-X
B	B-X
cells	B-X
.	B-X
Transcripts	B-X
encoding	B-X
gp350/220	B-X
,	B-X
the	B-X
major	B-X
coat	B-X
protein	B-X
of	B-X
EBV	B-X
,	B-X
were	B-X
identified	B-X
,	B-X
but	B-X
we	B-X
did	B-X
not	B-X
find	B-X
any	B-X
evidence	B-X
of	B-X
transcription	B-X
from	B-X
the	B-X
LMP-2A	B-X
or	B-X
EBER-1	B-X
loci	B-X
in	B-X
infected	B-X
thymocytes	B-X
.	B-X
These	B-X
observations	B-X
suggest	B-X
that	B-X
de	B-X
novo	B-X
EBV	B-X
infection	B-X
of	B-X
thymocytes	B-X
differs	B-X
from	B-X
infection	B-X
of	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
main	B-X
difference	B-X
is	B-X
that	B-X
with	B-X
thymocytes	B-X
,	B-X
no	B-X
evidence	B-X
could	B-X
be	B-X
found	B-X
that	B-X
the	B-X
virus	B-X
ever	B-X
circularizes	B-X
.	B-X
Rather	B-X
,	B-X
EBV	B-X
remains	B-X
in	B-X
a	B-X
linear	B-X
configuration	B-X
from	B-X
which	B-X
replicative	B-X
genes	B-X
are	B-X
transcribed	B-X
.	B-X

Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	O
genes	O
are	O
transcribed	O
.	O

Induction	O
of	O
Sp1	B-Protein
phosphorylation	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
independent	O
HIV	O
promoter	O
domain	O
activity	O
in	O
T	O
lymphocytes	O
stimulated	O
by	O
okadaic	O
acid	O
.	O

In	O
contrast	O
to	O
the	O
purely	O
enhancer	O
-	O
dependent	O
effect	O
of	O
cytokines	O
such	O
as	O
TNF	O
on	O
the	O
activity	O
of	O
the	O
HIV	O
regulatory	O
region	O
(	O
LTR	O
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
the	O
promoter	O
domain	O
of	O
the	O
LTR	O
.	O

The	O
inducibility	O
of	O
HIV	O
LTR	O
-	O
driven	O
luciferase	O
expression	O
constructs	O
in	O
lymphoblastoid	O
cells	O
stimulated	O
by	O
OKA	O
depended	O
on	O
both	O
functional	O
Sp1	B-Protein
binding	O
elements	O
and	O
the	O
ability	O
of	O
the	O
TATA	O
box	O
to	O
bind	O
the	O
protein	O
TBP	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
purely	B-X
enhancer-dependent	B-X
effect	B-X
of	B-X
cytokines	B-X
such	B-X
as	B-X
TNF	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
HIV	B-X
regulatory	B-X
region	B-X
(	B-X
LTR	B-X
)	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
okadaic	B-X
acid	B-X
(	B-X
OKA	B-X
)	B-X
activates	B-X
HIV	B-X
transcription	B-X
through	B-X
both	B-X
the	B-X
enhancer	B-X
,	B-X
responding	B-X
to	B-X
the	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
and	B-X
the	B-X
promoter	B-X
domain	B-X
of	B-X
the	B-X
LTR	B-X
.	B-X
The	B-X
inducibility	B-X
of	B-X
HIV	B-X
LTR-driven	B-X
luciferase	B-X
expression	B-X
constructs	B-X
in	B-X
lymphoblastoid	B-X
cells	B-X
stimulated	B-X
by	B-X
OKA	B-X
depended	B-X
on	B-X
both	B-X
functional	B-X
Sp1	B-X
binding	B-X
elements	B-X
and	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
TATA	B-X
box	B-X
to	B-X
bind	B-X
the	B-X
protein	B-X
TBP	B-X
.	B-X
In	B-X
both	B-X
transformed	B-X
and	B-X
normal	B-X
lymphocytes	B-X
,	B-X
OKA	B-X
stimulation	B-X
induced	B-X
intense	B-X
phosphorylation	B-X
of	B-X
the	B-X
constitutively	B-X
expressed	B-X
Sp1	B-X
protein	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
a	B-X
property	B-X
of	B-X
OKA	B-X
not	B-X
shared	B-X
by	B-X
TNF	B-X
,	B-X
phorbol	B-X
ester	B-X
,	B-X
or	B-X
PHA	B-X
and	B-X
interleukin	B-X
2	B-X
.	B-X
Responsiveness	B-X
of	B-X
LTR	B-X
constructs	B-X
deleted	B-X
of	B-X
kappa	B-X
B	B-X
elements	B-X
to	B-X
HIV	B-X
Tat	B-X
expression	B-X
was	B-X
increased	B-X
upon	B-X
OKA	B-X
but	B-X
not	B-X
TNF	B-X
stimulation	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
SP1	B-X
phosphorylation	B-X
induced	B-X
by	B-X
OKA	B-X
,	B-X
a	B-X
selective	B-X
inhibitor	B-X
of	B-X
the	B-X
serine-threonine	B-X
phosphatase	B-X
PP2A	B-X
,	B-X
facilitates	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
transcription	B-X
complex	B-X
involving	B-X
general	B-X
transcription	B-X
factors	B-X
,	B-X
HIV	B-X
Tat	B-X
,	B-X
and	B-X
Sp1	B-X
proteins	B-X
.	B-X
The	B-X
formation	B-X
of	B-X
this	B-X
complex	B-X
would	B-X
increase	B-X
,	B-X
independently	B-X
of	B-X
an	B-X
in	B-X
synergy	B-X
with	B-X
NF-kappa	B-X
B	B-X
,	B-X
the	B-X
low	B-X
basal	B-X
activity	B-X
of	B-X
the	B-X
HIV	B-X
LTR	B-X
observed	B-X
in	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X

In	O
both	O
transformed	O
and	O
normal	O
lymphocytes	O
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	B-Protein
protein	O
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	O
,	O
phorbol	O
ester	O
,	O
or	O
PHA	B-Protein
and	O
interleukin	B-Protein
2	I-Protein
.	O
<EOS>	B-X
Interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
is	B-X
a	B-X
T	B-X
cell	B-X
growth	B-X
factor	B-X
and	B-X
major	B-X
modulator	B-X
of	B-X
T	B-X
helper	B-X
(	B-X
Th	B-X
)	B-X
cell	B-X
differentiation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
and	B-X
characterized	B-X
a	B-X
monoclonal	B-X
antibody	B-X
to	B-X
equine	B-X
IL-2	B-X
(	B-X
anti-IL-2	B-X
mAb	B-X
,	B-X
clone	B-X
158-1	B-X
)	B-X
.	B-X
The	B-X
IL-2	B-X
mAb	B-X
detected	B-X
rIL-2	B-X
by	B-X
ELISA	B-X
,	B-X
intracellular	B-X
staining	B-X
and	B-X
flow	B-X
cytometry	B-X
analysis	B-X
and	B-X
Western	B-X
blotting	B-X
.	B-X
The	B-X
IL-2	B-X
mAb	B-X
was	B-X
also	B-X
paired	B-X
with	B-X
a	B-X
polyclonal	B-X
IL-2	B-X
detection	B-X
antibody	B-X
in	B-X
both	B-X
ELISA	B-X
and	B-X
a	B-X
fluorescent	B-X
bead-based	B-X
assay	B-X
.	B-X
When	B-X
these	B-X
two	B-X
assays	B-X
were	B-X
compared	B-X
using	B-X
identical	B-X
reagents	B-X
there	B-X
was	B-X
an	B-X
improved	B-X
analytical	B-X
sensitivity	B-X
(	B-X
46pg/ml	B-X
)	B-X
and	B-X
wider	B-X
linear	B-X
quantification	B-X
range	B-X
(	B-X
46-100,000pg/ml	B-X
)	B-X
of	B-X
IL-2	B-X
quantification	B-X
using	B-X
the	B-X
fluorescent	B-X
bead	B-X
assay	B-X
.	B-X
Equine	B-X
rIL-2	B-X
standards	B-X
were	B-X
expressed	B-X
in	B-X
both	B-X
yeast	B-X
and	B-X
mammalian	B-X
cells	B-X
but	B-X
the	B-X
mammalian	B-X
cell-expressed	B-X
rIL-2	B-X
standard	B-X
was	B-X
found	B-X
to	B-X
be	B-X
most	B-X
accurate	B-X
for	B-X
native	B-X
IL-2	B-X
quantification	B-X
.	B-X
Using	B-X
this	B-X
system	B-X
we	B-X
found	B-X
that	B-X
stimulation	B-X
of	B-X
equine	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
ionomycin	B-X
induced	B-X
IL-2	B-X
secretion	B-X
most	B-X
potently	B-X
.	B-X
Pokeweed	B-X
mitogen	B-X
(	B-X
PWM	B-X
)	B-X
consistently	B-X
resulted	B-X
in	B-X
low	B-X
amounts	B-X
of	B-X
IL-2	B-X
from	B-X
PBMC	B-X
,	B-X
while	B-X
concanavalin	B-X
A	B-X
(	B-X
ConA	B-X
)	B-X
,	B-X
phytohemagglutinin-L	B-X
(	B-X
PHA-L	B-X
)	B-X
and	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
either	B-X
marginally	B-X
stimulated	B-X
or	B-X
failed	B-X
to	B-X
stimulate	B-X
IL-2	B-X
secretion	B-X
from	B-X
equine	B-X
PBMC	B-X
.	B-X
After	B-X
stimulation	B-X
of	B-X
equine	B-X
PBMC	B-X
with	B-X
PMA	B-X
and	B-X
ionomycin	B-X
,	B-X
IL-2	B-X
production	B-X
was	B-X
detected	B-X
in	B-X
13.0	B-X
%	B-X
(	B-X
range	B-X
7.5-16.8	B-X
%	B-X
)	B-X
of	B-X
the	B-X
lymphocytes	B-X
by	B-X
flow	B-X
cytometric	B-X
analysis	B-X
.	B-X
IL-2	B-X
expression	B-X
was	B-X
mainly	B-X
stimulated	B-X
in	B-X
CD4	B-X

Responsiveness	O
of	O
LTR	O
constructs	O
deleted	O
of	O
kappa	O
B	O
elements	O
to	O
HIV	O
Tat	B-Protein
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	O
stimulation	O
.	O

Our	O
results	O
suggest	O
that	O
SP1	B-Protein
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine	O
-	O
threonine	O
phosphatase	O
PP2A	B-Protein
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	O
complex	O
involving	O
general	O
transcription	O
factors	O
,	O
HIV	O
Tat	B-Protein
,	O
and	O
Sp1	B-Protein
proteins	O
.	O

The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF	O
-	O
kappa	O
B	O
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	O
LTR	O
observed	O
in	O
normal	O
T	O
lymphocytes	O
.	O

Human	O
MHC	O
class	O
II	O
gene	O
transcription	O
directed	O
by	O
the	O
carboxyl	O
terminus	O
of	O
CIITA	B-Protein
,	O
one	O
of	O
the	O
defective	O
genes	O
in	O
type	O
II	O
MHC	O
combined	O
immune	O
deficiency	O
.	O
<EOS>	B-X
Type	B-X
II	B-X
major	B-X
histocompatibility	B-X
complex	B-X
combined	B-X
immune	B-X
deficiency	B-X
(	B-X
type	B-X
II	B-X
MHC	B-X
CID	B-X
or	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
)	B-X
is	B-X
a	B-X
congenital	B-X
immunodeficiency	B-X
disease	B-X
characterized	B-X
by	B-X
absent	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
defective	B-X
gene	B-X
in	B-X
group	B-X
II	B-X
type	B-X
II	B-X
MHC	B-X
CID	B-X
has	B-X
been	B-X
isolated	B-X
and	B-X
termed	B-X
CIITA	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
CIITA	B-X
is	B-X
an	B-X
MHC	B-X
class	B-X
II	B-X
gene-specific	B-X
transcription	B-X
activator	B-X
.	B-X
The	B-X
transcription	B-X
activation	B-X
function	B-X
is	B-X
provided	B-X
by	B-X
the	B-X
N-terminal	B-X
acidic	B-X
domain	B-X
(	B-X
amino	B-X
acids	B-X
26-137	B-X
)	B-X
,	B-X
which	B-X
is	B-X
experimentally	B-X
exchangeable	B-X
with	B-X
a	B-X
heterologous	B-X
viral	B-X
transcription-activating	B-X
domain	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
CIITA	B-X
for	B-X
three	B-X
major	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
DR	B-X
,	B-X
DQ	B-X
and	B-X
DP	B-X
,	B-X
is	B-X
mediated	B-X
by	B-X
its	B-X
remaining	B-X
C-terminal	B-X
residues	B-X
(	B-X
amino	B-X
acids	B-X
317-1130	B-X
)	B-X
.	B-X
The	B-X
transactivation	B-X
of	B-X
multiple	B-X
cis	B-X
elements	B-X
,	B-X
especially	B-X
S	B-X
and	B-X
X2	B-X
,	B-X
of	B-X
the	B-X
DR	B-X
alpha	B-X
proximal	B-X
promoter	B-X
in	B-X
group	B-X
II	B-X
CID	B-X
cells	B-X
is	B-X
CIITA	B-X
dependent	B-X
.	B-X
Since	B-X
CIITA	B-X
overexpression	B-X
in	B-X
normal	B-X
cells	B-X
did	B-X
not	B-X
increase	B-X
class	B-X
II	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
initiation	B-X
of	B-X
CIITA	B-X
expression	B-X
serves	B-X
as	B-X
the	B-X
on-off	B-X
switch	B-X
,	B-X
while	B-X
availability	B-X
of	B-X
downstream	B-X
interactor	B-X
(	B-X
s	B-X
)	B-X
limits	B-X
transcription	B-X
.	B-X

Type	O
II	O
major	O
histocompatibility	O
complex	O
combined	O
immune	O
deficiency	O
(	O
type	O
II	O
MHC	O
CID	O
or	O
bare	O
lymphocyte	O
syndrome	O
)	O
is	O
a	O
congenital	O
immunodeficiency	O
disease	O
characterized	O
by	O
absent	O
MHC	O
class	O
II	O
expression	O
.	O
<EOS>	B-X
Type	B-X
II	B-X
major	B-X
histocompatibility	B-X
complex	B-X
combined	B-X
immune	B-X
deficiency	B-X
(	B-X
type	B-X
II	B-X
MHC	B-X
CID	B-X
or	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
)	B-X
is	B-X
a	B-X
congenital	B-X
immunodeficiency	B-X
disease	B-X
characterized	B-X
by	B-X
absent	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
defective	B-X
gene	B-X
in	B-X
group	B-X
II	B-X
type	B-X
II	B-X
MHC	B-X
CID	B-X
has	B-X
been	B-X
isolated	B-X
and	B-X
termed	B-X
CIITA	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
CIITA	B-X
is	B-X
an	B-X
MHC	B-X
class	B-X
II	B-X
gene-specific	B-X
transcription	B-X
activator	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
CIITA	B-X
for	B-X
three	B-X
major	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
DR	B-X
,	B-X
DQ	B-X
and	B-X
DP	B-X
,	B-X
is	B-X
mediated	B-X
by	B-X
its	B-X
remaining	B-X
C-terminal	B-X
residues	B-X
(	B-X
amino	B-X
acids	B-X
317-1130	B-X
)	B-X
.	B-X
The	B-X
transactivation	B-X
of	B-X
multiple	B-X
cis	B-X
elements	B-X
,	B-X
especially	B-X
S	B-X
and	B-X
X2	B-X
,	B-X
of	B-X
the	B-X
DR	B-X
alpha	B-X
proximal	B-X
promoter	B-X
in	B-X
group	B-X
II	B-X
CID	B-X
cells	B-X
is	B-X
CIITA	B-X
dependent	B-X
.	B-X
Since	B-X
CIITA	B-X
overexpression	B-X
in	B-X
normal	B-X
cells	B-X
did	B-X
not	B-X
increase	B-X
class	B-X
II	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
initiation	B-X
of	B-X
CIITA	B-X
expression	B-X
serves	B-X
as	B-X
the	B-X
on-off	B-X
switch	B-X
,	B-X
while	B-X
availability	B-X
of	B-X
downstream	B-X
interactor	B-X
(	B-X
s	B-X
)	B-X
limits	B-X
transcription	B-X
.	B-X

Four	O
distinct	O
complementation	O
groups	O
have	O
been	O
identified	O
.	O
<EOS>	B-X
Only	B-X
few	B-X
enzymes	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
peroxisomal	B-X
proteins	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
so	B-X
far	B-X
;	B-X
the	B-X
three	B-X
enzymes	B-X
involved	B-X
in	B-X
beta-oxidation	B-X
of	B-X
fatty	B-X
acids	B-X
,	B-X
enzymes	B-X
of	B-X
the	B-X
glyoxylate	B-X
cycle	B-X
,	B-X
catalase	B-X
A	B-X
and	B-X
the	B-X
PAS3	B-X
gene	B-X
product	B-X
have	B-X
been	B-X
unequivocally	B-X
assigned	B-X
to	B-X
the	B-X
peroxisomal	B-X
compartment	B-X
.	B-X
These	B-X
mutants	B-X
could	B-X
be	B-X
divided	B-X
in	B-X
two	B-X
groups	B-X
:	B-X
those	B-X
with	B-X
defects	B-X
in	B-X
structural	B-X
genes	B-X
of	B-X
beta-oxidation	B-X
enzymes	B-X
(	B-X
fox-mutants	B-X
)	B-X
and	B-X
those	B-X
with	B-X
defects	B-X
in	B-X
peroxisomal	B-X
assembly	B-X
(	B-X
pas-mutants	B-X
)	B-X
.	B-X
All	B-X
fox-mutants	B-X
possess	B-X
morphologically	B-X
normal	B-X
peroxisomes	B-X
and	B-X
can	B-X
be	B-X
assigned	B-X
to	B-X
one	B-X
of	B-X
three	B-X
complementation	B-X
groups	B-X
(	B-X
FOX1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
)	B-X
.	B-X
The	B-X
pas-mutants	B-X
isolated	B-X
are	B-X
distributed	B-X
among	B-X
13	B-X
complementation	B-X
groups	B-X
and	B-X
represent	B-X
3	B-X
different	B-X
classes	B-X
:	B-X
peroxisomes	B-X
are	B-X
either	B-X
morphologically	B-X
not	B-X
detectable	B-X
(	B-X
type	B-X
I	B-X
)	B-X
or	B-X
present	B-X
but	B-X
non-proliferating	B-X
(	B-X
type	B-X
II	B-X
)	B-X
.	B-X
The	B-X
third	B-X
class	B-X
of	B-X
mutants	B-X
contains	B-X
peroxisomes	B-X
normal	B-X
in	B-X
size	B-X
and	B-X
number	B-X
,	B-X
however	B-X
,	B-X
distinct	B-X
peroxisomal	B-X
matrix	B-X
proteins	B-X
are	B-X
mislocalized	B-X
(	B-X
type	B-X
III	B-X
)	B-X
.	B-X
Five	B-X
additional	B-X
complementation	B-X
groups	B-X
were	B-X
found	B-X
in	B-X
the	B-X
laboratory	B-X
of	B-X
H.F.	B-X
Tabak	B-X
.	B-X

Recently	O
,	O
the	O
defective	O
gene	O
in	O
group	O
II	O
type	O
II	O
MHC	O
CID	O
has	O
been	O
isolated	O
and	O
termed	O
CIITA	B-Protein
.	O
<EOS>	B-X
Type	B-X
II	B-X
major	B-X
histocompatibility	B-X
complex	B-X
combined	B-X
immune	B-X
deficiency	B-X
(	B-X
type	B-X
II	B-X
MHC	B-X
CID	B-X
or	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
)	B-X
is	B-X
a	B-X
congenital	B-X
immunodeficiency	B-X
disease	B-X
characterized	B-X
by	B-X
absent	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
.	B-X
Four	B-X
distinct	B-X
complementation	B-X
groups	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
defective	B-X
gene	B-X
in	B-X
group	B-X
II	B-X
type	B-X
II	B-X
MHC	B-X
CID	B-X
has	B-X
been	B-X
isolated	B-X
and	B-X
termed	B-X
CIITA	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
CIITA	B-X
is	B-X
an	B-X
MHC	B-X
class	B-X
II	B-X
gene-specific	B-X
transcription	B-X
activator	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
CIITA	B-X
for	B-X
three	B-X
major	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
DR	B-X
,	B-X
DQ	B-X
and	B-X
DP	B-X
,	B-X
is	B-X
mediated	B-X
by	B-X
its	B-X
remaining	B-X
C-terminal	B-X
residues	B-X
(	B-X
amino	B-X
acids	B-X
317-1130	B-X
)	B-X
.	B-X
The	B-X
transactivation	B-X
of	B-X
multiple	B-X
cis	B-X
elements	B-X
,	B-X
especially	B-X
S	B-X
and	B-X
X2	B-X
,	B-X
of	B-X
the	B-X
DR	B-X
alpha	B-X
proximal	B-X
promoter	B-X
in	B-X
group	B-X
II	B-X
CID	B-X
cells	B-X
is	B-X
CIITA	B-X
dependent	B-X
.	B-X
Since	B-X
CIITA	B-X
overexpression	B-X
in	B-X
normal	B-X
cells	B-X
did	B-X
not	B-X
increase	B-X
class	B-X
II	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
initiation	B-X
of	B-X
CIITA	B-X
expression	B-X
serves	B-X
as	B-X
the	B-X
on-off	B-X
switch	B-X
,	B-X
while	B-X
availability	B-X
of	B-X
downstream	B-X
interactor	B-X
(	B-X
s	B-X
)	B-X
limits	B-X
transcription	B-X
.	B-X

Here	O
,	O
we	O
demonstrate	O
that	O
CIITA	B-Protein
is	O
an	O
MHC	O
class	O
II	O
gene	O
-	O
specific	O
transcription	O
activator	O
.	O
<EOS>	B-X
By	B-X
virtue	B-X
of	B-X
its	B-X
control	B-X
over	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
(	B-X
MHC-II	B-X
)	B-X
gene	B-X
expression	B-X
,	B-X
CIITA	B-X
represents	B-X
a	B-X
key	B-X
molecule	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
adaptive	B-X
immune	B-X
responses	B-X
.	B-X
It	B-X
was	B-X
first	B-X
identified	B-X
as	B-X
a	B-X
factor	B-X
that	B-X
is	B-X
defective	B-X
in	B-X
MHC-II	B-X
deficiency	B-X
,	B-X
a	B-X
hereditary	B-X
disease	B-X
characterized	B-X
by	B-X
the	B-X
absence	B-X
of	B-X
MHC-II	B-X
expression	B-X
.	B-X
CIITA	B-X
is	B-X
a	B-X
highly	B-X
regulated	B-X
transactivator	B-X
that	B-X
governs	B-X
all	B-X
spatial	B-X
,	B-X
temporal	B-X
,	B-X
and	B-X
quantitative	B-X
aspects	B-X
of	B-X
MHC-II	B-X
expression	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
act	B-X
as	B-X
a	B-X
non-DNA-binding	B-X
transcriptional	B-X
coactivator	B-X
,	B-X
but	B-X
evidence	B-X
that	B-X
it	B-X
actually	B-X
functions	B-X
at	B-X
the	B-X
level	B-X
of	B-X
MHC-II	B-X
promoters	B-X
was	B-X
lacking	B-X
.	B-X
By	B-X
means	B-X
of	B-X
chromatin	B-X
immunoprecipitation	B-X
assays	B-X
,	B-X
we	B-X
show	B-X
here	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
CIITA	B-X
is	B-X
physically	B-X
associated	B-X
with	B-X
MHC-II	B-X
,	B-X
as	B-X
well	B-X
as	B-X
HLA-DM	B-X
,	B-X
Ii	B-X
,	B-X
MHC-I	B-X
,	B-X
and	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
m	B-X
promoters	B-X
in	B-X
vivo	B-X
.	B-X
To	B-X
dissect	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
CIITA	B-X
is	B-X
recruited	B-X
to	B-X
the	B-X
promoter	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
a	B-X
DNA-dependent	B-X
coimmunoprecipitation	B-X
assay	B-X
and	B-X
a	B-X
pull-down	B-X
assay	B-X
using	B-X
immobilized	B-X
promoter	B-X
templates	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
CIITA	B-X
recruitment	B-X
depends	B-X
on	B-X
multiple	B-X
,	B-X
synergistic	B-X
protein-protein	B-X
interactions	B-X
with	B-X
DNA-bound	B-X
factors	B-X
constituting	B-X
the	B-X
MHC-II	B-X
enhanceosome	B-X
.	B-X
CIITA	B-X
therefore	B-X
represents	B-X
a	B-X
paradigm	B-X
for	B-X
a	B-X
novel	B-X
type	B-X
of	B-X
regulatory	B-X
and	B-X
gene-specific	B-X
transcriptional	B-X
cofactor	B-X
.	B-X

The	O
transcription	O
activation	O
function	O
is	O
provided	O
by	O
the	O
N	O
-	O
terminal	O
acidic	O
domain	O
(	O
amino	O
acids	O
26	O
-	O
137	O
)	O
,	O
which	O
is	O
experimentally	O
exchangeable	O
with	O
a	O
heterologous	O
viral	O
transcription	O
-	O
activating	O
domain	O
.	O

The	O
specificity	O
of	O
CIITA	B-Protein
for	O
three	O
major	O
MHC	O
class	O
II	O
genes	O
,	O
DR	O
,	O
DQ	O
and	O
DP	O
,	O
is	O
mediated	O
by	O
its	O
remaining	O
C	O
-	O
terminal	O
residues	O
(	O
amino	O
acids	O
317	O
-	O
1130	O
)	O
.	O
<EOS>	B-X
Type	B-X
II	B-X
major	B-X
histocompatibility	B-X
complex	B-X
combined	B-X
immune	B-X
deficiency	B-X
(	B-X
type	B-X
II	B-X
MHC	B-X
CID	B-X
or	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
)	B-X
is	B-X
a	B-X
congenital	B-X
immunodeficiency	B-X
disease	B-X
characterized	B-X
by	B-X
absent	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
defective	B-X
gene	B-X
in	B-X
group	B-X
II	B-X
type	B-X
II	B-X
MHC	B-X
CID	B-X
has	B-X
been	B-X
isolated	B-X
and	B-X
termed	B-X
CIITA	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
CIITA	B-X
is	B-X
an	B-X
MHC	B-X
class	B-X
II	B-X
gene-specific	B-X
transcription	B-X
activator	B-X
.	B-X
The	B-X
transcription	B-X
activation	B-X
function	B-X
is	B-X
provided	B-X
by	B-X
the	B-X
N-terminal	B-X
acidic	B-X
domain	B-X
(	B-X
amino	B-X
acids	B-X
26-137	B-X
)	B-X
,	B-X
which	B-X
is	B-X
experimentally	B-X
exchangeable	B-X
with	B-X
a	B-X
heterologous	B-X
viral	B-X
transcription-activating	B-X
domain	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
CIITA	B-X
for	B-X
three	B-X
major	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
DR	B-X
,	B-X
DQ	B-X
and	B-X
DP	B-X
,	B-X
is	B-X
mediated	B-X
by	B-X
its	B-X
remaining	B-X
C-terminal	B-X
residues	B-X
(	B-X
amino	B-X
acids	B-X
317-1130	B-X
)	B-X
.	B-X
The	B-X
transactivation	B-X
of	B-X
multiple	B-X
cis	B-X
elements	B-X
,	B-X
especially	B-X
S	B-X
and	B-X
X2	B-X
,	B-X
of	B-X
the	B-X
DR	B-X
alpha	B-X
proximal	B-X
promoter	B-X
in	B-X
group	B-X
II	B-X
CID	B-X
cells	B-X
is	B-X
CIITA	B-X
dependent	B-X
.	B-X
Since	B-X
CIITA	B-X
overexpression	B-X
in	B-X
normal	B-X
cells	B-X
did	B-X
not	B-X
increase	B-X
class	B-X
II	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
initiation	B-X
of	B-X
CIITA	B-X
expression	B-X
serves	B-X
as	B-X
the	B-X
on-off	B-X
switch	B-X
,	B-X
while	B-X
availability	B-X
of	B-X
downstream	B-X
interactor	B-X
(	B-X
s	B-X
)	B-X
limits	B-X
transcription	B-X
.	B-X

The	O
transactivation	O
of	O
multiple	O
cis	O
elements	O
,	O
especially	O
S	O
and	O
X2	O
,	O
of	O
the	O
DR	B-Protein
alpha	I-Protein
proximal	O
promoter	O
in	O
group	O
II	O
CID	O
cells	O
is	O
CIITA	B-Protein
dependent	O
.	O
<EOS>	B-X
Type	B-X
II	B-X
major	B-X
histocompatibility	B-X
complex	B-X
combined	B-X
immune	B-X
deficiency	B-X
(	B-X
type	B-X
II	B-X
MHC	B-X
CID	B-X
or	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
)	B-X
is	B-X
a	B-X
congenital	B-X
immunodeficiency	B-X
disease	B-X
characterized	B-X
by	B-X
absent	B-X
MHC	B-X
class	B-X
II	B-X
expression	B-X
.	B-X
Four	B-X
distinct	B-X
complementation	B-X
groups	B-X
have	B-X
been	B-X
identified	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
defective	B-X
gene	B-X
in	B-X
group	B-X
II	B-X
type	B-X
II	B-X
MHC	B-X
CID	B-X
has	B-X
been	B-X
isolated	B-X
and	B-X
termed	B-X
CIITA	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
CIITA	B-X
is	B-X
an	B-X
MHC	B-X
class	B-X
II	B-X
gene-specific	B-X
transcription	B-X
activator	B-X
.	B-X
The	B-X
specificity	B-X
of	B-X
CIITA	B-X
for	B-X
three	B-X
major	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
DR	B-X
,	B-X
DQ	B-X
and	B-X
DP	B-X
,	B-X
is	B-X
mediated	B-X
by	B-X
its	B-X
remaining	B-X
C-terminal	B-X
residues	B-X
(	B-X
amino	B-X
acids	B-X
317-1130	B-X
)	B-X
.	B-X
The	B-X
transactivation	B-X
of	B-X
multiple	B-X
cis	B-X
elements	B-X
,	B-X
especially	B-X
S	B-X
and	B-X
X2	B-X
,	B-X
of	B-X
the	B-X
DR	B-X
alpha	B-X
proximal	B-X
promoter	B-X
in	B-X
group	B-X
II	B-X
CID	B-X
cells	B-X
is	B-X
CIITA	B-X
dependent	B-X
.	B-X
Since	B-X
CIITA	B-X
overexpression	B-X
in	B-X
normal	B-X
cells	B-X
did	B-X
not	B-X
increase	B-X
class	B-X
II	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
initiation	B-X
of	B-X
CIITA	B-X
expression	B-X
serves	B-X
as	B-X
the	B-X
on-off	B-X
switch	B-X
,	B-X
while	B-X
availability	B-X
of	B-X
downstream	B-X
interactor	B-X
(	B-X
s	B-X
)	B-X
limits	B-X
transcription	B-X
.	B-X

Since	O
CIITA	B-Protein
overexpression	O
in	O
normal	O
cells	O
did	O
not	O
increase	O
class	O
II	O
expression	O
,	O
we	O
propose	O
that	O
initiation	O
of	O
CIITA	B-Protein
expression	O
serves	O
as	O
the	O
on	O
-	O
off	O
switch	O
,	O
while	O
availability	O
of	O
downstream	O
interactor	O
(	O
s	O
)	O
limits	O
transcription	O
.	O
<EOS>	B-X
Endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
,	B-X
selectively	B-X
expressed	B-X
in	B-X
vascular	B-X
endothelial	B-X
cells	B-X
,	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
a	B-X
range	B-X
of	B-X
biological	B-X
and	B-X
pathological	B-X
processes	B-X
.	B-X
eNOS	B-X
levels	B-X
can	B-X
be	B-X
altered	B-X
by	B-X
extrinsic	B-X
and	B-X
intrinsic	B-X
cues	B-X
at	B-X
the	B-X
transcriptional	B-X
level	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
the	B-X
epigenetic	B-X
mechanism	B-X
whereby	B-X
the	B-X
pro-inflammatory	B-X
cytokine	B-X
interferon	B-X
gamma	B-X
(	B-X
IFN-γ	B-X
)	B-X
represses	B-X
eNOS	B-X
transcription	B-X
.	B-X
In	B-X
response	B-X
to	B-X
IFN-γ	B-X
treatment	B-X
,	B-X
there	B-X
was	B-X
a	B-X
simultaneous	B-X
down-regulation	B-X
of	B-X
eNOS	B-X
expression	B-X
and	B-X
up-regulation	B-X
of	B-X
class	B-X
II	B-X
trans-activator	B-X
(	B-X
CIITA	B-X
)	B-X
.	B-X
Over-expression	B-X
of	B-X
CIITA	B-X
directly	B-X
repressed	B-X
eNOS	B-X
promoter	B-X
while	B-X
CIITA	B-X
knockdown	B-X
attenuated	B-X
IFN-γ	B-X
induced	B-X
eNOS	B-X
repression	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
assay	B-X
revealed	B-X
that	B-X
IFN-γ	B-X
stimulation	B-X
promoted	B-X
CIITA	B-X
occupancy	B-X
on	B-X
the	B-X
proximal	B-X
eNOS	B-X
(	B-X
-430/-168	B-X
)	B-X
.	B-X
Coincidently	B-X
,	B-X
CIITA	B-X
recruitment	B-X
to	B-X
the	B-X
eNOS	B-X
promoter	B-X
was	B-X
paralleled	B-X
by	B-X
the	B-X
disappearance	B-X
of	B-X
trimethylated	B-X
histone	B-X
H3K4	B-X
(	B-X
H3K4Me3	B-X
)	B-X
and	B-X
the	B-X
enrichment	B-X
of	B-X
trimethylated	B-X
H3K9	B-X
(	B-X
H3K9Me3	B-X
)	B-X
with	B-X
no	B-X
significant	B-X
changes	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
trimethylated	B-X
H3K27	B-X
(	B-X
H3K27Me3	B-X
)	B-X
or	B-X
trimethylated	B-X
H4K20	B-X
(	B-X
H4K20Me3	B-X
)	B-X
.	B-X
In	B-X
accordance	B-X
,	B-X
CIITA	B-X
depletion	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
normalization	B-X
of	B-X
H3K4Me3	B-X
and	B-X
H3K9Me3	B-X
on	B-X
the	B-X
eNOS	B-X
promoter	B-X
.	B-X
Mechanistically	B-X
,	B-X
CIITA	B-X
interacted	B-X
with	B-X
and	B-X
enlisted	B-X
the	B-X
histone	B-X
H3K9	B-X
trimethyltransferase	B-X
SUV39H1	B-X
to	B-X
the	B-X
eNOS	B-X
promoter	B-X
to	B-X
repress	B-X
transcription	B-X
.	B-X
IFN-γ	B-X
treatment	B-X
augmented	B-X
SUV39H1	B-X
expression	B-X
and	B-X
promoted	B-X
SUV39H1	B-X
recruitment	B-X
to	B-X
the	B-X
eNOS	B-X
promoter	B-X
in	B-X
endothelial	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
data	B-X
reveal	B-X
a	B-X
novel	B-X
role	B-X
for	B-X
CIITA	B-X
in	B-X
endothelial	B-X
cells	B-X
and	B-X
present	B-X
SUV39H1	B-X
as	B-X
a	B-X
druggable	B-X
target	B-X
in	B-X
the	B-X
intervention	B-X
of	B-X
endothelial	B-X
dysfunction	B-X
.	B-X

Abnormal	O
regulation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
in	O
lpr	O
CD4	B-Protein
-	O
CD8	O
-	O
T	O
lymphocytes	O
results	O
in	O
constitutive	O
expression	O
of	O
a	O
novel	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
-	O
binding	O
factor	O
.	O
<EOS>	B-X
The	B-X
inert	B-X
quality	B-X
of	B-X
MRL-Ipr/Ipr	B-X
(	B-X
Ipr	B-X
)	B-X
peripheral	B-X
CD4-CD8-	B-X
(	B-X
CD4-8-	B-X
)	B-X
T	B-X
cells	B-X
manifests	B-X
primarily	B-X
as	B-X
an	B-X
inability	B-X
to	B-X
proliferate	B-X
or	B-X
produce	B-X
IL-2	B-X
in	B-X
response	B-X
to	B-X
TCR	B-X
or	B-X
mitogenic	B-X
stimulation	B-X
.	B-X
Yet	B-X
these	B-X
same	B-X
cells	B-X
do	B-X
initiate	B-X
early	B-X
TCR-mediated	B-X
signaling	B-X
events	B-X
,	B-X
such	B-X
as	B-X
generation	B-X
of	B-X
inositol	B-X
phosphates	B-X
and	B-X
increased	B-X
intracellular	B-X
calcium	B-X
.	B-X
They	B-X
also	B-X
display	B-X
constitutively	B-X
high	B-X
levels	B-X
of	B-X
p59fyn	B-X
and	B-X
CD3	B-X
zeta	B-X
tyrosine	B-X
phosphorylation	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
second	B-X
messengers	B-X
in	B-X
T	B-X
cells	B-X
normally	B-X
leads	B-X
to	B-X
downstream	B-X
signaling	B-X
that	B-X
results	B-X
in	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
compared	B-X
the	B-X
activation	B-X
state	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
promoter	B-X
region	B-X
in	B-X
freshly	B-X
isolated	B-X
and	B-X
stimulated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
with	B-X
that	B-X
of	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
octamer	B-X
,	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50-p65	B-X
heterodimer	B-X
)	B-X
,	B-X
and	B-X
AP-1	B-X
transcriptional	B-X
factors	B-X
are	B-X
constitutively	B-X
elevated	B-X
in	B-X
freshly	B-X
isolated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
activated	B-X
phenotype	B-X
of	B-X
these	B-X
cells	B-X
.	B-X
Upon	B-X
stimulation	B-X
with	B-X
mitogens	B-X
,	B-X
formation	B-X
of	B-X
the	B-X
transactivating	B-X
complex	B-X
,	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NF-AT	B-X
)	B-X
,	B-X
occurs	B-X
with	B-X
normal	B-X
kinetics	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
activating	B-X
NF-AT	B-X
complex	B-X
never	B-X
reach	B-X
those	B-X
observed	B-X
in	B-X
similarly	B-X
stimulated	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
nuclear	B-X
extracts	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
display	B-X
high	B-X
levels	B-X
of	B-X
a	B-X
novel	B-X
specific	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
,	B-X
which	B-X
is	B-X
present	B-X
at	B-X
much	B-X
lower	B-X
levels	B-X
in	B-X
freshly	B-X
isolated	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Upon	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
novel	B-X
NF-AT-binding	B-X
factor	B-X
is	B-X
rapidly	B-X
down-regulated	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
persists	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
two	B-X
abnormalities	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
to	B-X
account	B-X
for	B-X
the	B-X
defect	B-X
in	B-X
IL-2	B-X
production	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X

The	O
inert	O
quality	O
of	O
MRL	O
-	O
Ipr	O
/	O
Ipr	O
(	O
Ipr	O
)	O
peripheral	O
CD4	B-Protein
-	O
CD8	O
-	O
(	O
CD4	O
-	O
8	O
-	O
)	O
T	O
cells	O
manifests	O
primarily	O
as	O
an	O
inability	O
to	O
proliferate	O
or	O
produce	O
IL	B-Protein
-	I-Protein
2	I-Protein
in	O
response	O
to	O
TCR	O
or	O
mitogenic	O
stimulation	O
.	O
<EOS>	B-X
A	B-X
C-terminal	B-X
fragment	B-X
(	B-X
amino	B-X
acids	B-X
681	B-X
to	B-X
1285	B-X
)	B-X
was	B-X
catalytically	B-X
active	B-X
.	B-X
When	B-X
microinjected	B-X
into	B-X
quiescent	B-X
Swiss	B-X
3T3	B-X
cells	B-X
,	B-X
it	B-X
induced	B-X
changes	B-X
in	B-X
cell	B-X
morphology	B-X
typical	B-X
of	B-X
toxin-treated	B-X
cells	B-X
and	B-X
stimulated	B-X
DNA	B-X
synthesis	B-X
.	B-X
The	B-X
inactive	B-X
mutant	B-X
containing	B-X
a	B-X
mutation	B-X
near	B-X
the	B-X
C	B-X
terminus	B-X
(	B-X
C1165S	B-X
)	B-X
also	B-X
bound	B-X
to	B-X
cells	B-X
in	B-X
this	B-X
assay	B-X
.	B-X
Antibodies	B-X
to	B-X
the	B-X
C	B-X
terminus	B-X
of	B-X
PMT	B-X
were	B-X
microinjected	B-X
into	B-X
cells	B-X
and	B-X
inhibited	B-X
the	B-X
activity	B-X
of	B-X
toxin	B-X
added	B-X
subsequently	B-X
to	B-X
the	B-X
medium	B-X
,	B-X
confirming	B-X
that	B-X
the	B-X
C	B-X
terminus	B-X
contains	B-X
the	B-X
active	B-X
site	B-X
.	B-X

Yet	O
these	O
same	O
cells	O
do	O
initiate	O
early	O
TCR	O
-	O
mediated	O
signaling	O
events	O
,	O
such	O
as	O
generation	O
of	O
inositol	O
phosphates	O
and	O
increased	O
intracellular	O
calcium	O
.	O
<EOS>	B-X
The	B-X
inert	B-X
quality	B-X
of	B-X
MRL-Ipr/Ipr	B-X
(	B-X
Ipr	B-X
)	B-X
peripheral	B-X
CD4-CD8-	B-X
(	B-X
CD4-8-	B-X
)	B-X
T	B-X
cells	B-X
manifests	B-X
primarily	B-X
as	B-X
an	B-X
inability	B-X
to	B-X
proliferate	B-X
or	B-X
produce	B-X
IL-2	B-X
in	B-X
response	B-X
to	B-X
TCR	B-X
or	B-X
mitogenic	B-X
stimulation	B-X
.	B-X
Yet	B-X
these	B-X
same	B-X
cells	B-X
do	B-X
initiate	B-X
early	B-X
TCR-mediated	B-X
signaling	B-X
events	B-X
,	B-X
such	B-X
as	B-X
generation	B-X
of	B-X
inositol	B-X
phosphates	B-X
and	B-X
increased	B-X
intracellular	B-X
calcium	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
second	B-X
messengers	B-X
in	B-X
T	B-X
cells	B-X
normally	B-X
leads	B-X
to	B-X
downstream	B-X
signaling	B-X
that	B-X
results	B-X
in	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
compared	B-X
the	B-X
activation	B-X
state	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
promoter	B-X
region	B-X
in	B-X
freshly	B-X
isolated	B-X
and	B-X
stimulated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
with	B-X
that	B-X
of	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
octamer	B-X
,	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50-p65	B-X
heterodimer	B-X
)	B-X
,	B-X
and	B-X
AP-1	B-X
transcriptional	B-X
factors	B-X
are	B-X
constitutively	B-X
elevated	B-X
in	B-X
freshly	B-X
isolated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
activated	B-X
phenotype	B-X
of	B-X
these	B-X
cells	B-X
.	B-X
Upon	B-X
stimulation	B-X
with	B-X
mitogens	B-X
,	B-X
formation	B-X
of	B-X
the	B-X
transactivating	B-X
complex	B-X
,	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NF-AT	B-X
)	B-X
,	B-X
occurs	B-X
with	B-X
normal	B-X
kinetics	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
activating	B-X
NF-AT	B-X
complex	B-X
never	B-X
reach	B-X
those	B-X
observed	B-X
in	B-X
similarly	B-X
stimulated	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
nuclear	B-X
extracts	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
display	B-X
high	B-X
levels	B-X
of	B-X
a	B-X
novel	B-X
specific	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
,	B-X
which	B-X
is	B-X
present	B-X
at	B-X
much	B-X
lower	B-X
levels	B-X
in	B-X
freshly	B-X
isolated	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Upon	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
novel	B-X
NF-AT-binding	B-X
factor	B-X
is	B-X
rapidly	B-X
down-regulated	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
persists	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
two	B-X
abnormalities	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
to	B-X
account	B-X
for	B-X
the	B-X
defect	B-X
in	B-X
IL-2	B-X
production	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X

They	O
also	O
display	O
constitutively	O
high	O
levels	O
of	O
p59fyn	B-Protein
and	O
CD3	B-Protein
zeta	I-Protein
tyrosine	O
phosphorylation	O
.	O
<EOS>	B-X
T	B-X
cells	B-X
freshly	B-X
isolated	B-X
from	B-X
the	B-X
peripheral	B-X
lymph	B-X
nodes	B-X
of	B-X
autoimmune	B-X
MRL	B-X
lpr/lpr	B-X
(	B-X
lpr	B-X
)	B-X
mice	B-X
contain	B-X
a	B-X
large	B-X
proportion	B-X
of	B-X
functionally	B-X
non-mature	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
-alpha	B-X
beta+CD3+CD2-CD4-CD8-	B-X
T	B-X
cells	B-X
displaying	B-X
the	B-X
B	B-X
cell	B-X
isoform	B-X
of	B-X
CD45	B-X
,	B-X
B220	B-X
.	B-X
However	B-X
,	B-X
increased	B-X
levels	B-X
of	B-X
inositol	B-X
phosphates	B-X
and	B-X
a	B-X
rapid	B-X
mobilization	B-X
of	B-X
Ca2+	B-X
do	B-X
occur	B-X
upon	B-X
stimulation	B-X
of	B-X
the	B-X
TcR/CD3	B-X
complex	B-X
.	B-X
Furthermore	B-X
,	B-X
lpr	B-X
CD4-CD8-T	B-X
cells	B-X
contain	B-X
high	B-X
levels	B-X
of	B-X
transcripts	B-X
for	B-X
the	B-X
src-family	B-X
tyrosine	B-X
kinase	B-X
p59fyn	B-X
,	B-X
and	B-X
express	B-X
a	B-X
constitutively	B-X
tyrosine-phosphorylated	B-X
CD3-zeta	B-X
chain	B-X
.	B-X
In	B-X
parallel	B-X
with	B-X
this	B-X
gain	B-X
in	B-X
function	B-X
,	B-X
the	B-X
population	B-X
of	B-X
cells	B-X
obtained	B-X
after	B-X
1	B-X
week	B-X
in	B-X
culture	B-X
retains	B-X
the	B-X
TcR-alpha	B-X
beta	B-X
+	B-X
CD4-CD8-	B-X
phenotype	B-X
,	B-X
yet	B-X
displays	B-X
increased	B-X
levels	B-X
of	B-X
CD2	B-X
,	B-X
decreased	B-X
surface	B-X
B220	B-X
,	B-X
and	B-X
normal	B-X
amounts	B-X
of	B-X
p59fyn-specific	B-X
transcripts	B-X
.	B-X

The	O
generation	O
of	O
second	O
messengers	O
in	O
T	O
cells	O
normally	O
leads	O
to	O
downstream	O
signaling	O
that	O
results	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
.	O

We	O
,	O
therefore	O
,	O
compared	O
the	O
activation	O
state	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
promoter	O
region	O
in	O
freshly	O
isolated	O
and	O
stimulated	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
with	O
that	O
of	O
normal	O
T	O
lymphocytes	O
.	O
<EOS>	B-X
The	B-X
inert	B-X
quality	B-X
of	B-X
MRL-Ipr/Ipr	B-X
(	B-X
Ipr	B-X
)	B-X
peripheral	B-X
CD4-CD8-	B-X
(	B-X
CD4-8-	B-X
)	B-X
T	B-X
cells	B-X
manifests	B-X
primarily	B-X
as	B-X
an	B-X
inability	B-X
to	B-X
proliferate	B-X
or	B-X
produce	B-X
IL-2	B-X
in	B-X
response	B-X
to	B-X
TCR	B-X
or	B-X
mitogenic	B-X
stimulation	B-X
.	B-X
Yet	B-X
these	B-X
same	B-X
cells	B-X
do	B-X
initiate	B-X
early	B-X
TCR-mediated	B-X
signaling	B-X
events	B-X
,	B-X
such	B-X
as	B-X
generation	B-X
of	B-X
inositol	B-X
phosphates	B-X
and	B-X
increased	B-X
intracellular	B-X
calcium	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
second	B-X
messengers	B-X
in	B-X
T	B-X
cells	B-X
normally	B-X
leads	B-X
to	B-X
downstream	B-X
signaling	B-X
that	B-X
results	B-X
in	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
compared	B-X
the	B-X
activation	B-X
state	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
promoter	B-X
region	B-X
in	B-X
freshly	B-X
isolated	B-X
and	B-X
stimulated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
with	B-X
that	B-X
of	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
octamer	B-X
,	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50-p65	B-X
heterodimer	B-X
)	B-X
,	B-X
and	B-X
AP-1	B-X
transcriptional	B-X
factors	B-X
are	B-X
constitutively	B-X
elevated	B-X
in	B-X
freshly	B-X
isolated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
activated	B-X
phenotype	B-X
of	B-X
these	B-X
cells	B-X
.	B-X
Upon	B-X
stimulation	B-X
with	B-X
mitogens	B-X
,	B-X
formation	B-X
of	B-X
the	B-X
transactivating	B-X
complex	B-X
,	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NF-AT	B-X
)	B-X
,	B-X
occurs	B-X
with	B-X
normal	B-X
kinetics	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
activating	B-X
NF-AT	B-X
complex	B-X
never	B-X
reach	B-X
those	B-X
observed	B-X
in	B-X
similarly	B-X
stimulated	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
nuclear	B-X
extracts	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
display	B-X
high	B-X
levels	B-X
of	B-X
a	B-X
novel	B-X
specific	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
,	B-X
which	B-X
is	B-X
present	B-X
at	B-X
much	B-X
lower	B-X
levels	B-X
in	B-X
freshly	B-X
isolated	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Upon	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
novel	B-X
NF-AT-binding	B-X
factor	B-X
is	B-X
rapidly	B-X
down-regulated	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
persists	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
two	B-X
abnormalities	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
to	B-X
account	B-X
for	B-X
the	B-X
defect	B-X
in	B-X
IL-2	B-X
production	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X

Levels	O
of	O
the	O
octamer	O
,	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-Protein
-	O
p65	B-Protein
heterodimer	O
)	O
,	O
and	O
AP	O
-	O
1	O
transcriptional	O
factors	O
are	O
constitutively	O
elevated	O
in	O
freshly	O
isolated	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
,	O
consistent	O
with	O
the	O
activated	O
phenotype	O
of	O
these	O
cells	O
.	O
<EOS>	B-X
The	B-X
inert	B-X
quality	B-X
of	B-X
MRL-Ipr/Ipr	B-X
(	B-X
Ipr	B-X
)	B-X
peripheral	B-X
CD4-CD8-	B-X
(	B-X
CD4-8-	B-X
)	B-X
T	B-X
cells	B-X
manifests	B-X
primarily	B-X
as	B-X
an	B-X
inability	B-X
to	B-X
proliferate	B-X
or	B-X
produce	B-X
IL-2	B-X
in	B-X
response	B-X
to	B-X
TCR	B-X
or	B-X
mitogenic	B-X
stimulation	B-X
.	B-X
Yet	B-X
these	B-X
same	B-X
cells	B-X
do	B-X
initiate	B-X
early	B-X
TCR-mediated	B-X
signaling	B-X
events	B-X
,	B-X
such	B-X
as	B-X
generation	B-X
of	B-X
inositol	B-X
phosphates	B-X
and	B-X
increased	B-X
intracellular	B-X
calcium	B-X
.	B-X
They	B-X
also	B-X
display	B-X
constitutively	B-X
high	B-X
levels	B-X
of	B-X
p59fyn	B-X
and	B-X
CD3	B-X
zeta	B-X
tyrosine	B-X
phosphorylation	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
second	B-X
messengers	B-X
in	B-X
T	B-X
cells	B-X
normally	B-X
leads	B-X
to	B-X
downstream	B-X
signaling	B-X
that	B-X
results	B-X
in	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
compared	B-X
the	B-X
activation	B-X
state	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
promoter	B-X
region	B-X
in	B-X
freshly	B-X
isolated	B-X
and	B-X
stimulated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
with	B-X
that	B-X
of	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
octamer	B-X
,	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50-p65	B-X
heterodimer	B-X
)	B-X
,	B-X
and	B-X
AP-1	B-X
transcriptional	B-X
factors	B-X
are	B-X
constitutively	B-X
elevated	B-X
in	B-X
freshly	B-X
isolated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
activated	B-X
phenotype	B-X
of	B-X
these	B-X
cells	B-X
.	B-X
Upon	B-X
stimulation	B-X
with	B-X
mitogens	B-X
,	B-X
formation	B-X
of	B-X
the	B-X
transactivating	B-X
complex	B-X
,	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NF-AT	B-X
)	B-X
,	B-X
occurs	B-X
with	B-X
normal	B-X
kinetics	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
activating	B-X
NF-AT	B-X
complex	B-X
never	B-X
reach	B-X
those	B-X
observed	B-X
in	B-X
similarly	B-X
stimulated	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
nuclear	B-X
extracts	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
display	B-X
high	B-X
levels	B-X
of	B-X
a	B-X
novel	B-X
specific	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
,	B-X
which	B-X
is	B-X
present	B-X
at	B-X
much	B-X
lower	B-X
levels	B-X
in	B-X
freshly	B-X
isolated	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Upon	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
novel	B-X
NF-AT-binding	B-X
factor	B-X
is	B-X
rapidly	B-X
down-regulated	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
persists	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
two	B-X
abnormalities	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
to	B-X
account	B-X
for	B-X
the	B-X
defect	B-X
in	B-X
IL-2	B-X
production	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X

Upon	O
stimulation	O
with	O
mitogens	O
,	O
formation	O
of	O
the	O
transactivating	O
complex	O
,	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
,	O
occurs	O
with	O
normal	O
kinetics	O
in	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
.	O
<EOS>	B-X
The	B-X
inert	B-X
quality	B-X
of	B-X
MRL-Ipr/Ipr	B-X
(	B-X
Ipr	B-X
)	B-X
peripheral	B-X
CD4-CD8-	B-X
(	B-X
CD4-8-	B-X
)	B-X
T	B-X
cells	B-X
manifests	B-X
primarily	B-X
as	B-X
an	B-X
inability	B-X
to	B-X
proliferate	B-X
or	B-X
produce	B-X
IL-2	B-X
in	B-X
response	B-X
to	B-X
TCR	B-X
or	B-X
mitogenic	B-X
stimulation	B-X
.	B-X
Yet	B-X
these	B-X
same	B-X
cells	B-X
do	B-X
initiate	B-X
early	B-X
TCR-mediated	B-X
signaling	B-X
events	B-X
,	B-X
such	B-X
as	B-X
generation	B-X
of	B-X
inositol	B-X
phosphates	B-X
and	B-X
increased	B-X
intracellular	B-X
calcium	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
second	B-X
messengers	B-X
in	B-X
T	B-X
cells	B-X
normally	B-X
leads	B-X
to	B-X
downstream	B-X
signaling	B-X
that	B-X
results	B-X
in	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
compared	B-X
the	B-X
activation	B-X
state	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
promoter	B-X
region	B-X
in	B-X
freshly	B-X
isolated	B-X
and	B-X
stimulated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
with	B-X
that	B-X
of	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
octamer	B-X
,	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50-p65	B-X
heterodimer	B-X
)	B-X
,	B-X
and	B-X
AP-1	B-X
transcriptional	B-X
factors	B-X
are	B-X
constitutively	B-X
elevated	B-X
in	B-X
freshly	B-X
isolated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
activated	B-X
phenotype	B-X
of	B-X
these	B-X
cells	B-X
.	B-X
Upon	B-X
stimulation	B-X
with	B-X
mitogens	B-X
,	B-X
formation	B-X
of	B-X
the	B-X
transactivating	B-X
complex	B-X
,	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NF-AT	B-X
)	B-X
,	B-X
occurs	B-X
with	B-X
normal	B-X
kinetics	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
activating	B-X
NF-AT	B-X
complex	B-X
never	B-X
reach	B-X
those	B-X
observed	B-X
in	B-X
similarly	B-X
stimulated	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
nuclear	B-X
extracts	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
display	B-X
high	B-X
levels	B-X
of	B-X
a	B-X
novel	B-X
specific	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
,	B-X
which	B-X
is	B-X
present	B-X
at	B-X
much	B-X
lower	B-X
levels	B-X
in	B-X
freshly	B-X
isolated	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Upon	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
novel	B-X
NF-AT-binding	B-X
factor	B-X
is	B-X
rapidly	B-X
down-regulated	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
persists	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
two	B-X
abnormalities	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
to	B-X
account	B-X
for	B-X
the	B-X
defect	B-X
in	B-X
IL-2	B-X
production	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X

Yet	O
,	O
the	O
levels	O
of	O
the	O
activating	O
NF	O
-	O
AT	O
complex	O
never	O
reach	O
those	O
observed	O
in	O
similarly	O
stimulated	O
normal	O
T	O
cells	O
.	O
<EOS>	B-X
The	B-X
inert	B-X
quality	B-X
of	B-X
MRL-Ipr/Ipr	B-X
(	B-X
Ipr	B-X
)	B-X
peripheral	B-X
CD4-CD8-	B-X
(	B-X
CD4-8-	B-X
)	B-X
T	B-X
cells	B-X
manifests	B-X
primarily	B-X
as	B-X
an	B-X
inability	B-X
to	B-X
proliferate	B-X
or	B-X
produce	B-X
IL-2	B-X
in	B-X
response	B-X
to	B-X
TCR	B-X
or	B-X
mitogenic	B-X
stimulation	B-X
.	B-X
Yet	B-X
these	B-X
same	B-X
cells	B-X
do	B-X
initiate	B-X
early	B-X
TCR-mediated	B-X
signaling	B-X
events	B-X
,	B-X
such	B-X
as	B-X
generation	B-X
of	B-X
inositol	B-X
phosphates	B-X
and	B-X
increased	B-X
intracellular	B-X
calcium	B-X
.	B-X
They	B-X
also	B-X
display	B-X
constitutively	B-X
high	B-X
levels	B-X
of	B-X
p59fyn	B-X
and	B-X
CD3	B-X
zeta	B-X
tyrosine	B-X
phosphorylation	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
second	B-X
messengers	B-X
in	B-X
T	B-X
cells	B-X
normally	B-X
leads	B-X
to	B-X
downstream	B-X
signaling	B-X
that	B-X
results	B-X
in	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
compared	B-X
the	B-X
activation	B-X
state	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
promoter	B-X
region	B-X
in	B-X
freshly	B-X
isolated	B-X
and	B-X
stimulated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
with	B-X
that	B-X
of	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
octamer	B-X
,	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50-p65	B-X
heterodimer	B-X
)	B-X
,	B-X
and	B-X
AP-1	B-X
transcriptional	B-X
factors	B-X
are	B-X
constitutively	B-X
elevated	B-X
in	B-X
freshly	B-X
isolated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
activated	B-X
phenotype	B-X
of	B-X
these	B-X
cells	B-X
.	B-X
Upon	B-X
stimulation	B-X
with	B-X
mitogens	B-X
,	B-X
formation	B-X
of	B-X
the	B-X
transactivating	B-X
complex	B-X
,	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NF-AT	B-X
)	B-X
,	B-X
occurs	B-X
with	B-X
normal	B-X
kinetics	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
activating	B-X
NF-AT	B-X
complex	B-X
never	B-X
reach	B-X
those	B-X
observed	B-X
in	B-X
similarly	B-X
stimulated	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
nuclear	B-X
extracts	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
display	B-X
high	B-X
levels	B-X
of	B-X
a	B-X
novel	B-X
specific	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
,	B-X
which	B-X
is	B-X
present	B-X
at	B-X
much	B-X
lower	B-X
levels	B-X
in	B-X
freshly	B-X
isolated	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Upon	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
novel	B-X
NF-AT-binding	B-X
factor	B-X
is	B-X
rapidly	B-X
down-regulated	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
persists	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
two	B-X
abnormalities	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
to	B-X
account	B-X
for	B-X
the	B-X
defect	B-X
in	B-X
IL-2	B-X
production	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X

Furthermore	O
,	O
nuclear	O
extracts	O
from	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF	O
-	O
AT	O
site	O
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	O
T	O
lymphocytes	O
.	O
<EOS>	B-X
The	B-X
inert	B-X
quality	B-X
of	B-X
MRL-Ipr/Ipr	B-X
(	B-X
Ipr	B-X
)	B-X
peripheral	B-X
CD4-CD8-	B-X
(	B-X
CD4-8-	B-X
)	B-X
T	B-X
cells	B-X
manifests	B-X
primarily	B-X
as	B-X
an	B-X
inability	B-X
to	B-X
proliferate	B-X
or	B-X
produce	B-X
IL-2	B-X
in	B-X
response	B-X
to	B-X
TCR	B-X
or	B-X
mitogenic	B-X
stimulation	B-X
.	B-X
Yet	B-X
these	B-X
same	B-X
cells	B-X
do	B-X
initiate	B-X
early	B-X
TCR-mediated	B-X
signaling	B-X
events	B-X
,	B-X
such	B-X
as	B-X
generation	B-X
of	B-X
inositol	B-X
phosphates	B-X
and	B-X
increased	B-X
intracellular	B-X
calcium	B-X
.	B-X
They	B-X
also	B-X
display	B-X
constitutively	B-X
high	B-X
levels	B-X
of	B-X
p59fyn	B-X
and	B-X
CD3	B-X
zeta	B-X
tyrosine	B-X
phosphorylation	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
second	B-X
messengers	B-X
in	B-X
T	B-X
cells	B-X
normally	B-X
leads	B-X
to	B-X
downstream	B-X
signaling	B-X
that	B-X
results	B-X
in	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
compared	B-X
the	B-X
activation	B-X
state	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
promoter	B-X
region	B-X
in	B-X
freshly	B-X
isolated	B-X
and	B-X
stimulated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
with	B-X
that	B-X
of	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
octamer	B-X
,	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50-p65	B-X
heterodimer	B-X
)	B-X
,	B-X
and	B-X
AP-1	B-X
transcriptional	B-X
factors	B-X
are	B-X
constitutively	B-X
elevated	B-X
in	B-X
freshly	B-X
isolated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
activated	B-X
phenotype	B-X
of	B-X
these	B-X
cells	B-X
.	B-X
Upon	B-X
stimulation	B-X
with	B-X
mitogens	B-X
,	B-X
formation	B-X
of	B-X
the	B-X
transactivating	B-X
complex	B-X
,	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NF-AT	B-X
)	B-X
,	B-X
occurs	B-X
with	B-X
normal	B-X
kinetics	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
activating	B-X
NF-AT	B-X
complex	B-X
never	B-X
reach	B-X
those	B-X
observed	B-X
in	B-X
similarly	B-X
stimulated	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
nuclear	B-X
extracts	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
display	B-X
high	B-X
levels	B-X
of	B-X
a	B-X
novel	B-X
specific	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
,	B-X
which	B-X
is	B-X
present	B-X
at	B-X
much	B-X
lower	B-X
levels	B-X
in	B-X
freshly	B-X
isolated	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Upon	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
novel	B-X
NF-AT-binding	B-X
factor	B-X
is	B-X
rapidly	B-X
down-regulated	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
persists	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
two	B-X
abnormalities	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
to	B-X
account	B-X
for	B-X
the	B-X
defect	B-X
in	B-X
IL-2	B-X
production	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X

Upon	O
mitogenic	O
stimulation	O
,	O
the	O
binding	O
activity	O
of	O
the	O
novel	O
NF	O
-	O
AT	O
-	O
binding	O
factor	O
is	O
rapidly	O
down	O
-	O
regulated	O
in	O
normal	O
T	O
cells	O
,	O
but	O
persists	O
at	O
high	O
levels	O
in	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
.	O
<EOS>	B-X
The	B-X
inert	B-X
quality	B-X
of	B-X
MRL-Ipr/Ipr	B-X
(	B-X
Ipr	B-X
)	B-X
peripheral	B-X
CD4-CD8-	B-X
(	B-X
CD4-8-	B-X
)	B-X
T	B-X
cells	B-X
manifests	B-X
primarily	B-X
as	B-X
an	B-X
inability	B-X
to	B-X
proliferate	B-X
or	B-X
produce	B-X
IL-2	B-X
in	B-X
response	B-X
to	B-X
TCR	B-X
or	B-X
mitogenic	B-X
stimulation	B-X
.	B-X
Yet	B-X
these	B-X
same	B-X
cells	B-X
do	B-X
initiate	B-X
early	B-X
TCR-mediated	B-X
signaling	B-X
events	B-X
,	B-X
such	B-X
as	B-X
generation	B-X
of	B-X
inositol	B-X
phosphates	B-X
and	B-X
increased	B-X
intracellular	B-X
calcium	B-X
.	B-X
They	B-X
also	B-X
display	B-X
constitutively	B-X
high	B-X
levels	B-X
of	B-X
p59fyn	B-X
and	B-X
CD3	B-X
zeta	B-X
tyrosine	B-X
phosphorylation	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
second	B-X
messengers	B-X
in	B-X
T	B-X
cells	B-X
normally	B-X
leads	B-X
to	B-X
downstream	B-X
signaling	B-X
that	B-X
results	B-X
in	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
compared	B-X
the	B-X
activation	B-X
state	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
promoter	B-X
region	B-X
in	B-X
freshly	B-X
isolated	B-X
and	B-X
stimulated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
with	B-X
that	B-X
of	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
octamer	B-X
,	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50-p65	B-X
heterodimer	B-X
)	B-X
,	B-X
and	B-X
AP-1	B-X
transcriptional	B-X
factors	B-X
are	B-X
constitutively	B-X
elevated	B-X
in	B-X
freshly	B-X
isolated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
activated	B-X
phenotype	B-X
of	B-X
these	B-X
cells	B-X
.	B-X
Upon	B-X
stimulation	B-X
with	B-X
mitogens	B-X
,	B-X
formation	B-X
of	B-X
the	B-X
transactivating	B-X
complex	B-X
,	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NF-AT	B-X
)	B-X
,	B-X
occurs	B-X
with	B-X
normal	B-X
kinetics	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
activating	B-X
NF-AT	B-X
complex	B-X
never	B-X
reach	B-X
those	B-X
observed	B-X
in	B-X
similarly	B-X
stimulated	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
nuclear	B-X
extracts	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
display	B-X
high	B-X
levels	B-X
of	B-X
a	B-X
novel	B-X
specific	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
,	B-X
which	B-X
is	B-X
present	B-X
at	B-X
much	B-X
lower	B-X
levels	B-X
in	B-X
freshly	B-X
isolated	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Upon	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
novel	B-X
NF-AT-binding	B-X
factor	B-X
is	B-X
rapidly	B-X
down-regulated	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
persists	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
two	B-X
abnormalities	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
to	B-X
account	B-X
for	B-X
the	B-X
defect	B-X
in	B-X
IL-2	B-X
production	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X

These	O
two	O
abnormalities	O
at	O
the	O
NF	O
-	O
AT	O
site	O
provide	O
a	O
potential	O
mechanism	O
to	O
account	O
for	O
the	O
defect	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
from	O
Ipr	O
CD4	O
-	O
8	O
-	O
T	O
cells	O
.	O
<EOS>	B-X
The	B-X
inert	B-X
quality	B-X
of	B-X
MRL-Ipr/Ipr	B-X
(	B-X
Ipr	B-X
)	B-X
peripheral	B-X
CD4-CD8-	B-X
(	B-X
CD4-8-	B-X
)	B-X
T	B-X
cells	B-X
manifests	B-X
primarily	B-X
as	B-X
an	B-X
inability	B-X
to	B-X
proliferate	B-X
or	B-X
produce	B-X
IL-2	B-X
in	B-X
response	B-X
to	B-X
TCR	B-X
or	B-X
mitogenic	B-X
stimulation	B-X
.	B-X
Yet	B-X
these	B-X
same	B-X
cells	B-X
do	B-X
initiate	B-X
early	B-X
TCR-mediated	B-X
signaling	B-X
events	B-X
,	B-X
such	B-X
as	B-X
generation	B-X
of	B-X
inositol	B-X
phosphates	B-X
and	B-X
increased	B-X
intracellular	B-X
calcium	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
second	B-X
messengers	B-X
in	B-X
T	B-X
cells	B-X
normally	B-X
leads	B-X
to	B-X
downstream	B-X
signaling	B-X
that	B-X
results	B-X
in	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
We	B-X
,	B-X
therefore	B-X
,	B-X
compared	B-X
the	B-X
activation	B-X
state	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
promoter	B-X
region	B-X
in	B-X
freshly	B-X
isolated	B-X
and	B-X
stimulated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
with	B-X
that	B-X
of	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Levels	B-X
of	B-X
the	B-X
octamer	B-X
,	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50-p65	B-X
heterodimer	B-X
)	B-X
,	B-X
and	B-X
AP-1	B-X
transcriptional	B-X
factors	B-X
are	B-X
constitutively	B-X
elevated	B-X
in	B-X
freshly	B-X
isolated	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
activated	B-X
phenotype	B-X
of	B-X
these	B-X
cells	B-X
.	B-X
Upon	B-X
stimulation	B-X
with	B-X
mitogens	B-X
,	B-X
formation	B-X
of	B-X
the	B-X
transactivating	B-X
complex	B-X
,	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NF-AT	B-X
)	B-X
,	B-X
occurs	B-X
with	B-X
normal	B-X
kinetics	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
the	B-X
activating	B-X
NF-AT	B-X
complex	B-X
never	B-X
reach	B-X
those	B-X
observed	B-X
in	B-X
similarly	B-X
stimulated	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
nuclear	B-X
extracts	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
display	B-X
high	B-X
levels	B-X
of	B-X
a	B-X
novel	B-X
specific	B-X
binding	B-X
activity	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
,	B-X
which	B-X
is	B-X
present	B-X
at	B-X
much	B-X
lower	B-X
levels	B-X
in	B-X
freshly	B-X
isolated	B-X
normal	B-X
T	B-X
lymphocytes	B-X
.	B-X
Upon	B-X
mitogenic	B-X
stimulation	B-X
,	B-X
the	B-X
binding	B-X
activity	B-X
of	B-X
the	B-X
novel	B-X
NF-AT-binding	B-X
factor	B-X
is	B-X
rapidly	B-X
down-regulated	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
persists	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
two	B-X
abnormalities	B-X
at	B-X
the	B-X
NF-AT	B-X
site	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
to	B-X
account	B-X
for	B-X
the	B-X
defect	B-X
in	B-X
IL-2	B-X
production	B-X
from	B-X
Ipr	B-X
CD4-8-	B-X
T	B-X
cells	B-X
.	B-X

GM	B-Protein
-	I-Protein
CSF	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	O
cells	O
.	O

Antigen	O
complexed	O
with	O
major	O
histocompatibility	O
complex	O
class	O
I	O
or	O
II	O
molecules	O
on	O
the	O
surface	O
of	O
antigen	O
presenting	O
cells	O
interacts	O
with	O
the	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
on	O
the	O
surface	O
of	O
T	O
cells	O
and	O
initiates	O
an	O
activation	O
cascade	O
.	O

So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	O
cytokines	O
produced	O
by	O
antigen	O
presenting	O
cells	O
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
positive	B-X
and	B-X
negative	B-X
receptors	B-X
that	B-X
allow	B-X
the	B-X
fine	B-X
tuning	B-X
of	B-X
the	B-X
immune	B-X
cells	B-X
.	B-X
This	B-X
regulation	B-X
relies	B-X
on	B-X
receptors	B-X
that	B-X
were	B-X
initially	B-X
described	B-X
in	B-X
T	B-X
lymphocytes	B-X
,	B-X
but	B-X
have	B-X
now	B-X
been	B-X
identified	B-X
on	B-X
cells	B-X
from	B-X
both	B-X
innate	B-X
and	B-X
acquired	B-X
immunity	B-X
.	B-X
The	B-X
co-stimulatory	B-X
receptors	B-X
can	B-X
allow	B-X
cell	B-X
activation	B-X
or	B-X
amplify	B-X
it	B-X
,	B-X
regulate	B-X
cell	B-X
suvival	B-X
and	B-X
determine	B-X
their	B-X
effector	B-X
functions	B-X
.	B-X
The	B-X
co-inhibitory	B-X
receptors	B-X
can	B-X
either	B-X
prevent	B-X
,	B-X
decrease	B-X
of	B-X
inhibit	B-X
the	B-X
activation	B-X
and	B-X
differentiation	B-X
process	B-X
.	B-X
The	B-X
co-stimulatory	B-X
and	B-X
co-inhibitory	B-X
molecules	B-X
belong	B-X
mainly	B-X
to	B-X
the	B-X
so-called	B-X
Ig	B-X
superfamily	B-X
and	B-X
historically	B-X
were	B-X
called	B-X
<	B-X
<	B-X
CD28	B-X
and	B-X
B7	B-X
family	B-X
>	B-X
>	B-X
.	B-X
The	B-X
members	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR	B-X
)	B-X
family	B-X
devoid	B-X
of	B-X
intra-cytoplasmic	B-X
death	B-X
domain	B-X
but	B-X
binding	B-X
TNF	B-X
receptor	B-X
associated	B-X
factors	B-X
(	B-X
TRAF	B-X
)	B-X
are	B-X
also	B-X
important	B-X
but	B-X
are	B-X
up	B-X
to	B-X
now	B-X
mainly	B-X
co-stimulatory	B-X
.	B-X
The	B-X
pathways	B-X
used	B-X
by	B-X
the	B-X
co-stimulatory	B-X
receptors	B-X
are	B-X
also	B-X
not	B-X
completely	B-X
understood	B-X
and	B-X
rely	B-X
for	B-X
CD28	B-X
both	B-X
on	B-X
signal	B-X
similar	B-X
to	B-X
the	B-X
one	B-X
elicited	B-X
by	B-X
TcR	B-X
and	B-X
consequently	B-X
increasing	B-X
the	B-X
overall	B-X
signal	B-X
and	B-X
other	B-X
more	B-X
specific	B-X
,	B-X
elicited	B-X
by	B-X
the	B-X
activation	B-X
of	B-X
PI3-OH	B-X
kinase	B-X
,	B-X
vav1	B-X
and	B-X
rearrangement	B-X
of	B-X
cytoskeleton	B-X
.	B-X

High	O
levels	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
also	O
required	O
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O

The	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
requires	O
sequences	O
in	O
the	O
promoter	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	O
located	O
3kb	O
upstream	O
to	O
respond	O
to	O
TCR	O
-	O
like	O
signals	O
.	O
<EOS>	B-X
Antigen	B-X
complexed	B-X
with	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
I	B-X
or	B-X
II	B-X
molecules	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
antigen	B-X
presenting	B-X
cells	B-X
interacts	B-X
with	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
T	B-X
cells	B-X
and	B-X
initiates	B-X
an	B-X
activation	B-X
cascade	B-X
.	B-X
So	B-X
called	B-X
costimulatory	B-X
signals	B-X
,	B-X
mediated	B-X
by	B-X
other	B-X
cell	B-X
surface	B-X
interactions	B-X
or	B-X
soluble	B-X
cytokines	B-X
produced	B-X
by	B-X
antigen	B-X
presenting	B-X
cells	B-X
,	B-X
are	B-X
also	B-X
required	B-X
for	B-X
complete	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
also	B-X
required	B-X
both	B-X
TCR	B-X
and	B-X
costimulatory	B-X
signals	B-X
.	B-X
The	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
requires	B-X
sequences	B-X
in	B-X
the	B-X
promoter	B-X
as	B-X
well	B-X
as	B-X
a	B-X
powerful	B-X
enhancer	B-X
located	B-X
3kb	B-X
upstream	B-X
to	B-X
respond	B-X
to	B-X
TCR-like	B-X
signals	B-X
.	B-X
These	B-X
promoter	B-X
and	B-X
enhancer	B-X
regions	B-X
are	B-X
mainly	B-X
activated	B-X
by	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NFAT	B-X
)	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
NFAT	B-X
by	B-X
TCR	B-X
signals	B-X
has	B-X
been	B-X
well	B-X
described	B-X
for	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
and	B-X
IL-4	B-X
gene	B-X
transcription	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
Costimulatory	B-X
signals	B-X
,	B-X
such	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
CD28	B-X
cell	B-X
surface	B-X
molecule	B-X
on	B-X
T	B-X
cells	B-X
,	B-X
lead	B-X
to	B-X
activation	B-X
through	B-X
a	B-X
distinct	B-X
region	B-X
of	B-X
the	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
promoter	B-X
.	B-X
This	B-X
region	B-X
is	B-X
termed	B-X
the	B-X
CK-1	B-X
or	B-X
CD28RE	B-X
and	B-X
appears	B-X
to	B-X
bind	B-X
specific	B-X
members	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
the	B-X
HTLV-1	B-X
transactivator	B-X
protein	B-X
,	B-X
tax	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
costimulatory	B-X
signal	B-X
for	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
gene	B-X
transcription	B-X
,	B-X
in	B-X
that	B-X
it	B-X
can	B-X
cooperate	B-X
with	B-X
TCR	B-X
signals	B-X
to	B-X
mediate	B-X
high	B-X
level	B-X
gene	B-X
expression	B-X
.	B-X
Tax	B-X
activates	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
through	B-X
the	B-X
CK-1/CD28RE	B-X
region	B-X
and	B-X
also	B-X
activates	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
binding	B-X
to	B-X
this	B-X
region	B-X
.	B-X
However	B-X
,	B-X
other	B-X
transcription	B-X
factors	B-X
or	B-X
coactivators	B-X
of	B-X
NF-kappa	B-X
B	B-X
are	B-X
required	B-X
for	B-X
tax	B-X
activation	B-X
but	B-X
these	B-X
remain	B-X
to	B-X
be	B-X
identified	B-X
.	B-X
This	B-X
observation	B-X
,	B-X
together	B-X
with	B-X
the	B-X
fact	B-X
that	B-X
both	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
respond	B-X
to	B-X
TCR	B-X
signals	B-X
via	B-X
NFAT	B-X
,	B-X
implies	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
conservation	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
.	B-X

These	O
promoter	O
and	O
enhancer	O
regions	O
are	O
mainly	O
activated	O
by	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
.	O
<EOS>	B-X
The	B-X
NFAT	B-X
(	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
)	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
consists	B-X
of	B-X
four	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-regulated	B-X
members	B-X
(	B-X
NFAT1-NFAT4	B-X
)	B-X
,	B-X
which	B-X
were	B-X
first	B-X
described	B-X
in	B-X
T	B-X
lymphocytes	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
their	B-X
well-documented	B-X
role	B-X
in	B-X
T	B-X
lymphocytes	B-X
,	B-X
where	B-X
they	B-X
control	B-X
gene	B-X
expression	B-X
during	B-X
cell	B-X
activation	B-X
and	B-X
differentiation	B-X
,	B-X
NFAT	B-X
proteins	B-X
are	B-X
also	B-X
expressed	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
cells	B-X
and	B-X
tissue	B-X
types	B-X
and	B-X
regulate	B-X
genes	B-X
involved	B-X
in	B-X
cell	B-X
cycle	B-X
,	B-X
apoptosis	B-X
,	B-X
angiogenesis	B-X
and	B-X
metastasis	B-X
.	B-X
The	B-X
NFAT	B-X
proteins	B-X
share	B-X
a	B-X
highly	B-X
conserved	B-X
DNA-binding	B-X
domain	B-X
(	B-X
DBD	B-X
)	B-X
,	B-X
which	B-X
allows	B-X
all	B-X
NFAT	B-X
members	B-X
to	B-X
bind	B-X
to	B-X
the	B-X
same	B-X
DNA	B-X
sequence	B-X
in	B-X
enhancers	B-X
or	B-X
promoter	B-X
regions	B-X
.	B-X
The	B-X
same	B-X
DNA-binding	B-X
specificity	B-X
suggests	B-X
redundant	B-X
roles	B-X
for	B-X
the	B-X
NFAT	B-X
proteins	B-X
,	B-X
which	B-X
is	B-X
true	B-X
during	B-X
the	B-X
regulation	B-X
of	B-X
some	B-X
genes	B-X
such	B-X
as	B-X
IL-2	B-X
and	B-X
p21	B-X
.	B-X
However	B-X
,	B-X
it	B-X
has	B-X
become	B-X
increasingly	B-X
clear	B-X
that	B-X
different	B-X
NFAT	B-X
proteins	B-X
and	B-X
even	B-X
isoforms	B-X
can	B-X
have	B-X
unique	B-X
functions	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
address	B-X
the	B-X
possible	B-X
reasons	B-X
for	B-X
these	B-X
distinct	B-X
roles	B-X
,	B-X
particularly	B-X
regarding	B-X
N-	B-X
and	B-X
C-terminal	B-X
transactivation	B-X
regions	B-X
(	B-X
TADs	B-X
)	B-X
and	B-X
the	B-X
partner	B-X
proteins	B-X
that	B-X
interact	B-X
with	B-X
these	B-X
TADs	B-X
.	B-X
We	B-X
also	B-X
discuss	B-X
the	B-X
genes	B-X
regulated	B-X
by	B-X
NFAT	B-X
during	B-X
cell	B-X
cycle	B-X
regulation	B-X
and	B-X
apoptosis	B-X
and	B-X
the	B-X
role	B-X
of	B-X
NFAT	B-X
during	B-X
tumorigenesis	B-X
.	B-X

The	O
activation	O
of	O
NFAT	O
by	O
TCR	O
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
gene	O
transcription	O
in	O
T	O
cells	O
.	O

Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	B-Protein
cell	O
surface	O
molecule	O
on	O
T	O
cells	O
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
promoter	O
.	O

This	O
region	O
is	O
termed	O
the	O
CK	O
-	O
1	O
or	O
CD28RE	O
and	O
appears	O
to	O
bind	O
specific	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
family	O
of	O
transcription	O
factors	O
.	O
<EOS>	B-X
There	B-X
are	B-X
few	B-X
reported	B-X
cases	B-X
in	B-X
the	B-X
literature	B-X
of	B-X
this	B-X
association	B-X
,	B-X
which	B-X
is	B-X
termed	B-X
hypocalcemic	B-X
cardiomyopathy	B-X
.	B-X
We	B-X
report	B-X
the	B-X
case	B-X
of	B-X
a	B-X
61-year-old	B-X
woman	B-X
with	B-X
no	B-X
relevant	B-X
medical	B-X
history	B-X
,	B-X
admitted	B-X
for	B-X
progressively	B-X
worsening	B-X
exertional	B-X
dyspnea	B-X
,	B-X
orthopnea	B-X
and	B-X
edema	B-X
of	B-X
the	B-X
lower	B-X
limbs	B-X
for	B-X
a	B-X
previous	B-X
month	B-X
.	B-X
Physical	B-X
examination	B-X
showed	B-X
diffuse	B-X
muscle	B-X
spasms	B-X
,	B-X
with	B-X
no	B-X
signs	B-X
of	B-X
latent	B-X
tetany.Further	B-X
investigation	B-X
revealed	B-X
ionized	B-X
calcium	B-X
0.54	B-X
mmol/l	B-X
(	B-X
normal	B-X
1.12-1.30	B-X
)	B-X
,	B-X
phosphorus	B-X
9.8	B-X
mg/dl	B-X
,	B-X
parathyroid	B-X
hormone	B-X
<	B-X
2.5	B-X
pg/ml	B-X
and	B-X
CK	B-X
>	B-X
3000	B-X
U/l	B-X
,	B-X
with	B-X
normal	B-X
thyroid	B-X
function	B-X
.	B-X
The	B-X
echocardiogram	B-X
revealed	B-X
regional	B-X
wall	B-X
motion	B-X
abnormalities	B-X
,	B-X
coronary	B-X
angiography	B-X
was	B-X
normal	B-X
and	B-X
a	B-X
cranial	B-X
CT	B-X
scan	B-X
detected	B-X
calcification	B-X
of	B-X
basal	B-X
ganglia	B-X
and	B-X
white	B-X
matter	B-X
.	B-X

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
infects	O
T	O
cells	O
and	O
can	O
lead	O
to	O
increase	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
expression	O
.	O

We	O
have	O
found	O
that	O
the	O
HTLV	O
-	O
1	O
transactivator	O
protein	O
,	O
tax	B-Protein
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	O
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O
<EOS>	B-X
Antigen	B-X
complexed	B-X
with	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
I	B-X
or	B-X
II	B-X
molecules	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
antigen	B-X
presenting	B-X
cells	B-X
interacts	B-X
with	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
T	B-X
cells	B-X
and	B-X
initiates	B-X
an	B-X
activation	B-X
cascade	B-X
.	B-X
So	B-X
called	B-X
costimulatory	B-X
signals	B-X
,	B-X
mediated	B-X
by	B-X
other	B-X
cell	B-X
surface	B-X
interactions	B-X
or	B-X
soluble	B-X
cytokines	B-X
produced	B-X
by	B-X
antigen	B-X
presenting	B-X
cells	B-X
,	B-X
are	B-X
also	B-X
required	B-X
for	B-X
complete	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
also	B-X
required	B-X
both	B-X
TCR	B-X
and	B-X
costimulatory	B-X
signals	B-X
.	B-X
The	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
requires	B-X
sequences	B-X
in	B-X
the	B-X
promoter	B-X
as	B-X
well	B-X
as	B-X
a	B-X
powerful	B-X
enhancer	B-X
located	B-X
3kb	B-X
upstream	B-X
to	B-X
respond	B-X
to	B-X
TCR-like	B-X
signals	B-X
.	B-X
These	B-X
promoter	B-X
and	B-X
enhancer	B-X
regions	B-X
are	B-X
mainly	B-X
activated	B-X
by	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NFAT	B-X
)	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
NFAT	B-X
by	B-X
TCR	B-X
signals	B-X
has	B-X
been	B-X
well	B-X
described	B-X
for	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
and	B-X
IL-4	B-X
gene	B-X
transcription	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
Costimulatory	B-X
signals	B-X
,	B-X
such	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
CD28	B-X
cell	B-X
surface	B-X
molecule	B-X
on	B-X
T	B-X
cells	B-X
,	B-X
lead	B-X
to	B-X
activation	B-X
through	B-X
a	B-X
distinct	B-X
region	B-X
of	B-X
the	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
promoter	B-X
.	B-X
This	B-X
region	B-X
is	B-X
termed	B-X
the	B-X
CK-1	B-X
or	B-X
CD28RE	B-X
and	B-X
appears	B-X
to	B-X
bind	B-X
specific	B-X
members	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Human	B-X
T	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV-1	B-X
)	B-X
infects	B-X
T	B-X
cells	B-X
and	B-X
can	B-X
lead	B-X
to	B-X
increase	B-X
GM-CSF	B-X
expression	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
the	B-X
HTLV-1	B-X
transactivator	B-X
protein	B-X
,	B-X
tax	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
costimulatory	B-X
signal	B-X
for	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
gene	B-X
transcription	B-X
,	B-X
in	B-X
that	B-X
it	B-X
can	B-X
cooperate	B-X
with	B-X
TCR	B-X
signals	B-X
to	B-X
mediate	B-X
high	B-X
level	B-X
gene	B-X
expression	B-X
.	B-X
Tax	B-X
activates	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
through	B-X
the	B-X
CK-1/CD28RE	B-X
region	B-X
and	B-X
also	B-X
activates	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
binding	B-X
to	B-X
this	B-X
region	B-X
.	B-X
However	B-X
,	B-X
other	B-X
transcription	B-X
factors	B-X
or	B-X
coactivators	B-X
of	B-X
NF-kappa	B-X
B	B-X
are	B-X
required	B-X
for	B-X
tax	B-X
activation	B-X
but	B-X
these	B-X
remain	B-X
to	B-X
be	B-X
identified	B-X
.	B-X
The	B-X
CK-1/CD28RE	B-X
of	B-X
GM-CSF	B-X
shows	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
similarity	B-X
to	B-X
the	B-X
IL-2	B-X
CD28RE	B-X
and	B-X
the	B-X
IL-3	B-X
gene	B-X
also	B-X
contains	B-X
a	B-X
related	B-X
region	B-X
.	B-X
This	B-X
observation	B-X
,	B-X
together	B-X
with	B-X
the	B-X
fact	B-X
that	B-X
both	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
respond	B-X
to	B-X
TCR	B-X
signals	B-X
via	B-X
NFAT	B-X
,	B-X
implies	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
conservation	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
.	B-X

Tax	B-Protein
activates	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
through	O
the	O
CK	O
-	O
1	O
/	O
CD28RE	O
region	O
and	O
also	O
activates	O
nuclear	O
factor	O
-	O
kappa	O
B	O
binding	O
to	O
this	O
region	O
.	O
<EOS>	B-X
So	B-X
called	B-X
costimulatory	B-X
signals	B-X
,	B-X
mediated	B-X
by	B-X
other	B-X
cell	B-X
surface	B-X
interactions	B-X
or	B-X
soluble	B-X
cytokines	B-X
produced	B-X
by	B-X
antigen	B-X
presenting	B-X
cells	B-X
,	B-X
are	B-X
also	B-X
required	B-X
for	B-X
complete	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
also	B-X
required	B-X
both	B-X
TCR	B-X
and	B-X
costimulatory	B-X
signals	B-X
.	B-X
The	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
requires	B-X
sequences	B-X
in	B-X
the	B-X
promoter	B-X
as	B-X
well	B-X
as	B-X
a	B-X
powerful	B-X
enhancer	B-X
located	B-X
3kb	B-X
upstream	B-X
to	B-X
respond	B-X
to	B-X
TCR-like	B-X
signals	B-X
.	B-X
These	B-X
promoter	B-X
and	B-X
enhancer	B-X
regions	B-X
are	B-X
mainly	B-X
activated	B-X
by	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NFAT	B-X
)	B-X
.	B-X
Costimulatory	B-X
signals	B-X
,	B-X
such	B-X
as	B-X
activation	B-X
of	B-X
the	B-X
CD28	B-X
cell	B-X
surface	B-X
molecule	B-X
on	B-X
T	B-X
cells	B-X
,	B-X
lead	B-X
to	B-X
activation	B-X
through	B-X
a	B-X
distinct	B-X
region	B-X
of	B-X
the	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
promoter	B-X
.	B-X
This	B-X
region	B-X
is	B-X
termed	B-X
the	B-X
CK-1	B-X
or	B-X
CD28RE	B-X
and	B-X
appears	B-X
to	B-X
bind	B-X
specific	B-X
members	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Human	B-X
T	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV-1	B-X
)	B-X
infects	B-X
T	B-X
cells	B-X
and	B-X
can	B-X
lead	B-X
to	B-X
increase	B-X
GM-CSF	B-X
expression	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
the	B-X
HTLV-1	B-X
transactivator	B-X
protein	B-X
,	B-X
tax	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
costimulatory	B-X
signal	B-X
for	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
gene	B-X
transcription	B-X
,	B-X
in	B-X
that	B-X
it	B-X
can	B-X
cooperate	B-X
with	B-X
TCR	B-X
signals	B-X
to	B-X
mediate	B-X
high	B-X
level	B-X
gene	B-X
expression	B-X
.	B-X
Tax	B-X
activates	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
through	B-X
the	B-X
CK-1/CD28RE	B-X
region	B-X
and	B-X
also	B-X
activates	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
binding	B-X
to	B-X
this	B-X
region	B-X
.	B-X
However	B-X
,	B-X
other	B-X
transcription	B-X
factors	B-X
or	B-X
coactivators	B-X
of	B-X
NF-kappa	B-X
B	B-X
are	B-X
required	B-X
for	B-X
tax	B-X
activation	B-X
but	B-X
these	B-X
remain	B-X
to	B-X
be	B-X
identified	B-X
.	B-X
The	B-X
CK-1/CD28RE	B-X
of	B-X
GM-CSF	B-X
shows	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
similarity	B-X
to	B-X
the	B-X
IL-2	B-X
CD28RE	B-X
and	B-X
the	B-X
IL-3	B-X
gene	B-X
also	B-X
contains	B-X
a	B-X
related	B-X
region	B-X
.	B-X
This	B-X
observation	B-X
,	B-X
together	B-X
with	B-X
the	B-X
fact	B-X
that	B-X
both	B-X
GM-CSF	B-X
and	B-X
IL-2	B-X
respond	B-X
to	B-X
TCR	B-X
signals	B-X
via	B-X
NFAT	B-X
,	B-X
implies	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
conservation	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cytokine	B-X
gene	B-X
expression	B-X
in	B-X
T	B-X
cells	B-X
.	B-X

However	O
,	O
other	O
transcription	O
factors	O
or	O
coactivators	O
of	O
NF	O
-	O
kappa	O
B	O
are	O
required	O
for	O
tax	B-Protein
activation	O
but	O
these	O
remain	O
to	O
be	O
identified	O
.	O
<EOS>	B-X
WRKY	B-X
transcription	B-X
factors	B-X
are	B-X
one	B-X
of	B-X
the	B-X
largest	B-X
families	B-X
of	B-X
transcriptional	B-X
regulators	B-X
in	B-X
plants	B-X
and	B-X
form	B-X
integral	B-X
parts	B-X
of	B-X
signalling	B-X
webs	B-X
that	B-X
modulate	B-X
many	B-X
plant	B-X
processes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
recent	B-X
significant	B-X
progress	B-X
in	B-X
WRKY	B-X
transcription	B-X
factor	B-X
research	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
is	B-X
becoming	B-X
clear	B-X
that	B-X
a	B-X
single	B-X
WRKY	B-X
transcription	B-X
factor	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
regulating	B-X
several	B-X
seemingly	B-X
disparate	B-X
processes	B-X
.	B-X
Mechanisms	B-X
of	B-X
signalling	B-X
and	B-X
transcriptional	B-X
regulation	B-X
are	B-X
being	B-X
dissected	B-X
,	B-X
uncovering	B-X
WRKY	B-X
protein	B-X
functions	B-X
via	B-X
interactions	B-X
with	B-X
a	B-X
diverse	B-X
array	B-X
of	B-X
protein	B-X
partners	B-X
,	B-X
including	B-X
MAP	B-X
kinases	B-X
,	B-X
MAP	B-X
kinase	B-X
kinases	B-X
,	B-X
14-3-3	B-X
proteins	B-X
,	B-X
calmodulin	B-X
,	B-X
histone	B-X
deacetylases	B-X
,	B-X
resistance	B-X
proteins	B-X
and	B-X
other	B-X
WRKY	B-X
transcription	B-X
factors	B-X
.	B-X
WRKY	B-X
genes	B-X
exhibit	B-X
extensive	B-X
autoregulation	B-X
and	B-X
cross-regulation	B-X
that	B-X
facilitates	B-X
transcriptional	B-X
reprogramming	B-X
in	B-X
a	B-X
dynamic	B-X
web	B-X
with	B-X
built-in	B-X
redundancy	B-X
.	B-X

The	O
CK	O
-	O
1	O
/	O
CD28RE	O
of	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
CD28RE	O
and	O
the	O
IL	B-Protein
-	I-Protein
3	I-Protein
gene	O
also	O
contains	O
a	O
related	O
region	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
respond	O
to	O
TCR	O
signals	O
via	O
NFAT	O
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

MIP1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
,	O
a	O
novel	O
transcription	O
factor	O
expressed	O
in	O
hematopoietic	O
cells	O
that	O
is	O
crucial	O
for	O
transcription	O
of	O
the	O
human	O
MIP	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
gene	O
.	O
<EOS>	B-X
Murine	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
1	B-X
alpha	B-X
(	B-X
MIP-1	B-X
alpha	B-X
)	B-X
and	B-X
its	B-X
human	B-X
equivalent	B-X
(	B-X
GOS19	B-X
,	B-X
LD78	B-X
,	B-X
or	B-X
AT464	B-X
)	B-X
are	B-X
members	B-X
of	B-X
the	B-X
-C-C	B-X
family	B-X
of	B-X
low-molecular-weight	B-X
chemokines	B-X
.	B-X
Secreted	B-X
from	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
macrophages	B-X
,	B-X
bone	B-X
marrow-derived	B-X
MIP-1	B-X
alpha/GOS19	B-X
inhibits	B-X
primitive	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
homeostatic	B-X
control	B-X
of	B-X
stem	B-X
cell	B-X
proliferation	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
the	B-X
mechanisms	B-X
which	B-X
control	B-X
the	B-X
expression	B-X
of	B-X
MIP-1	B-X
alpha/GOS19	B-X
.	B-X
Previous	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
a	B-X
set	B-X
of	B-X
widely	B-X
expressed	B-X
transcription	B-X
factors	B-X
(	B-X
the	B-X
ICK-1	B-X
family	B-X
)	B-X
affect	B-X
the	B-X
GOS19	B-X
promoter	B-X
.	B-X
One	B-X
member	B-X
,	B-X
ICK-1A	B-X
,	B-X
behaves	B-X
as	B-X
a	B-X
strong	B-X
negative	B-X
regulator	B-X
.	B-X
In	B-X
this	B-X
communication	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
pathway	B-X
of	B-X
induction	B-X
in	B-X
the	B-X
macrophage	B-X
cell	B-X
line	B-X
U937	B-X
is	B-X
different	B-X
from	B-X
that	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ICK-1	B-X
binding	B-X
site	B-X
does	B-X
not	B-X
confer	B-X
negative	B-X
regulation	B-X
in	B-X
U937	B-X
cells	B-X
.	B-X
We	B-X
provide	B-X
evidence	B-X
for	B-X
an	B-X
additional	B-X
binding	B-X
site	B-X
,	B-X
the	B-X
MIP-1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
(	B-X
MNP	B-X
)	B-X
site	B-X
,	B-X
which	B-X
overlaps	B-X
the	B-X
ICK-1	B-X
site	B-X
.	B-X
Interaction	B-X
of	B-X
nuclear	B-X
extracts	B-X
from	B-X
various	B-X
cell	B-X
lines	B-X
and	B-X
tissue	B-X
with	B-X
the	B-X
MNP	B-X
site	B-X
leads	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
fast-migrating	B-X
protein-DNA	B-X
complexes	B-X
with	B-X
similar	B-X
but	B-X
distinct	B-X
electrophoretic	B-X
mobilities	B-X
.	B-X
A	B-X
mutation	B-X
of	B-X
the	B-X
MNP	B-X
site	B-X
which	B-X
does	B-X
not	B-X
abrogate	B-X
ICK-1	B-X
binding	B-X
inactivates	B-X
the	B-X
GOS19.1	B-X
promoter	B-X
in	B-X
U937	B-X
cells	B-X
and	B-X
reduces	B-X
its	B-X
activity	B-X
by	B-X
fourfold	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
MNP	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
binding	B-X
at	B-X
the	B-X
MNP	B-X
site	B-X
constitutes	B-X
a	B-X
novel	B-X
transcription	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
expressed	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X

Murine	O
macrophage	B-Protein
inflammatory	I-Protein
protein	I-Protein
1	I-Protein
alpha	I-Protein
(	O
MIP	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
)	O
and	O
its	O
human	O
equivalent	O
(	O
GOS19	B-Protein
,	O
LD78	B-Protein
,	O
or	O
AT464	B-Protein
)	O
are	O
members	O
of	O
the	O
-	O
C	O
-	O
C	O
family	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
chemokines	O
.	O

Secreted	O
from	O
activated	O
T	O
cells	O
and	O
macrophages	O
,	O
bone	O
marrow	O
-	O
derived	O
MIP	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
/	O
GOS19	B-Protein
inhibits	O
primitive	O
hematopoietic	O
stem	O
cells	O
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	O
cell	O
proliferation	O
.	O
<EOS>	B-X
Murine	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
1	B-X
alpha	B-X
(	B-X
MIP-1	B-X
alpha	B-X
)	B-X
and	B-X
its	B-X
human	B-X
equivalent	B-X
(	B-X
GOS19	B-X
,	B-X
LD78	B-X
,	B-X
or	B-X
AT464	B-X
)	B-X
are	B-X
members	B-X
of	B-X
the	B-X
-C-C	B-X
family	B-X
of	B-X
low-molecular-weight	B-X
chemokines	B-X
.	B-X
Secreted	B-X
from	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
macrophages	B-X
,	B-X
bone	B-X
marrow-derived	B-X
MIP-1	B-X
alpha/GOS19	B-X
inhibits	B-X
primitive	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
homeostatic	B-X
control	B-X
of	B-X
stem	B-X
cell	B-X
proliferation	B-X
.	B-X
It	B-X
also	B-X
induces	B-X
chemotaxis	B-X
and	B-X
inflammatory	B-X
responses	B-X
in	B-X
mature	B-X
cell	B-X
types	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
the	B-X
mechanisms	B-X
which	B-X
control	B-X
the	B-X
expression	B-X
of	B-X
MIP-1	B-X
alpha/GOS19	B-X
.	B-X
Previous	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
a	B-X
set	B-X
of	B-X
widely	B-X
expressed	B-X
transcription	B-X
factors	B-X
(	B-X
the	B-X
ICK-1	B-X
family	B-X
)	B-X
affect	B-X
the	B-X
GOS19	B-X
promoter	B-X
.	B-X
One	B-X
member	B-X
,	B-X
ICK-1A	B-X
,	B-X
behaves	B-X
as	B-X
a	B-X
strong	B-X
negative	B-X
regulator	B-X
.	B-X
In	B-X
this	B-X
communication	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
pathway	B-X
of	B-X
induction	B-X
in	B-X
the	B-X
macrophage	B-X
cell	B-X
line	B-X
U937	B-X
is	B-X
different	B-X
from	B-X
that	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ICK-1	B-X
binding	B-X
site	B-X
does	B-X
not	B-X
confer	B-X
negative	B-X
regulation	B-X
in	B-X
U937	B-X
cells	B-X
.	B-X
We	B-X
provide	B-X
evidence	B-X
for	B-X
an	B-X
additional	B-X
binding	B-X
site	B-X
,	B-X
the	B-X
MIP-1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
(	B-X
MNP	B-X
)	B-X
site	B-X
,	B-X
which	B-X
overlaps	B-X
the	B-X
ICK-1	B-X
site	B-X
.	B-X
Interaction	B-X
of	B-X
nuclear	B-X
extracts	B-X
from	B-X
various	B-X
cell	B-X
lines	B-X
and	B-X
tissue	B-X
with	B-X
the	B-X
MNP	B-X
site	B-X
leads	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
fast-migrating	B-X
protein-DNA	B-X
complexes	B-X
with	B-X
similar	B-X
but	B-X
distinct	B-X
electrophoretic	B-X
mobilities	B-X
.	B-X
A	B-X
mutation	B-X
of	B-X
the	B-X
MNP	B-X
site	B-X
which	B-X
does	B-X
not	B-X
abrogate	B-X
ICK-1	B-X
binding	B-X
inactivates	B-X
the	B-X
GOS19.1	B-X
promoter	B-X
in	B-X
U937	B-X
cells	B-X
and	B-X
reduces	B-X
its	B-X
activity	B-X
by	B-X
fourfold	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
MNP	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
binding	B-X
at	B-X
the	B-X
MNP	B-X
site	B-X
constitutes	B-X
a	B-X
novel	B-X
transcription	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
expressed	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	O
cell	O
types	O
.	O
<EOS>	B-X
The	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
initiated	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
a	B-X
pathogen	B-X
with	B-X
airway	B-X
surfaces	B-X
constitute	B-X
vital	B-X
mechanisms	B-X
to	B-X
eradicate	B-X
an	B-X
infection	B-X
.	B-X
Sentinel	B-X
dendritic	B-X
cells	B-X
embedded	B-X
in	B-X
the	B-X
mucosa	B-X
migrate	B-X
to	B-X
the	B-X
lymph	B-X
nodes	B-X
to	B-X
induce	B-X
immune	B-X
responses	B-X
,	B-X
whereas	B-X
epithelial	B-X
cells	B-X
release	B-X
chemokines	B-X
to	B-X
recruit	B-X
inflammatory	B-X
cells	B-X
engaged	B-X
in	B-X
the	B-X
active	B-X
destruction	B-X
of	B-X
the	B-X
intruder	B-X
.	B-X
All	B-X
immune	B-X
and	B-X
inflammatory	B-X
cells	B-X
are	B-X
regulated	B-X
by	B-X
customized	B-X
purinergic	B-X
networks	B-X
of	B-X
receptors	B-X
and	B-X
ectonucleotidases	B-X
.	B-X
The	B-X
general	B-X
concept	B-X
is	B-X
that	B-X
bacterial	B-X
products	B-X
induce	B-X
ATP	B-X
release	B-X
,	B-X
which	B-X
activates	B-X
P2	B-X
receptors	B-X
to	B-X
initiate	B-X
an	B-X
inflammatory	B-X
response	B-X
,	B-X
and	B-X
is	B-X
terminated	B-X
by	B-X
the	B-X
conversion	B-X
of	B-X
ATP	B-X
into	B-X
adenosine	B-X
(	B-X
ADO	B-X
)	B-X
to	B-X
initiate	B-X
P1	B-X
receptor-mediated	B-X
negative	B-X
feedback	B-X
responses	B-X
.	B-X
This	B-X
material	B-X
also	B-X
reconciles	B-X
decades	B-X
of	B-X
research	B-X
by	B-X
exposing	B-X
the	B-X
specificity	B-X
and	B-X
plasticity	B-X
of	B-X
the	B-X
signaling	B-X
network	B-X
expressed	B-X
by	B-X
each	B-X
immune	B-X
and	B-X
inflammatory	B-X
cell	B-X
,	B-X
which	B-X
changes	B-X
through	B-X
cell	B-X
differentiation	B-X
and	B-X
in	B-X
response	B-X
to	B-X
infectious	B-X
or	B-X
inflammatory	B-X
mediators	B-X
.	B-X

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
/	O
GOS19	B-Protein
.	O
<EOS>	B-X
Murine	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
1	B-X
alpha	B-X
(	B-X
MIP-1	B-X
alpha	B-X
)	B-X
and	B-X
its	B-X
human	B-X
equivalent	B-X
(	B-X
GOS19	B-X
,	B-X
LD78	B-X
,	B-X
or	B-X
AT464	B-X
)	B-X
are	B-X
members	B-X
of	B-X
the	B-X
-C-C	B-X
family	B-X
of	B-X
low-molecular-weight	B-X
chemokines	B-X
.	B-X
Secreted	B-X
from	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
macrophages	B-X
,	B-X
bone	B-X
marrow-derived	B-X
MIP-1	B-X
alpha/GOS19	B-X
inhibits	B-X
primitive	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
homeostatic	B-X
control	B-X
of	B-X
stem	B-X
cell	B-X
proliferation	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
the	B-X
mechanisms	B-X
which	B-X
control	B-X
the	B-X
expression	B-X
of	B-X
MIP-1	B-X
alpha/GOS19	B-X
.	B-X
Previous	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
a	B-X
set	B-X
of	B-X
widely	B-X
expressed	B-X
transcription	B-X
factors	B-X
(	B-X
the	B-X
ICK-1	B-X
family	B-X
)	B-X
affect	B-X
the	B-X
GOS19	B-X
promoter	B-X
.	B-X
One	B-X
member	B-X
,	B-X
ICK-1A	B-X
,	B-X
behaves	B-X
as	B-X
a	B-X
strong	B-X
negative	B-X
regulator	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ICK-1	B-X
binding	B-X
site	B-X
does	B-X
not	B-X
confer	B-X
negative	B-X
regulation	B-X
in	B-X
U937	B-X
cells	B-X
.	B-X
We	B-X
provide	B-X
evidence	B-X
for	B-X
an	B-X
additional	B-X
binding	B-X
site	B-X
,	B-X
the	B-X
MIP-1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
(	B-X
MNP	B-X
)	B-X
site	B-X
,	B-X
which	B-X
overlaps	B-X
the	B-X
ICK-1	B-X
site	B-X
.	B-X
A	B-X
mutation	B-X
of	B-X
the	B-X
MNP	B-X
site	B-X
which	B-X
does	B-X
not	B-X
abrogate	B-X
ICK-1	B-X
binding	B-X
inactivates	B-X
the	B-X
GOS19.1	B-X
promoter	B-X
in	B-X
U937	B-X
cells	B-X
and	B-X
reduces	B-X
its	B-X
activity	B-X
by	B-X
fourfold	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	O
T	O
cells	O
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	O
factors	O
(	O
the	O
ICK	O
-	O
1	O
family	O
)	O
affect	O
the	O
GOS19	B-Protein
promoter	O
.	O

One	O
member	O
,	O
ICK	B-Protein
-	I-Protein
1A	I-Protein
,	O
behaves	O
as	O
a	O
strong	O
negative	O
regulator	O
.	O

In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	O
cell	O
line	O
U937	O
is	O
different	O
from	O
that	O
in	O
Jurkat	O
cells	O
.	O
<EOS>	B-X
Murine	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
1	B-X
alpha	B-X
(	B-X
MIP-1	B-X
alpha	B-X
)	B-X
and	B-X
its	B-X
human	B-X
equivalent	B-X
(	B-X
GOS19	B-X
,	B-X
LD78	B-X
,	B-X
or	B-X
AT464	B-X
)	B-X
are	B-X
members	B-X
of	B-X
the	B-X
-C-C	B-X
family	B-X
of	B-X
low-molecular-weight	B-X
chemokines	B-X
.	B-X
Secreted	B-X
from	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
macrophages	B-X
,	B-X
bone	B-X
marrow-derived	B-X
MIP-1	B-X
alpha/GOS19	B-X
inhibits	B-X
primitive	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
homeostatic	B-X
control	B-X
of	B-X
stem	B-X
cell	B-X
proliferation	B-X
.	B-X
It	B-X
also	B-X
induces	B-X
chemotaxis	B-X
and	B-X
inflammatory	B-X
responses	B-X
in	B-X
mature	B-X
cell	B-X
types	B-X
.	B-X
Previous	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
a	B-X
set	B-X
of	B-X
widely	B-X
expressed	B-X
transcription	B-X
factors	B-X
(	B-X
the	B-X
ICK-1	B-X
family	B-X
)	B-X
affect	B-X
the	B-X
GOS19	B-X
promoter	B-X
.	B-X
In	B-X
this	B-X
communication	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
pathway	B-X
of	B-X
induction	B-X
in	B-X
the	B-X
macrophage	B-X
cell	B-X
line	B-X
U937	B-X
is	B-X
different	B-X
from	B-X
that	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ICK-1	B-X
binding	B-X
site	B-X
does	B-X
not	B-X
confer	B-X
negative	B-X
regulation	B-X
in	B-X
U937	B-X
cells	B-X
.	B-X
We	B-X
provide	B-X
evidence	B-X
for	B-X
an	B-X
additional	B-X
binding	B-X
site	B-X
,	B-X
the	B-X
MIP-1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
(	B-X
MNP	B-X
)	B-X
site	B-X
,	B-X
which	B-X
overlaps	B-X
the	B-X
ICK-1	B-X
site	B-X
.	B-X
Interaction	B-X
of	B-X
nuclear	B-X
extracts	B-X
from	B-X
various	B-X
cell	B-X
lines	B-X
and	B-X
tissue	B-X
with	B-X
the	B-X
MNP	B-X
site	B-X
leads	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
fast-migrating	B-X
protein-DNA	B-X
complexes	B-X
with	B-X
similar	B-X
but	B-X
distinct	B-X
electrophoretic	B-X
mobilities	B-X
.	B-X
A	B-X
mutation	B-X
of	B-X
the	B-X
MNP	B-X
site	B-X
which	B-X
does	B-X
not	B-X
abrogate	B-X
ICK-1	B-X
binding	B-X
inactivates	B-X
the	B-X
GOS19.1	B-X
promoter	B-X
in	B-X
U937	B-X
cells	B-X
and	B-X
reduces	B-X
its	B-X
activity	B-X
by	B-X
fourfold	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
MNP	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
binding	B-X
at	B-X
the	B-X
MNP	B-X
site	B-X
constitutes	B-X
a	B-X
novel	B-X
transcription	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
expressed	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X

Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK	O
-	O
1	O
binding	O
site	O
does	O
not	O
confer	O
negative	O
regulation	O
in	O
U937	O
cells	O
.	O
<EOS>	B-X
Jingzhaotoxin-III	B-X
(	B-X
JZTX-III	B-X
)	B-X
is	B-X
a	B-X
peptide	B-X
toxin	B-X
isolated	B-X
from	B-X
the	B-X
venom	B-X
of	B-X
the	B-X
Chinese	B-X
spider	B-X
Chilobrachys	B-X
jingzhao	B-X
that	B-X
inhibits	B-X
Nav	B-X
channels	B-X
of	B-X
rat	B-X
cardiac	B-X
myocytes	B-X
by	B-X
modifying	B-X
voltage-dependent	B-X
gating	B-X
and	B-X
also	B-X
binds	B-X
to	B-X
Kv2.1	B-X
channel	B-X
(	B-X
Kd	B-X
=	B-X
0.43	B-X
microM	B-X
)	B-X
with	B-X
an	B-X
action	B-X
model	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
hanatoxin1	B-X
and	B-X
SGTx1	B-X
.	B-X
The	B-X
solution	B-X
structure	B-X
of	B-X
JZTX-III	B-X
was	B-X
determined	B-X
by	B-X
(	B-X
1	B-X
)	B-X
H	B-X
2D	B-X
NMR	B-X
method	B-X
.	B-X
The	B-X
toxin	B-X
adopts	B-X
an	B-X
ICK	B-X
motif	B-X
composed	B-X
of	B-X
three	B-X
beta-strands	B-X
connected	B-X
by	B-X
four	B-X
turns	B-X
.	B-X
Structural	B-X
comparison	B-X
of	B-X
JZTX-III	B-X
with	B-X
those	B-X
of	B-X
other	B-X
ICK	B-X
motif	B-X
peptides	B-X
shows	B-X
that	B-X
they	B-X
all	B-X
adopt	B-X
a	B-X
conserved	B-X
surface	B-X
profile	B-X
,	B-X
a	B-X
hydrophobic	B-X
patch	B-X
surrounded	B-X
by	B-X
charged	B-X
residues	B-X
,	B-X
which	B-X
might	B-X
be	B-X
the	B-X
crucial	B-X
site	B-X
for	B-X
voltage-gating	B-X
ion	B-X
channel	B-X
inhibition	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
similar	B-X
action	B-X
model	B-X
of	B-X
JZTX-III	B-X
affecting	B-X
both	B-X
Kv	B-X
and	B-X
Nav	B-X
channels	B-X
implies	B-X
that	B-X
JZTX-III	B-X
recognized	B-X
a	B-X
conserved	B-X
receptor	B-X
within	B-X
the	B-X
voltage	B-X
sensing	B-X
domains	B-X
,	B-X
which	B-X
is	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
hanatoxin1	B-X
binding	B-X
to	B-X
both	B-X
Kv	B-X
and	B-X
Cav	B-X
channels	B-X
.	B-X

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	O
site	O
,	O
the	O
MIP	O
-	O
1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
site	O
,	O
which	O
overlaps	O
the	O
ICK	O
-	O
1	O
site	O
.	O
<EOS>	B-X
Murine	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
1	B-X
alpha	B-X
(	B-X
MIP-1	B-X
alpha	B-X
)	B-X
and	B-X
its	B-X
human	B-X
equivalent	B-X
(	B-X
GOS19	B-X
,	B-X
LD78	B-X
,	B-X
or	B-X
AT464	B-X
)	B-X
are	B-X
members	B-X
of	B-X
the	B-X
-C-C	B-X
family	B-X
of	B-X
low-molecular-weight	B-X
chemokines	B-X
.	B-X
Secreted	B-X
from	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
macrophages	B-X
,	B-X
bone	B-X
marrow-derived	B-X
MIP-1	B-X
alpha/GOS19	B-X
inhibits	B-X
primitive	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
homeostatic	B-X
control	B-X
of	B-X
stem	B-X
cell	B-X
proliferation	B-X
.	B-X
Therefore	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
understand	B-X
the	B-X
mechanisms	B-X
which	B-X
control	B-X
the	B-X
expression	B-X
of	B-X
MIP-1	B-X
alpha/GOS19	B-X
.	B-X
Previous	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
a	B-X
set	B-X
of	B-X
widely	B-X
expressed	B-X
transcription	B-X
factors	B-X
(	B-X
the	B-X
ICK-1	B-X
family	B-X
)	B-X
affect	B-X
the	B-X
GOS19	B-X
promoter	B-X
.	B-X
One	B-X
member	B-X
,	B-X
ICK-1A	B-X
,	B-X
behaves	B-X
as	B-X
a	B-X
strong	B-X
negative	B-X
regulator	B-X
.	B-X
In	B-X
this	B-X
communication	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
pathway	B-X
of	B-X
induction	B-X
in	B-X
the	B-X
macrophage	B-X
cell	B-X
line	B-X
U937	B-X
is	B-X
different	B-X
from	B-X
that	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ICK-1	B-X
binding	B-X
site	B-X
does	B-X
not	B-X
confer	B-X
negative	B-X
regulation	B-X
in	B-X
U937	B-X
cells	B-X
.	B-X
We	B-X
provide	B-X
evidence	B-X
for	B-X
an	B-X
additional	B-X
binding	B-X
site	B-X
,	B-X
the	B-X
MIP-1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
(	B-X
MNP	B-X
)	B-X
site	B-X
,	B-X
which	B-X
overlaps	B-X
the	B-X
ICK-1	B-X
site	B-X
.	B-X
Interaction	B-X
of	B-X
nuclear	B-X
extracts	B-X
from	B-X
various	B-X
cell	B-X
lines	B-X
and	B-X
tissue	B-X
with	B-X
the	B-X
MNP	B-X
site	B-X
leads	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
fast-migrating	B-X
protein-DNA	B-X
complexes	B-X
with	B-X
similar	B-X
but	B-X
distinct	B-X
electrophoretic	B-X
mobilities	B-X
.	B-X
A	B-X
mutation	B-X
of	B-X
the	B-X
MNP	B-X
site	B-X
which	B-X
does	B-X
not	B-X
abrogate	B-X
ICK-1	B-X
binding	B-X
inactivates	B-X
the	B-X
GOS19.1	B-X
promoter	B-X
in	B-X
U937	B-X
cells	B-X
and	B-X
reduces	B-X
its	B-X
activity	B-X
by	B-X
fourfold	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
MNP	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
binding	B-X
at	B-X
the	B-X
MNP	B-X
site	B-X
constitutes	B-X
a	B-X
novel	B-X
transcription	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
expressed	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X

Interaction	O
of	O
nuclear	O
extracts	O
from	O
various	O
cell	O
lines	O
and	O
tissue	O
with	O
the	O
MNP	O
site	O
leads	O
to	O
the	O
formation	O
of	O
fast	O
-	O
migrating	O
protein	O
-	O
DNA	O
complexes	O
with	O
similar	O
but	O
distinct	O
electrophoretic	O
mobilities	O
.	O

A	O
mutation	O
of	O
the	O
MNP	O
site	O
which	O
does	O
not	O
abrogate	O
ICK	O
-	O
1	O
binding	O
inactivates	O
the	O
GOS19	O
.	O
1	O
promoter	O
in	O
U937	O
cells	O
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	O
cells	O
.	O
<EOS>	B-X
Crystallographic	B-X
,	B-X
spectroscopic	B-X
,	B-X
directed	B-X
mutagenesis	B-X
,	B-X
and	B-X
kinetic	B-X
studies	B-X
showed	B-X
that	B-X
these	B-X
'hybrid	B-X
'	B-X
properties	B-X
are	B-X
due	B-X
to	B-X
the	B-X
coexistence	B-X
in	B-X
a	B-X
single	B-X
protein	B-X
of	B-X
different	B-X
catalytic	B-X
sites	B-X
reminiscent	B-X
of	B-X
those	B-X
present	B-X
in	B-X
the	B-X
other	B-X
basidiomycete	B-X
peroxidase	B-X
families	B-X
.	B-X
Crystal	B-X
structures	B-X
of	B-X
wild	B-X
and	B-X
recombinant	B-X
VP	B-X
,	B-X
and	B-X
kinetics	B-X
of	B-X
mutated	B-X
variants	B-X
,	B-X
revealed	B-X
certain	B-X
differences	B-X
in	B-X
its	B-X
Mn-oxidation	B-X
site	B-X
compared	B-X
with	B-X
MnP	B-X
.	B-X
These	B-X
result	B-X
in	B-X
efficient	B-X
Mn	B-X
(	B-X
2+	B-X
)	B-X
oxidation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
only	B-X
two	B-X
of	B-X
the	B-X
three	B-X
acidic	B-X
residues	B-X
forming	B-X
its	B-X
binding	B-X
site	B-X
.	B-X
These	B-X
compounds	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
AMPK	B-X
through	B-X
binding	B-X
to	B-X
a	B-X
novel	B-X
allosteric	B-X
drug	B-X
and	B-X
metabolite	B-X
(	B-X
ADaM	B-X
)	B-X
-binding	B-X
site	B-X
on	B-X
AMPK	B-X
,	B-X
and	B-X
it	B-X
is	B-X
possible	B-X
that	B-X
other	B-X
molecules	B-X
might	B-X
similarly	B-X
bind	B-X
this	B-X
site	B-X
.	B-X
We	B-X
identified	B-X
a	B-X
natural	B-X
plant	B-X
dihydrophenathrene	B-X
,	B-X
Lusianthridin	B-X
,	B-X
which	B-X
allosterically	B-X
activates	B-X
and	B-X
protects	B-X
AMPK	B-X
from	B-X
dephosphorylation	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
ADaM	B-X
site	B-X
.	B-X
Similar	B-X
to	B-X
other	B-X
ADaM	B-X
site	B-X
activators	B-X
,	B-X
Lusianthridin	B-X
showed	B-X
preferential	B-X
activation	B-X
of	B-X
AMPKβ1-containing	B-X
complexes	B-X
in	B-X
intact	B-X
cells	B-X
and	B-X
was	B-X
unable	B-X
to	B-X
activate	B-X
an	B-X
AMPKβ1	B-X
S108A	B-X
mutant	B-X
.	B-X
This	B-X
ability	B-X
of	B-X
Lusianthridin	B-X
to	B-X
inhibit	B-X
lipogenesis	B-X
was	B-X
impaired	B-X
in	B-X
hepatocytes	B-X
from	B-X
β1	B-X
S108A	B-X
knock-in	B-X
mice	B-X
and	B-X
mice	B-X
bearing	B-X
a	B-X
mutation	B-X
at	B-X
the	B-X
AMPK	B-X
phosphorylation	B-X
site	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
1/2	B-X
.	B-X
The	B-X
emergence	B-X
of	B-X
natural	B-X
plant	B-X
compounds	B-X
that	B-X
regulate	B-X
AMPK	B-X
through	B-X
the	B-X
ADaM	B-X
site	B-X
raises	B-X
the	B-X
distinct	B-X
possibility	B-X
that	B-X
other	B-X
natural	B-X
compounds	B-X
share	B-X
a	B-X
common	B-X
mechanism	B-X
of	B-X
regulation	B-X
.	B-X

We	O
propose	O
that	O
the	O
MNP	O
protein	O
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	O
site	O
constitutes	O
a	O
novel	O
transcription	O
factor	O
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O
<EOS>	B-X
Murine	B-X
macrophage	B-X
inflammatory	B-X
protein	B-X
1	B-X
alpha	B-X
(	B-X
MIP-1	B-X
alpha	B-X
)	B-X
and	B-X
its	B-X
human	B-X
equivalent	B-X
(	B-X
GOS19	B-X
,	B-X
LD78	B-X
,	B-X
or	B-X
AT464	B-X
)	B-X
are	B-X
members	B-X
of	B-X
the	B-X
-C-C	B-X
family	B-X
of	B-X
low-molecular-weight	B-X
chemokines	B-X
.	B-X
Secreted	B-X
from	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
macrophages	B-X
,	B-X
bone	B-X
marrow-derived	B-X
MIP-1	B-X
alpha/GOS19	B-X
inhibits	B-X
primitive	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
and	B-X
appears	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
homeostatic	B-X
control	B-X
of	B-X
stem	B-X
cell	B-X
proliferation	B-X
.	B-X
Previous	B-X
work	B-X
has	B-X
shown	B-X
that	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
a	B-X
set	B-X
of	B-X
widely	B-X
expressed	B-X
transcription	B-X
factors	B-X
(	B-X
the	B-X
ICK-1	B-X
family	B-X
)	B-X
affect	B-X
the	B-X
GOS19	B-X
promoter	B-X
.	B-X
In	B-X
this	B-X
communication	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
the	B-X
pathway	B-X
of	B-X
induction	B-X
in	B-X
the	B-X
macrophage	B-X
cell	B-X
line	B-X
U937	B-X
is	B-X
different	B-X
from	B-X
that	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ICK-1	B-X
binding	B-X
site	B-X
does	B-X
not	B-X
confer	B-X
negative	B-X
regulation	B-X
in	B-X
U937	B-X
cells	B-X
.	B-X
We	B-X
provide	B-X
evidence	B-X
for	B-X
an	B-X
additional	B-X
binding	B-X
site	B-X
,	B-X
the	B-X
MIP-1	B-X
alpha	B-X
nuclear	B-X
protein	B-X
(	B-X
MNP	B-X
)	B-X
site	B-X
,	B-X
which	B-X
overlaps	B-X
the	B-X
ICK-1	B-X
site	B-X
.	B-X
Interaction	B-X
of	B-X
nuclear	B-X
extracts	B-X
from	B-X
various	B-X
cell	B-X
lines	B-X
and	B-X
tissue	B-X
with	B-X
the	B-X
MNP	B-X
site	B-X
leads	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
fast-migrating	B-X
protein-DNA	B-X
complexes	B-X
with	B-X
similar	B-X
but	B-X
distinct	B-X
electrophoretic	B-X
mobilities	B-X
.	B-X
A	B-X
mutation	B-X
of	B-X
the	B-X
MNP	B-X
site	B-X
which	B-X
does	B-X
not	B-X
abrogate	B-X
ICK-1	B-X
binding	B-X
inactivates	B-X
the	B-X
GOS19.1	B-X
promoter	B-X
in	B-X
U937	B-X
cells	B-X
and	B-X
reduces	B-X
its	B-X
activity	B-X
by	B-X
fourfold	B-X
in	B-X
Jurkat	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
the	B-X
MNP	B-X
protein	B-X
(	B-X
s	B-X
)	B-X
binding	B-X
at	B-X
the	B-X
MNP	B-X
site	B-X
constitutes	B-X
a	B-X
novel	B-X
transcription	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
expressed	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X

Ligand	O
-	O
dependent	O
repression	O
of	O
the	O
erythroid	O
transcription	O
factor	O
GATA	B-Protein
-	I-Protein
1	I-Protein
by	O
the	O
estrogen	B-Protein
receptor	I-Protein
.	O
<EOS>	B-X
High-dose	B-X
estrogen	B-X
administration	B-X
induces	B-X
anemia	B-X
in	B-X
mammals	B-X
.	B-X
In	B-X
chickens	B-X
,	B-X
estrogens	B-X
stimulate	B-X
outgrowth	B-X
of	B-X
bone	B-X
marrow-derived	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
and	B-X
delay	B-X
their	B-X
maturation	B-X
.	B-X
This	B-X
delay	B-X
is	B-X
associated	B-X
with	B-X
down-regulation	B-X
of	B-X
many	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
,	B-X
including	B-X
alpha-	B-X
and	B-X
beta-globin	B-X
,	B-X
band	B-X
3	B-X
,	B-X
band	B-X
4.1	B-X
,	B-X
and	B-X
the	B-X
erythroid	B-X
cell-specific	B-X
histone	B-X
H5	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
estrogens	B-X
also	B-X
reduce	B-X
the	B-X
number	B-X
of	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
in	B-X
primary	B-X
human	B-X
bone	B-X
marrow	B-X
cultures	B-X
.	B-X
To	B-X
address	B-X
potential	B-X
mechanisms	B-X
by	B-X
which	B-X
estrogens	B-X
suppress	B-X
erythropoiesis	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
their	B-X
effects	B-X
on	B-X
GATA-1	B-X
,	B-X
an	B-X
erythroid	B-X
transcription	B-X
factor	B-X
that	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
and	B-X
is	B-X
necessary	B-X
for	B-X
full	B-X
maturation	B-X
of	B-X
erythrocytes	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
GATA-1	B-X
is	B-X
strongly	B-X
repressed	B-X
by	B-X
the	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
and	B-X
that	B-X
this	B-X
repression	B-X
is	B-X
reversible	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
4-hydroxytamoxifen	B-X
.	B-X
ER-mediated	B-X
repression	B-X
of	B-X
GATA-1	B-X
activity	B-X
occurs	B-X
on	B-X
an	B-X
artificial	B-X
promoter	B-X
containing	B-X
a	B-X
single	B-X
GATA-binding	B-X
site	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
an	B-X
intact	B-X
promoter	B-X
which	B-X
is	B-X
normally	B-X
regulated	B-X
by	B-X
GATA-1	B-X
.	B-X
GATA-1	B-X
and	B-X
ER	B-X
bind	B-X
to	B-X
each	B-X
other	B-X
in	B-X
vitro	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
DNA	B-X
.	B-X
In	B-X
coimmunoprecipitation	B-X
experiments	B-X
using	B-X
transfected	B-X
COS	B-X
cells	B-X
,	B-X
GATA-1	B-X
and	B-X
ER	B-X
associate	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
.	B-X
Mapping	B-X
experiments	B-X
indicate	B-X
that	B-X
GATA-1	B-X
and	B-X
the	B-X
ER	B-X
form	B-X
at	B-X
least	B-X
two	B-X
contacts	B-X
,	B-X
which	B-X
involve	B-X
the	B-X
finger	B-X
region	B-X
and	B-X
the	B-X
N-terminal	B-X
activation	B-X
domain	B-X
of	B-X
GATA-1	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
estrogens	B-X
exert	B-X
effects	B-X
on	B-X
erythropoiesis	B-X
by	B-X
modulating	B-X
GATA-1	B-X
activity	B-X
through	B-X
protein-protein	B-X
interaction	B-X
with	B-X
the	B-X
ER	B-X
.	B-X
Interference	B-X
with	B-X
GATA-binding	B-X
proteins	B-X
may	B-X
be	B-X
one	B-X
mechanism	B-X
by	B-X
which	B-X
steroid	B-X
hormones	B-X
modulate	B-X
cellular	B-X
differentiation	B-X
.	B-X

High	O
-	O
dose	O
estrogen	O
administration	O
induces	O
anemia	O
in	O
mammals	O
.	O
<EOS>	B-X
High-dose	B-X
estrogen	B-X
administration	B-X
induces	B-X
anemia	B-X
in	B-X
mammals	B-X
.	B-X
In	B-X
chickens	B-X
,	B-X
estrogens	B-X
stimulate	B-X
outgrowth	B-X
of	B-X
bone	B-X
marrow-derived	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
and	B-X
delay	B-X
their	B-X
maturation	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
estrogens	B-X
also	B-X
reduce	B-X
the	B-X
number	B-X
of	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
in	B-X
primary	B-X
human	B-X
bone	B-X
marrow	B-X
cultures	B-X
.	B-X
To	B-X
address	B-X
potential	B-X
mechanisms	B-X
by	B-X
which	B-X
estrogens	B-X
suppress	B-X
erythropoiesis	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
their	B-X
effects	B-X
on	B-X
GATA-1	B-X
,	B-X
an	B-X
erythroid	B-X
transcription	B-X
factor	B-X
that	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
and	B-X
is	B-X
necessary	B-X
for	B-X
full	B-X
maturation	B-X
of	B-X
erythrocytes	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
GATA-1	B-X
is	B-X
strongly	B-X
repressed	B-X
by	B-X
the	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
and	B-X
that	B-X
this	B-X
repression	B-X
is	B-X
reversible	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
4-hydroxytamoxifen	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
estrogens	B-X
exert	B-X
effects	B-X
on	B-X
erythropoiesis	B-X
by	B-X
modulating	B-X
GATA-1	B-X
activity	B-X
through	B-X
protein-protein	B-X
interaction	B-X
with	B-X
the	B-X
ER	B-X
.	B-X

In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	O
marrow	O
-	O
derived	O
erythroid	O
progenitor	O
cells	O
and	O
delay	O
their	O
maturation	O
.	O
<EOS>	B-X
In	B-X
chickens	B-X
,	B-X
estrogens	B-X
stimulate	B-X
outgrowth	B-X
of	B-X
bone	B-X
marrow-derived	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
and	B-X
delay	B-X
their	B-X
maturation	B-X
.	B-X
This	B-X
delay	B-X
is	B-X
associated	B-X
with	B-X
down-regulation	B-X
of	B-X
many	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
,	B-X
including	B-X
alpha-	B-X
and	B-X
beta-globin	B-X
,	B-X
band	B-X
3	B-X
,	B-X
band	B-X
4.1	B-X
,	B-X
and	B-X
the	B-X
erythroid	B-X
cell-specific	B-X
histone	B-X
H5	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
estrogens	B-X
also	B-X
reduce	B-X
the	B-X
number	B-X
of	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
in	B-X
primary	B-X
human	B-X
bone	B-X
marrow	B-X
cultures	B-X
.	B-X
To	B-X
address	B-X
potential	B-X
mechanisms	B-X
by	B-X
which	B-X
estrogens	B-X
suppress	B-X
erythropoiesis	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
their	B-X
effects	B-X
on	B-X
GATA-1	B-X
,	B-X
an	B-X
erythroid	B-X
transcription	B-X
factor	B-X
that	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
and	B-X
is	B-X
necessary	B-X
for	B-X
full	B-X
maturation	B-X
of	B-X
erythrocytes	B-X
.	B-X
In	B-X
coimmunoprecipitation	B-X
experiments	B-X
using	B-X
transfected	B-X
COS	B-X
cells	B-X
,	B-X
GATA-1	B-X
and	B-X
ER	B-X
associate	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
estrogens	B-X
exert	B-X
effects	B-X
on	B-X
erythropoiesis	B-X
by	B-X
modulating	B-X
GATA-1	B-X
activity	B-X
through	B-X
protein-protein	B-X
interaction	B-X
with	B-X
the	B-X
ER	B-X
.	B-X

This	O
delay	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
many	O
erythroid	O
cell	O
-	O
specific	O
genes	O
,	O
including	O
alpha	B-Protein
-	I-Protein
and	O
beta	B-Protein
-	I-Protein
globin	I-Protein
,	O
band	O
3	O
,	O
band	O
4	O
.	O
1	O
,	O
and	O
the	O
erythroid	O
cell	O
-	O
specific	O
histone	O
H5	B-Protein
.	O
<EOS>	B-X
In	B-X
chickens	B-X
,	B-X
estrogens	B-X
stimulate	B-X
outgrowth	B-X
of	B-X
bone	B-X
marrow-derived	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
and	B-X
delay	B-X
their	B-X
maturation	B-X
.	B-X
This	B-X
delay	B-X
is	B-X
associated	B-X
with	B-X
down-regulation	B-X
of	B-X
many	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
,	B-X
including	B-X
alpha-	B-X
and	B-X
beta-globin	B-X
,	B-X
band	B-X
3	B-X
,	B-X
band	B-X
4.1	B-X
,	B-X
and	B-X
the	B-X
erythroid	B-X
cell-specific	B-X
histone	B-X
H5	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
estrogens	B-X
also	B-X
reduce	B-X
the	B-X
number	B-X
of	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
in	B-X
primary	B-X
human	B-X
bone	B-X
marrow	B-X
cultures	B-X
.	B-X
To	B-X
address	B-X
potential	B-X
mechanisms	B-X
by	B-X
which	B-X
estrogens	B-X
suppress	B-X
erythropoiesis	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
their	B-X
effects	B-X
on	B-X
GATA-1	B-X
,	B-X
an	B-X
erythroid	B-X
transcription	B-X
factor	B-X
that	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
and	B-X
is	B-X
necessary	B-X
for	B-X
full	B-X
maturation	B-X
of	B-X
erythrocytes	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
GATA-1	B-X
is	B-X
strongly	B-X
repressed	B-X
by	B-X
the	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
and	B-X
that	B-X
this	B-X
repression	B-X
is	B-X
reversible	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
4-hydroxytamoxifen	B-X
.	B-X
ER-mediated	B-X
repression	B-X
of	B-X
GATA-1	B-X
activity	B-X
occurs	B-X
on	B-X
an	B-X
artificial	B-X
promoter	B-X
containing	B-X
a	B-X
single	B-X
GATA-binding	B-X
site	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
an	B-X
intact	B-X
promoter	B-X
which	B-X
is	B-X
normally	B-X
regulated	B-X
by	B-X
GATA-1	B-X
.	B-X
GATA-1	B-X
and	B-X
ER	B-X
bind	B-X
to	B-X
each	B-X
other	B-X
in	B-X
vitro	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
DNA	B-X
.	B-X
In	B-X
coimmunoprecipitation	B-X
experiments	B-X
using	B-X
transfected	B-X
COS	B-X
cells	B-X
,	B-X
GATA-1	B-X
and	B-X
ER	B-X
associate	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
.	B-X
Mapping	B-X
experiments	B-X
indicate	B-X
that	B-X
GATA-1	B-X
and	B-X
the	B-X
ER	B-X
form	B-X
at	B-X
least	B-X
two	B-X
contacts	B-X
,	B-X
which	B-X
involve	B-X
the	B-X
finger	B-X
region	B-X
and	B-X
the	B-X
N-terminal	B-X
activation	B-X
domain	B-X
of	B-X
GATA-1	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
estrogens	B-X
exert	B-X
effects	B-X
on	B-X
erythropoiesis	B-X
by	B-X
modulating	B-X
GATA-1	B-X
activity	B-X
through	B-X
protein-protein	B-X
interaction	B-X
with	B-X
the	B-X
ER	B-X
.	B-X
Interference	B-X
with	B-X
GATA-binding	B-X
proteins	B-X
may	B-X
be	B-X
one	B-X
mechanism	B-X
by	B-X
which	B-X
steroid	B-X
hormones	B-X
modulate	B-X
cellular	B-X
differentiation	B-X
.	B-X

We	O
show	O
here	O
that	O
estrogens	O
also	O
reduce	O
the	O
number	O
of	O
erythroid	O
progenitor	O
cells	O
in	O
primary	O
human	O
bone	O
marrow	O
cultures	O
.	O
<EOS>	B-X
In	B-X
chickens	B-X
,	B-X
estrogens	B-X
stimulate	B-X
outgrowth	B-X
of	B-X
bone	B-X
marrow-derived	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
and	B-X
delay	B-X
their	B-X
maturation	B-X
.	B-X
This	B-X
delay	B-X
is	B-X
associated	B-X
with	B-X
down-regulation	B-X
of	B-X
many	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
,	B-X
including	B-X
alpha-	B-X
and	B-X
beta-globin	B-X
,	B-X
band	B-X
3	B-X
,	B-X
band	B-X
4.1	B-X
,	B-X
and	B-X
the	B-X
erythroid	B-X
cell-specific	B-X
histone	B-X
H5	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
estrogens	B-X
also	B-X
reduce	B-X
the	B-X
number	B-X
of	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
in	B-X
primary	B-X
human	B-X
bone	B-X
marrow	B-X
cultures	B-X
.	B-X
To	B-X
address	B-X
potential	B-X
mechanisms	B-X
by	B-X
which	B-X
estrogens	B-X
suppress	B-X
erythropoiesis	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
their	B-X
effects	B-X
on	B-X
GATA-1	B-X
,	B-X
an	B-X
erythroid	B-X
transcription	B-X
factor	B-X
that	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
and	B-X
is	B-X
necessary	B-X
for	B-X
full	B-X
maturation	B-X
of	B-X
erythrocytes	B-X
.	B-X
In	B-X
coimmunoprecipitation	B-X
experiments	B-X
using	B-X
transfected	B-X
COS	B-X
cells	B-X
,	B-X
GATA-1	B-X
and	B-X
ER	B-X
associate	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
estrogens	B-X
exert	B-X
effects	B-X
on	B-X
erythropoiesis	B-X
by	B-X
modulating	B-X
GATA-1	B-X
activity	B-X
through	B-X
protein-protein	B-X
interaction	B-X
with	B-X
the	B-X
ER	B-X
.	B-X

To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	O
on	O
GATA	B-Protein
-	I-Protein
1	I-Protein
,	O
an	O
erythroid	O
transcription	O
factor	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	O
cell	O
-	O
specific	O
genes	O
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	O
.	O
<EOS>	B-X
In	B-X
chickens	B-X
,	B-X
estrogens	B-X
stimulate	B-X
outgrowth	B-X
of	B-X
bone	B-X
marrow-derived	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
and	B-X
delay	B-X
their	B-X
maturation	B-X
.	B-X
This	B-X
delay	B-X
is	B-X
associated	B-X
with	B-X
down-regulation	B-X
of	B-X
many	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
,	B-X
including	B-X
alpha-	B-X
and	B-X
beta-globin	B-X
,	B-X
band	B-X
3	B-X
,	B-X
band	B-X
4.1	B-X
,	B-X
and	B-X
the	B-X
erythroid	B-X
cell-specific	B-X
histone	B-X
H5	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
estrogens	B-X
also	B-X
reduce	B-X
the	B-X
number	B-X
of	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
in	B-X
primary	B-X
human	B-X
bone	B-X
marrow	B-X
cultures	B-X
.	B-X
To	B-X
address	B-X
potential	B-X
mechanisms	B-X
by	B-X
which	B-X
estrogens	B-X
suppress	B-X
erythropoiesis	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
their	B-X
effects	B-X
on	B-X
GATA-1	B-X
,	B-X
an	B-X
erythroid	B-X
transcription	B-X
factor	B-X
that	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
and	B-X
is	B-X
necessary	B-X
for	B-X
full	B-X
maturation	B-X
of	B-X
erythrocytes	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
GATA-1	B-X
is	B-X
strongly	B-X
repressed	B-X
by	B-X
the	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
and	B-X
that	B-X
this	B-X
repression	B-X
is	B-X
reversible	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
4-hydroxytamoxifen	B-X
.	B-X
ER-mediated	B-X
repression	B-X
of	B-X
GATA-1	B-X
activity	B-X
occurs	B-X
on	B-X
an	B-X
artificial	B-X
promoter	B-X
containing	B-X
a	B-X
single	B-X
GATA-binding	B-X
site	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
an	B-X
intact	B-X
promoter	B-X
which	B-X
is	B-X
normally	B-X
regulated	B-X
by	B-X
GATA-1	B-X
.	B-X
GATA-1	B-X
and	B-X
ER	B-X
bind	B-X
to	B-X
each	B-X
other	B-X
in	B-X
vitro	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
DNA	B-X
.	B-X
In	B-X
coimmunoprecipitation	B-X
experiments	B-X
using	B-X
transfected	B-X
COS	B-X
cells	B-X
,	B-X
GATA-1	B-X
and	B-X
ER	B-X
associate	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
.	B-X
Mapping	B-X
experiments	B-X
indicate	B-X
that	B-X
GATA-1	B-X
and	B-X
the	B-X
ER	B-X
form	B-X
at	B-X
least	B-X
two	B-X
contacts	B-X
,	B-X
which	B-X
involve	B-X
the	B-X
finger	B-X
region	B-X
and	B-X
the	B-X
N-terminal	B-X
activation	B-X
domain	B-X
of	B-X
GATA-1	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
estrogens	B-X
exert	B-X
effects	B-X
on	B-X
erythropoiesis	B-X
by	B-X
modulating	B-X
GATA-1	B-X
activity	B-X
through	B-X
protein-protein	B-X
interaction	B-X
with	B-X
the	B-X
ER	B-X
.	B-X
Interference	B-X
with	B-X
GATA-binding	B-X
proteins	B-X
may	B-X
be	B-X
one	B-X
mechanism	B-X
by	B-X
which	B-X
steroid	B-X
hormones	B-X
modulate	B-X
cellular	B-X
differentiation	B-X
.	B-X

We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA	B-Protein
-	I-Protein
1	I-Protein
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	B-Protein
receptor	I-Protein
(	O
ER	B-Protein
)	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4	O
-	O
hydroxytamoxifen	O
.	O

ER	B-Protein
-	O
mediated	O
repression	O
of	O
GATA	B-Protein
-	I-Protein
1	I-Protein
activity	O
occurs	O
on	O
an	O
artificial	O
promoter	O
containing	O
a	O
single	O
GATA	O
-	O
binding	O
site	O
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	O
promoter	O
which	O
is	O
normally	O
regulated	O
by	O
GATA	B-Protein
-	I-Protein
1	I-Protein
.	O

GATA	B-Protein
-	I-Protein
1	I-Protein
and	O
ER	B-Protein
bind	O
to	O
each	O
other	O
in	O
vitro	O
in	O
the	O
absence	O
of	O
DNA	O
.	O
<EOS>	B-X
This	B-X
delay	B-X
is	B-X
associated	B-X
with	B-X
down-regulation	B-X
of	B-X
many	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
,	B-X
including	B-X
alpha-	B-X
and	B-X
beta-globin	B-X
,	B-X
band	B-X
3	B-X
,	B-X
band	B-X
4.1	B-X
,	B-X
and	B-X
the	B-X
erythroid	B-X
cell-specific	B-X
histone	B-X
H5	B-X
.	B-X
To	B-X
address	B-X
potential	B-X
mechanisms	B-X
by	B-X
which	B-X
estrogens	B-X
suppress	B-X
erythropoiesis	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
their	B-X
effects	B-X
on	B-X
GATA-1	B-X
,	B-X
an	B-X
erythroid	B-X
transcription	B-X
factor	B-X
that	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
and	B-X
is	B-X
necessary	B-X
for	B-X
full	B-X
maturation	B-X
of	B-X
erythrocytes	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
GATA-1	B-X
is	B-X
strongly	B-X
repressed	B-X
by	B-X
the	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
and	B-X
that	B-X
this	B-X
repression	B-X
is	B-X
reversible	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
4-hydroxytamoxifen	B-X
.	B-X
ER-mediated	B-X
repression	B-X
of	B-X
GATA-1	B-X
activity	B-X
occurs	B-X
on	B-X
an	B-X
artificial	B-X
promoter	B-X
containing	B-X
a	B-X
single	B-X
GATA-binding	B-X
site	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
an	B-X
intact	B-X
promoter	B-X
which	B-X
is	B-X
normally	B-X
regulated	B-X
by	B-X
GATA-1	B-X
.	B-X
GATA-1	B-X
and	B-X
ER	B-X
bind	B-X
to	B-X
each	B-X
other	B-X
in	B-X
vitro	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
DNA	B-X
.	B-X
In	B-X
coimmunoprecipitation	B-X
experiments	B-X
using	B-X
transfected	B-X
COS	B-X
cells	B-X
,	B-X
GATA-1	B-X
and	B-X
ER	B-X
associate	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
.	B-X
Mapping	B-X
experiments	B-X
indicate	B-X
that	B-X
GATA-1	B-X
and	B-X
the	B-X
ER	B-X
form	B-X
at	B-X
least	B-X
two	B-X
contacts	B-X
,	B-X
which	B-X
involve	B-X
the	B-X
finger	B-X
region	B-X
and	B-X
the	B-X
N-terminal	B-X
activation	B-X
domain	B-X
of	B-X
GATA-1	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
estrogens	B-X
exert	B-X
effects	B-X
on	B-X
erythropoiesis	B-X
by	B-X
modulating	B-X
GATA-1	B-X
activity	B-X
through	B-X
protein-protein	B-X
interaction	B-X
with	B-X
the	B-X
ER	B-X
.	B-X
Interference	B-X
with	B-X
GATA-binding	B-X
proteins	B-X
may	B-X
be	B-X
one	B-X
mechanism	B-X
by	B-X
which	B-X
steroid	B-X
hormones	B-X
modulate	B-X
cellular	B-X
differentiation	B-X
.	B-X

In	O
coimmunoprecipitation	O
experiments	O
using	O
transfected	O
COS	O
cells	O
,	O
GATA	B-Protein
-	I-Protein
1	I-Protein
and	O
ER	B-Protein
associate	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

Mapping	O
experiments	O
indicate	O
that	O
GATA	B-Protein
-	I-Protein
1	I-Protein
and	O
the	O
ER	B-Protein
form	O
at	O
least	O
two	O
contacts	O
,	O
which	O
involve	O
the	O
finger	O
region	O
and	O
the	O
N	O
-	O
terminal	O
activation	O
domain	O
of	O
GATA	B-Protein
-	I-Protein
1	I-Protein
.	O

We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA	B-Protein
-	I-Protein
1	I-Protein
activity	O
through	O
protein	O
-	O
protein	O
interaction	O
with	O
the	O
ER	B-Protein
.	O
<EOS>	B-X
In	B-X
chickens	B-X
,	B-X
estrogens	B-X
stimulate	B-X
outgrowth	B-X
of	B-X
bone	B-X
marrow-derived	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
and	B-X
delay	B-X
their	B-X
maturation	B-X
.	B-X
This	B-X
delay	B-X
is	B-X
associated	B-X
with	B-X
down-regulation	B-X
of	B-X
many	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
,	B-X
including	B-X
alpha-	B-X
and	B-X
beta-globin	B-X
,	B-X
band	B-X
3	B-X
,	B-X
band	B-X
4.1	B-X
,	B-X
and	B-X
the	B-X
erythroid	B-X
cell-specific	B-X
histone	B-X
H5	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
estrogens	B-X
also	B-X
reduce	B-X
the	B-X
number	B-X
of	B-X
erythroid	B-X
progenitor	B-X
cells	B-X
in	B-X
primary	B-X
human	B-X
bone	B-X
marrow	B-X
cultures	B-X
.	B-X
To	B-X
address	B-X
potential	B-X
mechanisms	B-X
by	B-X
which	B-X
estrogens	B-X
suppress	B-X
erythropoiesis	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
their	B-X
effects	B-X
on	B-X
GATA-1	B-X
,	B-X
an	B-X
erythroid	B-X
transcription	B-X
factor	B-X
that	B-X
participates	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
majority	B-X
of	B-X
erythroid	B-X
cell-specific	B-X
genes	B-X
and	B-X
is	B-X
necessary	B-X
for	B-X
full	B-X
maturation	B-X
of	B-X
erythrocytes	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
GATA-1	B-X
is	B-X
strongly	B-X
repressed	B-X
by	B-X
the	B-X
estrogen	B-X
receptor	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
and	B-X
that	B-X
this	B-X
repression	B-X
is	B-X
reversible	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
4-hydroxytamoxifen	B-X
.	B-X
ER-mediated	B-X
repression	B-X
of	B-X
GATA-1	B-X
activity	B-X
occurs	B-X
on	B-X
an	B-X
artificial	B-X
promoter	B-X
containing	B-X
a	B-X
single	B-X
GATA-binding	B-X
site	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
context	B-X
of	B-X
an	B-X
intact	B-X
promoter	B-X
which	B-X
is	B-X
normally	B-X
regulated	B-X
by	B-X
GATA-1	B-X
.	B-X
GATA-1	B-X
and	B-X
ER	B-X
bind	B-X
to	B-X
each	B-X
other	B-X
in	B-X
vitro	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
DNA	B-X
.	B-X
In	B-X
coimmunoprecipitation	B-X
experiments	B-X
using	B-X
transfected	B-X
COS	B-X
cells	B-X
,	B-X
GATA-1	B-X
and	B-X
ER	B-X
associate	B-X
in	B-X
a	B-X
ligand-dependent	B-X
manner	B-X
.	B-X
Mapping	B-X
experiments	B-X
indicate	B-X
that	B-X
GATA-1	B-X
and	B-X
the	B-X
ER	B-X
form	B-X
at	B-X
least	B-X
two	B-X
contacts	B-X
,	B-X
which	B-X
involve	B-X
the	B-X
finger	B-X
region	B-X
and	B-X
the	B-X
N-terminal	B-X
activation	B-X
domain	B-X
of	B-X
GATA-1	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
estrogens	B-X
exert	B-X
effects	B-X
on	B-X
erythropoiesis	B-X
by	B-X
modulating	B-X
GATA-1	B-X
activity	B-X
through	B-X
protein-protein	B-X
interaction	B-X
with	B-X
the	B-X
ER	B-X
.	B-X
Interference	B-X
with	B-X
GATA-binding	B-X
proteins	B-X
may	B-X
be	B-X
one	B-X
mechanism	B-X
by	B-X
which	B-X
steroid	B-X
hormones	B-X
modulate	B-X
cellular	B-X
differentiation	B-X
.	B-X

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
<EOS>	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X

Activation	O
of	O
pp90rsk	O
and	O
early	B-Protein
growth	I-Protein
response	I-Protein
-	I-Protein
1	I-Protein
gene	O
expression	O
by	O
pokeweed	O
mitogen	O
in	O
human	O
B	O
cells	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
pokeweed	O
mitogen	O
(	O
PWM	O
)	O
on	O
the	O
induction	O
of	O
early	B-Protein
growth	I-Protein
response	I-Protein
-	I-Protein
1	I-Protein
gene	O
(	O
EGR	B-Protein
-	I-Protein
1	I-Protein
)	O
in	O
normal	O
human	O
B	O
cells	O
.	O

PWM	O
regulates	O
EGR	B-Protein
-	I-Protein
1	I-Protein
gene	O
expression	O
by	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
.	O
<EOS>	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
pokeweed	B-X
mitogen	B-X
(	B-X
PWM	B-X
)	B-X
on	B-X
the	B-X
induction	B-X
of	B-X
early	B-X
growth	B-X
response-1	B-X
gene	B-X
(	B-X
EGR-1	B-X
)	B-X
in	B-X
normal	B-X
human	B-X
B	B-X
cells	B-X
.	B-X
PWM	B-X
regulates	B-X
EGR-1	B-X
gene	B-X
expression	B-X
by	B-X
both	B-X
transcriptional	B-X
and	B-X
post-transcriptional	B-X
mechanisms	B-X
.	B-X
Transient	B-X
transfection	B-X
assays	B-X
with	B-X
EGR-1	B-X
promoter	B-X
fragments	B-X
linked	B-X
to	B-X
the	B-X
chloramphenicol	B-X
acetyltransferase	B-X
(	B-X
CAT	B-X
)	B-X
gene	B-X
demonstrated	B-X
that	B-X
PWM	B-X
induced	B-X
EGR-1	B-X
transcription	B-X
is	B-X
conferred	B-X
by	B-X
the	B-X
CArG	B-X
motif	B-X
(	B-X
C	B-X
C	B-X
[	B-X
AT	B-X
]	B-X
6GG	B-X
)	B-X
in	B-X
the	B-X
EGR-1	B-X
promoter	B-X
.	B-X
The	B-X
results	B-X
further	B-X
demonstrated	B-X
the	B-X
activation	B-X
of	B-X
S6	B-X
kinase	B-X
(	B-X
pp90rsk	B-X
)	B-X
,	B-X
evidenced	B-X
by	B-X
phosphorylation	B-X
of	B-X
S6	B-X
and	B-X
serum	B-X
response	B-X
factor	B-X
(	B-X
SRF	B-X
)	B-X
peptides	B-X
,	B-X
in	B-X
PWM	B-X
treated	B-X
B	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
PWM	B-X
is	B-X
able	B-X
to	B-X
initiate	B-X
an	B-X
intracytoplasmic	B-X
signalling	B-X
cascade	B-X
and	B-X
EGR-1	B-X
induction	B-X
in	B-X
normal	B-X
human	B-X
B	B-X
cells	B-X
.	B-X

Transient	O
transfection	O
assays	O
with	O
EGR	B-Protein
-	I-Protein
1	I-Protein
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	B-Protein
acetyltransferase	I-Protein
(	O
CAT	B-Protein
)	O
gene	O
demonstrated	O
that	O
PWM	O
induced	O
EGR	B-Protein
-	I-Protein
1	I-Protein
transcription	O
is	O
conferred	O
by	O
the	O
CArG	O
motif	O
(	O
C	O
C	O
[	O
AT	O
]	O
6GG	O
)	O
in	O
the	O
EGR	B-Protein
-	I-Protein
1	I-Protein
promoter	O
.	O

The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	O
kinase	O
(	O
pp90rsk	O
)	O
,	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	O
and	O
serum	B-Protein
response	I-Protein
factor	I-Protein
(	O
SRF	B-Protein
)	O
peptides	O
,	O
in	O
PWM	O
treated	O
B	O
cells	O
.	O
<EOS>	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
pokeweed	B-X
mitogen	B-X
(	B-X
PWM	B-X
)	B-X
on	B-X
the	B-X
induction	B-X
of	B-X
early	B-X
growth	B-X
response-1	B-X
gene	B-X
(	B-X
EGR-1	B-X
)	B-X
in	B-X
normal	B-X
human	B-X
B	B-X
cells	B-X
.	B-X
PWM	B-X
regulates	B-X
EGR-1	B-X
gene	B-X
expression	B-X
by	B-X
both	B-X
transcriptional	B-X
and	B-X
post-transcriptional	B-X
mechanisms	B-X
.	B-X
Transient	B-X
transfection	B-X
assays	B-X
with	B-X
EGR-1	B-X
promoter	B-X
fragments	B-X
linked	B-X
to	B-X
the	B-X
chloramphenicol	B-X
acetyltransferase	B-X
(	B-X
CAT	B-X
)	B-X
gene	B-X
demonstrated	B-X
that	B-X
PWM	B-X
induced	B-X
EGR-1	B-X
transcription	B-X
is	B-X
conferred	B-X
by	B-X
the	B-X
CArG	B-X
motif	B-X
(	B-X
C	B-X
C	B-X
[	B-X
AT	B-X
]	B-X
6GG	B-X
)	B-X
in	B-X
the	B-X
EGR-1	B-X
promoter	B-X
.	B-X
The	B-X
results	B-X
further	B-X
demonstrated	B-X
the	B-X
activation	B-X
of	B-X
S6	B-X
kinase	B-X
(	B-X
pp90rsk	B-X
)	B-X
,	B-X
evidenced	B-X
by	B-X
phosphorylation	B-X
of	B-X
S6	B-X
and	B-X
serum	B-X
response	B-X
factor	B-X
(	B-X
SRF	B-X
)	B-X
peptides	B-X
,	B-X
in	B-X
PWM	B-X
treated	B-X
B	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
PWM	B-X
is	B-X
able	B-X
to	B-X
initiate	B-X
an	B-X
intracytoplasmic	B-X
signalling	B-X
cascade	B-X
and	B-X
EGR-1	B-X
induction	B-X
in	B-X
normal	B-X
human	B-X
B	B-X
cells	B-X
.	B-X

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
PWM	O
is	O
able	O
to	O
initiate	O
an	O
intracytoplasmic	O
signalling	O
cascade	O
and	O
EGR	B-Protein
-	I-Protein
1	I-Protein
induction	O
in	O
normal	O
human	O
B	O
cells	O
.	O

NF	O
-	O
kappa	O
B	O
controls	O
expression	O
of	O
inhibitor	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
:	O
evidence	O
for	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O
<EOS>	B-X
The	B-X
eukaryotic	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
participates	B-X
in	B-X
many	B-X
parts	B-X
of	B-X
the	B-X
genetic	B-X
program	B-X
mediating	B-X
T	B-X
lymphocyte	B-X
activation	B-X
and	B-X
growth	B-X
.	B-X
Nuclear	B-X
expression	B-X
of	B-X
NF-kappa	B-X
B	B-X
occurs	B-X
after	B-X
its	B-X
induced	B-X
dissociation	B-X
from	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Phorbol	B-X
ester	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
induction	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
is	B-X
associated	B-X
with	B-X
both	B-X
the	B-X
degradation	B-X
of	B-X
performed	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
expression	B-X
.	B-X
Transfection	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
is	B-X
specifically	B-X
induced	B-X
by	B-X
the	B-X
65-kilodalton	B-X
transactivating	B-X
subunit	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
Association	B-X
of	B-X
the	B-X
newly	B-X
synthesized	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
with	B-X
p65	B-X
restores	B-X
intracellular	B-X
inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
prolongs	B-X
the	B-X
survival	B-X
of	B-X
this	B-X
labile	B-X
inhibitor	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
that	B-X
NF-kappa	B-X
B	B-X
controls	B-X
the	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
by	B-X
means	B-X
of	B-X
an	B-X
inducible	B-X
autoregulatory	B-X
pathway	B-X
.	B-X

The	O
eukaryotic	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	O
lymphocyte	O
activation	O
and	O
growth	O
.	O
<EOS>	B-X
The	B-X
eukaryotic	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
participates	B-X
in	B-X
many	B-X
parts	B-X
of	B-X
the	B-X
genetic	B-X
program	B-X
mediating	B-X
T	B-X
lymphocyte	B-X
activation	B-X
and	B-X
growth	B-X
.	B-X
Nuclear	B-X
expression	B-X
of	B-X
NF-kappa	B-X
B	B-X
occurs	B-X
after	B-X
its	B-X
induced	B-X
dissociation	B-X
from	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Phorbol	B-X
ester	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
induction	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
is	B-X
associated	B-X
with	B-X
both	B-X
the	B-X
degradation	B-X
of	B-X
performed	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
expression	B-X
.	B-X
Transfection	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
is	B-X
specifically	B-X
induced	B-X
by	B-X
the	B-X
65-kilodalton	B-X
transactivating	B-X
subunit	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
Association	B-X
of	B-X
the	B-X
newly	B-X
synthesized	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
with	B-X
p65	B-X
restores	B-X
intracellular	B-X
inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
prolongs	B-X
the	B-X
survival	B-X
of	B-X
this	B-X
labile	B-X
inhibitor	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
that	B-X
NF-kappa	B-X
B	B-X
controls	B-X
the	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
by	B-X
means	B-X
of	B-X
an	B-X
inducible	B-X
autoregulatory	B-X
pathway	B-X
.	B-X

Nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
occurs	O
after	O
its	O
induced	O
dissociation	O
from	O
its	O
cytoplasmic	O
inhibitor	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
.	O
<EOS>	B-X
The	B-X
eukaryotic	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
participates	B-X
in	B-X
many	B-X
parts	B-X
of	B-X
the	B-X
genetic	B-X
program	B-X
mediating	B-X
T	B-X
lymphocyte	B-X
activation	B-X
and	B-X
growth	B-X
.	B-X
Nuclear	B-X
expression	B-X
of	B-X
NF-kappa	B-X
B	B-X
occurs	B-X
after	B-X
its	B-X
induced	B-X
dissociation	B-X
from	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Phorbol	B-X
ester	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
induction	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
is	B-X
associated	B-X
with	B-X
both	B-X
the	B-X
degradation	B-X
of	B-X
performed	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
expression	B-X
.	B-X
Transfection	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
is	B-X
specifically	B-X
induced	B-X
by	B-X
the	B-X
65-kilodalton	B-X
transactivating	B-X
subunit	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
Association	B-X
of	B-X
the	B-X
newly	B-X
synthesized	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
with	B-X
p65	B-X
restores	B-X
intracellular	B-X
inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
prolongs	B-X
the	B-X
survival	B-X
of	B-X
this	B-X
labile	B-X
inhibitor	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
that	B-X
NF-kappa	B-X
B	B-X
controls	B-X
the	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
by	B-X
means	B-X
of	B-X
an	B-X
inducible	B-X
autoregulatory	B-X
pathway	B-X
.	B-X

Phorbol	O
ester	O
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
induction	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
is	O
associated	O
with	O
both	O
the	O
degradation	O
of	O
performed	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
and	O
the	O
activation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
gene	O
expression	O
.	O
<EOS>	B-X
The	B-X
eukaryotic	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
participates	B-X
in	B-X
many	B-X
parts	B-X
of	B-X
the	B-X
genetic	B-X
program	B-X
mediating	B-X
T	B-X
lymphocyte	B-X
activation	B-X
and	B-X
growth	B-X
.	B-X
Nuclear	B-X
expression	B-X
of	B-X
NF-kappa	B-X
B	B-X
occurs	B-X
after	B-X
its	B-X
induced	B-X
dissociation	B-X
from	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Phorbol	B-X
ester	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
induction	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
is	B-X
associated	B-X
with	B-X
both	B-X
the	B-X
degradation	B-X
of	B-X
performed	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
expression	B-X
.	B-X
Transfection	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
is	B-X
specifically	B-X
induced	B-X
by	B-X
the	B-X
65-kilodalton	B-X
transactivating	B-X
subunit	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
Association	B-X
of	B-X
the	B-X
newly	B-X
synthesized	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
with	B-X
p65	B-X
restores	B-X
intracellular	B-X
inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
prolongs	B-X
the	B-X
survival	B-X
of	B-X
this	B-X
labile	B-X
inhibitor	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
that	B-X
NF-kappa	B-X
B	B-X
controls	B-X
the	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
by	B-X
means	B-X
of	B-X
an	B-X
inducible	B-X
autoregulatory	B-X
pathway	B-X
.	B-X

Transfection	O
studies	O
indicate	O
that	O
the	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
gene	O
is	O
specifically	O
induced	O
by	O
the	O
65	O
-	O
kilodalton	O
transactivating	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
The	B-X
eukaryotic	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
participates	B-X
in	B-X
many	B-X
parts	B-X
of	B-X
the	B-X
genetic	B-X
program	B-X
mediating	B-X
T	B-X
lymphocyte	B-X
activation	B-X
and	B-X
growth	B-X
.	B-X
Nuclear	B-X
expression	B-X
of	B-X
NF-kappa	B-X
B	B-X
occurs	B-X
after	B-X
its	B-X
induced	B-X
dissociation	B-X
from	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Phorbol	B-X
ester	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
induction	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
is	B-X
associated	B-X
with	B-X
both	B-X
the	B-X
degradation	B-X
of	B-X
performed	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
expression	B-X
.	B-X
Transfection	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
is	B-X
specifically	B-X
induced	B-X
by	B-X
the	B-X
65-kilodalton	B-X
transactivating	B-X
subunit	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
Association	B-X
of	B-X
the	B-X
newly	B-X
synthesized	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
with	B-X
p65	B-X
restores	B-X
intracellular	B-X
inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
prolongs	B-X
the	B-X
survival	B-X
of	B-X
this	B-X
labile	B-X
inhibitor	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
that	B-X
NF-kappa	B-X
B	B-X
controls	B-X
the	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
by	B-X
means	B-X
of	B-X
an	B-X
inducible	B-X
autoregulatory	B-X
pathway	B-X
.	B-X

Association	O
of	O
the	O
newly	O
synthesized	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
with	O
p65	B-Protein
restores	O
intracellular	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
and	O
prolongs	O
the	O
survival	O
of	O
this	O
labile	O
inhibitor	O
.	O
<EOS>	B-X
The	B-X
eukaryotic	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
participates	B-X
in	B-X
many	B-X
parts	B-X
of	B-X
the	B-X
genetic	B-X
program	B-X
mediating	B-X
T	B-X
lymphocyte	B-X
activation	B-X
and	B-X
growth	B-X
.	B-X
Nuclear	B-X
expression	B-X
of	B-X
NF-kappa	B-X
B	B-X
occurs	B-X
after	B-X
its	B-X
induced	B-X
dissociation	B-X
from	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Phorbol	B-X
ester	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
induction	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
is	B-X
associated	B-X
with	B-X
both	B-X
the	B-X
degradation	B-X
of	B-X
performed	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
expression	B-X
.	B-X
Transfection	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
is	B-X
specifically	B-X
induced	B-X
by	B-X
the	B-X
65-kilodalton	B-X
transactivating	B-X
subunit	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
Association	B-X
of	B-X
the	B-X
newly	B-X
synthesized	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
with	B-X
p65	B-X
restores	B-X
intracellular	B-X
inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
prolongs	B-X
the	B-X
survival	B-X
of	B-X
this	B-X
labile	B-X
inhibitor	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
that	B-X
NF-kappa	B-X
B	B-X
controls	B-X
the	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
by	B-X
means	B-X
of	B-X
an	B-X
inducible	B-X
autoregulatory	B-X
pathway	B-X
.	B-X

Together	O
,	O
these	O
results	O
show	O
that	O
NF	O
-	O
kappa	O
B	O
controls	O
the	O
expression	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O
<EOS>	B-X
The	B-X
eukaryotic	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
participates	B-X
in	B-X
many	B-X
parts	B-X
of	B-X
the	B-X
genetic	B-X
program	B-X
mediating	B-X
T	B-X
lymphocyte	B-X
activation	B-X
and	B-X
growth	B-X
.	B-X
Nuclear	B-X
expression	B-X
of	B-X
NF-kappa	B-X
B	B-X
occurs	B-X
after	B-X
its	B-X
induced	B-X
dissociation	B-X
from	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
Phorbol	B-X
ester	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
induction	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
is	B-X
associated	B-X
with	B-X
both	B-X
the	B-X
degradation	B-X
of	B-X
performed	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
expression	B-X
.	B-X
Transfection	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
gene	B-X
is	B-X
specifically	B-X
induced	B-X
by	B-X
the	B-X
65-kilodalton	B-X
transactivating	B-X
subunit	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
Association	B-X
of	B-X
the	B-X
newly	B-X
synthesized	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
with	B-X
p65	B-X
restores	B-X
intracellular	B-X
inhibition	B-X
of	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
and	B-X
prolongs	B-X
the	B-X
survival	B-X
of	B-X
this	B-X
labile	B-X
inhibitor	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
that	B-X
NF-kappa	B-X
B	B-X
controls	B-X
the	B-X
expression	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
by	B-X
means	B-X
of	B-X
an	B-X
inducible	B-X
autoregulatory	B-X
pathway	B-X
.	B-X

Activation	O
of	O
primary	O
human	O
T	O
-	O
lymphocytes	O
through	O
CD2	B-Protein
plus	O
CD28	B-Protein
adhesion	O
molecules	O
induces	O
long	O
-	O
term	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Stimulation	O
of	O
highly	O
purified	O
human	O
T	O
-	O
cells	O
via	O
CD2	B-Protein
and	O
CD28	B-Protein
adhesion	O
molecules	O
induces	O
and	O
maintains	O
proliferation	O
for	O
more	O
than	O
3	O
weeks	O
.	O

This	O
potent	O
interleukin	B-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
-	O
dependent	O
activation	O
does	O
not	O
require	O
monocytes	O
or	O
accessory	O
cells	O
.	O
<EOS>	B-X
Interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
controls	B-X
the	B-X
homeostasis	B-X
and	B-X
function	B-X
of	B-X
regulatory	B-X
T	B-X
(	B-X
T	B-X
Although	B-X
originally	B-X
described	B-X
as	B-X
a	B-X
potent	B-X
T	B-X
cell	B-X
growth	B-X
factor	B-X
in	B-X
vitro	B-X
,	B-X
the	B-X
main	B-X
non	B-X
redundant	B-X
role	B-X
of	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
in	B-X
vivo	B-X
is	B-X
now	B-X
known	B-X
to	B-X
be	B-X
the	B-X
maintenance	B-X
of	B-X
peripheral	B-X
T	B-X
cell	B-X
tolerance	B-X
.	B-X
As	B-X
well	B-X
as	B-X
promoting	B-X
the	B-X
proliferation	B-X
and	B-X
survival	B-X
of	B-X
recently	B-X
activated	B-X
effector	B-X
T	B-X
cells	B-X
,	B-X
IL-2	B-X
also	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
regulatory	B-X
T	B-X
cell	B-X
(	B-X
Treg	B-X
)	B-X
homeostasis	B-X
and	B-X
has	B-X
been	B-X
variously	B-X
described	B-X
as	B-X
promoting	B-X
the	B-X
thymic	B-X
development	B-X
,	B-X
peripheral	B-X
homeostasis	B-X
and	B-X
suppressive	B-X
function	B-X
of	B-X
Tregs	B-X
.	B-X
These	B-X
observations	B-X
,	B-X
stemming	B-X
largely	B-X
from	B-X
studies	B-X
on	B-X
various	B-X
murine	B-X
models	B-X
of	B-X
IL-2	B-X
and	B-X
IL-2	B-X
receptor	B-X
deficiency	B-X
,	B-X
have	B-X
prompted	B-X
a	B-X
greater	B-X
understanding	B-X
of	B-X
the	B-X
pro-tolerogenic	B-X
nature	B-X
of	B-X
IL-2	B-X
dependent	B-X
signaling	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
current	B-X
knowledge	B-X
concerning	B-X
the	B-X
importance	B-X
of	B-X
IL-2	B-X
mediated	B-X
signaling	B-X
in	B-X
Treg	B-X
biology	B-X
as	B-X
well	B-X
as	B-X
its	B-X
relevance	B-X
to	B-X
possible	B-X
therapeutic	B-X
applications	B-X
.	B-X

Long	O
-	O
lasting	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptivity	O
is	O
associated	O
with	O
high	O
-	O
level	O
expression	O
of	O
the	O
inducible	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
chain	I-Protein
(	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
)	O
gene	O
that	O
is	O
regulated	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
highly	B-X
purified	B-X
human	B-X
T-cells	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
and	B-X
maintains	B-X
proliferation	B-X
for	B-X
more	B-X
than	B-X
3	B-X
weeks	B-X
.	B-X
This	B-X
potent	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
-dependent	B-X
activation	B-X
does	B-X
not	B-X
require	B-X
monocytes	B-X
or	B-X
accessory	B-X
cells	B-X
.	B-X
Long-lasting	B-X
IL-2	B-X
receptivity	B-X
is	B-X
associated	B-X
with	B-X
high-level	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
IL-2	B-X
receptor	B-X
alpha	B-X
chain	B-X
(	B-X
IL-2R	B-X
alpha	B-X
)	B-X
gene	B-X
that	B-X
is	B-X
regulated	B-X
at	B-X
both	B-X
transcriptional	B-X
and	B-X
posttranscriptional	B-X
levels	B-X
.	B-X
Increase	B-X
of	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
transcription	B-X
involves	B-X
the	B-X
enhanced	B-X
binding	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
to	B-X
its	B-X
consensus	B-X
sequence	B-X
in	B-X
the	B-X
5'-regulatory	B-X
region	B-X
of	B-X
the	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
.	B-X
To	B-X
dissect	B-X
the	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
unusually	B-X
persistent	B-X
transcription	B-X
of	B-X
the	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
binding	B-X
to	B-X
a	B-X
radiolabeled	B-X
IL-2R	B-X
alpha	B-X
kappa	B-X
B-specific	B-X
oligonucleotide	B-X
probe	B-X
during	B-X
the	B-X
time	B-X
course	B-X
of	B-X
CD2	B-X
+	B-X
CD28	B-X
activation	B-X
.	B-X
Both	B-X
inducible	B-X
complexes	B-X
persisted	B-X
for	B-X
at	B-X
least	B-X
3	B-X
weeks	B-X
.	B-X
Their	B-X
relative	B-X
levels	B-X
were	B-X
very	B-X
similar	B-X
for	B-X
the	B-X
duration	B-X
of	B-X
proliferation	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
CD2	B-X
+	B-X
CD28	B-X
activation	B-X
triggered	B-X
a	B-X
significant	B-X
intracellular	B-X
thiol	B-X
decrease	B-X
,	B-X
suggesting	B-X
that	B-X
oxygen	B-X
radicals	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
of	B-X
adhesion	B-X
molecules	B-X
.	B-X
Finally	B-X
,	B-X
micromolar	B-X
amounts	B-X
of	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
an	B-X
oxygen	B-X
radical	B-X
scavenger	B-X
that	B-X
efficiently	B-X
blocked	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
T-lymphocytes	B-X
,	B-X
also	B-X
inhibited	B-X
IL-2	B-X
secretion	B-X
,	B-X
IL-2R	B-X
alpha	B-X
cell	B-X
surface	B-X
expression	B-X
,	B-X
and	B-X
T-cell	B-X
proliferation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
NF-kappa	B-X
B	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
long-term	B-X
activation	B-X
of	B-X
human	B-X
primary	B-X
T-lymphocytes	B-X
via	B-X
CD2	B-X
+	B-X
CD28	B-X
.	B-X

Increase	O
of	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
gene	O
transcription	O
involves	O
the	O
enhanced	O
binding	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
-	O
regulatory	O
region	O
of	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
gene	O
.	O
<EOS>	B-X
This	B-X
potent	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
-dependent	B-X
activation	B-X
does	B-X
not	B-X
require	B-X
monocytes	B-X
or	B-X
accessory	B-X
cells	B-X
.	B-X
Long-lasting	B-X
IL-2	B-X
receptivity	B-X
is	B-X
associated	B-X
with	B-X
high-level	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
IL-2	B-X
receptor	B-X
alpha	B-X
chain	B-X
(	B-X
IL-2R	B-X
alpha	B-X
)	B-X
gene	B-X
that	B-X
is	B-X
regulated	B-X
at	B-X
both	B-X
transcriptional	B-X
and	B-X
posttranscriptional	B-X
levels	B-X
.	B-X
Increase	B-X
of	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
transcription	B-X
involves	B-X
the	B-X
enhanced	B-X
binding	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
to	B-X
its	B-X
consensus	B-X
sequence	B-X
in	B-X
the	B-X
5'-regulatory	B-X
region	B-X
of	B-X
the	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
.	B-X
To	B-X
dissect	B-X
the	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
unusually	B-X
persistent	B-X
transcription	B-X
of	B-X
the	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
binding	B-X
to	B-X
a	B-X
radiolabeled	B-X
IL-2R	B-X
alpha	B-X
kappa	B-X
B-specific	B-X
oligonucleotide	B-X
probe	B-X
during	B-X
the	B-X
time	B-X
course	B-X
of	B-X
CD2	B-X
+	B-X
CD28	B-X
activation	B-X
.	B-X
Resting	B-X
T-cell	B-X
nuclear	B-X
extracts	B-X
contained	B-X
KBF1/p50	B-X
homodimer	B-X
.	B-X
After	B-X
stimulation	B-X
,	B-X
two	B-X
new	B-X
kappa	B-X
B-specific	B-X
complexes	B-X
were	B-X
identified	B-X
as	B-X
NF-kappa	B-X
B	B-X
p50-p65	B-X
heterodimer	B-X
and	B-X
putative	B-X
c-Rel	B-X
homodimer	B-X
or	B-X
c-Rel-p65	B-X
heterodimer	B-X
.	B-X
Both	B-X
inducible	B-X
complexes	B-X
persisted	B-X
for	B-X
at	B-X
least	B-X
3	B-X
weeks	B-X
.	B-X
Finally	B-X
,	B-X
micromolar	B-X
amounts	B-X
of	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
an	B-X
oxygen	B-X
radical	B-X
scavenger	B-X
that	B-X
efficiently	B-X
blocked	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
T-lymphocytes	B-X
,	B-X
also	B-X
inhibited	B-X
IL-2	B-X
secretion	B-X
,	B-X
IL-2R	B-X
alpha	B-X
cell	B-X
surface	B-X
expression	B-X
,	B-X
and	B-X
T-cell	B-X
proliferation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
NF-kappa	B-X
B	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
long-term	B-X
activation	B-X
of	B-X
human	B-X
primary	B-X
T-lymphocytes	B-X
via	B-X
CD2	B-X
+	B-X
CD28	B-X
.	B-X

To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusually	O
persistent	O
transcription	O
of	O
the	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
gene	O
,	O
we	O
analyzed	O
nuclear	O
NF	O
-	O
kappa	O
B	O
binding	O
to	O
a	O
radiolabeled	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
kappa	O
B	O
-	O
specific	O
oligonucleotide	O
probe	O
during	O
the	O
time	O
course	O
of	O
CD2	B-Protein
+	O
CD28	B-Protein
activation	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
highly	B-X
purified	B-X
human	B-X
T-cells	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
and	B-X
maintains	B-X
proliferation	B-X
for	B-X
more	B-X
than	B-X
3	B-X
weeks	B-X
.	B-X
This	B-X
potent	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
-dependent	B-X
activation	B-X
does	B-X
not	B-X
require	B-X
monocytes	B-X
or	B-X
accessory	B-X
cells	B-X
.	B-X
Long-lasting	B-X
IL-2	B-X
receptivity	B-X
is	B-X
associated	B-X
with	B-X
high-level	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
IL-2	B-X
receptor	B-X
alpha	B-X
chain	B-X
(	B-X
IL-2R	B-X
alpha	B-X
)	B-X
gene	B-X
that	B-X
is	B-X
regulated	B-X
at	B-X
both	B-X
transcriptional	B-X
and	B-X
posttranscriptional	B-X
levels	B-X
.	B-X
Increase	B-X
of	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
transcription	B-X
involves	B-X
the	B-X
enhanced	B-X
binding	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
to	B-X
its	B-X
consensus	B-X
sequence	B-X
in	B-X
the	B-X
5'-regulatory	B-X
region	B-X
of	B-X
the	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
.	B-X
To	B-X
dissect	B-X
the	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
unusually	B-X
persistent	B-X
transcription	B-X
of	B-X
the	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
binding	B-X
to	B-X
a	B-X
radiolabeled	B-X
IL-2R	B-X
alpha	B-X
kappa	B-X
B-specific	B-X
oligonucleotide	B-X
probe	B-X
during	B-X
the	B-X
time	B-X
course	B-X
of	B-X
CD2	B-X
+	B-X
CD28	B-X
activation	B-X
.	B-X
Resting	B-X
T-cell	B-X
nuclear	B-X
extracts	B-X
contained	B-X
KBF1/p50	B-X
homodimer	B-X
.	B-X
After	B-X
stimulation	B-X
,	B-X
two	B-X
new	B-X
kappa	B-X
B-specific	B-X
complexes	B-X
were	B-X
identified	B-X
as	B-X
NF-kappa	B-X
B	B-X
p50-p65	B-X
heterodimer	B-X
and	B-X
putative	B-X
c-Rel	B-X
homodimer	B-X
or	B-X
c-Rel-p65	B-X
heterodimer	B-X
.	B-X
Both	B-X
inducible	B-X
complexes	B-X
persisted	B-X
for	B-X
at	B-X
least	B-X
3	B-X
weeks	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
CD2	B-X
+	B-X
CD28	B-X
activation	B-X
triggered	B-X
a	B-X
significant	B-X
intracellular	B-X
thiol	B-X
decrease	B-X
,	B-X
suggesting	B-X
that	B-X
oxygen	B-X
radicals	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
of	B-X
adhesion	B-X
molecules	B-X
.	B-X
Finally	B-X
,	B-X
micromolar	B-X
amounts	B-X
of	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
an	B-X
oxygen	B-X
radical	B-X
scavenger	B-X
that	B-X
efficiently	B-X
blocked	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
T-lymphocytes	B-X
,	B-X
also	B-X
inhibited	B-X
IL-2	B-X
secretion	B-X
,	B-X
IL-2R	B-X
alpha	B-X
cell	B-X
surface	B-X
expression	B-X
,	B-X
and	B-X
T-cell	B-X
proliferation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
NF-kappa	B-X
B	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
long-term	B-X
activation	B-X
of	B-X
human	B-X
primary	B-X
T-lymphocytes	B-X
via	B-X
CD2	B-X
+	B-X
CD28	B-X
.	B-X

Resting	O
T	O
-	O
cell	O
nuclear	O
extracts	O
contained	O
KBF1	B-Protein
/	O
p50	B-Protein
homodimer	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
highly	B-X
purified	B-X
human	B-X
T-cells	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
and	B-X
maintains	B-X
proliferation	B-X
for	B-X
more	B-X
than	B-X
3	B-X
weeks	B-X
.	B-X
This	B-X
potent	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
-dependent	B-X
activation	B-X
does	B-X
not	B-X
require	B-X
monocytes	B-X
or	B-X
accessory	B-X
cells	B-X
.	B-X
To	B-X
dissect	B-X
the	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
unusually	B-X
persistent	B-X
transcription	B-X
of	B-X
the	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
binding	B-X
to	B-X
a	B-X
radiolabeled	B-X
IL-2R	B-X
alpha	B-X
kappa	B-X
B-specific	B-X
oligonucleotide	B-X
probe	B-X
during	B-X
the	B-X
time	B-X
course	B-X
of	B-X
CD2	B-X
+	B-X
CD28	B-X
activation	B-X
.	B-X
Resting	B-X
T-cell	B-X
nuclear	B-X
extracts	B-X
contained	B-X
KBF1/p50	B-X
homodimer	B-X
.	B-X
After	B-X
stimulation	B-X
,	B-X
two	B-X
new	B-X
kappa	B-X
B-specific	B-X
complexes	B-X
were	B-X
identified	B-X
as	B-X
NF-kappa	B-X
B	B-X
p50-p65	B-X
heterodimer	B-X
and	B-X
putative	B-X
c-Rel	B-X
homodimer	B-X
or	B-X
c-Rel-p65	B-X
heterodimer	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
CD2	B-X
+	B-X
CD28	B-X
activation	B-X
triggered	B-X
a	B-X
significant	B-X
intracellular	B-X
thiol	B-X
decrease	B-X
,	B-X
suggesting	B-X
that	B-X
oxygen	B-X
radicals	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
of	B-X
adhesion	B-X
molecules	B-X
.	B-X
Finally	B-X
,	B-X
micromolar	B-X
amounts	B-X
of	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
an	B-X
oxygen	B-X
radical	B-X
scavenger	B-X
that	B-X
efficiently	B-X
blocked	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
T-lymphocytes	B-X
,	B-X
also	B-X
inhibited	B-X
IL-2	B-X
secretion	B-X
,	B-X
IL-2R	B-X
alpha	B-X
cell	B-X
surface	B-X
expression	B-X
,	B-X
and	B-X
T-cell	B-X
proliferation	B-X
.	B-X

After	O
stimulation	O
,	O
two	O
new	O
kappa	O
B	O
-	O
specific	O
complexes	O
were	O
identified	O
as	O
NF	O
-	O
kappa	O
B	O
p50	B-Protein
-	O
p65	B-Protein
heterodimer	O
and	O
putative	O
c	B-Protein
-	I-Protein
Rel	I-Protein
homodimer	O
or	O
c	B-Protein
-	I-Protein
Rel	I-Protein
-	O
p65	B-Protein
heterodimer	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF-κB	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
.	B-X
In	B-X
mammals	B-X
,	B-X
the	B-X
NF-κB/Rel	B-X
family	B-X
comprises	B-X
five	B-X
members	B-X
:	B-X
p50	B-X
,	B-X
p52	B-X
,	B-X
p65	B-X
(	B-X
Rel-A	B-X
)	B-X
,	B-X
c-Rel	B-X
,	B-X
and	B-X
Rel-B	B-X
proteins	B-X
,	B-X
which	B-X
form	B-X
homo-	B-X
or	B-X
heterodimers	B-X
and	B-X
remain	B-X
as	B-X
an	B-X
inactive	B-X
complex	B-X
with	B-X
the	B-X
inhibitory	B-X
molecules	B-X
called	B-X
IκB	B-X
proteins	B-X
in	B-X
resting	B-X
cells	B-X
.	B-X
Two	B-X
distinct	B-X
NF-κB	B-X
signaling	B-X
pathways	B-X
have	B-X
been	B-X
described	B-X
:	B-X
1	B-X
)	B-X
the	B-X
canonical	B-X
pathway	B-X
primarily	B-X
activated	B-X
by	B-X
pathogens	B-X
and	B-X
inflammatory	B-X
mediators	B-X
,	B-X
and	B-X
2	B-X
)	B-X
the	B-X
noncanonical	B-X
pathway	B-X
mostly	B-X
activated	B-X
by	B-X
developmental	B-X
cues	B-X
.	B-X
The	B-X
most	B-X
abundant	B-X
form	B-X
of	B-X
NF-κB	B-X
activated	B-X
by	B-X
pathologic	B-X
stimuli	B-X
via	B-X
the	B-X
canonical	B-X
pathway	B-X
is	B-X
the	B-X
p65	B-X
:	B-X
p50	B-X
heterodimer	B-X
.	B-X
Disproportionate	B-X
increase	B-X
in	B-X
activated	B-X
p65	B-X
and	B-X
subsequent	B-X
transactivation	B-X
of	B-X
effector	B-X
molecules	B-X
is	B-X
integral	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
many	B-X
chronic	B-X
diseases	B-X
such	B-X
as	B-X
the	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
,	B-X
multiple	B-X
sclerosis	B-X
,	B-X
and	B-X
even	B-X
neurodegenerative	B-X
pathologies	B-X
.	B-X
Hence	B-X
,	B-X
the	B-X
NF-κB	B-X
p65	B-X
signaling	B-X
pathway	B-X
has	B-X
been	B-X
a	B-X
pivotal	B-X
point	B-X
for	B-X
intense	B-X
drug	B-X
discovery	B-X
and	B-X
development	B-X
.	B-X
This	B-X
review	B-X
begins	B-X
with	B-X
an	B-X
overview	B-X
of	B-X
p65-mediated	B-X
signaling	B-X
followed	B-X
by	B-X
discussion	B-X
of	B-X
strategies	B-X
that	B-X
directly	B-X
target	B-X
NF-κB	B-X
p65	B-X
in	B-X
the	B-X
context	B-X
of	B-X
chronic	B-X
inflammation	B-X
.	B-X

Both	O
inducible	O
complexes	O
persisted	O
for	O
at	O
least	O
3	O
weeks	O
.	O
<EOS>	B-X
Data	B-X
from	B-X
animal	B-X
studies	B-X
suggested	B-X
that	B-X
higher	B-X
dosages	B-X
of	B-X
liposomal	B-X
amphotericin	B-X
B	B-X
might	B-X
improve	B-X
efficacy	B-X
;	B-X
however	B-X
,	B-X
in	B-X
the	B-X
AmBiLoad	B-X
trial	B-X
in	B-X
patients	B-X
with	B-X
invasive	B-X
mould	B-X
infection	B-X
,	B-X
there	B-X
was	B-X
no	B-X
statistical	B-X
difference	B-X
in	B-X
efficacy	B-X
between	B-X
the	B-X
standard	B-X
dosage	B-X
of	B-X
liposomal	B-X
amphotericin	B-X
B	B-X
3	B-X
mg/kg/day	B-X
and	B-X
a	B-X
higher	B-X
10	B-X
mg/kg/day	B-X
dosage	B-X
,	B-X
although	B-X
the	B-X
standard	B-X
dosage	B-X
was	B-X
better	B-X
tolerated	B-X
.	B-X
In	B-X
several	B-X
randomized	B-X
,	B-X
double-blind	B-X
trials	B-X
(	B-X
n	B-X
=	B-X
73-1095	B-X
)	B-X
in	B-X
adult	B-X
and/or	B-X
paediatric	B-X
patients	B-X
,	B-X
liposomal	B-X
amphotericin	B-X
B	B-X
was	B-X
effective	B-X
as	B-X
empirical	B-X
therapy	B-X
or	B-X
as	B-X
treatment	B-X
for	B-X
confirmed	B-X
invasive	B-X
fungal	B-X
infections	B-X
,	B-X
including	B-X
invasive	B-X
candidiasis	B-X
,	B-X
candidaemia	B-X
,	B-X
invasive	B-X
mould	B-X
infection	B-X
(	B-X
mainly	B-X
aspergillosis	B-X
)	B-X
,	B-X
histoplasmosis	B-X
and	B-X
cryptococcal	B-X
meningitis	B-X
.	B-X
All	B-X
agents	B-X
were	B-X
administered	B-X
as	B-X
an	B-X
intravenous	B-X
infusion	B-X
;	B-X
the	B-X
typical	B-X
dosage	B-X
for	B-X
liposomal	B-X
amphotericin	B-X
B	B-X
was	B-X
3	B-X
mg/kg/day	B-X
.	B-X
Treatment	B-X
was	B-X
generally	B-X
given	B-X
for	B-X
1-2	B-X
weeks	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
invasive	B-X
mould	B-X
infection	B-X
(	B-X
mainly	B-X
aspergillosis	B-X
)	B-X
,	B-X
there	B-X
was	B-X
no	B-X
difference	B-X
in	B-X
efficacy	B-X
between	B-X
a	B-X
higher	B-X
dosage	B-X
of	B-X
liposomal	B-X
amphotericin	B-X
B	B-X
(	B-X
10	B-X
mg/kg/day	B-X
)	B-X
and	B-X
the	B-X
standard	B-X
dosage	B-X
(	B-X
3	B-X
mg/kg/day	B-X
)	B-X
,	B-X
with	B-X
46	B-X
%	B-X
and	B-X
50	B-X
%	B-X
of	B-X
patients	B-X
experiencing	B-X
a	B-X
favourable	B-X
overall	B-X
response	B-X
.	B-X
In	B-X
well	B-X
designed	B-X
clinical	B-X
trials	B-X
,	B-X
liposomal	B-X
amphotericin	B-X
B	B-X
was	B-X
generally	B-X
at	B-X
least	B-X
as	B-X
well	B-X
tolerated	B-X
as	B-X
other	B-X
lipid-associated	B-X
formulations	B-X
of	B-X
amphotericin	B-X
B	B-X
and	B-X
better	B-X
tolerated	B-X
than	B-X
amphotericin	B-X
B	B-X
deoxycholate	B-X
in	B-X
adult	B-X
and	B-X
paediatric	B-X
patients	B-X
.	B-X
A	B-X
higher	B-X
than	B-X
recommended	B-X
dosage	B-X
of	B-X
liposomal	B-X
amphotericin	B-X
B	B-X
(	B-X
10	B-X
mg/kg/day	B-X
)	B-X
was	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
incidence	B-X
of	B-X
nephrotoxicity	B-X
compared	B-X
with	B-X
the	B-X
standard	B-X
dosage	B-X
(	B-X
3	B-X
mg/kg/day	B-X
)	B-X
,	B-X
although	B-X
the	B-X
incidence	B-X
of	B-X
infusion-related	B-X
reactions	B-X
did	B-X
not	B-X
differ	B-X
between	B-X
treatment	B-X
groups	B-X
.	B-X

Their	O
relative	O
levels	O
were	O
very	O
similar	O
for	O
the	O
duration	O
of	O
proliferation	O
.	O
<EOS>	B-X
Similar	B-X
increases	B-X
are	B-X
seen	B-X
in	B-X
young	B-X
women	B-X
following	B-X
the	B-X
termination	B-X
of	B-X
statural	B-X
growth	B-X
in	B-X
response	B-X
to	B-X
athletic	B-X
training	B-X
,	B-X
but	B-X
not	B-X
to	B-X
more	B-X
limited	B-X
levels	B-X
of	B-X
physical	B-X
activity	B-X
characteristic	B-X
of	B-X
longitudinal	B-X
training	B-X
studies	B-X
.	B-X
After	B-X
9-12	B-X
months	B-X
of	B-X
regular	B-X
exercise	B-X
,	B-X
young	B-X
adult	B-X
women	B-X
often	B-X
show	B-X
very	B-X
small	B-X
benefits	B-X
to	B-X
bone	B-X
health	B-X
,	B-X
possibly	B-X
because	B-X
of	B-X
large	B-X
subject	B-X
attrition	B-X
rates	B-X
,	B-X
inadequate	B-X
exercise	B-X
intensity	B-X
,	B-X
duration	B-X
or	B-X
frequency	B-X
,	B-X
or	B-X
because	B-X
at	B-X
this	B-X
stage	B-X
of	B-X
life	B-X
accumulation	B-X
of	B-X
bone	B-X
mass	B-X
may	B-X
be	B-X
at	B-X
its	B-X
natural	B-X
peak	B-X
.	B-X
They	B-X
posit	B-X
that	B-X
exercise	B-X
should	B-X
:	B-X
(	B-X
i	B-X
)	B-X
be	B-X
dynamic	B-X
,	B-X
not	B-X
static	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
exceed	B-X
a	B-X
threshold	B-X
intensity	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
exceed	B-X
a	B-X
threshold	B-X
strain	B-X
frequency	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
be	B-X
relatively	B-X
brief	B-X
but	B-X
intermittent	B-X
;	B-X
(	B-X
v	B-X
)	B-X
impose	B-X
an	B-X
unusual	B-X
loading	B-X
pattern	B-X
on	B-X
the	B-X
bones	B-X
;	B-X
(	B-X
vi	B-X
)	B-X
be	B-X
supported	B-X
by	B-X
unlimited	B-X
nutrient	B-X
energy	B-X
;	B-X
and	B-X
(	B-X
vii	B-X
)	B-X
include	B-X
adequate	B-X
calcium	B-X
and	B-X
cholecalciferol	B-X
(	B-X
vitamin	B-X
D3	B-X
)	B-X
availability	B-X
.	B-X
The	B-X
durational	B-X
effects	B-X
of	B-X
chronic	B-X
stress	B-X
on	B-X
the	B-X
Fallopian	B-X
tubes	B-X
and	B-X
uterus	B-X
were	B-X
studied	B-X
by	B-X
exposing	B-X
rats	B-X
to	B-X
stressors	B-X
in	B-X
the	B-X
form	B-X
of	B-X
restraint	B-X
(	B-X
1h	B-X
)	B-X
and	B-X
forced	B-X
swimming	B-X
(	B-X
15min	B-X
)	B-X
daily	B-X
for	B-X
4	B-X
,	B-X
8	B-X
or	B-X
12	B-X
weeks	B-X
.	B-X
All	B-X
time	B-X
periods	B-X
of	B-X
stress	B-X
exposure	B-X
resulted	B-X
in	B-X
decreased	B-X
weight	B-X
of	B-X
the	B-X
body	B-X
and	B-X
Fallopian	B-X
tubes	B-X
;	B-X
however	B-X
,	B-X
the	B-X
relative	B-X
weight	B-X
of	B-X
the	B-X
uterus	B-X
and	B-X
serum	B-X
concentrations	B-X
of	B-X
oestradiol	B-X
and	B-X
insulin	B-X
increased	B-X
significantly	B-X
.	B-X
The	B-X
antioxidant	B-X
potential	B-X
was	B-X
decreased	B-X
with	B-X
increased	B-X
malondialdehyde	B-X
concentrations	B-X
in	B-X
the	B-X
Fallopian	B-X
tubes	B-X
following	B-X
all	B-X
durations	B-X
of	B-X
exposure	B-X
and	B-X
after	B-X
4	B-X
and	B-X
8	B-X
weeks	B-X
of	B-X
stress	B-X
exposure	B-X
in	B-X
the	B-X
uterus	B-X
.	B-X
The	B-X
antioxidant	B-X
enzyme	B-X
activities	B-X
and	B-X
malondialdehyde	B-X
concentration	B-X
in	B-X
the	B-X
Fallopian	B-X
tubes	B-X
of	B-X
all	B-X
recovery	B-X
group	B-X
rats	B-X
were	B-X
similar	B-X
to	B-X
stressed	B-X
rats	B-X
.	B-X
However	B-X
,	B-X
in	B-X
the	B-X
uterus	B-X
these	B-X
parameters	B-X
were	B-X
similar	B-X
to	B-X
controls	B-X
in	B-X
recovery	B-X
group	B-X
rats	B-X
after	B-X
4	B-X
weeks	B-X
or	B-X
8	B-X
weeks	B-X
of	B-X
exposure	B-X
,	B-X
but	B-X
after	B-X
12	B-X
weeks	B-X
of	B-X
stress	B-X
exposure	B-X
these	B-X
parameters	B-X
did	B-X
not	B-X
return	B-X
to	B-X
control	B-X
levels	B-X
following	B-X
the	B-X
recovery	B-X
period	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
that	B-X
chronic	B-X
stress	B-X
elicits	B-X
an	B-X
irreversible	B-X
decrease	B-X
in	B-X
antioxidant	B-X
defence	B-X
in	B-X
the	B-X
Fallopian	B-X
tubes	B-X
irrespective	B-X
of	B-X
exposure	B-X
duration	B-X
,	B-X
whereas	B-X
the	B-X
uterus	B-X
develops	B-X
reversible	B-X
oxidative	B-X
stress	B-X
under	B-X
short-term	B-X
exposure	B-X
but	B-X
increased	B-X
antioxidant	B-X
potential	B-X
with	B-X
endometrial	B-X
proliferation	B-X
following	B-X
long-term	B-X
exposure	B-X
.	B-X

In	O
parallel	O
,	O
CD2	B-Protein
+	O
CD28	B-Protein
activation	O
triggered	O
a	O
significant	O
intracellular	O
thiol	O
decrease	O
,	O
suggesting	O
that	O
oxygen	O
radicals	O
are	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
adhesion	O
molecules	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
highly	B-X
purified	B-X
human	B-X
T-cells	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
and	B-X
maintains	B-X
proliferation	B-X
for	B-X
more	B-X
than	B-X
3	B-X
weeks	B-X
.	B-X
This	B-X
potent	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
-dependent	B-X
activation	B-X
does	B-X
not	B-X
require	B-X
monocytes	B-X
or	B-X
accessory	B-X
cells	B-X
.	B-X
To	B-X
dissect	B-X
the	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
unusually	B-X
persistent	B-X
transcription	B-X
of	B-X
the	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
binding	B-X
to	B-X
a	B-X
radiolabeled	B-X
IL-2R	B-X
alpha	B-X
kappa	B-X
B-specific	B-X
oligonucleotide	B-X
probe	B-X
during	B-X
the	B-X
time	B-X
course	B-X
of	B-X
CD2	B-X
+	B-X
CD28	B-X
activation	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
CD2	B-X
+	B-X
CD28	B-X
activation	B-X
triggered	B-X
a	B-X
significant	B-X
intracellular	B-X
thiol	B-X
decrease	B-X
,	B-X
suggesting	B-X
that	B-X
oxygen	B-X
radicals	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
of	B-X
adhesion	B-X
molecules	B-X
.	B-X
Finally	B-X
,	B-X
micromolar	B-X
amounts	B-X
of	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
an	B-X
oxygen	B-X
radical	B-X
scavenger	B-X
that	B-X
efficiently	B-X
blocked	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
T-lymphocytes	B-X
,	B-X
also	B-X
inhibited	B-X
IL-2	B-X
secretion	B-X
,	B-X
IL-2R	B-X
alpha	B-X
cell	B-X
surface	B-X
expression	B-X
,	B-X
and	B-X
T-cell	B-X
proliferation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
NF-kappa	B-X
B	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
long-term	B-X
activation	B-X
of	B-X
human	B-X
primary	B-X
T-lymphocytes	B-X
via	B-X
CD2	B-X
+	B-X
CD28	B-X
.	B-X

Finally	O
,	O
micromolar	O
amounts	O
of	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxygen	O
radical	O
scavenger	O
that	O
efficiently	O
blocked	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
T	O
-	O
lymphocytes	O
,	O
also	O
inhibited	O
IL	B-Protein
-	I-Protein
2	I-Protein
secretion	O
,	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
cell	O
surface	O
expression	O
,	O
and	O
T	O
-	O
cell	O
proliferation	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
an	O
important	O
role	O
in	O
long	O
-	O
term	O
activation	O
of	O
human	O
primary	O
T	O
-	O
lymphocytes	O
via	O
CD2	B-Protein
+	O
CD28	B-Protein
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
highly	B-X
purified	B-X
human	B-X
T-cells	B-X
via	B-X
CD2	B-X
and	B-X
CD28	B-X
adhesion	B-X
molecules	B-X
induces	B-X
and	B-X
maintains	B-X
proliferation	B-X
for	B-X
more	B-X
than	B-X
3	B-X
weeks	B-X
.	B-X
This	B-X
potent	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
-dependent	B-X
activation	B-X
does	B-X
not	B-X
require	B-X
monocytes	B-X
or	B-X
accessory	B-X
cells	B-X
.	B-X
Increase	B-X
of	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
transcription	B-X
involves	B-X
the	B-X
enhanced	B-X
binding	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
to	B-X
its	B-X
consensus	B-X
sequence	B-X
in	B-X
the	B-X
5'-regulatory	B-X
region	B-X
of	B-X
the	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
.	B-X
To	B-X
dissect	B-X
the	B-X
molecular	B-X
basis	B-X
for	B-X
the	B-X
unusually	B-X
persistent	B-X
transcription	B-X
of	B-X
the	B-X
IL-2R	B-X
alpha	B-X
gene	B-X
,	B-X
we	B-X
analyzed	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
binding	B-X
to	B-X
a	B-X
radiolabeled	B-X
IL-2R	B-X
alpha	B-X
kappa	B-X
B-specific	B-X
oligonucleotide	B-X
probe	B-X
during	B-X
the	B-X
time	B-X
course	B-X
of	B-X
CD2	B-X
+	B-X
CD28	B-X
activation	B-X
.	B-X
Resting	B-X
T-cell	B-X
nuclear	B-X
extracts	B-X
contained	B-X
KBF1/p50	B-X
homodimer	B-X
.	B-X
After	B-X
stimulation	B-X
,	B-X
two	B-X
new	B-X
kappa	B-X
B-specific	B-X
complexes	B-X
were	B-X
identified	B-X
as	B-X
NF-kappa	B-X
B	B-X
p50-p65	B-X
heterodimer	B-X
and	B-X
putative	B-X
c-Rel	B-X
homodimer	B-X
or	B-X
c-Rel-p65	B-X
heterodimer	B-X
.	B-X
Both	B-X
inducible	B-X
complexes	B-X
persisted	B-X
for	B-X
at	B-X
least	B-X
3	B-X
weeks	B-X
.	B-X
In	B-X
parallel	B-X
,	B-X
CD2	B-X
+	B-X
CD28	B-X
activation	B-X
triggered	B-X
a	B-X
significant	B-X
intracellular	B-X
thiol	B-X
decrease	B-X
,	B-X
suggesting	B-X
that	B-X
oxygen	B-X
radicals	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
signaling	B-X
pathway	B-X
of	B-X
adhesion	B-X
molecules	B-X
.	B-X
Finally	B-X
,	B-X
micromolar	B-X
amounts	B-X
of	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
an	B-X
oxygen	B-X
radical	B-X
scavenger	B-X
that	B-X
efficiently	B-X
blocked	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
T-lymphocytes	B-X
,	B-X
also	B-X
inhibited	B-X
IL-2	B-X
secretion	B-X
,	B-X
IL-2R	B-X
alpha	B-X
cell	B-X
surface	B-X
expression	B-X
,	B-X
and	B-X
T-cell	B-X
proliferation	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
NF-kappa	B-X
B	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
long-term	B-X
activation	B-X
of	B-X
human	B-X
primary	B-X
T-lymphocytes	B-X
via	B-X
CD2	B-X
+	B-X
CD28	B-X
.	B-X

Synergism	O
between	O
the	O
CD3	O
antigen	O
-	O
and	O
CD2	O
antigen	O
-	O
derived	O
signals	O
.	O
<EOS>	B-X
We	B-X
have	B-X
demonstrated	B-X
earlier	B-X
that	B-X
the	B-X
crosslinkage	B-X
of	B-X
the	B-X
CD3/TCR	B-X
complex	B-X
with	B-X
the	B-X
CD2	B-X
antigen	B-X
results	B-X
in	B-X
the	B-X
proliferation	B-X
of	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
the	B-X
molecular	B-X
and	B-X
nuclear	B-X
basis	B-X
for	B-X
this	B-X
synergism	B-X
,	B-X
we	B-X
have	B-X
explored	B-X
the	B-X
induction	B-X
of	B-X
DNA-binding	B-X
proteins	B-X
in	B-X
highly	B-X
purified	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
signaled	B-X
via	B-X
the	B-X
CD3	B-X
and/or	B-X
CD2	B-X
proteins	B-X
.	B-X
Our	B-X
studies	B-X
demonstrate	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
CD3	B-X
antigen-derived	B-X
signals	B-X
and	B-X
CD2	B-X
antigen-derived	B-X
signals	B-X
are	B-X
synergistic	B-X
in	B-X
inducing	B-X
the	B-X
emergence	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
bind	B-X
to	B-X
the	B-X
NF-AT1	B-X
,	B-X
AP-1	B-X
,	B-X
and	B-X
NF-kB	B-X
sites	B-X
located	B-X
in	B-X
the	B-X
promoter/enhancer	B-X
region	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
Moreover	B-X
,	B-X
cyclosporine	B-X
,	B-X
at	B-X
concentrations	B-X
readily	B-X
accomplished	B-X
in	B-X
clinical	B-X
practice	B-X
,	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
emergence	B-X
of	B-X
these	B-X
DNA-binding	B-X
proteins	B-X
in	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
signaled	B-X
via	B-X
cell	B-X
surface	B-X
proteins	B-X
implicated	B-X
in	B-X
antigen-dependent	B-X
T	B-X
cell	B-X
activation	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
stimulated	B-X
by	B-X
mobilization	B-X
of	B-X
cellular	B-X
calcium	B-X
and	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
.	B-X

Exploration	O
at	O
the	O
level	O
of	O
induction	O
of	O
DNA	O
-	O
binding	O
proteins	O
and	O
characterization	O
of	O
the	O
inhibitory	O
activity	O
of	O
cyclosporine	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
this	B-X
synergism	B-X
was	B-X
perceptible	B-X
at	B-X
the	B-X
level	B-X
of	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
,	B-X
a	B-X
process	B-X
critical	B-X
for	B-X
T	B-X
cell	B-X
growth	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
the	B-X
molecular	B-X
and	B-X
nuclear	B-X
basis	B-X
for	B-X
this	B-X
synergism	B-X
,	B-X
we	B-X
have	B-X
explored	B-X
the	B-X
induction	B-X
of	B-X
DNA-binding	B-X
proteins	B-X
in	B-X
highly	B-X
purified	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
signaled	B-X
via	B-X
the	B-X
CD3	B-X
and/or	B-X
CD2	B-X
proteins	B-X
.	B-X
The	B-X
emergence	B-X
of	B-X
nuclear	B-X
binding	B-X
proteins	B-X
was	B-X
investigated	B-X
using	B-X
interleukin-2	B-X
sequence	B-X
specific	B-X
oligonucleotide	B-X
probes	B-X
in	B-X
the	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
.	B-X
Moreover	B-X
,	B-X
cyclosporine	B-X
,	B-X
at	B-X
concentrations	B-X
readily	B-X
accomplished	B-X
in	B-X
clinical	B-X
practice	B-X
,	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
emergence	B-X
of	B-X
these	B-X
DNA-binding	B-X
proteins	B-X
in	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
signaled	B-X
via	B-X
cell	B-X
surface	B-X
proteins	B-X
implicated	B-X
in	B-X
antigen-dependent	B-X
T	B-X
cell	B-X
activation	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
stimulated	B-X
by	B-X
mobilization	B-X
of	B-X
cellular	B-X
calcium	B-X
and	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
.	B-X

We	O
have	O
demonstrated	O
earlier	O
that	O
the	O
crosslinkage	O
of	O
the	O
CD3	O
/	O
TCR	O
complex	O
with	O
the	O
CD2	O
antigen	O
results	O
in	O
the	O
proliferation	O
of	O
normal	O
human	O
T	O
cells	O
.	O

The	O
effect	O
of	O
this	O
synergism	O
was	O
perceptible	O
at	O
the	O
level	O
of	O
induction	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
,	O
a	O
process	O
critical	O
for	O
T	O
cell	O
growth	O
.	O

To	O
further	O
understand	O
the	O
molecular	O
and	O
nuclear	O
basis	O
for	O
this	O
synergism	O
,	O
we	O
have	O
explored	O
the	O
induction	O
of	O
DNA	O
-	O
binding	O
proteins	O
in	O
highly	O
purified	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
the	O
CD3	O
and	O
/	O
or	O
CD2	O
proteins	O
.	O
<EOS>	B-X
With	B-X
advancements	B-X
in	B-X
structural	B-X
and	B-X
molecular	B-X
biology	B-X
methods	B-X
,	B-X
several	B-X
methods	B-X
are	B-X
now	B-X
available	B-X
to	B-X
study	B-X
protein	B-X
homo-	B-X
and	B-X
heterodimerization	B-X
and	B-X
their	B-X
inhibition	B-X
by	B-X
drug-like	B-X
molecules	B-X
.	B-X
Examples	B-X
of	B-X
homo-	B-X
and	B-X
heterodimers	B-X
of	B-X
proteins	B-X
,	B-X
their	B-X
structural	B-X
and	B-X
functional	B-X
aspects	B-X
,	B-X
and	B-X
some	B-X
of	B-X
the	B-X
inhibitors	B-X
that	B-X
have	B-X
clinical	B-X
importance	B-X
are	B-X
discussed	B-X
.	B-X
The	B-X
design	B-X
of	B-X
PPI	B-X
inhibitors	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
heterodimers	B-X
and	B-X
CD2-CD58	B-X
is	B-X
discussed	B-X
in	B-X
detail	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
provide	B-X
a	B-X
principal	B-X
understanding	B-X
of	B-X
the	B-X
known	B-X
physiological	B-X
signaling	B-X
cascades	B-X
,	B-X
which	B-X
are	B-X
recruited	B-X
by	B-X
Cd	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
and	B-X
to	B-X
highlight	B-X
the	B-X
fact	B-X
that	B-X
Cd	B-X
(	B-X
2+	B-X
)	B-X
,	B-X
similarly	B-X
to	B-X
other	B-X
toxic	B-X
metals	B-X
,	B-X
disrupts	B-X
physiological	B-X
signal	B-X
transduction	B-X
.	B-X
In	B-X
principle	B-X
,	B-X
second	B-X
messengers	B-X
are	B-X
generated	B-X
at	B-X
the	B-X
time	B-X
of	B-X
receptor	B-X
activation	B-X
,	B-X
are	B-X
short-lived	B-X
,	B-X
and	B-X
act	B-X
specifically	B-X
in	B-X
space	B-X
and	B-X
time	B-X
through	B-X
non-covalent	B-X
binding	B-X
on	B-X
effectors	B-X
to	B-X
transiently	B-X
alter	B-X
their	B-X
activity	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
Cd	B-X
(	B-X
2+	B-X
)	B-X
on	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-	B-X
,	B-X
cAMP-	B-X
,	B-X
NO-	B-X
,	B-X
ROS-	B-X
,	B-X
MAP-kinase-	B-X
,	B-X
PKB/Akt-	B-X
,	B-X
nuclear	B-X
factor-kappa	B-X
B-	B-X
,	B-X
and	B-X
developmental	B-X
signaling	B-X
is	B-X
critically	B-X
discussed	B-X
.	B-X

The	O
effect	O
of	O
transmembrane	O
signaling	O
of	O
T	O
cells	O
with	O
ionomycin	O
,	O
and	O
/	O
or	O
sn	O
-	O
1	O
,	O
2	O
dioctanoyl	O
glycerol	O
,	O
was	O
also	O
determined	O
.	O
<EOS>	B-X
The	B-X
potentiation	B-X
by	B-X
1,2-dioctanoyl-sn-glycerol	B-X
(	B-X
DiC8	B-X
)	B-X
of	B-X
ionomycin-induced	B-X
platelet	B-X
production	B-X
of	B-X
12-hydroxy-5,8,10-heptadecatrienoic	B-X
acid	B-X
(	B-X
HHT	B-X
)	B-X
and	B-X
12-hydroxy-5,8,10,14-eicosatetraenoic	B-X
acid	B-X
(	B-X
12-HETE	B-X
)	B-X
was	B-X
investigated	B-X
in	B-X
correlation	B-X
with	B-X
extracellular	B-X
Ca2+	B-X
concentrations	B-X
and	B-X
increases	B-X
in	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
,	B-X
as	B-X
detected	B-X
with	B-X
aequorin	B-X
and	B-X
fura-2	B-X
.	B-X
Extracellular	B-X
Ca2+	B-X
concentrations	B-X
greatly	B-X
influenced	B-X
the	B-X
production	B-X
of	B-X
arachidonic	B-X
acid	B-X
metabolites	B-X
induced	B-X
by	B-X
DiC8	B-X
and	B-X
ionomycin	B-X
,	B-X
while	B-X
that	B-X
induced	B-X
by	B-X
ionomycin	B-X
alone	B-X
was	B-X
minimally	B-X
affected	B-X
by	B-X
variation	B-X
of	B-X
the	B-X
extracellular	B-X
Ca2+	B-X
concentration	B-X
.	B-X
In	B-X
the	B-X
synergy	B-X
between	B-X
ionomycin	B-X
and	B-X
20	B-X
microM	B-X
DiC8	B-X
,	B-X
the	B-X
optimal	B-X
concentrations	B-X
of	B-X
ionomycin	B-X
shifted	B-X
from	B-X
high	B-X
to	B-X
low	B-X
with	B-X
increasing	B-X
concentrations	B-X
of	B-X
extracellular	B-X
Ca2+	B-X
,	B-X
suggesting	B-X
that	B-X
there	B-X
might	B-X
be	B-X
a	B-X
range	B-X
of	B-X
optimal	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
for	B-X
the	B-X
production	B-X
of	B-X
the	B-X
arachidonic	B-X
acid	B-X
metabolites	B-X
.	B-X
This	B-X
hypothesis	B-X
was	B-X
confirmed	B-X
by	B-X
simultaneous	B-X
measurements	B-X
of	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
increases	B-X
,	B-X
and	B-X
the	B-X
production	B-X
of	B-X
the	B-X
arachidonic	B-X
acid	B-X
metabolites	B-X
.	B-X
With	B-X
the	B-X
aequorin	B-X
method	B-X
,	B-X
the	B-X
optimal	B-X
concentrations	B-X
of	B-X
[	B-X
Ca2+	B-X
]	B-X
i	B-X
fell	B-X
to	B-X
between	B-X
10	B-X
microM	B-X
and	B-X
20	B-X
microM	B-X
,	B-X
and	B-X
with	B-X
the	B-X
fura-2	B-X
method	B-X
,	B-X
it	B-X
fell	B-X
to	B-X
between	B-X
800	B-X
nM	B-X
and	B-X
1800	B-X
nM	B-X
.	B-X
Direct	B-X
measurements	B-X
of	B-X
[	B-X
14C	B-X
]	B-X
arachidonic	B-X
acid	B-X
release	B-X
suggested	B-X
that	B-X
the	B-X
DiC8-potentiated	B-X
production	B-X
of	B-X
arachidonic	B-X
acid	B-X
metabolites	B-X
induced	B-X
by	B-X
ionomycin	B-X
was	B-X
attributable	B-X
to	B-X
increased	B-X
arachidonic	B-X
acid	B-X
release	B-X
.	B-X
Since	B-X
ionomycin	B-X
and	B-X
DiC8	B-X
induced	B-X
relatively	B-X
low	B-X
levels	B-X
of	B-X
phosphatidic	B-X
acid	B-X
production	B-X
,	B-X
an	B-X
indicator	B-X
of	B-X
phospholipase	B-X
C	B-X
activation	B-X
,	B-X
it	B-X
was	B-X
suggested	B-X
that	B-X
the	B-X
increased	B-X
arachidonic	B-X
acid	B-X
release	B-X
was	B-X
largely	B-X
dependent	B-X
upon	B-X
phospholipase	B-X
A2	B-X
.	B-X
Synergy	B-X
between	B-X
DiC8	B-X
and	B-X
ionomycin	B-X
was	B-X
also	B-X
observed	B-X
with	B-X
aggregation	B-X
and	B-X
serotonin	B-X
release	B-X
.	B-X
Aggregation	B-X
was	B-X
induced	B-X
by	B-X
lower	B-X
concentrations	B-X
of	B-X
ionomycin	B-X
,	B-X
and	B-X
appeared	B-X
to	B-X
be	B-X
more	B-X
dependent	B-X
upon	B-X
extracellular	B-X
Ca2+	B-X
,	B-X
while	B-X
serotonin	B-X
release	B-X
required	B-X
higher	B-X
concentrations	B-X
of	B-X
ionomycin	B-X
,	B-X
and	B-X
variations	B-X
in	B-X
extracellular	B-X
Ca2+	B-X
affected	B-X
the	B-X
response	B-X
minimally	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
mechanisms	B-X
underlying	B-X
the	B-X
synergy	B-X
between	B-X
protein	B-X
kinase	B-X
C	B-X
activation	B-X
and	B-X
Ca2+	B-X
mobilization	B-X
differ	B-X
among	B-X
the	B-X
three	B-X
functions	B-X
evaluated	B-X
in	B-X
this	B-X
study	B-X
.	B-X

The	O
emergence	O
of	O
nuclear	O
binding	O
proteins	O
was	O
investigated	O
using	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
sequence	O
specific	O
oligonucleotide	O
probes	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
<EOS>	B-X
We	B-X
have	B-X
demonstrated	B-X
earlier	B-X
that	B-X
the	B-X
crosslinkage	B-X
of	B-X
the	B-X
CD3/TCR	B-X
complex	B-X
with	B-X
the	B-X
CD2	B-X
antigen	B-X
results	B-X
in	B-X
the	B-X
proliferation	B-X
of	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
this	B-X
synergism	B-X
was	B-X
perceptible	B-X
at	B-X
the	B-X
level	B-X
of	B-X
induction	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
,	B-X
a	B-X
process	B-X
critical	B-X
for	B-X
T	B-X
cell	B-X
growth	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
the	B-X
molecular	B-X
and	B-X
nuclear	B-X
basis	B-X
for	B-X
this	B-X
synergism	B-X
,	B-X
we	B-X
have	B-X
explored	B-X
the	B-X
induction	B-X
of	B-X
DNA-binding	B-X
proteins	B-X
in	B-X
highly	B-X
purified	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
signaled	B-X
via	B-X
the	B-X
CD3	B-X
and/or	B-X
CD2	B-X
proteins	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
transmembrane	B-X
signaling	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
ionomycin	B-X
,	B-X
and/or	B-X
sn-1,2	B-X
dioctanoyl	B-X
glycerol	B-X
,	B-X
was	B-X
also	B-X
determined	B-X
.	B-X
The	B-X
emergence	B-X
of	B-X
nuclear	B-X
binding	B-X
proteins	B-X
was	B-X
investigated	B-X
using	B-X
interleukin-2	B-X
sequence	B-X
specific	B-X
oligonucleotide	B-X
probes	B-X
in	B-X
the	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
.	B-X
Our	B-X
studies	B-X
demonstrate	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
CD3	B-X
antigen-derived	B-X
signals	B-X
and	B-X
CD2	B-X
antigen-derived	B-X
signals	B-X
are	B-X
synergistic	B-X
in	B-X
inducing	B-X
the	B-X
emergence	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
bind	B-X
to	B-X
the	B-X
NF-AT1	B-X
,	B-X
AP-1	B-X
,	B-X
and	B-X
NF-kB	B-X
sites	B-X
located	B-X
in	B-X
the	B-X
promoter/enhancer	B-X
region	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
Moreover	B-X
,	B-X
cyclosporine	B-X
,	B-X
at	B-X
concentrations	B-X
readily	B-X
accomplished	B-X
in	B-X
clinical	B-X
practice	B-X
,	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
emergence	B-X
of	B-X
these	B-X
DNA-binding	B-X
proteins	B-X
in	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
signaled	B-X
via	B-X
cell	B-X
surface	B-X
proteins	B-X
implicated	B-X
in	B-X
antigen-dependent	B-X
T	B-X
cell	B-X
activation	B-X
and	B-X
in	B-X
T	B-X
cells	B-X
stimulated	B-X
by	B-X
mobilization	B-X
of	B-X
cellular	B-X
calcium	B-X
and	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
.	B-X

Our	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
CD3	O
antigen	O
-	O
derived	O
signals	O
and	O
CD2	O
antigen	O
-	O
derived	O
signals	O
are	O
synergistic	O
in	O
inducing	O
the	O
emergence	O
of	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
NF	O
-	O
AT1	O
,	O
AP	O
-	O
1	O
,	O
and	O
NF	O
-	O
kB	O
sites	O
located	O
in	O
the	O
promoter	O
/	O
enhancer	O
region	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
.	O

Moreover	O
,	O
cyclosporine	O
,	O
at	O
concentrations	O
readily	O
accomplished	O
in	O
clinical	O
practice	O
,	O
was	O
found	O
to	O
inhibit	O
the	O
emergence	O
of	O
these	O
DNA	O
-	O
binding	O
proteins	O
in	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
cell	O
surface	O
proteins	O
implicated	O
in	O
antigen	O
-	O
dependent	O
T	O
cell	O
activation	O
and	O
in	O
T	O
cells	O
stimulated	O
by	O
mobilization	O
of	O
cellular	O
calcium	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

Antisense	O
oligonucleotides	O
to	O
the	O
p65	B-Protein
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
block	O
CD11b	B-Protein
expression	O
and	O
alter	O
adhesion	O
properties	O
of	O
differentiated	O
HL	O
-	O
60	O
granulocytes	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
pleiotropic	O
regulator	O
of	O
a	O
variety	O
of	O
genes	O
implicated	O
in	O
the	O
cellular	O
response	O
to	O
injury	O
.	O
<EOS>	B-X
NF-kappa	B-X
B	B-X
is	B-X
a	B-X
pleiotropic	B-X
regulator	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
genes	B-X
implicated	B-X
in	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
injury	B-X
.	B-X
This	B-X
function	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
coordinated	B-X
binding	B-X
of	B-X
subunits	B-X
of	B-X
NF-kappa	B-X
B	B-X
to	B-X
distinct	B-X
regions	B-X
of	B-X
the	B-X
promoter	B-X
elements	B-X
of	B-X
numerous	B-X
genes	B-X
,	B-X
including	B-X
cytokines	B-X
,	B-X
growth	B-X
factor	B-X
receptors	B-X
,	B-X
and	B-X
adhesion	B-X
molecules	B-X
.	B-X
Antisense	B-X
phosphorothioate	B-X
oligonucleotides	B-X
to	B-X
the	B-X
p50	B-X
and	B-X
p65	B-X
subunits	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
complex	B-X
were	B-X
used	B-X
to	B-X
define	B-X
the	B-X
physiologic	B-X
role	B-X
of	B-X
this	B-X
transcription	B-X
factor	B-X
in	B-X
resting	B-X
and	B-X
stimulated	B-X
granulocytes	B-X
.	B-X
This	B-X
reduction	B-X
was	B-X
accompanied	B-X
by	B-X
rapid	B-X
changes	B-X
in	B-X
the	B-X
cellular	B-X
adhesion	B-X
of	B-X
dimethyl	B-X
sulfoxide-differentiated	B-X
HL-60	B-X
leukemia	B-X
cells	B-X
stimulated	B-X
by	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
antisense	B-X
oligomers	B-X
to	B-X
p65	B-X
can	B-X
be	B-X
used	B-X
to	B-X
define	B-X
the	B-X
role	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
the	B-X
activation	B-X
pathways	B-X
of	B-X
neutrophils	B-X
.	B-X

This	O
function	O
has	O
been	O
attributed	O
to	O
the	O
coordinated	O
binding	O
of	O
subunits	O
of	O
NF	O
-	O
kappa	O
B	O
to	O
distinct	O
regions	O
of	O
the	O
promoter	O
elements	O
of	O
numerous	O
genes	O
,	O
including	O
cytokines	O
,	O
growth	O
factor	O
receptors	O
,	O
and	O
adhesion	O
molecules	O
.	O

Antisense	O
phosphorothioate	O
oligonucleotides	O
to	O
the	O
p50	B-Protein
and	O
p65	B-Protein
subunits	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
were	O
used	O
to	O
define	O
the	O
physiologic	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
resting	O
and	O
stimulated	O
granulocytes	O
.	O

A	O
reduction	O
in	O
the	O
expression	O
of	O
p65	B-Protein
was	O
produced	O
by	O
treatment	O
with	O
the	O
phosphorothioate	O
antisense	O
oligodeoxynucleotide	O
.	O
<EOS>	B-X
Antisense	B-X
phosphorothioate	B-X
oligonucleotides	B-X
to	B-X
the	B-X
p50	B-X
and	B-X
p65	B-X
subunits	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
complex	B-X
were	B-X
used	B-X
to	B-X
define	B-X
the	B-X
physiologic	B-X
role	B-X
of	B-X
this	B-X
transcription	B-X
factor	B-X
in	B-X
resting	B-X
and	B-X
stimulated	B-X
granulocytes	B-X
.	B-X
A	B-X
reduction	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
p65	B-X
was	B-X
produced	B-X
by	B-X
treatment	B-X
with	B-X
the	B-X
phosphorothioate	B-X
antisense	B-X
oligodeoxynucleotide	B-X
.	B-X
This	B-X
reduction	B-X
was	B-X
accompanied	B-X
by	B-X
rapid	B-X
changes	B-X
in	B-X
the	B-X
cellular	B-X
adhesion	B-X
of	B-X
dimethyl	B-X
sulfoxide-differentiated	B-X
HL-60	B-X
leukemia	B-X
cells	B-X
stimulated	B-X
by	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
.	B-X
These	B-X
effects	B-X
were	B-X
characterized	B-X
by	B-X
a	B-X
marked	B-X
reduction	B-X
in	B-X
CD11b	B-X
integrin	B-X
expression	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
treated	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
p65	B-X
antisense	B-X
oligomer	B-X
effectively	B-X
abolished	B-X
an	B-X
upregulation	B-X
of	B-X
CD11b	B-X
that	B-X
was	B-X
produced	B-X
by	B-X
formyl-met-leu-phe	B-X
and	B-X
TPA	B-X
.	B-X
However	B-X
,	B-X
the	B-X
p65	B-X
antisense	B-X
phosphorothioate	B-X
oligodeoxynucleotide	B-X
had	B-X
no	B-X
significant	B-X
effect	B-X
on	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
or	B-X
on	B-X
phagocytosis	B-X
by	B-X
these	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
antisense	B-X
oligomers	B-X
to	B-X
p65	B-X
can	B-X
be	B-X
used	B-X
to	B-X
define	B-X
the	B-X
role	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
the	B-X
activation	B-X
pathways	B-X
of	B-X
neutrophils	B-X
.	B-X

This	O
reduction	O
was	O
accompanied	O
by	O
rapid	O
changes	O
in	O
the	O
cellular	O
adhesion	O
of	O
dimethyl	O
sulfoxide	O
-	O
differentiated	O
HL	O
-	O
60	O
leukemia	O
cells	O
stimulated	O
by	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O
<EOS>	B-X
NF-kappa	B-X
B	B-X
is	B-X
a	B-X
pleiotropic	B-X
regulator	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
genes	B-X
implicated	B-X
in	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
injury	B-X
.	B-X
This	B-X
function	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
coordinated	B-X
binding	B-X
of	B-X
subunits	B-X
of	B-X
NF-kappa	B-X
B	B-X
to	B-X
distinct	B-X
regions	B-X
of	B-X
the	B-X
promoter	B-X
elements	B-X
of	B-X
numerous	B-X
genes	B-X
,	B-X
including	B-X
cytokines	B-X
,	B-X
growth	B-X
factor	B-X
receptors	B-X
,	B-X
and	B-X
adhesion	B-X
molecules	B-X
.	B-X
Antisense	B-X
phosphorothioate	B-X
oligonucleotides	B-X
to	B-X
the	B-X
p50	B-X
and	B-X
p65	B-X
subunits	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
complex	B-X
were	B-X
used	B-X
to	B-X
define	B-X
the	B-X
physiologic	B-X
role	B-X
of	B-X
this	B-X
transcription	B-X
factor	B-X
in	B-X
resting	B-X
and	B-X
stimulated	B-X
granulocytes	B-X
.	B-X
A	B-X
reduction	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
p65	B-X
was	B-X
produced	B-X
by	B-X
treatment	B-X
with	B-X
the	B-X
phosphorothioate	B-X
antisense	B-X
oligodeoxynucleotide	B-X
.	B-X
This	B-X
reduction	B-X
was	B-X
accompanied	B-X
by	B-X
rapid	B-X
changes	B-X
in	B-X
the	B-X
cellular	B-X
adhesion	B-X
of	B-X
dimethyl	B-X
sulfoxide-differentiated	B-X
HL-60	B-X
leukemia	B-X
cells	B-X
stimulated	B-X
by	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
.	B-X
These	B-X
effects	B-X
were	B-X
characterized	B-X
by	B-X
a	B-X
marked	B-X
reduction	B-X
in	B-X
CD11b	B-X
integrin	B-X
expression	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
treated	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
p65	B-X
antisense	B-X
oligomer	B-X
effectively	B-X
abolished	B-X
an	B-X
upregulation	B-X
of	B-X
CD11b	B-X
that	B-X
was	B-X
produced	B-X
by	B-X
formyl-met-leu-phe	B-X
and	B-X
TPA	B-X
.	B-X
However	B-X
,	B-X
the	B-X
p65	B-X
antisense	B-X
phosphorothioate	B-X
oligodeoxynucleotide	B-X
had	B-X
no	B-X
significant	B-X
effect	B-X
on	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
or	B-X
on	B-X
phagocytosis	B-X
by	B-X
these	B-X
cells	B-X
.	B-X

These	O
effects	O
were	O
characterized	O
by	O
a	O
marked	O
reduction	O
in	O
CD11b	B-Protein
integrin	O
expression	O
on	O
the	O
surface	O
of	O
treated	O
cells	O
.	O
<EOS>	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
is	B-X
characterized	B-X
by	B-X
the	B-X
deposition	B-X
of	B-X
β-amyloid	B-X
(	B-X
Aβ	B-X
)	B-X
senile	B-X
plaques	B-X
and	B-X
tau-associated	B-X
neurofibrillary	B-X
tangles	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
monocytic	B-X
cells	B-X
can	B-X
migrate	B-X
into	B-X
the	B-X
AD	B-X
brain	B-X
toward	B-X
Aβ	B-X
plaques	B-X
and	B-X
reduce	B-X
plaque	B-X
burden	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
whether	B-X
the	B-X
administration	B-X
of	B-X
intravenous	B-X
infusions	B-X
of	B-X
'young	B-X
'	B-X
CD11b-positive	B-X
(	B-X
+	B-X
)	B-X
monocytes	B-X
into	B-X
an	B-X
AD	B-X
mouse	B-X
model	B-X
can	B-X
enhance	B-X
Aβ	B-X
plaque	B-X
clearance	B-X
and	B-X
attenuate	B-X
cognitive	B-X
deficits	B-X
.	B-X
Peripheral	B-X
monocytes	B-X
were	B-X
isolated	B-X
from	B-X
two-week-old	B-X
wildtype	B-X
mice	B-X
using	B-X
the	B-X
Pluriselect	B-X
CD11b+	B-X
isolation	B-X
method	B-X
and	B-X
characterized	B-X
by	B-X
FACS	B-X
analysis	B-X
for	B-X
surface	B-X
marker	B-X
expression	B-X
and	B-X
effective	B-X
phagocytosis	B-X
of	B-X
1	B-X
μm	B-X
fluorescent	B-X
microspheres	B-X
,	B-X
FITC-Dextran	B-X
or	B-X
FITC-Aβ1-42	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
that	B-X
infusions	B-X
of	B-X
two-week-old	B-X
CD11b+	B-X
monocytes	B-X
into	B-X
adult	B-X
APPSwDI	B-X
mice	B-X
results	B-X
in	B-X
a	B-X
transient	B-X
improvement	B-X
of	B-X
memory	B-X
function	B-X
,	B-X
a	B-X
reduction	B-X
(	B-X
30	B-X
%	B-X
)	B-X
in	B-X
Aβ	B-X
plaque	B-X
load	B-X
and	B-X
significantly	B-X
in	B-X
small	B-X
(	B-X
<	B-X
20	B-X
μm	B-X
)	B-X
and	B-X
large	B-X
(	B-X
>	B-X
40	B-X
μm	B-X
)	B-X
plaques	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
observe	B-X
a	B-X
reduction	B-X
in	B-X
Iba1+	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
no	B-X
marked	B-X
elevations	B-X
in	B-X
cytokine	B-X
levels	B-X
or	B-X
other	B-X
indicators	B-X
of	B-X
inflammation	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
young	B-X
CD11b+	B-X
monocytes	B-X
may	B-X
serve	B-X
as	B-X
therapeutic	B-X
candidates	B-X
for	B-X
improved	B-X
Aβ	B-X
clearance	B-X
in	B-X
AD	B-X
.	B-X

Furthermore	O
,	O
the	O
p65	B-Protein
antisense	O
oligomer	O
effectively	O
abolished	O
an	O
upregulation	O
of	O
CD11b	B-Protein
that	O
was	O
produced	O
by	O
formyl	O
-	O
met	O
-	O
leu	O
-	O
phe	O
and	O
TPA	O
.	O
<EOS>	B-X
Antisense	B-X
phosphorothioate	B-X
oligonucleotides	B-X
to	B-X
the	B-X
p50	B-X
and	B-X
p65	B-X
subunits	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
complex	B-X
were	B-X
used	B-X
to	B-X
define	B-X
the	B-X
physiologic	B-X
role	B-X
of	B-X
this	B-X
transcription	B-X
factor	B-X
in	B-X
resting	B-X
and	B-X
stimulated	B-X
granulocytes	B-X
.	B-X
A	B-X
reduction	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
p65	B-X
was	B-X
produced	B-X
by	B-X
treatment	B-X
with	B-X
the	B-X
phosphorothioate	B-X
antisense	B-X
oligodeoxynucleotide	B-X
.	B-X
This	B-X
reduction	B-X
was	B-X
accompanied	B-X
by	B-X
rapid	B-X
changes	B-X
in	B-X
the	B-X
cellular	B-X
adhesion	B-X
of	B-X
dimethyl	B-X
sulfoxide-differentiated	B-X
HL-60	B-X
leukemia	B-X
cells	B-X
stimulated	B-X
by	B-X
12-O-tetradecanoylphorbol	B-X
13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
.	B-X
These	B-X
effects	B-X
were	B-X
characterized	B-X
by	B-X
a	B-X
marked	B-X
reduction	B-X
in	B-X
CD11b	B-X
integrin	B-X
expression	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
treated	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
p65	B-X
antisense	B-X
oligomer	B-X
effectively	B-X
abolished	B-X
an	B-X
upregulation	B-X
of	B-X
CD11b	B-X
that	B-X
was	B-X
produced	B-X
by	B-X
formyl-met-leu-phe	B-X
and	B-X
TPA	B-X
.	B-X
However	B-X
,	B-X
the	B-X
p65	B-X
antisense	B-X
phosphorothioate	B-X
oligodeoxynucleotide	B-X
had	B-X
no	B-X
significant	B-X
effect	B-X
on	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
or	B-X
on	B-X
phagocytosis	B-X
by	B-X
these	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
antisense	B-X
oligomers	B-X
to	B-X
p65	B-X
can	B-X
be	B-X
used	B-X
to	B-X
define	B-X
the	B-X
role	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
the	B-X
activation	B-X
pathways	B-X
of	B-X
neutrophils	B-X
.	B-X

However	O
,	O
the	O
p65	B-Protein
antisense	O
phosphorothioate	O
oligodeoxynucleotide	O
had	O
no	O
significant	O
effect	O
on	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
or	O
on	O
phagocytosis	O
by	O
these	O
cells	O
.	O
<EOS>	B-X
Neutrophils	B-X
are	B-X
immune	B-X
cells	B-X
with	B-X
unusual	B-X
biological	B-X
features	B-X
that	B-X
furnish	B-X
potent	B-X
antimicrobial	B-X
properties	B-X
.	B-X
These	B-X
cells	B-X
phagocytose	B-X
and	B-X
subsequently	B-X
kill	B-X
prokaryotic	B-X
and	B-X
eukaryotic	B-X
organisms	B-X
very	B-X
efficiently	B-X
.	B-X
They	B-X
can	B-X
unleash	B-X
their	B-X
effectors	B-X
into	B-X
the	B-X
extracellular	B-X
space	B-X
,	B-X
where	B-X
,	B-X
even	B-X
post-mortem	B-X
,	B-X
their	B-X
killing	B-X
machinery	B-X
can	B-X
endure	B-X
and	B-X
remain	B-X
functional	B-X
.	B-X
During	B-X
the	B-X
past	B-X
decades	B-X
,	B-X
the	B-X
secretory	B-X
property	B-X
and	B-X
chemotaxis	B-X
of	B-X
microglia	B-X
have	B-X
been	B-X
well-studied	B-X
,	B-X
while	B-X
relatively	B-X
less	B-X
attention	B-X
has	B-X
been	B-X
paid	B-X
to	B-X
microglial	B-X
phagocytosis	B-X
.	B-X

These	O
findings	O
indicate	O
that	O
antisense	O
oligomers	O
to	O
p65	B-Protein
can	O
be	O
used	O
to	O
define	O
the	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
activation	O
pathways	O
of	O
neutrophils	O
.	O
<EOS>	B-X
NF-kappa	B-X
B	B-X
is	B-X
a	B-X
pleiotropic	B-X
regulator	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
genes	B-X
implicated	B-X
in	B-X
the	B-X
cellular	B-X
response	B-X
to	B-X
injury	B-X
.	B-X
This	B-X
function	B-X
has	B-X
been	B-X
attributed	B-X
to	B-X
the	B-X
coordinated	B-X
binding	B-X
of	B-X
subunits	B-X
of	B-X
NF-kappa	B-X
B	B-X
to	B-X
distinct	B-X
regions	B-X
of	B-X
the	B-X
promoter	B-X
elements	B-X
of	B-X
numerous	B-X
genes	B-X
,	B-X
including	B-X
cytokines	B-X
,	B-X
growth	B-X
factor	B-X
receptors	B-X
,	B-X
and	B-X
adhesion	B-X
molecules	B-X
.	B-X
Antisense	B-X
phosphorothioate	B-X
oligonucleotides	B-X
to	B-X
the	B-X
p50	B-X
and	B-X
p65	B-X
subunits	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
complex	B-X
were	B-X
used	B-X
to	B-X
define	B-X
the	B-X
physiologic	B-X
role	B-X
of	B-X
this	B-X
transcription	B-X
factor	B-X
in	B-X
resting	B-X
and	B-X
stimulated	B-X
granulocytes	B-X
.	B-X
A	B-X
reduction	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
p65	B-X
was	B-X
produced	B-X
by	B-X
treatment	B-X
with	B-X
the	B-X
phosphorothioate	B-X
antisense	B-X
oligodeoxynucleotide	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
p65	B-X
antisense	B-X
oligomer	B-X
effectively	B-X
abolished	B-X
an	B-X
upregulation	B-X
of	B-X
CD11b	B-X
that	B-X
was	B-X
produced	B-X
by	B-X
formyl-met-leu-phe	B-X
and	B-X
TPA	B-X
.	B-X
However	B-X
,	B-X
the	B-X
p65	B-X
antisense	B-X
phosphorothioate	B-X
oligodeoxynucleotide	B-X
had	B-X
no	B-X
significant	B-X
effect	B-X
on	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
intermediates	B-X
or	B-X
on	B-X
phagocytosis	B-X
by	B-X
these	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
antisense	B-X
oligomers	B-X
to	B-X
p65	B-X
can	B-X
be	B-X
used	B-X
to	B-X
define	B-X
the	B-X
role	B-X
of	B-X
NF-kappa	B-X
B	B-X
in	B-X
the	B-X
activation	B-X
pathways	B-X
of	B-X
neutrophils	B-X
.	B-X

Human	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
2	I-Protein
gene	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
most	B-X
significant	B-X
challenges	B-X
of	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X
research	B-X
is	B-X
to	B-X
understand	B-X
how	B-X
alterations	B-X
in	B-X
the	B-X
symbiotic	B-X
relationship	B-X
between	B-X
the	B-X
genetic	B-X
composition	B-X
of	B-X
the	B-X
host	B-X
and	B-X
the	B-X
intestinal	B-X
microbiota	B-X
,	B-X
under	B-X
impact	B-X
of	B-X
specific	B-X
environmental	B-X
factors	B-X
,	B-X
lead	B-X
to	B-X
chronic	B-X
intestinal	B-X
inflammation	B-X
.	B-X
Genome-wide	B-X
association	B-X
studies	B-X
,	B-X
followed	B-X
by	B-X
functional	B-X
studies	B-X
,	B-X
have	B-X
identified	B-X
a	B-X
role	B-X
for	B-X
numerous	B-X
autophagy	B-X
genes	B-X
in	B-X
IBD	B-X
,	B-X
especially	B-X
in	B-X
Crohn	B-X
disease	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
many	B-X
regions	B-X
of	B-X
the	B-X
eye	B-X
evolved	B-X
mechanisms	B-X
to	B-X
deliver	B-X
immune	B-X
cells	B-X
to	B-X
sites	B-X
of	B-X
dysgenesis	B-X
,	B-X
injury	B-X
,	B-X
or	B-X
in	B-X
response	B-X
to	B-X
the	B-X
many	B-X
age-related	B-X
pathologies	B-X
.	B-X
The	B-X
improved	B-X
understanding	B-X
of	B-X
JE	B-X
pathogenesis	B-X
might	B-X
lay	B-X
a	B-X
foundation	B-X
for	B-X
the	B-X
development	B-X
of	B-X
novel	B-X
therapies	B-X
to	B-X
halt	B-X
JE	B-X
.	B-X

Intron	O
-	O
exon	O
organization	O
and	O
functional	O
analysis	O
of	O
5	O
'	O
-	O
flanking	O
region	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
genomic	B-X
DNA	B-X
for	B-X
human	B-X
IRF-2	B-X
gene	B-X
,	B-X
determined	B-X
the	B-X
intron-exon	B-X
structure	B-X
of	B-X
the	B-X
human	B-X
IRF-2	B-X
gene	B-X
,	B-X
mapped	B-X
the	B-X
major	B-X
transcription	B-X
initiation	B-X
site	B-X
,	B-X
identified	B-X
a	B-X
number	B-X
of	B-X
potential	B-X
regulatory	B-X
elements	B-X
in	B-X
the	B-X
5'-flanking	B-X
region	B-X
,	B-X
and	B-X
localized	B-X
the	B-X
IRF-2	B-X
gene	B-X
on	B-X
human	B-X
chromosome	B-X
4	B-X
.	B-X
The	B-X
IRF-2	B-X
promoter	B-X
region	B-X
contains	B-X
a	B-X
CpG	B-X
island	B-X
,	B-X
with	B-X
several	B-X
GC	B-X
boxes	B-X
,	B-X
a	B-X
putative	B-X
NF-kappa	B-X
B-binding	B-X
site	B-X
,	B-X
and	B-X
a	B-X
CAAT	B-X
box	B-X
,	B-X
but	B-X
no	B-X
TATA	B-X
box	B-X
.	B-X
When	B-X
the	B-X
promoter	B-X
region	B-X
was	B-X
linked	B-X
with	B-X
a	B-X
heterologous	B-X
reporter	B-X
gene	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
promoter	B-X
region	B-X
is	B-X
inducible	B-X
by	B-X
both	B-X
interferons	B-X
(	B-X
interferon-alpha	B-X
and	B-X
-gamma	B-X
)	B-X
and	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
.	B-X
The	B-X
region	B-X
which	B-X
induced	B-X
these	B-X
inductions	B-X
was	B-X
identified	B-X
as	B-X
being	B-X
confined	B-X
to	B-X
40	B-X
nucleotides	B-X
5	B-X
'	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
initiation	B-X
site	B-X
by	B-X
testing	B-X
a	B-X
series	B-X
of	B-X
clones	B-X
with	B-X
truncated	B-X
promoter	B-X
of	B-X
IRF-2	B-X
.	B-X
This	B-X
region	B-X
contains	B-X
elements	B-X
which	B-X
are	B-X
shared	B-X
with	B-X
the	B-X
transcriptional	B-X
enhancers	B-X
of	B-X
other	B-X
genes	B-X
including	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
,	B-X
interferon	B-X
beta	B-X
,	B-X
and	B-X
interferon-inducible	B-X
genes	B-X
.	B-X

Interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
2	I-Protein
(	O
IRF	B-Protein
-	I-Protein
2	I-Protein
)	O
is	O
a	O
transcriptional	O
regulatory	O
protein	O
that	O
terminates	O
interferon	B-Protein
beta	I-Protein
expression	O
initiated	O
by	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
1	I-Protein
.	O
<EOS>	B-X
Interferon	B-X
regulatory	B-X
factor	B-X
2	B-X
(	B-X
IRF-2	B-X
)	B-X
is	B-X
a	B-X
transcriptional	B-X
regulatory	B-X
protein	B-X
that	B-X
terminates	B-X
interferon	B-X
beta	B-X
expression	B-X
initiated	B-X
by	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
genomic	B-X
DNA	B-X
for	B-X
human	B-X
IRF-2	B-X
gene	B-X
,	B-X
determined	B-X
the	B-X
intron-exon	B-X
structure	B-X
of	B-X
the	B-X
human	B-X
IRF-2	B-X
gene	B-X
,	B-X
mapped	B-X
the	B-X
major	B-X
transcription	B-X
initiation	B-X
site	B-X
,	B-X
identified	B-X
a	B-X
number	B-X
of	B-X
potential	B-X
regulatory	B-X
elements	B-X
in	B-X
the	B-X
5'-flanking	B-X
region	B-X
,	B-X
and	B-X
localized	B-X
the	B-X
IRF-2	B-X
gene	B-X
on	B-X
human	B-X
chromosome	B-X
4	B-X
.	B-X
The	B-X
IRF-2	B-X
promoter	B-X
region	B-X
contains	B-X
a	B-X
CpG	B-X
island	B-X
,	B-X
with	B-X
several	B-X
GC	B-X
boxes	B-X
,	B-X
a	B-X
putative	B-X
NF-kappa	B-X
B-binding	B-X
site	B-X
,	B-X
and	B-X
a	B-X
CAAT	B-X
box	B-X
,	B-X
but	B-X
no	B-X
TATA	B-X
box	B-X
.	B-X
When	B-X
the	B-X
promoter	B-X
region	B-X
was	B-X
linked	B-X
with	B-X
a	B-X
heterologous	B-X
reporter	B-X
gene	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
promoter	B-X
region	B-X
is	B-X
inducible	B-X
by	B-X
both	B-X
interferons	B-X
(	B-X
interferon-alpha	B-X
and	B-X
-gamma	B-X
)	B-X
and	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
.	B-X
The	B-X
region	B-X
which	B-X
induced	B-X
these	B-X
inductions	B-X
was	B-X
identified	B-X
as	B-X
being	B-X
confined	B-X
to	B-X
40	B-X
nucleotides	B-X
5	B-X
'	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
initiation	B-X
site	B-X
by	B-X
testing	B-X
a	B-X
series	B-X
of	B-X
clones	B-X
with	B-X
truncated	B-X
promoter	B-X
of	B-X
IRF-2	B-X
.	B-X
This	B-X
region	B-X
contains	B-X
elements	B-X
which	B-X
are	B-X
shared	B-X
with	B-X
the	B-X
transcriptional	B-X
enhancers	B-X
of	B-X
other	B-X
genes	B-X
including	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
,	B-X
interferon	B-X
beta	B-X
,	B-X
and	B-X
interferon-inducible	B-X
genes	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
not	B-X
only	B-X
triggers	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
interferon	B-X
signal	B-X
transduction	B-X
pathway	B-X
,	B-X
but	B-X
also	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
limiting	B-X
the	B-X
duration	B-X
of	B-X
this	B-X
response	B-X
by	B-X
activating	B-X
the	B-X
transcription	B-X
of	B-X
IRF-2	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
isolated	O
the	O
genomic	O
DNA	O
for	O
human	O
IRF	B-Protein
-	I-Protein
2	I-Protein
gene	O
,	O
determined	O
the	O
intron	O
-	O
exon	O
structure	O
of	O
the	O
human	O
IRF	B-Protein
-	I-Protein
2	I-Protein
gene	O
,	O
mapped	O
the	O
major	O
transcription	O
initiation	O
site	O
,	O
identified	O
a	O
number	O
of	O
potential	O
regulatory	O
elements	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
,	O
and	O
localized	O
the	O
IRF	B-Protein
-	I-Protein
2	I-Protein
gene	O
on	O
human	O
chromosome	O
4	O
.	O
<EOS>	B-X
Interferon	B-X
regulatory	B-X
factor	B-X
2	B-X
(	B-X
IRF-2	B-X
)	B-X
is	B-X
a	B-X
transcriptional	B-X
regulatory	B-X
protein	B-X
that	B-X
terminates	B-X
interferon	B-X
beta	B-X
expression	B-X
initiated	B-X
by	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
genomic	B-X
DNA	B-X
for	B-X
human	B-X
IRF-2	B-X
gene	B-X
,	B-X
determined	B-X
the	B-X
intron-exon	B-X
structure	B-X
of	B-X
the	B-X
human	B-X
IRF-2	B-X
gene	B-X
,	B-X
mapped	B-X
the	B-X
major	B-X
transcription	B-X
initiation	B-X
site	B-X
,	B-X
identified	B-X
a	B-X
number	B-X
of	B-X
potential	B-X
regulatory	B-X
elements	B-X
in	B-X
the	B-X
5'-flanking	B-X
region	B-X
,	B-X
and	B-X
localized	B-X
the	B-X
IRF-2	B-X
gene	B-X
on	B-X
human	B-X
chromosome	B-X
4	B-X
.	B-X
The	B-X
IRF-2	B-X
promoter	B-X
region	B-X
contains	B-X
a	B-X
CpG	B-X
island	B-X
,	B-X
with	B-X
several	B-X
GC	B-X
boxes	B-X
,	B-X
a	B-X
putative	B-X
NF-kappa	B-X
B-binding	B-X
site	B-X
,	B-X
and	B-X
a	B-X
CAAT	B-X
box	B-X
,	B-X
but	B-X
no	B-X
TATA	B-X
box	B-X
.	B-X
When	B-X
the	B-X
promoter	B-X
region	B-X
was	B-X
linked	B-X
with	B-X
a	B-X
heterologous	B-X
reporter	B-X
gene	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
promoter	B-X
region	B-X
is	B-X
inducible	B-X
by	B-X
both	B-X
interferons	B-X
(	B-X
interferon-alpha	B-X
and	B-X
-gamma	B-X
)	B-X
and	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
.	B-X
The	B-X
region	B-X
which	B-X
induced	B-X
these	B-X
inductions	B-X
was	B-X
identified	B-X
as	B-X
being	B-X
confined	B-X
to	B-X
40	B-X
nucleotides	B-X
5	B-X
'	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
initiation	B-X
site	B-X
by	B-X
testing	B-X
a	B-X
series	B-X
of	B-X
clones	B-X
with	B-X
truncated	B-X
promoter	B-X
of	B-X
IRF-2	B-X
.	B-X
This	B-X
region	B-X
contains	B-X
elements	B-X
which	B-X
are	B-X
shared	B-X
with	B-X
the	B-X
transcriptional	B-X
enhancers	B-X
of	B-X
other	B-X
genes	B-X
including	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
,	B-X
interferon	B-X
beta	B-X
,	B-X
and	B-X
interferon-inducible	B-X
genes	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
not	B-X
only	B-X
triggers	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
interferon	B-X
signal	B-X
transduction	B-X
pathway	B-X
,	B-X
but	B-X
also	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
limiting	B-X
the	B-X
duration	B-X
of	B-X
this	B-X
response	B-X
by	B-X
activating	B-X
the	B-X
transcription	B-X
of	B-X
IRF-2	B-X
.	B-X

The	O
IRF	B-Protein
-	I-Protein
2	I-Protein
promoter	O
region	O
contains	O
a	O
CpG	O
island	O
,	O
with	O
several	O
GC	O
boxes	O
,	O
a	O
putative	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
site	O
,	O
and	O
a	O
CAAT	O
box	O
,	O
but	O
no	O
TATA	O
box	O
.	O

When	O
the	O
promoter	O
region	O
was	O
linked	O
with	O
a	O
heterologous	O
reporter	O
gene	O
,	O
we	O
found	O
that	O
the	O
promoter	O
region	O
is	O
inducible	O
by	O
both	O
interferons	O
(	O
interferon	B-Protein
-	I-Protein
alpha	I-Protein
and	O
-	B-Protein
gamma	I-Protein
)	O
and	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
1	I-Protein
.	O
<EOS>	B-X
Interferon	B-X
regulatory	B-X
factor	B-X
2	B-X
(	B-X
IRF-2	B-X
)	B-X
is	B-X
a	B-X
transcriptional	B-X
regulatory	B-X
protein	B-X
that	B-X
terminates	B-X
interferon	B-X
beta	B-X
expression	B-X
initiated	B-X
by	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
genomic	B-X
DNA	B-X
for	B-X
human	B-X
IRF-2	B-X
gene	B-X
,	B-X
determined	B-X
the	B-X
intron-exon	B-X
structure	B-X
of	B-X
the	B-X
human	B-X
IRF-2	B-X
gene	B-X
,	B-X
mapped	B-X
the	B-X
major	B-X
transcription	B-X
initiation	B-X
site	B-X
,	B-X
identified	B-X
a	B-X
number	B-X
of	B-X
potential	B-X
regulatory	B-X
elements	B-X
in	B-X
the	B-X
5'-flanking	B-X
region	B-X
,	B-X
and	B-X
localized	B-X
the	B-X
IRF-2	B-X
gene	B-X
on	B-X
human	B-X
chromosome	B-X
4	B-X
.	B-X
The	B-X
IRF-2	B-X
promoter	B-X
region	B-X
contains	B-X
a	B-X
CpG	B-X
island	B-X
,	B-X
with	B-X
several	B-X
GC	B-X
boxes	B-X
,	B-X
a	B-X
putative	B-X
NF-kappa	B-X
B-binding	B-X
site	B-X
,	B-X
and	B-X
a	B-X
CAAT	B-X
box	B-X
,	B-X
but	B-X
no	B-X
TATA	B-X
box	B-X
.	B-X
When	B-X
the	B-X
promoter	B-X
region	B-X
was	B-X
linked	B-X
with	B-X
a	B-X
heterologous	B-X
reporter	B-X
gene	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
promoter	B-X
region	B-X
is	B-X
inducible	B-X
by	B-X
both	B-X
interferons	B-X
(	B-X
interferon-alpha	B-X
and	B-X
-gamma	B-X
)	B-X
and	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
.	B-X
The	B-X
region	B-X
which	B-X
induced	B-X
these	B-X
inductions	B-X
was	B-X
identified	B-X
as	B-X
being	B-X
confined	B-X
to	B-X
40	B-X
nucleotides	B-X
5	B-X
'	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
initiation	B-X
site	B-X
by	B-X
testing	B-X
a	B-X
series	B-X
of	B-X
clones	B-X
with	B-X
truncated	B-X
promoter	B-X
of	B-X
IRF-2	B-X
.	B-X
This	B-X
region	B-X
contains	B-X
elements	B-X
which	B-X
are	B-X
shared	B-X
with	B-X
the	B-X
transcriptional	B-X
enhancers	B-X
of	B-X
other	B-X
genes	B-X
including	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
,	B-X
interferon	B-X
beta	B-X
,	B-X
and	B-X
interferon-inducible	B-X
genes	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
not	B-X
only	B-X
triggers	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
interferon	B-X
signal	B-X
transduction	B-X
pathway	B-X
,	B-X
but	B-X
also	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
limiting	B-X
the	B-X
duration	B-X
of	B-X
this	B-X
response	B-X
by	B-X
activating	B-X
the	B-X
transcription	B-X
of	B-X
IRF-2	B-X
.	B-X

The	O
region	O
which	O
induced	O
these	O
inductions	O
was	O
identified	O
as	O
being	O
confined	O
to	O
40	O
nucleotides	O
5	O
'	O
to	O
the	O
major	O
transcriptional	O
initiation	O
site	O
by	O
testing	O
a	O
series	O
of	O
clones	O
with	O
truncated	O
promoter	O
of	O
IRF	B-Protein
-	I-Protein
2	I-Protein
.	O

This	O
region	O
contains	O
elements	O
which	O
are	O
shared	O
with	O
the	O
transcriptional	O
enhancers	O
of	O
other	O
genes	O
including	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
1	I-Protein
,	O
interferon	B-Protein
beta	I-Protein
,	O
and	O
interferon	O
-	O
inducible	O
genes	O
.	O
<EOS>	B-X
Interferon	B-X
regulatory	B-X
factor	B-X
2	B-X
(	B-X
IRF-2	B-X
)	B-X
is	B-X
a	B-X
transcriptional	B-X
regulatory	B-X
protein	B-X
that	B-X
terminates	B-X
interferon	B-X
beta	B-X
expression	B-X
initiated	B-X
by	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
isolated	B-X
the	B-X
genomic	B-X
DNA	B-X
for	B-X
human	B-X
IRF-2	B-X
gene	B-X
,	B-X
determined	B-X
the	B-X
intron-exon	B-X
structure	B-X
of	B-X
the	B-X
human	B-X
IRF-2	B-X
gene	B-X
,	B-X
mapped	B-X
the	B-X
major	B-X
transcription	B-X
initiation	B-X
site	B-X
,	B-X
identified	B-X
a	B-X
number	B-X
of	B-X
potential	B-X
regulatory	B-X
elements	B-X
in	B-X
the	B-X
5'-flanking	B-X
region	B-X
,	B-X
and	B-X
localized	B-X
the	B-X
IRF-2	B-X
gene	B-X
on	B-X
human	B-X
chromosome	B-X
4	B-X
.	B-X
The	B-X
IRF-2	B-X
promoter	B-X
region	B-X
contains	B-X
a	B-X
CpG	B-X
island	B-X
,	B-X
with	B-X
several	B-X
GC	B-X
boxes	B-X
,	B-X
a	B-X
putative	B-X
NF-kappa	B-X
B-binding	B-X
site	B-X
,	B-X
and	B-X
a	B-X
CAAT	B-X
box	B-X
,	B-X
but	B-X
no	B-X
TATA	B-X
box	B-X
.	B-X
When	B-X
the	B-X
promoter	B-X
region	B-X
was	B-X
linked	B-X
with	B-X
a	B-X
heterologous	B-X
reporter	B-X
gene	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
promoter	B-X
region	B-X
is	B-X
inducible	B-X
by	B-X
both	B-X
interferons	B-X
(	B-X
interferon-alpha	B-X
and	B-X
-gamma	B-X
)	B-X
and	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
.	B-X
The	B-X
region	B-X
which	B-X
induced	B-X
these	B-X
inductions	B-X
was	B-X
identified	B-X
as	B-X
being	B-X
confined	B-X
to	B-X
40	B-X
nucleotides	B-X
5	B-X
'	B-X
to	B-X
the	B-X
major	B-X
transcriptional	B-X
initiation	B-X
site	B-X
by	B-X
testing	B-X
a	B-X
series	B-X
of	B-X
clones	B-X
with	B-X
truncated	B-X
promoter	B-X
of	B-X
IRF-2	B-X
.	B-X
This	B-X
region	B-X
contains	B-X
elements	B-X
which	B-X
are	B-X
shared	B-X
with	B-X
the	B-X
transcriptional	B-X
enhancers	B-X
of	B-X
other	B-X
genes	B-X
including	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
,	B-X
interferon	B-X
beta	B-X
,	B-X
and	B-X
interferon-inducible	B-X
genes	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
interferon	B-X
regulatory	B-X
factor	B-X
1	B-X
not	B-X
only	B-X
triggers	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
interferon	B-X
signal	B-X
transduction	B-X
pathway	B-X
,	B-X
but	B-X
also	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
limiting	B-X
the	B-X
duration	B-X
of	B-X
this	B-X
response	B-X
by	B-X
activating	B-X
the	B-X
transcription	B-X
of	B-X
IRF-2	B-X
.	B-X

These	O
data	O
suggest	O
that	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
1	I-Protein
not	O
only	O
triggers	O
the	O
activation	O
of	O
the	O
interferon	O
signal	O
transduction	O
pathway	O
,	O
but	O
also	O
may	O
play	O
a	O
role	O
in	O
limiting	O
the	O
duration	O
of	O
this	O
response	O
by	O
activating	O
the	O
transcription	O
of	O
IRF	B-Protein
-	I-Protein
2	I-Protein
.	O
<EOS>	B-X
Among	B-X
the	B-X
many	B-X
IFN-inducible	B-X
proteins	B-X
are	B-X
the	B-X
Interferon	B-X
Regulatory	B-X
Factors	B-X
(	B-X
IRFs	B-X
)	B-X
,	B-X
a	B-X
family	B-X
of	B-X
transcription	B-X
regulators	B-X
,	B-X
originally	B-X
consisting	B-X
of	B-X
the	B-X
well-characterized	B-X
IRF-1	B-X
and	B-X
IRF-2	B-X
proteins	B-X
;	B-X
the	B-X
family	B-X
has	B-X
now	B-X
expanded	B-X
to	B-X
over	B-X
10	B-X
members	B-X
and	B-X
is	B-X
still	B-X
growing	B-X
.	B-X
The	B-X
present	B-X
review	B-X
provides	B-X
a	B-X
detailed	B-X
description	B-X
of	B-X
recently	B-X
characterized	B-X
IRF	B-X
family	B-X
members	B-X
.	B-X
Studies	B-X
analyzing	B-X
IRF-expressing	B-X
cell	B-X
lines	B-X
and	B-X
IRF	B-X
knockout	B-X
mice	B-X
reveal	B-X
that	B-X
each	B-X
member	B-X
of	B-X
the	B-X
IRF	B-X
family	B-X
exerts	B-X
distinct	B-X
roles	B-X
in	B-X
biological	B-X
processes	B-X
such	B-X
as	B-X
pathogen	B-X
response	B-X
,	B-X
cytokine	B-X
signalling	B-X
,	B-X
cell	B-X
growth	B-X
regulation	B-X
and	B-X
hematopoietic	B-X
development	B-X
.	B-X
Understanding	B-X
the	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
IRFs	B-X
affect	B-X
these	B-X
important	B-X
cellular	B-X
events	B-X
and	B-X
IFN	B-X
expression	B-X
will	B-X
contribute	B-X
to	B-X
a	B-X
greater	B-X
understanding	B-X
of	B-X
events	B-X
leading	B-X
to	B-X
various	B-X
viral	B-X
,	B-X
immune	B-X
and	B-X
malignant	B-X
disease	B-X
states	B-X
and	B-X
will	B-X
suggest	B-X
novel	B-X
strategies	B-X
for	B-X
antiviral	B-X
and	B-X
immune	B-X
modulatory	B-X
therapy	B-X
.	B-X

Overproduction	O
of	O
NFKB2	B-Protein
(	O
lyt	B-Protein
-	I-Protein
10	I-Protein
)	O
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
:	O
a	O
mechanism	O
for	O
HTLV	O
-	O
I	O
Tax	B-Protein
-	O
mediated	O
trans	O
-	O
activation	O
via	O
the	O
NF	O
-	O
kappa	O
B	O
signalling	O
pathway	O
.	O

Molecular	O
,	O
biochemical	O
and	O
epidemiological	O
evidence	O
implicate	O
HTLV	O
-	O
I	O
as	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O
<EOS>	B-X
Molecular	B-X
,	B-X
biochemical	B-X
and	B-X
epidemiological	B-X
evidence	B-X
implicate	B-X
HTLV-I	B-X
as	B-X
an	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
.	B-X
The	B-X
Tax	B-X
protein	B-X
of	B-X
HTLV-I	B-X
,	B-X
a	B-X
positive	B-X
transcriptional	B-X
activator	B-X
of	B-X
HTLV-I	B-X
gene	B-X
expression	B-X
,	B-X
is	B-X
a	B-X
viral	B-X
oncogene	B-X
that	B-X
also	B-X
increases	B-X
transcription	B-X
of	B-X
cellular	B-X
genes	B-X
including	B-X
GM-CSF	B-X
,	B-X
IL-2R	B-X
alpha	B-X
and	B-X
IL-2	B-X
.	B-X
One	B-X
of	B-X
the	B-X
cellular	B-X
targets	B-X
of	B-X
the	B-X
trans-activating	B-X
effects	B-X
of	B-X
Tax	B-X
is	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
,	B-X
pleiotropic	B-X
regulators	B-X
of	B-X
immunoregulatory	B-X
,	B-X
cytokine	B-X
and	B-X
viral	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
NFKB2	B-X
(	B-X
lyt-10	B-X
)	B-X
and	B-X
c-Rel	B-X
are	B-X
overexpressed	B-X
in	B-X
HTLV-I	B-X
infected	B-X
and	B-X
Tax-expressing	B-X
cells	B-X
and	B-X
,	B-X
together	B-X
,	B-X
account	B-X
for	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
constitutive	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
before	B-X
and	B-X
after	B-X
PMA	B-X
stimulation	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
NFKB2	B-X
precursor	B-X
is	B-X
physically	B-X
associated	B-X
with	B-X
c-Rel	B-X
and	B-X
with	B-X
Tax	B-X
in	B-X
HTLV-I	B-X
infected	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
NFKB2	B-X
synthesis	B-X
and	B-X
processing	B-X
allows	B-X
continuous	B-X
nuclear	B-X
expression	B-X
of	B-X
an	B-X
otherwise	B-X
cytoplasmic	B-X
protein	B-X
and	B-X
,	B-X
in	B-X
conjunction	B-X
with	B-X
overexpression	B-X
of	B-X
c-Rel	B-X
,	B-X
NFKB2	B-X
alters	B-X
the	B-X
NF-kappa	B-X
B	B-X
signalling	B-X
pathway	B-X
and	B-X
contributes	B-X
to	B-X
leukemic	B-X
transformation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
HTLV-I	B-X
.	B-X

The	O
Tax	B-Protein
protein	O
of	O
HTLV	O
-	O
I	O
,	O
a	O
positive	O
transcriptional	O
activator	O
of	O
HTLV	O
-	O
I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	O
genes	O
including	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
,	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O
<EOS>	B-X
Molecular	B-X
,	B-X
biochemical	B-X
and	B-X
epidemiological	B-X
evidence	B-X
implicate	B-X
HTLV-I	B-X
as	B-X
an	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
.	B-X
The	B-X
Tax	B-X
protein	B-X
of	B-X
HTLV-I	B-X
,	B-X
a	B-X
positive	B-X
transcriptional	B-X
activator	B-X
of	B-X
HTLV-I	B-X
gene	B-X
expression	B-X
,	B-X
is	B-X
a	B-X
viral	B-X
oncogene	B-X
that	B-X
also	B-X
increases	B-X
transcription	B-X
of	B-X
cellular	B-X
genes	B-X
including	B-X
GM-CSF	B-X
,	B-X
IL-2R	B-X
alpha	B-X
and	B-X
IL-2	B-X
.	B-X
One	B-X
of	B-X
the	B-X
cellular	B-X
targets	B-X
of	B-X
the	B-X
trans-activating	B-X
effects	B-X
of	B-X
Tax	B-X
is	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
,	B-X
pleiotropic	B-X
regulators	B-X
of	B-X
immunoregulatory	B-X
,	B-X
cytokine	B-X
and	B-X
viral	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
NFKB2	B-X
(	B-X
lyt-10	B-X
)	B-X
and	B-X
c-Rel	B-X
are	B-X
overexpressed	B-X
in	B-X
HTLV-I	B-X
infected	B-X
and	B-X
Tax-expressing	B-X
cells	B-X
and	B-X
,	B-X
together	B-X
,	B-X
account	B-X
for	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
constitutive	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
before	B-X
and	B-X
after	B-X
PMA	B-X
stimulation	B-X
.	B-X
Most	B-X
importantly	B-X
,	B-X
we	B-X
show	B-X
a	B-X
Tax-dependent	B-X
correlation	B-X
between	B-X
expression	B-X
of	B-X
NFKB2	B-X
(	B-X
p100	B-X
)	B-X
and	B-X
processing	B-X
to	B-X
the	B-X
DNA	B-X
binding	B-X
NFKB2	B-X
(	B-X
p52	B-X
)	B-X
form	B-X
,	B-X
induction	B-X
of	B-X
c-Rel	B-X
,	B-X
and	B-X
trans-activation	B-X
of	B-X
NF-kappa	B-X
B-mediated	B-X
gene	B-X
expression	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
NFKB2	B-X
precursor	B-X
is	B-X
physically	B-X
associated	B-X
with	B-X
c-Rel	B-X
and	B-X
with	B-X
Tax	B-X
in	B-X
HTLV-I	B-X
infected	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
NFKB2	B-X
synthesis	B-X
and	B-X
processing	B-X
allows	B-X
continuous	B-X
nuclear	B-X
expression	B-X
of	B-X
an	B-X
otherwise	B-X
cytoplasmic	B-X
protein	B-X
and	B-X
,	B-X
in	B-X
conjunction	B-X
with	B-X
overexpression	B-X
of	B-X
c-Rel	B-X
,	B-X
NFKB2	B-X
alters	B-X
the	B-X
NF-kappa	B-X
B	B-X
signalling	B-X
pathway	B-X
and	B-X
contributes	B-X
to	B-X
leukemic	B-X
transformation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
HTLV-I	B-X
.	B-X

One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans	O
-	O
activating	O
effects	O
of	O
Tax	B-Protein
is	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
,	O
pleiotropic	O
regulators	O
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O
<EOS>	B-X
The	B-X
viral	B-X
oncogene	B-X
Tax	B-X
derived	B-X
from	B-X
human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
is	B-X
a	B-X
positive	B-X
transcriptional	B-X
activator	B-X
of	B-X
HTLV-1	B-X
gene	B-X
expression	B-X
.	B-X
Tax	B-X
is	B-X
also	B-X
able	B-X
to	B-X
indirectly	B-X
stimulate	B-X
transcription	B-X
of	B-X
several	B-X
growth	B-X
regulatory	B-X
genes	B-X
by	B-X
an	B-X
indirect	B-X
mechanism	B-X
via	B-X
association	B-X
with	B-X
host	B-X
transcription	B-X
factors	B-X
.	B-X
One	B-X
of	B-X
the	B-X
cellular	B-X
targets	B-X
of	B-X
the	B-X
trans-activating	B-X
effects	B-X
of	B-X
Tax	B-X
is	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
family	B-X
transcription	B-X
factors	B-X
,	B-X
pleiotropic	B-X
regulators	B-X
of	B-X
immunoregulatory	B-X
,	B-X
cytokine	B-X
,	B-X
and	B-X
viral	B-X
gene	B-X
expression	B-X
.	B-X
Recent	B-X
studies	B-X
demonstrated	B-X
that	B-X
specific	B-X
subunits	B-X
of	B-X
NF-kappa	B-X
B	B-X
(	B-X
NFKB2	B-X
(	B-X
p	B-X
100	B-X
)	B-X
and	B-X
c-Rel	B-X
)	B-X
were	B-X
overexpressed	B-X
in	B-X
HTLV-I-infected	B-X
and	B-X
Tax-expressing	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
Tax	B-X
physically	B-X
associated	B-X
with	B-X
NFKB2	B-X
(	B-X
p	B-X
100	B-X
)	B-X
.	B-X
Monospecific	B-X
antibodies	B-X
directed	B-X
against	B-X
individual	B-X
NF-kappa	B-X
B	B-X
subunits	B-X
were	B-X
generated	B-X
and	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
consequences	B-X
of	B-X
the	B-X
interactions	B-X
between	B-X
Tax	B-X
and	B-X
NF-kappa	B-X
B	B-X
in	B-X
a	B-X
cotransfection-immunofluorescence	B-X
assay	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
:	B-X
(	B-X
1	B-X
)	B-X
distinct	B-X
compartmentalization	B-X
of	B-X
NF-kappa	B-X
B	B-X
precursors	B-X
and	B-X
products	B-X
,	B-X
(	B-X
2	B-X
)	B-X
differential	B-X
induction	B-X
of	B-X
the	B-X
endogenous	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
protein	B-X
by	B-X
transfected	B-X
NF-kappa	B-X
B	B-X
subunits	B-X
,	B-X
(	B-X
3	B-X
)	B-X
subcellular	B-X
relocalization	B-X
of	B-X
Tax	B-X
to	B-X
the	B-X
cytoplasm	B-X
or	B-X
nucleus	B-X
depending	B-X
on	B-X
the	B-X
coexpressed	B-X
NF-kappa	B-X
B	B-X
subunit	B-X
,	B-X
and	B-X
(	B-X
4	B-X
)	B-X
Tax	B-X
interaction	B-X
with	B-X
the	B-X
Rel	B-X
homology	B-X
domain	B-X
region	B-X
of	B-X
NFKB2	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
the	B-X
transcription	B-X
modulatory	B-X
influence	B-X
of	B-X
HTLV-I	B-X
Tax	B-X
may	B-X
be	B-X
significantly	B-X
influenced	B-X
by	B-X
cytoplasmic-nuclear	B-X
partitioning	B-X
associated	B-X
with	B-X
the	B-X
NF-kappa	B-X
B	B-X
proteins	B-X
.	B-X

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
NFKB2	B-Protein
(	O
lyt	B-Protein
-	I-Protein
10	I-Protein
)	O
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
are	O
overexpressed	O
in	O
HTLV	O
-	O
I	O
infected	O
and	O
Tax	B-Protein
-	O
expressing	O
cells	O
and	O
,	O
together	O
,	O
account	O
for	O
the	O
majority	O
of	O
the	O
constitutive	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
these	O
cells	O
before	O
and	O
after	O
PMA	O
stimulation	O
.	O

Most	O
importantly	O
,	O
we	O
show	O
a	O
Tax	B-Protein
-	O
dependent	O
correlation	O
between	O
expression	O
of	O
NFKB2	B-Protein
(	O
p100	B-Protein
)	O
and	O
processing	O
to	O
the	O
DNA	O
binding	O
NFKB2	B-Protein
(	O
p52	B-Protein
)	O
form	O
,	O
induction	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
and	O
trans	O
-	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
mediated	O
gene	O
expression	O
.	O

Furthermore	O
,	O
the	O
NFKB2	B-Protein
precursor	I-Protein
is	O
physically	O
associated	O
with	O
c	B-Protein
-	I-Protein
Rel	I-Protein
and	O
with	O
Tax	B-Protein
in	O
HTLV	O
-	O
I	O
infected	O
cells	O
.	O

We	O
propose	O
that	O
NFKB2	B-Protein
synthesis	O
and	O
processing	O
allows	O
continuous	O
nuclear	O
expression	O
of	O
an	O
otherwise	O
cytoplasmic	O
protein	O
and	O
,	O
in	O
conjunction	O
with	O
overexpression	O
of	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
NFKB2	B-Protein
alters	O
the	O
NF	O
-	O
kappa	O
B	O
signalling	O
pathway	O
and	O
contributes	O
to	O
leukemic	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O
<EOS>	B-X
Molecular	B-X
,	B-X
biochemical	B-X
and	B-X
epidemiological	B-X
evidence	B-X
implicate	B-X
HTLV-I	B-X
as	B-X
an	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
(	B-X
ATL	B-X
)	B-X
.	B-X
The	B-X
Tax	B-X
protein	B-X
of	B-X
HTLV-I	B-X
,	B-X
a	B-X
positive	B-X
transcriptional	B-X
activator	B-X
of	B-X
HTLV-I	B-X
gene	B-X
expression	B-X
,	B-X
is	B-X
a	B-X
viral	B-X
oncogene	B-X
that	B-X
also	B-X
increases	B-X
transcription	B-X
of	B-X
cellular	B-X
genes	B-X
including	B-X
GM-CSF	B-X
,	B-X
IL-2R	B-X
alpha	B-X
and	B-X
IL-2	B-X
.	B-X
One	B-X
of	B-X
the	B-X
cellular	B-X
targets	B-X
of	B-X
the	B-X
trans-activating	B-X
effects	B-X
of	B-X
Tax	B-X
is	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
,	B-X
pleiotropic	B-X
regulators	B-X
of	B-X
immunoregulatory	B-X
,	B-X
cytokine	B-X
and	B-X
viral	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
NFKB2	B-X
(	B-X
lyt-10	B-X
)	B-X
and	B-X
c-Rel	B-X
are	B-X
overexpressed	B-X
in	B-X
HTLV-I	B-X
infected	B-X
and	B-X
Tax-expressing	B-X
cells	B-X
and	B-X
,	B-X
together	B-X
,	B-X
account	B-X
for	B-X
the	B-X
majority	B-X
of	B-X
the	B-X
constitutive	B-X
NF-kappa	B-X
B	B-X
binding	B-X
activity	B-X
in	B-X
these	B-X
cells	B-X
before	B-X
and	B-X
after	B-X
PMA	B-X
stimulation	B-X
.	B-X
Most	B-X
importantly	B-X
,	B-X
we	B-X
show	B-X
a	B-X
Tax-dependent	B-X
correlation	B-X
between	B-X
expression	B-X
of	B-X
NFKB2	B-X
(	B-X
p100	B-X
)	B-X
and	B-X
processing	B-X
to	B-X
the	B-X
DNA	B-X
binding	B-X
NFKB2	B-X
(	B-X
p52	B-X
)	B-X
form	B-X
,	B-X
induction	B-X
of	B-X
c-Rel	B-X
,	B-X
and	B-X
trans-activation	B-X
of	B-X
NF-kappa	B-X
B-mediated	B-X
gene	B-X
expression	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
NFKB2	B-X
precursor	B-X
is	B-X
physically	B-X
associated	B-X
with	B-X
c-Rel	B-X
and	B-X
with	B-X
Tax	B-X
in	B-X
HTLV-I	B-X
infected	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
NFKB2	B-X
synthesis	B-X
and	B-X
processing	B-X
allows	B-X
continuous	B-X
nuclear	B-X
expression	B-X
of	B-X
an	B-X
otherwise	B-X
cytoplasmic	B-X
protein	B-X
and	B-X
,	B-X
in	B-X
conjunction	B-X
with	B-X
overexpression	B-X
of	B-X
c-Rel	B-X
,	B-X
NFKB2	B-X
alters	B-X
the	B-X
NF-kappa	B-X
B	B-X
signalling	B-X
pathway	B-X
and	B-X
contributes	B-X
to	B-X
leukemic	B-X
transformation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
HTLV-I	B-X
.	B-X

Autoregulation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transactivator	O
RelA	B-Protein
(	O
p65	B-Protein
)	O
by	O
multiple	O
cytoplasmic	O
inhibitors	O
containing	O
ankyrin	O
motifs	O
.	O
<EOS>	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
functions	B-X
as	B-X
the	B-X
critical	B-X
transactivating	B-X
component	B-X
of	B-X
the	B-X
heterodimeric	B-X
p50-p65	B-X
NF-kappa	B-X
B	B-X
complex	B-X
and	B-X
contains	B-X
a	B-X
high-affinity	B-X
binding	B-X
site	B-X
for	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
After	B-X
cellular	B-X
activation	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
in	B-X
concert	B-X
with	B-X
the	B-X
induced	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
The	B-X
present	B-X
study	B-X
demonstrates	B-X
that	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha-induced	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
is	B-X
preceded	B-X
by	B-X
its	B-X
rapid	B-X
phosphorylation	B-X
in	B-X
vivo	B-X
.	B-X
However	B-X
,	B-X
these	B-X
effects	B-X
on	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
result	B-X
in	B-X
nuclear	B-X
mobilization	B-X
of	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
entire	B-X
cytoplasmic	B-X
pool	B-X
of	B-X
RelA	B-X
.	B-X
Subsequent	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
(	B-X
i	B-X
)	B-X
cytoplasmic	B-X
RelA	B-X
is	B-X
stably	B-X
associated	B-X
not	B-X
only	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
but	B-X
also	B-X
with	B-X
other	B-X
ankyrin	B-X
motif-rich	B-X
proteins	B-X
including	B-X
the	B-X
products	B-X
of	B-X
the	B-X
NF-kappa	B-X
B2	B-X
(	B-X
p100	B-X
)	B-X
and	B-X
NF-kappa	B-X
B1	B-X
(	B-X
p105	B-X
)	B-X
genes	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
in	B-X
contrast	B-X
to	B-X
RelA-I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
RelA-p100	B-X
cytoplasmic	B-X
complexes	B-X
are	B-X
not	B-X
dissociated	B-X
following	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
activation	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
p100	B-X
functions	B-X
as	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
RelA-mediated	B-X
transcription	B-X
in	B-X
vivo	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
the	B-X
interaction	B-X
of	B-X
RelA	B-X
and	B-X
p100	B-X
involves	B-X
the	B-X
conserved	B-X
Rel	B-X
homology	B-X
domain	B-X
of	B-X
both	B-X
proteins	B-X
but	B-X
not	B-X
the	B-X
nuclear	B-X
localization	B-X
signal	B-X
of	B-X
RelA	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
binding	B-X
;	B-X
(	B-X
v	B-X
)	B-X
p100	B-X
inhibition	B-X
of	B-X
RelA	B-X
function	B-X
requires	B-X
the	B-X
C-terminal	B-X
ankyrin	B-X
motif	B-X
domain	B-X
,	B-X
which	B-X
mediates	B-X
cytoplasmic	B-X
retention	B-X
of	B-X
RelA	B-X
;	B-X
and	B-X
(	B-X
vi	B-X
)	B-X
as	B-X
observed	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
nuclear	B-X
RelA	B-X
stimulates	B-X
p100	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
.	B-X
These	B-X
findings	B-X
thus	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
second	B-X
inducible	B-X
autoregulated	B-X
inhibitory	B-X
pathway	B-X
that	B-X
helps	B-X
ensure	B-X
the	B-X
rapid	B-X
but	B-X
transient	B-X
action	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
.	B-X

RelA	B-Protein
(	O
p65	B-Protein
)	O
functions	O
as	O
the	O
critical	O
transactivating	O
component	O
of	O
the	O
heterodimeric	O
p50	B-Protein
-	O
p65	B-Protein
NF	O
-	O
kappa	O
B	O
complex	O
and	O
contains	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
for	O
its	O
cytoplasmic	O
inhibitor	O
,	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
.	O
<EOS>	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
functions	B-X
as	B-X
the	B-X
critical	B-X
transactivating	B-X
component	B-X
of	B-X
the	B-X
heterodimeric	B-X
p50-p65	B-X
NF-kappa	B-X
B	B-X
complex	B-X
and	B-X
contains	B-X
a	B-X
high-affinity	B-X
binding	B-X
site	B-X
for	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
After	B-X
cellular	B-X
activation	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
in	B-X
concert	B-X
with	B-X
the	B-X
induced	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
The	B-X
present	B-X
study	B-X
demonstrates	B-X
that	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha-induced	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
is	B-X
preceded	B-X
by	B-X
its	B-X
rapid	B-X
phosphorylation	B-X
in	B-X
vivo	B-X
.	B-X
However	B-X
,	B-X
these	B-X
effects	B-X
on	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
result	B-X
in	B-X
nuclear	B-X
mobilization	B-X
of	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
entire	B-X
cytoplasmic	B-X
pool	B-X
of	B-X
RelA	B-X
.	B-X
Subsequent	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
(	B-X
i	B-X
)	B-X
cytoplasmic	B-X
RelA	B-X
is	B-X
stably	B-X
associated	B-X
not	B-X
only	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
but	B-X
also	B-X
with	B-X
other	B-X
ankyrin	B-X
motif-rich	B-X
proteins	B-X
including	B-X
the	B-X
products	B-X
of	B-X
the	B-X
NF-kappa	B-X
B2	B-X
(	B-X
p100	B-X
)	B-X
and	B-X
NF-kappa	B-X
B1	B-X
(	B-X
p105	B-X
)	B-X
genes	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
in	B-X
contrast	B-X
to	B-X
RelA-I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
RelA-p100	B-X
cytoplasmic	B-X
complexes	B-X
are	B-X
not	B-X
dissociated	B-X
following	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
activation	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
p100	B-X
functions	B-X
as	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
RelA-mediated	B-X
transcription	B-X
in	B-X
vivo	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
the	B-X
interaction	B-X
of	B-X
RelA	B-X
and	B-X
p100	B-X
involves	B-X
the	B-X
conserved	B-X
Rel	B-X
homology	B-X
domain	B-X
of	B-X
both	B-X
proteins	B-X
but	B-X
not	B-X
the	B-X
nuclear	B-X
localization	B-X
signal	B-X
of	B-X
RelA	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
binding	B-X
;	B-X
(	B-X
v	B-X
)	B-X
p100	B-X
inhibition	B-X
of	B-X
RelA	B-X
function	B-X
requires	B-X
the	B-X
C-terminal	B-X
ankyrin	B-X
motif	B-X
domain	B-X
,	B-X
which	B-X
mediates	B-X
cytoplasmic	B-X
retention	B-X
of	B-X
RelA	B-X
;	B-X
and	B-X
(	B-X
vi	B-X
)	B-X
as	B-X
observed	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
nuclear	B-X
RelA	B-X
stimulates	B-X
p100	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
.	B-X
These	B-X
findings	B-X
thus	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
second	B-X
inducible	B-X
autoregulated	B-X
inhibitory	B-X
pathway	B-X
that	B-X
helps	B-X
ensure	B-X
the	B-X
rapid	B-X
but	B-X
transient	B-X
action	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
.	B-X

After	O
cellular	O
activation	O
,	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
is	O
rapidly	O
degraded	O
in	O
concert	O
with	O
the	O
induced	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
functions	B-X
as	B-X
the	B-X
critical	B-X
transactivating	B-X
component	B-X
of	B-X
the	B-X
heterodimeric	B-X
p50-p65	B-X
NF-kappa	B-X
B	B-X
complex	B-X
and	B-X
contains	B-X
a	B-X
high-affinity	B-X
binding	B-X
site	B-X
for	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
After	B-X
cellular	B-X
activation	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
in	B-X
concert	B-X
with	B-X
the	B-X
induced	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
The	B-X
present	B-X
study	B-X
demonstrates	B-X
that	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha-induced	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
is	B-X
preceded	B-X
by	B-X
its	B-X
rapid	B-X
phosphorylation	B-X
in	B-X
vivo	B-X
.	B-X
However	B-X
,	B-X
these	B-X
effects	B-X
on	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
result	B-X
in	B-X
nuclear	B-X
mobilization	B-X
of	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
entire	B-X
cytoplasmic	B-X
pool	B-X
of	B-X
RelA	B-X
.	B-X
Subsequent	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
(	B-X
i	B-X
)	B-X
cytoplasmic	B-X
RelA	B-X
is	B-X
stably	B-X
associated	B-X
not	B-X
only	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
but	B-X
also	B-X
with	B-X
other	B-X
ankyrin	B-X
motif-rich	B-X
proteins	B-X
including	B-X
the	B-X
products	B-X
of	B-X
the	B-X
NF-kappa	B-X
B2	B-X
(	B-X
p100	B-X
)	B-X
and	B-X
NF-kappa	B-X
B1	B-X
(	B-X
p105	B-X
)	B-X
genes	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
in	B-X
contrast	B-X
to	B-X
RelA-I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
RelA-p100	B-X
cytoplasmic	B-X
complexes	B-X
are	B-X
not	B-X
dissociated	B-X
following	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
activation	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
p100	B-X
functions	B-X
as	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
RelA-mediated	B-X
transcription	B-X
in	B-X
vivo	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
the	B-X
interaction	B-X
of	B-X
RelA	B-X
and	B-X
p100	B-X
involves	B-X
the	B-X
conserved	B-X
Rel	B-X
homology	B-X
domain	B-X
of	B-X
both	B-X
proteins	B-X
but	B-X
not	B-X
the	B-X
nuclear	B-X
localization	B-X
signal	B-X
of	B-X
RelA	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
binding	B-X
;	B-X
(	B-X
v	B-X
)	B-X
p100	B-X
inhibition	B-X
of	B-X
RelA	B-X
function	B-X
requires	B-X
the	B-X
C-terminal	B-X
ankyrin	B-X
motif	B-X
domain	B-X
,	B-X
which	B-X
mediates	B-X
cytoplasmic	B-X
retention	B-X
of	B-X
RelA	B-X
;	B-X
and	B-X
(	B-X
vi	B-X
)	B-X
as	B-X
observed	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
nuclear	B-X
RelA	B-X
stimulates	B-X
p100	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
.	B-X
These	B-X
findings	B-X
thus	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
second	B-X
inducible	B-X
autoregulated	B-X
inhibitory	B-X
pathway	B-X
that	B-X
helps	B-X
ensure	B-X
the	B-X
rapid	B-X
but	B-X
transient	B-X
action	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
.	B-X

The	O
present	O
study	O
demonstrates	O
that	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
-	O
induced	O
degradation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
in	O
human	O
T	O
cells	O
is	O
preceded	O
by	O
its	O
rapid	O
phosphorylation	O
in	O
vivo	O
.	O

However	O
,	O
these	O
effects	O
on	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
result	O
in	O
nuclear	O
mobilization	O
of	O
only	O
a	O
fraction	O
of	O
the	O
entire	O
cytoplasmic	O
pool	O
of	O
RelA	B-Protein
.	O

Subsequent	O
studies	O
have	O
revealed	O
that	O
(	O
i	O
)	O
cytoplasmic	O
RelA	B-Protein
is	O
stably	O
associated	O
not	O
only	O
with	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
but	O
also	O
with	O
other	O
ankyrin	O
motif	O
-	O
rich	O
proteins	O
including	O
the	O
products	O
of	O
the	O
NF	B-Protein
-	I-Protein
kappa	I-Protein
B2	I-Protein
(	O
p100	B-Protein
)	O
and	O
NF	B-Protein
-	I-Protein
kappa	I-Protein
B1	I-Protein
(	O
p105	B-Protein
)	O
genes	O
;	O
(	O
ii	O
)	O
in	O
contrast	O
to	O
RelA	B-Protein
-	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
,	O
RelA	B-Protein
-	O
p100	B-Protein
cytoplasmic	O
complexes	O
are	O
not	O
dissociated	O
following	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
activation	O
;	O
(	O
iii	O
)	O
p100	B-Protein
functions	O
as	O
a	O
potent	O
inhibitor	O
of	O
RelA	B-Protein
-	O
mediated	O
transcription	O
in	O
vivo	O
;	O
(	O
iv	O
)	O
the	O
interaction	O
of	O
RelA	B-Protein
and	O
p100	B-Protein
involves	O
the	O
conserved	O
Rel	O
homology	O
domain	O
of	O
both	O
proteins	O
but	O
not	O
the	O
nuclear	O
localization	O
signal	O
of	O
RelA	B-Protein
,	O
which	O
is	O
required	O
for	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
binding	O
;	O
(	O
v	O
)	O
p100	B-Protein
inhibition	O
of	O
RelA	B-Protein
function	O
requires	O
the	O
C	O
-	O
terminal	O
ankyrin	O
motif	O
domain	O
,	O
which	O
mediates	O
cytoplasmic	O
retention	O
of	O
RelA	B-Protein
;	O
and	O
(	O
vi	O
)	O
as	O
observed	O
with	O
I	B-Protein
kappa	I-Protein
B	I-Protein
alpha	I-Protein
,	O
nuclear	O
RelA	B-Protein
stimulates	O
p100	B-Protein
mRNA	O
and	O
protein	O
expression	O
.	O

These	O
findings	O
thus	O
reveal	O
the	O
presence	O
of	O
a	O
second	O
inducible	O
autoregulated	O
inhibitory	O
pathway	O
that	O
helps	O
ensure	O
the	O
rapid	O
but	O
transient	O
action	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
RelA	B-X
(	B-X
p65	B-X
)	B-X
functions	B-X
as	B-X
the	B-X
critical	B-X
transactivating	B-X
component	B-X
of	B-X
the	B-X
heterodimeric	B-X
p50-p65	B-X
NF-kappa	B-X
B	B-X
complex	B-X
and	B-X
contains	B-X
a	B-X
high-affinity	B-X
binding	B-X
site	B-X
for	B-X
its	B-X
cytoplasmic	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
After	B-X
cellular	B-X
activation	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
is	B-X
rapidly	B-X
degraded	B-X
in	B-X
concert	B-X
with	B-X
the	B-X
induced	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
The	B-X
present	B-X
study	B-X
demonstrates	B-X
that	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha-induced	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
is	B-X
preceded	B-X
by	B-X
its	B-X
rapid	B-X
phosphorylation	B-X
in	B-X
vivo	B-X
.	B-X
However	B-X
,	B-X
these	B-X
effects	B-X
on	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
result	B-X
in	B-X
nuclear	B-X
mobilization	B-X
of	B-X
only	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
entire	B-X
cytoplasmic	B-X
pool	B-X
of	B-X
RelA	B-X
.	B-X
Subsequent	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
(	B-X
i	B-X
)	B-X
cytoplasmic	B-X
RelA	B-X
is	B-X
stably	B-X
associated	B-X
not	B-X
only	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
but	B-X
also	B-X
with	B-X
other	B-X
ankyrin	B-X
motif-rich	B-X
proteins	B-X
including	B-X
the	B-X
products	B-X
of	B-X
the	B-X
NF-kappa	B-X
B2	B-X
(	B-X
p100	B-X
)	B-X
and	B-X
NF-kappa	B-X
B1	B-X
(	B-X
p105	B-X
)	B-X
genes	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
in	B-X
contrast	B-X
to	B-X
RelA-I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
RelA-p100	B-X
cytoplasmic	B-X
complexes	B-X
are	B-X
not	B-X
dissociated	B-X
following	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
activation	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
p100	B-X
functions	B-X
as	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
RelA-mediated	B-X
transcription	B-X
in	B-X
vivo	B-X
;	B-X
(	B-X
iv	B-X
)	B-X
the	B-X
interaction	B-X
of	B-X
RelA	B-X
and	B-X
p100	B-X
involves	B-X
the	B-X
conserved	B-X
Rel	B-X
homology	B-X
domain	B-X
of	B-X
both	B-X
proteins	B-X
but	B-X
not	B-X
the	B-X
nuclear	B-X
localization	B-X
signal	B-X
of	B-X
RelA	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
binding	B-X
;	B-X
(	B-X
v	B-X
)	B-X
p100	B-X
inhibition	B-X
of	B-X
RelA	B-X
function	B-X
requires	B-X
the	B-X
C-terminal	B-X
ankyrin	B-X
motif	B-X
domain	B-X
,	B-X
which	B-X
mediates	B-X
cytoplasmic	B-X
retention	B-X
of	B-X
RelA	B-X
;	B-X
and	B-X
(	B-X
vi	B-X
)	B-X
as	B-X
observed	B-X
with	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
nuclear	B-X
RelA	B-X
stimulates	B-X
p100	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
.	B-X
These	B-X
findings	B-X
thus	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
second	B-X
inducible	B-X
autoregulated	B-X
inhibitory	B-X
pathway	B-X
that	B-X
helps	B-X
ensure	B-X
the	B-X
rapid	B-X
but	B-X
transient	B-X
action	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
.	B-X

Calcineurin	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	O
kappa	O
B	O
/	O
MAD3	B-Protein
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
Calcineurin	B-X
,	B-X
a	B-X
Ca2+/calmodulin-dependent	B-X
protein	B-X
phosphatase	B-X
,	B-X
is	B-X
the	B-X
FK-506-	B-X
and	B-X
CsA-sensitive	B-X
enzyme	B-X
required	B-X
for	B-X
TcR	B-X
mediated	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X
We	B-X
report	B-X
that	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
calcineurin	B-X
partially	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
activate	B-X
the	B-X
IL-2	B-X
promoter	B-X
elements	B-X
IL-2A	B-X
(	B-X
which	B-X
binds	B-X
the	B-X
factors	B-X
OAP	B-X
and	B-X
Oct-1	B-X
)	B-X
and	B-X
IL-2E	B-X
(	B-X
which	B-X
binds	B-X
NF-AT	B-X
)	B-X
,	B-X
and	B-X
completely	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
stimulate	B-X
an	B-X
NF-kappa	B-X
B-dependent	B-X
element	B-X
.	B-X
Calcineurin	B-X
stimulates	B-X
the	B-X
NF-kappa	B-X
B	B-X
element	B-X
by	B-X
enhancing	B-X
inactivation	B-X
of	B-X
I	B-X
kappa	B-X
B/MAD3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
thereby	B-X
increasing	B-X
the	B-X
amount	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
in	B-X
vivo	B-X
that	B-X
activation	B-X
of	B-X
a	B-X
protein	B-X
phosphatase	B-X
can	B-X
inactivate	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
and	B-X
suggest	B-X
one	B-X
possible	B-X
explanation	B-X
for	B-X
mechanism-based	B-X
toxicities	B-X
associated	B-X
with	B-X
FK-506	B-X
and	B-X
CsA	B-X
by	B-X
demonstrating	B-X
that	B-X
these	B-X
drugs	B-X
can	B-X
inhibit	B-X
the	B-X
calcineurin-dependent	B-X
activation	B-X
of	B-X
a	B-X
virtually	B-X
ubiquitous	B-X
transcription	B-X
factor	B-X
.	B-X

The	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
promoter	O
consists	O
of	O
several	O
independent	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
responsive	O
elements	O
.	O
<EOS>	B-X
The	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
promoter	B-X
consists	B-X
of	B-X
several	B-X
independent	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
responsive	B-X
elements	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
promoters	B-X
dependent	B-X
on	B-X
these	B-X
elements	B-X
is	B-X
inhibitable	B-X
by	B-X
the	B-X
immunosuppressants	B-X
cyclosporin	B-X
A	B-X
(	B-X
CsA	B-X
)	B-X
and	B-X
tacrolimus	B-X
(	B-X
FK-506	B-X
)	B-X
.	B-X
Calcineurin	B-X
,	B-X
a	B-X
Ca2+/calmodulin-dependent	B-X
protein	B-X
phosphatase	B-X
,	B-X
is	B-X
the	B-X
FK-506-	B-X
and	B-X
CsA-sensitive	B-X
enzyme	B-X
required	B-X
for	B-X
TcR	B-X
mediated	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X
We	B-X
report	B-X
that	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
calcineurin	B-X
partially	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
activate	B-X
the	B-X
IL-2	B-X
promoter	B-X
elements	B-X
IL-2A	B-X
(	B-X
which	B-X
binds	B-X
the	B-X
factors	B-X
OAP	B-X
and	B-X
Oct-1	B-X
)	B-X
and	B-X
IL-2E	B-X
(	B-X
which	B-X
binds	B-X
NF-AT	B-X
)	B-X
,	B-X
and	B-X
completely	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
stimulate	B-X
an	B-X
NF-kappa	B-X
B-dependent	B-X
element	B-X
.	B-X

The	O
induction	O
of	O
promoters	O
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK	O
-	O
506	O
)	O
.	O
<EOS>	B-X
The	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
promoter	B-X
consists	B-X
of	B-X
several	B-X
independent	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
responsive	B-X
elements	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
promoters	B-X
dependent	B-X
on	B-X
these	B-X
elements	B-X
is	B-X
inhibitable	B-X
by	B-X
the	B-X
immunosuppressants	B-X
cyclosporin	B-X
A	B-X
(	B-X
CsA	B-X
)	B-X
and	B-X
tacrolimus	B-X
(	B-X
FK-506	B-X
)	B-X
.	B-X
Calcineurin	B-X
,	B-X
a	B-X
Ca2+/calmodulin-dependent	B-X
protein	B-X
phosphatase	B-X
,	B-X
is	B-X
the	B-X
FK-506-	B-X
and	B-X
CsA-sensitive	B-X
enzyme	B-X
required	B-X
for	B-X
TcR	B-X
mediated	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X
We	B-X
report	B-X
that	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
calcineurin	B-X
partially	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
activate	B-X
the	B-X
IL-2	B-X
promoter	B-X
elements	B-X
IL-2A	B-X
(	B-X
which	B-X
binds	B-X
the	B-X
factors	B-X
OAP	B-X
and	B-X
Oct-1	B-X
)	B-X
and	B-X
IL-2E	B-X
(	B-X
which	B-X
binds	B-X
NF-AT	B-X
)	B-X
,	B-X
and	B-X
completely	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
stimulate	B-X
an	B-X
NF-kappa	B-X
B-dependent	B-X
element	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
in	B-X
vivo	B-X
that	B-X
activation	B-X
of	B-X
a	B-X
protein	B-X
phosphatase	B-X
can	B-X
inactivate	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
and	B-X
suggest	B-X
one	B-X
possible	B-X
explanation	B-X
for	B-X
mechanism-based	B-X
toxicities	B-X
associated	B-X
with	B-X
FK-506	B-X
and	B-X
CsA	B-X
by	B-X
demonstrating	B-X
that	B-X
these	B-X
drugs	B-X
can	B-X
inhibit	B-X
the	B-X
calcineurin-dependent	B-X
activation	B-X
of	B-X
a	B-X
virtually	B-X
ubiquitous	B-X
transcription	B-X
factor	B-X
.	B-X

Calcineurin	O
,	O
a	O
Ca2	O
+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
phosphatase	O
,	O
is	O
the	O
FK	O
-	O
506	O
-	O
and	O
CsA	O
-	O
sensitive	O
enzyme	O
required	O
for	O
TcR	O
mediated	O
activation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
.	O
<EOS>	B-X
Antigen	B-X
recognition	B-X
by	B-X
the	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
initiates	B-X
events	B-X
including	B-X
lymphokine	B-X
gene	B-X
transcription	B-X
,	B-X
particularly	B-X
interleukin-2	B-X
,	B-X
that	B-X
lead	B-X
to	B-X
T-cell	B-X
activation	B-X
.	B-X
The	B-X
immunosuppressive	B-X
drugs	B-X
,	B-X
cyclosporin	B-X
A	B-X
(	B-X
CsA	B-X
)	B-X
and	B-X
FK-506	B-X
,	B-X
prevent	B-X
T-cell	B-X
proliferation	B-X
by	B-X
inhibiting	B-X
a	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-dependent	B-X
event	B-X
required	B-X
for	B-X
induction	B-X
of	B-X
interleukin-2	B-X
transcription	B-X
.	B-X
Complexes	B-X
of	B-X
FK-506	B-X
or	B-X
CsA	B-X
and	B-X
their	B-X
respective	B-X
intracellular	B-X
binding	B-X
proteins	B-X
inhibit	B-X
the	B-X
calmodulin-dependent	B-X
protein	B-X
phosphatase	B-X
,	B-X
calcineurin	B-X
,	B-X
in	B-X
vitro	B-X
.	B-X
Calcineurin	B-X
,	B-X
although	B-X
present	B-X
in	B-X
lymphocytes	B-X
,	B-X
has	B-X
not	B-X
been	B-X
implicated	B-X
in	B-X
TCR-mediated	B-X
activation	B-X
of	B-X
lymphokine	B-X
genes	B-X
or	B-X
in	B-X
transcriptional	B-X
regulation	B-X
in	B-X
general	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
transfection	B-X
of	B-X
a	B-X
calcineurin	B-X
catalytic	B-X
subunit	B-X
increases	B-X
the	B-X
50	B-X
%	B-X
inhibitory	B-X
concentration	B-X
(	B-X
IC50	B-X
)	B-X
of	B-X
the	B-X
immunosuppressants	B-X
FK-506	B-X
and	B-X
CsA	B-X
,	B-X
and	B-X
that	B-X
a	B-X
mutant	B-X
subunit	B-X
acts	B-X
in	B-X
synergy	B-X
with	B-X
phorbol	B-X
ester	B-X
alone	B-X
to	B-X
activate	B-X
the	B-X
interleukin-2	B-X
promoter	B-X
in	B-X
a	B-X
drug-sensitive	B-X
manner	B-X
.	B-X
These	B-X
results	B-X
implicate	B-X
calcineurin	B-X
as	B-X
a	B-X
component	B-X
of	B-X
the	B-X
TCR	B-X
signal	B-X
transduction	B-X
pathway	B-X
by	B-X
demonstrating	B-X
its	B-X
role	B-X
in	B-X
the	B-X
drug-sensitive	B-X
activation	B-X
of	B-X
the	B-X
interleukin-2	B-X
promoter	B-X
.	B-X

We	O
report	O
that	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	O
partially	O
substitutes	O
for	O
the	O
Ca2	O
+	O
co	O
-	O
stimulus	O
required	O
to	O
activate	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
elements	O
IL	O
-	O
2A	O
(	O
which	O
binds	O
the	O
factors	O
OAP	B-Protein
and	O
Oct	B-Protein
-	I-Protein
1	I-Protein
)	O
and	O
IL	O
-	O
2E	O
(	O
which	O
binds	O
NF	O
-	O
AT	O
)	O
,	O
and	O
completely	O
substitutes	O
for	O
the	O
Ca2	O
+	O
co	O
-	O
stimulus	O
required	O
to	O
stimulate	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
element	O
.	O
<EOS>	B-X
The	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
promoter	B-X
consists	B-X
of	B-X
several	B-X
independent	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
responsive	B-X
elements	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
promoters	B-X
dependent	B-X
on	B-X
these	B-X
elements	B-X
is	B-X
inhibitable	B-X
by	B-X
the	B-X
immunosuppressants	B-X
cyclosporin	B-X
A	B-X
(	B-X
CsA	B-X
)	B-X
and	B-X
tacrolimus	B-X
(	B-X
FK-506	B-X
)	B-X
.	B-X
Calcineurin	B-X
,	B-X
a	B-X
Ca2+/calmodulin-dependent	B-X
protein	B-X
phosphatase	B-X
,	B-X
is	B-X
the	B-X
FK-506-	B-X
and	B-X
CsA-sensitive	B-X
enzyme	B-X
required	B-X
for	B-X
TcR	B-X
mediated	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X
We	B-X
report	B-X
that	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
calcineurin	B-X
partially	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
activate	B-X
the	B-X
IL-2	B-X
promoter	B-X
elements	B-X
IL-2A	B-X
(	B-X
which	B-X
binds	B-X
the	B-X
factors	B-X
OAP	B-X
and	B-X
Oct-1	B-X
)	B-X
and	B-X
IL-2E	B-X
(	B-X
which	B-X
binds	B-X
NF-AT	B-X
)	B-X
,	B-X
and	B-X
completely	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
stimulate	B-X
an	B-X
NF-kappa	B-X
B-dependent	B-X
element	B-X
.	B-X
Calcineurin	B-X
stimulates	B-X
the	B-X
NF-kappa	B-X
B	B-X
element	B-X
by	B-X
enhancing	B-X
inactivation	B-X
of	B-X
I	B-X
kappa	B-X
B/MAD3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
thereby	B-X
increasing	B-X
the	B-X
amount	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
in	B-X
vivo	B-X
that	B-X
activation	B-X
of	B-X
a	B-X
protein	B-X
phosphatase	B-X
can	B-X
inactivate	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
and	B-X
suggest	B-X
one	B-X
possible	B-X
explanation	B-X
for	B-X
mechanism-based	B-X
toxicities	B-X
associated	B-X
with	B-X
FK-506	B-X
and	B-X
CsA	B-X
by	B-X
demonstrating	B-X
that	B-X
these	B-X
drugs	B-X
can	B-X
inhibit	B-X
the	B-X
calcineurin-dependent	B-X
activation	B-X
of	B-X
a	B-X
virtually	B-X
ubiquitous	B-X
transcription	B-X
factor	B-X
.	B-X

Calcineurin	O
stimulates	O
the	O
NF	O
-	O
kappa	O
B	O
element	O
by	O
enhancing	O
inactivation	O
of	O
I	O
kappa	O
B	O
/	O
MAD3	B-Protein
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
.	O
<EOS>	B-X
The	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
promoter	B-X
consists	B-X
of	B-X
several	B-X
independent	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
responsive	B-X
elements	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
promoters	B-X
dependent	B-X
on	B-X
these	B-X
elements	B-X
is	B-X
inhibitable	B-X
by	B-X
the	B-X
immunosuppressants	B-X
cyclosporin	B-X
A	B-X
(	B-X
CsA	B-X
)	B-X
and	B-X
tacrolimus	B-X
(	B-X
FK-506	B-X
)	B-X
.	B-X
Calcineurin	B-X
,	B-X
a	B-X
Ca2+/calmodulin-dependent	B-X
protein	B-X
phosphatase	B-X
,	B-X
is	B-X
the	B-X
FK-506-	B-X
and	B-X
CsA-sensitive	B-X
enzyme	B-X
required	B-X
for	B-X
TcR	B-X
mediated	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X
We	B-X
report	B-X
that	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
calcineurin	B-X
partially	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
activate	B-X
the	B-X
IL-2	B-X
promoter	B-X
elements	B-X
IL-2A	B-X
(	B-X
which	B-X
binds	B-X
the	B-X
factors	B-X
OAP	B-X
and	B-X
Oct-1	B-X
)	B-X
and	B-X
IL-2E	B-X
(	B-X
which	B-X
binds	B-X
NF-AT	B-X
)	B-X
,	B-X
and	B-X
completely	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
stimulate	B-X
an	B-X
NF-kappa	B-X
B-dependent	B-X
element	B-X
.	B-X
Calcineurin	B-X
stimulates	B-X
the	B-X
NF-kappa	B-X
B	B-X
element	B-X
by	B-X
enhancing	B-X
inactivation	B-X
of	B-X
I	B-X
kappa	B-X
B/MAD3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
thereby	B-X
increasing	B-X
the	B-X
amount	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
in	B-X
vivo	B-X
that	B-X
activation	B-X
of	B-X
a	B-X
protein	B-X
phosphatase	B-X
can	B-X
inactivate	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
and	B-X
suggest	B-X
one	B-X
possible	B-X
explanation	B-X
for	B-X
mechanism-based	B-X
toxicities	B-X
associated	B-X
with	B-X
FK-506	B-X
and	B-X
CsA	B-X
by	B-X
demonstrating	B-X
that	B-X
these	B-X
drugs	B-X
can	B-X
inhibit	B-X
the	B-X
calcineurin-dependent	B-X
activation	B-X
of	B-X
a	B-X
virtually	B-X
ubiquitous	B-X
transcription	B-X
factor	B-X
.	B-X

These	O
data	O
provide	O
the	O
first	O
demonstration	O
in	O
vivo	O
that	O
activation	O
of	O
a	O
protein	O
phosphatase	O
can	O
inactivate	O
I	O
kappa	O
B	O
,	O
and	O
suggest	O
one	O
possible	O
explanation	O
for	O
mechanism	O
-	O
based	O
toxicities	O
associated	O
with	O
FK	O
-	O
506	O
and	O
CsA	O
by	O
demonstrating	O
that	O
these	O
drugs	O
can	O
inhibit	O
the	O
calcineurin	O
-	O
dependent	O
activation	O
of	O
a	O
virtually	O
ubiquitous	O
transcription	O
factor	O
.	O
<EOS>	B-X
The	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
promoter	B-X
consists	B-X
of	B-X
several	B-X
independent	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
responsive	B-X
elements	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
promoters	B-X
dependent	B-X
on	B-X
these	B-X
elements	B-X
is	B-X
inhibitable	B-X
by	B-X
the	B-X
immunosuppressants	B-X
cyclosporin	B-X
A	B-X
(	B-X
CsA	B-X
)	B-X
and	B-X
tacrolimus	B-X
(	B-X
FK-506	B-X
)	B-X
.	B-X
Calcineurin	B-X
,	B-X
a	B-X
Ca2+/calmodulin-dependent	B-X
protein	B-X
phosphatase	B-X
,	B-X
is	B-X
the	B-X
FK-506-	B-X
and	B-X
CsA-sensitive	B-X
enzyme	B-X
required	B-X
for	B-X
TcR	B-X
mediated	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X
We	B-X
report	B-X
that	B-X
a	B-X
constitutively	B-X
active	B-X
form	B-X
of	B-X
calcineurin	B-X
partially	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
activate	B-X
the	B-X
IL-2	B-X
promoter	B-X
elements	B-X
IL-2A	B-X
(	B-X
which	B-X
binds	B-X
the	B-X
factors	B-X
OAP	B-X
and	B-X
Oct-1	B-X
)	B-X
and	B-X
IL-2E	B-X
(	B-X
which	B-X
binds	B-X
NF-AT	B-X
)	B-X
,	B-X
and	B-X
completely	B-X
substitutes	B-X
for	B-X
the	B-X
Ca2+	B-X
co-stimulus	B-X
required	B-X
to	B-X
stimulate	B-X
an	B-X
NF-kappa	B-X
B-dependent	B-X
element	B-X
.	B-X
Calcineurin	B-X
stimulates	B-X
the	B-X
NF-kappa	B-X
B	B-X
element	B-X
by	B-X
enhancing	B-X
inactivation	B-X
of	B-X
I	B-X
kappa	B-X
B/MAD3	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
thereby	B-X
increasing	B-X
the	B-X
amount	B-X
of	B-X
nuclear	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
binding	B-X
activity	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
demonstration	B-X
in	B-X
vivo	B-X
that	B-X
activation	B-X
of	B-X
a	B-X
protein	B-X
phosphatase	B-X
can	B-X
inactivate	B-X
I	B-X
kappa	B-X
B	B-X
,	B-X
and	B-X
suggest	B-X
one	B-X
possible	B-X
explanation	B-X
for	B-X
mechanism-based	B-X
toxicities	B-X
associated	B-X
with	B-X
FK-506	B-X
and	B-X
CsA	B-X
by	B-X
demonstrating	B-X
that	B-X
these	B-X
drugs	B-X
can	B-X
inhibit	B-X
the	B-X
calcineurin-dependent	B-X
activation	B-X
of	B-X
a	B-X
virtually	B-X
ubiquitous	B-X
transcription	B-X
factor	B-X
.	B-X

Activation	O
of	O
the	O
interleukin	B-Protein
6	I-Protein
gene	O
by	O
Mycobacterium	O
tuberculosis	O
or	O
lipopolysaccharide	O
is	O
mediated	O
by	O
nuclear	O
factors	O
NF	B-Protein
-	I-Protein
IL6	I-Protein
and	O
NF	O
-	O
kappa	O
B	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Apr	O
11	O
;	O
92	O
(	O
8	O
)	O
:	O
3632	O
]	O
<EOS>	B-X
Therefore	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
overactivated	B-X
inflammatory	B-X
M1	B-X
microglia	B-X
by	B-X
switching	B-X
to	B-X
the	B-X
protective	B-X
M2	B-X
phenotype	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
potential	B-X
therapeutic	B-X
strategy	B-X
in	B-X
neuroinﬂammatory	B-X
disorders	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
BV2	B-X
microglial	B-X
cell	B-X
line	B-X
was	B-X
pretreated	B-X
with	B-X
different	B-X
curcumin	B-X
concentrations	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
to	B-X
assess	B-X
the	B-X
anti-inﬂammatory	B-X
efﬁcacy	B-X
of	B-X
curcumin	B-X
based	B-X
on	B-X
the	B-X
morphological	B-X
and	B-X
inﬂammatory	B-X
changes	B-X
.	B-X
The	B-X
cytotoxicity	B-X
of	B-X
curcumin	B-X
for	B-X
BV2	B-X
cells	B-X
was	B-X
evaluated	B-X
using	B-X
the	B-X
CCK-8	B-X
assay	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
curcumin	B-X
concentrations	B-X
on	B-X
LPS-induced	B-X
BV2	B-X
cells	B-X
was	B-X
studied	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
was	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
levels	B-X
of	B-X
triggering	B-X
receptor	B-X
expressed	B-X
on	B-X
myeloid	B-X
cells	B-X
2	B-X
(	B-X
TREM2	B-X
)	B-X
,	B-X
toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
,	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-κB	B-X
)	B-X
p65	B-X
,	B-X
p-NF-κB	B-X
p65	B-X
,	B-X
IκB	B-X
,	B-X
and	B-X
p-IκB	B-X
expression	B-X
.	B-X
Results	B-X
showed	B-X
that	B-X
curcumin	B-X
concentrations	B-X
less	B-X
than	B-X
10	B-X
μM	B-X
did	B-X
not	B-X
induce	B-X
any	B-X
detectable	B-X
cytotoxicity	B-X
but	B-X
decreased	B-X
BV2	B-X
cell	B-X
viability	B-X
up	B-X
to	B-X
20	B-X
μM	B-X
.	B-X
Curcumin	B-X
treatment	B-X
switched	B-X
the	B-X
M1	B-X
pro-inﬂammatory	B-X
phenotype	B-X
to	B-X
the	B-X
M2	B-X
anti-inﬂammatory	B-X
phenotype	B-X
by	B-X
decreasing	B-X
the	B-X
expression	B-X
of	B-X
M1	B-X
markers	B-X
(	B-X
i.e.	B-X
,	B-X
iNOS	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
CD16/32	B-X
)	B-X
and	B-X
elevating	B-X
the	B-X
expression	B-X
of	B-X
M2	B-X
markers	B-X
(	B-X
i.e.	B-X
,	B-X
arginase	B-X
1	B-X
,	B-X
IL-4	B-X
,	B-X
IL-10	B-X
,	B-X
and	B-X
CD206	B-X
)	B-X
.	B-X
Interestingly	B-X
,	B-X
curcumin	B-X
attenuated	B-X
the	B-X
activation	B-X
of	B-X
TLR4/NF-κB	B-X
pathways	B-X
and	B-X
the	B-X
downregulation	B-X
of	B-X
TREM2	B-X
expression	B-X
in	B-X
LPS-activated	B-X
BV2	B-X
cells	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
curcumin	B-X
signiﬁcantly	B-X
alleviates	B-X
LPS-induced	B-X
inﬂammation	B-X
by	B-X
regulating	B-X
microglial	B-X
(	B-X
M1/M2	B-X
)	B-X
polarization	B-X
by	B-X
reducing	B-X
the	B-X
imbalance	B-X
of	B-X
TREM2	B-X
and	B-X
TLR4	B-X
and	B-X
balancing	B-X
the	B-X
downstream	B-X
NF-κB	B-X
activation	B-X
.	B-X

The	O
host	O
response	O
to	O
Mycobacterium	O
tuberculosis	O
includes	O
granuloma	O
formation	O
at	O
sites	O
of	O
infection	O
and	O
systemic	O
symptoms	O
.	O
<EOS>	B-X
The	B-X
host	B-X
response	B-X
to	B-X
Mycobacterium	B-X
tuberculosis	B-X
includes	B-X
granuloma	B-X
formation	B-X
at	B-X
sites	B-X
of	B-X
infection	B-X
and	B-X
systemic	B-X
symptoms	B-X
.	B-X
Cytokines	B-X
have	B-X
been	B-X
identified	B-X
by	B-X
immunohistochemistry	B-X
in	B-X
granulomas	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
bacillus	B-X
Calmette-Guérin	B-X
(	B-X
BCG	B-X
)	B-X
infection	B-X
and	B-X
are	B-X
released	B-X
by	B-X
mononuclear	B-X
phagocytes	B-X
upon	B-X
stimulation	B-X
by	B-X
mycobacterial	B-X
proteins	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
the	B-X
cytokine	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
clinical	B-X
manifestations	B-X
and	B-X
pathological	B-X
events	B-X
of	B-X
tuberculosis	B-X
infection	B-X
.	B-X
We	B-X
have	B-X
demonstrated	B-X
that	B-X
lipoarabinomannan	B-X
(	B-X
LAM	B-X
)	B-X
from	B-X
the	B-X
mycobacterial	B-X
cell	B-X
wall	B-X
,	B-X
which	B-X
was	B-X
virtually	B-X
devoid	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
stimulated	B-X
mononuclear	B-X
phagocytes	B-X
to	B-X
release	B-X
IL-6	B-X
in	B-X
a	B-X
dose-response	B-X
manner	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
NF-IL6	B-X
and	B-X
NF-kappa	B-X
B	B-X
sites	B-X
mediate	B-X
IL-6	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
both	B-X
LPS	B-X
and	B-X
LAM	B-X
,	B-X
acting	B-X
as	B-X
bacterial	B-X
or	B-X
mycobacterial	B-X
response	B-X
elements	B-X
.	B-X

Cytokines	O
have	O
been	O
identified	O
by	O
immunohistochemistry	O
in	O
granulomas	O
in	O
animal	O
models	O
of	O
bacillus	O
Calmette	O
-	O
Guerin	O
(	O
BCG	O
)	O
infection	O
and	O
are	O
released	O
by	O
mononuclear	O
phagocytes	O
upon	O
stimulation	O
by	O
mycobacterial	O
proteins	O
.	O
<EOS>	B-X
The	B-X
host	B-X
response	B-X
to	B-X
Mycobacterium	B-X
tuberculosis	B-X
includes	B-X
granuloma	B-X
formation	B-X
at	B-X
sites	B-X
of	B-X
infection	B-X
and	B-X
systemic	B-X
symptoms	B-X
.	B-X
Cytokines	B-X
have	B-X
been	B-X
identified	B-X
by	B-X
immunohistochemistry	B-X
in	B-X
granulomas	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
bacillus	B-X
Calmette-Guérin	B-X
(	B-X
BCG	B-X
)	B-X
infection	B-X
and	B-X
are	B-X
released	B-X
by	B-X
mononuclear	B-X
phagocytes	B-X
upon	B-X
stimulation	B-X
by	B-X
mycobacterial	B-X
proteins	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
the	B-X
cytokine	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
clinical	B-X
manifestations	B-X
and	B-X
pathological	B-X
events	B-X
of	B-X
tuberculosis	B-X
infection	B-X
.	B-X
We	B-X
have	B-X
demonstrated	B-X
that	B-X
lipoarabinomannan	B-X
(	B-X
LAM	B-X
)	B-X
from	B-X
the	B-X
mycobacterial	B-X
cell	B-X
wall	B-X
,	B-X
which	B-X
was	B-X
virtually	B-X
devoid	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
stimulated	B-X
mononuclear	B-X
phagocytes	B-X
to	B-X
release	B-X
IL-6	B-X
in	B-X
a	B-X
dose-response	B-X
manner	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
NF-IL6	B-X
and	B-X
NF-kappa	B-X
B	B-X
sites	B-X
mediate	B-X
IL-6	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
both	B-X
LPS	B-X
and	B-X
LAM	B-X
,	B-X
acting	B-X
as	B-X
bacterial	B-X
or	B-X
mycobacterial	B-X
response	B-X
elements	B-X
.	B-X

In	O
this	O
regard	O
,	O
the	O
cytokine	O
interleukin	B-Protein
6	I-Protein
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
)	O
may	O
play	O
a	O
role	O
in	O
the	O
clinical	O
manifestations	O
and	O
pathological	O
events	O
of	O
tuberculosis	O
infection	O
.	O
<EOS>	B-X
The	B-X
host	B-X
response	B-X
to	B-X
Mycobacterium	B-X
tuberculosis	B-X
includes	B-X
granuloma	B-X
formation	B-X
at	B-X
sites	B-X
of	B-X
infection	B-X
and	B-X
systemic	B-X
symptoms	B-X
.	B-X
Cytokines	B-X
have	B-X
been	B-X
identified	B-X
by	B-X
immunohistochemistry	B-X
in	B-X
granulomas	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
bacillus	B-X
Calmette-Guérin	B-X
(	B-X
BCG	B-X
)	B-X
infection	B-X
and	B-X
are	B-X
released	B-X
by	B-X
mononuclear	B-X
phagocytes	B-X
upon	B-X
stimulation	B-X
by	B-X
mycobacterial	B-X
proteins	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
the	B-X
cytokine	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
clinical	B-X
manifestations	B-X
and	B-X
pathological	B-X
events	B-X
of	B-X
tuberculosis	B-X
infection	B-X
.	B-X
We	B-X
have	B-X
demonstrated	B-X
that	B-X
lipoarabinomannan	B-X
(	B-X
LAM	B-X
)	B-X
from	B-X
the	B-X
mycobacterial	B-X
cell	B-X
wall	B-X
,	B-X
which	B-X
was	B-X
virtually	B-X
devoid	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
stimulated	B-X
mononuclear	B-X
phagocytes	B-X
to	B-X
release	B-X
IL-6	B-X
in	B-X
a	B-X
dose-response	B-X
manner	B-X
.	B-X
LAM	B-X
and	B-X
LPS	B-X
were	B-X
potent	B-X
inducers	B-X
of	B-X
IL-6	B-X
gene	B-X
expression	B-X
in	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
.	B-X
Both	B-X
LAM-	B-X
and	B-X
LPS-inducible	B-X
IL-6	B-X
promoter	B-X
activity	B-X
was	B-X
localized	B-X
to	B-X
a	B-X
DNA	B-X
fragment	B-X
,	B-X
positions	B-X
-158	B-X
to	B-X
-49	B-X
,	B-X
by	B-X
deletion	B-X
analysis	B-X
and	B-X
chloramphenicol	B-X
acetyltransferase	B-X
assay	B-X
.	B-X
Two	B-X
nuclear	B-X
factor	B-X
NF-IL6	B-X
(	B-X
positions	B-X
-153	B-X
to	B-X
-145	B-X
and	B-X
-83	B-X
to	B-X
-75	B-X
)	B-X
and	B-X
one	B-X
nuclear	B-X
factor	B-X
NF-kappa	B-X
B	B-X
(	B-X
positions	B-X
-72	B-X
to	B-X
-63	B-X
)	B-X
motifs	B-X
are	B-X
present	B-X
within	B-X
this	B-X
fragment	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
of	B-X
one	B-X
or	B-X
more	B-X
of	B-X
these	B-X
motifs	B-X
within	B-X
the	B-X
IL-6	B-X
promoter	B-X
demonstrated	B-X
that	B-X
each	B-X
has	B-X
positive	B-X
regulatory	B-X
activity	B-X
and	B-X
that	B-X
they	B-X
could	B-X
act	B-X
in	B-X
a	B-X
function-	B-X
and	B-X
orientation-independent	B-X
manner	B-X
.	B-X
Deletion	B-X
of	B-X
all	B-X
three	B-X
elements	B-X
abolished	B-X
inducibility	B-X
of	B-X
IL-6	B-X
promoter	B-X
activity	B-X
by	B-X
both	B-X
LAM	B-X
and	B-X
LPS	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
NF-IL6	B-X
and	B-X
NF-kappa	B-X
B	B-X
sites	B-X
mediate	B-X
IL-6	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
both	B-X
LPS	B-X
and	B-X
LAM	B-X
,	B-X
acting	B-X
as	B-X
bacterial	B-X
or	B-X
mycobacterial	B-X
response	B-X
elements	B-X
.	B-X

We	O
have	O
demonstrated	O
that	O
lipoarabinomannan	O
(	O
LAM	O
)	O
from	O
the	O
mycobacterial	O
cell	O
wall	O
,	O
which	O
was	O
virtually	O
devoid	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
stimulated	O
mononuclear	O
phagocytes	O
to	O
release	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
a	O
dose	O
-	O
response	O
manner	O
.	O

LAM	O
and	O
LPS	O
were	O
potent	O
inducers	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O
<EOS>	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
the	B-X
cytokine	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
clinical	B-X
manifestations	B-X
and	B-X
pathological	B-X
events	B-X
of	B-X
tuberculosis	B-X
infection	B-X
.	B-X
We	B-X
have	B-X
demonstrated	B-X
that	B-X
lipoarabinomannan	B-X
(	B-X
LAM	B-X
)	B-X
from	B-X
the	B-X
mycobacterial	B-X
cell	B-X
wall	B-X
,	B-X
which	B-X
was	B-X
virtually	B-X
devoid	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
stimulated	B-X
mononuclear	B-X
phagocytes	B-X
to	B-X
release	B-X
IL-6	B-X
in	B-X
a	B-X
dose-response	B-X
manner	B-X
.	B-X
LAM	B-X
and	B-X
LPS	B-X
were	B-X
potent	B-X
inducers	B-X
of	B-X
IL-6	B-X
gene	B-X
expression	B-X
in	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
.	B-X
Both	B-X
LAM-	B-X
and	B-X
LPS-inducible	B-X
IL-6	B-X
promoter	B-X
activity	B-X
was	B-X
localized	B-X
to	B-X
a	B-X
DNA	B-X
fragment	B-X
,	B-X
positions	B-X
-158	B-X
to	B-X
-49	B-X
,	B-X
by	B-X
deletion	B-X
analysis	B-X
and	B-X
chloramphenicol	B-X
acetyltransferase	B-X
assay	B-X
.	B-X
Two	B-X
nuclear	B-X
factor	B-X
NF-IL6	B-X
(	B-X
positions	B-X
-153	B-X
to	B-X
-145	B-X
and	B-X
-83	B-X
to	B-X
-75	B-X
)	B-X
and	B-X
one	B-X
nuclear	B-X
factor	B-X
NF-kappa	B-X
B	B-X
(	B-X
positions	B-X
-72	B-X
to	B-X
-63	B-X
)	B-X
motifs	B-X
are	B-X
present	B-X
within	B-X
this	B-X
fragment	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
of	B-X
one	B-X
or	B-X
more	B-X
of	B-X
these	B-X
motifs	B-X
within	B-X
the	B-X
IL-6	B-X
promoter	B-X
demonstrated	B-X
that	B-X
each	B-X
has	B-X
positive	B-X
regulatory	B-X
activity	B-X
and	B-X
that	B-X
they	B-X
could	B-X
act	B-X
in	B-X
a	B-X
function-	B-X
and	B-X
orientation-independent	B-X
manner	B-X
.	B-X
Deletion	B-X
of	B-X
all	B-X
three	B-X
elements	B-X
abolished	B-X
inducibility	B-X
of	B-X
IL-6	B-X
promoter	B-X
activity	B-X
by	B-X
both	B-X
LAM	B-X
and	B-X
LPS	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
NF-IL6	B-X
and	B-X
NF-kappa	B-X
B	B-X
sites	B-X
mediate	B-X
IL-6	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
both	B-X
LPS	B-X
and	B-X
LAM	B-X
,	B-X
acting	B-X
as	B-X
bacterial	B-X
or	B-X
mycobacterial	B-X
response	B-X
elements	B-X
.	B-X

Both	O
LAM	O
-	O
and	O
LPS	O
-	O
inducible	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
activity	O
was	O
localized	O
to	O
a	O
DNA	O
fragment	O
,	O
positions	O
-	O
158	O
to	O
-	O
49	O
,	O
by	O
deletion	O
analysis	O
and	O
chloramphenicol	B-Protein
acetyltransferase	I-Protein
assay	O
.	O
<EOS>	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
the	B-X
cytokine	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
clinical	B-X
manifestations	B-X
and	B-X
pathological	B-X
events	B-X
of	B-X
tuberculosis	B-X
infection	B-X
.	B-X
We	B-X
have	B-X
demonstrated	B-X
that	B-X
lipoarabinomannan	B-X
(	B-X
LAM	B-X
)	B-X
from	B-X
the	B-X
mycobacterial	B-X
cell	B-X
wall	B-X
,	B-X
which	B-X
was	B-X
virtually	B-X
devoid	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
stimulated	B-X
mononuclear	B-X
phagocytes	B-X
to	B-X
release	B-X
IL-6	B-X
in	B-X
a	B-X
dose-response	B-X
manner	B-X
.	B-X
LAM	B-X
and	B-X
LPS	B-X
were	B-X
potent	B-X
inducers	B-X
of	B-X
IL-6	B-X
gene	B-X
expression	B-X
in	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
.	B-X
Both	B-X
LAM-	B-X
and	B-X
LPS-inducible	B-X
IL-6	B-X
promoter	B-X
activity	B-X
was	B-X
localized	B-X
to	B-X
a	B-X
DNA	B-X
fragment	B-X
,	B-X
positions	B-X
-158	B-X
to	B-X
-49	B-X
,	B-X
by	B-X
deletion	B-X
analysis	B-X
and	B-X
chloramphenicol	B-X
acetyltransferase	B-X
assay	B-X
.	B-X
Two	B-X
nuclear	B-X
factor	B-X
NF-IL6	B-X
(	B-X
positions	B-X
-153	B-X
to	B-X
-145	B-X
and	B-X
-83	B-X
to	B-X
-75	B-X
)	B-X
and	B-X
one	B-X
nuclear	B-X
factor	B-X
NF-kappa	B-X
B	B-X
(	B-X
positions	B-X
-72	B-X
to	B-X
-63	B-X
)	B-X
motifs	B-X
are	B-X
present	B-X
within	B-X
this	B-X
fragment	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
of	B-X
one	B-X
or	B-X
more	B-X
of	B-X
these	B-X
motifs	B-X
within	B-X
the	B-X
IL-6	B-X
promoter	B-X
demonstrated	B-X
that	B-X
each	B-X
has	B-X
positive	B-X
regulatory	B-X
activity	B-X
and	B-X
that	B-X
they	B-X
could	B-X
act	B-X
in	B-X
a	B-X
function-	B-X
and	B-X
orientation-independent	B-X
manner	B-X
.	B-X
Deletion	B-X
of	B-X
all	B-X
three	B-X
elements	B-X
abolished	B-X
inducibility	B-X
of	B-X
IL-6	B-X
promoter	B-X
activity	B-X
by	B-X
both	B-X
LAM	B-X
and	B-X
LPS	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
NF-IL6	B-X
and	B-X
NF-kappa	B-X
B	B-X
sites	B-X
mediate	B-X
IL-6	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
both	B-X
LPS	B-X
and	B-X
LAM	B-X
,	B-X
acting	B-X
as	B-X
bacterial	B-X
or	B-X
mycobacterial	B-X
response	B-X
elements	B-X
.	B-X

Two	O
nuclear	O
factor	O
NF	B-Protein
-	I-Protein
IL6	I-Protein
(	O
positions	O
-	O
153	O
to	O
-	O
145	O
and	O
-	O
83	O
to	O
-	O
75	O
)	O
and	O
one	O
nuclear	O
factor	O
NF	O
-	O
kappa	O
B	O
(	O
positions	O
-	O
72	O
to	O
-	O
63	O
)	O
motifs	O
are	O
present	O
within	O
this	O
fragment	O
.	O
<EOS>	B-X
Cytokines	B-X
have	B-X
been	B-X
identified	B-X
by	B-X
immunohistochemistry	B-X
in	B-X
granulomas	B-X
in	B-X
animal	B-X
models	B-X
of	B-X
bacillus	B-X
Calmette-Guérin	B-X
(	B-X
BCG	B-X
)	B-X
infection	B-X
and	B-X
are	B-X
released	B-X
by	B-X
mononuclear	B-X
phagocytes	B-X
upon	B-X
stimulation	B-X
by	B-X
mycobacterial	B-X
proteins	B-X
.	B-X
We	B-X
have	B-X
demonstrated	B-X
that	B-X
lipoarabinomannan	B-X
(	B-X
LAM	B-X
)	B-X
from	B-X
the	B-X
mycobacterial	B-X
cell	B-X
wall	B-X
,	B-X
which	B-X
was	B-X
virtually	B-X
devoid	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
stimulated	B-X
mononuclear	B-X
phagocytes	B-X
to	B-X
release	B-X
IL-6	B-X
in	B-X
a	B-X
dose-response	B-X
manner	B-X
.	B-X
Both	B-X
LAM-	B-X
and	B-X
LPS-inducible	B-X
IL-6	B-X
promoter	B-X
activity	B-X
was	B-X
localized	B-X
to	B-X
a	B-X
DNA	B-X
fragment	B-X
,	B-X
positions	B-X
-158	B-X
to	B-X
-49	B-X
,	B-X
by	B-X
deletion	B-X
analysis	B-X
and	B-X
chloramphenicol	B-X
acetyltransferase	B-X
assay	B-X
.	B-X
Two	B-X
nuclear	B-X
factor	B-X
NF-IL6	B-X
(	B-X
positions	B-X
-153	B-X
to	B-X
-145	B-X
and	B-X
-83	B-X
to	B-X
-75	B-X
)	B-X
and	B-X
one	B-X
nuclear	B-X
factor	B-X
NF-kappa	B-X
B	B-X
(	B-X
positions	B-X
-72	B-X
to	B-X
-63	B-X
)	B-X
motifs	B-X
are	B-X
present	B-X
within	B-X
this	B-X
fragment	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
of	B-X
one	B-X
or	B-X
more	B-X
of	B-X
these	B-X
motifs	B-X
within	B-X
the	B-X
IL-6	B-X
promoter	B-X
demonstrated	B-X
that	B-X
each	B-X
has	B-X
positive	B-X
regulatory	B-X
activity	B-X
and	B-X
that	B-X
they	B-X
could	B-X
act	B-X
in	B-X
a	B-X
function-	B-X
and	B-X
orientation-independent	B-X
manner	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
NF-IL6	B-X
and	B-X
NF-kappa	B-X
B	B-X
sites	B-X
mediate	B-X
IL-6	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
both	B-X
LPS	B-X
and	B-X
LAM	B-X
,	B-X
acting	B-X
as	B-X
bacterial	B-X
or	B-X
mycobacterial	B-X
response	B-X
elements	B-X
.	B-X

Site	O
-	O
directed	O
mutagenesis	O
of	O
one	O
or	O
more	O
of	O
these	O
motifs	O
within	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
demonstrated	O
that	O
each	O
has	O
positive	O
regulatory	O
activity	O
and	O
that	O
they	O
could	O
act	O
in	O
a	O
function	O
-	O
and	O
orientation	O
-	O
independent	O
manner	O
.	O
<EOS>	B-X
Site-directed	B-X
mutagenesis	B-X
is	B-X
a	B-X
PCR-based	B-X
method	B-X
to	B-X
mutate	B-X
specified	B-X
nucleotides	B-X
of	B-X
a	B-X
sequence	B-X
within	B-X
a	B-X
plasmid	B-X
vector	B-X
.	B-X
This	B-X
technique	B-X
allows	B-X
one	B-X
to	B-X
study	B-X
the	B-X
relative	B-X
importance	B-X
of	B-X
a	B-X
particular	B-X
amino	B-X
acid	B-X
for	B-X
protein	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
Typical	B-X
mutations	B-X
are	B-X
designed	B-X
to	B-X
disrupt	B-X
or	B-X
map	B-X
protein-protein	B-X
interactions	B-X
,	B-X
mimic	B-X
or	B-X
block	B-X
posttranslational	B-X
modifications	B-X
,	B-X
or	B-X
to	B-X
silence	B-X
enzymatic	B-X
activity	B-X
.	B-X
Use	B-X
of	B-X
such	B-X
a	B-X
primer	B-X
setup	B-X
in	B-X
the	B-X
PCR	B-X
reaction	B-X
,	B-X
with	B-X
one	B-X
of	B-X
the	B-X
primers	B-X
containing	B-X
the	B-X
desired	B-X
mismatch	B-X
mutation	B-X
,	B-X
results	B-X
in	B-X
the	B-X
amplification	B-X
of	B-X
a	B-X
linear	B-X
,	B-X
double-stranded	B-X
,	B-X
mutated	B-X
product	B-X
.	B-X
This	B-X
relatively	B-X
simple	B-X
site-directed	B-X
mutagenesis	B-X
procedure	B-X
is	B-X
of	B-X
major	B-X
importance	B-X
in	B-X
biology	B-X
and	B-X
biotechnology	B-X
today	B-X
where	B-X
it	B-X
is	B-X
commonly	B-X
employed	B-X
for	B-X
the	B-X
study	B-X
and	B-X
engineering	B-X
of	B-X
DNA	B-X
,	B-X
RNA	B-X
,	B-X
and	B-X
proteins	B-X
.	B-X

Deletion	O
of	O
all	O
three	O
elements	O
abolished	O
inducibility	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
activity	O
by	O
both	O
LAM	O
and	O
LPS	O
.	O
<EOS>	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
the	B-X
cytokine	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
clinical	B-X
manifestations	B-X
and	B-X
pathological	B-X
events	B-X
of	B-X
tuberculosis	B-X
infection	B-X
.	B-X
We	B-X
have	B-X
demonstrated	B-X
that	B-X
lipoarabinomannan	B-X
(	B-X
LAM	B-X
)	B-X
from	B-X
the	B-X
mycobacterial	B-X
cell	B-X
wall	B-X
,	B-X
which	B-X
was	B-X
virtually	B-X
devoid	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
stimulated	B-X
mononuclear	B-X
phagocytes	B-X
to	B-X
release	B-X
IL-6	B-X
in	B-X
a	B-X
dose-response	B-X
manner	B-X
.	B-X
LAM	B-X
and	B-X
LPS	B-X
were	B-X
potent	B-X
inducers	B-X
of	B-X
IL-6	B-X
gene	B-X
expression	B-X
in	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
.	B-X
Both	B-X
LAM-	B-X
and	B-X
LPS-inducible	B-X
IL-6	B-X
promoter	B-X
activity	B-X
was	B-X
localized	B-X
to	B-X
a	B-X
DNA	B-X
fragment	B-X
,	B-X
positions	B-X
-158	B-X
to	B-X
-49	B-X
,	B-X
by	B-X
deletion	B-X
analysis	B-X
and	B-X
chloramphenicol	B-X
acetyltransferase	B-X
assay	B-X
.	B-X
Two	B-X
nuclear	B-X
factor	B-X
NF-IL6	B-X
(	B-X
positions	B-X
-153	B-X
to	B-X
-145	B-X
and	B-X
-83	B-X
to	B-X
-75	B-X
)	B-X
and	B-X
one	B-X
nuclear	B-X
factor	B-X
NF-kappa	B-X
B	B-X
(	B-X
positions	B-X
-72	B-X
to	B-X
-63	B-X
)	B-X
motifs	B-X
are	B-X
present	B-X
within	B-X
this	B-X
fragment	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
of	B-X
one	B-X
or	B-X
more	B-X
of	B-X
these	B-X
motifs	B-X
within	B-X
the	B-X
IL-6	B-X
promoter	B-X
demonstrated	B-X
that	B-X
each	B-X
has	B-X
positive	B-X
regulatory	B-X
activity	B-X
and	B-X
that	B-X
they	B-X
could	B-X
act	B-X
in	B-X
a	B-X
function-	B-X
and	B-X
orientation-independent	B-X
manner	B-X
.	B-X
Deletion	B-X
of	B-X
all	B-X
three	B-X
elements	B-X
abolished	B-X
inducibility	B-X
of	B-X
IL-6	B-X
promoter	B-X
activity	B-X
by	B-X
both	B-X
LAM	B-X
and	B-X
LPS	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
the	B-X
NF-IL6	B-X
and	B-X
NF-kappa	B-X
B	B-X
sites	B-X
mediate	B-X
IL-6	B-X
induction	B-X
in	B-X
response	B-X
to	B-X
both	B-X
LPS	B-X
and	B-X
LAM	B-X
,	B-X
acting	B-X
as	B-X
bacterial	B-X
or	B-X
mycobacterial	B-X
response	B-X
elements	B-X
.	B-X

We	O
conclude	O
that	O
the	O
NF	B-Protein
-	I-Protein
IL6	I-Protein
and	O
NF	O
-	O
kappa	O
B	O
sites	O
mediate	O
IL	B-Protein
-	I-Protein
6	I-Protein
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	O
,	O
acting	O
as	O
bacterial	O
or	O
mycobacterial	O
response	O
elements	O
.	O
<EOS>	B-X
Detecting	B-X
and	B-X
treating	B-X
active	B-X
and	B-X
latent	B-X
tuberculosis	B-X
are	B-X
pivotal	B-X
elements	B-X
for	B-X
effective	B-X
infection	B-X
control	B-X
;	B-X
yet	B-X
,	B-X
due	B-X
to	B-X
their	B-X
significant	B-X
inherent	B-X
limitations	B-X
,	B-X
the	B-X
diagnostic	B-X
means	B-X
for	B-X
these	B-X
two	B-X
stages	B-X
of	B-X
tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
to	B-X
date	B-X
remain	B-X
suboptimal	B-X
.	B-X
This	B-X
paper	B-X
reviews	B-X
the	B-X
current	B-X
diagnostic	B-X
tools	B-X
for	B-X
mycobacterial	B-X
infection	B-X
and	B-X
focuses	B-X
on	B-X
the	B-X
application	B-X
of	B-X
flow	B-X
cytometry	B-X
as	B-X
a	B-X
promising	B-X
method	B-X
for	B-X
rapid	B-X
and	B-X
reliable	B-X
diagnosis	B-X
of	B-X
mycobacterial	B-X
infection	B-X
as	B-X
well	B-X
as	B-X
discrimination	B-X
between	B-X
active	B-X
and	B-X
latent	B-X
TB	B-X
:	B-X
it	B-X
summarizes	B-X
diagnostic	B-X
biomarkers	B-X
distinguishing	B-X
the	B-X
two	B-X
states	B-X
of	B-X
infection	B-X
and	B-X
also	B-X
features	B-X
of	B-X
the	B-X
distinct	B-X
immune	B-X
response	B-X
against	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
Mtb	B-X
)	B-X
at	B-X
certain	B-X
stages	B-X
of	B-X
infection	B-X
as	B-X
revealed	B-X
by	B-X
flow	B-X
cytometry	B-X
to	B-X
date	B-X
.	B-X
Tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
is	B-X
the	B-X
leading	B-X
cause	B-X
of	B-X
mortality	B-X
globally	B-X
resulting	B-X
from	B-X
an	B-X
infectious	B-X
disease	B-X
,	B-X
killing	B-X
almost	B-X
1.6	B-X
million	B-X
people	B-X
annually	B-X
and	B-X
accounting	B-X
for	B-X
approximately	B-X
30	B-X
%	B-X
of	B-X
deaths	B-X
attributed	B-X
to	B-X
antimicrobial	B-X
resistance	B-X
(	B-X
AMR	B-X
)	B-X
.	B-X
The	B-X
prevalence	B-X
of	B-X
nontuberculous	B-X
mycobacterial	B-X
(	B-X
NTM	B-X
)	B-X
lung	B-X
disease	B-X
is	B-X
increasing	B-X
in	B-X
the	B-X
USA	B-X
.	B-X

Calcineurin	O
activates	O
transcription	O
from	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
in	O
synergy	O
with	O
either	O
protein	O
kinase	O
C	O
or	O
NF	O
-	O
kappa	O
B	O
/	O
AP	O
-	O
1	O
in	O
T	O
cells	O
.	O
<EOS>	B-X
Two	B-X
cis-acting	B-X
elements	B-X
GM-kappa	B-X
B/GC-box	B-X
and	B-X
CLE0	B-X
,	B-X
of	B-X
the	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
gene	B-X
are	B-X
required	B-X
for	B-X
maximal	B-X
induction	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
by	B-X
costimulation	B-X
with	B-X
phorbol-12-myristate	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
Ca2+	B-X
ionophore	B-X
(	B-X
A23187	B-X
)	B-X
.	B-X
The	B-X
GM-kappa	B-X
B	B-X
sequence	B-X
is	B-X
recognized	B-X
by	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
is	B-X
mainly	B-X
induced	B-X
by	B-X
PMA	B-X
.	B-X
The	B-X
CLE0	B-X
sequence	B-X
interacts	B-X
with	B-X
factors	B-X
,	B-X
related	B-X
to	B-X
a	B-X
PMA-induced	B-X
AP-1	B-X
and	B-X
a	B-X
PMA/A23187-induced	B-X
NF-AT	B-X
.	B-X
We	B-X
examined	B-X
whether	B-X
signal	B-X
transducing	B-X
components	B-X
in	B-X
T	B-X
cells	B-X
can	B-X
activate	B-X
transcription	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
.	B-X
Cotransfection	B-X
of	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50/p65	B-X
)	B-X
-	B-X
or	B-X
AP-1	B-X
(	B-X
c-Jun/c-Fos	B-X
)	B-X
-expression	B-X
vectors	B-X
into	B-X
Jurkat	B-X
cells	B-X
with	B-X
a	B-X
luciferase	B-X
reporter	B-X
containing	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
did	B-X
not	B-X
stimulate	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
cotransfection	B-X
with	B-X
a	B-X
combination	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
significantly	B-X
augmented	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
containing	B-X
the	B-X
GM-kappa	B-X
B/GC-box	B-X
and	B-X
the	B-X
CLE0	B-X
(	B-X
AP-1/NF-AT	B-X
)	B-X
.	B-X
Expression	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
calcineurin	B-X
(	B-X
CN	B-X
)	B-X
,	B-X
a	B-X
Ca2+/calmodulin-dependent	B-X
protein	B-X
phosphatase	B-X
,	B-X
potentiated	B-X
by	B-X
two	B-X
fold	B-X
the	B-X
transcriptional	B-X
activation	B-X
by	B-X
NF-kappa	B-X
B/AP-1	B-X
.	B-X
Both	B-X
constitutively	B-X
active	B-X
forms	B-X
of	B-X
CN	B-X
and	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
synergistically	B-X
activated	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
cooperation	B-X
among	B-X
NF-kappa	B-X
B-	B-X
,	B-X
AP-1-	B-X
and	B-X
NF-AT-binding	B-X
sequences	B-X
is	B-X
required	B-X
for	B-X
induction	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
through	B-X
PKC-	B-X
and	B-X
Ca2+-signaling	B-X
pathways	B-X
downstream	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

Two	O
cis	O
-	O
acting	O
elements	O
GM	O
-	O
kappa	O
B	O
/	O
GC	O
-	O
box	O
and	O
CLE0	O
,	O
of	O
the	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
gene	O
are	O
required	O
for	O
maximal	O
induction	O
in	O
Jurkat	O
T	O
cells	O
by	O
costimulation	O
with	O
phorbol	O
-	O
12	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
(	O
A23187	O
)	O
.	O

The	O
GM	O
-	O
kappa	O
B	O
sequence	O
is	O
recognized	O
by	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
is	O
mainly	O
induced	O
by	O
PMA	O
.	O
<EOS>	B-X
Tax	B-X
also	B-X
activates	B-X
the	B-X
transcription	B-X
of	B-X
cellular	B-X
genes	B-X
such	B-X
as	B-X
interleukin	B-X
2	B-X
,	B-X
interleukin	B-X
2	B-X
receptor	B-X
(	B-X
IL2R	B-X
)	B-X
,	B-X
GM-CSF	B-X
,	B-X
vimentin	B-X
,	B-X
c-fos	B-X
,	B-X
c-jun	B-X
as	B-X
well	B-X
as	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
I	B-X
genes	B-X
.	B-X
One	B-X
class	B-X
of	B-X
target	B-X
sites	B-X
for	B-X
Tax	B-X
are	B-X
the	B-X
kappa	B-X
B	B-X
sequences	B-X
which	B-X
are	B-X
bound	B-X
by	B-X
members	B-X
of	B-X
the	B-X
rel/NF-kappa	B-X
B	B-X
family	B-X
.	B-X
It	B-X
has	B-X
been	B-X
previously	B-X
shown	B-X
that	B-X
Tax	B-X
is	B-X
able	B-X
to	B-X
induce	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
transcription	B-X
factor	B-X
is	B-X
normally	B-X
controlled	B-X
through	B-X
cytoplasmic	B-X
retention	B-X
by	B-X
either	B-X
of	B-X
two	B-X
types	B-X
of	B-X
molecules	B-X
:	B-X
the	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha/MAD3	B-X
or	B-X
the	B-X
p105	B-X
and	B-X
p100	B-X
precursors	B-X
of	B-X
the	B-X
p50	B-X
and	B-X
p52	B-X
DNA-binding	B-X
subunits	B-X
.	B-X
Treatment	B-X
of	B-X
cells	B-X
with	B-X
classical	B-X
NF-kappa	B-X
B	B-X
inducers	B-X
like	B-X
TNF	B-X
,	B-X
IL-1	B-X
,	B-X
PMA	B-X
or	B-X
LPS	B-X
results	B-X
in	B-X
MAD-3	B-X
degradation	B-X
followed	B-X
by	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
Tax	B-X
can	B-X
induce	B-X
translocation	B-X
of	B-X
members	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
family	B-X
retained	B-X
in	B-X
the	B-X
cytoplasm	B-X
through	B-X
interaction	B-X
with	B-X
either	B-X
p105	B-X
or	B-X
p100	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Tax	B-X
activates	B-X
NF-kappa	B-X
B	B-X
essentially	B-X
through	B-X
the	B-X
p105/p100-retention	B-X
pathway	B-X
.	B-X

The	O
CLE0	O
sequence	O
interacts	O
with	O
factors	O
,	O
related	O
to	O
a	O
PMA	O
-	O
induced	O
AP	O
-	O
1	O
and	O
a	O
PMA	O
/	O
A23187	O
-	O
induced	O
NF	O
-	O
AT	O
.	O

We	O
examined	O
whether	O
signal	O
transducing	O
components	O
in	O
T	O
cells	O
can	O
activate	O
transcription	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
gene	O
.	O

Cotransfection	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	B-Protein
/	O
p65	B-Protein
)	O
-	O
or	O
AP	O
-	O
1	O
(	O
c	B-Protein
-	I-Protein
Jun	I-Protein
/	O
c	B-Protein
-	I-Protein
Fos	I-Protein
)	O
-	O
expression	O
vectors	O
into	O
Jurkat	O
cells	O
with	O
a	O
luciferase	O
reporter	O
containing	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
did	O
not	O
stimulate	O
transcription	O
from	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
.	O

In	O
contrast	O
,	O
cotransfection	O
with	O
a	O
combination	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
significantly	O
augmented	O
transcription	O
from	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
containing	O
the	O
GM	O
-	O
kappa	O
B	O
/	O
GC	O
-	O
box	O
and	O
the	O
CLE0	O
(	O
AP	O
-	O
1	O
/	O
NF	O
-	O
AT	O
)	O
.	O
<EOS>	B-X
Two	B-X
cis-acting	B-X
elements	B-X
GM-kappa	B-X
B/GC-box	B-X
and	B-X
CLE0	B-X
,	B-X
of	B-X
the	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
gene	B-X
are	B-X
required	B-X
for	B-X
maximal	B-X
induction	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
by	B-X
costimulation	B-X
with	B-X
phorbol-12-myristate	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
Ca2+	B-X
ionophore	B-X
(	B-X
A23187	B-X
)	B-X
.	B-X
The	B-X
GM-kappa	B-X
B	B-X
sequence	B-X
is	B-X
recognized	B-X
by	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
is	B-X
mainly	B-X
induced	B-X
by	B-X
PMA	B-X
.	B-X
The	B-X
CLE0	B-X
sequence	B-X
interacts	B-X
with	B-X
factors	B-X
,	B-X
related	B-X
to	B-X
a	B-X
PMA-induced	B-X
AP-1	B-X
and	B-X
a	B-X
PMA/A23187-induced	B-X
NF-AT	B-X
.	B-X
We	B-X
examined	B-X
whether	B-X
signal	B-X
transducing	B-X
components	B-X
in	B-X
T	B-X
cells	B-X
can	B-X
activate	B-X
transcription	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
.	B-X
Cotransfection	B-X
of	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50/p65	B-X
)	B-X
-	B-X
or	B-X
AP-1	B-X
(	B-X
c-Jun/c-Fos	B-X
)	B-X
-expression	B-X
vectors	B-X
into	B-X
Jurkat	B-X
cells	B-X
with	B-X
a	B-X
luciferase	B-X
reporter	B-X
containing	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
did	B-X
not	B-X
stimulate	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
cotransfection	B-X
with	B-X
a	B-X
combination	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
significantly	B-X
augmented	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
containing	B-X
the	B-X
GM-kappa	B-X
B/GC-box	B-X
and	B-X
the	B-X
CLE0	B-X
(	B-X
AP-1/NF-AT	B-X
)	B-X
.	B-X
Expression	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
calcineurin	B-X
(	B-X
CN	B-X
)	B-X
,	B-X
a	B-X
Ca2+/calmodulin-dependent	B-X
protein	B-X
phosphatase	B-X
,	B-X
potentiated	B-X
by	B-X
two	B-X
fold	B-X
the	B-X
transcriptional	B-X
activation	B-X
by	B-X
NF-kappa	B-X
B/AP-1	B-X
.	B-X
Both	B-X
constitutively	B-X
active	B-X
forms	B-X
of	B-X
CN	B-X
and	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
synergistically	B-X
activated	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
cooperation	B-X
among	B-X
NF-kappa	B-X
B-	B-X
,	B-X
AP-1-	B-X
and	B-X
NF-AT-binding	B-X
sequences	B-X
is	B-X
required	B-X
for	B-X
induction	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
through	B-X
PKC-	B-X
and	B-X
Ca2+-signaling	B-X
pathways	B-X
downstream	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

Expression	O
of	O
a	O
constitutively	O
active	O
calcineurin	O
(	O
CN	O
)	O
,	O
a	O
Ca2	B-Protein
+	I-Protein
/	I-Protein
calmodulin	I-Protein
-	I-Protein
dependent	I-Protein
protein	I-Protein
phosphatase	I-Protein
,	O
potentiated	O
by	O
two	O
fold	O
the	O
transcriptional	O
activation	O
by	O
NF	O
-	O
kappa	O
B	O
/	O
AP	O
-	O
1	O
.	O

Both	O
constitutively	O
active	O
forms	O
of	O
CN	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
synergistically	O
activated	O
transcription	O
from	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
promoter	O
.	O
<EOS>	B-X
Two	B-X
cis-acting	B-X
elements	B-X
GM-kappa	B-X
B/GC-box	B-X
and	B-X
CLE0	B-X
,	B-X
of	B-X
the	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
gene	B-X
are	B-X
required	B-X
for	B-X
maximal	B-X
induction	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
by	B-X
costimulation	B-X
with	B-X
phorbol-12-myristate	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
Ca2+	B-X
ionophore	B-X
(	B-X
A23187	B-X
)	B-X
.	B-X
The	B-X
GM-kappa	B-X
B	B-X
sequence	B-X
is	B-X
recognized	B-X
by	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
is	B-X
mainly	B-X
induced	B-X
by	B-X
PMA	B-X
.	B-X
The	B-X
CLE0	B-X
sequence	B-X
interacts	B-X
with	B-X
factors	B-X
,	B-X
related	B-X
to	B-X
a	B-X
PMA-induced	B-X
AP-1	B-X
and	B-X
a	B-X
PMA/A23187-induced	B-X
NF-AT	B-X
.	B-X
We	B-X
examined	B-X
whether	B-X
signal	B-X
transducing	B-X
components	B-X
in	B-X
T	B-X
cells	B-X
can	B-X
activate	B-X
transcription	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
.	B-X
Cotransfection	B-X
of	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50/p65	B-X
)	B-X
-	B-X
or	B-X
AP-1	B-X
(	B-X
c-Jun/c-Fos	B-X
)	B-X
-expression	B-X
vectors	B-X
into	B-X
Jurkat	B-X
cells	B-X
with	B-X
a	B-X
luciferase	B-X
reporter	B-X
containing	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
did	B-X
not	B-X
stimulate	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
cotransfection	B-X
with	B-X
a	B-X
combination	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
significantly	B-X
augmented	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
containing	B-X
the	B-X
GM-kappa	B-X
B/GC-box	B-X
and	B-X
the	B-X
CLE0	B-X
(	B-X
AP-1/NF-AT	B-X
)	B-X
.	B-X
Expression	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
calcineurin	B-X
(	B-X
CN	B-X
)	B-X
,	B-X
a	B-X
Ca2+/calmodulin-dependent	B-X
protein	B-X
phosphatase	B-X
,	B-X
potentiated	B-X
by	B-X
two	B-X
fold	B-X
the	B-X
transcriptional	B-X
activation	B-X
by	B-X
NF-kappa	B-X
B/AP-1	B-X
.	B-X
Both	B-X
constitutively	B-X
active	B-X
forms	B-X
of	B-X
CN	B-X
and	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
synergistically	B-X
activated	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
cooperation	B-X
among	B-X
NF-kappa	B-X
B-	B-X
,	B-X
AP-1-	B-X
and	B-X
NF-AT-binding	B-X
sequences	B-X
is	B-X
required	B-X
for	B-X
induction	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
through	B-X
PKC-	B-X
and	B-X
Ca2+-signaling	B-X
pathways	B-X
downstream	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

These	O
results	O
suggest	O
that	O
cooperation	O
among	O
NF	O
-	O
kappa	O
B	O
-	O
,	O
AP	O
-	O
1	O
-	O
and	O
NF	O
-	O
AT	O
-	O
binding	O
sequences	O
is	O
required	O
for	O
induction	O
of	O
the	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
gene	O
through	O
PKC	O
-	O
and	O
Ca2	O
+	O
-	O
signaling	O
pathways	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O
<EOS>	B-X
Two	B-X
cis-acting	B-X
elements	B-X
GM-kappa	B-X
B/GC-box	B-X
and	B-X
CLE0	B-X
,	B-X
of	B-X
the	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
gene	B-X
are	B-X
required	B-X
for	B-X
maximal	B-X
induction	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
by	B-X
costimulation	B-X
with	B-X
phorbol-12-myristate	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
Ca2+	B-X
ionophore	B-X
(	B-X
A23187	B-X
)	B-X
.	B-X
The	B-X
GM-kappa	B-X
B	B-X
sequence	B-X
is	B-X
recognized	B-X
by	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
is	B-X
mainly	B-X
induced	B-X
by	B-X
PMA	B-X
.	B-X
The	B-X
CLE0	B-X
sequence	B-X
interacts	B-X
with	B-X
factors	B-X
,	B-X
related	B-X
to	B-X
a	B-X
PMA-induced	B-X
AP-1	B-X
and	B-X
a	B-X
PMA/A23187-induced	B-X
NF-AT	B-X
.	B-X
We	B-X
examined	B-X
whether	B-X
signal	B-X
transducing	B-X
components	B-X
in	B-X
T	B-X
cells	B-X
can	B-X
activate	B-X
transcription	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
.	B-X
Cotransfection	B-X
of	B-X
NF-kappa	B-X
B	B-X
(	B-X
p50/p65	B-X
)	B-X
-	B-X
or	B-X
AP-1	B-X
(	B-X
c-Jun/c-Fos	B-X
)	B-X
-expression	B-X
vectors	B-X
into	B-X
Jurkat	B-X
cells	B-X
with	B-X
a	B-X
luciferase	B-X
reporter	B-X
containing	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
did	B-X
not	B-X
stimulate	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
cotransfection	B-X
with	B-X
a	B-X
combination	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
significantly	B-X
augmented	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
containing	B-X
the	B-X
GM-kappa	B-X
B/GC-box	B-X
and	B-X
the	B-X
CLE0	B-X
(	B-X
AP-1/NF-AT	B-X
)	B-X
.	B-X
Expression	B-X
of	B-X
a	B-X
constitutively	B-X
active	B-X
calcineurin	B-X
(	B-X
CN	B-X
)	B-X
,	B-X
a	B-X
Ca2+/calmodulin-dependent	B-X
protein	B-X
phosphatase	B-X
,	B-X
potentiated	B-X
by	B-X
two	B-X
fold	B-X
the	B-X
transcriptional	B-X
activation	B-X
by	B-X
NF-kappa	B-X
B/AP-1	B-X
.	B-X
Both	B-X
constitutively	B-X
active	B-X
forms	B-X
of	B-X
CN	B-X
and	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
synergistically	B-X
activated	B-X
transcription	B-X
from	B-X
the	B-X
GM-CSF	B-X
promoter	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
cooperation	B-X
among	B-X
NF-kappa	B-X
B-	B-X
,	B-X
AP-1-	B-X
and	B-X
NF-AT-binding	B-X
sequences	B-X
is	B-X
required	B-X
for	B-X
induction	B-X
of	B-X
the	B-X
GM-CSF	B-X
gene	B-X
through	B-X
PKC-	B-X
and	B-X
Ca2+-signaling	B-X
pathways	B-X
downstream	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X

Cell	O
-	O
specific	O
bifunctional	O
role	O
of	O
Jun	O
oncogene	O
family	O
members	O
on	O
glucocorticoid	O
receptor	O
-	O
dependent	O
transcription	O
.	O
<EOS>	B-X
Interaction	B-X
between	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
-	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
-mediated	B-X
signaling	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
PKC	B-X
activating	B-X
phorbol	B-X
ester	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
to	B-X
inhibit	B-X
GR-dependent	B-X
transcription	B-X
of	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
this	B-X
interference	B-X
is	B-X
cell	B-X
specific	B-X
,	B-X
as	B-X
TPA	B-X
augmented	B-X
dexamethasone-induced	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
MMTV	B-X
LTR	B-X
in	B-X
several	B-X
T	B-X
cell	B-X
lines	B-X
but	B-X
was	B-X
inhibitory	B-X
in	B-X
NIH-3T3	B-X
fibroblasts	B-X
.	B-X
The	B-X
effect	B-X
was	B-X
abrogated	B-X
by	B-X
the	B-X
PKC	B-X
inhibitor	B-X
staurosporine	B-X
,	B-X
suggesting	B-X
a	B-X
role	B-X
for	B-X
PKC	B-X
.	B-X
Increased	B-X
c-jun	B-X
,	B-X
jun-B	B-X
,	B-X
and	B-X
jun-D	B-X
expression	B-X
above	B-X
basal	B-X
levels	B-X
and	B-X
increased	B-X
transcriptional	B-X
activity	B-X
of	B-X
AP-1/TPA	B-X
responsive	B-X
elements	B-X
fused	B-X
to	B-X
chloramphenicol	B-X
acetyl-transferase	B-X
vectors	B-X
were	B-X
observed	B-X
in	B-X
T	B-X
cells	B-X
treated	B-X
with	B-X
TPA	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
dexamethasone	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
Jun	B-X
proteins	B-X
to	B-X
cooperate	B-X
with	B-X
GR	B-X
in	B-X
T	B-X
cells	B-X
has	B-X
been	B-X
investigated	B-X
after	B-X
transfection	B-X
of	B-X
c-jun	B-X
,	B-X
jun-B	B-X
,	B-X
or	B-X
jun-D	B-X
expression	B-X
vectors	B-X
,	B-X
which	B-X
augmented	B-X
GR-dependent	B-X
transcription	B-X
from	B-X
either	B-X
MMTV	B-X
LTR	B-X
or	B-X
GRE	B-X
.	B-X
Conversely	B-X
,	B-X
c-jun	B-X
and	B-X
jun-B	B-X
transfection	B-X
blunted	B-X
GR-dependent	B-X
transcription	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
c-fos	B-X
had	B-X
a	B-X
negative	B-X
influence	B-X
on	B-X
GR	B-X
function	B-X
and	B-X
correlated	B-X
with	B-X
the	B-X
cell-specific	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
activity	B-X
of	B-X
Jun	B-X
with	B-X
respect	B-X
to	B-X
GR	B-X
;	B-X
high	B-X
basal	B-X
expression	B-X
of	B-X
c-fos	B-X
as	B-X
well	B-X
as	B-X
AP-1	B-X
DNA	B-X
binding	B-X
and	B-X
transcriptional	B-X
activity	B-X
were	B-X
observed	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
overexpression	B-X
of	B-X
exogenous	B-X
c-fos	B-X
has	B-X
an	B-X
inhibitory	B-X
effect	B-X
on	B-X
GR-dependent	B-X
transcription	B-X
from	B-X
GRE	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Jun	B-X
plays	B-X
a	B-X
bifunctional	B-X
role	B-X
on	B-X
GR-dependent	B-X
transcriptional	B-X
activation	B-X
of	B-X
GRE	B-X
,	B-X
selecting	B-X
either	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
activity	B-X
depending	B-X
on	B-X
the	B-X
cell-specific	B-X
microenvironment	B-X
.	B-X

Interaction	O
between	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
-	O
and	O
glucocorticoid	B-Protein
receptor	I-Protein
(	O
GR	B-Protein
)	O
-	O
mediated	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
the	O
PKC	O
activating	O
phorbol	O
ester	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
to	O
inhibit	O
GR	B-Protein
-	O
dependent	O
transcription	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O
<EOS>	B-X
Interaction	B-X
between	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
-	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
-mediated	B-X
signaling	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
PKC	B-X
activating	B-X
phorbol	B-X
ester	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
to	B-X
inhibit	B-X
GR-dependent	B-X
transcription	B-X
of	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
this	B-X
interference	B-X
is	B-X
cell	B-X
specific	B-X
,	B-X
as	B-X
TPA	B-X
augmented	B-X
dexamethasone-induced	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
MMTV	B-X
LTR	B-X
in	B-X
several	B-X
T	B-X
cell	B-X
lines	B-X
but	B-X
was	B-X
inhibitory	B-X
in	B-X
NIH-3T3	B-X
fibroblasts	B-X
.	B-X
TPA-GR	B-X
synergism	B-X
was	B-X
determined	B-X
to	B-X
have	B-X
occurred	B-X
at	B-X
the	B-X
GR-responsive	B-X
element	B-X
(	B-X
GRE	B-X
)	B-X
level	B-X
by	B-X
functional	B-X
analysis	B-X
of	B-X
deletion	B-X
mutants	B-X
or	B-X
synthetic	B-X
GRE	B-X
oligonucleotides	B-X
driving	B-X
chloramphenicol	B-X
acetyl-transferase	B-X
expression	B-X
.	B-X
Synergism	B-X
required	B-X
an	B-X
intact	B-X
GR	B-X
DNA-binding	B-X
domain	B-X
,	B-X
whereas	B-X
amino-	B-X
or	B-X
carboxyl-terminal	B-X
domains	B-X
were	B-X
dispensable	B-X
.	B-X
The	B-X
effect	B-X
was	B-X
abrogated	B-X
by	B-X
the	B-X
PKC	B-X
inhibitor	B-X
staurosporine	B-X
,	B-X
suggesting	B-X
a	B-X
role	B-X
for	B-X
PKC	B-X
.	B-X
Increased	B-X
c-jun	B-X
,	B-X
jun-B	B-X
,	B-X
and	B-X
jun-D	B-X
expression	B-X
above	B-X
basal	B-X
levels	B-X
and	B-X
increased	B-X
transcriptional	B-X
activity	B-X
of	B-X
AP-1/TPA	B-X
responsive	B-X
elements	B-X
fused	B-X
to	B-X
chloramphenicol	B-X
acetyl-transferase	B-X
vectors	B-X
were	B-X
observed	B-X
in	B-X
T	B-X
cells	B-X
treated	B-X
with	B-X
TPA	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
dexamethasone	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
Jun	B-X
proteins	B-X
to	B-X
cooperate	B-X
with	B-X
GR	B-X
in	B-X
T	B-X
cells	B-X
has	B-X
been	B-X
investigated	B-X
after	B-X
transfection	B-X
of	B-X
c-jun	B-X
,	B-X
jun-B	B-X
,	B-X
or	B-X
jun-D	B-X
expression	B-X
vectors	B-X
,	B-X
which	B-X
augmented	B-X
GR-dependent	B-X
transcription	B-X
from	B-X
either	B-X
MMTV	B-X
LTR	B-X
or	B-X
GRE	B-X
.	B-X
Conversely	B-X
,	B-X
c-jun	B-X
and	B-X
jun-B	B-X
transfection	B-X
blunted	B-X
GR-dependent	B-X
transcription	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
c-fos	B-X
had	B-X
a	B-X
negative	B-X
influence	B-X
on	B-X
GR	B-X
function	B-X
and	B-X
correlated	B-X
with	B-X
the	B-X
cell-specific	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
activity	B-X
of	B-X
Jun	B-X
with	B-X
respect	B-X
to	B-X
GR	B-X
;	B-X
high	B-X
basal	B-X
expression	B-X
of	B-X
c-fos	B-X
as	B-X
well	B-X
as	B-X
AP-1	B-X
DNA	B-X
binding	B-X
and	B-X
transcriptional	B-X
activity	B-X
were	B-X
observed	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
overexpression	B-X
of	B-X
exogenous	B-X
c-fos	B-X
has	B-X
an	B-X
inhibitory	B-X
effect	B-X
on	B-X
GR-dependent	B-X
transcription	B-X
from	B-X
GRE	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Jun	B-X
plays	B-X
a	B-X
bifunctional	B-X
role	B-X
on	B-X
GR-dependent	B-X
transcriptional	B-X
activation	B-X
of	B-X
GRE	B-X
,	B-X
selecting	B-X
either	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
activity	B-X
depending	B-X
on	B-X
the	B-X
cell-specific	B-X
microenvironment	B-X
.	B-X

Here	O
we	O
report	O
that	O
this	O
interference	O
is	O
cell	O
specific	O
,	O
as	O
TPA	O
augmented	O
dexamethasone	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
MMTV	O
LTR	O
in	O
several	O
T	O
cell	O
lines	O
but	O
was	O
inhibitory	O
in	O
NIH	O
-	O
3T3	O
fibroblasts	O
.	O
<EOS>	B-X
Interaction	B-X
between	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
-	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
-mediated	B-X
signaling	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
PKC	B-X
activating	B-X
phorbol	B-X
ester	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
to	B-X
inhibit	B-X
GR-dependent	B-X
transcription	B-X
of	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
this	B-X
interference	B-X
is	B-X
cell	B-X
specific	B-X
,	B-X
as	B-X
TPA	B-X
augmented	B-X
dexamethasone-induced	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
MMTV	B-X
LTR	B-X
in	B-X
several	B-X
T	B-X
cell	B-X
lines	B-X
but	B-X
was	B-X
inhibitory	B-X
in	B-X
NIH-3T3	B-X
fibroblasts	B-X
.	B-X
TPA-GR	B-X
synergism	B-X
was	B-X
determined	B-X
to	B-X
have	B-X
occurred	B-X
at	B-X
the	B-X
GR-responsive	B-X
element	B-X
(	B-X
GRE	B-X
)	B-X
level	B-X
by	B-X
functional	B-X
analysis	B-X
of	B-X
deletion	B-X
mutants	B-X
or	B-X
synthetic	B-X
GRE	B-X
oligonucleotides	B-X
driving	B-X
chloramphenicol	B-X
acetyl-transferase	B-X
expression	B-X
.	B-X
Increased	B-X
c-jun	B-X
,	B-X
jun-B	B-X
,	B-X
and	B-X
jun-D	B-X
expression	B-X
above	B-X
basal	B-X
levels	B-X
and	B-X
increased	B-X
transcriptional	B-X
activity	B-X
of	B-X
AP-1/TPA	B-X
responsive	B-X
elements	B-X
fused	B-X
to	B-X
chloramphenicol	B-X
acetyl-transferase	B-X
vectors	B-X
were	B-X
observed	B-X
in	B-X
T	B-X
cells	B-X
treated	B-X
with	B-X
TPA	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
dexamethasone	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
Jun	B-X
proteins	B-X
to	B-X
cooperate	B-X
with	B-X
GR	B-X
in	B-X
T	B-X
cells	B-X
has	B-X
been	B-X
investigated	B-X
after	B-X
transfection	B-X
of	B-X
c-jun	B-X
,	B-X
jun-B	B-X
,	B-X
or	B-X
jun-D	B-X
expression	B-X
vectors	B-X
,	B-X
which	B-X
augmented	B-X
GR-dependent	B-X
transcription	B-X
from	B-X
either	B-X
MMTV	B-X
LTR	B-X
or	B-X
GRE	B-X
.	B-X
Conversely	B-X
,	B-X
c-jun	B-X
and	B-X
jun-B	B-X
transfection	B-X
blunted	B-X
GR-dependent	B-X
transcription	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
c-fos	B-X
had	B-X
a	B-X
negative	B-X
influence	B-X
on	B-X
GR	B-X
function	B-X
and	B-X
correlated	B-X
with	B-X
the	B-X
cell-specific	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
activity	B-X
of	B-X
Jun	B-X
with	B-X
respect	B-X
to	B-X
GR	B-X
;	B-X
high	B-X
basal	B-X
expression	B-X
of	B-X
c-fos	B-X
as	B-X
well	B-X
as	B-X
AP-1	B-X
DNA	B-X
binding	B-X
and	B-X
transcriptional	B-X
activity	B-X
were	B-X
observed	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
overexpression	B-X
of	B-X
exogenous	B-X
c-fos	B-X
has	B-X
an	B-X
inhibitory	B-X
effect	B-X
on	B-X
GR-dependent	B-X
transcription	B-X
from	B-X
GRE	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Jun	B-X
plays	B-X
a	B-X
bifunctional	B-X
role	B-X
on	B-X
GR-dependent	B-X
transcriptional	B-X
activation	B-X
of	B-X
GRE	B-X
,	B-X
selecting	B-X
either	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
activity	B-X
depending	B-X
on	B-X
the	B-X
cell-specific	B-X
microenvironment	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
intracellular	B-X
levels	B-X
of	B-X
c-fos	B-X
appear	B-X
to	B-X
be	B-X
influential	B-X
.	B-X

TPA	O
-	O
GR	B-Protein
synergism	O
was	O
determined	O
to	O
have	O
occurred	O
at	O
the	O
GR	B-Protein
-	O
responsive	O
element	O
(	O
GRE	O
)	O
level	O
by	O
functional	O
analysis	O
of	O
deletion	O
mutants	O
or	O
synthetic	O
GRE	O
oligonucleotides	O
driving	O
chloramphenicol	B-Protein
acetyl	I-Protein
-	I-Protein
transferase	I-Protein
expression	O
.	O
<EOS>	B-X
Interaction	B-X
between	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
-	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
-mediated	B-X
signaling	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
PKC	B-X
activating	B-X
phorbol	B-X
ester	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
to	B-X
inhibit	B-X
GR-dependent	B-X
transcription	B-X
of	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
this	B-X
interference	B-X
is	B-X
cell	B-X
specific	B-X
,	B-X
as	B-X
TPA	B-X
augmented	B-X
dexamethasone-induced	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
MMTV	B-X
LTR	B-X
in	B-X
several	B-X
T	B-X
cell	B-X
lines	B-X
but	B-X
was	B-X
inhibitory	B-X
in	B-X
NIH-3T3	B-X
fibroblasts	B-X
.	B-X
TPA-GR	B-X
synergism	B-X
was	B-X
determined	B-X
to	B-X
have	B-X
occurred	B-X
at	B-X
the	B-X
GR-responsive	B-X
element	B-X
(	B-X
GRE	B-X
)	B-X
level	B-X
by	B-X
functional	B-X
analysis	B-X
of	B-X
deletion	B-X
mutants	B-X
or	B-X
synthetic	B-X
GRE	B-X
oligonucleotides	B-X
driving	B-X
chloramphenicol	B-X
acetyl-transferase	B-X
expression	B-X
.	B-X
Synergism	B-X
required	B-X
an	B-X
intact	B-X
GR	B-X
DNA-binding	B-X
domain	B-X
,	B-X
whereas	B-X
amino-	B-X
or	B-X
carboxyl-terminal	B-X
domains	B-X
were	B-X
dispensable	B-X
.	B-X
Increased	B-X
c-jun	B-X
,	B-X
jun-B	B-X
,	B-X
and	B-X
jun-D	B-X
expression	B-X
above	B-X
basal	B-X
levels	B-X
and	B-X
increased	B-X
transcriptional	B-X
activity	B-X
of	B-X
AP-1/TPA	B-X
responsive	B-X
elements	B-X
fused	B-X
to	B-X
chloramphenicol	B-X
acetyl-transferase	B-X
vectors	B-X
were	B-X
observed	B-X
in	B-X
T	B-X
cells	B-X
treated	B-X
with	B-X
TPA	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
dexamethasone	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
Jun	B-X
proteins	B-X
to	B-X
cooperate	B-X
with	B-X
GR	B-X
in	B-X
T	B-X
cells	B-X
has	B-X
been	B-X
investigated	B-X
after	B-X
transfection	B-X
of	B-X
c-jun	B-X
,	B-X
jun-B	B-X
,	B-X
or	B-X
jun-D	B-X
expression	B-X
vectors	B-X
,	B-X
which	B-X
augmented	B-X
GR-dependent	B-X
transcription	B-X
from	B-X
either	B-X
MMTV	B-X
LTR	B-X
or	B-X
GRE	B-X
.	B-X
Conversely	B-X
,	B-X
c-jun	B-X
and	B-X
jun-B	B-X
transfection	B-X
blunted	B-X
GR-dependent	B-X
transcription	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
c-fos	B-X
had	B-X
a	B-X
negative	B-X
influence	B-X
on	B-X
GR	B-X
function	B-X
and	B-X
correlated	B-X
with	B-X
the	B-X
cell-specific	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
activity	B-X
of	B-X
Jun	B-X
with	B-X
respect	B-X
to	B-X
GR	B-X
;	B-X
high	B-X
basal	B-X
expression	B-X
of	B-X
c-fos	B-X
as	B-X
well	B-X
as	B-X
AP-1	B-X
DNA	B-X
binding	B-X
and	B-X
transcriptional	B-X
activity	B-X
were	B-X
observed	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
overexpression	B-X
of	B-X
exogenous	B-X
c-fos	B-X
has	B-X
an	B-X
inhibitory	B-X
effect	B-X
on	B-X
GR-dependent	B-X
transcription	B-X
from	B-X
GRE	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Jun	B-X
plays	B-X
a	B-X
bifunctional	B-X
role	B-X
on	B-X
GR-dependent	B-X
transcriptional	B-X
activation	B-X
of	B-X
GRE	B-X
,	B-X
selecting	B-X
either	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
activity	B-X
depending	B-X
on	B-X
the	B-X
cell-specific	B-X
microenvironment	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
intracellular	B-X
levels	B-X
of	B-X
c-fos	B-X
appear	B-X
to	B-X
be	B-X
influential	B-X
.	B-X

Synergism	O
required	O
an	O
intact	O
GR	B-Protein
DNA	O
-	O
binding	O
domain	O
,	O
whereas	O
amino	O
-	O
or	O
carboxyl	O
-	O
terminal	O
domains	O
were	O
dispensable	O
.	O
<EOS>	B-X
Despite	B-X
these	B-X
differences	B-X
,	B-X
all	B-X
polyomaviruses	B-X
share	B-X
a	B-X
common	B-X
strategy	B-X
of	B-X
productive	B-X
infection	B-X
,	B-X
expressing	B-X
T	B-X
antigens	B-X
which	B-X
act	B-X
both	B-X
on	B-X
cellular	B-X
targets	B-X
,	B-X
preparing	B-X
cellular	B-X
metabolism	B-X
for	B-X
supporting	B-X
optimal	B-X
viral	B-X
replication	B-X
,	B-X
and	B-X
then	B-X
on	B-X
targets	B-X
within	B-X
the	B-X
viral	B-X
genome	B-X
,	B-X
to	B-X
regulate	B-X
viral	B-X
DNA	B-X
replication	B-X
,	B-X
transcription	B-X
,	B-X
and	B-X
assembly	B-X
.	B-X
(	B-X
i	B-X
)	B-X
Comparison	B-X
of	B-X
the	B-X
domain	B-X
organization	B-X
of	B-X
different	B-X
large	B-X
T	B-X
antigens	B-X
reveals	B-X
that	B-X
these	B-X
proteins	B-X
fall	B-X
into	B-X
two	B-X
structural	B-X
classes	B-X
.	B-X
Members	B-X
of	B-X
the	B-X
SV40	B-X
class	B-X
,	B-X
which	B-X
include	B-X
SV40	B-X
,	B-X
JCV	B-X
,	B-X
BKV	B-X
,	B-X
and	B-X
SA12	B-X
,	B-X
possess	B-X
a	B-X
carboxyl-terminal	B-X
domain	B-X
,	B-X
which	B-X
in	B-X
SV40	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
dispensable	B-X
for	B-X
viral	B-X
DNA	B-X
replication	B-X
but	B-X
essential	B-X
for	B-X
virion	B-X
assembly	B-X
.	B-X
The	B-X
PyV	B-X
class	B-X
lacks	B-X
the	B-X
carboxyl-terminal	B-X
domain	B-X
and	B-X
carries	B-X
additional	B-X
amino	B-X
acids	B-X
within	B-X
the	B-X
amino-terminal	B-X
domain	B-X
.	B-X
When	B-X
total	B-X
amino	B-X
acid	B-X
identity	B-X
is	B-X
examined	B-X
,	B-X
members	B-X
of	B-X
the	B-X
SV40	B-X
class	B-X
show	B-X
the	B-X
highest	B-X
degree	B-X
of	B-X
conservation	B-X
(	B-X
65	B-X
to	B-X
85	B-X
%	B-X
)	B-X
,	B-X
while	B-X
sequence	B-X
identity	B-X
among	B-X
the	B-X
remaining	B-X
viruses	B-X
varies	B-X
from	B-X
18	B-X
to	B-X
55	B-X
%	B-X
.	B-X
(	B-X
ii	B-X
)	B-X
The	B-X
DNA	B-X
binding	B-X
domains	B-X
of	B-X
most	B-X
large	B-X
T	B-X
antigens	B-X
are	B-X
closely	B-X
related	B-X
,	B-X
with	B-X
amino	B-X
acid	B-X
identities	B-X
ranging	B-X
from	B-X
35	B-X
to	B-X
86	B-X
%	B-X
.	B-X
Several	B-X
residues	B-X
within	B-X
this	B-X
domain	B-X
are	B-X
invariant	B-X
among	B-X
all	B-X
T	B-X
antigens	B-X
.	B-X
All	B-X
of	B-X
these	B-X
viruses	B-X
have	B-X
multiple	B-X
copies	B-X
of	B-X
the	B-X
consensus	B-X
T-antigen-binding	B-X
pentanucleotide	B-X
(	B-X
GAGGC	B-X
)	B-X
in	B-X
their	B-X
ori	B-X
region	B-X
,	B-X
suggesting	B-X
that	B-X
all	B-X
T	B-X
antigens	B-X
recognize	B-X
this	B-X
sequence	B-X
.	B-X
The	B-X
putative	B-X
DNA	B-X
binding	B-X
domain	B-X
of	B-X
this	B-X
protein	B-X
shows	B-X
little	B-X
or	B-X
no	B-X
sequence	B-X
relation	B-X
to	B-X
that	B-X
of	B-X
other	B-X
T	B-X
antigens	B-X
.	B-X

The	O
effect	O
was	O
abrogated	O
by	O
the	O
PKC	O
inhibitor	O
staurosporine	O
,	O
suggesting	O
a	O
role	O
for	O
PKC	O
.	O
<EOS>	B-X
Nicotine	B-X
induces	B-X
activation	B-X
of	B-X
PKC	B-X
alpha	B-X
and	B-X
the	B-X
MAPKs	B-X
ERK1	B-X
and	B-X
ERK2	B-X
,	B-X
which	B-X
are	B-X
physiological	B-X
Bcl2	B-X
kinases	B-X
.	B-X
Furthermore	B-X
,	B-X
ET-18-OCH3	B-X
,	B-X
a	B-X
specific	B-X
phospholipase	B-X
C	B-X
(	B-X
PLC	B-X
)	B-X
inhibitor	B-X
,	B-X
blocks	B-X
nicotine-stimulated	B-X
Bcl2	B-X
phosphorylation	B-X
and	B-X
promotes	B-X
apoptosis	B-X
,	B-X
suggesting	B-X
that	B-X
PLC	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
nicotine	B-X
activation	B-X
of	B-X
Bcl2	B-X
kinases	B-X
.	B-X
PKC412	B-X
is	B-X
a	B-X
kinase	B-X
inhibitor	B-X
that	B-X
blocks	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptors	B-X
,	B-X
platelet-derived	B-X
growth	B-X
factor	B-X
receptor	B-X
FLT3	B-X
,	B-X
and	B-X
other	B-X
class	B-X
III	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
.	B-X
The	B-X
enthusiasm	B-X
for	B-X
this	B-X
compound	B-X
is	B-X
based	B-X
on	B-X
its	B-X
inhibitory	B-X
effect	B-X
even	B-X
in	B-X
the	B-X
case	B-X
of	B-X
FLT3	B-X
mutations	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
analyze	B-X
the	B-X
role	B-X
of	B-X
FLT3	B-X
in	B-X
pancreatic	B-X
cancer	B-X
and	B-X
to	B-X
study	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
combined	B-X
inhibition	B-X
of	B-X
neovascularization	B-X
and	B-X
mitogenesis	B-X
in	B-X
this	B-X
disease	B-X
.	B-X

Increased	O
c	B-Protein
-	I-Protein
jun	I-Protein
,	O
jun	B-Protein
-	I-Protein
B	I-Protein
,	O
and	O
jun	B-Protein
-	I-Protein
D	I-Protein
expression	O
above	O
basal	O
levels	O
and	O
increased	O
transcriptional	O
activity	O
of	O
AP	O
-	O
1	O
/	O
TPA	O
responsive	O
elements	O
fused	O
to	O
chloramphenicol	B-Protein
acetyl	I-Protein
-	I-Protein
transferase	I-Protein
vectors	O
were	O
observed	O
in	O
T	O
cells	O
treated	O
with	O
TPA	O
alone	O
or	O
in	O
combination	O
with	O
dexamethasone	O
.	O
<EOS>	B-X
Isatuximab	B-X
(	B-X
Sarclisa	B-X
Triplet	B-X
regimens	B-X
,	B-X
such	B-X
as	B-X
lenalidomide	B-X
,	B-X
bortezomib	B-X
,	B-X
and	B-X
dexamethasone	B-X
(	B-X
RVd	B-X
)	B-X
or	B-X
thalidomide	B-X
,	B-X
bortezomib	B-X
,	B-X
and	B-X
dexamethasone	B-X
(	B-X
VTd	B-X
)	B-X
,	B-X
are	B-X
standard	B-X
induction	B-X
therapies	B-X
for	B-X
transplant-eligible	B-X
patients	B-X
with	B-X
newly	B-X
diagnosed	B-X
multiple	B-X
myeloma	B-X
(	B-X
NDMM	B-X
)	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
daratumumab	B-X
to	B-X
RVd	B-X
and	B-X
VTd	B-X
has	B-X
been	B-X
investigated	B-X
in	B-X
the	B-X
GRIFFIN	B-X
and	B-X
CASSIOPEIA	B-X
trials	B-X
,	B-X
respectively	B-X
,	B-X
resulting	B-X
in	B-X
improvement	B-X
in	B-X
the	B-X
rate	B-X
of	B-X
minimal	B-X
residual	B-X
disease	B-X
(	B-X
MRD	B-X
)	B-X
negativity	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
conducted	B-X
a	B-X
cost-effectiveness	B-X
analysis	B-X
with	B-X
a	B-X
10-year	B-X
time	B-X
horizon	B-X
to	B-X
compare	B-X
first-line	B-X
and	B-X
second-line	B-X
use	B-X
of	B-X
daratumumab	B-X
for	B-X
transplant-eligible	B-X
patients	B-X
with	B-X
NDMM	B-X
.	B-X
Because	B-X
long-term	B-X
follow-up	B-X
data	B-X
for	B-X
these	B-X
clinical	B-X
trials	B-X
are	B-X
not	B-X
yet	B-X
available	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
Markov	B-X
model	B-X
that	B-X
uses	B-X
MRD	B-X
status	B-X
to	B-X
predict	B-X
progression-free	B-X
survival	B-X
.	B-X
Daratumumab	B-X
was	B-X
used	B-X
either	B-X
in	B-X
the	B-X
first-line	B-X
setting	B-X
in	B-X
combination	B-X
with	B-X
RVd	B-X
or	B-X
VTd	B-X
or	B-X
in	B-X
the	B-X
second-line	B-X
setting	B-X
with	B-X
carfilzomib	B-X
plus	B-X
dexamethasone	B-X
(	B-X
Kd	B-X
)	B-X
.	B-X
Quality-adjusted	B-X
life-years	B-X
(	B-X
QALYs	B-X
)	B-X
and	B-X
incremental	B-X
cost-effectiveness	B-X
ratios	B-X
were	B-X
calculated	B-X
from	B-X
a	B-X
Japanese	B-X
and	B-X
US	B-X
payer	B-X
perspective	B-X
.	B-X
In	B-X
the	B-X
Japanese	B-X
analysis	B-X
,	B-X
D-RVd	B-X
showed	B-X
higher	B-X
QALYs	B-X
(	B-X
5.43	B-X
vs	B-X
5.18	B-X
)	B-X
and	B-X
lower	B-X
costs	B-X
(	B-X
¥64	B-X
479,793	B-X
vs	B-X
¥71	B-X
287	B-X
569	B-X
)	B-X
compared	B-X
with	B-X
RVd	B-X
,	B-X
and	B-X
D-VTd	B-X
showed	B-X
higher	B-X
QALYs	B-X
(	B-X
5.67	B-X
vs	B-X
5.42	B-X
)	B-X
and	B-X
lower	B-X
costs	B-X
(	B-X
¥43	B-X
600	B-X
310	B-X
vs	B-X
¥49	B-X
471,941	B-X
)	B-X
compared	B-X
with	B-X
VTd	B-X
.	B-X
Similarly	B-X
,	B-X
the	B-X
US	B-X
analysis	B-X
demonstrated	B-X
dominance	B-X
of	B-X
a	B-X
strategy	B-X
incorporating	B-X
daratumumab	B-X
in	B-X
first-line	B-X
treatment	B-X
regimens	B-X
.	B-X
Given	B-X
that	B-X
overall	B-X
costs	B-X
are	B-X
reduced	B-X
and	B-X
outcomes	B-X
are	B-X
improved	B-X
when	B-X
daratumumab	B-X
is	B-X
used	B-X
as	B-X
part	B-X
of	B-X
a	B-X
first-line	B-X
regimen	B-X
,	B-X
the	B-X
economic	B-X
analysis	B-X
indicates	B-X
that	B-X
addition	B-X
of	B-X
daratumumab	B-X
to	B-X
first-line	B-X
RVd	B-X
and	B-X
VTd	B-X
regimens	B-X
is	B-X
a	B-X
dominant	B-X
strategy	B-X
compared	B-X
with	B-X
reserving	B-X
its	B-X
use	B-X
for	B-X
the	B-X
second-line	B-X
setting	B-X
.	B-X

The	O
ability	O
of	O
Jun	O
proteins	O
to	O
cooperate	O
with	O
GR	B-Protein
in	O
T	O
cells	O
has	O
been	O
investigated	O
after	O
transfection	O
of	O
c	B-Protein
-	I-Protein
jun	I-Protein
,	O
jun	B-Protein
-	I-Protein
B	I-Protein
,	O
or	O
jun	B-Protein
-	I-Protein
D	I-Protein
expression	O
vectors	O
,	O
which	O
augmented	O
GR	B-Protein
-	O
dependent	O
transcription	O
from	O
either	O
MMTV	O
LTR	O
or	O
GRE	O
.	O
<EOS>	B-X
Meyer	B-X
is	B-X
a	B-X
type	B-X
of	B-X
herbal	B-X
plant	B-X
that	B-X
has	B-X
frequently	B-X
been	B-X
used	B-X
in	B-X
many	B-X
Asian	B-X
countries	B-X
to	B-X
treat	B-X
a	B-X
variety	B-X
of	B-X
diseases	B-X
.	B-X
Ginseng	B-X
is	B-X
considered	B-X
to	B-X
exhibit	B-X
anti-inflammatory	B-X
and	B-X
anti-oxidative	B-X
pharmacological	B-X
effects	B-X
.	B-X
However	B-X
,	B-X
the	B-X
specific	B-X
mechanism	B-X
is	B-X
still	B-X
not	B-X
entirely	B-X
understood	B-X
.	B-X
Glioma-related	B-X
epilepsy	B-X
(	B-X
GRE	B-X
)	B-X
is	B-X
defined	B-X
as	B-X
symptomatic	B-X
epileptic	B-X
seizures	B-X
secondary	B-X
to	B-X
gliomas	B-X
,	B-X
it	B-X
brings	B-X
both	B-X
heavy	B-X
financial	B-X
and	B-X
psychosocial	B-X
burdens	B-X
to	B-X
patients	B-X
with	B-X
diffuse	B-X
glioma	B-X
and	B-X
significantly	B-X
decreases	B-X
their	B-X
quality	B-X
of	B-X
life	B-X
.	B-X
To	B-X
date	B-X
,	B-X
there	B-X
have	B-X
been	B-X
no	B-X
clinical	B-X
guidelines	B-X
that	B-X
provide	B-X
recommendations	B-X
for	B-X
the	B-X
optimal	B-X
diagnostic	B-X
and	B-X
therapeutic	B-X
procedures	B-X
for	B-X
GRE	B-X
patients	B-X
.	B-X

Conversely	O
,	O
c	B-Protein
-	I-Protein
jun	I-Protein
and	O
jun	B-Protein
-	I-Protein
B	I-Protein
transfection	O
blunted	O
GR	B-Protein
-	O
dependent	O
transcription	O
in	O
HeLa	O
cells	O
.	O

The	O
presence	O
of	O
c	B-Protein
-	I-Protein
fos	I-Protein
had	O
a	O
negative	O
influence	O
on	O
GR	B-Protein
function	O
and	O
correlated	O
with	O
the	O
cell	O
-	O
specific	O
synergistic	O
or	O
antagonistic	O
activity	O
of	O
Jun	O
with	O
respect	O
to	O
GR	B-Protein
;	O
high	O
basal	O
expression	O
of	O
c	B-Protein
-	I-Protein
fos	I-Protein
as	O
well	O
as	O
AP	O
-	O
1	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
were	O
observed	O
in	O
HeLa	O
cells	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O
<EOS>	B-X
As	B-X
a	B-X
result	B-X
of	B-X
human	B-X
activities	B-X
,	B-X
the	B-X
pollution	B-X
of	B-X
metals	B-X
is	B-X
becoming	B-X
ubiquitous	B-X
in	B-X
the	B-X
environment	B-X
.	B-X
Among	B-X
various	B-X
toxicological	B-X
mechanisms	B-X
of	B-X
action	B-X
,	B-X
metals	B-X
have	B-X
been	B-X
considered	B-X
as	B-X
endocrine-disrupting	B-X
chemicals	B-X
(	B-X
EDCs	B-X
)	B-X
through	B-X
interference	B-X
with	B-X
steroid	B-X
receptors	B-X
.	B-X
However	B-X
,	B-X
information	B-X
regarding	B-X
the	B-X
potential	B-X
endocrine	B-X
disruption	B-X
of	B-X
metals	B-X
on	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
and	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
MR	B-X
)	B-X
is	B-X
especially	B-X
scarce	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
a	B-X
total	B-X
of	B-X
16	B-X
metals	B-X
were	B-X
assessed	B-X
for	B-X
their	B-X
GR/MR	B-X
activities	B-X
using	B-X
luciferase	B-X
reporter	B-X
gene	B-X
assay	B-X
.	B-X
None	B-X
of	B-X
the	B-X
tested	B-X
metals	B-X
exhibited	B-X
GR	B-X
or	B-X
MR	B-X
agonistic	B-X
activity	B-X
,	B-X
but	B-X
a	B-X
total	B-X
of	B-X
7	B-X
and	B-X
5	B-X
candidate	B-X
metals	B-X
showed	B-X
obvious	B-X
GR	B-X
and	B-X
MR	B-X
antagonistic	B-X
properties	B-X
,	B-X
respectively	B-X
.	B-X
All	B-X
7	B-X
GR	B-X
antagonistic	B-X
metals	B-X
[	B-X
BaCl	B-X

Furthermore	O
overexpression	O
of	O
exogenous	O
c	B-Protein
-	I-Protein
fos	I-Protein
has	O
an	O
inhibitory	O
effect	O
on	O
GR	B-Protein
-	O
dependent	O
transcription	O
from	O
GRE	O
in	O
T	O
cells	O
.	O

We	O
propose	O
that	O
Jun	O
plays	O
a	O
bifunctional	O
role	O
on	O
GR	B-Protein
-	O
dependent	O
transcriptional	O
activation	O
of	O
GRE	O
,	O
selecting	O
either	O
synergistic	O
or	O
antagonistic	O
activity	O
depending	O
on	O
the	O
cell	O
-	O
specific	O
microenvironment	O
.	O
<EOS>	B-X
Age	B-X
and	B-X
activity	B-X
might	B-X
be	B-X
considered	B-X
the	B-X
two	B-X
antagonistic	B-X
key	B-X
regulators	B-X
of	B-X
adult	B-X
neurogenesis	B-X
.	B-X
It	B-X
is	B-X
,	B-X
thus	B-X
,	B-X
proposed	B-X
that	B-X
activity-dependent	B-X
regulation	B-X
of	B-X
adult	B-X
neurogenesis	B-X
might	B-X
contribute	B-X
to	B-X
some	B-X
sort	B-X
of	B-X
``	B-X
neural	B-X
reserve	B-X
,	B-X
''	B-X
the	B-X
brain	B-X
's	B-X
ability	B-X
to	B-X
compensate	B-X
functional	B-X
loss	B-X
associated	B-X
with	B-X
aging	B-X
or	B-X
neurodegeneration	B-X
.	B-X
Activity	B-X
can	B-X
have	B-X
nonspecific	B-X
and	B-X
specific	B-X
effects	B-X
on	B-X
adult	B-X
neurogenesis	B-X
.	B-X
Mechanistically	B-X
,	B-X
nonspecific	B-X
stimuli	B-X
that	B-X
largely	B-X
affect	B-X
precursor	B-X
cell	B-X
stages	B-X
might	B-X
be	B-X
related	B-X
by	B-X
the	B-X
local	B-X
microenvironment	B-X
,	B-X
whereas	B-X
more	B-X
specific	B-X
,	B-X
survival-promoting	B-X
effects	B-X
take	B-X
place	B-X
at	B-X
later	B-X
stages	B-X
of	B-X
neuronal	B-X
development	B-X
and	B-X
require	B-X
the	B-X
synaptic	B-X
integration	B-X
of	B-X
the	B-X
new	B-X
cell	B-X
and	B-X
its	B-X
particular	B-X
synaptic	B-X
plasticity	B-X
.	B-X

In	O
this	O
regard	O
,	O
intracellular	O
levels	O
of	O
c	B-Protein
-	I-Protein
fos	I-Protein
appear	O
to	O
be	O
influential	O
.	O
<EOS>	B-X
Interaction	B-X
between	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
-	B-X
and	B-X
glucocorticoid	B-X
receptor	B-X
(	B-X
GR	B-X
)	B-X
-mediated	B-X
signaling	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
PKC	B-X
activating	B-X
phorbol	B-X
ester	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
to	B-X
inhibit	B-X
GR-dependent	B-X
transcription	B-X
of	B-X
the	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
(	B-X
MMTV	B-X
)	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
this	B-X
interference	B-X
is	B-X
cell	B-X
specific	B-X
,	B-X
as	B-X
TPA	B-X
augmented	B-X
dexamethasone-induced	B-X
transcriptional	B-X
activation	B-X
of	B-X
the	B-X
MMTV	B-X
LTR	B-X
in	B-X
several	B-X
T	B-X
cell	B-X
lines	B-X
but	B-X
was	B-X
inhibitory	B-X
in	B-X
NIH-3T3	B-X
fibroblasts	B-X
.	B-X
TPA-GR	B-X
synergism	B-X
was	B-X
determined	B-X
to	B-X
have	B-X
occurred	B-X
at	B-X
the	B-X
GR-responsive	B-X
element	B-X
(	B-X
GRE	B-X
)	B-X
level	B-X
by	B-X
functional	B-X
analysis	B-X
of	B-X
deletion	B-X
mutants	B-X
or	B-X
synthetic	B-X
GRE	B-X
oligonucleotides	B-X
driving	B-X
chloramphenicol	B-X
acetyl-transferase	B-X
expression	B-X
.	B-X
Synergism	B-X
required	B-X
an	B-X
intact	B-X
GR	B-X
DNA-binding	B-X
domain	B-X
,	B-X
whereas	B-X
amino-	B-X
or	B-X
carboxyl-terminal	B-X
domains	B-X
were	B-X
dispensable	B-X
.	B-X
The	B-X
effect	B-X
was	B-X
abrogated	B-X
by	B-X
the	B-X
PKC	B-X
inhibitor	B-X
staurosporine	B-X
,	B-X
suggesting	B-X
a	B-X
role	B-X
for	B-X
PKC	B-X
.	B-X
Increased	B-X
c-jun	B-X
,	B-X
jun-B	B-X
,	B-X
and	B-X
jun-D	B-X
expression	B-X
above	B-X
basal	B-X
levels	B-X
and	B-X
increased	B-X
transcriptional	B-X
activity	B-X
of	B-X
AP-1/TPA	B-X
responsive	B-X
elements	B-X
fused	B-X
to	B-X
chloramphenicol	B-X
acetyl-transferase	B-X
vectors	B-X
were	B-X
observed	B-X
in	B-X
T	B-X
cells	B-X
treated	B-X
with	B-X
TPA	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
dexamethasone	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
Jun	B-X
proteins	B-X
to	B-X
cooperate	B-X
with	B-X
GR	B-X
in	B-X
T	B-X
cells	B-X
has	B-X
been	B-X
investigated	B-X
after	B-X
transfection	B-X
of	B-X
c-jun	B-X
,	B-X
jun-B	B-X
,	B-X
or	B-X
jun-D	B-X
expression	B-X
vectors	B-X
,	B-X
which	B-X
augmented	B-X
GR-dependent	B-X
transcription	B-X
from	B-X
either	B-X
MMTV	B-X
LTR	B-X
or	B-X
GRE	B-X
.	B-X
Conversely	B-X
,	B-X
c-jun	B-X
and	B-X
jun-B	B-X
transfection	B-X
blunted	B-X
GR-dependent	B-X
transcription	B-X
in	B-X
HeLa	B-X
cells	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
c-fos	B-X
had	B-X
a	B-X
negative	B-X
influence	B-X
on	B-X
GR	B-X
function	B-X
and	B-X
correlated	B-X
with	B-X
the	B-X
cell-specific	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
activity	B-X
of	B-X
Jun	B-X
with	B-X
respect	B-X
to	B-X
GR	B-X
;	B-X
high	B-X
basal	B-X
expression	B-X
of	B-X
c-fos	B-X
as	B-X
well	B-X
as	B-X
AP-1	B-X
DNA	B-X
binding	B-X
and	B-X
transcriptional	B-X
activity	B-X
were	B-X
observed	B-X
in	B-X
HeLa	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
Furthermore	B-X
overexpression	B-X
of	B-X
exogenous	B-X
c-fos	B-X
has	B-X
an	B-X
inhibitory	B-X
effect	B-X
on	B-X
GR-dependent	B-X
transcription	B-X
from	B-X
GRE	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
Jun	B-X
plays	B-X
a	B-X
bifunctional	B-X
role	B-X
on	B-X
GR-dependent	B-X
transcriptional	B-X
activation	B-X
of	B-X
GRE	B-X
,	B-X
selecting	B-X
either	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
activity	B-X
depending	B-X
on	B-X
the	B-X
cell-specific	B-X
microenvironment	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
intracellular	B-X
levels	B-X
of	B-X
c-fos	B-X
appear	B-X
to	B-X
be	B-X
influential	B-X
.	B-X

Defective	O
translocation	O
of	O
protein	O
kinase	O
C	O
in	O
multidrug	O
-	O
resistant	O
HL	O
-	O
60	O
cells	O
confers	O
a	O
reversible	O
loss	O
of	O
phorbol	O
ester	O
-	O
induced	O
monocytic	O
differentiation	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
human	B-X
HL-60	B-X
myeloid	B-X
leukemia	B-X
cells	B-X
differentiate	B-X
in	B-X
response	B-X
to	B-X
phorbol	B-X
esters	B-X
.	B-X
This	B-X
event	B-X
is	B-X
associated	B-X
with	B-X
induction	B-X
of	B-X
the	B-X
c-jun	B-X
early	B-X
response	B-X
gene	B-X
and	B-X
appearance	B-X
of	B-X
a	B-X
monocytic	B-X
phenotype	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vincristine-selected	B-X
,	B-X
multidrug	B-X
resistance	B-X
on	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
-induced	B-X
HL-60	B-X
cell	B-X
differentiation	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
multidrug-resistant	B-X
HL-60	B-X
cells	B-X
,	B-X
designated	B-X
HL-60/vinc	B-X
,	B-X
fail	B-X
to	B-X
respond	B-X
to	B-X
TPA	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
c-jun	B-X
transcripts	B-X
or	B-X
other	B-X
phenotypic	B-X
characteristics	B-X
of	B-X
monocytic	B-X
differentiation	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
treatment	B-X
of	B-X
HL-60/vinc	B-X
cells	B-X
with	B-X
okadaic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
serine/threonine	B-X
protein	B-X
phosphatases	B-X
,	B-X
induces	B-X
c-jun	B-X
transcription	B-X
,	B-X
growth	B-X
arrest	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
c-fms	B-X
gene	B-X
.	B-X
Studies	B-X
were	B-X
also	B-X
performed	B-X
with	B-X
an	B-X
HL-60/vinc	B-X
revertant	B-X
(	B-X
HL-60/vinc/R	B-X
)	B-X
line	B-X
that	B-X
has	B-X
regained	B-X
partial	B-X
sensitivity	B-X
to	B-X
vincristine	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
HL-60/vinc/R	B-X
cells	B-X
respond	B-X
to	B-X
TPA	B-X
with	B-X
induction	B-X
of	B-X
a	B-X
monocytic	B-X
phenotype	B-X
,	B-X
but	B-X
not	B-X
c-jun	B-X
expression	B-X
,	B-X
suggests	B-X
that	B-X
c-jun	B-X
induction	B-X
is	B-X
not	B-X
obligatory	B-X
for	B-X
monocytic	B-X
differentiation	B-X
.	B-X
Other	B-X
studies	B-X
further	B-X
demonstrate	B-X
that	B-X
the	B-X
jun-B	B-X
and	B-X
fra-1	B-X
genes	B-X
are	B-X
induced	B-X
by	B-X
TPA	B-X
in	B-X
both	B-X
HL-60/vinc	B-X
and	B-X
HL-60/vinc/R	B-X
cells	B-X
,	B-X
whereas	B-X
c-fos	B-X
expression	B-X
is	B-X
attenuated	B-X
in	B-X
the	B-X
HL-60/vinc	B-X
line	B-X
.	B-X
Since	B-X
TPA	B-X
activates	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
we	B-X
examined	B-X
translocation	B-X
of	B-X
PKC	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
membrane	B-X
fraction	B-X
.	B-X
Although	B-X
HL-60	B-X
and	B-X
HL-60/vinc/R	B-X
cells	B-X
demonstrated	B-X
translocation	B-X
of	B-X
PKC	B-X
activity	B-X
,	B-X
this	B-X
subcellular	B-X
redistribution	B-X
was	B-X
undetectable	B-X
in	B-X
HL-60/vinc	B-X
cells	B-X
.	B-X
Activity	B-X
of	B-X
the	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
family	B-X
with	B-X
associated	B-X
phosphorylation	B-X
of	B-X
c-Jun	B-X
Y-peptide	B-X
was	B-X
markedly	B-X
diminished	B-X
in	B-X
TPA-treated	B-X
HL-60/vinc	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
response	B-X
to	B-X
okadaic	B-X
acid	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
vincristine	B-X
resistance	B-X
confers	B-X
insensitivity	B-X
to	B-X
TPA-induced	B-X
differentiation	B-X
and	B-X
can	B-X
include	B-X
defects	B-X
in	B-X
PKC-mediated	B-X
signaling	B-X
events	B-X
and	B-X
induction	B-X
of	B-X
jun/fos	B-X
early	B-X
response	B-X
gene	B-X
expression	B-X
.	B-X

Previous	O
studies	O
have	O
demonstrated	O
that	O
human	O
HL	O
-	O
60	O
myeloid	O
leukemia	O
cells	O
differentiate	O
in	O
response	O
to	O
phorbol	O
esters	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
human	B-X
HL-60	B-X
myeloid	B-X
leukemia	B-X
cells	B-X
differentiate	B-X
in	B-X
response	B-X
to	B-X
phorbol	B-X
esters	B-X
.	B-X
This	B-X
event	B-X
is	B-X
associated	B-X
with	B-X
induction	B-X
of	B-X
the	B-X
c-jun	B-X
early	B-X
response	B-X
gene	B-X
and	B-X
appearance	B-X
of	B-X
a	B-X
monocytic	B-X
phenotype	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vincristine-selected	B-X
,	B-X
multidrug	B-X
resistance	B-X
on	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
-induced	B-X
HL-60	B-X
cell	B-X
differentiation	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
multidrug-resistant	B-X
HL-60	B-X
cells	B-X
,	B-X
designated	B-X
HL-60/vinc	B-X
,	B-X
fail	B-X
to	B-X
respond	B-X
to	B-X
TPA	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
c-jun	B-X
transcripts	B-X
or	B-X
other	B-X
phenotypic	B-X
characteristics	B-X
of	B-X
monocytic	B-X
differentiation	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
treatment	B-X
of	B-X
HL-60/vinc	B-X
cells	B-X
with	B-X
okadaic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
serine/threonine	B-X
protein	B-X
phosphatases	B-X
,	B-X
induces	B-X
c-jun	B-X
transcription	B-X
,	B-X
growth	B-X
arrest	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
c-fms	B-X
gene	B-X
.	B-X
Studies	B-X
were	B-X
also	B-X
performed	B-X
with	B-X
an	B-X
HL-60/vinc	B-X
revertant	B-X
(	B-X
HL-60/vinc/R	B-X
)	B-X
line	B-X
that	B-X
has	B-X
regained	B-X
partial	B-X
sensitivity	B-X
to	B-X
vincristine	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
HL-60/vinc/R	B-X
cells	B-X
respond	B-X
to	B-X
TPA	B-X
with	B-X
induction	B-X
of	B-X
a	B-X
monocytic	B-X
phenotype	B-X
,	B-X
but	B-X
not	B-X
c-jun	B-X
expression	B-X
,	B-X
suggests	B-X
that	B-X
c-jun	B-X
induction	B-X
is	B-X
not	B-X
obligatory	B-X
for	B-X
monocytic	B-X
differentiation	B-X
.	B-X
Other	B-X
studies	B-X
further	B-X
demonstrate	B-X
that	B-X
the	B-X
jun-B	B-X
and	B-X
fra-1	B-X
genes	B-X
are	B-X
induced	B-X
by	B-X
TPA	B-X
in	B-X
both	B-X
HL-60/vinc	B-X
and	B-X
HL-60/vinc/R	B-X
cells	B-X
,	B-X
whereas	B-X
c-fos	B-X
expression	B-X
is	B-X
attenuated	B-X
in	B-X
the	B-X
HL-60/vinc	B-X
line	B-X
.	B-X
Although	B-X
HL-60	B-X
and	B-X
HL-60/vinc/R	B-X
cells	B-X
demonstrated	B-X
translocation	B-X
of	B-X
PKC	B-X
activity	B-X
,	B-X
this	B-X
subcellular	B-X
redistribution	B-X
was	B-X
undetectable	B-X
in	B-X
HL-60/vinc	B-X
cells	B-X
.	B-X
Activity	B-X
of	B-X
the	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
family	B-X
with	B-X
associated	B-X
phosphorylation	B-X
of	B-X
c-Jun	B-X
Y-peptide	B-X
was	B-X
markedly	B-X
diminished	B-X
in	B-X
TPA-treated	B-X
HL-60/vinc	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
response	B-X
to	B-X
okadaic	B-X
acid	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
vincristine	B-X
resistance	B-X
confers	B-X
insensitivity	B-X
to	B-X
TPA-induced	B-X
differentiation	B-X
and	B-X
can	B-X
include	B-X
defects	B-X
in	B-X
PKC-mediated	B-X
signaling	B-X
events	B-X
and	B-X
induction	B-X
of	B-X
jun/fos	B-X
early	B-X
response	B-X
gene	B-X
expression	B-X
.	B-X

This	O
event	O
is	O
associated	O
with	O
induction	O
of	O
the	O
c	B-Protein
-	I-Protein
jun	I-Protein
early	O
response	O
gene	O
and	O
appearance	O
of	O
a	O
monocytic	O
phenotype	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
vincristine	O
-	O
selected	O
,	O
multidrug	O
resistance	O
on	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
-	O
induced	O
HL	O
-	O
60	O
cell	O
differentiation	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
human	B-X
HL-60	B-X
myeloid	B-X
leukemia	B-X
cells	B-X
differentiate	B-X
in	B-X
response	B-X
to	B-X
phorbol	B-X
esters	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vincristine-selected	B-X
,	B-X
multidrug	B-X
resistance	B-X
on	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
-induced	B-X
HL-60	B-X
cell	B-X
differentiation	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
multidrug-resistant	B-X
HL-60	B-X
cells	B-X
,	B-X
designated	B-X
HL-60/vinc	B-X
,	B-X
fail	B-X
to	B-X
respond	B-X
to	B-X
TPA	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
c-jun	B-X
transcripts	B-X
or	B-X
other	B-X
phenotypic	B-X
characteristics	B-X
of	B-X
monocytic	B-X
differentiation	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
treatment	B-X
of	B-X
HL-60/vinc	B-X
cells	B-X
with	B-X
okadaic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
serine/threonine	B-X
protein	B-X
phosphatases	B-X
,	B-X
induces	B-X
c-jun	B-X
transcription	B-X
,	B-X
growth	B-X
arrest	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
c-fms	B-X
gene	B-X
.	B-X
Studies	B-X
were	B-X
also	B-X
performed	B-X
with	B-X
an	B-X
HL-60/vinc	B-X
revertant	B-X
(	B-X
HL-60/vinc/R	B-X
)	B-X
line	B-X
that	B-X
has	B-X
regained	B-X
partial	B-X
sensitivity	B-X
to	B-X
vincristine	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
HL-60/vinc/R	B-X
cells	B-X
respond	B-X
to	B-X
TPA	B-X
with	B-X
induction	B-X
of	B-X
a	B-X
monocytic	B-X
phenotype	B-X
,	B-X
but	B-X
not	B-X
c-jun	B-X
expression	B-X
,	B-X
suggests	B-X
that	B-X
c-jun	B-X
induction	B-X
is	B-X
not	B-X
obligatory	B-X
for	B-X
monocytic	B-X
differentiation	B-X
.	B-X
Other	B-X
studies	B-X
further	B-X
demonstrate	B-X
that	B-X
the	B-X
jun-B	B-X
and	B-X
fra-1	B-X
genes	B-X
are	B-X
induced	B-X
by	B-X
TPA	B-X
in	B-X
both	B-X
HL-60/vinc	B-X
and	B-X
HL-60/vinc/R	B-X
cells	B-X
,	B-X
whereas	B-X
c-fos	B-X
expression	B-X
is	B-X
attenuated	B-X
in	B-X
the	B-X
HL-60/vinc	B-X
line	B-X
.	B-X
Since	B-X
TPA	B-X
activates	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
we	B-X
examined	B-X
translocation	B-X
of	B-X
PKC	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
membrane	B-X
fraction	B-X
.	B-X
Although	B-X
HL-60	B-X
and	B-X
HL-60/vinc/R	B-X
cells	B-X
demonstrated	B-X
translocation	B-X
of	B-X
PKC	B-X
activity	B-X
,	B-X
this	B-X
subcellular	B-X
redistribution	B-X
was	B-X
undetectable	B-X
in	B-X
HL-60/vinc	B-X
cells	B-X
.	B-X
Activity	B-X
of	B-X
the	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
family	B-X
with	B-X
associated	B-X
phosphorylation	B-X
of	B-X
c-Jun	B-X
Y-peptide	B-X
was	B-X
markedly	B-X
diminished	B-X
in	B-X
TPA-treated	B-X
HL-60/vinc	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
response	B-X
to	B-X
okadaic	B-X
acid	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
vincristine	B-X
resistance	B-X
confers	B-X
insensitivity	B-X
to	B-X
TPA-induced	B-X
differentiation	B-X
and	B-X
can	B-X
include	B-X
defects	B-X
in	B-X
PKC-mediated	B-X
signaling	B-X
events	B-X
and	B-X
induction	B-X
of	B-X
jun/fos	B-X
early	B-X
response	B-X
gene	B-X
expression	B-X
.	B-X

The	O
results	O
demonstrate	O
that	O
multidrug	O
-	O
resistant	O
HL	O
-	O
60	O
cells	O
,	O
designated	O
HL	O
-	O
60	O
/	O
vinc	O
,	O
fail	O
to	O
respond	O
to	O
TPA	O
with	O
an	O
increase	O
in	O
c	B-Protein
-	I-Protein
jun	I-Protein
transcripts	O
or	O
other	O
phenotypic	O
characteristics	O
of	O
monocytic	O
differentiation	O
.	O
<EOS>	B-X
Neonatal	B-X
leukaemia	B-X
is	B-X
defined	B-X
as	B-X
occurring	B-X
within	B-X
the	B-X
first	B-X
28	B-X
days	B-X
of	B-X
life	B-X
and	B-X
most	B-X
,	B-X
if	B-X
not	B-X
all	B-X
,	B-X
cases	B-X
are	B-X
congenital	B-X
.	B-X
With	B-X
the	B-X
exception	B-X
of	B-X
Down	B-X
syndrome-associated	B-X
transient	B-X
abnormal	B-X
myelopoiesis	B-X
,	B-X
which	B-X
is	B-X
not	B-X
considered	B-X
here	B-X
,	B-X
neonatal	B-X
leukaemias	B-X
are	B-X
rare	B-X
.	B-X
In	B-X
two-thirds	B-X
of	B-X
patients	B-X
the	B-X
disease	B-X
manifests	B-X
as	B-X
an	B-X
acute	B-X
myeloid	B-X
leukaemia	B-X
,	B-X
frequently	B-X
with	B-X
monocytic/monoblastic	B-X
characteristics	B-X
.	B-X
Most	B-X
other	B-X
cases	B-X
are	B-X
acute	B-X
lymphoblastic	B-X
leukaemia	B-X
,	B-X
particularly	B-X
B	B-X
lineage	B-X
,	B-X
but	B-X
some	B-X
are	B-X
mixed	B-X
phenotype	B-X
or	B-X
blastic	B-X
plasmacytoid	B-X
dendritic	B-X
cell	B-X
neoplasms	B-X
.	B-X
The	B-X
most	B-X
frequently	B-X
observed	B-X
cytogenetic/molecular	B-X
abnormality	B-X
is	B-X
t	B-X
(	B-X
4	B-X
;	B-X
11	B-X
)	B-X
(	B-X
q21.3	B-X
;	B-X
q23.3	B-X
)	B-X
/KMT2A-AFF1	B-X
followed	B-X
by	B-X
t	B-X
(	B-X
1	B-X
;	B-X
22	B-X
)	B-X
(	B-X
p13.3	B-X
;	B-X
q13.1	B-X
)	B-X
/RBM15-MKL1	B-X
and	B-X
t	B-X
(	B-X
8	B-X
;	B-X
16	B-X
)	B-X
(	B-X
p11.2	B-X
;	B-X
p13.3	B-X
)	B-X
/KAT6A-CREBBP	B-X
.	B-X
Common	B-X
clinical	B-X
features	B-X
include	B-X
prominent	B-X
hepatosplenomegaly	B-X
and	B-X
a	B-X
high	B-X
incidence	B-X
of	B-X
skin	B-X
involvement	B-X
,	B-X
sometimes	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
bone	B-X
marrow	B-X
disease	B-X
.	B-X
A	B-X
distinctive	B-X
feature	B-X
is	B-X
the	B-X
occurrence	B-X
of	B-X
spontaneous	B-X
remission	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
particularly	B-X
in	B-X
association	B-X
with	B-X
t	B-X
(	B-X
8	B-X
;	B-X
16	B-X
)	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarise	B-X
current	B-X
knowledge	B-X
of	B-X
the	B-X
clinical	B-X
,	B-X
cytogenetic	B-X
and	B-X
molecular	B-X
features	B-X
of	B-X
neonatal	B-X
leukaemia	B-X
and	B-X
discuss	B-X
clinical	B-X
management	B-X
of	B-X
these	B-X
cases	B-X
.	B-X

By	O
contrast	O
,	O
treatment	O
of	O
HL	O
-	O
60	O
/	O
vinc	O
cells	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine	O
/	O
threonine	O
protein	O
phosphatases	O
,	O
induces	O
c	B-Protein
-	I-Protein
jun	I-Protein
transcription	O
,	O
growth	O
arrest	O
,	O
and	O
expression	O
of	O
the	O
c	B-Protein
-	I-Protein
fms	I-Protein
gene	O
.	O

Studies	O
were	O
also	O
performed	O
with	O
an	O
HL	O
-	O
60	O
/	O
vinc	O
revertant	O
(	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
)	O
line	O
that	O
has	O
regained	O
partial	O
sensitivity	O
to	O
vincristine	O
.	O

The	O
finding	O
that	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
cells	O
respond	O
to	O
TPA	O
with	O
induction	O
of	O
a	O
monocytic	O
phenotype	O
,	O
but	O
not	O
c	B-Protein
-	I-Protein
jun	I-Protein
expression	O
,	O
suggests	O
that	O
c	B-Protein
-	I-Protein
jun	I-Protein
induction	O
is	O
not	O
obligatory	O
for	O
monocytic	O
differentiation	O
.	O

Other	O
studies	O
further	O
demonstrate	O
that	O
the	O
jun	B-Protein
-	I-Protein
B	I-Protein
and	O
fra	B-Protein
-	I-Protein
1	I-Protein
genes	O
are	O
induced	O
by	O
TPA	O
in	O
both	O
HL	O
-	O
60	O
/	O
vinc	O
and	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
cells	O
,	O
whereas	O
c	B-Protein
-	I-Protein
fos	I-Protein
expression	O
is	O
attenuated	O
in	O
the	O
HL	O
-	O
60	O
/	O
vinc	O
line	O
.	O

Since	O
TPA	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
we	O
examined	O
translocation	O
of	O
PKC	O
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
fraction	O
.	O

Although	O
HL	O
-	O
60	O
and	O
HL	O
-	O
60	O
/	O
vinc	O
/	O
R	O
cells	O
demonstrated	O
translocation	O
of	O
PKC	O
activity	O
,	O
this	O
subcellular	O
redistribution	O
was	O
undetectable	O
in	O
HL	O
-	O
60	O
/	O
vinc	O
cells	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
human	B-X
HL-60	B-X
myeloid	B-X
leukemia	B-X
cells	B-X
differentiate	B-X
in	B-X
response	B-X
to	B-X
phorbol	B-X
esters	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vincristine-selected	B-X
,	B-X
multidrug	B-X
resistance	B-X
on	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
-induced	B-X
HL-60	B-X
cell	B-X
differentiation	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
multidrug-resistant	B-X
HL-60	B-X
cells	B-X
,	B-X
designated	B-X
HL-60/vinc	B-X
,	B-X
fail	B-X
to	B-X
respond	B-X
to	B-X
TPA	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
c-jun	B-X
transcripts	B-X
or	B-X
other	B-X
phenotypic	B-X
characteristics	B-X
of	B-X
monocytic	B-X
differentiation	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
treatment	B-X
of	B-X
HL-60/vinc	B-X
cells	B-X
with	B-X
okadaic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
serine/threonine	B-X
protein	B-X
phosphatases	B-X
,	B-X
induces	B-X
c-jun	B-X
transcription	B-X
,	B-X
growth	B-X
arrest	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
c-fms	B-X
gene	B-X
.	B-X
Studies	B-X
were	B-X
also	B-X
performed	B-X
with	B-X
an	B-X
HL-60/vinc	B-X
revertant	B-X
(	B-X
HL-60/vinc/R	B-X
)	B-X
line	B-X
that	B-X
has	B-X
regained	B-X
partial	B-X
sensitivity	B-X
to	B-X
vincristine	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
HL-60/vinc/R	B-X
cells	B-X
respond	B-X
to	B-X
TPA	B-X
with	B-X
induction	B-X
of	B-X
a	B-X
monocytic	B-X
phenotype	B-X
,	B-X
but	B-X
not	B-X
c-jun	B-X
expression	B-X
,	B-X
suggests	B-X
that	B-X
c-jun	B-X
induction	B-X
is	B-X
not	B-X
obligatory	B-X
for	B-X
monocytic	B-X
differentiation	B-X
.	B-X
Other	B-X
studies	B-X
further	B-X
demonstrate	B-X
that	B-X
the	B-X
jun-B	B-X
and	B-X
fra-1	B-X
genes	B-X
are	B-X
induced	B-X
by	B-X
TPA	B-X
in	B-X
both	B-X
HL-60/vinc	B-X
and	B-X
HL-60/vinc/R	B-X
cells	B-X
,	B-X
whereas	B-X
c-fos	B-X
expression	B-X
is	B-X
attenuated	B-X
in	B-X
the	B-X
HL-60/vinc	B-X
line	B-X
.	B-X
Since	B-X
TPA	B-X
activates	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
we	B-X
examined	B-X
translocation	B-X
of	B-X
PKC	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
membrane	B-X
fraction	B-X
.	B-X
Although	B-X
HL-60	B-X
and	B-X
HL-60/vinc/R	B-X
cells	B-X
demonstrated	B-X
translocation	B-X
of	B-X
PKC	B-X
activity	B-X
,	B-X
this	B-X
subcellular	B-X
redistribution	B-X
was	B-X
undetectable	B-X
in	B-X
HL-60/vinc	B-X
cells	B-X
.	B-X
Activity	B-X
of	B-X
the	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
family	B-X
with	B-X
associated	B-X
phosphorylation	B-X
of	B-X
c-Jun	B-X
Y-peptide	B-X
was	B-X
markedly	B-X
diminished	B-X
in	B-X
TPA-treated	B-X
HL-60/vinc	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
response	B-X
to	B-X
okadaic	B-X
acid	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
vincristine	B-X
resistance	B-X
confers	B-X
insensitivity	B-X
to	B-X
TPA-induced	B-X
differentiation	B-X
and	B-X
can	B-X
include	B-X
defects	B-X
in	B-X
PKC-mediated	B-X
signaling	B-X
events	B-X
and	B-X
induction	B-X
of	B-X
jun/fos	B-X
early	B-X
response	B-X
gene	B-X
expression	B-X
.	B-X

Activity	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
family	O
with	O
associated	O
phosphorylation	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
Y	O
-	O
peptide	O
was	O
markedly	O
diminished	O
in	O
TPA	O
-	O
treated	O
HL	O
-	O
60	O
/	O
vinc	O
cells	O
,	O
but	O
not	O
in	O
response	O
to	O
okadaic	O
acid	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
vincristine	O
resistance	O
confers	O
insensitivity	O
to	O
TPA	O
-	O
induced	O
differentiation	O
and	O
can	O
include	O
defects	O
in	O
PKC	O
-	O
mediated	O
signaling	O
events	O
and	O
induction	O
of	O
jun	O
/	O
fos	O
early	O
response	O
gene	O
expression	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
human	B-X
HL-60	B-X
myeloid	B-X
leukemia	B-X
cells	B-X
differentiate	B-X
in	B-X
response	B-X
to	B-X
phorbol	B-X
esters	B-X
.	B-X
This	B-X
event	B-X
is	B-X
associated	B-X
with	B-X
induction	B-X
of	B-X
the	B-X
c-jun	B-X
early	B-X
response	B-X
gene	B-X
and	B-X
appearance	B-X
of	B-X
a	B-X
monocytic	B-X
phenotype	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
have	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vincristine-selected	B-X
,	B-X
multidrug	B-X
resistance	B-X
on	B-X
12-O-tetradecanoylphorbol-13-acetate	B-X
(	B-X
TPA	B-X
)	B-X
-induced	B-X
HL-60	B-X
cell	B-X
differentiation	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
multidrug-resistant	B-X
HL-60	B-X
cells	B-X
,	B-X
designated	B-X
HL-60/vinc	B-X
,	B-X
fail	B-X
to	B-X
respond	B-X
to	B-X
TPA	B-X
with	B-X
an	B-X
increase	B-X
in	B-X
c-jun	B-X
transcripts	B-X
or	B-X
other	B-X
phenotypic	B-X
characteristics	B-X
of	B-X
monocytic	B-X
differentiation	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
treatment	B-X
of	B-X
HL-60/vinc	B-X
cells	B-X
with	B-X
okadaic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
serine/threonine	B-X
protein	B-X
phosphatases	B-X
,	B-X
induces	B-X
c-jun	B-X
transcription	B-X
,	B-X
growth	B-X
arrest	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
c-fms	B-X
gene	B-X
.	B-X
Studies	B-X
were	B-X
also	B-X
performed	B-X
with	B-X
an	B-X
HL-60/vinc	B-X
revertant	B-X
(	B-X
HL-60/vinc/R	B-X
)	B-X
line	B-X
that	B-X
has	B-X
regained	B-X
partial	B-X
sensitivity	B-X
to	B-X
vincristine	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
HL-60/vinc/R	B-X
cells	B-X
respond	B-X
to	B-X
TPA	B-X
with	B-X
induction	B-X
of	B-X
a	B-X
monocytic	B-X
phenotype	B-X
,	B-X
but	B-X
not	B-X
c-jun	B-X
expression	B-X
,	B-X
suggests	B-X
that	B-X
c-jun	B-X
induction	B-X
is	B-X
not	B-X
obligatory	B-X
for	B-X
monocytic	B-X
differentiation	B-X
.	B-X
Other	B-X
studies	B-X
further	B-X
demonstrate	B-X
that	B-X
the	B-X
jun-B	B-X
and	B-X
fra-1	B-X
genes	B-X
are	B-X
induced	B-X
by	B-X
TPA	B-X
in	B-X
both	B-X
HL-60/vinc	B-X
and	B-X
HL-60/vinc/R	B-X
cells	B-X
,	B-X
whereas	B-X
c-fos	B-X
expression	B-X
is	B-X
attenuated	B-X
in	B-X
the	B-X
HL-60/vinc	B-X
line	B-X
.	B-X
Since	B-X
TPA	B-X
activates	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
we	B-X
examined	B-X
translocation	B-X
of	B-X
PKC	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
membrane	B-X
fraction	B-X
.	B-X
Although	B-X
HL-60	B-X
and	B-X
HL-60/vinc/R	B-X
cells	B-X
demonstrated	B-X
translocation	B-X
of	B-X
PKC	B-X
activity	B-X
,	B-X
this	B-X
subcellular	B-X
redistribution	B-X
was	B-X
undetectable	B-X
in	B-X
HL-60/vinc	B-X
cells	B-X
.	B-X
Activity	B-X
of	B-X
the	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
family	B-X
with	B-X
associated	B-X
phosphorylation	B-X
of	B-X
c-Jun	B-X
Y-peptide	B-X
was	B-X
markedly	B-X
diminished	B-X
in	B-X
TPA-treated	B-X
HL-60/vinc	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
response	B-X
to	B-X
okadaic	B-X
acid	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
vincristine	B-X
resistance	B-X
confers	B-X
insensitivity	B-X
to	B-X
TPA-induced	B-X
differentiation	B-X
and	B-X
can	B-X
include	B-X
defects	B-X
in	B-X
PKC-mediated	B-X
signaling	B-X
events	B-X
and	B-X
induction	B-X
of	B-X
jun/fos	B-X
early	B-X
response	B-X
gene	B-X
expression	B-X
.	B-X

Initiation	B-Protein
binding	I-Protein
repressor	I-Protein
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	B-Protein
h5	I-Protein
gene	O
,	O
is	O
a	O
glycosylated	O
member	O
of	O
a	O
family	O
of	O
cell	O
growth	O
regulators	O
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O

Initiation	B-Protein
binding	I-Protein
repressor	I-Protein
[	O
corrected	O
]	O
(	O
IBR	B-Protein
)	O
is	O
a	O
chicken	O
erythrocyte	O
factor	O
(	O
apparent	O
molecular	O
mass	O
,	O
70	O
to	O
73	O
kDa	O
)	O
that	O
binds	O
to	O
the	O
sequences	O
spanning	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	B-Protein
h5	I-Protein
gene	O
,	O
repressing	O
its	O
transcription	O
.	O

A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	O
erythroid	O
precursors	O
,	O
do	O
not	O
have	O
IBR	B-Protein
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	B-Protein
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	O
the	O
same	O
IBR	B-Protein
sites	O
.	O
<EOS>	B-X
Initiation	B-X
binding	B-X
repressor	B-X
[	B-X
corrected	B-X
]	B-X
(	B-X
IBR	B-X
)	B-X
is	B-X
a	B-X
chicken	B-X
erythrocyte	B-X
factor	B-X
(	B-X
apparent	B-X
molecular	B-X
mass	B-X
,	B-X
70	B-X
to	B-X
73	B-X
kDa	B-X
)	B-X
that	B-X
binds	B-X
to	B-X
the	B-X
sequences	B-X
spanning	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
of	B-X
the	B-X
histone	B-X
h5	B-X
gene	B-X
,	B-X
repressing	B-X
its	B-X
transcription	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
other	B-X
cells	B-X
,	B-X
including	B-X
transformed	B-X
erythroid	B-X
precursors	B-X
,	B-X
do	B-X
not	B-X
have	B-X
IBR	B-X
but	B-X
a	B-X
factor	B-X
referred	B-X
to	B-X
as	B-X
IBF	B-X
(	B-X
68	B-X
to	B-X
70	B-X
kDa	B-X
)	B-X
that	B-X
recognizes	B-X
the	B-X
same	B-X
IBR	B-X
sites	B-X
.	B-X
We	B-X
have	B-X
cloned	B-X
the	B-X
IBR	B-X
cDNA	B-X
and	B-X
studied	B-X
the	B-X
relationship	B-X
of	B-X
IBR	B-X
and	B-X
IBF	B-X
.	B-X
IBR	B-X
is	B-X
a	B-X
503-amino-acid-long	B-X
acidic	B-X
protein	B-X
which	B-X
is	B-X
99.0	B-X
%	B-X
identical	B-X
to	B-X
the	B-X
recently	B-X
reported	B-X
human	B-X
NRF-1/alpha-Pal	B-X
factor	B-X
and	B-X
highly	B-X
related	B-X
to	B-X
the	B-X
invertebrate	B-X
transcription	B-X
factors	B-X
P3A2	B-X
and	B-X
erected	B-X
wing	B-X
gene	B-X
product	B-X
(	B-X
EWG	B-X
)	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
IBR	B-X
and	B-X
IBF	B-X
are	B-X
most	B-X
likely	B-X
identical	B-X
proteins	B-X
,	B-X
differing	B-X
in	B-X
their	B-X
degree	B-X
of	B-X
glycosylation	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
several	B-X
molecular	B-X
aspects	B-X
of	B-X
IBR/F	B-X
and	B-X
shown	B-X
that	B-X
the	B-X
factor	B-X
associates	B-X
as	B-X
stable	B-X
homodimers	B-X
and	B-X
that	B-X
the	B-X
dimer	B-X
is	B-X
the	B-X
relevant	B-X
DNA-binding	B-X
species	B-X
.	B-X
The	B-X
evolutionarily	B-X
conserved	B-X
N-terminal	B-X
half	B-X
of	B-X
IBR/F	B-X
harbors	B-X
the	B-X
DNA-binding/dimerization	B-X
domain	B-X
(	B-X
outer	B-X
limits	B-X
,	B-X
127	B-X
to	B-X
283	B-X
)	B-X
,	B-X
one	B-X
or	B-X
several	B-X
casein	B-X
kinase	B-X
II	B-X
sites	B-X
(	B-X
37	B-X
to	B-X
67	B-X
)	B-X
,	B-X
and	B-X
a	B-X
bipartite	B-X
nuclear	B-X
localization	B-X
signal	B-X
(	B-X
89	B-X
to	B-X
106	B-X
)	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
nuclear	B-X
targeting	B-X
.	B-X
Binding	B-X
site	B-X
selection	B-X
revealed	B-X
that	B-X
the	B-X
alternating	B-X
RCGCRYGCGY	B-X
consensus	B-X
constitutes	B-X
high-affinity	B-X
IBR/F	B-X
binding	B-X
sites	B-X
and	B-X
that	B-X
the	B-X
direct-repeat	B-X
palindrome	B-X
TGCGCATGCGCA	B-X
is	B-X
the	B-X
optimal	B-X
site	B-X
.	B-X
A	B-X
survey	B-X
of	B-X
genes	B-X
potentially	B-X
regulated	B-X
by	B-X
this	B-X
family	B-X
of	B-X
factors	B-X
primarily	B-X
revealed	B-X
genes	B-X
involved	B-X
in	B-X
growth-related	B-X
metabolism	B-X
.	B-X

We	O
have	O
cloned	O
the	O
IBR	B-Protein
cDNA	O
and	O
studied	O
the	O
relationship	O
of	O
IBR	B-Protein
and	O
IBF	B-Protein
.	O
<EOS>	B-X
Initiation	B-X
binding	B-X
repressor	B-X
[	B-X
corrected	B-X
]	B-X
(	B-X
IBR	B-X
)	B-X
is	B-X
a	B-X
chicken	B-X
erythrocyte	B-X
factor	B-X
(	B-X
apparent	B-X
molecular	B-X
mass	B-X
,	B-X
70	B-X
to	B-X
73	B-X
kDa	B-X
)	B-X
that	B-X
binds	B-X
to	B-X
the	B-X
sequences	B-X
spanning	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
of	B-X
the	B-X
histone	B-X
h5	B-X
gene	B-X
,	B-X
repressing	B-X
its	B-X
transcription	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
other	B-X
cells	B-X
,	B-X
including	B-X
transformed	B-X
erythroid	B-X
precursors	B-X
,	B-X
do	B-X
not	B-X
have	B-X
IBR	B-X
but	B-X
a	B-X
factor	B-X
referred	B-X
to	B-X
as	B-X
IBF	B-X
(	B-X
68	B-X
to	B-X
70	B-X
kDa	B-X
)	B-X
that	B-X
recognizes	B-X
the	B-X
same	B-X
IBR	B-X
sites	B-X
.	B-X
We	B-X
have	B-X
cloned	B-X
the	B-X
IBR	B-X
cDNA	B-X
and	B-X
studied	B-X
the	B-X
relationship	B-X
of	B-X
IBR	B-X
and	B-X
IBF	B-X
.	B-X
IBR	B-X
is	B-X
a	B-X
503-amino-acid-long	B-X
acidic	B-X
protein	B-X
which	B-X
is	B-X
99.0	B-X
%	B-X
identical	B-X
to	B-X
the	B-X
recently	B-X
reported	B-X
human	B-X
NRF-1/alpha-Pal	B-X
factor	B-X
and	B-X
highly	B-X
related	B-X
to	B-X
the	B-X
invertebrate	B-X
transcription	B-X
factors	B-X
P3A2	B-X
and	B-X
erected	B-X
wing	B-X
gene	B-X
product	B-X
(	B-X
EWG	B-X
)	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
IBR	B-X
and	B-X
IBF	B-X
are	B-X
most	B-X
likely	B-X
identical	B-X
proteins	B-X
,	B-X
differing	B-X
in	B-X
their	B-X
degree	B-X
of	B-X
glycosylation	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
several	B-X
molecular	B-X
aspects	B-X
of	B-X
IBR/F	B-X
and	B-X
shown	B-X
that	B-X
the	B-X
factor	B-X
associates	B-X
as	B-X
stable	B-X
homodimers	B-X
and	B-X
that	B-X
the	B-X
dimer	B-X
is	B-X
the	B-X
relevant	B-X
DNA-binding	B-X
species	B-X
.	B-X
The	B-X
evolutionarily	B-X
conserved	B-X
N-terminal	B-X
half	B-X
of	B-X
IBR/F	B-X
harbors	B-X
the	B-X
DNA-binding/dimerization	B-X
domain	B-X
(	B-X
outer	B-X
limits	B-X
,	B-X
127	B-X
to	B-X
283	B-X
)	B-X
,	B-X
one	B-X
or	B-X
several	B-X
casein	B-X
kinase	B-X
II	B-X
sites	B-X
(	B-X
37	B-X
to	B-X
67	B-X
)	B-X
,	B-X
and	B-X
a	B-X
bipartite	B-X
nuclear	B-X
localization	B-X
signal	B-X
(	B-X
89	B-X
to	B-X
106	B-X
)	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
nuclear	B-X
targeting	B-X
.	B-X
Binding	B-X
site	B-X
selection	B-X
revealed	B-X
that	B-X
the	B-X
alternating	B-X
RCGCRYGCGY	B-X
consensus	B-X
constitutes	B-X
high-affinity	B-X
IBR/F	B-X
binding	B-X
sites	B-X
and	B-X
that	B-X
the	B-X
direct-repeat	B-X
palindrome	B-X
TGCGCATGCGCA	B-X
is	B-X
the	B-X
optimal	B-X
site	B-X
.	B-X

IBR	B-Protein
is	O
a	O
503	O
-	O
amino	O
-	O
acid	O
-	O
long	O
acidic	O
protein	O
which	O
is	O
99	O
.	O
0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	O
NRF	B-Protein
-	I-Protein
1	I-Protein
/	O
alpha	B-Protein
-	I-Protein
Pal	I-Protein
factor	I-Protein
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	O
factors	O
P3A2	B-Protein
and	O
erected	B-Protein
wing	I-Protein
gene	I-Protein
product	O
(	O
EWG	B-Protein
)	O
.	O

We	O
present	O
evidence	O
that	O
IBR	B-Protein
and	O
IBF	B-Protein
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O
<EOS>	B-X
Initiation	B-X
binding	B-X
repressor	B-X
[	B-X
corrected	B-X
]	B-X
(	B-X
IBR	B-X
)	B-X
is	B-X
a	B-X
chicken	B-X
erythrocyte	B-X
factor	B-X
(	B-X
apparent	B-X
molecular	B-X
mass	B-X
,	B-X
70	B-X
to	B-X
73	B-X
kDa	B-X
)	B-X
that	B-X
binds	B-X
to	B-X
the	B-X
sequences	B-X
spanning	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
of	B-X
the	B-X
histone	B-X
h5	B-X
gene	B-X
,	B-X
repressing	B-X
its	B-X
transcription	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
other	B-X
cells	B-X
,	B-X
including	B-X
transformed	B-X
erythroid	B-X
precursors	B-X
,	B-X
do	B-X
not	B-X
have	B-X
IBR	B-X
but	B-X
a	B-X
factor	B-X
referred	B-X
to	B-X
as	B-X
IBF	B-X
(	B-X
68	B-X
to	B-X
70	B-X
kDa	B-X
)	B-X
that	B-X
recognizes	B-X
the	B-X
same	B-X
IBR	B-X
sites	B-X
.	B-X
We	B-X
have	B-X
cloned	B-X
the	B-X
IBR	B-X
cDNA	B-X
and	B-X
studied	B-X
the	B-X
relationship	B-X
of	B-X
IBR	B-X
and	B-X
IBF	B-X
.	B-X
IBR	B-X
is	B-X
a	B-X
503-amino-acid-long	B-X
acidic	B-X
protein	B-X
which	B-X
is	B-X
99.0	B-X
%	B-X
identical	B-X
to	B-X
the	B-X
recently	B-X
reported	B-X
human	B-X
NRF-1/alpha-Pal	B-X
factor	B-X
and	B-X
highly	B-X
related	B-X
to	B-X
the	B-X
invertebrate	B-X
transcription	B-X
factors	B-X
P3A2	B-X
and	B-X
erected	B-X
wing	B-X
gene	B-X
product	B-X
(	B-X
EWG	B-X
)	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
IBR	B-X
and	B-X
IBF	B-X
are	B-X
most	B-X
likely	B-X
identical	B-X
proteins	B-X
,	B-X
differing	B-X
in	B-X
their	B-X
degree	B-X
of	B-X
glycosylation	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
several	B-X
molecular	B-X
aspects	B-X
of	B-X
IBR/F	B-X
and	B-X
shown	B-X
that	B-X
the	B-X
factor	B-X
associates	B-X
as	B-X
stable	B-X
homodimers	B-X
and	B-X
that	B-X
the	B-X
dimer	B-X
is	B-X
the	B-X
relevant	B-X
DNA-binding	B-X
species	B-X
.	B-X
The	B-X
evolutionarily	B-X
conserved	B-X
N-terminal	B-X
half	B-X
of	B-X
IBR/F	B-X
harbors	B-X
the	B-X
DNA-binding/dimerization	B-X
domain	B-X
(	B-X
outer	B-X
limits	B-X
,	B-X
127	B-X
to	B-X
283	B-X
)	B-X
,	B-X
one	B-X
or	B-X
several	B-X
casein	B-X
kinase	B-X
II	B-X
sites	B-X
(	B-X
37	B-X
to	B-X
67	B-X
)	B-X
,	B-X
and	B-X
a	B-X
bipartite	B-X
nuclear	B-X
localization	B-X
signal	B-X
(	B-X
89	B-X
to	B-X
106	B-X
)	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
nuclear	B-X
targeting	B-X
.	B-X
Binding	B-X
site	B-X
selection	B-X
revealed	B-X
that	B-X
the	B-X
alternating	B-X
RCGCRYGCGY	B-X
consensus	B-X
constitutes	B-X
high-affinity	B-X
IBR/F	B-X
binding	B-X
sites	B-X
and	B-X
that	B-X
the	B-X
direct-repeat	B-X
palindrome	B-X
TGCGCATGCGCA	B-X
is	B-X
the	B-X
optimal	B-X
site	B-X
.	B-X

We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR	B-Protein
/	O
F	B-Protein
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	O
and	O
that	O
the	O
dimer	O
is	O
the	O
relevant	O
DNA	O
-	O
binding	O
species	O
.	O
<EOS>	B-X
Initiation	B-X
binding	B-X
repressor	B-X
[	B-X
corrected	B-X
]	B-X
(	B-X
IBR	B-X
)	B-X
is	B-X
a	B-X
chicken	B-X
erythrocyte	B-X
factor	B-X
(	B-X
apparent	B-X
molecular	B-X
mass	B-X
,	B-X
70	B-X
to	B-X
73	B-X
kDa	B-X
)	B-X
that	B-X
binds	B-X
to	B-X
the	B-X
sequences	B-X
spanning	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
of	B-X
the	B-X
histone	B-X
h5	B-X
gene	B-X
,	B-X
repressing	B-X
its	B-X
transcription	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
other	B-X
cells	B-X
,	B-X
including	B-X
transformed	B-X
erythroid	B-X
precursors	B-X
,	B-X
do	B-X
not	B-X
have	B-X
IBR	B-X
but	B-X
a	B-X
factor	B-X
referred	B-X
to	B-X
as	B-X
IBF	B-X
(	B-X
68	B-X
to	B-X
70	B-X
kDa	B-X
)	B-X
that	B-X
recognizes	B-X
the	B-X
same	B-X
IBR	B-X
sites	B-X
.	B-X
We	B-X
have	B-X
cloned	B-X
the	B-X
IBR	B-X
cDNA	B-X
and	B-X
studied	B-X
the	B-X
relationship	B-X
of	B-X
IBR	B-X
and	B-X
IBF	B-X
.	B-X
IBR	B-X
is	B-X
a	B-X
503-amino-acid-long	B-X
acidic	B-X
protein	B-X
which	B-X
is	B-X
99.0	B-X
%	B-X
identical	B-X
to	B-X
the	B-X
recently	B-X
reported	B-X
human	B-X
NRF-1/alpha-Pal	B-X
factor	B-X
and	B-X
highly	B-X
related	B-X
to	B-X
the	B-X
invertebrate	B-X
transcription	B-X
factors	B-X
P3A2	B-X
and	B-X
erected	B-X
wing	B-X
gene	B-X
product	B-X
(	B-X
EWG	B-X
)	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
IBR	B-X
and	B-X
IBF	B-X
are	B-X
most	B-X
likely	B-X
identical	B-X
proteins	B-X
,	B-X
differing	B-X
in	B-X
their	B-X
degree	B-X
of	B-X
glycosylation	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
several	B-X
molecular	B-X
aspects	B-X
of	B-X
IBR/F	B-X
and	B-X
shown	B-X
that	B-X
the	B-X
factor	B-X
associates	B-X
as	B-X
stable	B-X
homodimers	B-X
and	B-X
that	B-X
the	B-X
dimer	B-X
is	B-X
the	B-X
relevant	B-X
DNA-binding	B-X
species	B-X
.	B-X
The	B-X
evolutionarily	B-X
conserved	B-X
N-terminal	B-X
half	B-X
of	B-X
IBR/F	B-X
harbors	B-X
the	B-X
DNA-binding/dimerization	B-X
domain	B-X
(	B-X
outer	B-X
limits	B-X
,	B-X
127	B-X
to	B-X
283	B-X
)	B-X
,	B-X
one	B-X
or	B-X
several	B-X
casein	B-X
kinase	B-X
II	B-X
sites	B-X
(	B-X
37	B-X
to	B-X
67	B-X
)	B-X
,	B-X
and	B-X
a	B-X
bipartite	B-X
nuclear	B-X
localization	B-X
signal	B-X
(	B-X
89	B-X
to	B-X
106	B-X
)	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
nuclear	B-X
targeting	B-X
.	B-X
Binding	B-X
site	B-X
selection	B-X
revealed	B-X
that	B-X
the	B-X
alternating	B-X
RCGCRYGCGY	B-X
consensus	B-X
constitutes	B-X
high-affinity	B-X
IBR/F	B-X
binding	B-X
sites	B-X
and	B-X
that	B-X
the	B-X
direct-repeat	B-X
palindrome	B-X
TGCGCATGCGCA	B-X
is	B-X
the	B-X
optimal	B-X
site	B-X
.	B-X
A	B-X
survey	B-X
of	B-X
genes	B-X
potentially	B-X
regulated	B-X
by	B-X
this	B-X
family	B-X
of	B-X
factors	B-X
primarily	B-X
revealed	B-X
genes	B-X
involved	B-X
in	B-X
growth-related	B-X
metabolism	B-X
.	B-X

The	O
evolutionarily	O
conserved	O
N	O
-	O
terminal	O
half	O
of	O
IBR	B-Protein
/	O
F	B-Protein
harbors	O
the	O
DNA	O
-	O
binding	O
/	O
dimerization	O
domain	O
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	O
kinase	O
II	O
sites	O
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	O
nuclear	O
localization	O
signal	O
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O

Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	O
RCGCRYGCGY	O
consensus	O
constitutes	O
high	O
-	O
affinity	O
IBR	B-Protein
/	O
F	B-Protein
binding	O
sites	O
and	O
that	O
the	O
direct	O
-	O
repeat	O
palindrome	O
TGCGCATGCGCA	O
is	O
the	O
optimal	O
site	O
.	O
<EOS>	B-X
Initiation	B-X
binding	B-X
repressor	B-X
[	B-X
corrected	B-X
]	B-X
(	B-X
IBR	B-X
)	B-X
is	B-X
a	B-X
chicken	B-X
erythrocyte	B-X
factor	B-X
(	B-X
apparent	B-X
molecular	B-X
mass	B-X
,	B-X
70	B-X
to	B-X
73	B-X
kDa	B-X
)	B-X
that	B-X
binds	B-X
to	B-X
the	B-X
sequences	B-X
spanning	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
of	B-X
the	B-X
histone	B-X
h5	B-X
gene	B-X
,	B-X
repressing	B-X
its	B-X
transcription	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
other	B-X
cells	B-X
,	B-X
including	B-X
transformed	B-X
erythroid	B-X
precursors	B-X
,	B-X
do	B-X
not	B-X
have	B-X
IBR	B-X
but	B-X
a	B-X
factor	B-X
referred	B-X
to	B-X
as	B-X
IBF	B-X
(	B-X
68	B-X
to	B-X
70	B-X
kDa	B-X
)	B-X
that	B-X
recognizes	B-X
the	B-X
same	B-X
IBR	B-X
sites	B-X
.	B-X
We	B-X
have	B-X
cloned	B-X
the	B-X
IBR	B-X
cDNA	B-X
and	B-X
studied	B-X
the	B-X
relationship	B-X
of	B-X
IBR	B-X
and	B-X
IBF	B-X
.	B-X
IBR	B-X
is	B-X
a	B-X
503-amino-acid-long	B-X
acidic	B-X
protein	B-X
which	B-X
is	B-X
99.0	B-X
%	B-X
identical	B-X
to	B-X
the	B-X
recently	B-X
reported	B-X
human	B-X
NRF-1/alpha-Pal	B-X
factor	B-X
and	B-X
highly	B-X
related	B-X
to	B-X
the	B-X
invertebrate	B-X
transcription	B-X
factors	B-X
P3A2	B-X
and	B-X
erected	B-X
wing	B-X
gene	B-X
product	B-X
(	B-X
EWG	B-X
)	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
IBR	B-X
and	B-X
IBF	B-X
are	B-X
most	B-X
likely	B-X
identical	B-X
proteins	B-X
,	B-X
differing	B-X
in	B-X
their	B-X
degree	B-X
of	B-X
glycosylation	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
several	B-X
molecular	B-X
aspects	B-X
of	B-X
IBR/F	B-X
and	B-X
shown	B-X
that	B-X
the	B-X
factor	B-X
associates	B-X
as	B-X
stable	B-X
homodimers	B-X
and	B-X
that	B-X
the	B-X
dimer	B-X
is	B-X
the	B-X
relevant	B-X
DNA-binding	B-X
species	B-X
.	B-X
The	B-X
evolutionarily	B-X
conserved	B-X
N-terminal	B-X
half	B-X
of	B-X
IBR/F	B-X
harbors	B-X
the	B-X
DNA-binding/dimerization	B-X
domain	B-X
(	B-X
outer	B-X
limits	B-X
,	B-X
127	B-X
to	B-X
283	B-X
)	B-X
,	B-X
one	B-X
or	B-X
several	B-X
casein	B-X
kinase	B-X
II	B-X
sites	B-X
(	B-X
37	B-X
to	B-X
67	B-X
)	B-X
,	B-X
and	B-X
a	B-X
bipartite	B-X
nuclear	B-X
localization	B-X
signal	B-X
(	B-X
89	B-X
to	B-X
106	B-X
)	B-X
which	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
nuclear	B-X
targeting	B-X
.	B-X
Binding	B-X
site	B-X
selection	B-X
revealed	B-X
that	B-X
the	B-X
alternating	B-X
RCGCRYGCGY	B-X
consensus	B-X
constitutes	B-X
high-affinity	B-X
IBR/F	B-X
binding	B-X
sites	B-X
and	B-X
that	B-X
the	B-X
direct-repeat	B-X
palindrome	B-X
TGCGCATGCGCA	B-X
is	B-X
the	B-X
optimal	B-X
site	B-X
.	B-X
A	B-X
survey	B-X
of	B-X
genes	B-X
potentially	B-X
regulated	B-X
by	B-X
this	B-X
family	B-X
of	B-X
factors	B-X
primarily	B-X
revealed	B-X
genes	B-X
involved	B-X
in	B-X
growth-related	B-X
metabolism	B-X
.	B-X

A	O
survey	O
of	O
genes	O
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	O
primarily	O
revealed	O
genes	O
involved	O
in	O
growth	O
-	O
related	O
metabolism	O
.	O
<EOS>	B-X
Identification	B-X
of	B-X
specific	B-X
genes	B-X
or	B-X
signaling	B-X
pathways	B-X
involved	B-X
in	B-X
development	B-X
of	B-X
melanoma	B-X
could	B-X
lead	B-X
to	B-X
new	B-X
therapies	B-X
that	B-X
target	B-X
and	B-X
correct	B-X
these	B-X
defects	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
revealed	B-X
deregulation	B-X
of	B-X
the	B-X
Akt	B-X
signaling	B-X
pathway	B-X
occurring	B-X
in	B-X
43-67	B-X
%	B-X
of	B-X
melanomas	B-X
.	B-X
Akt	B-X
kinase	B-X
family	B-X
members	B-X
,	B-X
Akt1/PKBalpha	B-X
,	B-X
Akt2/PKBbeta	B-X
and	B-X
Akt3/PKBgamma	B-X
,	B-X
share	B-X
extensive	B-X
structural	B-X
similarity	B-X
and	B-X
perform	B-X
common	B-X
as	B-X
well	B-X
as	B-X
unique	B-X
functions	B-X
within	B-X
cells	B-X
.	B-X
The	B-X
Akt	B-X
signaling	B-X
cascade	B-X
initiates	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
when	B-X
growth	B-X
factors	B-X
or	B-X
other	B-X
extracellular	B-X
stimuli	B-X
activate	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
.	B-X
The	B-X
balance	B-X
of	B-X
cellular	B-X
PIP3	B-X
is	B-X
regulated	B-X
primarily	B-X
by	B-X
a	B-X
phosphatase	B-X
called	B-X
PTEN	B-X
that	B-X
reduces	B-X
PIP3	B-X
levels	B-X
thereby	B-X
lowering	B-X
Akt	B-X
activity	B-X
.	B-X
This	B-X
review	B-X
surveys	B-X
recent	B-X
developments	B-X
in	B-X
Akt	B-X
deregulation	B-X
in	B-X
melanoma	B-X
and	B-X
its	B-X
potential	B-X
as	B-X
a	B-X
selective	B-X
therapeutic	B-X
target	B-X
in	B-X
patients	B-X
in	B-X
the	B-X
advanced	B-X
stages	B-X
of	B-X
this	B-X
disease	B-X
.	B-X

Inhibition	O
of	O
NF	O
-	O
AT	O
signal	O
transduction	O
events	O
by	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
calcineurin	O
.	O
<EOS>	B-X
An	B-X
inhibitory	B-X
,	B-X
``	B-X
dominant-negative	B-X
,	B-X
''	B-X
form	B-X
of	B-X
the	B-X
calcineurin	B-X
catalytic	B-X
(	B-X
A	B-X
)	B-X
subunit	B-X
was	B-X
prepared	B-X
,	B-X
which	B-X
lacks	B-X
the	B-X
calmodulin-binding	B-X
domain	B-X
,	B-X
autoinhibitory	B-X
domain	B-X
and	B-X
most	B-X
of	B-X
its	B-X
catalytic	B-X
core	B-X
but	B-X
possesses	B-X
the	B-X
regulatory	B-X
(	B-X
B	B-X
)	B-X
subunit	B-X
binding	B-X
domain	B-X
.	B-X
When	B-X
tested	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
block	B-X
calcineurin-dependent	B-X
signaling	B-X
in	B-X
Jurkat	B-X
cells	B-X
,	B-X
expression	B-X
of	B-X
this	B-X
``	B-X
B-subunit	B-X
knock-out	B-X
''	B-X
(	B-X
BKO	B-X
)	B-X
construct	B-X
suppressed	B-X
reporter	B-X
gene	B-X
activity	B-X
driven	B-X
by	B-X
NF-AT	B-X
,	B-X
the	B-X
pivotal	B-X
promoter	B-X
element	B-X
for	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
gene	B-X
induction	B-X
.	B-X
Immunoprecipitation	B-X
of	B-X
epitope-labeled	B-X
BKO	B-X
demonstrated	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
tight	B-X
complex	B-X
with	B-X
endogenous	B-X
B	B-X
subunit	B-X
in	B-X
Jurkat	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
an	B-X
inhibitory	B-X
mechanism	B-X
that	B-X
involves	B-X
the	B-X
sequestration	B-X
of	B-X
the	B-X
B	B-X
subunit	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
sharply	B-X
reduced	B-X
NF-AT	B-X
activity	B-X
produced	B-X
by	B-X
co-transfecting	B-X
BKO	B-X
could	B-X
be	B-X
``	B-X
rescued	B-X
''	B-X
by	B-X
overexpression	B-X
of	B-X
transfected	B-X
B	B-X
subunit	B-X
,	B-X
suggesting	B-X
that	B-X
depletion	B-X
of	B-X
this	B-X
subunit	B-X
was	B-X
responsible	B-X
for	B-X
the	B-X
inhibition	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
the	B-X
potential	B-X
utility	B-X
of	B-X
agents	B-X
that	B-X
disrupt	B-X
calcineurin-mediated	B-X
signal	B-X
transduction	B-X
pathways	B-X
by	B-X
blocking	B-X
formation	B-X
of	B-X
the	B-X
catalytically	B-X
active	B-X
dimer	B-X
of	B-X
calcineurin	B-X
A	B-X
and	B-X
B	B-X
subunits	B-X
.	B-X

An	O
inhibitory	O
,	O
"	O
dominant	O
-	O
negative	O
,	O
"	O
form	O
of	O
the	O
calcineurin	B-Protein
catalytic	I-Protein
(	I-Protein
A	I-Protein
)	I-Protein
subunit	I-Protein
was	O
prepared	O
,	O
which	O
lacks	O
the	O
calmodulin	B-Protein
-	O
binding	O
domain	O
,	O
autoinhibitory	O
domain	O
and	O
most	O
of	O
its	O
catalytic	O
core	O
but	O
possesses	O
the	O
regulatory	B-Protein
(	I-Protein
B	I-Protein
)	I-Protein
subunit	I-Protein
binding	O
domain	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	O
-	O
dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
"	O
B	O
-	O
subunit	O
knock	O
-	O
out	O
"	O
(	O
BKO	O
)	O
construct	O
suppressed	O
reporter	O
gene	O
activity	O
driven	O
by	O
NF	O
-	O
AT	O
,	O
the	O
pivotal	O
promoter	O
element	O
for	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
2	I-Protein
gene	O
induction	O
.	O
<EOS>	B-X
An	B-X
inhibitory	B-X
,	B-X
``	B-X
dominant-negative	B-X
,	B-X
''	B-X
form	B-X
of	B-X
the	B-X
calcineurin	B-X
catalytic	B-X
(	B-X
A	B-X
)	B-X
subunit	B-X
was	B-X
prepared	B-X
,	B-X
which	B-X
lacks	B-X
the	B-X
calmodulin-binding	B-X
domain	B-X
,	B-X
autoinhibitory	B-X
domain	B-X
and	B-X
most	B-X
of	B-X
its	B-X
catalytic	B-X
core	B-X
but	B-X
possesses	B-X
the	B-X
regulatory	B-X
(	B-X
B	B-X
)	B-X
subunit	B-X
binding	B-X
domain	B-X
.	B-X
When	B-X
tested	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
block	B-X
calcineurin-dependent	B-X
signaling	B-X
in	B-X
Jurkat	B-X
cells	B-X
,	B-X
expression	B-X
of	B-X
this	B-X
``	B-X
B-subunit	B-X
knock-out	B-X
''	B-X
(	B-X
BKO	B-X
)	B-X
construct	B-X
suppressed	B-X
reporter	B-X
gene	B-X
activity	B-X
driven	B-X
by	B-X
NF-AT	B-X
,	B-X
the	B-X
pivotal	B-X
promoter	B-X
element	B-X
for	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
gene	B-X
induction	B-X
.	B-X
Immunoprecipitation	B-X
of	B-X
epitope-labeled	B-X
BKO	B-X
demonstrated	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
tight	B-X
complex	B-X
with	B-X
endogenous	B-X
B	B-X
subunit	B-X
in	B-X
Jurkat	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
an	B-X
inhibitory	B-X
mechanism	B-X
that	B-X
involves	B-X
the	B-X
sequestration	B-X
of	B-X
the	B-X
B	B-X
subunit	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
sharply	B-X
reduced	B-X
NF-AT	B-X
activity	B-X
produced	B-X
by	B-X
co-transfecting	B-X
BKO	B-X
could	B-X
be	B-X
``	B-X
rescued	B-X
''	B-X
by	B-X
overexpression	B-X
of	B-X
transfected	B-X
B	B-X
subunit	B-X
,	B-X
suggesting	B-X
that	B-X
depletion	B-X
of	B-X
this	B-X
subunit	B-X
was	B-X
responsible	B-X
for	B-X
the	B-X
inhibition	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
the	B-X
potential	B-X
utility	B-X
of	B-X
agents	B-X
that	B-X
disrupt	B-X
calcineurin-mediated	B-X
signal	B-X
transduction	B-X
pathways	B-X
by	B-X
blocking	B-X
formation	B-X
of	B-X
the	B-X
catalytically	B-X
active	B-X
dimer	B-X
of	B-X
calcineurin	B-X
A	B-X
and	B-X
B	B-X
subunits	B-X
.	B-X

Immunoprecipitation	O
of	O
epitope	O
-	O
labeled	O
BKO	O
demonstrated	O
for	O
the	O
formation	O
of	O
a	O
tight	O
complex	O
with	O
endogenous	B-Protein
B	I-Protein
subunit	I-Protein
in	O
Jurkat	O
cells	O
,	O
consistent	O
with	O
an	O
inhibitory	O
mechanism	O
that	O
involves	O
the	O
sequestration	O
of	O
the	O
B	B-Protein
subunit	I-Protein
.	O

Furthermore	O
,	O
the	O
sharply	O
reduced	O
NF	O
-	O
AT	O
activity	O
produced	O
by	O
co	O
-	O
transfecting	O
BKO	O
could	O
be	O
"	O
rescued	O
"	O
by	O
overexpression	O
of	O
transfected	O
B	B-Protein
subunit	I-Protein
,	O
suggesting	O
that	O
depletion	O
of	O
this	O
subunit	O
was	O
responsible	O
for	O
the	O
inhibition	O
.	O
<EOS>	B-X
An	B-X
inhibitory	B-X
,	B-X
``	B-X
dominant-negative	B-X
,	B-X
''	B-X
form	B-X
of	B-X
the	B-X
calcineurin	B-X
catalytic	B-X
(	B-X
A	B-X
)	B-X
subunit	B-X
was	B-X
prepared	B-X
,	B-X
which	B-X
lacks	B-X
the	B-X
calmodulin-binding	B-X
domain	B-X
,	B-X
autoinhibitory	B-X
domain	B-X
and	B-X
most	B-X
of	B-X
its	B-X
catalytic	B-X
core	B-X
but	B-X
possesses	B-X
the	B-X
regulatory	B-X
(	B-X
B	B-X
)	B-X
subunit	B-X
binding	B-X
domain	B-X
.	B-X
When	B-X
tested	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
block	B-X
calcineurin-dependent	B-X
signaling	B-X
in	B-X
Jurkat	B-X
cells	B-X
,	B-X
expression	B-X
of	B-X
this	B-X
``	B-X
B-subunit	B-X
knock-out	B-X
''	B-X
(	B-X
BKO	B-X
)	B-X
construct	B-X
suppressed	B-X
reporter	B-X
gene	B-X
activity	B-X
driven	B-X
by	B-X
NF-AT	B-X
,	B-X
the	B-X
pivotal	B-X
promoter	B-X
element	B-X
for	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
gene	B-X
induction	B-X
.	B-X
Immunoprecipitation	B-X
of	B-X
epitope-labeled	B-X
BKO	B-X
demonstrated	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
tight	B-X
complex	B-X
with	B-X
endogenous	B-X
B	B-X
subunit	B-X
in	B-X
Jurkat	B-X
cells	B-X
,	B-X
consistent	B-X
with	B-X
an	B-X
inhibitory	B-X
mechanism	B-X
that	B-X
involves	B-X
the	B-X
sequestration	B-X
of	B-X
the	B-X
B	B-X
subunit	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
sharply	B-X
reduced	B-X
NF-AT	B-X
activity	B-X
produced	B-X
by	B-X
co-transfecting	B-X
BKO	B-X
could	B-X
be	B-X
``	B-X
rescued	B-X
''	B-X
by	B-X
overexpression	B-X
of	B-X
transfected	B-X
B	B-X
subunit	B-X
,	B-X
suggesting	B-X
that	B-X
depletion	B-X
of	B-X
this	B-X
subunit	B-X
was	B-X
responsible	B-X
for	B-X
the	B-X
inhibition	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
the	B-X
potential	B-X
utility	B-X
of	B-X
agents	B-X
that	B-X
disrupt	B-X
calcineurin-mediated	B-X
signal	B-X
transduction	B-X
pathways	B-X
by	B-X
blocking	B-X
formation	B-X
of	B-X
the	B-X
catalytically	B-X
active	B-X
dimer	B-X
of	B-X
calcineurin	B-X
A	B-X
and	B-X
B	B-X
subunits	B-X
.	B-X

These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin	O
-	O
mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	O
formation	O
of	O
the	O
catalytically	O
active	O
dimer	O
of	O
calcineurin	B-Protein
A	I-Protein
and	O
B	B-Protein
subunits	I-Protein
.	O

Modulation	O
of	O
endogenous	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
antagonist	I-Protein
results	O
in	O
opposing	O
effects	O
on	O
HIV	O
expression	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O
<EOS>	B-X
A	B-X
proportion	B-X
of	B-X
HIV-infected	B-X
individuals	B-X
experience	B-X
episodes	B-X
of	B-X
localized	B-X
or	B-X
systemic	B-X
bacterial	B-X
infections	B-X
caused	B-X
by	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
clinical	B-X
side	B-X
effects	B-X
of	B-X
these	B-X
infections	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
primarily	B-X
by	B-X
LPS	B-X
,	B-X
a	B-X
constituent	B-X
of	B-X
the	B-X
bacterial	B-X
cell	B-X
wall	B-X
of	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
The	B-X
present	B-X
study	B-X
examines	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
induction	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
,	B-X
a	B-X
promonocytic	B-X
cell	B-X
line	B-X
chronically	B-X
infected	B-X
with	B-X
HIV	B-X
.	B-X
Stimulation	B-X
of	B-X
U1	B-X
cells	B-X
by	B-X
LPS	B-X
alone	B-X
induced	B-X
minimal	B-X
levels	B-X
of	B-X
HIV	B-X
expression	B-X
,	B-X
which	B-X
was	B-X
significantly	B-X
enhanced	B-X
by	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
.	B-X
Costimulation	B-X
of	B-X
U1	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
of	B-X
steady-state	B-X
levels	B-X
of	B-X
HIV	B-X
RNA	B-X
;	B-X
however	B-X
,	B-X
only	B-X
a	B-X
weak	B-X
induction	B-X
of	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat-driven	B-X
transcription	B-X
,	B-X
which	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cellular	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
,	B-X
was	B-X
noted	B-X
.	B-X
Costimulation	B-X
of	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
induced	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
IL-8	B-X
,	B-X
IL-1	B-X
beta	B-X
and	B-X
IL-6	B-X
,	B-X
but	B-X
not	B-X
TNF-alpha	B-X
.	B-X
IL-1	B-X
receptor	B-X
antagonist	B-X
(	B-X
ra	B-X
)	B-X
inhibited	B-X
LPS	B-X
enhancement	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
GM-CSF-stimulated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
endogenous	B-X
IL-1	B-X
was	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
viral	B-X
production	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
anti-inflammatory	B-X
cytokines	B-X
inhibited	B-X
LPS	B-X
plus	B-X
GM-CSF-stimulated	B-X
HIV	B-X
expression	B-X
,	B-X
and	B-X
this	B-X
effect	B-X
closely	B-X
correlated	B-X
with	B-X
inhibition	B-X
of	B-X
IL-1	B-X
beta	B-X
release	B-X
and	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
with	B-X
up-regulation	B-X
of	B-X
endogenous	B-X
IL-1ra	B-X
production	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
balance	B-X
between	B-X
an	B-X
endogenously	B-X
produced	B-X
viral	B-X
inducer	B-X
(	B-X
IL-1	B-X
beta	B-X
)	B-X
and	B-X
an	B-X
inhibitor	B-X
(	B-X
IL-1ra	B-X
)	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
pathway	B-X
leading	B-X
to	B-X
modulation	B-X
of	B-X
HIV	B-X
expression	B-X
from	B-X
monocytic	B-X
cells	B-X
.	B-X

A	O
proportion	O
of	O
HIV	O
-	O
infected	O
individuals	O
experience	O
episodes	O
of	O
localized	O
or	O
systemic	O
bacterial	O
infections	O
caused	O
by	O
Gram	O
-	O
negative	O
bacteria	O
.	O
<EOS>	B-X
Since	B-X
first	B-X
identified	B-X
in	B-X
early	B-X
1977	B-X
,	B-X
bacteria	B-X
of	B-X
the	B-X
genus	B-X
Legionella	B-X
are	B-X
recognised	B-X
as	B-X
a	B-X
common	B-X
cause	B-X
of	B-X
community-acquired	B-X
pneumonia	B-X
and	B-X
a	B-X
rare	B-X
cause	B-X
of	B-X
hospital-acquired	B-X
pneumonia	B-X
.	B-X
Legionella	B-X
bacteria	B-X
multisystem	B-X
manifestations	B-X
mainly	B-X
affect	B-X
susceptible	B-X
patients	B-X
as	B-X
a	B-X
result	B-X
of	B-X
age	B-X
,	B-X
underlying	B-X
debilitating	B-X
conditions	B-X
,	B-X
or	B-X
immunosuppression	B-X
.	B-X
The	B-X
term	B-X
given	B-X
to	B-X
the	B-X
severe	B-X
pneumonia	B-X
and	B-X
systemic	B-X
infection	B-X
caused	B-X
by	B-X
Legionella	B-X
bacteria	B-X
is	B-X
Legionnaires	B-X
'	B-X
disease	B-X
.	B-X
The	B-X
most	B-X
common	B-X
atypical	B-X
pneumonias	B-X
are	B-X
caused	B-X
by	B-X
three	B-X
zoonotic	B-X
pathogens	B-X
,	B-X
Chlamydia	B-X
psittaci	B-X
(	B-X
psittacosis	B-X
)	B-X
,	B-X
Francisella	B-X
tularensis	B-X
(	B-X
tularemia	B-X
)	B-X
,	B-X
and	B-X
Coxiella	B-X
burnetii	B-X
(	B-X
Q	B-X
fever	B-X
)	B-X
,	B-X
and	B-X
three	B-X
nonzoonotic	B-X
pathogens	B-X
,	B-X
Chlamydia	B-X
pneumoniae	B-X
,	B-X
Mycoplasma	B-X
pneumoniae	B-X
,	B-X
and	B-X
Legionella	B-X
.	B-X
Atypical	B-X
CAPs	B-X
are	B-X
systemic	B-X
infectious	B-X
diseases	B-X
with	B-X
a	B-X
pulmonary	B-X
component	B-X
and	B-X
may	B-X
be	B-X
differentiated	B-X
clinically	B-X
from	B-X
typical	B-X
CAPs	B-X
by	B-X
the	B-X
pattern	B-X
of	B-X
extrapulmonary	B-X
organ	B-X
involvement	B-X
which	B-X
is	B-X
characteristic	B-X
for	B-X
each	B-X
atypical	B-X
CAP	B-X
.	B-X
Zoonotic	B-X
pneumonias	B-X
may	B-X
be	B-X
eliminated	B-X
from	B-X
diagnostic	B-X
consideration	B-X
with	B-X
a	B-X
negative	B-X
contact	B-X
history	B-X
.	B-X

Many	O
of	O
the	O
clinical	O
side	O
effects	O
of	O
these	O
infections	O
are	O
associated	O
with	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
which	O
are	O
induced	O
primarily	O
by	O
LPS	O
,	O
a	O
constituent	O
of	O
the	O
bacterial	O
cell	O
wall	O
of	O
Gram	O
-	O
negative	O
bacteria	O
.	O
<EOS>	B-X
A	B-X
proportion	B-X
of	B-X
HIV-infected	B-X
individuals	B-X
experience	B-X
episodes	B-X
of	B-X
localized	B-X
or	B-X
systemic	B-X
bacterial	B-X
infections	B-X
caused	B-X
by	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
clinical	B-X
side	B-X
effects	B-X
of	B-X
these	B-X
infections	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
primarily	B-X
by	B-X
LPS	B-X
,	B-X
a	B-X
constituent	B-X
of	B-X
the	B-X
bacterial	B-X
cell	B-X
wall	B-X
of	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
The	B-X
present	B-X
study	B-X
examines	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
induction	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
,	B-X
a	B-X
promonocytic	B-X
cell	B-X
line	B-X
chronically	B-X
infected	B-X
with	B-X
HIV	B-X
.	B-X
Stimulation	B-X
of	B-X
U1	B-X
cells	B-X
by	B-X
LPS	B-X
alone	B-X
induced	B-X
minimal	B-X
levels	B-X
of	B-X
HIV	B-X
expression	B-X
,	B-X
which	B-X
was	B-X
significantly	B-X
enhanced	B-X
by	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
.	B-X
Costimulation	B-X
of	B-X
U1	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
of	B-X
steady-state	B-X
levels	B-X
of	B-X
HIV	B-X
RNA	B-X
;	B-X
however	B-X
,	B-X
only	B-X
a	B-X
weak	B-X
induction	B-X
of	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat-driven	B-X
transcription	B-X
,	B-X
which	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cellular	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
,	B-X
was	B-X
noted	B-X
.	B-X
Costimulation	B-X
of	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
induced	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
IL-8	B-X
,	B-X
IL-1	B-X
beta	B-X
and	B-X
IL-6	B-X
,	B-X
but	B-X
not	B-X
TNF-alpha	B-X
.	B-X
IL-1	B-X
receptor	B-X
antagonist	B-X
(	B-X
ra	B-X
)	B-X
inhibited	B-X
LPS	B-X
enhancement	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
GM-CSF-stimulated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
endogenous	B-X
IL-1	B-X
was	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
viral	B-X
production	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
anti-inflammatory	B-X
cytokines	B-X
inhibited	B-X
LPS	B-X
plus	B-X
GM-CSF-stimulated	B-X
HIV	B-X
expression	B-X
,	B-X
and	B-X
this	B-X
effect	B-X
closely	B-X
correlated	B-X
with	B-X
inhibition	B-X
of	B-X
IL-1	B-X
beta	B-X
release	B-X
and	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
with	B-X
up-regulation	B-X
of	B-X
endogenous	B-X
IL-1ra	B-X
production	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
balance	B-X
between	B-X
an	B-X
endogenously	B-X
produced	B-X
viral	B-X
inducer	B-X
(	B-X
IL-1	B-X
beta	B-X
)	B-X
and	B-X
an	B-X
inhibitor	B-X
(	B-X
IL-1ra	B-X
)	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
pathway	B-X
leading	B-X
to	B-X
modulation	B-X
of	B-X
HIV	B-X
expression	B-X
from	B-X
monocytic	B-X
cells	B-X
.	B-X

The	O
present	O
study	O
examines	O
the	O
mechanisms	O
involved	O
in	O
LPS	O
-	O
mediated	O
induction	O
of	O
HIV	O
expression	O
in	O
U1	O
cells	O
,	O
a	O
promonocytic	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
.	O

Stimulation	O
of	O
U1	O
cells	O
by	O
LPS	O
alone	O
induced	O
minimal	O
levels	O
of	O
HIV	O
expression	O
,	O
which	O
was	O
significantly	O
enhanced	O
by	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
.	O
<EOS>	B-X
A	B-X
proportion	B-X
of	B-X
HIV-infected	B-X
individuals	B-X
experience	B-X
episodes	B-X
of	B-X
localized	B-X
or	B-X
systemic	B-X
bacterial	B-X
infections	B-X
caused	B-X
by	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
clinical	B-X
side	B-X
effects	B-X
of	B-X
these	B-X
infections	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
primarily	B-X
by	B-X
LPS	B-X
,	B-X
a	B-X
constituent	B-X
of	B-X
the	B-X
bacterial	B-X
cell	B-X
wall	B-X
of	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
The	B-X
present	B-X
study	B-X
examines	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
induction	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
,	B-X
a	B-X
promonocytic	B-X
cell	B-X
line	B-X
chronically	B-X
infected	B-X
with	B-X
HIV	B-X
.	B-X
Stimulation	B-X
of	B-X
U1	B-X
cells	B-X
by	B-X
LPS	B-X
alone	B-X
induced	B-X
minimal	B-X
levels	B-X
of	B-X
HIV	B-X
expression	B-X
,	B-X
which	B-X
was	B-X
significantly	B-X
enhanced	B-X
by	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
.	B-X
Costimulation	B-X
of	B-X
U1	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
of	B-X
steady-state	B-X
levels	B-X
of	B-X
HIV	B-X
RNA	B-X
;	B-X
however	B-X
,	B-X
only	B-X
a	B-X
weak	B-X
induction	B-X
of	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat-driven	B-X
transcription	B-X
,	B-X
which	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cellular	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
,	B-X
was	B-X
noted	B-X
.	B-X
Costimulation	B-X
of	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
induced	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
IL-8	B-X
,	B-X
IL-1	B-X
beta	B-X
and	B-X
IL-6	B-X
,	B-X
but	B-X
not	B-X
TNF-alpha	B-X
.	B-X
IL-1	B-X
receptor	B-X
antagonist	B-X
(	B-X
ra	B-X
)	B-X
inhibited	B-X
LPS	B-X
enhancement	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
GM-CSF-stimulated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
endogenous	B-X
IL-1	B-X
was	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
viral	B-X
production	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
anti-inflammatory	B-X
cytokines	B-X
inhibited	B-X
LPS	B-X
plus	B-X
GM-CSF-stimulated	B-X
HIV	B-X
expression	B-X
,	B-X
and	B-X
this	B-X
effect	B-X
closely	B-X
correlated	B-X
with	B-X
inhibition	B-X
of	B-X
IL-1	B-X
beta	B-X
release	B-X
and	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
with	B-X
up-regulation	B-X
of	B-X
endogenous	B-X
IL-1ra	B-X
production	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
balance	B-X
between	B-X
an	B-X
endogenously	B-X
produced	B-X
viral	B-X
inducer	B-X
(	B-X
IL-1	B-X
beta	B-X
)	B-X
and	B-X
an	B-X
inhibitor	B-X
(	B-X
IL-1ra	B-X
)	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
pathway	B-X
leading	B-X
to	B-X
modulation	B-X
of	B-X
HIV	B-X
expression	B-X
from	B-X
monocytic	B-X
cells	B-X
.	B-X

Costimulation	O
of	O
U1	O
cells	O
with	O
LPS	O
plus	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
resulted	O
in	O
the	O
accumulation	O
of	O
steady	O
-	O
state	O
levels	O
of	O
HIV	O
RNA	O
;	O
however	O
,	O
only	O
a	O
weak	O
induction	O
of	O
HIV	O
long	O
terminal	O
repeat	O
-	O
driven	O
transcription	O
,	O
which	O
was	O
not	O
associated	O
with	O
the	O
activation	O
of	O
the	O
cellular	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
,	O
was	O
noted	O
.	O
<EOS>	B-X
A	B-X
proportion	B-X
of	B-X
HIV-infected	B-X
individuals	B-X
experience	B-X
episodes	B-X
of	B-X
localized	B-X
or	B-X
systemic	B-X
bacterial	B-X
infections	B-X
caused	B-X
by	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
clinical	B-X
side	B-X
effects	B-X
of	B-X
these	B-X
infections	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
primarily	B-X
by	B-X
LPS	B-X
,	B-X
a	B-X
constituent	B-X
of	B-X
the	B-X
bacterial	B-X
cell	B-X
wall	B-X
of	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
The	B-X
present	B-X
study	B-X
examines	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
induction	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
,	B-X
a	B-X
promonocytic	B-X
cell	B-X
line	B-X
chronically	B-X
infected	B-X
with	B-X
HIV	B-X
.	B-X
Stimulation	B-X
of	B-X
U1	B-X
cells	B-X
by	B-X
LPS	B-X
alone	B-X
induced	B-X
minimal	B-X
levels	B-X
of	B-X
HIV	B-X
expression	B-X
,	B-X
which	B-X
was	B-X
significantly	B-X
enhanced	B-X
by	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
.	B-X
Costimulation	B-X
of	B-X
U1	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
of	B-X
steady-state	B-X
levels	B-X
of	B-X
HIV	B-X
RNA	B-X
;	B-X
however	B-X
,	B-X
only	B-X
a	B-X
weak	B-X
induction	B-X
of	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat-driven	B-X
transcription	B-X
,	B-X
which	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cellular	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
,	B-X
was	B-X
noted	B-X
.	B-X
Costimulation	B-X
of	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
induced	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
IL-8	B-X
,	B-X
IL-1	B-X
beta	B-X
and	B-X
IL-6	B-X
,	B-X
but	B-X
not	B-X
TNF-alpha	B-X
.	B-X
IL-1	B-X
receptor	B-X
antagonist	B-X
(	B-X
ra	B-X
)	B-X
inhibited	B-X
LPS	B-X
enhancement	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
GM-CSF-stimulated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
endogenous	B-X
IL-1	B-X
was	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
viral	B-X
production	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
anti-inflammatory	B-X
cytokines	B-X
inhibited	B-X
LPS	B-X
plus	B-X
GM-CSF-stimulated	B-X
HIV	B-X
expression	B-X
,	B-X
and	B-X
this	B-X
effect	B-X
closely	B-X
correlated	B-X
with	B-X
inhibition	B-X
of	B-X
IL-1	B-X
beta	B-X
release	B-X
and	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
with	B-X
up-regulation	B-X
of	B-X
endogenous	B-X
IL-1ra	B-X
production	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
balance	B-X
between	B-X
an	B-X
endogenously	B-X
produced	B-X
viral	B-X
inducer	B-X
(	B-X
IL-1	B-X
beta	B-X
)	B-X
and	B-X
an	B-X
inhibitor	B-X
(	B-X
IL-1ra	B-X
)	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
pathway	B-X
leading	B-X
to	B-X
modulation	B-X
of	B-X
HIV	B-X
expression	B-X
from	B-X
monocytic	B-X
cells	B-X
.	B-X

Costimulation	O
of	O
cells	O
with	O
LPS	O
plus	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
induced	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
but	O
not	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
.	O

IL	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
antagonist	I-Protein
(	I-Protein
ra	I-Protein
)	I-Protein
inhibited	O
LPS	O
enhancement	O
of	O
HIV	O
expression	O
in	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
-	O
stimulated	O
cells	O
,	O
suggesting	O
that	O
endogenous	O
IL	O
-	O
1	O
was	O
involved	O
in	O
LPS	O
-	O
mediated	O
viral	O
production	O
.	O
<EOS>	B-X
A	B-X
proportion	B-X
of	B-X
HIV-infected	B-X
individuals	B-X
experience	B-X
episodes	B-X
of	B-X
localized	B-X
or	B-X
systemic	B-X
bacterial	B-X
infections	B-X
caused	B-X
by	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
clinical	B-X
side	B-X
effects	B-X
of	B-X
these	B-X
infections	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
primarily	B-X
by	B-X
LPS	B-X
,	B-X
a	B-X
constituent	B-X
of	B-X
the	B-X
bacterial	B-X
cell	B-X
wall	B-X
of	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
The	B-X
present	B-X
study	B-X
examines	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
induction	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
,	B-X
a	B-X
promonocytic	B-X
cell	B-X
line	B-X
chronically	B-X
infected	B-X
with	B-X
HIV	B-X
.	B-X
Stimulation	B-X
of	B-X
U1	B-X
cells	B-X
by	B-X
LPS	B-X
alone	B-X
induced	B-X
minimal	B-X
levels	B-X
of	B-X
HIV	B-X
expression	B-X
,	B-X
which	B-X
was	B-X
significantly	B-X
enhanced	B-X
by	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
.	B-X
Costimulation	B-X
of	B-X
U1	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
of	B-X
steady-state	B-X
levels	B-X
of	B-X
HIV	B-X
RNA	B-X
;	B-X
however	B-X
,	B-X
only	B-X
a	B-X
weak	B-X
induction	B-X
of	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat-driven	B-X
transcription	B-X
,	B-X
which	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cellular	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
,	B-X
was	B-X
noted	B-X
.	B-X
Costimulation	B-X
of	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
induced	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
IL-8	B-X
,	B-X
IL-1	B-X
beta	B-X
and	B-X
IL-6	B-X
,	B-X
but	B-X
not	B-X
TNF-alpha	B-X
.	B-X
IL-1	B-X
receptor	B-X
antagonist	B-X
(	B-X
ra	B-X
)	B-X
inhibited	B-X
LPS	B-X
enhancement	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
GM-CSF-stimulated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
endogenous	B-X
IL-1	B-X
was	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
viral	B-X
production	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
anti-inflammatory	B-X
cytokines	B-X
inhibited	B-X
LPS	B-X
plus	B-X
GM-CSF-stimulated	B-X
HIV	B-X
expression	B-X
,	B-X
and	B-X
this	B-X
effect	B-X
closely	B-X
correlated	B-X
with	B-X
inhibition	B-X
of	B-X
IL-1	B-X
beta	B-X
release	B-X
and	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
with	B-X
up-regulation	B-X
of	B-X
endogenous	B-X
IL-1ra	B-X
production	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
balance	B-X
between	B-X
an	B-X
endogenously	B-X
produced	B-X
viral	B-X
inducer	B-X
(	B-X
IL-1	B-X
beta	B-X
)	B-X
and	B-X
an	B-X
inhibitor	B-X
(	B-X
IL-1ra	B-X
)	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
pathway	B-X
leading	B-X
to	B-X
modulation	B-X
of	B-X
HIV	B-X
expression	B-X
from	B-X
monocytic	B-X
cells	B-X
.	B-X

In	O
this	O
regard	O
,	O
anti	O
-	O
inflammatory	O
cytokines	O
inhibited	O
LPS	O
plus	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
-	O
stimulated	O
HIV	O
expression	O
,	O
and	O
this	O
effect	O
closely	O
correlated	O
with	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
release	O
and	O
,	O
in	O
particular	O
,	O
with	O
up	O
-	O
regulation	O
of	O
endogenous	O
IL	B-Protein
-	I-Protein
1ra	I-Protein
production	O
.	O
<EOS>	B-X
A	B-X
proportion	B-X
of	B-X
HIV-infected	B-X
individuals	B-X
experience	B-X
episodes	B-X
of	B-X
localized	B-X
or	B-X
systemic	B-X
bacterial	B-X
infections	B-X
caused	B-X
by	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
clinical	B-X
side	B-X
effects	B-X
of	B-X
these	B-X
infections	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
which	B-X
are	B-X
induced	B-X
primarily	B-X
by	B-X
LPS	B-X
,	B-X
a	B-X
constituent	B-X
of	B-X
the	B-X
bacterial	B-X
cell	B-X
wall	B-X
of	B-X
Gram-negative	B-X
bacteria	B-X
.	B-X
The	B-X
present	B-X
study	B-X
examines	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
induction	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
,	B-X
a	B-X
promonocytic	B-X
cell	B-X
line	B-X
chronically	B-X
infected	B-X
with	B-X
HIV	B-X
.	B-X
Stimulation	B-X
of	B-X
U1	B-X
cells	B-X
by	B-X
LPS	B-X
alone	B-X
induced	B-X
minimal	B-X
levels	B-X
of	B-X
HIV	B-X
expression	B-X
,	B-X
which	B-X
was	B-X
significantly	B-X
enhanced	B-X
by	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
.	B-X
Costimulation	B-X
of	B-X
U1	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
resulted	B-X
in	B-X
the	B-X
accumulation	B-X
of	B-X
steady-state	B-X
levels	B-X
of	B-X
HIV	B-X
RNA	B-X
;	B-X
however	B-X
,	B-X
only	B-X
a	B-X
weak	B-X
induction	B-X
of	B-X
HIV	B-X
long	B-X
terminal	B-X
repeat-driven	B-X
transcription	B-X
,	B-X
which	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
cellular	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
,	B-X
was	B-X
noted	B-X
.	B-X
Costimulation	B-X
of	B-X
cells	B-X
with	B-X
LPS	B-X
plus	B-X
GM-CSF	B-X
induced	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
IL-8	B-X
,	B-X
IL-1	B-X
beta	B-X
and	B-X
IL-6	B-X
,	B-X
but	B-X
not	B-X
TNF-alpha	B-X
.	B-X
IL-1	B-X
receptor	B-X
antagonist	B-X
(	B-X
ra	B-X
)	B-X
inhibited	B-X
LPS	B-X
enhancement	B-X
of	B-X
HIV	B-X
expression	B-X
in	B-X
GM-CSF-stimulated	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
endogenous	B-X
IL-1	B-X
was	B-X
involved	B-X
in	B-X
LPS-mediated	B-X
viral	B-X
production	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
anti-inflammatory	B-X
cytokines	B-X
inhibited	B-X
LPS	B-X
plus	B-X
GM-CSF-stimulated	B-X
HIV	B-X
expression	B-X
,	B-X
and	B-X
this	B-X
effect	B-X
closely	B-X
correlated	B-X
with	B-X
inhibition	B-X
of	B-X
IL-1	B-X
beta	B-X
release	B-X
and	B-X
,	B-X
in	B-X
particular	B-X
,	B-X
with	B-X
up-regulation	B-X
of	B-X
endogenous	B-X
IL-1ra	B-X
production	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
balance	B-X
between	B-X
an	B-X
endogenously	B-X
produced	B-X
viral	B-X
inducer	B-X
(	B-X
IL-1	B-X
beta	B-X
)	B-X
and	B-X
an	B-X
inhibitor	B-X
(	B-X
IL-1ra	B-X
)	B-X
may	B-X
represent	B-X
an	B-X
important	B-X
pathway	B-X
leading	B-X
to	B-X
modulation	B-X
of	B-X
HIV	B-X
expression	B-X
from	B-X
monocytic	B-X
cells	B-X
.	B-X

Thus	O
,	O
the	O
balance	O
between	O
an	O
endogenously	O
produced	O
viral	O
inducer	O
(	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
)	O
and	O
an	O
inhibitor	O
(	O
IL	B-Protein
-	I-Protein
1ra	I-Protein
)	O
may	O
represent	O
an	O
important	O
pathway	O
leading	O
to	O
modulation	O
of	O
HIV	O
expression	O
from	O
monocytic	O
cells	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
gene	O
in	O
normal	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

Convergence	O
of	O
costimulatory	O
signals	O
and	O
differences	O
from	O
transformed	O
T	O
cells	O
.	O
<EOS>	B-X
To	B-X
study	B-X
transcriptional	B-X
regulation	B-X
in	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
optimized	B-X
conditions	B-X
for	B-X
transient	B-X
transfection	B-X
.	B-X
Interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
promoter-reporter	B-X
gene	B-X
behavior	B-X
closely	B-X
parallels	B-X
the	B-X
endogenous	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
T	B-X
cell	B-X
receptor	B-X
and	B-X
costimulatory	B-X
signals	B-X
.	B-X
As	B-X
assessed	B-X
with	B-X
mutagenized	B-X
promoters	B-X
,	B-X
the	B-X
most	B-X
important	B-X
IL-2	B-X
cis-regulatory	B-X
elements	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
are	B-X
the	B-X
proximal	B-X
AP-1	B-X
site	B-X
and	B-X
the	B-X
NF-	B-X
kappaB	B-X
site	B-X
.	B-X
Both	B-X
primary	B-X
activation	B-X
,	B-X
with	B-X
phytohemagglutinin	B-X
or	B-X
antibodies	B-X
to	B-X
CD3	B-X
,	B-X
and	B-X
costimulation	B-X
,	B-X
provided	B-X
by	B-X
pairs	B-X
of	B-X
CD2	B-X
antibodies	B-X
or	B-X
B7-positive	B-X
(	B-X
B	B-X
cells	B-X
)	B-X
or	B-X
B7-negative	B-X
(	B-X
endothelial	B-X
)	B-X
accessory	B-X
cells	B-X
,	B-X
are	B-X
mediated	B-X
through	B-X
the	B-X
same	B-X
cis-elements	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cell	B-X
sites	B-X
are	B-X
much	B-X
less	B-X
important	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
than	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
IL-2	B-X
transcriptional	B-X
regulation	B-X
differs	B-X
in	B-X
tumor	B-X
cell	B-X
lines	B-X
compared	B-X
with	B-X
normal	B-X
T	B-X
cells	B-X
and	B-X
that	B-X
different	B-X
costimulatory	B-X
signals	B-X
converge	B-X
on	B-X
the	B-X
same	B-X
cis-elements	B-X
in	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X

To	O
study	O
transcriptional	O
regulation	O
in	O
normal	O
human	O
T	O
cells	O
,	O
we	O
have	O
optimized	O
conditions	O
for	O
transient	O
transfection	O
.	O

Interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
promoter	O
-	O
reporter	O
gene	O
behavior	O
closely	O
parallels	O
the	O
endogenous	O
gene	O
in	O
response	O
to	O
T	O
cell	O
receptor	O
and	O
costimulatory	O
signals	O
.	O

As	O
assessed	O
with	O
mutagenized	O
promoters	O
,	O
the	O
most	O
important	O
IL	B-Protein
-	I-Protein
2	I-Protein
cis	O
-	O
regulatory	O
elements	O
in	O
normal	O
T	O
cells	O
are	O
the	O
proximal	O
AP	O
-	O
1	O
site	O
and	O
the	O
NF	O
-	O
kappaB	O
site	O
.	O
<EOS>	B-X
To	B-X
study	B-X
transcriptional	B-X
regulation	B-X
in	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
optimized	B-X
conditions	B-X
for	B-X
transient	B-X
transfection	B-X
.	B-X
Interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
promoter-reporter	B-X
gene	B-X
behavior	B-X
closely	B-X
parallels	B-X
the	B-X
endogenous	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
T	B-X
cell	B-X
receptor	B-X
and	B-X
costimulatory	B-X
signals	B-X
.	B-X
As	B-X
assessed	B-X
with	B-X
mutagenized	B-X
promoters	B-X
,	B-X
the	B-X
most	B-X
important	B-X
IL-2	B-X
cis-regulatory	B-X
elements	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
are	B-X
the	B-X
proximal	B-X
AP-1	B-X
site	B-X
and	B-X
the	B-X
NF-	B-X
kappaB	B-X
site	B-X
.	B-X
Both	B-X
primary	B-X
activation	B-X
,	B-X
with	B-X
phytohemagglutinin	B-X
or	B-X
antibodies	B-X
to	B-X
CD3	B-X
,	B-X
and	B-X
costimulation	B-X
,	B-X
provided	B-X
by	B-X
pairs	B-X
of	B-X
CD2	B-X
antibodies	B-X
or	B-X
B7-positive	B-X
(	B-X
B	B-X
cells	B-X
)	B-X
or	B-X
B7-negative	B-X
(	B-X
endothelial	B-X
)	B-X
accessory	B-X
cells	B-X
,	B-X
are	B-X
mediated	B-X
through	B-X
the	B-X
same	B-X
cis-elements	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cell	B-X
sites	B-X
are	B-X
much	B-X
less	B-X
important	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
than	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
IL-2	B-X
transcriptional	B-X
regulation	B-X
differs	B-X
in	B-X
tumor	B-X
cell	B-X
lines	B-X
compared	B-X
with	B-X
normal	B-X
T	B-X
cells	B-X
and	B-X
that	B-X
different	B-X
costimulatory	B-X
signals	B-X
converge	B-X
on	B-X
the	B-X
same	B-X
cis-elements	B-X
in	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X

Both	O
primary	O
activation	O
,	O
with	O
phytohemagglutinin	B-Protein
or	O
antibodies	O
to	O
CD3	O
,	O
and	O
costimulation	O
,	O
provided	O
by	O
pairs	O
of	O
CD2	O
antibodies	O
or	O
B7	O
-	O
positive	O
(	O
B	O
cells	O
)	O
or	O
B7	O
-	O
negative	O
(	O
endothelial	O
)	O
accessory	O
cells	O
,	O
are	O
mediated	O
through	O
the	O
same	O
cis	O
-	O
elements	O
.	O
<EOS>	B-X
To	B-X
study	B-X
transcriptional	B-X
regulation	B-X
in	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
optimized	B-X
conditions	B-X
for	B-X
transient	B-X
transfection	B-X
.	B-X
As	B-X
assessed	B-X
with	B-X
mutagenized	B-X
promoters	B-X
,	B-X
the	B-X
most	B-X
important	B-X
IL-2	B-X
cis-regulatory	B-X
elements	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
are	B-X
the	B-X
proximal	B-X
AP-1	B-X
site	B-X
and	B-X
the	B-X
NF-	B-X
kappaB	B-X
site	B-X
.	B-X
Both	B-X
primary	B-X
activation	B-X
,	B-X
with	B-X
phytohemagglutinin	B-X
or	B-X
antibodies	B-X
to	B-X
CD3	B-X
,	B-X
and	B-X
costimulation	B-X
,	B-X
provided	B-X
by	B-X
pairs	B-X
of	B-X
CD2	B-X
antibodies	B-X
or	B-X
B7-positive	B-X
(	B-X
B	B-X
cells	B-X
)	B-X
or	B-X
B7-negative	B-X
(	B-X
endothelial	B-X
)	B-X
accessory	B-X
cells	B-X
,	B-X
are	B-X
mediated	B-X
through	B-X
the	B-X
same	B-X
cis-elements	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cell	B-X
sites	B-X
are	B-X
much	B-X
less	B-X
important	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
than	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
IL-2	B-X
transcriptional	B-X
regulation	B-X
differs	B-X
in	B-X
tumor	B-X
cell	B-X
lines	B-X
compared	B-X
with	B-X
normal	B-X
T	B-X
cells	B-X
and	B-X
that	B-X
different	B-X
costimulatory	B-X
signals	B-X
converge	B-X
on	B-X
the	B-X
same	B-X
cis-elements	B-X
in	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X

Interestingly	O
,	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
sites	O
are	O
much	O
less	O
important	O
in	O
normal	O
T	O
cells	O
than	O
in	O
Jurkat	O
T	O
cells	O
.	O

We	O
conclude	O
that	O
IL	B-Protein
-	I-Protein
2	I-Protein
transcriptional	O
regulation	O
differs	O
in	O
tumor	O
cell	O
lines	O
compared	O
with	O
normal	O
T	O
cells	O
and	O
that	O
different	O
costimulatory	O
signals	O
converge	O
on	O
the	O
same	O
cis	O
-	O
elements	O
in	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
.	O
<EOS>	B-X
To	B-X
study	B-X
transcriptional	B-X
regulation	B-X
in	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
,	B-X
we	B-X
have	B-X
optimized	B-X
conditions	B-X
for	B-X
transient	B-X
transfection	B-X
.	B-X
Interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
promoter-reporter	B-X
gene	B-X
behavior	B-X
closely	B-X
parallels	B-X
the	B-X
endogenous	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
T	B-X
cell	B-X
receptor	B-X
and	B-X
costimulatory	B-X
signals	B-X
.	B-X
As	B-X
assessed	B-X
with	B-X
mutagenized	B-X
promoters	B-X
,	B-X
the	B-X
most	B-X
important	B-X
IL-2	B-X
cis-regulatory	B-X
elements	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
are	B-X
the	B-X
proximal	B-X
AP-1	B-X
site	B-X
and	B-X
the	B-X
NF-	B-X
kappaB	B-X
site	B-X
.	B-X
Both	B-X
primary	B-X
activation	B-X
,	B-X
with	B-X
phytohemagglutinin	B-X
or	B-X
antibodies	B-X
to	B-X
CD3	B-X
,	B-X
and	B-X
costimulation	B-X
,	B-X
provided	B-X
by	B-X
pairs	B-X
of	B-X
CD2	B-X
antibodies	B-X
or	B-X
B7-positive	B-X
(	B-X
B	B-X
cells	B-X
)	B-X
or	B-X
B7-negative	B-X
(	B-X
endothelial	B-X
)	B-X
accessory	B-X
cells	B-X
,	B-X
are	B-X
mediated	B-X
through	B-X
the	B-X
same	B-X
cis-elements	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cell	B-X
sites	B-X
are	B-X
much	B-X
less	B-X
important	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
than	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
IL-2	B-X
transcriptional	B-X
regulation	B-X
differs	B-X
in	B-X
tumor	B-X
cell	B-X
lines	B-X
compared	B-X
with	B-X
normal	B-X
T	B-X
cells	B-X
and	B-X
that	B-X
different	B-X
costimulatory	B-X
signals	B-X
converge	B-X
on	B-X
the	B-X
same	B-X
cis-elements	B-X
in	B-X
the	B-X
IL-2	B-X
promoter	B-X
.	B-X

A	O
hydrophobic	O
domain	O
of	O
Ca2	B-Protein
+	I-Protein
-	I-Protein
modulating	I-Protein
cyclophilin	I-Protein
ligand	I-Protein
modulates	O
calcium	O
influx	O
signaling	O
in	O
T	O
lymphocytes	O
.	O

Ca2	B-Protein
+	I-Protein
-	I-Protein
modulating	I-Protein
cyclophilin	I-Protein
ligand	I-Protein
(	O
CAML	B-Protein
)	O
was	O
originally	O
described	O
as	O
a	O
cyclophilin	B-Protein
B	I-Protein
-	O
binding	O
protein	O
whose	O
overexpression	O
in	O
T	O
cells	O
causes	O
a	O
rise	O
in	O
intracellular	O
calcium	O
,	O
thus	O
activating	O
transcription	O
factors	O
responsible	O
for	O
the	O
early	O
immune	O
response	O
.	O

As	O
reported	O
here	O
,	O
structure	O
-	O
function	O
analysis	O
of	O
the	O
CAML	B-Protein
gene	O
in	O
Jurkat	O
T	O
cells	O
indicates	O
that	O
two	O
of	O
CAML	B-Protein
'	O
s	O
putative	O
membrane	O
-	O
spanning	O
domains	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
modulation	O
of	O
intracellular	O
calcium	O
.	O

We	O
propose	O
that	O
the	O
hydrophobic	O
C	O
-	O
terminal	O
tail	O
of	O
CAML	B-Protein
forms	O
its	O
effector	O
domain	O
,	O
thus	O
implicating	O
the	O
N	O
-	O
terminal	O
hydrophilic	O
domain	O
in	O
a	O
regulatory	O
role	O
.	O

These	O
findings	O
define	O
a	O
novel	O
protein	O
motif	O
that	O
functions	O
in	O
intracellular	O
calcium	O
signaling	O
.	O
<EOS>	B-X
Fourth	B-X
,	B-X
additional	B-X
studies	B-X
of	B-X
sarcomatoid	B-X
mesothelioma	B-X
have	B-X
defined	B-X
the	B-X
frequency	B-X
and	B-X
spectrum	B-X
of	B-X
various	B-X
histologic	B-X
and	B-X
immunohistochemical	B-X
features	B-X
,	B-X
including	B-X
heterologous	B-X
elements	B-X
.	B-X
Finally	B-X
,	B-X
pleural	B-X
well-differentiated	B-X
papillary	B-X
mesotheliomas	B-X
are	B-X
better	B-X
defined	B-X
and	B-X
cases	B-X
with	B-X
invasive	B-X
foci	B-X
are	B-X
recognized	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
inactivating	B-X
mutations	B-X
in	B-X
the	B-X
BRCA1-associated	B-X
protein	B-X
1	B-X
gene	B-X
in	B-X
sporadic	B-X
and	B-X
hereditary	B-X
mesothelioma	B-X
has	B-X
opened	B-X
up	B-X
a	B-X
variety	B-X
of	B-X
novel	B-X
molecular	B-X
,	B-X
clinical	B-X
,	B-X
and	B-X
diagnostic	B-X
investigations	B-X
.	B-X
A	B-X
fluorescence	B-X
in	B-X
situ	B-X
hybridization	B-X
(	B-X
FISH	B-X
)	B-X
positional	B-X
cloning	B-X
strategy	B-X
,	B-X
spanning	B-X
the	B-X
cytogenetically	B-X
defined	B-X
regions	B-X
on	B-X
chromosomes	B-X
1p36.3	B-X
and	B-X
3q25	B-X
,	B-X
confirmed	B-X
rearrangements	B-X
in	B-X
two	B-X
candidate	B-X
genes	B-X
from	B-X
these	B-X
loci	B-X
in	B-X
all	B-X
EHE	B-X
cases	B-X
tested	B-X
.	B-X

Interactions	O
of	O
a	O
transcriptional	O
activator	O
in	O
the	O
env	B-Protein
gene	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
with	O
activation	O
-	O
dependent	O
,	O
T	O
cell	O
-	O
specific	O
transacting	O
factors	O
.	O
<EOS>	B-X
The	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
env	B-X
gene	B-X
contains	B-X
a	B-X
transcriptional	B-X
activator	B-X
(	B-X
META	B-X
)	B-X
that	B-X
can	B-X
control	B-X
transcription	B-X
of	B-X
the	B-X
adjacent	B-X
long	B-X
terminal	B-X
repeat	B-X
region	B-X
.	B-X
Transcriptional	B-X
control	B-X
by	B-X
META	B-X
parallels	B-X
that	B-X
of	B-X
several	B-X
lymphokine	B-X
genes	B-X
,	B-X
being	B-X
specific	B-X
to	B-X
T	B-X
cells	B-X
,	B-X
dependent	B-X
on	B-X
their	B-X
activation	B-X
,	B-X
and	B-X
inhibited	B-X
by	B-X
the	B-X
immunosuppressive	B-X
drug	B-X
cyclosporine	B-X
(	B-X
CsA	B-X
)	B-X
.	B-X
DNase	B-X
I	B-X
footprinting	B-X
indicated	B-X
that	B-X
nuclear	B-X
factors	B-X
from	B-X
activated	B-X
T	B-X
lymphocytes	B-X
bound	B-X
a	B-X
promoter-proximal	B-X
site	B-X
,	B-X
META	B-X
(	B-X
P	B-X
)	B-X
,	B-X
and	B-X
a	B-X
promoter-distal	B-X
site	B-X
,	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
,	B-X
within	B-X
the	B-X
400-base	B-X
pair	B-X
META	B-X
region	B-X
.	B-X
Nuclear	B-X
factors	B-X
from	B-X
unstimulated	B-X
,	B-X
but	B-X
not	B-X
from	B-X
activated	B-X
cells	B-X
,	B-X
bound	B-X
a	B-X
site	B-X
,	B-X
META	B-X
(	B-X
D-	B-X
)	B-X
,	B-X
adjacent	B-X
to	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
.	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
directed	B-X
transcription	B-X
of	B-X
a	B-X
linked	B-X
luciferase	B-X
gene	B-X
,	B-X
and	B-X
gel	B-X
shift	B-X
analysis	B-X
revealed	B-X
binding	B-X
of	B-X
inducible	B-X
,	B-X
CsA-sensitive	B-X
T	B-X
cell	B-X
factors	B-X
,	B-X
in	B-X
parallel	B-X
with	B-X
transfection	B-X
results	B-X
.	B-X
The	B-X
SV40	B-X
core	B-X
sequence	B-X
competed	B-X
for	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
binding	B-X
factors	B-X
,	B-X
but	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
failed	B-X
to	B-X
compete	B-X
for	B-X
the	B-X
complexes	B-X
obtained	B-X
with	B-X
the	B-X
SV40	B-X
probe	B-X
.	B-X
Our	B-X
results	B-X
,	B-X
taken	B-X
together	B-X
,	B-X
indicate	B-X
that	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
transcriptional	B-X
enhancer	B-X
element	B-X
that	B-X
is	B-X
similar	B-X
in	B-X
its	B-X
cell-type	B-X
specificity	B-X
,	B-X
activation	B-X
dependence	B-X
,	B-X
and	B-X
CsA	B-X
sensitivity	B-X
to	B-X
the	B-X
NFAT	B-X
element	B-X
.	B-X
It	B-X
may	B-X
be	B-X
relevant	B-X
to	B-X
the	B-X
role	B-X
of	B-X
MMTV	B-X
in	B-X
expression	B-X
of	B-X
Mls	B-X
antigens	B-X
or	B-X
the	B-X
induction	B-X
of	B-X
T	B-X
cell	B-X
lymphomas	B-X
.	B-X

The	O
mouse	O
mammary	O
tumor	O
virus	O
env	B-Protein
gene	O
contains	O
a	O
transcriptional	O
activator	O
(	O
META	O
)	O
that	O
can	O
control	O
transcription	O
of	O
the	O
adjacent	O
long	O
terminal	O
repeat	O
region	O
.	O
<EOS>	B-X
The	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
env	B-X
gene	B-X
contains	B-X
a	B-X
transcriptional	B-X
activator	B-X
(	B-X
META	B-X
)	B-X
that	B-X
can	B-X
control	B-X
transcription	B-X
of	B-X
the	B-X
adjacent	B-X
long	B-X
terminal	B-X
repeat	B-X
region	B-X
.	B-X
Transcriptional	B-X
control	B-X
by	B-X
META	B-X
parallels	B-X
that	B-X
of	B-X
several	B-X
lymphokine	B-X
genes	B-X
,	B-X
being	B-X
specific	B-X
to	B-X
T	B-X
cells	B-X
,	B-X
dependent	B-X
on	B-X
their	B-X
activation	B-X
,	B-X
and	B-X
inhibited	B-X
by	B-X
the	B-X
immunosuppressive	B-X
drug	B-X
cyclosporine	B-X
(	B-X
CsA	B-X
)	B-X
.	B-X
DNase	B-X
I	B-X
footprinting	B-X
indicated	B-X
that	B-X
nuclear	B-X
factors	B-X
from	B-X
activated	B-X
T	B-X
lymphocytes	B-X
bound	B-X
a	B-X
promoter-proximal	B-X
site	B-X
,	B-X
META	B-X
(	B-X
P	B-X
)	B-X
,	B-X
and	B-X
a	B-X
promoter-distal	B-X
site	B-X
,	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
,	B-X
within	B-X
the	B-X
400-base	B-X
pair	B-X
META	B-X
region	B-X
.	B-X
Nuclear	B-X
factors	B-X
from	B-X
unstimulated	B-X
,	B-X
but	B-X
not	B-X
from	B-X
activated	B-X
cells	B-X
,	B-X
bound	B-X
a	B-X
site	B-X
,	B-X
META	B-X
(	B-X
D-	B-X
)	B-X
,	B-X
adjacent	B-X
to	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
.	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
directed	B-X
transcription	B-X
of	B-X
a	B-X
linked	B-X
luciferase	B-X
gene	B-X
,	B-X
and	B-X
gel	B-X
shift	B-X
analysis	B-X
revealed	B-X
binding	B-X
of	B-X
inducible	B-X
,	B-X
CsA-sensitive	B-X
T	B-X
cell	B-X
factors	B-X
,	B-X
in	B-X
parallel	B-X
with	B-X
transfection	B-X
results	B-X
.	B-X
Authentic	B-X
NFAT	B-X
and	B-X
NF-kappaB	B-X
targets	B-X
did	B-X
not	B-X
compete	B-X
for	B-X
the	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
binding	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
.	B-X
The	B-X
SV40	B-X
core	B-X
sequence	B-X
competed	B-X
for	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
binding	B-X
factors	B-X
,	B-X
but	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
failed	B-X
to	B-X
compete	B-X
for	B-X
the	B-X
complexes	B-X
obtained	B-X
with	B-X
the	B-X
SV40	B-X
probe	B-X
.	B-X
Our	B-X
results	B-X
,	B-X
taken	B-X
together	B-X
,	B-X
indicate	B-X
that	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
transcriptional	B-X
enhancer	B-X
element	B-X
that	B-X
is	B-X
similar	B-X
in	B-X
its	B-X
cell-type	B-X
specificity	B-X
,	B-X
activation	B-X
dependence	B-X
,	B-X
and	B-X
CsA	B-X
sensitivity	B-X
to	B-X
the	B-X
NFAT	B-X
element	B-X
.	B-X

Transcriptional	O
control	O
by	O
META	O
parallels	O
that	O
of	O
several	O
lymphokine	O
genes	O
,	O
being	O
specific	O
to	O
T	O
cells	O
,	O
dependent	O
on	O
their	O
activation	O
,	O
and	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporine	O
(	O
CsA	O
)	O
.	O

DNase	B-Protein
I	I-Protein
footprinting	O
indicated	O
that	O
nuclear	O
factors	O
from	O
activated	O
T	O
lymphocytes	O
bound	O
a	O
promoter	O
-	O
proximal	O
site	O
,	O
META	O
(	O
P	O
)	O
,	O
and	O
a	O
promoter	O
-	O
distal	O
site	O
,	O
META	O
(	O
D	O
+	O
)	O
,	O
within	O
the	O
400	O
-	O
base	O
pair	O
META	O
region	O
.	O

Nuclear	O
factors	O
from	O
unstimulated	O
,	O
but	O
not	O
from	O
activated	O
cells	O
,	O
bound	O
a	O
site	O
,	O
META	O
(	O
D	O
-	O
)	O
,	O
adjacent	O
to	O
META	O
(	O
D	O
+	O
)	O
.	O
<EOS>	B-X
The	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
env	B-X
gene	B-X
contains	B-X
a	B-X
transcriptional	B-X
activator	B-X
(	B-X
META	B-X
)	B-X
that	B-X
can	B-X
control	B-X
transcription	B-X
of	B-X
the	B-X
adjacent	B-X
long	B-X
terminal	B-X
repeat	B-X
region	B-X
.	B-X
Transcriptional	B-X
control	B-X
by	B-X
META	B-X
parallels	B-X
that	B-X
of	B-X
several	B-X
lymphokine	B-X
genes	B-X
,	B-X
being	B-X
specific	B-X
to	B-X
T	B-X
cells	B-X
,	B-X
dependent	B-X
on	B-X
their	B-X
activation	B-X
,	B-X
and	B-X
inhibited	B-X
by	B-X
the	B-X
immunosuppressive	B-X
drug	B-X
cyclosporine	B-X
(	B-X
CsA	B-X
)	B-X
.	B-X
DNase	B-X
I	B-X
footprinting	B-X
indicated	B-X
that	B-X
nuclear	B-X
factors	B-X
from	B-X
activated	B-X
T	B-X
lymphocytes	B-X
bound	B-X
a	B-X
promoter-proximal	B-X
site	B-X
,	B-X
META	B-X
(	B-X
P	B-X
)	B-X
,	B-X
and	B-X
a	B-X
promoter-distal	B-X
site	B-X
,	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
,	B-X
within	B-X
the	B-X
400-base	B-X
pair	B-X
META	B-X
region	B-X
.	B-X
Nuclear	B-X
factors	B-X
from	B-X
unstimulated	B-X
,	B-X
but	B-X
not	B-X
from	B-X
activated	B-X
cells	B-X
,	B-X
bound	B-X
a	B-X
site	B-X
,	B-X
META	B-X
(	B-X
D-	B-X
)	B-X
,	B-X
adjacent	B-X
to	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
.	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
directed	B-X
transcription	B-X
of	B-X
a	B-X
linked	B-X
luciferase	B-X
gene	B-X
,	B-X
and	B-X
gel	B-X
shift	B-X
analysis	B-X
revealed	B-X
binding	B-X
of	B-X
inducible	B-X
,	B-X
CsA-sensitive	B-X
T	B-X
cell	B-X
factors	B-X
,	B-X
in	B-X
parallel	B-X
with	B-X
transfection	B-X
results	B-X
.	B-X
Authentic	B-X
NFAT	B-X
and	B-X
NF-kappaB	B-X
targets	B-X
did	B-X
not	B-X
compete	B-X
for	B-X
the	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
binding	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
.	B-X
The	B-X
SV40	B-X
core	B-X
sequence	B-X
competed	B-X
for	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
binding	B-X
factors	B-X
,	B-X
but	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
failed	B-X
to	B-X
compete	B-X
for	B-X
the	B-X
complexes	B-X
obtained	B-X
with	B-X
the	B-X
SV40	B-X
probe	B-X
.	B-X
Our	B-X
results	B-X
,	B-X
taken	B-X
together	B-X
,	B-X
indicate	B-X
that	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
transcriptional	B-X
enhancer	B-X
element	B-X
that	B-X
is	B-X
similar	B-X
in	B-X
its	B-X
cell-type	B-X
specificity	B-X
,	B-X
activation	B-X
dependence	B-X
,	B-X
and	B-X
CsA	B-X
sensitivity	B-X
to	B-X
the	B-X
NFAT	B-X
element	B-X
.	B-X

META	O
(	O
D	O
+	O
)	O
directed	O
transcription	O
of	O
a	O
linked	O
luciferase	O
gene	O
,	O
and	O
gel	O
shift	O
analysis	O
revealed	O
binding	O
of	O
inducible	O
,	O
CsA	O
-	O
sensitive	O
T	O
cell	O
factors	O
,	O
in	O
parallel	O
with	O
transfection	O
results	O
.	O

Authentic	O
NFAT	O
and	O
NF	O
-	O
kappaB	O
targets	O
did	O
not	O
compete	O
for	O
the	O
META	O
(	O
D	O
+	O
)	O
binding	O
factor	O
(	O
s	O
)	O
.	O

The	O
SV40	B-Protein
core	O
sequence	O
competed	O
for	O
META	O
(	O
D	O
+	O
)	O
binding	O
factors	O
,	O
but	O
META	O
(	O
D	O
+	O
)	O
failed	O
to	O
compete	O
for	O
the	O
complexes	O
obtained	O
with	O
the	O
SV40	B-Protein
probe	O
.	O
<EOS>	B-X
The	B-X
mouse	B-X
mammary	B-X
tumor	B-X
virus	B-X
env	B-X
gene	B-X
contains	B-X
a	B-X
transcriptional	B-X
activator	B-X
(	B-X
META	B-X
)	B-X
that	B-X
can	B-X
control	B-X
transcription	B-X
of	B-X
the	B-X
adjacent	B-X
long	B-X
terminal	B-X
repeat	B-X
region	B-X
.	B-X
Transcriptional	B-X
control	B-X
by	B-X
META	B-X
parallels	B-X
that	B-X
of	B-X
several	B-X
lymphokine	B-X
genes	B-X
,	B-X
being	B-X
specific	B-X
to	B-X
T	B-X
cells	B-X
,	B-X
dependent	B-X
on	B-X
their	B-X
activation	B-X
,	B-X
and	B-X
inhibited	B-X
by	B-X
the	B-X
immunosuppressive	B-X
drug	B-X
cyclosporine	B-X
(	B-X
CsA	B-X
)	B-X
.	B-X
DNase	B-X
I	B-X
footprinting	B-X
indicated	B-X
that	B-X
nuclear	B-X
factors	B-X
from	B-X
activated	B-X
T	B-X
lymphocytes	B-X
bound	B-X
a	B-X
promoter-proximal	B-X
site	B-X
,	B-X
META	B-X
(	B-X
P	B-X
)	B-X
,	B-X
and	B-X
a	B-X
promoter-distal	B-X
site	B-X
,	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
,	B-X
within	B-X
the	B-X
400-base	B-X
pair	B-X
META	B-X
region	B-X
.	B-X
Nuclear	B-X
factors	B-X
from	B-X
unstimulated	B-X
,	B-X
but	B-X
not	B-X
from	B-X
activated	B-X
cells	B-X
,	B-X
bound	B-X
a	B-X
site	B-X
,	B-X
META	B-X
(	B-X
D-	B-X
)	B-X
,	B-X
adjacent	B-X
to	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
.	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
directed	B-X
transcription	B-X
of	B-X
a	B-X
linked	B-X
luciferase	B-X
gene	B-X
,	B-X
and	B-X
gel	B-X
shift	B-X
analysis	B-X
revealed	B-X
binding	B-X
of	B-X
inducible	B-X
,	B-X
CsA-sensitive	B-X
T	B-X
cell	B-X
factors	B-X
,	B-X
in	B-X
parallel	B-X
with	B-X
transfection	B-X
results	B-X
.	B-X
Authentic	B-X
NFAT	B-X
and	B-X
NF-kappaB	B-X
targets	B-X
did	B-X
not	B-X
compete	B-X
for	B-X
the	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
binding	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
.	B-X
The	B-X
SV40	B-X
core	B-X
sequence	B-X
competed	B-X
for	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
binding	B-X
factors	B-X
,	B-X
but	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
failed	B-X
to	B-X
compete	B-X
for	B-X
the	B-X
complexes	B-X
obtained	B-X
with	B-X
the	B-X
SV40	B-X
probe	B-X
.	B-X
Our	B-X
results	B-X
,	B-X
taken	B-X
together	B-X
,	B-X
indicate	B-X
that	B-X
META	B-X
(	B-X
D+	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
transcriptional	B-X
enhancer	B-X
element	B-X
that	B-X
is	B-X
similar	B-X
in	B-X
its	B-X
cell-type	B-X
specificity	B-X
,	B-X
activation	B-X
dependence	B-X
,	B-X
and	B-X
CsA	B-X
sensitivity	B-X
to	B-X
the	B-X
NFAT	B-X
element	B-X
.	B-X

Our	O
results	O
,	O
taken	O
together	O
,	O
indicate	O
that	O
META	O
(	O
D	O
+	O
)	O
is	O
a	O
novel	O
transcriptional	O
enhancer	O
element	O
that	O
is	O
similar	O
in	O
its	O
cell	O
-	O
type	O
specificity	O
,	O
activation	O
dependence	O
,	O
and	O
CsA	O
sensitivity	O
to	O
the	O
NFAT	O
element	O
.	O

It	O
may	O
be	O
relevant	O
to	O
the	O
role	O
of	O
MMTV	O
in	O
expression	O
of	O
Mls	O
antigens	O
or	O
the	O
induction	O
of	O
T	O
cell	O
lymphomas	O
.	O
<EOS>	B-X
Angioimmunoblastic	B-X
T-cell	B-X
lymphoma	B-X
(	B-X
AITL	B-X
)	B-X
is	B-X
an	B-X
uncommon	B-X
subtype	B-X
of	B-X
mature	B-X
peripheral	B-X
T-cell	B-X
lymphoma	B-X
(	B-X
PTCL	B-X
)	B-X
.	B-X
AITL	B-X
now	B-X
resides	B-X
under	B-X
the	B-X
umbrella	B-X
of	B-X
nodal	B-X
T-cell	B-X
lymphomas	B-X
with	B-X
follicular	B-X
T	B-X
helper	B-X
phenotype	B-X
.	B-X
Induction	B-X
strategies	B-X
continue	B-X
to	B-X
focus	B-X
on	B-X
increasing	B-X
complete	B-X
remission	B-X
rates	B-X
that	B-X
allow	B-X
more	B-X
transplant-eligible	B-X
patients	B-X
to	B-X
proceed	B-X
toward	B-X
consolidative	B-X
high-dose	B-X
therapy	B-X
and	B-X
autologous	B-X
stem	B-X
cell	B-X
rescue	B-X
with	B-X
improving	B-X
long-term	B-X
survival	B-X
.	B-X
There	B-X
are	B-X
several	B-X
clinical	B-X
trials	B-X
in	B-X
which	B-X
recently	B-X
approved	B-X
drugs	B-X
with	B-X
known	B-X
activity	B-X
in	B-X
AITL	B-X
are	B-X
paired	B-X
with	B-X
induction	B-X
regimens	B-X
with	B-X
the	B-X
hope	B-X
of	B-X
demonstrating	B-X
long-term	B-X
progression-free	B-X
survival	B-X
over	B-X
cyclophosphamide	B-X
,	B-X
doxorubicin	B-X
,	B-X
vincristine	B-X
,	B-X
and	B-X
prednisone	B-X
.	B-X
The	B-X
spectrum	B-X
of	B-X
AITL	B-X
from	B-X
diagnosis	B-X
to	B-X
treatment	B-X
is	B-X
reviewed	B-X
subsequently	B-X
in	B-X
a	B-X
fashion	B-X
that	B-X
may	B-X
one	B-X
day	B-X
lead	B-X
to	B-X
personalized	B-X
treatment	B-X
approaches	B-X
in	B-X
a	B-X
many-faced	B-X
disease	B-X
.	B-X

Monocytic	O
cell	O
type	O
-	O
specific	O
transcriptional	O
induction	O
of	O
collagenase	O
.	O
<EOS>	B-X
Interstitial	B-X
collagenase	B-X
(	B-X
MMP-1	B-X
)	B-X
,	B-X
a	B-X
metalloproteinase	B-X
produced	B-X
by	B-X
resident	B-X
and	B-X
inflammatory	B-X
cells	B-X
during	B-X
connective	B-X
tissue	B-X
turnover	B-X
,	B-X
cleaves	B-X
type	B-X
I	B-X
collagen	B-X
fibrils	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
collagenase	B-X
expression	B-X
is	B-X
cell-type	B-X
specific	B-X
;	B-X
bacterial	B-X
LPS	B-X
and	B-X
zymosan	B-X
,	B-X
a	B-X
yeast	B-X
cell	B-X
wall	B-X
derivative	B-X
,	B-X
are	B-X
potent	B-X
inducers	B-X
of	B-X
collagenase	B-X
expression	B-X
in	B-X
macrophages	B-X
,	B-X
but	B-X
do	B-X
not	B-X
alter	B-X
fibroblast	B-X
collagenase	B-X
expression	B-X
.	B-X
Since	B-X
promoter	B-X
elements	B-X
controlling	B-X
collagenase	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
have	B-X
not	B-X
been	B-X
previously	B-X
defined	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
delineate	B-X
responsive	B-X
cis-acting	B-X
elements	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
in	B-X
transiently	B-X
transfected	B-X
human	B-X
(	B-X
U937	B-X
)	B-X
and	B-X
murine	B-X
(	B-X
J774	B-X
)	B-X
monocytic	B-X
cell	B-X
lines	B-X
.	B-X
Deletion	B-X
constructs	B-X
containing	B-X
as	B-X
little	B-X
as	B-X
72	B-X
bp	B-X
of	B-X
5	B-X
'	B-X
-flanking	B-X
sequence	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
were	B-X
sufficient	B-X
for	B-X
LPS-	B-X
or	B-X
zymosan-mediated	B-X
transcriptional	B-X
induction	B-X
,	B-X
whereas	B-X
phorbol	B-X
inducibility	B-X
exhibited	B-X
an	B-X
absolute	B-X
requirement	B-X
for	B-X
upstream	B-X
elements	B-X
including	B-X
the	B-X
polyoma	B-X
enhancer	B-X
A-binding	B-X
protein-3	B-X
site	B-X
(	B-X
-83	B-X
to	B-X
-91	B-X
)	B-X
and	B-X
TTCA	B-X
sequence	B-X
(	B-X
-102	B-X
to	B-X
-105	B-X
)	B-X
in	B-X
both	B-X
monocytic	B-X
cells	B-X
and	B-X
fibroblasts	B-X
.	B-X
Nuclear	B-X
extracts	B-X
from	B-X
LPS-	B-X
and	B-X
zymosan-treated	B-X
cells	B-X
showed	B-X
strong	B-X
AP-1	B-X
activity	B-X
by	B-X
gel-shift	B-X
analysis	B-X
,	B-X
and	B-X
supershift	B-X
analysis	B-X
showed	B-X
the	B-X
AP-1	B-X
complexes	B-X
contained	B-X
specific	B-X
members	B-X
of	B-X
both	B-X
the	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
families	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
most	B-X
LPS	B-X
effects	B-X
,	B-X
AP-1	B-X
,	B-X
but	B-X
not	B-X
nuclear	B-X
factor-kappaB	B-X
,	B-X
mediates	B-X
LPS	B-X
induction	B-X
of	B-X
collagenase	B-X
transcription	B-X
in	B-X
macrophagelike	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
as	B-X
compared	B-X
to	B-X
regulation	B-X
by	B-X
phorbol	B-X
ester	B-X
,	B-X
collagenase	B-X
induction	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
cell	B-X
wall	B-X
derivatives	B-X
of	B-X
bacteria	B-X
or	B-X
yeast	B-X
is	B-X
largely	B-X
independent	B-X
of	B-X
upstream	B-X
promoter	B-X
sequences	B-X
.	B-X

Interstitial	O
collagenase	O
(	O
MMP	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
a	O
metalloproteinase	O
produced	O
by	O
resident	O
and	O
inflammatory	O
cells	O
during	O
connective	O
tissue	O
turnover	O
,	O
cleaves	O
type	O
I	O
collagen	O
fibrils	O
.	O
<EOS>	B-X
Interstitial	B-X
collagenase	B-X
(	B-X
MMP-1	B-X
)	B-X
,	B-X
a	B-X
metalloproteinase	B-X
produced	B-X
by	B-X
resident	B-X
and	B-X
inflammatory	B-X
cells	B-X
during	B-X
connective	B-X
tissue	B-X
turnover	B-X
,	B-X
cleaves	B-X
type	B-X
I	B-X
collagen	B-X
fibrils	B-X
.	B-X
This	B-X
catalytic	B-X
event	B-X
is	B-X
rate	B-X
limiting	B-X
in	B-X
remodeling	B-X
of	B-X
tissues	B-X
rich	B-X
in	B-X
fibrillar	B-X
collagen	B-X
such	B-X
as	B-X
the	B-X
skin	B-X
and	B-X
lungs	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
collagenase	B-X
expression	B-X
is	B-X
cell-type	B-X
specific	B-X
;	B-X
bacterial	B-X
LPS	B-X
and	B-X
zymosan	B-X
,	B-X
a	B-X
yeast	B-X
cell	B-X
wall	B-X
derivative	B-X
,	B-X
are	B-X
potent	B-X
inducers	B-X
of	B-X
collagenase	B-X
expression	B-X
in	B-X
macrophages	B-X
,	B-X
but	B-X
do	B-X
not	B-X
alter	B-X
fibroblast	B-X
collagenase	B-X
expression	B-X
.	B-X
Since	B-X
promoter	B-X
elements	B-X
controlling	B-X
collagenase	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
have	B-X
not	B-X
been	B-X
previously	B-X
defined	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
delineate	B-X
responsive	B-X
cis-acting	B-X
elements	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
in	B-X
transiently	B-X
transfected	B-X
human	B-X
(	B-X
U937	B-X
)	B-X
and	B-X
murine	B-X
(	B-X
J774	B-X
)	B-X
monocytic	B-X
cell	B-X
lines	B-X
.	B-X
Deletion	B-X
constructs	B-X
containing	B-X
as	B-X
little	B-X
as	B-X
72	B-X
bp	B-X
of	B-X
5	B-X
'	B-X
-flanking	B-X
sequence	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
were	B-X
sufficient	B-X
for	B-X
LPS-	B-X
or	B-X
zymosan-mediated	B-X
transcriptional	B-X
induction	B-X
,	B-X
whereas	B-X
phorbol	B-X
inducibility	B-X
exhibited	B-X
an	B-X
absolute	B-X
requirement	B-X
for	B-X
upstream	B-X
elements	B-X
including	B-X
the	B-X
polyoma	B-X
enhancer	B-X
A-binding	B-X
protein-3	B-X
site	B-X
(	B-X
-83	B-X
to	B-X
-91	B-X
)	B-X
and	B-X
TTCA	B-X
sequence	B-X
(	B-X
-102	B-X
to	B-X
-105	B-X
)	B-X
in	B-X
both	B-X
monocytic	B-X
cells	B-X
and	B-X
fibroblasts	B-X
.	B-X
Mutagenesis	B-X
of	B-X
the	B-X
activator	B-X
protein-1	B-X
[	B-X
AP-1	B-X
]	B-X
site	B-X
at	B-X
-72	B-X
abolished	B-X
basal	B-X
promoter	B-X
activity	B-X
and	B-X
LPS/zymosan	B-X
inducibility	B-X
,	B-X
while	B-X
mutagenesis	B-X
of	B-X
an	B-X
NF-kappaB-like	B-X
site	B-X
at	B-X
-20	B-X
to	B-X
-10	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
Nuclear	B-X
extracts	B-X
from	B-X
LPS-	B-X
and	B-X
zymosan-treated	B-X
cells	B-X
showed	B-X
strong	B-X
AP-1	B-X
activity	B-X
by	B-X
gel-shift	B-X
analysis	B-X
,	B-X
and	B-X
supershift	B-X
analysis	B-X
showed	B-X
the	B-X
AP-1	B-X
complexes	B-X
contained	B-X
specific	B-X
members	B-X
of	B-X
both	B-X
the	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
families	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
most	B-X
LPS	B-X
effects	B-X
,	B-X
AP-1	B-X
,	B-X
but	B-X
not	B-X
nuclear	B-X
factor-kappaB	B-X
,	B-X
mediates	B-X
LPS	B-X
induction	B-X
of	B-X
collagenase	B-X
transcription	B-X
in	B-X
macrophagelike	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
as	B-X
compared	B-X
to	B-X
regulation	B-X
by	B-X
phorbol	B-X
ester	B-X
,	B-X
collagenase	B-X
induction	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
cell	B-X
wall	B-X
derivatives	B-X
of	B-X
bacteria	B-X
or	B-X
yeast	B-X
is	B-X
largely	B-X
independent	B-X
of	B-X
upstream	B-X
promoter	B-X
sequences	B-X
.	B-X

This	O
catalytic	O
event	O
is	O
rate	O
limiting	O
in	O
remodeling	O
of	O
tissues	O
rich	O
in	O
fibrillar	O
collagen	O
such	O
as	O
the	O
skin	O
and	O
lungs	O
.	O

The	O
regulation	O
of	O
collagenase	O
expression	O
is	O
cell	O
-	O
type	O
specific	O
;	O
bacterial	O
LPS	O
and	O
zymosan	O
,	O
a	O
yeast	O
cell	O
wall	O
derivative	O
,	O
are	O
potent	O
inducers	O
of	O
collagenase	O
expression	O
in	O
macrophages	O
,	O
but	O
do	O
not	O
alter	O
fibroblast	O
collagenase	O
expression	O
.	O
<EOS>	B-X
Overexpression	B-X
of	B-X
the	B-X
92	B-X
kDa	B-X
type	B-X
IV	B-X
collagenase	B-X
(	B-X
MMP-9	B-X
)	B-X
contributes	B-X
to	B-X
cancer	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
to	B-X
date	B-X
,	B-X
there	B-X
are	B-X
few	B-X
known	B-X
regulators	B-X
of	B-X
expression	B-X
of	B-X
this	B-X
metalloproteinase	B-X
.	B-X
We	B-X
employed	B-X
an	B-X
expression	B-X
library	B-X
comprising	B-X
500,000	B-X
cDNA	B-X
clones	B-X
to	B-X
screen	B-X
for	B-X
novel	B-X
regulators	B-X
of	B-X
MMP-9	B-X
expression	B-X
.	B-X
HT1080	B-X
cells	B-X
were	B-X
transiently	B-X
co-transfected	B-X
with	B-X
an	B-X
MMP-9	B-X
promoter-luciferase	B-X
reporter	B-X
and	B-X
pools	B-X
of	B-X
the	B-X
cDNA	B-X
expression	B-X
library	B-X
.	B-X
This	B-X
brief	B-X
review	B-X
illustrates	B-X
the	B-X
utility	B-X
of	B-X
expression	B-X
cloning	B-X
in	B-X
identifying	B-X
specific	B-X
regulators	B-X
of	B-X
MMP-9	B-X
expression	B-X
.	B-X

Since	O
promoter	O
elements	O
controlling	O
collagenase	O
transcription	O
in	O
monocytic	O
cells	O
have	O
not	O
been	O
previously	O
defined	O
,	O
we	O
sought	O
to	O
delineate	O
responsive	O
cis	O
-	O
acting	O
elements	O
of	O
the	O
collagenase	O
promoter	O
in	O
transiently	O
transfected	O
human	O
(	O
U937	O
)	O
and	O
murine	O
(	O
J774	O
)	O
monocytic	O
cell	O
lines	O
.	O

Deletion	O
constructs	O
containing	O
as	O
little	O
as	O
72	O
bp	O
of	O
5	O
'	O
-	O
flanking	O
sequence	O
of	O
the	O
collagenase	O
promoter	O
were	O
sufficient	O
for	O
LPS	O
-	O
or	O
zymosan	O
-	O
mediated	O
transcriptional	O
induction	O
,	O
whereas	O
phorbol	O
inducibility	O
exhibited	O
an	O
absolute	O
requirement	O
for	O
upstream	O
elements	O
including	O
the	O
polyoma	O
enhancer	O
A	O
-	O
binding	O
protein	O
-	O
3	O
site	O
(	O
-	O
83	O
to	O
-	O
91	O
)	O
and	O
TTCA	O
sequence	O
(	O
-	O
102	O
to	O
-	O
105	O
)	O
in	O
both	O
monocytic	O
cells	O
and	O
fibroblasts	O
.	O
<EOS>	B-X
Interstitial	B-X
collagenase	B-X
(	B-X
MMP-1	B-X
)	B-X
,	B-X
a	B-X
metalloproteinase	B-X
produced	B-X
by	B-X
resident	B-X
and	B-X
inflammatory	B-X
cells	B-X
during	B-X
connective	B-X
tissue	B-X
turnover	B-X
,	B-X
cleaves	B-X
type	B-X
I	B-X
collagen	B-X
fibrils	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
collagenase	B-X
expression	B-X
is	B-X
cell-type	B-X
specific	B-X
;	B-X
bacterial	B-X
LPS	B-X
and	B-X
zymosan	B-X
,	B-X
a	B-X
yeast	B-X
cell	B-X
wall	B-X
derivative	B-X
,	B-X
are	B-X
potent	B-X
inducers	B-X
of	B-X
collagenase	B-X
expression	B-X
in	B-X
macrophages	B-X
,	B-X
but	B-X
do	B-X
not	B-X
alter	B-X
fibroblast	B-X
collagenase	B-X
expression	B-X
.	B-X
Since	B-X
promoter	B-X
elements	B-X
controlling	B-X
collagenase	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
have	B-X
not	B-X
been	B-X
previously	B-X
defined	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
delineate	B-X
responsive	B-X
cis-acting	B-X
elements	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
in	B-X
transiently	B-X
transfected	B-X
human	B-X
(	B-X
U937	B-X
)	B-X
and	B-X
murine	B-X
(	B-X
J774	B-X
)	B-X
monocytic	B-X
cell	B-X
lines	B-X
.	B-X
Deletion	B-X
constructs	B-X
containing	B-X
as	B-X
little	B-X
as	B-X
72	B-X
bp	B-X
of	B-X
5	B-X
'	B-X
-flanking	B-X
sequence	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
were	B-X
sufficient	B-X
for	B-X
LPS-	B-X
or	B-X
zymosan-mediated	B-X
transcriptional	B-X
induction	B-X
,	B-X
whereas	B-X
phorbol	B-X
inducibility	B-X
exhibited	B-X
an	B-X
absolute	B-X
requirement	B-X
for	B-X
upstream	B-X
elements	B-X
including	B-X
the	B-X
polyoma	B-X
enhancer	B-X
A-binding	B-X
protein-3	B-X
site	B-X
(	B-X
-83	B-X
to	B-X
-91	B-X
)	B-X
and	B-X
TTCA	B-X
sequence	B-X
(	B-X
-102	B-X
to	B-X
-105	B-X
)	B-X
in	B-X
both	B-X
monocytic	B-X
cells	B-X
and	B-X
fibroblasts	B-X
.	B-X
Mutagenesis	B-X
of	B-X
the	B-X
activator	B-X
protein-1	B-X
[	B-X
AP-1	B-X
]	B-X
site	B-X
at	B-X
-72	B-X
abolished	B-X
basal	B-X
promoter	B-X
activity	B-X
and	B-X
LPS/zymosan	B-X
inducibility	B-X
,	B-X
while	B-X
mutagenesis	B-X
of	B-X
an	B-X
NF-kappaB-like	B-X
site	B-X
at	B-X
-20	B-X
to	B-X
-10	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
Nuclear	B-X
extracts	B-X
from	B-X
LPS-	B-X
and	B-X
zymosan-treated	B-X
cells	B-X
showed	B-X
strong	B-X
AP-1	B-X
activity	B-X
by	B-X
gel-shift	B-X
analysis	B-X
,	B-X
and	B-X
supershift	B-X
analysis	B-X
showed	B-X
the	B-X
AP-1	B-X
complexes	B-X
contained	B-X
specific	B-X
members	B-X
of	B-X
both	B-X
the	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
families	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
most	B-X
LPS	B-X
effects	B-X
,	B-X
AP-1	B-X
,	B-X
but	B-X
not	B-X
nuclear	B-X
factor-kappaB	B-X
,	B-X
mediates	B-X
LPS	B-X
induction	B-X
of	B-X
collagenase	B-X
transcription	B-X
in	B-X
macrophagelike	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
as	B-X
compared	B-X
to	B-X
regulation	B-X
by	B-X
phorbol	B-X
ester	B-X
,	B-X
collagenase	B-X
induction	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
cell	B-X
wall	B-X
derivatives	B-X
of	B-X
bacteria	B-X
or	B-X
yeast	B-X
is	B-X
largely	B-X
independent	B-X
of	B-X
upstream	B-X
promoter	B-X
sequences	B-X
.	B-X

Mutagenesis	O
of	O
the	O
activator	O
protein	O
-	O
1	O
[	O
AP	O
-	O
1	O
]	O
site	O
at	O
-	O
72	O
abolished	O
basal	O
promoter	O
activity	O
and	O
LPS	O
/	O
zymosan	O
inducibility	O
,	O
while	O
mutagenesis	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
like	O
site	O
at	O
-	O
20	O
to	O
-	O
10	O
had	O
no	O
effect	O
.	O
<EOS>	B-X
Interstitial	B-X
collagenase	B-X
(	B-X
MMP-1	B-X
)	B-X
,	B-X
a	B-X
metalloproteinase	B-X
produced	B-X
by	B-X
resident	B-X
and	B-X
inflammatory	B-X
cells	B-X
during	B-X
connective	B-X
tissue	B-X
turnover	B-X
,	B-X
cleaves	B-X
type	B-X
I	B-X
collagen	B-X
fibrils	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
collagenase	B-X
expression	B-X
is	B-X
cell-type	B-X
specific	B-X
;	B-X
bacterial	B-X
LPS	B-X
and	B-X
zymosan	B-X
,	B-X
a	B-X
yeast	B-X
cell	B-X
wall	B-X
derivative	B-X
,	B-X
are	B-X
potent	B-X
inducers	B-X
of	B-X
collagenase	B-X
expression	B-X
in	B-X
macrophages	B-X
,	B-X
but	B-X
do	B-X
not	B-X
alter	B-X
fibroblast	B-X
collagenase	B-X
expression	B-X
.	B-X
Since	B-X
promoter	B-X
elements	B-X
controlling	B-X
collagenase	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
have	B-X
not	B-X
been	B-X
previously	B-X
defined	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
delineate	B-X
responsive	B-X
cis-acting	B-X
elements	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
in	B-X
transiently	B-X
transfected	B-X
human	B-X
(	B-X
U937	B-X
)	B-X
and	B-X
murine	B-X
(	B-X
J774	B-X
)	B-X
monocytic	B-X
cell	B-X
lines	B-X
.	B-X
Deletion	B-X
constructs	B-X
containing	B-X
as	B-X
little	B-X
as	B-X
72	B-X
bp	B-X
of	B-X
5	B-X
'	B-X
-flanking	B-X
sequence	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
were	B-X
sufficient	B-X
for	B-X
LPS-	B-X
or	B-X
zymosan-mediated	B-X
transcriptional	B-X
induction	B-X
,	B-X
whereas	B-X
phorbol	B-X
inducibility	B-X
exhibited	B-X
an	B-X
absolute	B-X
requirement	B-X
for	B-X
upstream	B-X
elements	B-X
including	B-X
the	B-X
polyoma	B-X
enhancer	B-X
A-binding	B-X
protein-3	B-X
site	B-X
(	B-X
-83	B-X
to	B-X
-91	B-X
)	B-X
and	B-X
TTCA	B-X
sequence	B-X
(	B-X
-102	B-X
to	B-X
-105	B-X
)	B-X
in	B-X
both	B-X
monocytic	B-X
cells	B-X
and	B-X
fibroblasts	B-X
.	B-X
Mutagenesis	B-X
of	B-X
the	B-X
activator	B-X
protein-1	B-X
[	B-X
AP-1	B-X
]	B-X
site	B-X
at	B-X
-72	B-X
abolished	B-X
basal	B-X
promoter	B-X
activity	B-X
and	B-X
LPS/zymosan	B-X
inducibility	B-X
,	B-X
while	B-X
mutagenesis	B-X
of	B-X
an	B-X
NF-kappaB-like	B-X
site	B-X
at	B-X
-20	B-X
to	B-X
-10	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
Nuclear	B-X
extracts	B-X
from	B-X
LPS-	B-X
and	B-X
zymosan-treated	B-X
cells	B-X
showed	B-X
strong	B-X
AP-1	B-X
activity	B-X
by	B-X
gel-shift	B-X
analysis	B-X
,	B-X
and	B-X
supershift	B-X
analysis	B-X
showed	B-X
the	B-X
AP-1	B-X
complexes	B-X
contained	B-X
specific	B-X
members	B-X
of	B-X
both	B-X
the	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
families	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
most	B-X
LPS	B-X
effects	B-X
,	B-X
AP-1	B-X
,	B-X
but	B-X
not	B-X
nuclear	B-X
factor-kappaB	B-X
,	B-X
mediates	B-X
LPS	B-X
induction	B-X
of	B-X
collagenase	B-X
transcription	B-X
in	B-X
macrophagelike	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
as	B-X
compared	B-X
to	B-X
regulation	B-X
by	B-X
phorbol	B-X
ester	B-X
,	B-X
collagenase	B-X
induction	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
cell	B-X
wall	B-X
derivatives	B-X
of	B-X
bacteria	B-X
or	B-X
yeast	B-X
is	B-X
largely	B-X
independent	B-X
of	B-X
upstream	B-X
promoter	B-X
sequences	B-X
.	B-X

Nuclear	O
extracts	O
from	O
LPS	O
-	O
and	O
zymosan	O
-	O
treated	O
cells	O
showed	O
strong	O
AP	O
-	O
1	O
activity	O
by	O
gel	O
-	O
shift	O
analysis	O
,	O
and	O
supershift	O
analysis	O
showed	O
the	O
AP	O
-	O
1	O
complexes	O
contained	O
specific	O
members	O
of	O
both	O
the	O
jun	O
and	O
fos	O
gene	O
families	O
.	O
<EOS>	B-X
Interstitial	B-X
collagenase	B-X
(	B-X
MMP-1	B-X
)	B-X
,	B-X
a	B-X
metalloproteinase	B-X
produced	B-X
by	B-X
resident	B-X
and	B-X
inflammatory	B-X
cells	B-X
during	B-X
connective	B-X
tissue	B-X
turnover	B-X
,	B-X
cleaves	B-X
type	B-X
I	B-X
collagen	B-X
fibrils	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
collagenase	B-X
expression	B-X
is	B-X
cell-type	B-X
specific	B-X
;	B-X
bacterial	B-X
LPS	B-X
and	B-X
zymosan	B-X
,	B-X
a	B-X
yeast	B-X
cell	B-X
wall	B-X
derivative	B-X
,	B-X
are	B-X
potent	B-X
inducers	B-X
of	B-X
collagenase	B-X
expression	B-X
in	B-X
macrophages	B-X
,	B-X
but	B-X
do	B-X
not	B-X
alter	B-X
fibroblast	B-X
collagenase	B-X
expression	B-X
.	B-X
Since	B-X
promoter	B-X
elements	B-X
controlling	B-X
collagenase	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
have	B-X
not	B-X
been	B-X
previously	B-X
defined	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
delineate	B-X
responsive	B-X
cis-acting	B-X
elements	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
in	B-X
transiently	B-X
transfected	B-X
human	B-X
(	B-X
U937	B-X
)	B-X
and	B-X
murine	B-X
(	B-X
J774	B-X
)	B-X
monocytic	B-X
cell	B-X
lines	B-X
.	B-X
Deletion	B-X
constructs	B-X
containing	B-X
as	B-X
little	B-X
as	B-X
72	B-X
bp	B-X
of	B-X
5	B-X
'	B-X
-flanking	B-X
sequence	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
were	B-X
sufficient	B-X
for	B-X
LPS-	B-X
or	B-X
zymosan-mediated	B-X
transcriptional	B-X
induction	B-X
,	B-X
whereas	B-X
phorbol	B-X
inducibility	B-X
exhibited	B-X
an	B-X
absolute	B-X
requirement	B-X
for	B-X
upstream	B-X
elements	B-X
including	B-X
the	B-X
polyoma	B-X
enhancer	B-X
A-binding	B-X
protein-3	B-X
site	B-X
(	B-X
-83	B-X
to	B-X
-91	B-X
)	B-X
and	B-X
TTCA	B-X
sequence	B-X
(	B-X
-102	B-X
to	B-X
-105	B-X
)	B-X
in	B-X
both	B-X
monocytic	B-X
cells	B-X
and	B-X
fibroblasts	B-X
.	B-X
Mutagenesis	B-X
of	B-X
the	B-X
activator	B-X
protein-1	B-X
[	B-X
AP-1	B-X
]	B-X
site	B-X
at	B-X
-72	B-X
abolished	B-X
basal	B-X
promoter	B-X
activity	B-X
and	B-X
LPS/zymosan	B-X
inducibility	B-X
,	B-X
while	B-X
mutagenesis	B-X
of	B-X
an	B-X
NF-kappaB-like	B-X
site	B-X
at	B-X
-20	B-X
to	B-X
-10	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
Nuclear	B-X
extracts	B-X
from	B-X
LPS-	B-X
and	B-X
zymosan-treated	B-X
cells	B-X
showed	B-X
strong	B-X
AP-1	B-X
activity	B-X
by	B-X
gel-shift	B-X
analysis	B-X
,	B-X
and	B-X
supershift	B-X
analysis	B-X
showed	B-X
the	B-X
AP-1	B-X
complexes	B-X
contained	B-X
specific	B-X
members	B-X
of	B-X
both	B-X
the	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
families	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
most	B-X
LPS	B-X
effects	B-X
,	B-X
AP-1	B-X
,	B-X
but	B-X
not	B-X
nuclear	B-X
factor-kappaB	B-X
,	B-X
mediates	B-X
LPS	B-X
induction	B-X
of	B-X
collagenase	B-X
transcription	B-X
in	B-X
macrophagelike	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
as	B-X
compared	B-X
to	B-X
regulation	B-X
by	B-X
phorbol	B-X
ester	B-X
,	B-X
collagenase	B-X
induction	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
cell	B-X
wall	B-X
derivatives	B-X
of	B-X
bacteria	B-X
or	B-X
yeast	B-X
is	B-X
largely	B-X
independent	B-X
of	B-X
upstream	B-X
promoter	B-X
sequences	B-X
.	B-X

These	O
data	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
most	O
LPS	O
effects	O
,	O
AP	O
-	O
1	O
,	O
but	O
not	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
mediates	O
LPS	O
induction	O
of	O
collagenase	O
transcription	O
in	O
macrophagelike	O
cells	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
MR	B-X
activation	B-X
modifies	B-X
macrophage	B-X
pro-inflammatory	B-X
signalling	B-X
,	B-X
changing	B-X
the	B-X
cardiac	B-X
tissue	B-X
response	B-X
to	B-X
injury	B-X
via	B-X
both	B-X
direct	B-X
gene	B-X
transcription	B-X
and	B-X
JNK/AP-1	B-X
second	B-X
messenger	B-X
pathways	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
MR-mediated	B-X
renal	B-X
electrolyte	B-X
homeostasis	B-X
is	B-X
critically	B-X
determined	B-X
by	B-X
DNA-binding-dependent	B-X
processes	B-X
.	B-X
Hence	B-X
,	B-X
ascertaining	B-X
the	B-X
relative	B-X
contribution	B-X
of	B-X
MR	B-X
actions	B-X
via	B-X
DNA	B-X
binding	B-X
or	B-X
alternative	B-X
pathways	B-X
on	B-X
macrophage	B-X
behaviour	B-X
and	B-X
cardiac	B-X
inflammation	B-X
may	B-X
provide	B-X
therapeutic	B-X
opportunities	B-X
which	B-X
separate	B-X
the	B-X
cardioprotective	B-X
effects	B-X
of	B-X
MR	B-X
antagonists	B-X
from	B-X
their	B-X
undesirable	B-X
renal	B-X
potassium-conserving	B-X
effects	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
demonstrated	B-X
that	B-X
MR	B-X
DNA	B-X
binding	B-X
is	B-X
required	B-X
for	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
but	B-X
not	B-X
phorbol	B-X
12-myristate-13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
,	B-X
induction	B-X
of	B-X
the	B-X
MAPK/pJNK	B-X
pathway	B-X
in	B-X
macrophages	B-X
.	B-X
Quantitative	B-X
RTPCR	B-X
for	B-X
pro-inflammatory	B-X
and	B-X
pro-fibrotic	B-X
targets	B-X
revealed	B-X
subsets	B-X
of	B-X
LPS-	B-X
and	B-X
PMA-induced	B-X
genes	B-X
that	B-X
were	B-X
either	B-X
enhanced	B-X
or	B-X
repressed	B-X
by	B-X
the	B-X
MR	B-X
via	B-X
actions	B-X
that	B-X
do	B-X
not	B-X
always	B-X
require	B-X
direct	B-X
MR-DNA	B-X
binding	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
MR	B-X
target	B-X
gene	B-X
and	B-X
profibrotic	B-X
factor	B-X
MMP12	B-X
identified	B-X
promoter	B-X
elements	B-X
that	B-X
are	B-X
regulated	B-X
by	B-X
combined	B-X
MR/MAPK/JNK	B-X
signalling	B-X
.	B-X
Our	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
MR	B-X
regulates	B-X
a	B-X
macrophage	B-X
pro-inflammatory	B-X
phenotype	B-X
and	B-X
cardiac	B-X
tissue	B-X
inflammation	B-X
,	B-X
partially	B-X
via	B-X
pathways	B-X
that	B-X
do	B-X
not	B-X
require	B-X
DNA	B-X
binding	B-X
.	B-X

Furthermore	O
,	O
as	O
compared	O
to	O
regulation	O
by	O
phorbol	O
ester	O
,	O
collagenase	O
induction	O
in	O
monocytic	O
cells	O
by	O
cell	O
wall	O
derivatives	O
of	O
bacteria	O
or	O
yeast	O
is	O
largely	O
independent	O
of	O
upstream	O
promoter	O
sequences	O
.	O
<EOS>	B-X
Interstitial	B-X
collagenase	B-X
(	B-X
MMP-1	B-X
)	B-X
,	B-X
a	B-X
metalloproteinase	B-X
produced	B-X
by	B-X
resident	B-X
and	B-X
inflammatory	B-X
cells	B-X
during	B-X
connective	B-X
tissue	B-X
turnover	B-X
,	B-X
cleaves	B-X
type	B-X
I	B-X
collagen	B-X
fibrils	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
collagenase	B-X
expression	B-X
is	B-X
cell-type	B-X
specific	B-X
;	B-X
bacterial	B-X
LPS	B-X
and	B-X
zymosan	B-X
,	B-X
a	B-X
yeast	B-X
cell	B-X
wall	B-X
derivative	B-X
,	B-X
are	B-X
potent	B-X
inducers	B-X
of	B-X
collagenase	B-X
expression	B-X
in	B-X
macrophages	B-X
,	B-X
but	B-X
do	B-X
not	B-X
alter	B-X
fibroblast	B-X
collagenase	B-X
expression	B-X
.	B-X
Since	B-X
promoter	B-X
elements	B-X
controlling	B-X
collagenase	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
have	B-X
not	B-X
been	B-X
previously	B-X
defined	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
delineate	B-X
responsive	B-X
cis-acting	B-X
elements	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
in	B-X
transiently	B-X
transfected	B-X
human	B-X
(	B-X
U937	B-X
)	B-X
and	B-X
murine	B-X
(	B-X
J774	B-X
)	B-X
monocytic	B-X
cell	B-X
lines	B-X
.	B-X
Deletion	B-X
constructs	B-X
containing	B-X
as	B-X
little	B-X
as	B-X
72	B-X
bp	B-X
of	B-X
5	B-X
'	B-X
-flanking	B-X
sequence	B-X
of	B-X
the	B-X
collagenase	B-X
promoter	B-X
were	B-X
sufficient	B-X
for	B-X
LPS-	B-X
or	B-X
zymosan-mediated	B-X
transcriptional	B-X
induction	B-X
,	B-X
whereas	B-X
phorbol	B-X
inducibility	B-X
exhibited	B-X
an	B-X
absolute	B-X
requirement	B-X
for	B-X
upstream	B-X
elements	B-X
including	B-X
the	B-X
polyoma	B-X
enhancer	B-X
A-binding	B-X
protein-3	B-X
site	B-X
(	B-X
-83	B-X
to	B-X
-91	B-X
)	B-X
and	B-X
TTCA	B-X
sequence	B-X
(	B-X
-102	B-X
to	B-X
-105	B-X
)	B-X
in	B-X
both	B-X
monocytic	B-X
cells	B-X
and	B-X
fibroblasts	B-X
.	B-X
Mutagenesis	B-X
of	B-X
the	B-X
activator	B-X
protein-1	B-X
[	B-X
AP-1	B-X
]	B-X
site	B-X
at	B-X
-72	B-X
abolished	B-X
basal	B-X
promoter	B-X
activity	B-X
and	B-X
LPS/zymosan	B-X
inducibility	B-X
,	B-X
while	B-X
mutagenesis	B-X
of	B-X
an	B-X
NF-kappaB-like	B-X
site	B-X
at	B-X
-20	B-X
to	B-X
-10	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
Nuclear	B-X
extracts	B-X
from	B-X
LPS-	B-X
and	B-X
zymosan-treated	B-X
cells	B-X
showed	B-X
strong	B-X
AP-1	B-X
activity	B-X
by	B-X
gel-shift	B-X
analysis	B-X
,	B-X
and	B-X
supershift	B-X
analysis	B-X
showed	B-X
the	B-X
AP-1	B-X
complexes	B-X
contained	B-X
specific	B-X
members	B-X
of	B-X
both	B-X
the	B-X
jun	B-X
and	B-X
fos	B-X
gene	B-X
families	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
most	B-X
LPS	B-X
effects	B-X
,	B-X
AP-1	B-X
,	B-X
but	B-X
not	B-X
nuclear	B-X
factor-kappaB	B-X
,	B-X
mediates	B-X
LPS	B-X
induction	B-X
of	B-X
collagenase	B-X
transcription	B-X
in	B-X
macrophagelike	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
as	B-X
compared	B-X
to	B-X
regulation	B-X
by	B-X
phorbol	B-X
ester	B-X
,	B-X
collagenase	B-X
induction	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
cell	B-X
wall	B-X
derivatives	B-X
of	B-X
bacteria	B-X
or	B-X
yeast	B-X
is	B-X
largely	B-X
independent	B-X
of	B-X
upstream	B-X
promoter	B-X
sequences	B-X
.	B-X

Inhibitory	O
effect	O
of	O
E3330	O
,	O
a	O
novel	O
quinone	O
derivative	O
able	O
to	O
suppress	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
generation	O
,	O
on	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
(	B-X
2E	B-X
)	B-X
-3-	B-X
[	B-X
5-	B-X
(	B-X
2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl	B-X
)	B-X
]	B-X
-2-nonyl-2-	B-X
propenoic	B-X
acid	B-X
(	B-X
E3330	B-X
)	B-X
,	B-X
is	B-X
a	B-X
novel	B-X
agent	B-X
with	B-X
hepatoprotective	B-X
activity	B-X
.	B-X
We	B-X
report	B-X
the	B-X
effect	B-X
of	B-X
E3330	B-X
on	B-X
transcriptional	B-X
activation	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-alpha	B-X
gene	B-X
and	B-X
on	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
activation	B-X
.	B-X
Nuclear	B-X
run-on	B-X
experiments	B-X
showed	B-X
that	B-X
E3330	B-X
decreases	B-X
transcriptional	B-X
activation	B-X
of	B-X
TNF-alpha	B-X
gene	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
in	B-X
human	B-X
peripheral	B-X
monocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
inhibitory	B-X
mechanisms	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
secreted-type	B-X
placental	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
PLAP	B-X
)	B-X
reporter	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
1.4-kb	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
A	B-X
stable	B-X
transformant	B-X
of	B-X
the	B-X
PLAP	B-X
reporter	B-X
gene	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
showed	B-X
very	B-X
little	B-X
activity	B-X
on	B-X
the	B-X
promoter	B-X
before	B-X
stimulation	B-X
,	B-X
whereas	B-X
LPS	B-X
stimulation	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
PLAP	B-X
activity	B-X
.	B-X
E3330	B-X
inhibited	B-X
this	B-X
induced	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
There	B-X
are	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
binding	B-X
sites	B-X
(	B-X
kappa	B-X
B-1	B-X
,	B-X
kappa	B-X
B-2	B-X
,	B-X
kappa	B-X
B-3	B-X
,	B-X
kappa	B-X
B-4	B-X
)	B-X
in	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
By	B-X
using	B-X
mutated	B-X
promoter-PLAP	B-X
plasmids	B-X
,	B-X
we	B-X
established	B-X
that	B-X
these	B-X
NF-kappa	B-X
B	B-X
sites	B-X
were	B-X
necessary	B-X
for	B-X
induction	B-X
of	B-X
TNF-alpha	B-X
transcription	B-X
on	B-X
stimulation	B-X
with	B-X
LPS	B-X
.	B-X
A	B-X
gel	B-X
retardation	B-X
experiment	B-X
with	B-X
synthetic	B-X
double-stranded	B-X
oligonucleotides	B-X
showed	B-X
that	B-X
activated	B-X
NF-kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50/p65	B-X
heterodimer	B-X
bound	B-X
to	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
probes	B-X
,	B-X
suggesting	B-X
that	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
recognition	B-X
sites	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inducible	B-X
TNF-alpha	B-X
expression	B-X
.	B-X
E3330	B-X
decreased	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
nuclei	B-X
,	B-X
suggesting	B-X
that	B-X
E3330	B-X
inhibits	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and/or	B-X
translocation	B-X
of	B-X
the	B-X
nuclei	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
with	B-X
anti-I	B-X
kappa	B-X
B-alpha	B-X
antibody	B-X
indicated	B-X
that	B-X
E3330	B-X
inhibited	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
which	B-X
is	B-X
an	B-X
inhibitory	B-X
protein	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
in	B-X
LPS-stimulated	B-X
monocytes	B-X
.	B-X
E3330	B-X
may	B-X
suppress	B-X
the	B-X
production	B-X
of	B-X
active	B-X
oxygen	B-X
species	B-X
serving	B-X
as	B-X
common	B-X
messengers	B-X
to	B-X
activate	B-X
NF-kappa	B-X
B	B-X
.	B-X

(	O
2E	O
)	O
-	O
3	O
-	O
[	O
5	O
-	O
(	O
2	O
,	O
3	O
-	O
Dimethoxy	O
-	O
6	O
-	O
methyl	O
-	O
1	O
,	O
4	O
-	O
benzoquinoyl	O
)	O
]	O
-	O
2	O
-	O
nonyl	O
-	O
2	O
-	O
propenoic	O
acid	O
(	O
E3330	O
)	O
,	O
is	O
a	O
novel	O
agent	O
with	O
hepatoprotective	O
activity	O
.	O

We	O
report	O
the	O
effect	O
of	O
E3330	O
on	O
transcriptional	O
activation	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
gene	O
and	O
on	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
activation	O
.	O
<EOS>	B-X
(	B-X
2E	B-X
)	B-X
-3-	B-X
[	B-X
5-	B-X
(	B-X
2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl	B-X
)	B-X
]	B-X
-2-nonyl-2-	B-X
propenoic	B-X
acid	B-X
(	B-X
E3330	B-X
)	B-X
,	B-X
is	B-X
a	B-X
novel	B-X
agent	B-X
with	B-X
hepatoprotective	B-X
activity	B-X
.	B-X
We	B-X
report	B-X
the	B-X
effect	B-X
of	B-X
E3330	B-X
on	B-X
transcriptional	B-X
activation	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-alpha	B-X
gene	B-X
and	B-X
on	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
activation	B-X
.	B-X
Nuclear	B-X
run-on	B-X
experiments	B-X
showed	B-X
that	B-X
E3330	B-X
decreases	B-X
transcriptional	B-X
activation	B-X
of	B-X
TNF-alpha	B-X
gene	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
in	B-X
human	B-X
peripheral	B-X
monocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
inhibitory	B-X
mechanisms	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
secreted-type	B-X
placental	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
PLAP	B-X
)	B-X
reporter	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
1.4-kb	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
A	B-X
stable	B-X
transformant	B-X
of	B-X
the	B-X
PLAP	B-X
reporter	B-X
gene	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
showed	B-X
very	B-X
little	B-X
activity	B-X
on	B-X
the	B-X
promoter	B-X
before	B-X
stimulation	B-X
,	B-X
whereas	B-X
LPS	B-X
stimulation	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
PLAP	B-X
activity	B-X
.	B-X
E3330	B-X
inhibited	B-X
this	B-X
induced	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
There	B-X
are	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
binding	B-X
sites	B-X
(	B-X
kappa	B-X
B-1	B-X
,	B-X
kappa	B-X
B-2	B-X
,	B-X
kappa	B-X
B-3	B-X
,	B-X
kappa	B-X
B-4	B-X
)	B-X
in	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
By	B-X
using	B-X
mutated	B-X
promoter-PLAP	B-X
plasmids	B-X
,	B-X
we	B-X
established	B-X
that	B-X
these	B-X
NF-kappa	B-X
B	B-X
sites	B-X
were	B-X
necessary	B-X
for	B-X
induction	B-X
of	B-X
TNF-alpha	B-X
transcription	B-X
on	B-X
stimulation	B-X
with	B-X
LPS	B-X
.	B-X
A	B-X
gel	B-X
retardation	B-X
experiment	B-X
with	B-X
synthetic	B-X
double-stranded	B-X
oligonucleotides	B-X
showed	B-X
that	B-X
activated	B-X
NF-kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50/p65	B-X
heterodimer	B-X
bound	B-X
to	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
probes	B-X
,	B-X
suggesting	B-X
that	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
recognition	B-X
sites	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inducible	B-X
TNF-alpha	B-X
expression	B-X
.	B-X
E3330	B-X
decreased	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
nuclei	B-X
,	B-X
suggesting	B-X
that	B-X
E3330	B-X
inhibits	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and/or	B-X
translocation	B-X
of	B-X
the	B-X
nuclei	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
with	B-X
anti-I	B-X
kappa	B-X
B-alpha	B-X
antibody	B-X
indicated	B-X
that	B-X
E3330	B-X
inhibited	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
which	B-X
is	B-X
an	B-X
inhibitory	B-X
protein	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
in	B-X
LPS-stimulated	B-X
monocytes	B-X
.	B-X
E3330	B-X
may	B-X
suppress	B-X
the	B-X
production	B-X
of	B-X
active	B-X
oxygen	B-X
species	B-X
serving	B-X
as	B-X
common	B-X
messengers	B-X
to	B-X
activate	B-X
NF-kappa	B-X
B	B-X
.	B-X

Nuclear	O
run	O
-	O
on	O
experiments	O
showed	O
that	O
E3330	O
decreases	O
transcriptional	O
activation	O
of	O
TNF	O
-	O
alpha	O
gene	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
in	O
human	O
peripheral	O
monocytes	O
.	O
<EOS>	B-X
(	B-X
2E	B-X
)	B-X
-3-	B-X
[	B-X
5-	B-X
(	B-X
2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl	B-X
)	B-X
]	B-X
-2-nonyl-2-	B-X
propenoic	B-X
acid	B-X
(	B-X
E3330	B-X
)	B-X
,	B-X
is	B-X
a	B-X
novel	B-X
agent	B-X
with	B-X
hepatoprotective	B-X
activity	B-X
.	B-X
We	B-X
report	B-X
the	B-X
effect	B-X
of	B-X
E3330	B-X
on	B-X
transcriptional	B-X
activation	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-alpha	B-X
gene	B-X
and	B-X
on	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
activation	B-X
.	B-X
Nuclear	B-X
run-on	B-X
experiments	B-X
showed	B-X
that	B-X
E3330	B-X
decreases	B-X
transcriptional	B-X
activation	B-X
of	B-X
TNF-alpha	B-X
gene	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
in	B-X
human	B-X
peripheral	B-X
monocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
inhibitory	B-X
mechanisms	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
secreted-type	B-X
placental	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
PLAP	B-X
)	B-X
reporter	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
1.4-kb	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
A	B-X
stable	B-X
transformant	B-X
of	B-X
the	B-X
PLAP	B-X
reporter	B-X
gene	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
showed	B-X
very	B-X
little	B-X
activity	B-X
on	B-X
the	B-X
promoter	B-X
before	B-X
stimulation	B-X
,	B-X
whereas	B-X
LPS	B-X
stimulation	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
PLAP	B-X
activity	B-X
.	B-X
E3330	B-X
inhibited	B-X
this	B-X
induced	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
There	B-X
are	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
binding	B-X
sites	B-X
(	B-X
kappa	B-X
B-1	B-X
,	B-X
kappa	B-X
B-2	B-X
,	B-X
kappa	B-X
B-3	B-X
,	B-X
kappa	B-X
B-4	B-X
)	B-X
in	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
By	B-X
using	B-X
mutated	B-X
promoter-PLAP	B-X
plasmids	B-X
,	B-X
we	B-X
established	B-X
that	B-X
these	B-X
NF-kappa	B-X
B	B-X
sites	B-X
were	B-X
necessary	B-X
for	B-X
induction	B-X
of	B-X
TNF-alpha	B-X
transcription	B-X
on	B-X
stimulation	B-X
with	B-X
LPS	B-X
.	B-X
A	B-X
gel	B-X
retardation	B-X
experiment	B-X
with	B-X
synthetic	B-X
double-stranded	B-X
oligonucleotides	B-X
showed	B-X
that	B-X
activated	B-X
NF-kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50/p65	B-X
heterodimer	B-X
bound	B-X
to	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
probes	B-X
,	B-X
suggesting	B-X
that	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
recognition	B-X
sites	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inducible	B-X
TNF-alpha	B-X
expression	B-X
.	B-X
E3330	B-X
decreased	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
nuclei	B-X
,	B-X
suggesting	B-X
that	B-X
E3330	B-X
inhibits	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and/or	B-X
translocation	B-X
of	B-X
the	B-X
nuclei	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
with	B-X
anti-I	B-X
kappa	B-X
B-alpha	B-X
antibody	B-X
indicated	B-X
that	B-X
E3330	B-X
inhibited	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
which	B-X
is	B-X
an	B-X
inhibitory	B-X
protein	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
in	B-X
LPS-stimulated	B-X
monocytes	B-X
.	B-X
E3330	B-X
may	B-X
suppress	B-X
the	B-X
production	B-X
of	B-X
active	B-X
oxygen	B-X
species	B-X
serving	B-X
as	B-X
common	B-X
messengers	B-X
to	B-X
activate	B-X
NF-kappa	B-X
B	B-X
.	B-X

To	O
investigate	O
the	O
inhibitory	O
mechanisms	O
,	O
we	O
constructed	O
a	O
secreted	O
-	O
type	O
placental	B-Protein
alkaline	I-Protein
phosphatase	I-Protein
(	O
PLAP	B-Protein
)	O
reporter	O
gene	O
whose	O
transcription	O
is	O
controlled	O
by	O
a	O
1	O
.	O
4	O
-	O
kb	O
human	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
promoter	O
.	O
<EOS>	B-X
(	B-X
2E	B-X
)	B-X
-3-	B-X
[	B-X
5-	B-X
(	B-X
2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl	B-X
)	B-X
]	B-X
-2-nonyl-2-	B-X
propenoic	B-X
acid	B-X
(	B-X
E3330	B-X
)	B-X
,	B-X
is	B-X
a	B-X
novel	B-X
agent	B-X
with	B-X
hepatoprotective	B-X
activity	B-X
.	B-X
We	B-X
report	B-X
the	B-X
effect	B-X
of	B-X
E3330	B-X
on	B-X
transcriptional	B-X
activation	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-alpha	B-X
gene	B-X
and	B-X
on	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
activation	B-X
.	B-X
Nuclear	B-X
run-on	B-X
experiments	B-X
showed	B-X
that	B-X
E3330	B-X
decreases	B-X
transcriptional	B-X
activation	B-X
of	B-X
TNF-alpha	B-X
gene	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
in	B-X
human	B-X
peripheral	B-X
monocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
inhibitory	B-X
mechanisms	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
secreted-type	B-X
placental	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
PLAP	B-X
)	B-X
reporter	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
1.4-kb	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
A	B-X
stable	B-X
transformant	B-X
of	B-X
the	B-X
PLAP	B-X
reporter	B-X
gene	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
showed	B-X
very	B-X
little	B-X
activity	B-X
on	B-X
the	B-X
promoter	B-X
before	B-X
stimulation	B-X
,	B-X
whereas	B-X
LPS	B-X
stimulation	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
PLAP	B-X
activity	B-X
.	B-X
E3330	B-X
inhibited	B-X
this	B-X
induced	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
There	B-X
are	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
binding	B-X
sites	B-X
(	B-X
kappa	B-X
B-1	B-X
,	B-X
kappa	B-X
B-2	B-X
,	B-X
kappa	B-X
B-3	B-X
,	B-X
kappa	B-X
B-4	B-X
)	B-X
in	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
By	B-X
using	B-X
mutated	B-X
promoter-PLAP	B-X
plasmids	B-X
,	B-X
we	B-X
established	B-X
that	B-X
these	B-X
NF-kappa	B-X
B	B-X
sites	B-X
were	B-X
necessary	B-X
for	B-X
induction	B-X
of	B-X
TNF-alpha	B-X
transcription	B-X
on	B-X
stimulation	B-X
with	B-X
LPS	B-X
.	B-X
A	B-X
gel	B-X
retardation	B-X
experiment	B-X
with	B-X
synthetic	B-X
double-stranded	B-X
oligonucleotides	B-X
showed	B-X
that	B-X
activated	B-X
NF-kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50/p65	B-X
heterodimer	B-X
bound	B-X
to	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
probes	B-X
,	B-X
suggesting	B-X
that	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
recognition	B-X
sites	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inducible	B-X
TNF-alpha	B-X
expression	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
with	B-X
anti-I	B-X
kappa	B-X
B-alpha	B-X
antibody	B-X
indicated	B-X
that	B-X
E3330	B-X
inhibited	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
which	B-X
is	B-X
an	B-X
inhibitory	B-X
protein	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
in	B-X
LPS-stimulated	B-X
monocytes	B-X
.	B-X

A	O
stable	O
transformant	O
of	O
the	O
PLAP	B-Protein
reporter	O
gene	O
derived	O
from	O
human	O
monocytic	O
cell	O
line	O
showed	O
very	O
little	O
activity	O
on	O
the	O
promoter	O
before	O
stimulation	O
,	O
whereas	O
LPS	O
stimulation	O
led	O
to	O
a	O
dramatic	O
increase	O
in	O
PLAP	B-Protein
activity	O
.	O
<EOS>	B-X
(	B-X
2E	B-X
)	B-X
-3-	B-X
[	B-X
5-	B-X
(	B-X
2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl	B-X
)	B-X
]	B-X
-2-nonyl-2-	B-X
propenoic	B-X
acid	B-X
(	B-X
E3330	B-X
)	B-X
,	B-X
is	B-X
a	B-X
novel	B-X
agent	B-X
with	B-X
hepatoprotective	B-X
activity	B-X
.	B-X
We	B-X
report	B-X
the	B-X
effect	B-X
of	B-X
E3330	B-X
on	B-X
transcriptional	B-X
activation	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-alpha	B-X
gene	B-X
and	B-X
on	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
activation	B-X
.	B-X
Nuclear	B-X
run-on	B-X
experiments	B-X
showed	B-X
that	B-X
E3330	B-X
decreases	B-X
transcriptional	B-X
activation	B-X
of	B-X
TNF-alpha	B-X
gene	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
in	B-X
human	B-X
peripheral	B-X
monocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
inhibitory	B-X
mechanisms	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
secreted-type	B-X
placental	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
PLAP	B-X
)	B-X
reporter	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
1.4-kb	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
A	B-X
stable	B-X
transformant	B-X
of	B-X
the	B-X
PLAP	B-X
reporter	B-X
gene	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
showed	B-X
very	B-X
little	B-X
activity	B-X
on	B-X
the	B-X
promoter	B-X
before	B-X
stimulation	B-X
,	B-X
whereas	B-X
LPS	B-X
stimulation	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
PLAP	B-X
activity	B-X
.	B-X
E3330	B-X
inhibited	B-X
this	B-X
induced	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
There	B-X
are	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
binding	B-X
sites	B-X
(	B-X
kappa	B-X
B-1	B-X
,	B-X
kappa	B-X
B-2	B-X
,	B-X
kappa	B-X
B-3	B-X
,	B-X
kappa	B-X
B-4	B-X
)	B-X
in	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
By	B-X
using	B-X
mutated	B-X
promoter-PLAP	B-X
plasmids	B-X
,	B-X
we	B-X
established	B-X
that	B-X
these	B-X
NF-kappa	B-X
B	B-X
sites	B-X
were	B-X
necessary	B-X
for	B-X
induction	B-X
of	B-X
TNF-alpha	B-X
transcription	B-X
on	B-X
stimulation	B-X
with	B-X
LPS	B-X
.	B-X
A	B-X
gel	B-X
retardation	B-X
experiment	B-X
with	B-X
synthetic	B-X
double-stranded	B-X
oligonucleotides	B-X
showed	B-X
that	B-X
activated	B-X
NF-kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50/p65	B-X
heterodimer	B-X
bound	B-X
to	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
probes	B-X
,	B-X
suggesting	B-X
that	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
recognition	B-X
sites	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inducible	B-X
TNF-alpha	B-X
expression	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
with	B-X
anti-I	B-X
kappa	B-X
B-alpha	B-X
antibody	B-X
indicated	B-X
that	B-X
E3330	B-X
inhibited	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
which	B-X
is	B-X
an	B-X
inhibitory	B-X
protein	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
in	B-X
LPS-stimulated	B-X
monocytes	B-X
.	B-X

E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

There	O
are	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
(	O
kappa	O
B	O
-	O
1	O
,	O
kappa	O
B	O
-	O
2	O
,	O
kappa	O
B	O
-	O
3	O
,	O
kappa	O
B	O
-	O
4	O
)	O
in	O
human	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
promoter	O
.	O
<EOS>	B-X
(	B-X
2E	B-X
)	B-X
-3-	B-X
[	B-X
5-	B-X
(	B-X
2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl	B-X
)	B-X
]	B-X
-2-nonyl-2-	B-X
propenoic	B-X
acid	B-X
(	B-X
E3330	B-X
)	B-X
,	B-X
is	B-X
a	B-X
novel	B-X
agent	B-X
with	B-X
hepatoprotective	B-X
activity	B-X
.	B-X
We	B-X
report	B-X
the	B-X
effect	B-X
of	B-X
E3330	B-X
on	B-X
transcriptional	B-X
activation	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-alpha	B-X
gene	B-X
and	B-X
on	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
activation	B-X
.	B-X
Nuclear	B-X
run-on	B-X
experiments	B-X
showed	B-X
that	B-X
E3330	B-X
decreases	B-X
transcriptional	B-X
activation	B-X
of	B-X
TNF-alpha	B-X
gene	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
in	B-X
human	B-X
peripheral	B-X
monocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
inhibitory	B-X
mechanisms	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
secreted-type	B-X
placental	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
PLAP	B-X
)	B-X
reporter	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
1.4-kb	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
A	B-X
stable	B-X
transformant	B-X
of	B-X
the	B-X
PLAP	B-X
reporter	B-X
gene	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
showed	B-X
very	B-X
little	B-X
activity	B-X
on	B-X
the	B-X
promoter	B-X
before	B-X
stimulation	B-X
,	B-X
whereas	B-X
LPS	B-X
stimulation	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
PLAP	B-X
activity	B-X
.	B-X
E3330	B-X
inhibited	B-X
this	B-X
induced	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
There	B-X
are	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
binding	B-X
sites	B-X
(	B-X
kappa	B-X
B-1	B-X
,	B-X
kappa	B-X
B-2	B-X
,	B-X
kappa	B-X
B-3	B-X
,	B-X
kappa	B-X
B-4	B-X
)	B-X
in	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
By	B-X
using	B-X
mutated	B-X
promoter-PLAP	B-X
plasmids	B-X
,	B-X
we	B-X
established	B-X
that	B-X
these	B-X
NF-kappa	B-X
B	B-X
sites	B-X
were	B-X
necessary	B-X
for	B-X
induction	B-X
of	B-X
TNF-alpha	B-X
transcription	B-X
on	B-X
stimulation	B-X
with	B-X
LPS	B-X
.	B-X
A	B-X
gel	B-X
retardation	B-X
experiment	B-X
with	B-X
synthetic	B-X
double-stranded	B-X
oligonucleotides	B-X
showed	B-X
that	B-X
activated	B-X
NF-kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50/p65	B-X
heterodimer	B-X
bound	B-X
to	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
probes	B-X
,	B-X
suggesting	B-X
that	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
recognition	B-X
sites	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inducible	B-X
TNF-alpha	B-X
expression	B-X
.	B-X
E3330	B-X
decreased	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
nuclei	B-X
,	B-X
suggesting	B-X
that	B-X
E3330	B-X
inhibits	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and/or	B-X
translocation	B-X
of	B-X
the	B-X
nuclei	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
with	B-X
anti-I	B-X
kappa	B-X
B-alpha	B-X
antibody	B-X
indicated	B-X
that	B-X
E3330	B-X
inhibited	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
which	B-X
is	B-X
an	B-X
inhibitory	B-X
protein	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
in	B-X
LPS-stimulated	B-X
monocytes	B-X
.	B-X
E3330	B-X
may	B-X
suppress	B-X
the	B-X
production	B-X
of	B-X
active	B-X
oxygen	B-X
species	B-X
serving	B-X
as	B-X
common	B-X
messengers	B-X
to	B-X
activate	B-X
NF-kappa	B-X
B	B-X
.	B-X

By	O
using	O
mutated	O
promoter	O
-	O
PLAP	B-Protein
plasmids	O
,	O
we	O
established	O
that	O
these	O
NF	O
-	O
kappa	O
B	O
sites	O
were	O
necessary	O
for	O
induction	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
transcription	O
on	O
stimulation	O
with	O
LPS	O
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
effect	B-X
of	B-X
E3330	B-X
on	B-X
transcriptional	B-X
activation	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-alpha	B-X
gene	B-X
and	B-X
on	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
activation	B-X
.	B-X
Nuclear	B-X
run-on	B-X
experiments	B-X
showed	B-X
that	B-X
E3330	B-X
decreases	B-X
transcriptional	B-X
activation	B-X
of	B-X
TNF-alpha	B-X
gene	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
in	B-X
human	B-X
peripheral	B-X
monocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
inhibitory	B-X
mechanisms	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
secreted-type	B-X
placental	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
PLAP	B-X
)	B-X
reporter	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
1.4-kb	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
A	B-X
stable	B-X
transformant	B-X
of	B-X
the	B-X
PLAP	B-X
reporter	B-X
gene	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
showed	B-X
very	B-X
little	B-X
activity	B-X
on	B-X
the	B-X
promoter	B-X
before	B-X
stimulation	B-X
,	B-X
whereas	B-X
LPS	B-X
stimulation	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
PLAP	B-X
activity	B-X
.	B-X
E3330	B-X
inhibited	B-X
this	B-X
induced	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
There	B-X
are	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
binding	B-X
sites	B-X
(	B-X
kappa	B-X
B-1	B-X
,	B-X
kappa	B-X
B-2	B-X
,	B-X
kappa	B-X
B-3	B-X
,	B-X
kappa	B-X
B-4	B-X
)	B-X
in	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
By	B-X
using	B-X
mutated	B-X
promoter-PLAP	B-X
plasmids	B-X
,	B-X
we	B-X
established	B-X
that	B-X
these	B-X
NF-kappa	B-X
B	B-X
sites	B-X
were	B-X
necessary	B-X
for	B-X
induction	B-X
of	B-X
TNF-alpha	B-X
transcription	B-X
on	B-X
stimulation	B-X
with	B-X
LPS	B-X
.	B-X
A	B-X
gel	B-X
retardation	B-X
experiment	B-X
with	B-X
synthetic	B-X
double-stranded	B-X
oligonucleotides	B-X
showed	B-X
that	B-X
activated	B-X
NF-kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50/p65	B-X
heterodimer	B-X
bound	B-X
to	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
probes	B-X
,	B-X
suggesting	B-X
that	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
recognition	B-X
sites	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inducible	B-X
TNF-alpha	B-X
expression	B-X
.	B-X
E3330	B-X
decreased	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
nuclei	B-X
,	B-X
suggesting	B-X
that	B-X
E3330	B-X
inhibits	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and/or	B-X
translocation	B-X
of	B-X
the	B-X
nuclei	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
with	B-X
anti-I	B-X
kappa	B-X
B-alpha	B-X
antibody	B-X
indicated	B-X
that	B-X
E3330	B-X
inhibited	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
which	B-X
is	B-X
an	B-X
inhibitory	B-X
protein	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
in	B-X
LPS-stimulated	B-X
monocytes	B-X
.	B-X
E3330	B-X
may	B-X
suppress	B-X
the	B-X
production	B-X
of	B-X
active	B-X
oxygen	B-X
species	B-X
serving	B-X
as	B-X
common	B-X
messengers	B-X
to	B-X
activate	B-X
NF-kappa	B-X
B	B-X
.	B-X

A	O
gel	O
retardation	O
experiment	O
with	O
synthetic	O
double	O
-	O
stranded	O
oligonucleotides	O
showed	O
that	O
activated	O
NF	O
-	O
kappa	O
B	O
consisting	O
of	O
p50	B-Protein
/	O
p65	B-Protein
heterodimer	O
bound	O
to	O
all	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
DNA	O
probes	O
,	O
suggesting	O
that	O
all	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
recognition	O
sites	O
play	O
an	O
important	O
role	O
in	O
inducible	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
expression	O
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
effect	B-X
of	B-X
E3330	B-X
on	B-X
transcriptional	B-X
activation	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-alpha	B-X
gene	B-X
and	B-X
on	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
activation	B-X
.	B-X
Nuclear	B-X
run-on	B-X
experiments	B-X
showed	B-X
that	B-X
E3330	B-X
decreases	B-X
transcriptional	B-X
activation	B-X
of	B-X
TNF-alpha	B-X
gene	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
in	B-X
human	B-X
peripheral	B-X
monocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
inhibitory	B-X
mechanisms	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
secreted-type	B-X
placental	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
PLAP	B-X
)	B-X
reporter	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
1.4-kb	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
A	B-X
stable	B-X
transformant	B-X
of	B-X
the	B-X
PLAP	B-X
reporter	B-X
gene	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
showed	B-X
very	B-X
little	B-X
activity	B-X
on	B-X
the	B-X
promoter	B-X
before	B-X
stimulation	B-X
,	B-X
whereas	B-X
LPS	B-X
stimulation	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
PLAP	B-X
activity	B-X
.	B-X
There	B-X
are	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
binding	B-X
sites	B-X
(	B-X
kappa	B-X
B-1	B-X
,	B-X
kappa	B-X
B-2	B-X
,	B-X
kappa	B-X
B-3	B-X
,	B-X
kappa	B-X
B-4	B-X
)	B-X
in	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
By	B-X
using	B-X
mutated	B-X
promoter-PLAP	B-X
plasmids	B-X
,	B-X
we	B-X
established	B-X
that	B-X
these	B-X
NF-kappa	B-X
B	B-X
sites	B-X
were	B-X
necessary	B-X
for	B-X
induction	B-X
of	B-X
TNF-alpha	B-X
transcription	B-X
on	B-X
stimulation	B-X
with	B-X
LPS	B-X
.	B-X
A	B-X
gel	B-X
retardation	B-X
experiment	B-X
with	B-X
synthetic	B-X
double-stranded	B-X
oligonucleotides	B-X
showed	B-X
that	B-X
activated	B-X
NF-kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50/p65	B-X
heterodimer	B-X
bound	B-X
to	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
probes	B-X
,	B-X
suggesting	B-X
that	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
recognition	B-X
sites	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inducible	B-X
TNF-alpha	B-X
expression	B-X
.	B-X
E3330	B-X
decreased	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
nuclei	B-X
,	B-X
suggesting	B-X
that	B-X
E3330	B-X
inhibits	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and/or	B-X
translocation	B-X
of	B-X
the	B-X
nuclei	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
with	B-X
anti-I	B-X
kappa	B-X
B-alpha	B-X
antibody	B-X
indicated	B-X
that	B-X
E3330	B-X
inhibited	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
which	B-X
is	B-X
an	B-X
inhibitory	B-X
protein	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
in	B-X
LPS-stimulated	B-X
monocytes	B-X
.	B-X
E3330	B-X
may	B-X
suppress	B-X
the	B-X
production	B-X
of	B-X
active	B-X
oxygen	B-X
species	B-X
serving	B-X
as	B-X
common	B-X
messengers	B-X
to	B-X
activate	B-X
NF-kappa	B-X
B	B-X
.	B-X

E3330	O
decreased	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
nuclei	O
,	O
suggesting	O
that	O
E3330	O
inhibits	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
/	O
or	O
translocation	O
of	O
the	O
nuclei	O
.	O
<EOS>	B-X
During	B-X
the	B-X
processes	B-X
of	B-X
inflammation	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
may	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
enhancement	B-X
of	B-X
inflammatory	B-X
responses	B-X
and	B-X
may	B-X
initiate	B-X
brain	B-X
damage	B-X
because	B-X
the	B-X
BBB	B-X
constitutes	B-X
an	B-X
interface	B-X
between	B-X
the	B-X
brain	B-X
parenchyma	B-X
and	B-X
the	B-X
bloodstream	B-X
containing	B-X
blood	B-X
cells	B-X
and	B-X
plasma	B-X
.	B-X
The	B-X
BBB	B-X
has	B-X
a	B-X
distinct	B-X
structure	B-X
compared	B-X
with	B-X
those	B-X
in	B-X
peripheral	B-X
tissues	B-X
:	B-X
it	B-X
is	B-X
composed	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
with	B-X
tight	B-X
junctions	B-X
,	B-X
numerous	B-X
pericytes	B-X
surrounding	B-X
endothelial	B-X
cells	B-X
,	B-X
astrocytic	B-X
endfeet	B-X
,	B-X
and	B-X
a	B-X
basement	B-X
membrane	B-X
structure	B-X
.	B-X
Under	B-X
physiological	B-X
conditions	B-X
,	B-X
the	B-X
BBB	B-X
should	B-X
function	B-X
as	B-X
an	B-X
important	B-X
element	B-X
in	B-X
the	B-X
neurovascular	B-X
unit	B-X
(	B-X
NVU	B-X
)	B-X
.	B-X
High	B-X
mobility	B-X
group	B-X
box-1	B-X
(	B-X
HMGB1	B-X
)	B-X
,	B-X
a	B-X
nonhistone	B-X
nuclear	B-X
protein	B-X
,	B-X
is	B-X
ubiquitously	B-X
expressed	B-X
in	B-X
almost	B-X
all	B-X
kinds	B-X
of	B-X
cells	B-X
.	B-X
HMGB1	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
the	B-X
maintenance	B-X
of	B-X
chromatin	B-X
structure	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
transcription	B-X
activity	B-X
,	B-X
and	B-X
DNA	B-X
repair	B-X
in	B-X
nuclei	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
HMGB1	B-X
is	B-X
considered	B-X
to	B-X
be	B-X
a	B-X
representative	B-X
damage-associated	B-X
molecular	B-X
pattern	B-X
(	B-X
DAMP	B-X
)	B-X
because	B-X
it	B-X
is	B-X
translocated	B-X
and	B-X
released	B-X
extracellularly	B-X
from	B-X
different	B-X
types	B-X
of	B-X
brain	B-X
cells	B-X
,	B-X
including	B-X
neurons	B-X
and	B-X
glia	B-X
,	B-X
contributing	B-X
to	B-X
the	B-X
pathophysiology	B-X
of	B-X
many	B-X
diseases	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
HMGB1	B-X
release	B-X
or	B-X
the	B-X
neutralization	B-X
of	B-X
extracellular	B-X
HMGB1	B-X
produces	B-X
beneficial	B-X
effects	B-X
on	B-X
brain	B-X
injuries	B-X
induced	B-X
by	B-X
ischemia	B-X
,	B-X
hemorrhage	B-X
,	B-X
trauma	B-X
,	B-X
epilepsy	B-X
,	B-X
and	B-X
Alzheimer	B-X
's	B-X
amyloidpathy	B-X
in	B-X
animal	B-X
models	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
improvement	B-X
of	B-X
the	B-X
neurological	B-X
symptoms	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
the	B-X
dynamics	B-X
of	B-X
HMGB1	B-X
translocation	B-X
in	B-X
different	B-X
disease	B-X
conditions	B-X
in	B-X
the	B-X
CNS	B-X
and	B-X
discuss	B-X
the	B-X
functional	B-X
roles	B-X
of	B-X
extracellular	B-X
HMGB1	B-X
in	B-X
BBB	B-X
disruption	B-X
and	B-X
brain	B-X
inflammation	B-X
.	B-X
This	B-X
review	B-X
will	B-X
provide	B-X
novel	B-X
insights	B-X
toward	B-X
an	B-X
improved	B-X
understanding	B-X
of	B-X
a	B-X
common	B-X
pathophysiological	B-X
process	B-X
of	B-X
CNS	B-X
diseases	B-X
,	B-X
namely	B-X
,	B-X
BBB	B-X
disruption	B-X
mediated	B-X
by	B-X
HMGB1	B-X
.	B-X
It	B-X
is	B-X
proposed	B-X
that	B-X
HMGB1	B-X
might	B-X
be	B-X
an	B-X
excellent	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
CNS	B-X
diseases	B-X
with	B-X
BBB	B-X
disruption	B-X
.	B-X

Western	O
blotting	O
analysis	O
with	O
anti	O
-	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
antibody	O
indicated	O
that	O
E3330	O
inhibited	O
degradation	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
,	O
which	O
is	O
an	O
inhibitory	O
protein	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
in	O
LPS	O
-	O
stimulated	O
monocytes	O
.	O
<EOS>	B-X
(	B-X
2E	B-X
)	B-X
-3-	B-X
[	B-X
5-	B-X
(	B-X
2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl	B-X
)	B-X
]	B-X
-2-nonyl-2-	B-X
propenoic	B-X
acid	B-X
(	B-X
E3330	B-X
)	B-X
,	B-X
is	B-X
a	B-X
novel	B-X
agent	B-X
with	B-X
hepatoprotective	B-X
activity	B-X
.	B-X
We	B-X
report	B-X
the	B-X
effect	B-X
of	B-X
E3330	B-X
on	B-X
transcriptional	B-X
activation	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-alpha	B-X
gene	B-X
and	B-X
on	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
activation	B-X
.	B-X
Nuclear	B-X
run-on	B-X
experiments	B-X
showed	B-X
that	B-X
E3330	B-X
decreases	B-X
transcriptional	B-X
activation	B-X
of	B-X
TNF-alpha	B-X
gene	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
in	B-X
human	B-X
peripheral	B-X
monocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
inhibitory	B-X
mechanisms	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
secreted-type	B-X
placental	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
PLAP	B-X
)	B-X
reporter	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
1.4-kb	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
A	B-X
stable	B-X
transformant	B-X
of	B-X
the	B-X
PLAP	B-X
reporter	B-X
gene	B-X
derived	B-X
from	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
showed	B-X
very	B-X
little	B-X
activity	B-X
on	B-X
the	B-X
promoter	B-X
before	B-X
stimulation	B-X
,	B-X
whereas	B-X
LPS	B-X
stimulation	B-X
led	B-X
to	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
PLAP	B-X
activity	B-X
.	B-X
E3330	B-X
inhibited	B-X
this	B-X
induced	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
There	B-X
are	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
binding	B-X
sites	B-X
(	B-X
kappa	B-X
B-1	B-X
,	B-X
kappa	B-X
B-2	B-X
,	B-X
kappa	B-X
B-3	B-X
,	B-X
kappa	B-X
B-4	B-X
)	B-X
in	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
By	B-X
using	B-X
mutated	B-X
promoter-PLAP	B-X
plasmids	B-X
,	B-X
we	B-X
established	B-X
that	B-X
these	B-X
NF-kappa	B-X
B	B-X
sites	B-X
were	B-X
necessary	B-X
for	B-X
induction	B-X
of	B-X
TNF-alpha	B-X
transcription	B-X
on	B-X
stimulation	B-X
with	B-X
LPS	B-X
.	B-X
A	B-X
gel	B-X
retardation	B-X
experiment	B-X
with	B-X
synthetic	B-X
double-stranded	B-X
oligonucleotides	B-X
showed	B-X
that	B-X
activated	B-X
NF-kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50/p65	B-X
heterodimer	B-X
bound	B-X
to	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
probes	B-X
,	B-X
suggesting	B-X
that	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
recognition	B-X
sites	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inducible	B-X
TNF-alpha	B-X
expression	B-X
.	B-X
E3330	B-X
decreased	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
nuclei	B-X
,	B-X
suggesting	B-X
that	B-X
E3330	B-X
inhibits	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and/or	B-X
translocation	B-X
of	B-X
the	B-X
nuclei	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
with	B-X
anti-I	B-X
kappa	B-X
B-alpha	B-X
antibody	B-X
indicated	B-X
that	B-X
E3330	B-X
inhibited	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
which	B-X
is	B-X
an	B-X
inhibitory	B-X
protein	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
in	B-X
LPS-stimulated	B-X
monocytes	B-X
.	B-X
E3330	B-X
may	B-X
suppress	B-X
the	B-X
production	B-X
of	B-X
active	B-X
oxygen	B-X
species	B-X
serving	B-X
as	B-X
common	B-X
messengers	B-X
to	B-X
activate	B-X
NF-kappa	B-X
B	B-X
.	B-X

E3330	O
may	O
suppress	O
the	O
production	O
of	O
active	O
oxygen	O
species	O
serving	O
as	O
common	O
messengers	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
(	B-X
2E	B-X
)	B-X
-3-	B-X
[	B-X
5-	B-X
(	B-X
2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl	B-X
)	B-X
]	B-X
-2-nonyl-2-	B-X
propenoic	B-X
acid	B-X
(	B-X
E3330	B-X
)	B-X
,	B-X
is	B-X
a	B-X
novel	B-X
agent	B-X
with	B-X
hepatoprotective	B-X
activity	B-X
.	B-X
We	B-X
report	B-X
the	B-X
effect	B-X
of	B-X
E3330	B-X
on	B-X
transcriptional	B-X
activation	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-alpha	B-X
gene	B-X
and	B-X
on	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B	B-X
activation	B-X
.	B-X
Nuclear	B-X
run-on	B-X
experiments	B-X
showed	B-X
that	B-X
E3330	B-X
decreases	B-X
transcriptional	B-X
activation	B-X
of	B-X
TNF-alpha	B-X
gene	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
stimulation	B-X
in	B-X
human	B-X
peripheral	B-X
monocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
inhibitory	B-X
mechanisms	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
secreted-type	B-X
placental	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
PLAP	B-X
)	B-X
reporter	B-X
gene	B-X
whose	B-X
transcription	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
1.4-kb	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
E3330	B-X
inhibited	B-X
this	B-X
induced	B-X
promoter	B-X
activity	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
There	B-X
are	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
binding	B-X
sites	B-X
(	B-X
kappa	B-X
B-1	B-X
,	B-X
kappa	B-X
B-2	B-X
,	B-X
kappa	B-X
B-3	B-X
,	B-X
kappa	B-X
B-4	B-X
)	B-X
in	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
.	B-X
By	B-X
using	B-X
mutated	B-X
promoter-PLAP	B-X
plasmids	B-X
,	B-X
we	B-X
established	B-X
that	B-X
these	B-X
NF-kappa	B-X
B	B-X
sites	B-X
were	B-X
necessary	B-X
for	B-X
induction	B-X
of	B-X
TNF-alpha	B-X
transcription	B-X
on	B-X
stimulation	B-X
with	B-X
LPS	B-X
.	B-X
A	B-X
gel	B-X
retardation	B-X
experiment	B-X
with	B-X
synthetic	B-X
double-stranded	B-X
oligonucleotides	B-X
showed	B-X
that	B-X
activated	B-X
NF-kappa	B-X
B	B-X
consisting	B-X
of	B-X
p50/p65	B-X
heterodimer	B-X
bound	B-X
to	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
DNA	B-X
probes	B-X
,	B-X
suggesting	B-X
that	B-X
all	B-X
four	B-X
putative	B-X
NF-kappa	B-X
B	B-X
recognition	B-X
sites	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inducible	B-X
TNF-alpha	B-X
expression	B-X
.	B-X
E3330	B-X
decreased	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
nuclei	B-X
,	B-X
suggesting	B-X
that	B-X
E3330	B-X
inhibits	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and/or	B-X
translocation	B-X
of	B-X
the	B-X
nuclei	B-X
.	B-X
Western	B-X
blotting	B-X
analysis	B-X
with	B-X
anti-I	B-X
kappa	B-X
B-alpha	B-X
antibody	B-X
indicated	B-X
that	B-X
E3330	B-X
inhibited	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
which	B-X
is	B-X
an	B-X
inhibitory	B-X
protein	B-X
of	B-X
NF-kappa	B-X
B	B-X
,	B-X
in	B-X
LPS-stimulated	B-X
monocytes	B-X
.	B-X
E3330	B-X
may	B-X
suppress	B-X
the	B-X
production	B-X
of	B-X
active	B-X
oxygen	B-X
species	B-X
serving	B-X
as	B-X
common	B-X
messengers	B-X
to	B-X
activate	B-X
NF-kappa	B-X
B	B-X
.	B-X

The	O
role	O
of	O
p16	B-Protein
in	O
the	O
E2F	O
-	O
dependent	O
thymidine	B-Protein
kinase	I-Protein
regulation	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
alterations	B-X
of	B-X
the	B-X
MTS1	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
chromosome	B-X
9p21	B-X
,	B-X
which	B-X
encodes	B-X
p16	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
cyclin-dependent-kinase-4	B-X
and	B-X
6	B-X
,	B-X
in	B-X
tumorigenesis	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
retinoblastoma	B-X
protein	B-X
by	B-X
cyclin-dependent	B-X
kinases	B-X
4	B-X
and	B-X
6	B-X
prevents	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
transcription	B-X
factor	B-X
E2F	B-X
,	B-X
which	B-X
subsequently	B-X
promotes	B-X
the	B-X
expression	B-X
of	B-X
S	B-X
phase	B-X
regulated	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
thymidine	B-X
kinase	B-X
.	B-X
Although	B-X
a	B-X
role	B-X
of	B-X
p16	B-X
in	B-X
this	B-X
regulation	B-X
has	B-X
been	B-X
presumed	B-X
,	B-X
there	B-X
is	B-X
no	B-X
proof	B-X
so	B-X
far	B-X
that	B-X
loss	B-X
of	B-X
this	B-X
tumor	B-X
suppressor	B-X
gene	B-X
really	B-X
affects	B-X
E2F-mediated	B-X
regulations	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
in	B-X
phytohemagglutinin-stimulated	B-X
normal	B-X
human	B-X
lymphocytes	B-X
and	B-X
in	B-X
the	B-X
p16-negative	B-X
human	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
.	B-X
Compared	B-X
to	B-X
normal	B-X
lymphocytes	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
exhibited	B-X
an	B-X
altered	B-X
cell	B-X
cycle	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
a	B-X
much	B-X
higher	B-X
intracellular	B-X
activity	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
and	B-X
higher	B-X
thymidine	B-X
kinase	B-X
mRNA	B-X
expression	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
p16	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
caused	B-X
arrest	B-X
in	B-X
G1	B-X
,	B-X
but	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
the	B-X
cell	B-X
growth	B-X
of	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
,	B-X
although	B-X
all	B-X
of	B-X
them	B-X
express	B-X
functional	B-X
retinoblastoma	B-X
protein	B-X
.	B-X
Nevertheless	B-X
,	B-X
in	B-X
the	B-X
two	B-X
leukemia	B-X
cell	B-X
lines	B-X
transient	B-X
overexpression	B-X
of	B-X
p16	B-X
reestablished	B-X
the	B-X
normal	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
paralleled	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
the	B-X
underphosphorylated	B-X
form	B-X
of	B-X
retinoblastoma	B-X
protein	B-X
and	B-X
decrease	B-X
of	B-X
free	B-X
E2F	B-X
bound	B-X
to	B-X
its	B-X
motif	B-X
in	B-X
the	B-X
thymidine	B-X
kinase	B-X
promoter	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
loss	B-X
of	B-X
p16	B-X
causes	B-X
upregulation	B-X
of	B-X
this	B-X
DNA	B-X
precursor	B-X
pathway	B-X
enzyme	B-X
via	B-X
activation	B-X
of	B-X
E2F	B-X
by	B-X
a	B-X
mechanism	B-X
involving	B-X
retinoblastoma	B-X
protein	B-X
.	B-X

The	O
role	O
of	O
alterations	O
of	O
the	O
MTS1	B-Protein
tumor	O
suppressor	O
gene	O
on	O
chromosome	O
9p21	O
,	O
which	O
encodes	O
p16	B-Protein
,	O
the	O
inhibitor	O
of	O
cyclin	B-Protein
-	I-Protein
dependent	I-Protein
-	I-Protein
kinase	I-Protein
-	I-Protein
4	I-Protein
and	O
6	B-Protein
,	O
in	O
tumorigenesis	O
is	O
not	O
yet	O
clear	O
.	O

Phosphorylation	O
of	O
the	O
retinoblastoma	B-Protein
protein	I-Protein
by	O
cyclin	B-Protein
-	I-Protein
dependent	I-Protein
kinases	I-Protein
4	I-Protein
and	O
6	B-Protein
prevents	O
its	O
interaction	O
with	O
the	O
transcription	O
factor	O
E2F	O
,	O
which	O
subsequently	O
promotes	O
the	O
expression	O
of	O
S	O
phase	O
regulated	O
genes	O
,	O
such	O
as	O
thymidine	B-Protein
kinase	I-Protein
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
alterations	B-X
of	B-X
the	B-X
MTS1	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
chromosome	B-X
9p21	B-X
,	B-X
which	B-X
encodes	B-X
p16	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
cyclin-dependent-kinase-4	B-X
and	B-X
6	B-X
,	B-X
in	B-X
tumorigenesis	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
retinoblastoma	B-X
protein	B-X
by	B-X
cyclin-dependent	B-X
kinases	B-X
4	B-X
and	B-X
6	B-X
prevents	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
transcription	B-X
factor	B-X
E2F	B-X
,	B-X
which	B-X
subsequently	B-X
promotes	B-X
the	B-X
expression	B-X
of	B-X
S	B-X
phase	B-X
regulated	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
thymidine	B-X
kinase	B-X
.	B-X
Although	B-X
a	B-X
role	B-X
of	B-X
p16	B-X
in	B-X
this	B-X
regulation	B-X
has	B-X
been	B-X
presumed	B-X
,	B-X
there	B-X
is	B-X
no	B-X
proof	B-X
so	B-X
far	B-X
that	B-X
loss	B-X
of	B-X
this	B-X
tumor	B-X
suppressor	B-X
gene	B-X
really	B-X
affects	B-X
E2F-mediated	B-X
regulations	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
in	B-X
phytohemagglutinin-stimulated	B-X
normal	B-X
human	B-X
lymphocytes	B-X
and	B-X
in	B-X
the	B-X
p16-negative	B-X
human	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
.	B-X
Compared	B-X
to	B-X
normal	B-X
lymphocytes	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
exhibited	B-X
an	B-X
altered	B-X
cell	B-X
cycle	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
a	B-X
much	B-X
higher	B-X
intracellular	B-X
activity	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
and	B-X
higher	B-X
thymidine	B-X
kinase	B-X
mRNA	B-X
expression	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
p16	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
caused	B-X
arrest	B-X
in	B-X
G1	B-X
,	B-X
but	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
the	B-X
cell	B-X
growth	B-X
of	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
,	B-X
although	B-X
all	B-X
of	B-X
them	B-X
express	B-X
functional	B-X
retinoblastoma	B-X
protein	B-X
.	B-X
Nevertheless	B-X
,	B-X
in	B-X
the	B-X
two	B-X
leukemia	B-X
cell	B-X
lines	B-X
transient	B-X
overexpression	B-X
of	B-X
p16	B-X
reestablished	B-X
the	B-X
normal	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
paralleled	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
the	B-X
underphosphorylated	B-X
form	B-X
of	B-X
retinoblastoma	B-X
protein	B-X
and	B-X
decrease	B-X
of	B-X
free	B-X
E2F	B-X
bound	B-X
to	B-X
its	B-X
motif	B-X
in	B-X
the	B-X
thymidine	B-X
kinase	B-X
promoter	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
loss	B-X
of	B-X
p16	B-X
causes	B-X
upregulation	B-X
of	B-X
this	B-X
DNA	B-X
precursor	B-X
pathway	B-X
enzyme	B-X
via	B-X
activation	B-X
of	B-X
E2F	B-X
by	B-X
a	B-X
mechanism	B-X
involving	B-X
retinoblastoma	B-X
protein	B-X
.	B-X

Although	O
a	O
role	O
of	O
p16	B-Protein
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	O
of	O
this	O
tumor	O
suppressor	O
gene	O
really	O
affects	O
E2F	O
-	O
mediated	O
regulations	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
alterations	B-X
of	B-X
the	B-X
MTS1	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
chromosome	B-X
9p21	B-X
,	B-X
which	B-X
encodes	B-X
p16	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
cyclin-dependent-kinase-4	B-X
and	B-X
6	B-X
,	B-X
in	B-X
tumorigenesis	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
retinoblastoma	B-X
protein	B-X
by	B-X
cyclin-dependent	B-X
kinases	B-X
4	B-X
and	B-X
6	B-X
prevents	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
transcription	B-X
factor	B-X
E2F	B-X
,	B-X
which	B-X
subsequently	B-X
promotes	B-X
the	B-X
expression	B-X
of	B-X
S	B-X
phase	B-X
regulated	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
thymidine	B-X
kinase	B-X
.	B-X
Although	B-X
a	B-X
role	B-X
of	B-X
p16	B-X
in	B-X
this	B-X
regulation	B-X
has	B-X
been	B-X
presumed	B-X
,	B-X
there	B-X
is	B-X
no	B-X
proof	B-X
so	B-X
far	B-X
that	B-X
loss	B-X
of	B-X
this	B-X
tumor	B-X
suppressor	B-X
gene	B-X
really	B-X
affects	B-X
E2F-mediated	B-X
regulations	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
in	B-X
phytohemagglutinin-stimulated	B-X
normal	B-X
human	B-X
lymphocytes	B-X
and	B-X
in	B-X
the	B-X
p16-negative	B-X
human	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
.	B-X
Compared	B-X
to	B-X
normal	B-X
lymphocytes	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
exhibited	B-X
an	B-X
altered	B-X
cell	B-X
cycle	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
a	B-X
much	B-X
higher	B-X
intracellular	B-X
activity	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
and	B-X
higher	B-X
thymidine	B-X
kinase	B-X
mRNA	B-X
expression	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
p16	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
caused	B-X
arrest	B-X
in	B-X
G1	B-X
,	B-X
but	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
the	B-X
cell	B-X
growth	B-X
of	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
,	B-X
although	B-X
all	B-X
of	B-X
them	B-X
express	B-X
functional	B-X
retinoblastoma	B-X
protein	B-X
.	B-X
Nevertheless	B-X
,	B-X
in	B-X
the	B-X
two	B-X
leukemia	B-X
cell	B-X
lines	B-X
transient	B-X
overexpression	B-X
of	B-X
p16	B-X
reestablished	B-X
the	B-X
normal	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
paralleled	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
the	B-X
underphosphorylated	B-X
form	B-X
of	B-X
retinoblastoma	B-X
protein	B-X
and	B-X
decrease	B-X
of	B-X
free	B-X
E2F	B-X
bound	B-X
to	B-X
its	B-X
motif	B-X
in	B-X
the	B-X
thymidine	B-X
kinase	B-X
promoter	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
loss	B-X
of	B-X
p16	B-X
causes	B-X
upregulation	B-X
of	B-X
this	B-X
DNA	B-X
precursor	B-X
pathway	B-X
enzyme	B-X
via	B-X
activation	B-X
of	B-X
E2F	B-X
by	B-X
a	B-X
mechanism	B-X
involving	B-X
retinoblastoma	B-X
protein	B-X
.	B-X

We	O
investigated	O
the	O
regulation	O
of	O
thymidine	B-Protein
kinase	I-Protein
in	O
phytohemagglutinin	B-Protein
-	O
stimulated	O
normal	O
human	O
lymphocytes	O
and	O
in	O
the	O
p16	B-Protein
-	O
negative	O
human	O
acute	O
lymphoblastic	O
leukemia	O
cell	O
lines	O
,	O
MOLT	O
-	O
4	O
and	O
CEM	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
alterations	B-X
of	B-X
the	B-X
MTS1	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
chromosome	B-X
9p21	B-X
,	B-X
which	B-X
encodes	B-X
p16	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
cyclin-dependent-kinase-4	B-X
and	B-X
6	B-X
,	B-X
in	B-X
tumorigenesis	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
retinoblastoma	B-X
protein	B-X
by	B-X
cyclin-dependent	B-X
kinases	B-X
4	B-X
and	B-X
6	B-X
prevents	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
transcription	B-X
factor	B-X
E2F	B-X
,	B-X
which	B-X
subsequently	B-X
promotes	B-X
the	B-X
expression	B-X
of	B-X
S	B-X
phase	B-X
regulated	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
thymidine	B-X
kinase	B-X
.	B-X
Although	B-X
a	B-X
role	B-X
of	B-X
p16	B-X
in	B-X
this	B-X
regulation	B-X
has	B-X
been	B-X
presumed	B-X
,	B-X
there	B-X
is	B-X
no	B-X
proof	B-X
so	B-X
far	B-X
that	B-X
loss	B-X
of	B-X
this	B-X
tumor	B-X
suppressor	B-X
gene	B-X
really	B-X
affects	B-X
E2F-mediated	B-X
regulations	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
in	B-X
phytohemagglutinin-stimulated	B-X
normal	B-X
human	B-X
lymphocytes	B-X
and	B-X
in	B-X
the	B-X
p16-negative	B-X
human	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
.	B-X
Compared	B-X
to	B-X
normal	B-X
lymphocytes	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
exhibited	B-X
an	B-X
altered	B-X
cell	B-X
cycle	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
a	B-X
much	B-X
higher	B-X
intracellular	B-X
activity	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
and	B-X
higher	B-X
thymidine	B-X
kinase	B-X
mRNA	B-X
expression	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
p16	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
caused	B-X
arrest	B-X
in	B-X
G1	B-X
,	B-X
but	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
the	B-X
cell	B-X
growth	B-X
of	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
,	B-X
although	B-X
all	B-X
of	B-X
them	B-X
express	B-X
functional	B-X
retinoblastoma	B-X
protein	B-X
.	B-X
Nevertheless	B-X
,	B-X
in	B-X
the	B-X
two	B-X
leukemia	B-X
cell	B-X
lines	B-X
transient	B-X
overexpression	B-X
of	B-X
p16	B-X
reestablished	B-X
the	B-X
normal	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
paralleled	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
the	B-X
underphosphorylated	B-X
form	B-X
of	B-X
retinoblastoma	B-X
protein	B-X
and	B-X
decrease	B-X
of	B-X
free	B-X
E2F	B-X
bound	B-X
to	B-X
its	B-X
motif	B-X
in	B-X
the	B-X
thymidine	B-X
kinase	B-X
promoter	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
loss	B-X
of	B-X
p16	B-X
causes	B-X
upregulation	B-X
of	B-X
this	B-X
DNA	B-X
precursor	B-X
pathway	B-X
enzyme	B-X
via	B-X
activation	B-X
of	B-X
E2F	B-X
by	B-X
a	B-X
mechanism	B-X
involving	B-X
retinoblastoma	B-X
protein	B-X
.	B-X

Compared	O
to	O
normal	O
lymphocytes	O
,	O
MOLT	O
-	O
4	O
and	O
CEM	O
cells	O
exhibited	O
an	O
altered	O
cell	O
cycle	O
regulation	O
of	O
thymidine	B-Protein
kinase	I-Protein
,	O
a	O
much	O
higher	O
intracellular	O
activity	O
of	O
this	O
enzyme	O
,	O
and	O
higher	O
thymidine	B-Protein
kinase	I-Protein
mRNA	O
expression	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
alterations	B-X
of	B-X
the	B-X
MTS1	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
chromosome	B-X
9p21	B-X
,	B-X
which	B-X
encodes	B-X
p16	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
cyclin-dependent-kinase-4	B-X
and	B-X
6	B-X
,	B-X
in	B-X
tumorigenesis	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
retinoblastoma	B-X
protein	B-X
by	B-X
cyclin-dependent	B-X
kinases	B-X
4	B-X
and	B-X
6	B-X
prevents	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
transcription	B-X
factor	B-X
E2F	B-X
,	B-X
which	B-X
subsequently	B-X
promotes	B-X
the	B-X
expression	B-X
of	B-X
S	B-X
phase	B-X
regulated	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
thymidine	B-X
kinase	B-X
.	B-X
Although	B-X
a	B-X
role	B-X
of	B-X
p16	B-X
in	B-X
this	B-X
regulation	B-X
has	B-X
been	B-X
presumed	B-X
,	B-X
there	B-X
is	B-X
no	B-X
proof	B-X
so	B-X
far	B-X
that	B-X
loss	B-X
of	B-X
this	B-X
tumor	B-X
suppressor	B-X
gene	B-X
really	B-X
affects	B-X
E2F-mediated	B-X
regulations	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
in	B-X
phytohemagglutinin-stimulated	B-X
normal	B-X
human	B-X
lymphocytes	B-X
and	B-X
in	B-X
the	B-X
p16-negative	B-X
human	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
.	B-X
Compared	B-X
to	B-X
normal	B-X
lymphocytes	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
exhibited	B-X
an	B-X
altered	B-X
cell	B-X
cycle	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
a	B-X
much	B-X
higher	B-X
intracellular	B-X
activity	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
and	B-X
higher	B-X
thymidine	B-X
kinase	B-X
mRNA	B-X
expression	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
p16	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
caused	B-X
arrest	B-X
in	B-X
G1	B-X
,	B-X
but	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
the	B-X
cell	B-X
growth	B-X
of	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
,	B-X
although	B-X
all	B-X
of	B-X
them	B-X
express	B-X
functional	B-X
retinoblastoma	B-X
protein	B-X
.	B-X
Nevertheless	B-X
,	B-X
in	B-X
the	B-X
two	B-X
leukemia	B-X
cell	B-X
lines	B-X
transient	B-X
overexpression	B-X
of	B-X
p16	B-X
reestablished	B-X
the	B-X
normal	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
paralleled	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
the	B-X
underphosphorylated	B-X
form	B-X
of	B-X
retinoblastoma	B-X
protein	B-X
and	B-X
decrease	B-X
of	B-X
free	B-X
E2F	B-X
bound	B-X
to	B-X
its	B-X
motif	B-X
in	B-X
the	B-X
thymidine	B-X
kinase	B-X
promoter	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
loss	B-X
of	B-X
p16	B-X
causes	B-X
upregulation	B-X
of	B-X
this	B-X
DNA	B-X
precursor	B-X
pathway	B-X
enzyme	B-X
via	B-X
activation	B-X
of	B-X
E2F	B-X
by	B-X
a	B-X
mechanism	B-X
involving	B-X
retinoblastoma	B-X
protein	B-X
.	B-X

Transient	O
expression	O
of	O
p16	B-Protein
in	O
normal	O
human	O
lymphocytes	O
caused	O
arrest	O
in	O
G1	O
,	O
but	O
was	O
without	O
effect	O
on	O
the	O
cell	O
growth	O
of	O
MOLT	O
-	O
4	O
and	O
CEM	O
cells	O
,	O
although	O
all	O
of	O
them	O
express	O
functional	O
retinoblastoma	B-Protein
protein	I-Protein
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
alterations	B-X
of	B-X
the	B-X
MTS1	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
chromosome	B-X
9p21	B-X
,	B-X
which	B-X
encodes	B-X
p16	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
cyclin-dependent-kinase-4	B-X
and	B-X
6	B-X
,	B-X
in	B-X
tumorigenesis	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
retinoblastoma	B-X
protein	B-X
by	B-X
cyclin-dependent	B-X
kinases	B-X
4	B-X
and	B-X
6	B-X
prevents	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
transcription	B-X
factor	B-X
E2F	B-X
,	B-X
which	B-X
subsequently	B-X
promotes	B-X
the	B-X
expression	B-X
of	B-X
S	B-X
phase	B-X
regulated	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
thymidine	B-X
kinase	B-X
.	B-X
Although	B-X
a	B-X
role	B-X
of	B-X
p16	B-X
in	B-X
this	B-X
regulation	B-X
has	B-X
been	B-X
presumed	B-X
,	B-X
there	B-X
is	B-X
no	B-X
proof	B-X
so	B-X
far	B-X
that	B-X
loss	B-X
of	B-X
this	B-X
tumor	B-X
suppressor	B-X
gene	B-X
really	B-X
affects	B-X
E2F-mediated	B-X
regulations	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
in	B-X
phytohemagglutinin-stimulated	B-X
normal	B-X
human	B-X
lymphocytes	B-X
and	B-X
in	B-X
the	B-X
p16-negative	B-X
human	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
.	B-X
Compared	B-X
to	B-X
normal	B-X
lymphocytes	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
exhibited	B-X
an	B-X
altered	B-X
cell	B-X
cycle	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
a	B-X
much	B-X
higher	B-X
intracellular	B-X
activity	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
and	B-X
higher	B-X
thymidine	B-X
kinase	B-X
mRNA	B-X
expression	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
p16	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
caused	B-X
arrest	B-X
in	B-X
G1	B-X
,	B-X
but	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
the	B-X
cell	B-X
growth	B-X
of	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
,	B-X
although	B-X
all	B-X
of	B-X
them	B-X
express	B-X
functional	B-X
retinoblastoma	B-X
protein	B-X
.	B-X
Nevertheless	B-X
,	B-X
in	B-X
the	B-X
two	B-X
leukemia	B-X
cell	B-X
lines	B-X
transient	B-X
overexpression	B-X
of	B-X
p16	B-X
reestablished	B-X
the	B-X
normal	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
paralleled	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
the	B-X
underphosphorylated	B-X
form	B-X
of	B-X
retinoblastoma	B-X
protein	B-X
and	B-X
decrease	B-X
of	B-X
free	B-X
E2F	B-X
bound	B-X
to	B-X
its	B-X
motif	B-X
in	B-X
the	B-X
thymidine	B-X
kinase	B-X
promoter	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
loss	B-X
of	B-X
p16	B-X
causes	B-X
upregulation	B-X
of	B-X
this	B-X
DNA	B-X
precursor	B-X
pathway	B-X
enzyme	B-X
via	B-X
activation	B-X
of	B-X
E2F	B-X
by	B-X
a	B-X
mechanism	B-X
involving	B-X
retinoblastoma	B-X
protein	B-X
.	B-X

Nevertheless	O
,	O
in	O
the	O
two	O
leukemia	O
cell	O
lines	O
transient	O
overexpression	O
of	O
p16	B-Protein
reestablished	O
the	O
normal	O
regulation	O
of	O
thymidine	B-Protein
kinase	I-Protein
,	O
paralleled	O
by	O
an	O
increase	O
of	O
the	O
underphosphorylated	O
form	O
of	O
retinoblastoma	B-Protein
protein	I-Protein
and	O
decrease	O
of	O
free	O
E2F	O
bound	O
to	O
its	O
motif	O
in	O
the	O
thymidine	B-Protein
kinase	I-Protein
promoter	O
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
alterations	B-X
of	B-X
the	B-X
MTS1	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
chromosome	B-X
9p21	B-X
,	B-X
which	B-X
encodes	B-X
p16	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
cyclin-dependent-kinase-4	B-X
and	B-X
6	B-X
,	B-X
in	B-X
tumorigenesis	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
retinoblastoma	B-X
protein	B-X
by	B-X
cyclin-dependent	B-X
kinases	B-X
4	B-X
and	B-X
6	B-X
prevents	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
transcription	B-X
factor	B-X
E2F	B-X
,	B-X
which	B-X
subsequently	B-X
promotes	B-X
the	B-X
expression	B-X
of	B-X
S	B-X
phase	B-X
regulated	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
thymidine	B-X
kinase	B-X
.	B-X
Although	B-X
a	B-X
role	B-X
of	B-X
p16	B-X
in	B-X
this	B-X
regulation	B-X
has	B-X
been	B-X
presumed	B-X
,	B-X
there	B-X
is	B-X
no	B-X
proof	B-X
so	B-X
far	B-X
that	B-X
loss	B-X
of	B-X
this	B-X
tumor	B-X
suppressor	B-X
gene	B-X
really	B-X
affects	B-X
E2F-mediated	B-X
regulations	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
in	B-X
phytohemagglutinin-stimulated	B-X
normal	B-X
human	B-X
lymphocytes	B-X
and	B-X
in	B-X
the	B-X
p16-negative	B-X
human	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
.	B-X
Compared	B-X
to	B-X
normal	B-X
lymphocytes	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
exhibited	B-X
an	B-X
altered	B-X
cell	B-X
cycle	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
a	B-X
much	B-X
higher	B-X
intracellular	B-X
activity	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
and	B-X
higher	B-X
thymidine	B-X
kinase	B-X
mRNA	B-X
expression	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
p16	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
caused	B-X
arrest	B-X
in	B-X
G1	B-X
,	B-X
but	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
the	B-X
cell	B-X
growth	B-X
of	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
,	B-X
although	B-X
all	B-X
of	B-X
them	B-X
express	B-X
functional	B-X
retinoblastoma	B-X
protein	B-X
.	B-X
Nevertheless	B-X
,	B-X
in	B-X
the	B-X
two	B-X
leukemia	B-X
cell	B-X
lines	B-X
transient	B-X
overexpression	B-X
of	B-X
p16	B-X
reestablished	B-X
the	B-X
normal	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
paralleled	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
the	B-X
underphosphorylated	B-X
form	B-X
of	B-X
retinoblastoma	B-X
protein	B-X
and	B-X
decrease	B-X
of	B-X
free	B-X
E2F	B-X
bound	B-X
to	B-X
its	B-X
motif	B-X
in	B-X
the	B-X
thymidine	B-X
kinase	B-X
promoter	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
loss	B-X
of	B-X
p16	B-X
causes	B-X
upregulation	B-X
of	B-X
this	B-X
DNA	B-X
precursor	B-X
pathway	B-X
enzyme	B-X
via	B-X
activation	B-X
of	B-X
E2F	B-X
by	B-X
a	B-X
mechanism	B-X
involving	B-X
retinoblastoma	B-X
protein	B-X
.	B-X

We	O
demonstrate	O
that	O
loss	O
of	O
p16	B-Protein
causes	O
upregulation	O
of	O
this	O
DNA	O
precursor	O
pathway	O
enzyme	O
via	O
activation	O
of	O
E2F	O
by	O
a	O
mechanism	O
involving	O
retinoblastoma	B-Protein
protein	I-Protein
.	O
<EOS>	B-X
The	B-X
role	B-X
of	B-X
alterations	B-X
of	B-X
the	B-X
MTS1	B-X
tumor	B-X
suppressor	B-X
gene	B-X
on	B-X
chromosome	B-X
9p21	B-X
,	B-X
which	B-X
encodes	B-X
p16	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
cyclin-dependent-kinase-4	B-X
and	B-X
6	B-X
,	B-X
in	B-X
tumorigenesis	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
retinoblastoma	B-X
protein	B-X
by	B-X
cyclin-dependent	B-X
kinases	B-X
4	B-X
and	B-X
6	B-X
prevents	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
transcription	B-X
factor	B-X
E2F	B-X
,	B-X
which	B-X
subsequently	B-X
promotes	B-X
the	B-X
expression	B-X
of	B-X
S	B-X
phase	B-X
regulated	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
thymidine	B-X
kinase	B-X
.	B-X
Although	B-X
a	B-X
role	B-X
of	B-X
p16	B-X
in	B-X
this	B-X
regulation	B-X
has	B-X
been	B-X
presumed	B-X
,	B-X
there	B-X
is	B-X
no	B-X
proof	B-X
so	B-X
far	B-X
that	B-X
loss	B-X
of	B-X
this	B-X
tumor	B-X
suppressor	B-X
gene	B-X
really	B-X
affects	B-X
E2F-mediated	B-X
regulations	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
in	B-X
phytohemagglutinin-stimulated	B-X
normal	B-X
human	B-X
lymphocytes	B-X
and	B-X
in	B-X
the	B-X
p16-negative	B-X
human	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
.	B-X
Compared	B-X
to	B-X
normal	B-X
lymphocytes	B-X
,	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
exhibited	B-X
an	B-X
altered	B-X
cell	B-X
cycle	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
a	B-X
much	B-X
higher	B-X
intracellular	B-X
activity	B-X
of	B-X
this	B-X
enzyme	B-X
,	B-X
and	B-X
higher	B-X
thymidine	B-X
kinase	B-X
mRNA	B-X
expression	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
p16	B-X
in	B-X
normal	B-X
human	B-X
lymphocytes	B-X
caused	B-X
arrest	B-X
in	B-X
G1	B-X
,	B-X
but	B-X
was	B-X
without	B-X
effect	B-X
on	B-X
the	B-X
cell	B-X
growth	B-X
of	B-X
MOLT-4	B-X
and	B-X
CEM	B-X
cells	B-X
,	B-X
although	B-X
all	B-X
of	B-X
them	B-X
express	B-X
functional	B-X
retinoblastoma	B-X
protein	B-X
.	B-X
Nevertheless	B-X
,	B-X
in	B-X
the	B-X
two	B-X
leukemia	B-X
cell	B-X
lines	B-X
transient	B-X
overexpression	B-X
of	B-X
p16	B-X
reestablished	B-X
the	B-X
normal	B-X
regulation	B-X
of	B-X
thymidine	B-X
kinase	B-X
,	B-X
paralleled	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
the	B-X
underphosphorylated	B-X
form	B-X
of	B-X
retinoblastoma	B-X
protein	B-X
and	B-X
decrease	B-X
of	B-X
free	B-X
E2F	B-X
bound	B-X
to	B-X
its	B-X
motif	B-X
in	B-X
the	B-X
thymidine	B-X
kinase	B-X
promoter	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
loss	B-X
of	B-X
p16	B-X
causes	B-X
upregulation	B-X
of	B-X
this	B-X
DNA	B-X
precursor	B-X
pathway	B-X
enzyme	B-X
via	B-X
activation	B-X
of	B-X
E2F	B-X
by	B-X
a	B-X
mechanism	B-X
involving	B-X
retinoblastoma	B-X
protein	B-X
.	B-X

Rel	B-Protein
-	O
deficient	O
T	O
cells	O
exhibit	O
defects	O
in	O
production	O
of	O
interleukin	B-Protein
3	I-Protein
and	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
.	O
<EOS>	B-X
The	B-X
c-rel	B-X
protooncogene	B-X
encodes	B-X
a	B-X
subunit	B-X
of	B-X
the	B-X
NF-kappa	B-X
B-like	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Mice	B-X
lacking	B-X
Rel	B-X
are	B-X
defective	B-X
in	B-X
mitogenic	B-X
activation	B-X
of	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
and	B-X
display	B-X
impaired	B-X
humoral	B-X
immunity	B-X
.	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
that	B-X
accompany	B-X
the	B-X
T-cell	B-X
stimulation	B-X
defects	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
Rel	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
cell	B-X
surface	B-X
activation	B-X
markers	B-X
and	B-X
cytokine	B-X
production	B-X
in	B-X
mitogen-stimulated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
cell	B-X
surface	B-X
markers	B-X
including	B-X
the	B-X
interleukin	B-X
2	B-X
receptor	B-X
alpha	B-X
(	B-X
IL-2R	B-X
alpha	B-X
)	B-X
chain	B-X
(	B-X
CD25	B-X
)	B-X
,	B-X
CD69	B-X
and	B-X
L-selectin	B-X
(	B-X
CD62	B-X
)	B-X
is	B-X
normal	B-X
in	B-X
mitogen-activated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
cytokine	B-X
production	B-X
is	B-X
impaired	B-X
.	B-X
In	B-X
Rel-/-	B-X
splenic	B-X
T	B-X
cell	B-X
cultures	B-X
stimulated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
and	B-X
ionomycin	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
IL-3	B-X
,	B-X
IL-5	B-X
,	B-X
granulocyte-	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
,	B-X
and	B-X
gamma	B-X
interferon	B-X
(	B-X
IFN-gamma	B-X
)	B-X
were	B-X
only	B-X
2-	B-X
to	B-X
3-fold	B-X
lower	B-X
compared	B-X
with	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
anti-CD3	B-X
and	B-X
anti-CD28	B-X
stimulated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
fail	B-X
to	B-X
proliferate	B-X
,	B-X
make	B-X
little	B-X
or	B-X
no	B-X
detectable	B-X
cytokines	B-X
.	B-X
Exogenous	B-X
IL-2	B-X
,	B-X
which	B-X
restitutes	B-X
the	B-X
proliferative	B-X
response	B-X
of	B-X
the	B-X
anti-CD3-	B-X
and	B-X
anti-CD28-treated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
restores	B-X
production	B-X
of	B-X
IL-5	B-X
,	B-X
TNF-alpha	B-X
,	B-X
and	B-X
IFN-gamma	B-X
,	B-X
but	B-X
not	B-X
IL-3	B-X
and	B-X
GM-CSF	B-X
expression	B-X
to	B-X
approximately	B-X
normal	B-X
levels	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
mitogen-activated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
lipopolysaccharide-stimulated	B-X
Rel-/-	B-X
macrophages	B-X
produce	B-X
higher	B-X
than	B-X
normal	B-X
levels	B-X
of	B-X
GM-CSF	B-X
.	B-X
These	B-X
findings	B-X
establish	B-X
that	B-X
Rel	B-X
can	B-X
function	B-X
as	B-X
an	B-X
activator	B-X
or	B-X
repressor	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
is	B-X
required	B-X
by	B-X
T	B-X
lymphocytes	B-X
for	B-X
production	B-X
of	B-X
IL-3	B-X
and	B-X
GM-CSF	B-X
.	B-X

The	O
c	B-Protein
-	I-Protein
rel	I-Protein
protooncogene	O
encodes	O
a	O
subunit	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
family	O
of	O
transcription	O
factors	O
.	O

Mice	O
lacking	O
Rel	B-Protein
are	O
defective	O
in	O
mitogenic	O
activation	O
of	O
B	O
and	O
T	O
lymphocytes	O
and	O
display	O
impaired	O
humoral	O
immunity	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
changes	O
in	O
gene	O
expression	O
that	O
accompany	O
the	O
T	O
-	O
cell	O
stimulation	O
defects	O
associated	O
with	O
the	O
loss	O
of	O
Rel	B-Protein
,	O
we	O
have	O
examined	O
the	O
expression	O
of	O
cell	O
surface	O
activation	O
markers	O
and	O
cytokine	O
production	O
in	O
mitogen	O
-	O
stimulated	O
Rel	B-Protein
-	O
/	O
-	O
T	O
cells	O
.	O

The	O
expression	O
of	O
cell	O
surface	O
markers	O
including	O
the	O
interleukin	B-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
(	I-Protein
IL	I-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
)	I-Protein
chain	I-Protein
(	O
CD25	B-Protein
)	O
,	O
CD69	B-Protein
and	O
L	B-Protein
-	I-Protein
selectin	I-Protein
(	O
CD62	B-Protein
)	O
is	O
normal	O
in	O
mitogen	O
-	O
activated	O
Rel	B-Protein
-	O
/	O
-	O
T	O
cells	O
,	O
but	O
cytokine	O
production	O
is	O
impaired	O
.	O
<EOS>	B-X
Mice	B-X
lacking	B-X
Rel	B-X
are	B-X
defective	B-X
in	B-X
mitogenic	B-X
activation	B-X
of	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
and	B-X
display	B-X
impaired	B-X
humoral	B-X
immunity	B-X
.	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
that	B-X
accompany	B-X
the	B-X
T-cell	B-X
stimulation	B-X
defects	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
Rel	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
cell	B-X
surface	B-X
activation	B-X
markers	B-X
and	B-X
cytokine	B-X
production	B-X
in	B-X
mitogen-stimulated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
cell	B-X
surface	B-X
markers	B-X
including	B-X
the	B-X
interleukin	B-X
2	B-X
receptor	B-X
alpha	B-X
(	B-X
IL-2R	B-X
alpha	B-X
)	B-X
chain	B-X
(	B-X
CD25	B-X
)	B-X
,	B-X
CD69	B-X
and	B-X
L-selectin	B-X
(	B-X
CD62	B-X
)	B-X
is	B-X
normal	B-X
in	B-X
mitogen-activated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
cytokine	B-X
production	B-X
is	B-X
impaired	B-X
.	B-X
In	B-X
Rel-/-	B-X
splenic	B-X
T	B-X
cell	B-X
cultures	B-X
stimulated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
and	B-X
ionomycin	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
IL-3	B-X
,	B-X
IL-5	B-X
,	B-X
granulocyte-	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
,	B-X
and	B-X
gamma	B-X
interferon	B-X
(	B-X
IFN-gamma	B-X
)	B-X
were	B-X
only	B-X
2-	B-X
to	B-X
3-fold	B-X
lower	B-X
compared	B-X
with	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
anti-CD3	B-X
and	B-X
anti-CD28	B-X
stimulated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
fail	B-X
to	B-X
proliferate	B-X
,	B-X
make	B-X
little	B-X
or	B-X
no	B-X
detectable	B-X
cytokines	B-X
.	B-X
Exogenous	B-X
IL-2	B-X
,	B-X
which	B-X
restitutes	B-X
the	B-X
proliferative	B-X
response	B-X
of	B-X
the	B-X
anti-CD3-	B-X
and	B-X
anti-CD28-treated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
restores	B-X
production	B-X
of	B-X
IL-5	B-X
,	B-X
TNF-alpha	B-X
,	B-X
and	B-X
IFN-gamma	B-X
,	B-X
but	B-X
not	B-X
IL-3	B-X
and	B-X
GM-CSF	B-X
expression	B-X
to	B-X
approximately	B-X
normal	B-X
levels	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
mitogen-activated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
lipopolysaccharide-stimulated	B-X
Rel-/-	B-X
macrophages	B-X
produce	B-X
higher	B-X
than	B-X
normal	B-X
levels	B-X
of	B-X
GM-CSF	B-X
.	B-X
These	B-X
findings	B-X
establish	B-X
that	B-X
Rel	B-X
can	B-X
function	B-X
as	B-X
an	B-X
activator	B-X
or	B-X
repressor	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
is	B-X
required	B-X
by	B-X
T	B-X
lymphocytes	B-X
for	B-X
production	B-X
of	B-X
IL-3	B-X
and	B-X
GM-CSF	B-X
.	B-X

In	O
Rel	B-Protein
-	O
/	O
-	O
splenic	O
T	O
cell	O
cultures	O
stimulated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
and	O
ionomycin	O
,	O
the	O
levels	O
of	O
IL	B-Protein
-	I-Protein
3	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
,	O
and	O
gamma	B-Protein
interferon	I-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
were	O
only	O
2	O
-	O
to	O
3	O
-	O
fold	O
lower	O
compared	O
with	O
normal	O
T	O
cells	O
.	O
<EOS>	B-X
The	B-X
c-rel	B-X
protooncogene	B-X
encodes	B-X
a	B-X
subunit	B-X
of	B-X
the	B-X
NF-kappa	B-X
B-like	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Mice	B-X
lacking	B-X
Rel	B-X
are	B-X
defective	B-X
in	B-X
mitogenic	B-X
activation	B-X
of	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
and	B-X
display	B-X
impaired	B-X
humoral	B-X
immunity	B-X
.	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
that	B-X
accompany	B-X
the	B-X
T-cell	B-X
stimulation	B-X
defects	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
Rel	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
cell	B-X
surface	B-X
activation	B-X
markers	B-X
and	B-X
cytokine	B-X
production	B-X
in	B-X
mitogen-stimulated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
cell	B-X
surface	B-X
markers	B-X
including	B-X
the	B-X
interleukin	B-X
2	B-X
receptor	B-X
alpha	B-X
(	B-X
IL-2R	B-X
alpha	B-X
)	B-X
chain	B-X
(	B-X
CD25	B-X
)	B-X
,	B-X
CD69	B-X
and	B-X
L-selectin	B-X
(	B-X
CD62	B-X
)	B-X
is	B-X
normal	B-X
in	B-X
mitogen-activated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
cytokine	B-X
production	B-X
is	B-X
impaired	B-X
.	B-X
In	B-X
Rel-/-	B-X
splenic	B-X
T	B-X
cell	B-X
cultures	B-X
stimulated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
and	B-X
ionomycin	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
IL-3	B-X
,	B-X
IL-5	B-X
,	B-X
granulocyte-	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
,	B-X
and	B-X
gamma	B-X
interferon	B-X
(	B-X
IFN-gamma	B-X
)	B-X
were	B-X
only	B-X
2-	B-X
to	B-X
3-fold	B-X
lower	B-X
compared	B-X
with	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
anti-CD3	B-X
and	B-X
anti-CD28	B-X
stimulated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
fail	B-X
to	B-X
proliferate	B-X
,	B-X
make	B-X
little	B-X
or	B-X
no	B-X
detectable	B-X
cytokines	B-X
.	B-X
Exogenous	B-X
IL-2	B-X
,	B-X
which	B-X
restitutes	B-X
the	B-X
proliferative	B-X
response	B-X
of	B-X
the	B-X
anti-CD3-	B-X
and	B-X
anti-CD28-treated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
restores	B-X
production	B-X
of	B-X
IL-5	B-X
,	B-X
TNF-alpha	B-X
,	B-X
and	B-X
IFN-gamma	B-X
,	B-X
but	B-X
not	B-X
IL-3	B-X
and	B-X
GM-CSF	B-X
expression	B-X
to	B-X
approximately	B-X
normal	B-X
levels	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
mitogen-activated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
lipopolysaccharide-stimulated	B-X
Rel-/-	B-X
macrophages	B-X
produce	B-X
higher	B-X
than	B-X
normal	B-X
levels	B-X
of	B-X
GM-CSF	B-X
.	B-X
These	B-X
findings	B-X
establish	B-X
that	B-X
Rel	B-X
can	B-X
function	B-X
as	B-X
an	B-X
activator	B-X
or	B-X
repressor	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
is	B-X
required	B-X
by	B-X
T	B-X
lymphocytes	B-X
for	B-X
production	B-X
of	B-X
IL-3	B-X
and	B-X
GM-CSF	B-X
.	B-X

In	O
contrast	O
,	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD28	B-Protein
stimulated	O
Rel	B-Protein
-	O
/	O
-	O
T	O
cells	O
,	O
which	O
fail	O
to	O
proliferate	O
,	O
make	O
little	O
or	O
no	O
detectable	O
cytokines	O
.	O
<EOS>	B-X
Enzyme-linked	B-X
immune	B-X
absorbent	B-X
spot	B-X
(	B-X
Elispot	B-X
)	B-X
is	B-X
a	B-X
quantitative	B-X
method	B-X
for	B-X
measuring	B-X
relevant	B-X
parameters	B-X
of	B-X
T-cell	B-X
activation	B-X
.	B-X
The	B-X
sensitivity	B-X
of	B-X
Elispot	B-X
allows	B-X
the	B-X
detection	B-X
of	B-X
low-frequency	B-X
antigen-specific	B-X
T-cells	B-X
that	B-X
secrete	B-X
cytokines	B-X
and	B-X
effector	B-X
molecules	B-X
,	B-X
such	B-X
as	B-X
granzyme	B-X
B	B-X
and	B-X
perforin	B-X
.	B-X
Cytotoxic	B-X
T-cell	B-X
(	B-X
CTL	B-X
)	B-X
studies	B-X
have	B-X
taken	B-X
advantage	B-X
with	B-X
this	B-X
high-throughput	B-X
technology	B-X
by	B-X
providing	B-X
insights	B-X
of	B-X
quantity	B-X
and	B-X
immune	B-X
kinetics	B-X
.	B-X
Actually	B-X
,	B-X
CTL	B-X
monitoring	B-X
by	B-X
Elispot	B-X
is	B-X
a	B-X
gold	B-X
standard	B-X
for	B-X
the	B-X
evaluation	B-X
of	B-X
antigen-specific	B-X
T-cell	B-X
immunity	B-X
in	B-X
clinical	B-X
trials	B-X
and	B-X
vaccine	B-X
candidates	B-X
where	B-X
the	B-X
ability	B-X
to	B-X
detect	B-X
rare	B-X
antigen-specific	B-X
T-cells	B-X
is	B-X
of	B-X
relevance	B-X
for	B-X
immune	B-X
diagnostic	B-X
.	B-X

Exogenous	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
which	O
restitutes	O
the	O
proliferative	O
response	O
of	O
the	O
anti	O
-	O
CD3	O
-	O
and	O
anti	O
-	O
CD28	B-Protein
-	O
treated	O
Rel	O
-	O
/	O
-	O
T	O
cells	O
,	O
restores	O
production	O
of	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
3	I-Protein
and	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
expression	O
to	O
approximately	O
normal	O
levels	O
.	O

In	O
contrast	O
to	O
mitogen	O
-	O
activated	O
Rel	B-Protein
-	O
/	O
-	O
T	O
cells	O
,	O
lipopolysaccharide	O
-	O
stimulated	O
Rel	B-Protein
-	O
/	O
-	O
macrophages	O
produce	O
higher	O
than	O
normal	O
levels	O
of	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
.	O
<EOS>	B-X
Mice	B-X
lacking	B-X
Rel	B-X
are	B-X
defective	B-X
in	B-X
mitogenic	B-X
activation	B-X
of	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
and	B-X
display	B-X
impaired	B-X
humoral	B-X
immunity	B-X
.	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
identify	B-X
changes	B-X
in	B-X
gene	B-X
expression	B-X
that	B-X
accompany	B-X
the	B-X
T-cell	B-X
stimulation	B-X
defects	B-X
associated	B-X
with	B-X
the	B-X
loss	B-X
of	B-X
Rel	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
cell	B-X
surface	B-X
activation	B-X
markers	B-X
and	B-X
cytokine	B-X
production	B-X
in	B-X
mitogen-stimulated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
cell	B-X
surface	B-X
markers	B-X
including	B-X
the	B-X
interleukin	B-X
2	B-X
receptor	B-X
alpha	B-X
(	B-X
IL-2R	B-X
alpha	B-X
)	B-X
chain	B-X
(	B-X
CD25	B-X
)	B-X
,	B-X
CD69	B-X
and	B-X
L-selectin	B-X
(	B-X
CD62	B-X
)	B-X
is	B-X
normal	B-X
in	B-X
mitogen-activated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
but	B-X
cytokine	B-X
production	B-X
is	B-X
impaired	B-X
.	B-X
In	B-X
Rel-/-	B-X
splenic	B-X
T	B-X
cell	B-X
cultures	B-X
stimulated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
and	B-X
ionomycin	B-X
,	B-X
the	B-X
levels	B-X
of	B-X
IL-3	B-X
,	B-X
IL-5	B-X
,	B-X
granulocyte-	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
,	B-X
and	B-X
gamma	B-X
interferon	B-X
(	B-X
IFN-gamma	B-X
)	B-X
were	B-X
only	B-X
2-	B-X
to	B-X
3-fold	B-X
lower	B-X
compared	B-X
with	B-X
normal	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
anti-CD3	B-X
and	B-X
anti-CD28	B-X
stimulated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
which	B-X
fail	B-X
to	B-X
proliferate	B-X
,	B-X
make	B-X
little	B-X
or	B-X
no	B-X
detectable	B-X
cytokines	B-X
.	B-X
Exogenous	B-X
IL-2	B-X
,	B-X
which	B-X
restitutes	B-X
the	B-X
proliferative	B-X
response	B-X
of	B-X
the	B-X
anti-CD3-	B-X
and	B-X
anti-CD28-treated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
restores	B-X
production	B-X
of	B-X
IL-5	B-X
,	B-X
TNF-alpha	B-X
,	B-X
and	B-X
IFN-gamma	B-X
,	B-X
but	B-X
not	B-X
IL-3	B-X
and	B-X
GM-CSF	B-X
expression	B-X
to	B-X
approximately	B-X
normal	B-X
levels	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
mitogen-activated	B-X
Rel-/-	B-X
T	B-X
cells	B-X
,	B-X
lipopolysaccharide-stimulated	B-X
Rel-/-	B-X
macrophages	B-X
produce	B-X
higher	B-X
than	B-X
normal	B-X
levels	B-X
of	B-X
GM-CSF	B-X
.	B-X
These	B-X
findings	B-X
establish	B-X
that	B-X
Rel	B-X
can	B-X
function	B-X
as	B-X
an	B-X
activator	B-X
or	B-X
repressor	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
is	B-X
required	B-X
by	B-X
T	B-X
lymphocytes	B-X
for	B-X
production	B-X
of	B-X
IL-3	B-X
and	B-X
GM-CSF	B-X
.	B-X

These	O
findings	O
establish	O
that	O
Rel	B-Protein
can	O
function	O
as	O
an	O
activator	O
or	O
repressor	O
of	O
gene	O
expression	O
and	O
is	O
required	O
by	O
T	O
lymphocytes	O
for	O
production	O
of	O
IL	B-Protein
-	I-Protein
3	I-Protein
and	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
.	O
<EOS>	B-X
Here	B-X
,	B-X
through	B-X
two	B-X
mixed	B-X
bone	B-X
marrow	B-X
chimeric	B-X
experiments	B-X
,	B-X
we	B-X
identified	B-X
Peli1	B-X
,	B-X
a	B-X
T	B-X
cell-enriched	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
,	B-X
as	B-X
an	B-X
intrinsic	B-X
regulator	B-X
that	B-X
inhibits	B-X
Tfh	B-X
cell	B-X
differentiation	B-X
.	B-X
Peli1	B-X
deficiency	B-X
significantly	B-X
promoted	B-X
c-Rel-mediated	B-X
inducible	B-X
T-cell	B-X
costimulator	B-X
(	B-X
ICOS	B-X
)	B-X
expression	B-X
,	B-X
and	B-X
PELI1	B-X
mRNA	B-X
expression	B-X
was	B-X
negatively	B-X
associated	B-X
with	B-X
ICOS	B-X
expression	B-X
on	B-X
human	B-X
CD4	B-X
To	B-X
establish	B-X
efficient	B-X
replication	B-X
,	B-X
viruses	B-X
have	B-X
developed	B-X
several	B-X
strategies	B-X
to	B-X
escape	B-X
from	B-X
the	B-X
host	B-X
IFN	B-X
response	B-X
.	B-X
Japanese	B-X
encephalitis	B-X
virus	B-X
(	B-X
JEV	B-X
)	B-X
NS1	B-X
'	B-X
,	B-X
a	B-X
larger	B-X
NS1-related	B-X
protein	B-X
,	B-X
is	B-X
known	B-X
to	B-X
inhibit	B-X
the	B-X
mitochondrial	B-X
antiviral	B-X
signaling	B-X
(	B-X
MAVS	B-X
)	B-X
-mediated	B-X
IFN-β	B-X
induction	B-X
by	B-X
increasing	B-X
the	B-X
binding	B-X
of	B-X
transcription	B-X
factors	B-X
(	B-X
CREB	B-X
and	B-X
c-Rel	B-X
)	B-X
to	B-X
the	B-X
microRNA	B-X
22	B-X
(	B-X
miRNA-22	B-X
)	B-X
promoter	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
NS1	B-X
'	B-X
induces	B-X
the	B-X
recruitment	B-X
of	B-X
CREB	B-X
and	B-X
c-Rel	B-X
onto	B-X
the	B-X
miRNA-22	B-X
promoter	B-X
is	B-X
unknown	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
CREB	B-X
phosphorylation	B-X
and	B-X
c-Rel	B-X
activation	B-X
through	B-X
the	B-X
IκBα	B-X
phosphorylation	B-X
were	B-X
observed	B-X
to	B-X
be	B-X
enhanced	B-X
upon	B-X
the	B-X
augmentation	B-X
of	B-X
CDK1	B-X
phosphorylation	B-X
by	B-X
NS1	B-X
'	B-X
.	B-X

Human	O
T	O
lymphotropic	O
virus	O
-	O
I	O
infection	O
of	O
human	O
T	O
lymphocytes	O
induces	O
expression	O
of	O
the	O
beta	O
-	O
galactoside	O
-	O
binding	O
lectin	O
,	O
galectin	B-Protein
-	I-Protein
3	I-Protein
.	O

Animal	O
lectins	O
play	O
important	O
roles	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
via	O
their	O
recognition	O
of	O
glycoconjugates	O
.	O

Galectin	B-Protein
-	I-Protein
3	I-Protein
is	O
a	O
beta	O
-	O
galactoside	O
-	O
binding	O
lectin	O
previously	O
designated	O
as	O
epsilon	B-Protein
BP	I-Protein
(	O
IgE	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
)	O
,	O
CBP35	B-Protein
,	O
Mac	B-Protein
-	I-Protein
2	I-Protein
,	O
L	B-Protein
-	I-Protein
29	I-Protein
,	O
and	O
L	B-Protein
-	I-Protein
34	I-Protein
,	O
and	O
its	O
expression	O
has	O
been	O
associated	O
with	O
various	O
physiological	O
and	O
pathological	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
tumor	O
transformation	O
,	O
and	O
metastasis	O
.	O
<EOS>	B-X
Animal	B-X
lectins	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
biological	B-X
processes	B-X
via	B-X
their	B-X
recognition	B-X
of	B-X
glycoconjugates	B-X
.	B-X
Galectin-3	B-X
is	B-X
a	B-X
beta-galactoside-binding	B-X
lectin	B-X
previously	B-X
designated	B-X
as	B-X
epsilon	B-X
BP	B-X
(	B-X
IgE-binding	B-X
protein	B-X
)	B-X
,	B-X
CBP35	B-X
,	B-X
Mac-2	B-X
,	B-X
L-29	B-X
,	B-X
and	B-X
L-34	B-X
,	B-X
and	B-X
its	B-X
expression	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
various	B-X
physiological	B-X
and	B-X
pathological	B-X
processes	B-X
,	B-X
including	B-X
cell	B-X
growth	B-X
,	B-X
tumor	B-X
transformation	B-X
,	B-X
and	B-X
metastasis	B-X
.	B-X
Galectin-3	B-X
is	B-X
widely	B-X
distributed	B-X
in	B-X
various	B-X
tissues	B-X
and	B-X
cell	B-X
types	B-X
and	B-X
is	B-X
expressed	B-X
in	B-X
many	B-X
leukocytes	B-X
,	B-X
with	B-X
the	B-X
notable	B-X
exception	B-X
of	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
galectin-3	B-X
is	B-X
abundantly	B-X
expressed	B-X
in	B-X
a	B-X
number	B-X
of	B-X
human	B-X
T	B-X
lymphotropic	B-X
virus	B-X
(	B-X
HTLV	B-X
)	B-X
-I-infected	B-X
human	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
F6T	B-X
,	B-X
HUT	B-X
102	B-X
,	B-X
K3T	B-X
,	B-X
MT-2	B-X
,	B-X
and	B-X
SLB-I	B-X
,	B-X
but	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
non-HTLV-I-infected	B-X
T	B-X
cell	B-X
lines	B-X
such	B-X
as	B-X
Jurkat	B-X
,	B-X
CEM	B-X
,	B-X
and	B-X
MOLT-4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
galectin-3	B-X
level	B-X
was	B-X
markedly	B-X
increased	B-X
in	B-X
human	B-X
thymocytes	B-X
after	B-X
infection	B-X
with	B-X
HTLV-I	B-X
as	B-X
compared	B-X
with	B-X
uninfected	B-X
thymocytes	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
galectin-3	B-X
expression	B-X
appeared	B-X
to	B-X
correlate	B-X
well	B-X
with	B-X
HTLV-I	B-X
gene	B-X
expression	B-X
,	B-X
as	B-X
undetectable	B-X
or	B-X
very	B-X
low	B-X
levels	B-X
of	B-X
galectin-3	B-X
were	B-X
found	B-X
in	B-X
the	B-X
S1T	B-X
and	B-X
ATL-1K	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
are	B-X
nonproductively	B-X
infected	B-X
with	B-X
HTLV-I	B-X
.	B-X
In	B-X
co-transfection	B-X
experiments	B-X
,	B-X
the	B-X
galectin-3	B-X
promoter	B-X
was	B-X
significantly	B-X
up-regulated	B-X
by	B-X
expression	B-X
vectors	B-X
encoding	B-X
the	B-X
40-kd	B-X
Tax	B-X
protein	B-X
,	B-X
a	B-X
potent	B-X
transactivator	B-X
in	B-X
HTLV-I	B-X
.	B-X
Analysis	B-X
of	B-X
various	B-X
Tax	B-X
mutants	B-X
suggested	B-X
that	B-X
galectin-3	B-X
promoter	B-X
induction	B-X
is	B-X
dependent	B-X
on	B-X
activation	B-X
of	B-X
the	B-X
cyclic-AMP-responsive	B-X
element	B-X
binding	B-X
protein/activation	B-X
transcription	B-X
factor	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
nuclear	B-X
factor-kappa	B-X
B/Rel	B-X
induction	B-X
.	B-X
Transfection	B-X
of	B-X
human	B-X
promonocytic	B-X
U-937	B-X
cells	B-X
with	B-X
an	B-X
HTLV-I	B-X
Tax	B-X
expression	B-X
vector	B-X
induced	B-X
galectin-3	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
line	B-X
.	B-X
Functionally	B-X
,	B-X
galectin-3	B-X
was	B-X
shown	B-X
to	B-X
activate	B-X
interleukin-2	B-X
production	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
HTLV-I	B-X
Tax	B-X
production	B-X
induces	B-X
the	B-X
transcription	B-X
and	B-X
subsequent	B-X
synthesis	B-X
and	B-X
secretion	B-X
of	B-X
galectin-3	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
may	B-X
further	B-X
activate	B-X
these	B-X
T	B-X
cells	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
altered	B-X
properties	B-X
of	B-X
cell	B-X
growth	B-X
found	B-X
in	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
induced	B-X
by	B-X
HTLV-I	B-X
.	B-X

Galectin	B-Protein
-	I-Protein
3	I-Protein
is	O
widely	O
distributed	O
in	O
various	O
tissues	O
and	O
cell	O
types	O
and	O
is	O
expressed	O
in	O
many	O
leukocytes	O
,	O
with	O
the	O
notable	O
exception	O
of	O
B	O
and	O
T	O
lymphocytes	O
.	O

We	O
now	O
report	O
that	O
galectin	B-Protein
-	I-Protein
3	I-Protein
is	O
abundantly	O
expressed	O
in	O
a	O
number	O
of	O
human	O
T	O
lymphotropic	O
virus	O
(	O
HTLV	O
)	O
-	O
I	O
-	O
infected	O
human	O
T	O
cell	O
lines	O
,	O
including	O
F6T	O
,	O
HUT	O
102	O
,	O
K3T	O
,	O
MT	O
-	O
2	O
,	O
and	O
SLB	O
-	O
I	O
,	O
but	O
is	O
not	O
expressed	O
in	O
non	O
-	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
cell	O
lines	O
such	O
as	O
Jurkat	O
,	O
CEM	O
,	O
and	O
MOLT	O
-	O
4	O
.	O

In	O
addition	O
,	O
the	O
galectin	B-Protein
-	I-Protein
3	I-Protein
level	O
was	O
markedly	O
increased	O
in	O
human	O
thymocytes	O
after	O
infection	O
with	O
HTLV	O
-	O
I	O
as	O
compared	O
with	O
uninfected	O
thymocytes	O
.	O
<EOS>	B-X
Galectin-3	B-X
is	B-X
a	B-X
beta-galactoside-binding	B-X
lectin	B-X
previously	B-X
designated	B-X
as	B-X
epsilon	B-X
BP	B-X
(	B-X
IgE-binding	B-X
protein	B-X
)	B-X
,	B-X
CBP35	B-X
,	B-X
Mac-2	B-X
,	B-X
L-29	B-X
,	B-X
and	B-X
L-34	B-X
,	B-X
and	B-X
its	B-X
expression	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
various	B-X
physiological	B-X
and	B-X
pathological	B-X
processes	B-X
,	B-X
including	B-X
cell	B-X
growth	B-X
,	B-X
tumor	B-X
transformation	B-X
,	B-X
and	B-X
metastasis	B-X
.	B-X
Galectin-3	B-X
is	B-X
widely	B-X
distributed	B-X
in	B-X
various	B-X
tissues	B-X
and	B-X
cell	B-X
types	B-X
and	B-X
is	B-X
expressed	B-X
in	B-X
many	B-X
leukocytes	B-X
,	B-X
with	B-X
the	B-X
notable	B-X
exception	B-X
of	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
galectin-3	B-X
is	B-X
abundantly	B-X
expressed	B-X
in	B-X
a	B-X
number	B-X
of	B-X
human	B-X
T	B-X
lymphotropic	B-X
virus	B-X
(	B-X
HTLV	B-X
)	B-X
-I-infected	B-X
human	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
F6T	B-X
,	B-X
HUT	B-X
102	B-X
,	B-X
K3T	B-X
,	B-X
MT-2	B-X
,	B-X
and	B-X
SLB-I	B-X
,	B-X
but	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
non-HTLV-I-infected	B-X
T	B-X
cell	B-X
lines	B-X
such	B-X
as	B-X
Jurkat	B-X
,	B-X
CEM	B-X
,	B-X
and	B-X
MOLT-4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
galectin-3	B-X
level	B-X
was	B-X
markedly	B-X
increased	B-X
in	B-X
human	B-X
thymocytes	B-X
after	B-X
infection	B-X
with	B-X
HTLV-I	B-X
as	B-X
compared	B-X
with	B-X
uninfected	B-X
thymocytes	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
galectin-3	B-X
expression	B-X
appeared	B-X
to	B-X
correlate	B-X
well	B-X
with	B-X
HTLV-I	B-X
gene	B-X
expression	B-X
,	B-X
as	B-X
undetectable	B-X
or	B-X
very	B-X
low	B-X
levels	B-X
of	B-X
galectin-3	B-X
were	B-X
found	B-X
in	B-X
the	B-X
S1T	B-X
and	B-X
ATL-1K	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
are	B-X
nonproductively	B-X
infected	B-X
with	B-X
HTLV-I	B-X
.	B-X
In	B-X
co-transfection	B-X
experiments	B-X
,	B-X
the	B-X
galectin-3	B-X
promoter	B-X
was	B-X
significantly	B-X
up-regulated	B-X
by	B-X
expression	B-X
vectors	B-X
encoding	B-X
the	B-X
40-kd	B-X
Tax	B-X
protein	B-X
,	B-X
a	B-X
potent	B-X
transactivator	B-X
in	B-X
HTLV-I	B-X
.	B-X
Analysis	B-X
of	B-X
various	B-X
Tax	B-X
mutants	B-X
suggested	B-X
that	B-X
galectin-3	B-X
promoter	B-X
induction	B-X
is	B-X
dependent	B-X
on	B-X
activation	B-X
of	B-X
the	B-X
cyclic-AMP-responsive	B-X
element	B-X
binding	B-X
protein/activation	B-X
transcription	B-X
factor	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
nuclear	B-X
factor-kappa	B-X
B/Rel	B-X
induction	B-X
.	B-X
Transfection	B-X
of	B-X
human	B-X
promonocytic	B-X
U-937	B-X
cells	B-X
with	B-X
an	B-X
HTLV-I	B-X
Tax	B-X
expression	B-X
vector	B-X
induced	B-X
galectin-3	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
line	B-X
.	B-X
Functionally	B-X
,	B-X
galectin-3	B-X
was	B-X
shown	B-X
to	B-X
activate	B-X
interleukin-2	B-X
production	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
HTLV-I	B-X
Tax	B-X
production	B-X
induces	B-X
the	B-X
transcription	B-X
and	B-X
subsequent	B-X
synthesis	B-X
and	B-X
secretion	B-X
of	B-X
galectin-3	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
may	B-X
further	B-X
activate	B-X
these	B-X
T	B-X
cells	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
altered	B-X
properties	B-X
of	B-X
cell	B-X
growth	B-X
found	B-X
in	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
induced	B-X
by	B-X
HTLV-I	B-X
.	B-X

The	O
up	O
-	O
regulation	O
of	O
galectin	B-Protein
-	I-Protein
3	I-Protein
expression	O
appeared	O
to	O
correlate	O
well	O
with	O
HTLV	O
-	O
I	O
gene	O
expression	O
,	O
as	O
undetectable	O
or	O
very	O
low	O
levels	O
of	O
galectin	B-Protein
-	I-Protein
3	I-Protein
were	O
found	O
in	O
the	O
S1T	O
and	O
ATL	O
-	O
1K	O
cell	O
lines	O
,	O
which	O
are	O
nonproductively	O
infected	O
with	O
HTLV	O
-	O
I	O
.	O
<EOS>	B-X
Galectin-3	B-X
is	B-X
a	B-X
beta-galactoside-binding	B-X
lectin	B-X
previously	B-X
designated	B-X
as	B-X
epsilon	B-X
BP	B-X
(	B-X
IgE-binding	B-X
protein	B-X
)	B-X
,	B-X
CBP35	B-X
,	B-X
Mac-2	B-X
,	B-X
L-29	B-X
,	B-X
and	B-X
L-34	B-X
,	B-X
and	B-X
its	B-X
expression	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
various	B-X
physiological	B-X
and	B-X
pathological	B-X
processes	B-X
,	B-X
including	B-X
cell	B-X
growth	B-X
,	B-X
tumor	B-X
transformation	B-X
,	B-X
and	B-X
metastasis	B-X
.	B-X
Galectin-3	B-X
is	B-X
widely	B-X
distributed	B-X
in	B-X
various	B-X
tissues	B-X
and	B-X
cell	B-X
types	B-X
and	B-X
is	B-X
expressed	B-X
in	B-X
many	B-X
leukocytes	B-X
,	B-X
with	B-X
the	B-X
notable	B-X
exception	B-X
of	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
galectin-3	B-X
is	B-X
abundantly	B-X
expressed	B-X
in	B-X
a	B-X
number	B-X
of	B-X
human	B-X
T	B-X
lymphotropic	B-X
virus	B-X
(	B-X
HTLV	B-X
)	B-X
-I-infected	B-X
human	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
F6T	B-X
,	B-X
HUT	B-X
102	B-X
,	B-X
K3T	B-X
,	B-X
MT-2	B-X
,	B-X
and	B-X
SLB-I	B-X
,	B-X
but	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
non-HTLV-I-infected	B-X
T	B-X
cell	B-X
lines	B-X
such	B-X
as	B-X
Jurkat	B-X
,	B-X
CEM	B-X
,	B-X
and	B-X
MOLT-4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
galectin-3	B-X
level	B-X
was	B-X
markedly	B-X
increased	B-X
in	B-X
human	B-X
thymocytes	B-X
after	B-X
infection	B-X
with	B-X
HTLV-I	B-X
as	B-X
compared	B-X
with	B-X
uninfected	B-X
thymocytes	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
galectin-3	B-X
expression	B-X
appeared	B-X
to	B-X
correlate	B-X
well	B-X
with	B-X
HTLV-I	B-X
gene	B-X
expression	B-X
,	B-X
as	B-X
undetectable	B-X
or	B-X
very	B-X
low	B-X
levels	B-X
of	B-X
galectin-3	B-X
were	B-X
found	B-X
in	B-X
the	B-X
S1T	B-X
and	B-X
ATL-1K	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
are	B-X
nonproductively	B-X
infected	B-X
with	B-X
HTLV-I	B-X
.	B-X
In	B-X
co-transfection	B-X
experiments	B-X
,	B-X
the	B-X
galectin-3	B-X
promoter	B-X
was	B-X
significantly	B-X
up-regulated	B-X
by	B-X
expression	B-X
vectors	B-X
encoding	B-X
the	B-X
40-kd	B-X
Tax	B-X
protein	B-X
,	B-X
a	B-X
potent	B-X
transactivator	B-X
in	B-X
HTLV-I	B-X
.	B-X
Analysis	B-X
of	B-X
various	B-X
Tax	B-X
mutants	B-X
suggested	B-X
that	B-X
galectin-3	B-X
promoter	B-X
induction	B-X
is	B-X
dependent	B-X
on	B-X
activation	B-X
of	B-X
the	B-X
cyclic-AMP-responsive	B-X
element	B-X
binding	B-X
protein/activation	B-X
transcription	B-X
factor	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
nuclear	B-X
factor-kappa	B-X
B/Rel	B-X
induction	B-X
.	B-X
Transfection	B-X
of	B-X
human	B-X
promonocytic	B-X
U-937	B-X
cells	B-X
with	B-X
an	B-X
HTLV-I	B-X
Tax	B-X
expression	B-X
vector	B-X
induced	B-X
galectin-3	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
line	B-X
.	B-X
Functionally	B-X
,	B-X
galectin-3	B-X
was	B-X
shown	B-X
to	B-X
activate	B-X
interleukin-2	B-X
production	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
HTLV-I	B-X
Tax	B-X
production	B-X
induces	B-X
the	B-X
transcription	B-X
and	B-X
subsequent	B-X
synthesis	B-X
and	B-X
secretion	B-X
of	B-X
galectin-3	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
may	B-X
further	B-X
activate	B-X
these	B-X
T	B-X
cells	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
altered	B-X
properties	B-X
of	B-X
cell	B-X
growth	B-X
found	B-X
in	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
induced	B-X
by	B-X
HTLV-I	B-X
.	B-X

In	O
co	O
-	O
transfection	O
experiments	O
,	O
the	O
galectin	B-Protein
-	I-Protein
3	I-Protein
promoter	O
was	O
significantly	O
up	O
-	O
regulated	O
by	O
expression	O
vectors	O
encoding	O
the	O
40	O
-	O
kd	O
Tax	B-Protein
protein	O
,	O
a	O
potent	O
transactivator	O
in	O
HTLV	O
-	O
I	O
.	O
<EOS>	B-X
Animal	B-X
lectins	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
biological	B-X
processes	B-X
via	B-X
their	B-X
recognition	B-X
of	B-X
glycoconjugates	B-X
.	B-X
Galectin-3	B-X
is	B-X
a	B-X
beta-galactoside-binding	B-X
lectin	B-X
previously	B-X
designated	B-X
as	B-X
epsilon	B-X
BP	B-X
(	B-X
IgE-binding	B-X
protein	B-X
)	B-X
,	B-X
CBP35	B-X
,	B-X
Mac-2	B-X
,	B-X
L-29	B-X
,	B-X
and	B-X
L-34	B-X
,	B-X
and	B-X
its	B-X
expression	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
various	B-X
physiological	B-X
and	B-X
pathological	B-X
processes	B-X
,	B-X
including	B-X
cell	B-X
growth	B-X
,	B-X
tumor	B-X
transformation	B-X
,	B-X
and	B-X
metastasis	B-X
.	B-X
Galectin-3	B-X
is	B-X
widely	B-X
distributed	B-X
in	B-X
various	B-X
tissues	B-X
and	B-X
cell	B-X
types	B-X
and	B-X
is	B-X
expressed	B-X
in	B-X
many	B-X
leukocytes	B-X
,	B-X
with	B-X
the	B-X
notable	B-X
exception	B-X
of	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
galectin-3	B-X
is	B-X
abundantly	B-X
expressed	B-X
in	B-X
a	B-X
number	B-X
of	B-X
human	B-X
T	B-X
lymphotropic	B-X
virus	B-X
(	B-X
HTLV	B-X
)	B-X
-I-infected	B-X
human	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
F6T	B-X
,	B-X
HUT	B-X
102	B-X
,	B-X
K3T	B-X
,	B-X
MT-2	B-X
,	B-X
and	B-X
SLB-I	B-X
,	B-X
but	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
non-HTLV-I-infected	B-X
T	B-X
cell	B-X
lines	B-X
such	B-X
as	B-X
Jurkat	B-X
,	B-X
CEM	B-X
,	B-X
and	B-X
MOLT-4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
galectin-3	B-X
level	B-X
was	B-X
markedly	B-X
increased	B-X
in	B-X
human	B-X
thymocytes	B-X
after	B-X
infection	B-X
with	B-X
HTLV-I	B-X
as	B-X
compared	B-X
with	B-X
uninfected	B-X
thymocytes	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
galectin-3	B-X
expression	B-X
appeared	B-X
to	B-X
correlate	B-X
well	B-X
with	B-X
HTLV-I	B-X
gene	B-X
expression	B-X
,	B-X
as	B-X
undetectable	B-X
or	B-X
very	B-X
low	B-X
levels	B-X
of	B-X
galectin-3	B-X
were	B-X
found	B-X
in	B-X
the	B-X
S1T	B-X
and	B-X
ATL-1K	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
are	B-X
nonproductively	B-X
infected	B-X
with	B-X
HTLV-I	B-X
.	B-X
In	B-X
co-transfection	B-X
experiments	B-X
,	B-X
the	B-X
galectin-3	B-X
promoter	B-X
was	B-X
significantly	B-X
up-regulated	B-X
by	B-X
expression	B-X
vectors	B-X
encoding	B-X
the	B-X
40-kd	B-X
Tax	B-X
protein	B-X
,	B-X
a	B-X
potent	B-X
transactivator	B-X
in	B-X
HTLV-I	B-X
.	B-X
Analysis	B-X
of	B-X
various	B-X
Tax	B-X
mutants	B-X
suggested	B-X
that	B-X
galectin-3	B-X
promoter	B-X
induction	B-X
is	B-X
dependent	B-X
on	B-X
activation	B-X
of	B-X
the	B-X
cyclic-AMP-responsive	B-X
element	B-X
binding	B-X
protein/activation	B-X
transcription	B-X
factor	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
nuclear	B-X
factor-kappa	B-X
B/Rel	B-X
induction	B-X
.	B-X
Transfection	B-X
of	B-X
human	B-X
promonocytic	B-X
U-937	B-X
cells	B-X
with	B-X
an	B-X
HTLV-I	B-X
Tax	B-X
expression	B-X
vector	B-X
induced	B-X
galectin-3	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
line	B-X
.	B-X
Functionally	B-X
,	B-X
galectin-3	B-X
was	B-X
shown	B-X
to	B-X
activate	B-X
interleukin-2	B-X
production	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
HTLV-I	B-X
Tax	B-X
production	B-X
induces	B-X
the	B-X
transcription	B-X
and	B-X
subsequent	B-X
synthesis	B-X
and	B-X
secretion	B-X
of	B-X
galectin-3	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
may	B-X
further	B-X
activate	B-X
these	B-X
T	B-X
cells	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
altered	B-X
properties	B-X
of	B-X
cell	B-X
growth	B-X
found	B-X
in	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
induced	B-X
by	B-X
HTLV-I	B-X
.	B-X

Analysis	O
of	O
various	O
Tax	B-Protein
mutants	O
suggested	O
that	O
galectin	B-Protein
-	I-Protein
3	I-Protein
promoter	O
induction	O
is	O
dependent	O
on	O
activation	O
of	O
the	O
cyclic	O
-	O
AMP	O
-	O
responsive	O
element	O
binding	O
protein	O
/	O
activation	O
transcription	O
factor	O
family	O
of	O
transcription	O
factors	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
nuclear	O
factor	O
-	O
kappa	O
B	O
/	O
Rel	O
induction	O
.	O
<EOS>	B-X
Galectin-3	B-X
is	B-X
a	B-X
beta-galactoside-binding	B-X
lectin	B-X
previously	B-X
designated	B-X
as	B-X
epsilon	B-X
BP	B-X
(	B-X
IgE-binding	B-X
protein	B-X
)	B-X
,	B-X
CBP35	B-X
,	B-X
Mac-2	B-X
,	B-X
L-29	B-X
,	B-X
and	B-X
L-34	B-X
,	B-X
and	B-X
its	B-X
expression	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
various	B-X
physiological	B-X
and	B-X
pathological	B-X
processes	B-X
,	B-X
including	B-X
cell	B-X
growth	B-X
,	B-X
tumor	B-X
transformation	B-X
,	B-X
and	B-X
metastasis	B-X
.	B-X
Galectin-3	B-X
is	B-X
widely	B-X
distributed	B-X
in	B-X
various	B-X
tissues	B-X
and	B-X
cell	B-X
types	B-X
and	B-X
is	B-X
expressed	B-X
in	B-X
many	B-X
leukocytes	B-X
,	B-X
with	B-X
the	B-X
notable	B-X
exception	B-X
of	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
galectin-3	B-X
is	B-X
abundantly	B-X
expressed	B-X
in	B-X
a	B-X
number	B-X
of	B-X
human	B-X
T	B-X
lymphotropic	B-X
virus	B-X
(	B-X
HTLV	B-X
)	B-X
-I-infected	B-X
human	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
F6T	B-X
,	B-X
HUT	B-X
102	B-X
,	B-X
K3T	B-X
,	B-X
MT-2	B-X
,	B-X
and	B-X
SLB-I	B-X
,	B-X
but	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
non-HTLV-I-infected	B-X
T	B-X
cell	B-X
lines	B-X
such	B-X
as	B-X
Jurkat	B-X
,	B-X
CEM	B-X
,	B-X
and	B-X
MOLT-4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
galectin-3	B-X
level	B-X
was	B-X
markedly	B-X
increased	B-X
in	B-X
human	B-X
thymocytes	B-X
after	B-X
infection	B-X
with	B-X
HTLV-I	B-X
as	B-X
compared	B-X
with	B-X
uninfected	B-X
thymocytes	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
galectin-3	B-X
expression	B-X
appeared	B-X
to	B-X
correlate	B-X
well	B-X
with	B-X
HTLV-I	B-X
gene	B-X
expression	B-X
,	B-X
as	B-X
undetectable	B-X
or	B-X
very	B-X
low	B-X
levels	B-X
of	B-X
galectin-3	B-X
were	B-X
found	B-X
in	B-X
the	B-X
S1T	B-X
and	B-X
ATL-1K	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
are	B-X
nonproductively	B-X
infected	B-X
with	B-X
HTLV-I	B-X
.	B-X
In	B-X
co-transfection	B-X
experiments	B-X
,	B-X
the	B-X
galectin-3	B-X
promoter	B-X
was	B-X
significantly	B-X
up-regulated	B-X
by	B-X
expression	B-X
vectors	B-X
encoding	B-X
the	B-X
40-kd	B-X
Tax	B-X
protein	B-X
,	B-X
a	B-X
potent	B-X
transactivator	B-X
in	B-X
HTLV-I	B-X
.	B-X
Analysis	B-X
of	B-X
various	B-X
Tax	B-X
mutants	B-X
suggested	B-X
that	B-X
galectin-3	B-X
promoter	B-X
induction	B-X
is	B-X
dependent	B-X
on	B-X
activation	B-X
of	B-X
the	B-X
cyclic-AMP-responsive	B-X
element	B-X
binding	B-X
protein/activation	B-X
transcription	B-X
factor	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
nuclear	B-X
factor-kappa	B-X
B/Rel	B-X
induction	B-X
.	B-X
Transfection	B-X
of	B-X
human	B-X
promonocytic	B-X
U-937	B-X
cells	B-X
with	B-X
an	B-X
HTLV-I	B-X
Tax	B-X
expression	B-X
vector	B-X
induced	B-X
galectin-3	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
line	B-X
.	B-X
Functionally	B-X
,	B-X
galectin-3	B-X
was	B-X
shown	B-X
to	B-X
activate	B-X
interleukin-2	B-X
production	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
HTLV-I	B-X
Tax	B-X
production	B-X
induces	B-X
the	B-X
transcription	B-X
and	B-X
subsequent	B-X
synthesis	B-X
and	B-X
secretion	B-X
of	B-X
galectin-3	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
may	B-X
further	B-X
activate	B-X
these	B-X
T	B-X
cells	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
altered	B-X
properties	B-X
of	B-X
cell	B-X
growth	B-X
found	B-X
in	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
induced	B-X
by	B-X
HTLV-I	B-X
.	B-X

Transfection	O
of	O
human	O
promonocytic	O
U	O
-	O
937	O
cells	O
with	O
an	O
HTLV	O
-	O
I	O
Tax	B-Protein
expression	O
vector	O
induced	O
galectin	B-Protein
-	I-Protein
3	I-Protein
expression	O
in	O
this	O
cell	O
line	O
.	O
<EOS>	B-X
Galectin-3	B-X
is	B-X
a	B-X
beta-galactoside-binding	B-X
lectin	B-X
previously	B-X
designated	B-X
as	B-X
epsilon	B-X
BP	B-X
(	B-X
IgE-binding	B-X
protein	B-X
)	B-X
,	B-X
CBP35	B-X
,	B-X
Mac-2	B-X
,	B-X
L-29	B-X
,	B-X
and	B-X
L-34	B-X
,	B-X
and	B-X
its	B-X
expression	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
various	B-X
physiological	B-X
and	B-X
pathological	B-X
processes	B-X
,	B-X
including	B-X
cell	B-X
growth	B-X
,	B-X
tumor	B-X
transformation	B-X
,	B-X
and	B-X
metastasis	B-X
.	B-X
Galectin-3	B-X
is	B-X
widely	B-X
distributed	B-X
in	B-X
various	B-X
tissues	B-X
and	B-X
cell	B-X
types	B-X
and	B-X
is	B-X
expressed	B-X
in	B-X
many	B-X
leukocytes	B-X
,	B-X
with	B-X
the	B-X
notable	B-X
exception	B-X
of	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
.	B-X
We	B-X
now	B-X
report	B-X
that	B-X
galectin-3	B-X
is	B-X
abundantly	B-X
expressed	B-X
in	B-X
a	B-X
number	B-X
of	B-X
human	B-X
T	B-X
lymphotropic	B-X
virus	B-X
(	B-X
HTLV	B-X
)	B-X
-I-infected	B-X
human	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
including	B-X
F6T	B-X
,	B-X
HUT	B-X
102	B-X
,	B-X
K3T	B-X
,	B-X
MT-2	B-X
,	B-X
and	B-X
SLB-I	B-X
,	B-X
but	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
non-HTLV-I-infected	B-X
T	B-X
cell	B-X
lines	B-X
such	B-X
as	B-X
Jurkat	B-X
,	B-X
CEM	B-X
,	B-X
and	B-X
MOLT-4	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
galectin-3	B-X
level	B-X
was	B-X
markedly	B-X
increased	B-X
in	B-X
human	B-X
thymocytes	B-X
after	B-X
infection	B-X
with	B-X
HTLV-I	B-X
as	B-X
compared	B-X
with	B-X
uninfected	B-X
thymocytes	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
galectin-3	B-X
expression	B-X
appeared	B-X
to	B-X
correlate	B-X
well	B-X
with	B-X
HTLV-I	B-X
gene	B-X
expression	B-X
,	B-X
as	B-X
undetectable	B-X
or	B-X
very	B-X
low	B-X
levels	B-X
of	B-X
galectin-3	B-X
were	B-X
found	B-X
in	B-X
the	B-X
S1T	B-X
and	B-X
ATL-1K	B-X
cell	B-X
lines	B-X
,	B-X
which	B-X
are	B-X
nonproductively	B-X
infected	B-X
with	B-X
HTLV-I	B-X
.	B-X
In	B-X
co-transfection	B-X
experiments	B-X
,	B-X
the	B-X
galectin-3	B-X
promoter	B-X
was	B-X
significantly	B-X
up-regulated	B-X
by	B-X
expression	B-X
vectors	B-X
encoding	B-X
the	B-X
40-kd	B-X
Tax	B-X
protein	B-X
,	B-X
a	B-X
potent	B-X
transactivator	B-X
in	B-X
HTLV-I	B-X
.	B-X
Analysis	B-X
of	B-X
various	B-X
Tax	B-X
mutants	B-X
suggested	B-X
that	B-X
galectin-3	B-X
promoter	B-X
induction	B-X
is	B-X
dependent	B-X
on	B-X
activation	B-X
of	B-X
the	B-X
cyclic-AMP-responsive	B-X
element	B-X
binding	B-X
protein/activation	B-X
transcription	B-X
factor	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
nuclear	B-X
factor-kappa	B-X
B/Rel	B-X
induction	B-X
.	B-X
Transfection	B-X
of	B-X
human	B-X
promonocytic	B-X
U-937	B-X
cells	B-X
with	B-X
an	B-X
HTLV-I	B-X
Tax	B-X
expression	B-X
vector	B-X
induced	B-X
galectin-3	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
line	B-X
.	B-X
Functionally	B-X
,	B-X
galectin-3	B-X
was	B-X
shown	B-X
to	B-X
activate	B-X
interleukin-2	B-X
production	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
HTLV-I	B-X
Tax	B-X
production	B-X
induces	B-X
the	B-X
transcription	B-X
and	B-X
subsequent	B-X
synthesis	B-X
and	B-X
secretion	B-X
of	B-X
galectin-3	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
may	B-X
further	B-X
activate	B-X
these	B-X
T	B-X
cells	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
altered	B-X
properties	B-X
of	B-X
cell	B-X
growth	B-X
found	B-X
in	B-X
adult	B-X
T	B-X
cell	B-X
leukemia	B-X
induced	B-X
by	B-X
HTLV-I	B-X
.	B-X

Functionally	O
,	O
galectin	B-Protein
-	I-Protein
3	I-Protein
was	O
shown	O
to	O
activate	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
production	O
in	O
Jurkat	O
T	O
cells	O
.	O

Together	O
,	O
these	O
findings	O
raise	O
the	O
possibility	O
that	O
HTLV	O
-	O
I	O
Tax	B-Protein
production	O
induces	O
the	O
transcription	O
and	O
subsequent	O
synthesis	O
and	O
secretion	O
of	O
galectin	B-Protein
-	I-Protein
3	I-Protein
,	O
which	O
in	O
turn	O
may	O
further	O
activate	O
these	O
T	O
cells	O
and	O
contribute	O
to	O
the	O
altered	O
properties	O
of	O
cell	O
growth	O
found	O
in	O
adult	O
T	O
cell	O
leukemia	O
induced	O
by	O
HTLV	O
-	O
I	O
.	O

Nuclear	O
appearance	O
of	O
a	O
factor	O
that	O
binds	O
the	O
CD28	B-Protein
response	O
element	O
within	O
the	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
enhancer	O
correlates	O
with	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
production	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
requires	B-X
the	B-X
combined	B-X
signaling	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
and	B-X
costimulatory	B-X
molecules	B-X
such	B-X
as	B-X
CD28	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
T	B-X
cells	B-X
to	B-X
produce	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
control	B-X
point	B-X
in	B-X
T	B-X
lymphocyte	B-X
activation	B-X
.	B-X
The	B-X
IL-2	B-X
enhancer	B-X
contains	B-X
a	B-X
functional	B-X
motif	B-X
named	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
that	B-X
serves	B-X
a	B-X
role	B-X
as	B-X
a	B-X
target	B-X
for	B-X
mitogenic	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
.	B-X
The	B-X
CD28RE	B-X
sequence	B-X
reveals	B-X
similarity	B-X
to	B-X
the	B-X
consensus	B-X
kappaB	B-X
binding	B-X
motif	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
CD28RE	B-X
binds	B-X
an	B-X
inducible	B-X
protein	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
35	B-X
kDa	B-X
called	B-X
nuclear	B-X
factor	B-X
of	B-X
mitogenic-activated	B-X
T	B-X
cells	B-X
(	B-X
NF-MATp35	B-X
)	B-X
that	B-X
is	B-X
clearly	B-X
different	B-X
from	B-X
the	B-X
known	B-X
NF-	B-X
kappaB/Rel	B-X
family	B-X
members	B-X
.	B-X
Induction	B-X
of	B-X
NF-MATp35	B-X
was	B-X
shown	B-X
to	B-X
depend	B-X
on	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
and	B-X
was	B-X
restricted	B-X
to	B-X
T	B-X
cells	B-X
that	B-X
received	B-X
a	B-X
mitogenic	B-X
combination	B-X
of	B-X
T	B-X
cell	B-X
stimuli	B-X
,	B-X
not	B-X
necessarily	B-X
including	B-X
CD28	B-X
signaling	B-X
.	B-X
Nonmitogenic	B-X
T	B-X
cell	B-X
stimulation	B-X
did	B-X
not	B-X
result	B-X
in	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
.	B-X
Similar	B-X
to	B-X
its	B-X
effect	B-X
on	B-X
IL-2	B-X
production	B-X
,	B-X
cyclosporin	B-X
A	B-X
inhibited	B-X
the	B-X
induction	B-X
of	B-X
NF-MATp35	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
shows	B-X
excellent	B-X
correlation	B-X
with	B-X
IL-2	B-X
production	B-X
,	B-X
which	B-X
is	B-X
a	B-X
unique	B-X
characteristic	B-X
among	B-X
nuclear	B-X
factors	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
IL-2	B-X
gene	B-X
expression	B-X
.	B-X

Activation	O
of	O
T	O
lymphocytes	O
requires	O
the	O
combined	O
signaling	O
of	O
the	O
T	O
cell	O
receptor	O
and	O
costimulatory	O
molecules	O
such	O
as	O
CD28	B-Protein
.	O

The	O
ability	O
of	O
T	O
cells	O
to	O
produce	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
is	O
a	O
critical	O
control	O
point	O
in	O
T	O
lymphocyte	O
activation	O
.	O

The	O
IL	B-Protein
-	I-Protein
2	I-Protein
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	B-Protein
response	O
element	O
(	O
CD28RE	O
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
requires	B-X
the	B-X
combined	B-X
signaling	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
and	B-X
costimulatory	B-X
molecules	B-X
such	B-X
as	B-X
CD28	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
T	B-X
cells	B-X
to	B-X
produce	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
control	B-X
point	B-X
in	B-X
T	B-X
lymphocyte	B-X
activation	B-X
.	B-X
The	B-X
IL-2	B-X
enhancer	B-X
contains	B-X
a	B-X
functional	B-X
motif	B-X
named	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
that	B-X
serves	B-X
a	B-X
role	B-X
as	B-X
a	B-X
target	B-X
for	B-X
mitogenic	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
.	B-X
The	B-X
CD28RE	B-X
sequence	B-X
reveals	B-X
similarity	B-X
to	B-X
the	B-X
consensus	B-X
kappaB	B-X
binding	B-X
motif	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
CD28RE	B-X
binds	B-X
an	B-X
inducible	B-X
protein	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
35	B-X
kDa	B-X
called	B-X
nuclear	B-X
factor	B-X
of	B-X
mitogenic-activated	B-X
T	B-X
cells	B-X
(	B-X
NF-MATp35	B-X
)	B-X
that	B-X
is	B-X
clearly	B-X
different	B-X
from	B-X
the	B-X
known	B-X
NF-	B-X
kappaB/Rel	B-X
family	B-X
members	B-X
.	B-X
Induction	B-X
of	B-X
NF-MATp35	B-X
was	B-X
shown	B-X
to	B-X
depend	B-X
on	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
and	B-X
was	B-X
restricted	B-X
to	B-X
T	B-X
cells	B-X
that	B-X
received	B-X
a	B-X
mitogenic	B-X
combination	B-X
of	B-X
T	B-X
cell	B-X
stimuli	B-X
,	B-X
not	B-X
necessarily	B-X
including	B-X
CD28	B-X
signaling	B-X
.	B-X
Nonmitogenic	B-X
T	B-X
cell	B-X
stimulation	B-X
did	B-X
not	B-X
result	B-X
in	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
mitogenic	B-X
combinations	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
are	B-X
integrated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
NF-MATp35	B-X
induction	B-X
.	B-X
Similar	B-X
to	B-X
its	B-X
effect	B-X
on	B-X
IL-2	B-X
production	B-X
,	B-X
cyclosporin	B-X
A	B-X
inhibited	B-X
the	B-X
induction	B-X
of	B-X
NF-MATp35	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
shows	B-X
excellent	B-X
correlation	B-X
with	B-X
IL-2	B-X
production	B-X
,	B-X
which	B-X
is	B-X
a	B-X
unique	B-X
characteristic	B-X
among	B-X
nuclear	B-X
factors	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
IL-2	B-X
gene	B-X
expression	B-X
.	B-X

The	O
CD28RE	O
sequence	O
reveals	O
similarity	O
to	O
the	O
consensus	O
kappaB	O
binding	O
motif	O
.	O

Here	O
we	O
demonstrate	O
that	O
CD28RE	O
binds	O
an	O
inducible	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
35	O
kDa	O
called	O
nuclear	O
factor	O
of	O
mitogenic	O
-	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
MATp35	O
)	O
that	O
is	O
clearly	O
different	O
from	O
the	O
known	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
members	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
T	B-X
cells	B-X
to	B-X
produce	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
control	B-X
point	B-X
in	B-X
T	B-X
lymphocyte	B-X
activation	B-X
.	B-X
The	B-X
IL-2	B-X
enhancer	B-X
contains	B-X
a	B-X
functional	B-X
motif	B-X
named	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
that	B-X
serves	B-X
a	B-X
role	B-X
as	B-X
a	B-X
target	B-X
for	B-X
mitogenic	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
.	B-X
The	B-X
CD28RE	B-X
sequence	B-X
reveals	B-X
similarity	B-X
to	B-X
the	B-X
consensus	B-X
kappaB	B-X
binding	B-X
motif	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
CD28RE	B-X
binds	B-X
an	B-X
inducible	B-X
protein	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
35	B-X
kDa	B-X
called	B-X
nuclear	B-X
factor	B-X
of	B-X
mitogenic-activated	B-X
T	B-X
cells	B-X
(	B-X
NF-MATp35	B-X
)	B-X
that	B-X
is	B-X
clearly	B-X
different	B-X
from	B-X
the	B-X
known	B-X
NF-	B-X
kappaB/Rel	B-X
family	B-X
members	B-X
.	B-X
Induction	B-X
of	B-X
NF-MATp35	B-X
was	B-X
shown	B-X
to	B-X
depend	B-X
on	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
and	B-X
was	B-X
restricted	B-X
to	B-X
T	B-X
cells	B-X
that	B-X
received	B-X
a	B-X
mitogenic	B-X
combination	B-X
of	B-X
T	B-X
cell	B-X
stimuli	B-X
,	B-X
not	B-X
necessarily	B-X
including	B-X
CD28	B-X
signaling	B-X
.	B-X
Nonmitogenic	B-X
T	B-X
cell	B-X
stimulation	B-X
did	B-X
not	B-X
result	B-X
in	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
mitogenic	B-X
combinations	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
are	B-X
integrated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
NF-MATp35	B-X
induction	B-X
.	B-X
Similar	B-X
to	B-X
its	B-X
effect	B-X
on	B-X
IL-2	B-X
production	B-X
,	B-X
cyclosporin	B-X
A	B-X
inhibited	B-X
the	B-X
induction	B-X
of	B-X
NF-MATp35	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
shows	B-X
excellent	B-X
correlation	B-X
with	B-X
IL-2	B-X
production	B-X
,	B-X
which	B-X
is	B-X
a	B-X
unique	B-X
characteristic	B-X
among	B-X
nuclear	B-X
factors	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
IL-2	B-X
gene	B-X
expression	B-X
.	B-X

Induction	O
of	O
NF	O
-	O
MATp35	O
was	O
shown	O
to	O
depend	O
on	O
de	O
novo	O
protein	O
synthesis	O
and	O
was	O
restricted	O
to	O
T	O
cells	O
that	O
received	O
a	O
mitogenic	O
combination	O
of	O
T	O
cell	O
stimuli	O
,	O
not	O
necessarily	O
including	O
CD28	B-Protein
signaling	O
.	O

Nonmitogenic	O
T	O
cell	O
stimulation	O
did	O
not	O
result	O
in	O
appearance	O
of	O
NF	O
-	O
MATp35	O
.	O
<EOS>	B-X
The	B-X
CD7	B-X
molecule	B-X
is	B-X
a	B-X
40-kDa	B-X
member	B-X
of	B-X
the	B-X
Ig	B-X
superfamily	B-X
that	B-X
has	B-X
structural	B-X
homology	B-X
to	B-X
the	B-X
murine	B-X
Thy-1	B-X
molecule	B-X
and	B-X
is	B-X
acquired	B-X
early	B-X
in	B-X
human	B-X
T	B-X
cell	B-X
ontogeny	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
expression	B-X
of	B-X
the	B-X
CD7	B-X
molecule	B-X
is	B-X
markedly	B-X
up-regulated	B-X
during	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
signals	B-X
required	B-X
for	B-X
CD7	B-X
up-regulation	B-X
on	B-X
human	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
found	B-X
that	B-X
nonmitogenic	B-X
amounts	B-X
of	B-X
ionomycin	B-X
selectively	B-X
and	B-X
maximally	B-X
up-regulated	B-X
T	B-X
cell	B-X
CD7	B-X
on	B-X
mature	B-X
(	B-X
peripheral	B-X
blood	B-X
)	B-X
T	B-X
cells	B-X
after	B-X
24	B-X
h.	B-X
Whereas	B-X
CD7	B-X
expression	B-X
was	B-X
increased	B-X
78	B-X
+/-	B-X
25	B-X
%	B-X
by	B-X
0.5	B-X
microM	B-X
ionomycin	B-X
,	B-X
expression	B-X
of	B-X
CD25	B-X
(	B-X
IL-2R	B-X
alpha	B-X
)	B-X
,	B-X
class	B-X
II	B-X
MHC	B-X
,	B-X
4F2	B-X
,	B-X
transferrin	B-X
receptor	B-X
,	B-X
CD2	B-X
,	B-X
CD3	B-X
,	B-X
CD4	B-X
,	B-X
CD5	B-X
,	B-X
and	B-X
CD8	B-X
molecules	B-X
was	B-X
not	B-X
increased	B-X
.	B-X
Ionomycin-induced	B-X
CD7	B-X
surface	B-X
expression	B-X
was	B-X
associated	B-X
with	B-X
peak	B-X
increases	B-X
in	B-X
CD7	B-X
mRNA	B-X
after	B-X
4	B-X
to	B-X
6	B-X
h.	B-X
Transcriptional	B-X
analysis	B-X
and	B-X
CD7	B-X
mRNA	B-X
half-life	B-X
determination	B-X
revealed	B-X
the	B-X
increase	B-X
in	B-X
CD7	B-X
mRNA	B-X
was	B-X
the	B-X
result	B-X
of	B-X
increased	B-X
CD7	B-X
gene	B-X
transcription	B-X
1	B-X
h	B-X
after	B-X
ionomycin	B-X
stimulation	B-X
and	B-X
was	B-X
not	B-X
due	B-X
to	B-X
prolongation	B-X
of	B-X
CD7	B-X
mRNA	B-X
half-life	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
surface	B-X
CD7	B-X
expression	B-X
by	B-X
ionomycin	B-X
was	B-X
dependent	B-X
on	B-X
extracellular	B-X
calcium	B-X
and	B-X
did	B-X
not	B-X
require	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
cell	B-X
tyrosine	B-X
protein	B-X
kinase	B-X
.	B-X
Mitogenic	B-X
CD2	B-X
and	B-X
CD3	B-X
mAb	B-X
as	B-X
well	B-X
as	B-X
stimulation	B-X
of	B-X
T	B-X
cells	B-X
by	B-X
PHA	B-X
also	B-X
up-regulated	B-X
CD7	B-X
expression	B-X
.	B-X

These	O
results	O
indicate	O
that	O
mitogenic	O
combinations	O
of	O
T	O
cell	O
activation	O
signals	O
are	O
integrated	O
at	O
the	O
level	O
of	O
NF	O
-	O
MATp35	O
induction	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
requires	B-X
the	B-X
combined	B-X
signaling	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
and	B-X
costimulatory	B-X
molecules	B-X
such	B-X
as	B-X
CD28	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
T	B-X
cells	B-X
to	B-X
produce	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
control	B-X
point	B-X
in	B-X
T	B-X
lymphocyte	B-X
activation	B-X
.	B-X
The	B-X
IL-2	B-X
enhancer	B-X
contains	B-X
a	B-X
functional	B-X
motif	B-X
named	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
that	B-X
serves	B-X
a	B-X
role	B-X
as	B-X
a	B-X
target	B-X
for	B-X
mitogenic	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
CD28RE	B-X
binds	B-X
an	B-X
inducible	B-X
protein	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
35	B-X
kDa	B-X
called	B-X
nuclear	B-X
factor	B-X
of	B-X
mitogenic-activated	B-X
T	B-X
cells	B-X
(	B-X
NF-MATp35	B-X
)	B-X
that	B-X
is	B-X
clearly	B-X
different	B-X
from	B-X
the	B-X
known	B-X
NF-	B-X
kappaB/Rel	B-X
family	B-X
members	B-X
.	B-X
Induction	B-X
of	B-X
NF-MATp35	B-X
was	B-X
shown	B-X
to	B-X
depend	B-X
on	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
and	B-X
was	B-X
restricted	B-X
to	B-X
T	B-X
cells	B-X
that	B-X
received	B-X
a	B-X
mitogenic	B-X
combination	B-X
of	B-X
T	B-X
cell	B-X
stimuli	B-X
,	B-X
not	B-X
necessarily	B-X
including	B-X
CD28	B-X
signaling	B-X
.	B-X
Nonmitogenic	B-X
T	B-X
cell	B-X
stimulation	B-X
did	B-X
not	B-X
result	B-X
in	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
mitogenic	B-X
combinations	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
are	B-X
integrated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
NF-MATp35	B-X
induction	B-X
.	B-X
Similar	B-X
to	B-X
its	B-X
effect	B-X
on	B-X
IL-2	B-X
production	B-X
,	B-X
cyclosporin	B-X
A	B-X
inhibited	B-X
the	B-X
induction	B-X
of	B-X
NF-MATp35	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
shows	B-X
excellent	B-X
correlation	B-X
with	B-X
IL-2	B-X
production	B-X
,	B-X
which	B-X
is	B-X
a	B-X
unique	B-X
characteristic	B-X
among	B-X
nuclear	B-X
factors	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
IL-2	B-X
gene	B-X
expression	B-X
.	B-X

Similar	O
to	O
its	O
effect	O
on	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
,	O
cyclosporin	O
A	O
inhibited	O
the	O
induction	O
of	O
NF	O
-	O
MATp35	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
requires	B-X
the	B-X
combined	B-X
signaling	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
and	B-X
costimulatory	B-X
molecules	B-X
such	B-X
as	B-X
CD28	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
T	B-X
cells	B-X
to	B-X
produce	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
control	B-X
point	B-X
in	B-X
T	B-X
lymphocyte	B-X
activation	B-X
.	B-X
The	B-X
IL-2	B-X
enhancer	B-X
contains	B-X
a	B-X
functional	B-X
motif	B-X
named	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
that	B-X
serves	B-X
a	B-X
role	B-X
as	B-X
a	B-X
target	B-X
for	B-X
mitogenic	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
.	B-X
The	B-X
CD28RE	B-X
sequence	B-X
reveals	B-X
similarity	B-X
to	B-X
the	B-X
consensus	B-X
kappaB	B-X
binding	B-X
motif	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
CD28RE	B-X
binds	B-X
an	B-X
inducible	B-X
protein	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
35	B-X
kDa	B-X
called	B-X
nuclear	B-X
factor	B-X
of	B-X
mitogenic-activated	B-X
T	B-X
cells	B-X
(	B-X
NF-MATp35	B-X
)	B-X
that	B-X
is	B-X
clearly	B-X
different	B-X
from	B-X
the	B-X
known	B-X
NF-	B-X
kappaB/Rel	B-X
family	B-X
members	B-X
.	B-X
Induction	B-X
of	B-X
NF-MATp35	B-X
was	B-X
shown	B-X
to	B-X
depend	B-X
on	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
and	B-X
was	B-X
restricted	B-X
to	B-X
T	B-X
cells	B-X
that	B-X
received	B-X
a	B-X
mitogenic	B-X
combination	B-X
of	B-X
T	B-X
cell	B-X
stimuli	B-X
,	B-X
not	B-X
necessarily	B-X
including	B-X
CD28	B-X
signaling	B-X
.	B-X
Nonmitogenic	B-X
T	B-X
cell	B-X
stimulation	B-X
did	B-X
not	B-X
result	B-X
in	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
mitogenic	B-X
combinations	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
are	B-X
integrated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
NF-MATp35	B-X
induction	B-X
.	B-X
Similar	B-X
to	B-X
its	B-X
effect	B-X
on	B-X
IL-2	B-X
production	B-X
,	B-X
cyclosporin	B-X
A	B-X
inhibited	B-X
the	B-X
induction	B-X
of	B-X
NF-MATp35	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
shows	B-X
excellent	B-X
correlation	B-X
with	B-X
IL-2	B-X
production	B-X
,	B-X
which	B-X
is	B-X
a	B-X
unique	B-X
characteristic	B-X
among	B-X
nuclear	B-X
factors	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
IL-2	B-X
gene	B-X
expression	B-X
.	B-X

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
MATp35	O
shows	O
excellent	O
correlation	O
with	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
,	O
which	O
is	O
a	O
unique	O
characteristic	O
among	O
nuclear	O
factors	O
implicated	O
in	O
the	O
control	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
expression	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
requires	B-X
the	B-X
combined	B-X
signaling	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
and	B-X
costimulatory	B-X
molecules	B-X
such	B-X
as	B-X
CD28	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
T	B-X
cells	B-X
to	B-X
produce	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
is	B-X
a	B-X
critical	B-X
control	B-X
point	B-X
in	B-X
T	B-X
lymphocyte	B-X
activation	B-X
.	B-X
The	B-X
IL-2	B-X
enhancer	B-X
contains	B-X
a	B-X
functional	B-X
motif	B-X
named	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
that	B-X
serves	B-X
a	B-X
role	B-X
as	B-X
a	B-X
target	B-X
for	B-X
mitogenic	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
.	B-X
The	B-X
CD28RE	B-X
sequence	B-X
reveals	B-X
similarity	B-X
to	B-X
the	B-X
consensus	B-X
kappaB	B-X
binding	B-X
motif	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
CD28RE	B-X
binds	B-X
an	B-X
inducible	B-X
protein	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
approximately	B-X
35	B-X
kDa	B-X
called	B-X
nuclear	B-X
factor	B-X
of	B-X
mitogenic-activated	B-X
T	B-X
cells	B-X
(	B-X
NF-MATp35	B-X
)	B-X
that	B-X
is	B-X
clearly	B-X
different	B-X
from	B-X
the	B-X
known	B-X
NF-	B-X
kappaB/Rel	B-X
family	B-X
members	B-X
.	B-X
Induction	B-X
of	B-X
NF-MATp35	B-X
was	B-X
shown	B-X
to	B-X
depend	B-X
on	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
and	B-X
was	B-X
restricted	B-X
to	B-X
T	B-X
cells	B-X
that	B-X
received	B-X
a	B-X
mitogenic	B-X
combination	B-X
of	B-X
T	B-X
cell	B-X
stimuli	B-X
,	B-X
not	B-X
necessarily	B-X
including	B-X
CD28	B-X
signaling	B-X
.	B-X
Nonmitogenic	B-X
T	B-X
cell	B-X
stimulation	B-X
did	B-X
not	B-X
result	B-X
in	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
mitogenic	B-X
combinations	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
signals	B-X
are	B-X
integrated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
NF-MATp35	B-X
induction	B-X
.	B-X
Similar	B-X
to	B-X
its	B-X
effect	B-X
on	B-X
IL-2	B-X
production	B-X
,	B-X
cyclosporin	B-X
A	B-X
inhibited	B-X
the	B-X
induction	B-X
of	B-X
NF-MATp35	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-MATp35	B-X
shows	B-X
excellent	B-X
correlation	B-X
with	B-X
IL-2	B-X
production	B-X
,	B-X
which	B-X
is	B-X
a	B-X
unique	B-X
characteristic	B-X
among	B-X
nuclear	B-X
factors	B-X
implicated	B-X
in	B-X
the	B-X
control	B-X
of	B-X
IL-2	B-X
gene	B-X
expression	B-X
.	B-X

Preassociation	O
of	O
STAT1	B-Protein
with	O
STAT2	B-Protein
and	O
STAT3	B-Protein
in	O
separate	O
signalling	O
complexes	O
prior	O
to	O
cytokine	O
stimulation	O
.	O
<EOS>	B-X
A	B-X
variety	B-X
of	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
act	B-X
through	B-X
an	B-X
induction	B-X
of	B-X
gene	B-X
expression	B-X
mediated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
latent	B-X
transcription	B-X
factors	B-X
called	B-X
STAT	B-X
(	B-X
signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
)	B-X
proteins	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
STAT	B-X
protein	B-X
heterocomplexes	B-X
exist	B-X
prior	B-X
to	B-X
cytokine	B-X
treatment	B-X
.	B-X
When	B-X
unstimulated	B-X
HeLa	B-X
cells	B-X
are	B-X
ruptured	B-X
in	B-X
hypotonic	B-X
buffer	B-X
without	B-X
salt	B-X
or	B-X
detergent	B-X
,	B-X
immunoadsorption	B-X
of	B-X
either	B-X
STAT1	B-X
or	B-X
STAT2	B-X
from	B-X
the	B-X
resulting	B-X
cytosol	B-X
yields	B-X
coimmunoadsorption	B-X
of	B-X
the	B-X
other	B-X
STAT	B-X
protein	B-X
.	B-X
Similarly	B-X
,	B-X
STAT1-STAT3	B-X
heterocomplexes	B-X
are	B-X
coimmunoadsorbed	B-X
from	B-X
hypotonic	B-X
cytosol	B-X
.	B-X
STAT1	B-X
and	B-X
STAT2	B-X
or	B-X
STAT1	B-X
and	B-X
STAT3	B-X
translated	B-X
in	B-X
reticulocyte	B-X
lysate	B-X
spontaneously	B-X
form	B-X
heterocomplexes	B-X
when	B-X
the	B-X
translation	B-X
lysates	B-X
are	B-X
mixed	B-X
at	B-X
0	B-X
degrees	B-X
C.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
interferon-alpha	B-X
/beta-induced	B-X
tyrosine	B-X
phosphorylation	B-X
increases	B-X
the	B-X
stability	B-X
of	B-X
a	B-X
preexisting	B-X
,	B-X
latent	B-X
,	B-X
STAT1-STAT2	B-X
signaling	B-X
complex	B-X
.	B-X
Newly	B-X
translated	B-X
STAT1	B-X
binds	B-X
in	B-X
equilibrium	B-X
fashion	B-X
to	B-X
STAT2	B-X
and	B-X
STAT3	B-X
,	B-X
but	B-X
we	B-X
show	B-X
that	B-X
STAT2	B-X
and	B-X
STAT3	B-X
exist	B-X
in	B-X
separate	B-X
heterocomplexes	B-X
with	B-X
STAT1	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
in	B-X
which	B-X
STAT1	B-X
contains	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
other	B-X
STAT	B-X
proteins	B-X
.	B-X

A	O
variety	O
of	O
cytokines	O
and	O
growth	O
factors	O
act	O
through	O
an	O
induction	O
of	O
gene	O
expression	O
mediated	O
by	O
a	O
family	O
of	O
latent	O
transcription	O
factors	O
called	O
STAT	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
proteins	O
.	O
<EOS>	B-X
A	B-X
variety	B-X
of	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
act	B-X
through	B-X
an	B-X
induction	B-X
of	B-X
gene	B-X
expression	B-X
mediated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
latent	B-X
transcription	B-X
factors	B-X
called	B-X
STAT	B-X
(	B-X
signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
)	B-X
proteins	B-X
.	B-X
Ligand-induced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
STATs	B-X
promotes	B-X
their	B-X
homodimer	B-X
and	B-X
heterodimer	B-X
formation	B-X
and	B-X
subsequent	B-X
nuclear	B-X
translocation	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
STAT	B-X
protein	B-X
heterocomplexes	B-X
exist	B-X
prior	B-X
to	B-X
cytokine	B-X
treatment	B-X
.	B-X
When	B-X
unstimulated	B-X
HeLa	B-X
cells	B-X
are	B-X
ruptured	B-X
in	B-X
hypotonic	B-X
buffer	B-X
without	B-X
salt	B-X
or	B-X
detergent	B-X
,	B-X
immunoadsorption	B-X
of	B-X
either	B-X
STAT1	B-X
or	B-X
STAT2	B-X
from	B-X
the	B-X
resulting	B-X
cytosol	B-X
yields	B-X
coimmunoadsorption	B-X
of	B-X
the	B-X
other	B-X
STAT	B-X
protein	B-X
.	B-X
Similarly	B-X
,	B-X
STAT1-STAT3	B-X
heterocomplexes	B-X
are	B-X
coimmunoadsorbed	B-X
from	B-X
hypotonic	B-X
cytosol	B-X
.	B-X
STAT1	B-X
and	B-X
STAT2	B-X
or	B-X
STAT1	B-X
and	B-X
STAT3	B-X
translated	B-X
in	B-X
reticulocyte	B-X
lysate	B-X
spontaneously	B-X
form	B-X
heterocomplexes	B-X
when	B-X
the	B-X
translation	B-X
lysates	B-X
are	B-X
mixed	B-X
at	B-X
0	B-X
degrees	B-X
C.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
interferon-alpha	B-X
/beta-induced	B-X
tyrosine	B-X
phosphorylation	B-X
increases	B-X
the	B-X
stability	B-X
of	B-X
a	B-X
preexisting	B-X
,	B-X
latent	B-X
,	B-X
STAT1-STAT2	B-X
signaling	B-X
complex	B-X
.	B-X
Newly	B-X
translated	B-X
STAT1	B-X
binds	B-X
in	B-X
equilibrium	B-X
fashion	B-X
to	B-X
STAT2	B-X
and	B-X
STAT3	B-X
,	B-X
but	B-X
we	B-X
show	B-X
that	B-X
STAT2	B-X
and	B-X
STAT3	B-X
exist	B-X
in	B-X
separate	B-X
heterocomplexes	B-X
with	B-X
STAT1	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
in	B-X
which	B-X
STAT1	B-X
contains	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
other	B-X
STAT	B-X
proteins	B-X
.	B-X

Ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
STATs	O
promotes	O
their	O
homodimer	O
and	O
heterodimer	O
formation	O
and	O
subsequent	O
nuclear	O
translocation	O
.	O
<EOS>	B-X
Ligand-induced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
STATs	B-X
promotes	B-X
their	B-X
homodimer	B-X
and	B-X
heterodimer	B-X
formation	B-X
and	B-X
subsequent	B-X
nuclear	B-X
translocation	B-X
.	B-X
STAT1	B-X
and	B-X
STAT2	B-X
or	B-X
STAT1	B-X
and	B-X
STAT3	B-X
translated	B-X
in	B-X
reticulocyte	B-X
lysate	B-X
spontaneously	B-X
form	B-X
heterocomplexes	B-X
when	B-X
the	B-X
translation	B-X
lysates	B-X
are	B-X
mixed	B-X
at	B-X
0	B-X
degrees	B-X
C.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
interferon-alpha	B-X
/beta-induced	B-X
tyrosine	B-X
phosphorylation	B-X
increases	B-X
the	B-X
stability	B-X
of	B-X
a	B-X
preexisting	B-X
,	B-X
latent	B-X
,	B-X
STAT1-STAT2	B-X
signaling	B-X
complex	B-X
.	B-X

We	O
demonstrate	O
here	O
that	O
STAT	O
protein	O
heterocomplexes	O
exist	O
prior	O
to	O
cytokine	O
treatment	O
.	O
<EOS>	B-X
A	B-X
variety	B-X
of	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
act	B-X
through	B-X
an	B-X
induction	B-X
of	B-X
gene	B-X
expression	B-X
mediated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
latent	B-X
transcription	B-X
factors	B-X
called	B-X
STAT	B-X
(	B-X
signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
)	B-X
proteins	B-X
.	B-X
Ligand-induced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
STATs	B-X
promotes	B-X
their	B-X
homodimer	B-X
and	B-X
heterodimer	B-X
formation	B-X
and	B-X
subsequent	B-X
nuclear	B-X
translocation	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
STAT	B-X
protein	B-X
heterocomplexes	B-X
exist	B-X
prior	B-X
to	B-X
cytokine	B-X
treatment	B-X
.	B-X
When	B-X
unstimulated	B-X
HeLa	B-X
cells	B-X
are	B-X
ruptured	B-X
in	B-X
hypotonic	B-X
buffer	B-X
without	B-X
salt	B-X
or	B-X
detergent	B-X
,	B-X
immunoadsorption	B-X
of	B-X
either	B-X
STAT1	B-X
or	B-X
STAT2	B-X
from	B-X
the	B-X
resulting	B-X
cytosol	B-X
yields	B-X
coimmunoadsorption	B-X
of	B-X
the	B-X
other	B-X
STAT	B-X
protein	B-X
.	B-X
Similarly	B-X
,	B-X
STAT1-STAT3	B-X
heterocomplexes	B-X
are	B-X
coimmunoadsorbed	B-X
from	B-X
hypotonic	B-X
cytosol	B-X
.	B-X
STAT1	B-X
and	B-X
STAT2	B-X
or	B-X
STAT1	B-X
and	B-X
STAT3	B-X
translated	B-X
in	B-X
reticulocyte	B-X
lysate	B-X
spontaneously	B-X
form	B-X
heterocomplexes	B-X
when	B-X
the	B-X
translation	B-X
lysates	B-X
are	B-X
mixed	B-X
at	B-X
0	B-X
degrees	B-X
C.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
interferon-alpha	B-X
/beta-induced	B-X
tyrosine	B-X
phosphorylation	B-X
increases	B-X
the	B-X
stability	B-X
of	B-X
a	B-X
preexisting	B-X
,	B-X
latent	B-X
,	B-X
STAT1-STAT2	B-X
signaling	B-X
complex	B-X
.	B-X
Newly	B-X
translated	B-X
STAT1	B-X
binds	B-X
in	B-X
equilibrium	B-X
fashion	B-X
to	B-X
STAT2	B-X
and	B-X
STAT3	B-X
,	B-X
but	B-X
we	B-X
show	B-X
that	B-X
STAT2	B-X
and	B-X
STAT3	B-X
exist	B-X
in	B-X
separate	B-X
heterocomplexes	B-X
with	B-X
STAT1	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
in	B-X
which	B-X
STAT1	B-X
contains	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
other	B-X
STAT	B-X
proteins	B-X
.	B-X

When	O
unstimulated	O
HeLa	O
cells	O
are	O
ruptured	O
in	O
hypotonic	O
buffer	O
without	O
salt	O
or	O
detergent	O
,	O
immunoadsorption	O
of	O
either	O
STAT1	B-Protein
or	O
STAT2	B-Protein
from	O
the	O
resulting	O
cytosol	O
yields	O
coimmunoadsorption	O
of	O
the	O
other	O
STAT	O
protein	O
.	O
<EOS>	B-X
A	B-X
variety	B-X
of	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
act	B-X
through	B-X
an	B-X
induction	B-X
of	B-X
gene	B-X
expression	B-X
mediated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
latent	B-X
transcription	B-X
factors	B-X
called	B-X
STAT	B-X
(	B-X
signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
)	B-X
proteins	B-X
.	B-X
Ligand-induced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
STATs	B-X
promotes	B-X
their	B-X
homodimer	B-X
and	B-X
heterodimer	B-X
formation	B-X
and	B-X
subsequent	B-X
nuclear	B-X
translocation	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
STAT	B-X
protein	B-X
heterocomplexes	B-X
exist	B-X
prior	B-X
to	B-X
cytokine	B-X
treatment	B-X
.	B-X
When	B-X
unstimulated	B-X
HeLa	B-X
cells	B-X
are	B-X
ruptured	B-X
in	B-X
hypotonic	B-X
buffer	B-X
without	B-X
salt	B-X
or	B-X
detergent	B-X
,	B-X
immunoadsorption	B-X
of	B-X
either	B-X
STAT1	B-X
or	B-X
STAT2	B-X
from	B-X
the	B-X
resulting	B-X
cytosol	B-X
yields	B-X
coimmunoadsorption	B-X
of	B-X
the	B-X
other	B-X
STAT	B-X
protein	B-X
.	B-X
Similarly	B-X
,	B-X
STAT1-STAT3	B-X
heterocomplexes	B-X
are	B-X
coimmunoadsorbed	B-X
from	B-X
hypotonic	B-X
cytosol	B-X
.	B-X
STAT1	B-X
and	B-X
STAT2	B-X
or	B-X
STAT1	B-X
and	B-X
STAT3	B-X
translated	B-X
in	B-X
reticulocyte	B-X
lysate	B-X
spontaneously	B-X
form	B-X
heterocomplexes	B-X
when	B-X
the	B-X
translation	B-X
lysates	B-X
are	B-X
mixed	B-X
at	B-X
0	B-X
degrees	B-X
C.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
interferon-alpha	B-X
/beta-induced	B-X
tyrosine	B-X
phosphorylation	B-X
increases	B-X
the	B-X
stability	B-X
of	B-X
a	B-X
preexisting	B-X
,	B-X
latent	B-X
,	B-X
STAT1-STAT2	B-X
signaling	B-X
complex	B-X
.	B-X
Newly	B-X
translated	B-X
STAT1	B-X
binds	B-X
in	B-X
equilibrium	B-X
fashion	B-X
to	B-X
STAT2	B-X
and	B-X
STAT3	B-X
,	B-X
but	B-X
we	B-X
show	B-X
that	B-X
STAT2	B-X
and	B-X
STAT3	B-X
exist	B-X
in	B-X
separate	B-X
heterocomplexes	B-X
with	B-X
STAT1	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
in	B-X
which	B-X
STAT1	B-X
contains	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
other	B-X
STAT	B-X
proteins	B-X
.	B-X

Similarly	O
,	O
STAT1	B-Protein
-	O
STAT3	B-Protein
heterocomplexes	O
are	O
coimmunoadsorbed	O
from	O
hypotonic	O
cytosol	O
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
STAT	B-X
protein	B-X
heterocomplexes	B-X
exist	B-X
prior	B-X
to	B-X
cytokine	B-X
treatment	B-X
.	B-X
When	B-X
unstimulated	B-X
HeLa	B-X
cells	B-X
are	B-X
ruptured	B-X
in	B-X
hypotonic	B-X
buffer	B-X
without	B-X
salt	B-X
or	B-X
detergent	B-X
,	B-X
immunoadsorption	B-X
of	B-X
either	B-X
STAT1	B-X
or	B-X
STAT2	B-X
from	B-X
the	B-X
resulting	B-X
cytosol	B-X
yields	B-X
coimmunoadsorption	B-X
of	B-X
the	B-X
other	B-X
STAT	B-X
protein	B-X
.	B-X
Similarly	B-X
,	B-X
STAT1-STAT3	B-X
heterocomplexes	B-X
are	B-X
coimmunoadsorbed	B-X
from	B-X
hypotonic	B-X
cytosol	B-X
.	B-X
STAT1	B-X
and	B-X
STAT2	B-X
or	B-X
STAT1	B-X
and	B-X
STAT3	B-X
translated	B-X
in	B-X
reticulocyte	B-X
lysate	B-X
spontaneously	B-X
form	B-X
heterocomplexes	B-X
when	B-X
the	B-X
translation	B-X
lysates	B-X
are	B-X
mixed	B-X
at	B-X
0	B-X
degrees	B-X
C.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
interferon-alpha	B-X
/beta-induced	B-X
tyrosine	B-X
phosphorylation	B-X
increases	B-X
the	B-X
stability	B-X
of	B-X
a	B-X
preexisting	B-X
,	B-X
latent	B-X
,	B-X
STAT1-STAT2	B-X
signaling	B-X
complex	B-X
.	B-X
Newly	B-X
translated	B-X
STAT1	B-X
binds	B-X
in	B-X
equilibrium	B-X
fashion	B-X
to	B-X
STAT2	B-X
and	B-X
STAT3	B-X
,	B-X
but	B-X
we	B-X
show	B-X
that	B-X
STAT2	B-X
and	B-X
STAT3	B-X
exist	B-X
in	B-X
separate	B-X
heterocomplexes	B-X
with	B-X
STAT1	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
in	B-X
which	B-X
STAT1	B-X
contains	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
other	B-X
STAT	B-X
proteins	B-X
.	B-X

STAT1	B-Protein
and	O
STAT2	B-Protein
or	O
STAT1	B-Protein
and	O
STAT3	B-Protein
translated	O
in	O
reticulocyte	O
lysate	O
spontaneously	O
form	O
heterocomplexes	O
when	O
the	O
translation	O
lysates	O
are	O
mixed	O
at	O
0	O
degrees	O
C	O
.	O
<EOS>	B-X
ASFV	B-X
has	B-X
a	B-X
complex	B-X
structure	B-X
and	B-X
encodes	B-X
150-167	B-X
proteins	B-X
;	B-X
however	B-X
,	B-X
the	B-X
function	B-X
of	B-X
most	B-X
of	B-X
these	B-X
proteins	B-X
is	B-X
unknown	B-X
.	B-X
This	B-X
study	B-X
identified	B-X
ASFV	B-X
MGF360-9L	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
the	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
-β	B-X
signal	B-X
.	B-X
Further	B-X
evidence	B-X
showed	B-X
that	B-X
MGF360-9L	B-X
interacts	B-X
with	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
(	B-X
STAT	B-X
)	B-X
1	B-X
and	B-X
STAT2	B-X
and	B-X
degrades	B-X
STAT1	B-X
and	B-X
STAT2	B-X
through	B-X
apoptosis	B-X
and	B-X
ubiquitin-proteasome	B-X
pathways	B-X
,	B-X
respectively	B-X
.	B-X
Previous	B-X
study	B-X
showed	B-X
that	B-X
PEDV	B-X
nonstructural	B-X
protein	B-X
7	B-X
(	B-X
nsp7	B-X
)	B-X
,	B-X
a	B-X
component	B-X
of	B-X
the	B-X
viral	B-X
replicase	B-X
polyprotein	B-X
,	B-X
can	B-X
antagonize	B-X
ploy	B-X
(	B-X
I	B-X
:	B-X
C	B-X
)	B-X
-induced	B-X
type	B-X
I	B-X
IFN	B-X
production	B-X
.	B-X
PEDV	B-X
nsp7	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
protein	B-X
and	B-X
phosphorylation	B-X
levels	B-X
of	B-X
JAK1	B-X
,	B-X
Tyk2	B-X
,	B-X
STAT1	B-X
,	B-X
and	B-X
STAT2	B-X
or	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
interferon-stimulated	B-X
gene	B-X
factor	B-X
3	B-X
(	B-X
ISGF3	B-X
)	B-X
complex	B-X
.	B-X
However	B-X
,	B-X
PEDV	B-X
nsp7	B-X
prevented	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
STAT1	B-X
and	B-X
STAT2	B-X
.	B-X
Mechanistically	B-X
,	B-X
PEDV	B-X
nsp7	B-X
interacted	B-X
with	B-X
the	B-X
DNA	B-X
binding	B-X
domain	B-X
of	B-X
STAT1/STAT2	B-X
,	B-X
which	B-X
sequestered	B-X
the	B-X
interaction	B-X
between	B-X
karyopherin	B-X
α1	B-X
(	B-X
KPNA1	B-X
)	B-X
and	B-X
STAT1	B-X
,	B-X
thereby	B-X
blocking	B-X
the	B-X
nuclear	B-X
transport	B-X
of	B-X
ISGF3	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
data	B-X
reveal	B-X
a	B-X
new	B-X
mechanism	B-X
developed	B-X
by	B-X
PEDV	B-X
to	B-X
inhibit	B-X
type	B-X
I	B-X
IFN	B-X
signaling	B-X
pathway	B-X
.	B-X

Our	O
data	O
suggest	O
that	O
interferon	O
-	O
alpha	O
/	O
beta	O
-	O
induced	O
tyrosine	O
phosphorylation	O
increases	O
the	O
stability	O
of	O
a	O
preexisting	O
,	O
latent	O
,	O
STAT1	B-Protein
-	O
STAT2	B-Protein
signaling	O
complex	O
.	O
<EOS>	B-X
A	B-X
variety	B-X
of	B-X
cytokines	B-X
and	B-X
growth	B-X
factors	B-X
act	B-X
through	B-X
an	B-X
induction	B-X
of	B-X
gene	B-X
expression	B-X
mediated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
latent	B-X
transcription	B-X
factors	B-X
called	B-X
STAT	B-X
(	B-X
signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
)	B-X
proteins	B-X
.	B-X
Ligand-induced	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
STATs	B-X
promotes	B-X
their	B-X
homodimer	B-X
and	B-X
heterodimer	B-X
formation	B-X
and	B-X
subsequent	B-X
nuclear	B-X
translocation	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
STAT	B-X
protein	B-X
heterocomplexes	B-X
exist	B-X
prior	B-X
to	B-X
cytokine	B-X
treatment	B-X
.	B-X
When	B-X
unstimulated	B-X
HeLa	B-X
cells	B-X
are	B-X
ruptured	B-X
in	B-X
hypotonic	B-X
buffer	B-X
without	B-X
salt	B-X
or	B-X
detergent	B-X
,	B-X
immunoadsorption	B-X
of	B-X
either	B-X
STAT1	B-X
or	B-X
STAT2	B-X
from	B-X
the	B-X
resulting	B-X
cytosol	B-X
yields	B-X
coimmunoadsorption	B-X
of	B-X
the	B-X
other	B-X
STAT	B-X
protein	B-X
.	B-X
Similarly	B-X
,	B-X
STAT1-STAT3	B-X
heterocomplexes	B-X
are	B-X
coimmunoadsorbed	B-X
from	B-X
hypotonic	B-X
cytosol	B-X
.	B-X
STAT1	B-X
and	B-X
STAT2	B-X
or	B-X
STAT1	B-X
and	B-X
STAT3	B-X
translated	B-X
in	B-X
reticulocyte	B-X
lysate	B-X
spontaneously	B-X
form	B-X
heterocomplexes	B-X
when	B-X
the	B-X
translation	B-X
lysates	B-X
are	B-X
mixed	B-X
at	B-X
0	B-X
degrees	B-X
C.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
interferon-alpha	B-X
/beta-induced	B-X
tyrosine	B-X
phosphorylation	B-X
increases	B-X
the	B-X
stability	B-X
of	B-X
a	B-X
preexisting	B-X
,	B-X
latent	B-X
,	B-X
STAT1-STAT2	B-X
signaling	B-X
complex	B-X
.	B-X
Newly	B-X
translated	B-X
STAT1	B-X
binds	B-X
in	B-X
equilibrium	B-X
fashion	B-X
to	B-X
STAT2	B-X
and	B-X
STAT3	B-X
,	B-X
but	B-X
we	B-X
show	B-X
that	B-X
STAT2	B-X
and	B-X
STAT3	B-X
exist	B-X
in	B-X
separate	B-X
heterocomplexes	B-X
with	B-X
STAT1	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
in	B-X
which	B-X
STAT1	B-X
contains	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
other	B-X
STAT	B-X
proteins	B-X
.	B-X

Newly	O
translated	O
STAT1	B-Protein
binds	O
in	O
equilibrium	O
fashion	O
to	O
STAT2	B-Protein
and	O
STAT3	B-Protein
,	O
but	O
we	O
show	O
that	O
STAT2	B-Protein
and	O
STAT3	B-Protein
exist	O
in	O
separate	O
heterocomplexes	O
with	O
STAT1	B-Protein
,	O
consistent	O
with	O
a	O
model	O
in	O
which	O
STAT1	B-Protein
contains	O
a	O
common	O
binding	O
site	O
for	O
other	O
STAT	O
proteins	O
.	O

Inhibition	O
of	O
p105	B-Protein
processing	O
by	O
NF	O
-	O
kappaB	O
proteins	O
in	O
transiently	O
transfected	O
cells	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
involves	B-X
proteasome-mediated	B-X
processing	B-X
of	B-X
the	B-X
NF-kappaB1	B-X
p105	B-X
precursor	B-X
protein	B-X
,	B-X
which	B-X
generates	B-X
the	B-X
p50	B-X
subunit	B-X
of	B-X
NF-kappaB	B-X
.	B-X
The	B-X
processing	B-X
of	B-X
p105	B-X
occurs	B-X
constitutively	B-X
in	B-X
vivo	B-X
but	B-X
can	B-X
be	B-X
markedly	B-X
enhanced	B-X
by	B-X
various	B-X
cellular	B-X
activation	B-X
agents	B-X
,	B-X
although	B-X
the	B-X
underlying	B-X
regulatory	B-X
mechanism	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
signal-mediated	B-X
induction	B-X
of	B-X
p105	B-X
processing	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
is	B-X
associated	B-X
with	B-X
de	B-X
novo	B-X
synthesis	B-X
of	B-X
this	B-X
precursor	B-X
protein	B-X
.	B-X
Transient	B-X
transfection	B-X
studies	B-X
performed	B-X
in	B-X
COS7	B-X
cells	B-X
revealed	B-X
that	B-X
the	B-X
newly	B-X
synthesized	B-X
p105	B-X
protein	B-X
appears	B-X
to	B-X
be	B-X
more	B-X
rapidly	B-X
processed	B-X
compared	B-X
to	B-X
its	B-X
accumulated	B-X
form	B-X
that	B-X
is	B-X
already	B-X
associated	B-X
with	B-X
the	B-X
processed	B-X
product	B-X
p50	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
processing	B-X
rate	B-X
of	B-X
p105	B-X
is	B-X
markedly	B-X
inhibited	B-X
in	B-X
cells	B-X
co-transfected	B-X
with	B-X
p50	B-X
or	B-X
other	B-X
NF-kappaB	B-X
subunits	B-X
,	B-X
including	B-X
RelA	B-X
and	B-X
c-Rel	B-X
,	B-X
that	B-X
physically	B-X
interact	B-X
with	B-X
p105	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
processing	B-X
of	B-X
p105	B-X
is	B-X
subject	B-X
to	B-X
negative	B-X
regulation	B-X
by	B-X
the	B-X
various	B-X
NF-kappaB	B-X
subunits	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
p105	B-X
undergoes	B-X
degradation	B-X
in	B-X
lipopolysaccharide-stimulated	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
is	B-X
not	B-X
coupled	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
p50	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
demonstrate	B-X
that	B-X
the	B-X
processing	B-X
and	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
are	B-X
differentially	B-X
regulated	B-X
.	B-X

Regulation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
involves	O
proteasome	O
-	O
mediated	O
processing	O
of	O
the	O
NF	B-Protein
-	I-Protein
kappaB1	I-Protein
p105	B-Protein
precursor	O
protein	O
,	O
which	O
generates	O
the	O
p50	B-Protein
subunit	O
of	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
NF-κB	B-X
is	B-X
a	B-X
key	B-X
transcriptional	B-X
regulator	B-X
involved	B-X
in	B-X
inflammation	B-X
and	B-X
cell	B-X
proliferation	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
transformation	B-X
.	B-X
Several	B-X
key	B-X
steps	B-X
in	B-X
its	B-X
activation	B-X
are	B-X
mediated	B-X
by	B-X
the	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
system	B-X
.	B-X
One	B-X
uncharacterized	B-X
step	B-X
is	B-X
limited	B-X
proteasomal	B-X
processing	B-X
of	B-X
the	B-X
NF-κB1	B-X
precursor	B-X
p105	B-X
to	B-X
the	B-X
p50	B-X
active	B-X
subunit	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
KPC1	B-X
as	B-X
the	B-X
Ub	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
that	B-X
binds	B-X
to	B-X
the	B-X
ankyrin	B-X
repeats	B-X
domain	B-X
of	B-X
p105	B-X
,	B-X
ubiquitinates	B-X
it	B-X
,	B-X
and	B-X
mediates	B-X
its	B-X
processing	B-X
both	B-X
under	B-X
basal	B-X
conditions	B-X
and	B-X
following	B-X
signaling	B-X
.	B-X
Overexpression	B-X
of	B-X
KPC1	B-X
inhibits	B-X
tumor	B-X
growth	B-X
likely	B-X
mediated	B-X
via	B-X
excessive	B-X
generation	B-X
of	B-X
p50	B-X
.	B-X
Also	B-X
,	B-X
overabundance	B-X
of	B-X
p50	B-X
downregulates	B-X
p65	B-X
,	B-X
suggesting	B-X
that	B-X
a	B-X
p50-p50	B-X
homodimer	B-X
may	B-X
modulate	B-X
transcription	B-X
in	B-X
place	B-X
of	B-X
the	B-X
tumorigenic	B-X
p50-p65	B-X
.	B-X
Overall	B-X
,	B-X
KPC1	B-X
regulation	B-X
of	B-X
NF-κB1	B-X
processing	B-X
appears	B-X
to	B-X
constitute	B-X
an	B-X
important	B-X
balancing	B-X
step	B-X
among	B-X
the	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
activities	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
in	B-X
cell	B-X
growth	B-X
control	B-X
.	B-X

The	O
processing	O
of	O
p105	B-Protein
occurs	O
constitutively	O
in	O
vivo	O
but	O
can	O
be	O
markedly	O
enhanced	O
by	O
various	O
cellular	O
activation	O
agents	O
,	O
although	O
the	O
underlying	O
regulatory	O
mechanism	O
is	O
not	O
yet	O
clear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
signal	O
-	O
mediated	O
induction	O
of	O
p105	B-Protein
processing	O
in	O
human	O
T	O
cells	O
is	O
associated	O
with	O
de	O
novo	O
synthesis	O
of	O
this	O
precursor	O
protein	O
.	O

Transient	O
transfection	O
studies	O
performed	O
in	O
COS7	O
cells	O
revealed	O
that	O
the	O
newly	O
synthesized	O
p105	B-Protein
protein	O
appears	O
to	O
be	O
more	O
rapidly	O
processed	O
compared	O
to	O
its	O
accumulated	O
form	O
that	O
is	O
already	O
associated	O
with	O
the	O
processed	O
product	O
p50	B-Protein
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
involves	B-X
proteasome-mediated	B-X
processing	B-X
of	B-X
the	B-X
NF-kappaB1	B-X
p105	B-X
precursor	B-X
protein	B-X
,	B-X
which	B-X
generates	B-X
the	B-X
p50	B-X
subunit	B-X
of	B-X
NF-kappaB	B-X
.	B-X
The	B-X
processing	B-X
of	B-X
p105	B-X
occurs	B-X
constitutively	B-X
in	B-X
vivo	B-X
but	B-X
can	B-X
be	B-X
markedly	B-X
enhanced	B-X
by	B-X
various	B-X
cellular	B-X
activation	B-X
agents	B-X
,	B-X
although	B-X
the	B-X
underlying	B-X
regulatory	B-X
mechanism	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
signal-mediated	B-X
induction	B-X
of	B-X
p105	B-X
processing	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
is	B-X
associated	B-X
with	B-X
de	B-X
novo	B-X
synthesis	B-X
of	B-X
this	B-X
precursor	B-X
protein	B-X
.	B-X
Transient	B-X
transfection	B-X
studies	B-X
performed	B-X
in	B-X
COS7	B-X
cells	B-X
revealed	B-X
that	B-X
the	B-X
newly	B-X
synthesized	B-X
p105	B-X
protein	B-X
appears	B-X
to	B-X
be	B-X
more	B-X
rapidly	B-X
processed	B-X
compared	B-X
to	B-X
its	B-X
accumulated	B-X
form	B-X
that	B-X
is	B-X
already	B-X
associated	B-X
with	B-X
the	B-X
processed	B-X
product	B-X
p50	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
processing	B-X
rate	B-X
of	B-X
p105	B-X
is	B-X
markedly	B-X
inhibited	B-X
in	B-X
cells	B-X
co-transfected	B-X
with	B-X
p50	B-X
or	B-X
other	B-X
NF-kappaB	B-X
subunits	B-X
,	B-X
including	B-X
RelA	B-X
and	B-X
c-Rel	B-X
,	B-X
that	B-X
physically	B-X
interact	B-X
with	B-X
p105	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
processing	B-X
of	B-X
p105	B-X
is	B-X
subject	B-X
to	B-X
negative	B-X
regulation	B-X
by	B-X
the	B-X
various	B-X
NF-kappaB	B-X
subunits	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
p105	B-X
undergoes	B-X
degradation	B-X
in	B-X
lipopolysaccharide-stimulated	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
is	B-X
not	B-X
coupled	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
p50	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
demonstrate	B-X
that	B-X
the	B-X
processing	B-X
and	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
are	B-X
differentially	B-X
regulated	B-X
.	B-X

Interestingly	O
,	O
the	O
processing	O
rate	O
of	O
p105	B-Protein
is	O
markedly	O
inhibited	O
in	O
cells	O
co	O
-	O
transfected	O
with	O
p50	B-Protein
or	O
other	O
NF	O
-	O
kappaB	O
subunits	O
,	O
including	O
RelA	B-Protein
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
that	O
physically	O
interact	O
with	O
p105	B-Protein
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
involves	B-X
proteasome-mediated	B-X
processing	B-X
of	B-X
the	B-X
NF-kappaB1	B-X
p105	B-X
precursor	B-X
protein	B-X
,	B-X
which	B-X
generates	B-X
the	B-X
p50	B-X
subunit	B-X
of	B-X
NF-kappaB	B-X
.	B-X
The	B-X
processing	B-X
of	B-X
p105	B-X
occurs	B-X
constitutively	B-X
in	B-X
vivo	B-X
but	B-X
can	B-X
be	B-X
markedly	B-X
enhanced	B-X
by	B-X
various	B-X
cellular	B-X
activation	B-X
agents	B-X
,	B-X
although	B-X
the	B-X
underlying	B-X
regulatory	B-X
mechanism	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
signal-mediated	B-X
induction	B-X
of	B-X
p105	B-X
processing	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
is	B-X
associated	B-X
with	B-X
de	B-X
novo	B-X
synthesis	B-X
of	B-X
this	B-X
precursor	B-X
protein	B-X
.	B-X
Transient	B-X
transfection	B-X
studies	B-X
performed	B-X
in	B-X
COS7	B-X
cells	B-X
revealed	B-X
that	B-X
the	B-X
newly	B-X
synthesized	B-X
p105	B-X
protein	B-X
appears	B-X
to	B-X
be	B-X
more	B-X
rapidly	B-X
processed	B-X
compared	B-X
to	B-X
its	B-X
accumulated	B-X
form	B-X
that	B-X
is	B-X
already	B-X
associated	B-X
with	B-X
the	B-X
processed	B-X
product	B-X
p50	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
processing	B-X
rate	B-X
of	B-X
p105	B-X
is	B-X
markedly	B-X
inhibited	B-X
in	B-X
cells	B-X
co-transfected	B-X
with	B-X
p50	B-X
or	B-X
other	B-X
NF-kappaB	B-X
subunits	B-X
,	B-X
including	B-X
RelA	B-X
and	B-X
c-Rel	B-X
,	B-X
that	B-X
physically	B-X
interact	B-X
with	B-X
p105	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
processing	B-X
of	B-X
p105	B-X
is	B-X
subject	B-X
to	B-X
negative	B-X
regulation	B-X
by	B-X
the	B-X
various	B-X
NF-kappaB	B-X
subunits	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
p105	B-X
undergoes	B-X
degradation	B-X
in	B-X
lipopolysaccharide-stimulated	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
is	B-X
not	B-X
coupled	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
p50	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
demonstrate	B-X
that	B-X
the	B-X
processing	B-X
and	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
are	B-X
differentially	B-X
regulated	B-X
.	B-X

These	O
findings	O
suggest	O
that	O
the	O
processing	O
of	O
p105	B-Protein
is	O
subject	O
to	O
negative	O
regulation	O
by	O
the	O
various	O
NF	O
-	O
kappaB	O
subunits	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
involves	B-X
proteasome-mediated	B-X
processing	B-X
of	B-X
the	B-X
NF-kappaB1	B-X
p105	B-X
precursor	B-X
protein	B-X
,	B-X
which	B-X
generates	B-X
the	B-X
p50	B-X
subunit	B-X
of	B-X
NF-kappaB	B-X
.	B-X
The	B-X
processing	B-X
of	B-X
p105	B-X
occurs	B-X
constitutively	B-X
in	B-X
vivo	B-X
but	B-X
can	B-X
be	B-X
markedly	B-X
enhanced	B-X
by	B-X
various	B-X
cellular	B-X
activation	B-X
agents	B-X
,	B-X
although	B-X
the	B-X
underlying	B-X
regulatory	B-X
mechanism	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
signal-mediated	B-X
induction	B-X
of	B-X
p105	B-X
processing	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
is	B-X
associated	B-X
with	B-X
de	B-X
novo	B-X
synthesis	B-X
of	B-X
this	B-X
precursor	B-X
protein	B-X
.	B-X
Transient	B-X
transfection	B-X
studies	B-X
performed	B-X
in	B-X
COS7	B-X
cells	B-X
revealed	B-X
that	B-X
the	B-X
newly	B-X
synthesized	B-X
p105	B-X
protein	B-X
appears	B-X
to	B-X
be	B-X
more	B-X
rapidly	B-X
processed	B-X
compared	B-X
to	B-X
its	B-X
accumulated	B-X
form	B-X
that	B-X
is	B-X
already	B-X
associated	B-X
with	B-X
the	B-X
processed	B-X
product	B-X
p50	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
processing	B-X
rate	B-X
of	B-X
p105	B-X
is	B-X
markedly	B-X
inhibited	B-X
in	B-X
cells	B-X
co-transfected	B-X
with	B-X
p50	B-X
or	B-X
other	B-X
NF-kappaB	B-X
subunits	B-X
,	B-X
including	B-X
RelA	B-X
and	B-X
c-Rel	B-X
,	B-X
that	B-X
physically	B-X
interact	B-X
with	B-X
p105	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
processing	B-X
of	B-X
p105	B-X
is	B-X
subject	B-X
to	B-X
negative	B-X
regulation	B-X
by	B-X
the	B-X
various	B-X
NF-kappaB	B-X
subunits	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
p105	B-X
undergoes	B-X
degradation	B-X
in	B-X
lipopolysaccharide-stimulated	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
is	B-X
not	B-X
coupled	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
p50	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
demonstrate	B-X
that	B-X
the	B-X
processing	B-X
and	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
are	B-X
differentially	B-X
regulated	B-X
.	B-X

We	O
further	O
demonstrate	O
that	O
p105	B-Protein
undergoes	O
degradation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
involves	B-X
proteasome-mediated	B-X
processing	B-X
of	B-X
the	B-X
NF-kappaB1	B-X
p105	B-X
precursor	B-X
protein	B-X
,	B-X
which	B-X
generates	B-X
the	B-X
p50	B-X
subunit	B-X
of	B-X
NF-kappaB	B-X
.	B-X
The	B-X
processing	B-X
of	B-X
p105	B-X
occurs	B-X
constitutively	B-X
in	B-X
vivo	B-X
but	B-X
can	B-X
be	B-X
markedly	B-X
enhanced	B-X
by	B-X
various	B-X
cellular	B-X
activation	B-X
agents	B-X
,	B-X
although	B-X
the	B-X
underlying	B-X
regulatory	B-X
mechanism	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
signal-mediated	B-X
induction	B-X
of	B-X
p105	B-X
processing	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
is	B-X
associated	B-X
with	B-X
de	B-X
novo	B-X
synthesis	B-X
of	B-X
this	B-X
precursor	B-X
protein	B-X
.	B-X
Transient	B-X
transfection	B-X
studies	B-X
performed	B-X
in	B-X
COS7	B-X
cells	B-X
revealed	B-X
that	B-X
the	B-X
newly	B-X
synthesized	B-X
p105	B-X
protein	B-X
appears	B-X
to	B-X
be	B-X
more	B-X
rapidly	B-X
processed	B-X
compared	B-X
to	B-X
its	B-X
accumulated	B-X
form	B-X
that	B-X
is	B-X
already	B-X
associated	B-X
with	B-X
the	B-X
processed	B-X
product	B-X
p50	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
processing	B-X
rate	B-X
of	B-X
p105	B-X
is	B-X
markedly	B-X
inhibited	B-X
in	B-X
cells	B-X
co-transfected	B-X
with	B-X
p50	B-X
or	B-X
other	B-X
NF-kappaB	B-X
subunits	B-X
,	B-X
including	B-X
RelA	B-X
and	B-X
c-Rel	B-X
,	B-X
that	B-X
physically	B-X
interact	B-X
with	B-X
p105	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
processing	B-X
of	B-X
p105	B-X
is	B-X
subject	B-X
to	B-X
negative	B-X
regulation	B-X
by	B-X
the	B-X
various	B-X
NF-kappaB	B-X
subunits	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
p105	B-X
undergoes	B-X
degradation	B-X
in	B-X
lipopolysaccharide-stimulated	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
is	B-X
not	B-X
coupled	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
p50	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
demonstrate	B-X
that	B-X
the	B-X
processing	B-X
and	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
are	B-X
differentially	B-X
regulated	B-X
.	B-X

However	O
,	O
the	O
inducible	O
degradation	O
of	O
p105	B-Protein
is	O
not	O
coupled	O
with	O
the	O
generation	O
of	O
p50	B-Protein
.	O
<EOS>	B-X
The	B-X
mammalian	B-X
Rel/NF-kappaB	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
,	B-X
including	B-X
RelA	B-X
,	B-X
c-Rel	B-X
,	B-X
RelB	B-X
,	B-X
NF-kappaB1	B-X
(	B-X
p50	B-X
and	B-X
its	B-X
precursor	B-X
p105	B-X
)	B-X
,	B-X
and	B-X
NF-kappaB2	B-X
(	B-X
p52	B-X
and	B-X
its	B-X
precursor	B-X
p100	B-X
)	B-X
,	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
by	B-X
regulating	B-X
several	B-X
processes	B-X
ranging	B-X
from	B-X
the	B-X
development	B-X
and	B-X
survival	B-X
of	B-X
lymphocytes	B-X
and	B-X
lymphoid	B-X
organs	B-X
to	B-X
the	B-X
control	B-X
of	B-X
immune	B-X
responses	B-X
and	B-X
malignant	B-X
transformation	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
transcription	B-X
factor	B-X
is	B-X
normally	B-X
controlled	B-X
through	B-X
cytoplasmic	B-X
retention	B-X
by	B-X
either	B-X
of	B-X
two	B-X
types	B-X
of	B-X
molecules	B-X
:	B-X
the	B-X
inhibitor	B-X
I	B-X
kappa	B-X
B	B-X
alpha/MAD3	B-X
or	B-X
the	B-X
p105	B-X
and	B-X
p100	B-X
precursors	B-X
of	B-X
the	B-X
p50	B-X
and	B-X
p52	B-X
DNA-binding	B-X
subunits	B-X
.	B-X
Treatment	B-X
of	B-X
cells	B-X
with	B-X
classical	B-X
NF-kappa	B-X
B	B-X
inducers	B-X
like	B-X
TNF	B-X
,	B-X
IL-1	B-X
,	B-X
PMA	B-X
or	B-X
LPS	B-X
results	B-X
in	B-X
MAD-3	B-X
degradation	B-X
followed	B-X
by	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappa	B-X
B	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
dissociation	B-X
of	B-X
the	B-X
cytoplasmic	B-X
p105/p100-containing	B-X
complexes	B-X
are	B-X
largely	B-X
unknown	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
that	B-X
Tax	B-X
can	B-X
induce	B-X
translocation	B-X
of	B-X
members	B-X
of	B-X
the	B-X
NF-kappa	B-X
B	B-X
family	B-X
retained	B-X
in	B-X
the	B-X
cytoplasm	B-X
through	B-X
interaction	B-X
with	B-X
either	B-X
p105	B-X
or	B-X
p100	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
Tax	B-X
induces	B-X
no	B-X
apparent	B-X
degradation	B-X
of	B-X
MAD-3	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Tax	B-X
activates	B-X
NF-kappa	B-X
B	B-X
essentially	B-X
through	B-X
the	B-X
p105/p100-retention	B-X
pathway	B-X
.	B-X

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
the	O
processing	O
and	O
inducible	O
degradation	O
of	O
p105	B-Protein
are	O
differentially	O
regulated	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
involves	B-X
proteasome-mediated	B-X
processing	B-X
of	B-X
the	B-X
NF-kappaB1	B-X
p105	B-X
precursor	B-X
protein	B-X
,	B-X
which	B-X
generates	B-X
the	B-X
p50	B-X
subunit	B-X
of	B-X
NF-kappaB	B-X
.	B-X
The	B-X
processing	B-X
of	B-X
p105	B-X
occurs	B-X
constitutively	B-X
in	B-X
vivo	B-X
but	B-X
can	B-X
be	B-X
markedly	B-X
enhanced	B-X
by	B-X
various	B-X
cellular	B-X
activation	B-X
agents	B-X
,	B-X
although	B-X
the	B-X
underlying	B-X
regulatory	B-X
mechanism	B-X
is	B-X
not	B-X
yet	B-X
clear	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
signal-mediated	B-X
induction	B-X
of	B-X
p105	B-X
processing	B-X
in	B-X
human	B-X
T	B-X
cells	B-X
is	B-X
associated	B-X
with	B-X
de	B-X
novo	B-X
synthesis	B-X
of	B-X
this	B-X
precursor	B-X
protein	B-X
.	B-X
Transient	B-X
transfection	B-X
studies	B-X
performed	B-X
in	B-X
COS7	B-X
cells	B-X
revealed	B-X
that	B-X
the	B-X
newly	B-X
synthesized	B-X
p105	B-X
protein	B-X
appears	B-X
to	B-X
be	B-X
more	B-X
rapidly	B-X
processed	B-X
compared	B-X
to	B-X
its	B-X
accumulated	B-X
form	B-X
that	B-X
is	B-X
already	B-X
associated	B-X
with	B-X
the	B-X
processed	B-X
product	B-X
p50	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
processing	B-X
rate	B-X
of	B-X
p105	B-X
is	B-X
markedly	B-X
inhibited	B-X
in	B-X
cells	B-X
co-transfected	B-X
with	B-X
p50	B-X
or	B-X
other	B-X
NF-kappaB	B-X
subunits	B-X
,	B-X
including	B-X
RelA	B-X
and	B-X
c-Rel	B-X
,	B-X
that	B-X
physically	B-X
interact	B-X
with	B-X
p105	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
processing	B-X
of	B-X
p105	B-X
is	B-X
subject	B-X
to	B-X
negative	B-X
regulation	B-X
by	B-X
the	B-X
various	B-X
NF-kappaB	B-X
subunits	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
p105	B-X
undergoes	B-X
degradation	B-X
in	B-X
lipopolysaccharide-stimulated	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
is	B-X
not	B-X
coupled	B-X
with	B-X
the	B-X
generation	B-X
of	B-X
p50	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
studies	B-X
demonstrate	B-X
that	B-X
the	B-X
processing	B-X
and	B-X
inducible	B-X
degradation	B-X
of	B-X
p105	B-X
are	B-X
differentially	B-X
regulated	B-X
.	B-X

Globin	O
gene	O
switching	O
.	O
<EOS>	B-X
Ex	B-X
vivo	B-X
gene	B-X
therapy	B-X
through	B-X
globin	B-X
gene	B-X
addition	B-X
has	B-X
been	B-X
investigated	B-X
extensively	B-X
and	B-X
is	B-X
currently	B-X
being	B-X
tested	B-X
in	B-X
clinical	B-X
trials	B-X
that	B-X
have	B-X
begun	B-X
reporting	B-X
encouraging	B-X
data	B-X
.	B-X
Recent	B-X
improvements	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
pathways	B-X
controlling	B-X
mammalian	B-X
erythropoiesis	B-X
and	B-X
globin	B-X
switching	B-X
offer	B-X
new	B-X
and	B-X
exciting	B-X
therapeutic	B-X
options	B-X
.	B-X
Rapid	B-X
and	B-X
substantial	B-X
advances	B-X
in	B-X
genome	B-X
engineering	B-X
tools	B-X
,	B-X
particularly	B-X
CRISPR/Cas9	B-X
,	B-X
have	B-X
raised	B-X
the	B-X
possibility	B-X
of	B-X
genetic	B-X
correction	B-X
in	B-X
induced	B-X
pluripotent	B-X
stem	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
patient-derived	B-X
hematopoietic	B-X
stem	B-X
and	B-X
progenitor	B-X
cells	B-X
.	B-X
During	B-X
ontogenesis	B-X
,	B-X
the	B-X
composition	B-X
of	B-X
these	B-X
subunits	B-X
changes	B-X
.	B-X
Genes	B-X
encoding	B-X
different	B-X
α-	B-X
and	B-X
β-polypeptide	B-X
chains	B-X
are	B-X
located	B-X
in	B-X
two	B-X
multigene	B-X
clusters	B-X
on	B-X
different	B-X
chromosomes	B-X
.	B-X
Each	B-X
cluster	B-X
contains	B-X
several	B-X
genes	B-X
that	B-X
are	B-X
expressed	B-X
at	B-X
different	B-X
stages	B-X
of	B-X
ontogenesis	B-X
.	B-X
The	B-X
phenomenon	B-X
of	B-X
stage-specific	B-X
transcription	B-X
of	B-X
globin	B-X
genes	B-X
is	B-X
referred	B-X
to	B-X
as	B-X
globin	B-X
gene	B-X
switching	B-X
.	B-X
Mechanisms	B-X
of	B-X
expression	B-X
switching	B-X
,	B-X
stage-specific	B-X
activation	B-X
,	B-X
and	B-X
repression	B-X
of	B-X
transcription	B-X
of	B-X
α-	B-X
and	B-X
β-globin	B-X
genes	B-X
are	B-X
of	B-X
interest	B-X
from	B-X
both	B-X
theoretical	B-X
and	B-X
practical	B-X
points	B-X
of	B-X
view	B-X
.	B-X
Alteration	B-X
of	B-X
balanced	B-X
expression	B-X
of	B-X
globin	B-X
genes	B-X
,	B-X
which	B-X
usually	B-X
occurs	B-X
due	B-X
to	B-X
damage	B-X
to	B-X
adult	B-X
β-globin	B-X
genes	B-X
,	B-X
leads	B-X
to	B-X
development	B-X
of	B-X
severe	B-X
diseases	B-X
-	B-X
hemoglobinopathies	B-X
.	B-X
In	B-X
most	B-X
cases	B-X
,	B-X
reactivation	B-X
of	B-X
the	B-X
fetal	B-X
hemoglobin	B-X
gene	B-X
in	B-X
patients	B-X
with	B-X
β-thalassemia	B-X
and	B-X
sickle	B-X
cell	B-X
disease	B-X
can	B-X
reduce	B-X
negative	B-X
consequences	B-X
of	B-X
irreversible	B-X
alterations	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
β-globin	B-X
genes	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
current	B-X
state	B-X
of	B-X
research	B-X
on	B-X
genetic	B-X
and	B-X
epigenetic	B-X
mechanisms	B-X
underlying	B-X
stage-specific	B-X
switching	B-X
of	B-X
β-globin	B-X
genes	B-X
.	B-X

In	O
vivo	O
protein	O
-	O
DNA	O
interactions	O
of	O
the	O
human	O
beta	B-Protein
-	I-Protein
globin	I-Protein
locus	O
in	O
erythroid	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
gene	O
program	O
.	O
<EOS>	B-X
A	B-X
more	B-X
detailed	B-X
understanding	B-X
of	B-X
the	B-X
switch	B-X
from	B-X
fetal	B-X
to	B-X
adult	B-X
hemoglobin	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
regulators	B-X
such	B-X
as	B-X
BCL11A	B-X
provide	B-X
hope	B-X
that	B-X
these	B-X
findings	B-X
will	B-X
be	B-X
translated	B-X
into	B-X
genomic-based	B-X
approaches	B-X
to	B-X
the	B-X
therapeutic	B-X
reactivation	B-X
of	B-X
hemoglobin	B-X
F	B-X
production	B-X
in	B-X
patients	B-X
with	B-X
SCA	B-X
.	B-X
Meanwhile	B-X
,	B-X
an	B-X
unprecedented	B-X
number	B-X
of	B-X
new	B-X
drugs	B-X
aimed	B-X
at	B-X
both	B-X
the	B-X
treatment	B-X
and	B-X
prevention	B-X
of	B-X
end-organ	B-X
damage	B-X
are	B-X
now	B-X
in	B-X
the	B-X
pipeline	B-X
,	B-X
outcomes	B-X
from	B-X
potentially	B-X
curative	B-X
treatments	B-X
such	B-X
as	B-X
allogeneic	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
transplantation	B-X
are	B-X
improving	B-X
,	B-X
and	B-X
great	B-X
strides	B-X
are	B-X
being	B-X
made	B-X
in	B-X
gene	B-X
therapy	B-X
,	B-X
where	B-X
methods	B-X
employing	B-X
both	B-X
antisickling	B-X
β-globin	B-X
lentiviral	B-X
vectors	B-X
and	B-X
gene	B-X
editing	B-X
are	B-X
now	B-X
entering	B-X
clinical	B-X
trials	B-X
.	B-X
Re-expression	B-X
of	B-X
the	B-X
paralogous	B-X
γ-globin	B-X
genes	B-X
(	B-X
HBG1/2	B-X
)	B-X
could	B-X
be	B-X
a	B-X
universal	B-X
strategy	B-X
to	B-X
ameliorate	B-X
the	B-X
severe	B-X
β-globin	B-X
disorders	B-X
sickle	B-X
cell	B-X
disease	B-X
(	B-X
SCD	B-X
)	B-X
and	B-X
β-thalassemia	B-X
by	B-X
induction	B-X
of	B-X
fetal	B-X
hemoglobin	B-X
(	B-X
HbF	B-X
,	B-X
α	B-X
Several	B-X
medications	B-X
in	B-X
development	B-X
aim	B-X
to	B-X
induce	B-X
hemoglobin	B-X
F	B-X
(	B-X
HbF	B-X
)	B-X
:	B-X
sirolimus	B-X
,	B-X
benserazide	B-X
,	B-X
and	B-X
IMR-687	B-X
(	B-X
a	B-X
phosphodiesterase	B-X
9	B-X
inhibitor	B-X
)	B-X
.	B-X
Through	B-X
a	B-X
gene	B-X
addition	B-X
approach	B-X
,	B-X
lentiviral	B-X
vectors	B-X
have	B-X
been	B-X
used	B-X
to	B-X
introduce	B-X
a	B-X
β-globin	B-X
gene	B-X
into	B-X
autologous	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
One	B-X
such	B-X
product	B-X
,	B-X
betibeglogene	B-X
autotemcel	B-X
(	B-X
beti-cel	B-X
)	B-X
,	B-X
has	B-X
reached	B-X
phase	B-X
3	B-X
trials	B-X
with	B-X
promising	B-X
results	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
2	B-X
gene	B-X
editing	B-X
techniques	B-X
(	B-X
CRISPR-Cas9	B-X
and	B-X
zinc-finger	B-X
nucleases	B-X
)	B-X
are	B-X
under	B-X
investigation	B-X
as	B-X
a	B-X
means	B-X
to	B-X
silence	B-X
BCL11A	B-X
to	B-X
induce	B-X
HbF	B-X
with	B-X
agents	B-X
designated	B-X
CTX001	B-X
and	B-X
ST-400	B-X
,	B-X
respectively	B-X
.	B-X

To	O
characterize	O
the	O
protein	O
-	O
DNA	O
interactions	O
important	O
for	O
the	O
developmental	O
control	O
of	O
the	O
human	O
beta	B-Protein
-	I-Protein
globin	I-Protein
locus	O
,	O
we	O
analyzed	O
by	O
in	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
erythroid	O
cells	O
expressing	O
either	O
the	O
fetal	B-Protein
or	O
the	O
adult	B-Protein
globin	I-Protein
developmental	O
program	O
.	O
<EOS>	B-X
Increased	B-X
production	B-X
of	B-X
fetal	B-X
hemoglobin	B-X
(	B-X
HbF	B-X
)	B-X
can	B-X
ameliorate	B-X
the	B-X
severity	B-X
of	B-X
sickle	B-X
cell	B-X
disease	B-X
and	B-X
β-thalassemia	B-X
The	B-X
level	B-X
of	B-X
fetal	B-X
hemoglobin	B-X
(	B-X
HbF	B-X
)	B-X
modifies	B-X
the	B-X
severity	B-X
of	B-X
the	B-X
common	B-X
β-globin	B-X
disorders	B-X
.	B-X
Knowledge	B-X
of	B-X
the	B-X
normal	B-X
mechanisms	B-X
that	B-X
repress	B-X
HbF	B-X
in	B-X
the	B-X
adult	B-X
stage	B-X
has	B-X
remained	B-X
limited	B-X
until	B-X
recently	B-X
despite	B-X
nearly	B-X
3	B-X
decades	B-X
of	B-X
molecular	B-X
investigation	B-X
,	B-X
in	B-X
part	B-X
because	B-X
of	B-X
imperfect	B-X
model	B-X
systems	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
provided	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
developmental	B-X
regulation	B-X
of	B-X
globin	B-X
genes	B-X
and	B-X
identified	B-X
specific	B-X
transcription	B-X
factors	B-X
and	B-X
epigenetic	B-X
regulators	B-X
responsible	B-X
for	B-X
physiologic	B-X
silencing	B-X
of	B-X
HbF	B-X
.	B-X
Most	B-X
prominent	B-X
among	B-X
these	B-X
regulators	B-X
is	B-X
BCL11A	B-X
,	B-X
a	B-X
transcriptional	B-X
repressor	B-X
that	B-X
inhibits	B-X
adult-stage	B-X
HbF	B-X
expression	B-X
.	B-X
KLF1	B-X
and	B-X
c-Myb	B-X
are	B-X
additional	B-X
critical	B-X
HbF-regulating	B-X
erythroid	B-X
transcription	B-X
factors	B-X
more	B-X
broadly	B-X
involved	B-X
in	B-X
erythroid	B-X
gene	B-X
expression	B-X
programs	B-X
.	B-X
Chromatin	B-X
modifiers	B-X
,	B-X
including	B-X
histone	B-X
deacetylases	B-X
and	B-X
DNA	B-X
methyltransferases	B-X
,	B-X
also	B-X
play	B-X
key	B-X
roles	B-X
in	B-X
orchestrating	B-X
appropriate	B-X
globin	B-X
gene	B-X
expression	B-X
.	B-X

In	O
the	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
of	O
the	O
beta	B-Protein
-	I-Protein
globin	I-Protein
locus	O
,	O
in	O
vivo	O
footprints	O
on	O
NF	O
-	O
E2	O
(	O
or	O
AP	O
-	O
1	O
)	O
and	O
GATA	B-Protein
-	I-Protein
1	I-Protein
motifs	O
remained	O
the	O
same	O
regardless	O
of	O
whether	O
the	O
fetal	B-Protein
or	O
the	O
adult	B-Protein
globin	I-Protein
genes	I-Protein
are	O
expressed	O
.	O
<EOS>	B-X
The	B-X
benign	B-X
condition	B-X
hereditary	B-X
persistence	B-X
of	B-X
fetal	B-X
hemoglobin	B-X
(	B-X
HPFH	B-X
)	B-X
is	B-X
known	B-X
to	B-X
ameliorate	B-X
symptoms	B-X
of	B-X
co-inherited	B-X
β-hemoglobinopathies	B-X
,	B-X
such	B-X
as	B-X
sickle	B-X
cell	B-X
disease	B-X
and	B-X
β-thalassemia	B-X
.	B-X
The	B-X
condition	B-X
is	B-X
sometimes	B-X
associated	B-X
with	B-X
point	B-X
mutations	B-X
in	B-X
the	B-X
fetal	B-X
globin	B-X
promoters	B-X
that	B-X
disrupt	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
repressors	B-X
BCL11A	B-X
or	B-X
ZBTB7A/LRF	B-X
,	B-X
which	B-X
have	B-X
been	B-X
extensively	B-X
studied	B-X
.	B-X
HPFH	B-X
is	B-X
also	B-X
associated	B-X
with	B-X
a	B-X
range	B-X
of	B-X
deletions	B-X
within	B-X
the	B-X
β-globin	B-X
locus	B-X
that	B-X
all	B-X
reside	B-X
downstream	B-X
of	B-X
the	B-X
fetal	B-X
HBG2	B-X
gene	B-X
.	B-X
Numerous	B-X
different	B-X
mechanisms	B-X
have	B-X
been	B-X
proposed	B-X
to	B-X
explain	B-X
how	B-X
downstream	B-X
deletions	B-X
can	B-X
boost	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
fetal	B-X
globin	B-X
genes	B-X
,	B-X
including	B-X
the	B-X
deletion	B-X
of	B-X
silencer	B-X
elements	B-X
,	B-X
of	B-X
genes	B-X
encoding	B-X
noncoding	B-X
RNA	B-X
,	B-X
and	B-X
bringing	B-X
downstream	B-X
enhancer	B-X
elements	B-X
into	B-X
proximity	B-X
with	B-X
the	B-X
fetal	B-X
globin	B-X
gene	B-X
promoters	B-X
.	B-X
In	B-X
all	B-X
cases	B-X
where	B-X
fetal	B-X
globin	B-X
is	B-X
upregulated	B-X
,	B-X
the	B-X
proximal	B-X
adult	B-X
β-globin	B-X
(	B-X
HBB	B-X
)	B-X
promoter	B-X
is	B-X
deleted	B-X
.	B-X
We	B-X
use	B-X
clustered	B-X
regularly	B-X
interspaced	B-X
short	B-X
palindromic	B-X
repeats-mediated	B-X
gene	B-X
editing	B-X
to	B-X
delete	B-X
or	B-X
disrupt	B-X
elements	B-X
within	B-X
the	B-X
promoter	B-X
and	B-X
find	B-X
that	B-X
virtually	B-X
all	B-X
mutations	B-X
that	B-X
reduce	B-X
ΗΒΒ	B-X
promoter	B-X
activity	B-X
result	B-X
in	B-X
elevated	B-X
fetal	B-X
globin	B-X
expression	B-X
.	B-X
These	B-X
results	B-X
fit	B-X
with	B-X
previous	B-X
models	B-X
where	B-X
the	B-X
fetal	B-X
and	B-X
adult	B-X
globin	B-X
genes	B-X
compete	B-X
for	B-X
the	B-X
distal	B-X
locus	B-X
control	B-X
region	B-X
and	B-X
suggest	B-X
that	B-X
targeting	B-X
the	B-X
ΗΒΒ	B-X
promoter	B-X
might	B-X
be	B-X
explored	B-X
to	B-X
elevate	B-X
fetal	B-X
globin	B-X
and	B-X
reduce	B-X
sickle	B-X
globin	B-X
expression	B-X
as	B-X
a	B-X
treatment	B-X
of	B-X
β-hemoglobinopathies	B-X
.	B-X

In	O
contrast	O
,	O
in	O
vivo	O
footprints	O
on	O
GT	O
(	O
CACCC	O
)	O
motifs	O
differed	O
between	O
the	O
cells	O
expressing	O
the	O
fetal	B-Protein
or	O
the	O
adult	B-Protein
globin	I-Protein
program	O
.	O
<EOS>	B-X
A	B-X
high	B-X
level	B-X
of	B-X
erythrocyte	B-X
fetal	B-X
hemoglobin	B-X
(	B-X
HbF	B-X
)	B-X
comprising	B-X
α-	B-X
and	B-X
γ-globins	B-X
may	B-X
ameliorate	B-X
these	B-X
manifestations	B-X
by	B-X
mitigating	B-X
sickle	B-X
hemoglobin	B-X
polymerization	B-X
and	B-X
erythrocyte	B-X
sickling	B-X
.	B-X
Re-expression	B-X
of	B-X
the	B-X
paralogous	B-X
γ-globin	B-X
genes	B-X
(	B-X
HBG1/2	B-X
)	B-X
could	B-X
be	B-X
a	B-X
universal	B-X
strategy	B-X
to	B-X
ameliorate	B-X
the	B-X
severe	B-X
β-globin	B-X
disorders	B-X
sickle	B-X
cell	B-X
disease	B-X
(	B-X
SCD	B-X
)	B-X
and	B-X
β-thalassemia	B-X
by	B-X
induction	B-X
of	B-X
fetal	B-X
hemoglobin	B-X
(	B-X
HbF	B-X
,	B-X
α	B-X
Sickle	B-X
cell	B-X
disease	B-X
(	B-X
SCD	B-X
)	B-X
is	B-X
an	B-X
inherited	B-X
blood	B-X
condition	B-X
resulting	B-X
from	B-X
abnormal	B-X
hemoglobin	B-X
production	B-X
.	B-X
The	B-X
only	B-X
curative	B-X
treatment	B-X
of	B-X
SCD	B-X
at	B-X
this	B-X
time	B-X
is	B-X
bone	B-X
marrow	B-X
transplantation	B-X
(	B-X
also	B-X
called	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
transplantation	B-X
)	B-X
using	B-X
healthy	B-X
blood	B-X
stem	B-X
cells	B-X
from	B-X
an	B-X
unaffected	B-X
brother	B-X
or	B-X
sister	B-X
or	B-X
from	B-X
an	B-X
unrelated	B-X
donor	B-X
if	B-X
one	B-X
can	B-X
be	B-X
identified	B-X
who	B-X
is	B-X
a	B-X
match	B-X
in	B-X
tissue	B-X
typing	B-X
.	B-X
The	B-X
use	B-X
of	B-X
autologous	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
and	B-X
alternative	B-X
types	B-X
of	B-X
genetic	B-X
modifications	B-X
is	B-X
currently	B-X
under	B-X
study	B-X
in	B-X
clinical	B-X
research	B-X
trials	B-X
for	B-X
this	B-X
disease	B-X
.	B-X
The	B-X
approaches	B-X
include	B-X
the	B-X
use	B-X
of	B-X
viral	B-X
vectors	B-X
to	B-X
express	B-X
globin	B-X
genes	B-X
that	B-X
are	B-X
modified	B-X
to	B-X
prevent	B-X
sickle	B-X
hemoglobin	B-X
polymerization	B-X
or	B-X
to	B-X
express	B-X
interfering	B-X
RNAs	B-X
to	B-X
``	B-X
flip	B-X
the	B-X
switch	B-X
''	B-X
in	B-X
adult	B-X
red	B-X
cells	B-X
from	B-X
adult	B-X
β-sickle	B-X
hemoglobin	B-X
to	B-X
fetal	B-X
hemoglobin	B-X
using	B-X
a	B-X
physiologic	B-X
switch	B-X
,	B-X
and	B-X
several	B-X
gene	B-X
editing	B-X
approaches	B-X
with	B-X
the	B-X
goal	B-X
of	B-X
inducing	B-X
fetal	B-X
hemoglobin	B-X
or	B-X
correcting/modifying	B-X
the	B-X
actual	B-X
sickle	B-X
mutation	B-X
.	B-X

In	O
promoter	O
regions	O
,	O
the	O
actively	O
transcribed	O
genes	O
demonstrated	O
extensive	O
and	O
consistent	O
footprints	O
over	O
the	O
canonical	O
elements	O
,	O
such	O
as	O
CACCC	O
and	O
CCAAT	O
motifs	O
.	O
<EOS>	B-X
In	B-X
the	B-X
locus	B-X
control	B-X
region	B-X
(	B-X
LCR	B-X
)	B-X
of	B-X
the	B-X
beta-globin	B-X
locus	B-X
,	B-X
in	B-X
vivo	B-X
footprints	B-X
on	B-X
NF-E2	B-X
(	B-X
or	B-X
AP-1	B-X
)	B-X
and	B-X
GATA-1	B-X
motifs	B-X
remained	B-X
the	B-X
same	B-X
regardless	B-X
of	B-X
whether	B-X
the	B-X
fetal	B-X
or	B-X
the	B-X
adult	B-X
globin	B-X
genes	B-X
are	B-X
expressed	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
in	B-X
vivo	B-X
footprints	B-X
on	B-X
GT	B-X
(	B-X
CACCC	B-X
)	B-X
motifs	B-X
differed	B-X
between	B-X
the	B-X
cells	B-X
expressing	B-X
the	B-X
fetal	B-X
or	B-X
the	B-X
adult	B-X
globin	B-X
program	B-X
.	B-X
In	B-X
promoter	B-X
regions	B-X
,	B-X
the	B-X
actively	B-X
transcribed	B-X
genes	B-X
demonstrated	B-X
extensive	B-X
and	B-X
consistent	B-X
footprints	B-X
over	B-X
the	B-X
canonical	B-X
elements	B-X
,	B-X
such	B-X
as	B-X
CACCC	B-X
and	B-X
CCAAT	B-X
motifs	B-X
.	B-X
The	B-X
adult	B-X
globin	B-X
expressing	B-X
cells	B-X
displayed	B-X
more	B-X
extensive	B-X
footprints	B-X
than	B-X
the	B-X
fetal	B-X
globin	B-X
expressing	B-X
cells	B-X
in	B-X
the	B-X
3	B-X
'	B-X
regulatory	B-X
sequences	B-X
of	B-X
both	B-X
the	B-X
Agamma-	B-X
and	B-X
the	B-X
beta-globin	B-X
genes	B-X
,	B-X
suggesting	B-X
a	B-X
role	B-X
of	B-X
these	B-X
3	B-X
'	B-X
elements	B-X
in	B-X
beta-globin	B-X
gene	B-X
expression	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
bulk	B-X
of	B-X
protein-DNA	B-X
interactions	B-X
that	B-X
underlies	B-X
the	B-X
developmental	B-X
control	B-X
of	B-X
globin	B-X
genes	B-X
takes	B-X
place	B-X
in	B-X
the	B-X
gamma-	B-X
and	B-X
beta-globin	B-X
gene	B-X
promoters	B-X
,	B-X
and	B-X
that	B-X
GT	B-X
motifs	B-X
of	B-X
the	B-X
beta-globin	B-X
locus	B-X
LCR	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
developmental	B-X
regulation	B-X
of	B-X
human	B-X
beta-globin	B-X
gene	B-X
expression	B-X
,	B-X
perhaps	B-X
by	B-X
increasing	B-X
the	B-X
probability	B-X
of	B-X
interaction	B-X
of	B-X
the	B-X
LCR	B-X
holocomplex	B-X
with	B-X
the	B-X
fetal	B-X
or	B-X
the	B-X
adult	B-X
globin	B-X
gene	B-X
.	B-X

The	O
adult	O
globin	O
expressing	O
cells	O
displayed	O
more	O
extensive	O
footprints	O
than	O
the	O
fetal	O
globin	O
expressing	O
cells	O
in	O
the	O
3	O
'	O
regulatory	O
sequences	O
of	O
both	O
the	O
Agamma	B-Protein
-	I-Protein
and	O
the	O
beta	B-Protein
-	I-Protein
globin	I-Protein
genes	O
,	O
suggesting	O
a	O
role	O
of	O
these	O
3	O
'	O
elements	O
in	O
beta	B-Protein
-	I-Protein
globin	I-Protein
gene	O
expression	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
bulk	O
of	O
protein	O
-	O
DNA	O
interactions	O
that	O
underlies	O
the	O
developmental	O
control	O
of	O
globin	O
genes	O
takes	O
place	O
in	O
the	O
gamma	B-Protein
-	I-Protein
and	O
beta	B-Protein
-	I-Protein
globin	I-Protein
gene	O
promoters	O
,	O
and	O
that	O
GT	O
motifs	O
of	O
the	O
beta	B-Protein
-	I-Protein
globin	I-Protein
locus	O
LCR	O
may	O
play	O
a	O
role	O
in	O
the	O
developmental	O
regulation	O
of	O
human	O
beta	B-Protein
-	I-Protein
globin	I-Protein
gene	O
expression	O
,	O
perhaps	O
by	O
increasing	O
the	O
probability	O
of	O
interaction	O
of	O
the	O
LCR	O
holocomplex	O
with	O
the	O
fetal	B-Protein
or	O
the	O
adult	B-Protein
globin	I-Protein
gene	O
.	O
<EOS>	B-X
The	B-X
clinical	B-X
heterogeneity	B-X
of	B-X
β-hemoglobinopathies	B-X
is	B-X
so	B-X
variable	B-X
that	B-X
it	B-X
prompted	B-X
the	B-X
researchers	B-X
to	B-X
identify	B-X
the	B-X
genetic	B-X
modulators	B-X
of	B-X
these	B-X
diseases	B-X
.	B-X
Though	B-X
the	B-X
primary	B-X
modulator	B-X
is	B-X
the	B-X
type	B-X
of	B-X
β-globin	B-X
mutation	B-X
which	B-X
affects	B-X
the	B-X
degree	B-X
of	B-X
β-globin	B-X
chain	B-X
synthesis	B-X
,	B-X
the	B-X
co-inheritance	B-X
of	B-X
α-thalassemia	B-X
and	B-X
the	B-X
fetal	B-X
hemoglobin	B-X
(	B-X
HbF	B-X
)	B-X
levels	B-X
also	B-X
act	B-X
as	B-X
potent	B-X
secondary	B-X
genetic	B-X
modifiers	B-X
.	B-X
As	B-X
elevated	B-X
HbF	B-X
levels	B-X
ameliorate	B-X
the	B-X
severity	B-X
of	B-X
hemoglobinopathies	B-X
,	B-X
in	B-X
this	B-X
review	B-X
,	B-X
the	B-X
genetic	B-X
modulators	B-X
lying	B-X
within	B-X
and	B-X
outside	B-X
the	B-X
β-globin	B-X
gene	B-X
cluster	B-X
with	B-X
their	B-X
plausible	B-X
role	B-X
in	B-X
governing	B-X
the	B-X
HbF	B-X
levels	B-X
have	B-X
been	B-X
summarised	B-X
,	B-X
which	B-X
in	B-X
future	B-X
may	B-X
act	B-X
as	B-X
potential	B-X
therapeutic	B-X
targets	B-X
.	B-X
Fetal	B-X
haemoglobin	B-X
(	B-X
HbF	B-X
)	B-X
levels	B-X
have	B-X
a	B-X
clinically	B-X
beneficial	B-X
effect	B-X
on	B-X
sickle	B-X
cell	B-X
disease	B-X
(	B-X
SCD	B-X
)	B-X
.	B-X
Patients	B-X
with	B-X
SCD	B-X
demonstrate	B-X
extreme	B-X
variability	B-X
in	B-X
HbF	B-X
levels	B-X
(	B-X
1-30	B-X
%	B-X
)	B-X
,	B-X
a	B-X
large	B-X
part	B-X
of	B-X
which	B-X
is	B-X
likely	B-X
genetically	B-X
determined	B-X
.	B-X
The	B-X
main	B-X
genetic	B-X
modifier	B-X
loci	B-X
for	B-X
HbF	B-X
persistence	B-X
,	B-X
HBS1L-MYB	B-X
,	B-X
BCL11A	B-X
and	B-X
the	B-X
β-globin	B-X
gene	B-X
cluster	B-X
in	B-X
adults	B-X
also	B-X
act	B-X
in	B-X
SCD	B-X
patients	B-X
.	B-X
We	B-X
propose	B-X
a	B-X
model	B-X
of	B-X
how	B-X
HbF	B-X
modifier	B-X
genes	B-X
and	B-X
disease	B-X
pathology	B-X
interact	B-X
to	B-X
shape	B-X
HbF	B-X
levels	B-X
measured	B-X
in	B-X
patients	B-X
.	B-X
We	B-X
review	B-X
current	B-X
knowledge	B-X
on	B-X
the	B-X
action	B-X
of	B-X
these	B-X
loci	B-X
in	B-X
SCD	B-X
,	B-X
their	B-X
genetic	B-X
architecture	B-X
,	B-X
and	B-X
their	B-X
putative	B-X
functional	B-X
components	B-X
.	B-X
At	B-X
each	B-X
locus	B-X
,	B-X
one	B-X
strong	B-X
candidate	B-X
for	B-X
a	B-X
causative	B-X
,	B-X
functional	B-X
DNA	B-X
change	B-X
has	B-X
been	B-X
proposed	B-X
:	B-X
Xmn1-HBG2	B-X
at	B-X
the	B-X
β-globin	B-X
cluster	B-X
,	B-X
rs1427407	B-X
at	B-X
BCL11A	B-X
and	B-X
the	B-X
3	B-X
bp	B-X
deletion	B-X
rs66650371	B-X
at	B-X
HBS1L-MYB	B-X
.	B-X
Further	B-X
progress	B-X
in	B-X
understanding	B-X
the	B-X
genetic	B-X
control	B-X
of	B-X
HbF	B-X
levels	B-X
requires	B-X
that	B-X
confounding	B-X
factors	B-X
inherent	B-X
in	B-X
SCD	B-X
,	B-X
such	B-X
as	B-X
ethnic	B-X
complexity	B-X
,	B-X
the	B-X
role	B-X
of	B-X
F	B-X
cells	B-X
and	B-X
the	B-X
influence	B-X
of	B-X
drugs	B-X
,	B-X
are	B-X
suitably	B-X
addressed	B-X
.	B-X

Interleukin	B-Protein
10	I-Protein
induced	O
c	B-Protein
-	I-Protein
fos	I-Protein
expression	O
in	O
human	O
B	O
cells	O
by	O
activation	O
of	O
divergent	O
protein	O
kinases	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
is	O
a	O
potent	O
mediator	O
of	O
human	O
B	O
cell	O
growth	O
and	O
plasma	O
cell	O
formation	O
.	O

However	O
,	O
signal	O
transduction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
B	O
cells	O
is	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
on	O
the	O
expression	O
of	O
the	O
protooncogene	O
c	B-Protein
-	I-Protein
fos	I-Protein
was	O
investigated	O
,	O
because	O
Fos	O
plays	O
a	O
potential	O
role	O
in	O
the	O
regulation	O
of	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

B	O
cells	O
were	O
purified	O
from	O
buffy	O
coat	O
preparations	O
of	O
healthy	O
blood	O
donors	O
by	O
positive	O
selection	O
using	O
an	O
anti	O
CD20	B-Protein
monoclonal	O
antibody	O
and	O
a	O
MiniMACS	O
separation	O
unit	O
.	O

B	O
cells	O
were	O
prestimulated	O
with	O
SAC	O
for	O
48	O
hrs	O
.	O
<EOS>	B-X
IL-10	B-X
is	B-X
a	B-X
potent	B-X
mediator	B-X
of	B-X
human	B-X
B	B-X
cell	B-X
growth	B-X
and	B-X
plasma	B-X
cell	B-X
formation	B-X
.	B-X
However	B-X
,	B-X
signal	B-X
transduction	B-X
of	B-X
IL-10	B-X
in	B-X
B	B-X
cells	B-X
is	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
the	B-X
effect	B-X
of	B-X
IL-10	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
protooncogene	B-X
c-fos	B-X
was	B-X
investigated	B-X
,	B-X
because	B-X
Fos	B-X
plays	B-X
a	B-X
potential	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
B	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
B	B-X
cells	B-X
were	B-X
purified	B-X
from	B-X
buffy	B-X
coat	B-X
preparations	B-X
of	B-X
healthy	B-X
blood	B-X
donors	B-X
by	B-X
positive	B-X
selection	B-X
using	B-X
an	B-X
anti	B-X
CD20	B-X
monoclonal	B-X
antibody	B-X
and	B-X
a	B-X
MiniMACS	B-X
separation	B-X
unit	B-X
.	B-X
B	B-X
cells	B-X
were	B-X
prestimulated	B-X
with	B-X
SAC	B-X
for	B-X
48	B-X
hrs	B-X
.	B-X
Then	B-X
,	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
medium	B-X
or	B-X
IL-10	B-X
(	B-X
100	B-X
ng/ml	B-X
)	B-X
for	B-X
10	B-X
to	B-X
120	B-X
min	B-X
.	B-X
After	B-X
2	B-X
hrs	B-X
c-fos	B-X
expression	B-X
declined	B-X
to	B-X
basal	B-X
levels	B-X
.	B-X
The	B-X
IL-10	B-X
effect	B-X
on	B-X
c-fos	B-X
expression	B-X
was	B-X
not	B-X
blocked	B-X
by	B-X
polymyxin	B-X
B	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
these	B-X
data	B-X
show	B-X
that	B-X
IL-10	B-X
induces	B-X
c-fos	B-X
expression	B-X
in	B-X
human	B-X
B-cells	B-X
by	B-X
activation	B-X
of	B-X
tyrosine	B-X
and	B-X
serine/threonine	B-X
kinases	B-X
.	B-X
Since	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
on	B-X
IL-10	B-X
induced	B-X
signal	B-X
transduction	B-X
,	B-X
these	B-X
data	B-X
may	B-X
help	B-X
to	B-X
identify	B-X
the	B-X
intracellular	B-X
mechanisms	B-X
by	B-X
which	B-X
IL-10	B-X
stimulates	B-X
human	B-X
B-cells	B-X
.	B-X

Then	O
,	O
cells	O
were	O
incubated	O
with	O
medium	O
or	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
10	O
to	O
120	O
min	O
.	O
<EOS>	B-X
Live	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
can	B-X
be	B-X
frozen	B-X
and	B-X
thawed	B-X
for	B-X
later	B-X
analyses	B-X
by	B-X
adding	B-X
and	B-X
removing	B-X
a	B-X
cryoprotectant	B-X
,	B-X
such	B-X
as	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
.	B-X
Laboratories	B-X
across	B-X
the	B-X
world	B-X
use	B-X
various	B-X
procedures	B-X
,	B-X
but	B-X
published	B-X
evidence	B-X
of	B-X
optimal	B-X
thawing	B-X
procedures	B-X
is	B-X
scarce	B-X
.	B-X
Cholesterol	B-X
content	B-X
of	B-X
cells	B-X
must	B-X
be	B-X
maintained	B-X
within	B-X
the	B-X
very	B-X
tight	B-X
limits	B-X
,	B-X
too	B-X
much	B-X
or	B-X
too	B-X
little	B-X
cholesterol	B-X
in	B-X
a	B-X
cell	B-X
results	B-X
in	B-X
disruption	B-X
of	B-X
cellular	B-X
membranes	B-X
,	B-X
apoptosis	B-X
and	B-X
necrosis	B-X
.	B-X
Cells	B-X
can	B-X
source	B-X
cholesterol	B-X
from	B-X
intracellular	B-X
synthesis	B-X
and	B-X
from	B-X
plasma	B-X
lipoproteins	B-X
,	B-X
both	B-X
sources	B-X
are	B-X
sufficient	B-X
to	B-X
fully	B-X
satisfy	B-X
cells	B-X
'	B-X
requirements	B-X
for	B-X
cholesterol	B-X
.	B-X
With	B-X
the	B-X
exception	B-X
of	B-X
hepatocytes	B-X
and	B-X
to	B-X
some	B-X
degree	B-X
adrenocortical	B-X
cells	B-X
,	B-X
cells	B-X
are	B-X
unable	B-X
to	B-X
degrade	B-X
cholesterol	B-X
.	B-X
Cells	B-X
have	B-X
two	B-X
options	B-X
to	B-X
reduce	B-X
their	B-X
cholesterol	B-X
content	B-X
:	B-X
to	B-X
convert	B-X
cholesterol	B-X
into	B-X
cholesteryl	B-X
esters	B-X
,	B-X
an	B-X
option	B-X
with	B-X
limited	B-X
capacity	B-X
as	B-X
overloading	B-X
cells	B-X
with	B-X
cholesteryl	B-X
esters	B-X
is	B-X
also	B-X
toxic	B-X
,	B-X
and	B-X
cholesterol	B-X
efflux	B-X
,	B-X
an	B-X
option	B-X
with	B-X
potentially	B-X
unlimited	B-X
capacity	B-X
.	B-X
Cholesterol	B-X
efflux	B-X
is	B-X
a	B-X
specific	B-X
process	B-X
that	B-X
is	B-X
regulated	B-X
by	B-X
a	B-X
number	B-X
of	B-X
intracellular	B-X
transporters	B-X
,	B-X
such	B-X
as	B-X
ATP	B-X
binding	B-X
cassette	B-X
transporter	B-X
proteins	B-X
A1	B-X
(	B-X
ABCA1	B-X
)	B-X
and	B-X
G1	B-X
(	B-X
ABCG1	B-X
)	B-X
and	B-X
scavenger	B-X
receptor	B-X
type	B-X
B1	B-X
.	B-X
The	B-X
cholesterol	B-X
efflux	B-X
assay	B-X
is	B-X
designed	B-X
to	B-X
quantitate	B-X
the	B-X
rate	B-X
of	B-X
cholesterol	B-X
efflux	B-X
from	B-X
cultured	B-X
cells	B-X
.	B-X
It	B-X
measures	B-X
the	B-X
capacity	B-X
of	B-X
cells	B-X
to	B-X
maintain	B-X
cholesterol	B-X
efflux	B-X
and/or	B-X
the	B-X
capacity	B-X
of	B-X
plasma	B-X
acceptors	B-X
to	B-X
accept	B-X
cholesterol	B-X
released	B-X
from	B-X
cells	B-X
.	B-X
The	B-X
assay	B-X
consists	B-X
of	B-X
the	B-X
following	B-X
steps	B-X
.	B-X
Step	B-X
1	B-X
:	B-X
labelling	B-X
cellular	B-X
cholesterol	B-X
by	B-X
adding	B-X
labelled	B-X
cholesterol	B-X
to	B-X
serum-containing	B-X
medium	B-X
and	B-X
incubating	B-X
with	B-X
cells	B-X
for	B-X
24-48	B-X
h.	B-X
This	B-X
step	B-X
may	B-X
be	B-X
combined	B-X
with	B-X
loading	B-X
of	B-X
cells	B-X
with	B-X
cholesterol	B-X
.	B-X
Step	B-X
2	B-X
:	B-X
incubation	B-X
of	B-X
cells	B-X
in	B-X
serum-free	B-X
medium	B-X
to	B-X
equilibrate	B-X
labelled	B-X
cholesterol	B-X
among	B-X
all	B-X
intracellular	B-X
cholesterol	B-X
pools	B-X
.	B-X
Step	B-X
3	B-X
:	B-X
incubation	B-X
of	B-X
cells	B-X
with	B-X
extracellular	B-X
acceptor	B-X
and	B-X
quantitation	B-X
of	B-X
movement	B-X
of	B-X
labelled	B-X
cholesterol	B-X
from	B-X
cells	B-X
to	B-X
the	B-X
acceptor	B-X
.	B-X
The	B-X
assay	B-X
delivers	B-X
the	B-X
following	B-X
information	B-X
:	B-X
(	B-X
i	B-X
)	B-X
how	B-X
a	B-X
particular	B-X
treatment	B-X
(	B-X
a	B-X
mutation	B-X
,	B-X
a	B-X
knock-down	B-X
,	B-X
an	B-X
overexpression	B-X
or	B-X
a	B-X
treatment	B-X
)	B-X
affects	B-X
the	B-X
capacity	B-X
of	B-X
cell	B-X
to	B-X
efflux	B-X
cholesterol	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
how	B-X
the	B-X
capacity	B-X
of	B-X
plasma	B-X
acceptors	B-X
to	B-X
accept	B-X
cholesterol	B-X
is	B-X
affected	B-X
by	B-X
a	B-X
disease	B-X
or	B-X
a	B-X
treatment	B-X
.	B-X

RNA	O
was	O
extracted	O
by	O
phenol	O
/	O
chloroform	O
and	O
c	B-Protein
-	I-Protein
fos	I-Protein
expression	O
was	O
analyzed	O
by	O
PCR	O
assisted	O
mRNA	O
assay	O
.	O

A	O
significant	O
2	O
-	O
4	O
fold	O
increase	O
of	O
c	B-Protein
-	I-Protein
fos	I-Protein
expression	O
was	O
observed	O
within	O
30	O
min	O
of	O
stimulation	O
with	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

After	O
2	O
hrs	O
c	B-Protein
-	I-Protein
fos	I-Protein
expression	O
declined	O
to	O
basal	O
levels	O
.	O
<EOS>	B-X
IL-10	B-X
is	B-X
a	B-X
potent	B-X
mediator	B-X
of	B-X
human	B-X
B	B-X
cell	B-X
growth	B-X
and	B-X
plasma	B-X
cell	B-X
formation	B-X
.	B-X
However	B-X
,	B-X
signal	B-X
transduction	B-X
of	B-X
IL-10	B-X
in	B-X
B	B-X
cells	B-X
is	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
the	B-X
effect	B-X
of	B-X
IL-10	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
protooncogene	B-X
c-fos	B-X
was	B-X
investigated	B-X
,	B-X
because	B-X
Fos	B-X
plays	B-X
a	B-X
potential	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
B	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
B	B-X
cells	B-X
were	B-X
purified	B-X
from	B-X
buffy	B-X
coat	B-X
preparations	B-X
of	B-X
healthy	B-X
blood	B-X
donors	B-X
by	B-X
positive	B-X
selection	B-X
using	B-X
an	B-X
anti	B-X
CD20	B-X
monoclonal	B-X
antibody	B-X
and	B-X
a	B-X
MiniMACS	B-X
separation	B-X
unit	B-X
.	B-X
B	B-X
cells	B-X
were	B-X
prestimulated	B-X
with	B-X
SAC	B-X
for	B-X
48	B-X
hrs	B-X
.	B-X
Then	B-X
,	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
medium	B-X
or	B-X
IL-10	B-X
(	B-X
100	B-X
ng/ml	B-X
)	B-X
for	B-X
10	B-X
to	B-X
120	B-X
min	B-X
.	B-X
RNA	B-X
was	B-X
extracted	B-X
by	B-X
phenol/chloroform	B-X
and	B-X
c-fos	B-X
expression	B-X
was	B-X
analyzed	B-X
by	B-X
PCR	B-X
assisted	B-X
mRNA	B-X
assay	B-X
.	B-X
A	B-X
significant	B-X
2-4	B-X
fold	B-X
increase	B-X
of	B-X
c-fos	B-X
expression	B-X
was	B-X
observed	B-X
within	B-X
30	B-X
min	B-X
of	B-X
stimulation	B-X
with	B-X
IL-10	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
After	B-X
2	B-X
hrs	B-X
c-fos	B-X
expression	B-X
declined	B-X
to	B-X
basal	B-X
levels	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
IL-10	B-X
was	B-X
dose-dependent	B-X
with	B-X
a	B-X
maximum	B-X
stimulation	B-X
using	B-X
100	B-X
ng/ml	B-X
of	B-X
IL-10	B-X
.	B-X
The	B-X
IL-10	B-X
effect	B-X
on	B-X
c-fos	B-X
expression	B-X
was	B-X
not	B-X
blocked	B-X
by	B-X
polymyxin	B-X
B	B-X
.	B-X
Using	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
genistein	B-X
(	B-X
10	B-X
microM	B-X
)	B-X
a	B-X
complete	B-X
inhibition	B-X
of	B-X
IL-10	B-X
induced	B-X
c-fos	B-X
expression	B-X
was	B-X
observed	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
H-7	B-X
(	B-X
10	B-X
microM	B-X
)	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
serine/threonine	B-X
kinases	B-X
,	B-X
significantly	B-X
blocked	B-X
IL-10	B-X
mediated	B-X
c-fos	B-X
expression	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
these	B-X
data	B-X
show	B-X
that	B-X
IL-10	B-X
induces	B-X
c-fos	B-X
expression	B-X
in	B-X
human	B-X
B-cells	B-X
by	B-X
activation	B-X
of	B-X
tyrosine	B-X
and	B-X
serine/threonine	B-X
kinases	B-X
.	B-X
Since	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
on	B-X
IL-10	B-X
induced	B-X
signal	B-X
transduction	B-X
,	B-X
these	B-X
data	B-X
may	B-X
help	B-X
to	B-X
identify	B-X
the	B-X
intracellular	B-X
mechanisms	B-X
by	B-X
which	B-X
IL-10	B-X
stimulates	B-X
human	B-X
B-cells	B-X
.	B-X

The	O
effect	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
was	O
dose	O
-	O
dependent	O
with	O
a	O
maximum	O
stimulation	O
using	O
100	O
ng	O
/	O
ml	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

The	O
IL	B-Protein
-	I-Protein
10	I-Protein
effect	O
on	O
c	B-Protein
-	I-Protein
fos	I-Protein
expression	O
was	O
not	O
blocked	O
by	O
polymyxin	O
B	O
.	O

Using	O
the	O
tyrosine	O
kinase	O
inhibitor	O
genistein	O
(	O
10	O
microM	O
)	O
a	O
complete	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
induced	O
c	B-Protein
-	I-Protein
fos	I-Protein
expression	O
was	O
observed	O
.	O
<EOS>	B-X
IL-10	B-X
is	B-X
a	B-X
potent	B-X
mediator	B-X
of	B-X
human	B-X
B	B-X
cell	B-X
growth	B-X
and	B-X
plasma	B-X
cell	B-X
formation	B-X
.	B-X
However	B-X
,	B-X
signal	B-X
transduction	B-X
of	B-X
IL-10	B-X
in	B-X
B	B-X
cells	B-X
is	B-X
poorly	B-X
understood	B-X
.	B-X
In	B-X
this	B-X
study	B-X
the	B-X
effect	B-X
of	B-X
IL-10	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
protooncogene	B-X
c-fos	B-X
was	B-X
investigated	B-X
,	B-X
because	B-X
Fos	B-X
plays	B-X
a	B-X
potential	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
B	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
B	B-X
cells	B-X
were	B-X
purified	B-X
from	B-X
buffy	B-X
coat	B-X
preparations	B-X
of	B-X
healthy	B-X
blood	B-X
donors	B-X
by	B-X
positive	B-X
selection	B-X
using	B-X
an	B-X
anti	B-X
CD20	B-X
monoclonal	B-X
antibody	B-X
and	B-X
a	B-X
MiniMACS	B-X
separation	B-X
unit	B-X
.	B-X
B	B-X
cells	B-X
were	B-X
prestimulated	B-X
with	B-X
SAC	B-X
for	B-X
48	B-X
hrs	B-X
.	B-X
Then	B-X
,	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
medium	B-X
or	B-X
IL-10	B-X
(	B-X
100	B-X
ng/ml	B-X
)	B-X
for	B-X
10	B-X
to	B-X
120	B-X
min	B-X
.	B-X
RNA	B-X
was	B-X
extracted	B-X
by	B-X
phenol/chloroform	B-X
and	B-X
c-fos	B-X
expression	B-X
was	B-X
analyzed	B-X
by	B-X
PCR	B-X
assisted	B-X
mRNA	B-X
assay	B-X
.	B-X
A	B-X
significant	B-X
2-4	B-X
fold	B-X
increase	B-X
of	B-X
c-fos	B-X
expression	B-X
was	B-X
observed	B-X
within	B-X
30	B-X
min	B-X
of	B-X
stimulation	B-X
with	B-X
IL-10	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
After	B-X
2	B-X
hrs	B-X
c-fos	B-X
expression	B-X
declined	B-X
to	B-X
basal	B-X
levels	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
IL-10	B-X
was	B-X
dose-dependent	B-X
with	B-X
a	B-X
maximum	B-X
stimulation	B-X
using	B-X
100	B-X
ng/ml	B-X
of	B-X
IL-10	B-X
.	B-X
The	B-X
IL-10	B-X
effect	B-X
on	B-X
c-fos	B-X
expression	B-X
was	B-X
not	B-X
blocked	B-X
by	B-X
polymyxin	B-X
B	B-X
.	B-X
Using	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
genistein	B-X
(	B-X
10	B-X
microM	B-X
)	B-X
a	B-X
complete	B-X
inhibition	B-X
of	B-X
IL-10	B-X
induced	B-X
c-fos	B-X
expression	B-X
was	B-X
observed	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
H-7	B-X
(	B-X
10	B-X
microM	B-X
)	B-X
,	B-X
a	B-X
specific	B-X
inhibitor	B-X
of	B-X
serine/threonine	B-X
kinases	B-X
,	B-X
significantly	B-X
blocked	B-X
IL-10	B-X
mediated	B-X
c-fos	B-X
expression	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
these	B-X
data	B-X
show	B-X
that	B-X
IL-10	B-X
induces	B-X
c-fos	B-X
expression	B-X
in	B-X
human	B-X
B-cells	B-X
by	B-X
activation	B-X
of	B-X
tyrosine	B-X
and	B-X
serine/threonine	B-X
kinases	B-X
.	B-X
Since	B-X
this	B-X
is	B-X
the	B-X
first	B-X
report	B-X
on	B-X
IL-10	B-X
induced	B-X
signal	B-X
transduction	B-X
,	B-X
these	B-X
data	B-X
may	B-X
help	B-X
to	B-X
identify	B-X
the	B-X
intracellular	B-X
mechanisms	B-X
by	B-X
which	B-X
IL-10	B-X
stimulates	B-X
human	B-X
B-cells	B-X
.	B-X

In	O
addition	O
,	O
H	O
-	O
7	O
(	O
10	O
microM	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
serine	O
/	O
threonine	O
kinases	O
,	O
significantly	O
blocked	O
IL	B-Protein
-	I-Protein
10	I-Protein
mediated	O
c	B-Protein
-	I-Protein
fos	I-Protein
expression	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
show	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
induces	O
c	B-Protein
-	I-Protein
fos	I-Protein
expression	O
in	O
human	O
B	O
-	O
cells	O
by	O
activation	O
of	O
tyrosine	O
and	O
serine	O
/	O
threonine	O
kinases	O
.	O

Since	O
this	O
is	O
the	O
first	O
report	O
on	O
IL	B-Protein
-	I-Protein
10	I-Protein
induced	O
signal	O
transduction	O
,	O
these	O
data	O
may	O
help	O
to	O
identify	O
the	O
intracellular	O
mechanisms	O
by	O
which	O
IL	B-Protein
-	I-Protein
10	I-Protein
stimulates	O
human	O
B	O
-	O
cells	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
inhibits	O
nuclear	O
factor	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
CD3	O
-	O
stimulated	O
human	O
peripheral	O
T	O
lymphocytes	O
.	O
<EOS>	B-X
IL-10	B-X
markedly	B-X
reduces	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
induced	B-X
in	B-X
PBMC	B-X
by	B-X
stimulation	B-X
with	B-X
the	B-X
anti-CD3	B-X
mAb	B-X
OKT3	B-X
.	B-X
The	B-X
inhibition	B-X
is	B-X
exerted	B-X
specifically	B-X
on	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
activation	B-X
induced	B-X
by	B-X
mAb	B-X
OKT3	B-X
,	B-X
and	B-X
not	B-X
that	B-X
produced	B-X
by	B-X
PMA	B-X
.	B-X
As	B-X
judged	B-X
by	B-X
supershifting	B-X
the	B-X
DNA-protein	B-X
complexes	B-X
with	B-X
Abs	B-X
recognizing	B-X
specific	B-X
components	B-X
of	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
protein	B-X
family	B-X
,	B-X
the	B-X
p50/p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
heterodimeric	B-X
form	B-X
of	B-X
NF-kappa	B-X
B	B-X
is	B-X
primarily	B-X
affected	B-X
.	B-X
The	B-X
maximal	B-X
effect	B-X
is	B-X
observed	B-X
at	B-X
the	B-X
IL-10	B-X
concentration	B-X
of	B-X
20	B-X
U/ml	B-X
.	B-X
IL-10	B-X
inhibitory	B-X
activity	B-X
is	B-X
exerted	B-X
on	B-X
T	B-X
lymphocytes	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
monocytes	B-X
.	B-X
Indeed	B-X
,	B-X
monocytes	B-X
pretreated	B-X
with	B-X
IL-10	B-X
are	B-X
able	B-X
so	B-X
inhibit	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
activity	B-X
in	B-X
purified	B-X
T	B-X
lymphocytes	B-X
stimulated	B-X
with	B-X
OKT3	B-X
.	B-X
Soluble	B-X
factors	B-X
do	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
inhibition	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
up-regulation	B-X
of	B-X
CD80	B-X
Ag	B-X
,	B-X
found	B-X
on	B-X
monocytes	B-X
obtained	B-X
from	B-X
PBMC	B-X
incubated	B-X
with	B-X
OKT3	B-X
,	B-X
is	B-X
not	B-X
detected	B-X
after	B-X
addition	B-X
of	B-X
IL-10	B-X
,	B-X
and	B-X
the	B-X
anti-CD28	B-X
mAb	B-X
CLB-CD28/1	B-X
restores	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
IL-10-inhibited	B-X
lymphocytes	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
inhibition	B-X
might	B-X
be	B-X
ascribed	B-X
to	B-X
a	B-X
lack	B-X
of	B-X
cooperation	B-X
between	B-X
accessory	B-X
cells	B-X
and	B-X
T	B-X
lymphocytes	B-X
,	B-X
resulting	B-X
from	B-X
down-regulation	B-X
of	B-X
a	B-X
costimulatory	B-X
molecule	B-X
,	B-X
such	B-X
as	B-X
CD80	B-X
,	B-X
produced	B-X
by	B-X
IL-10	B-X
on	B-X
activated	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
IL-10	B-X
can	B-X
inhibit	B-X
the	B-X
induction	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
CD3-stimulated	B-X
T	B-X
lymphocytes	B-X
.	B-X
Since	B-X
inappropriate	B-X
activation	B-X
of	B-X
kappa	B-X
B-driven	B-X
genes	B-X
has	B-X
a	B-X
physiopathologic	B-X
role	B-X
in	B-X
a	B-X
number	B-X
of	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
HIV	B-X
infection	B-X
,	B-X
our	B-X
findings	B-X
support	B-X
the	B-X
possibility	B-X
of	B-X
using	B-X
this	B-X
cytokine	B-X
to	B-X
suppress	B-X
an	B-X
undesirable	B-X
activation	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
.	B-X

IL	B-Protein
-	I-Protein
10	I-Protein
markedly	O
reduces	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
induced	O
in	O
PBMC	O
by	O
stimulation	O
with	O
the	O
anti	O
-	O
CD3	O
mAb	O
OKT3	O
.	O
<EOS>	B-X
IL-10	B-X
markedly	B-X
reduces	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
induced	B-X
in	B-X
PBMC	B-X
by	B-X
stimulation	B-X
with	B-X
the	B-X
anti-CD3	B-X
mAb	B-X
OKT3	B-X
.	B-X
The	B-X
inhibition	B-X
is	B-X
exerted	B-X
specifically	B-X
on	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
activation	B-X
induced	B-X
by	B-X
mAb	B-X
OKT3	B-X
,	B-X
and	B-X
not	B-X
that	B-X
produced	B-X
by	B-X
PMA	B-X
.	B-X
As	B-X
judged	B-X
by	B-X
supershifting	B-X
the	B-X
DNA-protein	B-X
complexes	B-X
with	B-X
Abs	B-X
recognizing	B-X
specific	B-X
components	B-X
of	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
protein	B-X
family	B-X
,	B-X
the	B-X
p50/p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
heterodimeric	B-X
form	B-X
of	B-X
NF-kappa	B-X
B	B-X
is	B-X
primarily	B-X
affected	B-X
.	B-X
The	B-X
maximal	B-X
effect	B-X
is	B-X
observed	B-X
at	B-X
the	B-X
IL-10	B-X
concentration	B-X
of	B-X
20	B-X
U/ml	B-X
.	B-X
IL-10	B-X
inhibitory	B-X
activity	B-X
is	B-X
exerted	B-X
on	B-X
T	B-X
lymphocytes	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
monocytes	B-X
.	B-X
Indeed	B-X
,	B-X
monocytes	B-X
pretreated	B-X
with	B-X
IL-10	B-X
are	B-X
able	B-X
so	B-X
inhibit	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
activity	B-X
in	B-X
purified	B-X
T	B-X
lymphocytes	B-X
stimulated	B-X
with	B-X
OKT3	B-X
.	B-X
Soluble	B-X
factors	B-X
do	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
inhibition	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
up-regulation	B-X
of	B-X
CD80	B-X
Ag	B-X
,	B-X
found	B-X
on	B-X
monocytes	B-X
obtained	B-X
from	B-X
PBMC	B-X
incubated	B-X
with	B-X
OKT3	B-X
,	B-X
is	B-X
not	B-X
detected	B-X
after	B-X
addition	B-X
of	B-X
IL-10	B-X
,	B-X
and	B-X
the	B-X
anti-CD28	B-X
mAb	B-X
CLB-CD28/1	B-X
restores	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
IL-10-inhibited	B-X
lymphocytes	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
inhibition	B-X
might	B-X
be	B-X
ascribed	B-X
to	B-X
a	B-X
lack	B-X
of	B-X
cooperation	B-X
between	B-X
accessory	B-X
cells	B-X
and	B-X
T	B-X
lymphocytes	B-X
,	B-X
resulting	B-X
from	B-X
down-regulation	B-X
of	B-X
a	B-X
costimulatory	B-X
molecule	B-X
,	B-X
such	B-X
as	B-X
CD80	B-X
,	B-X
produced	B-X
by	B-X
IL-10	B-X
on	B-X
activated	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
IL-10	B-X
can	B-X
inhibit	B-X
the	B-X
induction	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
CD3-stimulated	B-X
T	B-X
lymphocytes	B-X
.	B-X
Since	B-X
inappropriate	B-X
activation	B-X
of	B-X
kappa	B-X
B-driven	B-X
genes	B-X
has	B-X
a	B-X
physiopathologic	B-X
role	B-X
in	B-X
a	B-X
number	B-X
of	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
HIV	B-X
infection	B-X
,	B-X
our	B-X
findings	B-X
support	B-X
the	B-X
possibility	B-X
of	B-X
using	B-X
this	B-X
cytokine	B-X
to	B-X
suppress	B-X
an	B-X
undesirable	B-X
activation	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
.	B-X

The	O
inhibition	O
is	O
exerted	O
specifically	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
activation	O
induced	O
by	O
mAb	O
OKT3	O
,	O
and	O
not	O
that	O
produced	O
by	O
PMA	O
.	O

As	O
judged	O
by	O
supershifting	O
the	O
DNA	O
-	O
protein	O
complexes	O
with	O
Abs	O
recognizing	O
specific	O
components	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
protein	O
family	O
,	O
the	O
p50	B-Protein
/	O
p65	B-Protein
(	O
Rel	B-Protein
A	I-Protein
)	O
heterodimeric	O
form	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
primarily	O
affected	O
.	O
<EOS>	B-X
IL-10	B-X
markedly	B-X
reduces	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
induced	B-X
in	B-X
PBMC	B-X
by	B-X
stimulation	B-X
with	B-X
the	B-X
anti-CD3	B-X
mAb	B-X
OKT3	B-X
.	B-X
The	B-X
inhibition	B-X
is	B-X
exerted	B-X
specifically	B-X
on	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
activation	B-X
induced	B-X
by	B-X
mAb	B-X
OKT3	B-X
,	B-X
and	B-X
not	B-X
that	B-X
produced	B-X
by	B-X
PMA	B-X
.	B-X
As	B-X
judged	B-X
by	B-X
supershifting	B-X
the	B-X
DNA-protein	B-X
complexes	B-X
with	B-X
Abs	B-X
recognizing	B-X
specific	B-X
components	B-X
of	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
protein	B-X
family	B-X
,	B-X
the	B-X
p50/p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
heterodimeric	B-X
form	B-X
of	B-X
NF-kappa	B-X
B	B-X
is	B-X
primarily	B-X
affected	B-X
.	B-X
Indeed	B-X
,	B-X
monocytes	B-X
pretreated	B-X
with	B-X
IL-10	B-X
are	B-X
able	B-X
so	B-X
inhibit	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
activity	B-X
in	B-X
purified	B-X
T	B-X
lymphocytes	B-X
stimulated	B-X
with	B-X
OKT3	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
up-regulation	B-X
of	B-X
CD80	B-X
Ag	B-X
,	B-X
found	B-X
on	B-X
monocytes	B-X
obtained	B-X
from	B-X
PBMC	B-X
incubated	B-X
with	B-X
OKT3	B-X
,	B-X
is	B-X
not	B-X
detected	B-X
after	B-X
addition	B-X
of	B-X
IL-10	B-X
,	B-X
and	B-X
the	B-X
anti-CD28	B-X
mAb	B-X
CLB-CD28/1	B-X
restores	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
IL-10-inhibited	B-X
lymphocytes	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
inhibition	B-X
might	B-X
be	B-X
ascribed	B-X
to	B-X
a	B-X
lack	B-X
of	B-X
cooperation	B-X
between	B-X
accessory	B-X
cells	B-X
and	B-X
T	B-X
lymphocytes	B-X
,	B-X
resulting	B-X
from	B-X
down-regulation	B-X
of	B-X
a	B-X
costimulatory	B-X
molecule	B-X
,	B-X
such	B-X
as	B-X
CD80	B-X
,	B-X
produced	B-X
by	B-X
IL-10	B-X
on	B-X
activated	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
IL-10	B-X
can	B-X
inhibit	B-X
the	B-X
induction	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
CD3-stimulated	B-X
T	B-X
lymphocytes	B-X
.	B-X
Since	B-X
inappropriate	B-X
activation	B-X
of	B-X
kappa	B-X
B-driven	B-X
genes	B-X
has	B-X
a	B-X
physiopathologic	B-X
role	B-X
in	B-X
a	B-X
number	B-X
of	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
HIV	B-X
infection	B-X
,	B-X
our	B-X
findings	B-X
support	B-X
the	B-X
possibility	B-X
of	B-X
using	B-X
this	B-X
cytokine	B-X
to	B-X
suppress	B-X
an	B-X
undesirable	B-X
activation	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
.	B-X

The	O
maximal	O
effect	O
is	O
observed	O
at	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
concentration	O
of	O
20	O
U	O
/	O
ml	O
.	O
<EOS>	B-X
IL-10	B-X
markedly	B-X
reduces	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
induced	B-X
in	B-X
PBMC	B-X
by	B-X
stimulation	B-X
with	B-X
the	B-X
anti-CD3	B-X
mAb	B-X
OKT3	B-X
.	B-X
The	B-X
maximal	B-X
effect	B-X
is	B-X
observed	B-X
at	B-X
the	B-X
IL-10	B-X
concentration	B-X
of	B-X
20	B-X
U/ml	B-X
.	B-X
IL-10	B-X
inhibitory	B-X
activity	B-X
is	B-X
exerted	B-X
on	B-X
T	B-X
lymphocytes	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
monocytes	B-X
.	B-X
Indeed	B-X
,	B-X
monocytes	B-X
pretreated	B-X
with	B-X
IL-10	B-X
are	B-X
able	B-X
so	B-X
inhibit	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
activity	B-X
in	B-X
purified	B-X
T	B-X
lymphocytes	B-X
stimulated	B-X
with	B-X
OKT3	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
up-regulation	B-X
of	B-X
CD80	B-X
Ag	B-X
,	B-X
found	B-X
on	B-X
monocytes	B-X
obtained	B-X
from	B-X
PBMC	B-X
incubated	B-X
with	B-X
OKT3	B-X
,	B-X
is	B-X
not	B-X
detected	B-X
after	B-X
addition	B-X
of	B-X
IL-10	B-X
,	B-X
and	B-X
the	B-X
anti-CD28	B-X
mAb	B-X
CLB-CD28/1	B-X
restores	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
IL-10-inhibited	B-X
lymphocytes	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
inhibition	B-X
might	B-X
be	B-X
ascribed	B-X
to	B-X
a	B-X
lack	B-X
of	B-X
cooperation	B-X
between	B-X
accessory	B-X
cells	B-X
and	B-X
T	B-X
lymphocytes	B-X
,	B-X
resulting	B-X
from	B-X
down-regulation	B-X
of	B-X
a	B-X
costimulatory	B-X
molecule	B-X
,	B-X
such	B-X
as	B-X
CD80	B-X
,	B-X
produced	B-X
by	B-X
IL-10	B-X
on	B-X
activated	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
IL-10	B-X
can	B-X
inhibit	B-X
the	B-X
induction	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
CD3-stimulated	B-X
T	B-X
lymphocytes	B-X
.	B-X

IL	B-Protein
-	I-Protein
10	I-Protein
inhibitory	O
activity	O
is	O
exerted	O
on	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
monocytes	O
.	O

Indeed	O
,	O
monocytes	O
pretreated	O
with	O
IL	B-Protein
-	I-Protein
10	I-Protein
are	O
able	O
so	O
inhibit	O
NF	O
-	O
kappa	O
B	O
nuclear	O
activity	O
in	O
purified	O
T	O
lymphocytes	O
stimulated	O
with	O
OKT3	O
.	O
<EOS>	B-X
IL-10	B-X
markedly	B-X
reduces	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
induced	B-X
in	B-X
PBMC	B-X
by	B-X
stimulation	B-X
with	B-X
the	B-X
anti-CD3	B-X
mAb	B-X
OKT3	B-X
.	B-X
The	B-X
inhibition	B-X
is	B-X
exerted	B-X
specifically	B-X
on	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
activation	B-X
induced	B-X
by	B-X
mAb	B-X
OKT3	B-X
,	B-X
and	B-X
not	B-X
that	B-X
produced	B-X
by	B-X
PMA	B-X
.	B-X
As	B-X
judged	B-X
by	B-X
supershifting	B-X
the	B-X
DNA-protein	B-X
complexes	B-X
with	B-X
Abs	B-X
recognizing	B-X
specific	B-X
components	B-X
of	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
protein	B-X
family	B-X
,	B-X
the	B-X
p50/p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
heterodimeric	B-X
form	B-X
of	B-X
NF-kappa	B-X
B	B-X
is	B-X
primarily	B-X
affected	B-X
.	B-X
The	B-X
maximal	B-X
effect	B-X
is	B-X
observed	B-X
at	B-X
the	B-X
IL-10	B-X
concentration	B-X
of	B-X
20	B-X
U/ml	B-X
.	B-X
IL-10	B-X
inhibitory	B-X
activity	B-X
is	B-X
exerted	B-X
on	B-X
T	B-X
lymphocytes	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
monocytes	B-X
.	B-X
Indeed	B-X
,	B-X
monocytes	B-X
pretreated	B-X
with	B-X
IL-10	B-X
are	B-X
able	B-X
so	B-X
inhibit	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
activity	B-X
in	B-X
purified	B-X
T	B-X
lymphocytes	B-X
stimulated	B-X
with	B-X
OKT3	B-X
.	B-X
Soluble	B-X
factors	B-X
do	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
inhibition	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
up-regulation	B-X
of	B-X
CD80	B-X
Ag	B-X
,	B-X
found	B-X
on	B-X
monocytes	B-X
obtained	B-X
from	B-X
PBMC	B-X
incubated	B-X
with	B-X
OKT3	B-X
,	B-X
is	B-X
not	B-X
detected	B-X
after	B-X
addition	B-X
of	B-X
IL-10	B-X
,	B-X
and	B-X
the	B-X
anti-CD28	B-X
mAb	B-X
CLB-CD28/1	B-X
restores	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
IL-10-inhibited	B-X
lymphocytes	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
inhibition	B-X
might	B-X
be	B-X
ascribed	B-X
to	B-X
a	B-X
lack	B-X
of	B-X
cooperation	B-X
between	B-X
accessory	B-X
cells	B-X
and	B-X
T	B-X
lymphocytes	B-X
,	B-X
resulting	B-X
from	B-X
down-regulation	B-X
of	B-X
a	B-X
costimulatory	B-X
molecule	B-X
,	B-X
such	B-X
as	B-X
CD80	B-X
,	B-X
produced	B-X
by	B-X
IL-10	B-X
on	B-X
activated	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
IL-10	B-X
can	B-X
inhibit	B-X
the	B-X
induction	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
CD3-stimulated	B-X
T	B-X
lymphocytes	B-X
.	B-X
Since	B-X
inappropriate	B-X
activation	B-X
of	B-X
kappa	B-X
B-driven	B-X
genes	B-X
has	B-X
a	B-X
physiopathologic	B-X
role	B-X
in	B-X
a	B-X
number	B-X
of	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
HIV	B-X
infection	B-X
,	B-X
our	B-X
findings	B-X
support	B-X
the	B-X
possibility	B-X
of	B-X
using	B-X
this	B-X
cytokine	B-X
to	B-X
suppress	B-X
an	B-X
undesirable	B-X
activation	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
.	B-X

Soluble	O
factors	O
do	O
not	O
appear	O
to	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
inhibition	O
.	O
<EOS>	B-X
Drug	B-X
bioavailability	B-X
after	B-X
oral	B-X
administration	B-X
is	B-X
affected	B-X
by	B-X
anumber	B-X
of	B-X
different	B-X
factors	B-X
,	B-X
including	B-X
physicochemical	B-X
properties	B-X
of	B-X
the	B-X
drug	B-X
,	B-X
physiological	B-X
aspects	B-X
,	B-X
the	B-X
type	B-X
of	B-X
dosage	B-X
form	B-X
,	B-X
food	B-X
intake	B-X
,	B-X
biorhythms	B-X
,	B-X
and	B-X
intra-	B-X
and	B-X
interindividual	B-X
variability	B-X
of	B-X
the	B-X
human	B-X
population	B-X
.	B-X
Furthermore	B-X
,	B-X
this	B-X
review	B-X
also	B-X
presents	B-X
insights	B-X
into	B-X
the	B-X
factors	B-X
affecting	B-X
the	B-X
antisolvent	B-X
coprecipitation	B-X
process	B-X
.	B-X
This	B-X
article	B-X
also	B-X
describes	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
each	B-X
technique	B-X
used	B-X
in	B-X
solubilization	B-X
enhancement	B-X
.	B-X
Not	B-X
only	B-X
drug	B-X
substances	B-X
,	B-X
but	B-X
also	B-X
excipients	B-X
are	B-X
susceptible	B-X
to	B-X
different	B-X
degradation	B-X
mechanisms	B-X
.	B-X
We	B-X
will	B-X
also	B-X
illustrate	B-X
how	B-X
the	B-X
quality	B-X
of	B-X
a	B-X
solid	B-X
dosage	B-X
form	B-X
varies	B-X
with	B-X
time	B-X
under	B-X
the	B-X
influence	B-X
of	B-X
different	B-X
environmental	B-X
factors	B-X
.	B-X

On	O
the	O
other	O
hand	O
,	O
the	O
up	O
-	O
regulation	O
of	O
CD80	B-Protein
Ag	I-Protein
,	O
found	O
on	O
monocytes	O
obtained	O
from	O
PBMC	O
incubated	O
with	O
OKT3	O
,	O
is	O
not	O
detected	O
after	O
addition	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
and	O
the	O
anti	O
-	O
CD28	B-Protein
mAb	O
CLB	O
-	O
CD28	O
/	O
1	O
restores	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
inhibited	O
lymphocytes	O
.	O

Therefore	O
,	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
inhibition	O
might	O
be	O
ascribed	O
to	O
a	O
lack	O
of	O
cooperation	O
between	O
accessory	O
cells	O
and	O
T	O
lymphocytes	O
,	O
resulting	O
from	O
down	O
-	O
regulation	O
of	O
a	O
costimulatory	O
molecule	O
,	O
such	O
as	O
CD80	B-Protein
,	O
produced	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
on	O
activated	O
monocytes	O
.	O

Our	O
results	O
demonstrate	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
can	O
inhibit	O
the	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
CD3	O
-	O
stimulated	O
T	O
lymphocytes	O
.	O
<EOS>	B-X
IL-10	B-X
markedly	B-X
reduces	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
induced	B-X
in	B-X
PBMC	B-X
by	B-X
stimulation	B-X
with	B-X
the	B-X
anti-CD3	B-X
mAb	B-X
OKT3	B-X
.	B-X
The	B-X
inhibition	B-X
is	B-X
exerted	B-X
specifically	B-X
on	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
activation	B-X
induced	B-X
by	B-X
mAb	B-X
OKT3	B-X
,	B-X
and	B-X
not	B-X
that	B-X
produced	B-X
by	B-X
PMA	B-X
.	B-X
As	B-X
judged	B-X
by	B-X
supershifting	B-X
the	B-X
DNA-protein	B-X
complexes	B-X
with	B-X
Abs	B-X
recognizing	B-X
specific	B-X
components	B-X
of	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
protein	B-X
family	B-X
,	B-X
the	B-X
p50/p65	B-X
(	B-X
Rel	B-X
A	B-X
)	B-X
heterodimeric	B-X
form	B-X
of	B-X
NF-kappa	B-X
B	B-X
is	B-X
primarily	B-X
affected	B-X
.	B-X
The	B-X
maximal	B-X
effect	B-X
is	B-X
observed	B-X
at	B-X
the	B-X
IL-10	B-X
concentration	B-X
of	B-X
20	B-X
U/ml	B-X
.	B-X
IL-10	B-X
inhibitory	B-X
activity	B-X
is	B-X
exerted	B-X
on	B-X
T	B-X
lymphocytes	B-X
and	B-X
is	B-X
mediated	B-X
by	B-X
monocytes	B-X
.	B-X
Indeed	B-X
,	B-X
monocytes	B-X
pretreated	B-X
with	B-X
IL-10	B-X
are	B-X
able	B-X
so	B-X
inhibit	B-X
NF-kappa	B-X
B	B-X
nuclear	B-X
activity	B-X
in	B-X
purified	B-X
T	B-X
lymphocytes	B-X
stimulated	B-X
with	B-X
OKT3	B-X
.	B-X
Soluble	B-X
factors	B-X
do	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
inhibition	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
up-regulation	B-X
of	B-X
CD80	B-X
Ag	B-X
,	B-X
found	B-X
on	B-X
monocytes	B-X
obtained	B-X
from	B-X
PBMC	B-X
incubated	B-X
with	B-X
OKT3	B-X
,	B-X
is	B-X
not	B-X
detected	B-X
after	B-X
addition	B-X
of	B-X
IL-10	B-X
,	B-X
and	B-X
the	B-X
anti-CD28	B-X
mAb	B-X
CLB-CD28/1	B-X
restores	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
IL-10-inhibited	B-X
lymphocytes	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
inhibition	B-X
might	B-X
be	B-X
ascribed	B-X
to	B-X
a	B-X
lack	B-X
of	B-X
cooperation	B-X
between	B-X
accessory	B-X
cells	B-X
and	B-X
T	B-X
lymphocytes	B-X
,	B-X
resulting	B-X
from	B-X
down-regulation	B-X
of	B-X
a	B-X
costimulatory	B-X
molecule	B-X
,	B-X
such	B-X
as	B-X
CD80	B-X
,	B-X
produced	B-X
by	B-X
IL-10	B-X
on	B-X
activated	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
IL-10	B-X
can	B-X
inhibit	B-X
the	B-X
induction	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
nuclear	B-X
activity	B-X
in	B-X
CD3-stimulated	B-X
T	B-X
lymphocytes	B-X
.	B-X
Since	B-X
inappropriate	B-X
activation	B-X
of	B-X
kappa	B-X
B-driven	B-X
genes	B-X
has	B-X
a	B-X
physiopathologic	B-X
role	B-X
in	B-X
a	B-X
number	B-X
of	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
HIV	B-X
infection	B-X
,	B-X
our	B-X
findings	B-X
support	B-X
the	B-X
possibility	B-X
of	B-X
using	B-X
this	B-X
cytokine	B-X
to	B-X
suppress	B-X
an	B-X
undesirable	B-X
activation	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
.	B-X

Since	O
inappropriate	O
activation	O
of	O
kappa	O
B	O
-	O
driven	O
genes	O
has	O
a	O
physiopathologic	O
role	O
in	O
a	O
number	O
of	O
diseases	O
,	O
such	O
as	O
HIV	O
infection	O
,	O
our	O
findings	O
support	O
the	O
possibility	O
of	O
using	O
this	O
cytokine	O
to	O
suppress	O
an	O
undesirable	O
activation	O
of	O
these	O
transcription	O
factors	O
.	O

Vitamin	O
D3	O
-	O
and	O
retinoic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
:	O
interactions	O
between	O
the	O
endogenous	O
vitamin	B-Protein
D3	I-Protein
receptor	I-Protein
,	O
retinoic	O
acid	O
receptors	O
,	O
and	O
retinoid	O
X	O
receptors	O
in	O
U	O
-	O
937	O
cells	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
1,25	B-X
alpha-dihydroxycholecalciferol	B-X
(	B-X
VitD3	B-X
)	B-X
are	B-X
potent	B-X
regulators	B-X
of	B-X
hematopoletic	B-X
differentiation	B-X
.	B-X
Yet	B-X
,	B-X
little	B-X
is	B-X
known	B-X
as	B-X
to	B-X
how	B-X
the	B-X
RA	B-X
and	B-X
VitD3	B-X
receptor	B-X
network	B-X
operates	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
and	B-X
whether	B-X
receptor	B-X
interactions	B-X
can	B-X
explain	B-X
the	B-X
interplay	B-X
between	B-X
the	B-X
RA-	B-X
and	B-X
VitD3-signaling	B-X
pathways	B-X
during	B-X
differentiation	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
endogenous	B-X
RA	B-X
and	B-X
VitD3	B-X
receptors	B-X
[	B-X
retinoic	B-X
acid	B-X
receptors	B-X
(	B-X
RARs	B-X
)	B-X
,	B-X
retinoid	B-X
X	B-X
receptors	B-X
(	B-X
RXRs	B-X
)	B-X
,	B-X
and	B-X
VitD3	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
]	B-X
in	B-X
the	B-X
U-937	B-X
cell	B-X
line	B-X
,	B-X
in	B-X
which	B-X
RA	B-X
and	B-X
VitD3	B-X
induce	B-X
distinct	B-X
monocytic	B-X
differentiation	B-X
pathways	B-X
.	B-X
VitD3	B-X
induction	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VDR/RXR	B-X
DNA-binding	B-X
complexes	B-X
on	B-X
both	B-X
VitD3	B-X
response	B-X
elements	B-X
and	B-X
RA	B-X
response	B-X
elements	B-X
(	B-X
RAREs	B-X
)	B-X
.	B-X
However	B-X
,	B-X
transcriptional	B-X
activation	B-X
was	B-X
only	B-X
observed	B-X
from	B-X
a	B-X
VitD3	B-X
response	B-X
element-driven	B-X
reporter	B-X
construct	B-X
.	B-X
Several	B-X
DNA-binding	B-X
complexes	B-X
were	B-X
detected	B-X
on	B-X
RAREs	B-X
in	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Stimulation	B-X
by	B-X
RA	B-X
resulted	B-X
in	B-X
increased	B-X
RAR	B-X
beta/RXR	B-X
DNA	B-X
binding	B-X
,	B-X
activated	B-X
RARE-dependent	B-X
transcription	B-X
,	B-X
and	B-X
increased	B-X
expression	B-X
of	B-X
RAR-beta	B-X
.	B-X
Concomitant	B-X
stimulation	B-X
by	B-X
VitD3	B-X
inhibited	B-X
the	B-X
RA-stimulated	B-X
formation	B-X
of	B-X
RAR	B-X
beta/RXR	B-X
heterodimers	B-X
,	B-X
favoring	B-X
VDR/RXR	B-X
binding	B-X
to	B-X
the	B-X
RARE	B-X
.	B-X
Also	B-X
,	B-X
VitD3	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
CD23	B-X
and	B-X
CD49f	B-X
,	B-X
characteristic	B-X
markers	B-X
of	B-X
retinoid-induced	B-X
U-937	B-X
cell	B-X
differentiation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
neither	B-X
the	B-X
RA-stimulated	B-X
,	B-X
RARE-mediated	B-X
transcription	B-X
nor	B-X
the	B-X
induced	B-X
RAR-beta	B-X
expression	B-X
was	B-X
suppressed	B-X
by	B-X
VitD3	B-X
,	B-X
suggesting	B-X
that	B-X
VitD3	B-X
selectively	B-X
inhibited	B-X
the	B-X
retinoid-induced	B-X
differentiation	B-X
program	B-X
but	B-X
not	B-X
the	B-X
RARE-mediated	B-X
signal	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
complex	B-X
role	B-X
for	B-X
VitD3	B-X
in	B-X
modifying	B-X
the	B-X
retinoid	B-X
differentiation	B-X
pathway	B-X
and	B-X
may	B-X
have	B-X
implications	B-X
for	B-X
differentiation-inducing	B-X
therapy	B-X
of	B-X
hematopoietic	B-X
tumors	B-X
.	B-X

Retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25	O
alpha	O
-	O
dihydroxycholecalciferol	O
(	O
VitD3	O
)	O
are	O
potent	O
regulators	O
of	O
hematopoletic	O
differentiation	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
1,25	B-X
alpha-dihydroxycholecalciferol	B-X
(	B-X
VitD3	B-X
)	B-X
are	B-X
potent	B-X
regulators	B-X
of	B-X
hematopoletic	B-X
differentiation	B-X
.	B-X
Yet	B-X
,	B-X
little	B-X
is	B-X
known	B-X
as	B-X
to	B-X
how	B-X
the	B-X
RA	B-X
and	B-X
VitD3	B-X
receptor	B-X
network	B-X
operates	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
and	B-X
whether	B-X
receptor	B-X
interactions	B-X
can	B-X
explain	B-X
the	B-X
interplay	B-X
between	B-X
the	B-X
RA-	B-X
and	B-X
VitD3-signaling	B-X
pathways	B-X
during	B-X
differentiation	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
endogenous	B-X
RA	B-X
and	B-X
VitD3	B-X
receptors	B-X
[	B-X
retinoic	B-X
acid	B-X
receptors	B-X
(	B-X
RARs	B-X
)	B-X
,	B-X
retinoid	B-X
X	B-X
receptors	B-X
(	B-X
RXRs	B-X
)	B-X
,	B-X
and	B-X
VitD3	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
]	B-X
in	B-X
the	B-X
U-937	B-X
cell	B-X
line	B-X
,	B-X
in	B-X
which	B-X
RA	B-X
and	B-X
VitD3	B-X
induce	B-X
distinct	B-X
monocytic	B-X
differentiation	B-X
pathways	B-X
.	B-X
VitD3	B-X
induction	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VDR/RXR	B-X
DNA-binding	B-X
complexes	B-X
on	B-X
both	B-X
VitD3	B-X
response	B-X
elements	B-X
and	B-X
RA	B-X
response	B-X
elements	B-X
(	B-X
RAREs	B-X
)	B-X
.	B-X
However	B-X
,	B-X
transcriptional	B-X
activation	B-X
was	B-X
only	B-X
observed	B-X
from	B-X
a	B-X
VitD3	B-X
response	B-X
element-driven	B-X
reporter	B-X
construct	B-X
.	B-X
Several	B-X
DNA-binding	B-X
complexes	B-X
were	B-X
detected	B-X
on	B-X
RAREs	B-X
in	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Stimulation	B-X
by	B-X
RA	B-X
resulted	B-X
in	B-X
increased	B-X
RAR	B-X
beta/RXR	B-X
DNA	B-X
binding	B-X
,	B-X
activated	B-X
RARE-dependent	B-X
transcription	B-X
,	B-X
and	B-X
increased	B-X
expression	B-X
of	B-X
RAR-beta	B-X
.	B-X
Concomitant	B-X
stimulation	B-X
by	B-X
VitD3	B-X
inhibited	B-X
the	B-X
RA-stimulated	B-X
formation	B-X
of	B-X
RAR	B-X
beta/RXR	B-X
heterodimers	B-X
,	B-X
favoring	B-X
VDR/RXR	B-X
binding	B-X
to	B-X
the	B-X
RARE	B-X
.	B-X
Also	B-X
,	B-X
VitD3	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
CD23	B-X
and	B-X
CD49f	B-X
,	B-X
characteristic	B-X
markers	B-X
of	B-X
retinoid-induced	B-X
U-937	B-X
cell	B-X
differentiation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
neither	B-X
the	B-X
RA-stimulated	B-X
,	B-X
RARE-mediated	B-X
transcription	B-X
nor	B-X
the	B-X
induced	B-X
RAR-beta	B-X
expression	B-X
was	B-X
suppressed	B-X
by	B-X
VitD3	B-X
,	B-X
suggesting	B-X
that	B-X
VitD3	B-X
selectively	B-X
inhibited	B-X
the	B-X
retinoid-induced	B-X
differentiation	B-X
program	B-X
but	B-X
not	B-X
the	B-X
RARE-mediated	B-X
signal	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
complex	B-X
role	B-X
for	B-X
VitD3	B-X
in	B-X
modifying	B-X
the	B-X
retinoid	B-X
differentiation	B-X
pathway	B-X
and	B-X
may	B-X
have	B-X
implications	B-X
for	B-X
differentiation-inducing	B-X
therapy	B-X
of	B-X
hematopoietic	B-X
tumors	B-X
.	B-X

Yet	O
,	O
little	O
is	O
known	O
as	O
to	O
how	O
the	O
RA	O
and	O
VitD3	O
receptor	O
network	O
operates	O
in	O
hematopoietic	O
cells	O
,	O
and	O
whether	O
receptor	O
interactions	O
can	O
explain	O
the	O
interplay	O
between	O
the	O
RA	O
-	O
and	O
VitD3	O
-	O
signaling	O
pathways	O
during	O
differentiation	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
1,25	B-X
alpha-dihydroxycholecalciferol	B-X
(	B-X
VitD3	B-X
)	B-X
are	B-X
potent	B-X
regulators	B-X
of	B-X
hematopoletic	B-X
differentiation	B-X
.	B-X
Yet	B-X
,	B-X
little	B-X
is	B-X
known	B-X
as	B-X
to	B-X
how	B-X
the	B-X
RA	B-X
and	B-X
VitD3	B-X
receptor	B-X
network	B-X
operates	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
and	B-X
whether	B-X
receptor	B-X
interactions	B-X
can	B-X
explain	B-X
the	B-X
interplay	B-X
between	B-X
the	B-X
RA-	B-X
and	B-X
VitD3-signaling	B-X
pathways	B-X
during	B-X
differentiation	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
endogenous	B-X
RA	B-X
and	B-X
VitD3	B-X
receptors	B-X
[	B-X
retinoic	B-X
acid	B-X
receptors	B-X
(	B-X
RARs	B-X
)	B-X
,	B-X
retinoid	B-X
X	B-X
receptors	B-X
(	B-X
RXRs	B-X
)	B-X
,	B-X
and	B-X
VitD3	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
]	B-X
in	B-X
the	B-X
U-937	B-X
cell	B-X
line	B-X
,	B-X
in	B-X
which	B-X
RA	B-X
and	B-X
VitD3	B-X
induce	B-X
distinct	B-X
monocytic	B-X
differentiation	B-X
pathways	B-X
.	B-X
VitD3	B-X
induction	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VDR/RXR	B-X
DNA-binding	B-X
complexes	B-X
on	B-X
both	B-X
VitD3	B-X
response	B-X
elements	B-X
and	B-X
RA	B-X
response	B-X
elements	B-X
(	B-X
RAREs	B-X
)	B-X
.	B-X
However	B-X
,	B-X
transcriptional	B-X
activation	B-X
was	B-X
only	B-X
observed	B-X
from	B-X
a	B-X
VitD3	B-X
response	B-X
element-driven	B-X
reporter	B-X
construct	B-X
.	B-X
Several	B-X
DNA-binding	B-X
complexes	B-X
were	B-X
detected	B-X
on	B-X
RAREs	B-X
in	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Stimulation	B-X
by	B-X
RA	B-X
resulted	B-X
in	B-X
increased	B-X
RAR	B-X
beta/RXR	B-X
DNA	B-X
binding	B-X
,	B-X
activated	B-X
RARE-dependent	B-X
transcription	B-X
,	B-X
and	B-X
increased	B-X
expression	B-X
of	B-X
RAR-beta	B-X
.	B-X
Concomitant	B-X
stimulation	B-X
by	B-X
VitD3	B-X
inhibited	B-X
the	B-X
RA-stimulated	B-X
formation	B-X
of	B-X
RAR	B-X
beta/RXR	B-X
heterodimers	B-X
,	B-X
favoring	B-X
VDR/RXR	B-X
binding	B-X
to	B-X
the	B-X
RARE	B-X
.	B-X
Also	B-X
,	B-X
VitD3	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
CD23	B-X
and	B-X
CD49f	B-X
,	B-X
characteristic	B-X
markers	B-X
of	B-X
retinoid-induced	B-X
U-937	B-X
cell	B-X
differentiation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
neither	B-X
the	B-X
RA-stimulated	B-X
,	B-X
RARE-mediated	B-X
transcription	B-X
nor	B-X
the	B-X
induced	B-X
RAR-beta	B-X
expression	B-X
was	B-X
suppressed	B-X
by	B-X
VitD3	B-X
,	B-X
suggesting	B-X
that	B-X
VitD3	B-X
selectively	B-X
inhibited	B-X
the	B-X
retinoid-induced	B-X
differentiation	B-X
program	B-X
but	B-X
not	B-X
the	B-X
RARE-mediated	B-X
signal	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
complex	B-X
role	B-X
for	B-X
VitD3	B-X
in	B-X
modifying	B-X
the	B-X
retinoid	B-X
differentiation	B-X
pathway	B-X
and	B-X
may	B-X
have	B-X
implications	B-X
for	B-X
differentiation-inducing	B-X
therapy	B-X
of	B-X
hematopoietic	B-X
tumors	B-X
.	B-X

Therefore	O
,	O
we	O
analyzed	O
the	O
expression	O
,	O
DNA	O
binding	O
,	O
and	O
transcriptional	O
activity	O
of	O
the	O
endogenous	O
RA	O
and	O
VitD3	O
receptors	O
[	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
,	O
retinoid	O
X	O
receptors	O
(	O
RXRs	O
)	O
,	O
and	O
VitD3	B-Protein
receptor	I-Protein
(	O
VDR	B-Protein
)	O
]	O
in	O
the	O
U	O
-	O
937	O
cell	O
line	O
,	O
in	O
which	O
RA	O
and	O
VitD3	O
induce	O
distinct	O
monocytic	O
differentiation	O
pathways	O
.	O

VitD3	O
induction	O
resulted	O
in	O
the	O
formation	O
of	O
VDR	B-Protein
/	O
RXR	O
DNA	O
-	O
binding	O
complexes	O
on	O
both	O
VitD3	O
response	O
elements	O
and	O
RA	O
response	O
elements	O
(	O
RAREs	O
)	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
1,25	B-X
alpha-dihydroxycholecalciferol	B-X
(	B-X
VitD3	B-X
)	B-X
are	B-X
potent	B-X
regulators	B-X
of	B-X
hematopoletic	B-X
differentiation	B-X
.	B-X
Yet	B-X
,	B-X
little	B-X
is	B-X
known	B-X
as	B-X
to	B-X
how	B-X
the	B-X
RA	B-X
and	B-X
VitD3	B-X
receptor	B-X
network	B-X
operates	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
and	B-X
whether	B-X
receptor	B-X
interactions	B-X
can	B-X
explain	B-X
the	B-X
interplay	B-X
between	B-X
the	B-X
RA-	B-X
and	B-X
VitD3-signaling	B-X
pathways	B-X
during	B-X
differentiation	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
endogenous	B-X
RA	B-X
and	B-X
VitD3	B-X
receptors	B-X
[	B-X
retinoic	B-X
acid	B-X
receptors	B-X
(	B-X
RARs	B-X
)	B-X
,	B-X
retinoid	B-X
X	B-X
receptors	B-X
(	B-X
RXRs	B-X
)	B-X
,	B-X
and	B-X
VitD3	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
]	B-X
in	B-X
the	B-X
U-937	B-X
cell	B-X
line	B-X
,	B-X
in	B-X
which	B-X
RA	B-X
and	B-X
VitD3	B-X
induce	B-X
distinct	B-X
monocytic	B-X
differentiation	B-X
pathways	B-X
.	B-X
VitD3	B-X
induction	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VDR/RXR	B-X
DNA-binding	B-X
complexes	B-X
on	B-X
both	B-X
VitD3	B-X
response	B-X
elements	B-X
and	B-X
RA	B-X
response	B-X
elements	B-X
(	B-X
RAREs	B-X
)	B-X
.	B-X
However	B-X
,	B-X
transcriptional	B-X
activation	B-X
was	B-X
only	B-X
observed	B-X
from	B-X
a	B-X
VitD3	B-X
response	B-X
element-driven	B-X
reporter	B-X
construct	B-X
.	B-X
Several	B-X
DNA-binding	B-X
complexes	B-X
were	B-X
detected	B-X
on	B-X
RAREs	B-X
in	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Stimulation	B-X
by	B-X
RA	B-X
resulted	B-X
in	B-X
increased	B-X
RAR	B-X
beta/RXR	B-X
DNA	B-X
binding	B-X
,	B-X
activated	B-X
RARE-dependent	B-X
transcription	B-X
,	B-X
and	B-X
increased	B-X
expression	B-X
of	B-X
RAR-beta	B-X
.	B-X
Concomitant	B-X
stimulation	B-X
by	B-X
VitD3	B-X
inhibited	B-X
the	B-X
RA-stimulated	B-X
formation	B-X
of	B-X
RAR	B-X
beta/RXR	B-X
heterodimers	B-X
,	B-X
favoring	B-X
VDR/RXR	B-X
binding	B-X
to	B-X
the	B-X
RARE	B-X
.	B-X
Also	B-X
,	B-X
VitD3	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
CD23	B-X
and	B-X
CD49f	B-X
,	B-X
characteristic	B-X
markers	B-X
of	B-X
retinoid-induced	B-X
U-937	B-X
cell	B-X
differentiation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
neither	B-X
the	B-X
RA-stimulated	B-X
,	B-X
RARE-mediated	B-X
transcription	B-X
nor	B-X
the	B-X
induced	B-X
RAR-beta	B-X
expression	B-X
was	B-X
suppressed	B-X
by	B-X
VitD3	B-X
,	B-X
suggesting	B-X
that	B-X
VitD3	B-X
selectively	B-X
inhibited	B-X
the	B-X
retinoid-induced	B-X
differentiation	B-X
program	B-X
but	B-X
not	B-X
the	B-X
RARE-mediated	B-X
signal	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
complex	B-X
role	B-X
for	B-X
VitD3	B-X
in	B-X
modifying	B-X
the	B-X
retinoid	B-X
differentiation	B-X
pathway	B-X
and	B-X
may	B-X
have	B-X
implications	B-X
for	B-X
differentiation-inducing	B-X
therapy	B-X
of	B-X
hematopoietic	B-X
tumors	B-X
.	B-X

However	O
,	O
transcriptional	O
activation	O
was	O
only	O
observed	O
from	O
a	O
VitD3	O
response	O
element	O
-	O
driven	O
reporter	O
construct	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
1,25	B-X
alpha-dihydroxycholecalciferol	B-X
(	B-X
VitD3	B-X
)	B-X
are	B-X
potent	B-X
regulators	B-X
of	B-X
hematopoletic	B-X
differentiation	B-X
.	B-X
Yet	B-X
,	B-X
little	B-X
is	B-X
known	B-X
as	B-X
to	B-X
how	B-X
the	B-X
RA	B-X
and	B-X
VitD3	B-X
receptor	B-X
network	B-X
operates	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
and	B-X
whether	B-X
receptor	B-X
interactions	B-X
can	B-X
explain	B-X
the	B-X
interplay	B-X
between	B-X
the	B-X
RA-	B-X
and	B-X
VitD3-signaling	B-X
pathways	B-X
during	B-X
differentiation	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
endogenous	B-X
RA	B-X
and	B-X
VitD3	B-X
receptors	B-X
[	B-X
retinoic	B-X
acid	B-X
receptors	B-X
(	B-X
RARs	B-X
)	B-X
,	B-X
retinoid	B-X
X	B-X
receptors	B-X
(	B-X
RXRs	B-X
)	B-X
,	B-X
and	B-X
VitD3	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
]	B-X
in	B-X
the	B-X
U-937	B-X
cell	B-X
line	B-X
,	B-X
in	B-X
which	B-X
RA	B-X
and	B-X
VitD3	B-X
induce	B-X
distinct	B-X
monocytic	B-X
differentiation	B-X
pathways	B-X
.	B-X
VitD3	B-X
induction	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VDR/RXR	B-X
DNA-binding	B-X
complexes	B-X
on	B-X
both	B-X
VitD3	B-X
response	B-X
elements	B-X
and	B-X
RA	B-X
response	B-X
elements	B-X
(	B-X
RAREs	B-X
)	B-X
.	B-X
However	B-X
,	B-X
transcriptional	B-X
activation	B-X
was	B-X
only	B-X
observed	B-X
from	B-X
a	B-X
VitD3	B-X
response	B-X
element-driven	B-X
reporter	B-X
construct	B-X
.	B-X
Concomitant	B-X
stimulation	B-X
by	B-X
VitD3	B-X
inhibited	B-X
the	B-X
RA-stimulated	B-X
formation	B-X
of	B-X
RAR	B-X
beta/RXR	B-X
heterodimers	B-X
,	B-X
favoring	B-X
VDR/RXR	B-X
binding	B-X
to	B-X
the	B-X
RARE	B-X
.	B-X
Also	B-X
,	B-X
VitD3	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
CD23	B-X
and	B-X
CD49f	B-X
,	B-X
characteristic	B-X
markers	B-X
of	B-X
retinoid-induced	B-X
U-937	B-X
cell	B-X
differentiation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
neither	B-X
the	B-X
RA-stimulated	B-X
,	B-X
RARE-mediated	B-X
transcription	B-X
nor	B-X
the	B-X
induced	B-X
RAR-beta	B-X
expression	B-X
was	B-X
suppressed	B-X
by	B-X
VitD3	B-X
,	B-X
suggesting	B-X
that	B-X
VitD3	B-X
selectively	B-X
inhibited	B-X
the	B-X
retinoid-induced	B-X
differentiation	B-X
program	B-X
but	B-X
not	B-X
the	B-X
RARE-mediated	B-X
signal	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
complex	B-X
role	B-X
for	B-X
VitD3	B-X
in	B-X
modifying	B-X
the	B-X
retinoid	B-X
differentiation	B-X
pathway	B-X
and	B-X
may	B-X
have	B-X
implications	B-X
for	B-X
differentiation-inducing	B-X
therapy	B-X
of	B-X
hematopoietic	B-X
tumors	B-X
.	B-X

Several	O
DNA	O
-	O
binding	O
complexes	O
were	O
detected	O
on	O
RAREs	O
in	O
undifferentiated	O
cells	O
.	O
<EOS>	B-X
Yet	B-X
,	B-X
little	B-X
is	B-X
known	B-X
as	B-X
to	B-X
how	B-X
the	B-X
RA	B-X
and	B-X
VitD3	B-X
receptor	B-X
network	B-X
operates	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
and	B-X
whether	B-X
receptor	B-X
interactions	B-X
can	B-X
explain	B-X
the	B-X
interplay	B-X
between	B-X
the	B-X
RA-	B-X
and	B-X
VitD3-signaling	B-X
pathways	B-X
during	B-X
differentiation	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
endogenous	B-X
RA	B-X
and	B-X
VitD3	B-X
receptors	B-X
[	B-X
retinoic	B-X
acid	B-X
receptors	B-X
(	B-X
RARs	B-X
)	B-X
,	B-X
retinoid	B-X
X	B-X
receptors	B-X
(	B-X
RXRs	B-X
)	B-X
,	B-X
and	B-X
VitD3	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
]	B-X
in	B-X
the	B-X
U-937	B-X
cell	B-X
line	B-X
,	B-X
in	B-X
which	B-X
RA	B-X
and	B-X
VitD3	B-X
induce	B-X
distinct	B-X
monocytic	B-X
differentiation	B-X
pathways	B-X
.	B-X
VitD3	B-X
induction	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VDR/RXR	B-X
DNA-binding	B-X
complexes	B-X
on	B-X
both	B-X
VitD3	B-X
response	B-X
elements	B-X
and	B-X
RA	B-X
response	B-X
elements	B-X
(	B-X
RAREs	B-X
)	B-X
.	B-X
Several	B-X
DNA-binding	B-X
complexes	B-X
were	B-X
detected	B-X
on	B-X
RAREs	B-X
in	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Stimulation	B-X
by	B-X
RA	B-X
resulted	B-X
in	B-X
increased	B-X
RAR	B-X
beta/RXR	B-X
DNA	B-X
binding	B-X
,	B-X
activated	B-X
RARE-dependent	B-X
transcription	B-X
,	B-X
and	B-X
increased	B-X
expression	B-X
of	B-X
RAR-beta	B-X
.	B-X
Concomitant	B-X
stimulation	B-X
by	B-X
VitD3	B-X
inhibited	B-X
the	B-X
RA-stimulated	B-X
formation	B-X
of	B-X
RAR	B-X
beta/RXR	B-X
heterodimers	B-X
,	B-X
favoring	B-X
VDR/RXR	B-X
binding	B-X
to	B-X
the	B-X
RARE	B-X
.	B-X

Stimulation	O
by	O
RA	O
resulted	O
in	O
increased	O
RAR	B-Protein
beta	I-Protein
/	O
RXR	O
DNA	O
binding	O
,	O
activated	O
RARE	O
-	O
dependent	O
transcription	O
,	O
and	O
increased	O
expression	O
of	O
RAR	B-Protein
-	I-Protein
beta	I-Protein
.	O

Concomitant	O
stimulation	O
by	O
VitD3	O
inhibited	O
the	O
RA	O
-	O
stimulated	O
formation	O
of	O
RAR	B-Protein
beta	I-Protein
/	O
RXR	O
heterodimers	O
,	O
favoring	O
VDR	B-Protein
/	O
RXR	O
binding	O
to	O
the	O
RARE	O
.	O

Also	O
,	O
VitD3	O
inhibited	O
the	O
expression	O
of	O
CD23	B-Protein
and	O
CD49f	B-Protein
,	O
characteristic	O
markers	O
of	O
retinoid	O
-	O
induced	O
U	O
-	O
937	O
cell	O
differentiation	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
1,25	B-X
alpha-dihydroxycholecalciferol	B-X
(	B-X
VitD3	B-X
)	B-X
are	B-X
potent	B-X
regulators	B-X
of	B-X
hematopoletic	B-X
differentiation	B-X
.	B-X
Yet	B-X
,	B-X
little	B-X
is	B-X
known	B-X
as	B-X
to	B-X
how	B-X
the	B-X
RA	B-X
and	B-X
VitD3	B-X
receptor	B-X
network	B-X
operates	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
and	B-X
whether	B-X
receptor	B-X
interactions	B-X
can	B-X
explain	B-X
the	B-X
interplay	B-X
between	B-X
the	B-X
RA-	B-X
and	B-X
VitD3-signaling	B-X
pathways	B-X
during	B-X
differentiation	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
endogenous	B-X
RA	B-X
and	B-X
VitD3	B-X
receptors	B-X
[	B-X
retinoic	B-X
acid	B-X
receptors	B-X
(	B-X
RARs	B-X
)	B-X
,	B-X
retinoid	B-X
X	B-X
receptors	B-X
(	B-X
RXRs	B-X
)	B-X
,	B-X
and	B-X
VitD3	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
]	B-X
in	B-X
the	B-X
U-937	B-X
cell	B-X
line	B-X
,	B-X
in	B-X
which	B-X
RA	B-X
and	B-X
VitD3	B-X
induce	B-X
distinct	B-X
monocytic	B-X
differentiation	B-X
pathways	B-X
.	B-X
VitD3	B-X
induction	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VDR/RXR	B-X
DNA-binding	B-X
complexes	B-X
on	B-X
both	B-X
VitD3	B-X
response	B-X
elements	B-X
and	B-X
RA	B-X
response	B-X
elements	B-X
(	B-X
RAREs	B-X
)	B-X
.	B-X
However	B-X
,	B-X
transcriptional	B-X
activation	B-X
was	B-X
only	B-X
observed	B-X
from	B-X
a	B-X
VitD3	B-X
response	B-X
element-driven	B-X
reporter	B-X
construct	B-X
.	B-X
Several	B-X
DNA-binding	B-X
complexes	B-X
were	B-X
detected	B-X
on	B-X
RAREs	B-X
in	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Stimulation	B-X
by	B-X
RA	B-X
resulted	B-X
in	B-X
increased	B-X
RAR	B-X
beta/RXR	B-X
DNA	B-X
binding	B-X
,	B-X
activated	B-X
RARE-dependent	B-X
transcription	B-X
,	B-X
and	B-X
increased	B-X
expression	B-X
of	B-X
RAR-beta	B-X
.	B-X
Concomitant	B-X
stimulation	B-X
by	B-X
VitD3	B-X
inhibited	B-X
the	B-X
RA-stimulated	B-X
formation	B-X
of	B-X
RAR	B-X
beta/RXR	B-X
heterodimers	B-X
,	B-X
favoring	B-X
VDR/RXR	B-X
binding	B-X
to	B-X
the	B-X
RARE	B-X
.	B-X
Also	B-X
,	B-X
VitD3	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
CD23	B-X
and	B-X
CD49f	B-X
,	B-X
characteristic	B-X
markers	B-X
of	B-X
retinoid-induced	B-X
U-937	B-X
cell	B-X
differentiation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
neither	B-X
the	B-X
RA-stimulated	B-X
,	B-X
RARE-mediated	B-X
transcription	B-X
nor	B-X
the	B-X
induced	B-X
RAR-beta	B-X
expression	B-X
was	B-X
suppressed	B-X
by	B-X
VitD3	B-X
,	B-X
suggesting	B-X
that	B-X
VitD3	B-X
selectively	B-X
inhibited	B-X
the	B-X
retinoid-induced	B-X
differentiation	B-X
program	B-X
but	B-X
not	B-X
the	B-X
RARE-mediated	B-X
signal	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
complex	B-X
role	B-X
for	B-X
VitD3	B-X
in	B-X
modifying	B-X
the	B-X
retinoid	B-X
differentiation	B-X
pathway	B-X
and	B-X
may	B-X
have	B-X
implications	B-X
for	B-X
differentiation-inducing	B-X
therapy	B-X
of	B-X
hematopoietic	B-X
tumors	B-X
.	B-X

In	O
contrast	O
,	O
neither	O
the	O
RA	O
-	O
stimulated	O
,	O
RARE	O
-	O
mediated	O
transcription	O
nor	O
the	O
induced	O
RAR	B-Protein
-	I-Protein
beta	I-Protein
expression	O
was	O
suppressed	O
by	O
VitD3	O
,	O
suggesting	O
that	O
VitD3	O
selectively	O
inhibited	O
the	O
retinoid	O
-	O
induced	O
differentiation	O
program	O
but	O
not	O
the	O
RARE	O
-	O
mediated	O
signal	O
.	O

These	O
results	O
demonstrate	O
a	O
complex	O
role	O
for	O
VitD3	O
in	O
modifying	O
the	O
retinoid	O
differentiation	O
pathway	O
and	O
may	O
have	O
implications	O
for	O
differentiation	O
-	O
inducing	O
therapy	O
of	O
hematopoietic	O
tumors	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
and	B-X
1,25	B-X
alpha-dihydroxycholecalciferol	B-X
(	B-X
VitD3	B-X
)	B-X
are	B-X
potent	B-X
regulators	B-X
of	B-X
hematopoletic	B-X
differentiation	B-X
.	B-X
Yet	B-X
,	B-X
little	B-X
is	B-X
known	B-X
as	B-X
to	B-X
how	B-X
the	B-X
RA	B-X
and	B-X
VitD3	B-X
receptor	B-X
network	B-X
operates	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
and	B-X
whether	B-X
receptor	B-X
interactions	B-X
can	B-X
explain	B-X
the	B-X
interplay	B-X
between	B-X
the	B-X
RA-	B-X
and	B-X
VitD3-signaling	B-X
pathways	B-X
during	B-X
differentiation	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
expression	B-X
,	B-X
DNA	B-X
binding	B-X
,	B-X
and	B-X
transcriptional	B-X
activity	B-X
of	B-X
the	B-X
endogenous	B-X
RA	B-X
and	B-X
VitD3	B-X
receptors	B-X
[	B-X
retinoic	B-X
acid	B-X
receptors	B-X
(	B-X
RARs	B-X
)	B-X
,	B-X
retinoid	B-X
X	B-X
receptors	B-X
(	B-X
RXRs	B-X
)	B-X
,	B-X
and	B-X
VitD3	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
]	B-X
in	B-X
the	B-X
U-937	B-X
cell	B-X
line	B-X
,	B-X
in	B-X
which	B-X
RA	B-X
and	B-X
VitD3	B-X
induce	B-X
distinct	B-X
monocytic	B-X
differentiation	B-X
pathways	B-X
.	B-X
VitD3	B-X
induction	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
VDR/RXR	B-X
DNA-binding	B-X
complexes	B-X
on	B-X
both	B-X
VitD3	B-X
response	B-X
elements	B-X
and	B-X
RA	B-X
response	B-X
elements	B-X
(	B-X
RAREs	B-X
)	B-X
.	B-X
However	B-X
,	B-X
transcriptional	B-X
activation	B-X
was	B-X
only	B-X
observed	B-X
from	B-X
a	B-X
VitD3	B-X
response	B-X
element-driven	B-X
reporter	B-X
construct	B-X
.	B-X
Several	B-X
DNA-binding	B-X
complexes	B-X
were	B-X
detected	B-X
on	B-X
RAREs	B-X
in	B-X
undifferentiated	B-X
cells	B-X
.	B-X
Concomitant	B-X
stimulation	B-X
by	B-X
VitD3	B-X
inhibited	B-X
the	B-X
RA-stimulated	B-X
formation	B-X
of	B-X
RAR	B-X
beta/RXR	B-X
heterodimers	B-X
,	B-X
favoring	B-X
VDR/RXR	B-X
binding	B-X
to	B-X
the	B-X
RARE	B-X
.	B-X
Also	B-X
,	B-X
VitD3	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
CD23	B-X
and	B-X
CD49f	B-X
,	B-X
characteristic	B-X
markers	B-X
of	B-X
retinoid-induced	B-X
U-937	B-X
cell	B-X
differentiation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
neither	B-X
the	B-X
RA-stimulated	B-X
,	B-X
RARE-mediated	B-X
transcription	B-X
nor	B-X
the	B-X
induced	B-X
RAR-beta	B-X
expression	B-X
was	B-X
suppressed	B-X
by	B-X
VitD3	B-X
,	B-X
suggesting	B-X
that	B-X
VitD3	B-X
selectively	B-X
inhibited	B-X
the	B-X
retinoid-induced	B-X
differentiation	B-X
program	B-X
but	B-X
not	B-X
the	B-X
RARE-mediated	B-X
signal	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
a	B-X
complex	B-X
role	B-X
for	B-X
VitD3	B-X
in	B-X
modifying	B-X
the	B-X
retinoid	B-X
differentiation	B-X
pathway	B-X
and	B-X
may	B-X
have	B-X
implications	B-X
for	B-X
differentiation-inducing	B-X
therapy	B-X
of	B-X
hematopoietic	B-X
tumors	B-X
.	B-X

Calcium	O
-	O
dependent	O
immediate	O
-	O
early	O
gene	O
induction	O
in	O
lymphocytes	O
is	O
negatively	O
regulated	O
by	O
p21Ha	B-Protein
-	I-Protein
ras	I-Protein
.	O
<EOS>	B-X
The	B-X
induction	B-X
of	B-X
immediate-early	B-X
(	B-X
IE	B-X
)	B-X
response	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
egr-1	B-X
,	B-X
c-fos	B-X
,	B-X
and	B-X
c-jun	B-X
,	B-X
occurs	B-X
rapidly	B-X
after	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
.	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
,	B-X
a	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
factor	B-X
,	B-X
mediates	B-X
T-cell	B-X
signal	B-X
transduction	B-X
through	B-X
PKC-dependent	B-X
and	B-X
PKC-independent	B-X
pathways	B-X
.	B-X
The	B-X
involvement	B-X
of	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
calcium-dependent	B-X
signals	B-X
has	B-X
been	B-X
suggested	B-X
through	B-X
analysis	B-X
of	B-X
its	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
NF-AT	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
inductions	B-X
of	B-X
the	B-X
IE	B-X
genes	B-X
in	B-X
response	B-X
to	B-X
calcium	B-X
signals	B-X
in	B-X
Jurkat	B-X
cells	B-X
(	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
)	B-X
and	B-X
their	B-X
correlated	B-X
consequences	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
negatively	B-X
regulated	B-X
the	B-X
induction	B-X
of	B-X
IE	B-X
genes	B-X
by	B-X
calcium	B-X
ionophore	B-X
.	B-X
This	B-X
inhibition	B-X
of	B-X
calcium-activated	B-X
IE	B-X
gene	B-X
induction	B-X
was	B-X
reversed	B-X
by	B-X
treatment	B-X
with	B-X
cyclosporin	B-X
A	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
calcineurin	B-X
in	B-X
this	B-X
regulation	B-X
.	B-X
A	B-X
later	B-X
result	B-X
of	B-X
inhibition	B-X
of	B-X
this	B-X
activation	B-X
pathway	B-X
by	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
was	B-X
down-regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
AP-1	B-X
and	B-X
subsequent	B-X
coordinate	B-X
reductions	B-X
in	B-X
IL-2	B-X
gene	B-X
expression	B-X
and	B-X
protein	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p2l	B-X
(	B-X
ras	B-X
)	B-X
is	B-X
an	B-X
essential	B-X
mediator	B-X
in	B-X
generating	B-X
not	B-X
only	B-X
positive	B-X
but	B-X
also	B-X
negative	B-X
modulatory	B-X
mechanisms	B-X
controlling	B-X
the	B-X
competence	B-X
of	B-X
T	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
inductive	B-X
stimulations	B-X
.	B-X

The	O
induction	O
of	O
immediate	O
-	O
early	O
(	O
IE	O
)	O
response	O
genes	O
,	O
such	O
as	O
egr	B-Protein
-	I-Protein
1	I-Protein
,	O
c	B-Protein
-	I-Protein
fos	I-Protein
,	O
and	O
c	B-Protein
-	I-Protein
jun	I-Protein
,	O
occurs	O
rapidly	O
after	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O

The	O
process	O
of	O
activation	O
involves	O
calcium	O
mobilization	O
,	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
and	O
phosphorylation	O
of	O
tyrosine	O
kinases	O
.	O
<EOS>	B-X
The	B-X
L-type	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
channel	B-X
is	B-X
the	B-X
primary	B-X
voltage-dependent	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-influx	B-X
pathway	B-X
in	B-X
many	B-X
excitable	B-X
and	B-X
secretory	B-X
cells	B-X
,	B-X
and	B-X
direct	B-X
phosphorylation	B-X
by	B-X
different	B-X
kinases	B-X
is	B-X
one	B-X
of	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
its	B-X
activity	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
participation	B-X
of	B-X
Ser/Thr	B-X
kinases	B-X
and	B-X
tyrosine	B-X
kinases	B-X
(	B-X
TKs	B-X
)	B-X
in	B-X
depolarization-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
in	B-X
the	B-X
endocrine	B-X
somatomammotrope	B-X
cell	B-X
line	B-X
GH3	B-X
.	B-X
Intracellular	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
concentration	B-X
(	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
)	B-X
was	B-X
measured	B-X
using	B-X
a	B-X
spectrofluorometric	B-X
method	B-X
with	B-X
fura	B-X
2-AM	B-X
,	B-X
and	B-X
12.5	B-X
mM	B-X
KCl	B-X
(	B-X
K	B-X
(	B-X
+	B-X
)	B-X
)	B-X
was	B-X
used	B-X
as	B-X
a	B-X
depolarization	B-X
stimulus	B-X
.	B-X
K	B-X
(	B-X
+	B-X
)	B-X
induced	B-X
an	B-X
abrupt	B-X
spike	B-X
(	B-X
peak	B-X
)	B-X
in	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
that	B-X
was	B-X
abolished	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
nifedipine	B-X
,	B-X
showing	B-X
that	B-X
K	B-X
(	B-X
+	B-X
)	B-X
enhances	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
,	B-X
preferably	B-X
activating	B-X
L-type	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
channels	B-X
.	B-X
H89	B-X
,	B-X
a	B-X
selective	B-X
PKA	B-X
inhibitor	B-X
,	B-X
significantly	B-X
reduced	B-X
depolarization-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
mobilization	B-X
in	B-X
a	B-X
concentration-related	B-X
manner	B-X
when	B-X
it	B-X
was	B-X
applied	B-X
before	B-X
or	B-X
after	B-X
K	B-X
(	B-X
+	B-X
)	B-X
,	B-X
and	B-X
okadaic	B-X
acid	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
Ser/Thr	B-X
phosphatases	B-X
,	B-X
which	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
regulate	B-X
PKA-stimulated	B-X
L-type	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
channels	B-X
,	B-X
increased	B-X
K	B-X
(	B-X
+	B-X
)	B-X
-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
entry	B-X
.	B-X
When	B-X
PKC	B-X
was	B-X
activated	B-X
by	B-X
PMA	B-X
,	B-X
the	B-X
K	B-X
(	B-X
+	B-X
)	B-X
-evoked	B-X
peak	B-X
in	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
plateau	B-X
phase	B-X
,	B-X
was	B-X
significantly	B-X
reduced	B-X
,	B-X
and	B-X
chelerythrine	B-X
(	B-X
a	B-X
PKC	B-X
inhibitor	B-X
)	B-X
potentiated	B-X
the	B-X
K	B-X
(	B-X
+	B-X
)	B-X
-induced	B-X
increase	B-X
in	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
,	B-X
indicating	B-X
an	B-X
inhibitory	B-X
role	B-X
of	B-X
PKC	B-X
in	B-X
voltage-dependent	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
channel	B-X
(	B-X
VDCC	B-X
)	B-X
activity	B-X
.	B-X
Genistein	B-X
,	B-X
a	B-X
TK	B-X
inhibitor	B-X
,	B-X
reduced	B-X
the	B-X
K	B-X
(	B-X
+	B-X
)	B-X
-evoked	B-X
increase	B-X
in	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
,	B-X
but	B-X
,	B-X
unexpectedly	B-X
,	B-X
the	B-X
tyrosine	B-X
phosphatase	B-X
inhibitor	B-X
orthovanadate	B-X
reduced	B-X
not	B-X
only	B-X
basal	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
levels	B-X
but	B-X
,	B-X
also	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
during	B-X
the	B-X
plateau	B-X
phase	B-X
.	B-X
Both	B-X
results	B-X
suggest	B-X
that	B-X
different	B-X
TKs	B-X
may	B-X
act	B-X
differentially	B-X
on	B-X
VDCC	B-X
activation	B-X
.	B-X
Activation	B-X
of	B-X
receptor	B-X
TKs	B-X
with	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
or	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
potentiated	B-X
K	B-X
(	B-X
+	B-X
)	B-X
-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
,	B-X
and	B-X
AG-1478	B-X
(	B-X
an	B-X
EGF	B-X
receptor	B-X
inhibitor	B-X
)	B-X
decreased	B-X
it	B-X
.	B-X
However	B-X
,	B-X
inhibition	B-X
of	B-X
the	B-X
non-receptor	B-X
TK	B-X
pp60	B-X
c-Src	B-X
enhanced	B-X
K	B-X
(	B-X
+	B-X
)	B-X
-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
.	B-X
The	B-X
present	B-X
study	B-X
strongly	B-X
demonstrates	B-X
that	B-X
a	B-X
complex	B-X
equilibrium	B-X
among	B-X
different	B-X
kinases	B-X
and	B-X
phosphatases	B-X
regulates	B-X
VDCC	B-X
activity	B-X
in	B-X
the	B-X
pituitary	B-X
cell	B-X
line	B-X
GH3	B-X
:	B-X
PKA	B-X
and	B-X
receptor	B-X
TKs	B-X
,	B-X
such	B-X
as	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
receptor	B-X
and	B-X
EGF	B-X
receptor	B-X
,	B-X
enhance	B-X
depolarization-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
,	B-X
whereas	B-X
PKC	B-X
and	B-X
c-Src	B-X
have	B-X
an	B-X
inhibitory	B-X
effect	B-X
.	B-X
These	B-X
kinases	B-X
modulate	B-X
membrane	B-X
depolarization	B-X
and	B-X
may	B-X
therefore	B-X
participate	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
a	B-X
plethora	B-X
of	B-X
intracellular	B-X
processes	B-X
,	B-X
such	B-X
as	B-X
hormone	B-X
secretion	B-X
,	B-X
gene	B-X
expression	B-X
,	B-X
protein	B-X
synthesis	B-X
,	B-X
and	B-X
cell	B-X
proliferation	B-X
,	B-X
in	B-X
pituitary	B-X
cells	B-X
.	B-X

p21	B-Protein
(	I-Protein
ras	I-Protein
)	I-Protein
,	O
a	O
guanine	O
nucleotide	O
binding	O
factor	O
,	O
mediates	O
T	O
-	O
cell	O
signal	O
transduction	O
through	O
PKC	O
-	O
dependent	O
and	O
PKC	O
-	O
independent	O
pathways	O
.	O
<EOS>	B-X
The	B-X
process	B-X
of	B-X
activation	B-X
involves	B-X
calcium	B-X
mobilization	B-X
,	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
and	B-X
phosphorylation	B-X
of	B-X
tyrosine	B-X
kinases	B-X
.	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
,	B-X
a	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
factor	B-X
,	B-X
mediates	B-X
T-cell	B-X
signal	B-X
transduction	B-X
through	B-X
PKC-dependent	B-X
and	B-X
PKC-independent	B-X
pathways	B-X
.	B-X
The	B-X
involvement	B-X
of	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
calcium-dependent	B-X
signals	B-X
has	B-X
been	B-X
suggested	B-X
through	B-X
analysis	B-X
of	B-X
its	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
NF-AT	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
inductions	B-X
of	B-X
the	B-X
IE	B-X
genes	B-X
in	B-X
response	B-X
to	B-X
calcium	B-X
signals	B-X
in	B-X
Jurkat	B-X
cells	B-X
(	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
)	B-X
and	B-X
their	B-X
correlated	B-X
consequences	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
negatively	B-X
regulated	B-X
the	B-X
induction	B-X
of	B-X
IE	B-X
genes	B-X
by	B-X
calcium	B-X
ionophore	B-X
.	B-X
A	B-X
later	B-X
result	B-X
of	B-X
inhibition	B-X
of	B-X
this	B-X
activation	B-X
pathway	B-X
by	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
was	B-X
down-regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
AP-1	B-X
and	B-X
subsequent	B-X
coordinate	B-X
reductions	B-X
in	B-X
IL-2	B-X
gene	B-X
expression	B-X
and	B-X
protein	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p2l	B-X
(	B-X
ras	B-X
)	B-X
is	B-X
an	B-X
essential	B-X
mediator	B-X
in	B-X
generating	B-X
not	B-X
only	B-X
positive	B-X
but	B-X
also	B-X
negative	B-X
modulatory	B-X
mechanisms	B-X
controlling	B-X
the	B-X
competence	B-X
of	B-X
T	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
inductive	B-X
stimulations	B-X
.	B-X

The	O
involvement	O
of	O
p21	B-Protein
(	I-Protein
ras	I-Protein
)	I-Protein
in	O
the	O
regulation	O
of	O
calcium	O
-	O
dependent	O
signals	O
has	O
been	O
suggested	O
through	O
analysis	O
of	O
its	O
role	O
in	O
the	O
activation	O
of	O
NF	O
-	O
AT	O
.	O
<EOS>	B-X
The	B-X
induction	B-X
of	B-X
immediate-early	B-X
(	B-X
IE	B-X
)	B-X
response	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
egr-1	B-X
,	B-X
c-fos	B-X
,	B-X
and	B-X
c-jun	B-X
,	B-X
occurs	B-X
rapidly	B-X
after	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
process	B-X
of	B-X
activation	B-X
involves	B-X
calcium	B-X
mobilization	B-X
,	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
and	B-X
phosphorylation	B-X
of	B-X
tyrosine	B-X
kinases	B-X
.	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
,	B-X
a	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
factor	B-X
,	B-X
mediates	B-X
T-cell	B-X
signal	B-X
transduction	B-X
through	B-X
PKC-dependent	B-X
and	B-X
PKC-independent	B-X
pathways	B-X
.	B-X
The	B-X
involvement	B-X
of	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
calcium-dependent	B-X
signals	B-X
has	B-X
been	B-X
suggested	B-X
through	B-X
analysis	B-X
of	B-X
its	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
NF-AT	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
inductions	B-X
of	B-X
the	B-X
IE	B-X
genes	B-X
in	B-X
response	B-X
to	B-X
calcium	B-X
signals	B-X
in	B-X
Jurkat	B-X
cells	B-X
(	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
)	B-X
and	B-X
their	B-X
correlated	B-X
consequences	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
negatively	B-X
regulated	B-X
the	B-X
induction	B-X
of	B-X
IE	B-X
genes	B-X
by	B-X
calcium	B-X
ionophore	B-X
.	B-X
This	B-X
inhibition	B-X
of	B-X
calcium-activated	B-X
IE	B-X
gene	B-X
induction	B-X
was	B-X
reversed	B-X
by	B-X
treatment	B-X
with	B-X
cyclosporin	B-X
A	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
calcineurin	B-X
in	B-X
this	B-X
regulation	B-X
.	B-X
A	B-X
later	B-X
result	B-X
of	B-X
inhibition	B-X
of	B-X
this	B-X
activation	B-X
pathway	B-X
by	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
was	B-X
down-regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
AP-1	B-X
and	B-X
subsequent	B-X
coordinate	B-X
reductions	B-X
in	B-X
IL-2	B-X
gene	B-X
expression	B-X
and	B-X
protein	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p2l	B-X
(	B-X
ras	B-X
)	B-X
is	B-X
an	B-X
essential	B-X
mediator	B-X
in	B-X
generating	B-X
not	B-X
only	B-X
positive	B-X
but	B-X
also	B-X
negative	B-X
modulatory	B-X
mechanisms	B-X
controlling	B-X
the	B-X
competence	B-X
of	B-X
T	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
inductive	B-X
stimulations	B-X
.	B-X

We	O
have	O
investigated	O
the	O
inductions	O
of	O
the	O
IE	O
genes	O
in	O
response	O
to	O
calcium	O
signals	O
in	O
Jurkat	O
cells	O
(	O
in	O
the	O
presence	O
of	O
activated	O
p21	B-Protein
(	I-Protein
ras	I-Protein
)	I-Protein
)	O
and	O
their	O
correlated	O
consequences	O
.	O
<EOS>	B-X
The	B-X
induction	B-X
of	B-X
immediate-early	B-X
(	B-X
IE	B-X
)	B-X
response	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
egr-1	B-X
,	B-X
c-fos	B-X
,	B-X
and	B-X
c-jun	B-X
,	B-X
occurs	B-X
rapidly	B-X
after	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
process	B-X
of	B-X
activation	B-X
involves	B-X
calcium	B-X
mobilization	B-X
,	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
and	B-X
phosphorylation	B-X
of	B-X
tyrosine	B-X
kinases	B-X
.	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
,	B-X
a	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
factor	B-X
,	B-X
mediates	B-X
T-cell	B-X
signal	B-X
transduction	B-X
through	B-X
PKC-dependent	B-X
and	B-X
PKC-independent	B-X
pathways	B-X
.	B-X
The	B-X
involvement	B-X
of	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
calcium-dependent	B-X
signals	B-X
has	B-X
been	B-X
suggested	B-X
through	B-X
analysis	B-X
of	B-X
its	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
NF-AT	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
inductions	B-X
of	B-X
the	B-X
IE	B-X
genes	B-X
in	B-X
response	B-X
to	B-X
calcium	B-X
signals	B-X
in	B-X
Jurkat	B-X
cells	B-X
(	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
)	B-X
and	B-X
their	B-X
correlated	B-X
consequences	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
negatively	B-X
regulated	B-X
the	B-X
induction	B-X
of	B-X
IE	B-X
genes	B-X
by	B-X
calcium	B-X
ionophore	B-X
.	B-X
This	B-X
inhibition	B-X
of	B-X
calcium-activated	B-X
IE	B-X
gene	B-X
induction	B-X
was	B-X
reversed	B-X
by	B-X
treatment	B-X
with	B-X
cyclosporin	B-X
A	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
calcineurin	B-X
in	B-X
this	B-X
regulation	B-X
.	B-X
A	B-X
later	B-X
result	B-X
of	B-X
inhibition	B-X
of	B-X
this	B-X
activation	B-X
pathway	B-X
by	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
was	B-X
down-regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
AP-1	B-X
and	B-X
subsequent	B-X
coordinate	B-X
reductions	B-X
in	B-X
IL-2	B-X
gene	B-X
expression	B-X
and	B-X
protein	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p2l	B-X
(	B-X
ras	B-X
)	B-X
is	B-X
an	B-X
essential	B-X
mediator	B-X
in	B-X
generating	B-X
not	B-X
only	B-X
positive	B-X
but	B-X
also	B-X
negative	B-X
modulatory	B-X
mechanisms	B-X
controlling	B-X
the	B-X
competence	B-X
of	B-X
T	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
inductive	B-X
stimulations	B-X
.	B-X

The	O
expression	O
of	O
activated	O
p21	B-Protein
(	I-Protein
ras	I-Protein
)	I-Protein
negatively	O
regulated	O
the	O
induction	O
of	O
IE	O
genes	O
by	O
calcium	O
ionophore	O
.	O
<EOS>	B-X
The	B-X
induction	B-X
of	B-X
immediate-early	B-X
(	B-X
IE	B-X
)	B-X
response	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
egr-1	B-X
,	B-X
c-fos	B-X
,	B-X
and	B-X
c-jun	B-X
,	B-X
occurs	B-X
rapidly	B-X
after	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
process	B-X
of	B-X
activation	B-X
involves	B-X
calcium	B-X
mobilization	B-X
,	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
and	B-X
phosphorylation	B-X
of	B-X
tyrosine	B-X
kinases	B-X
.	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
,	B-X
a	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
factor	B-X
,	B-X
mediates	B-X
T-cell	B-X
signal	B-X
transduction	B-X
through	B-X
PKC-dependent	B-X
and	B-X
PKC-independent	B-X
pathways	B-X
.	B-X
The	B-X
involvement	B-X
of	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
calcium-dependent	B-X
signals	B-X
has	B-X
been	B-X
suggested	B-X
through	B-X
analysis	B-X
of	B-X
its	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
NF-AT	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
inductions	B-X
of	B-X
the	B-X
IE	B-X
genes	B-X
in	B-X
response	B-X
to	B-X
calcium	B-X
signals	B-X
in	B-X
Jurkat	B-X
cells	B-X
(	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
)	B-X
and	B-X
their	B-X
correlated	B-X
consequences	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
negatively	B-X
regulated	B-X
the	B-X
induction	B-X
of	B-X
IE	B-X
genes	B-X
by	B-X
calcium	B-X
ionophore	B-X
.	B-X
This	B-X
inhibition	B-X
of	B-X
calcium-activated	B-X
IE	B-X
gene	B-X
induction	B-X
was	B-X
reversed	B-X
by	B-X
treatment	B-X
with	B-X
cyclosporin	B-X
A	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
calcineurin	B-X
in	B-X
this	B-X
regulation	B-X
.	B-X
A	B-X
later	B-X
result	B-X
of	B-X
inhibition	B-X
of	B-X
this	B-X
activation	B-X
pathway	B-X
by	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
was	B-X
down-regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
AP-1	B-X
and	B-X
subsequent	B-X
coordinate	B-X
reductions	B-X
in	B-X
IL-2	B-X
gene	B-X
expression	B-X
and	B-X
protein	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p2l	B-X
(	B-X
ras	B-X
)	B-X
is	B-X
an	B-X
essential	B-X
mediator	B-X
in	B-X
generating	B-X
not	B-X
only	B-X
positive	B-X
but	B-X
also	B-X
negative	B-X
modulatory	B-X
mechanisms	B-X
controlling	B-X
the	B-X
competence	B-X
of	B-X
T	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
inductive	B-X
stimulations	B-X
.	B-X

This	O
inhibition	O
of	O
calcium	O
-	O
activated	O
IE	O
gene	O
induction	O
was	O
reversed	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
,	O
suggesting	O
the	O
involvement	O
of	O
calcineurin	O
in	O
this	O
regulation	O
.	O
<EOS>	B-X
The	B-X
induction	B-X
of	B-X
immediate-early	B-X
(	B-X
IE	B-X
)	B-X
response	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
egr-1	B-X
,	B-X
c-fos	B-X
,	B-X
and	B-X
c-jun	B-X
,	B-X
occurs	B-X
rapidly	B-X
after	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
process	B-X
of	B-X
activation	B-X
involves	B-X
calcium	B-X
mobilization	B-X
,	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
and	B-X
phosphorylation	B-X
of	B-X
tyrosine	B-X
kinases	B-X
.	B-X
The	B-X
involvement	B-X
of	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
calcium-dependent	B-X
signals	B-X
has	B-X
been	B-X
suggested	B-X
through	B-X
analysis	B-X
of	B-X
its	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
NF-AT	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
inductions	B-X
of	B-X
the	B-X
IE	B-X
genes	B-X
in	B-X
response	B-X
to	B-X
calcium	B-X
signals	B-X
in	B-X
Jurkat	B-X
cells	B-X
(	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
)	B-X
and	B-X
their	B-X
correlated	B-X
consequences	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
negatively	B-X
regulated	B-X
the	B-X
induction	B-X
of	B-X
IE	B-X
genes	B-X
by	B-X
calcium	B-X
ionophore	B-X
.	B-X
This	B-X
inhibition	B-X
of	B-X
calcium-activated	B-X
IE	B-X
gene	B-X
induction	B-X
was	B-X
reversed	B-X
by	B-X
treatment	B-X
with	B-X
cyclosporin	B-X
A	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
calcineurin	B-X
in	B-X
this	B-X
regulation	B-X
.	B-X
A	B-X
later	B-X
result	B-X
of	B-X
inhibition	B-X
of	B-X
this	B-X
activation	B-X
pathway	B-X
by	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
was	B-X
down-regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
AP-1	B-X
and	B-X
subsequent	B-X
coordinate	B-X
reductions	B-X
in	B-X
IL-2	B-X
gene	B-X
expression	B-X
and	B-X
protein	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p2l	B-X
(	B-X
ras	B-X
)	B-X
is	B-X
an	B-X
essential	B-X
mediator	B-X
in	B-X
generating	B-X
not	B-X
only	B-X
positive	B-X
but	B-X
also	B-X
negative	B-X
modulatory	B-X
mechanisms	B-X
controlling	B-X
the	B-X
competence	B-X
of	B-X
T	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
inductive	B-X
stimulations	B-X
.	B-X

A	O
later	O
result	O
of	O
inhibition	O
of	O
this	O
activation	O
pathway	O
by	O
p21	B-Protein
(	I-Protein
ras	I-Protein
)	O
was	O
down	O
-	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
and	O
subsequent	O
coordinate	O
reductions	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
expression	O
and	O
protein	O
production	O
.	O
<EOS>	B-X
The	B-X
induction	B-X
of	B-X
immediate-early	B-X
(	B-X
IE	B-X
)	B-X
response	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
egr-1	B-X
,	B-X
c-fos	B-X
,	B-X
and	B-X
c-jun	B-X
,	B-X
occurs	B-X
rapidly	B-X
after	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
process	B-X
of	B-X
activation	B-X
involves	B-X
calcium	B-X
mobilization	B-X
,	B-X
activation	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
and	B-X
phosphorylation	B-X
of	B-X
tyrosine	B-X
kinases	B-X
.	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
,	B-X
a	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
factor	B-X
,	B-X
mediates	B-X
T-cell	B-X
signal	B-X
transduction	B-X
through	B-X
PKC-dependent	B-X
and	B-X
PKC-independent	B-X
pathways	B-X
.	B-X
The	B-X
involvement	B-X
of	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
calcium-dependent	B-X
signals	B-X
has	B-X
been	B-X
suggested	B-X
through	B-X
analysis	B-X
of	B-X
its	B-X
role	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
NF-AT	B-X
.	B-X
We	B-X
have	B-X
investigated	B-X
the	B-X
inductions	B-X
of	B-X
the	B-X
IE	B-X
genes	B-X
in	B-X
response	B-X
to	B-X
calcium	B-X
signals	B-X
in	B-X
Jurkat	B-X
cells	B-X
(	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
)	B-X
and	B-X
their	B-X
correlated	B-X
consequences	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
activated	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
negatively	B-X
regulated	B-X
the	B-X
induction	B-X
of	B-X
IE	B-X
genes	B-X
by	B-X
calcium	B-X
ionophore	B-X
.	B-X
This	B-X
inhibition	B-X
of	B-X
calcium-activated	B-X
IE	B-X
gene	B-X
induction	B-X
was	B-X
reversed	B-X
by	B-X
treatment	B-X
with	B-X
cyclosporin	B-X
A	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
calcineurin	B-X
in	B-X
this	B-X
regulation	B-X
.	B-X
A	B-X
later	B-X
result	B-X
of	B-X
inhibition	B-X
of	B-X
this	B-X
activation	B-X
pathway	B-X
by	B-X
p21	B-X
(	B-X
ras	B-X
)	B-X
was	B-X
down-regulation	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
AP-1	B-X
and	B-X
subsequent	B-X
coordinate	B-X
reductions	B-X
in	B-X
IL-2	B-X
gene	B-X
expression	B-X
and	B-X
protein	B-X
production	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
p2l	B-X
(	B-X
ras	B-X
)	B-X
is	B-X
an	B-X
essential	B-X
mediator	B-X
in	B-X
generating	B-X
not	B-X
only	B-X
positive	B-X
but	B-X
also	B-X
negative	B-X
modulatory	B-X
mechanisms	B-X
controlling	B-X
the	B-X
competence	B-X
of	B-X
T	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
inductive	B-X
stimulations	B-X
.	B-X

These	O
results	O
suggest	O
that	O
p2l	B-Protein
(	I-Protein
ras	I-Protein
)	I-Protein
is	O
an	O
essential	O
mediator	O
in	O
generating	O
not	O
only	O
positive	O
but	O
also	O
negative	O
modulatory	O
mechanisms	O
controlling	O
the	O
competence	O
of	O
T	O
cells	O
in	O
response	O
to	O
inductive	O
stimulations	O
.	O

Apoptosis	O
signaling	O
pathways	O
in	O
normal	O
T	O
cells	O
:	O
differential	O
activity	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
on	O
glucocorticoid	O
-	O
and	O
Fas	B-Protein
-	O
mediated	O
cytotoxicity	O
.	O
<EOS>	B-X
Fas-mediated	B-X
apoptosis	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
immune	B-X
response	B-X
in	B-X
peripheral	B-X
T	B-X
cells	B-X
.	B-X
Restimulation	B-X
of	B-X
T	B-X
cell	B-X
blasts	B-X
up-regulates	B-X
Fas	B-X
and	B-X
Fas	B-X
ligand	B-X
expression	B-X
,	B-X
with	B-X
subsequent	B-X
interaction	B-X
leading	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
tumor	B-X
cells	B-X
blocks	B-X
apoptosis	B-X
induced	B-X
by	B-X
many	B-X
stimuli	B-X
,	B-X
but	B-X
inhibition	B-X
of	B-X
Fas-mediated	B-X
killing	B-X
has	B-X
not	B-X
been	B-X
consistently	B-X
observed	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
behavior	B-X
of	B-X
Bcl-2	B-X
in	B-X
normal	B-X
cells	B-X
,	B-X
T	B-X
cell	B-X
blasts	B-X
were	B-X
transiently	B-X
transfected	B-X
with	B-X
Bcl-2	B-X
and	B-X
related	B-X
gene	B-X
products	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
on	B-X
apoptotic	B-X
signaling	B-X
.	B-X
Transient	B-X
overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
mouse	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
blasts	B-X
did	B-X
not	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
whereas	B-X
etoposide-	B-X
and	B-X
glucocorticoid-induced	B-X
cytotoxicity	B-X
was	B-X
potently	B-X
inhibited	B-X
.	B-X
Expression	B-X
of	B-X
Bcl-xL	B-X
and	B-X
adenovirus	B-X
E1B	B-X
19K	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
anti-Fas	B-X
killing	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
interleukin-1beta-converting	B-X
enzyme	B-X
family	B-X
protease	B-X
inhibitors	B-X
Ac-DEVD-CHO	B-X
and	B-X
CrmA	B-X
blocked	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
peripheral	B-X
T	B-X
cells	B-X
use	B-X
distinct	B-X
apoptosis	B-X
signaling	B-X
pathways	B-X
with	B-X
differential	B-X
sensitivity	B-X
to	B-X
Bcl-2	B-X
and	B-X
interleukin-1beta-converting	B-X
enzyme	B-X
family	B-X
protease	B-X
inhibitors	B-X
.	B-X
Since	B-X
T	B-X
cells	B-X
normally	B-X
express	B-X
Bcl-2	B-X
and	B-X
Bcl-xL	B-X
following	B-X
activation	B-X
,	B-X
their	B-X
inability	B-X
to	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
may	B-X
allow	B-X
for	B-X
the	B-X
elimination	B-X
of	B-X
self-reactive	B-X
cells	B-X
and	B-X
the	B-X
appropriate	B-X
regulation	B-X
of	B-X
immune	B-X
responses	B-X
.	B-X

Fas	B-Protein
-	O
mediated	O
apoptosis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
peripheral	O
T	O
cells	O
.	O
<EOS>	B-X
In	B-X
CD4	B-X
T	B-X
cells	B-X
,	B-X
AICD	B-X
is	B-X
mediated	B-X
mainly	B-X
through	B-X
Fas/FasL	B-X
interactions	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
CD4	B-X
molecule	B-X
plays	B-X
an	B-X
essential	B-X
regulatory	B-X
role	B-X
of	B-X
TCR	B-X
dependent	B-X
AICD	B-X
.	B-X
The	B-X
resistance	B-X
of	B-X
CD4	B-X
negative	B-X
5kc	B-X
T	B-X
cells	B-X
to	B-X
AICD	B-X
was	B-X
due	B-X
to	B-X
selective	B-X
inhibition	B-X
of	B-X
FasL	B-X
expression	B-X
and	B-X
it	B-X
could	B-X
be	B-X
reversed	B-X
by	B-X
addition	B-X
of	B-X
recombinant	B-X
FasL	B-X
.	B-X
Furthermore	B-X
,	B-X
a	B-X
direct	B-X
functional	B-X
link	B-X
between	B-X
CD4	B-X
and	B-X
FasL	B-X
was	B-X
demonstrated	B-X
by	B-X
induction	B-X
of	B-X
FasL	B-X
upon	B-X
CD4	B-X
crosslinking	B-X
in	B-X
a	B-X
TCR	B-X
independent	B-X
fashion	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
CD4	B-X
interaction	B-X
with	B-X
MHC/peptide	B-X
complex	B-X
in	B-X
mediating	B-X
AICD	B-X
was	B-X
also	B-X
evident	B-X
in	B-X
normal	B-X
T	B-X
cells	B-X
that	B-X
could	B-X
survive	B-X
chronic	B-X
stimulation	B-X
with	B-X
anti-CD3	B-X
but	B-X
died	B-X
after	B-X
short	B-X
period	B-X
of	B-X
proliferation	B-X
after	B-X
stimulation	B-X
with	B-X
MHC/peptide	B-X
.	B-X
Thus	B-X
it	B-X
appears	B-X
that	B-X
AICD	B-X
is	B-X
controlled	B-X
by	B-X
the	B-X
CD4	B-X
molecule	B-X
via	B-X
regulation	B-X
of	B-X
FasL	B-X
expression	B-X
.	B-X
These	B-X
findings	B-X
have	B-X
important	B-X
implications	B-X
for	B-X
our	B-X
understanding	B-X
of	B-X
mechanisms	B-X
of	B-X
peripheral	B-X
tolerance	B-X
as	B-X
well	B-X
as	B-X
pathogenesis	B-X
of	B-X
autoimmune	B-X
diseases	B-X
.	B-X

Restimulation	O
of	O
T	O
cell	O
blasts	O
up	O
-	O
regulates	O
Fas	B-Protein
and	O
Fas	B-Protein
ligand	I-Protein
expression	O
,	O
with	O
subsequent	O
interaction	O
leading	O
to	O
cell	O
death	O
.	O
<EOS>	B-X
Fas-mediated	B-X
apoptosis	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
immune	B-X
response	B-X
in	B-X
peripheral	B-X
T	B-X
cells	B-X
.	B-X
Restimulation	B-X
of	B-X
T	B-X
cell	B-X
blasts	B-X
up-regulates	B-X
Fas	B-X
and	B-X
Fas	B-X
ligand	B-X
expression	B-X
,	B-X
with	B-X
subsequent	B-X
interaction	B-X
leading	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
tumor	B-X
cells	B-X
blocks	B-X
apoptosis	B-X
induced	B-X
by	B-X
many	B-X
stimuli	B-X
,	B-X
but	B-X
inhibition	B-X
of	B-X
Fas-mediated	B-X
killing	B-X
has	B-X
not	B-X
been	B-X
consistently	B-X
observed	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
behavior	B-X
of	B-X
Bcl-2	B-X
in	B-X
normal	B-X
cells	B-X
,	B-X
T	B-X
cell	B-X
blasts	B-X
were	B-X
transiently	B-X
transfected	B-X
with	B-X
Bcl-2	B-X
and	B-X
related	B-X
gene	B-X
products	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
on	B-X
apoptotic	B-X
signaling	B-X
.	B-X
Transient	B-X
overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
mouse	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
blasts	B-X
did	B-X
not	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
whereas	B-X
etoposide-	B-X
and	B-X
glucocorticoid-induced	B-X
cytotoxicity	B-X
was	B-X
potently	B-X
inhibited	B-X
.	B-X
Expression	B-X
of	B-X
Bcl-xL	B-X
and	B-X
adenovirus	B-X
E1B	B-X
19K	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
anti-Fas	B-X
killing	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
interleukin-1beta-converting	B-X
enzyme	B-X
family	B-X
protease	B-X
inhibitors	B-X
Ac-DEVD-CHO	B-X
and	B-X
CrmA	B-X
blocked	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
peripheral	B-X
T	B-X
cells	B-X
use	B-X
distinct	B-X
apoptosis	B-X
signaling	B-X
pathways	B-X
with	B-X
differential	B-X
sensitivity	B-X
to	B-X
Bcl-2	B-X
and	B-X
interleukin-1beta-converting	B-X
enzyme	B-X
family	B-X
protease	B-X
inhibitors	B-X
.	B-X
Since	B-X
T	B-X
cells	B-X
normally	B-X
express	B-X
Bcl-2	B-X
and	B-X
Bcl-xL	B-X
following	B-X
activation	B-X
,	B-X
their	B-X
inability	B-X
to	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
may	B-X
allow	B-X
for	B-X
the	B-X
elimination	B-X
of	B-X
self-reactive	B-X
cells	B-X
and	B-X
the	B-X
appropriate	B-X
regulation	B-X
of	B-X
immune	B-X
responses	B-X
.	B-X

Overexpression	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
in	O
tumor	O
cells	O
blocks	O
apoptosis	O
induced	O
by	O
many	O
stimuli	O
,	O
but	O
inhibition	O
of	O
Fas	B-Protein
-	O
mediated	O
killing	O
has	O
not	O
been	O
consistently	O
observed	O
.	O

To	O
examine	O
the	O
behavior	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
in	O
normal	O
cells	O
,	O
T	O
cell	O
blasts	O
were	O
transiently	O
transfected	O
with	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
and	O
related	O
gene	O
products	O
to	O
determine	O
the	O
effect	O
on	O
apoptotic	O
signaling	O
.	O
<EOS>	B-X
Fas-mediated	B-X
apoptosis	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
immune	B-X
response	B-X
in	B-X
peripheral	B-X
T	B-X
cells	B-X
.	B-X
Restimulation	B-X
of	B-X
T	B-X
cell	B-X
blasts	B-X
up-regulates	B-X
Fas	B-X
and	B-X
Fas	B-X
ligand	B-X
expression	B-X
,	B-X
with	B-X
subsequent	B-X
interaction	B-X
leading	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
tumor	B-X
cells	B-X
blocks	B-X
apoptosis	B-X
induced	B-X
by	B-X
many	B-X
stimuli	B-X
,	B-X
but	B-X
inhibition	B-X
of	B-X
Fas-mediated	B-X
killing	B-X
has	B-X
not	B-X
been	B-X
consistently	B-X
observed	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
behavior	B-X
of	B-X
Bcl-2	B-X
in	B-X
normal	B-X
cells	B-X
,	B-X
T	B-X
cell	B-X
blasts	B-X
were	B-X
transiently	B-X
transfected	B-X
with	B-X
Bcl-2	B-X
and	B-X
related	B-X
gene	B-X
products	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
on	B-X
apoptotic	B-X
signaling	B-X
.	B-X
Transient	B-X
overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
mouse	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
blasts	B-X
did	B-X
not	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
whereas	B-X
etoposide-	B-X
and	B-X
glucocorticoid-induced	B-X
cytotoxicity	B-X
was	B-X
potently	B-X
inhibited	B-X
.	B-X
Expression	B-X
of	B-X
Bcl-xL	B-X
and	B-X
adenovirus	B-X
E1B	B-X
19K	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
anti-Fas	B-X
killing	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
peripheral	B-X
T	B-X
cells	B-X
use	B-X
distinct	B-X
apoptosis	B-X
signaling	B-X
pathways	B-X
with	B-X
differential	B-X
sensitivity	B-X
to	B-X
Bcl-2	B-X
and	B-X
interleukin-1beta-converting	B-X
enzyme	B-X
family	B-X
protease	B-X
inhibitors	B-X
.	B-X
Since	B-X
T	B-X
cells	B-X
normally	B-X
express	B-X
Bcl-2	B-X
and	B-X
Bcl-xL	B-X
following	B-X
activation	B-X
,	B-X
their	B-X
inability	B-X
to	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
may	B-X
allow	B-X
for	B-X
the	B-X
elimination	B-X
of	B-X
self-reactive	B-X
cells	B-X
and	B-X
the	B-X
appropriate	B-X
regulation	B-X
of	B-X
immune	B-X
responses	B-X
.	B-X

Transient	O
overexpression	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
in	O
mouse	O
and	O
human	O
T	O
cell	O
blasts	O
did	O
not	O
block	O
Fas	B-Protein
-	O
mediated	O
apoptosis	O
,	O
whereas	O
etoposide	O
-	O
and	O
glucocorticoid	O
-	O
induced	O
cytotoxicity	O
was	O
potently	O
inhibited	O
.	O

Expression	O
of	O
Bcl	B-Protein
-	I-Protein
xL	I-Protein
and	O
adenovirus	O
E1B	B-Protein
19K	I-Protein
did	O
not	O
interfere	O
with	O
anti	O
-	O
Fas	B-Protein
killing	O
.	O
<EOS>	B-X
The	B-X
adenovirus	B-X
E1B	B-X
19K	B-X
protein	B-X
can	B-X
inhibit	B-X
apoptosis	B-X
induced	B-X
by	B-X
E1A	B-X
,	B-X
tumour-necrosis	B-X
factor-alpha	B-X
,	B-X
FAS	B-X
antigen	B-X
and	B-X
nerve	B-X
growth	B-X
factor	B-X
deprivation	B-X
.	B-X
The	B-X
molecular	B-X
basis	B-X
of	B-X
this	B-X
inhibition	B-X
remains	B-X
poorly	B-X
understood	B-X
,	B-X
but	B-X
the	B-X
fact	B-X
that	B-X
protection	B-X
is	B-X
seen	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
other	B-X
viral	B-X
proteins	B-X
suggests	B-X
that	B-X
E1B	B-X
19K	B-X
targets	B-X
cellular	B-X
proteins	B-X
.	B-X
We	B-X
report	B-X
here	B-X
the	B-X
identification	B-X
of	B-X
three	B-X
cellular	B-X
proteins	B-X
that	B-X
bind	B-X
E1B	B-X
19K	B-X
.	B-X
This	B-X
protein	B-X
,	B-X
which	B-X
is	B-X
expressed	B-X
in	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cell	B-X
types	B-X
,	B-X
binds	B-X
to	B-X
E1B	B-X
19K	B-X
and	B-X
to	B-X
the	B-X
Bcl-2	B-X
homologue	B-X
Bcl-XL	B-X
(	B-X
ref	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
overexpression	B-X
of	B-X
bak	B-X
in	B-X
sympathetic	B-X
neurons	B-X
deprived	B-X
of	B-X
nerve	B-X
growth	B-X
factor	B-X
accelerates	B-X
apoptosis	B-X
and	B-X
blocks	B-X
the	B-X
protective	B-X
effect	B-X
of	B-X
co-injected	B-X
E1B	B-X
19K	B-X
.	B-X

In	O
contrast	O
,	O
interleukin	O
-	O
1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac	O
-	O
DEVD	O
-	O
CHO	O
and	O
CrmA	O
blocked	O
Fas	B-Protein
-	O
mediated	O
apoptosis	O
.	O
<EOS>	B-X
Fas-mediated	B-X
apoptosis	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
immune	B-X
response	B-X
in	B-X
peripheral	B-X
T	B-X
cells	B-X
.	B-X
Restimulation	B-X
of	B-X
T	B-X
cell	B-X
blasts	B-X
up-regulates	B-X
Fas	B-X
and	B-X
Fas	B-X
ligand	B-X
expression	B-X
,	B-X
with	B-X
subsequent	B-X
interaction	B-X
leading	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
tumor	B-X
cells	B-X
blocks	B-X
apoptosis	B-X
induced	B-X
by	B-X
many	B-X
stimuli	B-X
,	B-X
but	B-X
inhibition	B-X
of	B-X
Fas-mediated	B-X
killing	B-X
has	B-X
not	B-X
been	B-X
consistently	B-X
observed	B-X
.	B-X
Transient	B-X
overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
mouse	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
blasts	B-X
did	B-X
not	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
whereas	B-X
etoposide-	B-X
and	B-X
glucocorticoid-induced	B-X
cytotoxicity	B-X
was	B-X
potently	B-X
inhibited	B-X
.	B-X
Expression	B-X
of	B-X
Bcl-xL	B-X
and	B-X
adenovirus	B-X
E1B	B-X
19K	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
anti-Fas	B-X
killing	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
interleukin-1beta-converting	B-X
enzyme	B-X
family	B-X
protease	B-X
inhibitors	B-X
Ac-DEVD-CHO	B-X
and	B-X
CrmA	B-X
blocked	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
peripheral	B-X
T	B-X
cells	B-X
use	B-X
distinct	B-X
apoptosis	B-X
signaling	B-X
pathways	B-X
with	B-X
differential	B-X
sensitivity	B-X
to	B-X
Bcl-2	B-X
and	B-X
interleukin-1beta-converting	B-X
enzyme	B-X
family	B-X
protease	B-X
inhibitors	B-X
.	B-X
Since	B-X
T	B-X
cells	B-X
normally	B-X
express	B-X
Bcl-2	B-X
and	B-X
Bcl-xL	B-X
following	B-X
activation	B-X
,	B-X
their	B-X
inability	B-X
to	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
may	B-X
allow	B-X
for	B-X
the	B-X
elimination	B-X
of	B-X
self-reactive	B-X
cells	B-X
and	B-X
the	B-X
appropriate	B-X
regulation	B-X
of	B-X
immune	B-X
responses	B-X
.	B-X

These	O
results	O
suggest	O
that	O
peripheral	O
T	O
cells	O
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
and	O
interleukin	B-Protein
-	I-Protein
1beta	I-Protein
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O
<EOS>	B-X
Fas-mediated	B-X
apoptosis	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
immune	B-X
response	B-X
in	B-X
peripheral	B-X
T	B-X
cells	B-X
.	B-X
Overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
tumor	B-X
cells	B-X
blocks	B-X
apoptosis	B-X
induced	B-X
by	B-X
many	B-X
stimuli	B-X
,	B-X
but	B-X
inhibition	B-X
of	B-X
Fas-mediated	B-X
killing	B-X
has	B-X
not	B-X
been	B-X
consistently	B-X
observed	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
behavior	B-X
of	B-X
Bcl-2	B-X
in	B-X
normal	B-X
cells	B-X
,	B-X
T	B-X
cell	B-X
blasts	B-X
were	B-X
transiently	B-X
transfected	B-X
with	B-X
Bcl-2	B-X
and	B-X
related	B-X
gene	B-X
products	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
on	B-X
apoptotic	B-X
signaling	B-X
.	B-X
Transient	B-X
overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
mouse	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
blasts	B-X
did	B-X
not	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
whereas	B-X
etoposide-	B-X
and	B-X
glucocorticoid-induced	B-X
cytotoxicity	B-X
was	B-X
potently	B-X
inhibited	B-X
.	B-X
Expression	B-X
of	B-X
Bcl-xL	B-X
and	B-X
adenovirus	B-X
E1B	B-X
19K	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
anti-Fas	B-X
killing	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
interleukin-1beta-converting	B-X
enzyme	B-X
family	B-X
protease	B-X
inhibitors	B-X
Ac-DEVD-CHO	B-X
and	B-X
CrmA	B-X
blocked	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
peripheral	B-X
T	B-X
cells	B-X
use	B-X
distinct	B-X
apoptosis	B-X
signaling	B-X
pathways	B-X
with	B-X
differential	B-X
sensitivity	B-X
to	B-X
Bcl-2	B-X
and	B-X
interleukin-1beta-converting	B-X
enzyme	B-X
family	B-X
protease	B-X
inhibitors	B-X
.	B-X
Since	B-X
T	B-X
cells	B-X
normally	B-X
express	B-X
Bcl-2	B-X
and	B-X
Bcl-xL	B-X
following	B-X
activation	B-X
,	B-X
their	B-X
inability	B-X
to	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
may	B-X
allow	B-X
for	B-X
the	B-X
elimination	B-X
of	B-X
self-reactive	B-X
cells	B-X
and	B-X
the	B-X
appropriate	B-X
regulation	B-X
of	B-X
immune	B-X
responses	B-X
.	B-X

Since	O
T	O
cells	O
normally	O
express	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
and	O
Bcl	B-Protein
-	I-Protein
xL	I-Protein
following	O
activation	O
,	O
their	O
inability	O
to	O
block	O
Fas	B-Protein
-	O
mediated	O
apoptosis	O
may	O
allow	O
for	O
the	O
elimination	O
of	O
self	O
-	O
reactive	O
cells	O
and	O
the	O
appropriate	O
regulation	O
of	O
immune	O
responses	O
.	O
<EOS>	B-X
Fas-mediated	B-X
apoptosis	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
the	B-X
immune	B-X
response	B-X
in	B-X
peripheral	B-X
T	B-X
cells	B-X
.	B-X
Restimulation	B-X
of	B-X
T	B-X
cell	B-X
blasts	B-X
up-regulates	B-X
Fas	B-X
and	B-X
Fas	B-X
ligand	B-X
expression	B-X
,	B-X
with	B-X
subsequent	B-X
interaction	B-X
leading	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
Overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
tumor	B-X
cells	B-X
blocks	B-X
apoptosis	B-X
induced	B-X
by	B-X
many	B-X
stimuli	B-X
,	B-X
but	B-X
inhibition	B-X
of	B-X
Fas-mediated	B-X
killing	B-X
has	B-X
not	B-X
been	B-X
consistently	B-X
observed	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
behavior	B-X
of	B-X
Bcl-2	B-X
in	B-X
normal	B-X
cells	B-X
,	B-X
T	B-X
cell	B-X
blasts	B-X
were	B-X
transiently	B-X
transfected	B-X
with	B-X
Bcl-2	B-X
and	B-X
related	B-X
gene	B-X
products	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
on	B-X
apoptotic	B-X
signaling	B-X
.	B-X
Transient	B-X
overexpression	B-X
of	B-X
Bcl-2	B-X
in	B-X
mouse	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
blasts	B-X
did	B-X
not	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
,	B-X
whereas	B-X
etoposide-	B-X
and	B-X
glucocorticoid-induced	B-X
cytotoxicity	B-X
was	B-X
potently	B-X
inhibited	B-X
.	B-X
Expression	B-X
of	B-X
Bcl-xL	B-X
and	B-X
adenovirus	B-X
E1B	B-X
19K	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
anti-Fas	B-X
killing	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
interleukin-1beta-converting	B-X
enzyme	B-X
family	B-X
protease	B-X
inhibitors	B-X
Ac-DEVD-CHO	B-X
and	B-X
CrmA	B-X
blocked	B-X
Fas-mediated	B-X
apoptosis	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
peripheral	B-X
T	B-X
cells	B-X
use	B-X
distinct	B-X
apoptosis	B-X
signaling	B-X
pathways	B-X
with	B-X
differential	B-X
sensitivity	B-X
to	B-X
Bcl-2	B-X
and	B-X
interleukin-1beta-converting	B-X
enzyme	B-X
family	B-X
protease	B-X
inhibitors	B-X
.	B-X
Since	B-X
T	B-X
cells	B-X
normally	B-X
express	B-X
Bcl-2	B-X
and	B-X
Bcl-xL	B-X
following	B-X
activation	B-X
,	B-X
their	B-X
inability	B-X
to	B-X
block	B-X
Fas-mediated	B-X
apoptosis	B-X
may	B-X
allow	B-X
for	B-X
the	B-X
elimination	B-X
of	B-X
self-reactive	B-X
cells	B-X
and	B-X
the	B-X
appropriate	B-X
regulation	B-X
of	B-X
immune	B-X
responses	B-X
.	B-X

Interferons	O
induce	O
normal	O
and	O
aberrant	O
retinoic	B-Protein
-	I-Protein
acid	I-Protein
receptors	I-Protein
type	I-Protein
alpha	I-Protein
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
:	O
potentiation	O
of	O
the	O
induction	O
of	O
retinoid	O
-	O
dependent	O
differentiation	O
markers	O
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
the	B-X
acute	B-X
promyelocytic	B-X
(	B-X
APL	B-X
)	B-X
cell	B-X
line	B-X
NB4	B-X
with	B-X
interferon	B-X
alpha	B-X
(	B-X
IFN	B-X
(	B-X
alpha	B-X
)	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
IFN	B-X
(	B-X
beta	B-X
)	B-X
and	B-X
gamma	B-X
,	B-X
results	B-X
in	B-X
an	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
transcripts	B-X
coding	B-X
for	B-X
retinoic-acid	B-X
receptor	B-X
type	B-X
alpha	B-X
(	B-X
RAR	B-X
(	B-X
alpha	B-X
)	B-X
)	B-X
and	B-X
the	B-X
leukemia-specific	B-X
retinoic	B-X
acid	B-X
receptor	B-X
PML-RAR	B-X
.	B-X
Transcriptional	B-X
induction	B-X
of	B-X
the	B-X
RAR	B-X
(	B-X
alpha	B-X
)	B-X
and	B-X
PML-RAR	B-X
mRNAs	B-X
is	B-X
rapid	B-X
and	B-X
it	B-X
is	B-X
parallelled	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
corresponding	B-X
proteins	B-X
.	B-X
Up-regulation	B-X
of	B-X
RAR	B-X
(	B-X
alpha	B-X
)	B-X
and	B-X
PML-RAR	B-X
gene	B-X
expression	B-X
by	B-X
IFN	B-X
(	B-X
alpha	B-X
)	B-X
is	B-X
accompanied	B-X
by	B-X
a	B-X
strong	B-X
potentiation	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
2	B-X
retinoid-dependent	B-X
granulocytic	B-X
markers	B-X
,	B-X
i.e.	B-X
,	B-X
granulocyte-colony-stimulating	B-X
factor	B-X
receptor	B-X
mRNA	B-X
and	B-X
leukocyte	B-X
alkaline	B-X
phosphatase	B-X
.	B-X
However	B-X
,	B-X
IFN	B-X
(	B-X
alpha	B-X
)	B-X
does	B-X
not	B-X
have	B-X
any	B-X
effects	B-X
on	B-X
the	B-X
retinoid-dependent	B-X
regulation	B-X
of	B-X
the	B-X
myeloid	B-X
surface	B-X
markers	B-X
CD11b	B-X
and	B-X
CD33	B-X
.	B-X
The	B-X
IFN-dependent	B-X
increase	B-X
in	B-X
RAR	B-X
(	B-X
alpha	B-X
)	B-X
levels	B-X
and	B-X
the	B-X
enhancing	B-X
effect	B-X
of	B-X
the	B-X
cytokine	B-X
on	B-X
retinoid-dependent	B-X
granulocytic	B-X
markers	B-X
expression	B-X
may	B-X
be	B-X
a	B-X
characteristic	B-X
of	B-X
PML-RAR	B-X
positive	B-X
cells	B-X
,	B-X
since	B-X
the	B-X
phenomena	B-X
are	B-X
not	B-X
observed	B-X
in	B-X
HL-60	B-X
promyelocytes	B-X
.	B-X
Interferons	B-X
as	B-X
well	B-X
as	B-X
retinoids	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
NB4	B-X
cells	B-X
,	B-X
although	B-X
the	B-X
2	B-X
classes	B-X
of	B-X
compounds	B-X
do	B-X
not	B-X
significantly	B-X
interact	B-X
in	B-X
terms	B-X
of	B-X
anti-proliferative	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
the	B-X
possible	B-X
use	B-X
of	B-X
combinations	B-X
between	B-X
IFNs	B-X
and	B-X
retinoic	B-X
acid	B-X
in	B-X
the	B-X
cyto-differentiating	B-X
treatment	B-X
of	B-X
APL	B-X
patients	B-X
.	B-X

Treatment	O
of	O
the	O
acute	O
promyelocytic	O
(	O
APL	O
)	O
cell	O
line	O
NB4	O
with	O
interferon	O
alpha	O
(	O
IFN	O
(	O
alpha	O
)	O
)	O
,	O
as	O
well	O
as	O
IFN	O
(	O
beta	O
)	O
and	O
gamma	O
,	O
results	O
in	O
an	O
increased	O
expression	O
of	O
the	O
transcripts	O
coding	O
for	O
retinoic	B-Protein
-	I-Protein
acid	I-Protein
receptor	I-Protein
type	I-Protein
alpha	I-Protein
(	O
RAR	B-Protein
(	I-Protein
alpha	I-Protein
)	I-Protein
)	O
and	O
the	O
leukemia	B-Protein
-	I-Protein
specific	I-Protein
retinoic	I-Protein
acid	I-Protein
receptor	I-Protein
PML	B-Protein
-	I-Protein
RAR	I-Protein
.	O

Transcriptional	O
induction	O
of	O
the	O
RAR	B-Protein
(	I-Protein
alpha	I-Protein
)	I-Protein
and	O
PML	B-Protein
-	I-Protein
RAR	I-Protein
mRNAs	O
is	O
rapid	O
and	O
it	O
is	O
parallelled	O
by	O
an	O
increase	O
in	O
the	O
corresponding	O
proteins	O
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
the	B-X
acute	B-X
promyelocytic	B-X
(	B-X
APL	B-X
)	B-X
cell	B-X
line	B-X
NB4	B-X
with	B-X
interferon	B-X
alpha	B-X
(	B-X
IFN	B-X
(	B-X
alpha	B-X
)	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
IFN	B-X
(	B-X
beta	B-X
)	B-X
and	B-X
gamma	B-X
,	B-X
results	B-X
in	B-X
an	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
transcripts	B-X
coding	B-X
for	B-X
retinoic-acid	B-X
receptor	B-X
type	B-X
alpha	B-X
(	B-X
RAR	B-X
(	B-X
alpha	B-X
)	B-X
)	B-X
and	B-X
the	B-X
leukemia-specific	B-X
retinoic	B-X
acid	B-X
receptor	B-X
PML-RAR	B-X
.	B-X
Transcriptional	B-X
induction	B-X
of	B-X
the	B-X
RAR	B-X
(	B-X
alpha	B-X
)	B-X
and	B-X
PML-RAR	B-X
mRNAs	B-X
is	B-X
rapid	B-X
and	B-X
it	B-X
is	B-X
parallelled	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
corresponding	B-X
proteins	B-X
.	B-X
Up-regulation	B-X
of	B-X
RAR	B-X
(	B-X
alpha	B-X
)	B-X
and	B-X
PML-RAR	B-X
gene	B-X
expression	B-X
by	B-X
IFN	B-X
(	B-X
alpha	B-X
)	B-X
is	B-X
accompanied	B-X
by	B-X
a	B-X
strong	B-X
potentiation	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
2	B-X
retinoid-dependent	B-X
granulocytic	B-X
markers	B-X
,	B-X
i.e.	B-X
,	B-X
granulocyte-colony-stimulating	B-X
factor	B-X
receptor	B-X
mRNA	B-X
and	B-X
leukocyte	B-X
alkaline	B-X
phosphatase	B-X
.	B-X
However	B-X
,	B-X
IFN	B-X
(	B-X
alpha	B-X
)	B-X
does	B-X
not	B-X
have	B-X
any	B-X
effects	B-X
on	B-X
the	B-X
retinoid-dependent	B-X
regulation	B-X
of	B-X
the	B-X
myeloid	B-X
surface	B-X
markers	B-X
CD11b	B-X
and	B-X
CD33	B-X
.	B-X
The	B-X
IFN-dependent	B-X
increase	B-X
in	B-X
RAR	B-X
(	B-X
alpha	B-X
)	B-X
levels	B-X
and	B-X
the	B-X
enhancing	B-X
effect	B-X
of	B-X
the	B-X
cytokine	B-X
on	B-X
retinoid-dependent	B-X
granulocytic	B-X
markers	B-X
expression	B-X
may	B-X
be	B-X
a	B-X
characteristic	B-X
of	B-X
PML-RAR	B-X
positive	B-X
cells	B-X
,	B-X
since	B-X
the	B-X
phenomena	B-X
are	B-X
not	B-X
observed	B-X
in	B-X
HL-60	B-X
promyelocytes	B-X
.	B-X

Up	O
-	O
regulation	O
of	O
RAR	B-Protein
(	I-Protein
alpha	I-Protein
)	I-Protein
and	O
PML	B-Protein
-	I-Protein
RAR	I-Protein
gene	O
expression	O
by	O
IFN	O
(	O
alpha	O
)	O
is	O
accompanied	O
by	O
a	O
strong	O
potentiation	O
in	O
the	O
induction	O
of	O
2	O
retinoid	O
-	O
dependent	O
granulocytic	O
markers	O
,	O
i	O
.	O
e	O
.	O
,	O
granulocyte	B-Protein
-	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
receptor	I-Protein
mRNA	O
and	O
leukocyte	B-Protein
alkaline	I-Protein
phosphatase	I-Protein
.	O

However	O
,	O
IFN	O
(	O
alpha	O
)	O
does	O
not	O
have	O
any	O
effects	O
on	O
the	O
retinoid	O
-	O
dependent	O
regulation	O
of	O
the	O
myeloid	O
surface	O
markers	O
CD11b	B-Protein
and	O
CD33	B-Protein
.	O
<EOS>	B-X
Most	B-X
studies	B-X
have	B-X
emphasized	B-X
the	B-X
important	B-X
role	B-X
of	B-X
IFN-α	B-X
in	B-X
SLE	B-X
,	B-X
but	B-X
our	B-X
previous	B-X
study	B-X
suggested	B-X
a	B-X
nonnegligible	B-X
role	B-X
of	B-X
IFN-γ	B-X
in	B-X
SLE	B-X
.	B-X
Some	B-X
scholars	B-X
previously	B-X
found	B-X
that	B-X
IFN-γ	B-X
is	B-X
abnormally	B-X
elevated	B-X
as	B-X
early	B-X
as	B-X
before	B-X
the	B-X
classification	B-X
of	B-X
SLE	B-X
and	B-X
before	B-X
the	B-X
emergence	B-X
of	B-X
autoantibodies	B-X
and	B-X
IFN-α	B-X
.	B-X
Due	B-X
to	B-X
the	B-X
large	B-X
overlap	B-X
between	B-X
IFN-α	B-X
and	B-X
IFN-γ	B-X
,	B-X
SLE	B-X
is	B-X
mostly	B-X
characterized	B-X
by	B-X
expression	B-X
of	B-X
the	B-X
IFN-α	B-X
gene	B-X
after	B-X
onset	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IFN-γ	B-X
in	B-X
SLE	B-X
may	B-X
be	B-X
underestimated	B-X
.	B-X
This	B-X
article	B-X
mainly	B-X
reviews	B-X
the	B-X
role	B-X
of	B-X
IFN-γ	B-X
in	B-X
SLE	B-X
and	B-X
focuses	B-X
on	B-X
the	B-X
nonnegligible	B-X
role	B-X
of	B-X
IFN-γ	B-X
in	B-X
SLE	B-X
to	B-X
gain	B-X
a	B-X
more	B-X
comprehensive	B-X
understanding	B-X
of	B-X
the	B-X
disease	B-X
.	B-X

The	O
IFN	O
-	O
dependent	O
increase	O
in	O
RAR	B-Protein
(	I-Protein
alpha	I-Protein
)	I-Protein
levels	O
and	O
the	O
enhancing	O
effect	O
of	O
the	O
cytokine	O
on	O
retinoid	O
-	O
dependent	O
granulocytic	O
markers	O
expression	O
may	O
be	O
a	O
characteristic	O
of	O
PML	B-Protein
-	I-Protein
RAR	I-Protein
positive	O
cells	O
,	O
since	O
the	O
phenomena	O
are	O
not	O
observed	O
in	O
HL	O
-	O
60	O
promyelocytes	O
.	O

Interferons	O
as	O
well	O
as	O
retinoids	O
inhibit	O
the	O
growth	O
of	O
NB4	O
cells	O
,	O
although	O
the	O
2	O
classes	O
of	O
compounds	O
do	O
not	O
significantly	O
interact	O
in	O
terms	O
of	O
anti	O
-	O
proliferative	O
activity	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
use	O
of	O
combinations	O
between	O
IFNs	O
and	O
retinoic	O
acid	O
in	O
the	O
cyto	O
-	O
differentiating	O
treatment	O
of	O
APL	O
patients	O
.	O
<EOS>	B-X
Treatment	B-X
of	B-X
the	B-X
acute	B-X
promyelocytic	B-X
(	B-X
APL	B-X
)	B-X
cell	B-X
line	B-X
NB4	B-X
with	B-X
interferon	B-X
alpha	B-X
(	B-X
IFN	B-X
(	B-X
alpha	B-X
)	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
IFN	B-X
(	B-X
beta	B-X
)	B-X
and	B-X
gamma	B-X
,	B-X
results	B-X
in	B-X
an	B-X
increased	B-X
expression	B-X
of	B-X
the	B-X
transcripts	B-X
coding	B-X
for	B-X
retinoic-acid	B-X
receptor	B-X
type	B-X
alpha	B-X
(	B-X
RAR	B-X
(	B-X
alpha	B-X
)	B-X
)	B-X
and	B-X
the	B-X
leukemia-specific	B-X
retinoic	B-X
acid	B-X
receptor	B-X
PML-RAR	B-X
.	B-X
The	B-X
IFN-dependent	B-X
increase	B-X
in	B-X
RAR	B-X
(	B-X
alpha	B-X
)	B-X
levels	B-X
and	B-X
the	B-X
enhancing	B-X
effect	B-X
of	B-X
the	B-X
cytokine	B-X
on	B-X
retinoid-dependent	B-X
granulocytic	B-X
markers	B-X
expression	B-X
may	B-X
be	B-X
a	B-X
characteristic	B-X
of	B-X
PML-RAR	B-X
positive	B-X
cells	B-X
,	B-X
since	B-X
the	B-X
phenomena	B-X
are	B-X
not	B-X
observed	B-X
in	B-X
HL-60	B-X
promyelocytes	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
the	B-X
possible	B-X
use	B-X
of	B-X
combinations	B-X
between	B-X
IFNs	B-X
and	B-X
retinoic	B-X
acid	B-X
in	B-X
the	B-X
cyto-differentiating	B-X
treatment	B-X
of	B-X
APL	B-X
patients	B-X
.	B-X

An	O
IL	B-Protein
-	I-Protein
2	I-Protein
response	O
element	O
in	O
the	O
human	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
chain	I-Protein
promoter	O
is	O
a	O
composite	O
element	O
that	O
binds	O
Stat5	B-Protein
,	O
Elf	B-Protein
-	I-Protein
1	I-Protein
,	O
HMG	B-Protein
-	I-Protein
I	I-Protein
(	I-Protein
Y	I-Protein
)	I-Protein
and	O
a	O
GATA	O
family	O
protein	O
.	O

Expression	O
of	O
the	O
human	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	I-Protein
IL	I-Protein
-	I-Protein
2	I-Protein
)	I-Protein
receptor	I-Protein
alpha	I-Protein
chain	I-Protein
gene	O
is	O
potently	O
upregulated	O
by	O
its	O
own	O
ligand	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
human	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
receptor	B-X
alpha	B-X
chain	B-X
gene	B-X
is	B-X
potently	B-X
upregulated	B-X
by	B-X
its	B-X
own	B-X
ligand	B-X
,	B-X
IL-2	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
characterize	B-X
an	B-X
essential	B-X
upstream	B-X
IL-2	B-X
response	B-X
element	B-X
that	B-X
contains	B-X
both	B-X
consensus	B-X
and	B-X
non-consensus	B-X
GAS	B-X
motifs	B-X
,	B-X
two	B-X
putative	B-X
Ets	B-X
binding	B-X
sites	B-X
(	B-X
EBS	B-X
)	B-X
,	B-X
one	B-X
of	B-X
which	B-X
overlaps	B-X
the	B-X
consensus	B-X
GAS	B-X
motif	B-X
,	B-X
and	B-X
a	B-X
GATA	B-X
motif	B-X
,	B-X
which	B-X
overlaps	B-X
the	B-X
non-consensus	B-X
GAS	B-X
motif	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
although	B-X
the	B-X
individual	B-X
components	B-X
of	B-X
this	B-X
element	B-X
do	B-X
not	B-X
respond	B-X
to	B-X
IL-2	B-X
,	B-X
together	B-X
they	B-X
form	B-X
a	B-X
composite	B-X
element	B-X
capable	B-X
of	B-X
conferring	B-X
IL-2	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
.	B-X
Multiple	B-X
factors	B-X
including	B-X
Stat5	B-X
,	B-X
Elf-1	B-X
,	B-X
HMG-I	B-X
(	B-X
Y	B-X
)	B-X
and	B-X
GATA	B-X
family	B-X
proteins	B-X
bind	B-X
to	B-X
the	B-X
IL-2	B-X
response	B-X
element	B-X
and	B-X
mutation	B-X
of	B-X
any	B-X
one	B-X
of	B-X
these	B-X
binding	B-X
sites	B-X
diminishes	B-X
the	B-X
activity	B-X
of	B-X
this	B-X
element	B-X
.	B-X
An	B-X
unidentified	B-X
Ets	B-X
family	B-X
protein	B-X
binds	B-X
to	B-X
the	B-X
EBS	B-X
overlapping	B-X
the	B-X
consensus	B-X
GAS	B-X
motif	B-X
and	B-X
appears	B-X
to	B-X
negatively	B-X
regulate	B-X
the	B-X
human	B-X
IL-2R	B-X
alpha	B-X
promoter	B-X
.	B-X
Thus	B-X
,	B-X
IL-2-induced	B-X
IL-2R	B-X
alpha	B-X
promoter	B-X
activity	B-X
requires	B-X
a	B-X
complex	B-X
upstream	B-X
element	B-X
,	B-X
which	B-X
appears	B-X
to	B-X
contain	B-X
binding	B-X
sites	B-X
for	B-X
both	B-X
positive	B-X
and	B-X
negative	B-X
regulatory	B-X
factors	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
characterize	O
an	O
essential	O
upstream	O
IL	B-Protein
-	I-Protein
2	I-Protein
response	O
element	O
that	O
contains	O
both	O
consensus	O
and	O
non	O
-	O
consensus	O
GAS	O
motifs	O
,	O
two	O
putative	O
Ets	O
binding	O
sites	O
(	O
EBS	O
)	O
,	O
one	O
of	O
which	O
overlaps	O
the	O
consensus	O
GAS	O
motif	O
,	O
and	O
a	O
GATA	O
motif	O
,	O
which	O
overlaps	O
the	O
non	O
-	O
consensus	O
GAS	O
motif	O
.	O

We	O
demonstrate	O
that	O
although	O
the	O
individual	O
components	O
of	O
this	O
element	O
do	O
not	O
respond	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
together	O
they	O
form	O
a	O
composite	O
element	O
capable	O
of	O
conferring	O
IL	B-Protein
-	I-Protein
2	I-Protein
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
.	O
<EOS>	B-X
The	B-X
Healthy	B-X
Eating	B-X
Index	B-X
(	B-X
HEI	B-X
)	B-X
,	B-X
a	B-X
diet	B-X
quality	B-X
index	B-X
that	B-X
measures	B-X
alignment	B-X
with	B-X
the	B-X
Dietary	B-X
Guidelines	B-X
for	B-X
Americans	B-X
,	B-X
was	B-X
updated	B-X
with	B-X
the	B-X
2015-2020	B-X
Dietary	B-X
Guidelines	B-X
for	B-X
Americans	B-X
.	B-X
Aging	B-X
is	B-X
associated	B-X
with	B-X
changes	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
with	B-X
a	B-X
decline	B-X
in	B-X
protective	B-X
components	B-X
(	B-X
immunosenescence	B-X
)	B-X
,	B-X
increasing	B-X
susceptibility	B-X
to	B-X
infectious	B-X
disease	B-X
,	B-X
and	B-X
a	B-X
chronic	B-X
elevation	B-X
in	B-X
low-grade	B-X
inflammation	B-X
(	B-X
inflammaging	B-X
)	B-X
,	B-X
increasing	B-X
the	B-X
risk	B-X
of	B-X
multiple	B-X
noncommunicable	B-X
diseases	B-X
.	B-X
Some	B-X
trials	B-X
report	B-X
that	B-X
providing	B-X
these	B-X
micronutrients	B-X
as	B-X
individual	B-X
supplements	B-X
can	B-X
reverse	B-X
immune	B-X
deficits	B-X
in	B-X
older	B-X
people	B-X
and/or	B-X
in	B-X
those	B-X
with	B-X
insufficient	B-X
intakes	B-X
.	B-X
Probiotic	B-X
,	B-X
prebiotic	B-X
,	B-X
or	B-X
synbiotic	B-X
strategies	B-X
that	B-X
modulate	B-X
the	B-X
gut	B-X
microbiota	B-X
,	B-X
especially	B-X
by	B-X
promoting	B-X
the	B-X
colonization	B-X
of	B-X
lactobacilli	B-X
and	B-X
bifidobacteria	B-X
,	B-X
have	B-X
been	B-X
demonstrated	B-X
to	B-X
modulate	B-X
some	B-X
immune	B-X
and	B-X
inflammatory	B-X
biomarkers	B-X
in	B-X
older	B-X
people	B-X
and	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
,	B-X
to	B-X
reduce	B-X
the	B-X
risk	B-X
and	B-X
severity	B-X
of	B-X
gastrointestinal	B-X
and	B-X
respiratory	B-X
infections	B-X
,	B-X
although	B-X
,	B-X
again	B-X
,	B-X
the	B-X
evidence	B-X
is	B-X
inconsistent	B-X
.	B-X

Multiple	O
factors	O
including	O
Stat5	B-Protein
,	O
Elf	B-Protein
-	I-Protein
1	I-Protein
,	O
HMG	B-Protein
-	I-Protein
I	I-Protein
(	I-Protein
Y	I-Protein
)	I-Protein
and	O
GATA	O
family	O
proteins	O
bind	O
to	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
response	O
element	O
and	O
mutation	O
of	O
any	O
one	O
of	O
these	O
binding	O
sites	O
diminishes	O
the	O
activity	O
of	O
this	O
element	O
.	O

An	O
unidentified	O
Ets	O
family	O
protein	O
binds	O
to	O
the	O
EBS	O
overlapping	O
the	O
consensus	O
GAS	O
motif	O
and	O
appears	O
to	O
negatively	O
regulate	O
the	O
human	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
promoter	O
.	O

Thus	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
IL	B-Protein
-	I-Protein
2R	I-Protein
alpha	I-Protein
promoter	O
activity	O
requires	O
a	O
complex	O
upstream	O
element	O
,	O
which	O
appears	O
to	O
contain	O
binding	O
sites	O
for	O
both	O
positive	O
and	O
negative	O
regulatory	O
factors	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
human	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
receptor	B-X
alpha	B-X
chain	B-X
gene	B-X
is	B-X
potently	B-X
upregulated	B-X
by	B-X
its	B-X
own	B-X
ligand	B-X
,	B-X
IL-2	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
characterize	B-X
an	B-X
essential	B-X
upstream	B-X
IL-2	B-X
response	B-X
element	B-X
that	B-X
contains	B-X
both	B-X
consensus	B-X
and	B-X
non-consensus	B-X
GAS	B-X
motifs	B-X
,	B-X
two	B-X
putative	B-X
Ets	B-X
binding	B-X
sites	B-X
(	B-X
EBS	B-X
)	B-X
,	B-X
one	B-X
of	B-X
which	B-X
overlaps	B-X
the	B-X
consensus	B-X
GAS	B-X
motif	B-X
,	B-X
and	B-X
a	B-X
GATA	B-X
motif	B-X
,	B-X
which	B-X
overlaps	B-X
the	B-X
non-consensus	B-X
GAS	B-X
motif	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
although	B-X
the	B-X
individual	B-X
components	B-X
of	B-X
this	B-X
element	B-X
do	B-X
not	B-X
respond	B-X
to	B-X
IL-2	B-X
,	B-X
together	B-X
they	B-X
form	B-X
a	B-X
composite	B-X
element	B-X
capable	B-X
of	B-X
conferring	B-X
IL-2	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
.	B-X
Multiple	B-X
factors	B-X
including	B-X
Stat5	B-X
,	B-X
Elf-1	B-X
,	B-X
HMG-I	B-X
(	B-X
Y	B-X
)	B-X
and	B-X
GATA	B-X
family	B-X
proteins	B-X
bind	B-X
to	B-X
the	B-X
IL-2	B-X
response	B-X
element	B-X
and	B-X
mutation	B-X
of	B-X
any	B-X
one	B-X
of	B-X
these	B-X
binding	B-X
sites	B-X
diminishes	B-X
the	B-X
activity	B-X
of	B-X
this	B-X
element	B-X
.	B-X
An	B-X
unidentified	B-X
Ets	B-X
family	B-X
protein	B-X
binds	B-X
to	B-X
the	B-X
EBS	B-X
overlapping	B-X
the	B-X
consensus	B-X
GAS	B-X
motif	B-X
and	B-X
appears	B-X
to	B-X
negatively	B-X
regulate	B-X
the	B-X
human	B-X
IL-2R	B-X
alpha	B-X
promoter	B-X
.	B-X
Thus	B-X
,	B-X
IL-2-induced	B-X
IL-2R	B-X
alpha	B-X
promoter	B-X
activity	B-X
requires	B-X
a	B-X
complex	B-X
upstream	B-X
element	B-X
,	B-X
which	B-X
appears	B-X
to	B-X
contain	B-X
binding	B-X
sites	B-X
for	B-X
both	B-X
positive	B-X
and	B-X
negative	B-X
regulatory	B-X
factors	B-X
.	B-X

Active	O
suppression	O
of	O
the	O
class	B-Protein
II	I-Protein
transactivator	I-Protein
-	O
encoding	O
AIR	O
-	O
1	O
locus	O
is	O
responsible	O
for	O
the	O
lack	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
gene	O
expression	O
observed	O
during	O
differentiation	O
from	O
B	O
cells	O
to	O
plasma	O
cells	O
.	O

In	O
this	O
study	O
the	O
genetic	O
control	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
gene	O
expression	O
during	O
the	O
transition	O
from	O
B	O
cell	O
to	O
plasma	O
cell	O
has	O
been	O
analyzed	O
.	O

Class	O
II	O
molecules	O
are	O
not	O
expressed	O
in	O
plasma	O
cells	O
because	O
of	O
an	O
active	O
suppression	O
resulting	O
in	O
the	O
abrogation	O
of	O
class	O
II	O
gene	O
transcription	O
.	O
<EOS>	B-X
B	B-X
cells	B-X
can	B-X
not	B-X
generate	B-X
high-affinity	B-X
antibodies	B-X
without	B-X
T	B-X
cell	B-X
help	B-X
.	B-X
The	B-X
Major	B-X
Histocompatibility	B-X
Complex	B-X
(	B-X
MHC	B-X
)	B-X
locus	B-X
encodes	B-X
classical	B-X
MHC	B-X
class	B-X
I	B-X
and	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
and	B-X
nonclassical	B-X
MHC-I	B-X
molecules	B-X
.	B-X
The	B-X
architecture	B-X
of	B-X
these	B-X
molecules	B-X
is	B-X
ideally	B-X
suited	B-X
to	B-X
capture	B-X
and	B-X
present	B-X
an	B-X
array	B-X
of	B-X
peptide	B-X
antigens	B-X
(	B-X
Ags	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
CD1	B-X
family	B-X
members	B-X
and	B-X
MR1	B-X
are	B-X
MHC	B-X
class	B-X
I-like	B-X
molecules	B-X
that	B-X
bind	B-X
lipid-based	B-X
Ags	B-X
and	B-X
vitamin	B-X
B	B-X
precursors	B-X
,	B-X
respectively	B-X
.	B-X
These	B-X
Ag-bound	B-X
molecules	B-X
are	B-X
subsequently	B-X
recognized	B-X
by	B-X
T	B-X
cell	B-X
antigen	B-X
receptors	B-X
(	B-X
TCRs	B-X
)	B-X
expressed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
T	B-X
lymphocytes	B-X
.	B-X
Investigators	B-X
have	B-X
determined	B-X
over	B-X
thirty	B-X
unique	B-X
TCR-peptide-MHC-I	B-X
complex	B-X
structures	B-X
and	B-X
twenty	B-X
unique	B-X
TCR-peptide-MHC-II	B-X
complex	B-X
structures	B-X
.	B-X
Structural	B-X
studies	B-X
on	B-X
TCR-mediated	B-X
recognition	B-X
of	B-X
lipid	B-X
and	B-X
metabolite	B-X
Ags	B-X
have	B-X
been	B-X
mostly	B-X
confined	B-X
to	B-X
TCRs	B-X
from	B-X
innate-like	B-X
natural	B-X
killer	B-X
T	B-X
cells	B-X
and	B-X
mucosal-associated	B-X
invariant	B-X
T	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
Accordingly	B-X
,	B-X
TCRs	B-X
show	B-X
remarkable	B-X
structural	B-X
and	B-X
biological	B-X
versatility	B-X
in	B-X
engaging	B-X
different	B-X
classes	B-X
of	B-X
Ag	B-X
that	B-X
are	B-X
presented	B-X
by	B-X
polymorphic	B-X
and	B-X
monomorphic	B-X
Ag-presenting	B-X
molecules	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
.	B-X

We	O
show	O
here	O
that	O
the	O
plasma	O
cell	O
-	O
specific	O
repressor	O
function	O
,	O
designated	O
SIR	O
(	O
suppressor	O
of	O
immune	O
response	O
genes	O
)	O
,	O
does	O
not	O
act	O
directly	O
on	O
the	O
transcription	O
of	O
class	O
II	O
genes	O
,	O
but	O
instead	O
on	O
the	O
transcription	O
of	O
the	O
AIR	O
-	O
1	O
gene	O
,	O
whose	O
product	O
,	O
the	O
class	B-Protein
II	I-Protein
transactivator	I-Protein
(	O
CIITA	B-Protein
)	O
,	O
is	O
fundamental	O
for	O
the	O
regulation	O
of	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

This	O
was	O
unambiguously	O
demonstrated	O
by	O
the	O
fact	O
that	O
plasmacytoma	O
x	O
B	O
cell	O
hybrids	O
carrying	O
an	O
AIR	O
-	O
1	O
locus	O
derived	O
from	O
CIITA	B-Protein
-	O
expressing	O
cells	O
do	O
not	O
express	O
CIITA	B-Protein
-	O
specific	O
transcripts	O
.	O

Transfection	O
of	O
a	O
cDNA	O
containing	O
the	O
human	O
CIITA	B-Protein
coding	O
sequence	O
under	O
the	O
control	O
of	O
an	O
heterologous	O
promoter	O
restores	O
expression	O
of	O
human	O
MHC	O
class	O
II	O
genes	O
in	O
the	O
hybrids	O
and	O
is	O
responsible	O
for	O
de	O
novo	O
expression	O
of	O
mouse	O
MHC	O
class	O
II	O
genes	O
in	O
both	O
the	O
mouse	O
plasmacytoma	O
cell	O
line	O
and	O
the	O
hybrids	O
.	O

These	O
results	O
confirm	O
and	O
extend	O
the	O
notion	O
of	O
the	O
functional	O
conservation	O
of	O
the	O
AIR	O
-	O
1	O
gene	O
product	O
across	O
species	O
barriers	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
the	B-X
genetic	B-X
control	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
class	B-X
II	B-X
gene	B-X
expression	B-X
during	B-X
the	B-X
transition	B-X
from	B-X
B	B-X
cell	B-X
to	B-X
plasma	B-X
cell	B-X
has	B-X
been	B-X
analyzed	B-X
.	B-X
Class	B-X
II	B-X
molecules	B-X
are	B-X
not	B-X
expressed	B-X
in	B-X
plasma	B-X
cells	B-X
because	B-X
of	B-X
an	B-X
active	B-X
suppression	B-X
resulting	B-X
in	B-X
the	B-X
abrogation	B-X
of	B-X
class	B-X
II	B-X
gene	B-X
transcription	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
the	B-X
plasma	B-X
cell-specific	B-X
repressor	B-X
function	B-X
,	B-X
designated	B-X
SIR	B-X
(	B-X
suppressor	B-X
of	B-X
immune	B-X
response	B-X
genes	B-X
)	B-X
,	B-X
does	B-X
not	B-X
act	B-X
directly	B-X
on	B-X
the	B-X
transcription	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
but	B-X
instead	B-X
on	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
AIR-1	B-X
gene	B-X
,	B-X
whose	B-X
product	B-X
,	B-X
the	B-X
class	B-X
II	B-X
transactivator	B-X
(	B-X
CIITA	B-X
)	B-X
,	B-X
is	B-X
fundamental	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
constitutive	B-X
and	B-X
inducible	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
.	B-X
This	B-X
was	B-X
unambiguously	B-X
demonstrated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
plasmacytoma	B-X
x	B-X
B	B-X
cell	B-X
hybrids	B-X
carrying	B-X
an	B-X
AIR-1	B-X
locus	B-X
derived	B-X
from	B-X
CIITA-expressing	B-X
cells	B-X
do	B-X
not	B-X
express	B-X
CIITA-specific	B-X
transcripts	B-X
.	B-X
Transfection	B-X
of	B-X
a	B-X
cDNA	B-X
containing	B-X
the	B-X
human	B-X
CIITA	B-X
coding	B-X
sequence	B-X
under	B-X
the	B-X
control	B-X
of	B-X
an	B-X
heterologous	B-X
promoter	B-X
restores	B-X
expression	B-X
of	B-X
human	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
in	B-X
the	B-X
hybrids	B-X
and	B-X
is	B-X
responsible	B-X
for	B-X
de	B-X
novo	B-X
expression	B-X
of	B-X
mouse	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
in	B-X
both	B-X
the	B-X
mouse	B-X
plasmacytoma	B-X
cell	B-X
line	B-X
and	B-X
the	B-X
hybrids	B-X
.	B-X
These	B-X
results	B-X
confirm	B-X
and	B-X
extend	B-X
the	B-X
notion	B-X
of	B-X
the	B-X
functional	B-X
conservation	B-X
of	B-X
the	B-X
AIR-1	B-X
gene	B-X
product	B-X
across	B-X
species	B-X
barriers	B-X
.	B-X

Interestingly	O
,	O
in	O
CIITA	B-Protein
-	O
transfected	O
cell	O
hybrids	O
,	O
cell	O
surface	O
expression	O
of	O
the	O
human	O
HLA	O
-	O
DQ	O
heterodimer	O
was	O
not	O
observed	O
.	O

This	O
result	O
was	O
not	O
attributable	O
to	O
lack	O
of	O
HLA	B-Protein
-	I-Protein
DQ	I-Protein
alpha	I-Protein
or	O
-	B-Protein
DQ	I-Protein
beta	I-Protein
transcription	O
,	O
because	O
both	O
transcripts	O
were	O
present	O
in	O
the	O
CIITA	B-Protein
-	O
transfected	O
hybrids	O
,	O
although	O
at	O
reduced	O
levels	O
.	O
<EOS>	B-X
Cell	B-X
death	B-X
was	B-X
once	B-X
believed	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
one	B-X
of	B-X
two	B-X
distinct	B-X
processes	B-X
,	B-X
apoptosis	B-X
(	B-X
also	B-X
known	B-X
as	B-X
programmed	B-X
cell	B-X
death	B-X
)	B-X
or	B-X
necrosis	B-X
(	B-X
uncontrolled	B-X
cell	B-X
death	B-X
)	B-X
;	B-X
in	B-X
recent	B-X
years	B-X
,	B-X
however	B-X
,	B-X
several	B-X
other	B-X
forms	B-X
of	B-X
cell	B-X
death	B-X
have	B-X
been	B-X
discovered	B-X
highlighting	B-X
that	B-X
a	B-X
cell	B-X
can	B-X
die	B-X
via	B-X
a	B-X
number	B-X
of	B-X
differing	B-X
pathways	B-X
.	B-X
The	B-X
result	B-X
being	B-X
the	B-X
clearance	B-X
of	B-X
cells	B-X
from	B-X
the	B-X
body	B-X
,	B-X
with	B-X
minimal	B-X
damage	B-X
to	B-X
surrounding	B-X
tissues	B-X
.	B-X
Necrosis	B-X
,	B-X
however	B-X
,	B-X
is	B-X
generally	B-X
characterised	B-X
to	B-X
be	B-X
the	B-X
uncontrolled	B-X
death	B-X
of	B-X
the	B-X
cell	B-X
,	B-X
usually	B-X
following	B-X
a	B-X
severe	B-X
insult	B-X
,	B-X
resulting	B-X
in	B-X
spillage	B-X
of	B-X
the	B-X
contents	B-X
of	B-X
the	B-X
cell	B-X
into	B-X
surrounding	B-X
tissues	B-X
and	B-X
subsequent	B-X
damage	B-X
thereof	B-X
.	B-X
Failure	B-X
of	B-X
apoptosis	B-X
and	B-X
the	B-X
resultant	B-X
accumulation	B-X
of	B-X
damaged	B-X
cells	B-X
in	B-X
the	B-X
body	B-X
can	B-X
result	B-X
in	B-X
various	B-X
forms	B-X
of	B-X
cancer	B-X
.	B-X

These	O
findings	O
further	O
support	O
our	O
previous	O
observations	O
on	O
the	O
distinct	O
regulation	O
of	O
expression	O
of	O
the	O
human	O
HLA	O
-	O
DQ	O
class	O
II	O
subset	O
,	O
which	O
may	O
be	O
thus	O
controlled	O
at	O
the	O
posttranscriptional	O
level	O
by	O
a	O
CIITA	B-Protein
-	O
independent	O
mechanism	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
the	B-X
genetic	B-X
control	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
class	B-X
II	B-X
gene	B-X
expression	B-X
during	B-X
the	B-X
transition	B-X
from	B-X
B	B-X
cell	B-X
to	B-X
plasma	B-X
cell	B-X
has	B-X
been	B-X
analyzed	B-X
.	B-X
Class	B-X
II	B-X
molecules	B-X
are	B-X
not	B-X
expressed	B-X
in	B-X
plasma	B-X
cells	B-X
because	B-X
of	B-X
an	B-X
active	B-X
suppression	B-X
resulting	B-X
in	B-X
the	B-X
abrogation	B-X
of	B-X
class	B-X
II	B-X
gene	B-X
transcription	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
the	B-X
plasma	B-X
cell-specific	B-X
repressor	B-X
function	B-X
,	B-X
designated	B-X
SIR	B-X
(	B-X
suppressor	B-X
of	B-X
immune	B-X
response	B-X
genes	B-X
)	B-X
,	B-X
does	B-X
not	B-X
act	B-X
directly	B-X
on	B-X
the	B-X
transcription	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
but	B-X
instead	B-X
on	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
AIR-1	B-X
gene	B-X
,	B-X
whose	B-X
product	B-X
,	B-X
the	B-X
class	B-X
II	B-X
transactivator	B-X
(	B-X
CIITA	B-X
)	B-X
,	B-X
is	B-X
fundamental	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
constitutive	B-X
and	B-X
inducible	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
.	B-X
This	B-X
was	B-X
unambiguously	B-X
demonstrated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
plasmacytoma	B-X
x	B-X
B	B-X
cell	B-X
hybrids	B-X
carrying	B-X
an	B-X
AIR-1	B-X
locus	B-X
derived	B-X
from	B-X
CIITA-expressing	B-X
cells	B-X
do	B-X
not	B-X
express	B-X
CIITA-specific	B-X
transcripts	B-X
.	B-X
Transfection	B-X
of	B-X
a	B-X
cDNA	B-X
containing	B-X
the	B-X
human	B-X
CIITA	B-X
coding	B-X
sequence	B-X
under	B-X
the	B-X
control	B-X
of	B-X
an	B-X
heterologous	B-X
promoter	B-X
restores	B-X
expression	B-X
of	B-X
human	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
in	B-X
the	B-X
hybrids	B-X
and	B-X
is	B-X
responsible	B-X
for	B-X
de	B-X
novo	B-X
expression	B-X
of	B-X
mouse	B-X
MHC	B-X
class	B-X
II	B-X
genes	B-X
in	B-X
both	B-X
the	B-X
mouse	B-X
plasmacytoma	B-X
cell	B-X
line	B-X
and	B-X
the	B-X
hybrids	B-X
.	B-X
Interestingly	B-X
,	B-X
in	B-X
CIITA-transfected	B-X
cell	B-X
hybrids	B-X
,	B-X
cell	B-X
surface	B-X
expression	B-X
of	B-X
the	B-X
human	B-X
HLA-DQ	B-X
heterodimer	B-X
was	B-X
not	B-X
observed	B-X
.	B-X
This	B-X
result	B-X
was	B-X
not	B-X
attributable	B-X
to	B-X
lack	B-X
of	B-X
HLA-DQ	B-X
alpha	B-X
or	B-X
-DQ	B-X
beta	B-X
transcription	B-X
,	B-X
because	B-X
both	B-X
transcripts	B-X
were	B-X
present	B-X
in	B-X
the	B-X
CIITA-transfected	B-X
hybrids	B-X
,	B-X
although	B-X
at	B-X
reduced	B-X
levels	B-X
.	B-X
These	B-X
findings	B-X
further	B-X
support	B-X
our	B-X
previous	B-X
observations	B-X
on	B-X
the	B-X
distinct	B-X
regulation	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
human	B-X
HLA-DQ	B-X
class	B-X
II	B-X
subset	B-X
,	B-X
which	B-X
may	B-X
be	B-X
thus	B-X
controlled	B-X
at	B-X
the	B-X
posttranscriptional	B-X
level	B-X
by	B-X
a	B-X
CIITA-independent	B-X
mechanism	B-X
.	B-X

Silencing	O
of	O
human	O
fetal	B-Protein
globin	I-Protein
expression	O
is	O
impaired	O
in	O
the	O
absence	O
of	O
the	O
adult	O
beta	O
-	O
globin	O
gene	O
activator	O
protein	O
EKLF	B-Protein
.	O
<EOS>	B-X
Globin	B-X
genes	B-X
are	B-X
subject	B-X
to	B-X
tissue-specific	B-X
and	B-X
developmental	B-X
stage-specific	B-X
regulation	B-X
.	B-X
A	B-X
switch	B-X
from	B-X
human	B-X
fetal	B-X
(	B-X
gamma	B-X
)	B-X
-to	B-X
adult	B-X
(	B-X
beta	B-X
)	B-X
-globin	B-X
expression	B-X
occurs	B-X
within	B-X
erythroid	B-X
precursor	B-X
cells	B-X
of	B-X
the	B-X
adult	B-X
lineage	B-X
.	B-X
Previously	B-X
we	B-X
and	B-X
others	B-X
showed	B-X
by	B-X
targeted	B-X
gene	B-X
disruption	B-X
that	B-X
the	B-X
zinc	B-X
finger	B-X
gene	B-X
,	B-X
erythroid	B-X
Krüppel-like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
,	B-X
is	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
the	B-X
beta-globin	B-X
gene	B-X
in	B-X
mice	B-X
,	B-X
presumably	B-X
through	B-X
interaction	B-X
with	B-X
a	B-X
high-affinity	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
proximal	B-X
promoter	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
EKLF	B-X
in	B-X
the	B-X
developmental	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
gamma-globin	B-X
gene	B-X
we	B-X
interbred	B-X
EKLF	B-X
heterozygotes	B-X
(	B-X
+/-	B-X
)	B-X
with	B-X
mice	B-X
harboring	B-X
a	B-X
human	B-X
beta-globin	B-X
yeast	B-X
artificial	B-X
chromosome	B-X
transgene	B-X
.	B-X
We	B-X
find	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EKLF	B-X
,	B-X
while	B-X
human	B-X
beta-globin	B-X
expression	B-X
is	B-X
dramatically	B-X
reduced	B-X
,	B-X
gamma-globin	B-X
transcripts	B-X
are	B-X
elevated	B-X
approximately	B-X
5-fold	B-X
.	B-X
Impaired	B-X
silencing	B-X
of	B-X
gamma-globin	B-X
expression	B-X
identifies	B-X
EKLF	B-X
as	B-X
the	B-X
first	B-X
transcription	B-X
factor	B-X
participating	B-X
quantitatively	B-X
in	B-X
the	B-X
gamma-globin	B-X
to	B-X
beta-globin	B-X
switch	B-X
.	B-X
Our	B-X
findings	B-X
are	B-X
compatible	B-X
with	B-X
a	B-X
competitive	B-X
model	B-X
of	B-X
switching	B-X
in	B-X
which	B-X
EKLF	B-X
mediates	B-X
an	B-X
adult	B-X
stage-specific	B-X
interaction	B-X
between	B-X
the	B-X
beta-globin	B-X
gene	B-X
promoter	B-X
and	B-X
the	B-X
locus	B-X
control	B-X
region	B-X
that	B-X
excludes	B-X
the	B-X
gamma-globin	B-X
gene	B-X
.	B-X

Globin	O
genes	O
are	O
subject	O
to	O
tissue	O
-	O
specific	O
and	O
developmental	O
stage	O
-	O
specific	O
regulation	O
.	O
<EOS>	B-X
The	B-X
human	B-X
beta-globin	B-X
gene	B-X
locus	B-X
is	B-X
the	B-X
subject	B-X
of	B-X
intense	B-X
study	B-X
,	B-X
and	B-X
over	B-X
the	B-X
past	B-X
two	B-X
decades	B-X
a	B-X
wealth	B-X
of	B-X
information	B-X
has	B-X
accumulated	B-X
on	B-X
how	B-X
tissue-specific	B-X
and	B-X
stage-specific	B-X
expression	B-X
of	B-X
its	B-X
genes	B-X
is	B-X
achieved	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
introduce	B-X
the	B-X
fundamental	B-X
characteristics	B-X
of	B-X
globin	B-X
locus	B-X
regulation	B-X
as	B-X
well	B-X
as	B-X
questions	B-X
on	B-X
which	B-X
much	B-X
of	B-X
the	B-X
current	B-X
research	B-X
is	B-X
predicated	B-X
.	B-X
These	B-X
complexes	B-X
are	B-X
used	B-X
to	B-X
establish	B-X
accessible	B-X
chromatin	B-X
domains	B-X
,	B-X
allowing	B-X
basal	B-X
factors	B-X
to	B-X
be	B-X
loaded	B-X
on	B-X
to	B-X
specific	B-X
globin	B-X
gene	B-X
promoters	B-X
in	B-X
a	B-X
developmental	B-X
stage-specific	B-X
manner	B-X
.	B-X
At	B-X
different	B-X
stages	B-X
of	B-X
mammalian	B-X
development	B-X
,	B-X
distinct	B-X
embryonic	B-X
,	B-X
fetal	B-X
and	B-X
adult	B-X
haemoglobins	B-X
are	B-X
synthesized	B-X
in	B-X
erythroid	B-X
cells	B-X
,	B-X
a	B-X
process	B-X
termed	B-X
haemoglobin	B-X
switching	B-X
.	B-X
To	B-X
study	B-X
the	B-X
developmental	B-X
regulation	B-X
of	B-X
globin	B-X
gene	B-X
expression	B-X
,	B-X
we	B-X
have	B-X
produced	B-X
transgenic	B-X
mice	B-X
in	B-X
which	B-X
cloned	B-X
globin	B-X
genes	B-X
are	B-X
present	B-X
in	B-X
erythroid	B-X
cells	B-X
throughout	B-X
development	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
adult	B-X
mice	B-X
in	B-X
several	B-X
transgenic	B-X
lines	B-X
carrying	B-X
a	B-X
hybrid	B-X
mouse/human	B-X
adult	B-X
beta-globin	B-X
gene	B-X
,	B-X
expressed	B-X
the	B-X
gene	B-X
in	B-X
a	B-X
correct	B-X
tissue-specific	B-X
manner	B-X
.	B-X
This	B-X
finding	B-X
raised	B-X
the	B-X
question	B-X
of	B-X
whether	B-X
an	B-X
exogenous	B-X
globin	B-X
gene	B-X
could	B-X
also	B-X
be	B-X
subject	B-X
to	B-X
appropriate	B-X
stage-specific	B-X
regulation	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
the	B-X
hybrid	B-X
beta-globin	B-X
gene	B-X
,	B-X
like	B-X
the	B-X
endogenous	B-X
adult	B-X
beta-globin	B-X
genes	B-X
,	B-X
is	B-X
inactive	B-X
in	B-X
yolk	B-X
sac-derived	B-X
embryonic	B-X
erythroid	B-X
cells	B-X
and	B-X
is	B-X
expressed	B-X
for	B-X
the	B-X
first	B-X
time	B-X
in	B-X
fetal	B-X
liver	B-X
erythroid	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
a	B-X
stage-specific	B-X
pattern	B-X
of	B-X
expression	B-X
can	B-X
be	B-X
conferred	B-X
by	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
closely	B-X
linked	B-X
to	B-X
an	B-X
adult	B-X
beta-globin	B-X
gene	B-X
.	B-X
They	B-X
also	B-X
suggest	B-X
that	B-X
the	B-X
embryonic	B-X
and	B-X
adult	B-X
beta-globin	B-X
genes	B-X
in	B-X
the	B-X
mouse	B-X
are	B-X
activated	B-X
(	B-X
or	B-X
repressed	B-X
)	B-X
by	B-X
distinct	B-X
trans-acting	B-X
regulatory	B-X
factors	B-X
present	B-X
in	B-X
embryonic	B-X
,	B-X
fetal	B-X
and	B-X
adult	B-X
erythroid	B-X
cells	B-X
.	B-X

A	O
switch	O
from	O
human	B-Protein
fetal	I-Protein
(	I-Protein
gamma	I-Protein
)	I-Protein
-	I-Protein
to	O
adult	B-Protein
(	I-Protein
beta	I-Protein
)	I-Protein
-	I-Protein
globin	I-Protein
expression	O
occurs	O
within	O
erythroid	O
precursor	O
cells	O
of	O
the	O
adult	O
lineage	O
.	O
<EOS>	B-X
The	B-X
mechanisms	B-X
underlying	B-X
the	B-X
human	B-X
fetal-to-adult	B-X
beta-globin	B-X
gene	B-X
switch	B-X
remain	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
While	B-X
there	B-X
is	B-X
substantial	B-X
experimental	B-X
evidence	B-X
to	B-X
suggest	B-X
that	B-X
promoter	B-X
DNA	B-X
methylation	B-X
is	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
,	B-X
most	B-X
data	B-X
come	B-X
from	B-X
studies	B-X
in	B-X
nonhuman	B-X
systems	B-X
.	B-X
We	B-X
have	B-X
evaluated	B-X
human	B-X
gamma-	B-X
and	B-X
beta-globin	B-X
promoter	B-X
methylation	B-X
in	B-X
primary	B-X
human	B-X
fetal	B-X
liver	B-X
(	B-X
FL	B-X
)	B-X
and	B-X
adult	B-X
bone	B-X
marrow	B-X
(	B-X
ABM	B-X
)	B-X
erythroid	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
show	B-X
that	B-X
,	B-X
in	B-X
general	B-X
,	B-X
promoter	B-X
methylation	B-X
and	B-X
gene	B-X
expression	B-X
are	B-X
inversely	B-X
related	B-X
.	B-X
However	B-X
,	B-X
CpGs	B-X
at	B-X
-162	B-X
of	B-X
the	B-X
gamma	B-X
promoter	B-X
and	B-X
-126	B-X
of	B-X
the	B-X
beta	B-X
promoter	B-X
are	B-X
hypomethylated	B-X
in	B-X
ABM	B-X
and	B-X
FL	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
also	B-X
studied	B-X
gamma-globin	B-X
promoter	B-X
methylation	B-X
during	B-X
in	B-X
vitro	B-X
differentiation	B-X
of	B-X
erythroid	B-X
cells	B-X
.	B-X
The	B-X
gamma	B-X
promoters	B-X
are	B-X
initially	B-X
hypermethylated	B-X
in	B-X
CD34	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
.	B-X
The	B-X
upstream	B-X
gamma	B-X
promoter	B-X
CpGs	B-X
become	B-X
hypomethylated	B-X
during	B-X
the	B-X
preerythroid	B-X
phase	B-X
of	B-X
differentiation	B-X
and	B-X
are	B-X
then	B-X
remethylated	B-X
later	B-X
,	B-X
during	B-X
erythropoiesis	B-X
.	B-X
The	B-X
period	B-X
of	B-X
promoter	B-X
hypomethylation	B-X
correlates	B-X
with	B-X
transient	B-X
gamma-globin	B-X
gene	B-X
expression	B-X
and	B-X
may	B-X
explain	B-X
the	B-X
previously	B-X
observed	B-X
fetal	B-X
hemoglobin	B-X
production	B-X
that	B-X
occurs	B-X
during	B-X
early	B-X
adult	B-X
erythropoiesis	B-X
.	B-X
These	B-X
results	B-X
provide	B-X
the	B-X
first	B-X
comprehensive	B-X
survey	B-X
of	B-X
developmental	B-X
changes	B-X
in	B-X
human	B-X
gamma-	B-X
and	B-X
beta-globin	B-X
promoter	B-X
methylation	B-X
and	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
promoter	B-X
methylation	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
human	B-X
beta-globin	B-X
locus	B-X
gene	B-X
switching	B-X
.	B-X

Previously	O
we	O
and	O
others	O
showed	O
by	O
targeted	O
gene	O
disruption	O
that	O
the	O
zinc	O
finger	O
gene	O
,	O
erythroid	B-Protein
Kruppel	I-Protein
-	I-Protein
like	I-Protein
factor	I-Protein
(	O
EKLF	B-Protein
)	O
,	O
is	O
required	O
for	O
expression	O
of	O
the	O
beta	B-Protein
-	I-Protein
globin	I-Protein
gene	O
in	O
mice	O
,	O
presumably	O
through	O
interaction	O
with	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
in	O
the	O
proximal	O
promoter	O
.	O
<EOS>	B-X
Globin	B-X
genes	B-X
are	B-X
subject	B-X
to	B-X
tissue-specific	B-X
and	B-X
developmental	B-X
stage-specific	B-X
regulation	B-X
.	B-X
A	B-X
switch	B-X
from	B-X
human	B-X
fetal	B-X
(	B-X
gamma	B-X
)	B-X
-to	B-X
adult	B-X
(	B-X
beta	B-X
)	B-X
-globin	B-X
expression	B-X
occurs	B-X
within	B-X
erythroid	B-X
precursor	B-X
cells	B-X
of	B-X
the	B-X
adult	B-X
lineage	B-X
.	B-X
Previously	B-X
we	B-X
and	B-X
others	B-X
showed	B-X
by	B-X
targeted	B-X
gene	B-X
disruption	B-X
that	B-X
the	B-X
zinc	B-X
finger	B-X
gene	B-X
,	B-X
erythroid	B-X
Krüppel-like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
,	B-X
is	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
the	B-X
beta-globin	B-X
gene	B-X
in	B-X
mice	B-X
,	B-X
presumably	B-X
through	B-X
interaction	B-X
with	B-X
a	B-X
high-affinity	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
proximal	B-X
promoter	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
EKLF	B-X
in	B-X
the	B-X
developmental	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
gamma-globin	B-X
gene	B-X
we	B-X
interbred	B-X
EKLF	B-X
heterozygotes	B-X
(	B-X
+/-	B-X
)	B-X
with	B-X
mice	B-X
harboring	B-X
a	B-X
human	B-X
beta-globin	B-X
yeast	B-X
artificial	B-X
chromosome	B-X
transgene	B-X
.	B-X
We	B-X
find	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EKLF	B-X
,	B-X
while	B-X
human	B-X
beta-globin	B-X
expression	B-X
is	B-X
dramatically	B-X
reduced	B-X
,	B-X
gamma-globin	B-X
transcripts	B-X
are	B-X
elevated	B-X
approximately	B-X
5-fold	B-X
.	B-X
Impaired	B-X
silencing	B-X
of	B-X
gamma-globin	B-X
expression	B-X
identifies	B-X
EKLF	B-X
as	B-X
the	B-X
first	B-X
transcription	B-X
factor	B-X
participating	B-X
quantitatively	B-X
in	B-X
the	B-X
gamma-globin	B-X
to	B-X
beta-globin	B-X
switch	B-X
.	B-X
Our	B-X
findings	B-X
are	B-X
compatible	B-X
with	B-X
a	B-X
competitive	B-X
model	B-X
of	B-X
switching	B-X
in	B-X
which	B-X
EKLF	B-X
mediates	B-X
an	B-X
adult	B-X
stage-specific	B-X
interaction	B-X
between	B-X
the	B-X
beta-globin	B-X
gene	B-X
promoter	B-X
and	B-X
the	B-X
locus	B-X
control	B-X
region	B-X
that	B-X
excludes	B-X
the	B-X
gamma-globin	B-X
gene	B-X
.	B-X

To	O
examine	O
the	O
role	O
of	O
EKLF	B-Protein
in	O
the	O
developmental	O
regulation	O
of	O
the	O
human	O
gamma	B-Protein
-	I-Protein
globin	I-Protein
gene	O
we	O
interbred	O
EKLF	B-Protein
heterozygotes	O
(	O
+	O
/	O
-	O
)	O
with	O
mice	O
harboring	O
a	O
human	O
beta	B-Protein
-	I-Protein
globin	I-Protein
yeast	O
artificial	O
chromosome	O
transgene	O
.	O
<EOS>	B-X
Globin	B-X
genes	B-X
are	B-X
subject	B-X
to	B-X
tissue-specific	B-X
and	B-X
developmental	B-X
stage-specific	B-X
regulation	B-X
.	B-X
A	B-X
switch	B-X
from	B-X
human	B-X
fetal	B-X
(	B-X
gamma	B-X
)	B-X
-to	B-X
adult	B-X
(	B-X
beta	B-X
)	B-X
-globin	B-X
expression	B-X
occurs	B-X
within	B-X
erythroid	B-X
precursor	B-X
cells	B-X
of	B-X
the	B-X
adult	B-X
lineage	B-X
.	B-X
Previously	B-X
we	B-X
and	B-X
others	B-X
showed	B-X
by	B-X
targeted	B-X
gene	B-X
disruption	B-X
that	B-X
the	B-X
zinc	B-X
finger	B-X
gene	B-X
,	B-X
erythroid	B-X
Krüppel-like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
,	B-X
is	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
the	B-X
beta-globin	B-X
gene	B-X
in	B-X
mice	B-X
,	B-X
presumably	B-X
through	B-X
interaction	B-X
with	B-X
a	B-X
high-affinity	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
proximal	B-X
promoter	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
EKLF	B-X
in	B-X
the	B-X
developmental	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
gamma-globin	B-X
gene	B-X
we	B-X
interbred	B-X
EKLF	B-X
heterozygotes	B-X
(	B-X
+/-	B-X
)	B-X
with	B-X
mice	B-X
harboring	B-X
a	B-X
human	B-X
beta-globin	B-X
yeast	B-X
artificial	B-X
chromosome	B-X
transgene	B-X
.	B-X
We	B-X
find	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EKLF	B-X
,	B-X
while	B-X
human	B-X
beta-globin	B-X
expression	B-X
is	B-X
dramatically	B-X
reduced	B-X
,	B-X
gamma-globin	B-X
transcripts	B-X
are	B-X
elevated	B-X
approximately	B-X
5-fold	B-X
.	B-X
Impaired	B-X
silencing	B-X
of	B-X
gamma-globin	B-X
expression	B-X
identifies	B-X
EKLF	B-X
as	B-X
the	B-X
first	B-X
transcription	B-X
factor	B-X
participating	B-X
quantitatively	B-X
in	B-X
the	B-X
gamma-globin	B-X
to	B-X
beta-globin	B-X
switch	B-X
.	B-X
Our	B-X
findings	B-X
are	B-X
compatible	B-X
with	B-X
a	B-X
competitive	B-X
model	B-X
of	B-X
switching	B-X
in	B-X
which	B-X
EKLF	B-X
mediates	B-X
an	B-X
adult	B-X
stage-specific	B-X
interaction	B-X
between	B-X
the	B-X
beta-globin	B-X
gene	B-X
promoter	B-X
and	B-X
the	B-X
locus	B-X
control	B-X
region	B-X
that	B-X
excludes	B-X
the	B-X
gamma-globin	B-X
gene	B-X
.	B-X

We	O
find	O
that	O
in	O
the	O
absence	O
of	O
EKLF	B-Protein
,	O
while	O
human	O
beta	B-Protein
-	I-Protein
globin	I-Protein
expression	O
is	O
dramatically	O
reduced	O
,	O
gamma	B-Protein
-	I-Protein
globin	I-Protein
transcripts	O
are	O
elevated	O
approximately	O
5	O
-	O
fold	O
.	O
<EOS>	B-X
A	B-X
switch	B-X
from	B-X
human	B-X
fetal	B-X
(	B-X
gamma	B-X
)	B-X
-to	B-X
adult	B-X
(	B-X
beta	B-X
)	B-X
-globin	B-X
expression	B-X
occurs	B-X
within	B-X
erythroid	B-X
precursor	B-X
cells	B-X
of	B-X
the	B-X
adult	B-X
lineage	B-X
.	B-X
Previously	B-X
we	B-X
and	B-X
others	B-X
showed	B-X
by	B-X
targeted	B-X
gene	B-X
disruption	B-X
that	B-X
the	B-X
zinc	B-X
finger	B-X
gene	B-X
,	B-X
erythroid	B-X
Krüppel-like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
,	B-X
is	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
the	B-X
beta-globin	B-X
gene	B-X
in	B-X
mice	B-X
,	B-X
presumably	B-X
through	B-X
interaction	B-X
with	B-X
a	B-X
high-affinity	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
proximal	B-X
promoter	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
EKLF	B-X
in	B-X
the	B-X
developmental	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
gamma-globin	B-X
gene	B-X
we	B-X
interbred	B-X
EKLF	B-X
heterozygotes	B-X
(	B-X
+/-	B-X
)	B-X
with	B-X
mice	B-X
harboring	B-X
a	B-X
human	B-X
beta-globin	B-X
yeast	B-X
artificial	B-X
chromosome	B-X
transgene	B-X
.	B-X
We	B-X
find	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EKLF	B-X
,	B-X
while	B-X
human	B-X
beta-globin	B-X
expression	B-X
is	B-X
dramatically	B-X
reduced	B-X
,	B-X
gamma-globin	B-X
transcripts	B-X
are	B-X
elevated	B-X
approximately	B-X
5-fold	B-X
.	B-X
Impaired	B-X
silencing	B-X
of	B-X
gamma-globin	B-X
expression	B-X
identifies	B-X
EKLF	B-X
as	B-X
the	B-X
first	B-X
transcription	B-X
factor	B-X
participating	B-X
quantitatively	B-X
in	B-X
the	B-X
gamma-globin	B-X
to	B-X
beta-globin	B-X
switch	B-X
.	B-X
Our	B-X
findings	B-X
are	B-X
compatible	B-X
with	B-X
a	B-X
competitive	B-X
model	B-X
of	B-X
switching	B-X
in	B-X
which	B-X
EKLF	B-X
mediates	B-X
an	B-X
adult	B-X
stage-specific	B-X
interaction	B-X
between	B-X
the	B-X
beta-globin	B-X
gene	B-X
promoter	B-X
and	B-X
the	B-X
locus	B-X
control	B-X
region	B-X
that	B-X
excludes	B-X
the	B-X
gamma-globin	B-X
gene	B-X
.	B-X

Impaired	O
silencing	O
of	O
gamma	B-Protein
-	I-Protein
globin	I-Protein
expression	O
identifies	O
EKLF	B-Protein
as	O
the	O
first	O
transcription	O
factor	O
participating	O
quantitatively	O
in	O
the	O
gamma	B-Protein
-	I-Protein
globin	I-Protein
to	O
beta	B-Protein
-	I-Protein
globin	I-Protein
switch	O
.	O
<EOS>	B-X
A	B-X
switch	B-X
from	B-X
human	B-X
fetal	B-X
(	B-X
gamma	B-X
)	B-X
-to	B-X
adult	B-X
(	B-X
beta	B-X
)	B-X
-globin	B-X
expression	B-X
occurs	B-X
within	B-X
erythroid	B-X
precursor	B-X
cells	B-X
of	B-X
the	B-X
adult	B-X
lineage	B-X
.	B-X
Previously	B-X
we	B-X
and	B-X
others	B-X
showed	B-X
by	B-X
targeted	B-X
gene	B-X
disruption	B-X
that	B-X
the	B-X
zinc	B-X
finger	B-X
gene	B-X
,	B-X
erythroid	B-X
Krüppel-like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
,	B-X
is	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
the	B-X
beta-globin	B-X
gene	B-X
in	B-X
mice	B-X
,	B-X
presumably	B-X
through	B-X
interaction	B-X
with	B-X
a	B-X
high-affinity	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
proximal	B-X
promoter	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
EKLF	B-X
in	B-X
the	B-X
developmental	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
gamma-globin	B-X
gene	B-X
we	B-X
interbred	B-X
EKLF	B-X
heterozygotes	B-X
(	B-X
+/-	B-X
)	B-X
with	B-X
mice	B-X
harboring	B-X
a	B-X
human	B-X
beta-globin	B-X
yeast	B-X
artificial	B-X
chromosome	B-X
transgene	B-X
.	B-X
We	B-X
find	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EKLF	B-X
,	B-X
while	B-X
human	B-X
beta-globin	B-X
expression	B-X
is	B-X
dramatically	B-X
reduced	B-X
,	B-X
gamma-globin	B-X
transcripts	B-X
are	B-X
elevated	B-X
approximately	B-X
5-fold	B-X
.	B-X
Impaired	B-X
silencing	B-X
of	B-X
gamma-globin	B-X
expression	B-X
identifies	B-X
EKLF	B-X
as	B-X
the	B-X
first	B-X
transcription	B-X
factor	B-X
participating	B-X
quantitatively	B-X
in	B-X
the	B-X
gamma-globin	B-X
to	B-X
beta-globin	B-X
switch	B-X
.	B-X
Our	B-X
findings	B-X
are	B-X
compatible	B-X
with	B-X
a	B-X
competitive	B-X
model	B-X
of	B-X
switching	B-X
in	B-X
which	B-X
EKLF	B-X
mediates	B-X
an	B-X
adult	B-X
stage-specific	B-X
interaction	B-X
between	B-X
the	B-X
beta-globin	B-X
gene	B-X
promoter	B-X
and	B-X
the	B-X
locus	B-X
control	B-X
region	B-X
that	B-X
excludes	B-X
the	B-X
gamma-globin	B-X
gene	B-X
.	B-X

Our	O
findings	O
are	O
compatible	O
with	O
a	O
competitive	O
model	O
of	O
switching	O
in	O
which	O
EKLF	B-Protein
mediates	O
an	O
adult	O
stage	O
-	O
specific	O
interaction	O
between	O
the	O
beta	B-Protein
-	I-Protein
globin	I-Protein
gene	O
promoter	O
and	O
the	O
locus	O
control	O
region	O
that	O
excludes	O
the	O
gamma	B-Protein
-	I-Protein
globin	I-Protein
gene	O
.	O
<EOS>	B-X
Globin	B-X
genes	B-X
are	B-X
subject	B-X
to	B-X
tissue-specific	B-X
and	B-X
developmental	B-X
stage-specific	B-X
regulation	B-X
.	B-X
A	B-X
switch	B-X
from	B-X
human	B-X
fetal	B-X
(	B-X
gamma	B-X
)	B-X
-to	B-X
adult	B-X
(	B-X
beta	B-X
)	B-X
-globin	B-X
expression	B-X
occurs	B-X
within	B-X
erythroid	B-X
precursor	B-X
cells	B-X
of	B-X
the	B-X
adult	B-X
lineage	B-X
.	B-X
Previously	B-X
we	B-X
and	B-X
others	B-X
showed	B-X
by	B-X
targeted	B-X
gene	B-X
disruption	B-X
that	B-X
the	B-X
zinc	B-X
finger	B-X
gene	B-X
,	B-X
erythroid	B-X
Krüppel-like	B-X
factor	B-X
(	B-X
EKLF	B-X
)	B-X
,	B-X
is	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
the	B-X
beta-globin	B-X
gene	B-X
in	B-X
mice	B-X
,	B-X
presumably	B-X
through	B-X
interaction	B-X
with	B-X
a	B-X
high-affinity	B-X
binding	B-X
site	B-X
in	B-X
the	B-X
proximal	B-X
promoter	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
EKLF	B-X
in	B-X
the	B-X
developmental	B-X
regulation	B-X
of	B-X
the	B-X
human	B-X
gamma-globin	B-X
gene	B-X
we	B-X
interbred	B-X
EKLF	B-X
heterozygotes	B-X
(	B-X
+/-	B-X
)	B-X
with	B-X
mice	B-X
harboring	B-X
a	B-X
human	B-X
beta-globin	B-X
yeast	B-X
artificial	B-X
chromosome	B-X
transgene	B-X
.	B-X
We	B-X
find	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EKLF	B-X
,	B-X
while	B-X
human	B-X
beta-globin	B-X
expression	B-X
is	B-X
dramatically	B-X
reduced	B-X
,	B-X
gamma-globin	B-X
transcripts	B-X
are	B-X
elevated	B-X
approximately	B-X
5-fold	B-X
.	B-X
Impaired	B-X
silencing	B-X
of	B-X
gamma-globin	B-X
expression	B-X
identifies	B-X
EKLF	B-X
as	B-X
the	B-X
first	B-X
transcription	B-X
factor	B-X
participating	B-X
quantitatively	B-X
in	B-X
the	B-X
gamma-globin	B-X
to	B-X
beta-globin	B-X
switch	B-X
.	B-X
Our	B-X
findings	B-X
are	B-X
compatible	B-X
with	B-X
a	B-X
competitive	B-X
model	B-X
of	B-X
switching	B-X
in	B-X
which	B-X
EKLF	B-X
mediates	B-X
an	B-X
adult	B-X
stage-specific	B-X
interaction	B-X
between	B-X
the	B-X
beta-globin	B-X
gene	B-X
promoter	B-X
and	B-X
the	B-X
locus	B-X
control	B-X
region	B-X
that	B-X
excludes	B-X
the	B-X
gamma-globin	B-X
gene	B-X
.	B-X

Nasal	O
NK	O
-	O
and	O
T	O
-	O
cell	O
lymphomas	O
share	O
the	O
same	O
type	O
of	O
Epstein	O
-	O
Barr	O
virus	O
latency	O
as	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
'	O
s	O
disease	O
.	O

Nasal	O
T	O
/	O
NK	O
-	O
cell	O
lymphomas	O
can	O
be	O
further	O
separated	O
into	O
those	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lineage	O
or	O
of	O
T	O
-	O
cell	O
lineage	O
,	O
with	O
differences	O
in	O
cellular	O
phenotype	O
,	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
gene	O
rearrangement	O
and	O
TcR	O
transcript	O
expression	O
.	O
<EOS>	B-X
Although	B-X
nasal	B-X
lymphomas	B-X
showing	B-X
midfacial	B-X
destructive	B-X
lesions	B-X
had	B-X
been	B-X
classified	B-X
as	B-X
T-cell	B-X
lymphomas	B-X
,	B-X
their	B-X
exact	B-X
cellular	B-X
origin	B-X
is	B-X
still	B-X
unclear	B-X
.	B-X
Although	B-X
they	B-X
usually	B-X
express	B-X
a	B-X
restricted	B-X
number	B-X
of	B-X
T-cell-related	B-X
antigens	B-X
,	B-X
namely	B-X
,	B-X
CD2	B-X
,	B-X
CD43	B-X
,	B-X
and	B-X
CD45RO	B-X
,	B-X
other	B-X
pan-T	B-X
or	B-X
subset-T-lineage	B-X
antigens	B-X
,	B-X
such	B-X
as	B-X
CD3	B-X
(	B-X
membrane	B-X
)	B-X
,	B-X
CD5	B-X
,	B-X
CD4	B-X
,	B-X
CD8	B-X
,	B-X
and	B-X
CD7	B-X
,	B-X
are	B-X
frequently	B-X
absent	B-X
.	B-X
Conversely	B-X
,	B-X
they	B-X
often	B-X
express	B-X
a	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell-associated	B-X
antigen	B-X
,	B-X
CD56	B-X
,	B-X
but	B-X
lack	B-X
other	B-X
mature	B-X
NK	B-X
markets	B-X
.	B-X
To	B-X
study	B-X
their	B-X
cellular	B-X
origin	B-X
further	B-X
,	B-X
the	B-X
authors	B-X
analyzed	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
gene	B-X
transcription	B-X
in	B-X
three	B-X
cases	B-X
of	B-X
nasal	B-X
lymphomas	B-X
and	B-X
correlated	B-X
the	B-X
findings	B-X
with	B-X
the	B-X
phenotype	B-X
and	B-X
gene	B-X
rearrangement	B-X
data	B-X
.	B-X
Two	B-X
cases	B-X
of	B-X
nasal	B-X
lymphomas	B-X
with	B-X
CD2+CD3	B-X
(	B-X
Leu4	B-X
)	B-X
-CD19-CD56+	B-X
phenotype	B-X
were	B-X
shown	B-X
to	B-X
express	B-X
truncated	B-X
1.0-kb	B-X
Tbeta	B-X
and	B-X
multiple	B-X
unrearranged	B-X
Tdelta	B-X
transcripts	B-X
with	B-X
germline	B-X
TCR	B-X
beta	B-X
,	B-X
gamma	B-X
,	B-X
delta	B-X
,	B-X
and	B-X
immunoglobulin	B-X
heavy-chain	B-X
joining	B-X
region	B-X
(	B-X
JH	B-X
)	B-X
genes	B-X
,	B-X
consistent	B-X
with	B-X
NK	B-X
cell	B-X
lineage	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
one	B-X
case	B-X
of	B-X
nasal	B-X
lymphoma	B-X
with	B-X
CD2+CD3	B-X
(	B-X
Leu4	B-X
)	B-X
+CD8+CD19-CD56+	B-X
phenotype	B-X
expressed	B-X
full-length	B-X
Talpha	B-X
,	B-X
Tbeta	B-X
,	B-X
and	B-X
Tgamma	B-X
transcripts	B-X
rearranged	B-X
TCR	B-X
beta	B-X
,	B-X
gamma	B-X
,	B-X
and	B-X
deleted	B-X
TCR	B-X
delta	B-X
genes	B-X
,	B-X
indicating	B-X
T-lineage	B-X
,	B-X
These	B-X
results	B-X
support	B-X
the	B-X
view	B-X
that	B-X
nasal	B-X
lymphomas	B-X
can	B-X
separated	B-X
into	B-X
NK-cell	B-X
and	B-X
T-cell	B-X
neoplasms	B-X
,	B-X
based	B-X
on	B-X
differences	B-X
genotypic	B-X
characteristics	B-X
.	B-X
The	B-X
possibility	B-X
of	B-X
these	B-X
tumors	B-X
being	B-X
derived	B-X
from	B-X
a	B-X
putative	B-X
common	B-X
precursor	B-X
cell	B-X
merits	B-X
further	B-X
investigation	B-X
.	B-X

Both	O
NK	O
-	O
and	O
T	O
-	O
cell	O
subtypes	O
are	O
closely	O
associated	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

In	O
this	O
study	O
,	O
EBV	O
gene	O
expression	O
was	O
determined	O
in	O
23	O
cases	O
of	O
nasal	O
lymphoma	O
(	O
NL	O
)	O
by	O
in	O
situ	O
hybridisation	O
(	O
ISH	O
)	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
immunohistochemistry	O
(	O
IH	O
)	O
.	O
<EOS>	B-X
Nasal	B-X
T/NK-cell	B-X
lymphomas	B-X
can	B-X
be	B-X
further	B-X
separated	B-X
into	B-X
those	B-X
of	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
lineage	B-X
or	B-X
of	B-X
T-cell	B-X
lineage	B-X
,	B-X
with	B-X
differences	B-X
in	B-X
cellular	B-X
phenotype	B-X
,	B-X
T-cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
gene	B-X
rearrangement	B-X
and	B-X
TcR	B-X
transcript	B-X
expression	B-X
.	B-X
Both	B-X
NK-	B-X
and	B-X
T-cell	B-X
subtypes	B-X
are	B-X
closely	B-X
associated	B-X
with	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
EBV	B-X
gene	B-X
expression	B-X
was	B-X
determined	B-X
in	B-X
23	B-X
cases	B-X
of	B-X
nasal	B-X
lymphoma	B-X
(	B-X
NL	B-X
)	B-X
by	B-X
in	B-X
situ	B-X
hybridisation	B-X
(	B-X
ISH	B-X
)	B-X
,	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
and	B-X
immunohistochemistry	B-X
(	B-X
IH	B-X
)	B-X
.	B-X
Of	B-X
the	B-X
23	B-X
cases	B-X
,	B-X
19	B-X
were	B-X
classified	B-X
as	B-X
NK-cell	B-X
and	B-X
4	B-X
as	B-X
T-cell	B-X
tumours	B-X
.	B-X
ISH	B-X
for	B-X
EBV-encoded	B-X
small	B-X
non-polyadenylated	B-X
RNAs	B-X
showed	B-X
that	B-X
all	B-X
cases	B-X
,	B-X
whether	B-X
NK	B-X
or	B-X
T	B-X
,	B-X
harboured	B-X
EBV	B-X
in	B-X
virtually	B-X
all	B-X
tumour	B-X
cells	B-X
.	B-X
RT-PCR	B-X
demonstrated	B-X
that	B-X
NL	B-X
of	B-X
both	B-X
subtypes	B-X
expressed	B-X
EBNAI	B-X
of	B-X
the	B-X
QUK	B-X
splice	B-X
pattern	B-X
,	B-X
the	B-X
latent	B-X
membrane	B-X
proteins	B-X
,	B-X
LMP1	B-X
and	B-X
2	B-X
and	B-X
the	B-X
BamHI	B-X
A	B-X
rightward	B-X
transcripts	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EBNA2	B-X
mRNAs	B-X
,	B-X
compatible	B-X
with	B-X
the	B-X
latency	B-X
type	B-X
II	B-X
pattern	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
analysis	B-X
of	B-X
EBV	B-X
protein	B-X
expression	B-X
by	B-X
IH	B-X
revealed	B-X
a	B-X
heterogeneous	B-X
pattern	B-X
of	B-X
EBV	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
single-cell	B-X
level	B-X
consisting	B-X
of	B-X
both	B-X
LMP1+	B-X
and	B-X
LMP1-	B-X
tumour	B-X
cells	B-X
,	B-X
suggesting	B-X
a	B-X
mixture	B-X
of	B-X
latency	B-X
I	B-X
and	B-X
II	B-X
.	B-X
Although	B-X
2	B-X
early	B-X
lytic	B-X
transcripts	B-X
,	B-X
BZLF1	B-X
and	B-X
BHRF1	B-X
,	B-X
were	B-X
also	B-X
detected	B-X
in	B-X
13	B-X
and	B-X
10	B-X
cases	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
lack	B-X
of	B-X
ZEBRA	B-X
staining	B-X
in	B-X
any	B-X
case	B-X
indicates	B-X
that	B-X
these	B-X
lytic	B-X
transcripts	B-X
are	B-X
most	B-X
likely	B-X
expressed	B-X
by	B-X
rare	B-X
cells	B-X
in	B-X
the	B-X
biopsies	B-X
entering	B-X
lytic	B-X
cycle	B-X
.	B-X
The	B-X
viral	B-X
transcriptional	B-X
pattern	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
nasopharyngeal	B-X
carcinoma	B-X
and	B-X
Hodgkin	B-X
's	B-X
disease	B-X
suggests	B-X
that	B-X
EBV	B-X
can	B-X
exploit	B-X
common	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
gene	B-X
transcription	B-X
in	B-X
diverse	B-X
host	B-X
cell	B-X
types	B-X
.	B-X
Down-regulation	B-X
of	B-X
immunogenic	B-X
proteins	B-X
(	B-X
EBNA2-EBNA6	B-X
)	B-X
in	B-X
nasal	B-X
lymphoma	B-X
may	B-X
enable	B-X
tumour	B-X
cells	B-X
to	B-X
evade	B-X
host	B-X
cytotoxic	B-X
T-cell	B-X
surveillance	B-X
.	B-X

Of	O
the	O
23	O
cases	O
,	O
19	O
were	O
classified	O
as	O
NK	O
-	O
cell	O
and	O
4	O
as	O
T	O
-	O
cell	O
tumours	O
.	O

ISH	O
for	O
EBV	O
-	O
encoded	O
small	O
non	O
-	O
polyadenylated	O
RNAs	O
showed	O
that	O
all	O
cases	O
,	O
whether	O
NK	O
or	O
T	O
,	O
harboured	O
EBV	O
in	O
virtually	O
all	O
tumour	O
cells	O
.	O
<EOS>	B-X
Extranodal	B-X
NK/T-cell	B-X
lymphoma	B-X
is	B-X
a	B-X
neoplasm	B-X
of	B-X
NK	B-X
cells	B-X
or	B-X
cytotoxic	B-X
T	B-X
cells	B-X
presenting	B-X
in	B-X
extranodal	B-X
sites	B-X
,	B-X
most	B-X
often	B-X
in	B-X
the	B-X
nasal	B-X
cavity	B-X
.	B-X
Tumor	B-X
subsets	B-X
express	B-X
NK	B-X
cell	B-X
receptors	B-X
,	B-X
CD95/CD95L	B-X
,	B-X
CD30	B-X
,	B-X
MYC	B-X
,	B-X
and	B-X
PDL1	B-X
.	B-X
Virtually	B-X
all	B-X
the	B-X
tumor	B-X
cells	B-X
harbor	B-X
the	B-X
EBV	B-X
genome	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
lymphomagenesis	B-X
as	B-X
an	B-X
epigenetic	B-X
driver	B-X
.	B-X
EBV-encoded	B-X
oncoproteins	B-X
modulate	B-X
the	B-X
host-cell	B-X
epigenetic	B-X
machinery	B-X
,	B-X
reprogramming	B-X
the	B-X
viral	B-X
and	B-X
host	B-X
epigenomes	B-X
using	B-X
host	B-X
epigenetic	B-X
modifiers	B-X
.	B-X
NGS	B-X
analysis	B-X
revealed	B-X
the	B-X
mutational	B-X
landscape	B-X
of	B-X
ENKTL	B-X
,	B-X
predominantly	B-X
involving	B-X
the	B-X
JAK-STAT	B-X
pathway	B-X
,	B-X
epigenetic	B-X
modifications	B-X
,	B-X
the	B-X
RNA	B-X
helicase	B-X
family	B-X
,	B-X
the	B-X
RAS/MAP	B-X
kinase	B-X
pathway	B-X
,	B-X
and	B-X
tumor	B-X
suppressors	B-X
,	B-X
which	B-X
indicate	B-X
an	B-X
important	B-X
role	B-X
of	B-X
these	B-X
pathways	B-X
and	B-X
this	B-X
group	B-X
of	B-X
genes	B-X
in	B-X
the	B-X
lymphomagenesis	B-X
of	B-X
ENKTL	B-X
.	B-X
Recently	B-X
,	B-X
three	B-X
molecular	B-X
subtypes	B-X
were	B-X
proposed	B-X
,	B-X
the	B-X
tumor-suppressor/immune-modulator	B-X
(	B-X
TSIM	B-X
)	B-X
,	B-X
MGA-BRDT	B-X
(	B-X
MB	B-X
)	B-X
,	B-X
and	B-X
HDAC9-EP300-ARID1A	B-X
(	B-X
HEA	B-X
)	B-X
subtypes	B-X
,	B-X
and	B-X
they	B-X
are	B-X
well-correlated	B-X
with	B-X
the	B-X
cell	B-X
of	B-X
origin	B-X
,	B-X
EBV	B-X
pattern	B-X
,	B-X
genomic	B-X
alterations	B-X
,	B-X
and	B-X
clinical	B-X
outcomes	B-X
.	B-X
A	B-X
future	B-X
investigation	B-X
into	B-X
the	B-X
function	B-X
and	B-X
interaction	B-X
of	B-X
discovered	B-X
genes	B-X
would	B-X
be	B-X
very	B-X
helpful	B-X
for	B-X
better	B-X
understanding	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
ENKTL	B-X
and	B-X
establishing	B-X
better	B-X
treatment	B-X
strategies	B-X
.	B-X

RT	O
-	O
PCR	O
demonstrated	O
that	O
NL	O
of	O
both	O
subtypes	O
expressed	O
EBNAI	B-Protein
of	O
the	O
QUK	O
splice	O
pattern	O
,	O
the	O
latent	O
membrane	O
proteins	O
,	O
LMP1	B-Protein
and	O
2	B-Protein
and	O
the	O
BamHI	O
A	O
rightward	O
transcripts	O
in	O
the	O
absence	O
of	O
EBNA2	B-Protein
mRNAs	O
,	O
compatible	O
with	O
the	O
latency	O
type	O
II	O
pattern	O
.	O
<EOS>	B-X
Nasal	B-X
T/NK-cell	B-X
lymphomas	B-X
can	B-X
be	B-X
further	B-X
separated	B-X
into	B-X
those	B-X
of	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
lineage	B-X
or	B-X
of	B-X
T-cell	B-X
lineage	B-X
,	B-X
with	B-X
differences	B-X
in	B-X
cellular	B-X
phenotype	B-X
,	B-X
T-cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
gene	B-X
rearrangement	B-X
and	B-X
TcR	B-X
transcript	B-X
expression	B-X
.	B-X
Both	B-X
NK-	B-X
and	B-X
T-cell	B-X
subtypes	B-X
are	B-X
closely	B-X
associated	B-X
with	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
EBV	B-X
gene	B-X
expression	B-X
was	B-X
determined	B-X
in	B-X
23	B-X
cases	B-X
of	B-X
nasal	B-X
lymphoma	B-X
(	B-X
NL	B-X
)	B-X
by	B-X
in	B-X
situ	B-X
hybridisation	B-X
(	B-X
ISH	B-X
)	B-X
,	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
and	B-X
immunohistochemistry	B-X
(	B-X
IH	B-X
)	B-X
.	B-X
Of	B-X
the	B-X
23	B-X
cases	B-X
,	B-X
19	B-X
were	B-X
classified	B-X
as	B-X
NK-cell	B-X
and	B-X
4	B-X
as	B-X
T-cell	B-X
tumours	B-X
.	B-X
RT-PCR	B-X
demonstrated	B-X
that	B-X
NL	B-X
of	B-X
both	B-X
subtypes	B-X
expressed	B-X
EBNAI	B-X
of	B-X
the	B-X
QUK	B-X
splice	B-X
pattern	B-X
,	B-X
the	B-X
latent	B-X
membrane	B-X
proteins	B-X
,	B-X
LMP1	B-X
and	B-X
2	B-X
and	B-X
the	B-X
BamHI	B-X
A	B-X
rightward	B-X
transcripts	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EBNA2	B-X
mRNAs	B-X
,	B-X
compatible	B-X
with	B-X
the	B-X
latency	B-X
type	B-X
II	B-X
pattern	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
analysis	B-X
of	B-X
EBV	B-X
protein	B-X
expression	B-X
by	B-X
IH	B-X
revealed	B-X
a	B-X
heterogeneous	B-X
pattern	B-X
of	B-X
EBV	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
single-cell	B-X
level	B-X
consisting	B-X
of	B-X
both	B-X
LMP1+	B-X
and	B-X
LMP1-	B-X
tumour	B-X
cells	B-X
,	B-X
suggesting	B-X
a	B-X
mixture	B-X
of	B-X
latency	B-X
I	B-X
and	B-X
II	B-X
.	B-X
Although	B-X
2	B-X
early	B-X
lytic	B-X
transcripts	B-X
,	B-X
BZLF1	B-X
and	B-X
BHRF1	B-X
,	B-X
were	B-X
also	B-X
detected	B-X
in	B-X
13	B-X
and	B-X
10	B-X
cases	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
lack	B-X
of	B-X
ZEBRA	B-X
staining	B-X
in	B-X
any	B-X
case	B-X
indicates	B-X
that	B-X
these	B-X
lytic	B-X
transcripts	B-X
are	B-X
most	B-X
likely	B-X
expressed	B-X
by	B-X
rare	B-X
cells	B-X
in	B-X
the	B-X
biopsies	B-X
entering	B-X
lytic	B-X
cycle	B-X
.	B-X
The	B-X
viral	B-X
transcriptional	B-X
pattern	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
nasopharyngeal	B-X
carcinoma	B-X
and	B-X
Hodgkin	B-X
's	B-X
disease	B-X
suggests	B-X
that	B-X
EBV	B-X
can	B-X
exploit	B-X
common	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
gene	B-X
transcription	B-X
in	B-X
diverse	B-X
host	B-X
cell	B-X
types	B-X
.	B-X
Down-regulation	B-X
of	B-X
immunogenic	B-X
proteins	B-X
(	B-X
EBNA2-EBNA6	B-X
)	B-X
in	B-X
nasal	B-X
lymphoma	B-X
may	B-X
enable	B-X
tumour	B-X
cells	B-X
to	B-X
evade	B-X
host	B-X
cytotoxic	B-X
T-cell	B-X
surveillance	B-X
.	B-X

In	O
addition	O
,	O
analysis	O
of	O
EBV	O
protein	O
expression	O
by	O
IH	O
revealed	O
a	O
heterogeneous	O
pattern	O
of	O
EBV	O
gene	O
expression	O
at	O
the	O
single	O
-	O
cell	O
level	O
consisting	O
of	O
both	O
LMP1	B-Protein
+	O
and	O
LMP1	B-Protein
-	O
tumour	O
cells	O
,	O
suggesting	O
a	O
mixture	O
of	O
latency	O
I	O
and	O
II	O
.	O
<EOS>	B-X
Nasal	B-X
T/NK-cell	B-X
lymphomas	B-X
can	B-X
be	B-X
further	B-X
separated	B-X
into	B-X
those	B-X
of	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
lineage	B-X
or	B-X
of	B-X
T-cell	B-X
lineage	B-X
,	B-X
with	B-X
differences	B-X
in	B-X
cellular	B-X
phenotype	B-X
,	B-X
T-cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
gene	B-X
rearrangement	B-X
and	B-X
TcR	B-X
transcript	B-X
expression	B-X
.	B-X
Both	B-X
NK-	B-X
and	B-X
T-cell	B-X
subtypes	B-X
are	B-X
closely	B-X
associated	B-X
with	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
EBV	B-X
gene	B-X
expression	B-X
was	B-X
determined	B-X
in	B-X
23	B-X
cases	B-X
of	B-X
nasal	B-X
lymphoma	B-X
(	B-X
NL	B-X
)	B-X
by	B-X
in	B-X
situ	B-X
hybridisation	B-X
(	B-X
ISH	B-X
)	B-X
,	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
and	B-X
immunohistochemistry	B-X
(	B-X
IH	B-X
)	B-X
.	B-X
Of	B-X
the	B-X
23	B-X
cases	B-X
,	B-X
19	B-X
were	B-X
classified	B-X
as	B-X
NK-cell	B-X
and	B-X
4	B-X
as	B-X
T-cell	B-X
tumours	B-X
.	B-X
ISH	B-X
for	B-X
EBV-encoded	B-X
small	B-X
non-polyadenylated	B-X
RNAs	B-X
showed	B-X
that	B-X
all	B-X
cases	B-X
,	B-X
whether	B-X
NK	B-X
or	B-X
T	B-X
,	B-X
harboured	B-X
EBV	B-X
in	B-X
virtually	B-X
all	B-X
tumour	B-X
cells	B-X
.	B-X
RT-PCR	B-X
demonstrated	B-X
that	B-X
NL	B-X
of	B-X
both	B-X
subtypes	B-X
expressed	B-X
EBNAI	B-X
of	B-X
the	B-X
QUK	B-X
splice	B-X
pattern	B-X
,	B-X
the	B-X
latent	B-X
membrane	B-X
proteins	B-X
,	B-X
LMP1	B-X
and	B-X
2	B-X
and	B-X
the	B-X
BamHI	B-X
A	B-X
rightward	B-X
transcripts	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EBNA2	B-X
mRNAs	B-X
,	B-X
compatible	B-X
with	B-X
the	B-X
latency	B-X
type	B-X
II	B-X
pattern	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
analysis	B-X
of	B-X
EBV	B-X
protein	B-X
expression	B-X
by	B-X
IH	B-X
revealed	B-X
a	B-X
heterogeneous	B-X
pattern	B-X
of	B-X
EBV	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
single-cell	B-X
level	B-X
consisting	B-X
of	B-X
both	B-X
LMP1+	B-X
and	B-X
LMP1-	B-X
tumour	B-X
cells	B-X
,	B-X
suggesting	B-X
a	B-X
mixture	B-X
of	B-X
latency	B-X
I	B-X
and	B-X
II	B-X
.	B-X
Although	B-X
2	B-X
early	B-X
lytic	B-X
transcripts	B-X
,	B-X
BZLF1	B-X
and	B-X
BHRF1	B-X
,	B-X
were	B-X
also	B-X
detected	B-X
in	B-X
13	B-X
and	B-X
10	B-X
cases	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
lack	B-X
of	B-X
ZEBRA	B-X
staining	B-X
in	B-X
any	B-X
case	B-X
indicates	B-X
that	B-X
these	B-X
lytic	B-X
transcripts	B-X
are	B-X
most	B-X
likely	B-X
expressed	B-X
by	B-X
rare	B-X
cells	B-X
in	B-X
the	B-X
biopsies	B-X
entering	B-X
lytic	B-X
cycle	B-X
.	B-X
The	B-X
viral	B-X
transcriptional	B-X
pattern	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
nasopharyngeal	B-X
carcinoma	B-X
and	B-X
Hodgkin	B-X
's	B-X
disease	B-X
suggests	B-X
that	B-X
EBV	B-X
can	B-X
exploit	B-X
common	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
gene	B-X
transcription	B-X
in	B-X
diverse	B-X
host	B-X
cell	B-X
types	B-X
.	B-X
Down-regulation	B-X
of	B-X
immunogenic	B-X
proteins	B-X
(	B-X
EBNA2-EBNA6	B-X
)	B-X
in	B-X
nasal	B-X
lymphoma	B-X
may	B-X
enable	B-X
tumour	B-X
cells	B-X
to	B-X
evade	B-X
host	B-X
cytotoxic	B-X
T-cell	B-X
surveillance	B-X
.	B-X

Although	O
2	O
early	O
lytic	O
transcripts	O
,	O
BZLF1	B-Protein
and	O
BHRF1	B-Protein
,	O
were	O
also	O
detected	O
in	O
13	O
and	O
10	O
cases	O
,	O
respectively	O
,	O
the	O
lack	O
of	O
ZEBRA	B-Protein
staining	O
in	O
any	O
case	O
indicates	O
that	O
these	O
lytic	O
transcripts	O
are	O
most	O
likely	O
expressed	O
by	O
rare	O
cells	O
in	O
the	O
biopsies	O
entering	O
lytic	O
cycle	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
EBV	B-X
gene	B-X
expression	B-X
was	B-X
determined	B-X
in	B-X
23	B-X
cases	B-X
of	B-X
nasal	B-X
lymphoma	B-X
(	B-X
NL	B-X
)	B-X
by	B-X
in	B-X
situ	B-X
hybridisation	B-X
(	B-X
ISH	B-X
)	B-X
,	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
and	B-X
immunohistochemistry	B-X
(	B-X
IH	B-X
)	B-X
.	B-X
Of	B-X
the	B-X
23	B-X
cases	B-X
,	B-X
19	B-X
were	B-X
classified	B-X
as	B-X
NK-cell	B-X
and	B-X
4	B-X
as	B-X
T-cell	B-X
tumours	B-X
.	B-X
ISH	B-X
for	B-X
EBV-encoded	B-X
small	B-X
non-polyadenylated	B-X
RNAs	B-X
showed	B-X
that	B-X
all	B-X
cases	B-X
,	B-X
whether	B-X
NK	B-X
or	B-X
T	B-X
,	B-X
harboured	B-X
EBV	B-X
in	B-X
virtually	B-X
all	B-X
tumour	B-X
cells	B-X
.	B-X
RT-PCR	B-X
demonstrated	B-X
that	B-X
NL	B-X
of	B-X
both	B-X
subtypes	B-X
expressed	B-X
EBNAI	B-X
of	B-X
the	B-X
QUK	B-X
splice	B-X
pattern	B-X
,	B-X
the	B-X
latent	B-X
membrane	B-X
proteins	B-X
,	B-X
LMP1	B-X
and	B-X
2	B-X
and	B-X
the	B-X
BamHI	B-X
A	B-X
rightward	B-X
transcripts	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EBNA2	B-X
mRNAs	B-X
,	B-X
compatible	B-X
with	B-X
the	B-X
latency	B-X
type	B-X
II	B-X
pattern	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
analysis	B-X
of	B-X
EBV	B-X
protein	B-X
expression	B-X
by	B-X
IH	B-X
revealed	B-X
a	B-X
heterogeneous	B-X
pattern	B-X
of	B-X
EBV	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
single-cell	B-X
level	B-X
consisting	B-X
of	B-X
both	B-X
LMP1+	B-X
and	B-X
LMP1-	B-X
tumour	B-X
cells	B-X
,	B-X
suggesting	B-X
a	B-X
mixture	B-X
of	B-X
latency	B-X
I	B-X
and	B-X
II	B-X
.	B-X
Although	B-X
2	B-X
early	B-X
lytic	B-X
transcripts	B-X
,	B-X
BZLF1	B-X
and	B-X
BHRF1	B-X
,	B-X
were	B-X
also	B-X
detected	B-X
in	B-X
13	B-X
and	B-X
10	B-X
cases	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
lack	B-X
of	B-X
ZEBRA	B-X
staining	B-X
in	B-X
any	B-X
case	B-X
indicates	B-X
that	B-X
these	B-X
lytic	B-X
transcripts	B-X
are	B-X
most	B-X
likely	B-X
expressed	B-X
by	B-X
rare	B-X
cells	B-X
in	B-X
the	B-X
biopsies	B-X
entering	B-X
lytic	B-X
cycle	B-X
.	B-X
Down-regulation	B-X
of	B-X
immunogenic	B-X
proteins	B-X
(	B-X
EBNA2-EBNA6	B-X
)	B-X
in	B-X
nasal	B-X
lymphoma	B-X
may	B-X
enable	B-X
tumour	B-X
cells	B-X
to	B-X
evade	B-X
host	B-X
cytotoxic	B-X
T-cell	B-X
surveillance	B-X
.	B-X

The	O
viral	O
transcriptional	O
pattern	O
similar	O
to	O
that	O
of	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
'	O
s	O
disease	O
suggests	O
that	O
EBV	O
can	O
exploit	O
common	O
regulatory	O
mechanisms	O
for	O
gene	O
transcription	O
in	O
diverse	O
host	O
cell	O
types	O
.	O
<EOS>	B-X
Nasal	B-X
T/NK-cell	B-X
lymphomas	B-X
can	B-X
be	B-X
further	B-X
separated	B-X
into	B-X
those	B-X
of	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
lineage	B-X
or	B-X
of	B-X
T-cell	B-X
lineage	B-X
,	B-X
with	B-X
differences	B-X
in	B-X
cellular	B-X
phenotype	B-X
,	B-X
T-cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
gene	B-X
rearrangement	B-X
and	B-X
TcR	B-X
transcript	B-X
expression	B-X
.	B-X
Both	B-X
NK-	B-X
and	B-X
T-cell	B-X
subtypes	B-X
are	B-X
closely	B-X
associated	B-X
with	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
EBV	B-X
gene	B-X
expression	B-X
was	B-X
determined	B-X
in	B-X
23	B-X
cases	B-X
of	B-X
nasal	B-X
lymphoma	B-X
(	B-X
NL	B-X
)	B-X
by	B-X
in	B-X
situ	B-X
hybridisation	B-X
(	B-X
ISH	B-X
)	B-X
,	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
and	B-X
immunohistochemistry	B-X
(	B-X
IH	B-X
)	B-X
.	B-X
Of	B-X
the	B-X
23	B-X
cases	B-X
,	B-X
19	B-X
were	B-X
classified	B-X
as	B-X
NK-cell	B-X
and	B-X
4	B-X
as	B-X
T-cell	B-X
tumours	B-X
.	B-X
ISH	B-X
for	B-X
EBV-encoded	B-X
small	B-X
non-polyadenylated	B-X
RNAs	B-X
showed	B-X
that	B-X
all	B-X
cases	B-X
,	B-X
whether	B-X
NK	B-X
or	B-X
T	B-X
,	B-X
harboured	B-X
EBV	B-X
in	B-X
virtually	B-X
all	B-X
tumour	B-X
cells	B-X
.	B-X
RT-PCR	B-X
demonstrated	B-X
that	B-X
NL	B-X
of	B-X
both	B-X
subtypes	B-X
expressed	B-X
EBNAI	B-X
of	B-X
the	B-X
QUK	B-X
splice	B-X
pattern	B-X
,	B-X
the	B-X
latent	B-X
membrane	B-X
proteins	B-X
,	B-X
LMP1	B-X
and	B-X
2	B-X
and	B-X
the	B-X
BamHI	B-X
A	B-X
rightward	B-X
transcripts	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EBNA2	B-X
mRNAs	B-X
,	B-X
compatible	B-X
with	B-X
the	B-X
latency	B-X
type	B-X
II	B-X
pattern	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
analysis	B-X
of	B-X
EBV	B-X
protein	B-X
expression	B-X
by	B-X
IH	B-X
revealed	B-X
a	B-X
heterogeneous	B-X
pattern	B-X
of	B-X
EBV	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
single-cell	B-X
level	B-X
consisting	B-X
of	B-X
both	B-X
LMP1+	B-X
and	B-X
LMP1-	B-X
tumour	B-X
cells	B-X
,	B-X
suggesting	B-X
a	B-X
mixture	B-X
of	B-X
latency	B-X
I	B-X
and	B-X
II	B-X
.	B-X
Although	B-X
2	B-X
early	B-X
lytic	B-X
transcripts	B-X
,	B-X
BZLF1	B-X
and	B-X
BHRF1	B-X
,	B-X
were	B-X
also	B-X
detected	B-X
in	B-X
13	B-X
and	B-X
10	B-X
cases	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
lack	B-X
of	B-X
ZEBRA	B-X
staining	B-X
in	B-X
any	B-X
case	B-X
indicates	B-X
that	B-X
these	B-X
lytic	B-X
transcripts	B-X
are	B-X
most	B-X
likely	B-X
expressed	B-X
by	B-X
rare	B-X
cells	B-X
in	B-X
the	B-X
biopsies	B-X
entering	B-X
lytic	B-X
cycle	B-X
.	B-X
The	B-X
viral	B-X
transcriptional	B-X
pattern	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
nasopharyngeal	B-X
carcinoma	B-X
and	B-X
Hodgkin	B-X
's	B-X
disease	B-X
suggests	B-X
that	B-X
EBV	B-X
can	B-X
exploit	B-X
common	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
gene	B-X
transcription	B-X
in	B-X
diverse	B-X
host	B-X
cell	B-X
types	B-X
.	B-X
Down-regulation	B-X
of	B-X
immunogenic	B-X
proteins	B-X
(	B-X
EBNA2-EBNA6	B-X
)	B-X
in	B-X
nasal	B-X
lymphoma	B-X
may	B-X
enable	B-X
tumour	B-X
cells	B-X
to	B-X
evade	B-X
host	B-X
cytotoxic	B-X
T-cell	B-X
surveillance	B-X
.	B-X

Down	O
-	O
regulation	O
of	O
immunogenic	O
proteins	O
(	O
EBNA2	B-Protein
-	O
EBNA6	B-Protein
)	O
in	O
nasal	O
lymphoma	O
may	O
enable	O
tumour	O
cells	O
to	O
evade	O
host	O
cytotoxic	O
T	O
-	O
cell	O
surveillance	O
.	O
<EOS>	B-X
Nasal	B-X
T/NK-cell	B-X
lymphomas	B-X
can	B-X
be	B-X
further	B-X
separated	B-X
into	B-X
those	B-X
of	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cell	B-X
lineage	B-X
or	B-X
of	B-X
T-cell	B-X
lineage	B-X
,	B-X
with	B-X
differences	B-X
in	B-X
cellular	B-X
phenotype	B-X
,	B-X
T-cell	B-X
receptor	B-X
(	B-X
TcR	B-X
)	B-X
gene	B-X
rearrangement	B-X
and	B-X
TcR	B-X
transcript	B-X
expression	B-X
.	B-X
Both	B-X
NK-	B-X
and	B-X
T-cell	B-X
subtypes	B-X
are	B-X
closely	B-X
associated	B-X
with	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
EBV	B-X
gene	B-X
expression	B-X
was	B-X
determined	B-X
in	B-X
23	B-X
cases	B-X
of	B-X
nasal	B-X
lymphoma	B-X
(	B-X
NL	B-X
)	B-X
by	B-X
in	B-X
situ	B-X
hybridisation	B-X
(	B-X
ISH	B-X
)	B-X
,	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
and	B-X
immunohistochemistry	B-X
(	B-X
IH	B-X
)	B-X
.	B-X
Of	B-X
the	B-X
23	B-X
cases	B-X
,	B-X
19	B-X
were	B-X
classified	B-X
as	B-X
NK-cell	B-X
and	B-X
4	B-X
as	B-X
T-cell	B-X
tumours	B-X
.	B-X
ISH	B-X
for	B-X
EBV-encoded	B-X
small	B-X
non-polyadenylated	B-X
RNAs	B-X
showed	B-X
that	B-X
all	B-X
cases	B-X
,	B-X
whether	B-X
NK	B-X
or	B-X
T	B-X
,	B-X
harboured	B-X
EBV	B-X
in	B-X
virtually	B-X
all	B-X
tumour	B-X
cells	B-X
.	B-X
RT-PCR	B-X
demonstrated	B-X
that	B-X
NL	B-X
of	B-X
both	B-X
subtypes	B-X
expressed	B-X
EBNAI	B-X
of	B-X
the	B-X
QUK	B-X
splice	B-X
pattern	B-X
,	B-X
the	B-X
latent	B-X
membrane	B-X
proteins	B-X
,	B-X
LMP1	B-X
and	B-X
2	B-X
and	B-X
the	B-X
BamHI	B-X
A	B-X
rightward	B-X
transcripts	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
EBNA2	B-X
mRNAs	B-X
,	B-X
compatible	B-X
with	B-X
the	B-X
latency	B-X
type	B-X
II	B-X
pattern	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
analysis	B-X
of	B-X
EBV	B-X
protein	B-X
expression	B-X
by	B-X
IH	B-X
revealed	B-X
a	B-X
heterogeneous	B-X
pattern	B-X
of	B-X
EBV	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
single-cell	B-X
level	B-X
consisting	B-X
of	B-X
both	B-X
LMP1+	B-X
and	B-X
LMP1-	B-X
tumour	B-X
cells	B-X
,	B-X
suggesting	B-X
a	B-X
mixture	B-X
of	B-X
latency	B-X
I	B-X
and	B-X
II	B-X
.	B-X
Although	B-X
2	B-X
early	B-X
lytic	B-X
transcripts	B-X
,	B-X
BZLF1	B-X
and	B-X
BHRF1	B-X
,	B-X
were	B-X
also	B-X
detected	B-X
in	B-X
13	B-X
and	B-X
10	B-X
cases	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
lack	B-X
of	B-X
ZEBRA	B-X
staining	B-X
in	B-X
any	B-X
case	B-X
indicates	B-X
that	B-X
these	B-X
lytic	B-X
transcripts	B-X
are	B-X
most	B-X
likely	B-X
expressed	B-X
by	B-X
rare	B-X
cells	B-X
in	B-X
the	B-X
biopsies	B-X
entering	B-X
lytic	B-X
cycle	B-X
.	B-X
The	B-X
viral	B-X
transcriptional	B-X
pattern	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
nasopharyngeal	B-X
carcinoma	B-X
and	B-X
Hodgkin	B-X
's	B-X
disease	B-X
suggests	B-X
that	B-X
EBV	B-X
can	B-X
exploit	B-X
common	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
gene	B-X
transcription	B-X
in	B-X
diverse	B-X
host	B-X
cell	B-X
types	B-X
.	B-X
Down-regulation	B-X
of	B-X
immunogenic	B-X
proteins	B-X
(	B-X
EBNA2-EBNA6	B-X
)	B-X
in	B-X
nasal	B-X
lymphoma	B-X
may	B-X
enable	B-X
tumour	B-X
cells	B-X
to	B-X
evade	B-X
host	B-X
cytotoxic	B-X
T-cell	B-X
surveillance	B-X
.	B-X

Identification	O
and	O
characterization	O
of	O
a	O
leukocyte	O
-	O
specific	O
component	O
of	O
the	O
nuclear	O
body	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
body	B-X
(	B-X
NB	B-X
)	B-X
is	B-X
a	B-X
cellular	B-X
organelle	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
serum	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
was	B-X
used	B-X
to	B-X
identify	B-X
a	B-X
cDNA	B-X
encoding	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
NB	B-X
,	B-X
a	B-X
140-kDa	B-X
protein	B-X
designated	B-X
Sp140	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
Sp140	B-X
mRNA	B-X
were	B-X
detected	B-X
in	B-X
human	B-X
spleen	B-X
and	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
,	B-X
but	B-X
not	B-X
other	B-X
human	B-X
tissues	B-X
.	B-X

The	O
nuclear	O
body	O
(	O
NB	O
)	O
is	O
a	O
cellular	O
organelle	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
body	B-X
(	B-X
NB	B-X
)	B-X
is	B-X
a	B-X
cellular	B-X
organelle	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X
The	B-X
NB	B-X
is	B-X
also	B-X
a	B-X
target	B-X
of	B-X
antibodies	B-X
in	B-X
the	B-X
serum	B-X
of	B-X
patients	B-X
with	B-X
the	B-X
autoimmune	B-X
disease	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
serum	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
was	B-X
used	B-X
to	B-X
identify	B-X
a	B-X
cDNA	B-X
encoding	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
NB	B-X
,	B-X
a	B-X
140-kDa	B-X
protein	B-X
designated	B-X
Sp140	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
amino-terminal	B-X
portion	B-X
of	B-X
Sp140	B-X
was	B-X
similar	B-X
to	B-X
Sp100	B-X
,	B-X
a	B-X
previously	B-X
identified	B-X
NB	B-X
protein	B-X
.	B-X
The	B-X
level	B-X
of	B-X
SP140	B-X
mRNA	B-X
in	B-X
myeloid	B-X
precursor	B-X
cell	B-X
lines	B-X
HL60	B-X
and	B-X
NB4	B-X
markedly	B-X
increased	B-X
in	B-X
response	B-X
to	B-X
chemically	B-X
induced	B-X
cellular	B-X
differentiation	B-X
.	B-X
Immunohistochemical	B-X
techniques	B-X
were	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
SP140	B-X
localized	B-X
to	B-X
the	B-X
NB	B-X
in	B-X
differentiated	B-X
HL60	B-X
and	B-X
NB4	B-X
cells	B-X
.	B-X
The	B-X
location	B-X
of	B-X
Sp140	B-X
in	B-X
the	B-X
NB	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
in	B-X
cells	B-X
involved	B-X
in	B-X
host	B-X
defense	B-X
,	B-X
suggest	B-X
that	B-X
Sp140	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X

The	O
NB	O
is	O
also	O
a	O
target	O
of	O
antibodies	O
in	O
the	O
serum	O
of	O
patients	O
with	O
the	O
autoimmune	O
disease	O
primary	O
biliary	O
cirrhosis	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
body	B-X
(	B-X
NB	B-X
)	B-X
is	B-X
a	B-X
cellular	B-X
organelle	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X
The	B-X
NB	B-X
is	B-X
also	B-X
a	B-X
target	B-X
of	B-X
antibodies	B-X
in	B-X
the	B-X
serum	B-X
of	B-X
patients	B-X
with	B-X
the	B-X
autoimmune	B-X
disease	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
serum	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
was	B-X
used	B-X
to	B-X
identify	B-X
a	B-X
cDNA	B-X
encoding	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
NB	B-X
,	B-X
a	B-X
140-kDa	B-X
protein	B-X
designated	B-X
Sp140	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
amino-terminal	B-X
portion	B-X
of	B-X
Sp140	B-X
was	B-X
similar	B-X
to	B-X
Sp100	B-X
,	B-X
a	B-X
previously	B-X
identified	B-X
NB	B-X
protein	B-X
.	B-X
The	B-X
level	B-X
of	B-X
SP140	B-X
mRNA	B-X
in	B-X
myeloid	B-X
precursor	B-X
cell	B-X
lines	B-X
HL60	B-X
and	B-X
NB4	B-X
markedly	B-X
increased	B-X
in	B-X
response	B-X
to	B-X
chemically	B-X
induced	B-X
cellular	B-X
differentiation	B-X
.	B-X
Immunohistochemical	B-X
techniques	B-X
were	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
SP140	B-X
localized	B-X
to	B-X
the	B-X
NB	B-X
in	B-X
differentiated	B-X
HL60	B-X
and	B-X
NB4	B-X
cells	B-X
.	B-X
The	B-X
location	B-X
of	B-X
Sp140	B-X
in	B-X
the	B-X
NB	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
in	B-X
cells	B-X
involved	B-X
in	B-X
host	B-X
defense	B-X
,	B-X
suggest	B-X
that	B-X
Sp140	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X

In	O
this	O
study	O
,	O
serum	O
from	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
a	O
novel	O
component	O
of	O
the	O
NB	O
,	O
a	O
140	O
-	O
kDa	O
protein	O
designated	O
Sp140	B-Protein
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
body	B-X
(	B-X
NB	B-X
)	B-X
is	B-X
a	B-X
cellular	B-X
organelle	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X
The	B-X
NB	B-X
is	B-X
also	B-X
a	B-X
target	B-X
of	B-X
antibodies	B-X
in	B-X
the	B-X
serum	B-X
of	B-X
patients	B-X
with	B-X
the	B-X
autoimmune	B-X
disease	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
serum	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
was	B-X
used	B-X
to	B-X
identify	B-X
a	B-X
cDNA	B-X
encoding	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
NB	B-X
,	B-X
a	B-X
140-kDa	B-X
protein	B-X
designated	B-X
Sp140	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
amino-terminal	B-X
portion	B-X
of	B-X
Sp140	B-X
was	B-X
similar	B-X
to	B-X
Sp100	B-X
,	B-X
a	B-X
previously	B-X
identified	B-X
NB	B-X
protein	B-X
.	B-X
The	B-X
carboxyl	B-X
portion	B-X
of	B-X
Sp140	B-X
contained	B-X
a	B-X
zinc-finger	B-X
domain	B-X
and	B-X
a	B-X
bromodomain	B-X
,	B-X
motifs	B-X
that	B-X
are	B-X
present	B-X
in	B-X
proteins	B-X
regulating	B-X
gene	B-X
transcription	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
Sp140	B-X
mRNA	B-X
were	B-X
detected	B-X
in	B-X
human	B-X
spleen	B-X
and	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
,	B-X
but	B-X
not	B-X
other	B-X
human	B-X
tissues	B-X
.	B-X
The	B-X
level	B-X
of	B-X
SP140	B-X
mRNA	B-X
in	B-X
myeloid	B-X
precursor	B-X
cell	B-X
lines	B-X
HL60	B-X
and	B-X
NB4	B-X
markedly	B-X
increased	B-X
in	B-X
response	B-X
to	B-X
chemically	B-X
induced	B-X
cellular	B-X
differentiation	B-X
.	B-X
Immunohistochemical	B-X
techniques	B-X
were	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
SP140	B-X
localized	B-X
to	B-X
the	B-X
NB	B-X
in	B-X
differentiated	B-X
HL60	B-X
and	B-X
NB4	B-X
cells	B-X
.	B-X
The	B-X
location	B-X
of	B-X
Sp140	B-X
in	B-X
the	B-X
NB	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
in	B-X
cells	B-X
involved	B-X
in	B-X
host	B-X
defense	B-X
,	B-X
suggest	B-X
that	B-X
Sp140	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
Sp140	B-Protein
was	O
similar	O
to	O
Sp100	B-Protein
,	O
a	O
previously	O
identified	O
NB	O
protein	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
body	B-X
(	B-X
NB	B-X
)	B-X
is	B-X
a	B-X
cellular	B-X
organelle	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X
The	B-X
NB	B-X
is	B-X
also	B-X
a	B-X
target	B-X
of	B-X
antibodies	B-X
in	B-X
the	B-X
serum	B-X
of	B-X
patients	B-X
with	B-X
the	B-X
autoimmune	B-X
disease	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
serum	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
was	B-X
used	B-X
to	B-X
identify	B-X
a	B-X
cDNA	B-X
encoding	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
NB	B-X
,	B-X
a	B-X
140-kDa	B-X
protein	B-X
designated	B-X
Sp140	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
amino-terminal	B-X
portion	B-X
of	B-X
Sp140	B-X
was	B-X
similar	B-X
to	B-X
Sp100	B-X
,	B-X
a	B-X
previously	B-X
identified	B-X
NB	B-X
protein	B-X
.	B-X
The	B-X
carboxyl	B-X
portion	B-X
of	B-X
Sp140	B-X
contained	B-X
a	B-X
zinc-finger	B-X
domain	B-X
and	B-X
a	B-X
bromodomain	B-X
,	B-X
motifs	B-X
that	B-X
are	B-X
present	B-X
in	B-X
proteins	B-X
regulating	B-X
gene	B-X
transcription	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
Sp140	B-X
mRNA	B-X
were	B-X
detected	B-X
in	B-X
human	B-X
spleen	B-X
and	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
,	B-X
but	B-X
not	B-X
other	B-X
human	B-X
tissues	B-X
.	B-X
The	B-X
level	B-X
of	B-X
SP140	B-X
mRNA	B-X
in	B-X
myeloid	B-X
precursor	B-X
cell	B-X
lines	B-X
HL60	B-X
and	B-X
NB4	B-X
markedly	B-X
increased	B-X
in	B-X
response	B-X
to	B-X
chemically	B-X
induced	B-X
cellular	B-X
differentiation	B-X
.	B-X
Immunohistochemical	B-X
techniques	B-X
were	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
SP140	B-X
localized	B-X
to	B-X
the	B-X
NB	B-X
in	B-X
differentiated	B-X
HL60	B-X
and	B-X
NB4	B-X
cells	B-X
.	B-X
The	B-X
location	B-X
of	B-X
Sp140	B-X
in	B-X
the	B-X
NB	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
in	B-X
cells	B-X
involved	B-X
in	B-X
host	B-X
defense	B-X
,	B-X
suggest	B-X
that	B-X
Sp140	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X

The	O
carboxyl	O
portion	O
of	O
Sp140	B-Protein
contained	O
a	O
zinc	O
-	O
finger	O
domain	O
and	O
a	O
bromodomain	O
,	O
motifs	O
that	O
are	O
present	O
in	O
proteins	O
regulating	O
gene	O
transcription	O
.	O

High	O
levels	O
of	O
Sp140	B-Protein
mRNA	O
were	O
detected	O
in	O
human	O
spleen	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
but	O
not	O
other	O
human	O
tissues	O
.	O

The	O
level	O
of	O
SP140	B-Protein
mRNA	O
in	O
myeloid	O
precursor	O
cell	O
lines	O
HL60	O
and	O
NB4	O
markedly	O
increased	O
in	O
response	O
to	O
chemically	O
induced	O
cellular	O
differentiation	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
body	B-X
(	B-X
NB	B-X
)	B-X
is	B-X
a	B-X
cellular	B-X
organelle	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
Sp140	B-X
mRNA	B-X
were	B-X
detected	B-X
in	B-X
human	B-X
spleen	B-X
and	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
,	B-X
but	B-X
not	B-X
other	B-X
human	B-X
tissues	B-X
.	B-X
The	B-X
level	B-X
of	B-X
SP140	B-X
mRNA	B-X
in	B-X
myeloid	B-X
precursor	B-X
cell	B-X
lines	B-X
HL60	B-X
and	B-X
NB4	B-X
markedly	B-X
increased	B-X
in	B-X
response	B-X
to	B-X
chemically	B-X
induced	B-X
cellular	B-X
differentiation	B-X
.	B-X
Immunohistochemical	B-X
techniques	B-X
were	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
SP140	B-X
localized	B-X
to	B-X
the	B-X
NB	B-X
in	B-X
differentiated	B-X
HL60	B-X
and	B-X
NB4	B-X
cells	B-X
.	B-X
The	B-X
location	B-X
of	B-X
Sp140	B-X
in	B-X
the	B-X
NB	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
in	B-X
cells	B-X
involved	B-X
in	B-X
host	B-X
defense	B-X
,	B-X
suggest	B-X
that	B-X
Sp140	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X

Immunohistochemical	O
techniques	O
were	O
used	O
to	O
demonstrate	O
that	O
SP140	B-Protein
localized	O
to	O
the	O
NB	O
in	O
differentiated	O
HL60	O
and	O
NB4	O
cells	O
.	O

The	O
location	O
of	O
Sp140	B-Protein
in	O
the	O
NB	O
,	O
and	O
expression	O
of	O
this	O
gene	O
in	O
cells	O
involved	O
in	O
host	O
defense	O
,	O
suggest	O
that	O
Sp140	B-Protein
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
body	B-X
(	B-X
NB	B-X
)	B-X
is	B-X
a	B-X
cellular	B-X
organelle	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X
The	B-X
NB	B-X
is	B-X
also	B-X
a	B-X
target	B-X
of	B-X
antibodies	B-X
in	B-X
the	B-X
serum	B-X
of	B-X
patients	B-X
with	B-X
the	B-X
autoimmune	B-X
disease	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
serum	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
was	B-X
used	B-X
to	B-X
identify	B-X
a	B-X
cDNA	B-X
encoding	B-X
a	B-X
novel	B-X
component	B-X
of	B-X
the	B-X
NB	B-X
,	B-X
a	B-X
140-kDa	B-X
protein	B-X
designated	B-X
Sp140	B-X
.	B-X
The	B-X
predicted	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
amino-terminal	B-X
portion	B-X
of	B-X
Sp140	B-X
was	B-X
similar	B-X
to	B-X
Sp100	B-X
,	B-X
a	B-X
previously	B-X
identified	B-X
NB	B-X
protein	B-X
.	B-X
The	B-X
carboxyl	B-X
portion	B-X
of	B-X
Sp140	B-X
contained	B-X
a	B-X
zinc-finger	B-X
domain	B-X
and	B-X
a	B-X
bromodomain	B-X
,	B-X
motifs	B-X
that	B-X
are	B-X
present	B-X
in	B-X
proteins	B-X
regulating	B-X
gene	B-X
transcription	B-X
.	B-X
High	B-X
levels	B-X
of	B-X
Sp140	B-X
mRNA	B-X
were	B-X
detected	B-X
in	B-X
human	B-X
spleen	B-X
and	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
,	B-X
but	B-X
not	B-X
other	B-X
human	B-X
tissues	B-X
.	B-X
The	B-X
level	B-X
of	B-X
SP140	B-X
mRNA	B-X
in	B-X
myeloid	B-X
precursor	B-X
cell	B-X
lines	B-X
HL60	B-X
and	B-X
NB4	B-X
markedly	B-X
increased	B-X
in	B-X
response	B-X
to	B-X
chemically	B-X
induced	B-X
cellular	B-X
differentiation	B-X
.	B-X
Immunohistochemical	B-X
techniques	B-X
were	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
SP140	B-X
localized	B-X
to	B-X
the	B-X
NB	B-X
in	B-X
differentiated	B-X
HL60	B-X
and	B-X
NB4	B-X
cells	B-X
.	B-X
The	B-X
location	B-X
of	B-X
Sp140	B-X
in	B-X
the	B-X
NB	B-X
,	B-X
and	B-X
expression	B-X
of	B-X
this	B-X
gene	B-X
in	B-X
cells	B-X
involved	B-X
in	B-X
host	B-X
defense	B-X
,	B-X
suggest	B-X
that	B-X
Sp140	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
acute	B-X
promyelocytic	B-X
leukemia	B-X
and	B-X
viral	B-X
infection	B-X
.	B-X

Potent	O
gene	O
regulatory	O
and	O
antiproliferative	O
activities	O
of	O
20	O
-	O
methyl	O
analogues	O
of	O
1	O
,	O
25	O
dihydroxyvitamin	O
D3	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
active	B-X
form	B-X
of	B-X
vitamin	B-X
D3	B-X
,	B-X
1,25-dihydroxyvitamin	B-X
D3	B-X
(	B-X
VD	B-X
)	B-X
,	B-X
regulates	B-X
cellular	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
This	B-X
made	B-X
the	B-X
need	B-X
for	B-X
VD	B-X
analogues	B-X
with	B-X
selectively	B-X
increased	B-X
cell	B-X
regulatory	B-X
properties	B-X
.	B-X
Studies	B-X
with	B-X
20-epi	B-X
analogues	B-X
pointed	B-X
out	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
carbon-20	B-X
position	B-X
and	B-X
led	B-X
to	B-X
the	B-X
development	B-X
of	B-X
20-methyl	B-X
derivatives	B-X
of	B-X
VD	B-X
.	B-X
In	B-X
this	B-X
report	B-X
the	B-X
biological	B-X
properties	B-X
of	B-X
the	B-X
compounds	B-X
ZK161422	B-X
and	B-X
ZK157202	B-X
,	B-X
which	B-X
are	B-X
20-methyl-	B-X
and	B-X
20-methyl-23-eneanalogues	B-X
,	B-X
respectively	B-X
,	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
comparison	B-X
with	B-X
VD	B-X
.	B-X
However	B-X
,	B-X
compared	B-X
to	B-X
VD	B-X
,	B-X
their	B-X
antiproliferative	B-X
effect	B-X
is	B-X
up	B-X
to	B-X
30-fold	B-X
higher	B-X
on	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
even	B-X
up	B-X
to	B-X
300-fold	B-X
higher	B-X
on	B-X
human	B-X
breast	B-X
cancer	B-X
MCF-7	B-X
cells	B-X
.	B-X
Whereas	B-X
the	B-X
hypercalcemic	B-X
effect	B-X
for	B-X
ZK157202	B-X
is	B-X
also	B-X
increased	B-X
10-fold	B-X
,	B-X
ZK161422	B-X
has	B-X
the	B-X
same	B-X
calcium-mobilizing	B-X
potency	B-X
as	B-X
VD	B-X
.	B-X
Moreover	B-X
,	B-X
ZK161422	B-X
,	B-X
but	B-X
not	B-X
ZK157202	B-X
,	B-X
showed	B-X
preference	B-X
for	B-X
gene	B-X
activation	B-X
from	B-X
a	B-X
promoter	B-X
carrying	B-X
a	B-X
VD	B-X
response	B-X
element	B-X
with	B-X
a	B-X
palindromic	B-X
arrangement	B-X
of	B-X
two	B-X
hexameric	B-X
receptor	B-X
binding	B-X
sites	B-X
spaced	B-X
by	B-X
9	B-X
nucleotides	B-X
(	B-X
IP9	B-X
)	B-X
rather	B-X
than	B-X
for	B-X
activation	B-X
from	B-X
a	B-X
response	B-X
element	B-X
formed	B-X
by	B-X
a	B-X
direct	B-X
repeat	B-X
spaced	B-X
by	B-X
3	B-X
nucleotides	B-X
(	B-X
DR3	B-X
)	B-X
.	B-X
This	B-X
observation	B-X
supports	B-X
a	B-X
model	B-X
,	B-X
in	B-X
which	B-X
promoter	B-X
selectivity	B-X
reflects	B-X
the	B-X
selectively	B-X
increased	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VD	B-X
analogues	B-X
.	B-X

The	O
biological	O
active	O
form	O
of	O
vitamin	O
D3	O
,	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
(	O
VD	O
)	O
,	O
regulates	O
cellular	O
growth	O
and	O
differentiation	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
active	B-X
form	B-X
of	B-X
vitamin	B-X
D3	B-X
,	B-X
1,25-dihydroxyvitamin	B-X
D3	B-X
(	B-X
VD	B-X
)	B-X
,	B-X
regulates	B-X
cellular	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
However	B-X
,	B-X
hypercalcemia	B-X
is	B-X
a	B-X
side	B-X
effect	B-X
,	B-X
which	B-X
is	B-X
caused	B-X
by	B-X
VD	B-X
's	B-X
classical	B-X
action	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
calcium	B-X
homeostasis	B-X
.	B-X
This	B-X
made	B-X
the	B-X
need	B-X
for	B-X
VD	B-X
analogues	B-X
with	B-X
selectively	B-X
increased	B-X
cell	B-X
regulatory	B-X
properties	B-X
.	B-X
Studies	B-X
with	B-X
20-epi	B-X
analogues	B-X
pointed	B-X
out	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
carbon-20	B-X
position	B-X
and	B-X
led	B-X
to	B-X
the	B-X
development	B-X
of	B-X
20-methyl	B-X
derivatives	B-X
of	B-X
VD	B-X
.	B-X
In	B-X
this	B-X
report	B-X
the	B-X
biological	B-X
properties	B-X
of	B-X
the	B-X
compounds	B-X
ZK161422	B-X
and	B-X
ZK157202	B-X
,	B-X
which	B-X
are	B-X
20-methyl-	B-X
and	B-X
20-methyl-23-eneanalogues	B-X
,	B-X
respectively	B-X
,	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
comparison	B-X
with	B-X
VD	B-X
.	B-X
Both	B-X
compounds	B-X
show	B-X
about	B-X
2-fold	B-X
lower	B-X
affinity	B-X
to	B-X
the	B-X
VD	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
than	B-X
VD	B-X
.	B-X
However	B-X
,	B-X
compared	B-X
to	B-X
VD	B-X
,	B-X
their	B-X
antiproliferative	B-X
effect	B-X
is	B-X
up	B-X
to	B-X
30-fold	B-X
higher	B-X
on	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
even	B-X
up	B-X
to	B-X
300-fold	B-X
higher	B-X
on	B-X
human	B-X
breast	B-X
cancer	B-X
MCF-7	B-X
cells	B-X
.	B-X
Whereas	B-X
the	B-X
hypercalcemic	B-X
effect	B-X
for	B-X
ZK157202	B-X
is	B-X
also	B-X
increased	B-X
10-fold	B-X
,	B-X
ZK161422	B-X
has	B-X
the	B-X
same	B-X
calcium-mobilizing	B-X
potency	B-X
as	B-X
VD	B-X
.	B-X
Moreover	B-X
,	B-X
ZK161422	B-X
,	B-X
but	B-X
not	B-X
ZK157202	B-X
,	B-X
showed	B-X
preference	B-X
for	B-X
gene	B-X
activation	B-X
from	B-X
a	B-X
promoter	B-X
carrying	B-X
a	B-X
VD	B-X
response	B-X
element	B-X
with	B-X
a	B-X
palindromic	B-X
arrangement	B-X
of	B-X
two	B-X
hexameric	B-X
receptor	B-X
binding	B-X
sites	B-X
spaced	B-X
by	B-X
9	B-X
nucleotides	B-X
(	B-X
IP9	B-X
)	B-X
rather	B-X
than	B-X
for	B-X
activation	B-X
from	B-X
a	B-X
response	B-X
element	B-X
formed	B-X
by	B-X
a	B-X
direct	B-X
repeat	B-X
spaced	B-X
by	B-X
3	B-X
nucleotides	B-X
(	B-X
DR3	B-X
)	B-X
.	B-X
This	B-X
observation	B-X
supports	B-X
a	B-X
model	B-X
,	B-X
in	B-X
which	B-X
promoter	B-X
selectivity	B-X
reflects	B-X
the	B-X
selectively	B-X
increased	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VD	B-X
analogues	B-X
.	B-X

This	O
provides	O
the	O
hormone	O
with	O
an	O
interesting	O
therapeutic	O
potential	O
.	O
<EOS>	B-X
The	B-X
glucagon-like	B-X
peptide-1	B-X
(	B-X
GLP-1	B-X
)	B-X
is	B-X
a	B-X
multifaceted	B-X
hormone	B-X
with	B-X
broad	B-X
pharmacological	B-X
potential	B-X
.	B-X
Improved	B-X
Survival	B-X
With	B-X
Enzalutamide	B-X
in	B-X
Patients	B-X
With	B-X
Metastatic	B-X
Hormone-Sensitive	B-X
Prostate	B-X
Cancer	B-X
.	B-X
Current	B-X
perspectives	B-X
on	B-X
the	B-X
neurobiology	B-X
of	B-X
human	B-X
prosociality	B-X
suggest	B-X
that	B-X
it	B-X
is	B-X
deeply	B-X
rooted	B-X
in	B-X
the	B-X
neuroendocrine	B-X
architecture	B-X
of	B-X
the	B-X
social	B-X
brain	B-X
and	B-X
emphasize	B-X
the	B-X
modulatory	B-X
role	B-X
of	B-X
the	B-X
neuropeptide	B-X
hormone	B-X
oxytocin	B-X
.	B-X
After	B-X
providing	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
state-of-the-art	B-X
research	B-X
on	B-X
oxytocin	B-X
's	B-X
exogenous	B-X
use	B-X
,	B-X
we	B-X
elaborate	B-X
on	B-X
the	B-X
peptide	B-X
's	B-X
modulatory	B-X
role	B-X
in	B-X
the	B-X
context	B-X
of	B-X
care-based	B-X
altruism	B-X
,	B-X
cooperation	B-X
,	B-X
and	B-X
conflict	B-X
and	B-X
discuss	B-X
its	B-X
potential	B-X
for	B-X
therapeutic	B-X
interventions	B-X
in	B-X
psychiatric	B-X
disorders	B-X
characterized	B-X
by	B-X
social	B-X
dysfunction	B-X
.	B-X

However	O
,	O
hypercalcemia	O
is	O
a	O
side	O
effect	O
,	O
which	O
is	O
caused	O
by	O
VD	O
'	O
s	O
classical	O
action	O
,	O
the	O
regulation	O
of	O
calcium	O
homeostasis	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
active	B-X
form	B-X
of	B-X
vitamin	B-X
D3	B-X
,	B-X
1,25-dihydroxyvitamin	B-X
D3	B-X
(	B-X
VD	B-X
)	B-X
,	B-X
regulates	B-X
cellular	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
However	B-X
,	B-X
hypercalcemia	B-X
is	B-X
a	B-X
side	B-X
effect	B-X
,	B-X
which	B-X
is	B-X
caused	B-X
by	B-X
VD	B-X
's	B-X
classical	B-X
action	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
calcium	B-X
homeostasis	B-X
.	B-X
This	B-X
made	B-X
the	B-X
need	B-X
for	B-X
VD	B-X
analogues	B-X
with	B-X
selectively	B-X
increased	B-X
cell	B-X
regulatory	B-X
properties	B-X
.	B-X
Studies	B-X
with	B-X
20-epi	B-X
analogues	B-X
pointed	B-X
out	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
carbon-20	B-X
position	B-X
and	B-X
led	B-X
to	B-X
the	B-X
development	B-X
of	B-X
20-methyl	B-X
derivatives	B-X
of	B-X
VD	B-X
.	B-X
In	B-X
this	B-X
report	B-X
the	B-X
biological	B-X
properties	B-X
of	B-X
the	B-X
compounds	B-X
ZK161422	B-X
and	B-X
ZK157202	B-X
,	B-X
which	B-X
are	B-X
20-methyl-	B-X
and	B-X
20-methyl-23-eneanalogues	B-X
,	B-X
respectively	B-X
,	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
comparison	B-X
with	B-X
VD	B-X
.	B-X
Both	B-X
compounds	B-X
show	B-X
about	B-X
2-fold	B-X
lower	B-X
affinity	B-X
to	B-X
the	B-X
VD	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
than	B-X
VD	B-X
.	B-X
However	B-X
,	B-X
compared	B-X
to	B-X
VD	B-X
,	B-X
their	B-X
antiproliferative	B-X
effect	B-X
is	B-X
up	B-X
to	B-X
30-fold	B-X
higher	B-X
on	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
even	B-X
up	B-X
to	B-X
300-fold	B-X
higher	B-X
on	B-X
human	B-X
breast	B-X
cancer	B-X
MCF-7	B-X
cells	B-X
.	B-X
Whereas	B-X
the	B-X
hypercalcemic	B-X
effect	B-X
for	B-X
ZK157202	B-X
is	B-X
also	B-X
increased	B-X
10-fold	B-X
,	B-X
ZK161422	B-X
has	B-X
the	B-X
same	B-X
calcium-mobilizing	B-X
potency	B-X
as	B-X
VD	B-X
.	B-X
Moreover	B-X
,	B-X
ZK161422	B-X
,	B-X
but	B-X
not	B-X
ZK157202	B-X
,	B-X
showed	B-X
preference	B-X
for	B-X
gene	B-X
activation	B-X
from	B-X
a	B-X
promoter	B-X
carrying	B-X
a	B-X
VD	B-X
response	B-X
element	B-X
with	B-X
a	B-X
palindromic	B-X
arrangement	B-X
of	B-X
two	B-X
hexameric	B-X
receptor	B-X
binding	B-X
sites	B-X
spaced	B-X
by	B-X
9	B-X
nucleotides	B-X
(	B-X
IP9	B-X
)	B-X
rather	B-X
than	B-X
for	B-X
activation	B-X
from	B-X
a	B-X
response	B-X
element	B-X
formed	B-X
by	B-X
a	B-X
direct	B-X
repeat	B-X
spaced	B-X
by	B-X
3	B-X
nucleotides	B-X
(	B-X
DR3	B-X
)	B-X
.	B-X
This	B-X
observation	B-X
supports	B-X
a	B-X
model	B-X
,	B-X
in	B-X
which	B-X
promoter	B-X
selectivity	B-X
reflects	B-X
the	B-X
selectively	B-X
increased	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VD	B-X
analogues	B-X
.	B-X

This	O
made	O
the	O
need	O
for	O
VD	O
analogues	O
with	O
selectively	O
increased	O
cell	O
regulatory	O
properties	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
active	B-X
form	B-X
of	B-X
vitamin	B-X
D3	B-X
,	B-X
1,25-dihydroxyvitamin	B-X
D3	B-X
(	B-X
VD	B-X
)	B-X
,	B-X
regulates	B-X
cellular	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
However	B-X
,	B-X
hypercalcemia	B-X
is	B-X
a	B-X
side	B-X
effect	B-X
,	B-X
which	B-X
is	B-X
caused	B-X
by	B-X
VD	B-X
's	B-X
classical	B-X
action	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
calcium	B-X
homeostasis	B-X
.	B-X
This	B-X
made	B-X
the	B-X
need	B-X
for	B-X
VD	B-X
analogues	B-X
with	B-X
selectively	B-X
increased	B-X
cell	B-X
regulatory	B-X
properties	B-X
.	B-X
Studies	B-X
with	B-X
20-epi	B-X
analogues	B-X
pointed	B-X
out	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
carbon-20	B-X
position	B-X
and	B-X
led	B-X
to	B-X
the	B-X
development	B-X
of	B-X
20-methyl	B-X
derivatives	B-X
of	B-X
VD	B-X
.	B-X
In	B-X
this	B-X
report	B-X
the	B-X
biological	B-X
properties	B-X
of	B-X
the	B-X
compounds	B-X
ZK161422	B-X
and	B-X
ZK157202	B-X
,	B-X
which	B-X
are	B-X
20-methyl-	B-X
and	B-X
20-methyl-23-eneanalogues	B-X
,	B-X
respectively	B-X
,	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
comparison	B-X
with	B-X
VD	B-X
.	B-X
Both	B-X
compounds	B-X
show	B-X
about	B-X
2-fold	B-X
lower	B-X
affinity	B-X
to	B-X
the	B-X
VD	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
than	B-X
VD	B-X
.	B-X
However	B-X
,	B-X
compared	B-X
to	B-X
VD	B-X
,	B-X
their	B-X
antiproliferative	B-X
effect	B-X
is	B-X
up	B-X
to	B-X
30-fold	B-X
higher	B-X
on	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
even	B-X
up	B-X
to	B-X
300-fold	B-X
higher	B-X
on	B-X
human	B-X
breast	B-X
cancer	B-X
MCF-7	B-X
cells	B-X
.	B-X
Whereas	B-X
the	B-X
hypercalcemic	B-X
effect	B-X
for	B-X
ZK157202	B-X
is	B-X
also	B-X
increased	B-X
10-fold	B-X
,	B-X
ZK161422	B-X
has	B-X
the	B-X
same	B-X
calcium-mobilizing	B-X
potency	B-X
as	B-X
VD	B-X
.	B-X
Moreover	B-X
,	B-X
ZK161422	B-X
,	B-X
but	B-X
not	B-X
ZK157202	B-X
,	B-X
showed	B-X
preference	B-X
for	B-X
gene	B-X
activation	B-X
from	B-X
a	B-X
promoter	B-X
carrying	B-X
a	B-X
VD	B-X
response	B-X
element	B-X
with	B-X
a	B-X
palindromic	B-X
arrangement	B-X
of	B-X
two	B-X
hexameric	B-X
receptor	B-X
binding	B-X
sites	B-X
spaced	B-X
by	B-X
9	B-X
nucleotides	B-X
(	B-X
IP9	B-X
)	B-X
rather	B-X
than	B-X
for	B-X
activation	B-X
from	B-X
a	B-X
response	B-X
element	B-X
formed	B-X
by	B-X
a	B-X
direct	B-X
repeat	B-X
spaced	B-X
by	B-X
3	B-X
nucleotides	B-X
(	B-X
DR3	B-X
)	B-X
.	B-X
This	B-X
observation	B-X
supports	B-X
a	B-X
model	B-X
,	B-X
in	B-X
which	B-X
promoter	B-X
selectivity	B-X
reflects	B-X
the	B-X
selectively	B-X
increased	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VD	B-X
analogues	B-X
.	B-X

Studies	O
with	O
20	O
-	O
epi	O
analogues	O
pointed	O
out	O
the	O
importance	O
of	O
the	O
carbon	O
-	O
20	O
position	O
and	O
led	O
to	O
the	O
development	O
of	O
20	O
-	O
methyl	O
derivatives	O
of	O
VD	O
.	O

In	O
this	O
report	O
the	O
biological	O
properties	O
of	O
the	O
compounds	O
ZK161422	O
and	O
ZK157202	O
,	O
which	O
are	O
20	O
-	O
methyl	O
-	O
and	O
20	O
-	O
methyl	O
-	O
23	O
-	O
eneanalogues	O
,	O
respectively	O
,	O
have	O
been	O
analyzed	O
in	O
comparison	O
with	O
VD	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
active	B-X
form	B-X
of	B-X
vitamin	B-X
D3	B-X
,	B-X
1,25-dihydroxyvitamin	B-X
D3	B-X
(	B-X
VD	B-X
)	B-X
,	B-X
regulates	B-X
cellular	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
However	B-X
,	B-X
hypercalcemia	B-X
is	B-X
a	B-X
side	B-X
effect	B-X
,	B-X
which	B-X
is	B-X
caused	B-X
by	B-X
VD	B-X
's	B-X
classical	B-X
action	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
calcium	B-X
homeostasis	B-X
.	B-X
This	B-X
made	B-X
the	B-X
need	B-X
for	B-X
VD	B-X
analogues	B-X
with	B-X
selectively	B-X
increased	B-X
cell	B-X
regulatory	B-X
properties	B-X
.	B-X
Studies	B-X
with	B-X
20-epi	B-X
analogues	B-X
pointed	B-X
out	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
carbon-20	B-X
position	B-X
and	B-X
led	B-X
to	B-X
the	B-X
development	B-X
of	B-X
20-methyl	B-X
derivatives	B-X
of	B-X
VD	B-X
.	B-X
In	B-X
this	B-X
report	B-X
the	B-X
biological	B-X
properties	B-X
of	B-X
the	B-X
compounds	B-X
ZK161422	B-X
and	B-X
ZK157202	B-X
,	B-X
which	B-X
are	B-X
20-methyl-	B-X
and	B-X
20-methyl-23-eneanalogues	B-X
,	B-X
respectively	B-X
,	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
comparison	B-X
with	B-X
VD	B-X
.	B-X
Both	B-X
compounds	B-X
show	B-X
about	B-X
2-fold	B-X
lower	B-X
affinity	B-X
to	B-X
the	B-X
VD	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
than	B-X
VD	B-X
.	B-X
However	B-X
,	B-X
compared	B-X
to	B-X
VD	B-X
,	B-X
their	B-X
antiproliferative	B-X
effect	B-X
is	B-X
up	B-X
to	B-X
30-fold	B-X
higher	B-X
on	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
even	B-X
up	B-X
to	B-X
300-fold	B-X
higher	B-X
on	B-X
human	B-X
breast	B-X
cancer	B-X
MCF-7	B-X
cells	B-X
.	B-X
Whereas	B-X
the	B-X
hypercalcemic	B-X
effect	B-X
for	B-X
ZK157202	B-X
is	B-X
also	B-X
increased	B-X
10-fold	B-X
,	B-X
ZK161422	B-X
has	B-X
the	B-X
same	B-X
calcium-mobilizing	B-X
potency	B-X
as	B-X
VD	B-X
.	B-X
Moreover	B-X
,	B-X
ZK161422	B-X
,	B-X
but	B-X
not	B-X
ZK157202	B-X
,	B-X
showed	B-X
preference	B-X
for	B-X
gene	B-X
activation	B-X
from	B-X
a	B-X
promoter	B-X
carrying	B-X
a	B-X
VD	B-X
response	B-X
element	B-X
with	B-X
a	B-X
palindromic	B-X
arrangement	B-X
of	B-X
two	B-X
hexameric	B-X
receptor	B-X
binding	B-X
sites	B-X
spaced	B-X
by	B-X
9	B-X
nucleotides	B-X
(	B-X
IP9	B-X
)	B-X
rather	B-X
than	B-X
for	B-X
activation	B-X
from	B-X
a	B-X
response	B-X
element	B-X
formed	B-X
by	B-X
a	B-X
direct	B-X
repeat	B-X
spaced	B-X
by	B-X
3	B-X
nucleotides	B-X
(	B-X
DR3	B-X
)	B-X
.	B-X
This	B-X
observation	B-X
supports	B-X
a	B-X
model	B-X
,	B-X
in	B-X
which	B-X
promoter	B-X
selectivity	B-X
reflects	B-X
the	B-X
selectively	B-X
increased	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VD	B-X
analogues	B-X
.	B-X

Both	O
compounds	O
show	O
about	O
2	O
-	O
fold	O
lower	O
affinity	O
to	O
the	O
VD	B-Protein
receptor	I-Protein
(	O
VDR	B-Protein
)	O
than	O
VD	O
.	O

However	O
,	O
compared	O
to	O
VD	O
,	O
their	O
antiproliferative	O
effect	O
is	O
up	O
to	O
30	O
-	O
fold	O
higher	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
even	O
up	O
to	O
300	O
-	O
fold	O
higher	O
on	O
human	O
breast	O
cancer	O
MCF	O
-	O
7	O
cells	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
active	B-X
form	B-X
of	B-X
vitamin	B-X
D3	B-X
,	B-X
1,25-dihydroxyvitamin	B-X
D3	B-X
(	B-X
VD	B-X
)	B-X
,	B-X
regulates	B-X
cellular	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
However	B-X
,	B-X
hypercalcemia	B-X
is	B-X
a	B-X
side	B-X
effect	B-X
,	B-X
which	B-X
is	B-X
caused	B-X
by	B-X
VD	B-X
's	B-X
classical	B-X
action	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
calcium	B-X
homeostasis	B-X
.	B-X
This	B-X
made	B-X
the	B-X
need	B-X
for	B-X
VD	B-X
analogues	B-X
with	B-X
selectively	B-X
increased	B-X
cell	B-X
regulatory	B-X
properties	B-X
.	B-X
Studies	B-X
with	B-X
20-epi	B-X
analogues	B-X
pointed	B-X
out	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
carbon-20	B-X
position	B-X
and	B-X
led	B-X
to	B-X
the	B-X
development	B-X
of	B-X
20-methyl	B-X
derivatives	B-X
of	B-X
VD	B-X
.	B-X
In	B-X
this	B-X
report	B-X
the	B-X
biological	B-X
properties	B-X
of	B-X
the	B-X
compounds	B-X
ZK161422	B-X
and	B-X
ZK157202	B-X
,	B-X
which	B-X
are	B-X
20-methyl-	B-X
and	B-X
20-methyl-23-eneanalogues	B-X
,	B-X
respectively	B-X
,	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
comparison	B-X
with	B-X
VD	B-X
.	B-X
Both	B-X
compounds	B-X
show	B-X
about	B-X
2-fold	B-X
lower	B-X
affinity	B-X
to	B-X
the	B-X
VD	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
than	B-X
VD	B-X
.	B-X
However	B-X
,	B-X
compared	B-X
to	B-X
VD	B-X
,	B-X
their	B-X
antiproliferative	B-X
effect	B-X
is	B-X
up	B-X
to	B-X
30-fold	B-X
higher	B-X
on	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
even	B-X
up	B-X
to	B-X
300-fold	B-X
higher	B-X
on	B-X
human	B-X
breast	B-X
cancer	B-X
MCF-7	B-X
cells	B-X
.	B-X
Whereas	B-X
the	B-X
hypercalcemic	B-X
effect	B-X
for	B-X
ZK157202	B-X
is	B-X
also	B-X
increased	B-X
10-fold	B-X
,	B-X
ZK161422	B-X
has	B-X
the	B-X
same	B-X
calcium-mobilizing	B-X
potency	B-X
as	B-X
VD	B-X
.	B-X
Moreover	B-X
,	B-X
ZK161422	B-X
,	B-X
but	B-X
not	B-X
ZK157202	B-X
,	B-X
showed	B-X
preference	B-X
for	B-X
gene	B-X
activation	B-X
from	B-X
a	B-X
promoter	B-X
carrying	B-X
a	B-X
VD	B-X
response	B-X
element	B-X
with	B-X
a	B-X
palindromic	B-X
arrangement	B-X
of	B-X
two	B-X
hexameric	B-X
receptor	B-X
binding	B-X
sites	B-X
spaced	B-X
by	B-X
9	B-X
nucleotides	B-X
(	B-X
IP9	B-X
)	B-X
rather	B-X
than	B-X
for	B-X
activation	B-X
from	B-X
a	B-X
response	B-X
element	B-X
formed	B-X
by	B-X
a	B-X
direct	B-X
repeat	B-X
spaced	B-X
by	B-X
3	B-X
nucleotides	B-X
(	B-X
DR3	B-X
)	B-X
.	B-X
This	B-X
observation	B-X
supports	B-X
a	B-X
model	B-X
,	B-X
in	B-X
which	B-X
promoter	B-X
selectivity	B-X
reflects	B-X
the	B-X
selectively	B-X
increased	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VD	B-X
analogues	B-X
.	B-X

Whereas	O
the	O
hypercalcemic	O
effect	O
for	O
ZK157202	O
is	O
also	O
increased	O
10	O
-	O
fold	O
,	O
ZK161422	O
has	O
the	O
same	O
calcium	O
-	O
mobilizing	O
potency	O
as	O
VD	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
active	B-X
form	B-X
of	B-X
vitamin	B-X
D3	B-X
,	B-X
1,25-dihydroxyvitamin	B-X
D3	B-X
(	B-X
VD	B-X
)	B-X
,	B-X
regulates	B-X
cellular	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
However	B-X
,	B-X
hypercalcemia	B-X
is	B-X
a	B-X
side	B-X
effect	B-X
,	B-X
which	B-X
is	B-X
caused	B-X
by	B-X
VD	B-X
's	B-X
classical	B-X
action	B-X
,	B-X
the	B-X
regulation	B-X
of	B-X
calcium	B-X
homeostasis	B-X
.	B-X
This	B-X
made	B-X
the	B-X
need	B-X
for	B-X
VD	B-X
analogues	B-X
with	B-X
selectively	B-X
increased	B-X
cell	B-X
regulatory	B-X
properties	B-X
.	B-X
Studies	B-X
with	B-X
20-epi	B-X
analogues	B-X
pointed	B-X
out	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
carbon-20	B-X
position	B-X
and	B-X
led	B-X
to	B-X
the	B-X
development	B-X
of	B-X
20-methyl	B-X
derivatives	B-X
of	B-X
VD	B-X
.	B-X
In	B-X
this	B-X
report	B-X
the	B-X
biological	B-X
properties	B-X
of	B-X
the	B-X
compounds	B-X
ZK161422	B-X
and	B-X
ZK157202	B-X
,	B-X
which	B-X
are	B-X
20-methyl-	B-X
and	B-X
20-methyl-23-eneanalogues	B-X
,	B-X
respectively	B-X
,	B-X
have	B-X
been	B-X
analyzed	B-X
in	B-X
comparison	B-X
with	B-X
VD	B-X
.	B-X
Both	B-X
compounds	B-X
show	B-X
about	B-X
2-fold	B-X
lower	B-X
affinity	B-X
to	B-X
the	B-X
VD	B-X
receptor	B-X
(	B-X
VDR	B-X
)	B-X
than	B-X
VD	B-X
.	B-X
However	B-X
,	B-X
compared	B-X
to	B-X
VD	B-X
,	B-X
their	B-X
antiproliferative	B-X
effect	B-X
is	B-X
up	B-X
to	B-X
30-fold	B-X
higher	B-X
on	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
and	B-X
even	B-X
up	B-X
to	B-X
300-fold	B-X
higher	B-X
on	B-X
human	B-X
breast	B-X
cancer	B-X
MCF-7	B-X
cells	B-X
.	B-X
Whereas	B-X
the	B-X
hypercalcemic	B-X
effect	B-X
for	B-X
ZK157202	B-X
is	B-X
also	B-X
increased	B-X
10-fold	B-X
,	B-X
ZK161422	B-X
has	B-X
the	B-X
same	B-X
calcium-mobilizing	B-X
potency	B-X
as	B-X
VD	B-X
.	B-X
Moreover	B-X
,	B-X
ZK161422	B-X
,	B-X
but	B-X
not	B-X
ZK157202	B-X
,	B-X
showed	B-X
preference	B-X
for	B-X
gene	B-X
activation	B-X
from	B-X
a	B-X
promoter	B-X
carrying	B-X
a	B-X
VD	B-X
response	B-X
element	B-X
with	B-X
a	B-X
palindromic	B-X
arrangement	B-X
of	B-X
two	B-X
hexameric	B-X
receptor	B-X
binding	B-X
sites	B-X
spaced	B-X
by	B-X
9	B-X
nucleotides	B-X
(	B-X
IP9	B-X
)	B-X
rather	B-X
than	B-X
for	B-X
activation	B-X
from	B-X
a	B-X
response	B-X
element	B-X
formed	B-X
by	B-X
a	B-X
direct	B-X
repeat	B-X
spaced	B-X
by	B-X
3	B-X
nucleotides	B-X
(	B-X
DR3	B-X
)	B-X
.	B-X
This	B-X
observation	B-X
supports	B-X
a	B-X
model	B-X
,	B-X
in	B-X
which	B-X
promoter	B-X
selectivity	B-X
reflects	B-X
the	B-X
selectively	B-X
increased	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VD	B-X
analogues	B-X
.	B-X

Moreover	O
,	O
ZK161422	O
,	O
but	O
not	O
ZK157202	O
,	O
showed	O
preference	O
for	O
gene	O
activation	O
from	O
a	O
promoter	O
carrying	O
a	O
VD	O
response	O
element	O
with	O
a	O
palindromic	O
arrangement	O
of	O
two	O
hexameric	O
receptor	O
binding	O
sites	O
spaced	O
by	O
9	O
nucleotides	O
(	O
IP9	O
)	O
rather	O
than	O
for	O
activation	O
from	O
a	O
response	O
element	O
formed	O
by	O
a	O
direct	O
repeat	O
spaced	O
by	O
3	O
nucleotides	O
(	O
DR3	O
)	O
.	O

This	O
observation	O
supports	O
a	O
model	O
,	O
in	O
which	O
promoter	O
selectivity	O
reflects	O
the	O
selectively	O
increased	O
antiproliferative	O
effect	O
of	O
VD	O
analogues	O
.	O

Second	O
messenger	O
up	O
-	O
regulation	O
of	O
androgen	O
receptor	O
gene	O
transcription	O
is	O
absent	O
in	O
androgen	O
insensitive	O
human	O
prostatic	O
carcinoma	O
cell	O
lines	O
,	O
PC	O
-	O
3	O
and	O
DU	O
-	O
145	O
.	O

A	O
theoretical	O
pathway	O
of	O
transcriptional	O
regulation	O
of	O
the	O
androgen	B-Protein
receptor	I-Protein
(	O
AR	B-Protein
)	O
gene	O
is	O
via	O
a	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
present	O
in	O
its	O
promoter	O
region	O
(	O
-	O
508	O
to	O
-	O
501	O
)	O
.	O

After	O
20	O
h	O
of	O
stimulation	O
with	O
8	O
-	O
bromo	O
-	O
cAMP	O
,	O
AR	B-Protein
mRNA	O
was	O
upregulated	O
in	O
LNCaP	O
but	O
not	O
in	O
either	O
PC	O
-	O
3	O
or	O
DU	O
-	O
145	O
cell	O
lines	O
.	O
<EOS>	B-X
Various	B-X
preclinical	B-X
models	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
clarify	B-X
the	B-X
pathophysiology	B-X
of	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
.	B-X
Traditional	B-X
PCa	B-X
cell	B-X
lines	B-X
from	B-X
clinical	B-X
metastatic	B-X
lesions	B-X
,	B-X
as	B-X
exemplified	B-X
by	B-X
DU-145	B-X
,	B-X
PC-3	B-X
,	B-X
and	B-X
LNCaP	B-X
cells	B-X
,	B-X
are	B-X
useful	B-X
tools	B-X
to	B-X
define	B-X
mechanisms	B-X
underlying	B-X
tumorigenesis	B-X
and	B-X
drug	B-X
resistance	B-X
.	B-X
Cell	B-X
line-based	B-X
experiments	B-X
,	B-X
however	B-X
,	B-X
have	B-X
limitations	B-X
for	B-X
preclinical	B-X
studies	B-X
because	B-X
those	B-X
cells	B-X
are	B-X
basically	B-X
adapted	B-X
to	B-X
2-dimensional	B-X
monolayer	B-X
culture	B-X
conditions	B-X
,	B-X
in	B-X
which	B-X
the	B-X
majority	B-X
of	B-X
primary	B-X
PCa	B-X
cells	B-X
can	B-X
not	B-X
survive	B-X
.	B-X
Recent	B-X
tissue	B-X
engineering	B-X
enables	B-X
generation	B-X
of	B-X
PCa	B-X
patient-derived	B-X
xenografts	B-X
(	B-X
PDXs	B-X
)	B-X
from	B-X
both	B-X
primary	B-X
and	B-X
metastatic	B-X
lesions	B-X
.	B-X
Compared	B-X
with	B-X
fresh	B-X
PCa	B-X
tissue	B-X
transplantation	B-X
in	B-X
athymic	B-X
mice	B-X
,	B-X
co-injection	B-X
of	B-X
PCa	B-X
tissues	B-X
with	B-X
extracellular	B-X
matrix	B-X
in	B-X
highly	B-X
immunodeficient	B-X
mice	B-X
has	B-X
remarkably	B-X
improved	B-X
the	B-X
success	B-X
rate	B-X
of	B-X
PDX	B-X
generation	B-X
.	B-X
PDX	B-X
models	B-X
have	B-X
advantages	B-X
to	B-X
appropriately	B-X
recapitulate	B-X
the	B-X
molecular	B-X
diversity	B-X
,	B-X
cellular	B-X
heterogeneity	B-X
,	B-X
and	B-X
histology	B-X
of	B-X
original	B-X
patient	B-X
tumors	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
PDX	B-X
models	B-X
,	B-X
patient-derived	B-X
organoid	B-X
and	B-X
spheroid	B-X
PCa	B-X
models	B-X
in	B-X
3-dimensional	B-X
culture	B-X
are	B-X
more	B-X
feasible	B-X
tools	B-X
for	B-X
in	B-X
vitro	B-X
studies	B-X
for	B-X
retaining	B-X
the	B-X
characteristics	B-X
of	B-X
patient	B-X
tumors	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
review	B-X
PCa	B-X
preclinical	B-X
model	B-X
cell	B-X
lines	B-X
and	B-X
their	B-X
sublines	B-X
,	B-X
PDXs	B-X
,	B-X
and	B-X
patient-derived	B-X
organoid	B-X
and	B-X
spheroid	B-X
models	B-X
.	B-X
These	B-X
PCa	B-X
models	B-X
will	B-X
be	B-X
applied	B-X
to	B-X
the	B-X
development	B-X
of	B-X
new	B-X
strategies	B-X
for	B-X
cancer	B-X
precision	B-X
medicine	B-X
.	B-X

We	O
have	O
demonstrated	O
that	O
the	O
level	O
of	O
CRE	B-Protein
binding	I-Protein
protein	I-Protein
(	O
CREB	B-Protein
)	O
was	O
the	O
same	O
in	O
all	O
cell	O
lines	O
and	O
that	O
the	O
putative	O
AR	B-Protein
-	O
CRE	O
forms	O
specific	O
and	O
compatible	O
protein	O
interactions	O
with	O
CREB	B-Protein
.	O
<EOS>	B-X
A	B-X
theoretical	B-X
pathway	B-X
of	B-X
transcriptional	B-X
regulation	B-X
of	B-X
the	B-X
androgen	B-X
receptor	B-X
(	B-X
AR	B-X
)	B-X
gene	B-X
is	B-X
via	B-X
a	B-X
cAMP	B-X
response	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
present	B-X
in	B-X
its	B-X
promoter	B-X
region	B-X
(	B-X
-508	B-X
to	B-X
-501	B-X
)	B-X
.	B-X
After	B-X
20	B-X
h	B-X
of	B-X
stimulation	B-X
with	B-X
8-bromo-cAMP	B-X
,	B-X
AR	B-X
mRNA	B-X
was	B-X
upregulated	B-X
in	B-X
LNCaP	B-X
but	B-X
not	B-X
in	B-X
either	B-X
PC-3	B-X
or	B-X
DU-145	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
have	B-X
demonstrated	B-X
that	B-X
the	B-X
level	B-X
of	B-X
CRE	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
was	B-X
the	B-X
same	B-X
in	B-X
all	B-X
cell	B-X
lines	B-X
and	B-X
that	B-X
the	B-X
putative	B-X
AR-CRE	B-X
forms	B-X
specific	B-X
and	B-X
compatible	B-X
protein	B-X
interactions	B-X
with	B-X
CREB	B-X
.	B-X
The	B-X
ability	B-X
to	B-X
regulate	B-X
AR	B-X
gene	B-X
transcription	B-X
via	B-X
the	B-X
second	B-X
messenger	B-X
pathway	B-X
is	B-X
lost	B-X
in	B-X
the	B-X
PC-3	B-X
and	B-X
DU-145	B-X
cell	B-X
lines	B-X
.	B-X

The	O
ability	O
to	O
regulate	O
AR	B-Protein
gene	O
transcription	O
via	O
the	O
second	O
messenger	O
pathway	O
is	O
lost	O
in	O
the	O
PC	O
-	O
3	O
and	O
DU	O
-	O
145	O
cell	O
lines	O
.	O

This	O
may	O
be	O
an	O
important	O
primary	O
mechanism	O
of	O
androgen	O
insensitivity	O
in	O
prostate	O
cancer	O
.	O
<EOS>	B-X
Ca2+	B-X
homeostasis	B-X
mechanisms	B-X
,	B-X
in	B-X
which	B-X
the	B-X
Ca2+	B-X
entry	B-X
pathways	B-X
play	B-X
a	B-X
key	B-X
role	B-X
,	B-X
are	B-X
critically	B-X
involved	B-X
in	B-X
both	B-X
normal	B-X
function	B-X
and	B-X
cancerous	B-X
transformation	B-X
of	B-X
prostate	B-X
epithelial	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
using	B-X
the	B-X
lymph	B-X
node	B-X
carcinoma	B-X
of	B-X
the	B-X
prostate	B-X
(	B-X
LNCaP	B-X
)	B-X
cell	B-X
line	B-X
as	B-X
a	B-X
major	B-X
experimental	B-X
model	B-X
,	B-X
we	B-X
characterize	B-X
prostate-specific	B-X
store-operated	B-X
Ca2+	B-X
channels	B-X
(	B-X
SOCs	B-X
)	B-X
--	B-X
a	B-X
primary	B-X
Ca2+	B-X
entry	B-X
pathway	B-X
for	B-X
non-excitable	B-X
cells	B-X
--	B-X
for	B-X
the	B-X
first	B-X
time	B-X
.	B-X
We	B-X
show	B-X
that	B-X
prostate-specific	B-X
SOCs	B-X
share	B-X
major	B-X
store-dependent	B-X
,	B-X
kinetic	B-X
,	B-X
permeation	B-X
,	B-X
inwardly	B-X
rectifying	B-X
,	B-X
and	B-X
pharmacological	B-X
(	B-X
including	B-X
dual	B-X
,	B-X
potentiation/inhibition	B-X
concentration-dependent	B-X
sensitivity	B-X
to	B-X
2-APB	B-X
)	B-X
properties	B-X
with	B-X
``	B-X
classical	B-X
''	B-X
Ca2+	B-X
release-activated	B-X
Ca2+	B-X
channels	B-X
(	B-X
CRAC	B-X
)	B-X
,	B-X
but	B-X
have	B-X
a	B-X
higher	B-X
single	B-X
channel	B-X
conductance	B-X
(	B-X
3.2	B-X
and	B-X
12pS	B-X
in	B-X
Ca2+-	B-X
and	B-X
Na+-permeable	B-X
modes	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
The	B-X
TRPC1	B-X
and	B-X
TRPV6	B-X
members	B-X
of	B-X
the	B-X
transient	B-X
receptor	B-X
potential	B-X
(	B-X
TRP	B-X
)	B-X
channel	B-X
family	B-X
are	B-X
the	B-X
most	B-X
likely	B-X
molecular	B-X
candidates	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
prostate-specific	B-X
endogenous	B-X
SOCs	B-X
.	B-X
Differentiation	B-X
of	B-X
LNCaP	B-X
cells	B-X
to	B-X
an	B-X
androgen-insensitive	B-X
,	B-X
apoptotic-resistant	B-X
neuroendocrine	B-X
phenotype	B-X
downregulates	B-X
SOC	B-X
current	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
prostate-specific	B-X
SOCs	B-X
are	B-X
important	B-X
determinants	B-X
in	B-X
the	B-X
transition	B-X
to	B-X
androgen-independent	B-X
prostate	B-X
cancer	B-X
.	B-X

Activation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
in	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
by	O
hypochlorous	O
acid	O
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
such	O
as	O
hydrogen	O
peroxide	O
serve	O
as	O
second	O
messengers	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
and	O
hence	O
in	O
the	O
activation	O
and	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
in	O
human	O
cells	O
.	O
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
such	B-X
as	B-X
hydrogen	B-X
peroxide	B-X
serve	B-X
as	B-X
second	B-X
messengers	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
and	B-X
hence	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
replication	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
During	B-X
inflammatory	B-X
reactions	B-X
,	B-X
many	B-X
oxidative	B-X
species	B-X
are	B-X
produced	B-X
,	B-X
one	B-X
of	B-X
which	B-X
is	B-X
hypochlorous	B-X
acid	B-X
(	B-X
HOCl	B-X
)	B-X
,	B-X
which	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
microbicidal	B-X
effects	B-X
of	B-X
activated	B-X
human	B-X
polymorphonuclear	B-X
leukocytes	B-X
.	B-X
Treatment	B-X
of	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
with	B-X
micromolar	B-X
concentrations	B-X
of	B-X
HOCl	B-X
promoted	B-X
the	B-X
appearance	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
(	B-X
the	B-X
heterodimer	B-X
p50/p65	B-X
)	B-X
in	B-X
the	B-X
nucleus	B-X
of	B-X
the	B-X
cells	B-X
,	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitory	B-X
subunits	B-X
(	B-X
IkappaB	B-X
)	B-X
demonstrated	B-X
that	B-X
both	B-X
IkappaB-alpha	B-X
proteolysis	B-X
and	B-X
p105	B-X
processing	B-X
were	B-X
induced	B-X
by	B-X
the	B-X
treatment	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
was	B-X
very	B-X
effective	B-X
when	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
hyperthermia	B-X
before	B-X
being	B-X
treated	B-X
with	B-X
HOCl	B-X
.	B-X
Various	B-X
antioxidants	B-X
,	B-X
such	B-X
as	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
p-bromophenacyl-bromide	B-X
and	B-X
nordihydroguaiaretic	B-X
acid	B-X
could	B-X
strongly	B-X
reduce	B-X
NF-kappaB	B-X
translocation	B-X
,	B-X
demonstrating	B-X
the	B-X
importance	B-X
of	B-X
oxidative	B-X
species	B-X
in	B-X
the	B-X
transduction	B-X
mechanism	B-X
.	B-X
Moreover	B-X
,	B-X
ACH-2	B-X
cells	B-X
treated	B-X
with	B-X
HOCl	B-X
or	B-X
H2O2	B-X
released	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
the	B-X
supernatants	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
TNF-alpha	B-X
release	B-X
in	B-X
NF-kappaB	B-X
induction	B-X
by	B-X
HOCl	B-X
or	B-X
H2O2	B-X
was	B-X
demonstrated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
:	B-X
(	B-X
1	B-X
)	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappaB	B-X
was	B-X
promoted	B-X
in	B-X
untreated	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
synergism	B-X
between	B-X
TNF-alpha	B-X
and	B-X
HOCl	B-X
was	B-X
detected	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
HOCl	B-X
should	B-X
be	B-X
considered	B-X
as	B-X
an	B-X
oxidative	B-X
species	B-X
capable	B-X
of	B-X
inducing	B-X
NF-kappaB	B-X
in	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
through	B-X
a	B-X
transduction	B-X
mechanism	B-X
involving	B-X
ROS	B-X
,	B-X
and	B-X
having	B-X
a	B-X
long-distance	B-X
effect	B-X
through	B-X
subsequent	B-X
TNF-alpha	B-X
release	B-X
.	B-X

During	O
inflammatory	O
reactions	O
,	O
many	O
oxidative	O
species	O
are	O
produced	O
,	O
one	O
of	O
which	O
is	O
hypochlorous	O
acid	O
(	O
HOCl	O
)	O
,	O
which	O
is	O
responsible	O
for	O
the	O
microbicidal	O
effects	O
of	O
activated	O
human	O
polymorphonuclear	O
leukocytes	O
.	O
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
such	B-X
as	B-X
hydrogen	B-X
peroxide	B-X
serve	B-X
as	B-X
second	B-X
messengers	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
and	B-X
hence	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
replication	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
During	B-X
inflammatory	B-X
reactions	B-X
,	B-X
many	B-X
oxidative	B-X
species	B-X
are	B-X
produced	B-X
,	B-X
one	B-X
of	B-X
which	B-X
is	B-X
hypochlorous	B-X
acid	B-X
(	B-X
HOCl	B-X
)	B-X
,	B-X
which	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
microbicidal	B-X
effects	B-X
of	B-X
activated	B-X
human	B-X
polymorphonuclear	B-X
leukocytes	B-X
.	B-X
Treatment	B-X
of	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
with	B-X
micromolar	B-X
concentrations	B-X
of	B-X
HOCl	B-X
promoted	B-X
the	B-X
appearance	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
(	B-X
the	B-X
heterodimer	B-X
p50/p65	B-X
)	B-X
in	B-X
the	B-X
nucleus	B-X
of	B-X
the	B-X
cells	B-X
,	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
was	B-X
very	B-X
effective	B-X
when	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
hyperthermia	B-X
before	B-X
being	B-X
treated	B-X
with	B-X
HOCl	B-X
.	B-X
Various	B-X
antioxidants	B-X
,	B-X
such	B-X
as	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
p-bromophenacyl-bromide	B-X
and	B-X
nordihydroguaiaretic	B-X
acid	B-X
could	B-X
strongly	B-X
reduce	B-X
NF-kappaB	B-X
translocation	B-X
,	B-X
demonstrating	B-X
the	B-X
importance	B-X
of	B-X
oxidative	B-X
species	B-X
in	B-X
the	B-X
transduction	B-X
mechanism	B-X
.	B-X
Moreover	B-X
,	B-X
ACH-2	B-X
cells	B-X
treated	B-X
with	B-X
HOCl	B-X
or	B-X
H2O2	B-X
released	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
the	B-X
supernatants	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
TNF-alpha	B-X
release	B-X
in	B-X
NF-kappaB	B-X
induction	B-X
by	B-X
HOCl	B-X
or	B-X
H2O2	B-X
was	B-X
demonstrated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
:	B-X
(	B-X
1	B-X
)	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappaB	B-X
was	B-X
promoted	B-X
in	B-X
untreated	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
synergism	B-X
between	B-X
TNF-alpha	B-X
and	B-X
HOCl	B-X
was	B-X
detected	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
HOCl	B-X
should	B-X
be	B-X
considered	B-X
as	B-X
an	B-X
oxidative	B-X
species	B-X
capable	B-X
of	B-X
inducing	B-X
NF-kappaB	B-X
in	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
through	B-X
a	B-X
transduction	B-X
mechanism	B-X
involving	B-X
ROS	B-X
,	B-X
and	B-X
having	B-X
a	B-X
long-distance	B-X
effect	B-X
through	B-X
subsequent	B-X
TNF-alpha	B-X
release	B-X
.	B-X

Treatment	O
of	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
with	O
micromolar	O
concentrations	O
of	O
HOCl	O
promoted	O
the	O
appearance	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
(	O
the	O
heterodimer	O
p50	B-Protein
/	O
p65	B-Protein
)	O
in	O
the	O
nucleus	O
of	O
the	O
cells	O
,	O
even	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
.	O

Western	O
blot	O
analysis	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitory	O
subunits	O
(	O
IkappaB	O
)	O
demonstrated	O
that	O
both	O
IkappaB	B-Protein
-	I-Protein
alpha	I-Protein
proteolysis	O
and	O
p105	B-Protein
processing	O
were	O
induced	O
by	O
the	O
treatment	O
.	O
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
such	B-X
as	B-X
hydrogen	B-X
peroxide	B-X
serve	B-X
as	B-X
second	B-X
messengers	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
and	B-X
hence	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
replication	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
Treatment	B-X
of	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
with	B-X
micromolar	B-X
concentrations	B-X
of	B-X
HOCl	B-X
promoted	B-X
the	B-X
appearance	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
(	B-X
the	B-X
heterodimer	B-X
p50/p65	B-X
)	B-X
in	B-X
the	B-X
nucleus	B-X
of	B-X
the	B-X
cells	B-X
,	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitory	B-X
subunits	B-X
(	B-X
IkappaB	B-X
)	B-X
demonstrated	B-X
that	B-X
both	B-X
IkappaB-alpha	B-X
proteolysis	B-X
and	B-X
p105	B-X
processing	B-X
were	B-X
induced	B-X
by	B-X
the	B-X
treatment	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
was	B-X
very	B-X
effective	B-X
when	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
hyperthermia	B-X
before	B-X
being	B-X
treated	B-X
with	B-X
HOCl	B-X
.	B-X
Various	B-X
antioxidants	B-X
,	B-X
such	B-X
as	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
p-bromophenacyl-bromide	B-X
and	B-X
nordihydroguaiaretic	B-X
acid	B-X
could	B-X
strongly	B-X
reduce	B-X
NF-kappaB	B-X
translocation	B-X
,	B-X
demonstrating	B-X
the	B-X
importance	B-X
of	B-X
oxidative	B-X
species	B-X
in	B-X
the	B-X
transduction	B-X
mechanism	B-X
.	B-X
Moreover	B-X
,	B-X
ACH-2	B-X
cells	B-X
treated	B-X
with	B-X
HOCl	B-X
or	B-X
H2O2	B-X
released	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
the	B-X
supernatants	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
TNF-alpha	B-X
release	B-X
in	B-X
NF-kappaB	B-X
induction	B-X
by	B-X
HOCl	B-X
or	B-X
H2O2	B-X
was	B-X
demonstrated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
:	B-X
(	B-X
1	B-X
)	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappaB	B-X
was	B-X
promoted	B-X
in	B-X
untreated	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
synergism	B-X
between	B-X
TNF-alpha	B-X
and	B-X
HOCl	B-X
was	B-X
detected	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
HOCl	B-X
should	B-X
be	B-X
considered	B-X
as	B-X
an	B-X
oxidative	B-X
species	B-X
capable	B-X
of	B-X
inducing	B-X
NF-kappaB	B-X
in	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
through	B-X
a	B-X
transduction	B-X
mechanism	B-X
involving	B-X
ROS	B-X
,	B-X
and	B-X
having	B-X
a	B-X
long-distance	B-X
effect	B-X
through	B-X
subsequent	B-X
TNF-alpha	B-X
release	B-X
.	B-X

NF	O
-	O
kappaB	O
activation	O
was	O
very	O
effective	O
when	O
cells	O
were	O
subjected	O
to	O
hyperthermia	O
before	O
being	O
treated	O
with	O
HOCl	O
.	O
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
such	B-X
as	B-X
hydrogen	B-X
peroxide	B-X
serve	B-X
as	B-X
second	B-X
messengers	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
and	B-X
hence	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
replication	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
During	B-X
inflammatory	B-X
reactions	B-X
,	B-X
many	B-X
oxidative	B-X
species	B-X
are	B-X
produced	B-X
,	B-X
one	B-X
of	B-X
which	B-X
is	B-X
hypochlorous	B-X
acid	B-X
(	B-X
HOCl	B-X
)	B-X
,	B-X
which	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
microbicidal	B-X
effects	B-X
of	B-X
activated	B-X
human	B-X
polymorphonuclear	B-X
leukocytes	B-X
.	B-X
Treatment	B-X
of	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
with	B-X
micromolar	B-X
concentrations	B-X
of	B-X
HOCl	B-X
promoted	B-X
the	B-X
appearance	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
(	B-X
the	B-X
heterodimer	B-X
p50/p65	B-X
)	B-X
in	B-X
the	B-X
nucleus	B-X
of	B-X
the	B-X
cells	B-X
,	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitory	B-X
subunits	B-X
(	B-X
IkappaB	B-X
)	B-X
demonstrated	B-X
that	B-X
both	B-X
IkappaB-alpha	B-X
proteolysis	B-X
and	B-X
p105	B-X
processing	B-X
were	B-X
induced	B-X
by	B-X
the	B-X
treatment	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
was	B-X
very	B-X
effective	B-X
when	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
hyperthermia	B-X
before	B-X
being	B-X
treated	B-X
with	B-X
HOCl	B-X
.	B-X
Various	B-X
antioxidants	B-X
,	B-X
such	B-X
as	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
p-bromophenacyl-bromide	B-X
and	B-X
nordihydroguaiaretic	B-X
acid	B-X
could	B-X
strongly	B-X
reduce	B-X
NF-kappaB	B-X
translocation	B-X
,	B-X
demonstrating	B-X
the	B-X
importance	B-X
of	B-X
oxidative	B-X
species	B-X
in	B-X
the	B-X
transduction	B-X
mechanism	B-X
.	B-X
Moreover	B-X
,	B-X
ACH-2	B-X
cells	B-X
treated	B-X
with	B-X
HOCl	B-X
or	B-X
H2O2	B-X
released	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
the	B-X
supernatants	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
TNF-alpha	B-X
release	B-X
in	B-X
NF-kappaB	B-X
induction	B-X
by	B-X
HOCl	B-X
or	B-X
H2O2	B-X
was	B-X
demonstrated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
:	B-X
(	B-X
1	B-X
)	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappaB	B-X
was	B-X
promoted	B-X
in	B-X
untreated	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
synergism	B-X
between	B-X
TNF-alpha	B-X
and	B-X
HOCl	B-X
was	B-X
detected	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
HOCl	B-X
should	B-X
be	B-X
considered	B-X
as	B-X
an	B-X
oxidative	B-X
species	B-X
capable	B-X
of	B-X
inducing	B-X
NF-kappaB	B-X
in	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
through	B-X
a	B-X
transduction	B-X
mechanism	B-X
involving	B-X
ROS	B-X
,	B-X
and	B-X
having	B-X
a	B-X
long-distance	B-X
effect	B-X
through	B-X
subsequent	B-X
TNF-alpha	B-X
release	B-X
.	B-X

Various	O
antioxidants	O
,	O
such	O
as	O
pyrrolidine	O
dithiocarbamate	O
,	O
p	O
-	O
bromophenacyl	O
-	O
bromide	O
and	O
nordihydroguaiaretic	O
acid	O
could	O
strongly	O
reduce	O
NF	O
-	O
kappaB	O
translocation	O
,	O
demonstrating	O
the	O
importance	O
of	O
oxidative	O
species	O
in	O
the	O
transduction	O
mechanism	O
.	O
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
such	B-X
as	B-X
hydrogen	B-X
peroxide	B-X
serve	B-X
as	B-X
second	B-X
messengers	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
and	B-X
hence	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
replication	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
During	B-X
inflammatory	B-X
reactions	B-X
,	B-X
many	B-X
oxidative	B-X
species	B-X
are	B-X
produced	B-X
,	B-X
one	B-X
of	B-X
which	B-X
is	B-X
hypochlorous	B-X
acid	B-X
(	B-X
HOCl	B-X
)	B-X
,	B-X
which	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
microbicidal	B-X
effects	B-X
of	B-X
activated	B-X
human	B-X
polymorphonuclear	B-X
leukocytes	B-X
.	B-X
Treatment	B-X
of	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
with	B-X
micromolar	B-X
concentrations	B-X
of	B-X
HOCl	B-X
promoted	B-X
the	B-X
appearance	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
(	B-X
the	B-X
heterodimer	B-X
p50/p65	B-X
)	B-X
in	B-X
the	B-X
nucleus	B-X
of	B-X
the	B-X
cells	B-X
,	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitory	B-X
subunits	B-X
(	B-X
IkappaB	B-X
)	B-X
demonstrated	B-X
that	B-X
both	B-X
IkappaB-alpha	B-X
proteolysis	B-X
and	B-X
p105	B-X
processing	B-X
were	B-X
induced	B-X
by	B-X
the	B-X
treatment	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
was	B-X
very	B-X
effective	B-X
when	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
hyperthermia	B-X
before	B-X
being	B-X
treated	B-X
with	B-X
HOCl	B-X
.	B-X
Various	B-X
antioxidants	B-X
,	B-X
such	B-X
as	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
p-bromophenacyl-bromide	B-X
and	B-X
nordihydroguaiaretic	B-X
acid	B-X
could	B-X
strongly	B-X
reduce	B-X
NF-kappaB	B-X
translocation	B-X
,	B-X
demonstrating	B-X
the	B-X
importance	B-X
of	B-X
oxidative	B-X
species	B-X
in	B-X
the	B-X
transduction	B-X
mechanism	B-X
.	B-X
Moreover	B-X
,	B-X
ACH-2	B-X
cells	B-X
treated	B-X
with	B-X
HOCl	B-X
or	B-X
H2O2	B-X
released	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
the	B-X
supernatants	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
TNF-alpha	B-X
release	B-X
in	B-X
NF-kappaB	B-X
induction	B-X
by	B-X
HOCl	B-X
or	B-X
H2O2	B-X
was	B-X
demonstrated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
:	B-X
(	B-X
1	B-X
)	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappaB	B-X
was	B-X
promoted	B-X
in	B-X
untreated	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
synergism	B-X
between	B-X
TNF-alpha	B-X
and	B-X
HOCl	B-X
was	B-X
detected	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
HOCl	B-X
should	B-X
be	B-X
considered	B-X
as	B-X
an	B-X
oxidative	B-X
species	B-X
capable	B-X
of	B-X
inducing	B-X
NF-kappaB	B-X
in	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
through	B-X
a	B-X
transduction	B-X
mechanism	B-X
involving	B-X
ROS	B-X
,	B-X
and	B-X
having	B-X
a	B-X
long-distance	B-X
effect	B-X
through	B-X
subsequent	B-X
TNF-alpha	B-X
release	B-X
.	B-X

Moreover	O
,	O
ACH	O
-	O
2	O
cells	O
treated	O
with	O
HOCl	O
or	O
H2O2	O
released	O
tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
in	O
the	O
supernatants	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
of	B-X
Actovegin®	B-X
was	B-X
investigated	B-X
on	B-X
PMA-	B-X
and	B-X
LPS-induced	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
.	B-X
TNF-alpha	B-X
induced	B-X
rapid	B-X
and	B-X
sustained	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
whereas	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
induced	B-X
delayed	B-X
and	B-X
transient	B-X
activation	B-X
.	B-X
Both	B-X
TNF-alpha	B-X
and	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
induced	B-X
IL-18	B-X
mRNA	B-X
and	B-X
precursor	B-X
protein	B-X
in	B-X
cardiomyocytes	B-X
,	B-X
and	B-X
IL-18	B-X
release	B-X
into	B-X
culture	B-X
supernatants	B-X
.	B-X
However	B-X
,	B-X
only	B-X
TNF-alpha	B-X
led	B-X
to	B-X
sustained	B-X
expression	B-X
.	B-X
Expression	B-X
of	B-X
IL-18Rbeta	B-X
,	B-X
but	B-X
not	B-X
alpha	B-X
,	B-X
was	B-X
induced	B-X
by	B-X
both	B-X
agonists	B-X
.	B-X
TNF-alpha	B-X
and	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
induced	B-X
delayed	B-X
expression	B-X
of	B-X
IL-18	B-X
BP	B-X
.	B-X
Pretreatment	B-X
with	B-X
PDTC	B-X
attenuated	B-X
TNF-alpha	B-X
and	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
induced	B-X
IL-18	B-X
and	B-X
IL-18Rbeta	B-X
,	B-X
but	B-X
not	B-X
basal	B-X
expression	B-X
of	B-X
IL-18Ralpha	B-X
.	B-X

The	O
importance	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
release	O
in	O
NF	O
-	O
kappaB	O
induction	O
by	O
HOCl	O
or	O
H2O2	O
was	O
demonstrated	O
by	O
the	O
fact	O
that	O
:	O
(	O
1	O
)	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
kappaB	O
was	O
promoted	O
in	O
untreated	O
cells	O
;	O
and	O
(	O
2	O
)	O
synergism	O
between	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
HOCl	O
was	O
detected	O
.	O
<EOS>	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
such	B-X
as	B-X
hydrogen	B-X
peroxide	B-X
serve	B-X
as	B-X
second	B-X
messengers	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
and	B-X
hence	B-X
in	B-X
the	B-X
activation	B-X
and	B-X
replication	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
in	B-X
human	B-X
cells	B-X
.	B-X
During	B-X
inflammatory	B-X
reactions	B-X
,	B-X
many	B-X
oxidative	B-X
species	B-X
are	B-X
produced	B-X
,	B-X
one	B-X
of	B-X
which	B-X
is	B-X
hypochlorous	B-X
acid	B-X
(	B-X
HOCl	B-X
)	B-X
,	B-X
which	B-X
is	B-X
responsible	B-X
for	B-X
the	B-X
microbicidal	B-X
effects	B-X
of	B-X
activated	B-X
human	B-X
polymorphonuclear	B-X
leukocytes	B-X
.	B-X
Treatment	B-X
of	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
with	B-X
micromolar	B-X
concentrations	B-X
of	B-X
HOCl	B-X
promoted	B-X
the	B-X
appearance	B-X
of	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
(	B-X
the	B-X
heterodimer	B-X
p50/p65	B-X
)	B-X
in	B-X
the	B-X
nucleus	B-X
of	B-X
the	B-X
cells	B-X
,	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
de	B-X
novo	B-X
protein	B-X
synthesis	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
the	B-X
NF-kappaB	B-X
inhibitory	B-X
subunits	B-X
(	B-X
IkappaB	B-X
)	B-X
demonstrated	B-X
that	B-X
both	B-X
IkappaB-alpha	B-X
proteolysis	B-X
and	B-X
p105	B-X
processing	B-X
were	B-X
induced	B-X
by	B-X
the	B-X
treatment	B-X
.	B-X
NF-kappaB	B-X
activation	B-X
was	B-X
very	B-X
effective	B-X
when	B-X
cells	B-X
were	B-X
subjected	B-X
to	B-X
hyperthermia	B-X
before	B-X
being	B-X
treated	B-X
with	B-X
HOCl	B-X
.	B-X
Various	B-X
antioxidants	B-X
,	B-X
such	B-X
as	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
,	B-X
p-bromophenacyl-bromide	B-X
and	B-X
nordihydroguaiaretic	B-X
acid	B-X
could	B-X
strongly	B-X
reduce	B-X
NF-kappaB	B-X
translocation	B-X
,	B-X
demonstrating	B-X
the	B-X
importance	B-X
of	B-X
oxidative	B-X
species	B-X
in	B-X
the	B-X
transduction	B-X
mechanism	B-X
.	B-X
Moreover	B-X
,	B-X
ACH-2	B-X
cells	B-X
treated	B-X
with	B-X
HOCl	B-X
or	B-X
H2O2	B-X
released	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
in	B-X
the	B-X
supernatants	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
TNF-alpha	B-X
release	B-X
in	B-X
NF-kappaB	B-X
induction	B-X
by	B-X
HOCl	B-X
or	B-X
H2O2	B-X
was	B-X
demonstrated	B-X
by	B-X
the	B-X
fact	B-X
that	B-X
:	B-X
(	B-X
1	B-X
)	B-X
the	B-X
nuclear	B-X
appearance	B-X
of	B-X
NF-kappaB	B-X
was	B-X
promoted	B-X
in	B-X
untreated	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
2	B-X
)	B-X
synergism	B-X
between	B-X
TNF-alpha	B-X
and	B-X
HOCl	B-X
was	B-X
detected	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
HOCl	B-X
should	B-X
be	B-X
considered	B-X
as	B-X
an	B-X
oxidative	B-X
species	B-X
capable	B-X
of	B-X
inducing	B-X
NF-kappaB	B-X
in	B-X
a	B-X
T-lymphocytic	B-X
cell	B-X
line	B-X
through	B-X
a	B-X
transduction	B-X
mechanism	B-X
involving	B-X
ROS	B-X
,	B-X
and	B-X
having	B-X
a	B-X
long-distance	B-X
effect	B-X
through	B-X
subsequent	B-X
TNF-alpha	B-X
release	B-X
.	B-X

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
HOCl	O
should	O
be	O
considered	O
as	O
an	O
oxidative	O
species	O
capable	O
of	O
inducing	O
NF	O
-	O
kappaB	O
in	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
through	O
a	O
transduction	O
mechanism	O
involving	O
ROS	O
,	O
and	O
having	O
a	O
long	O
-	O
distance	O
effect	O
through	O
subsequent	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
release	O
.	O

Thymocytes	O
control	O
the	O
CD4	B-Protein
gene	O
differently	O
from	O
mature	O
T	O
lymphocytes	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
enhancer	B-X
,	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
silencer	B-X
of	B-X
the	B-X
human	B-X
CD4	B-X
gene	B-X
during	B-X
T	B-X
cell	B-X
development	B-X
using	B-X
transgenic	B-X
mice	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
on	B-X
thymic	B-X
populations	B-X
of	B-X
mice	B-X
carrying	B-X
transgenes	B-X
in	B-X
various	B-X
combinations	B-X
of	B-X
these	B-X
regulatory	B-X
DNA	B-X
elements	B-X
revealed	B-X
that	B-X
thymocytes	B-X
control	B-X
the	B-X
CD4	B-X
gene	B-X
in	B-X
a	B-X
different	B-X
manner	B-X
than	B-X
mature	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
5'-positive	B-X
regulatory	B-X
unit	B-X
,	B-X
consisting	B-X
of	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
5	B-X
'	B-X
enhancer	B-X
,	B-X
is	B-X
already	B-X
active	B-X
at	B-X
the	B-X
CD4-CD8-double-negative	B-X
(	B-X
DN	B-X
)	B-X
stage	B-X
of	B-X
development	B-X
.	B-X
However	B-X
,	B-X
its	B-X
activity	B-X
becomes	B-X
lower	B-X
in	B-X
the	B-X
double-positive	B-X
and	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
CD4+	B-X
CD8int/-	B-X
cell	B-X
population	B-X
,	B-X
indicating	B-X
that	B-X
an	B-X
additional	B-X
enhancer	B-X
,	B-X
located	B-X
in	B-X
either	B-X
the	B-X
first	B-X
or	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
the	B-X
CD4	B-X
gene	B-X
,	B-X
is	B-X
required	B-X
for	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
this	B-X
population	B-X
.	B-X
The	B-X
other	B-X
studied	B-X
regulatory	B-X
element	B-X
is	B-X
the	B-X
minimal	B-X
CD4	B-X
silencer	B-X
which	B-X
inhibits	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
peripheral	B-X
CD8	B-X
T	B-X
lymphocytes	B-X
.	B-X
This	B-X
silencer	B-X
is	B-X
inactive	B-X
in	B-X
the	B-X
most	B-X
immature	B-X
DN	B-X
thymocytes	B-X
,	B-X
which	B-X
probably	B-X
use	B-X
a	B-X
distinct	B-X
silencer	B-X
mechanism	B-X
to	B-X
down-regulate	B-X
CD4	B-X
gene	B-X
expression	B-X
.	B-X
Unexpectedly	B-X
,	B-X
the	B-X
CD4	B-X
silencer	B-X
is	B-X
also	B-X
active	B-X
in	B-X
CD4+	B-X
CD8int/-	B-X
cells	B-X
of	B-X
the	B-X
thymus	B-X
,	B-X
implying	B-X
that	B-X
an	B-X
anti-silencer	B-X
may	B-X
be	B-X
required	B-X
to	B-X
resume	B-X
CD4	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
population	B-X
.	B-X
Altogether	B-X
,	B-X
the	B-X
CD4	B-X
gene	B-X
is	B-X
regulated	B-X
by	B-X
several	B-X
positive	B-X
and	B-X
negative	B-X
regulatory	B-X
mechanisms	B-X
which	B-X
come	B-X
into	B-X
play	B-X
in	B-X
a	B-X
developmentally	B-X
coordinated	B-X
manner	B-X
.	B-X

We	O
analyzed	O
the	O
activity	O
of	O
the	O
enhancer	O
,	O
the	O
promoter	O
and	O
the	O
silencer	O
of	O
the	O
human	O
CD4	B-Protein
gene	O
during	O
T	O
cell	O
development	O
using	O
transgenic	O
mice	O
.	O

Immunofluorescence	O
studies	O
on	O
thymic	O
populations	O
of	O
mice	O
carrying	O
transgenes	O
in	O
various	O
combinations	O
of	O
these	O
regulatory	O
DNA	O
elements	O
revealed	O
that	O
thymocytes	O
control	O
the	O
CD4	B-Protein
gene	O
in	O
a	O
different	O
manner	O
than	O
mature	O
peripheral	O
T	O
lymphocytes	O
.	O

The	O
5	O
'	O
-	O
positive	O
regulatory	O
unit	O
,	O
consisting	O
of	O
the	O
promoter	O
and	O
the	O
5	O
'	O
enhancer	O
,	O
is	O
already	O
active	O
at	O
the	O
CD4	B-Protein
-	O
CD8	O
-	O
double	O
-	O
negative	O
(	O
DN	O
)	O
stage	O
of	O
development	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
enhancer	B-X
,	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
silencer	B-X
of	B-X
the	B-X
human	B-X
CD4	B-X
gene	B-X
during	B-X
T	B-X
cell	B-X
development	B-X
using	B-X
transgenic	B-X
mice	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
on	B-X
thymic	B-X
populations	B-X
of	B-X
mice	B-X
carrying	B-X
transgenes	B-X
in	B-X
various	B-X
combinations	B-X
of	B-X
these	B-X
regulatory	B-X
DNA	B-X
elements	B-X
revealed	B-X
that	B-X
thymocytes	B-X
control	B-X
the	B-X
CD4	B-X
gene	B-X
in	B-X
a	B-X
different	B-X
manner	B-X
than	B-X
mature	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
5'-positive	B-X
regulatory	B-X
unit	B-X
,	B-X
consisting	B-X
of	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
5	B-X
'	B-X
enhancer	B-X
,	B-X
is	B-X
already	B-X
active	B-X
at	B-X
the	B-X
CD4-CD8-double-negative	B-X
(	B-X
DN	B-X
)	B-X
stage	B-X
of	B-X
development	B-X
.	B-X
However	B-X
,	B-X
its	B-X
activity	B-X
becomes	B-X
lower	B-X
in	B-X
the	B-X
double-positive	B-X
and	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
CD4+	B-X
CD8int/-	B-X
cell	B-X
population	B-X
,	B-X
indicating	B-X
that	B-X
an	B-X
additional	B-X
enhancer	B-X
,	B-X
located	B-X
in	B-X
either	B-X
the	B-X
first	B-X
or	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
the	B-X
CD4	B-X
gene	B-X
,	B-X
is	B-X
required	B-X
for	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
this	B-X
population	B-X
.	B-X
The	B-X
other	B-X
studied	B-X
regulatory	B-X
element	B-X
is	B-X
the	B-X
minimal	B-X
CD4	B-X
silencer	B-X
which	B-X
inhibits	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
peripheral	B-X
CD8	B-X
T	B-X
lymphocytes	B-X
.	B-X
This	B-X
silencer	B-X
is	B-X
inactive	B-X
in	B-X
the	B-X
most	B-X
immature	B-X
DN	B-X
thymocytes	B-X
,	B-X
which	B-X
probably	B-X
use	B-X
a	B-X
distinct	B-X
silencer	B-X
mechanism	B-X
to	B-X
down-regulate	B-X
CD4	B-X
gene	B-X
expression	B-X
.	B-X
Unexpectedly	B-X
,	B-X
the	B-X
CD4	B-X
silencer	B-X
is	B-X
also	B-X
active	B-X
in	B-X
CD4+	B-X
CD8int/-	B-X
cells	B-X
of	B-X
the	B-X
thymus	B-X
,	B-X
implying	B-X
that	B-X
an	B-X
anti-silencer	B-X
may	B-X
be	B-X
required	B-X
to	B-X
resume	B-X
CD4	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
population	B-X
.	B-X
Altogether	B-X
,	B-X
the	B-X
CD4	B-X
gene	B-X
is	B-X
regulated	B-X
by	B-X
several	B-X
positive	B-X
and	B-X
negative	B-X
regulatory	B-X
mechanisms	B-X
which	B-X
come	B-X
into	B-X
play	B-X
in	B-X
a	B-X
developmentally	B-X
coordinated	B-X
manner	B-X
.	B-X

However	O
,	O
its	O
activity	O
becomes	O
lower	O
in	O
the	O
double	O
-	O
positive	O
and	O
a	O
fraction	O
of	O
the	O
CD4	O
+	O
CD8int	O
/	O
-	O
cell	O
population	O
,	O
indicating	O
that	O
an	O
additional	O
enhancer	O
,	O
located	O
in	O
either	O
the	O
first	O
or	O
the	O
third	O
intron	O
of	O
the	O
CD4	B-Protein
gene	O
,	O
is	O
required	O
for	O
CD4	B-Protein
gene	O
expression	O
in	O
this	O
population	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
enhancer	B-X
,	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
silencer	B-X
of	B-X
the	B-X
human	B-X
CD4	B-X
gene	B-X
during	B-X
T	B-X
cell	B-X
development	B-X
using	B-X
transgenic	B-X
mice	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
on	B-X
thymic	B-X
populations	B-X
of	B-X
mice	B-X
carrying	B-X
transgenes	B-X
in	B-X
various	B-X
combinations	B-X
of	B-X
these	B-X
regulatory	B-X
DNA	B-X
elements	B-X
revealed	B-X
that	B-X
thymocytes	B-X
control	B-X
the	B-X
CD4	B-X
gene	B-X
in	B-X
a	B-X
different	B-X
manner	B-X
than	B-X
mature	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
5'-positive	B-X
regulatory	B-X
unit	B-X
,	B-X
consisting	B-X
of	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
5	B-X
'	B-X
enhancer	B-X
,	B-X
is	B-X
already	B-X
active	B-X
at	B-X
the	B-X
CD4-CD8-double-negative	B-X
(	B-X
DN	B-X
)	B-X
stage	B-X
of	B-X
development	B-X
.	B-X
However	B-X
,	B-X
its	B-X
activity	B-X
becomes	B-X
lower	B-X
in	B-X
the	B-X
double-positive	B-X
and	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
CD4+	B-X
CD8int/-	B-X
cell	B-X
population	B-X
,	B-X
indicating	B-X
that	B-X
an	B-X
additional	B-X
enhancer	B-X
,	B-X
located	B-X
in	B-X
either	B-X
the	B-X
first	B-X
or	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
the	B-X
CD4	B-X
gene	B-X
,	B-X
is	B-X
required	B-X
for	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
this	B-X
population	B-X
.	B-X
The	B-X
other	B-X
studied	B-X
regulatory	B-X
element	B-X
is	B-X
the	B-X
minimal	B-X
CD4	B-X
silencer	B-X
which	B-X
inhibits	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
peripheral	B-X
CD8	B-X
T	B-X
lymphocytes	B-X
.	B-X
This	B-X
silencer	B-X
is	B-X
inactive	B-X
in	B-X
the	B-X
most	B-X
immature	B-X
DN	B-X
thymocytes	B-X
,	B-X
which	B-X
probably	B-X
use	B-X
a	B-X
distinct	B-X
silencer	B-X
mechanism	B-X
to	B-X
down-regulate	B-X
CD4	B-X
gene	B-X
expression	B-X
.	B-X
Unexpectedly	B-X
,	B-X
the	B-X
CD4	B-X
silencer	B-X
is	B-X
also	B-X
active	B-X
in	B-X
CD4+	B-X
CD8int/-	B-X
cells	B-X
of	B-X
the	B-X
thymus	B-X
,	B-X
implying	B-X
that	B-X
an	B-X
anti-silencer	B-X
may	B-X
be	B-X
required	B-X
to	B-X
resume	B-X
CD4	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
population	B-X
.	B-X
Altogether	B-X
,	B-X
the	B-X
CD4	B-X
gene	B-X
is	B-X
regulated	B-X
by	B-X
several	B-X
positive	B-X
and	B-X
negative	B-X
regulatory	B-X
mechanisms	B-X
which	B-X
come	B-X
into	B-X
play	B-X
in	B-X
a	B-X
developmentally	B-X
coordinated	B-X
manner	B-X
.	B-X

The	O
other	O
studied	O
regulatory	O
element	O
is	O
the	O
minimal	O
CD4	B-Protein
silencer	O
which	O
inhibits	O
CD4	B-Protein
gene	O
expression	O
in	O
peripheral	O
CD8	O
T	O
lymphocytes	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
enhancer	B-X
,	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
silencer	B-X
of	B-X
the	B-X
human	B-X
CD4	B-X
gene	B-X
during	B-X
T	B-X
cell	B-X
development	B-X
using	B-X
transgenic	B-X
mice	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
on	B-X
thymic	B-X
populations	B-X
of	B-X
mice	B-X
carrying	B-X
transgenes	B-X
in	B-X
various	B-X
combinations	B-X
of	B-X
these	B-X
regulatory	B-X
DNA	B-X
elements	B-X
revealed	B-X
that	B-X
thymocytes	B-X
control	B-X
the	B-X
CD4	B-X
gene	B-X
in	B-X
a	B-X
different	B-X
manner	B-X
than	B-X
mature	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
5'-positive	B-X
regulatory	B-X
unit	B-X
,	B-X
consisting	B-X
of	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
5	B-X
'	B-X
enhancer	B-X
,	B-X
is	B-X
already	B-X
active	B-X
at	B-X
the	B-X
CD4-CD8-double-negative	B-X
(	B-X
DN	B-X
)	B-X
stage	B-X
of	B-X
development	B-X
.	B-X
However	B-X
,	B-X
its	B-X
activity	B-X
becomes	B-X
lower	B-X
in	B-X
the	B-X
double-positive	B-X
and	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
CD4+	B-X
CD8int/-	B-X
cell	B-X
population	B-X
,	B-X
indicating	B-X
that	B-X
an	B-X
additional	B-X
enhancer	B-X
,	B-X
located	B-X
in	B-X
either	B-X
the	B-X
first	B-X
or	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
the	B-X
CD4	B-X
gene	B-X
,	B-X
is	B-X
required	B-X
for	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
this	B-X
population	B-X
.	B-X
The	B-X
other	B-X
studied	B-X
regulatory	B-X
element	B-X
is	B-X
the	B-X
minimal	B-X
CD4	B-X
silencer	B-X
which	B-X
inhibits	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
peripheral	B-X
CD8	B-X
T	B-X
lymphocytes	B-X
.	B-X
This	B-X
silencer	B-X
is	B-X
inactive	B-X
in	B-X
the	B-X
most	B-X
immature	B-X
DN	B-X
thymocytes	B-X
,	B-X
which	B-X
probably	B-X
use	B-X
a	B-X
distinct	B-X
silencer	B-X
mechanism	B-X
to	B-X
down-regulate	B-X
CD4	B-X
gene	B-X
expression	B-X
.	B-X
Unexpectedly	B-X
,	B-X
the	B-X
CD4	B-X
silencer	B-X
is	B-X
also	B-X
active	B-X
in	B-X
CD4+	B-X
CD8int/-	B-X
cells	B-X
of	B-X
the	B-X
thymus	B-X
,	B-X
implying	B-X
that	B-X
an	B-X
anti-silencer	B-X
may	B-X
be	B-X
required	B-X
to	B-X
resume	B-X
CD4	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
population	B-X
.	B-X
Altogether	B-X
,	B-X
the	B-X
CD4	B-X
gene	B-X
is	B-X
regulated	B-X
by	B-X
several	B-X
positive	B-X
and	B-X
negative	B-X
regulatory	B-X
mechanisms	B-X
which	B-X
come	B-X
into	B-X
play	B-X
in	B-X
a	B-X
developmentally	B-X
coordinated	B-X
manner	B-X
.	B-X

This	O
silencer	O
is	O
inactive	O
in	O
the	O
most	O
immature	O
DN	O
thymocytes	O
,	O
which	O
probably	O
use	O
a	O
distinct	O
silencer	O
mechanism	O
to	O
down	O
-	O
regulate	O
CD4	B-Protein
gene	O
expression	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
enhancer	B-X
,	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
silencer	B-X
of	B-X
the	B-X
human	B-X
CD4	B-X
gene	B-X
during	B-X
T	B-X
cell	B-X
development	B-X
using	B-X
transgenic	B-X
mice	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
on	B-X
thymic	B-X
populations	B-X
of	B-X
mice	B-X
carrying	B-X
transgenes	B-X
in	B-X
various	B-X
combinations	B-X
of	B-X
these	B-X
regulatory	B-X
DNA	B-X
elements	B-X
revealed	B-X
that	B-X
thymocytes	B-X
control	B-X
the	B-X
CD4	B-X
gene	B-X
in	B-X
a	B-X
different	B-X
manner	B-X
than	B-X
mature	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
5'-positive	B-X
regulatory	B-X
unit	B-X
,	B-X
consisting	B-X
of	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
5	B-X
'	B-X
enhancer	B-X
,	B-X
is	B-X
already	B-X
active	B-X
at	B-X
the	B-X
CD4-CD8-double-negative	B-X
(	B-X
DN	B-X
)	B-X
stage	B-X
of	B-X
development	B-X
.	B-X
However	B-X
,	B-X
its	B-X
activity	B-X
becomes	B-X
lower	B-X
in	B-X
the	B-X
double-positive	B-X
and	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
CD4+	B-X
CD8int/-	B-X
cell	B-X
population	B-X
,	B-X
indicating	B-X
that	B-X
an	B-X
additional	B-X
enhancer	B-X
,	B-X
located	B-X
in	B-X
either	B-X
the	B-X
first	B-X
or	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
the	B-X
CD4	B-X
gene	B-X
,	B-X
is	B-X
required	B-X
for	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
this	B-X
population	B-X
.	B-X
The	B-X
other	B-X
studied	B-X
regulatory	B-X
element	B-X
is	B-X
the	B-X
minimal	B-X
CD4	B-X
silencer	B-X
which	B-X
inhibits	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
peripheral	B-X
CD8	B-X
T	B-X
lymphocytes	B-X
.	B-X
This	B-X
silencer	B-X
is	B-X
inactive	B-X
in	B-X
the	B-X
most	B-X
immature	B-X
DN	B-X
thymocytes	B-X
,	B-X
which	B-X
probably	B-X
use	B-X
a	B-X
distinct	B-X
silencer	B-X
mechanism	B-X
to	B-X
down-regulate	B-X
CD4	B-X
gene	B-X
expression	B-X
.	B-X
Unexpectedly	B-X
,	B-X
the	B-X
CD4	B-X
silencer	B-X
is	B-X
also	B-X
active	B-X
in	B-X
CD4+	B-X
CD8int/-	B-X
cells	B-X
of	B-X
the	B-X
thymus	B-X
,	B-X
implying	B-X
that	B-X
an	B-X
anti-silencer	B-X
may	B-X
be	B-X
required	B-X
to	B-X
resume	B-X
CD4	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
population	B-X
.	B-X
Altogether	B-X
,	B-X
the	B-X
CD4	B-X
gene	B-X
is	B-X
regulated	B-X
by	B-X
several	B-X
positive	B-X
and	B-X
negative	B-X
regulatory	B-X
mechanisms	B-X
which	B-X
come	B-X
into	B-X
play	B-X
in	B-X
a	B-X
developmentally	B-X
coordinated	B-X
manner	B-X
.	B-X

Unexpectedly	O
,	O
the	O
CD4	B-Protein
silencer	O
is	O
also	O
active	O
in	O
CD4	B-Protein
+	O
CD8int	O
/	O
-	O
cells	O
of	O
the	O
thymus	O
,	O
implying	O
that	O
an	O
anti	O
-	O
silencer	O
may	O
be	O
required	O
to	O
resume	O
CD4	B-Protein
expression	O
in	O
this	O
cell	O
population	O
.	O
<EOS>	B-X
We	B-X
analyzed	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
enhancer	B-X
,	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
silencer	B-X
of	B-X
the	B-X
human	B-X
CD4	B-X
gene	B-X
during	B-X
T	B-X
cell	B-X
development	B-X
using	B-X
transgenic	B-X
mice	B-X
.	B-X
Immunofluorescence	B-X
studies	B-X
on	B-X
thymic	B-X
populations	B-X
of	B-X
mice	B-X
carrying	B-X
transgenes	B-X
in	B-X
various	B-X
combinations	B-X
of	B-X
these	B-X
regulatory	B-X
DNA	B-X
elements	B-X
revealed	B-X
that	B-X
thymocytes	B-X
control	B-X
the	B-X
CD4	B-X
gene	B-X
in	B-X
a	B-X
different	B-X
manner	B-X
than	B-X
mature	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
5'-positive	B-X
regulatory	B-X
unit	B-X
,	B-X
consisting	B-X
of	B-X
the	B-X
promoter	B-X
and	B-X
the	B-X
5	B-X
'	B-X
enhancer	B-X
,	B-X
is	B-X
already	B-X
active	B-X
at	B-X
the	B-X
CD4-CD8-double-negative	B-X
(	B-X
DN	B-X
)	B-X
stage	B-X
of	B-X
development	B-X
.	B-X
However	B-X
,	B-X
its	B-X
activity	B-X
becomes	B-X
lower	B-X
in	B-X
the	B-X
double-positive	B-X
and	B-X
a	B-X
fraction	B-X
of	B-X
the	B-X
CD4+	B-X
CD8int/-	B-X
cell	B-X
population	B-X
,	B-X
indicating	B-X
that	B-X
an	B-X
additional	B-X
enhancer	B-X
,	B-X
located	B-X
in	B-X
either	B-X
the	B-X
first	B-X
or	B-X
the	B-X
third	B-X
intron	B-X
of	B-X
the	B-X
CD4	B-X
gene	B-X
,	B-X
is	B-X
required	B-X
for	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
this	B-X
population	B-X
.	B-X
The	B-X
other	B-X
studied	B-X
regulatory	B-X
element	B-X
is	B-X
the	B-X
minimal	B-X
CD4	B-X
silencer	B-X
which	B-X
inhibits	B-X
CD4	B-X
gene	B-X
expression	B-X
in	B-X
peripheral	B-X
CD8	B-X
T	B-X
lymphocytes	B-X
.	B-X
This	B-X
silencer	B-X
is	B-X
inactive	B-X
in	B-X
the	B-X
most	B-X
immature	B-X
DN	B-X
thymocytes	B-X
,	B-X
which	B-X
probably	B-X
use	B-X
a	B-X
distinct	B-X
silencer	B-X
mechanism	B-X
to	B-X
down-regulate	B-X
CD4	B-X
gene	B-X
expression	B-X
.	B-X
Unexpectedly	B-X
,	B-X
the	B-X
CD4	B-X
silencer	B-X
is	B-X
also	B-X
active	B-X
in	B-X
CD4+	B-X
CD8int/-	B-X
cells	B-X
of	B-X
the	B-X
thymus	B-X
,	B-X
implying	B-X
that	B-X
an	B-X
anti-silencer	B-X
may	B-X
be	B-X
required	B-X
to	B-X
resume	B-X
CD4	B-X
expression	B-X
in	B-X
this	B-X
cell	B-X
population	B-X
.	B-X
Altogether	B-X
,	B-X
the	B-X
CD4	B-X
gene	B-X
is	B-X
regulated	B-X
by	B-X
several	B-X
positive	B-X
and	B-X
negative	B-X
regulatory	B-X
mechanisms	B-X
which	B-X
come	B-X
into	B-X
play	B-X
in	B-X
a	B-X
developmentally	B-X
coordinated	B-X
manner	B-X
.	B-X

Altogether	O
,	O
the	O
CD4	B-Protein
gene	O
is	O
regulated	O
by	O
several	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
which	O
come	O
into	O
play	O
in	O
a	O
developmentally	O
coordinated	O
manner	O
.	O

Triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
differentially	O
modulates	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
release	O
by	O
B	O
cells	O
at	O
distinct	O
stage	O
of	O
maturation	O
.	O

Triggering	O
of	O
HLA	O
class	O
II	O
antigens	O
by	O
the	O
anti	O
-	O
HLA	O
-	O
DR	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
L243	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
differentially	O
enhanced	O
the	O
release	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
by	O
the	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
cells	O
Ri	O
-	O
I	O
,	O
Ci	O
-	O
I	O
,	O
and	O
Sc	O
-	O
I	O
,	O
which	O
are	O
at	O
a	O
distinct	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
,	O
and	O
by	O
the	O
more	O
mature	O
Burkitt	O
lymphoma	O
cell	O
Raji	O
;	O
in	O
contrast	O
,	O
it	O
did	O
not	O
induce	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
release	O
by	O
the	O
pre	O
-	O
B	O
leukemia	O
cells	O
Nalm	O
-	O
6	O
and	O
BV173	O
.	O

TNF	B-Protein
-	I-Protein
alpha	I-Protein
release	O
peaked	O
at	O
24	O
h	O
and	O
decreased	O
thereafter	O
,	O
and	O
it	O
was	O
dose	O
dependent	O
and	O
preceded	O
by	O
an	O
increase	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
mRNA	O
detectable	O
after	O
3	O
h	O
of	O
stimulation	O
with	O
mAb	O
L243	O
.	O
<EOS>	B-X
Triggering	B-X
of	B-X
HLA	B-X
class	B-X
II	B-X
antigens	B-X
by	B-X
the	B-X
anti-HLA-DR	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
L243	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
and	B-X
differentially	B-X
enhanced	B-X
the	B-X
release	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
by	B-X
the	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
cells	B-X
Ri-I	B-X
,	B-X
Ci-I	B-X
,	B-X
and	B-X
Sc-I	B-X
,	B-X
which	B-X
are	B-X
at	B-X
a	B-X
distinct	B-X
stage	B-X
of	B-X
B-cell	B-X
differentiation	B-X
,	B-X
and	B-X
by	B-X
the	B-X
more	B-X
mature	B-X
Burkitt	B-X
lymphoma	B-X
cell	B-X
Raji	B-X
;	B-X
in	B-X
contrast	B-X
,	B-X
it	B-X
did	B-X
not	B-X
induce	B-X
TNF-alpha	B-X
release	B-X
by	B-X
the	B-X
pre-B	B-X
leukemia	B-X
cells	B-X
Nalm-6	B-X
and	B-X
BV173	B-X
.	B-X
TNF-alpha	B-X
release	B-X
peaked	B-X
at	B-X
24	B-X
h	B-X
and	B-X
decreased	B-X
thereafter	B-X
,	B-X
and	B-X
it	B-X
was	B-X
dose	B-X
dependent	B-X
and	B-X
preceded	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
TNF-alpha	B-X
mRNA	B-X
detectable	B-X
after	B-X
3	B-X
h	B-X
of	B-X
stimulation	B-X
with	B-X
mAb	B-X
L243	B-X
.	B-X
Secreted	B-X
TNF-alpha	B-X
mediated	B-X
the	B-X
enhancement	B-X
of	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
and	B-X
activator	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
binding	B-X
activity	B-X
;	B-X
in	B-X
fact	B-X
,	B-X
the	B-X
triggering	B-X
of	B-X
HLA-DR	B-X
antigens	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
antihuman	B-X
TNF-alpha-neutralizing	B-X
antibodies	B-X
did	B-X
not	B-X
upregulate	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
released	B-X
TNF-alpha	B-X
was	B-X
not	B-X
responsible	B-X
for	B-X
the	B-X
homotypic	B-X
aggregation	B-X
of	B-X
Ri-I	B-X
,	B-X
Ci-I	B-X
,	B-X
Sc-I	B-X
,	B-X
and	B-X
Raji	B-X
cells	B-X
induced	B-X
by	B-X
mAb	B-X
L243	B-X
,	B-X
and	B-X
it	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
proliferation	B-X
of	B-X
B	B-X
cells	B-X
investigated	B-X
.	B-X
Altogether	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
:	B-X
(	B-X
a	B-X
)	B-X
the	B-X
ability	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
release	B-X
TNF-alpha	B-X
after	B-X
triggering	B-X
of	B-X
HLA-DR	B-X
antigens	B-X
depends	B-X
on	B-X
their	B-X
stage	B-X
of	B-X
differentiation	B-X
;	B-X
(	B-X
b	B-X
)	B-X
levels	B-X
of	B-X
released	B-X
TNF-alpha	B-X
seem	B-X
to	B-X
correlate	B-X
with	B-X
the	B-X
stage	B-X
of	B-X
B-cell	B-X
maturation	B-X
but	B-X
do	B-X
not	B-X
correlate	B-X
with	B-X
the	B-X
amounts	B-X
of	B-X
cell	B-X
surface	B-X
HLA-DR	B-X
antigens	B-X
;	B-X
(	B-X
c	B-X
)	B-X
secreted	B-X
TNF-alpha	B-X
regulates	B-X
the	B-X
levels	B-X
of	B-X
expression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
by	B-X
an	B-X
autocrine	B-X
loop	B-X
;	B-X
and	B-X
(	B-X
d	B-X
)	B-X
intracellular	B-X
signals	B-X
mediating	B-X
TNF-alpha	B-X
release	B-X
by	B-X
B	B-X
cells	B-X
are	B-X
distinct	B-X
from	B-X
those	B-X
regulating	B-X
homotypic	B-X
aggregation	B-X
and	B-X
proliferation	B-X
.	B-X

Secreted	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
mediated	O
the	O
enhancement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
and	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
activity	O
;	O
in	O
fact	O
,	O
the	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
in	O
the	O
presence	O
of	O
antihuman	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
neutralizing	O
antibodies	O
did	O
not	O
upregulate	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
.	O
<EOS>	B-X
MicroRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
,	B-X
a	B-X
family	B-X
of	B-X
small	B-X
nonprotein-coding	B-X
RNAs	B-X
,	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
posttranscriptional	B-X
gene	B-X
regulation	B-X
by	B-X
acting	B-X
as	B-X
adaptors	B-X
for	B-X
the	B-X
miRNA-induced	B-X
silencing	B-X
complex	B-X
to	B-X
inhibit	B-X
gene	B-X
expression	B-X
by	B-X
targeting	B-X
mRNAs	B-X
for	B-X
translational	B-X
repression	B-X
and/or	B-X
cleavage	B-X
.	B-X
miR-155-5p	B-X
and	B-X
miR-155-3p	B-X
are	B-X
processed	B-X
from	B-X
the	B-X
B-cell	B-X
Integration	B-X
Cluster	B-X
(	B-X
BIC	B-X
)	B-X
gene	B-X
(	B-X
now	B-X
designated	B-X
,	B-X
MIR155	B-X
host	B-X
gene	B-X
or	B-X
MIR155HG	B-X
)	B-X
.	B-X
MiR-155-5p	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
both	B-X
activated	B-X
B-	B-X
and	B-X
T-cells	B-X
and	B-X
in	B-X
monocytes/macrophages	B-X
.	B-X
MiR-155-5p	B-X
is	B-X
one	B-X
of	B-X
the	B-X
best	B-X
characterized	B-X
miRNAs	B-X
and	B-X
recent	B-X
data	B-X
indicate	B-X
that	B-X
miR-155-5p	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
various	B-X
physiological	B-X
and	B-X
pathological	B-X
processes	B-X
such	B-X
as	B-X
hematopoietic	B-X
lineage	B-X
differentiation	B-X
,	B-X
immunity	B-X
,	B-X
inflammation	B-X
,	B-X
viral	B-X
infections	B-X
,	B-X
cancer	B-X
,	B-X
cardiovascular	B-X
disease	B-X
,	B-X
and	B-X
Down	B-X
syndrome	B-X
.	B-X
In	B-X
this	B-X
review	B-X
we	B-X
summarize	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
MIR155HG	B-X
expression	B-X
can	B-X
be	B-X
regulated	B-X
.	B-X
Given	B-X
that	B-X
the	B-X
pathologies	B-X
mediated	B-X
by	B-X
miR-155-5p	B-X
result	B-X
from	B-X
the	B-X
over-expression	B-X
of	B-X
this	B-X
miRNA	B-X
it	B-X
may	B-X
be	B-X
possible	B-X
to	B-X
therapeutically	B-X
attenuate	B-X
miR-155-5p	B-X
levels	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
several	B-X
pathological	B-X
processes	B-X
.	B-X

In	O
contrast	O
,	O
released	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
was	O
not	O
responsible	O
for	O
the	O
homotypic	O
aggregation	O
of	O
Ri	O
-	O
I	O
,	O
Ci	O
-	O
I	O
,	O
Sc	O
-	O
I	O
,	O
and	O
Raji	O
cells	O
induced	O
by	O
mAb	O
L243	O
,	O
and	O
it	O
did	O
not	O
affect	O
the	O
proliferation	O
of	O
B	O
cells	O
investigated	O
.	O
<EOS>	B-X
Therapeutic	B-X
agents	B-X
used	B-X
to	B-X
treat	B-X
sepsis‑induced	B-X
cardiac	B-X
dysfunction	B-X
are	B-X
designed	B-X
to	B-X
suppress	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
‑α	B-X
release	B-X
and	B-X
inhibit	B-X
cell	B-X
apoptosis	B-X
.	B-X
Exogenous	B-X
administration	B-X
of	B-X
growth	B-X
arrest‑specific	B-X
6	B-X
(	B-X
Gas6	B-X
)	B-X
exerts	B-X
several	B-X
biological	B-X
and	B-X
pharmacological	B-X
effects	B-X
;	B-X
however	B-X
,	B-X
the	B-X
role	B-X
of	B-X
Gas6	B-X
in	B-X
sepsis‑induced	B-X
myocardial	B-X
dysfunction	B-X
remains	B-X
unclear	B-X
.	B-X
Subsequently	B-X
,	B-X
mitogen‑activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
‑κB	B-X
activation	B-X
,	B-X
TNF‑α	B-X
expression	B-X
,	B-X
and	B-X
apoptosis	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
TP‑0903	B-X
(	B-X
15	B-X
nM	B-X
)	B-X
and	B-X
Wortmannin	B-X
(	B-X
3	B-X
nM	B-X
)	B-X
were	B-X
evaluated	B-X
.	B-X
The	B-X
morphological	B-X
alterations	B-X
of	B-X
H9C2	B-X
cells	B-X
were	B-X
visualized	B-X
by	B-X
phase‑contrast	B-X
microscopy	B-X
.	B-X
Cell	B-X
viability	B-X
was	B-X
determined	B-X
using	B-X
the	B-X
Cell	B-X
Counting	B-X
kit	B-X
8	B-X
assay	B-X
and	B-X
lactate	B-X
dehydrogenase	B-X
release	B-X
,	B-X
and	B-X
TNF‑α	B-X
release	B-X
was	B-X
analyzed	B-X
by	B-X
ELISA	B-X
analysis	B-X
.	B-X
The	B-X
expression	B-X
levels	B-X
of	B-X
Bax	B-X
and	B-X
Bcl‑2	B-X
,	B-X
and	B-X
the	B-X
phosphorylation	B-X
and	B-X
expression	B-X
levels	B-X
of	B-X
Axl	B-X
,	B-X
Akt	B-X
,	B-X
IκB‑α	B-X
,	B-X
p65	B-X
,	B-X
c‑Jun	B-X
N‑terminal	B-X
protein	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
,	B-X
extracellular	B-X
signal‑regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
and	B-X
p38	B-X
were	B-X
determined	B-X
by	B-X
western	B-X
blotting	B-X
.	B-X
Furthermore	B-X
,	B-X
immunofluorescence	B-X
analysis	B-X
was	B-X
performed	B-X
to	B-X
visualize	B-X
translocation	B-X
of	B-X
NF‑κB	B-X
p65	B-X
.	B-X
The	B-X
results	B-X
demonstrated	B-X
that	B-X
Gas6	B-X
suppressed	B-X
TNF‑α	B-X
release	B-X
and	B-X
inhibited	B-X
cell	B-X
apoptosis	B-X
,	B-X
and	B-X
attenuated	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
‑κB	B-X
and	B-X
mitogen‑activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
activation	B-X
via	B-X
the	B-X
Axl/PI3K/Akt	B-X
pathway	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
cardioprotective	B-X
properties	B-X
of	B-X
Gas6	B-X
on	B-X
the	B-X
suppression	B-X
of	B-X
LPS‑induced	B-X
TNF‑α	B-X
release	B-X
and	B-X
apoptosis	B-X
were	B-X
abolished	B-X
by	B-X
treatment	B-X
with	B-X
TP‑0903	B-X
(	B-X
an	B-X
Axl	B-X
inhibitor	B-X
)	B-X
and	B-X
Wortmannin	B-X
(	B-X
a	B-X
PI3K	B-X
inhibitor	B-X
)	B-X
.	B-X
Pretreatment	B-X
with	B-X
TP‑0903	B-X
and	B-X
Wortmannin	B-X
abrogated	B-X
the	B-X
effects	B-X
of	B-X
Gas6	B-X
on	B-X
phosphorylated‑IκB‑α	B-X
,	B-X
IκB‑α	B-X
,	B-X
NF‑κB	B-X
,	B-X
ERK1/2	B-X
,	B-X
JNK	B-X
and	B-X
p38	B-X
MAPK	B-X
.	B-X
These	B-X
findings	B-X
suggested	B-X
that	B-X
activation	B-X
of	B-X
Axl/PI3K/Akt	B-X
signaling	B-X
by	B-X
Gas6	B-X
may	B-X
inhibit	B-X
LPS‑induced	B-X
TNF‑α	B-X
expression	B-X
and	B-X
apoptosis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
MAPK	B-X
and	B-X
NF‑κB	B-X
activation	B-X
.	B-X

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
:	O
(	O
a	O
)	O
the	O
ability	O
of	O
B	O
cells	O
to	O
release	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
after	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
depends	O
on	O
their	O
stage	O
of	O
differentiation	O
;	O
(	O
b	O
)	O
levels	O
of	O
released	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
seem	O
to	O
correlate	O
with	O
the	O
stage	O
of	O
B	O
-	O
cell	O
maturation	O
but	O
do	O
not	O
correlate	O
with	O
the	O
amounts	O
of	O
cell	O
surface	O
HLA	O
-	O
DR	O
antigens	O
;	O
(	O
c	O
)	O
secreted	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
regulates	O
the	O
levels	O
of	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
by	O
an	O
autocrine	O
loop	O
;	O
and	O
(	O
d	O
)	O
intracellular	O
signals	O
mediating	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
release	O
by	O
B	O
cells	O
are	O
distinct	O
from	O
those	O
regulating	O
homotypic	O
aggregation	O
and	O
proliferation	O
.	O
<EOS>	B-X
Triggering	B-X
of	B-X
HLA	B-X
class	B-X
II	B-X
antigens	B-X
by	B-X
the	B-X
anti-HLA-DR	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
L243	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
and	B-X
differentially	B-X
enhanced	B-X
the	B-X
release	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
by	B-X
the	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
cells	B-X
Ri-I	B-X
,	B-X
Ci-I	B-X
,	B-X
and	B-X
Sc-I	B-X
,	B-X
which	B-X
are	B-X
at	B-X
a	B-X
distinct	B-X
stage	B-X
of	B-X
B-cell	B-X
differentiation	B-X
,	B-X
and	B-X
by	B-X
the	B-X
more	B-X
mature	B-X
Burkitt	B-X
lymphoma	B-X
cell	B-X
Raji	B-X
;	B-X
in	B-X
contrast	B-X
,	B-X
it	B-X
did	B-X
not	B-X
induce	B-X
TNF-alpha	B-X
release	B-X
by	B-X
the	B-X
pre-B	B-X
leukemia	B-X
cells	B-X
Nalm-6	B-X
and	B-X
BV173	B-X
.	B-X
TNF-alpha	B-X
release	B-X
peaked	B-X
at	B-X
24	B-X
h	B-X
and	B-X
decreased	B-X
thereafter	B-X
,	B-X
and	B-X
it	B-X
was	B-X
dose	B-X
dependent	B-X
and	B-X
preceded	B-X
by	B-X
an	B-X
increase	B-X
of	B-X
TNF-alpha	B-X
mRNA	B-X
detectable	B-X
after	B-X
3	B-X
h	B-X
of	B-X
stimulation	B-X
with	B-X
mAb	B-X
L243	B-X
.	B-X
Secreted	B-X
TNF-alpha	B-X
mediated	B-X
the	B-X
enhancement	B-X
of	B-X
nuclear	B-X
factor	B-X
kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
and	B-X
activator	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
binding	B-X
activity	B-X
;	B-X
in	B-X
fact	B-X
,	B-X
the	B-X
triggering	B-X
of	B-X
HLA-DR	B-X
antigens	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
antihuman	B-X
TNF-alpha-neutralizing	B-X
antibodies	B-X
did	B-X
not	B-X
upregulate	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
released	B-X
TNF-alpha	B-X
was	B-X
not	B-X
responsible	B-X
for	B-X
the	B-X
homotypic	B-X
aggregation	B-X
of	B-X
Ri-I	B-X
,	B-X
Ci-I	B-X
,	B-X
Sc-I	B-X
,	B-X
and	B-X
Raji	B-X
cells	B-X
induced	B-X
by	B-X
mAb	B-X
L243	B-X
,	B-X
and	B-X
it	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
proliferation	B-X
of	B-X
B	B-X
cells	B-X
investigated	B-X
.	B-X
Altogether	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
:	B-X
(	B-X
a	B-X
)	B-X
the	B-X
ability	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
release	B-X
TNF-alpha	B-X
after	B-X
triggering	B-X
of	B-X
HLA-DR	B-X
antigens	B-X
depends	B-X
on	B-X
their	B-X
stage	B-X
of	B-X
differentiation	B-X
;	B-X
(	B-X
b	B-X
)	B-X
levels	B-X
of	B-X
released	B-X
TNF-alpha	B-X
seem	B-X
to	B-X
correlate	B-X
with	B-X
the	B-X
stage	B-X
of	B-X
B-cell	B-X
maturation	B-X
but	B-X
do	B-X
not	B-X
correlate	B-X
with	B-X
the	B-X
amounts	B-X
of	B-X
cell	B-X
surface	B-X
HLA-DR	B-X
antigens	B-X
;	B-X
(	B-X
c	B-X
)	B-X
secreted	B-X
TNF-alpha	B-X
regulates	B-X
the	B-X
levels	B-X
of	B-X
expression	B-X
of	B-X
NF-kappa	B-X
B	B-X
and	B-X
AP-1	B-X
by	B-X
an	B-X
autocrine	B-X
loop	B-X
;	B-X
and	B-X
(	B-X
d	B-X
)	B-X
intracellular	B-X
signals	B-X
mediating	B-X
TNF-alpha	B-X
release	B-X
by	B-X
B	B-X
cells	B-X
are	B-X
distinct	B-X
from	B-X
those	B-X
regulating	B-X
homotypic	B-X
aggregation	B-X
and	B-X
proliferation	B-X
.	B-X

Cytomegalovirus	O
immediate	O
early	O
genes	O
upregulate	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
gene	O
expression	O
.	O
<EOS>	B-X
The	B-X
immediate	B-X
early	B-X
genes	B-X
(	B-X
IE	B-X
)	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
can	B-X
be	B-X
expressed	B-X
in	B-X
monocytic	B-X
cells	B-X
and	B-X
are	B-X
known	B-X
to	B-X
regulate	B-X
viral	B-X
and	B-X
cellular	B-X
genes	B-X
.	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
numerous	B-X
inflammatory	B-X
and	B-X
immune	B-X
processes	B-X
.	B-X
Interleukin-6	B-X
levels	B-X
are	B-X
increased	B-X
in	B-X
lung	B-X
transplant	B-X
patients	B-X
clinically	B-X
diagnosed	B-X
with	B-X
CMV	B-X
pneumonitis	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
IL-6	B-X
is	B-X
dependent	B-X
on	B-X
various	B-X
stimuli	B-X
that	B-X
include	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
viruses	B-X
,	B-X
and	B-X
other	B-X
cytokines	B-X
.	B-X
These	B-X
studies	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
CMV	B-X
IE	B-X
gene	B-X
products	B-X
to	B-X
modulate	B-X
IL-6	B-X
production	B-X
.	B-X

BACKGROUND	O
:	O
The	O
immediate	O
early	O
genes	O
(	O
IE	O
)	O
of	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
be	O
expressed	O
in	O
monocytic	O
cells	O
and	O
are	O
known	O
to	O
regulate	O
viral	O
and	O
cellular	O
genes	O
.	O
<EOS>	B-X
The	B-X
immediate	B-X
early	B-X
genes	B-X
(	B-X
IE	B-X
)	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
can	B-X
be	B-X
expressed	B-X
in	B-X
monocytic	B-X
cells	B-X
and	B-X
are	B-X
known	B-X
to	B-X
regulate	B-X
viral	B-X
and	B-X
cellular	B-X
genes	B-X
.	B-X
Interleukin-6	B-X
levels	B-X
are	B-X
increased	B-X
in	B-X
lung	B-X
transplant	B-X
patients	B-X
clinically	B-X
diagnosed	B-X
with	B-X
CMV	B-X
pneumonitis	B-X
.	B-X
These	B-X
studies	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
CMV	B-X
IE	B-X
gene	B-X
products	B-X
to	B-X
modulate	B-X
IL-6	B-X
production	B-X
.	B-X

Interleukin	B-Protein
-	I-Protein
6	I-Protein
(	O
IL	B-Protein
-	I-Protein
6	I-Protein
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O

Interleukin	B-Protein
-	I-Protein
6	I-Protein
levels	O
are	O
increased	O
in	O
lung	O
transplant	O
patients	O
clinically	O
diagnosed	O
with	O
CMV	O
pneumonitis	O
.	O
<EOS>	B-X
The	B-X
immediate	B-X
early	B-X
genes	B-X
(	B-X
IE	B-X
)	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
can	B-X
be	B-X
expressed	B-X
in	B-X
monocytic	B-X
cells	B-X
and	B-X
are	B-X
known	B-X
to	B-X
regulate	B-X
viral	B-X
and	B-X
cellular	B-X
genes	B-X
.	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
numerous	B-X
inflammatory	B-X
and	B-X
immune	B-X
processes	B-X
.	B-X
Interleukin-6	B-X
levels	B-X
are	B-X
increased	B-X
in	B-X
lung	B-X
transplant	B-X
patients	B-X
clinically	B-X
diagnosed	B-X
with	B-X
CMV	B-X
pneumonitis	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
IL-6	B-X
is	B-X
dependent	B-X
on	B-X
various	B-X
stimuli	B-X
that	B-X
include	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
viruses	B-X
,	B-X
and	B-X
other	B-X
cytokines	B-X
.	B-X
These	B-X
studies	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
CMV	B-X
IE	B-X
gene	B-X
products	B-X
to	B-X
modulate	B-X
IL-6	B-X
production	B-X
.	B-X

The	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
dependent	O
on	O
various	O
stimuli	O
that	O
include	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
viruses	O
,	O
and	O
other	O
cytokines	O
.	O
<EOS>	B-X
The	B-X
regulation	B-X
of	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
is	B-X
dependent	B-X
on	B-X
many	B-X
factors	B-X
that	B-X
include	B-X
numerous	B-X
stimuli	B-X
such	B-X
as	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
viruses	B-X
,	B-X
and	B-X
other	B-X
cytokines	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
the	B-X
ability	B-X
of	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
to	B-X
significantly	B-X
enhance	B-X
IL-6	B-X
mRNA	B-X
and	B-X
protein	B-X
production	B-X
in	B-X
LPS-stimulated	B-X
monocytes	B-X
and	B-X
THP-1	B-X
cells	B-X
.	B-X
IL-6	B-X
protein	B-X
production	B-X
was	B-X
increased	B-X
sevenfold	B-X
in	B-X
LPS-stimulated	B-X
cells	B-X
with	B-X
the	B-X
addition	B-X
of	B-X
IFN-gamma	B-X
.	B-X
IL-6	B-X
mRNA	B-X
production	B-X
was	B-X
increased	B-X
in	B-X
a	B-X
dose-dependent	B-X
fashion	B-X
up	B-X
to	B-X
15-fold	B-X
in	B-X
LPS-stimulated	B-X
cells	B-X
with	B-X
the	B-X
addition	B-X
of	B-X
IFN-gamma	B-X
.	B-X
The	B-X
enhanced	B-X
production	B-X
of	B-X
IL-6	B-X
mRNA	B-X
that	B-X
occurs	B-X
with	B-X
the	B-X
addition	B-X
of	B-X
IFN-gamma	B-X
to	B-X
LPS-stimulated	B-X
monocytic	B-X
cells	B-X
was	B-X
due	B-X
to	B-X
increased	B-X
transcription	B-X
of	B-X
IL-6	B-X
mRNA	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
IFN-gamma	B-X
to	B-X
enhance	B-X
IL-6	B-X
production	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
many	B-X
inflammatory	B-X
processes	B-X
.	B-X

These	O
studies	O
examined	O
the	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
modulate	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
.	O
<EOS>	B-X
The	B-X
immediate	B-X
early	B-X
genes	B-X
(	B-X
IE	B-X
)	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
can	B-X
be	B-X
expressed	B-X
in	B-X
monocytic	B-X
cells	B-X
and	B-X
are	B-X
known	B-X
to	B-X
regulate	B-X
viral	B-X
and	B-X
cellular	B-X
genes	B-X
.	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
numerous	B-X
inflammatory	B-X
and	B-X
immune	B-X
processes	B-X
.	B-X
Interleukin-6	B-X
levels	B-X
are	B-X
increased	B-X
in	B-X
lung	B-X
transplant	B-X
patients	B-X
clinically	B-X
diagnosed	B-X
with	B-X
CMV	B-X
pneumonitis	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
IL-6	B-X
is	B-X
dependent	B-X
on	B-X
various	B-X
stimuli	B-X
that	B-X
include	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
viruses	B-X
,	B-X
and	B-X
other	B-X
cytokines	B-X
.	B-X
These	B-X
studies	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
CMV	B-X
IE	B-X
gene	B-X
products	B-X
to	B-X
modulate	B-X
IL-6	B-X
production	B-X
.	B-X

METHODS	O
:	O
THP	O
-	O
1	O
cells	O
,	O
a	O
monocytic	O
cell	O
line	O
,	O
were	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
.	O
<EOS>	B-X
The	B-X
immediate	B-X
early	B-X
genes	B-X
(	B-X
IE	B-X
)	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
can	B-X
be	B-X
expressed	B-X
in	B-X
monocytic	B-X
cells	B-X
and	B-X
are	B-X
known	B-X
to	B-X
regulate	B-X
viral	B-X
and	B-X
cellular	B-X
genes	B-X
.	B-X
Interleukin-6	B-X
levels	B-X
are	B-X
increased	B-X
in	B-X
lung	B-X
transplant	B-X
patients	B-X
clinically	B-X
diagnosed	B-X
with	B-X
CMV	B-X
pneumonitis	B-X
.	B-X
These	B-X
studies	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
CMV	B-X
IE	B-X
gene	B-X
products	B-X
to	B-X
modulate	B-X
IL-6	B-X
production	B-X
.	B-X

Interleukin	B-Protein
-	I-Protein
6	I-Protein
protein	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
mRNA	O
were	O
measured	O
in	O
control	O
and	O
CMV	O
immediate	O
early	O
transfected	O
cells	O
.	O
<EOS>	B-X
The	B-X
immediate	B-X
early	B-X
genes	B-X
(	B-X
IE	B-X
)	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
can	B-X
be	B-X
expressed	B-X
in	B-X
monocytic	B-X
cells	B-X
and	B-X
are	B-X
known	B-X
to	B-X
regulate	B-X
viral	B-X
and	B-X
cellular	B-X
genes	B-X
.	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
numerous	B-X
inflammatory	B-X
and	B-X
immune	B-X
processes	B-X
.	B-X
Interleukin-6	B-X
levels	B-X
are	B-X
increased	B-X
in	B-X
lung	B-X
transplant	B-X
patients	B-X
clinically	B-X
diagnosed	B-X
with	B-X
CMV	B-X
pneumonitis	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
IL-6	B-X
is	B-X
dependent	B-X
on	B-X
various	B-X
stimuli	B-X
that	B-X
include	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
viruses	B-X
,	B-X
and	B-X
other	B-X
cytokines	B-X
.	B-X
These	B-X
studies	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
CMV	B-X
IE	B-X
gene	B-X
products	B-X
to	B-X
modulate	B-X
IL-6	B-X
production	B-X
.	B-X

Cotransfection	O
of	O
CMV	O
IE	O
genes	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
chloramphenicol	B-Protein
acetyl	I-Protein
transferase	I-Protein
(	O
CAT	B-Protein
)	O
or	O
IL	B-Protein
-	I-Protein
6	I-Protein
luciferase	O
constructs	O
were	O
used	O
to	O
study	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
activity	O
.	O
<EOS>	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
is	B-X
a	B-X
robust	B-X
protumor	B-X
cytokine	B-X
.	B-X
Several	B-X
studies	B-X
suggest	B-X
that	B-X
IL-6	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
tumors	B-X
.	B-X
Most	B-X
intracellular	B-X
protein	B-X
breakdown	B-X
occurs	B-X
in	B-X
eukaryotes	B-X
via	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
;	B-X
this	B-X
mechanism	B-X
may	B-X
also	B-X
be	B-X
involved	B-X
in	B-X
cancer	B-X
pathogenesis	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
evaluated	B-X
TFs	B-X
that	B-X
control	B-X
ACE2	B-X
expression	B-X
,	B-X
and	B-X
screened	B-X
for	B-X
small	B-X
molecule	B-X
compounds	B-X
that	B-X
could	B-X
modulate	B-X
ACE2	B-X
expression	B-X
to	B-X
block	B-X
SARS-CoV-2	B-X
from	B-X
entry	B-X
into	B-X
lung	B-X
epithelial	B-X
cells	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
Stat3	B-X
bound	B-X
ACE2	B-X
promoter	B-X
,	B-X
and	B-X
controlled	B-X
its	B-X
expression	B-X
in	B-X
16HBE	B-X
cells	B-X
stimulated	B-X
with	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
.	B-X
To	B-X
screen	B-X
for	B-X
medicinal	B-X
compounds	B-X
that	B-X
could	B-X
modulate	B-X
ACE2	B-X
expression	B-X
,	B-X
we	B-X
conducted	B-X
luciferase	B-X
assay	B-X
using	B-X
HLF	B-X
cells	B-X
transfected	B-X
with	B-X
ACE2	B-X
promoter-luciferase	B-X
constructs	B-X
.	B-X
Among	B-X
the	B-X
64	B-X
compounds	B-X
tested	B-X
,	B-X
6-O-angeloylplenolin	B-X
(	B-X
6-OAP	B-X
)	B-X
,	B-X
a	B-X
sesquiterpene	B-X
lactone	B-X
in	B-X
Chinese	B-X
medicinal	B-X
herb	B-X
Centipeda	B-X
minima	B-X
(	B-X
CM	B-X
)	B-X
,	B-X
represented	B-X
the	B-X
most	B-X
potent	B-X
ACE2	B-X
repressor	B-X
.	B-X
6-OAP	B-X
(	B-X
2.5	B-X
µM	B-X
)	B-X
inhibited	B-X
the	B-X
interaction	B-X
between	B-X
Stat3	B-X
protein	B-X
and	B-X
ACE2	B-X
promoter	B-X
,	B-X
thus	B-X
suppressed	B-X
ACE2	B-X
transcription	B-X
.	B-X
6-OAP	B-X
(	B-X
1.25-5	B-X
µM	B-X
)	B-X
and	B-X
its	B-X
parental	B-X
medicinal	B-X
herb	B-X
CM	B-X
(	B-X
0.125	B-X
%	B-X
-0.5	B-X
%	B-X
)	B-X
dose-dependently	B-X
downregulated	B-X
ACE2	B-X
in	B-X
16HBE	B-X
and	B-X
Beas-2B	B-X
cells	B-X
;	B-X
similar	B-X
results	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
lung	B-X
tissues	B-X
of	B-X
mice	B-X
following	B-X
administration	B-X
of	B-X
6-OAP	B-X
or	B-X
CM	B-X
for	B-X
one	B-X
month	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
6-OAP/CM	B-X
dose-dependently	B-X
reduced	B-X
IL-6	B-X
production	B-X
and	B-X
downregulated	B-X
chemokines	B-X
including	B-X
CXCL13	B-X
and	B-X
CX3CL1	B-X
in	B-X
16HBE	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
found	B-X
that	B-X
6-OAP/CM	B-X
inhibited	B-X
the	B-X
entry	B-X
of	B-X
SARS-CoV-2	B-X
S	B-X
protein	B-X
pseudovirus	B-X
into	B-X
target	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
6-OAP/CM	B-X
are	B-X
ACE2	B-X
inhibitors	B-X
that	B-X
may	B-X
potentially	B-X
protect	B-X
lung	B-X
epithelial	B-X
cells	B-X
from	B-X
SARS-CoV-2	B-X
infection	B-X
.	B-X

RESULTS	O
:	O
Interleukin	B-Protein
-	I-Protein
6	I-Protein
protein	O
and	O
mRNA	O
production	O
were	O
significantly	O
increased	O
in	O
cells	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
and	O
stimulated	O
with	O
LPS	O
compared	O
to	O
LPS	O
-	O
stimulated	O
control	O
cells	O
.	O
<EOS>	B-X
The	B-X
immediate	B-X
early	B-X
genes	B-X
(	B-X
IE	B-X
)	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
can	B-X
be	B-X
expressed	B-X
in	B-X
monocytic	B-X
cells	B-X
and	B-X
are	B-X
known	B-X
to	B-X
regulate	B-X
viral	B-X
and	B-X
cellular	B-X
genes	B-X
.	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
numerous	B-X
inflammatory	B-X
and	B-X
immune	B-X
processes	B-X
.	B-X
Interleukin-6	B-X
levels	B-X
are	B-X
increased	B-X
in	B-X
lung	B-X
transplant	B-X
patients	B-X
clinically	B-X
diagnosed	B-X
with	B-X
CMV	B-X
pneumonitis	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
IL-6	B-X
is	B-X
dependent	B-X
on	B-X
various	B-X
stimuli	B-X
that	B-X
include	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
viruses	B-X
,	B-X
and	B-X
other	B-X
cytokines	B-X
.	B-X
These	B-X
studies	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
CMV	B-X
IE	B-X
gene	B-X
products	B-X
to	B-X
modulate	B-X
IL-6	B-X
production	B-X
.	B-X

Cytomegalovirus	O
IE	O
gene	O
products	O
significantly	O
enhanced	O
LPS	O
stimulation	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
activity	O
in	O
both	O
IL	B-Protein
-	I-Protein
6	I-Protein
CAT	B-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
luciferase	O
assays	O
.	O

A	O
deletion	O
construct	O
that	O
contains	O
a	O
NF	O
-	O
kappa	O
B	O
site	O
but	O
is	O
missing	O
the	O
multiple	O
response	O
region	O
demonstrated	O
a	O
continued	O
increase	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
luciferase	O
activity	O
in	O
LPS	O
-	O
stimulated	O
CMV	O
transfected	O
cells	O
.	O

CONCLUSION	O
:	O
Cytomegalovirus	O
immediate	O
early	O
gene	O
products	O
significantly	O
enhanced	O
expression	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
in	O
LPS	O
-	O
stimulated	O
cells	O
.	O
<EOS>	B-X
The	B-X
immediate	B-X
early	B-X
genes	B-X
(	B-X
IE	B-X
)	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
can	B-X
be	B-X
expressed	B-X
in	B-X
monocytic	B-X
cells	B-X
and	B-X
are	B-X
known	B-X
to	B-X
regulate	B-X
viral	B-X
and	B-X
cellular	B-X
genes	B-X
.	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
numerous	B-X
inflammatory	B-X
and	B-X
immune	B-X
processes	B-X
.	B-X
Interleukin-6	B-X
levels	B-X
are	B-X
increased	B-X
in	B-X
lung	B-X
transplant	B-X
patients	B-X
clinically	B-X
diagnosed	B-X
with	B-X
CMV	B-X
pneumonitis	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
IL-6	B-X
is	B-X
dependent	B-X
on	B-X
various	B-X
stimuli	B-X
that	B-X
include	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
viruses	B-X
,	B-X
and	B-X
other	B-X
cytokines	B-X
.	B-X
These	B-X
studies	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
CMV	B-X
IE	B-X
gene	B-X
products	B-X
to	B-X
modulate	B-X
IL-6	B-X
production	B-X
.	B-X

The	O
increase	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
luciferase	O
activity	O
occurs	O
in	O
the	O
absence	O
of	O
the	O
multiple	O
response	O
region	O
,	O
the	O
area	O
of	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
responsive	O
to	O
IL	O
-	O
1	O
,	O
TNF	B-Protein
alpha	I-Protein
,	O
cyclic	O
amp	O
,	O
and	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
.	O
<EOS>	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
numerous	B-X
inflammatory	B-X
and	B-X
immune	B-X
processes	B-X
.	B-X
Interleukin-6	B-X
levels	B-X
are	B-X
increased	B-X
in	B-X
lung	B-X
transplant	B-X
patients	B-X
clinically	B-X
diagnosed	B-X
with	B-X
CMV	B-X
pneumonitis	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
IL-6	B-X
is	B-X
dependent	B-X
on	B-X
various	B-X
stimuli	B-X
that	B-X
include	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
viruses	B-X
,	B-X
and	B-X
other	B-X
cytokines	B-X
.	B-X
These	B-X
studies	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
CMV	B-X
IE	B-X
gene	B-X
products	B-X
to	B-X
modulate	B-X
IL-6	B-X
production	B-X
.	B-X

The	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
enhance	O
IL	B-Protein
-	I-Protein
6	I-Protein
production	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
inflammatory	O
states	O
associated	O
with	O
CMV	O
infection	O
.	O
<EOS>	B-X
The	B-X
immediate	B-X
early	B-X
genes	B-X
(	B-X
IE	B-X
)	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
(	B-X
CMV	B-X
)	B-X
can	B-X
be	B-X
expressed	B-X
in	B-X
monocytic	B-X
cells	B-X
and	B-X
are	B-X
known	B-X
to	B-X
regulate	B-X
viral	B-X
and	B-X
cellular	B-X
genes	B-X
.	B-X
Interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
numerous	B-X
inflammatory	B-X
and	B-X
immune	B-X
processes	B-X
.	B-X
Interleukin-6	B-X
levels	B-X
are	B-X
increased	B-X
in	B-X
lung	B-X
transplant	B-X
patients	B-X
clinically	B-X
diagnosed	B-X
with	B-X
CMV	B-X
pneumonitis	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
IL-6	B-X
is	B-X
dependent	B-X
on	B-X
various	B-X
stimuli	B-X
that	B-X
include	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
viruses	B-X
,	B-X
and	B-X
other	B-X
cytokines	B-X
.	B-X
These	B-X
studies	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
CMV	B-X
IE	B-X
gene	B-X
products	B-X
to	B-X
modulate	B-X
IL-6	B-X
production	B-X
.	B-X

Homodimerization	O
of	O
the	O
human	O
interleukin	B-Protein
4	I-Protein
receptor	I-Protein
alpha	I-Protein
chain	I-Protein
induces	O
Cepsilon	O
germline	O
transcripts	O
in	O
B	O
cells	O
in	O
the	O
absence	O
of	O
the	O
interleukin	B-Protein
2	I-Protein
receptor	I-Protein
gamma	I-Protein
chain	I-Protein
.	O

The	O
cytokines	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
13	I-Protein
play	O
a	O
critical	O
role	O
in	O
inducing	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
human	O
B	O
cells	O
.	O

The	O
IL	O
-	O
4	O
receptor	O
(	O
IL	O
-	O
4R	O
)	O
in	O
B	O
cells	O
is	O
composed	O
of	O
two	O
chains	O
,	O
the	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
binding	O
IL	B-Protein
-	I-Protein
4Ralpha	I-Protein
chain	I-Protein
,	O
which	O
is	O
shared	O
with	O
the	O
IL	O
-	O
13R	O
,	O
and	O
the	O
IL	B-Protein
-	I-Protein
2Rgamma	I-Protein
(	I-Protein
gammac	I-Protein
)	I-Protein
chain	I-Protein
,	O
which	O
is	O
shared	O
with	O
IL	B-Protein
-	I-Protein
7R	I-Protein
,	O
IL	B-Protein
-	I-Protein
9R	I-Protein
,	O
and	O
IL	O
-	O
15R	O
.	O

IL	B-Protein
-	I-Protein
4	I-Protein
induces	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
B	O
cells	O
from	O
patients	O
with	O
gammac	B-Protein
chain	I-Protein
deficiency	O
.	O

Induction	O
of	O
Cepsilon	O
germline	O
transcripts	O
by	O
IL	B-Protein
-	I-Protein
4	I-Protein
in	O
B	O
cells	O
that	O
lack	O
the	O
gammac	B-Protein
chain	I-Protein
may	O
involve	O
signaling	O
via	O
the	O
IL	O
-	O
13R	O
.	O

Alternatively	O
,	O
the	O
IL	B-Protein
-	I-Protein
4Ralpha	I-Protein
chain	I-Protein
may	O
transduce	O
intracellular	O
signals	O
that	O
lead	O
to	O
Cepsilon	O
gene	O
transcription	O
independently	O
of	O
its	O
association	O
with	O
other	O
chains	O
.	O
<EOS>	B-X
The	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
and	B-X
IL-13	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
inducing	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
and	B-X
IgE	B-X
isotype	B-X
switching	B-X
in	B-X
human	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
IL-4	B-X
receptor	B-X
(	B-X
IL-4R	B-X
)	B-X
in	B-X
B	B-X
cells	B-X
is	B-X
composed	B-X
of	B-X
two	B-X
chains	B-X
,	B-X
the	B-X
IL-4-binding	B-X
IL-4Ralpha	B-X
chain	B-X
,	B-X
which	B-X
is	B-X
shared	B-X
with	B-X
the	B-X
IL-13R	B-X
,	B-X
and	B-X
the	B-X
IL-2Rgamma	B-X
(	B-X
gammac	B-X
)	B-X
chain	B-X
,	B-X
which	B-X
is	B-X
shared	B-X
with	B-X
IL-7R	B-X
,	B-X
IL-9R	B-X
,	B-X
and	B-X
IL-15R	B-X
.	B-X
IL-4	B-X
induces	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
and	B-X
IgE	B-X
isotype	B-X
switching	B-X
in	B-X
B	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
gammac	B-X
chain	B-X
deficiency	B-X
.	B-X
Induction	B-X
of	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
by	B-X
IL-4	B-X
in	B-X
B	B-X
cells	B-X
that	B-X
lack	B-X
the	B-X
gammac	B-X
chain	B-X
may	B-X
involve	B-X
signaling	B-X
via	B-X
the	B-X
IL-13R	B-X
.	B-X
Alternatively	B-X
,	B-X
the	B-X
IL-4Ralpha	B-X
chain	B-X
may	B-X
transduce	B-X
intracellular	B-X
signals	B-X
that	B-X
lead	B-X
to	B-X
Cepsilon	B-X
gene	B-X
transcription	B-X
independently	B-X
of	B-X
its	B-X
association	B-X
with	B-X
other	B-X
chains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
ligand-induced	B-X
homodimerization	B-X
of	B-X
chimeric	B-X
surface	B-X
receptors	B-X
consisting	B-X
of	B-X
the	B-X
extracellular	B-X
and	B-X
transmembrane	B-X
domains	B-X
of	B-X
the	B-X
erythropoietin	B-X
receptor	B-X
and	B-X
of	B-X
the	B-X
intracellular	B-X
domain	B-X
of	B-X
IL-4Ralpha	B-X
induces	B-X
Janus	B-X
kinase	B-X
1	B-X
(	B-X
Jak1	B-X
)	B-X
activation	B-X
,	B-X
STAT6	B-X
activation	B-X
,	B-X
and	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
in	B-X
human	B-X
B	B-X
cell	B-X
line	B-X
BJAB	B-X
.	B-X
Disruption	B-X
of	B-X
the	B-X
Jak1-binding	B-X
proline-rich	B-X
Box1	B-X
region	B-X
of	B-X
IL-4Ralpha	B-X
abolished	B-X
signaling	B-X
by	B-X
this	B-X
chimeric	B-X
receptor	B-X
.	B-X
Furthermore	B-X
,	B-X
B	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
chimeric	B-X
CD8alpha/IL-4Ralpha	B-X
receptor	B-X
,	B-X
which	B-X
is	B-X
expressed	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
as	B-X
a	B-X
homodimer	B-X
,	B-X
constitutively	B-X
expressed	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
homodimerization	B-X
of	B-X
the	B-X
IL-4Ralpha	B-X
chain	B-X
is	B-X
sufficient	B-X
to	B-X
transduce	B-X
Jak1-dependent	B-X
intracellular	B-X
signals	B-X
that	B-X
lead	B-X
to	B-X
IgE	B-X
isotype	B-X
switching	B-X
.	B-X

We	O
show	O
that	O
ligand	O
-	O
induced	O
homodimerization	O
of	O
chimeric	O
surface	O
receptors	O
consisting	O
of	O
the	O
extracellular	O
and	O
transmembrane	O
domains	O
of	O
the	O
erythropoietin	B-Protein
receptor	O
and	O
of	O
the	O
intracellular	O
domain	O
of	O
IL	B-Protein
-	I-Protein
4Ralpha	I-Protein
induces	O
Janus	B-Protein
kinase	I-Protein
1	I-Protein
(	O
Jak1	B-Protein
)	O
activation	O
,	O
STAT6	B-Protein
activation	O
,	O
and	O
Cepsilon	O
germline	O
transcripts	O
in	O
human	O
B	O
cell	O
line	O
BJAB	O
.	O

Disruption	O
of	O
the	O
Jak1	B-Protein
-	O
binding	O
proline	O
-	O
rich	O
Box1	O
region	O
of	O
IL	B-Protein
-	I-Protein
4Ralpha	I-Protein
abolished	O
signaling	O
by	O
this	O
chimeric	O
receptor	O
.	O
<EOS>	B-X
The	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
and	B-X
IL-13	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
inducing	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
and	B-X
IgE	B-X
isotype	B-X
switching	B-X
in	B-X
human	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
IL-4	B-X
receptor	B-X
(	B-X
IL-4R	B-X
)	B-X
in	B-X
B	B-X
cells	B-X
is	B-X
composed	B-X
of	B-X
two	B-X
chains	B-X
,	B-X
the	B-X
IL-4-binding	B-X
IL-4Ralpha	B-X
chain	B-X
,	B-X
which	B-X
is	B-X
shared	B-X
with	B-X
the	B-X
IL-13R	B-X
,	B-X
and	B-X
the	B-X
IL-2Rgamma	B-X
(	B-X
gammac	B-X
)	B-X
chain	B-X
,	B-X
which	B-X
is	B-X
shared	B-X
with	B-X
IL-7R	B-X
,	B-X
IL-9R	B-X
,	B-X
and	B-X
IL-15R	B-X
.	B-X
IL-4	B-X
induces	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
and	B-X
IgE	B-X
isotype	B-X
switching	B-X
in	B-X
B	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
gammac	B-X
chain	B-X
deficiency	B-X
.	B-X
Induction	B-X
of	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
by	B-X
IL-4	B-X
in	B-X
B	B-X
cells	B-X
that	B-X
lack	B-X
the	B-X
gammac	B-X
chain	B-X
may	B-X
involve	B-X
signaling	B-X
via	B-X
the	B-X
IL-13R	B-X
.	B-X
Alternatively	B-X
,	B-X
the	B-X
IL-4Ralpha	B-X
chain	B-X
may	B-X
transduce	B-X
intracellular	B-X
signals	B-X
that	B-X
lead	B-X
to	B-X
Cepsilon	B-X
gene	B-X
transcription	B-X
independently	B-X
of	B-X
its	B-X
association	B-X
with	B-X
other	B-X
chains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
ligand-induced	B-X
homodimerization	B-X
of	B-X
chimeric	B-X
surface	B-X
receptors	B-X
consisting	B-X
of	B-X
the	B-X
extracellular	B-X
and	B-X
transmembrane	B-X
domains	B-X
of	B-X
the	B-X
erythropoietin	B-X
receptor	B-X
and	B-X
of	B-X
the	B-X
intracellular	B-X
domain	B-X
of	B-X
IL-4Ralpha	B-X
induces	B-X
Janus	B-X
kinase	B-X
1	B-X
(	B-X
Jak1	B-X
)	B-X
activation	B-X
,	B-X
STAT6	B-X
activation	B-X
,	B-X
and	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
in	B-X
human	B-X
B	B-X
cell	B-X
line	B-X
BJAB	B-X
.	B-X
Disruption	B-X
of	B-X
the	B-X
Jak1-binding	B-X
proline-rich	B-X
Box1	B-X
region	B-X
of	B-X
IL-4Ralpha	B-X
abolished	B-X
signaling	B-X
by	B-X
this	B-X
chimeric	B-X
receptor	B-X
.	B-X
Furthermore	B-X
,	B-X
B	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
chimeric	B-X
CD8alpha/IL-4Ralpha	B-X
receptor	B-X
,	B-X
which	B-X
is	B-X
expressed	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
as	B-X
a	B-X
homodimer	B-X
,	B-X
constitutively	B-X
expressed	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
homodimerization	B-X
of	B-X
the	B-X
IL-4Ralpha	B-X
chain	B-X
is	B-X
sufficient	B-X
to	B-X
transduce	B-X
Jak1-dependent	B-X
intracellular	B-X
signals	B-X
that	B-X
lead	B-X
to	B-X
IgE	B-X
isotype	B-X
switching	B-X
.	B-X

Furthermore	O
,	O
B	O
cells	O
transfected	O
with	O
a	O
chimeric	B-Protein
CD8alpha	I-Protein
/	I-Protein
IL	I-Protein
-	I-Protein
4Ralpha	I-Protein
receptor	I-Protein
,	O
which	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
homodimer	O
,	O
constitutively	O
expressed	O
Cepsilon	O
germline	O
transcripts	O
.	O
<EOS>	B-X
The	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
and	B-X
IL-13	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
inducing	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
and	B-X
IgE	B-X
isotype	B-X
switching	B-X
in	B-X
human	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
IL-4	B-X
receptor	B-X
(	B-X
IL-4R	B-X
)	B-X
in	B-X
B	B-X
cells	B-X
is	B-X
composed	B-X
of	B-X
two	B-X
chains	B-X
,	B-X
the	B-X
IL-4-binding	B-X
IL-4Ralpha	B-X
chain	B-X
,	B-X
which	B-X
is	B-X
shared	B-X
with	B-X
the	B-X
IL-13R	B-X
,	B-X
and	B-X
the	B-X
IL-2Rgamma	B-X
(	B-X
gammac	B-X
)	B-X
chain	B-X
,	B-X
which	B-X
is	B-X
shared	B-X
with	B-X
IL-7R	B-X
,	B-X
IL-9R	B-X
,	B-X
and	B-X
IL-15R	B-X
.	B-X
IL-4	B-X
induces	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
and	B-X
IgE	B-X
isotype	B-X
switching	B-X
in	B-X
B	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
gammac	B-X
chain	B-X
deficiency	B-X
.	B-X
Induction	B-X
of	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
by	B-X
IL-4	B-X
in	B-X
B	B-X
cells	B-X
that	B-X
lack	B-X
the	B-X
gammac	B-X
chain	B-X
may	B-X
involve	B-X
signaling	B-X
via	B-X
the	B-X
IL-13R	B-X
.	B-X
Alternatively	B-X
,	B-X
the	B-X
IL-4Ralpha	B-X
chain	B-X
may	B-X
transduce	B-X
intracellular	B-X
signals	B-X
that	B-X
lead	B-X
to	B-X
Cepsilon	B-X
gene	B-X
transcription	B-X
independently	B-X
of	B-X
its	B-X
association	B-X
with	B-X
other	B-X
chains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
ligand-induced	B-X
homodimerization	B-X
of	B-X
chimeric	B-X
surface	B-X
receptors	B-X
consisting	B-X
of	B-X
the	B-X
extracellular	B-X
and	B-X
transmembrane	B-X
domains	B-X
of	B-X
the	B-X
erythropoietin	B-X
receptor	B-X
and	B-X
of	B-X
the	B-X
intracellular	B-X
domain	B-X
of	B-X
IL-4Ralpha	B-X
induces	B-X
Janus	B-X
kinase	B-X
1	B-X
(	B-X
Jak1	B-X
)	B-X
activation	B-X
,	B-X
STAT6	B-X
activation	B-X
,	B-X
and	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
in	B-X
human	B-X
B	B-X
cell	B-X
line	B-X
BJAB	B-X
.	B-X
Disruption	B-X
of	B-X
the	B-X
Jak1-binding	B-X
proline-rich	B-X
Box1	B-X
region	B-X
of	B-X
IL-4Ralpha	B-X
abolished	B-X
signaling	B-X
by	B-X
this	B-X
chimeric	B-X
receptor	B-X
.	B-X
Furthermore	B-X
,	B-X
B	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
chimeric	B-X
CD8alpha/IL-4Ralpha	B-X
receptor	B-X
,	B-X
which	B-X
is	B-X
expressed	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
as	B-X
a	B-X
homodimer	B-X
,	B-X
constitutively	B-X
expressed	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
homodimerization	B-X
of	B-X
the	B-X
IL-4Ralpha	B-X
chain	B-X
is	B-X
sufficient	B-X
to	B-X
transduce	B-X
Jak1-dependent	B-X
intracellular	B-X
signals	B-X
that	B-X
lead	B-X
to	B-X
IgE	B-X
isotype	B-X
switching	B-X
.	B-X

These	O
results	O
suggest	O
that	O
homodimerization	O
of	O
the	O
IL	B-Protein
-	I-Protein
4Ralpha	I-Protein
chain	I-Protein
is	O
sufficient	O
to	O
transduce	O
Jak1	B-Protein
-	O
dependent	O
intracellular	O
signals	O
that	O
lead	O
to	O
IgE	O
isotype	O
switching	O
.	O
<EOS>	B-X
The	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
and	B-X
IL-13	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
inducing	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
and	B-X
IgE	B-X
isotype	B-X
switching	B-X
in	B-X
human	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
IL-4	B-X
receptor	B-X
(	B-X
IL-4R	B-X
)	B-X
in	B-X
B	B-X
cells	B-X
is	B-X
composed	B-X
of	B-X
two	B-X
chains	B-X
,	B-X
the	B-X
IL-4-binding	B-X
IL-4Ralpha	B-X
chain	B-X
,	B-X
which	B-X
is	B-X
shared	B-X
with	B-X
the	B-X
IL-13R	B-X
,	B-X
and	B-X
the	B-X
IL-2Rgamma	B-X
(	B-X
gammac	B-X
)	B-X
chain	B-X
,	B-X
which	B-X
is	B-X
shared	B-X
with	B-X
IL-7R	B-X
,	B-X
IL-9R	B-X
,	B-X
and	B-X
IL-15R	B-X
.	B-X
IL-4	B-X
induces	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
and	B-X
IgE	B-X
isotype	B-X
switching	B-X
in	B-X
B	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
gammac	B-X
chain	B-X
deficiency	B-X
.	B-X
Induction	B-X
of	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
by	B-X
IL-4	B-X
in	B-X
B	B-X
cells	B-X
that	B-X
lack	B-X
the	B-X
gammac	B-X
chain	B-X
may	B-X
involve	B-X
signaling	B-X
via	B-X
the	B-X
IL-13R	B-X
.	B-X
Alternatively	B-X
,	B-X
the	B-X
IL-4Ralpha	B-X
chain	B-X
may	B-X
transduce	B-X
intracellular	B-X
signals	B-X
that	B-X
lead	B-X
to	B-X
Cepsilon	B-X
gene	B-X
transcription	B-X
independently	B-X
of	B-X
its	B-X
association	B-X
with	B-X
other	B-X
chains	B-X
.	B-X
We	B-X
show	B-X
that	B-X
ligand-induced	B-X
homodimerization	B-X
of	B-X
chimeric	B-X
surface	B-X
receptors	B-X
consisting	B-X
of	B-X
the	B-X
extracellular	B-X
and	B-X
transmembrane	B-X
domains	B-X
of	B-X
the	B-X
erythropoietin	B-X
receptor	B-X
and	B-X
of	B-X
the	B-X
intracellular	B-X
domain	B-X
of	B-X
IL-4Ralpha	B-X
induces	B-X
Janus	B-X
kinase	B-X
1	B-X
(	B-X
Jak1	B-X
)	B-X
activation	B-X
,	B-X
STAT6	B-X
activation	B-X
,	B-X
and	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
in	B-X
human	B-X
B	B-X
cell	B-X
line	B-X
BJAB	B-X
.	B-X
Disruption	B-X
of	B-X
the	B-X
Jak1-binding	B-X
proline-rich	B-X
Box1	B-X
region	B-X
of	B-X
IL-4Ralpha	B-X
abolished	B-X
signaling	B-X
by	B-X
this	B-X
chimeric	B-X
receptor	B-X
.	B-X
Furthermore	B-X
,	B-X
B	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
chimeric	B-X
CD8alpha/IL-4Ralpha	B-X
receptor	B-X
,	B-X
which	B-X
is	B-X
expressed	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
as	B-X
a	B-X
homodimer	B-X
,	B-X
constitutively	B-X
expressed	B-X
Cepsilon	B-X
germline	B-X
transcripts	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
homodimerization	B-X
of	B-X
the	B-X
IL-4Ralpha	B-X
chain	B-X
is	B-X
sufficient	B-X
to	B-X
transduce	B-X
Jak1-dependent	B-X
intracellular	B-X
signals	B-X
that	B-X
lead	B-X
to	B-X
IgE	B-X
isotype	B-X
switching	B-X
.	B-X

Characterization	O
of	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
transduced	O
with	O
HTLV	O
-	O
I	O
Tax	B-Protein
mutants	O
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
.	O

Tax1	B-Protein
,	O
a	O
transcriptional	O
trans	O
-	O
activator	O
of	O
the	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
,	O
induces	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
through	O
interaction	O
with	O
at	O
least	O
three	O
distinct	O
cellular	O
transcription	O
factors	O
;	O
CREB	O
/	O
ATF	O
,	O
NF	O
-	O
kappaB	O
,	O
and	O
SRF	B-Protein
.	O
<EOS>	B-X
Tax1	B-X
,	B-X
a	B-X
transcriptional	B-X
trans-activator	B-X
of	B-X
the	B-X
Human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
,	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
many	B-X
cellular	B-X
genes	B-X
through	B-X
interaction	B-X
with	B-X
at	B-X
least	B-X
three	B-X
distinct	B-X
cellular	B-X
transcription	B-X
factors	B-X
;	B-X
CREB/ATF	B-X
,	B-X
NF-kappaB	B-X
,	B-X
and	B-X
SRF	B-X
.	B-X
This	B-X
Tax1-induced	B-X
activation	B-X
of	B-X
cellular	B-X
genes	B-X
is	B-X
considered	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
event	B-X
in	B-X
T-cell	B-X
transformation	B-X
by	B-X
HTLV-I	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
role	B-X
of	B-X
each	B-X
Tax1-inducible	B-X
transcriptional	B-X
pathway	B-X
in	B-X
T-cell	B-X
transformation	B-X
,	B-X
we	B-X
introduced	B-X
Tax1	B-X
mutants	B-X
with	B-X
different	B-X
trans-activating	B-X
phenotypes	B-X
into	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
(	B-X
PBL	B-X
)	B-X
by	B-X
retroviral	B-X
vectors	B-X
.	B-X
Analysis	B-X
of	B-X
these	B-X
PBLs	B-X
revealed	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
is	B-X
sufficient	B-X
to	B-X
promote	B-X
the	B-X
growth	B-X
response	B-X
to	B-X
IL-2	B-X
.	B-X
However	B-X
,	B-X
for	B-X
the	B-X
clonal	B-X
expansion	B-X
of	B-X
CD4+	B-X
T-cells	B-X
,	B-X
which	B-X
is	B-X
a	B-X
characteristic	B-X
result	B-X
of	B-X
HTLV-I	B-X
infection	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
CREB/ATF	B-X
and	B-X
SRF	B-X
pathways	B-X
is	B-X
also	B-X
required	B-X
.	B-X

This	O
Tax1	B-Protein
-	O
induced	O
activation	O
of	O
cellular	O
genes	O
is	O
considered	O
to	O
be	O
a	O
critical	O
event	O
in	O
T	O
-	O
cell	O
transformation	O
by	O
HTLV	O
-	O
I	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
each	O
Tax1	B-Protein
-	O
inducible	O
transcriptional	O
pathway	O
in	O
T	O
-	O
cell	O
transformation	O
,	O
we	O
introduced	O
Tax1	B-Protein
mutants	O
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
into	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
by	O
retroviral	O
vectors	O
.	O

Analysis	O
of	O
these	O
PBLs	O
revealed	O
that	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
is	O
sufficient	O
to	O
promote	O
the	O
growth	O
response	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O
<EOS>	B-X
Tax1	B-X
,	B-X
a	B-X
transcriptional	B-X
trans-activator	B-X
of	B-X
the	B-X
Human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
,	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
many	B-X
cellular	B-X
genes	B-X
through	B-X
interaction	B-X
with	B-X
at	B-X
least	B-X
three	B-X
distinct	B-X
cellular	B-X
transcription	B-X
factors	B-X
;	B-X
CREB/ATF	B-X
,	B-X
NF-kappaB	B-X
,	B-X
and	B-X
SRF	B-X
.	B-X
This	B-X
Tax1-induced	B-X
activation	B-X
of	B-X
cellular	B-X
genes	B-X
is	B-X
considered	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
event	B-X
in	B-X
T-cell	B-X
transformation	B-X
by	B-X
HTLV-I	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
role	B-X
of	B-X
each	B-X
Tax1-inducible	B-X
transcriptional	B-X
pathway	B-X
in	B-X
T-cell	B-X
transformation	B-X
,	B-X
we	B-X
introduced	B-X
Tax1	B-X
mutants	B-X
with	B-X
different	B-X
trans-activating	B-X
phenotypes	B-X
into	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
(	B-X
PBL	B-X
)	B-X
by	B-X
retroviral	B-X
vectors	B-X
.	B-X
Analysis	B-X
of	B-X
these	B-X
PBLs	B-X
revealed	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
is	B-X
sufficient	B-X
to	B-X
promote	B-X
the	B-X
growth	B-X
response	B-X
to	B-X
IL-2	B-X
.	B-X
However	B-X
,	B-X
for	B-X
the	B-X
clonal	B-X
expansion	B-X
of	B-X
CD4+	B-X
T-cells	B-X
,	B-X
which	B-X
is	B-X
a	B-X
characteristic	B-X
result	B-X
of	B-X
HTLV-I	B-X
infection	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
CREB/ATF	B-X
and	B-X
SRF	B-X
pathways	B-X
is	B-X
also	B-X
required	B-X
.	B-X

However	O
,	O
for	O
the	O
clonal	O
expansion	O
of	O
CD4	B-Protein
+	O
T	O
-	O
cells	O
,	O
which	O
is	O
a	O
characteristic	O
result	O
of	O
HTLV	O
-	O
I	O
infection	O
,	O
activation	O
of	O
the	O
CREB	O
/	O
ATF	O
and	O
SRF	B-Protein
pathways	O
is	O
also	O
required	O
.	O
<EOS>	B-X
Tax1	B-X
,	B-X
a	B-X
transcriptional	B-X
trans-activator	B-X
of	B-X
the	B-X
Human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
,	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
many	B-X
cellular	B-X
genes	B-X
through	B-X
interaction	B-X
with	B-X
at	B-X
least	B-X
three	B-X
distinct	B-X
cellular	B-X
transcription	B-X
factors	B-X
;	B-X
CREB/ATF	B-X
,	B-X
NF-kappaB	B-X
,	B-X
and	B-X
SRF	B-X
.	B-X
This	B-X
Tax1-induced	B-X
activation	B-X
of	B-X
cellular	B-X
genes	B-X
is	B-X
considered	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
event	B-X
in	B-X
T-cell	B-X
transformation	B-X
by	B-X
HTLV-I	B-X
.	B-X
Analysis	B-X
of	B-X
these	B-X
PBLs	B-X
revealed	B-X
that	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
is	B-X
sufficient	B-X
to	B-X
promote	B-X
the	B-X
growth	B-X
response	B-X
to	B-X
IL-2	B-X
.	B-X
However	B-X
,	B-X
for	B-X
the	B-X
clonal	B-X
expansion	B-X
of	B-X
CD4+	B-X
T-cells	B-X
,	B-X
which	B-X
is	B-X
a	B-X
characteristic	B-X
result	B-X
of	B-X
HTLV-I	B-X
infection	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
CREB/ATF	B-X
and	B-X
SRF	B-X
pathways	B-X
is	B-X
also	B-X
required	B-X
.	B-X

Involvement	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
human	O
mineralocorticoid	B-Protein
receptor	I-Protein
hormone	O
-	O
binding	O
domain	O
in	O
agonist	O
and	O
antagonist	O
binding	O
as	O
revealed	O
by	O
a	O
new	O
monoclonal	O
antibody	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
binding	O
to	O
the	O
human	O
mineralocorticoid	B-Protein
receptor	I-Protein
(	O
hMR	B-Protein
)	O
,	O
we	O
developed	O
a	O
new	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
raised	O
against	O
the	O
hormone	O
-	O
binding	O
domain	O
(	O
HBD	O
)	O
.	O

For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	O
protein	O
including	O
the	O
sequence	O
Thr729	O
-	O
Lys984	O
of	O
hMR	B-Protein
.	O
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
binding	B-X
to	B-X
the	B-X
human	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
hMR	B-X
)	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
new	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
raised	B-X
against	B-X
the	B-X
hormone-binding	B-X
domain	B-X
(	B-X
HBD	B-X
)	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
mice	B-X
were	B-X
immunized	B-X
with	B-X
a	B-X
fusion	B-X
protein	B-X
including	B-X
the	B-X
sequence	B-X
Thr729-Lys984	B-X
of	B-X
hMR	B-X
.	B-X
By	B-X
using	B-X
several	B-X
HBD	B-X
subfragments	B-X
,	B-X
the	B-X
mAb	B-X
18C7	B-X
epitope	B-X
was	B-X
located	B-X
in	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
from	B-X
Thr729	B-X
to	B-X
Leu765	B-X
.	B-X
We	B-X
then	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
antibody	B-X
on	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
binding	B-X
to	B-X
the	B-X
hMR	B-X
.	B-X
After	B-X
its	B-X
associated	B-X
proteins	B-X
,	B-X
especially	B-X
the	B-X
heat-shock	B-X
protein	B-X
hsp90	B-X
,	B-X
had	B-X
been	B-X
cross-linked	B-X
with	B-X
the	B-X
hMR	B-X
by	B-X
dimethylpimelimidate	B-X
,	B-X
18C7	B-X
was	B-X
still	B-X
able	B-X
to	B-X
react	B-X
with	B-X
the	B-X
receptor	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
steroid	B-X
binding	B-X
of	B-X
HBD	B-X
mutants	B-X
with	B-X
the	B-X
Thr729-Leu765	B-X
sequence	B-X
deleted	B-X
[	B-X
Jalaguier	B-X
,	B-X
Mesnier	B-X
,	B-X
Léger	B-X
and	B-X
Auzou	B-X
(	B-X
1996	B-X
)	B-X
J.	B-X
Steroid	B-X
Biochem	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
similar	B-X
behaviours	B-X
of	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
N-terminal	B-X
Thr729-Leu765	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
is	B-X
similarly	B-X
involved	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
both	B-X
hormones	B-X
.	B-X

After	O
ELISA	O
screening	O
,	O
mAb	O
18C7	O
was	O
selected	O
for	O
its	O
specificity	O
towards	O
the	O
HBD	O
.	O
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
binding	B-X
to	B-X
the	B-X
human	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
hMR	B-X
)	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
new	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
raised	B-X
against	B-X
the	B-X
hormone-binding	B-X
domain	B-X
(	B-X
HBD	B-X
)	B-X
.	B-X
After	B-X
ELISA	B-X
screening	B-X
,	B-X
mAb	B-X
18C7	B-X
was	B-X
selected	B-X
for	B-X
its	B-X
specificity	B-X
towards	B-X
the	B-X
HBD	B-X
.	B-X
By	B-X
using	B-X
several	B-X
HBD	B-X
subfragments	B-X
,	B-X
the	B-X
mAb	B-X
18C7	B-X
epitope	B-X
was	B-X
located	B-X
in	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
from	B-X
Thr729	B-X
to	B-X
Leu765	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
liganded	B-X
MR	B-X
,	B-X
it	B-X
was	B-X
able	B-X
to	B-X
partly	B-X
displace	B-X
(	B-X
20	B-X
%	B-X
)	B-X
the	B-X
hormone	B-X
from	B-X
its	B-X
binding	B-X
site	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
MR	B-X
before	B-X
aldosterone	B-X
or	B-X
progesterone	B-X
,	B-X
the	B-X
antibody	B-X
inhibited	B-X
75-80	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
18C7	B-X
on	B-X
the	B-X
binding	B-X
was	B-X
similar	B-X
with	B-X
both	B-X
hormones	B-X
.	B-X
After	B-X
its	B-X
associated	B-X
proteins	B-X
,	B-X
especially	B-X
the	B-X
heat-shock	B-X
protein	B-X
hsp90	B-X
,	B-X
had	B-X
been	B-X
cross-linked	B-X
with	B-X
the	B-X
hMR	B-X
by	B-X
dimethylpimelimidate	B-X
,	B-X
18C7	B-X
was	B-X
still	B-X
able	B-X
to	B-X
react	B-X
with	B-X
the	B-X
receptor	B-X
.	B-X
Our	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
epitope	B-X
recognized	B-X
by	B-X
18C7	B-X
was	B-X
directly	B-X
implicated	B-X
in	B-X
hormone	B-X
binding	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
steroid	B-X
binding	B-X
of	B-X
HBD	B-X
mutants	B-X
with	B-X
the	B-X
Thr729-Leu765	B-X
sequence	B-X
deleted	B-X
[	B-X
Jalaguier	B-X
,	B-X
Mesnier	B-X
,	B-X
Léger	B-X
and	B-X
Auzou	B-X
(	B-X
1996	B-X
)	B-X
J.	B-X
Steroid	B-X
Biochem	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
similar	B-X
behaviours	B-X
of	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
N-terminal	B-X
Thr729-Leu765	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
is	B-X
similarly	B-X
involved	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
both	B-X
hormones	B-X
.	B-X

This	O
antibody	O
recognized	O
both	O
the	O
denatured	O
and	O
native	O
MR	B-Protein
forms	O
,	O
as	O
well	O
as	O
the	O
hetero	O
-	O
oligomeric	O
MR	B-Protein
form	O
and	O
the	O
transformed	O
MR	B-Protein
state	O
.	O
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
binding	B-X
to	B-X
the	B-X
human	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
hMR	B-X
)	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
new	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
raised	B-X
against	B-X
the	B-X
hormone-binding	B-X
domain	B-X
(	B-X
HBD	B-X
)	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
mice	B-X
were	B-X
immunized	B-X
with	B-X
a	B-X
fusion	B-X
protein	B-X
including	B-X
the	B-X
sequence	B-X
Thr729-Lys984	B-X
of	B-X
hMR	B-X
.	B-X
This	B-X
antibody	B-X
recognized	B-X
both	B-X
the	B-X
denatured	B-X
and	B-X
native	B-X
MR	B-X
forms	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
hetero-oligomeric	B-X
MR	B-X
form	B-X
and	B-X
the	B-X
transformed	B-X
MR	B-X
state	B-X
.	B-X
We	B-X
then	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
antibody	B-X
on	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
binding	B-X
to	B-X
the	B-X
hMR	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
liganded	B-X
MR	B-X
,	B-X
it	B-X
was	B-X
able	B-X
to	B-X
partly	B-X
displace	B-X
(	B-X
20	B-X
%	B-X
)	B-X
the	B-X
hormone	B-X
from	B-X
its	B-X
binding	B-X
site	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
MR	B-X
before	B-X
aldosterone	B-X
or	B-X
progesterone	B-X
,	B-X
the	B-X
antibody	B-X
inhibited	B-X
75-80	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
.	B-X
A	B-X
sucrose	B-X
gradient	B-X
analysis	B-X
indicated	B-X
the	B-X
simultaneous	B-X
presence	B-X
of	B-X
two	B-X
kinds	B-X
of	B-X
receptor	B-X
complexes	B-X
:	B-X
the	B-X
steroid-MR	B-X
complex	B-X
and	B-X
the	B-X
antibody-MR	B-X
complex	B-X
.	B-X
After	B-X
its	B-X
associated	B-X
proteins	B-X
,	B-X
especially	B-X
the	B-X
heat-shock	B-X
protein	B-X
hsp90	B-X
,	B-X
had	B-X
been	B-X
cross-linked	B-X
with	B-X
the	B-X
hMR	B-X
by	B-X
dimethylpimelimidate	B-X
,	B-X
18C7	B-X
was	B-X
still	B-X
able	B-X
to	B-X
react	B-X
with	B-X
the	B-X
receptor	B-X
.	B-X
Our	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
epitope	B-X
recognized	B-X
by	B-X
18C7	B-X
was	B-X
directly	B-X
implicated	B-X
in	B-X
hormone	B-X
binding	B-X
.	B-X

By	O
using	O
several	O
HBD	O
subfragments	O
,	O
the	O
mAb	O
18C7	O
epitope	O
was	O
located	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
HBD	O
from	O
Thr729	O
to	O
Leu765	O
.	O

We	O
then	O
studied	O
the	O
effect	O
of	O
the	O
antibody	O
on	O
aldosterone	O
and	O
progesterone	O
binding	O
to	O
the	O
hMR	B-Protein
.	O

When	O
18C7	O
was	O
incubated	O
with	O
liganded	O
MR	B-Protein
,	O
it	O
was	O
able	O
to	O
partly	O
displace	O
(	O
20	O
%	O
)	O
the	O
hormone	O
from	O
its	O
binding	O
site	O
.	O
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
binding	B-X
to	B-X
the	B-X
human	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
hMR	B-X
)	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
new	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
raised	B-X
against	B-X
the	B-X
hormone-binding	B-X
domain	B-X
(	B-X
HBD	B-X
)	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
mice	B-X
were	B-X
immunized	B-X
with	B-X
a	B-X
fusion	B-X
protein	B-X
including	B-X
the	B-X
sequence	B-X
Thr729-Lys984	B-X
of	B-X
hMR	B-X
.	B-X
After	B-X
ELISA	B-X
screening	B-X
,	B-X
mAb	B-X
18C7	B-X
was	B-X
selected	B-X
for	B-X
its	B-X
specificity	B-X
towards	B-X
the	B-X
HBD	B-X
.	B-X
This	B-X
antibody	B-X
recognized	B-X
both	B-X
the	B-X
denatured	B-X
and	B-X
native	B-X
MR	B-X
forms	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
hetero-oligomeric	B-X
MR	B-X
form	B-X
and	B-X
the	B-X
transformed	B-X
MR	B-X
state	B-X
.	B-X
By	B-X
using	B-X
several	B-X
HBD	B-X
subfragments	B-X
,	B-X
the	B-X
mAb	B-X
18C7	B-X
epitope	B-X
was	B-X
located	B-X
in	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
from	B-X
Thr729	B-X
to	B-X
Leu765	B-X
.	B-X
We	B-X
then	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
antibody	B-X
on	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
binding	B-X
to	B-X
the	B-X
hMR	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
liganded	B-X
MR	B-X
,	B-X
it	B-X
was	B-X
able	B-X
to	B-X
partly	B-X
displace	B-X
(	B-X
20	B-X
%	B-X
)	B-X
the	B-X
hormone	B-X
from	B-X
its	B-X
binding	B-X
site	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
MR	B-X
before	B-X
aldosterone	B-X
or	B-X
progesterone	B-X
,	B-X
the	B-X
antibody	B-X
inhibited	B-X
75-80	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
18C7	B-X
on	B-X
the	B-X
binding	B-X
was	B-X
similar	B-X
with	B-X
both	B-X
hormones	B-X
.	B-X
A	B-X
sucrose	B-X
gradient	B-X
analysis	B-X
indicated	B-X
the	B-X
simultaneous	B-X
presence	B-X
of	B-X
two	B-X
kinds	B-X
of	B-X
receptor	B-X
complexes	B-X
:	B-X
the	B-X
steroid-MR	B-X
complex	B-X
and	B-X
the	B-X
antibody-MR	B-X
complex	B-X
.	B-X
After	B-X
its	B-X
associated	B-X
proteins	B-X
,	B-X
especially	B-X
the	B-X
heat-shock	B-X
protein	B-X
hsp90	B-X
,	B-X
had	B-X
been	B-X
cross-linked	B-X
with	B-X
the	B-X
hMR	B-X
by	B-X
dimethylpimelimidate	B-X
,	B-X
18C7	B-X
was	B-X
still	B-X
able	B-X
to	B-X
react	B-X
with	B-X
the	B-X
receptor	B-X
.	B-X
Our	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
epitope	B-X
recognized	B-X
by	B-X
18C7	B-X
was	B-X
directly	B-X
implicated	B-X
in	B-X
hormone	B-X
binding	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
steroid	B-X
binding	B-X
of	B-X
HBD	B-X
mutants	B-X
with	B-X
the	B-X
Thr729-Leu765	B-X
sequence	B-X
deleted	B-X
[	B-X
Jalaguier	B-X
,	B-X
Mesnier	B-X
,	B-X
Léger	B-X
and	B-X
Auzou	B-X
(	B-X
1996	B-X
)	B-X
J.	B-X
Steroid	B-X
Biochem	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
similar	B-X
behaviours	B-X
of	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
N-terminal	B-X
Thr729-Leu765	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
is	B-X
similarly	B-X
involved	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
both	B-X
hormones	B-X
.	B-X

When	O
18C7	O
was	O
incubated	O
with	O
MR	B-Protein
before	O
aldosterone	O
or	O
progesterone	O
,	O
the	O
antibody	O
inhibited	O
75	O
-	O
80	O
%	O
of	O
the	O
binding	O
.	O
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
binding	B-X
to	B-X
the	B-X
human	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
hMR	B-X
)	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
new	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
raised	B-X
against	B-X
the	B-X
hormone-binding	B-X
domain	B-X
(	B-X
HBD	B-X
)	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
mice	B-X
were	B-X
immunized	B-X
with	B-X
a	B-X
fusion	B-X
protein	B-X
including	B-X
the	B-X
sequence	B-X
Thr729-Lys984	B-X
of	B-X
hMR	B-X
.	B-X
After	B-X
ELISA	B-X
screening	B-X
,	B-X
mAb	B-X
18C7	B-X
was	B-X
selected	B-X
for	B-X
its	B-X
specificity	B-X
towards	B-X
the	B-X
HBD	B-X
.	B-X
This	B-X
antibody	B-X
recognized	B-X
both	B-X
the	B-X
denatured	B-X
and	B-X
native	B-X
MR	B-X
forms	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
hetero-oligomeric	B-X
MR	B-X
form	B-X
and	B-X
the	B-X
transformed	B-X
MR	B-X
state	B-X
.	B-X
By	B-X
using	B-X
several	B-X
HBD	B-X
subfragments	B-X
,	B-X
the	B-X
mAb	B-X
18C7	B-X
epitope	B-X
was	B-X
located	B-X
in	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
from	B-X
Thr729	B-X
to	B-X
Leu765	B-X
.	B-X
We	B-X
then	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
antibody	B-X
on	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
binding	B-X
to	B-X
the	B-X
hMR	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
liganded	B-X
MR	B-X
,	B-X
it	B-X
was	B-X
able	B-X
to	B-X
partly	B-X
displace	B-X
(	B-X
20	B-X
%	B-X
)	B-X
the	B-X
hormone	B-X
from	B-X
its	B-X
binding	B-X
site	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
MR	B-X
before	B-X
aldosterone	B-X
or	B-X
progesterone	B-X
,	B-X
the	B-X
antibody	B-X
inhibited	B-X
75-80	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
18C7	B-X
on	B-X
the	B-X
binding	B-X
was	B-X
similar	B-X
with	B-X
both	B-X
hormones	B-X
.	B-X
A	B-X
sucrose	B-X
gradient	B-X
analysis	B-X
indicated	B-X
the	B-X
simultaneous	B-X
presence	B-X
of	B-X
two	B-X
kinds	B-X
of	B-X
receptor	B-X
complexes	B-X
:	B-X
the	B-X
steroid-MR	B-X
complex	B-X
and	B-X
the	B-X
antibody-MR	B-X
complex	B-X
.	B-X
After	B-X
its	B-X
associated	B-X
proteins	B-X
,	B-X
especially	B-X
the	B-X
heat-shock	B-X
protein	B-X
hsp90	B-X
,	B-X
had	B-X
been	B-X
cross-linked	B-X
with	B-X
the	B-X
hMR	B-X
by	B-X
dimethylpimelimidate	B-X
,	B-X
18C7	B-X
was	B-X
still	B-X
able	B-X
to	B-X
react	B-X
with	B-X
the	B-X
receptor	B-X
.	B-X
Our	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
epitope	B-X
recognized	B-X
by	B-X
18C7	B-X
was	B-X
directly	B-X
implicated	B-X
in	B-X
hormone	B-X
binding	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
steroid	B-X
binding	B-X
of	B-X
HBD	B-X
mutants	B-X
with	B-X
the	B-X
Thr729-Leu765	B-X
sequence	B-X
deleted	B-X
[	B-X
Jalaguier	B-X
,	B-X
Mesnier	B-X
,	B-X
Léger	B-X
and	B-X
Auzou	B-X
(	B-X
1996	B-X
)	B-X
J.	B-X
Steroid	B-X
Biochem	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
similar	B-X
behaviours	B-X
of	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
N-terminal	B-X
Thr729-Leu765	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
is	B-X
similarly	B-X
involved	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
both	B-X
hormones	B-X
.	B-X

The	O
effect	O
of	O
18C7	O
on	O
the	O
binding	O
was	O
similar	O
with	O
both	O
hormones	O
.	O
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
binding	B-X
to	B-X
the	B-X
human	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
hMR	B-X
)	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
new	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
raised	B-X
against	B-X
the	B-X
hormone-binding	B-X
domain	B-X
(	B-X
HBD	B-X
)	B-X
.	B-X
After	B-X
ELISA	B-X
screening	B-X
,	B-X
mAb	B-X
18C7	B-X
was	B-X
selected	B-X
for	B-X
its	B-X
specificity	B-X
towards	B-X
the	B-X
HBD	B-X
.	B-X
By	B-X
using	B-X
several	B-X
HBD	B-X
subfragments	B-X
,	B-X
the	B-X
mAb	B-X
18C7	B-X
epitope	B-X
was	B-X
located	B-X
in	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
from	B-X
Thr729	B-X
to	B-X
Leu765	B-X
.	B-X
We	B-X
then	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
antibody	B-X
on	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
binding	B-X
to	B-X
the	B-X
hMR	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
liganded	B-X
MR	B-X
,	B-X
it	B-X
was	B-X
able	B-X
to	B-X
partly	B-X
displace	B-X
(	B-X
20	B-X
%	B-X
)	B-X
the	B-X
hormone	B-X
from	B-X
its	B-X
binding	B-X
site	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
MR	B-X
before	B-X
aldosterone	B-X
or	B-X
progesterone	B-X
,	B-X
the	B-X
antibody	B-X
inhibited	B-X
75-80	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
18C7	B-X
on	B-X
the	B-X
binding	B-X
was	B-X
similar	B-X
with	B-X
both	B-X
hormones	B-X
.	B-X
After	B-X
its	B-X
associated	B-X
proteins	B-X
,	B-X
especially	B-X
the	B-X
heat-shock	B-X
protein	B-X
hsp90	B-X
,	B-X
had	B-X
been	B-X
cross-linked	B-X
with	B-X
the	B-X
hMR	B-X
by	B-X
dimethylpimelimidate	B-X
,	B-X
18C7	B-X
was	B-X
still	B-X
able	B-X
to	B-X
react	B-X
with	B-X
the	B-X
receptor	B-X
.	B-X
Our	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
epitope	B-X
recognized	B-X
by	B-X
18C7	B-X
was	B-X
directly	B-X
implicated	B-X
in	B-X
hormone	B-X
binding	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
steroid	B-X
binding	B-X
of	B-X
HBD	B-X
mutants	B-X
with	B-X
the	B-X
Thr729-Leu765	B-X
sequence	B-X
deleted	B-X
[	B-X
Jalaguier	B-X
,	B-X
Mesnier	B-X
,	B-X
Léger	B-X
and	B-X
Auzou	B-X
(	B-X
1996	B-X
)	B-X
J.	B-X
Steroid	B-X
Biochem	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
similar	B-X
behaviours	B-X
of	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
N-terminal	B-X
Thr729-Leu765	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
is	B-X
similarly	B-X
involved	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
both	B-X
hormones	B-X
.	B-X

A	O
sucrose	O
gradient	O
analysis	O
indicated	O
the	O
simultaneous	O
presence	O
of	O
two	O
kinds	O
of	O
receptor	O
complexes	O
:	O
the	O
steroid	O
-	O
MR	B-Protein
complex	O
and	O
the	O
antibody	O
-	O
MR	B-Protein
complex	O
.	O
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
binding	B-X
to	B-X
the	B-X
human	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
hMR	B-X
)	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
new	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
raised	B-X
against	B-X
the	B-X
hormone-binding	B-X
domain	B-X
(	B-X
HBD	B-X
)	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
mice	B-X
were	B-X
immunized	B-X
with	B-X
a	B-X
fusion	B-X
protein	B-X
including	B-X
the	B-X
sequence	B-X
Thr729-Lys984	B-X
of	B-X
hMR	B-X
.	B-X
This	B-X
antibody	B-X
recognized	B-X
both	B-X
the	B-X
denatured	B-X
and	B-X
native	B-X
MR	B-X
forms	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
hetero-oligomeric	B-X
MR	B-X
form	B-X
and	B-X
the	B-X
transformed	B-X
MR	B-X
state	B-X
.	B-X
We	B-X
then	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
antibody	B-X
on	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
binding	B-X
to	B-X
the	B-X
hMR	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
liganded	B-X
MR	B-X
,	B-X
it	B-X
was	B-X
able	B-X
to	B-X
partly	B-X
displace	B-X
(	B-X
20	B-X
%	B-X
)	B-X
the	B-X
hormone	B-X
from	B-X
its	B-X
binding	B-X
site	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
MR	B-X
before	B-X
aldosterone	B-X
or	B-X
progesterone	B-X
,	B-X
the	B-X
antibody	B-X
inhibited	B-X
75-80	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
.	B-X
A	B-X
sucrose	B-X
gradient	B-X
analysis	B-X
indicated	B-X
the	B-X
simultaneous	B-X
presence	B-X
of	B-X
two	B-X
kinds	B-X
of	B-X
receptor	B-X
complexes	B-X
:	B-X
the	B-X
steroid-MR	B-X
complex	B-X
and	B-X
the	B-X
antibody-MR	B-X
complex	B-X
.	B-X
After	B-X
its	B-X
associated	B-X
proteins	B-X
,	B-X
especially	B-X
the	B-X
heat-shock	B-X
protein	B-X
hsp90	B-X
,	B-X
had	B-X
been	B-X
cross-linked	B-X
with	B-X
the	B-X
hMR	B-X
by	B-X
dimethylpimelimidate	B-X
,	B-X
18C7	B-X
was	B-X
still	B-X
able	B-X
to	B-X
react	B-X
with	B-X
the	B-X
receptor	B-X
.	B-X
Our	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
epitope	B-X
recognized	B-X
by	B-X
18C7	B-X
was	B-X
directly	B-X
implicated	B-X
in	B-X
hormone	B-X
binding	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
steroid	B-X
binding	B-X
of	B-X
HBD	B-X
mutants	B-X
with	B-X
the	B-X
Thr729-Leu765	B-X
sequence	B-X
deleted	B-X
[	B-X
Jalaguier	B-X
,	B-X
Mesnier	B-X
,	B-X
Léger	B-X
and	B-X
Auzou	B-X
(	B-X
1996	B-X
)	B-X
J.	B-X
Steroid	B-X
Biochem	B-X
.	B-X

After	O
its	O
associated	O
proteins	O
,	O
especially	O
the	O
heat	O
-	O
shock	O
protein	O
hsp90	B-Protein
,	O
had	O
been	O
cross	O
-	O
linked	O
with	O
the	O
hMR	B-Protein
by	O
dimethylpimelimidate	O
,	O
18C7	O
was	O
still	O
able	O
to	O
react	O
with	O
the	O
receptor	O
.	O
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
binding	B-X
to	B-X
the	B-X
human	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
hMR	B-X
)	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
new	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
raised	B-X
against	B-X
the	B-X
hormone-binding	B-X
domain	B-X
(	B-X
HBD	B-X
)	B-X
.	B-X
For	B-X
this	B-X
purpose	B-X
,	B-X
mice	B-X
were	B-X
immunized	B-X
with	B-X
a	B-X
fusion	B-X
protein	B-X
including	B-X
the	B-X
sequence	B-X
Thr729-Lys984	B-X
of	B-X
hMR	B-X
.	B-X
After	B-X
ELISA	B-X
screening	B-X
,	B-X
mAb	B-X
18C7	B-X
was	B-X
selected	B-X
for	B-X
its	B-X
specificity	B-X
towards	B-X
the	B-X
HBD	B-X
.	B-X
By	B-X
using	B-X
several	B-X
HBD	B-X
subfragments	B-X
,	B-X
the	B-X
mAb	B-X
18C7	B-X
epitope	B-X
was	B-X
located	B-X
in	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
from	B-X
Thr729	B-X
to	B-X
Leu765	B-X
.	B-X
We	B-X
then	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
antibody	B-X
on	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
binding	B-X
to	B-X
the	B-X
hMR	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
liganded	B-X
MR	B-X
,	B-X
it	B-X
was	B-X
able	B-X
to	B-X
partly	B-X
displace	B-X
(	B-X
20	B-X
%	B-X
)	B-X
the	B-X
hormone	B-X
from	B-X
its	B-X
binding	B-X
site	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
MR	B-X
before	B-X
aldosterone	B-X
or	B-X
progesterone	B-X
,	B-X
the	B-X
antibody	B-X
inhibited	B-X
75-80	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
18C7	B-X
on	B-X
the	B-X
binding	B-X
was	B-X
similar	B-X
with	B-X
both	B-X
hormones	B-X
.	B-X
A	B-X
sucrose	B-X
gradient	B-X
analysis	B-X
indicated	B-X
the	B-X
simultaneous	B-X
presence	B-X
of	B-X
two	B-X
kinds	B-X
of	B-X
receptor	B-X
complexes	B-X
:	B-X
the	B-X
steroid-MR	B-X
complex	B-X
and	B-X
the	B-X
antibody-MR	B-X
complex	B-X
.	B-X
After	B-X
its	B-X
associated	B-X
proteins	B-X
,	B-X
especially	B-X
the	B-X
heat-shock	B-X
protein	B-X
hsp90	B-X
,	B-X
had	B-X
been	B-X
cross-linked	B-X
with	B-X
the	B-X
hMR	B-X
by	B-X
dimethylpimelimidate	B-X
,	B-X
18C7	B-X
was	B-X
still	B-X
able	B-X
to	B-X
react	B-X
with	B-X
the	B-X
receptor	B-X
.	B-X
Our	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
epitope	B-X
recognized	B-X
by	B-X
18C7	B-X
was	B-X
directly	B-X
implicated	B-X
in	B-X
hormone	B-X
binding	B-X
.	B-X

Our	O
results	O
indicated	O
that	O
the	O
epitope	O
recognized	O
by	O
18C7	O
was	O
directly	O
implicated	O
in	O
hormone	O
binding	O
.	O
<EOS>	B-X
To	B-X
gain	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
mechanism	B-X
of	B-X
binding	B-X
to	B-X
the	B-X
human	B-X
mineralocorticoid	B-X
receptor	B-X
(	B-X
hMR	B-X
)	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
new	B-X
monoclonal	B-X
antibody	B-X
(	B-X
mAb	B-X
)	B-X
raised	B-X
against	B-X
the	B-X
hormone-binding	B-X
domain	B-X
(	B-X
HBD	B-X
)	B-X
.	B-X
After	B-X
ELISA	B-X
screening	B-X
,	B-X
mAb	B-X
18C7	B-X
was	B-X
selected	B-X
for	B-X
its	B-X
specificity	B-X
towards	B-X
the	B-X
HBD	B-X
.	B-X
This	B-X
antibody	B-X
recognized	B-X
both	B-X
the	B-X
denatured	B-X
and	B-X
native	B-X
MR	B-X
forms	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
hetero-oligomeric	B-X
MR	B-X
form	B-X
and	B-X
the	B-X
transformed	B-X
MR	B-X
state	B-X
.	B-X
By	B-X
using	B-X
several	B-X
HBD	B-X
subfragments	B-X
,	B-X
the	B-X
mAb	B-X
18C7	B-X
epitope	B-X
was	B-X
located	B-X
in	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
from	B-X
Thr729	B-X
to	B-X
Leu765	B-X
.	B-X
We	B-X
then	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
antibody	B-X
on	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
binding	B-X
to	B-X
the	B-X
hMR	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
liganded	B-X
MR	B-X
,	B-X
it	B-X
was	B-X
able	B-X
to	B-X
partly	B-X
displace	B-X
(	B-X
20	B-X
%	B-X
)	B-X
the	B-X
hormone	B-X
from	B-X
its	B-X
binding	B-X
site	B-X
.	B-X
When	B-X
18C7	B-X
was	B-X
incubated	B-X
with	B-X
MR	B-X
before	B-X
aldosterone	B-X
or	B-X
progesterone	B-X
,	B-X
the	B-X
antibody	B-X
inhibited	B-X
75-80	B-X
%	B-X
of	B-X
the	B-X
binding	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
18C7	B-X
on	B-X
the	B-X
binding	B-X
was	B-X
similar	B-X
with	B-X
both	B-X
hormones	B-X
.	B-X
A	B-X
sucrose	B-X
gradient	B-X
analysis	B-X
indicated	B-X
the	B-X
simultaneous	B-X
presence	B-X
of	B-X
two	B-X
kinds	B-X
of	B-X
receptor	B-X
complexes	B-X
:	B-X
the	B-X
steroid-MR	B-X
complex	B-X
and	B-X
the	B-X
antibody-MR	B-X
complex	B-X
.	B-X
After	B-X
its	B-X
associated	B-X
proteins	B-X
,	B-X
especially	B-X
the	B-X
heat-shock	B-X
protein	B-X
hsp90	B-X
,	B-X
had	B-X
been	B-X
cross-linked	B-X
with	B-X
the	B-X
hMR	B-X
by	B-X
dimethylpimelimidate	B-X
,	B-X
18C7	B-X
was	B-X
still	B-X
able	B-X
to	B-X
react	B-X
with	B-X
the	B-X
receptor	B-X
.	B-X
Our	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
epitope	B-X
recognized	B-X
by	B-X
18C7	B-X
was	B-X
directly	B-X
implicated	B-X
in	B-X
hormone	B-X
binding	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
steroid	B-X
binding	B-X
of	B-X
HBD	B-X
mutants	B-X
with	B-X
the	B-X
Thr729-Leu765	B-X
sequence	B-X
deleted	B-X
[	B-X
Jalaguier	B-X
,	B-X
Mesnier	B-X
,	B-X
Léger	B-X
and	B-X
Auzou	B-X
(	B-X
1996	B-X
)	B-X
J.	B-X
Steroid	B-X
Biochem	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
similar	B-X
behaviours	B-X
of	B-X
aldosterone	B-X
and	B-X
progesterone	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
N-terminal	B-X
Thr729-Leu765	B-X
region	B-X
of	B-X
the	B-X
HBD	B-X
is	B-X
similarly	B-X
involved	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
both	B-X
hormones	B-X
.	B-X

The	O
lack	O
of	O
steroid	O
binding	O
of	O
HBD	O
mutants	O
with	O
the	O
Thr729	O
-	O
Leu765	O
sequence	O
deleted	O
[	O
Jalaguier	O
,	O
Mesnier	O
,	O
Leger	O
and	O
Auzou	O
(	O
1996	O
)	O
J	O
.	O
Steroid	O
Biochem	O
.	O
Mol	O
.	O
Biol	O
.	O
57	O
,	O
43	O
-	O
50	O
]	O
supports	O
this	O
hypothesis	O
.	O

Because	O
of	O
the	O
similar	O
behaviours	O
of	O
aldosterone	O
and	O
progesterone	O
,	O
we	O
conclude	O
that	O
the	O
N	O
-	O
terminal	O
Thr729	O
-	O
Leu765	O
region	O
of	O
the	O
HBD	O
is	O
similarly	O
involved	O
in	O
the	O
binding	O
of	O
both	O
hormones	O
.	O

Abnormal	O
T	O
lymphocyte	O
development	O
induced	O
by	O
targeted	O
overexpression	O
of	O
IkappaB	B-Protein
alpha	I-Protein
.	O
<EOS>	B-X
Transgenic	B-X
mice	B-X
with	B-X
a	B-X
lymphocyte-specific	B-X
defect	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
were	B-X
produced	B-X
by	B-X
targeted	B-X
expression	B-X
of	B-X
human	B-X
IkappaB	B-X
alpha	B-X
.	B-X
The	B-X
proportion	B-X
of	B-X
mature	B-X
,	B-X
TCRhigh	B-X
thymocytes	B-X
of	B-X
the	B-X
alphabeta	B-X
lineage	B-X
was	B-X
reduced	B-X
,	B-X
and	B-X
the	B-X
remaining	B-X
TCRhigh	B-X
population	B-X
contained	B-X
an	B-X
unusually	B-X
high	B-X
proportion	B-X
of	B-X
double-positive	B-X
cells	B-X
.	B-X
This	B-X
defect	B-X
in	B-X
maturation	B-X
resulted	B-X
in	B-X
a	B-X
transgene	B-X
dose-dependent	B-X
reduction	B-X
in	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
,	B-X
with	B-X
the	B-X
CD8	B-X
lineage	B-X
being	B-X
more	B-X
severely	B-X
affected	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
direct	B-X
evidence	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
NF-kappaB/Rel	B-X
family	B-X
proteins	B-X
in	B-X
late	B-X
stages	B-X
of	B-X
T	B-X
lymphocyte	B-X
development	B-X
,	B-X
coincident	B-X
with	B-X
positive	B-X
and	B-X
negative	B-X
selection	B-X
.	B-X

A	O
role	O
in	O
thymic	O
maturation	O
for	O
factors	O
of	O
the	O
NF	O
-	O
kappaB	O
family	O
has	O
long	O
been	O
suspected	O
,	O
but	O
not	O
yet	O
proven	O
.	O

Transgenic	O
mice	O
with	O
a	O
lymphocyte	O
-	O
specific	O
defect	O
in	O
NF	O
-	O
kappaB	O
activation	O
were	O
produced	O
by	O
targeted	O
expression	O
of	O
human	O
IkappaB	B-Protein
alpha	I-Protein
.	O
<EOS>	B-X
A	B-X
role	B-X
in	B-X
thymic	B-X
maturation	B-X
for	B-X
factors	B-X
of	B-X
the	B-X
NF-kappaB	B-X
family	B-X
has	B-X
long	B-X
been	B-X
suspected	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
proven	B-X
.	B-X
Transgenic	B-X
mice	B-X
with	B-X
a	B-X
lymphocyte-specific	B-X
defect	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
were	B-X
produced	B-X
by	B-X
targeted	B-X
expression	B-X
of	B-X
human	B-X
IkappaB	B-X
alpha	B-X
.	B-X
The	B-X
thymic	B-X
cellularity	B-X
of	B-X
these	B-X
mice	B-X
was	B-X
significantly	B-X
decreased	B-X
.	B-X
The	B-X
proportion	B-X
of	B-X
mature	B-X
,	B-X
TCRhigh	B-X
thymocytes	B-X
of	B-X
the	B-X
alphabeta	B-X
lineage	B-X
was	B-X
reduced	B-X
,	B-X
and	B-X
the	B-X
remaining	B-X
TCRhigh	B-X
population	B-X
contained	B-X
an	B-X
unusually	B-X
high	B-X
proportion	B-X
of	B-X
double-positive	B-X
cells	B-X
.	B-X
This	B-X
defect	B-X
in	B-X
maturation	B-X
resulted	B-X
in	B-X
a	B-X
transgene	B-X
dose-dependent	B-X
reduction	B-X
in	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
,	B-X
with	B-X
the	B-X
CD8	B-X
lineage	B-X
being	B-X
more	B-X
severely	B-X
affected	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
direct	B-X
evidence	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
NF-kappaB/Rel	B-X
family	B-X
proteins	B-X
in	B-X
late	B-X
stages	B-X
of	B-X
T	B-X
lymphocyte	B-X
development	B-X
,	B-X
coincident	B-X
with	B-X
positive	B-X
and	B-X
negative	B-X
selection	B-X
.	B-X

The	O
thymic	O
cellularity	O
of	O
these	O
mice	O
was	O
significantly	O
decreased	O
.	O
<EOS>	B-X
We	B-X
have	B-X
shown	B-X
previously	B-X
that	B-X
posthematopoietic	B-X
cell	B-X
transplantation	B-X
thymic	B-X
function	B-X
was	B-X
improved	B-X
by	B-X
retroviral	B-X
overexpression	B-X
of	B-X
Wnt4	B-X
in	B-X
donor	B-X
hematopoietic	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
by	B-X
using	B-X
both	B-X
conventional	B-X
and	B-X
conditional	B-X
null	B-X
mutant	B-X
mice	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Wnt4	B-X
regulates	B-X
steady-state	B-X
thymic	B-X
cellularity	B-X
by	B-X
a	B-X
thymic	B-X
epithelial	B-X
cell	B-X
(	B-X
TEC	B-X
)	B-X
-dependent	B-X
mechanism	B-X
.	B-X
The	B-X
absence	B-X
of	B-X
Wnt4	B-X
suppressed	B-X
fetal	B-X
and	B-X
postnatal	B-X
thymic	B-X
expansion	B-X
and	B-X
resulted	B-X
in	B-X
decreased	B-X
TEC	B-X
numbers	B-X
,	B-X
an	B-X
alteration	B-X
of	B-X
the	B-X
medullary-to-cortical	B-X
TEC	B-X
ratio	B-X
,	B-X
and	B-X
a	B-X
disproportionate	B-X
loss	B-X
of	B-X
the	B-X
most	B-X
immature	B-X
cKit	B-X
(	B-X
hi	B-X
)	B-X
thymocyte	B-X
precursors	B-X
.	B-X
Wnt4	B-X
also	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
maintenance	B-X
of	B-X
adult	B-X
thymopoiesis	B-X
,	B-X
although	B-X
the	B-X
impact	B-X
of	B-X
its	B-X
deletion	B-X
once	B-X
thymic	B-X
involution	B-X
has	B-X
been	B-X
initiated	B-X
is	B-X
more	B-X
subtle	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
show	B-X
that	B-X
Wnt4	B-X
controls	B-X
thymic	B-X
size	B-X
by	B-X
modulating	B-X
TEC	B-X
expansion	B-X
and	B-X
the	B-X
earliest	B-X
,	B-X
TEC-dependent	B-X
steps	B-X
of	B-X
thymocyte	B-X
development	B-X
both	B-X
in	B-X
the	B-X
fetal	B-X
and	B-X
postnatal	B-X
thymus	B-X
.	B-X
Wnt4	B-X
and	B-X
its	B-X
downstream	B-X
signaling	B-X
pathways	B-X
could	B-X
thus	B-X
represent	B-X
interesting	B-X
candidates	B-X
to	B-X
improve	B-X
thymic	B-X
output	B-X
in	B-X
subjects	B-X
with	B-X
thymic	B-X
atrophy	B-X
.	B-X

The	O
proportion	O
of	O
mature	O
,	O
TCRhigh	O
thymocytes	O
of	O
the	O
alphabeta	O
lineage	O
was	O
reduced	O
,	O
and	O
the	O
remaining	O
TCRhigh	O
population	O
contained	O
an	O
unusually	O
high	O
proportion	O
of	O
double	O
-	O
positive	O
cells	O
.	O
<EOS>	B-X
The	B-X
proportion	B-X
of	B-X
mature	B-X
,	B-X
TCRhigh	B-X
thymocytes	B-X
of	B-X
the	B-X
alphabeta	B-X
lineage	B-X
was	B-X
reduced	B-X
,	B-X
and	B-X
the	B-X
remaining	B-X
TCRhigh	B-X
population	B-X
contained	B-X
an	B-X
unusually	B-X
high	B-X
proportion	B-X
of	B-X
double-positive	B-X
cells	B-X
.	B-X
This	B-X
defect	B-X
in	B-X
maturation	B-X
resulted	B-X
in	B-X
a	B-X
transgene	B-X
dose-dependent	B-X
reduction	B-X
in	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
,	B-X
with	B-X
the	B-X
CD8	B-X
lineage	B-X
being	B-X
more	B-X
severely	B-X
affected	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
direct	B-X
evidence	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
NF-kappaB/Rel	B-X
family	B-X
proteins	B-X
in	B-X
late	B-X
stages	B-X
of	B-X
T	B-X
lymphocyte	B-X
development	B-X
,	B-X
coincident	B-X
with	B-X
positive	B-X
and	B-X
negative	B-X
selection	B-X
.	B-X

This	O
defect	O
in	O
maturation	O
resulted	O
in	O
a	O
transgene	O
dose	O
-	O
dependent	O
reduction	O
in	O
peripheral	O
T	O
lymphocytes	O
,	O
with	O
the	O
CD8	O
lineage	O
being	O
more	O
severely	O
affected	O
.	O

These	O
data	O
provide	O
direct	O
evidence	O
for	O
the	O
involvement	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
proteins	O
in	O
late	O
stages	O
of	O
T	O
lymphocyte	O
development	O
,	O
coincident	O
with	O
positive	O
and	O
negative	O
selection	O
.	O
<EOS>	B-X
A	B-X
role	B-X
in	B-X
thymic	B-X
maturation	B-X
for	B-X
factors	B-X
of	B-X
the	B-X
NF-kappaB	B-X
family	B-X
has	B-X
long	B-X
been	B-X
suspected	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
proven	B-X
.	B-X
Transgenic	B-X
mice	B-X
with	B-X
a	B-X
lymphocyte-specific	B-X
defect	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
were	B-X
produced	B-X
by	B-X
targeted	B-X
expression	B-X
of	B-X
human	B-X
IkappaB	B-X
alpha	B-X
.	B-X
The	B-X
proportion	B-X
of	B-X
mature	B-X
,	B-X
TCRhigh	B-X
thymocytes	B-X
of	B-X
the	B-X
alphabeta	B-X
lineage	B-X
was	B-X
reduced	B-X
,	B-X
and	B-X
the	B-X
remaining	B-X
TCRhigh	B-X
population	B-X
contained	B-X
an	B-X
unusually	B-X
high	B-X
proportion	B-X
of	B-X
double-positive	B-X
cells	B-X
.	B-X
This	B-X
defect	B-X
in	B-X
maturation	B-X
resulted	B-X
in	B-X
a	B-X
transgene	B-X
dose-dependent	B-X
reduction	B-X
in	B-X
peripheral	B-X
T	B-X
lymphocytes	B-X
,	B-X
with	B-X
the	B-X
CD8	B-X
lineage	B-X
being	B-X
more	B-X
severely	B-X
affected	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
direct	B-X
evidence	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
NF-kappaB/Rel	B-X
family	B-X
proteins	B-X
in	B-X
late	B-X
stages	B-X
of	B-X
T	B-X
lymphocyte	B-X
development	B-X
,	B-X
coincident	B-X
with	B-X
positive	B-X
and	B-X
negative	B-X
selection	B-X
.	B-X

Sequential	O
development	O
of	O
structural	O
and	O
functional	O
alterations	O
in	O
T	O
cells	O
from	O
tumor	O
-	O
bearing	O
mice	O
.	O

The	O
TCR	O
alpha	O
beta	O
or	O
-	O
gamma	O
delta	O
chains	O
bind	O
the	O
peptide	O
ligand	O
,	O
whereas	O
the	O
associated	O
CD3	B-Protein
deltaepsilongamma	I-Protein
and	O
TCR	B-Protein
zeta	I-Protein
subunits	O
couple	O
the	O
TCR	O
to	O
intracellular	O
signal	O
transduction	O
components	O
.	O
<EOS>	B-X
The	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
expressed	B-X
by	B-X
T	B-X
lymphocytes	B-X
initiates	B-X
protective	B-X
immune	B-X
responses	B-X
to	B-X
pathogens	B-X
and	B-X
tumors	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
structural	B-X
basis	B-X
of	B-X
how	B-X
TCR	B-X
signaling	B-X
is	B-X
initiated	B-X
when	B-X
the	B-X
receptor	B-X
binds	B-X
to	B-X
peptide-loaded	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
pMHC	B-X
)	B-X
molecules	B-X
,	B-X
we	B-X
used	B-X
cryogenic	B-X
electron	B-X
microscopy	B-X
to	B-X
determine	B-X
the	B-X
structure	B-X
of	B-X
a	B-X
tumor-reactive	B-X
TCRαβ/CD3δγε	B-X
The	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
complicated	B-X
receptors	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
and	B-X
its	B-X
triggering	B-X
mechanism	B-X
remains	B-X
mysterious	B-X
.	B-X
As	B-X
an	B-X
octamer	B-X
complex	B-X
,	B-X
TCR	B-X
comprises	B-X
an	B-X
antigen-binding	B-X
subunit	B-X
(	B-X
TCRαβ	B-X
)	B-X
and	B-X
three	B-X
CD3	B-X
signaling	B-X
subunits	B-X
(	B-X
CD3ζζ	B-X
,	B-X
CD3δε	B-X
,	B-X
and	B-X
CD3γε	B-X
)	B-X
.	B-X
Engagement	B-X
of	B-X
TCRαβ	B-X
with	B-X
an	B-X
antigen	B-X
peptide	B-X
presented	B-X
on	B-X
the	B-X
MHC	B-X
leads	B-X
to	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
the	B-X
immunoreceptor	B-X
tyrosine-based	B-X
activation	B-X
motif	B-X
(	B-X
ITAM	B-X
)	B-X
in	B-X
CD3	B-X
cytoplasmic	B-X
domains	B-X
(	B-X
CDs	B-X
)	B-X
,	B-X
thus	B-X
translating	B-X
extracellular	B-X
binding	B-X
kinetics	B-X
to	B-X
intracellular	B-X
signaling	B-X
events	B-X
.	B-X
Whether	B-X
conformational	B-X
change	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
transmembrane	B-X
signal	B-X
transduction	B-X
of	B-X
TCR	B-X
is	B-X
under	B-X
debate	B-X
.	B-X
Attracted	B-X
by	B-X
the	B-X
complexity	B-X
and	B-X
functional	B-X
importance	B-X
of	B-X
TCR	B-X
,	B-X
many	B-X
groups	B-X
have	B-X
been	B-X
studying	B-X
TCR	B-X
structure	B-X
and	B-X
triggering	B-X
for	B-X
decades	B-X
using	B-X
diverse	B-X
biochemical	B-X
and	B-X
biophysical	B-X
tools	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
synthesize	B-X
these	B-X
structural	B-X
studies	B-X
and	B-X
discuss	B-X
the	B-X
relevance	B-X
of	B-X
the	B-X
conformational	B-X
change	B-X
model	B-X
in	B-X
TCR	B-X
triggering	B-X
.	B-X

Recently	O
,	O
several	O
groups	O
have	O
described	O
marked	O
alterations	O
in	O
signal	O
transduction	O
elements	O
in	O
T	O
cells	O
from	O
cancer	O
patients	O
or	O
in	O
mice	O
bearing	O
tumor	O
for	O
a	O
few	O
weeks	O
(	O
>	O
26	O
days	O
)	O
.	O
<EOS>	B-X
The	B-X
TCR	B-X
alpha	B-X
beta	B-X
or	B-X
-gamma	B-X
delta	B-X
chains	B-X
bind	B-X
the	B-X
peptide	B-X
ligand	B-X
,	B-X
whereas	B-X
the	B-X
associated	B-X
CD3	B-X
delta	B-X
epsilon	B-X
gamma	B-X
and	B-X
TCR	B-X
zeta	B-X
subunits	B-X
couple	B-X
the	B-X
TCR	B-X
to	B-X
intracellular	B-X
signal	B-X
transduction	B-X
components	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
groups	B-X
have	B-X
described	B-X
marked	B-X
alterations	B-X
in	B-X
signal	B-X
transduction	B-X
elements	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
cancer	B-X
patients	B-X
or	B-X
in	B-X
mice	B-X
bearing	B-X
tumor	B-X
for	B-X
a	B-X
few	B-X
weeks	B-X
(	B-X
>	B-X
26	B-X
days	B-X
)	B-X
.	B-X
The	B-X
sequence	B-X
in	B-X
which	B-X
these	B-X
alterations	B-X
develop	B-X
is	B-X
unknown	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
explore	B-X
the	B-X
kinetics	B-X
of	B-X
the	B-X
development	B-X
of	B-X
alterations	B-X
in	B-X
signal	B-X
transduction	B-X
molecules	B-X
(	B-X
TCR	B-X
zeta	B-X
chain	B-X
,	B-X
NF	B-X
kappaB	B-X
family	B-X
proteins	B-X
,	B-X
and	B-X
tyrosine	B-X
kinase	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
)	B-X
in	B-X
mice	B-X
bearing	B-X
MC38	B-X
colon	B-X
adenocarcinoma	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
alterations	B-X
in	B-X
NF	B-X
kappaB	B-X
family	B-X
proteins	B-X
,	B-X
specifically	B-X
the	B-X
failure	B-X
of	B-X
p65	B-X
translocation	B-X
to	B-X
the	B-X
nucleus	B-X
,	B-X
occur	B-X
earlier	B-X
and	B-X
more	B-X
frequently	B-X
than	B-X
the	B-X
decrease	B-X
in	B-X
zeta-chain	B-X
.	B-X
These	B-X
initial	B-X
changes	B-X
are	B-X
followed	B-X
by	B-X
the	B-X
eventual	B-X
loss	B-X
of	B-X
TCR	B-X
zeta	B-X
chain	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
and	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
cytotoxic	B-X
function	B-X
.	B-X

The	O
sequence	O
in	O
which	O
these	O
alterations	O
develop	O
is	O
unknown	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
developmental	B-X
landscapes	B-X
of	B-X
human	B-X
spermatogenesis	B-X
remain	B-X
unknown	B-X
.	B-X
A	B-X
hierarchical	B-X
model	B-X
was	B-X
established	B-X
,	B-X
which	B-X
was	B-X
characterized	B-X
by	B-X
the	B-X
sequential	B-X
and	B-X
stepwise	B-X
development	B-X
of	B-X
three	B-X
spermatogonia	B-X
subtypes	B-X
,	B-X
seven	B-X
spermatocyte	B-X
subtypes	B-X
,	B-X
and	B-X
four	B-X
spermatid	B-X
subtypes	B-X
.	B-X
Circular	B-X
RNAs	B-X
(	B-X
circRNAs	B-X
)	B-X
constitute	B-X
a	B-X
family	B-X
of	B-X
transcripts	B-X
with	B-X
unique	B-X
structures	B-X
and	B-X
still	B-X
largely	B-X
unknown	B-X
functions	B-X
.	B-X
Gene-based	B-X
diagnosis	B-X
classifies	B-X
variants	B-X
that	B-X
alter	B-X
canonical	B-X
splice	B-X
signals	B-X
as	B-X
pathogenic	B-X
,	B-X
but	B-X
due	B-X
to	B-X
imperfect	B-X
understanding	B-X
of	B-X
RNA	B-X
splice	B-X
signals	B-X
other	B-X
variants	B-X
that	B-X
may	B-X
create	B-X
or	B-X
eliminate	B-X
splice	B-X
sites	B-X
are	B-X
often	B-X
clinically	B-X
classified	B-X
as	B-X
variants	B-X
of	B-X
unknown	B-X
significance	B-X
(	B-X
VUS	B-X
)	B-X
.	B-X
To	B-X
improve	B-X
recognition	B-X
of	B-X
pathogenic	B-X
splice-altering	B-X
variants	B-X
in	B-X
AD	B-X
disorders	B-X
,	B-X
we	B-X
used	B-X
computational	B-X
tools	B-X
to	B-X
prioritize	B-X
VUS	B-X
and	B-X
developed	B-X
a	B-X
cell-based	B-X
minigene	B-X
splicing	B-X
assay	B-X
to	B-X
confirm	B-X
aberrant	B-X
splicing	B-X
.	B-X

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
kinetics	O
of	O
the	O
development	O
of	O
alterations	O
in	O
signal	O
transduction	O
molecules	O
(	O
TCR	B-Protein
zeta	I-Protein
chain	I-Protein
,	O
NF	O
kappaB	O
family	O
proteins	O
,	O
and	O
tyrosine	B-Protein
kinase	I-Protein
p56	I-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
)	O
in	O
mice	O
bearing	O
MC38	O
colon	O
adenocarcinoma	O
.	O
<EOS>	B-X
The	B-X
TCR	B-X
alpha	B-X
beta	B-X
or	B-X
-gamma	B-X
delta	B-X
chains	B-X
bind	B-X
the	B-X
peptide	B-X
ligand	B-X
,	B-X
whereas	B-X
the	B-X
associated	B-X
CD3	B-X
delta	B-X
epsilon	B-X
gamma	B-X
and	B-X
TCR	B-X
zeta	B-X
subunits	B-X
couple	B-X
the	B-X
TCR	B-X
to	B-X
intracellular	B-X
signal	B-X
transduction	B-X
components	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
groups	B-X
have	B-X
described	B-X
marked	B-X
alterations	B-X
in	B-X
signal	B-X
transduction	B-X
elements	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
cancer	B-X
patients	B-X
or	B-X
in	B-X
mice	B-X
bearing	B-X
tumor	B-X
for	B-X
a	B-X
few	B-X
weeks	B-X
(	B-X
>	B-X
26	B-X
days	B-X
)	B-X
.	B-X
The	B-X
sequence	B-X
in	B-X
which	B-X
these	B-X
alterations	B-X
develop	B-X
is	B-X
unknown	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
explore	B-X
the	B-X
kinetics	B-X
of	B-X
the	B-X
development	B-X
of	B-X
alterations	B-X
in	B-X
signal	B-X
transduction	B-X
molecules	B-X
(	B-X
TCR	B-X
zeta	B-X
chain	B-X
,	B-X
NF	B-X
kappaB	B-X
family	B-X
proteins	B-X
,	B-X
and	B-X
tyrosine	B-X
kinase	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
)	B-X
in	B-X
mice	B-X
bearing	B-X
MC38	B-X
colon	B-X
adenocarcinoma	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
alterations	B-X
in	B-X
NF	B-X
kappaB	B-X
family	B-X
proteins	B-X
,	B-X
specifically	B-X
the	B-X
failure	B-X
of	B-X
p65	B-X
translocation	B-X
to	B-X
the	B-X
nucleus	B-X
,	B-X
occur	B-X
earlier	B-X
and	B-X
more	B-X
frequently	B-X
than	B-X
the	B-X
decrease	B-X
in	B-X
zeta-chain	B-X
.	B-X
These	B-X
initial	B-X
changes	B-X
are	B-X
followed	B-X
by	B-X
the	B-X
eventual	B-X
loss	B-X
of	B-X
TCR	B-X
zeta	B-X
chain	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
and	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
cytotoxic	B-X
function	B-X
.	B-X
An	B-X
increased	B-X
rate	B-X
of	B-X
lysosomal	B-X
degradation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
mechanisms	B-X
responsible	B-X
for	B-X
the	B-X
loss	B-X
of	B-X
zeta-chain	B-X
.	B-X

The	O
results	O
demonstrate	O
that	O
alterations	O
in	O
NF	O
kappaB	O
family	O
proteins	O
,	O
specifically	O
the	O
failure	O
of	O
p65	B-Protein
translocation	O
to	O
the	O
nucleus	O
,	O
occur	O
earlier	O
and	O
more	O
frequently	O
than	O
the	O
decrease	O
in	O
zeta	O
-	O
chain	O
.	O

These	O
defects	O
are	O
paralleled	O
by	O
an	O
impaired	O
ability	O
to	O
produce	O
Th1	O
cytokines	O
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
.	O
<EOS>	B-X
The	B-X
TCR	B-X
alpha	B-X
beta	B-X
or	B-X
-gamma	B-X
delta	B-X
chains	B-X
bind	B-X
the	B-X
peptide	B-X
ligand	B-X
,	B-X
whereas	B-X
the	B-X
associated	B-X
CD3	B-X
delta	B-X
epsilon	B-X
gamma	B-X
and	B-X
TCR	B-X
zeta	B-X
subunits	B-X
couple	B-X
the	B-X
TCR	B-X
to	B-X
intracellular	B-X
signal	B-X
transduction	B-X
components	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
groups	B-X
have	B-X
described	B-X
marked	B-X
alterations	B-X
in	B-X
signal	B-X
transduction	B-X
elements	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
cancer	B-X
patients	B-X
or	B-X
in	B-X
mice	B-X
bearing	B-X
tumor	B-X
for	B-X
a	B-X
few	B-X
weeks	B-X
(	B-X
>	B-X
26	B-X
days	B-X
)	B-X
.	B-X
These	B-X
defects	B-X
are	B-X
paralleled	B-X
by	B-X
an	B-X
impaired	B-X
ability	B-X
to	B-X
produce	B-X
Th1	B-X
cytokines	B-X
(	B-X
IL-2	B-X
and	B-X
IFN-gamma	B-X
)	B-X
.	B-X

These	O
initial	O
changes	O
are	O
followed	O
by	O
the	O
eventual	O
loss	O
of	O
TCR	B-Protein
zeta	I-Protein
chain	I-Protein
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
and	O
a	O
marked	O
decrease	O
in	O
cytotoxic	O
function	O
.	O

An	O
increased	O
rate	O
of	O
lysosomal	O
degradation	O
is	O
one	O
of	O
the	O
mechanisms	O
responsible	O
for	O
the	O
loss	O
of	O
zeta	O
-	O
chain	O
.	O
<EOS>	B-X
The	B-X
TCR	B-X
alpha	B-X
beta	B-X
or	B-X
-gamma	B-X
delta	B-X
chains	B-X
bind	B-X
the	B-X
peptide	B-X
ligand	B-X
,	B-X
whereas	B-X
the	B-X
associated	B-X
CD3	B-X
delta	B-X
epsilon	B-X
gamma	B-X
and	B-X
TCR	B-X
zeta	B-X
subunits	B-X
couple	B-X
the	B-X
TCR	B-X
to	B-X
intracellular	B-X
signal	B-X
transduction	B-X
components	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
explore	B-X
the	B-X
kinetics	B-X
of	B-X
the	B-X
development	B-X
of	B-X
alterations	B-X
in	B-X
signal	B-X
transduction	B-X
molecules	B-X
(	B-X
TCR	B-X
zeta	B-X
chain	B-X
,	B-X
NF	B-X
kappaB	B-X
family	B-X
proteins	B-X
,	B-X
and	B-X
tyrosine	B-X
kinase	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
)	B-X
in	B-X
mice	B-X
bearing	B-X
MC38	B-X
colon	B-X
adenocarcinoma	B-X
.	B-X
The	B-X
results	B-X
demonstrate	B-X
that	B-X
alterations	B-X
in	B-X
NF	B-X
kappaB	B-X
family	B-X
proteins	B-X
,	B-X
specifically	B-X
the	B-X
failure	B-X
of	B-X
p65	B-X
translocation	B-X
to	B-X
the	B-X
nucleus	B-X
,	B-X
occur	B-X
earlier	B-X
and	B-X
more	B-X
frequently	B-X
than	B-X
the	B-X
decrease	B-X
in	B-X
zeta-chain	B-X
.	B-X
These	B-X
initial	B-X
changes	B-X
are	B-X
followed	B-X
by	B-X
the	B-X
eventual	B-X
loss	B-X
of	B-X
TCR	B-X
zeta	B-X
chain	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
and	B-X
a	B-X
marked	B-X
decrease	B-X
in	B-X
cytotoxic	B-X
function	B-X
.	B-X
An	B-X
increased	B-X
rate	B-X
of	B-X
lysosomal	B-X
degradation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
mechanisms	B-X
responsible	B-X
for	B-X
the	B-X
loss	B-X
of	B-X
zeta-chain	B-X
.	B-X

An	O
isotype	O
-	O
specific	O
activator	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
that	O
is	O
independent	O
of	O
class	B-Protein
II	I-Protein
transactivator	I-Protein
.	O
<EOS>	B-X
Patients	B-X
with	B-X
one	B-X
type	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
combined	B-X
immunodeficiency	B-X
have	B-X
mutations	B-X
in	B-X
a	B-X
gene	B-X
termed	B-X
class	B-X
II	B-X
transactivator	B-X
(	B-X
CIITA	B-X
)	B-X
,	B-X
which	B-X
coordinately	B-X
controls	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
three	B-X
major	B-X
human	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
HLA-DR	B-X
,	B-X
-DQ	B-X
,	B-X
and	B-X
-DP	B-X
.	B-X
It	B-X
was	B-X
possible	B-X
that	B-X
one	B-X
of	B-X
the	B-X
clone	B-X
13	B-X
CIITA	B-X
alleles	B-X
bore	B-X
a	B-X
mutation	B-X
that	B-X
allowed	B-X
HLA-DQ	B-X
,	B-X
but	B-X
not	B-X
HLA-DR	B-X
or	B-X
-DP	B-X
transcription	B-X
.	B-X
Alternatively	B-X
,	B-X
another	B-X
factor	B-X
,	B-X
distinct	B-X
from	B-X
CIITA	B-X
,	B-X
might	B-X
control	B-X
HLA-DQ	B-X
expression	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
CIITA	B-X
cDNAs	B-X
derived	B-X
by	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
from	B-X
clone	B-X
13	B-X
do	B-X
not	B-X
restore	B-X
expression	B-X
of	B-X
HLA-DQ	B-X
in	B-X
another	B-X
CIITA-deficient	B-X
cell	B-X
line	B-X
,	B-X
RJ2.2.5	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
CIITA	B-X
protein	B-X
is	B-X
detectable	B-X
in	B-X
clone	B-X
13	B-X
nuclear	B-X
extracts	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
HLA-DQ	B-X
isotype-specific	B-X
trans-acting	B-X
factor	B-X
,	B-X
which	B-X
functions	B-X
independently	B-X
of	B-X
CIITA	B-X
.	B-X

Patients	O
with	O
one	O
type	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
combined	O
immunodeficiency	O
have	O
mutations	O
in	O
a	O
gene	O
termed	O
class	B-Protein
II	I-Protein
transactivator	I-Protein
(	O
CIITA	B-Protein
)	O
,	O
which	O
coordinately	O
controls	O
the	O
transcription	O
of	O
the	O
three	O
major	O
human	O
class	O
II	O
genes	O
,	O
HLA	O
-	O
DR	O
,	O
-	O
DQ	O
,	O
and	O
-	O
DP	O
.	O

However	O
,	O
the	O
experimentally	O
derived	O
B	O
-	O
lymphoblastoid	O
cell	O
line	O
,	O
clone	O
13	O
,	O
expresses	O
high	O
levels	O
of	O
HLADQ	O
in	O
the	O
absence	O
of	O
HLA	O
-	O
DR	O
and	O
HLA	O
-	O
DP	O
,	O
despite	O
its	O
mapping	O
by	O
complementation	O
analysis	O
to	O
this	O
group	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
one	B-X
type	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
combined	B-X
immunodeficiency	B-X
have	B-X
mutations	B-X
in	B-X
a	B-X
gene	B-X
termed	B-X
class	B-X
II	B-X
transactivator	B-X
(	B-X
CIITA	B-X
)	B-X
,	B-X
which	B-X
coordinately	B-X
controls	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
three	B-X
major	B-X
human	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
HLA-DR	B-X
,	B-X
-DQ	B-X
,	B-X
and	B-X
-DP	B-X
.	B-X
However	B-X
,	B-X
the	B-X
experimentally	B-X
derived	B-X
B-lymphoblastoid	B-X
cell	B-X
line	B-X
,	B-X
clone	B-X
13	B-X
,	B-X
expresses	B-X
high	B-X
levels	B-X
of	B-X
HLADQ	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
HLA-DR	B-X
and	B-X
HLA-DP	B-X
,	B-X
despite	B-X
its	B-X
mapping	B-X
by	B-X
complementation	B-X
analysis	B-X
to	B-X
this	B-X
group	B-X
.	B-X
It	B-X
was	B-X
possible	B-X
that	B-X
one	B-X
of	B-X
the	B-X
clone	B-X
13	B-X
CIITA	B-X
alleles	B-X
bore	B-X
a	B-X
mutation	B-X
that	B-X
allowed	B-X
HLA-DQ	B-X
,	B-X
but	B-X
not	B-X
HLA-DR	B-X
or	B-X
-DP	B-X
transcription	B-X
.	B-X
Alternatively	B-X
,	B-X
another	B-X
factor	B-X
,	B-X
distinct	B-X
from	B-X
CIITA	B-X
,	B-X
might	B-X
control	B-X
HLA-DQ	B-X
expression	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
CIITA	B-X
cDNAs	B-X
derived	B-X
by	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
from	B-X
clone	B-X
13	B-X
do	B-X
not	B-X
restore	B-X
expression	B-X
of	B-X
HLA-DQ	B-X
in	B-X
another	B-X
CIITA-deficient	B-X
cell	B-X
line	B-X
,	B-X
RJ2.2.5	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
CIITA	B-X
protein	B-X
is	B-X
detectable	B-X
in	B-X
clone	B-X
13	B-X
nuclear	B-X
extracts	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
somatic	B-X
cell	B-X
fusion	B-X
between	B-X
clone	B-X
13	B-X
and	B-X
RJ2.2.5	B-X
restored	B-X
expression	B-X
of	B-X
the	B-X
HLA-DQ	B-X
haplotype	B-X
encoded	B-X
by	B-X
the	B-X
RJ2.2.5	B-X
DQB	B-X
gene	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
HLA-DQ	B-X
isotype-specific	B-X
trans-acting	B-X
factor	B-X
,	B-X
which	B-X
functions	B-X
independently	B-X
of	B-X
CIITA	B-X
.	B-X

It	O
was	O
possible	O
that	O
one	O
of	O
the	O
clone	O
13	O
CIITA	B-Protein
alleles	O
bore	O
a	O
mutation	O
that	O
allowed	O
HLA	O
-	O
DQ	O
,	O
but	O
not	O
HLA	O
-	O
DR	O
or	O
-	O
DP	O
transcription	O
.	O
<EOS>	B-X
Type	B-X
I	B-X
interferons	B-X
(	B-X
IFNs	B-X
)	B-X
(	B-X
IFN-α	B-X
,	B-X
IFN-β	B-X
)	B-X
and	B-X
type	B-X
III	B-X
IFNs	B-X
(	B-X
IFN-λ	B-X
)	B-X
share	B-X
many	B-X
properties	B-X
,	B-X
including	B-X
induction	B-X
by	B-X
viral	B-X
infection	B-X
,	B-X
activation	B-X
of	B-X
shared	B-X
signaling	B-X
pathways	B-X
,	B-X
and	B-X
transcriptional	B-X
programs	B-X
.	B-X
The	B-X
long	B-X
non-coding	B-X
RNA	B-X
X-inactive	B-X
specific	B-X
transcript	B-X
(	B-X
XIST	B-X
)	B-X
mediates	B-X
the	B-X
transcriptional	B-X
silencing	B-X
of	B-X
genes	B-X
on	B-X
the	B-X
X	B-X
chromosome	B-X
.	B-X
We	B-X
identify	B-X
rules	B-X
for	B-X
specific	B-X
targeting	B-X
of	B-X
transcriptional	B-X
repressors	B-X
(	B-X
CRISPRi	B-X
)	B-X
,	B-X
typically	B-X
achieving	B-X
90	B-X
%	B-X
-99	B-X
%	B-X
knockdown	B-X
with	B-X
minimal	B-X
off-target	B-X
effects	B-X
,	B-X
and	B-X
activators	B-X
(	B-X
CRISPRa	B-X
)	B-X
to	B-X
endogenous	B-X
genes	B-X
via	B-X
endonuclease-deficient	B-X
Cas9	B-X
.	B-X
The	B-X
Notch	B-X
protein	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
mechanistically	B-X
direct	B-X
transmembrane	B-X
receptors-the	B-X
intracellular	B-X
domain	B-X
contains	B-X
a	B-X
transcriptional	B-X
regulator	B-X
that	B-X
is	B-X
released	B-X
from	B-X
the	B-X
membrane	B-X
when	B-X
engagement	B-X
of	B-X
the	B-X
cognate	B-X
extracellular	B-X
ligand	B-X
induces	B-X
intramembrane	B-X
proteolysis	B-X
.	B-X
We	B-X
find	B-X
that	B-X
chimeric	B-X
forms	B-X
of	B-X
Notch	B-X
,	B-X
in	B-X
which	B-X
both	B-X
the	B-X
extracellular	B-X
sensor	B-X
module	B-X
and	B-X
the	B-X
intracellular	B-X
transcriptional	B-X
module	B-X
are	B-X
replaced	B-X
with	B-X
heterologous	B-X
protein	B-X
domains	B-X
,	B-X
can	B-X
serve	B-X
as	B-X
a	B-X
general	B-X
platform	B-X
for	B-X
generating	B-X
novel	B-X
cell-cell	B-X
contact	B-X
signaling	B-X
pathways	B-X
.	B-X

Alternatively	O
,	O
another	O
factor	O
,	O
distinct	O
from	O
CIITA	B-Protein
,	O
might	O
control	O
HLA	O
-	O
DQ	O
expression	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
one	B-X
type	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
combined	B-X
immunodeficiency	B-X
have	B-X
mutations	B-X
in	B-X
a	B-X
gene	B-X
termed	B-X
class	B-X
II	B-X
transactivator	B-X
(	B-X
CIITA	B-X
)	B-X
,	B-X
which	B-X
coordinately	B-X
controls	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
three	B-X
major	B-X
human	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
HLA-DR	B-X
,	B-X
-DQ	B-X
,	B-X
and	B-X
-DP	B-X
.	B-X
However	B-X
,	B-X
the	B-X
experimentally	B-X
derived	B-X
B-lymphoblastoid	B-X
cell	B-X
line	B-X
,	B-X
clone	B-X
13	B-X
,	B-X
expresses	B-X
high	B-X
levels	B-X
of	B-X
HLADQ	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
HLA-DR	B-X
and	B-X
HLA-DP	B-X
,	B-X
despite	B-X
its	B-X
mapping	B-X
by	B-X
complementation	B-X
analysis	B-X
to	B-X
this	B-X
group	B-X
.	B-X
It	B-X
was	B-X
possible	B-X
that	B-X
one	B-X
of	B-X
the	B-X
clone	B-X
13	B-X
CIITA	B-X
alleles	B-X
bore	B-X
a	B-X
mutation	B-X
that	B-X
allowed	B-X
HLA-DQ	B-X
,	B-X
but	B-X
not	B-X
HLA-DR	B-X
or	B-X
-DP	B-X
transcription	B-X
.	B-X
Alternatively	B-X
,	B-X
another	B-X
factor	B-X
,	B-X
distinct	B-X
from	B-X
CIITA	B-X
,	B-X
might	B-X
control	B-X
HLA-DQ	B-X
expression	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
CIITA	B-X
cDNAs	B-X
derived	B-X
by	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
from	B-X
clone	B-X
13	B-X
do	B-X
not	B-X
restore	B-X
expression	B-X
of	B-X
HLA-DQ	B-X
in	B-X
another	B-X
CIITA-deficient	B-X
cell	B-X
line	B-X
,	B-X
RJ2.2.5	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
CIITA	B-X
protein	B-X
is	B-X
detectable	B-X
in	B-X
clone	B-X
13	B-X
nuclear	B-X
extracts	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
somatic	B-X
cell	B-X
fusion	B-X
between	B-X
clone	B-X
13	B-X
and	B-X
RJ2.2.5	B-X
restored	B-X
expression	B-X
of	B-X
the	B-X
HLA-DQ	B-X
haplotype	B-X
encoded	B-X
by	B-X
the	B-X
RJ2.2.5	B-X
DQB	B-X
gene	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
HLA-DQ	B-X
isotype-specific	B-X
trans-acting	B-X
factor	B-X
,	B-X
which	B-X
functions	B-X
independently	B-X
of	B-X
CIITA	B-X
.	B-X

We	O
report	O
here	O
that	O
ectopic	O
expression	O
of	O
CIITA	B-Protein
cDNAs	O
derived	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
from	O
clone	O
13	O
do	O
not	O
restore	O
expression	O
of	O
HLA	O
-	O
DQ	O
in	O
another	O
CIITA	B-Protein
-	O
deficient	O
cell	O
line	O
,	O
RJ2	O
.	O
2	O
.	O
5	O
.	O

In	O
addition	O
,	O
no	O
CIITA	B-Protein
protein	O
is	O
detectable	O
in	O
clone	O
13	O
nuclear	O
extracts	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
one	B-X
type	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
combined	B-X
immunodeficiency	B-X
have	B-X
mutations	B-X
in	B-X
a	B-X
gene	B-X
termed	B-X
class	B-X
II	B-X
transactivator	B-X
(	B-X
CIITA	B-X
)	B-X
,	B-X
which	B-X
coordinately	B-X
controls	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
three	B-X
major	B-X
human	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
HLA-DR	B-X
,	B-X
-DQ	B-X
,	B-X
and	B-X
-DP	B-X
.	B-X
However	B-X
,	B-X
the	B-X
experimentally	B-X
derived	B-X
B-lymphoblastoid	B-X
cell	B-X
line	B-X
,	B-X
clone	B-X
13	B-X
,	B-X
expresses	B-X
high	B-X
levels	B-X
of	B-X
HLADQ	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
HLA-DR	B-X
and	B-X
HLA-DP	B-X
,	B-X
despite	B-X
its	B-X
mapping	B-X
by	B-X
complementation	B-X
analysis	B-X
to	B-X
this	B-X
group	B-X
.	B-X
It	B-X
was	B-X
possible	B-X
that	B-X
one	B-X
of	B-X
the	B-X
clone	B-X
13	B-X
CIITA	B-X
alleles	B-X
bore	B-X
a	B-X
mutation	B-X
that	B-X
allowed	B-X
HLA-DQ	B-X
,	B-X
but	B-X
not	B-X
HLA-DR	B-X
or	B-X
-DP	B-X
transcription	B-X
.	B-X
Alternatively	B-X
,	B-X
another	B-X
factor	B-X
,	B-X
distinct	B-X
from	B-X
CIITA	B-X
,	B-X
might	B-X
control	B-X
HLA-DQ	B-X
expression	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
CIITA	B-X
cDNAs	B-X
derived	B-X
by	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
from	B-X
clone	B-X
13	B-X
do	B-X
not	B-X
restore	B-X
expression	B-X
of	B-X
HLA-DQ	B-X
in	B-X
another	B-X
CIITA-deficient	B-X
cell	B-X
line	B-X
,	B-X
RJ2.2.5	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
CIITA	B-X
protein	B-X
is	B-X
detectable	B-X
in	B-X
clone	B-X
13	B-X
nuclear	B-X
extracts	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
somatic	B-X
cell	B-X
fusion	B-X
between	B-X
clone	B-X
13	B-X
and	B-X
RJ2.2.5	B-X
restored	B-X
expression	B-X
of	B-X
the	B-X
HLA-DQ	B-X
haplotype	B-X
encoded	B-X
by	B-X
the	B-X
RJ2.2.5	B-X
DQB	B-X
gene	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
HLA-DQ	B-X
isotype-specific	B-X
trans-acting	B-X
factor	B-X
,	B-X
which	B-X
functions	B-X
independently	B-X
of	B-X
CIITA	B-X
.	B-X

In	O
contrast	O
,	O
somatic	O
cell	O
fusion	O
between	O
clone	O
13	O
and	O
RJ2	O
.	O
2	O
.	O
5	O
restored	O
expression	O
of	O
the	O
HLA	O
-	O
DQ	O
haplotype	O
encoded	O
by	O
the	O
RJ2	O
.	O
2	O
.	O
5	O
DQB	O
gene	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
one	B-X
type	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
combined	B-X
immunodeficiency	B-X
have	B-X
mutations	B-X
in	B-X
a	B-X
gene	B-X
termed	B-X
class	B-X
II	B-X
transactivator	B-X
(	B-X
CIITA	B-X
)	B-X
,	B-X
which	B-X
coordinately	B-X
controls	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
three	B-X
major	B-X
human	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
HLA-DR	B-X
,	B-X
-DQ	B-X
,	B-X
and	B-X
-DP	B-X
.	B-X
However	B-X
,	B-X
the	B-X
experimentally	B-X
derived	B-X
B-lymphoblastoid	B-X
cell	B-X
line	B-X
,	B-X
clone	B-X
13	B-X
,	B-X
expresses	B-X
high	B-X
levels	B-X
of	B-X
HLADQ	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
HLA-DR	B-X
and	B-X
HLA-DP	B-X
,	B-X
despite	B-X
its	B-X
mapping	B-X
by	B-X
complementation	B-X
analysis	B-X
to	B-X
this	B-X
group	B-X
.	B-X
It	B-X
was	B-X
possible	B-X
that	B-X
one	B-X
of	B-X
the	B-X
clone	B-X
13	B-X
CIITA	B-X
alleles	B-X
bore	B-X
a	B-X
mutation	B-X
that	B-X
allowed	B-X
HLA-DQ	B-X
,	B-X
but	B-X
not	B-X
HLA-DR	B-X
or	B-X
-DP	B-X
transcription	B-X
.	B-X
Alternatively	B-X
,	B-X
another	B-X
factor	B-X
,	B-X
distinct	B-X
from	B-X
CIITA	B-X
,	B-X
might	B-X
control	B-X
HLA-DQ	B-X
expression	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
CIITA	B-X
cDNAs	B-X
derived	B-X
by	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
from	B-X
clone	B-X
13	B-X
do	B-X
not	B-X
restore	B-X
expression	B-X
of	B-X
HLA-DQ	B-X
in	B-X
another	B-X
CIITA-deficient	B-X
cell	B-X
line	B-X
,	B-X
RJ2.2.5	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
CIITA	B-X
protein	B-X
is	B-X
detectable	B-X
in	B-X
clone	B-X
13	B-X
nuclear	B-X
extracts	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
somatic	B-X
cell	B-X
fusion	B-X
between	B-X
clone	B-X
13	B-X
and	B-X
RJ2.2.5	B-X
restored	B-X
expression	B-X
of	B-X
the	B-X
HLA-DQ	B-X
haplotype	B-X
encoded	B-X
by	B-X
the	B-X
RJ2.2.5	B-X
DQB	B-X
gene	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
HLA-DQ	B-X
isotype-specific	B-X
trans-acting	B-X
factor	B-X
,	B-X
which	B-X
functions	B-X
independently	B-X
of	B-X
CIITA	B-X
.	B-X

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
the	O
existence	O
of	O
an	O
HLA	O
-	O
DQ	O
isotype	O
-	O
specific	O
trans	O
-	O
acting	O
factor	O
,	O
which	O
functions	O
independently	O
of	O
CIITA	B-Protein
.	O
<EOS>	B-X
Patients	B-X
with	B-X
one	B-X
type	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
combined	B-X
immunodeficiency	B-X
have	B-X
mutations	B-X
in	B-X
a	B-X
gene	B-X
termed	B-X
class	B-X
II	B-X
transactivator	B-X
(	B-X
CIITA	B-X
)	B-X
,	B-X
which	B-X
coordinately	B-X
controls	B-X
the	B-X
transcription	B-X
of	B-X
the	B-X
three	B-X
major	B-X
human	B-X
class	B-X
II	B-X
genes	B-X
,	B-X
HLA-DR	B-X
,	B-X
-DQ	B-X
,	B-X
and	B-X
-DP	B-X
.	B-X
However	B-X
,	B-X
the	B-X
experimentally	B-X
derived	B-X
B-lymphoblastoid	B-X
cell	B-X
line	B-X
,	B-X
clone	B-X
13	B-X
,	B-X
expresses	B-X
high	B-X
levels	B-X
of	B-X
HLADQ	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
HLA-DR	B-X
and	B-X
HLA-DP	B-X
,	B-X
despite	B-X
its	B-X
mapping	B-X
by	B-X
complementation	B-X
analysis	B-X
to	B-X
this	B-X
group	B-X
.	B-X
It	B-X
was	B-X
possible	B-X
that	B-X
one	B-X
of	B-X
the	B-X
clone	B-X
13	B-X
CIITA	B-X
alleles	B-X
bore	B-X
a	B-X
mutation	B-X
that	B-X
allowed	B-X
HLA-DQ	B-X
,	B-X
but	B-X
not	B-X
HLA-DR	B-X
or	B-X
-DP	B-X
transcription	B-X
.	B-X
Alternatively	B-X
,	B-X
another	B-X
factor	B-X
,	B-X
distinct	B-X
from	B-X
CIITA	B-X
,	B-X
might	B-X
control	B-X
HLA-DQ	B-X
expression	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
CIITA	B-X
cDNAs	B-X
derived	B-X
by	B-X
reverse	B-X
transcriptase	B-X
polymerase	B-X
chain	B-X
reaction	B-X
from	B-X
clone	B-X
13	B-X
do	B-X
not	B-X
restore	B-X
expression	B-X
of	B-X
HLA-DQ	B-X
in	B-X
another	B-X
CIITA-deficient	B-X
cell	B-X
line	B-X
,	B-X
RJ2.2.5	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
CIITA	B-X
protein	B-X
is	B-X
detectable	B-X
in	B-X
clone	B-X
13	B-X
nuclear	B-X
extracts	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
somatic	B-X
cell	B-X
fusion	B-X
between	B-X
clone	B-X
13	B-X
and	B-X
RJ2.2.5	B-X
restored	B-X
expression	B-X
of	B-X
the	B-X
HLA-DQ	B-X
haplotype	B-X
encoded	B-X
by	B-X
the	B-X
RJ2.2.5	B-X
DQB	B-X
gene	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
HLA-DQ	B-X
isotype-specific	B-X
trans-acting	B-X
factor	B-X
,	B-X
which	B-X
functions	B-X
independently	B-X
of	B-X
CIITA	B-X
.	B-X

Induction	O
of	O
cytokine	O
expression	O
in	O
leukocytes	O
by	O
binding	O
of	O
thrombin	O
-	O
stimulated	O
platelets	O
.	O
<EOS>	B-X
Activated	B-X
platelets	B-X
tether	B-X
and	B-X
activate	B-X
myeloid	B-X
leukocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
potential	B-X
relevance	B-X
of	B-X
this	B-X
mechanism	B-X
in	B-X
acute	B-X
myocardial	B-X
infarction	B-X
(	B-X
AMI	B-X
)	B-X
,	B-X
we	B-X
examined	B-X
cytokine	B-X
induction	B-X
by	B-X
leukocyte-platelet	B-X
adhesion	B-X
and	B-X
the	B-X
occurrence	B-X
of	B-X
leukocyte-platelet	B-X
conjugates	B-X
in	B-X
patients	B-X
with	B-X
AMI	B-X
.	B-X
Acute	B-X
coronary	B-X
diseases	B-X
are	B-X
characterized	B-X
by	B-X
elevated	B-X
levels	B-X
of	B-X
circulating	B-X
platelet-leukocyte	B-X
complexes	B-X
,	B-X
raising	B-X
the	B-X
possibility	B-X
that	B-X
proinflammatory	B-X
processes	B-X
might	B-X
be	B-X
initiated	B-X
in	B-X
leukocytes	B-X
after	B-X
platelet	B-X
adhesion	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
the	B-X
mechanism	B-X
of	B-X
platelet	B-X
binding	B-X
to	B-X
polymorphonuclear	B-X
leukocytes	B-X
,	B-X
monocytes	B-X
,	B-X
and	B-X
monocyte	B-X
subsets	B-X
and	B-X
investigated	B-X
the	B-X
potential	B-X
functional	B-X
consequences	B-X
of	B-X
monocyte	B-X
binding	B-X
to	B-X
minimally	B-X
activated	B-X
or	B-X
thrombin-activated	B-X
platelets	B-X
.	B-X

BACKGROUND	O
:	O
Activated	O
platelets	O
tether	O
and	O
activate	O
myeloid	O
leukocytes	O
.	O
<EOS>	B-X
Activated	B-X
platelets	B-X
tether	B-X
and	B-X
activate	B-X
myeloid	B-X
leukocytes	B-X
.	B-X

To	O
investigate	O
the	O
potential	O
relevance	O
of	O
this	O
mechanism	O
in	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
,	O
we	O
examined	O
cytokine	O
induction	O
by	O
leukocyte	O
-	O
platelet	O
adhesion	O
and	O
the	O
occurrence	O
of	O
leukocyte	O
-	O
platelet	O
conjugates	O
in	O
patients	O
with	O
AMI	O
.	O
<EOS>	B-X
Activated	B-X
platelets	B-X
tether	B-X
and	B-X
activate	B-X
myeloid	B-X
leukocytes	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
potential	B-X
relevance	B-X
of	B-X
this	B-X
mechanism	B-X
in	B-X
acute	B-X
myocardial	B-X
infarction	B-X
(	B-X
AMI	B-X
)	B-X
,	B-X
we	B-X
examined	B-X
cytokine	B-X
induction	B-X
by	B-X
leukocyte-platelet	B-X
adhesion	B-X
and	B-X
the	B-X
occurrence	B-X
of	B-X
leukocyte-platelet	B-X
conjugates	B-X
in	B-X
patients	B-X
with	B-X
AMI	B-X
.	B-X

METHODS	O
AND	O
RESULTS	O
:	O
We	O
obtained	O
peripheral	O
venous	O
blood	O
samples	O
in	O
20	O
patients	O
with	O
AMI	O
before	O
and	O
daily	O
for	O
5	O
days	O
after	O
direct	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
and	O
in	O
20	O
patients	O
undergoing	O
elective	O
PTCA	O
.	O
<EOS>	B-X
To	B-X
investigate	B-X
the	B-X
potential	B-X
relevance	B-X
of	B-X
this	B-X
mechanism	B-X
in	B-X
acute	B-X
myocardial	B-X
infarction	B-X
(	B-X
AMI	B-X
)	B-X
,	B-X
we	B-X
examined	B-X
cytokine	B-X
induction	B-X
by	B-X
leukocyte-platelet	B-X
adhesion	B-X
and	B-X
the	B-X
occurrence	B-X
of	B-X
leukocyte-platelet	B-X
conjugates	B-X
in	B-X
patients	B-X
with	B-X
AMI	B-X
.	B-X

Throughout	O
the	O
study	O
period	O
,	O
CD41	B-Protein
immunofluorescence	O
of	O
leukocytes	O
(	O
flow	O
cytometry	O
)	O
revealed	O
increased	O
leukocyte	O
-	O
platelet	O
adhesion	O
in	O
patients	O
with	O
AMI	O
compared	O
with	O
control	O
patients	O
(	O
mean	O
+	O
/	O
-	O
SE	O
of	O
fluorescence	O
[	O
channels	O
]	O
before	O
PTCA	O
:	O
77	O
+	O
/	O
-	O
16	O
versus	O
35	O
+	O
/	O
-	O
9	O
;	O
P	O
=	O
.	O
003	O
)	O
.	O

In	O
vitro	O
,	O
thrombin	B-Protein
-	O
stimulated	O
fixed	O
platelets	O
bound	O
to	O
neutrophils	O
and	O
monocytes	O
.	O
<EOS>	B-X
Activated	B-X
platelets	B-X
tether	B-X
and	B-X
activate	B-X
myeloid	B-X
leukocytes	B-X
.	B-X

Within	O
2	O
hours	O
,	O
this	O
resulted	O
in	O
increased	O
mRNA	O
for	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
,	I-Protein
1	I-Protein
beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
and	O
monocyte	B-Protein
chemoattractant	I-Protein
protein	I-Protein
(	I-Protein
MCP	I-Protein
)	I-Protein
-	I-Protein
1	I-Protein
in	O
unfractionated	O
leukocytes	O
.	O
<EOS>	B-X
Activated	B-X
platelets	B-X
tether	B-X
and	B-X
activate	B-X
myeloid	B-X
leukocytes	B-X
.	B-X

After	O
4	O
hours	O
,	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
and	O
IL	B-Protein
-	I-Protein
8	I-Protein
concentration	O
of	O
the	O
cell	O
-	O
free	O
supernatant	O
had	O
increased	O
by	O
268	O
+	O
/	O
-	O
36	O
%	O
and	O
210	O
+	O
/	O
-	O
7	O
%	O
,	O
respectively	O
,	O
and	O
cellular	O
MCP	B-Protein
-	I-Protein
1	I-Protein
content	O
had	O
increased	O
by	O
170	O
+	O
/	O
-	O
8	O
%	O
.	O

Addition	O
of	O
activated	O
platelets	O
to	O
adherent	O
monocytes	O
had	O
a	O
similar	O
effect	O
and	O
was	O
associated	O
with	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activation	O
.	O
<EOS>	B-X
Activated	B-X
platelets	B-X
tether	B-X
and	B-X
activate	B-X
myeloid	B-X
leukocytes	B-X
.	B-X

Inhibition	O
of	O
binding	O
by	O
anti	O
-	O
P	B-Protein
selectin	I-Protein
antibodies	O
reduced	O
the	O
effect	O
of	O
activated	O
platelets	O
on	O
cytokine	O
production	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
AMI	O
,	O
leukocyte	O
-	O
platelet	O
adhesion	O
is	O
increased	O
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
levels	B-X
of	B-X
platelet	B-X
interaction	B-X
with	B-X
circulating	B-X
CD34+	B-X
cells	B-X
in	B-X
patients	B-X
with	B-X
stable	B-X
angina	B-X
pectoris	B-X
(	B-X
SAP	B-X
)	B-X
and	B-X
acute	B-X
coronary	B-X
syndromes	B-X
(	B-X
ACS	B-X
)	B-X
and	B-X
to	B-X
study	B-X
the	B-X
functional	B-X
consequence	B-X
of	B-X
coaggregates	B-X
formation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
determine	B-X
whether	B-X
THBS3	B-X
expression	B-X
in	B-X
peripheral	B-X
blood	B-X
can	B-X
be	B-X
used	B-X
as	B-X
a	B-X
biomarker	B-X
to	B-X
predict	B-X
the	B-X
risk	B-X
of	B-X
acute	B-X
myocardial	B-X
infarction	B-X
(	B-X
AMI	B-X
)	B-X
.	B-X
Stent	B-X
implantation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
superior	B-X
to	B-X
balloon	B-X
angioplasty	B-X
in	B-X
patients	B-X
with	B-X
acute	B-X
myocardial	B-X
infarction	B-X
(	B-X
AMI	B-X
)	B-X
.	B-X
Newer	B-X
trials	B-X
indicate	B-X
that	B-X
platelet-leukocyte	B-X
aggregates	B-X
are	B-X
a	B-X
more	B-X
sensitive	B-X
marker	B-X
for	B-X
platelet	B-X
activation	B-X
than	B-X
platelet	B-X
surface	B-X
marker	B-X
.	B-X
Our	B-X
study	B-X
examined	B-X
platelet	B-X
activation	B-X
and	B-X
platelet-leukocyte	B-X
interaction	B-X
in	B-X
blood	B-X
in	B-X
patients	B-X
with	B-X
AMI	B-X
randomized	B-X
to	B-X
heparin-coated	B-X
stent	B-X
implantation	B-X
versus	B-X
balloon	B-X
angioplasty	B-X
.	B-X

Binding	O
of	O
activated	O
platelets	O
induces	O
IL	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
and	O
MCP	B-Protein
-	I-Protein
1	I-Protein
in	O
leukocytes	O
.	O
<EOS>	B-X
Activated	B-X
platelets	B-X
tether	B-X
and	B-X
activate	B-X
myeloid	B-X
leukocytes	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
exposure	B-X
of	B-X
monocytes	B-X
from	B-X
healthy	B-X
volunteers	B-X
to	B-X
platelets	B-X
from	B-X
patients	B-X
with	B-X
dengue	B-X
induced	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
cytokines	B-X
IL-1β	B-X
,	B-X
IL-8	B-X
,	B-X
IL-10	B-X
and	B-X
MCP-1	B-X
,	B-X
whereas	B-X
exposure	B-X
to	B-X
platelets	B-X
from	B-X
healthy	B-X
volunteers	B-X
only	B-X
induced	B-X
the	B-X
secretion	B-X
of	B-X
MCP-1	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
well-established	B-X
modulation	B-X
of	B-X
monocyte	B-X
cytokine	B-X
responses	B-X
by	B-X
activated	B-X
platelets	B-X
through	B-X
P-selectin	B-X
binding	B-X
,	B-X
we	B-X
found	B-X
that	B-X
interaction	B-X
of	B-X
monocytes	B-X
with	B-X
apoptotic	B-X
platelets	B-X
mediate	B-X
IL-10	B-X
secretion	B-X
through	B-X
phosphatidylserine	B-X
recognition	B-X
in	B-X
platelet-monocyte	B-X
aggregates	B-X
.	B-X
Moreover	B-X
,	B-X
IL-10	B-X
secretion	B-X
required	B-X
platelet-monocyte	B-X
contact	B-X
but	B-X
not	B-X
phagocytosis	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
demonstrate	B-X
that	B-X
activated	B-X
and	B-X
apoptotic	B-X
platelets	B-X
aggregate	B-X
with	B-X
monocytes	B-X
during	B-X
dengue	B-X
infection	B-X
and	B-X
signal	B-X
specific	B-X
cytokine	B-X
responses	B-X
that	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
dengue	B-X
.	B-X

Our	O
findings	O
suggest	O
that	O
leukocyte	O
-	O
platelet	O
adhesion	O
contributes	O
to	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
in	O
AMI	O
.	O

The	O
class	B-Protein
II	I-Protein
trans	I-Protein
-	I-Protein
activator	I-Protein
CIITA	B-Protein
interacts	O
with	O
the	O
TBP	B-Protein
-	O
associated	O
factor	O
TAFII32	B-Protein
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
trans-	B-X
activator	B-X
(	B-X
CIITA	B-X
)	B-X
is	B-X
the	B-X
main	B-X
transcriptional	B-X
co-activator	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
proteins	B-X
.	B-X
Its	B-X
N-terminal	B-X
125	B-X
amino	B-X
acids	B-X
function	B-X
as	B-X
an	B-X
independent	B-X
transcriptional	B-X
activation	B-X
domain	B-X
.	B-X
Using	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
two	B-X
of	B-X
these	B-X
predicted	B-X
alpha-helices	B-X
are	B-X
required	B-X
for	B-X
full	B-X
transcriptional	B-X
activation	B-X
by	B-X
CIITA	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
CIITA	B-X
protein	B-X
in	B-X
which	B-X
both	B-X
functional	B-X
alpha-helices	B-X
have	B-X
been	B-X
deleted	B-X
displays	B-X
a	B-X
dominant	B-X
negative	B-X
phenotype	B-X
.	B-X
This	B-X
activation	B-X
domain	B-X
of	B-X
CIITA	B-X
interacts	B-X
with	B-X
the	B-X
32	B-X
kDa	B-X
subunit	B-X
of	B-X
the	B-X
general	B-X
transcription	B-X
complex	B-X
TFIID	B-X
,	B-X
TAFII32	B-X
.	B-X
Decreased	B-X
transcriptional	B-X
activation	B-X
by	B-X
N-terminal	B-X
deletions	B-X
of	B-X
CIITA	B-X
is	B-X
correlated	B-X
directly	B-X
with	B-X
their	B-X
reduced	B-X
binding	B-X
to	B-X
TAFII32	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
interactions	B-X
between	B-X
TAFII32	B-X
and	B-X
CIITA	B-X
are	B-X
responsible	B-X
for	B-X
activation	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
.	B-X

The	O
class	B-Protein
II	I-Protein
trans	I-Protein
-	I-Protein
activator	I-Protein
(	O
CIITA	B-Protein
)	O
is	O
the	O
main	O
transcriptional	O
co	O
-	O
activator	O
for	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
proteins	O
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
trans-	B-X
activator	B-X
(	B-X
CIITA	B-X
)	B-X
is	B-X
the	B-X
main	B-X
transcriptional	B-X
co-activator	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
proteins	B-X
.	B-X
Its	B-X
N-terminal	B-X
125	B-X
amino	B-X
acids	B-X
function	B-X
as	B-X
an	B-X
independent	B-X
transcriptional	B-X
activation	B-X
domain	B-X
.	B-X
Analyses	B-X
of	B-X
the	B-X
primary	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
activation	B-X
domain	B-X
predict	B-X
the	B-X
presence	B-X
of	B-X
three	B-X
alpha-helices	B-X
,	B-X
each	B-X
with	B-X
a	B-X
high	B-X
proportion	B-X
of	B-X
acidic	B-X
residues	B-X
.	B-X
Using	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
two	B-X
of	B-X
these	B-X
predicted	B-X
alpha-helices	B-X
are	B-X
required	B-X
for	B-X
full	B-X
transcriptional	B-X
activation	B-X
by	B-X
CIITA	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
CIITA	B-X
protein	B-X
in	B-X
which	B-X
both	B-X
functional	B-X
alpha-helices	B-X
have	B-X
been	B-X
deleted	B-X
displays	B-X
a	B-X
dominant	B-X
negative	B-X
phenotype	B-X
.	B-X
This	B-X
activation	B-X
domain	B-X
of	B-X
CIITA	B-X
interacts	B-X
with	B-X
the	B-X
32	B-X
kDa	B-X
subunit	B-X
of	B-X
the	B-X
general	B-X
transcription	B-X
complex	B-X
TFIID	B-X
,	B-X
TAFII32	B-X
.	B-X
Decreased	B-X
transcriptional	B-X
activation	B-X
by	B-X
N-terminal	B-X
deletions	B-X
of	B-X
CIITA	B-X
is	B-X
correlated	B-X
directly	B-X
with	B-X
their	B-X
reduced	B-X
binding	B-X
to	B-X
TAFII32	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
interactions	B-X
between	B-X
TAFII32	B-X
and	B-X
CIITA	B-X
are	B-X
responsible	B-X
for	B-X
activation	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
.	B-X

Its	O
N	O
-	O
terminal	O
125	O
amino	O
acids	O
function	O
as	O
an	O
independent	O
transcriptional	O
activation	O
domain	O
.	O
<EOS>	B-X
Nrf1	B-X
(	B-X
nuclear	B-X
factor-erythroid	B-X
2	B-X
p45	B-X
subunit-related	B-X
factor	B-X
1	B-X
)	B-X
and	B-X
Nrf2	B-X
regulate	B-X
ARE	B-X
(	B-X
antioxidant	B-X
response	B-X
element	B-X
)	B-X
-driven	B-X
genes	B-X
.	B-X
At	B-X
its	B-X
N-terminal	B-X
end	B-X
,	B-X
Nrf1	B-X
contains	B-X
155	B-X
additional	B-X
amino	B-X
acids	B-X
that	B-X
are	B-X
absent	B-X
from	B-X
Nrf2	B-X
.	B-X
This	B-X
155-amino-acid	B-X
polypeptide	B-X
includes	B-X
the	B-X
N-terminal	B-X
domain	B-X
(	B-X
NTD	B-X
,	B-X
amino	B-X
acids	B-X
1-124	B-X
)	B-X
and	B-X
a	B-X
region	B-X
(	B-X
amino	B-X
acids	B-X
125-155	B-X
)	B-X
that	B-X
is	B-X
part	B-X
of	B-X
acidic	B-X
domain	B-X
1	B-X
(	B-X
amino	B-X
acids	B-X
125-295	B-X
)	B-X
.	B-X
Within	B-X
acidic	B-X
domain	B-X
1	B-X
,	B-X
residues	B-X
156-242	B-X
share	B-X
43	B-X
%	B-X
identity	B-X
with	B-X
the	B-X
Neh2	B-X
(	B-X
Nrf2-ECH	B-X
homology	B-X
2	B-X
)	B-X
degron	B-X
of	B-X
Nrf2	B-X
that	B-X
serves	B-X
to	B-X
destabilize	B-X
this	B-X
latter	B-X
transcription	B-X
factor	B-X
through	B-X
an	B-X
interaction	B-X
with	B-X
Keap1	B-X
(	B-X
Kelch-like	B-X
ECH-associated	B-X
protein	B-X
1	B-X
)	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
function	B-X
of	B-X
the	B-X
155-amino-acid	B-X
N-terminal	B-X
polypeptide	B-X
in	B-X
Nrf1	B-X
,	B-X
along	B-X
with	B-X
its	B-X
adjacent	B-X
Neh2-like	B-X
subdomain	B-X
.	B-X
Activation	B-X
of	B-X
ARE-driven	B-X
genes	B-X
by	B-X
Nrf1	B-X
was	B-X
negatively	B-X
controlled	B-X
by	B-X
the	B-X
NTD	B-X
(	B-X
N-terminal	B-X
domain	B-X
)	B-X
through	B-X
its	B-X
ability	B-X
to	B-X
direct	B-X
Nrf1	B-X
to	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
wild-type	B-X
Nrf1	B-X
and	B-X
mutants	B-X
lacking	B-X
either	B-X
the	B-X
NTD	B-X
or	B-X
portions	B-X
of	B-X
its	B-X
Neh2-like	B-X
subdomain	B-X
into	B-X
wild-type	B-X
and	B-X
mutant	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
indicated	B-X
that	B-X
Keap1	B-X
controls	B-X
neither	B-X
the	B-X
activity	B-X
of	B-X
Nrf1	B-X
nor	B-X
its	B-X
subcellular	B-X
distribution	B-X
.	B-X
Immunocytochemistry	B-X
showed	B-X
that	B-X
whereas	B-X
Nrf1	B-X
gave	B-X
primarily	B-X
cytoplasmic	B-X
staining	B-X
that	B-X
was	B-X
co-incident	B-X
with	B-X
that	B-X
of	B-X
an	B-X
endoplasmic-reticulum	B-X
marker	B-X
,	B-X
Nrf2	B-X
gave	B-X
primarily	B-X
nuclear	B-X
staining	B-X
.	B-X
Attachment	B-X
of	B-X
the	B-X
NTD	B-X
from	B-X
Nrf1	B-X
to	B-X
the	B-X
N-terminus	B-X
of	B-X
Nrf2	B-X
produced	B-X
a	B-X
fusion	B-X
protein	B-X
that	B-X
was	B-X
redirected	B-X
from	B-X
the	B-X
nucleus	B-X
to	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X
Although	B-X
this	B-X
NTD-Nrf2	B-X
fusion	B-X
protein	B-X
exhibited	B-X
less	B-X
transactivation	B-X
activity	B-X
than	B-X
wild-type	B-X
Nrf2	B-X
,	B-X
it	B-X
was	B-X
nevertheless	B-X
still	B-X
negatively	B-X
regulated	B-X
by	B-X
Keap1	B-X
.	B-X
Thus	B-X
Nrf1	B-X
and	B-X
Nrf2	B-X
are	B-X
targeted	B-X
to	B-X
different	B-X
subcellular	B-X
compartments	B-X
and	B-X
are	B-X
negatively	B-X
regulated	B-X
by	B-X
distinct	B-X
mechanisms	B-X
.	B-X

Analyses	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
the	O
activation	O
domain	O
predict	O
the	O
presence	O
of	O
three	O
alpha	O
-	O
helices	O
,	O
each	O
with	O
a	O
high	O
proportion	O
of	O
acidic	O
residues	O
.	O
<EOS>	B-X
Its	B-X
N-terminal	B-X
125	B-X
amino	B-X
acids	B-X
function	B-X
as	B-X
an	B-X
independent	B-X
transcriptional	B-X
activation	B-X
domain	B-X
.	B-X
Analyses	B-X
of	B-X
the	B-X
primary	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
activation	B-X
domain	B-X
predict	B-X
the	B-X
presence	B-X
of	B-X
three	B-X
alpha-helices	B-X
,	B-X
each	B-X
with	B-X
a	B-X
high	B-X
proportion	B-X
of	B-X
acidic	B-X
residues	B-X
.	B-X
Using	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
two	B-X
of	B-X
these	B-X
predicted	B-X
alpha-helices	B-X
are	B-X
required	B-X
for	B-X
full	B-X
transcriptional	B-X
activation	B-X
by	B-X
CIITA	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
CIITA	B-X
protein	B-X
in	B-X
which	B-X
both	B-X
functional	B-X
alpha-helices	B-X
have	B-X
been	B-X
deleted	B-X
displays	B-X
a	B-X
dominant	B-X
negative	B-X
phenotype	B-X
.	B-X
This	B-X
activation	B-X
domain	B-X
of	B-X
CIITA	B-X
interacts	B-X
with	B-X
the	B-X
32	B-X
kDa	B-X
subunit	B-X
of	B-X
the	B-X
general	B-X
transcription	B-X
complex	B-X
TFIID	B-X
,	B-X
TAFII32	B-X
.	B-X
Decreased	B-X
transcriptional	B-X
activation	B-X
by	B-X
N-terminal	B-X
deletions	B-X
of	B-X
CIITA	B-X
is	B-X
correlated	B-X
directly	B-X
with	B-X
their	B-X
reduced	B-X
binding	B-X
to	B-X
TAFII32	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
interactions	B-X
between	B-X
TAFII32	B-X
and	B-X
CIITA	B-X
are	B-X
responsible	B-X
for	B-X
activation	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
.	B-X

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
found	O
that	O
two	O
of	O
these	O
predicted	O
alpha	O
-	O
helices	O
are	O
required	O
for	O
full	O
transcriptional	O
activation	O
by	O
CIITA	B-Protein
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
trans-	B-X
activator	B-X
(	B-X
CIITA	B-X
)	B-X
is	B-X
the	B-X
main	B-X
transcriptional	B-X
co-activator	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
proteins	B-X
.	B-X
Its	B-X
N-terminal	B-X
125	B-X
amino	B-X
acids	B-X
function	B-X
as	B-X
an	B-X
independent	B-X
transcriptional	B-X
activation	B-X
domain	B-X
.	B-X
Analyses	B-X
of	B-X
the	B-X
primary	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
activation	B-X
domain	B-X
predict	B-X
the	B-X
presence	B-X
of	B-X
three	B-X
alpha-helices	B-X
,	B-X
each	B-X
with	B-X
a	B-X
high	B-X
proportion	B-X
of	B-X
acidic	B-X
residues	B-X
.	B-X
Using	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
two	B-X
of	B-X
these	B-X
predicted	B-X
alpha-helices	B-X
are	B-X
required	B-X
for	B-X
full	B-X
transcriptional	B-X
activation	B-X
by	B-X
CIITA	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
CIITA	B-X
protein	B-X
in	B-X
which	B-X
both	B-X
functional	B-X
alpha-helices	B-X
have	B-X
been	B-X
deleted	B-X
displays	B-X
a	B-X
dominant	B-X
negative	B-X
phenotype	B-X
.	B-X
This	B-X
activation	B-X
domain	B-X
of	B-X
CIITA	B-X
interacts	B-X
with	B-X
the	B-X
32	B-X
kDa	B-X
subunit	B-X
of	B-X
the	B-X
general	B-X
transcription	B-X
complex	B-X
TFIID	B-X
,	B-X
TAFII32	B-X
.	B-X
Decreased	B-X
transcriptional	B-X
activation	B-X
by	B-X
N-terminal	B-X
deletions	B-X
of	B-X
CIITA	B-X
is	B-X
correlated	B-X
directly	B-X
with	B-X
their	B-X
reduced	B-X
binding	B-X
to	B-X
TAFII32	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
interactions	B-X
between	B-X
TAFII32	B-X
and	B-X
CIITA	B-X
are	B-X
responsible	B-X
for	B-X
activation	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
.	B-X

Moreover	O
,	O
a	O
CIITA	B-Protein
protein	O
in	O
which	O
both	O
functional	O
alpha	O
-	O
helices	O
have	O
been	O
deleted	O
displays	O
a	O
dominant	O
negative	O
phenotype	O
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
trans-	B-X
activator	B-X
(	B-X
CIITA	B-X
)	B-X
is	B-X
the	B-X
main	B-X
transcriptional	B-X
co-activator	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
proteins	B-X
.	B-X
Analyses	B-X
of	B-X
the	B-X
primary	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
activation	B-X
domain	B-X
predict	B-X
the	B-X
presence	B-X
of	B-X
three	B-X
alpha-helices	B-X
,	B-X
each	B-X
with	B-X
a	B-X
high	B-X
proportion	B-X
of	B-X
acidic	B-X
residues	B-X
.	B-X
Using	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
two	B-X
of	B-X
these	B-X
predicted	B-X
alpha-helices	B-X
are	B-X
required	B-X
for	B-X
full	B-X
transcriptional	B-X
activation	B-X
by	B-X
CIITA	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
CIITA	B-X
protein	B-X
in	B-X
which	B-X
both	B-X
functional	B-X
alpha-helices	B-X
have	B-X
been	B-X
deleted	B-X
displays	B-X
a	B-X
dominant	B-X
negative	B-X
phenotype	B-X
.	B-X
This	B-X
activation	B-X
domain	B-X
of	B-X
CIITA	B-X
interacts	B-X
with	B-X
the	B-X
32	B-X
kDa	B-X
subunit	B-X
of	B-X
the	B-X
general	B-X
transcription	B-X
complex	B-X
TFIID	B-X
,	B-X
TAFII32	B-X
.	B-X
Decreased	B-X
transcriptional	B-X
activation	B-X
by	B-X
N-terminal	B-X
deletions	B-X
of	B-X
CIITA	B-X
is	B-X
correlated	B-X
directly	B-X
with	B-X
their	B-X
reduced	B-X
binding	B-X
to	B-X
TAFII32	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
interactions	B-X
between	B-X
TAFII32	B-X
and	B-X
CIITA	B-X
are	B-X
responsible	B-X
for	B-X
activation	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
.	B-X

This	O
activation	O
domain	O
of	O
CIITA	B-Protein
interacts	O
with	O
the	O
32	O
kDa	O
subunit	O
of	O
the	O
general	O
transcription	O
complex	O
TFIID	O
,	O
TAFII32	B-Protein
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
trans-	B-X
activator	B-X
(	B-X
CIITA	B-X
)	B-X
is	B-X
the	B-X
main	B-X
transcriptional	B-X
co-activator	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
proteins	B-X
.	B-X
Its	B-X
N-terminal	B-X
125	B-X
amino	B-X
acids	B-X
function	B-X
as	B-X
an	B-X
independent	B-X
transcriptional	B-X
activation	B-X
domain	B-X
.	B-X
Analyses	B-X
of	B-X
the	B-X
primary	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
activation	B-X
domain	B-X
predict	B-X
the	B-X
presence	B-X
of	B-X
three	B-X
alpha-helices	B-X
,	B-X
each	B-X
with	B-X
a	B-X
high	B-X
proportion	B-X
of	B-X
acidic	B-X
residues	B-X
.	B-X
Using	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
two	B-X
of	B-X
these	B-X
predicted	B-X
alpha-helices	B-X
are	B-X
required	B-X
for	B-X
full	B-X
transcriptional	B-X
activation	B-X
by	B-X
CIITA	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
CIITA	B-X
protein	B-X
in	B-X
which	B-X
both	B-X
functional	B-X
alpha-helices	B-X
have	B-X
been	B-X
deleted	B-X
displays	B-X
a	B-X
dominant	B-X
negative	B-X
phenotype	B-X
.	B-X
This	B-X
activation	B-X
domain	B-X
of	B-X
CIITA	B-X
interacts	B-X
with	B-X
the	B-X
32	B-X
kDa	B-X
subunit	B-X
of	B-X
the	B-X
general	B-X
transcription	B-X
complex	B-X
TFIID	B-X
,	B-X
TAFII32	B-X
.	B-X
Decreased	B-X
transcriptional	B-X
activation	B-X
by	B-X
N-terminal	B-X
deletions	B-X
of	B-X
CIITA	B-X
is	B-X
correlated	B-X
directly	B-X
with	B-X
their	B-X
reduced	B-X
binding	B-X
to	B-X
TAFII32	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
interactions	B-X
between	B-X
TAFII32	B-X
and	B-X
CIITA	B-X
are	B-X
responsible	B-X
for	B-X
activation	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
.	B-X

Decreased	O
transcriptional	O
activation	O
by	O
N	O
-	O
terminal	O
deletions	O
of	O
CIITA	B-Protein
is	O
correlated	O
directly	O
with	O
their	O
reduced	O
binding	O
to	O
TAFII32	B-Protein
.	O

We	O
conclude	O
that	O
interactions	O
between	O
TAFII32	B-Protein
and	O
CIITA	B-Protein
are	O
responsible	O
for	O
activation	O
of	O
class	O
II	O
genes	O
.	O
<EOS>	B-X
The	B-X
class	B-X
II	B-X
trans-	B-X
activator	B-X
(	B-X
CIITA	B-X
)	B-X
is	B-X
the	B-X
main	B-X
transcriptional	B-X
co-activator	B-X
for	B-X
the	B-X
expression	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
proteins	B-X
.	B-X
Its	B-X
N-terminal	B-X
125	B-X
amino	B-X
acids	B-X
function	B-X
as	B-X
an	B-X
independent	B-X
transcriptional	B-X
activation	B-X
domain	B-X
.	B-X
Analyses	B-X
of	B-X
the	B-X
primary	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
activation	B-X
domain	B-X
predict	B-X
the	B-X
presence	B-X
of	B-X
three	B-X
alpha-helices	B-X
,	B-X
each	B-X
with	B-X
a	B-X
high	B-X
proportion	B-X
of	B-X
acidic	B-X
residues	B-X
.	B-X
Using	B-X
site-directed	B-X
mutagenesis	B-X
,	B-X
we	B-X
found	B-X
that	B-X
two	B-X
of	B-X
these	B-X
predicted	B-X
alpha-helices	B-X
are	B-X
required	B-X
for	B-X
full	B-X
transcriptional	B-X
activation	B-X
by	B-X
CIITA	B-X
.	B-X
Moreover	B-X
,	B-X
a	B-X
CIITA	B-X
protein	B-X
in	B-X
which	B-X
both	B-X
functional	B-X
alpha-helices	B-X
have	B-X
been	B-X
deleted	B-X
displays	B-X
a	B-X
dominant	B-X
negative	B-X
phenotype	B-X
.	B-X
This	B-X
activation	B-X
domain	B-X
of	B-X
CIITA	B-X
interacts	B-X
with	B-X
the	B-X
32	B-X
kDa	B-X
subunit	B-X
of	B-X
the	B-X
general	B-X
transcription	B-X
complex	B-X
TFIID	B-X
,	B-X
TAFII32	B-X
.	B-X
Decreased	B-X
transcriptional	B-X
activation	B-X
by	B-X
N-terminal	B-X
deletions	B-X
of	B-X
CIITA	B-X
is	B-X
correlated	B-X
directly	B-X
with	B-X
their	B-X
reduced	B-X
binding	B-X
to	B-X
TAFII32	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
interactions	B-X
between	B-X
TAFII32	B-X
and	B-X
CIITA	B-X
are	B-X
responsible	B-X
for	B-X
activation	B-X
of	B-X
class	B-X
II	B-X
genes	B-X
.	B-X

Lipopolysaccharide	O
induction	O
of	O
the	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
promoter	O
in	O
human	O
monocytic	O
cells	O
.	O
<EOS>	B-X
Exposure	B-X
to	B-X
high	B-X
catecholamine	B-X
levels	B-X
is	B-X
associated	B-X
with	B-X
inflammatory	B-X
changes	B-X
of	B-X
myeloid	B-X
cells	B-X
and	B-X
atherosclerosis	B-X
,	B-X
but	B-X
the	B-X
underlying	B-X
mechanisms	B-X
are	B-X
only	B-X
partly	B-X
understood	B-X
.	B-X
Biosynthesis	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
is	B-X
predominantly	B-X
by	B-X
cells	B-X
of	B-X
the	B-X
monocytic	B-X
lineage	B-X
.	B-X
This	B-X
study	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
various	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
in	B-X
the	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induction	B-X
of	B-X
the	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
in	B-X
cells	B-X
of	B-X
monocytic	B-X
lineage	B-X
.	B-X
Functional	B-X
analysis	B-X
of	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
transfected	B-X
with	B-X
plasmids	B-X
containing	B-X
various	B-X
lengths	B-X
of	B-X
TNF-alpha	B-X
promoter	B-X
localized	B-X
enhancer	B-X
elements	B-X
in	B-X
a	B-X
region	B-X
(	B-X
-182	B-X
to	B-X
-37	B-X
base	B-X
pairs	B-X
(	B-X
bp	B-X
)	B-X
)	B-X
that	B-X
were	B-X
required	B-X
for	B-X
optimal	B-X
transcription	B-X
of	B-X
the	B-X
TNF-alpha	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
LPS	B-X
stimulation	B-X
induced	B-X
the	B-X
binding	B-X
of	B-X
cognate	B-X
nuclear	B-X
factors	B-X
to	B-X
the	B-X
Egr-1	B-X
and	B-X
kappaB3	B-X
sites	B-X
,	B-X
which	B-X
were	B-X
identified	B-X
as	B-X
Egr-1	B-X
and	B-X
p50/p65	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
CRE	B-X
and	B-X
kappaB3	B-X
sites	B-X
in	B-X
region	B-X
II	B-X
together	B-X
conferred	B-X
strong	B-X
LPS	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
,	B-X
whereas	B-X
individually	B-X
they	B-X
failed	B-X
to	B-X
provide	B-X
transcriptional	B-X
activation	B-X
.	B-X
Furthermore	B-X
,	B-X
increasing	B-X
the	B-X
spacing	B-X
between	B-X
the	B-X
CRE	B-X
and	B-X
the	B-X
kappaB3	B-X
sites	B-X
completely	B-X
abolished	B-X
LPS	B-X
induction	B-X
,	B-X
suggesting	B-X
a	B-X
cooperative	B-X
interaction	B-X
between	B-X
c-Jun	B-X
complexes	B-X
and	B-X
p50/p65	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
maximal	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TNF-alpha	B-X
promoter	B-X
is	B-X
mediated	B-X
by	B-X
concerted	B-X
participation	B-X
of	B-X
at	B-X
least	B-X
two	B-X
separate	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
.	B-X

Regulation	O
by	O
Egr	B-Protein
-	I-Protein
1	I-Protein
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
and	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
.	O
<EOS>	B-X
Nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
,	B-X
a	B-X
diffusible	B-X
molecule	B-X
acting	B-X
as	B-X
an	B-X
intercellular	B-X
and	B-X
intracellular	B-X
messenger	B-X
in	B-X
many	B-X
tissues	B-X
,	B-X
plays	B-X
multiple	B-X
roles	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
regulating	B-X
proliferation	B-X
,	B-X
survival	B-X
and	B-X
differentiation	B-X
of	B-X
neurons	B-X
,	B-X
NO	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
synaptic	B-X
activity	B-X
,	B-X
neural	B-X
plasticity	B-X
and	B-X
memory	B-X
formation	B-X
.	B-X
Long-lasting	B-X
effects	B-X
of	B-X
NO	B-X
,	B-X
a	B-X
simple	B-X
and	B-X
unstable	B-X
molecule	B-X
,	B-X
occur	B-X
through	B-X
regulation	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
modulation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
cAMP-response-element-binding	B-X
(	B-X
CREB	B-X
)	B-X
protein	B-X
is	B-X
an	B-X
important	B-X
transcription	B-X
factor	B-X
that	B-X
regulates	B-X
the	B-X
expression	B-X
of	B-X
several	B-X
genes	B-X
involved	B-X
in	B-X
survival	B-X
and	B-X
neuroprotection	B-X
as	B-X
well	B-X
as	B-X
in	B-X
synaptic	B-X
plasticity	B-X
and	B-X
memory	B-X
formation	B-X
.	B-X
Nitric	B-X
oxide	B-X
promotes	B-X
survival	B-X
and	B-X
differentiation	B-X
of	B-X
neural	B-X
cells	B-X
,	B-X
both	B-X
activating	B-X
through	B-X
cGMP	B-X
signaling	B-X
CREB	B-X
phosphorylation-dependent	B-X
transcriptional	B-X
activity	B-X
and	B-X
promoting	B-X
S-nitrosylation	B-X
of	B-X
nuclear	B-X
proteins	B-X
that	B-X
favor	B-X
CREB	B-X
binding	B-X
to	B-X
its	B-X
promoters	B-X
on	B-X
target	B-X
genes	B-X
.	B-X
Among	B-X
oncogenic	B-X
transcription	B-X
factors	B-X
,	B-X
N-Myc	B-X
is	B-X
important	B-X
in	B-X
neurogenesis	B-X
and	B-X
in	B-X
regulating	B-X
proliferation	B-X
of	B-X
neural-derived	B-X
tumor	B-X
cells	B-X
,	B-X
such	B-X
as	B-X
neuroblastomas	B-X
and	B-X
medulloblastomas	B-X
.	B-X
Nitric	B-X
oxide	B-X
negatively	B-X
regulates	B-X
the	B-X
proliferation	B-X
of	B-X
neuronal	B-X
precursors	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
proliferation	B-X
of	B-X
neuroblastoma	B-X
cells	B-X
,	B-X
by	B-X
downregulating	B-X
N-Myc	B-X
expression	B-X
through	B-X
cGMP	B-X
signaling	B-X
.	B-X
Other	B-X
oncogenic	B-X
transcription	B-X
factors	B-X
,	B-X
such	B-X
as	B-X
c-fos	B-X
and	B-X
c-jun	B-X
,	B-X
zinc-finger	B-X
transcription	B-X
factors	B-X
,	B-X
such	B-X
as	B-X
egr-1	B-X
,	B-X
and	B-X
NF-kappaB	B-X
are	B-X
regulated	B-X
by	B-X
NO	B-X
signaling	B-X
in	B-X
cGMP-dependent	B-X
way	B-X
or	B-X
through	B-X
nitrosative	B-X
conformational	B-X
changes	B-X
.	B-X
The	B-X
present	B-X
survey	B-X
of	B-X
how	B-X
NO	B-X
signaling	B-X
influences	B-X
neural	B-X
cells	B-X
through	B-X
regulation	B-X
of	B-X
transcription	B-X
factors	B-X
allows	B-X
us	B-X
to	B-X
predict	B-X
that	B-X
better	B-X
knowledge	B-X
of	B-X
these	B-X
interactions	B-X
will	B-X
provide	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
the	B-X
physiological	B-X
role	B-X
of	B-X
NO	B-X
in	B-X
the	B-X
nervous	B-X
system	B-X
in	B-X
order	B-X
to	B-X
conceive	B-X
novel	B-X
therapies	B-X
for	B-X
neural-derived	B-X
tumors	B-X
.	B-X

Biosynthesis	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
is	O
predominantly	O
by	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O
<EOS>	B-X
It	B-X
is	B-X
known	B-X
that	B-X
the	B-X
monocyte/macrophage	B-X
lineage	B-X
gives	B-X
rise	B-X
to	B-X
osteoclasts	B-X
(	B-X
OCs	B-X
)	B-X
by	B-X
the	B-X
action	B-X
of	B-X
macrophage	B-X
colony	B-X
stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
and	B-X
receptor	B-X
activator	B-X
of	B-X
nuclear	B-X
factor-kB	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
,	B-X
which	B-X
induce	B-X
cell	B-X
differentiation	B-X
through	B-X
their	B-X
receptors	B-X
,	B-X
c-fms	B-X
and	B-X
RANK	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
multinucleated	B-X
giant	B-X
cells	B-X
(	B-X
MGCs	B-X
)	B-X
generated	B-X
by	B-X
the	B-X
engagement	B-X
of	B-X
RANK/RANKL	B-X
are	B-X
typical	B-X
OCs	B-X
.	B-X
It	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
macrophages	B-X
can	B-X
be	B-X
polarized	B-X
in	B-X
vitro	B-X
towards	B-X
a	B-X
predominantly	B-X
M1	B-X
or	B-X
M2	B-X
phenotype	B-X
with	B-X
the	B-X
addition	B-X
of	B-X
granulocyte	B-X
macrophage-	B-X
(	B-X
GM-	B-X
)	B-X
CSF	B-X
or	B-X
M-CSF	B-X
,	B-X
respectively	B-X
.	B-X
Various	B-X
inflammatory	B-X
stimuli	B-X
known	B-X
to	B-X
induce	B-X
macrophage	B-X
polarization	B-X
,	B-X
such	B-X
as	B-X
LPS	B-X
or	B-X
TNF-α	B-X
,	B-X
can	B-X
alter	B-X
the	B-X
type	B-X
of	B-X
MGC	B-X
obtained	B-X
from	B-X
RANKL-induced	B-X
differentiation	B-X
.	B-X
This	B-X
review	B-X
aims	B-X
to	B-X
highlight	B-X
the	B-X
role	B-X
of	B-X
immune-related	B-X
stimuli	B-X
and	B-X
factors	B-X
in	B-X
inducing	B-X
macrophages	B-X
towards	B-X
the	B-X
osteoclastogenesis	B-X
choice	B-X
.	B-X

This	O
study	O
examined	O
the	O
role	O
of	O
various	O
cis	O
-	O
acting	O
regulatory	O
elements	O
in	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
human	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
promoter	O
in	O
cells	O
of	O
monocytic	O
lineage	O
.	O
<EOS>	B-X
Biosynthesis	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
is	B-X
predominantly	B-X
by	B-X
cells	B-X
of	B-X
the	B-X
monocytic	B-X
lineage	B-X
.	B-X
This	B-X
study	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
various	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
in	B-X
the	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induction	B-X
of	B-X
the	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
in	B-X
cells	B-X
of	B-X
monocytic	B-X
lineage	B-X
.	B-X
Functional	B-X
analysis	B-X
of	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
transfected	B-X
with	B-X
plasmids	B-X
containing	B-X
various	B-X
lengths	B-X
of	B-X
TNF-alpha	B-X
promoter	B-X
localized	B-X
enhancer	B-X
elements	B-X
in	B-X
a	B-X
region	B-X
(	B-X
-182	B-X
to	B-X
-37	B-X
base	B-X
pairs	B-X
(	B-X
bp	B-X
)	B-X
)	B-X
that	B-X
were	B-X
required	B-X
for	B-X
optimal	B-X
transcription	B-X
of	B-X
the	B-X
TNF-alpha	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X
LPS	B-X
stimulation	B-X
increased	B-X
the	B-X
binding	B-X
of	B-X
c-Jun-containing	B-X
complexes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
LPS	B-X
stimulation	B-X
induced	B-X
the	B-X
binding	B-X
of	B-X
cognate	B-X
nuclear	B-X
factors	B-X
to	B-X
the	B-X
Egr-1	B-X
and	B-X
kappaB3	B-X
sites	B-X
,	B-X
which	B-X
were	B-X
identified	B-X
as	B-X
Egr-1	B-X
and	B-X
p50/p65	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
CRE	B-X
and	B-X
kappaB3	B-X
sites	B-X
in	B-X
region	B-X
II	B-X
together	B-X
conferred	B-X
strong	B-X
LPS	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
,	B-X
whereas	B-X
individually	B-X
they	B-X
failed	B-X
to	B-X
provide	B-X
transcriptional	B-X
activation	B-X
.	B-X
Furthermore	B-X
,	B-X
increasing	B-X
the	B-X
spacing	B-X
between	B-X
the	B-X
CRE	B-X
and	B-X
the	B-X
kappaB3	B-X
sites	B-X
completely	B-X
abolished	B-X
LPS	B-X
induction	B-X
,	B-X
suggesting	B-X
a	B-X
cooperative	B-X
interaction	B-X
between	B-X
c-Jun	B-X
complexes	B-X
and	B-X
p50/p65	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
maximal	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TNF-alpha	B-X
promoter	B-X
is	B-X
mediated	B-X
by	B-X
concerted	B-X
participation	B-X
of	B-X
at	B-X
least	B-X
two	B-X
separate	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
.	B-X

Functional	O
analysis	O
of	O
monocytic	O
THP	O
-	O
1	O
cells	O
transfected	O
with	O
plasmids	O
containing	O
various	O
lengths	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
promoter	O
localized	O
enhancer	O
elements	O
in	O
a	O
region	O
(	O
-	O
182	O
to	O
-	O
37	O
base	O
pairs	O
(	O
bp	O
)	O
)	O
that	O
were	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
in	O
response	O
to	O
LPS	O
.	O

Two	O
regions	O
were	O
identified	O
:	O
region	O
I	O
(	O
-	O
182	O
to	O
-	O
162	O
bp	O
)	O
contained	O
an	O
overlapping	O
Sp1	B-Protein
/	O
Egr	B-Protein
-	I-Protein
1	I-Protein
site	O
,	O
and	O
region	O
II	O
(	O
-	O
119	O
to	O
-	O
88	O
)	O
contained	O
CRE	O
and	O
NF	O
-	O
kappaB	O
(	O
designated	O
kappaB3	O
)	O
sites	O
.	O
<EOS>	B-X
Biosynthesis	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
is	B-X
predominantly	B-X
by	B-X
cells	B-X
of	B-X
the	B-X
monocytic	B-X
lineage	B-X
.	B-X
This	B-X
study	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
various	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
in	B-X
the	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induction	B-X
of	B-X
the	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
in	B-X
cells	B-X
of	B-X
monocytic	B-X
lineage	B-X
.	B-X
Functional	B-X
analysis	B-X
of	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
transfected	B-X
with	B-X
plasmids	B-X
containing	B-X
various	B-X
lengths	B-X
of	B-X
TNF-alpha	B-X
promoter	B-X
localized	B-X
enhancer	B-X
elements	B-X
in	B-X
a	B-X
region	B-X
(	B-X
-182	B-X
to	B-X
-37	B-X
base	B-X
pairs	B-X
(	B-X
bp	B-X
)	B-X
)	B-X
that	B-X
were	B-X
required	B-X
for	B-X
optimal	B-X
transcription	B-X
of	B-X
the	B-X
TNF-alpha	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X
Two	B-X
regions	B-X
were	B-X
identified	B-X
:	B-X
region	B-X
I	B-X
(	B-X
-182	B-X
to	B-X
-162	B-X
bp	B-X
)	B-X
contained	B-X
an	B-X
overlapping	B-X
Sp1/Egr-1	B-X
site	B-X
,	B-X
and	B-X
region	B-X
II	B-X
(	B-X
-119	B-X
to	B-X
-88	B-X
)	B-X
contained	B-X
CRE	B-X
and	B-X
NF-kappaB	B-X
(	B-X
designated	B-X
kappaB3	B-X
)	B-X
sites	B-X
.	B-X
In	B-X
unstimulated	B-X
THP-1	B-X
,	B-X
CRE-binding	B-X
protein	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
c-Jun	B-X
complexes	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
the	B-X
CRE	B-X
site	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
LPS	B-X
stimulation	B-X
induced	B-X
the	B-X
binding	B-X
of	B-X
cognate	B-X
nuclear	B-X
factors	B-X
to	B-X
the	B-X
Egr-1	B-X
and	B-X
kappaB3	B-X
sites	B-X
,	B-X
which	B-X
were	B-X
identified	B-X
as	B-X
Egr-1	B-X
and	B-X
p50/p65	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
CRE	B-X
and	B-X
kappaB3	B-X
sites	B-X
in	B-X
region	B-X
II	B-X
together	B-X
conferred	B-X
strong	B-X
LPS	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
,	B-X
whereas	B-X
individually	B-X
they	B-X
failed	B-X
to	B-X
provide	B-X
transcriptional	B-X
activation	B-X
.	B-X
Furthermore	B-X
,	B-X
increasing	B-X
the	B-X
spacing	B-X
between	B-X
the	B-X
CRE	B-X
and	B-X
the	B-X
kappaB3	B-X
sites	B-X
completely	B-X
abolished	B-X
LPS	B-X
induction	B-X
,	B-X
suggesting	B-X
a	B-X
cooperative	B-X
interaction	B-X
between	B-X
c-Jun	B-X
complexes	B-X
and	B-X
p50/p65	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
maximal	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TNF-alpha	B-X
promoter	B-X
is	B-X
mediated	B-X
by	B-X
concerted	B-X
participation	B-X
of	B-X
at	B-X
least	B-X
two	B-X
separate	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
.	B-X

In	O
unstimulated	O
THP	O
-	O
1	O
,	O
CRE	O
-	O
binding	O
protein	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
complexes	O
were	O
found	O
to	O
bind	O
to	O
the	O
CRE	O
site	O
.	O

LPS	O
stimulation	O
increased	O
the	O
binding	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
-	O
containing	O
complexes	O
.	O
<EOS>	B-X
C/EBPbeta	B-X
is	B-X
one	B-X
of	B-X
the	B-X
key	B-X
transcription	B-X
factors	B-X
responsible	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
wide	B-X
array	B-X
of	B-X
genes	B-X
.	B-X
Like	B-X
many	B-X
proto-oncogenes	B-X
and	B-X
transcription	B-X
factors	B-X
,	B-X
transcription	B-X
of	B-X
C/EBPbeta	B-X
gene	B-X
can	B-X
be	B-X
induced	B-X
by	B-X
multiple	B-X
extracellular	B-X
signals	B-X
.	B-X
Using	B-X
nuclear	B-X
extracts	B-X
from	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
mouse	B-X
liver	B-X
,	B-X
five	B-X
trans-acting	B-X
factor-binding	B-X
motifs	B-X
,	B-X
URE1	B-X
(	B-X
-376	B-X
to	B-X
-352	B-X
)	B-X
,	B-X
URE2	B-X
(	B-X
-253	B-X
to	B-X
-223	B-X
)	B-X
,	B-X
URE3	B-X
(	B-X
-220	B-X
to	B-X
-190	B-X
)	B-X
,	B-X
URE4	B-X
(	B-X
-123	B-X
to	B-X
-103	B-X
)	B-X
,	B-X
and	B-X
URE5	B-X
(	B-X
-72	B-X
to	B-X
-45	B-X
)	B-X
were	B-X
identified	B-X
by	B-X
DNAse	B-X
I	B-X
footprinting	B-X
assays	B-X
.	B-X
Competition	B-X
and	B-X
supershift	B-X
analysis	B-X
of	B-X
the	B-X
complexes	B-X
formed	B-X
at	B-X
the	B-X
URE2	B-X
and	B-X
URE4	B-X
indicated	B-X
that	B-X
they	B-X
contain	B-X
CREB/ATF	B-X
and	B-X
AP-1	B-X
family	B-X
factors	B-X
.	B-X
Furthermore	B-X
,	B-X
recombinant	B-X
ATF2	B-X
and	B-X
c-Jun	B-X
proteins	B-X
from	B-X
mammalian	B-X
and	B-X
bacterial	B-X
cells	B-X
can	B-X
bind	B-X
to	B-X
URE2	B-X
and	B-X
URE4	B-X
but	B-X
not	B-X
URE1	B-X
.	B-X
Cotransfection	B-X
experiments	B-X
showed	B-X
that	B-X
ATF2	B-X
and	B-X
c-Jun	B-X
activate	B-X
the	B-X
C/EBPbeta	B-X
gene	B-X
expression	B-X
cooperatively	B-X
through	B-X
URE2	B-X
and	B-X
URE4	B-X
,	B-X
and	B-X
this	B-X
activation	B-X
was	B-X
greatly	B-X
increased	B-X
under	B-X
the	B-X
treatment	B-X
of	B-X
low	B-X
concentration	B-X
of	B-X
anisomycin	B-X
.	B-X
During	B-X
acute	B-X
phase	B-X
response	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
c-Jun	B-X
and	B-X
ATF2	B-X
was	B-X
found	B-X
to	B-X
correlate	B-X
with	B-X
C/EBPbeta	B-X
gene	B-X
expression	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
provide	B-X
the	B-X
evidences	B-X
that	B-X
both	B-X
c-Jun	B-X
and	B-X
ATF2	B-X
are	B-X
the	B-X
regulators	B-X
of	B-X
C/EBPbeta	B-X
gene	B-X
.	B-X

In	O
addition	O
,	O
LPS	O
stimulation	O
induced	O
the	O
binding	O
of	O
cognate	O
nuclear	O
factors	O
to	O
the	O
Egr	B-Protein
-	I-Protein
1	I-Protein
and	O
kappaB3	O
sites	O
,	O
which	O
were	O
identified	O
as	O
Egr	B-Protein
-	I-Protein
1	I-Protein
and	O
p50	B-Protein
/	O
p65	B-Protein
,	O
respectively	O
.	O

The	O
CRE	O
and	O
kappaB3	O
sites	O
in	O
region	O
II	O
together	O
conferred	O
strong	O
LPS	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
,	O
whereas	O
individually	O
they	O
failed	O
to	O
provide	O
transcriptional	O
activation	O
.	O
<EOS>	B-X
This	B-X
study	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
various	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
in	B-X
the	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induction	B-X
of	B-X
the	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
in	B-X
cells	B-X
of	B-X
monocytic	B-X
lineage	B-X
.	B-X
Functional	B-X
analysis	B-X
of	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
transfected	B-X
with	B-X
plasmids	B-X
containing	B-X
various	B-X
lengths	B-X
of	B-X
TNF-alpha	B-X
promoter	B-X
localized	B-X
enhancer	B-X
elements	B-X
in	B-X
a	B-X
region	B-X
(	B-X
-182	B-X
to	B-X
-37	B-X
base	B-X
pairs	B-X
(	B-X
bp	B-X
)	B-X
)	B-X
that	B-X
were	B-X
required	B-X
for	B-X
optimal	B-X
transcription	B-X
of	B-X
the	B-X
TNF-alpha	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X
Two	B-X
regions	B-X
were	B-X
identified	B-X
:	B-X
region	B-X
I	B-X
(	B-X
-182	B-X
to	B-X
-162	B-X
bp	B-X
)	B-X
contained	B-X
an	B-X
overlapping	B-X
Sp1/Egr-1	B-X
site	B-X
,	B-X
and	B-X
region	B-X
II	B-X
(	B-X
-119	B-X
to	B-X
-88	B-X
)	B-X
contained	B-X
CRE	B-X
and	B-X
NF-kappaB	B-X
(	B-X
designated	B-X
kappaB3	B-X
)	B-X
sites	B-X
.	B-X
In	B-X
unstimulated	B-X
THP-1	B-X
,	B-X
CRE-binding	B-X
protein	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
c-Jun	B-X
complexes	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
the	B-X
CRE	B-X
site	B-X
.	B-X
LPS	B-X
stimulation	B-X
increased	B-X
the	B-X
binding	B-X
of	B-X
c-Jun-containing	B-X
complexes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
LPS	B-X
stimulation	B-X
induced	B-X
the	B-X
binding	B-X
of	B-X
cognate	B-X
nuclear	B-X
factors	B-X
to	B-X
the	B-X
Egr-1	B-X
and	B-X
kappaB3	B-X
sites	B-X
,	B-X
which	B-X
were	B-X
identified	B-X
as	B-X
Egr-1	B-X
and	B-X
p50/p65	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
CRE	B-X
and	B-X
kappaB3	B-X
sites	B-X
in	B-X
region	B-X
II	B-X
together	B-X
conferred	B-X
strong	B-X
LPS	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
,	B-X
whereas	B-X
individually	B-X
they	B-X
failed	B-X
to	B-X
provide	B-X
transcriptional	B-X
activation	B-X
.	B-X
Furthermore	B-X
,	B-X
increasing	B-X
the	B-X
spacing	B-X
between	B-X
the	B-X
CRE	B-X
and	B-X
the	B-X
kappaB3	B-X
sites	B-X
completely	B-X
abolished	B-X
LPS	B-X
induction	B-X
,	B-X
suggesting	B-X
a	B-X
cooperative	B-X
interaction	B-X
between	B-X
c-Jun	B-X
complexes	B-X
and	B-X
p50/p65	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
maximal	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TNF-alpha	B-X
promoter	B-X
is	B-X
mediated	B-X
by	B-X
concerted	B-X
participation	B-X
of	B-X
at	B-X
least	B-X
two	B-X
separate	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
.	B-X

Furthermore	O
,	O
increasing	O
the	O
spacing	O
between	O
the	O
CRE	O
and	O
the	O
kappaB3	O
sites	O
completely	O
abolished	O
LPS	O
induction	O
,	O
suggesting	O
a	O
cooperative	O
interaction	O
between	O
c	B-Protein
-	I-Protein
Jun	I-Protein
complexes	O
and	O
p50	B-Protein
/	O
p65	B-Protein
.	O
<EOS>	B-X
Biosynthesis	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
is	B-X
predominantly	B-X
by	B-X
cells	B-X
of	B-X
the	B-X
monocytic	B-X
lineage	B-X
.	B-X
This	B-X
study	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
various	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
in	B-X
the	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induction	B-X
of	B-X
the	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
in	B-X
cells	B-X
of	B-X
monocytic	B-X
lineage	B-X
.	B-X
Functional	B-X
analysis	B-X
of	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
transfected	B-X
with	B-X
plasmids	B-X
containing	B-X
various	B-X
lengths	B-X
of	B-X
TNF-alpha	B-X
promoter	B-X
localized	B-X
enhancer	B-X
elements	B-X
in	B-X
a	B-X
region	B-X
(	B-X
-182	B-X
to	B-X
-37	B-X
base	B-X
pairs	B-X
(	B-X
bp	B-X
)	B-X
)	B-X
that	B-X
were	B-X
required	B-X
for	B-X
optimal	B-X
transcription	B-X
of	B-X
the	B-X
TNF-alpha	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X
Two	B-X
regions	B-X
were	B-X
identified	B-X
:	B-X
region	B-X
I	B-X
(	B-X
-182	B-X
to	B-X
-162	B-X
bp	B-X
)	B-X
contained	B-X
an	B-X
overlapping	B-X
Sp1/Egr-1	B-X
site	B-X
,	B-X
and	B-X
region	B-X
II	B-X
(	B-X
-119	B-X
to	B-X
-88	B-X
)	B-X
contained	B-X
CRE	B-X
and	B-X
NF-kappaB	B-X
(	B-X
designated	B-X
kappaB3	B-X
)	B-X
sites	B-X
.	B-X
In	B-X
unstimulated	B-X
THP-1	B-X
,	B-X
CRE-binding	B-X
protein	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
,	B-X
c-Jun	B-X
complexes	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
the	B-X
CRE	B-X
site	B-X
.	B-X
LPS	B-X
stimulation	B-X
increased	B-X
the	B-X
binding	B-X
of	B-X
c-Jun-containing	B-X
complexes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
LPS	B-X
stimulation	B-X
induced	B-X
the	B-X
binding	B-X
of	B-X
cognate	B-X
nuclear	B-X
factors	B-X
to	B-X
the	B-X
Egr-1	B-X
and	B-X
kappaB3	B-X
sites	B-X
,	B-X
which	B-X
were	B-X
identified	B-X
as	B-X
Egr-1	B-X
and	B-X
p50/p65	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
CRE	B-X
and	B-X
kappaB3	B-X
sites	B-X
in	B-X
region	B-X
II	B-X
together	B-X
conferred	B-X
strong	B-X
LPS	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
,	B-X
whereas	B-X
individually	B-X
they	B-X
failed	B-X
to	B-X
provide	B-X
transcriptional	B-X
activation	B-X
.	B-X
Furthermore	B-X
,	B-X
increasing	B-X
the	B-X
spacing	B-X
between	B-X
the	B-X
CRE	B-X
and	B-X
the	B-X
kappaB3	B-X
sites	B-X
completely	B-X
abolished	B-X
LPS	B-X
induction	B-X
,	B-X
suggesting	B-X
a	B-X
cooperative	B-X
interaction	B-X
between	B-X
c-Jun	B-X
complexes	B-X
and	B-X
p50/p65	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
maximal	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TNF-alpha	B-X
promoter	B-X
is	B-X
mediated	B-X
by	B-X
concerted	B-X
participation	B-X
of	B-X
at	B-X
least	B-X
two	B-X
separate	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
.	B-X

These	O
studies	O
indicate	O
that	O
maximal	O
LPS	O
induction	O
of	O
the	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
promoter	O
is	O
mediated	O
by	O
concerted	O
participation	O
of	O
at	O
least	O
two	O
separate	O
cis	O
-	O
acting	O
regulatory	O
elements	O
.	O
<EOS>	B-X
Biosynthesis	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
is	B-X
predominantly	B-X
by	B-X
cells	B-X
of	B-X
the	B-X
monocytic	B-X
lineage	B-X
.	B-X
This	B-X
study	B-X
examined	B-X
the	B-X
role	B-X
of	B-X
various	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
in	B-X
the	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induction	B-X
of	B-X
the	B-X
human	B-X
TNF-alpha	B-X
promoter	B-X
in	B-X
cells	B-X
of	B-X
monocytic	B-X
lineage	B-X
.	B-X
Functional	B-X
analysis	B-X
of	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
transfected	B-X
with	B-X
plasmids	B-X
containing	B-X
various	B-X
lengths	B-X
of	B-X
TNF-alpha	B-X
promoter	B-X
localized	B-X
enhancer	B-X
elements	B-X
in	B-X
a	B-X
region	B-X
(	B-X
-182	B-X
to	B-X
-37	B-X
base	B-X
pairs	B-X
(	B-X
bp	B-X
)	B-X
)	B-X
that	B-X
were	B-X
required	B-X
for	B-X
optimal	B-X
transcription	B-X
of	B-X
the	B-X
TNF-alpha	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X
LPS	B-X
stimulation	B-X
increased	B-X
the	B-X
binding	B-X
of	B-X
c-Jun-containing	B-X
complexes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
LPS	B-X
stimulation	B-X
induced	B-X
the	B-X
binding	B-X
of	B-X
cognate	B-X
nuclear	B-X
factors	B-X
to	B-X
the	B-X
Egr-1	B-X
and	B-X
kappaB3	B-X
sites	B-X
,	B-X
which	B-X
were	B-X
identified	B-X
as	B-X
Egr-1	B-X
and	B-X
p50/p65	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
CRE	B-X
and	B-X
kappaB3	B-X
sites	B-X
in	B-X
region	B-X
II	B-X
together	B-X
conferred	B-X
strong	B-X
LPS	B-X
responsiveness	B-X
to	B-X
a	B-X
heterologous	B-X
promoter	B-X
,	B-X
whereas	B-X
individually	B-X
they	B-X
failed	B-X
to	B-X
provide	B-X
transcriptional	B-X
activation	B-X
.	B-X
Furthermore	B-X
,	B-X
increasing	B-X
the	B-X
spacing	B-X
between	B-X
the	B-X
CRE	B-X
and	B-X
the	B-X
kappaB3	B-X
sites	B-X
completely	B-X
abolished	B-X
LPS	B-X
induction	B-X
,	B-X
suggesting	B-X
a	B-X
cooperative	B-X
interaction	B-X
between	B-X
c-Jun	B-X
complexes	B-X
and	B-X
p50/p65	B-X
.	B-X
These	B-X
studies	B-X
indicate	B-X
that	B-X
maximal	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TNF-alpha	B-X
promoter	B-X
is	B-X
mediated	B-X
by	B-X
concerted	B-X
participation	B-X
of	B-X
at	B-X
least	B-X
two	B-X
separate	B-X
cis-acting	B-X
regulatory	B-X
elements	B-X
.	B-X

Involvement	O
of	O
Rel	O
,	O
Fos	B-Protein
,	O
and	O
Jun	B-Protein
proteins	O
in	O
binding	O
activity	O
to	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
CD28	B-Protein
response	O
element	O
/	O
AP	O
-	O
1	O
sequence	O
in	O
human	O
T	O
cells	O
.	O

CD28	B-Protein
is	O
an	O
important	O
costimulatory	O
molecule	O
in	O
the	O
activation	O
of	O
human	O
T	O
cells	O
.	O

Costimulation	O
of	O
T	O
cells	O
through	O
both	O
the	O
Ag	O
receptor	O
and	O
CD28	B-Protein
leads	O
to	O
high	O
level	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
,	O
which	O
is	O
vital	O
to	O
the	O
development	O
of	O
an	O
immune	O
response	O
in	O
vivo	O
.	O

Previous	O
reports	O
have	O
suggested	O
the	O
CD28	B-Protein
stimulation	O
contributes	O
to	O
the	O
activation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
by	O
up	O
-	O
regulating	O
the	O
activity	O
of	O
several	O
transcription	O
factors	O
,	O
including	O
AP	O
-	O
1	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
/	O
Rel	O
family	O
members	O
as	O
well	O
as	O
an	O
uncharacterized	O
transcription	O
factor	O
called	O
CD28	B-Protein
response	O
complex	O
.	O

While	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
members	O
make	O
up	O
the	O
CD28	B-Protein
response	O
complex	O
transcription	O
factor	O
,	O
other	O
work	O
has	O
not	O
supported	O
this	O
conclusion	O
.	O

Recent	O
studies	O
suggest	O
that	O
the	O
CD28	B-Protein
response	O
element	O
(	O
CD28RE	O
)	O
does	O
not	O
function	O
independently	O
but	O
works	O
instead	O
in	O
conjunction	O
with	O
the	O
adjacent	O
promoter	O
proximal	O
AP	O
-	O
1	O
-	O
binding	O
site	O
and	O
this	O
hypothesis	O
is	O
confirmed	O
here	O
.	O
<EOS>	B-X
The	B-X
Tax	B-X
protein	B-X
of	B-X
human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV-1	B-X
)	B-X
upregulates	B-X
the	B-X
expression	B-X
of	B-X
several	B-X
cellular	B-X
genes	B-X
by	B-X
activating	B-X
members	B-X
of	B-X
both	B-X
the	B-X
NF-kappaB	B-X
and	B-X
bZIP	B-X
families	B-X
of	B-X
transcription	B-X
factors	B-X
.	B-X
Recent	B-X
studies	B-X
demonstrate	B-X
that	B-X
the	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
of	B-X
the	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
promoter	B-X
is	B-X
the	B-X
site	B-X
upregulated	B-X
by	B-X
Tax	B-X
in	B-X
stimulated	B-X
T	B-X
cells	B-X
.	B-X
Although	B-X
some	B-X
reports	B-X
suggest	B-X
that	B-X
this	B-X
site	B-X
is	B-X
transactivated	B-X
by	B-X
NF-kappaB	B-X
family	B-X
members	B-X
,	B-X
others	B-X
disagree	B-X
,	B-X
leaving	B-X
the	B-X
identity	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
(	B-X
s	B-X
)	B-X
binding	B-X
the	B-X
CD28RE	B-X
unclear	B-X
.	B-X
The	B-X
studies	B-X
presented	B-X
here	B-X
further	B-X
characterize	B-X
the	B-X
response	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
and	B-X
CD28RE	B-X
to	B-X
the	B-X
HTLV-1	B-X
Tax	B-X
protein	B-X
and	B-X
demonstrate	B-X
that	B-X
the	B-X
TATA-proximal	B-X
AP-1	B-X
binding	B-X
site	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
is	B-X
also	B-X
necessary	B-X
for	B-X
Tax	B-X
transactivation	B-X
in	B-X
stimulated	B-X
Jurkat	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
its	B-X
upregulation	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
which	B-X
requires	B-X
T-cell	B-X
stimulation	B-X
,	B-X
Tax	B-X
transactivates	B-X
the	B-X
isolated	B-X
CD28RE-AP-1	B-X
element	B-X
without	B-X
stimulation	B-X
but	B-X
is	B-X
greatly	B-X
synergized	B-X
by	B-X
calcium	B-X
ionophore	B-X
and	B-X
phorbol	B-X
ester	B-X
.	B-X
Additionally	B-X
,	B-X
transactivation	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
requires	B-X
the	B-X
Tax	B-X
activation	B-X
domain	B-X
involved	B-X
in	B-X
upregulation	B-X
of	B-X
bZIP-enhanced	B-X
transcription	B-X
while	B-X
the	B-X
NF-kappaB-activating	B-X
domain	B-X
of	B-X
Tax	B-X
is	B-X
dispensable	B-X
.	B-X
Interestingly	B-X
,	B-X
both	B-X
domains	B-X
appear	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
isolated	B-X
CD28RE-AP-1	B-X
sequence	B-X
in	B-X
the	B-X
context	B-X
of	B-X
a	B-X
heterologous	B-X
promoter	B-X
construct	B-X
.	B-X
This	B-X
strongly	B-X
suggests	B-X
that	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
is	B-X
insufficient	B-X
to	B-X
activate	B-X
transcription	B-X
via	B-X
the	B-X
CD28RE-AP-1	B-X
element	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
and	B-X
that	B-X
a	B-X
different	B-X
transcription	B-X
factor	B-X
,	B-X
upregulated	B-X
via	B-X
the	B-X
activation	B-X
domain	B-X
of	B-X
the	B-X
HTLV-1	B-X
Tax	B-X
protein	B-X
,	B-X
may	B-X
be	B-X
involved	B-X
.	B-X

Also	O
in	O
the	O
current	O
study	O
,	O
binding	O
activity	O
to	O
the	O
CD28RE	O
/	O
AP	O
-	O
1	O
sequence	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
is	O
evaluated	O
.	O

Although	O
four	O
specific	O
complexes	O
can	O
be	O
detected	O
binding	O
to	O
this	O
sequence	O
,	O
only	O
one	O
of	O
these	O
complexes	O
is	O
specific	O
for	O
both	O
the	O
CD28RE	O
and	O
the	O
adjacent	O
AP	O
-	O
1	O
site	O
.	O
<EOS>	B-X
Previous	B-X
reports	B-X
have	B-X
suggested	B-X
the	B-X
CD28	B-X
stimulation	B-X
contributes	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
by	B-X
up-regulating	B-X
the	B-X
activity	B-X
of	B-X
several	B-X
transcription	B-X
factors	B-X
,	B-X
including	B-X
AP-1	B-X
and	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
/Rel	B-X
family	B-X
members	B-X
as	B-X
well	B-X
as	B-X
an	B-X
uncharacterized	B-X
transcription	B-X
factor	B-X
called	B-X
CD28	B-X
response	B-X
complex	B-X
.	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
the	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
does	B-X
not	B-X
function	B-X
independently	B-X
but	B-X
works	B-X
instead	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
adjacent	B-X
promoter	B-X
proximal	B-X
AP-1-binding	B-X
site	B-X
and	B-X
this	B-X
hypothesis	B-X
is	B-X
confirmed	B-X
here	B-X
.	B-X
Also	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
binding	B-X
activity	B-X
to	B-X
the	B-X
CD28RE/AP-1	B-X
sequence	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
is	B-X
evaluated	B-X
.	B-X
Although	B-X
four	B-X
specific	B-X
complexes	B-X
can	B-X
be	B-X
detected	B-X
binding	B-X
to	B-X
this	B-X
sequence	B-X
,	B-X
only	B-X
one	B-X
of	B-X
these	B-X
complexes	B-X
is	B-X
specific	B-X
for	B-X
both	B-X
the	B-X
CD28RE	B-X
and	B-X
the	B-X
adjacent	B-X
AP-1	B-X
site	B-X
.	B-X
Of	B-X
the	B-X
NF-kappaB/Rel	B-X
family	B-X
members	B-X
tested	B-X
,	B-X
this	B-X
CD28RE/AP-1-specific	B-X
complex	B-X
contains	B-X
predominantly	B-X
c-Rel	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
both	B-X
p50	B-X
and	B-X
RelA	B-X
can	B-X
efficiently	B-X
bind	B-X
to	B-X
the	B-X
CD28RE	B-X
.	B-X
c-Fos	B-X
and	B-X
c-Jun	B-X
are	B-X
also	B-X
found	B-X
in	B-X
this	B-X
CD28RE/AP-1-specific	B-X
complex	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
functional	B-X
complexes	B-X
encompassing	B-X
both	B-X
the	B-X
CD28RE	B-X
and	B-X
the	B-X
AP-1-binding	B-X
sites	B-X
influence	B-X
IL-2	B-X
promoter	B-X
activity	B-X
in	B-X
CD28-costimulated	B-X
T	B-X
cells	B-X
.	B-X

Of	O
the	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
members	O
tested	O
,	O
this	O
CD28RE	O
/	O
AP	O
-	O
1	O
-	O
specific	O
complex	O
contains	O
predominantly	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
despite	O
the	O
fact	O
that	O
both	O
p50	B-Protein
and	O
RelA	B-Protein
can	O
efficiently	O
bind	O
to	O
the	O
CD28RE	O
.	O

c	B-Protein
-	I-Protein
Fos	I-Protein
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
are	O
also	O
found	O
in	O
this	O
CD28RE	O
/	O
AP	O
-	O
1	O
-	O
specific	O
complex	O
.	O

These	O
data	O
indicate	O
that	O
functional	O
complexes	O
encompassing	O
both	O
the	O
CD28RE	O
and	O
the	O
AP	O
-	O
1	O
-	O
binding	O
sites	O
influence	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
activity	O
in	O
CD28	B-Protein
-	O
costimulated	O
T	O
cells	O
.	O
<EOS>	B-X
CD28	B-X
is	B-X
an	B-X
important	B-X
costimulatory	B-X
molecule	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
.	B-X
Costimulation	B-X
of	B-X
T	B-X
cells	B-X
through	B-X
both	B-X
the	B-X
Ag	B-X
receptor	B-X
and	B-X
CD28	B-X
leads	B-X
to	B-X
high	B-X
level	B-X
IL-2	B-X
production	B-X
,	B-X
which	B-X
is	B-X
vital	B-X
to	B-X
the	B-X
development	B-X
of	B-X
an	B-X
immune	B-X
response	B-X
in	B-X
vivo	B-X
.	B-X
Previous	B-X
reports	B-X
have	B-X
suggested	B-X
the	B-X
CD28	B-X
stimulation	B-X
contributes	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
by	B-X
up-regulating	B-X
the	B-X
activity	B-X
of	B-X
several	B-X
transcription	B-X
factors	B-X
,	B-X
including	B-X
AP-1	B-X
and	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
/Rel	B-X
family	B-X
members	B-X
as	B-X
well	B-X
as	B-X
an	B-X
uncharacterized	B-X
transcription	B-X
factor	B-X
called	B-X
CD28	B-X
response	B-X
complex	B-X
.	B-X
While	B-X
several	B-X
lines	B-X
of	B-X
investigation	B-X
have	B-X
suggested	B-X
that	B-X
NF-kappaB/Rel	B-X
family	B-X
members	B-X
make	B-X
up	B-X
the	B-X
CD28	B-X
response	B-X
complex	B-X
transcription	B-X
factor	B-X
,	B-X
other	B-X
work	B-X
has	B-X
not	B-X
supported	B-X
this	B-X
conclusion	B-X
.	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
the	B-X
CD28	B-X
response	B-X
element	B-X
(	B-X
CD28RE	B-X
)	B-X
does	B-X
not	B-X
function	B-X
independently	B-X
but	B-X
works	B-X
instead	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
adjacent	B-X
promoter	B-X
proximal	B-X
AP-1-binding	B-X
site	B-X
and	B-X
this	B-X
hypothesis	B-X
is	B-X
confirmed	B-X
here	B-X
.	B-X
Also	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
binding	B-X
activity	B-X
to	B-X
the	B-X
CD28RE/AP-1	B-X
sequence	B-X
of	B-X
the	B-X
IL-2	B-X
promoter	B-X
is	B-X
evaluated	B-X
.	B-X
Although	B-X
four	B-X
specific	B-X
complexes	B-X
can	B-X
be	B-X
detected	B-X
binding	B-X
to	B-X
this	B-X
sequence	B-X
,	B-X
only	B-X
one	B-X
of	B-X
these	B-X
complexes	B-X
is	B-X
specific	B-X
for	B-X
both	B-X
the	B-X
CD28RE	B-X
and	B-X
the	B-X
adjacent	B-X
AP-1	B-X
site	B-X
.	B-X
Of	B-X
the	B-X
NF-kappaB/Rel	B-X
family	B-X
members	B-X
tested	B-X
,	B-X
this	B-X
CD28RE/AP-1-specific	B-X
complex	B-X
contains	B-X
predominantly	B-X
c-Rel	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
both	B-X
p50	B-X
and	B-X
RelA	B-X
can	B-X
efficiently	B-X
bind	B-X
to	B-X
the	B-X
CD28RE	B-X
.	B-X
c-Fos	B-X
and	B-X
c-Jun	B-X
are	B-X
also	B-X
found	B-X
in	B-X
this	B-X
CD28RE/AP-1-specific	B-X
complex	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
functional	B-X
complexes	B-X
encompassing	B-X
both	B-X
the	B-X
CD28RE	B-X
and	B-X
the	B-X
AP-1-binding	B-X
sites	B-X
influence	B-X
IL-2	B-X
promoter	B-X
activity	B-X
in	B-X
CD28-costimulated	B-X
T	B-X
cells	B-X
.	B-X

c	B-Protein
-	I-Protein
Myb	I-Protein
and	O
Ets	O
proteins	O
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	B-Protein
.	O
<EOS>	B-X
The	B-X
Zfh	B-X
family	B-X
of	B-X
zinc	B-X
finger/homeodomain	B-X
proteins	B-X
was	B-X
first	B-X
identified	B-X
in	B-X
Drosophila	B-X
where	B-X
it	B-X
is	B-X
required	B-X
for	B-X
differentiation	B-X
of	B-X
tissues	B-X
such	B-X
as	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
and	B-X
muscle	B-X
.	B-X
ZEB	B-X
,	B-X
a	B-X
vertebrate	B-X
homolog	B-X
of	B-X
Zfh-1	B-X
,	B-X
binds	B-X
a	B-X
subset	B-X
of	B-X
E	B-X
boxes	B-X
and	B-X
blocks	B-X
myogenesis	B-X
through	B-X
transcriptional	B-X
repression	B-X
of	B-X
muscle	B-X
genes	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
here	B-X
that	B-X
ZEB	B-X
also	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
controlling	B-X
hematopoietic	B-X
gene	B-X
transcription	B-X
.	B-X
Two	B-X
families	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
hematopoiesis	B-X
are	B-X
c-Myb	B-X
and	B-X
Ets	B-X
.	B-X
These	B-X
factors	B-X
act	B-X
synergistically	B-X
to	B-X
activate	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
synergy	B-X
is	B-X
required	B-X
for	B-X
transcription	B-X
of	B-X
at	B-X
least	B-X
several	B-X
important	B-X
hematopoietic	B-X
genes	B-X
.	B-X
ZEB	B-X
blocks	B-X
the	B-X
activity	B-X
of	B-X
c-Myb	B-X
and	B-X
Ets	B-X
individually	B-X
,	B-X
but	B-X
together	B-X
the	B-X
factors	B-X
synergize	B-X
to	B-X
resist	B-X
this	B-X
repression	B-X
.	B-X
Such	B-X
repression	B-X
imposes	B-X
a	B-X
requirement	B-X
for	B-X
both	B-X
c-Myb	B-X
and	B-X
Ets	B-X
for	B-X
transcriptional	B-X
activity	B-X
,	B-X
providing	B-X
one	B-X
explanation	B-X
for	B-X
why	B-X
synergy	B-X
between	B-X
these	B-X
factors	B-X
is	B-X
important	B-X
.	B-X
The	B-X
balance	B-X
between	B-X
repression	B-X
by	B-X
ZEB	B-X
and	B-X
transcriptional	B-X
activation	B-X
by	B-X
c-Myb/Ets	B-X
provides	B-X
a	B-X
flexible	B-X
regulatory	B-X
mechanism	B-X
for	B-X
controlling	B-X
gene	B-X
expression	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
one	B-X
target	B-X
of	B-X
this	B-X
positive/negative	B-X
regulation	B-X
in	B-X
vivo	B-X
is	B-X
the	B-X
alpha4	B-X
integrin	B-X
,	B-X
which	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
normal	B-X
hematopoiesis	B-X
and	B-X
function	B-X
of	B-X
mature	B-X
leukocytes	B-X
.	B-X

The	O
Zfh	O
family	O
of	O
zinc	O
finger	O
/	O
homeodomain	O
proteins	O
was	O
first	O
identified	O
in	O
Drosophila	O
where	O
it	O
is	O
required	O
for	O
differentiation	O
of	O
tissues	O
such	O
as	O
the	O
central	O
nervous	O
system	O
and	O
muscle	O
.	O
<EOS>	B-X
The	B-X
Zfh	B-X
family	B-X
of	B-X
zinc	B-X
finger/homeodomain	B-X
proteins	B-X
was	B-X
first	B-X
identified	B-X
in	B-X
Drosophila	B-X
where	B-X
it	B-X
is	B-X
required	B-X
for	B-X
differentiation	B-X
of	B-X
tissues	B-X
such	B-X
as	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
and	B-X
muscle	B-X
.	B-X
ZEB	B-X
,	B-X
a	B-X
vertebrate	B-X
homolog	B-X
of	B-X
Zfh-1	B-X
,	B-X
binds	B-X
a	B-X
subset	B-X
of	B-X
E	B-X
boxes	B-X
and	B-X
blocks	B-X
myogenesis	B-X
through	B-X
transcriptional	B-X
repression	B-X
of	B-X
muscle	B-X
genes	B-X
.	B-X
Two	B-X
families	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
hematopoiesis	B-X
are	B-X
c-Myb	B-X
and	B-X
Ets	B-X
.	B-X
These	B-X
factors	B-X
act	B-X
synergistically	B-X
to	B-X
activate	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
synergy	B-X
is	B-X
required	B-X
for	B-X
transcription	B-X
of	B-X
at	B-X
least	B-X
several	B-X
important	B-X
hematopoietic	B-X
genes	B-X
.	B-X

ZEB	B-Protein
,	O
a	O
vertebrate	O
homolog	O
of	O
Zfh	O
-	O
1	O
,	O
binds	O
a	O
subset	O
of	O
E	O
boxes	O
and	O
blocks	O
myogenesis	O
through	O
transcriptional	O
repression	O
of	O
muscle	O
genes	O
.	O

We	O
present	O
evidence	O
here	O
that	O
ZEB	B-Protein
also	O
has	O
an	O
important	O
role	O
in	O
controlling	O
hematopoietic	O
gene	O
transcription	O
.	O
<EOS>	B-X
ZEB	B-X
,	B-X
a	B-X
vertebrate	B-X
homolog	B-X
of	B-X
Zfh-1	B-X
,	B-X
binds	B-X
a	B-X
subset	B-X
of	B-X
E	B-X
boxes	B-X
and	B-X
blocks	B-X
myogenesis	B-X
through	B-X
transcriptional	B-X
repression	B-X
of	B-X
muscle	B-X
genes	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
here	B-X
that	B-X
ZEB	B-X
also	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
controlling	B-X
hematopoietic	B-X
gene	B-X
transcription	B-X
.	B-X
Two	B-X
families	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
hematopoiesis	B-X
are	B-X
c-Myb	B-X
and	B-X
Ets	B-X
.	B-X
These	B-X
factors	B-X
act	B-X
synergistically	B-X
to	B-X
activate	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
synergy	B-X
is	B-X
required	B-X
for	B-X
transcription	B-X
of	B-X
at	B-X
least	B-X
several	B-X
important	B-X
hematopoietic	B-X
genes	B-X
.	B-X
ZEB	B-X
blocks	B-X
the	B-X
activity	B-X
of	B-X
c-Myb	B-X
and	B-X
Ets	B-X
individually	B-X
,	B-X
but	B-X
together	B-X
the	B-X
factors	B-X
synergize	B-X
to	B-X
resist	B-X
this	B-X
repression	B-X
.	B-X
Such	B-X
repression	B-X
imposes	B-X
a	B-X
requirement	B-X
for	B-X
both	B-X
c-Myb	B-X
and	B-X
Ets	B-X
for	B-X
transcriptional	B-X
activity	B-X
,	B-X
providing	B-X
one	B-X
explanation	B-X
for	B-X
why	B-X
synergy	B-X
between	B-X
these	B-X
factors	B-X
is	B-X
important	B-X
.	B-X
The	B-X
balance	B-X
between	B-X
repression	B-X
by	B-X
ZEB	B-X
and	B-X
transcriptional	B-X
activation	B-X
by	B-X
c-Myb/Ets	B-X
provides	B-X
a	B-X
flexible	B-X
regulatory	B-X
mechanism	B-X
for	B-X
controlling	B-X
gene	B-X
expression	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
one	B-X
target	B-X
of	B-X
this	B-X
positive/negative	B-X
regulation	B-X
in	B-X
vivo	B-X
is	B-X
the	B-X
alpha4	B-X
integrin	B-X
,	B-X
which	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
normal	B-X
hematopoiesis	B-X
and	B-X
function	B-X
of	B-X
mature	B-X
leukocytes	B-X
.	B-X

Two	O
families	O
of	O
transcription	O
factors	O
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c	B-Protein
-	I-Protein
Myb	I-Protein
and	O
Ets	O
.	O

These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	O
genes	O
.	O
<EOS>	B-X
The	B-X
Zfh	B-X
family	B-X
of	B-X
zinc	B-X
finger/homeodomain	B-X
proteins	B-X
was	B-X
first	B-X
identified	B-X
in	B-X
Drosophila	B-X
where	B-X
it	B-X
is	B-X
required	B-X
for	B-X
differentiation	B-X
of	B-X
tissues	B-X
such	B-X
as	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
and	B-X
muscle	B-X
.	B-X
ZEB	B-X
,	B-X
a	B-X
vertebrate	B-X
homolog	B-X
of	B-X
Zfh-1	B-X
,	B-X
binds	B-X
a	B-X
subset	B-X
of	B-X
E	B-X
boxes	B-X
and	B-X
blocks	B-X
myogenesis	B-X
through	B-X
transcriptional	B-X
repression	B-X
of	B-X
muscle	B-X
genes	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
here	B-X
that	B-X
ZEB	B-X
also	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
controlling	B-X
hematopoietic	B-X
gene	B-X
transcription	B-X
.	B-X
Two	B-X
families	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
hematopoiesis	B-X
are	B-X
c-Myb	B-X
and	B-X
Ets	B-X
.	B-X
These	B-X
factors	B-X
act	B-X
synergistically	B-X
to	B-X
activate	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
synergy	B-X
is	B-X
required	B-X
for	B-X
transcription	B-X
of	B-X
at	B-X
least	B-X
several	B-X
important	B-X
hematopoietic	B-X
genes	B-X
.	B-X
ZEB	B-X
blocks	B-X
the	B-X
activity	B-X
of	B-X
c-Myb	B-X
and	B-X
Ets	B-X
individually	B-X
,	B-X
but	B-X
together	B-X
the	B-X
factors	B-X
synergize	B-X
to	B-X
resist	B-X
this	B-X
repression	B-X
.	B-X
Such	B-X
repression	B-X
imposes	B-X
a	B-X
requirement	B-X
for	B-X
both	B-X
c-Myb	B-X
and	B-X
Ets	B-X
for	B-X
transcriptional	B-X
activity	B-X
,	B-X
providing	B-X
one	B-X
explanation	B-X
for	B-X
why	B-X
synergy	B-X
between	B-X
these	B-X
factors	B-X
is	B-X
important	B-X
.	B-X
The	B-X
balance	B-X
between	B-X
repression	B-X
by	B-X
ZEB	B-X
and	B-X
transcriptional	B-X
activation	B-X
by	B-X
c-Myb/Ets	B-X
provides	B-X
a	B-X
flexible	B-X
regulatory	B-X
mechanism	B-X
for	B-X
controlling	B-X
gene	B-X
expression	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X

ZEB	B-Protein
blocks	O
the	O
activity	O
of	O
c	B-Protein
-	I-Protein
Myb	I-Protein
and	O
Ets	O
individually	O
,	O
but	O
together	O
the	O
factors	O
synergize	O
to	O
resist	O
this	O
repression	O
.	O
<EOS>	B-X
The	B-X
Zfh	B-X
family	B-X
of	B-X
zinc	B-X
finger/homeodomain	B-X
proteins	B-X
was	B-X
first	B-X
identified	B-X
in	B-X
Drosophila	B-X
where	B-X
it	B-X
is	B-X
required	B-X
for	B-X
differentiation	B-X
of	B-X
tissues	B-X
such	B-X
as	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
and	B-X
muscle	B-X
.	B-X
ZEB	B-X
,	B-X
a	B-X
vertebrate	B-X
homolog	B-X
of	B-X
Zfh-1	B-X
,	B-X
binds	B-X
a	B-X
subset	B-X
of	B-X
E	B-X
boxes	B-X
and	B-X
blocks	B-X
myogenesis	B-X
through	B-X
transcriptional	B-X
repression	B-X
of	B-X
muscle	B-X
genes	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
here	B-X
that	B-X
ZEB	B-X
also	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
controlling	B-X
hematopoietic	B-X
gene	B-X
transcription	B-X
.	B-X
Two	B-X
families	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
hematopoiesis	B-X
are	B-X
c-Myb	B-X
and	B-X
Ets	B-X
.	B-X
These	B-X
factors	B-X
act	B-X
synergistically	B-X
to	B-X
activate	B-X
transcription	B-X
,	B-X
and	B-X
this	B-X
synergy	B-X
is	B-X
required	B-X
for	B-X
transcription	B-X
of	B-X
at	B-X
least	B-X
several	B-X
important	B-X
hematopoietic	B-X
genes	B-X
.	B-X
ZEB	B-X
blocks	B-X
the	B-X
activity	B-X
of	B-X
c-Myb	B-X
and	B-X
Ets	B-X
individually	B-X
,	B-X
but	B-X
together	B-X
the	B-X
factors	B-X
synergize	B-X
to	B-X
resist	B-X
this	B-X
repression	B-X
.	B-X
Such	B-X
repression	B-X
imposes	B-X
a	B-X
requirement	B-X
for	B-X
both	B-X
c-Myb	B-X
and	B-X
Ets	B-X
for	B-X
transcriptional	B-X
activity	B-X
,	B-X
providing	B-X
one	B-X
explanation	B-X
for	B-X
why	B-X
synergy	B-X
between	B-X
these	B-X
factors	B-X
is	B-X
important	B-X
.	B-X
The	B-X
balance	B-X
between	B-X
repression	B-X
by	B-X
ZEB	B-X
and	B-X
transcriptional	B-X
activation	B-X
by	B-X
c-Myb/Ets	B-X
provides	B-X
a	B-X
flexible	B-X
regulatory	B-X
mechanism	B-X
for	B-X
controlling	B-X
gene	B-X
expression	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
one	B-X
target	B-X
of	B-X
this	B-X
positive/negative	B-X
regulation	B-X
in	B-X
vivo	B-X
is	B-X
the	B-X
alpha4	B-X
integrin	B-X
,	B-X
which	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
normal	B-X
hematopoiesis	B-X
and	B-X
function	B-X
of	B-X
mature	B-X
leukocytes	B-X
.	B-X

Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c	B-Protein
-	I-Protein
Myb	I-Protein
and	O
Ets	O
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O

The	O
balance	O
between	O
repression	O
by	O
ZEB	B-Protein
and	O
transcriptional	O
activation	O
by	O
c	B-Protein
-	I-Protein
Myb	I-Protein
/	O
Ets	O
provides	O
a	O
flexible	O
regulatory	O
mechanism	O
for	O
controlling	O
gene	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive	O
/	O
negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	B-Protein
integrin	I-Protein
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	O
leukocytes	O
.	O
<EOS>	B-X
We	B-X
present	B-X
evidence	B-X
here	B-X
that	B-X
ZEB	B-X
also	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
controlling	B-X
hematopoietic	B-X
gene	B-X
transcription	B-X
.	B-X
Two	B-X
families	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
required	B-X
for	B-X
normal	B-X
hematopoiesis	B-X
are	B-X
c-Myb	B-X
and	B-X
Ets	B-X
.	B-X
Such	B-X
repression	B-X
imposes	B-X
a	B-X
requirement	B-X
for	B-X
both	B-X
c-Myb	B-X
and	B-X
Ets	B-X
for	B-X
transcriptional	B-X
activity	B-X
,	B-X
providing	B-X
one	B-X
explanation	B-X
for	B-X
why	B-X
synergy	B-X
between	B-X
these	B-X
factors	B-X
is	B-X
important	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
one	B-X
target	B-X
of	B-X
this	B-X
positive/negative	B-X
regulation	B-X
in	B-X
vivo	B-X
is	B-X
the	B-X
alpha4	B-X
integrin	B-X
,	B-X
which	B-X
play	B-X
a	B-X
key	B-X
role	B-X
in	B-X
normal	B-X
hematopoiesis	B-X
and	B-X
function	B-X
of	B-X
mature	B-X
leukocytes	B-X
.	B-X

GABP	O
factors	O
bind	O
to	O
a	O
distal	O
interleukin	B-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
enhancer	O
and	O
contribute	O
to	O
c	B-Protein
-	I-Protein
Raf	I-Protein
-	O
mediated	O
increase	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
induction	O
.	O

Triggering	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
-	O
CD3	O
complex	O
activates	O
two	O
major	O
signal	O
cascades	O
in	O
T	O
lymphocytes	O
,	O
(	O
i	O
)	O
Ca2	O
+	O
-	O
dependent	O
signal	O
cascades	O
and	O
(	O
ii	O
)	O
protein	O
kinase	O
cascades	O
.	O

Both	O
signal	O
cascades	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
interleukin	B-Protein
2	I-Protein
(	B-Protein
IL	I-Protein
-	I-Protein
2	I-Protein
)	O
gene	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Prominent	O
protein	O
kinase	O
cascades	O
are	O
those	O
that	O
activate	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
.	O
<EOS>	B-X
Heterotrimeric	B-X
GTP-binding	B-X
protein	B-X
(	B-X
G-protein	B-X
)	B-X
-coupled	B-X
receptors	B-X
are	B-X
able	B-X
to	B-X
induce	B-X
a	B-X
variety	B-X
of	B-X
responses	B-X
including	B-X
cell	B-X
proliferation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
several	B-X
intracellular	B-X
kinase	B-X
cascades	B-X
.	B-X
Prominent	B-X
among	B-X
these	B-X
kinases	B-X
are	B-X
the	B-X
activation	B-X
of	B-X
mitogen-activated	B-X
protein	B-X
(	B-X
MAP	B-X
)	B-X
kinase	B-X
,	B-X
including	B-X
the	B-X
extracellular	B-X
signal-regulated	B-X
kinases	B-X
(	B-X
ERKs	B-X
)	B-X
,	B-X
ERK1	B-X
and	B-X
ERK2	B-X
(	B-X
p44mapk	B-X
and	B-X
p42mapk	B-X
,	B-X
respectively	B-X
)	B-X
;	B-X
stress-activated	B-X
protein	B-X
kinases	B-X
(	B-X
SAPKs/JNKs	B-X
)	B-X
;	B-X
and	B-X
p38	B-X
kinase	B-X
.	B-X
These	B-X
receptors	B-X
signal	B-X
through	B-X
G-proteins	B-X
.	B-X
Recent	B-X
data	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
activation	B-X
of	B-X
mitogen-activated	B-X
protein/ERK	B-X
kinase	B-X
induced	B-X
by	B-X
G-protein-coupled	B-X
receptors	B-X
is	B-X
mediated	B-X
by	B-X
both	B-X
Galpha	B-X
and	B-X
Gbetagamma	B-X
subunits	B-X
involving	B-X
a	B-X
common	B-X
signaling	B-X
pathway	B-X
with	B-X
receptor-tyrosine-kinases	B-X
.	B-X
Gbetagamma-mediated	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
activation	B-X
is	B-X
mediated	B-X
by	B-X
activation	B-X
of	B-X
phosphoinositide	B-X
3-kinase	B-X
,	B-X
followed	B-X
by	B-X
a	B-X
tyrosine	B-X
phosphorylation	B-X
event	B-X
,	B-X
and	B-X
proceeds	B-X
in	B-X
a	B-X
sequence	B-X
of	B-X
events	B-X
that	B-X
involve	B-X
functional	B-X
association	B-X
among	B-X
the	B-X
adaptor	B-X
proteins	B-X
Shc	B-X
,	B-X
Grb2	B-X
,	B-X
and	B-X
Sos	B-X
.	B-X
SAPKs/JNKs	B-X
and	B-X
p38	B-X
are	B-X
able	B-X
to	B-X
be	B-X
activated	B-X
by	B-X
Gbetagamma	B-X
proteins	B-X
in	B-X
a	B-X
pathway	B-X
involving	B-X
Rho	B-X
family	B-X
proteins	B-X
including	B-X
RhoA	B-X
,	B-X
Rac1	B-X
,	B-X
and	B-X
Cdc42	B-X
.	B-X

We	O
show	O
here	O
that	O
c	B-Protein
-	I-Protein
Raf	I-Protein
,	O
which	O
is	O
at	O
the	O
helm	O
of	O
the	O
classic	O
MAP	O
-	O
Erk	O
cascade	O
,	O
contributes	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
induction	O
through	O
a	O
distal	O
enhancer	O
element	O
spanning	O
the	O
nucleotides	O
from	O
positions	O
-	O
502	O
to	O
-	O
413	O
in	O
front	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
gene	O
.	O
<EOS>	B-X
Triggering	B-X
of	B-X
the	B-X
T-cell	B-X
receptor-CD3	B-X
complex	B-X
activates	B-X
two	B-X
major	B-X
signal	B-X
cascades	B-X
in	B-X
T	B-X
lymphocytes	B-X
,	B-X
(	B-X
i	B-X
)	B-X
Ca2+-dependent	B-X
signal	B-X
cascades	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
protein	B-X
kinase	B-X
cascades	B-X
.	B-X
Both	B-X
signal	B-X
cascades	B-X
contribute	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
gene	B-X
during	B-X
T-cell	B-X
activation	B-X
.	B-X
Prominent	B-X
protein	B-X
kinase	B-X
cascades	B-X
are	B-X
those	B-X
that	B-X
activate	B-X
mitogen-activated	B-X
protein	B-X
(	B-X
MAP	B-X
)	B-X
kinases	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
c-Raf	B-X
,	B-X
which	B-X
is	B-X
at	B-X
the	B-X
helm	B-X
of	B-X
the	B-X
classic	B-X
MAP-Erk	B-X
cascade	B-X
,	B-X
contributes	B-X
to	B-X
IL-2	B-X
induction	B-X
through	B-X
a	B-X
distal	B-X
enhancer	B-X
element	B-X
spanning	B-X
the	B-X
nucleotides	B-X
from	B-X
positions	B-X
-502	B-X
to	B-X
-413	B-X
in	B-X
front	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
Induction	B-X
of	B-X
this	B-X
distal	B-X
IL-2	B-X
enhancer	B-X
differs	B-X
from	B-X
induction	B-X
of	B-X
the	B-X
proximal	B-X
IL-2	B-X
promoter-enhancer	B-X
,	B-X
since	B-X
it	B-X
is	B-X
induced	B-X
by	B-X
phorbol	B-X
esters	B-X
alone	B-X
and	B-X
independent	B-X
from	B-X
Ca2+	B-X
signals	B-X
.	B-X
In	B-X
DNA-protein	B-X
binding	B-X
studies	B-X
,	B-X
we	B-X
detected	B-X
the	B-X
binding	B-X
of	B-X
transcription	B-X
factors	B-X
GABP	B-X
alpha	B-X
and	B-X
-beta	B-X
to	B-X
a	B-X
dyad	B-X
symmetry	B-X
element	B-X
(	B-X
DSE	B-X
)	B-X
of	B-X
the	B-X
distal	B-X
enhancer	B-X
,	B-X
which	B-X
is	B-X
formed	B-X
by	B-X
palindromic	B-X
binding	B-X
sites	B-X
of	B-X
Ets-like	B-X
factors	B-X
.	B-X
Introduction	B-X
of	B-X
point	B-X
mutations	B-X
suppressing	B-X
GABP	B-X
binding	B-X
to	B-X
the	B-X
DSE	B-X
interfered	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
distal	B-X
enhancer	B-X
and	B-X
the	B-X
entire	B-X
IL-2	B-X
promoter-enhancer	B-X
,	B-X
while	B-X
overexpression	B-X
of	B-X
both	B-X
GABP	B-X
factors	B-X
enhanced	B-X
the	B-X
IL-2	B-X
promoter-enhancer	B-X
induction	B-X
.	B-X
Overexpression	B-X
of	B-X
BXB	B-X
,	B-X
a	B-X
constitutive	B-X
active	B-X
version	B-X
of	B-X
c-Raf	B-X
,	B-X
and	B-X
of	B-X
further	B-X
members	B-X
of	B-X
the	B-X
Ras-Raf-Erk	B-X
signal	B-X
cascade	B-X
exerted	B-X
an	B-X
increase	B-X
of	B-X
GABP-mediated	B-X
promoter-enhancer	B-X
induction	B-X
.	B-X
In	B-X
conjunction	B-X
with	B-X
previously	B-X
published	B-X
data	B-X
on	B-X
c-Raf-induced	B-X
phosphorylation	B-X
of	B-X
GABP	B-X
factors	B-X
(	B-X
E.	B-X
Flory	B-X
,	B-X
A.	B-X
Hoffmeyer	B-X
,	B-X
U.	B-X
Smola	B-X
,	B-X
U.	B-X
R.	B-X
Rapp	B-X
,	B-X
and	B-X
J.	B-X
T.	B-X
Bruder	B-X
,	B-X
J.	B-X
Virol	B-X
.	B-X
70:2260-2268	B-X
,	B-X
1996	B-X
)	B-X
,	B-X
these	B-X
results	B-X
indicate	B-X
a	B-X
contribution	B-X
of	B-X
GABP	B-X
factors	B-X
to	B-X
the	B-X
Raf-mediated	B-X
enhancement	B-X
of	B-X
IL-2	B-X
induction	B-X
during	B-X
T-cell	B-X
activation	B-X
.	B-X

Induction	O
of	O
this	O
distal	O
IL	B-Protein
-	I-Protein
2	I-Protein
enhancer	O
differs	O
from	O
induction	O
of	O
the	O
proximal	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
-	O
enhancer	O
,	O
since	O
it	O
is	O
induced	O
by	O
phorbol	O
esters	O
alone	O
and	O
independent	O
from	O
Ca2	O
+	O
signals	O
.	O
<EOS>	B-X
Triggering	B-X
of	B-X
the	B-X
T-cell	B-X
receptor-CD3	B-X
complex	B-X
activates	B-X
two	B-X
major	B-X
signal	B-X
cascades	B-X
in	B-X
T	B-X
lymphocytes	B-X
,	B-X
(	B-X
i	B-X
)	B-X
Ca2+-dependent	B-X
signal	B-X
cascades	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
protein	B-X
kinase	B-X
cascades	B-X
.	B-X
Both	B-X
signal	B-X
cascades	B-X
contribute	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
gene	B-X
during	B-X
T-cell	B-X
activation	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
c-Raf	B-X
,	B-X
which	B-X
is	B-X
at	B-X
the	B-X
helm	B-X
of	B-X
the	B-X
classic	B-X
MAP-Erk	B-X
cascade	B-X
,	B-X
contributes	B-X
to	B-X
IL-2	B-X
induction	B-X
through	B-X
a	B-X
distal	B-X
enhancer	B-X
element	B-X
spanning	B-X
the	B-X
nucleotides	B-X
from	B-X
positions	B-X
-502	B-X
to	B-X
-413	B-X
in	B-X
front	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
Induction	B-X
of	B-X
this	B-X
distal	B-X
IL-2	B-X
enhancer	B-X
differs	B-X
from	B-X
induction	B-X
of	B-X
the	B-X
proximal	B-X
IL-2	B-X
promoter-enhancer	B-X
,	B-X
since	B-X
it	B-X
is	B-X
induced	B-X
by	B-X
phorbol	B-X
esters	B-X
alone	B-X
and	B-X
independent	B-X
from	B-X
Ca2+	B-X
signals	B-X
.	B-X
In	B-X
DNA-protein	B-X
binding	B-X
studies	B-X
,	B-X
we	B-X
detected	B-X
the	B-X
binding	B-X
of	B-X
transcription	B-X
factors	B-X
GABP	B-X
alpha	B-X
and	B-X
-beta	B-X
to	B-X
a	B-X
dyad	B-X
symmetry	B-X
element	B-X
(	B-X
DSE	B-X
)	B-X
of	B-X
the	B-X
distal	B-X
enhancer	B-X
,	B-X
which	B-X
is	B-X
formed	B-X
by	B-X
palindromic	B-X
binding	B-X
sites	B-X
of	B-X
Ets-like	B-X
factors	B-X
.	B-X
Introduction	B-X
of	B-X
point	B-X
mutations	B-X
suppressing	B-X
GABP	B-X
binding	B-X
to	B-X
the	B-X
DSE	B-X
interfered	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
distal	B-X
enhancer	B-X
and	B-X
the	B-X
entire	B-X
IL-2	B-X
promoter-enhancer	B-X
,	B-X
while	B-X
overexpression	B-X
of	B-X
both	B-X
GABP	B-X
factors	B-X
enhanced	B-X
the	B-X
IL-2	B-X
promoter-enhancer	B-X
induction	B-X
.	B-X
Overexpression	B-X
of	B-X
BXB	B-X
,	B-X
a	B-X
constitutive	B-X
active	B-X
version	B-X
of	B-X
c-Raf	B-X
,	B-X
and	B-X
of	B-X
further	B-X
members	B-X
of	B-X
the	B-X
Ras-Raf-Erk	B-X
signal	B-X
cascade	B-X
exerted	B-X
an	B-X
increase	B-X
of	B-X
GABP-mediated	B-X
promoter-enhancer	B-X
induction	B-X
.	B-X
In	B-X
conjunction	B-X
with	B-X
previously	B-X
published	B-X
data	B-X
on	B-X
c-Raf-induced	B-X
phosphorylation	B-X
of	B-X
GABP	B-X
factors	B-X
(	B-X
E.	B-X
Flory	B-X
,	B-X
A.	B-X
Hoffmeyer	B-X
,	B-X
U.	B-X
Smola	B-X
,	B-X
U.	B-X
R.	B-X
Rapp	B-X
,	B-X
and	B-X
J.	B-X
T.	B-X
Bruder	B-X
,	B-X
J.	B-X
Virol	B-X
.	B-X
70:2260-2268	B-X
,	B-X
1996	B-X
)	B-X
,	B-X
these	B-X
results	B-X
indicate	B-X
a	B-X
contribution	B-X
of	B-X
GABP	B-X
factors	B-X
to	B-X
the	B-X
Raf-mediated	B-X
enhancement	B-X
of	B-X
IL-2	B-X
induction	B-X
during	B-X
T-cell	B-X
activation	B-X
.	B-X

In	O
DNA	O
-	O
protein	O
binding	O
studies	O
,	O
we	O
detected	O
the	O
binding	O
of	O
transcription	O
factors	O
GABP	B-Protein
alpha	I-Protein
and	O
-	B-Protein
beta	I-Protein
to	O
a	O
dyad	O
symmetry	O
element	O
(	O
DSE	O
)	O
of	O
the	O
distal	O
enhancer	O
,	O
which	O
is	O
formed	O
by	O
palindromic	O
binding	O
sites	O
of	O
Ets	O
-	O
like	O
factors	O
.	O
<EOS>	B-X
Triggering	B-X
of	B-X
the	B-X
T-cell	B-X
receptor-CD3	B-X
complex	B-X
activates	B-X
two	B-X
major	B-X
signal	B-X
cascades	B-X
in	B-X
T	B-X
lymphocytes	B-X
,	B-X
(	B-X
i	B-X
)	B-X
Ca2+-dependent	B-X
signal	B-X
cascades	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
protein	B-X
kinase	B-X
cascades	B-X
.	B-X
Prominent	B-X
protein	B-X
kinase	B-X
cascades	B-X
are	B-X
those	B-X
that	B-X
activate	B-X
mitogen-activated	B-X
protein	B-X
(	B-X
MAP	B-X
)	B-X
kinases	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
c-Raf	B-X
,	B-X
which	B-X
is	B-X
at	B-X
the	B-X
helm	B-X
of	B-X
the	B-X
classic	B-X
MAP-Erk	B-X
cascade	B-X
,	B-X
contributes	B-X
to	B-X
IL-2	B-X
induction	B-X
through	B-X
a	B-X
distal	B-X
enhancer	B-X
element	B-X
spanning	B-X
the	B-X
nucleotides	B-X
from	B-X
positions	B-X
-502	B-X
to	B-X
-413	B-X
in	B-X
front	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
Induction	B-X
of	B-X
this	B-X
distal	B-X
IL-2	B-X
enhancer	B-X
differs	B-X
from	B-X
induction	B-X
of	B-X
the	B-X
proximal	B-X
IL-2	B-X
promoter-enhancer	B-X
,	B-X
since	B-X
it	B-X
is	B-X
induced	B-X
by	B-X
phorbol	B-X
esters	B-X
alone	B-X
and	B-X
independent	B-X
from	B-X
Ca2+	B-X
signals	B-X
.	B-X
In	B-X
DNA-protein	B-X
binding	B-X
studies	B-X
,	B-X
we	B-X
detected	B-X
the	B-X
binding	B-X
of	B-X
transcription	B-X
factors	B-X
GABP	B-X
alpha	B-X
and	B-X
-beta	B-X
to	B-X
a	B-X
dyad	B-X
symmetry	B-X
element	B-X
(	B-X
DSE	B-X
)	B-X
of	B-X
the	B-X
distal	B-X
enhancer	B-X
,	B-X
which	B-X
is	B-X
formed	B-X
by	B-X
palindromic	B-X
binding	B-X
sites	B-X
of	B-X
Ets-like	B-X
factors	B-X
.	B-X
Introduction	B-X
of	B-X
point	B-X
mutations	B-X
suppressing	B-X
GABP	B-X
binding	B-X
to	B-X
the	B-X
DSE	B-X
interfered	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
distal	B-X
enhancer	B-X
and	B-X
the	B-X
entire	B-X
IL-2	B-X
promoter-enhancer	B-X
,	B-X
while	B-X
overexpression	B-X
of	B-X
both	B-X
GABP	B-X
factors	B-X
enhanced	B-X
the	B-X
IL-2	B-X
promoter-enhancer	B-X
induction	B-X
.	B-X
Overexpression	B-X
of	B-X
BXB	B-X
,	B-X
a	B-X
constitutive	B-X
active	B-X
version	B-X
of	B-X
c-Raf	B-X
,	B-X
and	B-X
of	B-X
further	B-X
members	B-X
of	B-X
the	B-X
Ras-Raf-Erk	B-X
signal	B-X
cascade	B-X
exerted	B-X
an	B-X
increase	B-X
of	B-X
GABP-mediated	B-X
promoter-enhancer	B-X
induction	B-X
.	B-X
In	B-X
conjunction	B-X
with	B-X
previously	B-X
published	B-X
data	B-X
on	B-X
c-Raf-induced	B-X
phosphorylation	B-X
of	B-X
GABP	B-X
factors	B-X
(	B-X
E.	B-X
Flory	B-X
,	B-X
A.	B-X
Hoffmeyer	B-X
,	B-X
U.	B-X
Smola	B-X
,	B-X
U.	B-X
R.	B-X
Rapp	B-X
,	B-X
and	B-X
J.	B-X
T.	B-X
Bruder	B-X
,	B-X
J.	B-X
Virol	B-X
.	B-X
70:2260-2268	B-X
,	B-X
1996	B-X
)	B-X
,	B-X
these	B-X
results	B-X
indicate	B-X
a	B-X
contribution	B-X
of	B-X
GABP	B-X
factors	B-X
to	B-X
the	B-X
Raf-mediated	B-X
enhancement	B-X
of	B-X
IL-2	B-X
induction	B-X
during	B-X
T-cell	B-X
activation	B-X
.	B-X

Introduction	O
of	O
point	O
mutations	O
suppressing	O
GABP	O
binding	O
to	O
the	O
DSE	O
interfered	O
with	O
the	O
induction	O
of	O
the	O
distal	O
enhancer	O
and	O
the	O
entire	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
-	O
enhancer	O
,	O
while	O
overexpression	O
of	O
both	O
GABP	O
factors	O
enhanced	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
-	O
enhancer	O
induction	O
.	O

Overexpression	O
of	O
BXB	B-Protein
,	O
a	O
constitutive	O
active	O
version	O
of	O
c	B-Protein
-	I-Protein
Raf	I-Protein
,	O
and	O
of	O
further	O
members	O
of	O
the	O
Ras	O
-	O
Raf	O
-	O
Erk	O
signal	O
cascade	O
exerted	O
an	O
increase	O
of	O
GABP	O
-	O
mediated	O
promoter	O
-	O
enhancer	O
induction	O
.	O
<EOS>	B-X
Triggering	B-X
of	B-X
the	B-X
T-cell	B-X
receptor-CD3	B-X
complex	B-X
activates	B-X
two	B-X
major	B-X
signal	B-X
cascades	B-X
in	B-X
T	B-X
lymphocytes	B-X
,	B-X
(	B-X
i	B-X
)	B-X
Ca2+-dependent	B-X
signal	B-X
cascades	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
protein	B-X
kinase	B-X
cascades	B-X
.	B-X
Both	B-X
signal	B-X
cascades	B-X
contribute	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
gene	B-X
during	B-X
T-cell	B-X
activation	B-X
.	B-X
Prominent	B-X
protein	B-X
kinase	B-X
cascades	B-X
are	B-X
those	B-X
that	B-X
activate	B-X
mitogen-activated	B-X
protein	B-X
(	B-X
MAP	B-X
)	B-X
kinases	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
c-Raf	B-X
,	B-X
which	B-X
is	B-X
at	B-X
the	B-X
helm	B-X
of	B-X
the	B-X
classic	B-X
MAP-Erk	B-X
cascade	B-X
,	B-X
contributes	B-X
to	B-X
IL-2	B-X
induction	B-X
through	B-X
a	B-X
distal	B-X
enhancer	B-X
element	B-X
spanning	B-X
the	B-X
nucleotides	B-X
from	B-X
positions	B-X
-502	B-X
to	B-X
-413	B-X
in	B-X
front	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
of	B-X
the	B-X
IL-2	B-X
gene	B-X
.	B-X
Induction	B-X
of	B-X
this	B-X
distal	B-X
IL-2	B-X
enhancer	B-X
differs	B-X
from	B-X
induction	B-X
of	B-X
the	B-X
proximal	B-X
IL-2	B-X
promoter-enhancer	B-X
,	B-X
since	B-X
it	B-X
is	B-X
induced	B-X
by	B-X
phorbol	B-X
esters	B-X
alone	B-X
and	B-X
independent	B-X
from	B-X
Ca2+	B-X
signals	B-X
.	B-X
In	B-X
DNA-protein	B-X
binding	B-X
studies	B-X
,	B-X
we	B-X
detected	B-X
the	B-X
binding	B-X
of	B-X
transcription	B-X
factors	B-X
GABP	B-X
alpha	B-X
and	B-X
-beta	B-X
to	B-X
a	B-X
dyad	B-X
symmetry	B-X
element	B-X
(	B-X
DSE	B-X
)	B-X
of	B-X
the	B-X
distal	B-X
enhancer	B-X
,	B-X
which	B-X
is	B-X
formed	B-X
by	B-X
palindromic	B-X
binding	B-X
sites	B-X
of	B-X
Ets-like	B-X
factors	B-X
.	B-X
Introduction	B-X
of	B-X
point	B-X
mutations	B-X
suppressing	B-X
GABP	B-X
binding	B-X
to	B-X
the	B-X
DSE	B-X
interfered	B-X
with	B-X
the	B-X
induction	B-X
of	B-X
the	B-X
distal	B-X
enhancer	B-X
and	B-X
the	B-X
entire	B-X
IL-2	B-X
promoter-enhancer	B-X
,	B-X
while	B-X
overexpression	B-X
of	B-X
both	B-X
GABP	B-X
factors	B-X
enhanced	B-X
the	B-X
IL-2	B-X
promoter-enhancer	B-X
induction	B-X
.	B-X
Overexpression	B-X
of	B-X
BXB	B-X
,	B-X
a	B-X
constitutive	B-X
active	B-X
version	B-X
of	B-X
c-Raf	B-X
,	B-X
and	B-X
of	B-X
further	B-X
members	B-X
of	B-X
the	B-X
Ras-Raf-Erk	B-X
signal	B-X
cascade	B-X
exerted	B-X
an	B-X
increase	B-X
of	B-X
GABP-mediated	B-X
promoter-enhancer	B-X
induction	B-X
.	B-X
In	B-X
conjunction	B-X
with	B-X
previously	B-X
published	B-X
data	B-X
on	B-X
c-Raf-induced	B-X
phosphorylation	B-X
of	B-X
GABP	B-X
factors	B-X
(	B-X
E.	B-X
Flory	B-X
,	B-X
A.	B-X
Hoffmeyer	B-X
,	B-X
U.	B-X
Smola	B-X
,	B-X
U.	B-X
R.	B-X
Rapp	B-X
,	B-X
and	B-X
J.	B-X
T.	B-X
Bruder	B-X
,	B-X
J.	B-X
Virol	B-X
.	B-X
70:2260-2268	B-X
,	B-X
1996	B-X
)	B-X
,	B-X
these	B-X
results	B-X
indicate	B-X
a	B-X
contribution	B-X
of	B-X
GABP	B-X
factors	B-X
to	B-X
the	B-X
Raf-mediated	B-X
enhancement	B-X
of	B-X
IL-2	B-X
induction	B-X
during	B-X
T-cell	B-X
activation	B-X
.	B-X

In	O
conjunction	O
with	O
previously	O
published	O
data	O
on	O
c	B-Protein
-	I-Protein
Raf	I-Protein
-	O
induced	O
phosphorylation	O
of	O
GABP	O
factors	O
(	O
E	O
.	O
Flory	O
,	O
A	O
.	O
Hoffmeyer	O
,	O
U	O
.	O
Smola	O
,	O
U	O
.	O
R	O
.	O
Rapp	O
,	O
and	O
J	O
.	O
T	O
.	O
Bruder	O
,	O
J	O
.	O
Virol	O
.	O
70	O
:	O
2260	O
-	O
2268	O
,	O
1996	O
)	O
,	O
these	O
results	O
indicate	O
a	O
contribution	O
of	O
GABP	O
factors	O
to	O
the	O
Raf	O
-	O
mediated	O
enhancement	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
induction	O
during	O
T	O
-	O
cell	O
activation	O
.	O

Genomic	O
organization	O
,	O
sequence	O
,	O
and	O
transcriptional	O
regulation	O
of	O
the	O
human	O
eotaxin	B-Protein
gene	O
.	O
<EOS>	B-X
We	B-X
here	B-X
describe	B-X
the	B-X
genomic	B-X
organisation	B-X
(	B-X
3	B-X
exons	B-X
of	B-X
132	B-X
,	B-X
112	B-X
and	B-X
542	B-X
bp	B-X
and	B-X
2	B-X
introns	B-X
of	B-X
1211	B-X
and	B-X
378	B-X
bp	B-X
)	B-X
and	B-X
sequence	B-X
including	B-X
3	B-X
kb	B-X
of	B-X
DNA	B-X
from	B-X
the	B-X
immediate	B-X
5	B-X
'	B-X
upstream	B-X
region	B-X
of	B-X
the	B-X
human	B-X
eotaxin	B-X
gene	B-X
.	B-X
Among	B-X
the	B-X
regulatory	B-X
promoter	B-X
elements	B-X
potentially	B-X
regulating	B-X
eotaxin	B-X
gene	B-X
expression	B-X
and/or	B-X
mediating	B-X
the	B-X
effects	B-X
of	B-X
anti-inflammatory	B-X
drugs	B-X
we	B-X
identified	B-X
consensus	B-X
sequences	B-X
known	B-X
to	B-X
interact	B-X
with	B-X
nuclear	B-X
factors	B-X
like	B-X
NF-IL6	B-X
,	B-X
AP-1	B-X
,	B-X
a	B-X
NF-kappa-B	B-X
like	B-X
consensus	B-X
sequence	B-X
and	B-X
gamma-interferon-	B-X
as	B-X
well	B-X
as	B-X
glucocorticoid	B-X
response	B-X
elements	B-X
.	B-X
We	B-X
here	B-X
describe	B-X
the	B-X
genomic	B-X
organisation	B-X
(	B-X
3	B-X
exons	B-X
of	B-X
138	B-X
,	B-X
115	B-X
and	B-X
578	B-X
bp	B-X
,	B-X
2	B-X
introns	B-X
of	B-X
867	B-X
and	B-X
437	B-X
bp	B-X
and	B-X
1.4	B-X
kb	B-X
of	B-X
regulatory	B-X
sequences	B-X
from	B-X
the	B-X
immediate	B-X
5	B-X
'	B-X
upstream	B-X
region	B-X
)	B-X
,	B-X
sequence	B-X
(	B-X
genomic	B-X
and	B-X
transcribed	B-X
)	B-X
and	B-X
mRNA	B-X
expression	B-X
of	B-X
the	B-X
human	B-X
MCP-4	B-X
gene	B-X
in	B-X
dermal	B-X
fibroblasts	B-X
.	B-X
Among	B-X
the	B-X
promoter	B-X
elements	B-X
potentially	B-X
regulating	B-X
MCP-4	B-X
gene	B-X
expression	B-X
and/or	B-X
mediating	B-X
the	B-X
effects	B-X
of	B-X
anti-inflammatory	B-X
drugs	B-X
we	B-X
identified	B-X
consensus	B-X
sequences	B-X
known	B-X
to	B-X
interact	B-X
with	B-X
nuclear	B-X
factors	B-X
like	B-X
NF-IL6	B-X
,	B-X
AP-2	B-X
,	B-X
a	B-X
NF-kappaB	B-X
like	B-X
consensus	B-X
sequence	B-X
,	B-X
gamma-interferon-	B-X
response	B-X
and	B-X
YY-1	B-X
elements	B-X
as	B-X
well	B-X
as	B-X
glucocorticoid	B-X
response	B-X
elements	B-X
.	B-X
Like	B-X
MCP-3	B-X
,	B-X
MCP-4	B-X
mRNA	B-X
expression	B-X
in	B-X
dermal	B-X
fibroblasts	B-X
is	B-X
upregulated	B-X
by	B-X
TNF-alpha	B-X
,	B-X
IL-1alpha	B-X
,	B-X
IFN-gamma	B-X
or	B-X
IL-4	B-X
and	B-X
differs	B-X
from	B-X
RANTES	B-X
and	B-X
eotaxin	B-X
mRNA	B-X
expression	B-X
in	B-X
its	B-X
response	B-X
to	B-X
IFN-gamma	B-X
and/or	B-X
IL-4	B-X
.	B-X

Eotaxin	B-Protein
is	O
an	O
eosinophil	O
specific	O
beta	O
-	O
chemokine	O
assumed	O
to	O
be	O
involved	O
in	O
eosinophilic	O
inflammatory	O
diseases	O
such	O
as	O
atopic	O
dermatitis	O
,	O
allergic	O
rhinitis	O
,	O
asthma	O
and	O
parasitic	O
infections	O
.	O
<EOS>	B-X
Eotaxin	B-X
is	B-X
an	B-X
eosinophil	B-X
specific	B-X
beta-chemokine	B-X
assumed	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
eosinophilic	B-X
inflammatory	B-X
diseases	B-X
such	B-X
as	B-X
atopic	B-X
dermatitis	B-X
,	B-X
allergic	B-X
rhinitis	B-X
,	B-X
asthma	B-X
and	B-X
parasitic	B-X
infections	B-X
.	B-X
Its	B-X
expression	B-X
is	B-X
stimulus-	B-X
and	B-X
cell-specific	B-X
.	B-X
Among	B-X
the	B-X
regulatory	B-X
promoter	B-X
elements	B-X
potentially	B-X
regulating	B-X
eotaxin	B-X
gene	B-X
expression	B-X
and/or	B-X
mediating	B-X
the	B-X
effects	B-X
of	B-X
anti-inflammatory	B-X
drugs	B-X
we	B-X
identified	B-X
consensus	B-X
sequences	B-X
known	B-X
to	B-X
interact	B-X
with	B-X
nuclear	B-X
factors	B-X
like	B-X
NF-IL6	B-X
,	B-X
AP-1	B-X
,	B-X
a	B-X
NF-kappa-B	B-X
like	B-X
consensus	B-X
sequence	B-X
and	B-X
gamma-interferon-	B-X
as	B-X
well	B-X
as	B-X
glucocorticoid	B-X
response	B-X
elements	B-X
.	B-X

Its	O
expression	O
is	O
stimulus	O
-	O
and	O
cell	O
-	O
specific	O
.	O
<EOS>	B-X
How	B-X
this	B-X
transition	B-X
is	B-X
affected	B-X
by	B-X
time	B-X
and	B-X
sex	B-X
,	B-X
its	B-X
heterogeneity	B-X
at	B-X
the	B-X
single-cell	B-X
level	B-X
and	B-X
how	B-X
sub-states	B-X
are	B-X
spatially	B-X
distributed	B-X
in	B-X
the	B-X
brain	B-X
remains	B-X
unclear	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
transcriptome	B-X
changes	B-X
of	B-X
mouse	B-X
cortical	B-X
astrocytes	B-X
after	B-X
an	B-X
acute	B-X
inflammatory	B-X
stimulus	B-X
using	B-X
the	B-X
bacterial	B-X
cell	B-X
wall	B-X
endotoxin	B-X
lipopolysaccharide	B-X
.	B-X
By	B-X
sequencing	B-X
~80,000	B-X
astrocytes	B-X
at	B-X
single-cell	B-X
resolution	B-X
,	B-X
we	B-X
show	B-X
that	B-X
inflammation	B-X
causes	B-X
a	B-X
widespread	B-X
response	B-X
with	B-X
subtypes	B-X
of	B-X
astrocytes	B-X
undergoing	B-X
distinct	B-X
inflammatory	B-X
transitions	B-X
with	B-X
defined	B-X
transcriptomic	B-X
profiles	B-X
.	B-X
We	B-X
also	B-X
attribute	B-X
key	B-X
sub-states	B-X
of	B-X
inflammation-induced	B-X
reactive	B-X
astrocytes	B-X
to	B-X
specific	B-X
brain	B-X
regions	B-X
using	B-X
spatial	B-X
transcriptomics	B-X
and	B-X
in	B-X
situ	B-X
hybridization	B-X
.	B-X

We	O
here	O
describe	O
the	O
genomic	O
organisation	O
(	O
3	O
exons	O
of	O
132	O
,	O
112	O
and	O
542	O
bp	O
and	O
2	O
introns	O
of	O
1211	O
and	O
378	O
bp	O
)	O
and	O
sequence	O
including	O
3	O
kb	O
of	O
DNA	O
from	O
the	O
immediate	O
5	O
'	O
upstream	O
region	O
of	O
the	O
human	O
eotaxin	B-Protein
gene	O
.	O
<EOS>	B-X
We	B-X
here	B-X
describe	B-X
the	B-X
genomic	B-X
organisation	B-X
(	B-X
3	B-X
exons	B-X
of	B-X
132	B-X
,	B-X
112	B-X
and	B-X
542	B-X
bp	B-X
and	B-X
2	B-X
introns	B-X
of	B-X
1211	B-X
and	B-X
378	B-X
bp	B-X
)	B-X
and	B-X
sequence	B-X
including	B-X
3	B-X
kb	B-X
of	B-X
DNA	B-X
from	B-X
the	B-X
immediate	B-X
5	B-X
'	B-X
upstream	B-X
region	B-X
of	B-X
the	B-X
human	B-X
eotaxin	B-X
gene	B-X
.	B-X
Among	B-X
the	B-X
regulatory	B-X
promoter	B-X
elements	B-X
potentially	B-X
regulating	B-X
eotaxin	B-X
gene	B-X
expression	B-X
and/or	B-X
mediating	B-X
the	B-X
effects	B-X
of	B-X
anti-inflammatory	B-X
drugs	B-X
we	B-X
identified	B-X
consensus	B-X
sequences	B-X
known	B-X
to	B-X
interact	B-X
with	B-X
nuclear	B-X
factors	B-X
like	B-X
NF-IL6	B-X
,	B-X
AP-1	B-X
,	B-X
a	B-X
NF-kappa-B	B-X
like	B-X
consensus	B-X
sequence	B-X
and	B-X
gamma-interferon-	B-X
as	B-X
well	B-X
as	B-X
glucocorticoid	B-X
response	B-X
elements	B-X
.	B-X

Among	O
the	O
regulatory	O
promoter	O
elements	O
potentially	O
regulating	O
eotaxin	B-Protein
gene	O
expression	O
and	O
/	O
or	O
mediating	O
the	O
effects	O
of	O
anti	O
-	O
inflammatory	O
drugs	O
we	O
identified	O
consensus	O
sequences	O
known	O
to	O
interact	O
with	O
nuclear	O
factors	O
like	O
NF	B-Protein
-	I-Protein
IL6	I-Protein
,	O
AP	O
-	O
1	O
,	O
a	O
NF	O
-	O
kappa	O
-	O
B	O
like	O
consensus	O
sequence	O
and	O
gamma	B-Protein
-	I-Protein
interferon	I-Protein
-	O
as	O
well	O
as	O
glucocorticoid	O
response	O
elements	O
.	O
<EOS>	B-X
Eotaxin	B-X
is	B-X
an	B-X
eosinophil	B-X
specific	B-X
beta-chemokine	B-X
assumed	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
eosinophilic	B-X
inflammatory	B-X
diseases	B-X
such	B-X
as	B-X
atopic	B-X
dermatitis	B-X
,	B-X
allergic	B-X
rhinitis	B-X
,	B-X
asthma	B-X
and	B-X
parasitic	B-X
infections	B-X
.	B-X
Its	B-X
expression	B-X
is	B-X
stimulus-	B-X
and	B-X
cell-specific	B-X
.	B-X
We	B-X
here	B-X
describe	B-X
the	B-X
genomic	B-X
organisation	B-X
(	B-X
3	B-X
exons	B-X
of	B-X
132	B-X
,	B-X
112	B-X
and	B-X
542	B-X
bp	B-X
and	B-X
2	B-X
introns	B-X
of	B-X
1211	B-X
and	B-X
378	B-X
bp	B-X
)	B-X
and	B-X
sequence	B-X
including	B-X
3	B-X
kb	B-X
of	B-X
DNA	B-X
from	B-X
the	B-X
immediate	B-X
5	B-X
'	B-X
upstream	B-X
region	B-X
of	B-X
the	B-X
human	B-X
eotaxin	B-X
gene	B-X
.	B-X
Among	B-X
the	B-X
regulatory	B-X
promoter	B-X
elements	B-X
potentially	B-X
regulating	B-X
eotaxin	B-X
gene	B-X
expression	B-X
and/or	B-X
mediating	B-X
the	B-X
effects	B-X
of	B-X
anti-inflammatory	B-X
drugs	B-X
we	B-X
identified	B-X
consensus	B-X
sequences	B-X
known	B-X
to	B-X
interact	B-X
with	B-X
nuclear	B-X
factors	B-X
like	B-X
NF-IL6	B-X
,	B-X
AP-1	B-X
,	B-X
a	B-X
NF-kappa-B	B-X
like	B-X
consensus	B-X
sequence	B-X
and	B-X
gamma-interferon-	B-X
as	B-X
well	B-X
as	B-X
glucocorticoid	B-X
response	B-X
elements	B-X
.	B-X

Dysregulation	O
of	O
monocytic	O
nuclear	O
factor	O
-	O
kappa	O
B	O
by	O
oxidized	O
low	O
-	O
density	O
lipoprotein	O
.	O
<EOS>	B-X
Nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
/Rel	B-X
transcription	B-X
factors	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
atherosclerosis	B-X
,	B-X
as	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
human	B-X
atherosclerotic	B-X
lesions	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
oxidized	B-X
LDL	B-X
(	B-X
oxLDL	B-X
)	B-X
on	B-X
the	B-X
NF-kappa	B-X
B	B-X
system	B-X
in	B-X
human	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
adherent	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
short-term	B-X
incubation	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
oxLDL	B-X
activated	B-X
p50/p65	B-X
containing	B-X
NF-kappa	B-X
B	B-X
dimers	B-X
and	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
target	B-X
gene	B-X
IL-8	B-X
.	B-X
This	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
antioxidant	B-X
and	B-X
H2O2	B-X
scavenger	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
PSI	B-X
.	B-X
The	B-X
oxLDL-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
initial	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
followed	B-X
by	B-X
a	B-X
slight	B-X
transient	B-X
increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
this	B-X
inhibitor	B-X
protein	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
long-term	B-X
treatment	B-X
with	B-X
oxLDL	B-X
prevented	B-X
the	B-X
lipopolysaccharide-induced	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
inhibition	B-X
of	B-X
both	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
and	B-X
interleukin-1	B-X
beta	B-X
genes	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
additional	B-X
evidence	B-X
that	B-X
oxLDL	B-X
is	B-X
a	B-X
potent	B-X
modulator	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
suggest	B-X
that	B-X
(	B-X
dys	B-X
)	B-X
regulation	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
is	B-X
likely	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
atherogenesis	B-X
.	B-X

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
/	O
Rel	O
transcription	O
factors	O
may	O
be	O
involved	O
in	O
atherosclerosis	O
,	O
as	O
is	O
suggested	O
by	O
the	O
presence	O
of	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
atherosclerotic	O
lesions	O
.	O
<EOS>	B-X
Nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappaB	B-X
)	B-X
/Rel	B-X
transcription	B-X
factors	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
inducible	B-X
regulation	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
the	B-X
inflammatory	B-X
and	B-X
proliferative	B-X
responses	B-X
of	B-X
cells	B-X
.	B-X
The	B-X
present	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
elucidate	B-X
the	B-X
implication	B-X
of	B-X
NF-kappaB/Rel	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
atherosclerosis	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
dimeric	B-X
NF-kappaB	B-X
complex	B-X
is	B-X
regulated	B-X
at	B-X
a	B-X
posttranslational	B-X
level	B-X
and	B-X
requires	B-X
the	B-X
release	B-X
of	B-X
the	B-X
inhibitor	B-X
protein	B-X
IkappaB	B-X
.	B-X
The	B-X
newly	B-X
developed	B-X
mAb	B-X
alpha-p65mAb	B-X
recognizes	B-X
the	B-X
IkappaB	B-X
binding	B-X
region	B-X
on	B-X
the	B-X
p65	B-X
(	B-X
RelA	B-X
)	B-X
DNA	B-X
binding	B-X
subunit	B-X
and	B-X
therefore	B-X
selectively	B-X
reacts	B-X
with	B-X
p65	B-X
in	B-X
activated	B-X
NF-kappaB	B-X
.	B-X
Using	B-X
immunofluorescence	B-X
and	B-X
immunohistochemical	B-X
techniques	B-X
,	B-X
activated	B-X
NF-kappaB	B-X
was	B-X
detected	B-X
in	B-X
the	B-X
fibrotic-thickened	B-X
intima/media	B-X
and	B-X
atheromatous	B-X
areas	B-X
of	B-X
the	B-X
atherosclerotic	B-X
lesion	B-X
.	B-X
Activation	B-X
of	B-X
NF-kappaB	B-X
was	B-X
identified	B-X
in	B-X
smooth	B-X
muscle	B-X
cells	B-X
,	B-X
macrophages	B-X
,	B-X
and	B-X
endothelial	B-X
cells	B-X
.	B-X
Little	B-X
or	B-X
no	B-X
activated	B-X
NF-kappaB	B-X
was	B-X
detected	B-X
in	B-X
vessels	B-X
lacking	B-X
atherosclerosis	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
and	B-X
colocalization	B-X
of	B-X
activated	B-X
NF-kappaB	B-X
with	B-X
NF-kappaB	B-X
target	B-X
gene	B-X
expression	B-X
suggest	B-X
functional	B-X
implications	B-X
for	B-X
this	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
atherosclerotic	B-X
lesion	B-X
.	B-X
This	B-X
study	B-X
demonstrates	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
NF-kappaB	B-X
in	B-X
human	B-X
atherosclerotic	B-X
tissue	B-X
for	B-X
the	B-X
first	B-X
time	B-X
.	B-X
Atherosclerosis	B-X
,	B-X
characterized	B-X
by	B-X
features	B-X
of	B-X
chronic	B-X
inflammation	B-X
and	B-X
proliferative	B-X
processes	B-X
,	B-X
may	B-X
be	B-X
a	B-X
paradigm	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
NF-kappaB/Rel	B-X
in	B-X
chronic	B-X
inflammatory	B-X
disease	B-X
.	B-X

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
oxidized	O
LDL	O
(	O
oxLDL	O
)	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
system	O
in	O
human	O
THP	O
-	O
1	O
monocytic	O
cells	O
as	O
well	O
as	O
adherent	O
monocytes	O
.	O
<EOS>	B-X
Nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
/Rel	B-X
transcription	B-X
factors	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
atherosclerosis	B-X
,	B-X
as	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
human	B-X
atherosclerotic	B-X
lesions	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
oxidized	B-X
LDL	B-X
(	B-X
oxLDL	B-X
)	B-X
on	B-X
the	B-X
NF-kappa	B-X
B	B-X
system	B-X
in	B-X
human	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
adherent	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
short-term	B-X
incubation	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
oxLDL	B-X
activated	B-X
p50/p65	B-X
containing	B-X
NF-kappa	B-X
B	B-X
dimers	B-X
and	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
target	B-X
gene	B-X
IL-8	B-X
.	B-X
This	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
antioxidant	B-X
and	B-X
H2O2	B-X
scavenger	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
PSI	B-X
.	B-X
The	B-X
oxLDL-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
initial	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
followed	B-X
by	B-X
a	B-X
slight	B-X
transient	B-X
increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
this	B-X
inhibitor	B-X
protein	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
long-term	B-X
treatment	B-X
with	B-X
oxLDL	B-X
prevented	B-X
the	B-X
lipopolysaccharide-induced	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
inhibition	B-X
of	B-X
both	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
and	B-X
interleukin-1	B-X
beta	B-X
genes	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
additional	B-X
evidence	B-X
that	B-X
oxLDL	B-X
is	B-X
a	B-X
potent	B-X
modulator	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
suggest	B-X
that	B-X
(	B-X
dys	B-X
)	B-X
regulation	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
is	B-X
likely	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
atherogenesis	B-X
.	B-X

Our	O
results	O
demonstrate	O
that	O
short	O
-	O
term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	O
activated	O
p50	O
/	O
p65	O
containing	O
NF	O
-	O
kappa	O
B	O
dimers	O
and	O
induced	O
the	O
expression	O
of	O
the	O
target	O
gene	O
IL	O
-	O
8	O
.	O
<EOS>	B-X
Nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
/Rel	B-X
transcription	B-X
factors	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
atherosclerosis	B-X
,	B-X
as	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
human	B-X
atherosclerotic	B-X
lesions	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
oxidized	B-X
LDL	B-X
(	B-X
oxLDL	B-X
)	B-X
on	B-X
the	B-X
NF-kappa	B-X
B	B-X
system	B-X
in	B-X
human	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
adherent	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
short-term	B-X
incubation	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
oxLDL	B-X
activated	B-X
p50/p65	B-X
containing	B-X
NF-kappa	B-X
B	B-X
dimers	B-X
and	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
target	B-X
gene	B-X
IL-8	B-X
.	B-X
This	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
antioxidant	B-X
and	B-X
H2O2	B-X
scavenger	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
PSI	B-X
.	B-X
The	B-X
oxLDL-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
initial	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
followed	B-X
by	B-X
a	B-X
slight	B-X
transient	B-X
increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
this	B-X
inhibitor	B-X
protein	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
long-term	B-X
treatment	B-X
with	B-X
oxLDL	B-X
prevented	B-X
the	B-X
lipopolysaccharide-induced	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
inhibition	B-X
of	B-X
both	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
and	B-X
interleukin-1	B-X
beta	B-X
genes	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
additional	B-X
evidence	B-X
that	B-X
oxLDL	B-X
is	B-X
a	B-X
potent	B-X
modulator	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
suggest	B-X
that	B-X
(	B-X
dys	B-X
)	B-X
regulation	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
is	B-X
likely	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
atherogenesis	B-X
.	B-X

This	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
inhibited	O
by	O
the	O
antioxidant	O
and	O
H2O2	O
scavenger	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
PSI	O
.	O
<EOS>	B-X
Nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
/Rel	B-X
transcription	B-X
factors	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
atherosclerosis	B-X
,	B-X
as	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
human	B-X
atherosclerotic	B-X
lesions	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
oxidized	B-X
LDL	B-X
(	B-X
oxLDL	B-X
)	B-X
on	B-X
the	B-X
NF-kappa	B-X
B	B-X
system	B-X
in	B-X
human	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
adherent	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
short-term	B-X
incubation	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
oxLDL	B-X
activated	B-X
p50/p65	B-X
containing	B-X
NF-kappa	B-X
B	B-X
dimers	B-X
and	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
target	B-X
gene	B-X
IL-8	B-X
.	B-X
This	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
antioxidant	B-X
and	B-X
H2O2	B-X
scavenger	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
PSI	B-X
.	B-X
The	B-X
oxLDL-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
initial	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
followed	B-X
by	B-X
a	B-X
slight	B-X
transient	B-X
increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
this	B-X
inhibitor	B-X
protein	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
long-term	B-X
treatment	B-X
with	B-X
oxLDL	B-X
prevented	B-X
the	B-X
lipopolysaccharide-induced	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
inhibition	B-X
of	B-X
both	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
and	B-X
interleukin-1	B-X
beta	B-X
genes	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
additional	B-X
evidence	B-X
that	B-X
oxLDL	B-X
is	B-X
a	B-X
potent	B-X
modulator	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
suggest	B-X
that	B-X
(	B-X
dys	B-X
)	B-X
regulation	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
is	B-X
likely	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
atherogenesis	B-X
.	B-X

The	O
oxLDL	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
accompanied	O
by	O
an	O
initial	O
depletion	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
followed	O
by	O
a	O
slight	O
transient	O
increase	O
in	O
the	O
level	O
of	O
this	O
inhibitor	O
protein	O
.	O
<EOS>	B-X
Nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
/Rel	B-X
transcription	B-X
factors	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
atherosclerosis	B-X
,	B-X
as	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
human	B-X
atherosclerotic	B-X
lesions	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
oxidized	B-X
LDL	B-X
(	B-X
oxLDL	B-X
)	B-X
on	B-X
the	B-X
NF-kappa	B-X
B	B-X
system	B-X
in	B-X
human	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
adherent	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
short-term	B-X
incubation	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
oxLDL	B-X
activated	B-X
p50/p65	B-X
containing	B-X
NF-kappa	B-X
B	B-X
dimers	B-X
and	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
target	B-X
gene	B-X
IL-8	B-X
.	B-X
This	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
antioxidant	B-X
and	B-X
H2O2	B-X
scavenger	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
PSI	B-X
.	B-X
The	B-X
oxLDL-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
initial	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
followed	B-X
by	B-X
a	B-X
slight	B-X
transient	B-X
increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
this	B-X
inhibitor	B-X
protein	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
long-term	B-X
treatment	B-X
with	B-X
oxLDL	B-X
prevented	B-X
the	B-X
lipopolysaccharide-induced	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
inhibition	B-X
of	B-X
both	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
and	B-X
interleukin-1	B-X
beta	B-X
genes	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
additional	B-X
evidence	B-X
that	B-X
oxLDL	B-X
is	B-X
a	B-X
potent	B-X
modulator	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
suggest	B-X
that	B-X
(	B-X
dys	B-X
)	B-X
regulation	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
is	B-X
likely	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
atherogenesis	B-X
.	B-X

In	O
contrast	O
,	O
long	O
-	O
term	O
treatment	O
with	O
oxLDL	O
prevented	O
the	O
lipopolysaccharide	O
-	O
induced	O
depletion	O
of	O
I	B-Protein
kappa	I-Protein
B	I-Protein
-	I-Protein
alpha	I-Protein
,	O
accompanied	O
by	O
an	O
inhibition	O
of	O
both	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
the	O
expression	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
and	O
interleukin	B-Protein
-	I-Protein
1	I-Protein
beta	I-Protein
genes	O
.	O

These	O
observations	O
provide	O
additional	O
evidence	O
that	O
oxLDL	O
is	O
a	O
potent	O
modulator	O
of	O
gene	O
expression	O
and	O
suggest	O
that	O
(	O
dys	O
)	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
atherogenesis	O
.	O
<EOS>	B-X
Nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-kappa	B-X
B	B-X
)	B-X
/Rel	B-X
transcription	B-X
factors	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
atherosclerosis	B-X
,	B-X
as	B-X
is	B-X
suggested	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
activated	B-X
NF-kappa	B-X
B	B-X
in	B-X
human	B-X
atherosclerotic	B-X
lesions	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
oxidized	B-X
LDL	B-X
(	B-X
oxLDL	B-X
)	B-X
on	B-X
the	B-X
NF-kappa	B-X
B	B-X
system	B-X
in	B-X
human	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
adherent	B-X
monocytes	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
short-term	B-X
incubation	B-X
of	B-X
these	B-X
cells	B-X
with	B-X
oxLDL	B-X
activated	B-X
p50/p65	B-X
containing	B-X
NF-kappa	B-X
B	B-X
dimers	B-X
and	B-X
induced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
target	B-X
gene	B-X
IL-8	B-X
.	B-X
This	B-X
activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
antioxidant	B-X
and	B-X
H2O2	B-X
scavenger	B-X
pyrrolidine	B-X
dithiocarbamate	B-X
and	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
PSI	B-X
.	B-X
The	B-X
oxLDL-induced	B-X
NF-kappa	B-X
B	B-X
activation	B-X
was	B-X
accompanied	B-X
by	B-X
an	B-X
initial	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
followed	B-X
by	B-X
a	B-X
slight	B-X
transient	B-X
increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
this	B-X
inhibitor	B-X
protein	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
long-term	B-X
treatment	B-X
with	B-X
oxLDL	B-X
prevented	B-X
the	B-X
lipopolysaccharide-induced	B-X
depletion	B-X
of	B-X
I	B-X
kappa	B-X
B-alpha	B-X
,	B-X
accompanied	B-X
by	B-X
an	B-X
inhibition	B-X
of	B-X
both	B-X
NF-kappa	B-X
B	B-X
activation	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
and	B-X
interleukin-1	B-X
beta	B-X
genes	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
additional	B-X
evidence	B-X
that	B-X
oxLDL	B-X
is	B-X
a	B-X
potent	B-X
modulator	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
suggest	B-X
that	B-X
(	B-X
dys	B-X
)	B-X
regulation	B-X
of	B-X
NF-kappa	B-X
B/Rel	B-X
is	B-X
likely	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
atherogenesis	B-X
.	B-X

Suppression	O
of	O
MHC	O
class	O
II	O
expression	O
by	O
human	O
class	O
II	O
trans	O
-	O
activator	O
constructs	O
lacking	O
the	O
N	O
-	O
terminal	O
domain	O
.	O

The	O
class	B-Protein
II	I-Protein
trans	I-Protein
-	I-Protein
activator	I-Protein
(	O
CIITA	B-Protein
)	O
is	O
a	O
bi	O
-	O
or	O
multi	O
-	O
functional	O
domain	O
protein	O
which	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O
<EOS>	B-X
The	B-X
bare	B-X
lymphocyte	B-X
syndrome	B-X
(	B-X
BLS	B-X
)	B-X
is	B-X
a	B-X
hereditary	B-X
immunodeficiency	B-X
resulting	B-X
from	B-X
the	B-X
absence	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
(	B-X
MHCII	B-X
)	B-X
expression	B-X
.	B-X
Considering	B-X
the	B-X
central	B-X
role	B-X
of	B-X
MHCII	B-X
molecules	B-X
in	B-X
the	B-X
development	B-X
and	B-X
activation	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
it	B-X
is	B-X
not	B-X
surprising	B-X
that	B-X
the	B-X
immune	B-X
system	B-X
of	B-X
the	B-X
patients	B-X
is	B-X
severely	B-X
impaired	B-X
.	B-X
The	B-X
affected	B-X
genes	B-X
encode	B-X
RFXANK	B-X
,	B-X
RFX5	B-X
,	B-X
RFXAP	B-X
,	B-X
and	B-X
CIITA	B-X
,	B-X
four	B-X
regulatory	B-X
factors	B-X
that	B-X
are	B-X
highly	B-X
specific	B-X
and	B-X
essential	B-X
for	B-X
MHCII	B-X
genes	B-X
.	B-X
The	B-X
first	B-X
three	B-X
are	B-X
subunits	B-X
of	B-X
RFX	B-X
,	B-X
a	B-X
trimeric	B-X
complex	B-X
that	B-X
binds	B-X
to	B-X
all	B-X
MHCII	B-X
promoters	B-X
.	B-X
CIITA	B-X
is	B-X
a	B-X
non-DNA-binding	B-X
coactivator	B-X
that	B-X
functions	B-X
as	B-X
the	B-X
master	B-X
control	B-X
factor	B-X
for	B-X
MHCII	B-X
expression	B-X
.	B-X
The	B-X
study	B-X
of	B-X
RFX	B-X
and	B-X
CIITA	B-X
has	B-X
made	B-X
major	B-X
contributions	B-X
to	B-X
our	B-X
comprehension	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
controlling	B-X
MHCII	B-X
genes	B-X
and	B-X
has	B-X
made	B-X
this	B-X
system	B-X
into	B-X
a	B-X
textbook	B-X
model	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X

We	O
report	O
that	O
removal	O
of	O
the	O
N	O
-	O
terminal	O
151	O
amino	O
acids	O
,	O
encompassing	O
all	O
of	O
the	O
acidic	O
domain	O
but	O
leaving	O
intact	O
the	O
proline	O
/	O
serine	O
/	O
threonine	O
-	O
rich	O
domain	O
,	O
results	O
in	O
a	O
mutant	O
protein	O
with	O
potent	O
suppressive	O
properties	O
for	O
MHC	O
class	O
II	O
expression	O
.	O

HeLa	O
cells	O
stably	O
or	O
transiently	O
transfected	O
with	O
mutant	O
CIITA	B-Protein
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
MHC	O
class	O
II	O
antigen	O
induction	O
by	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
marked	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
expression	O
.	O
<EOS>	B-X
The	B-X
doxycycline	B-X
(	B-X
dox	B-X
)	B-X
-inducible	B-X
Tet-On	B-X
system	B-X
is	B-X
widely	B-X
used	B-X
to	B-X
control	B-X
gene	B-X
expression	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
This	B-X
system	B-X
is	B-X
based	B-X
on	B-X
the	B-X
bacterial	B-X
Tet	B-X
operon	B-X
,	B-X
which	B-X
has	B-X
been	B-X
modified	B-X
and	B-X
improved	B-X
for	B-X
its	B-X
function	B-X
in	B-X
eukaryotic	B-X
cells	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
optimal	B-X
system	B-X
for	B-X
different	B-X
applications	B-X
,	B-X
we	B-X
compared	B-X
Tet-On	B-X
variants	B-X
in	B-X
frequently	B-X
used	B-X
cell	B-X
types	B-X
that	B-X
were	B-X
either	B-X
transiently	B-X
transfected	B-X
with	B-X
the	B-X
relevant	B-X
plasmids	B-X
or	B-X
stably	B-X
transduced	B-X
with	B-X
an	B-X
``	B-X
all-in-one	B-X
''	B-X
lentiviral	B-X
vector	B-X
.	B-X
The	B-X
V10	B-X
variant	B-X
performed	B-X
optimally	B-X
in	B-X
the	B-X
transiently	B-X
transfected	B-X
cells	B-X
and	B-X
demonstrated	B-X
no	B-X
background	B-X
activity	B-X
without	B-X
dox	B-X
,	B-X
high	B-X
dox-induced	B-X
activity	B-X
and	B-X
the	B-X
highest	B-X
fold-induction	B-X
.	B-X
V16	B-X
performed	B-X
optimally	B-X
in	B-X
the	B-X
transduced	B-X
cells	B-X
and	B-X
demonstrated	B-X
the	B-X
highest	B-X
activity	B-X
and	B-X
dox-sensitivity	B-X
without	B-X
background	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
V16	B-X
demonstrated	B-X
more	B-X
robust	B-X
induction	B-X
of	B-X
gene	B-X
expression	B-X
after	B-X
a	B-X
latency	B-X
period	B-X
without	B-X
dox	B-X
.	B-X
V10	B-X
is	B-X
the	B-X
best	B-X
system	B-X
for	B-X
most	B-X
applications	B-X
in	B-X
which	B-X
the	B-X
DNA	B-X
is	B-X
episomally	B-X
present	B-X
in	B-X
cells	B-X
,	B-X
whereas	B-X
V16	B-X
may	B-X
be	B-X
optimal	B-X
when	B-X
the	B-X
Tet-On	B-X
components	B-X
are	B-X
stably	B-X
integrated	B-X
in	B-X
the	B-X
cellular	B-X
genome	B-X
.	B-X

Transient	O
transfection	O
of	O
a	O
B	O
lymphoma	O
line	O
resulted	O
in	O
up	O
to	O
89	O
%	O
reduction	O
of	O
constitutive	O
MHC	O
class	O
II	O
expression	O
within	O
5	O
days	O
and	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
synthesis	O
.	O

CD30	B-Protein
-	O
dependent	O
degradation	O
of	O
TRAF2	B-Protein
:	O
implications	O
for	O
negative	O
regulation	O
of	O
TRAF	O
signaling	O
and	O
the	O
control	O
of	O
cell	O
survival	O
.	O
<EOS>	B-X
CD30	B-X
is	B-X
a	B-X
cell-surface	B-X
receptor	B-X
that	B-X
can	B-X
augment	B-X
lymphocyte	B-X
activation	B-X
and	B-X
survival	B-X
through	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
.	B-X
CD30	B-X
,	B-X
however	B-X
,	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
lymphocytes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
one	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
CD30	B-X
signal	B-X
transduction	B-X
is	B-X
to	B-X
render	B-X
cells	B-X
sensitive	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
the	B-X
type	B-X
1	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR1	B-X
)	B-X
.	B-X
This	B-X
sensitization	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
TRAF-binding	B-X
sites	B-X
within	B-X
the	B-X
CD30	B-X
cytoplasmic	B-X
domain	B-X
.	B-X
One	B-X
of	B-X
the	B-X
proteins	B-X
that	B-X
binds	B-X
to	B-X
these	B-X
sites	B-X
is	B-X
TRAF2	B-X
,	B-X
a	B-X
signal	B-X
transduction	B-X
molecule	B-X
that	B-X
is	B-X
also	B-X
utilized	B-X
by	B-X
TNFR1	B-X
to	B-X
mediate	B-X
the	B-X
activation	B-X
of	B-X
several	B-X
downstream	B-X
kinases	B-X
and	B-X
transcription	B-X
factors	B-X
.	B-X
During	B-X
CD30	B-X
signal	B-X
transduction	B-X
,	B-X
we	B-X
found	B-X
that	B-X
binding	B-X
of	B-X
TRAF2	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD30	B-X
results	B-X
in	B-X
the	B-X
rapid	B-X
depletion	B-X
of	B-X
TRAF2	B-X
and	B-X
the	B-X
associated	B-X
protein	B-X
TRAF1	B-X
by	B-X
proteolysis	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
model	B-X
in	B-X
which	B-X
CD30	B-X
limits	B-X
its	B-X
own	B-X
ability	B-X
to	B-X
transduce	B-X
cell	B-X
survival	B-X
signals	B-X
through	B-X
signal-coupled	B-X
depletion	B-X
of	B-X
TRAF2	B-X
.	B-X
Depletion	B-X
of	B-X
intracellular	B-X
TRAF2	B-X
and	B-X
its	B-X
coassociated	B-X
proteins	B-X
also	B-X
increased	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cell	B-X
to	B-X
undergoing	B-X
apoptosis	B-X
during	B-X
activation	B-X
of	B-X
death-inducing	B-X
receptors	B-X
such	B-X
as	B-X
TNFR1	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
hypothesis	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant-negative	B-X
form	B-X
of	B-X
TRAF2	B-X
was	B-X
found	B-X
to	B-X
potentiate	B-X
TNFR1-mediated	B-X
death	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
through	B-X
which	B-X
CD30	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
TRAF-binding	B-X
members	B-X
of	B-X
the	B-X
TNFR	B-X
superfamily	B-X
,	B-X
can	B-X
negatively	B-X
regulate	B-X
cell	B-X
survival	B-X
.	B-X

CD30	B-Protein
is	O
a	O
cell	O
-	O
surface	O
receptor	O
that	O
can	O
augment	O
lymphocyte	O
activation	O
and	O
survival	O
through	O
its	O
ability	O
to	O
induce	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
CD30	B-X
is	B-X
a	B-X
cell-surface	B-X
receptor	B-X
that	B-X
can	B-X
augment	B-X
lymphocyte	B-X
activation	B-X
and	B-X
survival	B-X
through	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
.	B-X
CD30	B-X
,	B-X
however	B-X
,	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
lymphocytes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
one	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
CD30	B-X
signal	B-X
transduction	B-X
is	B-X
to	B-X
render	B-X
cells	B-X
sensitive	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
the	B-X
type	B-X
1	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR1	B-X
)	B-X
.	B-X
This	B-X
sensitization	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
TRAF-binding	B-X
sites	B-X
within	B-X
the	B-X
CD30	B-X
cytoplasmic	B-X
domain	B-X
.	B-X
One	B-X
of	B-X
the	B-X
proteins	B-X
that	B-X
binds	B-X
to	B-X
these	B-X
sites	B-X
is	B-X
TRAF2	B-X
,	B-X
a	B-X
signal	B-X
transduction	B-X
molecule	B-X
that	B-X
is	B-X
also	B-X
utilized	B-X
by	B-X
TNFR1	B-X
to	B-X
mediate	B-X
the	B-X
activation	B-X
of	B-X
several	B-X
downstream	B-X
kinases	B-X
and	B-X
transcription	B-X
factors	B-X
.	B-X
During	B-X
CD30	B-X
signal	B-X
transduction	B-X
,	B-X
we	B-X
found	B-X
that	B-X
binding	B-X
of	B-X
TRAF2	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD30	B-X
results	B-X
in	B-X
the	B-X
rapid	B-X
depletion	B-X
of	B-X
TRAF2	B-X
and	B-X
the	B-X
associated	B-X
protein	B-X
TRAF1	B-X
by	B-X
proteolysis	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
model	B-X
in	B-X
which	B-X
CD30	B-X
limits	B-X
its	B-X
own	B-X
ability	B-X
to	B-X
transduce	B-X
cell	B-X
survival	B-X
signals	B-X
through	B-X
signal-coupled	B-X
depletion	B-X
of	B-X
TRAF2	B-X
.	B-X
Depletion	B-X
of	B-X
intracellular	B-X
TRAF2	B-X
and	B-X
its	B-X
coassociated	B-X
proteins	B-X
also	B-X
increased	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cell	B-X
to	B-X
undergoing	B-X
apoptosis	B-X
during	B-X
activation	B-X
of	B-X
death-inducing	B-X
receptors	B-X
such	B-X
as	B-X
TNFR1	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
hypothesis	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant-negative	B-X
form	B-X
of	B-X
TRAF2	B-X
was	B-X
found	B-X
to	B-X
potentiate	B-X
TNFR1-mediated	B-X
death	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
through	B-X
which	B-X
CD30	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
TRAF-binding	B-X
members	B-X
of	B-X
the	B-X
TNFR	B-X
superfamily	B-X
,	B-X
can	B-X
negatively	B-X
regulate	B-X
cell	B-X
survival	B-X
.	B-X

CD30	B-Protein
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	O
.	O
<EOS>	B-X
CD30	B-X
,	B-X
a	B-X
TNFR	B-X
family	B-X
member	B-X
,	B-X
is	B-X
expressed	B-X
on	B-X
activated	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
and	B-X
B	B-X
cells	B-X
and	B-X
is	B-X
a	B-X
marker	B-X
of	B-X
Hodgkin	B-X
's	B-X
lymphoma	B-X
;	B-X
its	B-X
ligand	B-X
,	B-X
CD30L	B-X
(	B-X
CD153	B-X
)	B-X
is	B-X
expressed	B-X
by	B-X
activated	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
B	B-X
cells	B-X
,	B-X
and	B-X
macrophages	B-X
.	B-X
Signaling	B-X
via	B-X
CD30	B-X
can	B-X
lead	B-X
to	B-X
proliferation	B-X
or	B-X
cell	B-X
death	B-X
.	B-X
CD30-deficient	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
have	B-X
impaired	B-X
thymic	B-X
negative	B-X
selection	B-X
and	B-X
increased	B-X
autoreactivity	B-X
.	B-X
Although	B-X
human	B-X
alloreactive	B-X
T	B-X
cells	B-X
preferentially	B-X
reside	B-X
within	B-X
the	B-X
CD30	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
subset	B-X
,	B-X
implicating	B-X
CD30	B-X
as	B-X
a	B-X
regulator	B-X
of	B-X
T	B-X
cell	B-X
immune	B-X
responses	B-X
,	B-X
the	B-X
role	B-X
of	B-X
CD30/CD153	B-X
in	B-X
regulating	B-X
graft-vs-host	B-X
disease	B-X
(	B-X
GVHD	B-X
)	B-X
has	B-X
not	B-X
been	B-X
reported	B-X
.	B-X
We	B-X
used	B-X
a	B-X
neutralizing	B-X
anti-CD153	B-X
mAb	B-X
,	B-X
CD30	B-X
(	B-X
-/-	B-X
)	B-X
donor	B-X
mice	B-X
,	B-X
and	B-X
generated	B-X
CD153	B-X
(	B-X
-/-	B-X
)	B-X
recipient	B-X
mice	B-X
to	B-X
analyze	B-X
the	B-X
effect	B-X
of	B-X
CD30/CD153	B-X
interaction	B-X
on	B-X
GVHD	B-X
induction	B-X
.	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
CD30/CD153	B-X
pathway	B-X
is	B-X
a	B-X
potent	B-X
regulator	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
,	B-X
but	B-X
not	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
,	B-X
T	B-X
cell-mediated	B-X
GVHD	B-X
.	B-X
Although	B-X
blocking	B-X
CD30/CD153	B-X
interactions	B-X
in	B-X
vivo	B-X
did	B-X
not	B-X
affect	B-X
alloreactive	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
proliferation	B-X
or	B-X
apoptosis	B-X
,	B-X
a	B-X
substantial	B-X
reduction	B-X
in	B-X
donor	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
migration	B-X
into	B-X
the	B-X
gastrointestinal	B-X
tract	B-X
was	B-X
readily	B-X
observed	B-X
with	B-X
lesser	B-X
effects	B-X
in	B-X
other	B-X
GVHD	B-X
target	B-X
organs	B-X
.	B-X
Blockade	B-X
of	B-X
the	B-X
CD30/CD153	B-X
pathway	B-X
represents	B-X
a	B-X
new	B-X
approach	B-X
for	B-X
preventing	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell-mediated	B-X
GVHD	B-X
.	B-X

Here	O
we	O
show	O
that	O
one	O
of	O
the	O
effects	O
of	O
CD30	B-Protein
signal	O
transduction	O
is	O
to	O
render	O
cells	O
sensitive	O
to	O
apoptosis	O
induced	O
by	O
the	O
type	B-Protein
1	I-Protein
tumor	I-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
(	O
TNFR1	B-Protein
)	O
.	O
<EOS>	B-X
CD30	B-X
is	B-X
a	B-X
cell-surface	B-X
receptor	B-X
that	B-X
can	B-X
augment	B-X
lymphocyte	B-X
activation	B-X
and	B-X
survival	B-X
through	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
.	B-X
CD30	B-X
,	B-X
however	B-X
,	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
lymphocytes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
one	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
CD30	B-X
signal	B-X
transduction	B-X
is	B-X
to	B-X
render	B-X
cells	B-X
sensitive	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
the	B-X
type	B-X
1	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR1	B-X
)	B-X
.	B-X
This	B-X
sensitization	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
TRAF-binding	B-X
sites	B-X
within	B-X
the	B-X
CD30	B-X
cytoplasmic	B-X
domain	B-X
.	B-X
One	B-X
of	B-X
the	B-X
proteins	B-X
that	B-X
binds	B-X
to	B-X
these	B-X
sites	B-X
is	B-X
TRAF2	B-X
,	B-X
a	B-X
signal	B-X
transduction	B-X
molecule	B-X
that	B-X
is	B-X
also	B-X
utilized	B-X
by	B-X
TNFR1	B-X
to	B-X
mediate	B-X
the	B-X
activation	B-X
of	B-X
several	B-X
downstream	B-X
kinases	B-X
and	B-X
transcription	B-X
factors	B-X
.	B-X
During	B-X
CD30	B-X
signal	B-X
transduction	B-X
,	B-X
we	B-X
found	B-X
that	B-X
binding	B-X
of	B-X
TRAF2	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD30	B-X
results	B-X
in	B-X
the	B-X
rapid	B-X
depletion	B-X
of	B-X
TRAF2	B-X
and	B-X
the	B-X
associated	B-X
protein	B-X
TRAF1	B-X
by	B-X
proteolysis	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
model	B-X
in	B-X
which	B-X
CD30	B-X
limits	B-X
its	B-X
own	B-X
ability	B-X
to	B-X
transduce	B-X
cell	B-X
survival	B-X
signals	B-X
through	B-X
signal-coupled	B-X
depletion	B-X
of	B-X
TRAF2	B-X
.	B-X
Depletion	B-X
of	B-X
intracellular	B-X
TRAF2	B-X
and	B-X
its	B-X
coassociated	B-X
proteins	B-X
also	B-X
increased	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cell	B-X
to	B-X
undergoing	B-X
apoptosis	B-X
during	B-X
activation	B-X
of	B-X
death-inducing	B-X
receptors	B-X
such	B-X
as	B-X
TNFR1	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
hypothesis	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant-negative	B-X
form	B-X
of	B-X
TRAF2	B-X
was	B-X
found	B-X
to	B-X
potentiate	B-X
TNFR1-mediated	B-X
death	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
through	B-X
which	B-X
CD30	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
TRAF-binding	B-X
members	B-X
of	B-X
the	B-X
TNFR	B-X
superfamily	B-X
,	B-X
can	B-X
negatively	B-X
regulate	B-X
cell	B-X
survival	B-X
.	B-X

This	O
sensitization	O
is	O
dependent	O
on	O
the	O
TRAF	O
-	O
binding	O
sites	O
within	O
the	O
CD30	B-Protein
cytoplasmic	O
domain	O
.	O
<EOS>	B-X
CD30	B-X
is	B-X
a	B-X
cell-surface	B-X
receptor	B-X
that	B-X
can	B-X
augment	B-X
lymphocyte	B-X
activation	B-X
and	B-X
survival	B-X
through	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
.	B-X
CD30	B-X
,	B-X
however	B-X
,	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
lymphocytes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
one	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
CD30	B-X
signal	B-X
transduction	B-X
is	B-X
to	B-X
render	B-X
cells	B-X
sensitive	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
the	B-X
type	B-X
1	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR1	B-X
)	B-X
.	B-X
This	B-X
sensitization	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
TRAF-binding	B-X
sites	B-X
within	B-X
the	B-X
CD30	B-X
cytoplasmic	B-X
domain	B-X
.	B-X
One	B-X
of	B-X
the	B-X
proteins	B-X
that	B-X
binds	B-X
to	B-X
these	B-X
sites	B-X
is	B-X
TRAF2	B-X
,	B-X
a	B-X
signal	B-X
transduction	B-X
molecule	B-X
that	B-X
is	B-X
also	B-X
utilized	B-X
by	B-X
TNFR1	B-X
to	B-X
mediate	B-X
the	B-X
activation	B-X
of	B-X
several	B-X
downstream	B-X
kinases	B-X
and	B-X
transcription	B-X
factors	B-X
.	B-X
During	B-X
CD30	B-X
signal	B-X
transduction	B-X
,	B-X
we	B-X
found	B-X
that	B-X
binding	B-X
of	B-X
TRAF2	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD30	B-X
results	B-X
in	B-X
the	B-X
rapid	B-X
depletion	B-X
of	B-X
TRAF2	B-X
and	B-X
the	B-X
associated	B-X
protein	B-X
TRAF1	B-X
by	B-X
proteolysis	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
model	B-X
in	B-X
which	B-X
CD30	B-X
limits	B-X
its	B-X
own	B-X
ability	B-X
to	B-X
transduce	B-X
cell	B-X
survival	B-X
signals	B-X
through	B-X
signal-coupled	B-X
depletion	B-X
of	B-X
TRAF2	B-X
.	B-X
Depletion	B-X
of	B-X
intracellular	B-X
TRAF2	B-X
and	B-X
its	B-X
coassociated	B-X
proteins	B-X
also	B-X
increased	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cell	B-X
to	B-X
undergoing	B-X
apoptosis	B-X
during	B-X
activation	B-X
of	B-X
death-inducing	B-X
receptors	B-X
such	B-X
as	B-X
TNFR1	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
hypothesis	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant-negative	B-X
form	B-X
of	B-X
TRAF2	B-X
was	B-X
found	B-X
to	B-X
potentiate	B-X
TNFR1-mediated	B-X
death	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
through	B-X
which	B-X
CD30	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
TRAF-binding	B-X
members	B-X
of	B-X
the	B-X
TNFR	B-X
superfamily	B-X
,	B-X
can	B-X
negatively	B-X
regulate	B-X
cell	B-X
survival	B-X
.	B-X

One	O
of	O
the	O
proteins	O
that	O
binds	O
to	O
these	O
sites	O
is	O
TRAF2	B-Protein
,	O
a	O
signal	O
transduction	O
molecule	O
that	O
is	O
also	O
utilized	O
by	O
TNFR1	B-Protein
to	O
mediate	O
the	O
activation	O
of	O
several	O
downstream	O
kinases	O
and	O
transcription	O
factors	O
.	O
<EOS>	B-X
CD30	B-X
is	B-X
a	B-X
cell-surface	B-X
receptor	B-X
that	B-X
can	B-X
augment	B-X
lymphocyte	B-X
activation	B-X
and	B-X
survival	B-X
through	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
.	B-X
CD30	B-X
,	B-X
however	B-X
,	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
lymphocytes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
one	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
CD30	B-X
signal	B-X
transduction	B-X
is	B-X
to	B-X
render	B-X
cells	B-X
sensitive	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
the	B-X
type	B-X
1	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR1	B-X
)	B-X
.	B-X
This	B-X
sensitization	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
TRAF-binding	B-X
sites	B-X
within	B-X
the	B-X
CD30	B-X
cytoplasmic	B-X
domain	B-X
.	B-X
One	B-X
of	B-X
the	B-X
proteins	B-X
that	B-X
binds	B-X
to	B-X
these	B-X
sites	B-X
is	B-X
TRAF2	B-X
,	B-X
a	B-X
signal	B-X
transduction	B-X
molecule	B-X
that	B-X
is	B-X
also	B-X
utilized	B-X
by	B-X
TNFR1	B-X
to	B-X
mediate	B-X
the	B-X
activation	B-X
of	B-X
several	B-X
downstream	B-X
kinases	B-X
and	B-X
transcription	B-X
factors	B-X
.	B-X
During	B-X
CD30	B-X
signal	B-X
transduction	B-X
,	B-X
we	B-X
found	B-X
that	B-X
binding	B-X
of	B-X
TRAF2	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD30	B-X
results	B-X
in	B-X
the	B-X
rapid	B-X
depletion	B-X
of	B-X
TRAF2	B-X
and	B-X
the	B-X
associated	B-X
protein	B-X
TRAF1	B-X
by	B-X
proteolysis	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
model	B-X
in	B-X
which	B-X
CD30	B-X
limits	B-X
its	B-X
own	B-X
ability	B-X
to	B-X
transduce	B-X
cell	B-X
survival	B-X
signals	B-X
through	B-X
signal-coupled	B-X
depletion	B-X
of	B-X
TRAF2	B-X
.	B-X
Depletion	B-X
of	B-X
intracellular	B-X
TRAF2	B-X
and	B-X
its	B-X
coassociated	B-X
proteins	B-X
also	B-X
increased	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cell	B-X
to	B-X
undergoing	B-X
apoptosis	B-X
during	B-X
activation	B-X
of	B-X
death-inducing	B-X
receptors	B-X
such	B-X
as	B-X
TNFR1	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
hypothesis	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant-negative	B-X
form	B-X
of	B-X
TRAF2	B-X
was	B-X
found	B-X
to	B-X
potentiate	B-X
TNFR1-mediated	B-X
death	B-X
.	B-X

During	O
CD30	B-Protein
signal	O
transduction	O
,	O
we	O
found	O
that	O
binding	O
of	O
TRAF2	B-Protein
to	O
the	O
cytoplasmic	O
domain	O
of	O
CD30	B-Protein
results	O
in	O
the	O
rapid	O
depletion	O
of	O
TRAF2	B-Protein
and	O
the	O
associated	O
protein	O
TRAF1	B-Protein
by	O
proteolysis	O
.	O

These	O
data	O
suggest	O
a	O
model	O
in	O
which	O
CD30	B-Protein
limits	O
its	O
own	O
ability	O
to	O
transduce	O
cell	O
survival	O
signals	O
through	O
signal	O
-	O
coupled	O
depletion	O
of	O
TRAF2	B-Protein
.	O

Depletion	O
of	O
intracellular	O
TRAF2	B-Protein
and	O
its	O
coassociated	O
proteins	O
also	O
increased	O
the	O
sensitivity	O
of	O
the	O
cell	O
to	O
undergoing	O
apoptosis	O
during	O
activation	O
of	O
death	O
-	O
inducing	O
receptors	O
such	O
as	O
TNFR1	B-Protein
.	O
<EOS>	B-X
CD30	B-X
is	B-X
a	B-X
cell-surface	B-X
receptor	B-X
that	B-X
can	B-X
augment	B-X
lymphocyte	B-X
activation	B-X
and	B-X
survival	B-X
through	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
.	B-X
CD30	B-X
,	B-X
however	B-X
,	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
lymphocytes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
one	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
CD30	B-X
signal	B-X
transduction	B-X
is	B-X
to	B-X
render	B-X
cells	B-X
sensitive	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
the	B-X
type	B-X
1	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR1	B-X
)	B-X
.	B-X
One	B-X
of	B-X
the	B-X
proteins	B-X
that	B-X
binds	B-X
to	B-X
these	B-X
sites	B-X
is	B-X
TRAF2	B-X
,	B-X
a	B-X
signal	B-X
transduction	B-X
molecule	B-X
that	B-X
is	B-X
also	B-X
utilized	B-X
by	B-X
TNFR1	B-X
to	B-X
mediate	B-X
the	B-X
activation	B-X
of	B-X
several	B-X
downstream	B-X
kinases	B-X
and	B-X
transcription	B-X
factors	B-X
.	B-X
During	B-X
CD30	B-X
signal	B-X
transduction	B-X
,	B-X
we	B-X
found	B-X
that	B-X
binding	B-X
of	B-X
TRAF2	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD30	B-X
results	B-X
in	B-X
the	B-X
rapid	B-X
depletion	B-X
of	B-X
TRAF2	B-X
and	B-X
the	B-X
associated	B-X
protein	B-X
TRAF1	B-X
by	B-X
proteolysis	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
model	B-X
in	B-X
which	B-X
CD30	B-X
limits	B-X
its	B-X
own	B-X
ability	B-X
to	B-X
transduce	B-X
cell	B-X
survival	B-X
signals	B-X
through	B-X
signal-coupled	B-X
depletion	B-X
of	B-X
TRAF2	B-X
.	B-X
Depletion	B-X
of	B-X
intracellular	B-X
TRAF2	B-X
and	B-X
its	B-X
coassociated	B-X
proteins	B-X
also	B-X
increased	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cell	B-X
to	B-X
undergoing	B-X
apoptosis	B-X
during	B-X
activation	B-X
of	B-X
death-inducing	B-X
receptors	B-X
such	B-X
as	B-X
TNFR1	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
hypothesis	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant-negative	B-X
form	B-X
of	B-X
TRAF2	B-X
was	B-X
found	B-X
to	B-X
potentiate	B-X
TNFR1-mediated	B-X
death	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
through	B-X
which	B-X
CD30	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
TRAF-binding	B-X
members	B-X
of	B-X
the	B-X
TNFR	B-X
superfamily	B-X
,	B-X
can	B-X
negatively	B-X
regulate	B-X
cell	B-X
survival	B-X
.	B-X

Consistent	O
with	O
this	O
hypothesis	O
,	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
TRAF2	B-Protein
was	O
found	O
to	O
potentiate	O
TNFR1	B-Protein
-	O
mediated	O
death	O
.	O
<EOS>	B-X
CD30	B-X
,	B-X
however	B-X
,	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
lymphocytes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
one	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
CD30	B-X
signal	B-X
transduction	B-X
is	B-X
to	B-X
render	B-X
cells	B-X
sensitive	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
the	B-X
type	B-X
1	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR1	B-X
)	B-X
.	B-X
One	B-X
of	B-X
the	B-X
proteins	B-X
that	B-X
binds	B-X
to	B-X
these	B-X
sites	B-X
is	B-X
TRAF2	B-X
,	B-X
a	B-X
signal	B-X
transduction	B-X
molecule	B-X
that	B-X
is	B-X
also	B-X
utilized	B-X
by	B-X
TNFR1	B-X
to	B-X
mediate	B-X
the	B-X
activation	B-X
of	B-X
several	B-X
downstream	B-X
kinases	B-X
and	B-X
transcription	B-X
factors	B-X
.	B-X
During	B-X
CD30	B-X
signal	B-X
transduction	B-X
,	B-X
we	B-X
found	B-X
that	B-X
binding	B-X
of	B-X
TRAF2	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD30	B-X
results	B-X
in	B-X
the	B-X
rapid	B-X
depletion	B-X
of	B-X
TRAF2	B-X
and	B-X
the	B-X
associated	B-X
protein	B-X
TRAF1	B-X
by	B-X
proteolysis	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
model	B-X
in	B-X
which	B-X
CD30	B-X
limits	B-X
its	B-X
own	B-X
ability	B-X
to	B-X
transduce	B-X
cell	B-X
survival	B-X
signals	B-X
through	B-X
signal-coupled	B-X
depletion	B-X
of	B-X
TRAF2	B-X
.	B-X
Depletion	B-X
of	B-X
intracellular	B-X
TRAF2	B-X
and	B-X
its	B-X
coassociated	B-X
proteins	B-X
also	B-X
increased	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cell	B-X
to	B-X
undergoing	B-X
apoptosis	B-X
during	B-X
activation	B-X
of	B-X
death-inducing	B-X
receptors	B-X
such	B-X
as	B-X
TNFR1	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
hypothesis	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant-negative	B-X
form	B-X
of	B-X
TRAF2	B-X
was	B-X
found	B-X
to	B-X
potentiate	B-X
TNFR1-mediated	B-X
death	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
through	B-X
which	B-X
CD30	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
TRAF-binding	B-X
members	B-X
of	B-X
the	B-X
TNFR	B-X
superfamily	B-X
,	B-X
can	B-X
negatively	B-X
regulate	B-X
cell	B-X
survival	B-X
.	B-X

These	O
studies	O
provide	O
a	O
potential	O
mechanism	O
through	O
which	O
CD30	B-Protein
,	O
as	O
well	O
as	O
other	O
TRAF	O
-	O
binding	O
members	O
of	O
the	O
TNFR	O
superfamily	O
,	O
can	O
negatively	O
regulate	O
cell	O
survival	O
.	O
<EOS>	B-X
CD30	B-X
is	B-X
a	B-X
cell-surface	B-X
receptor	B-X
that	B-X
can	B-X
augment	B-X
lymphocyte	B-X
activation	B-X
and	B-X
survival	B-X
through	B-X
its	B-X
ability	B-X
to	B-X
induce	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
.	B-X
CD30	B-X
,	B-X
however	B-X
,	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptotic	B-X
cell	B-X
death	B-X
of	B-X
lymphocytes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
one	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
CD30	B-X
signal	B-X
transduction	B-X
is	B-X
to	B-X
render	B-X
cells	B-X
sensitive	B-X
to	B-X
apoptosis	B-X
induced	B-X
by	B-X
the	B-X
type	B-X
1	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR1	B-X
)	B-X
.	B-X
This	B-X
sensitization	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
TRAF-binding	B-X
sites	B-X
within	B-X
the	B-X
CD30	B-X
cytoplasmic	B-X
domain	B-X
.	B-X
One	B-X
of	B-X
the	B-X
proteins	B-X
that	B-X
binds	B-X
to	B-X
these	B-X
sites	B-X
is	B-X
TRAF2	B-X
,	B-X
a	B-X
signal	B-X
transduction	B-X
molecule	B-X
that	B-X
is	B-X
also	B-X
utilized	B-X
by	B-X
TNFR1	B-X
to	B-X
mediate	B-X
the	B-X
activation	B-X
of	B-X
several	B-X
downstream	B-X
kinases	B-X
and	B-X
transcription	B-X
factors	B-X
.	B-X
During	B-X
CD30	B-X
signal	B-X
transduction	B-X
,	B-X
we	B-X
found	B-X
that	B-X
binding	B-X
of	B-X
TRAF2	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD30	B-X
results	B-X
in	B-X
the	B-X
rapid	B-X
depletion	B-X
of	B-X
TRAF2	B-X
and	B-X
the	B-X
associated	B-X
protein	B-X
TRAF1	B-X
by	B-X
proteolysis	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
a	B-X
model	B-X
in	B-X
which	B-X
CD30	B-X
limits	B-X
its	B-X
own	B-X
ability	B-X
to	B-X
transduce	B-X
cell	B-X
survival	B-X
signals	B-X
through	B-X
signal-coupled	B-X
depletion	B-X
of	B-X
TRAF2	B-X
.	B-X
Depletion	B-X
of	B-X
intracellular	B-X
TRAF2	B-X
and	B-X
its	B-X
coassociated	B-X
proteins	B-X
also	B-X
increased	B-X
the	B-X
sensitivity	B-X
of	B-X
the	B-X
cell	B-X
to	B-X
undergoing	B-X
apoptosis	B-X
during	B-X
activation	B-X
of	B-X
death-inducing	B-X
receptors	B-X
such	B-X
as	B-X
TNFR1	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
hypothesis	B-X
,	B-X
expression	B-X
of	B-X
a	B-X
dominant-negative	B-X
form	B-X
of	B-X
TRAF2	B-X
was	B-X
found	B-X
to	B-X
potentiate	B-X
TNFR1-mediated	B-X
death	B-X
.	B-X
These	B-X
studies	B-X
provide	B-X
a	B-X
potential	B-X
mechanism	B-X
through	B-X
which	B-X
CD30	B-X
,	B-X
as	B-X
well	B-X
as	B-X
other	B-X
TRAF-binding	B-X
members	B-X
of	B-X
the	B-X
TNFR	B-X
superfamily	B-X
,	B-X
can	B-X
negatively	B-X
regulate	B-X
cell	B-X
survival	B-X
.	B-X

TNFalpha	B-Protein
cooperates	O
with	O
the	O
protein	O
kinase	O
A	O
pathway	O
to	O
synergistically	O
increase	O
HIV	O
-	O
1	O
LTR	O
transcription	O
via	O
downstream	O
TRE	O
-	O
like	O
cAMP	O
response	O
elements	O
.	O
<EOS>	B-X
Activating	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
binding	B-X
TPA	B-X
responsive	B-X
elements	B-X
(	B-X
TRE	B-X
)	B-X
are	B-X
located	B-X
downstream	B-X
of	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
in	B-X
the	B-X
U5	B-X
region	B-X
of	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
These	B-X
downstream	B-X
sequence	B-X
elements	B-X
,	B-X
termed	B-X
DSE	B-X
,	B-X
can	B-X
bind	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
transcription	B-X
factors	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
cAMP-responsive	B-X
elements	B-X
(	B-X
CRE	B-X
)	B-X
,	B-X
since	B-X
they	B-X
mediated	B-X
activation	B-X
signals	B-X
elicited	B-X
by	B-X
cholera	B-X
toxin	B-X
(	B-X
Ctx	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
activator	B-X
of	B-X
the	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signal	B-X
transduction	B-X
pathway	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
HIV-1	B-X
DSE	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
synergy	B-X
elicited	B-X
by	B-X
the	B-X
combination	B-X
of	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
.	B-X
Ctx	B-X
combined	B-X
with	B-X
TNFalpha	B-X
or	B-X
IL-1beta	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
increase	B-X
in	B-X
p24	B-X
antigen	B-X
production	B-X
in	B-X
U1	B-X
promonocytic	B-X
cells	B-X
.	B-X
Transfection	B-X
studies	B-X
of	B-X
LTR	B-X
reporter	B-X
constructs	B-X
indicated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
DSE	B-X
sites	B-X
abrogated	B-X
the	B-X
LTR-mediated	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
,	B-X
whereas	B-X
the	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
IL-1beta	B-X
was	B-X
unaffected	B-X
,	B-X
suggesting	B-X
TNFalpha	B-X
and	B-X
IL-1beta	B-X
cooperate	B-X
differently	B-X
with	B-X
the	B-X
cAMP/PKA	B-X
activation	B-X
pathway	B-X
to	B-X
induce	B-X
HIV-1	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
.	B-X
Because	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
TRE	B-X
sites	B-X
,	B-X
we	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
agonist	B-X
combinations	B-X
on	B-X
AP-1-dependent	B-X
transcription	B-X
.	B-X
TNFalpha	B-X
as	B-X
well	B-X
as	B-X
IL-1beta	B-X
cooperated	B-X
with	B-X
Ctx	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
activation	B-X
of	B-X
AP-1-mediated	B-X
transcription	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
TRE-like	B-X
cAMP-responsive	B-X
DSE	B-X
sites	B-X
within	B-X
the	B-X
5'-untranslated	B-X
leader	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
cooperativity	B-X
between	B-X
TNFalpha	B-X
and	B-X
the	B-X
cAMP/PKA	B-X
pathway	B-X
.	B-X
Since	B-X
the	B-X
DSE	B-X
and	B-X
TRE	B-X
sites	B-X
can	B-X
not	B-X
bind	B-X
CREB/ATF	B-X
homodimers	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
mechanism	B-X
in	B-X
which	B-X
the	B-X
HIV-1	B-X
DSE	B-X
bind	B-X
heterodimers	B-X
composed	B-X
of	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
proteins	B-X
.	B-X

Activating	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
binding	O
TPA	O
responsive	O
elements	O
(	O
TRE	O
)	O
are	O
located	O
downstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
the	O
U5	O
region	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

These	O
downstream	O
sequence	O
elements	O
,	O
termed	O
DSE	O
,	O
can	O
bind	O
both	O
AP	O
-	O
1	O
and	O
CREB	O
/	O
ATF	O
transcription	O
factors	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
the	O
DSE	O
are	O
also	O
cAMP	O
-	O
responsive	O
elements	O
(	O
CRE	O
)	O
,	O
since	O
they	O
mediated	O
activation	O
signals	O
elicited	O
by	O
cholera	O
toxin	O
(	O
Ctx	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
signal	O
transduction	O
pathway	O
.	O
<EOS>	B-X
Activating	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
binding	B-X
TPA	B-X
responsive	B-X
elements	B-X
(	B-X
TRE	B-X
)	B-X
are	B-X
located	B-X
downstream	B-X
of	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
in	B-X
the	B-X
U5	B-X
region	B-X
of	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
These	B-X
downstream	B-X
sequence	B-X
elements	B-X
,	B-X
termed	B-X
DSE	B-X
,	B-X
can	B-X
bind	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
transcription	B-X
factors	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
cAMP-responsive	B-X
elements	B-X
(	B-X
CRE	B-X
)	B-X
,	B-X
since	B-X
they	B-X
mediated	B-X
activation	B-X
signals	B-X
elicited	B-X
by	B-X
cholera	B-X
toxin	B-X
(	B-X
Ctx	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
activator	B-X
of	B-X
the	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signal	B-X
transduction	B-X
pathway	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
HIV-1	B-X
DSE	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
synergy	B-X
elicited	B-X
by	B-X
the	B-X
combination	B-X
of	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
.	B-X
Ctx	B-X
combined	B-X
with	B-X
TNFalpha	B-X
or	B-X
IL-1beta	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
increase	B-X
in	B-X
p24	B-X
antigen	B-X
production	B-X
in	B-X
U1	B-X
promonocytic	B-X
cells	B-X
.	B-X
Transfection	B-X
studies	B-X
of	B-X
LTR	B-X
reporter	B-X
constructs	B-X
indicated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
DSE	B-X
sites	B-X
abrogated	B-X
the	B-X
LTR-mediated	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
,	B-X
whereas	B-X
the	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
IL-1beta	B-X
was	B-X
unaffected	B-X
,	B-X
suggesting	B-X
TNFalpha	B-X
and	B-X
IL-1beta	B-X
cooperate	B-X
differently	B-X
with	B-X
the	B-X
cAMP/PKA	B-X
activation	B-X
pathway	B-X
to	B-X
induce	B-X
HIV-1	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
.	B-X
Because	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
TRE	B-X
sites	B-X
,	B-X
we	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
agonist	B-X
combinations	B-X
on	B-X
AP-1-dependent	B-X
transcription	B-X
.	B-X
TNFalpha	B-X
as	B-X
well	B-X
as	B-X
IL-1beta	B-X
cooperated	B-X
with	B-X
Ctx	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
activation	B-X
of	B-X
AP-1-mediated	B-X
transcription	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
TRE-like	B-X
cAMP-responsive	B-X
DSE	B-X
sites	B-X
within	B-X
the	B-X
5'-untranslated	B-X
leader	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
cooperativity	B-X
between	B-X
TNFalpha	B-X
and	B-X
the	B-X
cAMP/PKA	B-X
pathway	B-X
.	B-X
Since	B-X
the	B-X
DSE	B-X
and	B-X
TRE	B-X
sites	B-X
can	B-X
not	B-X
bind	B-X
CREB/ATF	B-X
homodimers	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
mechanism	B-X
in	B-X
which	B-X
the	B-X
HIV-1	B-X
DSE	B-X
bind	B-X
heterodimers	B-X
composed	B-X
of	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
proteins	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
HIV	O
-	O
1	O
DSE	O
can	O
mediate	O
the	O
transcriptional	O
synergy	O
elicited	O
by	O
the	O
combination	O
of	O
Ctx	O
and	O
TNFalpha	B-Protein
.	O

Ctx	O
combined	O
with	O
TNFalpha	B-Protein
or	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
to	O
produce	O
a	O
synergistic	O
increase	O
in	O
p24	B-Protein
antigen	I-Protein
production	O
in	O
U1	O
promonocytic	O
cells	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
revealed	B-X
new	B-X
immunomodulatory	B-X
effects	B-X
of	B-X
IFN-alpha	B-X
,	B-X
including	B-X
activities	B-X
on	B-X
T	B-X
cells	B-X
and	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
,	B-X
which	B-X
may	B-X
explain	B-X
the	B-X
immune	B-X
correlates	B-X
frequently	B-X
observed	B-X
in	B-X
some	B-X
categories	B-X
of	B-X
cancer	B-X
patients	B-X
responding	B-X
to	B-X
IFN-alpha	B-X
therapy	B-X
.	B-X
Of	B-X
note	B-X
,	B-X
new	B-X
knowledge	B-X
has	B-X
recently	B-X
been	B-X
generated	B-X
on	B-X
the	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
some	B-X
chemotherapeutic	B-X
agents	B-X
,	B-X
such	B-X
as	B-X
cyclophosphamide	B-X
(	B-X
CTX	B-X
)	B-X
,	B-X
on	B-X
cells	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
whose	B-X
effects	B-X
can	B-X
now	B-X
be	B-X
exploited	B-X
for	B-X
the	B-X
design	B-X
of	B-X
more	B-X
effective	B-X
combination	B-X
therapies	B-X
.	B-X
Anti-infection	B-X
therapy	B-X
combined	B-X
with	B-X
immunotherapy	B-X
is	B-X
one	B-X
of	B-X
the	B-X
important	B-X
research	B-X
approaches	B-X
for	B-X
treating	B-X
sepsis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
it	B-X
was	B-X
hypothesized	B-X
that	B-X
imipenem	B-X
combined	B-X
with	B-X
low-dose	B-X
cyclophosphamide	B-X
(	B-X
CTX	B-X
)	B-X
could	B-X
improve	B-X
the	B-X
sepsis	B-X
survival	B-X
rate	B-X
compared	B-X
with	B-X
imipenem	B-X
treatment	B-X
alone	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
alterations	B-X
in	B-X
the	B-X
intestinal	B-X
barrier	B-X
were	B-X
investigated	B-X
and	B-X
the	B-X
possible	B-X
mechanisms	B-X
of	B-X
altering	B-X
intestinal	B-X
barrier	B-X
function	B-X
in	B-X
septic	B-X
rats	B-X
treated	B-X
with	B-X
imipenem	B-X
combined	B-X
with	B-X
low-dose	B-X
CTX	B-X
or	B-X
imipenem	B-X
alone	B-X
were	B-X
explored	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
imipenem	B-X
combined	B-X
with	B-X
low-dose	B-X
CTX	B-X
on	B-X
the	B-X
intestinal	B-X
barrier	B-X
,	B-X
the	B-X
markers	B-X
of	B-X
histopathology	B-X
,	B-X
intestinal	B-X
permeability	B-X
,	B-X
intestinal	B-X
epithelial	B-X
apoptosis	B-X
,	B-X
cytokines	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-6	B-X
,	B-X
IL-10	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
,	B-X
and	B-X
tight	B-X
junction	B-X
proteins	B-X
zonula	B-X
occludens	B-X
(	B-X
ZO	B-X
)	B-X
-1	B-X
,	B-X
occludin	B-X
and	B-X
claudin-2	B-X
,	B-X
were	B-X
quantitatively	B-X
and	B-X
qualitatively	B-X
evaluated	B-X
.	B-X
The	B-X
results	B-X
indicated	B-X
that	B-X
imipenem	B-X
combined	B-X
with	B-X
low-dose	B-X
CTX	B-X
significantly	B-X
improved	B-X
the	B-X
survival	B-X
rate	B-X
of	B-X
rats	B-X
compared	B-X
with	B-X
imipenem	B-X
alone	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
However	B-X
,	B-X
no	B-X
significantly	B-X
difference	B-X
between	B-X
the	B-X
treatment	B-X
with	B-X
imipenem	B-X
combined	B-X
with	B-X
low-dose	B-X
CTX	B-X
and	B-X
imipenem	B-X
treatment	B-X
alone	B-X
was	B-X
indicated	B-X
with	B-X
regard	B-X
to	B-X
histopathology	B-X
,	B-X
intestinal	B-X
permeability	B-X
,	B-X
intestinal	B-X
epithelial	B-X
apoptosis	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
claudin-2	B-X
,	B-X
ZO-1	B-X
and	B-X
TNF-α	B-X
.	B-X
However	B-X
,	B-X
imipenem	B-X
combined	B-X
with	B-X
low-dose	B-X
CTX	B-X
significantly	B-X
reduced	B-X
IL-6	B-X
and	B-X
IL-10	B-X
expression	B-X
and	B-X
significantly	B-X
increased	B-X
occludin	B-X
expression	B-X
compared	B-X
with	B-X
imipenem	B-X
alone	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
It	B-X
was	B-X
concluded	B-X
that	B-X
imipenem	B-X
combined	B-X
with	B-X
low-dose	B-X
CTX	B-X
could	B-X
improve	B-X
the	B-X
survival	B-X
rate	B-X
of	B-X
rats	B-X
with	B-X
sepsis	B-X
compared	B-X
with	B-X
rats	B-X
treated	B-X
with	B-X
imipenem	B-X
alone	B-X
.	B-X
The	B-X
present	B-X
findings	B-X
suggest	B-X
that	B-X
imipenem	B-X
combined	B-X
with	B-X
low-dose	B-X
CTX	B-X
may	B-X
cause	B-X
damage	B-X
to	B-X
the	B-X
intestinal	B-X
barrier	B-X
function	B-X
and	B-X
the	B-X
mechanism	B-X
may	B-X
be	B-X
associated	B-X
with	B-X
a	B-X
reduction	B-X
in	B-X
IL-10	B-X
expression	B-X
.	B-X

Transfection	O
studies	O
of	O
LTR	O
reporter	O
constructs	O
indicated	O
that	O
mutation	O
of	O
the	O
DSE	O
sites	O
abrogated	O
the	O
LTR	O
-	O
mediated	O
synergy	O
induced	O
by	O
Ctx	O
and	O
TNFalpha	B-Protein
,	O
whereas	O
the	O
synergy	O
induced	O
by	O
Ctx	O
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
was	O
unaffected	O
,	O
suggesting	O
TNFalpha	B-Protein
and	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
cooperate	O
differently	O
with	O
the	O
cAMP	O
/	O
PKA	O
activation	O
pathway	O
to	O
induce	O
HIV	O
-	O
1	O
expression	O
in	O
U1	O
cells	O
.	O
<EOS>	B-X
Activating	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
binding	B-X
TPA	B-X
responsive	B-X
elements	B-X
(	B-X
TRE	B-X
)	B-X
are	B-X
located	B-X
downstream	B-X
of	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
in	B-X
the	B-X
U5	B-X
region	B-X
of	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
These	B-X
downstream	B-X
sequence	B-X
elements	B-X
,	B-X
termed	B-X
DSE	B-X
,	B-X
can	B-X
bind	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
transcription	B-X
factors	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
cAMP-responsive	B-X
elements	B-X
(	B-X
CRE	B-X
)	B-X
,	B-X
since	B-X
they	B-X
mediated	B-X
activation	B-X
signals	B-X
elicited	B-X
by	B-X
cholera	B-X
toxin	B-X
(	B-X
Ctx	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
activator	B-X
of	B-X
the	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signal	B-X
transduction	B-X
pathway	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
HIV-1	B-X
DSE	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
synergy	B-X
elicited	B-X
by	B-X
the	B-X
combination	B-X
of	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
.	B-X
Ctx	B-X
combined	B-X
with	B-X
TNFalpha	B-X
or	B-X
IL-1beta	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
increase	B-X
in	B-X
p24	B-X
antigen	B-X
production	B-X
in	B-X
U1	B-X
promonocytic	B-X
cells	B-X
.	B-X
Transfection	B-X
studies	B-X
of	B-X
LTR	B-X
reporter	B-X
constructs	B-X
indicated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
DSE	B-X
sites	B-X
abrogated	B-X
the	B-X
LTR-mediated	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
,	B-X
whereas	B-X
the	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
IL-1beta	B-X
was	B-X
unaffected	B-X
,	B-X
suggesting	B-X
TNFalpha	B-X
and	B-X
IL-1beta	B-X
cooperate	B-X
differently	B-X
with	B-X
the	B-X
cAMP/PKA	B-X
activation	B-X
pathway	B-X
to	B-X
induce	B-X
HIV-1	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
.	B-X
Because	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
TRE	B-X
sites	B-X
,	B-X
we	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
agonist	B-X
combinations	B-X
on	B-X
AP-1-dependent	B-X
transcription	B-X
.	B-X
TNFalpha	B-X
as	B-X
well	B-X
as	B-X
IL-1beta	B-X
cooperated	B-X
with	B-X
Ctx	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
activation	B-X
of	B-X
AP-1-mediated	B-X
transcription	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
TRE-like	B-X
cAMP-responsive	B-X
DSE	B-X
sites	B-X
within	B-X
the	B-X
5'-untranslated	B-X
leader	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
cooperativity	B-X
between	B-X
TNFalpha	B-X
and	B-X
the	B-X
cAMP/PKA	B-X
pathway	B-X
.	B-X
Since	B-X
the	B-X
DSE	B-X
and	B-X
TRE	B-X
sites	B-X
can	B-X
not	B-X
bind	B-X
CREB/ATF	B-X
homodimers	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
mechanism	B-X
in	B-X
which	B-X
the	B-X
HIV-1	B-X
DSE	B-X
bind	B-X
heterodimers	B-X
composed	B-X
of	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
proteins	B-X
.	B-X

Because	O
the	O
DSE	O
are	O
also	O
TRE	O
sites	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
the	O
agonist	O
combinations	O
on	O
AP	O
-	O
1	O
-	O
dependent	O
transcription	O
.	O
<EOS>	B-X
Activating	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
binding	B-X
TPA	B-X
responsive	B-X
elements	B-X
(	B-X
TRE	B-X
)	B-X
are	B-X
located	B-X
downstream	B-X
of	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
in	B-X
the	B-X
U5	B-X
region	B-X
of	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
These	B-X
downstream	B-X
sequence	B-X
elements	B-X
,	B-X
termed	B-X
DSE	B-X
,	B-X
can	B-X
bind	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
transcription	B-X
factors	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
cAMP-responsive	B-X
elements	B-X
(	B-X
CRE	B-X
)	B-X
,	B-X
since	B-X
they	B-X
mediated	B-X
activation	B-X
signals	B-X
elicited	B-X
by	B-X
cholera	B-X
toxin	B-X
(	B-X
Ctx	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
activator	B-X
of	B-X
the	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signal	B-X
transduction	B-X
pathway	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
HIV-1	B-X
DSE	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
synergy	B-X
elicited	B-X
by	B-X
the	B-X
combination	B-X
of	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
.	B-X
Ctx	B-X
combined	B-X
with	B-X
TNFalpha	B-X
or	B-X
IL-1beta	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
increase	B-X
in	B-X
p24	B-X
antigen	B-X
production	B-X
in	B-X
U1	B-X
promonocytic	B-X
cells	B-X
.	B-X
Transfection	B-X
studies	B-X
of	B-X
LTR	B-X
reporter	B-X
constructs	B-X
indicated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
DSE	B-X
sites	B-X
abrogated	B-X
the	B-X
LTR-mediated	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
,	B-X
whereas	B-X
the	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
IL-1beta	B-X
was	B-X
unaffected	B-X
,	B-X
suggesting	B-X
TNFalpha	B-X
and	B-X
IL-1beta	B-X
cooperate	B-X
differently	B-X
with	B-X
the	B-X
cAMP/PKA	B-X
activation	B-X
pathway	B-X
to	B-X
induce	B-X
HIV-1	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
.	B-X
Because	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
TRE	B-X
sites	B-X
,	B-X
we	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
agonist	B-X
combinations	B-X
on	B-X
AP-1-dependent	B-X
transcription	B-X
.	B-X
TNFalpha	B-X
as	B-X
well	B-X
as	B-X
IL-1beta	B-X
cooperated	B-X
with	B-X
Ctx	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
activation	B-X
of	B-X
AP-1-mediated	B-X
transcription	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
TRE-like	B-X
cAMP-responsive	B-X
DSE	B-X
sites	B-X
within	B-X
the	B-X
5'-untranslated	B-X
leader	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
cooperativity	B-X
between	B-X
TNFalpha	B-X
and	B-X
the	B-X
cAMP/PKA	B-X
pathway	B-X
.	B-X
Since	B-X
the	B-X
DSE	B-X
and	B-X
TRE	B-X
sites	B-X
can	B-X
not	B-X
bind	B-X
CREB/ATF	B-X
homodimers	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
mechanism	B-X
in	B-X
which	B-X
the	B-X
HIV-1	B-X
DSE	B-X
bind	B-X
heterodimers	B-X
composed	B-X
of	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
proteins	B-X
.	B-X

TNFalpha	B-Protein
as	O
well	O
as	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
cooperated	O
with	O
Ctx	O
to	O
produce	O
a	O
synergistic	O
activation	O
of	O
AP	O
-	O
1	O
-	O
mediated	O
transcription	O
.	O
<EOS>	B-X
Activating	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
binding	B-X
TPA	B-X
responsive	B-X
elements	B-X
(	B-X
TRE	B-X
)	B-X
are	B-X
located	B-X
downstream	B-X
of	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
in	B-X
the	B-X
U5	B-X
region	B-X
of	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
These	B-X
downstream	B-X
sequence	B-X
elements	B-X
,	B-X
termed	B-X
DSE	B-X
,	B-X
can	B-X
bind	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
transcription	B-X
factors	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
cAMP-responsive	B-X
elements	B-X
(	B-X
CRE	B-X
)	B-X
,	B-X
since	B-X
they	B-X
mediated	B-X
activation	B-X
signals	B-X
elicited	B-X
by	B-X
cholera	B-X
toxin	B-X
(	B-X
Ctx	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
activator	B-X
of	B-X
the	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signal	B-X
transduction	B-X
pathway	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
HIV-1	B-X
DSE	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
synergy	B-X
elicited	B-X
by	B-X
the	B-X
combination	B-X
of	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
.	B-X
Ctx	B-X
combined	B-X
with	B-X
TNFalpha	B-X
or	B-X
IL-1beta	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
increase	B-X
in	B-X
p24	B-X
antigen	B-X
production	B-X
in	B-X
U1	B-X
promonocytic	B-X
cells	B-X
.	B-X
Transfection	B-X
studies	B-X
of	B-X
LTR	B-X
reporter	B-X
constructs	B-X
indicated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
DSE	B-X
sites	B-X
abrogated	B-X
the	B-X
LTR-mediated	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
,	B-X
whereas	B-X
the	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
IL-1beta	B-X
was	B-X
unaffected	B-X
,	B-X
suggesting	B-X
TNFalpha	B-X
and	B-X
IL-1beta	B-X
cooperate	B-X
differently	B-X
with	B-X
the	B-X
cAMP/PKA	B-X
activation	B-X
pathway	B-X
to	B-X
induce	B-X
HIV-1	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
.	B-X
Because	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
TRE	B-X
sites	B-X
,	B-X
we	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
agonist	B-X
combinations	B-X
on	B-X
AP-1-dependent	B-X
transcription	B-X
.	B-X
TNFalpha	B-X
as	B-X
well	B-X
as	B-X
IL-1beta	B-X
cooperated	B-X
with	B-X
Ctx	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
activation	B-X
of	B-X
AP-1-mediated	B-X
transcription	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
TRE-like	B-X
cAMP-responsive	B-X
DSE	B-X
sites	B-X
within	B-X
the	B-X
5'-untranslated	B-X
leader	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
cooperativity	B-X
between	B-X
TNFalpha	B-X
and	B-X
the	B-X
cAMP/PKA	B-X
pathway	B-X
.	B-X
Since	B-X
the	B-X
DSE	B-X
and	B-X
TRE	B-X
sites	B-X
can	B-X
not	B-X
bind	B-X
CREB/ATF	B-X
homodimers	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
mechanism	B-X
in	B-X
which	B-X
the	B-X
HIV-1	B-X
DSE	B-X
bind	B-X
heterodimers	B-X
composed	B-X
of	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
proteins	B-X
.	B-X

These	O
data	O
indicate	O
that	O
the	O
TRE	O
-	O
like	O
cAMP	O
-	O
responsive	O
DSE	O
sites	O
within	O
the	O
5	O
'	O
-	O
untranslated	O
leader	O
can	O
mediate	O
the	O
transcriptional	O
cooperativity	O
between	O
TNFalpha	B-Protein
and	O
the	O
cAMP	O
/	O
PKA	O
pathway	O
.	O
<EOS>	B-X
Activating	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
binding	B-X
TPA	B-X
responsive	B-X
elements	B-X
(	B-X
TRE	B-X
)	B-X
are	B-X
located	B-X
downstream	B-X
of	B-X
the	B-X
transcription	B-X
initiation	B-X
site	B-X
in	B-X
the	B-X
U5	B-X
region	B-X
of	B-X
the	B-X
HIV-1	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
These	B-X
downstream	B-X
sequence	B-X
elements	B-X
,	B-X
termed	B-X
DSE	B-X
,	B-X
can	B-X
bind	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
transcription	B-X
factors	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
cAMP-responsive	B-X
elements	B-X
(	B-X
CRE	B-X
)	B-X
,	B-X
since	B-X
they	B-X
mediated	B-X
activation	B-X
signals	B-X
elicited	B-X
by	B-X
cholera	B-X
toxin	B-X
(	B-X
Ctx	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
activator	B-X
of	B-X
the	B-X
cAMP-dependent	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
signal	B-X
transduction	B-X
pathway	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
HIV-1	B-X
DSE	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
synergy	B-X
elicited	B-X
by	B-X
the	B-X
combination	B-X
of	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
.	B-X
Ctx	B-X
combined	B-X
with	B-X
TNFalpha	B-X
or	B-X
IL-1beta	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
increase	B-X
in	B-X
p24	B-X
antigen	B-X
production	B-X
in	B-X
U1	B-X
promonocytic	B-X
cells	B-X
.	B-X
Transfection	B-X
studies	B-X
of	B-X
LTR	B-X
reporter	B-X
constructs	B-X
indicated	B-X
that	B-X
mutation	B-X
of	B-X
the	B-X
DSE	B-X
sites	B-X
abrogated	B-X
the	B-X
LTR-mediated	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
TNFalpha	B-X
,	B-X
whereas	B-X
the	B-X
synergy	B-X
induced	B-X
by	B-X
Ctx	B-X
and	B-X
IL-1beta	B-X
was	B-X
unaffected	B-X
,	B-X
suggesting	B-X
TNFalpha	B-X
and	B-X
IL-1beta	B-X
cooperate	B-X
differently	B-X
with	B-X
the	B-X
cAMP/PKA	B-X
activation	B-X
pathway	B-X
to	B-X
induce	B-X
HIV-1	B-X
expression	B-X
in	B-X
U1	B-X
cells	B-X
.	B-X
Because	B-X
the	B-X
DSE	B-X
are	B-X
also	B-X
TRE	B-X
sites	B-X
,	B-X
we	B-X
assessed	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
agonist	B-X
combinations	B-X
on	B-X
AP-1-dependent	B-X
transcription	B-X
.	B-X
TNFalpha	B-X
as	B-X
well	B-X
as	B-X
IL-1beta	B-X
cooperated	B-X
with	B-X
Ctx	B-X
to	B-X
produce	B-X
a	B-X
synergistic	B-X
activation	B-X
of	B-X
AP-1-mediated	B-X
transcription	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
TRE-like	B-X
cAMP-responsive	B-X
DSE	B-X
sites	B-X
within	B-X
the	B-X
5'-untranslated	B-X
leader	B-X
can	B-X
mediate	B-X
the	B-X
transcriptional	B-X
cooperativity	B-X
between	B-X
TNFalpha	B-X
and	B-X
the	B-X
cAMP/PKA	B-X
pathway	B-X
.	B-X
Since	B-X
the	B-X
DSE	B-X
and	B-X
TRE	B-X
sites	B-X
can	B-X
not	B-X
bind	B-X
CREB/ATF	B-X
homodimers	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
mechanism	B-X
in	B-X
which	B-X
the	B-X
HIV-1	B-X
DSE	B-X
bind	B-X
heterodimers	B-X
composed	B-X
of	B-X
both	B-X
AP-1	B-X
and	B-X
CREB/ATF	B-X
proteins	B-X
.	B-X

Since	O
the	O
DSE	O
and	O
TRE	O
sites	O
cannot	O
bind	O
CREB	O
/	O
ATF	O
homodimers	O
,	O
we	O
propose	O
a	O
mechanism	O
in	O
which	O
the	O
HIV	O
-	O
1	O
DSE	O
bind	O
heterodimers	O
composed	O
of	O
both	O
AP	O
-	O
1	O
and	O
CREB	O
/	O
ATF	O
proteins	O
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O
<EOS>	B-X
No	B-X
abstract	B-X
Copyright	B-X
1997	B-X
Academic	B-X
Press	B-X
Limited	B-X
Copyright	B-X
1997	B-X
Academic	B-X
Press	B-X
.	B-X
Copyright	B-X
1997Academic	B-X
Press	B-X
Copyright	B-X
1997	B-X
Academic	B-X
Press	B-X
.	B-X
Copyright	B-X
1997Academic	B-X
Press	B-X

The	O
Epstein	O
-	O
Barr	O
virus	O
oncogene	O
product	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
engages	O
the	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
-	O
associated	O
death	O
domain	O
protein	O
to	O
mediate	O
B	O
lymphocyte	O
growth	O
transformation	O
and	O
activate	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
The	B-X
Epstein-Barr	B-X
virus	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
transformation	B-X
of	B-X
B	B-X
lymphocytes	B-X
into	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
.	B-X
Previous	B-X
data	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
that	B-X
LMP1	B-X
is	B-X
a	B-X
constitutively	B-X
activated	B-X
receptor	B-X
that	B-X
transduces	B-X
signals	B-X
for	B-X
transformation	B-X
through	B-X
its	B-X
carboxyl-terminal	B-X
cytoplasmic	B-X
tail	B-X
.	B-X
One	B-X
transformation	B-X
effector	B-X
site	B-X
(	B-X
TES1	B-X
)	B-X
,	B-X
located	B-X
within	B-X
the	B-X
membrane	B-X
proximal	B-X
45	B-X
residues	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
,	B-X
constitutively	B-X
engages	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factors	B-X
.	B-X
Signals	B-X
from	B-X
TES1	B-X
are	B-X
sufficient	B-X
to	B-X
drive	B-X
initial	B-X
proliferation	B-X
of	B-X
infected	B-X
resting	B-X
B	B-X
lymphocytes	B-X
,	B-X
but	B-X
most	B-X
lymphoblastoid	B-X
cells	B-X
infected	B-X
with	B-X
a	B-X
virus	B-X
that	B-X
does	B-X
not	B-X
express	B-X
the	B-X
155	B-X
residues	B-X
beyond	B-X
TES1	B-X
fail	B-X
to	B-X
grow	B-X
as	B-X
long-term	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
mutating	B-X
two	B-X
tyrosines	B-X
to	B-X
an	B-X
isoleucine	B-X
at	B-X
the	B-X
carboxyl	B-X
end	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
cripples	B-X
the	B-X
ability	B-X
of	B-X
EBV	B-X
to	B-X
cause	B-X
lymphoblastoid	B-X
cell	B-X
outgrowth	B-X
,	B-X
thereby	B-X
marking	B-X
a	B-X
second	B-X
transformation	B-X
effector	B-X
site	B-X
,	B-X
TES2	B-X
.	B-X
A	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
identified	B-X
TES2	B-X
interacting	B-X
proteins	B-X
,	B-X
including	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
death	B-X
domain	B-X
protein	B-X
(	B-X
TRADD	B-X
)	B-X
.	B-X
TRADD	B-X
was	B-X
the	B-X
only	B-X
protein	B-X
that	B-X
interacted	B-X
with	B-X
wild-type	B-X
TES2	B-X
and	B-X
not	B-X
with	B-X
isoleucine-mutated	B-X
TES2	B-X
.	B-X
TRADD	B-X
associated	B-X
with	B-X
wild-type	B-X
LMP1	B-X
but	B-X
not	B-X
with	B-X
isoleucine-mutated	B-X
LMP1	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
and	B-X
TRADD	B-X
constitutively	B-X
associated	B-X
with	B-X
LMP1	B-X
in	B-X
EBV-transformed	B-X
cells	B-X
.	B-X
In	B-X
transfection	B-X
assays	B-X
,	B-X
TRADD	B-X
and	B-X
TES2	B-X
synergistically	B-X
mediated	B-X
high-level	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
LMP1	B-X
appropriates	B-X
TRADD	B-X
to	B-X
enable	B-X
efficient	B-X
long-term	B-X
lymphoblastoid	B-X
cell	B-X
outgrowth	B-X
.	B-X
High-level	B-X
NF-kappaB	B-X
activation	B-X
also	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
long-term	B-X
outgrowth	B-X
.	B-X

The	O
Epstein	O
-	O
Barr	O
virus	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
(	O
LMP1	B-Protein
)	O
is	O
essential	O
for	O
the	O
transformation	O
of	O
B	O
lymphocytes	O
into	O
lymphoblastoid	O
cell	O
lines	O
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
transforms	B-X
resting	B-X
primary	B-X
human	B-X
B	B-X
lymphocytes	B-X
into	B-X
indefinitely	B-X
proliferating	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
and	B-X
is	B-X
associated	B-X
with	B-X
several	B-X
human	B-X
malignancies	B-X
in	B-X
vivo	B-X
.	B-X
Recombinant	B-X
EBV	B-X
genetic	B-X
analyses	B-X
combined	B-X
with	B-X
in	B-X
vitro	B-X
B	B-X
lymphocyte	B-X
transformation	B-X
assays	B-X
demonstrate	B-X
that	B-X
latent	B-X
infection	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
EBV-mediated	B-X
lymphocyte	B-X
transformation	B-X
.	B-X
LMP1	B-X
has	B-X
no	B-X
intrinsic	B-X
enzymatic	B-X
activity	B-X
but	B-X
instead	B-X
aggregates	B-X
cellular	B-X
proteins	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
signaling	B-X
pathway	B-X
to	B-X
activate	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
.	B-X
Mutants	B-X
rendering	B-X
LMP1	B-X
defective	B-X
in	B-X
these	B-X
protein	B-X
interactions	B-X
are	B-X
impaired	B-X
in	B-X
their	B-X
abilities	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
in	B-X
reporter	B-X
gene	B-X
assays	B-X
.	B-X
Concordantly	B-X
,	B-X
EBV	B-X
recombinants	B-X
with	B-X
LMP1	B-X
mutations	B-X
that	B-X
are	B-X
compromised	B-X
for	B-X
NF-kappaB	B-X
activation	B-X
are	B-X
impaired	B-X
for	B-X
growth	B-X
transformation	B-X
.	B-X
Thus	B-X
,	B-X
EBV-mediated	B-X
growth	B-X
transformation	B-X
is	B-X
genetically	B-X
and	B-X
biochemically	B-X
linked	B-X
to	B-X
LMP1-mediated	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
.	B-X

Previous	O
data	O
are	O
consistent	O
with	O
a	O
model	O
that	O
LMP1	B-Protein
is	O
a	O
constitutively	O
activated	O
receptor	O
that	O
transduces	O
signals	O
for	O
transformation	O
through	O
its	O
carboxyl	O
-	O
terminal	O
cytoplasmic	O
tail	O
.	O

One	O
transformation	O
effector	O
site	O
(	O
TES1	O
)	O
,	O
located	O
within	O
the	O
membrane	O
proximal	O
45	O
residues	O
of	O
the	O
cytoplasmic	O
tail	O
,	O
constitutively	O
engages	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
.	O
<EOS>	B-X
The	B-X
Epstein-Barr	B-X
virus	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
transformation	B-X
of	B-X
B	B-X
lymphocytes	B-X
into	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
.	B-X
Previous	B-X
data	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
that	B-X
LMP1	B-X
is	B-X
a	B-X
constitutively	B-X
activated	B-X
receptor	B-X
that	B-X
transduces	B-X
signals	B-X
for	B-X
transformation	B-X
through	B-X
its	B-X
carboxyl-terminal	B-X
cytoplasmic	B-X
tail	B-X
.	B-X
One	B-X
transformation	B-X
effector	B-X
site	B-X
(	B-X
TES1	B-X
)	B-X
,	B-X
located	B-X
within	B-X
the	B-X
membrane	B-X
proximal	B-X
45	B-X
residues	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
,	B-X
constitutively	B-X
engages	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factors	B-X
.	B-X
Signals	B-X
from	B-X
TES1	B-X
are	B-X
sufficient	B-X
to	B-X
drive	B-X
initial	B-X
proliferation	B-X
of	B-X
infected	B-X
resting	B-X
B	B-X
lymphocytes	B-X
,	B-X
but	B-X
most	B-X
lymphoblastoid	B-X
cells	B-X
infected	B-X
with	B-X
a	B-X
virus	B-X
that	B-X
does	B-X
not	B-X
express	B-X
the	B-X
155	B-X
residues	B-X
beyond	B-X
TES1	B-X
fail	B-X
to	B-X
grow	B-X
as	B-X
long-term	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
mutating	B-X
two	B-X
tyrosines	B-X
to	B-X
an	B-X
isoleucine	B-X
at	B-X
the	B-X
carboxyl	B-X
end	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
cripples	B-X
the	B-X
ability	B-X
of	B-X
EBV	B-X
to	B-X
cause	B-X
lymphoblastoid	B-X
cell	B-X
outgrowth	B-X
,	B-X
thereby	B-X
marking	B-X
a	B-X
second	B-X
transformation	B-X
effector	B-X
site	B-X
,	B-X
TES2	B-X
.	B-X
A	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
identified	B-X
TES2	B-X
interacting	B-X
proteins	B-X
,	B-X
including	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
death	B-X
domain	B-X
protein	B-X
(	B-X
TRADD	B-X
)	B-X
.	B-X
TRADD	B-X
associated	B-X
with	B-X
wild-type	B-X
LMP1	B-X
but	B-X
not	B-X
with	B-X
isoleucine-mutated	B-X
LMP1	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
and	B-X
TRADD	B-X
constitutively	B-X
associated	B-X
with	B-X
LMP1	B-X
in	B-X
EBV-transformed	B-X
cells	B-X
.	B-X

Signals	O
from	O
TES1	O
are	O
sufficient	O
to	O
drive	O
initial	O
proliferation	O
of	O
infected	O
resting	O
B	O
lymphocytes	O
,	O
but	O
most	O
lymphoblastoid	O
cells	O
infected	O
with	O
a	O
virus	O
that	O
does	O
not	O
express	O
the	O
155	O
residues	O
beyond	O
TES1	O
fail	O
to	O
grow	O
as	O
long	O
-	O
term	O
cell	O
lines	O
.	O

We	O
now	O
find	O
that	O
mutating	O
two	O
tyrosines	O
to	O
an	O
isoleucine	O
at	O
the	O
carboxyl	O
end	O
of	O
the	O
cytoplasmic	O
tail	O
cripples	O
the	O
ability	O
of	O
EBV	O
to	O
cause	O
lymphoblastoid	O
cell	O
outgrowth	O
,	O
thereby	O
marking	O
a	O
second	O
transformation	O
effector	O
site	O
,	O
TES2	O
.	O

A	O
yeast	O
two	O
-	O
hybrid	O
screen	O
identified	O
TES2	O
interacting	O
proteins	O
,	O
including	O
the	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
death	I-Protein
domain	I-Protein
protein	I-Protein
(	O
TRADD	B-Protein
)	O
.	O
<EOS>	B-X
The	B-X
Epstein-Barr	B-X
virus	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
transformation	B-X
of	B-X
B	B-X
lymphocytes	B-X
into	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
.	B-X
Previous	B-X
data	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
that	B-X
LMP1	B-X
is	B-X
a	B-X
constitutively	B-X
activated	B-X
receptor	B-X
that	B-X
transduces	B-X
signals	B-X
for	B-X
transformation	B-X
through	B-X
its	B-X
carboxyl-terminal	B-X
cytoplasmic	B-X
tail	B-X
.	B-X
One	B-X
transformation	B-X
effector	B-X
site	B-X
(	B-X
TES1	B-X
)	B-X
,	B-X
located	B-X
within	B-X
the	B-X
membrane	B-X
proximal	B-X
45	B-X
residues	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
,	B-X
constitutively	B-X
engages	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factors	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
mutating	B-X
two	B-X
tyrosines	B-X
to	B-X
an	B-X
isoleucine	B-X
at	B-X
the	B-X
carboxyl	B-X
end	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
cripples	B-X
the	B-X
ability	B-X
of	B-X
EBV	B-X
to	B-X
cause	B-X
lymphoblastoid	B-X
cell	B-X
outgrowth	B-X
,	B-X
thereby	B-X
marking	B-X
a	B-X
second	B-X
transformation	B-X
effector	B-X
site	B-X
,	B-X
TES2	B-X
.	B-X
A	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
identified	B-X
TES2	B-X
interacting	B-X
proteins	B-X
,	B-X
including	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
death	B-X
domain	B-X
protein	B-X
(	B-X
TRADD	B-X
)	B-X
.	B-X
TRADD	B-X
was	B-X
the	B-X
only	B-X
protein	B-X
that	B-X
interacted	B-X
with	B-X
wild-type	B-X
TES2	B-X
and	B-X
not	B-X
with	B-X
isoleucine-mutated	B-X
TES2	B-X
.	B-X
TRADD	B-X
associated	B-X
with	B-X
wild-type	B-X
LMP1	B-X
but	B-X
not	B-X
with	B-X
isoleucine-mutated	B-X
LMP1	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
and	B-X
TRADD	B-X
constitutively	B-X
associated	B-X
with	B-X
LMP1	B-X
in	B-X
EBV-transformed	B-X
cells	B-X
.	B-X
In	B-X
transfection	B-X
assays	B-X
,	B-X
TRADD	B-X
and	B-X
TES2	B-X
synergistically	B-X
mediated	B-X
high-level	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
LMP1	B-X
appropriates	B-X
TRADD	B-X
to	B-X
enable	B-X
efficient	B-X
long-term	B-X
lymphoblastoid	B-X
cell	B-X
outgrowth	B-X
.	B-X

TRADD	B-Protein
was	O
the	O
only	O
protein	O
that	O
interacted	O
with	O
wild	O
-	O
type	O
TES2	O
and	O
not	O
with	O
isoleucine	O
-	O
mutated	O
TES2	O
.	O

TRADD	B-Protein
associated	O
with	O
wild	O
-	O
type	O
LMP1	B-Protein
but	O
not	O
with	O
isoleucine	O
-	O
mutated	O
LMP1	B-Protein
in	O
mammalian	O
cells	O
,	O
and	O
TRADD	B-Protein
constitutively	O
associated	O
with	O
LMP1	B-Protein
in	O
EBV	O
-	O
transformed	O
cells	O
.	O
<EOS>	B-X
The	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-receptor	B-X
1-associated	B-X
death	B-X
domain	B-X
protein	B-X
(	B-X
TRADD	B-X
)	B-X
mediates	B-X
induction	B-X
of	B-X
apoptosis	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
by	B-X
cellular	B-X
TNF-receptor	B-X
1	B-X
(	B-X
TNFR1	B-X
)	B-X
.	B-X
TRADD	B-X
is	B-X
also	B-X
recruited	B-X
by	B-X
the	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
oncoprotein	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
LMP1	B-X
signaling	B-X
has	B-X
remained	B-X
enigmatic	B-X
.	B-X
In	B-X
human	B-X
B	B-X
lymphocytes	B-X
,	B-X
we	B-X
have	B-X
generated	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
the	B-X
first	B-X
genetic	B-X
knockout	B-X
of	B-X
TRADD	B-X
to	B-X
investigate	B-X
TRADD	B-X
's	B-X
role	B-X
in	B-X
LMP1	B-X
signal	B-X
transduction	B-X
.	B-X
Our	B-X
data	B-X
from	B-X
TRADD-deficient	B-X
cells	B-X
demonstrate	B-X
that	B-X
TRADD	B-X
is	B-X
a	B-X
critical	B-X
signaling	B-X
mediator	B-X
of	B-X
LMP1	B-X
that	B-X
is	B-X
required	B-X
for	B-X
LMP1	B-X
to	B-X
recruit	B-X
and	B-X
activate	B-X
I-kappaB	B-X
kinase	B-X
beta	B-X
(	B-X
IKKbeta	B-X
)	B-X
.	B-X
However	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
TNFR1	B-X
,	B-X
LMP1-induced	B-X
TRADD	B-X
signaling	B-X
does	B-X
not	B-X
induce	B-X
apoptosis	B-X
.	B-X
Searching	B-X
for	B-X
the	B-X
molecular	B-X
basis	B-X
for	B-X
this	B-X
observation	B-X
,	B-X
we	B-X
characterized	B-X
the	B-X
16	B-X
C-terminal	B-X
amino	B-X
acids	B-X
of	B-X
LMP1	B-X
as	B-X
an	B-X
autonomous	B-X
and	B-X
unique	B-X
virus-derived	B-X
TRADD-binding	B-X
domain	B-X
.	B-X
Replacing	B-X
the	B-X
death	B-X
domain	B-X
of	B-X
TNFR1	B-X
by	B-X
LMP1	B-X
's	B-X
TRADD-binding	B-X
domain	B-X
converts	B-X
TNFR1	B-X
into	B-X
a	B-X
nonapoptotic	B-X
receptor	B-X
that	B-X
activates	B-X
NF-kappaB	B-X
through	B-X
a	B-X
TRAF6-dependent	B-X
pathway	B-X
,	B-X
like	B-X
LMP1	B-X
but	B-X
unlike	B-X
wild-type	B-X
TNFR1	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
unique	B-X
interaction	B-X
of	B-X
LMP1	B-X
with	B-X
TRADD	B-X
encodes	B-X
the	B-X
transforming	B-X
phenotype	B-X
of	B-X
viral	B-X
TRADD	B-X
signaling	B-X
and	B-X
masks	B-X
TRADD	B-X
's	B-X
pro-apoptotic	B-X
function	B-X
.	B-X

In	O
transfection	O
assays	O
,	O
TRADD	B-Protein
and	O
TES2	B-Protein
synergistically	O
mediated	O
high	O
-	O
level	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
We	B-X
now	B-X
find	B-X
that	B-X
mutating	B-X
two	B-X
tyrosines	B-X
to	B-X
an	B-X
isoleucine	B-X
at	B-X
the	B-X
carboxyl	B-X
end	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
cripples	B-X
the	B-X
ability	B-X
of	B-X
EBV	B-X
to	B-X
cause	B-X
lymphoblastoid	B-X
cell	B-X
outgrowth	B-X
,	B-X
thereby	B-X
marking	B-X
a	B-X
second	B-X
transformation	B-X
effector	B-X
site	B-X
,	B-X
TES2	B-X
.	B-X
A	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
identified	B-X
TES2	B-X
interacting	B-X
proteins	B-X
,	B-X
including	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
death	B-X
domain	B-X
protein	B-X
(	B-X
TRADD	B-X
)	B-X
.	B-X
TRADD	B-X
was	B-X
the	B-X
only	B-X
protein	B-X
that	B-X
interacted	B-X
with	B-X
wild-type	B-X
TES2	B-X
and	B-X
not	B-X
with	B-X
isoleucine-mutated	B-X
TES2	B-X
.	B-X
TRADD	B-X
associated	B-X
with	B-X
wild-type	B-X
LMP1	B-X
but	B-X
not	B-X
with	B-X
isoleucine-mutated	B-X
LMP1	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
and	B-X
TRADD	B-X
constitutively	B-X
associated	B-X
with	B-X
LMP1	B-X
in	B-X
EBV-transformed	B-X
cells	B-X
.	B-X
In	B-X
transfection	B-X
assays	B-X
,	B-X
TRADD	B-X
and	B-X
TES2	B-X
synergistically	B-X
mediated	B-X
high-level	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
LMP1	B-X
appropriates	B-X
TRADD	B-X
to	B-X
enable	B-X
efficient	B-X
long-term	B-X
lymphoblastoid	B-X
cell	B-X
outgrowth	B-X
.	B-X
High-level	B-X
NF-kappaB	B-X
activation	B-X
also	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
long-term	B-X
outgrowth	B-X
.	B-X

These	O
results	O
indicate	O
that	O
LMP1	B-Protein
appropriates	O
TRADD	B-Protein
to	O
enable	O
efficient	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
outgrowth	O
.	O
<EOS>	B-X
The	B-X
Epstein-Barr	B-X
virus	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
transformation	B-X
of	B-X
B	B-X
lymphocytes	B-X
into	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
.	B-X
Previous	B-X
data	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
that	B-X
LMP1	B-X
is	B-X
a	B-X
constitutively	B-X
activated	B-X
receptor	B-X
that	B-X
transduces	B-X
signals	B-X
for	B-X
transformation	B-X
through	B-X
its	B-X
carboxyl-terminal	B-X
cytoplasmic	B-X
tail	B-X
.	B-X
Signals	B-X
from	B-X
TES1	B-X
are	B-X
sufficient	B-X
to	B-X
drive	B-X
initial	B-X
proliferation	B-X
of	B-X
infected	B-X
resting	B-X
B	B-X
lymphocytes	B-X
,	B-X
but	B-X
most	B-X
lymphoblastoid	B-X
cells	B-X
infected	B-X
with	B-X
a	B-X
virus	B-X
that	B-X
does	B-X
not	B-X
express	B-X
the	B-X
155	B-X
residues	B-X
beyond	B-X
TES1	B-X
fail	B-X
to	B-X
grow	B-X
as	B-X
long-term	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
mutating	B-X
two	B-X
tyrosines	B-X
to	B-X
an	B-X
isoleucine	B-X
at	B-X
the	B-X
carboxyl	B-X
end	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
cripples	B-X
the	B-X
ability	B-X
of	B-X
EBV	B-X
to	B-X
cause	B-X
lymphoblastoid	B-X
cell	B-X
outgrowth	B-X
,	B-X
thereby	B-X
marking	B-X
a	B-X
second	B-X
transformation	B-X
effector	B-X
site	B-X
,	B-X
TES2	B-X
.	B-X
A	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
identified	B-X
TES2	B-X
interacting	B-X
proteins	B-X
,	B-X
including	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
death	B-X
domain	B-X
protein	B-X
(	B-X
TRADD	B-X
)	B-X
.	B-X
TRADD	B-X
was	B-X
the	B-X
only	B-X
protein	B-X
that	B-X
interacted	B-X
with	B-X
wild-type	B-X
TES2	B-X
and	B-X
not	B-X
with	B-X
isoleucine-mutated	B-X
TES2	B-X
.	B-X
TRADD	B-X
associated	B-X
with	B-X
wild-type	B-X
LMP1	B-X
but	B-X
not	B-X
with	B-X
isoleucine-mutated	B-X
LMP1	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
and	B-X
TRADD	B-X
constitutively	B-X
associated	B-X
with	B-X
LMP1	B-X
in	B-X
EBV-transformed	B-X
cells	B-X
.	B-X
In	B-X
transfection	B-X
assays	B-X
,	B-X
TRADD	B-X
and	B-X
TES2	B-X
synergistically	B-X
mediated	B-X
high-level	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
LMP1	B-X
appropriates	B-X
TRADD	B-X
to	B-X
enable	B-X
efficient	B-X
long-term	B-X
lymphoblastoid	B-X
cell	B-X
outgrowth	B-X
.	B-X
High-level	B-X
NF-kappaB	B-X
activation	B-X
also	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
long-term	B-X
outgrowth	B-X
.	B-X

High	O
-	O
level	O
NF	O
-	O
kappaB	O
activation	O
also	O
appears	O
to	O
be	O
a	O
critical	O
component	O
of	O
long	O
-	O
term	O
outgrowth	O
.	O
<EOS>	B-X
Previous	B-X
data	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
model	B-X
that	B-X
LMP1	B-X
is	B-X
a	B-X
constitutively	B-X
activated	B-X
receptor	B-X
that	B-X
transduces	B-X
signals	B-X
for	B-X
transformation	B-X
through	B-X
its	B-X
carboxyl-terminal	B-X
cytoplasmic	B-X
tail	B-X
.	B-X
Signals	B-X
from	B-X
TES1	B-X
are	B-X
sufficient	B-X
to	B-X
drive	B-X
initial	B-X
proliferation	B-X
of	B-X
infected	B-X
resting	B-X
B	B-X
lymphocytes	B-X
,	B-X
but	B-X
most	B-X
lymphoblastoid	B-X
cells	B-X
infected	B-X
with	B-X
a	B-X
virus	B-X
that	B-X
does	B-X
not	B-X
express	B-X
the	B-X
155	B-X
residues	B-X
beyond	B-X
TES1	B-X
fail	B-X
to	B-X
grow	B-X
as	B-X
long-term	B-X
cell	B-X
lines	B-X
.	B-X
We	B-X
now	B-X
find	B-X
that	B-X
mutating	B-X
two	B-X
tyrosines	B-X
to	B-X
an	B-X
isoleucine	B-X
at	B-X
the	B-X
carboxyl	B-X
end	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
cripples	B-X
the	B-X
ability	B-X
of	B-X
EBV	B-X
to	B-X
cause	B-X
lymphoblastoid	B-X
cell	B-X
outgrowth	B-X
,	B-X
thereby	B-X
marking	B-X
a	B-X
second	B-X
transformation	B-X
effector	B-X
site	B-X
,	B-X
TES2	B-X
.	B-X
In	B-X
transfection	B-X
assays	B-X
,	B-X
TRADD	B-X
and	B-X
TES2	B-X
synergistically	B-X
mediated	B-X
high-level	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
LMP1	B-X
appropriates	B-X
TRADD	B-X
to	B-X
enable	B-X
efficient	B-X
long-term	B-X
lymphoblastoid	B-X
cell	B-X
outgrowth	B-X
.	B-X
High-level	B-X
NF-kappaB	B-X
activation	B-X
also	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
component	B-X
of	B-X
long-term	B-X
outgrowth	B-X
.	B-X

Transcription	O
factor	O
NF	O
-	O
kappaB	O
regulates	O
inducible	O
Oct	B-Protein
-	I-Protein
2	I-Protein
gene	O
expression	O
in	O
precursor	O
B	O
lymphocytes	O
.	O
<EOS>	B-X
The	B-X
POU	B-X
transcription	B-X
factors	B-X
Oct-1	B-X
and	B-X
Oct-2	B-X
regulate	B-X
the	B-X
activity	B-X
of	B-X
octamer-dependent	B-X
promoters	B-X
,	B-X
including	B-X
those	B-X
that	B-X
direct	B-X
transcription	B-X
from	B-X
rearranged	B-X
immunoglobulin	B-X
genes	B-X
.	B-X
Unlike	B-X
Oct-1	B-X
,	B-X
which	B-X
is	B-X
constitutively	B-X
expressed	B-X
in	B-X
many	B-X
cell	B-X
types	B-X
,	B-X
Oct-2	B-X
expression	B-X
is	B-X
restricted	B-X
primarily	B-X
to	B-X
B	B-X
lymphocytes	B-X
and	B-X
can	B-X
be	B-X
induced	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
by	B-X
stimulation	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
factors	B-X
that	B-X
mediate	B-X
this	B-X
induction	B-X
mechanism	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
monitored	B-X
Oct-2	B-X
expression	B-X
in	B-X
cells	B-X
arrested	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
an	B-X
LPS-responsive	B-X
member	B-X
of	B-X
the	B-X
Rel	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
Despite	B-X
stimulation	B-X
with	B-X
LPS	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
NF-kappaB	B-X
signaling	B-X
pathway	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
led	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
inducible	B-X
Oct-2	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
the	B-X
suppression	B-X
of	B-X
Oct-2-directed	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
This	B-X
biochemical	B-X
defect	B-X
correlated	B-X
with	B-X
a	B-X
specific	B-X
block	B-X
to	B-X
Oct-2	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
whereas	B-X
the	B-X
expression	B-X
of	B-X
Oct-1	B-X
was	B-X
unaffected	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
Oct-2	B-X
is	B-X
under	B-X
NF-kappaB	B-X
control	B-X
highlights	B-X
an	B-X
important	B-X
cross-talk	B-X
mechanism	B-X
involving	B-X
two	B-X
distinct	B-X
transcription	B-X
factor	B-X
families	B-X
that	B-X
regulate	B-X
B	B-X
lymphocyte	B-X
function	B-X
.	B-X

The	O
POU	O
transcription	O
factors	O
Oct	B-Protein
-	I-Protein
1	I-Protein
and	O
Oct	B-Protein
-	I-Protein
2	I-Protein
regulate	O
the	O
activity	O
of	O
octamer	O
-	O
dependent	O
promoters	O
,	O
including	O
those	O
that	O
direct	O
transcription	O
from	O
rearranged	O
immunoglobulin	O
genes	O
.	O
<EOS>	B-X
The	B-X
POU	B-X
transcription	B-X
factors	B-X
Oct-1	B-X
and	B-X
Oct-2	B-X
regulate	B-X
the	B-X
activity	B-X
of	B-X
octamer-dependent	B-X
promoters	B-X
,	B-X
including	B-X
those	B-X
that	B-X
direct	B-X
transcription	B-X
from	B-X
rearranged	B-X
immunoglobulin	B-X
genes	B-X
.	B-X
Unlike	B-X
Oct-1	B-X
,	B-X
which	B-X
is	B-X
constitutively	B-X
expressed	B-X
in	B-X
many	B-X
cell	B-X
types	B-X
,	B-X
Oct-2	B-X
expression	B-X
is	B-X
restricted	B-X
primarily	B-X
to	B-X
B	B-X
lymphocytes	B-X
and	B-X
can	B-X
be	B-X
induced	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
by	B-X
stimulation	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
factors	B-X
that	B-X
mediate	B-X
this	B-X
induction	B-X
mechanism	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
monitored	B-X
Oct-2	B-X
expression	B-X
in	B-X
cells	B-X
arrested	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
an	B-X
LPS-responsive	B-X
member	B-X
of	B-X
the	B-X
Rel	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
Despite	B-X
stimulation	B-X
with	B-X
LPS	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
NF-kappaB	B-X
signaling	B-X
pathway	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
led	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
inducible	B-X
Oct-2	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
the	B-X
suppression	B-X
of	B-X
Oct-2-directed	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
This	B-X
biochemical	B-X
defect	B-X
correlated	B-X
with	B-X
a	B-X
specific	B-X
block	B-X
to	B-X
Oct-2	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
whereas	B-X
the	B-X
expression	B-X
of	B-X
Oct-1	B-X
was	B-X
unaffected	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
Oct-2	B-X
is	B-X
under	B-X
NF-kappaB	B-X
control	B-X
highlights	B-X
an	B-X
important	B-X
cross-talk	B-X
mechanism	B-X
involving	B-X
two	B-X
distinct	B-X
transcription	B-X
factor	B-X
families	B-X
that	B-X
regulate	B-X
B	B-X
lymphocyte	B-X
function	B-X
.	B-X

Unlike	O
Oct	B-Protein
-	I-Protein
1	I-Protein
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
many	O
cell	O
types	O
,	O
Oct	B-Protein
-	I-Protein
2	I-Protein
expression	O
is	O
restricted	O
primarily	O
to	O
B	O
lymphocytes	O
and	O
can	O
be	O
induced	O
in	O
precursor	O
B	O
cells	O
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

However	O
,	O
the	O
precise	O
factors	O
that	O
mediate	O
this	O
induction	O
mechanism	O
remain	O
unknown	O
.	O
<EOS>	B-X
Hypoxic	B-X
tumor	B-X
microenvironment	B-X
(	B-X
TME	B-X
)	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
induction	B-X
of	B-X
cancer	B-X
stem	B-X
cell-like	B-X
phenotype	B-X
in	B-X
breast	B-X
cancer	B-X
and	B-X
contribute	B-X
to	B-X
chemoresistance	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
underlying	B-X
stemness	B-X
reprogramming	B-X
of	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
BCs	B-X
)	B-X
by	B-X
hypoxic	B-X
TME	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
underlying	B-X
molecular	B-X
mechanisms	B-X
of	B-X
hyperglycemia-induced	B-X
vascular	B-X
calcification	B-X
remain	B-X
largely	B-X
unknown	B-X
.	B-X
Inflammatory	B-X
bowel	B-X
disease	B-X
(	B-X
IBD	B-X
)	B-X
is	B-X
a	B-X
debilitating	B-X
and	B-X
widespread	B-X
immune-mediated	B-X
illness	B-X
characterized	B-X
by	B-X
excessive	B-X
inflammatory	B-X
and	B-X
effector	B-X
mucosal	B-X
responses	B-X
leading	B-X
to	B-X
tissue	B-X
destruction	B-X
at	B-X
the	B-X
gastrointestinal	B-X
tract	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
etiology	B-X
of	B-X
IBD	B-X
remains	B-X
unknown	B-X
.	B-X
Diet-induced	B-X
changes	B-X
in	B-X
the	B-X
composition	B-X
of	B-X
the	B-X
gut	B-X
microbiome	B-X
can	B-X
modulate	B-X
the	B-X
induction	B-X
of	B-X
regulatory	B-X
versus	B-X
effector	B-X
immune	B-X
responses	B-X
at	B-X
the	B-X
gut	B-X
mucosa	B-X
and	B-X
improve	B-X
health	B-X
outcomes	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
review	B-X
is	B-X
to	B-X
summarize	B-X
the	B-X
status	B-X
of	B-X
innovative	B-X
nutritional	B-X
interventions	B-X
against	B-X
gastrointestinal	B-X
inflammation	B-X
,	B-X
their	B-X
proposed	B-X
mechanisms	B-X
of	B-X
action	B-X
,	B-X
preclinical	B-X
and	B-X
clinical	B-X
efficacy	B-X
as	B-X
well	B-X
as	B-X
bioinformatics	B-X
and	B-X
computational	B-X
modeling	B-X
approaches	B-X
that	B-X
accelerate	B-X
discovery	B-X
in	B-X
nutritional	B-X
and	B-X
mucosal	B-X
immunology	B-X
research	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
monitored	O
Oct	B-Protein
-	I-Protein
2	I-Protein
expression	O
in	O
cells	O
arrested	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
an	O
LPS	O
-	O
responsive	O
member	O
of	O
the	O
Rel	O
transcription	O
factor	O
family	O
.	O
<EOS>	B-X
The	B-X
POU	B-X
transcription	B-X
factors	B-X
Oct-1	B-X
and	B-X
Oct-2	B-X
regulate	B-X
the	B-X
activity	B-X
of	B-X
octamer-dependent	B-X
promoters	B-X
,	B-X
including	B-X
those	B-X
that	B-X
direct	B-X
transcription	B-X
from	B-X
rearranged	B-X
immunoglobulin	B-X
genes	B-X
.	B-X
Unlike	B-X
Oct-1	B-X
,	B-X
which	B-X
is	B-X
constitutively	B-X
expressed	B-X
in	B-X
many	B-X
cell	B-X
types	B-X
,	B-X
Oct-2	B-X
expression	B-X
is	B-X
restricted	B-X
primarily	B-X
to	B-X
B	B-X
lymphocytes	B-X
and	B-X
can	B-X
be	B-X
induced	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
by	B-X
stimulation	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
factors	B-X
that	B-X
mediate	B-X
this	B-X
induction	B-X
mechanism	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
monitored	B-X
Oct-2	B-X
expression	B-X
in	B-X
cells	B-X
arrested	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
an	B-X
LPS-responsive	B-X
member	B-X
of	B-X
the	B-X
Rel	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
Despite	B-X
stimulation	B-X
with	B-X
LPS	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
NF-kappaB	B-X
signaling	B-X
pathway	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
led	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
inducible	B-X
Oct-2	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
the	B-X
suppression	B-X
of	B-X
Oct-2-directed	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
This	B-X
biochemical	B-X
defect	B-X
correlated	B-X
with	B-X
a	B-X
specific	B-X
block	B-X
to	B-X
Oct-2	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
whereas	B-X
the	B-X
expression	B-X
of	B-X
Oct-1	B-X
was	B-X
unaffected	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
Oct-2	B-X
is	B-X
under	B-X
NF-kappaB	B-X
control	B-X
highlights	B-X
an	B-X
important	B-X
cross-talk	B-X
mechanism	B-X
involving	B-X
two	B-X
distinct	B-X
transcription	B-X
factor	B-X
families	B-X
that	B-X
regulate	B-X
B	B-X
lymphocyte	B-X
function	B-X
.	B-X

Despite	O
stimulation	O
with	O
LPS	O
,	O
disruption	O
of	O
the	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
in	O
precursor	O
B	O
cells	O
led	O
to	O
the	O
loss	O
of	O
inducible	O
Oct	B-Protein
-	I-Protein
2	I-Protein
DNA	O
binding	O
activity	O
in	O
vitro	O
and	O
the	O
suppression	O
of	O
Oct	B-Protein
-	I-Protein
2	I-Protein
-	O
directed	O
transcription	O
in	O
vivo	O
.	O

This	O
biochemical	O
defect	O
correlated	O
with	O
a	O
specific	O
block	O
to	O
Oct	B-Protein
-	I-Protein
2	I-Protein
gene	O
expression	O
at	O
the	O
level	O
of	O
transcription	O
,	O
whereas	O
the	O
expression	O
of	O
Oct	B-Protein
-	I-Protein
1	I-Protein
was	O
unaffected	O
.	O
<EOS>	B-X
The	B-X
POU	B-X
transcription	B-X
factors	B-X
Oct-1	B-X
and	B-X
Oct-2	B-X
regulate	B-X
the	B-X
activity	B-X
of	B-X
octamer-dependent	B-X
promoters	B-X
,	B-X
including	B-X
those	B-X
that	B-X
direct	B-X
transcription	B-X
from	B-X
rearranged	B-X
immunoglobulin	B-X
genes	B-X
.	B-X
Unlike	B-X
Oct-1	B-X
,	B-X
which	B-X
is	B-X
constitutively	B-X
expressed	B-X
in	B-X
many	B-X
cell	B-X
types	B-X
,	B-X
Oct-2	B-X
expression	B-X
is	B-X
restricted	B-X
primarily	B-X
to	B-X
B	B-X
lymphocytes	B-X
and	B-X
can	B-X
be	B-X
induced	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
by	B-X
stimulation	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
monitored	B-X
Oct-2	B-X
expression	B-X
in	B-X
cells	B-X
arrested	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
an	B-X
LPS-responsive	B-X
member	B-X
of	B-X
the	B-X
Rel	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
Despite	B-X
stimulation	B-X
with	B-X
LPS	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
NF-kappaB	B-X
signaling	B-X
pathway	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
led	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
inducible	B-X
Oct-2	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
the	B-X
suppression	B-X
of	B-X
Oct-2-directed	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
This	B-X
biochemical	B-X
defect	B-X
correlated	B-X
with	B-X
a	B-X
specific	B-X
block	B-X
to	B-X
Oct-2	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
whereas	B-X
the	B-X
expression	B-X
of	B-X
Oct-1	B-X
was	B-X
unaffected	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
Oct-2	B-X
is	B-X
under	B-X
NF-kappaB	B-X
control	B-X
highlights	B-X
an	B-X
important	B-X
cross-talk	B-X
mechanism	B-X
involving	B-X
two	B-X
distinct	B-X
transcription	B-X
factor	B-X
families	B-X
that	B-X
regulate	B-X
B	B-X
lymphocyte	B-X
function	B-X
.	B-X

The	O
finding	O
that	O
Oct	B-Protein
-	I-Protein
2	I-Protein
is	O
under	O
NF	O
-	O
kappaB	O
control	O
highlights	O
an	O
important	O
cross	O
-	O
talk	O
mechanism	O
involving	O
two	O
distinct	O
transcription	O
factor	O
families	O
that	O
regulate	O
B	O
lymphocyte	O
function	O
.	O
<EOS>	B-X
The	B-X
POU	B-X
transcription	B-X
factors	B-X
Oct-1	B-X
and	B-X
Oct-2	B-X
regulate	B-X
the	B-X
activity	B-X
of	B-X
octamer-dependent	B-X
promoters	B-X
,	B-X
including	B-X
those	B-X
that	B-X
direct	B-X
transcription	B-X
from	B-X
rearranged	B-X
immunoglobulin	B-X
genes	B-X
.	B-X
Unlike	B-X
Oct-1	B-X
,	B-X
which	B-X
is	B-X
constitutively	B-X
expressed	B-X
in	B-X
many	B-X
cell	B-X
types	B-X
,	B-X
Oct-2	B-X
expression	B-X
is	B-X
restricted	B-X
primarily	B-X
to	B-X
B	B-X
lymphocytes	B-X
and	B-X
can	B-X
be	B-X
induced	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
by	B-X
stimulation	B-X
with	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
precise	B-X
factors	B-X
that	B-X
mediate	B-X
this	B-X
induction	B-X
mechanism	B-X
remain	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
monitored	B-X
Oct-2	B-X
expression	B-X
in	B-X
cells	B-X
arrested	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
an	B-X
LPS-responsive	B-X
member	B-X
of	B-X
the	B-X
Rel	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
Despite	B-X
stimulation	B-X
with	B-X
LPS	B-X
,	B-X
disruption	B-X
of	B-X
the	B-X
NF-kappaB	B-X
signaling	B-X
pathway	B-X
in	B-X
precursor	B-X
B	B-X
cells	B-X
led	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
inducible	B-X
Oct-2	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
vitro	B-X
and	B-X
the	B-X
suppression	B-X
of	B-X
Oct-2-directed	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
This	B-X
biochemical	B-X
defect	B-X
correlated	B-X
with	B-X
a	B-X
specific	B-X
block	B-X
to	B-X
Oct-2	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
whereas	B-X
the	B-X
expression	B-X
of	B-X
Oct-1	B-X
was	B-X
unaffected	B-X
.	B-X
The	B-X
finding	B-X
that	B-X
Oct-2	B-X
is	B-X
under	B-X
NF-kappaB	B-X
control	B-X
highlights	B-X
an	B-X
important	B-X
cross-talk	B-X
mechanism	B-X
involving	B-X
two	B-X
distinct	B-X
transcription	B-X
factor	B-X
families	B-X
that	B-X
regulate	B-X
B	B-X
lymphocyte	B-X
function	B-X
.	B-X

Paternal	O
expression	O
of	O
WT1	B-Protein
in	O
human	O
fibroblasts	O
and	O
lymphocytes	O
.	O
<EOS>	B-X
The	B-X
Wilms	B-X
'	B-X
tumor	B-X
suppressor	B-X
gene	B-X
(	B-X
WT1	B-X
)	B-X
was	B-X
previously	B-X
identified	B-X
as	B-X
being	B-X
imprinted	B-X
,	B-X
with	B-X
frequent	B-X
maternal	B-X
expression	B-X
in	B-X
human	B-X
placentae	B-X
and	B-X
fetal	B-X
brains	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
allele-specific	B-X
expression	B-X
of	B-X
WT1	B-X
in	B-X
cultured	B-X
human	B-X
fibroblasts	B-X
from	B-X
15	B-X
individuals	B-X
.	B-X
Seven	B-X
of	B-X
15	B-X
fibroblast	B-X
lines	B-X
were	B-X
heterozygous	B-X
for	B-X
polymorphic	B-X
alleles	B-X
,	B-X
and	B-X
the	B-X
expression	B-X
patterns	B-X
were	B-X
variable	B-X
,	B-X
i.e.	B-X
,	B-X
equal	B-X
,	B-X
unequal	B-X
or	B-X
monoallelic	B-X
paternal	B-X
expression	B-X
in	B-X
three	B-X
,	B-X
two	B-X
and	B-X
two	B-X
cases	B-X
,	B-X
respectively	B-X
.	B-X
Exclusive	B-X
paternal	B-X
expression	B-X
of	B-X
WT1	B-X
was	B-X
also	B-X
shown	B-X
in	B-X
non-cultured	B-X
peripheral	B-X
lymphocytes	B-X
from	B-X
the	B-X
latter	B-X
two	B-X
individuals	B-X
.	B-X
The	B-X
allele-specific	B-X
expression	B-X
profiles	B-X
of	B-X
other	B-X
imprinted	B-X
genes	B-X
,	B-X
IGF2	B-X
and	B-X
H19	B-X
,	B-X
on	B-X
human	B-X
chromosome	B-X
11	B-X
were	B-X
constant	B-X
and	B-X
consistent	B-X
with	B-X
those	B-X
in	B-X
other	B-X
tissues	B-X
.	B-X
Our	B-X
unexpected	B-X
observations	B-X
of	B-X
paternal	B-X
or	B-X
biallelic	B-X
expression	B-X
of	B-X
WT1	B-X
in	B-X
fibroblasts	B-X
and	B-X
lymphocytes	B-X
,	B-X
together	B-X
with	B-X
the	B-X
previous	B-X
findings	B-X
of	B-X
maternal	B-X
or	B-X
biallelic	B-X
expression	B-X
in	B-X
placentae	B-X
and	B-X
brains	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
allele-specific	B-X
regulatory	B-X
system	B-X
of	B-X
WT1	B-X
is	B-X
unique	B-X
and	B-X
may	B-X
be	B-X
controlled	B-X
by	B-X
a	B-X
putative	B-X
tissue-	B-X
and	B-X
individual-specific	B-X
modifier	B-X
.	B-X

The	O
Wilms	O
'	O
tumor	O
suppressor	O
gene	O
(	O
WT1	B-Protein
)	O
was	O
previously	O
identified	O
as	O
being	O
imprinted	O
,	O
with	O
frequent	O
maternal	O
expression	O
in	O
human	O
placentae	O
and	O
fetal	O
brains	O
.	O
<EOS>	B-X
The	B-X
Wilms	B-X
'	B-X
tumor	B-X
suppressor	B-X
gene	B-X
(	B-X
WT1	B-X
)	B-X
was	B-X
previously	B-X
identified	B-X
as	B-X
being	B-X
imprinted	B-X
,	B-X
with	B-X
frequent	B-X
maternal	B-X
expression	B-X
in	B-X
human	B-X
placentae	B-X
and	B-X
fetal	B-X
brains	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
allele-specific	B-X
expression	B-X
of	B-X
WT1	B-X
in	B-X
cultured	B-X
human	B-X
fibroblasts	B-X
from	B-X
15	B-X
individuals	B-X
.	B-X
Seven	B-X
of	B-X
15	B-X
fibroblast	B-X
lines	B-X
were	B-X
heterozygous	B-X
for	B-X
polymorphic	B-X
alleles	B-X
,	B-X
and	B-X
the	B-X
expression	B-X
patterns	B-X
were	B-X
variable	B-X
,	B-X
i.e.	B-X
,	B-X
equal	B-X
,	B-X
unequal	B-X
or	B-X
monoallelic	B-X
paternal	B-X
expression	B-X
in	B-X
three	B-X
,	B-X
two	B-X
and	B-X
two	B-X
cases	B-X
,	B-X
respectively	B-X
.	B-X
Exclusive	B-X
paternal	B-X
expression	B-X
of	B-X
WT1	B-X
was	B-X
also	B-X
shown	B-X
in	B-X
non-cultured	B-X
peripheral	B-X
lymphocytes	B-X
from	B-X
the	B-X
latter	B-X
two	B-X
individuals	B-X
.	B-X
The	B-X
allele-specific	B-X
expression	B-X
profiles	B-X
of	B-X
other	B-X
imprinted	B-X
genes	B-X
,	B-X
IGF2	B-X
and	B-X
H19	B-X
,	B-X
on	B-X
human	B-X
chromosome	B-X
11	B-X
were	B-X
constant	B-X
and	B-X
consistent	B-X
with	B-X
those	B-X
in	B-X
other	B-X
tissues	B-X
.	B-X
Our	B-X
unexpected	B-X
observations	B-X
of	B-X
paternal	B-X
or	B-X
biallelic	B-X
expression	B-X
of	B-X
WT1	B-X
in	B-X
fibroblasts	B-X
and	B-X
lymphocytes	B-X
,	B-X
together	B-X
with	B-X
the	B-X
previous	B-X
findings	B-X
of	B-X
maternal	B-X
or	B-X
biallelic	B-X
expression	B-X
in	B-X
placentae	B-X
and	B-X
brains	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
allele-specific	B-X
regulatory	B-X
system	B-X
of	B-X
WT1	B-X
is	B-X
unique	B-X
and	B-X
may	B-X
be	B-X
controlled	B-X
by	B-X
a	B-X
putative	B-X
tissue-	B-X
and	B-X
individual-specific	B-X
modifier	B-X
.	B-X

We	O
examined	O
the	O
allele	O
-	O
specific	O
expression	O
of	O
WT1	B-Protein
in	O
cultured	O
human	O
fibroblasts	O
from	O
15	O
individuals	O
.	O
<EOS>	B-X
The	B-X
Wilms	B-X
'	B-X
tumor	B-X
suppressor	B-X
gene	B-X
(	B-X
WT1	B-X
)	B-X
was	B-X
previously	B-X
identified	B-X
as	B-X
being	B-X
imprinted	B-X
,	B-X
with	B-X
frequent	B-X
maternal	B-X
expression	B-X
in	B-X
human	B-X
placentae	B-X
and	B-X
fetal	B-X
brains	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
allele-specific	B-X
expression	B-X
of	B-X
WT1	B-X
in	B-X
cultured	B-X
human	B-X
fibroblasts	B-X
from	B-X
15	B-X
individuals	B-X
.	B-X
Seven	B-X
of	B-X
15	B-X
fibroblast	B-X
lines	B-X
were	B-X
heterozygous	B-X
for	B-X
polymorphic	B-X
alleles	B-X
,	B-X
and	B-X
the	B-X
expression	B-X
patterns	B-X
were	B-X
variable	B-X
,	B-X
i.e.	B-X
,	B-X
equal	B-X
,	B-X
unequal	B-X
or	B-X
monoallelic	B-X
paternal	B-X
expression	B-X
in	B-X
three	B-X
,	B-X
two	B-X
and	B-X
two	B-X
cases	B-X
,	B-X
respectively	B-X
.	B-X
Exclusive	B-X
paternal	B-X
expression	B-X
of	B-X
WT1	B-X
was	B-X
also	B-X
shown	B-X
in	B-X
non-cultured	B-X
peripheral	B-X
lymphocytes	B-X
from	B-X
the	B-X
latter	B-X
two	B-X
individuals	B-X
.	B-X
The	B-X
allele-specific	B-X
expression	B-X
profiles	B-X
of	B-X
other	B-X
imprinted	B-X
genes	B-X
,	B-X
IGF2	B-X
and	B-X
H19	B-X
,	B-X
on	B-X
human	B-X
chromosome	B-X
11	B-X
were	B-X
constant	B-X
and	B-X
consistent	B-X
with	B-X
those	B-X
in	B-X
other	B-X
tissues	B-X
.	B-X
Our	B-X
unexpected	B-X
observations	B-X
of	B-X
paternal	B-X
or	B-X
biallelic	B-X
expression	B-X
of	B-X
WT1	B-X
in	B-X
fibroblasts	B-X
and	B-X
lymphocytes	B-X
,	B-X
together	B-X
with	B-X
the	B-X
previous	B-X
findings	B-X
of	B-X
maternal	B-X
or	B-X
biallelic	B-X
expression	B-X
in	B-X
placentae	B-X
and	B-X
brains	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
allele-specific	B-X
regulatory	B-X
system	B-X
of	B-X
WT1	B-X
is	B-X
unique	B-X
and	B-X
may	B-X
be	B-X
controlled	B-X
by	B-X
a	B-X
putative	B-X
tissue-	B-X
and	B-X
individual-specific	B-X
modifier	B-X
.	B-X

Seven	O
of	O
15	O
fibroblast	O
lines	O
were	O
heterozygous	O
for	O
polymorphic	O
alleles	O
,	O
and	O
the	O
expression	O
patterns	O
were	O
variable	O
,	O
i	O
.	O
e	O
.	O
,	O
equal	O
,	O
unequal	O
or	O
monoallelic	O
paternal	O
expression	O
in	O
three	O
,	O
two	O
and	O
two	O
cases	O
,	O
respectively	O
.	O
<EOS>	B-X
Glioma	B-X
includes	B-X
astrocytoma	B-X
,	B-X
oligodendroglioma	B-X
,	B-X
ependymoma	B-X
and	B-X
glioblastoma	B-X
.	B-X
We	B-X
previously	B-X
reported	B-X
the	B-X
epigenetic	B-X
silencing	B-X
of	B-X
paternally	B-X
expressed	B-X
gene	B-X
3	B-X
(	B-X
PEG3	B-X
)	B-X
in	B-X
glioma	B-X
cell	B-X
lines	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
methylation	B-X
of	B-X
an	B-X
exonic	B-X
CpG	B-X
island	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
PEG3	B-X
gene	B-X
in	B-X
20	B-X
glioma	B-X
and	B-X
5	B-X
non-tumor	B-X
tissue	B-X
samples	B-X
.	B-X
We	B-X
found	B-X
wide	B-X
variations	B-X
in	B-X
the	B-X
methylation	B-X
level	B-X
.	B-X
Hypomethylaiton	B-X
and	B-X
hypermethylation	B-X
was	B-X
found	B-X
in	B-X
3	B-X
and	B-X
4	B-X
glioma	B-X
tissue	B-X
samples	B-X
,	B-X
respectively	B-X
.	B-X
Monoallelic	B-X
expression	B-X
,	B-X
which	B-X
is	B-X
an	B-X
evidence	B-X
of	B-X
an	B-X
imprinted	B-X
gene	B-X
,	B-X
was	B-X
maintained	B-X
in	B-X
eight	B-X
out	B-X
of	B-X
nine	B-X
informative	B-X
cases	B-X
which	B-X
have	B-X
T/C	B-X
polymorphisms	B-X
in	B-X
PEG3	B-X
.	B-X
The	B-X
lower	B-X
gene	B-X
expression	B-X
,	B-X
which	B-X
suggested	B-X
epigenetic	B-X
silencing	B-X
of	B-X
PEG3	B-X
,	B-X
was	B-X
confirmed	B-X
statistically	B-X
in	B-X
glioblastoma	B-X
using	B-X
quantitative	B-X
reverse-transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
higher	B-X
expression	B-X
of	B-X
PEG3	B-X
in	B-X
two	B-X
out	B-X
of	B-X
three	B-X
oligodendrogliomas	B-X
.	B-X
A	B-X
negative	B-X
correlation	B-X
between	B-X
the	B-X
methylation	B-X
level	B-X
and	B-X
gene	B-X
expression	B-X
was	B-X
shown	B-X
by	B-X
regression	B-X
analysis	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
abnormal	B-X
regulation	B-X
of	B-X
PEG3	B-X
is	B-X
associated	B-X
with	B-X
several	B-X
glioma	B-X
subtypes	B-X
and	B-X
that	B-X
it	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
tumorigenesis	B-X
.	B-X

Exclusive	O
paternal	O
expression	O
of	O
WT1	B-Protein
was	O
also	O
shown	O
in	O
non	O
-	O
cultured	O
peripheral	O
lymphocytes	O
from	O
the	O
latter	O
two	O
individuals	O
.	O
<EOS>	B-X
The	B-X
Wilms	B-X
'	B-X
tumor	B-X
suppressor	B-X
gene	B-X
(	B-X
WT1	B-X
)	B-X
was	B-X
previously	B-X
identified	B-X
as	B-X
being	B-X
imprinted	B-X
,	B-X
with	B-X
frequent	B-X
maternal	B-X
expression	B-X
in	B-X
human	B-X
placentae	B-X
and	B-X
fetal	B-X
brains	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
allele-specific	B-X
expression	B-X
of	B-X
WT1	B-X
in	B-X
cultured	B-X
human	B-X
fibroblasts	B-X
from	B-X
15	B-X
individuals	B-X
.	B-X
Seven	B-X
of	B-X
15	B-X
fibroblast	B-X
lines	B-X
were	B-X
heterozygous	B-X
for	B-X
polymorphic	B-X
alleles	B-X
,	B-X
and	B-X
the	B-X
expression	B-X
patterns	B-X
were	B-X
variable	B-X
,	B-X
i.e.	B-X
,	B-X
equal	B-X
,	B-X
unequal	B-X
or	B-X
monoallelic	B-X
paternal	B-X
expression	B-X
in	B-X
three	B-X
,	B-X
two	B-X
and	B-X
two	B-X
cases	B-X
,	B-X
respectively	B-X
.	B-X
Exclusive	B-X
paternal	B-X
expression	B-X
of	B-X
WT1	B-X
was	B-X
also	B-X
shown	B-X
in	B-X
non-cultured	B-X
peripheral	B-X
lymphocytes	B-X
from	B-X
the	B-X
latter	B-X
two	B-X
individuals	B-X
.	B-X
The	B-X
allele-specific	B-X
expression	B-X
profiles	B-X
of	B-X
other	B-X
imprinted	B-X
genes	B-X
,	B-X
IGF2	B-X
and	B-X
H19	B-X
,	B-X
on	B-X
human	B-X
chromosome	B-X
11	B-X
were	B-X
constant	B-X
and	B-X
consistent	B-X
with	B-X
those	B-X
in	B-X
other	B-X
tissues	B-X
.	B-X
Our	B-X
unexpected	B-X
observations	B-X
of	B-X
paternal	B-X
or	B-X
biallelic	B-X
expression	B-X
of	B-X
WT1	B-X
in	B-X
fibroblasts	B-X
and	B-X
lymphocytes	B-X
,	B-X
together	B-X
with	B-X
the	B-X
previous	B-X
findings	B-X
of	B-X
maternal	B-X
or	B-X
biallelic	B-X
expression	B-X
in	B-X
placentae	B-X
and	B-X
brains	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
allele-specific	B-X
regulatory	B-X
system	B-X
of	B-X
WT1	B-X
is	B-X
unique	B-X
and	B-X
may	B-X
be	B-X
controlled	B-X
by	B-X
a	B-X
putative	B-X
tissue-	B-X
and	B-X
individual-specific	B-X
modifier	B-X
.	B-X

The	O
allele	O
-	O
specific	O
expression	O
profiles	O
of	O
other	O
imprinted	O
genes	O
,	O
IGF2	B-Protein
and	O
H19	B-Protein
,	O
on	O
human	O
chromosome	O
11	O
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O
<EOS>	B-X
The	B-X
Wilms	B-X
'	B-X
tumor	B-X
suppressor	B-X
gene	B-X
(	B-X
WT1	B-X
)	B-X
was	B-X
previously	B-X
identified	B-X
as	B-X
being	B-X
imprinted	B-X
,	B-X
with	B-X
frequent	B-X
maternal	B-X
expression	B-X
in	B-X
human	B-X
placentae	B-X
and	B-X
fetal	B-X
brains	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
allele-specific	B-X
expression	B-X
of	B-X
WT1	B-X
in	B-X
cultured	B-X
human	B-X
fibroblasts	B-X
from	B-X
15	B-X
individuals	B-X
.	B-X
Seven	B-X
of	B-X
15	B-X
fibroblast	B-X
lines	B-X
were	B-X
heterozygous	B-X
for	B-X
polymorphic	B-X
alleles	B-X
,	B-X
and	B-X
the	B-X
expression	B-X
patterns	B-X
were	B-X
variable	B-X
,	B-X
i.e.	B-X
,	B-X
equal	B-X
,	B-X
unequal	B-X
or	B-X
monoallelic	B-X
paternal	B-X
expression	B-X
in	B-X
three	B-X
,	B-X
two	B-X
and	B-X
two	B-X
cases	B-X
,	B-X
respectively	B-X
.	B-X
Exclusive	B-X
paternal	B-X
expression	B-X
of	B-X
WT1	B-X
was	B-X
also	B-X
shown	B-X
in	B-X
non-cultured	B-X
peripheral	B-X
lymphocytes	B-X
from	B-X
the	B-X
latter	B-X
two	B-X
individuals	B-X
.	B-X
The	B-X
allele-specific	B-X
expression	B-X
profiles	B-X
of	B-X
other	B-X
imprinted	B-X
genes	B-X
,	B-X
IGF2	B-X
and	B-X
H19	B-X
,	B-X
on	B-X
human	B-X
chromosome	B-X
11	B-X
were	B-X
constant	B-X
and	B-X
consistent	B-X
with	B-X
those	B-X
in	B-X
other	B-X
tissues	B-X
.	B-X
Our	B-X
unexpected	B-X
observations	B-X
of	B-X
paternal	B-X
or	B-X
biallelic	B-X
expression	B-X
of	B-X
WT1	B-X
in	B-X
fibroblasts	B-X
and	B-X
lymphocytes	B-X
,	B-X
together	B-X
with	B-X
the	B-X
previous	B-X
findings	B-X
of	B-X
maternal	B-X
or	B-X
biallelic	B-X
expression	B-X
in	B-X
placentae	B-X
and	B-X
brains	B-X
,	B-X
suggest	B-X
that	B-X
the	B-X
allele-specific	B-X
regulatory	B-X
system	B-X
of	B-X
WT1	B-X
is	B-X
unique	B-X
and	B-X
may	B-X
be	B-X
controlled	B-X
by	B-X
a	B-X
putative	B-X
tissue-	B-X
and	B-X
individual-specific	B-X
modifier	B-X
.	B-X

Our	O
unexpected	O
observations	O
of	O
paternal	O
or	O
biallelic	O
expression	O
of	O
WT1	B-Protein
in	O
fibroblasts	O
and	O
lymphocytes	O
,	O
together	O
with	O
the	O
previous	O
findings	O
of	O
maternal	O
or	O
biallelic	O
expression	O
in	O
placentae	O
and	O
brains	O
,	O
suggest	O
that	O
the	O
allele	O
-	O
specific	O
regulatory	O
system	O
of	O
WT1	B-Protein
is	O
unique	O
and	O
may	O
be	O
controlled	O
by	O
a	O
putative	O
tissue	O
-	O
and	O
individual	O
-	O
specific	O
modifier	O
.	O
<EOS>	B-X
Chromosomal	B-X
multiplication	B-X
of	B-X
the	B-X
UBE3A	B-X
gene	B-X
is	B-X
presumed	B-X
to	B-X
be	B-X
the	B-X
primary	B-X
driver	B-X
of	B-X
Dup15q	B-X
pathophysiology	B-X
,	B-X
given	B-X
that	B-X
UBE3A	B-X
exhibits	B-X
maternal	B-X
monoallelic	B-X
expression	B-X
in	B-X
neurons	B-X
and	B-X
that	B-X
maternal	B-X
duplications	B-X
typically	B-X
yield	B-X
far	B-X
more	B-X
severe	B-X
neurodevelopmental	B-X
outcomes	B-X
than	B-X
paternal	B-X
duplications	B-X
.	B-X
However	B-X
,	B-X
studies	B-X
into	B-X
the	B-X
pathogenic	B-X
effects	B-X
of	B-X
UBE3A	B-X
overexpression	B-X
in	B-X
mice	B-X
have	B-X
yielded	B-X
conflicting	B-X
results	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
previously	B-X
published	B-X
Ube3a	B-X
overexpression	B-X
models	B-X
,	B-X
Ube3aOE	B-X
mice	B-X
were	B-X
indistinguishable	B-X
from	B-X
wild-type	B-X
controls	B-X
on	B-X
a	B-X
number	B-X
of	B-X
molecular	B-X
and	B-X
behavioral	B-X
measures	B-X
,	B-X
despite	B-X
suffering	B-X
increased	B-X
mortality	B-X
when	B-X
challenged	B-X
with	B-X
seizures	B-X
,	B-X
a	B-X
phenotype	B-X
reminiscent	B-X
of	B-X
sudden	B-X
unexpected	B-X
death	B-X
in	B-X
epilepsy	B-X
.	B-X
Polygynous	B-X
mating	B-X
systems	B-X
with	B-X
group	B-X
fidelity	B-X
are	B-X
a	B-X
common	B-X
animal	B-X
organization	B-X
,	B-X
typically	B-X
consisting	B-X
of	B-X
multiple	B-X
females	B-X
in	B-X
a	B-X
mated	B-X
group	B-X
with	B-X
a	B-X
single	B-X
male	B-X
for	B-X
an	B-X
extended	B-X
period	B-X
(	B-X
sometimes	B-X
referred	B-X
to	B-X
as	B-X
harem	B-X
polygyny	B-X
)	B-X
.	B-X
Combining	B-X
data	B-X
on	B-X
larval	B-X
development	B-X
,	B-X
molecular	B-X
paternity	B-X
assignment	B-X
,	B-X
and	B-X
in	B-X
situ	B-X
behavioral	B-X
observations	B-X
,	B-X
we	B-X
reveal	B-X
high	B-X
fidelity	B-X
during	B-X
a	B-X
prolonged	B-X
breeding	B-X
season	B-X
in	B-X
a	B-X
Neotropical	B-X
polygynous	B-X
frog	B-X
.	B-X
This	B-X
system	B-X
likely	B-X
evolved	B-X
in	B-X
response	B-X
to	B-X
intense	B-X
competition	B-X
for	B-X
breeding	B-X
sites	B-X
and	B-X
intrasexual	B-X
competition	B-X
for	B-X
mates	B-X
.	B-X

Extinction	O
of	O
immunoglobulin	O
gene	O
expression	O
in	O
B	O
cells	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
is	O
preceded	O
by	O
rapid	O
nuclear	O
depletion	O
of	O
essential	O
transcription	O
factors	O
and	O
is	O
accompanied	O
by	O
widespread	O
inactivation	O
of	O
genes	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O

When	O
immunoglobulin	O
(	O
Ig	O
)	O
expressing	O
B	O
cells	O
are	O
fused	O
with	O
non	O
-	O
B	O
cells	O
,	O
Ig	O
expression	O
is	O
rapidly	O
suppressed	O
at	O
the	O
level	O
of	O
transcription	O
,	O
a	O
phenomenon	O
termed	O
extinction	O
.	O
<EOS>	B-X
When	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
expressing	B-X
B	B-X
cells	B-X
are	B-X
fused	B-X
with	B-X
non-B	B-X
cells	B-X
,	B-X
Ig	B-X
expression	B-X
is	B-X
rapidly	B-X
suppressed	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
a	B-X
phenomenon	B-X
termed	B-X
extinction	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
fusion	B-X
of	B-X
HeLa	B-X
cells	B-X
with	B-X
either	B-X
diploid	B-X
or	B-X
tetraploid	B-X
B	B-X
cells	B-X
(	B-X
Daudi	B-X
)	B-X
results	B-X
in	B-X
widespread	B-X
extinction	B-X
of	B-X
several	B-X
other	B-X
B	B-X
cell-encoded	B-X
genes	B-X
that	B-X
are	B-X
expressed	B-X
in	B-X
a	B-X
B	B-X
cell-specific	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
B	B-X
cell-expressed	B-X
genes	B-X
that	B-X
are	B-X
not	B-X
dependent	B-X
on	B-X
cell-specific	B-X
controls	B-X
is	B-X
unaffected	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
molecular	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
underlying	B-X
Ig	B-X
gene	B-X
extinction	B-X
can	B-X
be	B-X
explained	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
lack	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
essential	B-X
for	B-X
Ig	B-X
gene	B-X
transcription	B-X
.	B-X
These	B-X
transcription	B-X
factors	B-X
are	B-X
either	B-X
not	B-X
produced	B-X
due	B-X
to	B-X
block	B-X
of	B-X
transcription	B-X
of	B-X
their	B-X
respective	B-X
genes	B-X
(	B-X
Oct-2	B-X
,	B-X
OBF-1	B-X
,	B-X
PU.1	B-X
)	B-X
,	B-X
or	B-X
are	B-X
rendered	B-X
inactive	B-X
posttranslationally	B-X
(	B-X
NF-kappa	B-X
B	B-X
,	B-X
E47	B-X
)	B-X
.	B-X
By	B-X
isolating	B-X
Daudi	B-X
x	B-X
HeLa	B-X
heterokaryons	B-X
a	B-X
few	B-X
hours	B-X
after	B-X
fusion	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
initial	B-X
fate	B-X
of	B-X
two	B-X
B	B-X
cell-specific	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
Ig	B-X
gene	B-X
transcription	B-X
,	B-X
Oct-2	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
This	B-X
report	B-X
provides	B-X
the	B-X
first	B-X
demonstration	B-X
that	B-X
upon	B-X
fusion	B-X
with	B-X
HeLa	B-X
cells	B-X
,	B-X
the	B-X
nuclear	B-X
contents	B-X
of	B-X
B	B-X
cell-expressed	B-X
transcription	B-X
factors	B-X
are	B-X
depleted	B-X
within	B-X
a	B-X
few	B-X
hours	B-X
with	B-X
kinetics	B-X
that	B-X
are	B-X
as	B-X
fast	B-X
or	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
Ig	B-X
gene	B-X
extinction	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
extinction	B-X
of	B-X
Ig	B-X
genes	B-X
is	B-X
part	B-X
of	B-X
a	B-X
global	B-X
mechanism	B-X
that	B-X
suppresses	B-X
the	B-X
differentiation	B-X
program	B-X
foreign	B-X
to	B-X
the	B-X
HeLa	B-X
phenotype	B-X
.	B-X

Here	O
we	O
demonstrate	O
that	O
fusion	O
of	O
HeLa	O
cells	O
with	O
either	O
diploid	O
or	O
tetraploid	O
B	O
cells	O
(	O
Daudi	O
)	O
results	O
in	O
widespread	O
extinction	O
of	O
several	O
other	O
B	O
cell	O
-	O
encoded	O
genes	O
that	O
are	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O
<EOS>	B-X
When	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
expressing	B-X
B	B-X
cells	B-X
are	B-X
fused	B-X
with	B-X
non-B	B-X
cells	B-X
,	B-X
Ig	B-X
expression	B-X
is	B-X
rapidly	B-X
suppressed	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
a	B-X
phenomenon	B-X
termed	B-X
extinction	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
fusion	B-X
of	B-X
HeLa	B-X
cells	B-X
with	B-X
either	B-X
diploid	B-X
or	B-X
tetraploid	B-X
B	B-X
cells	B-X
(	B-X
Daudi	B-X
)	B-X
results	B-X
in	B-X
widespread	B-X
extinction	B-X
of	B-X
several	B-X
other	B-X
B	B-X
cell-encoded	B-X
genes	B-X
that	B-X
are	B-X
expressed	B-X
in	B-X
a	B-X
B	B-X
cell-specific	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
B	B-X
cell-expressed	B-X
genes	B-X
that	B-X
are	B-X
not	B-X
dependent	B-X
on	B-X
cell-specific	B-X
controls	B-X
is	B-X
unaffected	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
molecular	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
underlying	B-X
Ig	B-X
gene	B-X
extinction	B-X
can	B-X
be	B-X
explained	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
lack	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
essential	B-X
for	B-X
Ig	B-X
gene	B-X
transcription	B-X
.	B-X
These	B-X
transcription	B-X
factors	B-X
are	B-X
either	B-X
not	B-X
produced	B-X
due	B-X
to	B-X
block	B-X
of	B-X
transcription	B-X
of	B-X
their	B-X
respective	B-X
genes	B-X
(	B-X
Oct-2	B-X
,	B-X
OBF-1	B-X
,	B-X
PU.1	B-X
)	B-X
,	B-X
or	B-X
are	B-X
rendered	B-X
inactive	B-X
posttranslationally	B-X
(	B-X
NF-kappa	B-X
B	B-X
,	B-X
E47	B-X
)	B-X
.	B-X
By	B-X
isolating	B-X
Daudi	B-X
x	B-X
HeLa	B-X
heterokaryons	B-X
a	B-X
few	B-X
hours	B-X
after	B-X
fusion	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
initial	B-X
fate	B-X
of	B-X
two	B-X
B	B-X
cell-specific	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
Ig	B-X
gene	B-X
transcription	B-X
,	B-X
Oct-2	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
This	B-X
report	B-X
provides	B-X
the	B-X
first	B-X
demonstration	B-X
that	B-X
upon	B-X
fusion	B-X
with	B-X
HeLa	B-X
cells	B-X
,	B-X
the	B-X
nuclear	B-X
contents	B-X
of	B-X
B	B-X
cell-expressed	B-X
transcription	B-X
factors	B-X
are	B-X
depleted	B-X
within	B-X
a	B-X
few	B-X
hours	B-X
with	B-X
kinetics	B-X
that	B-X
are	B-X
as	B-X
fast	B-X
or	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
Ig	B-X
gene	B-X
extinction	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
extinguishing	B-X
mechanism	B-X
is	B-X
effective	B-X
very	B-X
early	B-X
after	B-X
fusion	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
extinction	B-X
of	B-X
Ig	B-X
genes	B-X
is	B-X
part	B-X
of	B-X
a	B-X
global	B-X
mechanism	B-X
that	B-X
suppresses	B-X
the	B-X
differentiation	B-X
program	B-X
foreign	B-X
to	B-X
the	B-X
HeLa	B-X
phenotype	B-X
.	B-X

In	O
contrast	O
,	O
expression	O
of	O
B	O
cell	O
-	O
expressed	O
genes	O
that	O
are	O
not	O
dependent	O
on	O
cell	O
-	O
specific	O
controls	O
is	O
unaffected	O
.	O
<EOS>	B-X
Using	B-X
small	B-X
conditional	B-X
RNA	B-X
sequencing	B-X
,	B-X
we	B-X
found	B-X
that	B-X
females	B-X
had	B-X
a	B-X
lower	B-X
percentage	B-X
of	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
a	B-X
higher	B-X
percentage	B-X
of	B-X
plasma	B-X
cells	B-X
in	B-X
peripheral	B-X
blood	B-X
compared	B-X
with	B-X
males	B-X
.	B-X
Bioinformatics	B-X
revealed	B-X
that	B-X
young	B-X
females	B-X
exhibited	B-X
an	B-X
overrepresentation	B-X
of	B-X
pathways	B-X
that	B-X
relate	B-X
to	B-X
T	B-X
and	B-X
B	B-X
cell	B-X
activation	B-X
.	B-X
Moreover	B-X
,	B-X
cell-cell	B-X
communication	B-X
analysis	B-X
revealed	B-X
evidence	B-X
of	B-X
increased	B-X
activity	B-X
of	B-X
the	B-X
BAFF/APRIL	B-X
systems	B-X
in	B-X
females	B-X
.	B-X
Notably	B-X
,	B-X
aging	B-X
increased	B-X
the	B-X
percentage	B-X
of	B-X
monocytes	B-X
and	B-X
reduced	B-X
the	B-X
percentage	B-X
of	B-X
naïve	B-X
T	B-X
cells	B-X
in	B-X
the	B-X
blood	B-X
and	B-X
the	B-X
number	B-X
of	B-X
differentially	B-X
expressed	B-X
genes	B-X
between	B-X
the	B-X
sexes	B-X
.	B-X
Aged	B-X
males	B-X
expressed	B-X
higher	B-X
levels	B-X
of	B-X
inflammatory	B-X
genes	B-X
.	B-X
Collectively	B-X
,	B-X
the	B-X
results	B-X
suggest	B-X
that	B-X
females	B-X
have	B-X
more	B-X
plasma	B-X
cells	B-X
in	B-X
the	B-X
circulation	B-X
and	B-X
a	B-X
stronger	B-X
BAFF/APRIL	B-X
system	B-X
,	B-X
which	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
stronger	B-X
adaptive	B-X
immune	B-X
response	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
males	B-X
have	B-X
a	B-X
higher	B-X
percentage	B-X
of	B-X
NK	B-X
cells	B-X
in	B-X
blood	B-X
and	B-X
a	B-X
higher	B-X
expression	B-X
of	B-X
certain	B-X
proinflammatory	B-X
genes	B-X
.	B-X

We	O
show	O
that	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
Ig	O
gene	O
extinction	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
lack	O
of	O
transcription	O
factors	O
that	O
are	O
essential	O
for	O
Ig	O
gene	O
transcription	O
.	O
<EOS>	B-X
When	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
expressing	B-X
B	B-X
cells	B-X
are	B-X
fused	B-X
with	B-X
non-B	B-X
cells	B-X
,	B-X
Ig	B-X
expression	B-X
is	B-X
rapidly	B-X
suppressed	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
a	B-X
phenomenon	B-X
termed	B-X
extinction	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
fusion	B-X
of	B-X
HeLa	B-X
cells	B-X
with	B-X
either	B-X
diploid	B-X
or	B-X
tetraploid	B-X
B	B-X
cells	B-X
(	B-X
Daudi	B-X
)	B-X
results	B-X
in	B-X
widespread	B-X
extinction	B-X
of	B-X
several	B-X
other	B-X
B	B-X
cell-encoded	B-X
genes	B-X
that	B-X
are	B-X
expressed	B-X
in	B-X
a	B-X
B	B-X
cell-specific	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
B	B-X
cell-expressed	B-X
genes	B-X
that	B-X
are	B-X
not	B-X
dependent	B-X
on	B-X
cell-specific	B-X
controls	B-X
is	B-X
unaffected	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
molecular	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
underlying	B-X
Ig	B-X
gene	B-X
extinction	B-X
can	B-X
be	B-X
explained	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
lack	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
essential	B-X
for	B-X
Ig	B-X
gene	B-X
transcription	B-X
.	B-X
These	B-X
transcription	B-X
factors	B-X
are	B-X
either	B-X
not	B-X
produced	B-X
due	B-X
to	B-X
block	B-X
of	B-X
transcription	B-X
of	B-X
their	B-X
respective	B-X
genes	B-X
(	B-X
Oct-2	B-X
,	B-X
OBF-1	B-X
,	B-X
PU.1	B-X
)	B-X
,	B-X
or	B-X
are	B-X
rendered	B-X
inactive	B-X
posttranslationally	B-X
(	B-X
NF-kappa	B-X
B	B-X
,	B-X
E47	B-X
)	B-X
.	B-X
By	B-X
isolating	B-X
Daudi	B-X
x	B-X
HeLa	B-X
heterokaryons	B-X
a	B-X
few	B-X
hours	B-X
after	B-X
fusion	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
initial	B-X
fate	B-X
of	B-X
two	B-X
B	B-X
cell-specific	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
Ig	B-X
gene	B-X
transcription	B-X
,	B-X
Oct-2	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
This	B-X
report	B-X
provides	B-X
the	B-X
first	B-X
demonstration	B-X
that	B-X
upon	B-X
fusion	B-X
with	B-X
HeLa	B-X
cells	B-X
,	B-X
the	B-X
nuclear	B-X
contents	B-X
of	B-X
B	B-X
cell-expressed	B-X
transcription	B-X
factors	B-X
are	B-X
depleted	B-X
within	B-X
a	B-X
few	B-X
hours	B-X
with	B-X
kinetics	B-X
that	B-X
are	B-X
as	B-X
fast	B-X
or	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
Ig	B-X
gene	B-X
extinction	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
extinguishing	B-X
mechanism	B-X
is	B-X
effective	B-X
very	B-X
early	B-X
after	B-X
fusion	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
extinction	B-X
of	B-X
Ig	B-X
genes	B-X
is	B-X
part	B-X
of	B-X
a	B-X
global	B-X
mechanism	B-X
that	B-X
suppresses	B-X
the	B-X
differentiation	B-X
program	B-X
foreign	B-X
to	B-X
the	B-X
HeLa	B-X
phenotype	B-X
.	B-X

These	O
transcription	O
factors	O
are	O
either	O
not	O
produced	O
due	O
to	O
block	O
of	O
transcription	O
of	O
their	O
respective	O
genes	O
(	O
Oct	B-Protein
-	I-Protein
2	I-Protein
,	O
OBF	B-Protein
-	I-Protein
1	I-Protein
,	O
PU	B-Protein
.	I-Protein
1	I-Protein
)	O
,	O
or	O
are	O
rendered	O
inactive	O
posttranslationally	O
(	O
NF	O
-	O
kappa	O
B	O
,	O
E47	B-Protein
)	O
.	O
<EOS>	B-X
When	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
expressing	B-X
B	B-X
cells	B-X
are	B-X
fused	B-X
with	B-X
non-B	B-X
cells	B-X
,	B-X
Ig	B-X
expression	B-X
is	B-X
rapidly	B-X
suppressed	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
a	B-X
phenomenon	B-X
termed	B-X
extinction	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
fusion	B-X
of	B-X
HeLa	B-X
cells	B-X
with	B-X
either	B-X
diploid	B-X
or	B-X
tetraploid	B-X
B	B-X
cells	B-X
(	B-X
Daudi	B-X
)	B-X
results	B-X
in	B-X
widespread	B-X
extinction	B-X
of	B-X
several	B-X
other	B-X
B	B-X
cell-encoded	B-X
genes	B-X
that	B-X
are	B-X
expressed	B-X
in	B-X
a	B-X
B	B-X
cell-specific	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
B	B-X
cell-expressed	B-X
genes	B-X
that	B-X
are	B-X
not	B-X
dependent	B-X
on	B-X
cell-specific	B-X
controls	B-X
is	B-X
unaffected	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
molecular	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
underlying	B-X
Ig	B-X
gene	B-X
extinction	B-X
can	B-X
be	B-X
explained	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
lack	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
essential	B-X
for	B-X
Ig	B-X
gene	B-X
transcription	B-X
.	B-X
These	B-X
transcription	B-X
factors	B-X
are	B-X
either	B-X
not	B-X
produced	B-X
due	B-X
to	B-X
block	B-X
of	B-X
transcription	B-X
of	B-X
their	B-X
respective	B-X
genes	B-X
(	B-X
Oct-2	B-X
,	B-X
OBF-1	B-X
,	B-X
PU.1	B-X
)	B-X
,	B-X
or	B-X
are	B-X
rendered	B-X
inactive	B-X
posttranslationally	B-X
(	B-X
NF-kappa	B-X
B	B-X
,	B-X
E47	B-X
)	B-X
.	B-X
By	B-X
isolating	B-X
Daudi	B-X
x	B-X
HeLa	B-X
heterokaryons	B-X
a	B-X
few	B-X
hours	B-X
after	B-X
fusion	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
initial	B-X
fate	B-X
of	B-X
two	B-X
B	B-X
cell-specific	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
Ig	B-X
gene	B-X
transcription	B-X
,	B-X
Oct-2	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
This	B-X
report	B-X
provides	B-X
the	B-X
first	B-X
demonstration	B-X
that	B-X
upon	B-X
fusion	B-X
with	B-X
HeLa	B-X
cells	B-X
,	B-X
the	B-X
nuclear	B-X
contents	B-X
of	B-X
B	B-X
cell-expressed	B-X
transcription	B-X
factors	B-X
are	B-X
depleted	B-X
within	B-X
a	B-X
few	B-X
hours	B-X
with	B-X
kinetics	B-X
that	B-X
are	B-X
as	B-X
fast	B-X
or	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
Ig	B-X
gene	B-X
extinction	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
extinction	B-X
of	B-X
Ig	B-X
genes	B-X
is	B-X
part	B-X
of	B-X
a	B-X
global	B-X
mechanism	B-X
that	B-X
suppresses	B-X
the	B-X
differentiation	B-X
program	B-X
foreign	B-X
to	B-X
the	B-X
HeLa	B-X
phenotype	B-X
.	B-X

By	O
isolating	O
Daudi	O
x	O
HeLa	O
heterokaryons	O
a	O
few	O
hours	O
after	O
fusion	O
,	O
we	O
have	O
studied	O
the	O
initial	O
fate	O
of	O
two	O
B	O
cell	O
-	O
specific	O
transcription	O
factors	O
involved	O
in	O
Ig	O
gene	O
transcription	O
,	O
Oct	B-Protein
-	I-Protein
2	I-Protein
and	O
NF	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
When	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
expressing	B-X
B	B-X
cells	B-X
are	B-X
fused	B-X
with	B-X
non-B	B-X
cells	B-X
,	B-X
Ig	B-X
expression	B-X
is	B-X
rapidly	B-X
suppressed	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
a	B-X
phenomenon	B-X
termed	B-X
extinction	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
fusion	B-X
of	B-X
HeLa	B-X
cells	B-X
with	B-X
either	B-X
diploid	B-X
or	B-X
tetraploid	B-X
B	B-X
cells	B-X
(	B-X
Daudi	B-X
)	B-X
results	B-X
in	B-X
widespread	B-X
extinction	B-X
of	B-X
several	B-X
other	B-X
B	B-X
cell-encoded	B-X
genes	B-X
that	B-X
are	B-X
expressed	B-X
in	B-X
a	B-X
B	B-X
cell-specific	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
B	B-X
cell-expressed	B-X
genes	B-X
that	B-X
are	B-X
not	B-X
dependent	B-X
on	B-X
cell-specific	B-X
controls	B-X
is	B-X
unaffected	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
molecular	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
underlying	B-X
Ig	B-X
gene	B-X
extinction	B-X
can	B-X
be	B-X
explained	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
lack	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
essential	B-X
for	B-X
Ig	B-X
gene	B-X
transcription	B-X
.	B-X
These	B-X
transcription	B-X
factors	B-X
are	B-X
either	B-X
not	B-X
produced	B-X
due	B-X
to	B-X
block	B-X
of	B-X
transcription	B-X
of	B-X
their	B-X
respective	B-X
genes	B-X
(	B-X
Oct-2	B-X
,	B-X
OBF-1	B-X
,	B-X
PU.1	B-X
)	B-X
,	B-X
or	B-X
are	B-X
rendered	B-X
inactive	B-X
posttranslationally	B-X
(	B-X
NF-kappa	B-X
B	B-X
,	B-X
E47	B-X
)	B-X
.	B-X
By	B-X
isolating	B-X
Daudi	B-X
x	B-X
HeLa	B-X
heterokaryons	B-X
a	B-X
few	B-X
hours	B-X
after	B-X
fusion	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
initial	B-X
fate	B-X
of	B-X
two	B-X
B	B-X
cell-specific	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
Ig	B-X
gene	B-X
transcription	B-X
,	B-X
Oct-2	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
This	B-X
report	B-X
provides	B-X
the	B-X
first	B-X
demonstration	B-X
that	B-X
upon	B-X
fusion	B-X
with	B-X
HeLa	B-X
cells	B-X
,	B-X
the	B-X
nuclear	B-X
contents	B-X
of	B-X
B	B-X
cell-expressed	B-X
transcription	B-X
factors	B-X
are	B-X
depleted	B-X
within	B-X
a	B-X
few	B-X
hours	B-X
with	B-X
kinetics	B-X
that	B-X
are	B-X
as	B-X
fast	B-X
or	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
Ig	B-X
gene	B-X
extinction	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
extinguishing	B-X
mechanism	B-X
is	B-X
effective	B-X
very	B-X
early	B-X
after	B-X
fusion	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
extinction	B-X
of	B-X
Ig	B-X
genes	B-X
is	B-X
part	B-X
of	B-X
a	B-X
global	B-X
mechanism	B-X
that	B-X
suppresses	B-X
the	B-X
differentiation	B-X
program	B-X
foreign	B-X
to	B-X
the	B-X
HeLa	B-X
phenotype	B-X
.	B-X

This	O
report	O
provides	O
the	O
first	O
demonstration	O
that	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
,	O
the	O
nuclear	O
contents	O
of	O
B	O
cell	O
-	O
expressed	O
transcription	O
factors	O
are	O
depleted	O
within	O
a	O
few	O
hours	O
with	O
kinetics	O
that	O
are	O
as	O
fast	O
or	O
faster	O
than	O
that	O
of	O
Ig	O
gene	O
extinction	O
.	O
<EOS>	B-X
When	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
expressing	B-X
B	B-X
cells	B-X
are	B-X
fused	B-X
with	B-X
non-B	B-X
cells	B-X
,	B-X
Ig	B-X
expression	B-X
is	B-X
rapidly	B-X
suppressed	B-X
at	B-X
the	B-X
level	B-X
of	B-X
transcription	B-X
,	B-X
a	B-X
phenomenon	B-X
termed	B-X
extinction	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
fusion	B-X
of	B-X
HeLa	B-X
cells	B-X
with	B-X
either	B-X
diploid	B-X
or	B-X
tetraploid	B-X
B	B-X
cells	B-X
(	B-X
Daudi	B-X
)	B-X
results	B-X
in	B-X
widespread	B-X
extinction	B-X
of	B-X
several	B-X
other	B-X
B	B-X
cell-encoded	B-X
genes	B-X
that	B-X
are	B-X
expressed	B-X
in	B-X
a	B-X
B	B-X
cell-specific	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
expression	B-X
of	B-X
B	B-X
cell-expressed	B-X
genes	B-X
that	B-X
are	B-X
not	B-X
dependent	B-X
on	B-X
cell-specific	B-X
controls	B-X
is	B-X
unaffected	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
molecular	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
underlying	B-X
Ig	B-X
gene	B-X
extinction	B-X
can	B-X
be	B-X
explained	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
lack	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
essential	B-X
for	B-X
Ig	B-X
gene	B-X
transcription	B-X
.	B-X
These	B-X
transcription	B-X
factors	B-X
are	B-X
either	B-X
not	B-X
produced	B-X
due	B-X
to	B-X
block	B-X
of	B-X
transcription	B-X
of	B-X
their	B-X
respective	B-X
genes	B-X
(	B-X
Oct-2	B-X
,	B-X
OBF-1	B-X
,	B-X
PU.1	B-X
)	B-X
,	B-X
or	B-X
are	B-X
rendered	B-X
inactive	B-X
posttranslationally	B-X
(	B-X
NF-kappa	B-X
B	B-X
,	B-X
E47	B-X
)	B-X
.	B-X
By	B-X
isolating	B-X
Daudi	B-X
x	B-X
HeLa	B-X
heterokaryons	B-X
a	B-X
few	B-X
hours	B-X
after	B-X
fusion	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
initial	B-X
fate	B-X
of	B-X
two	B-X
B	B-X
cell-specific	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
Ig	B-X
gene	B-X
transcription	B-X
,	B-X
Oct-2	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
This	B-X
report	B-X
provides	B-X
the	B-X
first	B-X
demonstration	B-X
that	B-X
upon	B-X
fusion	B-X
with	B-X
HeLa	B-X
cells	B-X
,	B-X
the	B-X
nuclear	B-X
contents	B-X
of	B-X
B	B-X
cell-expressed	B-X
transcription	B-X
factors	B-X
are	B-X
depleted	B-X
within	B-X
a	B-X
few	B-X
hours	B-X
with	B-X
kinetics	B-X
that	B-X
are	B-X
as	B-X
fast	B-X
or	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
Ig	B-X
gene	B-X
extinction	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
extinguishing	B-X
mechanism	B-X
is	B-X
effective	B-X
very	B-X
early	B-X
after	B-X
fusion	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
extinction	B-X
of	B-X
Ig	B-X
genes	B-X
is	B-X
part	B-X
of	B-X
a	B-X
global	B-X
mechanism	B-X
that	B-X
suppresses	B-X
the	B-X
differentiation	B-X
program	B-X
foreign	B-X
to	B-X
the	B-X
HeLa	B-X
phenotype	B-X
.	B-X

Thus	O
,	O
the	O
extinguishing	O
mechanism	O
is	O
effective	O
very	O
early	O
after	O
fusion	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
fusion	B-X
of	B-X
HeLa	B-X
cells	B-X
with	B-X
either	B-X
diploid	B-X
or	B-X
tetraploid	B-X
B	B-X
cells	B-X
(	B-X
Daudi	B-X
)	B-X
results	B-X
in	B-X
widespread	B-X
extinction	B-X
of	B-X
several	B-X
other	B-X
B	B-X
cell-encoded	B-X
genes	B-X
that	B-X
are	B-X
expressed	B-X
in	B-X
a	B-X
B	B-X
cell-specific	B-X
manner	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
molecular	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
underlying	B-X
Ig	B-X
gene	B-X
extinction	B-X
can	B-X
be	B-X
explained	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
a	B-X
lack	B-X
of	B-X
transcription	B-X
factors	B-X
that	B-X
are	B-X
essential	B-X
for	B-X
Ig	B-X
gene	B-X
transcription	B-X
.	B-X
By	B-X
isolating	B-X
Daudi	B-X
x	B-X
HeLa	B-X
heterokaryons	B-X
a	B-X
few	B-X
hours	B-X
after	B-X
fusion	B-X
,	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
initial	B-X
fate	B-X
of	B-X
two	B-X
B	B-X
cell-specific	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
Ig	B-X
gene	B-X
transcription	B-X
,	B-X
Oct-2	B-X
and	B-X
NF-kappa	B-X
B	B-X
.	B-X
This	B-X
report	B-X
provides	B-X
the	B-X
first	B-X
demonstration	B-X
that	B-X
upon	B-X
fusion	B-X
with	B-X
HeLa	B-X
cells	B-X
,	B-X
the	B-X
nuclear	B-X
contents	B-X
of	B-X
B	B-X
cell-expressed	B-X
transcription	B-X
factors	B-X
are	B-X
depleted	B-X
within	B-X
a	B-X
few	B-X
hours	B-X
with	B-X
kinetics	B-X
that	B-X
are	B-X
as	B-X
fast	B-X
or	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
Ig	B-X
gene	B-X
extinction	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
extinguishing	B-X
mechanism	B-X
is	B-X
effective	B-X
very	B-X
early	B-X
after	B-X
fusion	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
extinction	B-X
of	B-X
Ig	B-X
genes	B-X
is	B-X
part	B-X
of	B-X
a	B-X
global	B-X
mechanism	B-X
that	B-X
suppresses	B-X
the	B-X
differentiation	B-X
program	B-X
foreign	B-X
to	B-X
the	B-X
HeLa	B-X
phenotype	B-X
.	B-X

We	O
suggest	O
that	O
extinction	O
of	O
Ig	O
genes	O
is	O
part	O
of	O
a	O
global	O
mechanism	O
that	O
suppresses	O
the	O
differentiation	O
program	O
foreign	O
to	O
the	O
HeLa	O
phenotype	O
.	O

Regulation	O
of	O
Id3	B-Protein
cell	O
cycle	O
function	O
by	O
Cdk	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
phosphorylation	O
.	O
<EOS>	B-X
The	B-X
functions	B-X
of	B-X
basic	B-X
helix-loop-helix	B-X
(	B-X
bHLH	B-X
)	B-X
transcription	B-X
factors	B-X
in	B-X
activating	B-X
differentiation-linked	B-X
gene	B-X
expression	B-X
and	B-X
in	B-X
inducing	B-X
G1	B-X
cell	B-X
cycle	B-X
arrest	B-X
are	B-X
negatively	B-X
regulated	B-X
by	B-X
members	B-X
of	B-X
the	B-X
Id	B-X
family	B-X
of	B-X
HLH	B-X
proteins	B-X
.	B-X
These	B-X
bHLH	B-X
antagonists	B-X
are	B-X
induced	B-X
during	B-X
a	B-X
mitogenic	B-X
signalling	B-X
response	B-X
,	B-X
and	B-X
they	B-X
function	B-X
by	B-X
sequestering	B-X
their	B-X
bHLH	B-X
targets	B-X
in	B-X
inactive	B-X
heterodimers	B-X
that	B-X
are	B-X
unable	B-X
to	B-X
bind	B-X
to	B-X
specific	B-X
gene	B-X
regulatory	B-X
(	B-X
E	B-X
box	B-X
)	B-X
sequences	B-X
.	B-X
Recently	B-X
,	B-X
cyclin	B-X
E-Cdk2-	B-X
and	B-X
cyclin	B-X
A-Cdk2-dependent	B-X
phosphorylation	B-X
of	B-X
a	B-X
single	B-X
conserved	B-X
serine	B-X
residue	B-X
(	B-X
Ser5	B-X
)	B-X
in	B-X
Id2	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
occur	B-X
during	B-X
late	B-X
G1-to-S	B-X
phase	B-X
transition	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
and	B-X
this	B-X
neutralizes	B-X
the	B-X
function	B-X
of	B-X
Id2	B-X
in	B-X
abrogating	B-X
E-box-dependent	B-X
bHLH	B-X
homo-	B-X
or	B-X
heterodimer	B-X
complex	B-X
formation	B-X
in	B-X
vitro	B-X
(	B-X
E.	B-X
Hara	B-X
,	B-X
M.	B-X
Hall	B-X
,	B-X
and	B-X
G.	B-X
Peters	B-X
,	B-X
EMBO	B-X
J	B-X
.	B-X
16:332-342	B-X
,	B-X
1997	B-X
)	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
an	B-X
analogous	B-X
cell-cycle-regulated	B-X
phosphorylation	B-X
of	B-X
Id3	B-X
alters	B-X
the	B-X
specificity	B-X
of	B-X
Id3	B-X
for	B-X
abrogating	B-X
both	B-X
E-box-dependent	B-X
bHLH	B-X
homo-	B-X
or	B-X
heterodimer	B-X
complex	B-X
formation	B-X
in	B-X
vitro	B-X
and	B-X
E-box-dependent	B-X
reporter	B-X
gene	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
wild-type	B-X
Id3	B-X
,	B-X
an	B-X
Id3	B-X
Asp5	B-X
mutant	B-X
(	B-X
mimicking	B-X
phosphorylation	B-X
)	B-X
is	B-X
unable	B-X
to	B-X
promote	B-X
cell	B-X
cycle	B-X
S	B-X
phase	B-X
entry	B-X
in	B-X
transfected	B-X
fibroblasts	B-X
,	B-X
whereas	B-X
an	B-X
Id3	B-X
Ala5	B-X
mutant	B-X
(	B-X
ablating	B-X
phosphorylation	B-X
)	B-X
displays	B-X
an	B-X
activity	B-X
significantly	B-X
greater	B-X
than	B-X
that	B-X
of	B-X
wild-type	B-X
Id3	B-X
protein	B-X
.	B-X
Cdk2-dependent	B-X
phosphorylation	B-X
therefore	B-X
provides	B-X
a	B-X
switch	B-X
during	B-X
late	B-X
G1-to-S	B-X
phase	B-X
that	B-X
both	B-X
nullifies	B-X
an	B-X
early	B-X
G1	B-X
cell	B-X
cycle	B-X
regulatory	B-X
function	B-X
of	B-X
Id3	B-X
and	B-X
modulates	B-X
its	B-X
target	B-X
bHLH	B-X
specificity	B-X
.	B-X
These	B-X
data	B-X
also	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
Id3	B-X
to	B-X
promote	B-X
cell	B-X
cycle	B-X
S	B-X
phase	B-X
entry	B-X
is	B-X
not	B-X
simply	B-X
a	B-X
function	B-X
of	B-X
its	B-X
ability	B-X
to	B-X
modulate	B-X
bHLH	B-X
heterodimer-dependent	B-X
gene	B-X
expression	B-X
and	B-X
establish	B-X
a	B-X
biologically	B-X
important	B-X
mechanism	B-X
through	B-X
which	B-X
Cdk2	B-X
and	B-X
Id-bHLH	B-X
functions	B-X
are	B-X
integrated	B-X
in	B-X
the	B-X
coordination	B-X
of	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X

The	O
functions	O
of	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
transcription	O
factors	O
in	O
activating	O
differentiation	O
-	O
linked	O
gene	O
expression	O
and	O
in	O
inducing	O
G1	O
cell	O
cycle	O
arrest	O
are	O
negatively	O
regulated	O
by	O
members	O
of	O
the	O
Id	O
family	O
of	O
HLH	O
proteins	O
.	O
<EOS>	B-X
The	B-X
functions	B-X
of	B-X
basic	B-X
helix-loop-helix	B-X
(	B-X
bHLH	B-X
)	B-X
transcription	B-X
factors	B-X
in	B-X
activating	B-X
differentiation-linked	B-X
gene	B-X
expression	B-X
and	B-X
in	B-X
inducing	B-X
G1	B-X
cell	B-X
cycle	B-X
arrest	B-X
are	B-X
negatively	B-X
regulated	B-X
by	B-X
members	B-X
of	B-X
the	B-X
Id	B-X
family	B-X
of	B-X
HLH	B-X
proteins	B-X
.	B-X
These	B-X
bHLH	B-X
antagonists	B-X
are	B-X
induced	B-X
during	B-X
a	B-X
mitogenic	B-X
signalling	B-X
response	B-X
,	B-X
and	B-X
they	B-X
function	B-X
by	B-X
sequestering	B-X
their	B-X
bHLH	B-X
targets	B-X
in	B-X
inactive	B-X
heterodimers	B-X
that	B-X
are	B-X
unable	B-X
to	B-X
bind	B-X
to	B-X
specific	B-X
gene	B-X
regulatory	B-X
(	B-X
E	B-X
box	B-X
)	B-X
sequences	B-X
.	B-X
Recently	B-X
,	B-X
cyclin	B-X
E-Cdk2-	B-X
and	B-X
cyclin	B-X
A-Cdk2-dependent	B-X
phosphorylation	B-X
of	B-X
a	B-X
single	B-X
conserved	B-X
serine	B-X
residue	B-X
(	B-X
Ser5	B-X
)	B-X
in	B-X
Id2	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
occur	B-X
during	B-X
late	B-X
G1-to-S	B-X
phase	B-X
transition	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
and	B-X
this	B-X
neutralizes	B-X
the	B-X
function	B-X
of	B-X
Id2	B-X
in	B-X
abrogating	B-X
E-box-dependent	B-X
bHLH	B-X
homo-	B-X
or	B-X
heterodimer	B-X
complex	B-X
formation	B-X
in	B-X
vitro	B-X
(	B-X
E.	B-X
Hara	B-X
,	B-X
M.	B-X
Hall	B-X
,	B-X
and	B-X
G.	B-X
Peters	B-X
,	B-X
EMBO	B-X
J	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
an	B-X
analogous	B-X
cell-cycle-regulated	B-X
phosphorylation	B-X
of	B-X
Id3	B-X
alters	B-X
the	B-X
specificity	B-X
of	B-X
Id3	B-X
for	B-X
abrogating	B-X
both	B-X
E-box-dependent	B-X
bHLH	B-X
homo-	B-X
or	B-X
heterodimer	B-X
complex	B-X
formation	B-X
in	B-X
vitro	B-X
and	B-X
E-box-dependent	B-X
reporter	B-X
gene	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
wild-type	B-X
Id3	B-X
,	B-X
an	B-X
Id3	B-X
Asp5	B-X
mutant	B-X
(	B-X
mimicking	B-X
phosphorylation	B-X
)	B-X
is	B-X
unable	B-X
to	B-X
promote	B-X
cell	B-X
cycle	B-X
S	B-X
phase	B-X
entry	B-X
in	B-X
transfected	B-X
fibroblasts	B-X
,	B-X
whereas	B-X
an	B-X
Id3	B-X
Ala5	B-X
mutant	B-X
(	B-X
ablating	B-X
phosphorylation	B-X
)	B-X
displays	B-X
an	B-X
activity	B-X
significantly	B-X
greater	B-X
than	B-X
that	B-X
of	B-X
wild-type	B-X
Id3	B-X
protein	B-X
.	B-X
Cdk2-dependent	B-X
phosphorylation	B-X
therefore	B-X
provides	B-X
a	B-X
switch	B-X
during	B-X
late	B-X
G1-to-S	B-X
phase	B-X
that	B-X
both	B-X
nullifies	B-X
an	B-X
early	B-X
G1	B-X
cell	B-X
cycle	B-X
regulatory	B-X
function	B-X
of	B-X
Id3	B-X
and	B-X
modulates	B-X
its	B-X
target	B-X
bHLH	B-X
specificity	B-X
.	B-X
These	B-X
data	B-X
also	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
Id3	B-X
to	B-X
promote	B-X
cell	B-X
cycle	B-X
S	B-X
phase	B-X
entry	B-X
is	B-X
not	B-X
simply	B-X
a	B-X
function	B-X
of	B-X
its	B-X
ability	B-X
to	B-X
modulate	B-X
bHLH	B-X
heterodimer-dependent	B-X
gene	B-X
expression	B-X
and	B-X
establish	B-X
a	B-X
biologically	B-X
important	B-X
mechanism	B-X
through	B-X
which	B-X
Cdk2	B-X
and	B-X
Id-bHLH	B-X
functions	B-X
are	B-X
integrated	B-X
in	B-X
the	B-X
coordination	B-X
of	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X

These	O
bHLH	O
antagonists	O
are	O
induced	O
during	O
a	O
mitogenic	O
signalling	O
response	O
,	O
and	O
they	O
function	O
by	O
sequestering	O
their	O
bHLH	O
targets	O
in	O
inactive	O
heterodimers	O
that	O
are	O
unable	O
to	O
bind	O
to	O
specific	O
gene	O
regulatory	O
(	O
E	O
box	O
)	O
sequences	O
.	O
<EOS>	B-X
The	B-X
functions	B-X
of	B-X
basic	B-X
helix-loop-helix	B-X
(	B-X
bHLH	B-X
)	B-X
transcription	B-X
factors	B-X
in	B-X
activating	B-X
differentiation-linked	B-X
gene	B-X
expression	B-X
and	B-X
in	B-X
inducing	B-X
G1	B-X
cell	B-X
cycle	B-X
arrest	B-X
are	B-X
negatively	B-X
regulated	B-X
by	B-X
members	B-X
of	B-X
the	B-X
Id	B-X
family	B-X
of	B-X
HLH	B-X
proteins	B-X
.	B-X
These	B-X
bHLH	B-X
antagonists	B-X
are	B-X
induced	B-X
during	B-X
a	B-X
mitogenic	B-X
signalling	B-X
response	B-X
,	B-X
and	B-X
they	B-X
function	B-X
by	B-X
sequestering	B-X
their	B-X
bHLH	B-X
targets	B-X
in	B-X
inactive	B-X
heterodimers	B-X
that	B-X
are	B-X
unable	B-X
to	B-X
bind	B-X
to	B-X
specific	B-X
gene	B-X
regulatory	B-X
(	B-X
E	B-X
box	B-X
)	B-X
sequences	B-X
.	B-X
Recently	B-X
,	B-X
cyclin	B-X
E-Cdk2-	B-X
and	B-X
cyclin	B-X
A-Cdk2-dependent	B-X
phosphorylation	B-X
of	B-X
a	B-X
single	B-X
conserved	B-X
serine	B-X
residue	B-X
(	B-X
Ser5	B-X
)	B-X
in	B-X
Id2	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
occur	B-X
during	B-X
late	B-X
G1-to-S	B-X
phase	B-X
transition	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
and	B-X
this	B-X
neutralizes	B-X
the	B-X
function	B-X
of	B-X
Id2	B-X
in	B-X
abrogating	B-X
E-box-dependent	B-X
bHLH	B-X
homo-	B-X
or	B-X
heterodimer	B-X
complex	B-X
formation	B-X
in	B-X
vitro	B-X
(	B-X
E.	B-X
Hara	B-X
,	B-X
M.	B-X
Hall	B-X
,	B-X
and	B-X
G.	B-X
Peters	B-X
,	B-X
EMBO	B-X
J	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
an	B-X
analogous	B-X
cell-cycle-regulated	B-X
phosphorylation	B-X
of	B-X
Id3	B-X
alters	B-X
the	B-X
specificity	B-X
of	B-X
Id3	B-X
for	B-X
abrogating	B-X
both	B-X
E-box-dependent	B-X
bHLH	B-X
homo-	B-X
or	B-X
heterodimer	B-X
complex	B-X
formation	B-X
in	B-X
vitro	B-X
and	B-X
E-box-dependent	B-X
reporter	B-X
gene	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
wild-type	B-X
Id3	B-X
,	B-X
an	B-X
Id3	B-X
Asp5	B-X
mutant	B-X
(	B-X
mimicking	B-X
phosphorylation	B-X
)	B-X
is	B-X
unable	B-X
to	B-X
promote	B-X
cell	B-X
cycle	B-X
S	B-X
phase	B-X
entry	B-X
in	B-X
transfected	B-X
fibroblasts	B-X
,	B-X
whereas	B-X
an	B-X
Id3	B-X
Ala5	B-X
mutant	B-X
(	B-X
ablating	B-X
phosphorylation	B-X
)	B-X
displays	B-X
an	B-X
activity	B-X
significantly	B-X
greater	B-X
than	B-X
that	B-X
of	B-X
wild-type	B-X
Id3	B-X
protein	B-X
.	B-X
Cdk2-dependent	B-X
phosphorylation	B-X
therefore	B-X
provides	B-X
a	B-X
switch	B-X
during	B-X
late	B-X
G1-to-S	B-X
phase	B-X
that	B-X
both	B-X
nullifies	B-X
an	B-X
early	B-X
G1	B-X
cell	B-X
cycle	B-X
regulatory	B-X
function	B-X
of	B-X
Id3	B-X
and	B-X
modulates	B-X
its	B-X
target	B-X
bHLH	B-X
specificity	B-X
.	B-X
These	B-X
data	B-X
also	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
Id3	B-X
to	B-X
promote	B-X
cell	B-X
cycle	B-X
S	B-X
phase	B-X
entry	B-X
is	B-X
not	B-X
simply	B-X
a	B-X
function	B-X
of	B-X
its	B-X
ability	B-X
to	B-X
modulate	B-X
bHLH	B-X
heterodimer-dependent	B-X
gene	B-X
expression	B-X
and	B-X
establish	B-X
a	B-X
biologically	B-X
important	B-X
mechanism	B-X
through	B-X
which	B-X
Cdk2	B-X
and	B-X
Id-bHLH	B-X
functions	B-X
are	B-X
integrated	B-X
in	B-X
the	B-X
coordination	B-X
of	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X

Recently	O
,	O
cyclin	B-Protein
E	I-Protein
-	O
Cdk2	B-Protein
-	O
and	O
cyclin	B-Protein
A	I-Protein
-	O
Cdk2	B-Protein
-	O
dependent	O
phosphorylation	O
of	O
a	O
single	O
conserved	O
serine	O
residue	O
(	O
Ser5	O
)	O
in	O
Id2	B-Protein
has	O
been	O
shown	O
to	O
occur	O
during	O
late	O
G1	O
-	O
to	O
-	O
S	O
phase	O
transition	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
this	O
neutralizes	O
the	O
function	O
of	O
Id2	B-Protein
in	O
abrogating	O
E	O
-	O
box	O
-	O
dependent	O
bHLH	O
homo	O
-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
(	O
E	O
.	O
Hara	O
,	O
M	O
.	O
Hall	O
,	O
and	O
G	O
.	O
Peters	O
,	O
EMBO	O
J	O
.	O
16	O
:	O
332	O
-	O
342	O
,	O
1997	O
)	O
.	O

We	O
now	O
show	O
that	O
an	O
analogous	O
cell	O
-	O
cycle	O
-	O
regulated	O
phosphorylation	O
of	O
Id3	B-Protein
alters	O
the	O
specificity	O
of	O
Id3	B-Protein
for	O
abrogating	O
both	O
E	O
-	O
box	O
-	O
dependent	O
bHLH	O
homo	O
-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
and	O
E	O
-	O
box	O
-	O
dependent	O
reporter	O
gene	O
function	O
in	O
vivo	O
.	O

Furthermore	O
,	O
compared	O
with	O
wild	O
-	O
type	O
Id3	B-Protein
,	O
an	O
Id3	B-Protein
Asp5	O
mutant	O
(	O
mimicking	O
phosphorylation	O
)	O
is	O
unable	O
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
in	O
transfected	O
fibroblasts	O
,	O
whereas	O
an	O
Id3	B-Protein
Ala5	O
mutant	O
(	O
ablating	O
phosphorylation	O
)	O
displays	O
an	O
activity	O
significantly	O
greater	O
than	O
that	O
of	O
wild	O
-	O
type	O
Id3	B-Protein
protein	O
.	O
<EOS>	B-X
The	B-X
functions	B-X
of	B-X
basic	B-X
helix-loop-helix	B-X
(	B-X
bHLH	B-X
)	B-X
transcription	B-X
factors	B-X
in	B-X
activating	B-X
differentiation-linked	B-X
gene	B-X
expression	B-X
and	B-X
in	B-X
inducing	B-X
G1	B-X
cell	B-X
cycle	B-X
arrest	B-X
are	B-X
negatively	B-X
regulated	B-X
by	B-X
members	B-X
of	B-X
the	B-X
Id	B-X
family	B-X
of	B-X
HLH	B-X
proteins	B-X
.	B-X
These	B-X
bHLH	B-X
antagonists	B-X
are	B-X
induced	B-X
during	B-X
a	B-X
mitogenic	B-X
signalling	B-X
response	B-X
,	B-X
and	B-X
they	B-X
function	B-X
by	B-X
sequestering	B-X
their	B-X
bHLH	B-X
targets	B-X
in	B-X
inactive	B-X
heterodimers	B-X
that	B-X
are	B-X
unable	B-X
to	B-X
bind	B-X
to	B-X
specific	B-X
gene	B-X
regulatory	B-X
(	B-X
E	B-X
box	B-X
)	B-X
sequences	B-X
.	B-X
Recently	B-X
,	B-X
cyclin	B-X
E-Cdk2-	B-X
and	B-X
cyclin	B-X
A-Cdk2-dependent	B-X
phosphorylation	B-X
of	B-X
a	B-X
single	B-X
conserved	B-X
serine	B-X
residue	B-X
(	B-X
Ser5	B-X
)	B-X
in	B-X
Id2	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
occur	B-X
during	B-X
late	B-X
G1-to-S	B-X
phase	B-X
transition	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
and	B-X
this	B-X
neutralizes	B-X
the	B-X
function	B-X
of	B-X
Id2	B-X
in	B-X
abrogating	B-X
E-box-dependent	B-X
bHLH	B-X
homo-	B-X
or	B-X
heterodimer	B-X
complex	B-X
formation	B-X
in	B-X
vitro	B-X
(	B-X
E.	B-X
Hara	B-X
,	B-X
M.	B-X
Hall	B-X
,	B-X
and	B-X
G.	B-X
Peters	B-X
,	B-X
EMBO	B-X
J	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
an	B-X
analogous	B-X
cell-cycle-regulated	B-X
phosphorylation	B-X
of	B-X
Id3	B-X
alters	B-X
the	B-X
specificity	B-X
of	B-X
Id3	B-X
for	B-X
abrogating	B-X
both	B-X
E-box-dependent	B-X
bHLH	B-X
homo-	B-X
or	B-X
heterodimer	B-X
complex	B-X
formation	B-X
in	B-X
vitro	B-X
and	B-X
E-box-dependent	B-X
reporter	B-X
gene	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
compared	B-X
with	B-X
wild-type	B-X
Id3	B-X
,	B-X
an	B-X
Id3	B-X
Asp5	B-X
mutant	B-X
(	B-X
mimicking	B-X
phosphorylation	B-X
)	B-X
is	B-X
unable	B-X
to	B-X
promote	B-X
cell	B-X
cycle	B-X
S	B-X
phase	B-X
entry	B-X
in	B-X
transfected	B-X
fibroblasts	B-X
,	B-X
whereas	B-X
an	B-X
Id3	B-X
Ala5	B-X
mutant	B-X
(	B-X
ablating	B-X
phosphorylation	B-X
)	B-X
displays	B-X
an	B-X
activity	B-X
significantly	B-X
greater	B-X
than	B-X
that	B-X
of	B-X
wild-type	B-X
Id3	B-X
protein	B-X
.	B-X
Cdk2-dependent	B-X
phosphorylation	B-X
therefore	B-X
provides	B-X
a	B-X
switch	B-X
during	B-X
late	B-X
G1-to-S	B-X
phase	B-X
that	B-X
both	B-X
nullifies	B-X
an	B-X
early	B-X
G1	B-X
cell	B-X
cycle	B-X
regulatory	B-X
function	B-X
of	B-X
Id3	B-X
and	B-X
modulates	B-X
its	B-X
target	B-X
bHLH	B-X
specificity	B-X
.	B-X
These	B-X
data	B-X
also	B-X
demonstrate	B-X
that	B-X
the	B-X
ability	B-X
of	B-X
Id3	B-X
to	B-X
promote	B-X
cell	B-X
cycle	B-X
S	B-X
phase	B-X
entry	B-X
is	B-X
not	B-X
simply	B-X
a	B-X
function	B-X
of	B-X
its	B-X
ability	B-X
to	B-X
modulate	B-X
bHLH	B-X
heterodimer-dependent	B-X
gene	B-X
expression	B-X
and	B-X
establish	B-X
a	B-X
biologically	B-X
important	B-X
mechanism	B-X
through	B-X
which	B-X
Cdk2	B-X
and	B-X
Id-bHLH	B-X
functions	B-X
are	B-X
integrated	B-X
in	B-X
the	B-X
coordination	B-X
of	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X

Cdk2	B-Protein
-	O
dependent	O
phosphorylation	O
therefore	O
provides	O
a	O
switch	O
during	O
late	O
G1	O
-	O
to	O
-	O
S	O
phase	O
that	O
both	O
nullifies	O
an	O
early	O
G1	O
cell	O
cycle	O
regulatory	O
function	O
of	O
Id3	B-Protein
and	O
modulates	O
its	O
target	O
bHLH	O
specificity	O
.	O

These	O
data	O
also	O
demonstrate	O
that	O
the	O
ability	O
of	O
Id3	B-Protein
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
is	O
not	O
simply	O
a	O
function	O
of	O
its	O
ability	O
to	O
modulate	O
bHLH	O
heterodimer	O
-	O
dependent	O
gene	O
expression	O
and	O
establish	O
a	O
biologically	O
important	O
mechanism	O
through	O
which	O
Cdk2	B-Protein
and	O
Id	O
-	O
bHLH	O
functions	O
are	O
integrated	O
in	O
the	O
coordination	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Cytokine	O
rescue	O
from	O
glucocorticoid	O
induced	O
apoptosis	O
in	O
T	O
cells	O
is	O
mediated	O
through	O
inhibition	O
of	O
IkappaBalpha	B-Protein
.	O

We	O
previously	O
reported	O
that	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
causes	O
apoptosis	O
in	O
mature	O
Th	O
cell	O
lines	O
,	O
and	O
that	O
this	O
induction	O
of	O
cell	O
death	O
is	O
prevented	O
by	O
specific	O
cytokines	O
,	O
namely	O
,	O
by	O
IL	B-Protein
-	I-Protein
2	I-Protein
in	O
Th1	O
cells	O
and	O
by	O
IL	B-Protein
-	I-Protein
4	I-Protein
in	O
Th2	O
cells	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
,	B-X
a	B-X
synthetic	B-X
glucocorticoid	B-X
,	B-X
causes	B-X
apoptosis	B-X
in	B-X
mature	B-X
Th	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
that	B-X
this	B-X
induction	B-X
of	B-X
cell	B-X
death	B-X
is	B-X
prevented	B-X
by	B-X
specific	B-X
cytokines	B-X
,	B-X
namely	B-X
,	B-X
by	B-X
IL-2	B-X
in	B-X
Th1	B-X
cells	B-X
and	B-X
by	B-X
IL-4	B-X
in	B-X
Th2	B-X
cells	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
this	B-X
differential	B-X
rescue	B-X
by	B-X
specific	B-X
cytokines	B-X
in	B-X
Th	B-X
cells	B-X
correlates	B-X
with	B-X
the	B-X
level	B-X
of	B-X
IkappaBalpha	B-X
that	B-X
is	B-X
regulated	B-X
by	B-X
DEX	B-X
and	B-X
cytokines	B-X
.	B-X
In	B-X
both	B-X
cell	B-X
types	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
IkappaBalpha	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
evaluated	B-X
by	B-X
DEX	B-X
treatment	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
DEX-mediated	B-X
IkappaBalpha	B-X
induction	B-X
was	B-X
completely	B-X
inhibited	B-X
by	B-X
IL-2	B-X
,	B-X
but	B-X
not	B-X
IL-4	B-X
,	B-X
in	B-X
Th1	B-X
cells	B-X
,	B-X
while	B-X
the	B-X
reverse	B-X
profile	B-X
was	B-X
seen	B-X
in	B-X
Th2	B-X
cells	B-X
.	B-X
In	B-X
both	B-X
cell	B-X
types	B-X
,	B-X
the	B-X
cytokine	B-X
that	B-X
inhibits	B-X
the	B-X
induction	B-X
of	B-X
IkappaBalpha	B-X
by	B-X
DEX	B-X
,	B-X
also	B-X
rescues	B-X
these	B-X
cells	B-X
from	B-X
DEX-induced	B-X
apoptosis	B-X
,	B-X
although	B-X
the	B-X
rescue	B-X
cytokine	B-X
is	B-X
different	B-X
in	B-X
Th1	B-X
and	B-X
Th2	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
imply	B-X
that	B-X
T	B-X
cells	B-X
need	B-X
to	B-X
maintain	B-X
a	B-X
certain	B-X
level	B-X
of	B-X
NF-kappaB	B-X
transcriptional	B-X
activity	B-X
in	B-X
order	B-X
to	B-X
survive	B-X
;	B-X
up-	B-X
or	B-X
down-regulation	B-X
of	B-X
nuclear	B-X
NF	B-X
kappaB	B-X
through	B-X
modulation	B-X
of	B-X
IkappaBalpha	B-X
expression	B-X
by	B-X
cytokines	B-X
or	B-X
DEX	B-X
may	B-X
lead	B-X
to	B-X
cell	B-X
survival	B-X
or	B-X
cell	B-X
death	B-X
,	B-X
respectively	B-X
.	B-X

We	O
now	O
show	O
that	O
this	O
differential	O
rescue	O
by	O
specific	O
cytokines	O
in	O
Th	O
cells	O
correlates	O
with	O
the	O
level	O
of	O
IkappaBalpha	B-Protein
that	O
is	O
regulated	O
by	O
DEX	O
and	O
cytokines	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
,	B-X
a	B-X
synthetic	B-X
glucocorticoid	B-X
,	B-X
causes	B-X
apoptosis	B-X
in	B-X
mature	B-X
Th	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
that	B-X
this	B-X
induction	B-X
of	B-X
cell	B-X
death	B-X
is	B-X
prevented	B-X
by	B-X
specific	B-X
cytokines	B-X
,	B-X
namely	B-X
,	B-X
by	B-X
IL-2	B-X
in	B-X
Th1	B-X
cells	B-X
and	B-X
by	B-X
IL-4	B-X
in	B-X
Th2	B-X
cells	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
this	B-X
differential	B-X
rescue	B-X
by	B-X
specific	B-X
cytokines	B-X
in	B-X
Th	B-X
cells	B-X
correlates	B-X
with	B-X
the	B-X
level	B-X
of	B-X
IkappaBalpha	B-X
that	B-X
is	B-X
regulated	B-X
by	B-X
DEX	B-X
and	B-X
cytokines	B-X
.	B-X
In	B-X
both	B-X
cell	B-X
types	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
IkappaBalpha	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
evaluated	B-X
by	B-X
DEX	B-X
treatment	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
DEX-mediated	B-X
IkappaBalpha	B-X
induction	B-X
was	B-X
completely	B-X
inhibited	B-X
by	B-X
IL-2	B-X
,	B-X
but	B-X
not	B-X
IL-4	B-X
,	B-X
in	B-X
Th1	B-X
cells	B-X
,	B-X
while	B-X
the	B-X
reverse	B-X
profile	B-X
was	B-X
seen	B-X
in	B-X
Th2	B-X
cells	B-X
.	B-X
In	B-X
both	B-X
cell	B-X
types	B-X
,	B-X
the	B-X
cytokine	B-X
that	B-X
inhibits	B-X
the	B-X
induction	B-X
of	B-X
IkappaBalpha	B-X
by	B-X
DEX	B-X
,	B-X
also	B-X
rescues	B-X
these	B-X
cells	B-X
from	B-X
DEX-induced	B-X
apoptosis	B-X
,	B-X
although	B-X
the	B-X
rescue	B-X
cytokine	B-X
is	B-X
different	B-X
in	B-X
Th1	B-X
and	B-X
Th2	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
imply	B-X
that	B-X
T	B-X
cells	B-X
need	B-X
to	B-X
maintain	B-X
a	B-X
certain	B-X
level	B-X
of	B-X
NF-kappaB	B-X
transcriptional	B-X
activity	B-X
in	B-X
order	B-X
to	B-X
survive	B-X
;	B-X
up-	B-X
or	B-X
down-regulation	B-X
of	B-X
nuclear	B-X
NF	B-X
kappaB	B-X
through	B-X
modulation	B-X
of	B-X
IkappaBalpha	B-X
expression	B-X
by	B-X
cytokines	B-X
or	B-X
DEX	B-X
may	B-X
lead	B-X
to	B-X
cell	B-X
survival	B-X
or	B-X
cell	B-X
death	B-X
,	B-X
respectively	B-X
.	B-X

In	O
both	O
cell	O
types	O
the	O
cellular	O
levels	O
of	O
IkappaBalpha	B-Protein
mRNA	O
and	O
protein	O
were	O
evaluated	O
by	O
DEX	O
treatment	O
.	O
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
anti-inflammatory	B-X
effects	B-X
and	B-X
mechanism	B-X
of	B-X
bergenin	B-X
in	B-X
TNF-α-stimulated	B-X
human	B-X
bronchial	B-X
epithelial	B-X
(	B-X
16-HBE	B-X
)	B-X
cells	B-X
.	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
,	B-X
a	B-X
synthetic	B-X
glucocorticoid	B-X
,	B-X
causes	B-X
apoptosis	B-X
in	B-X
mature	B-X
Th	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
that	B-X
this	B-X
induction	B-X
of	B-X
cell	B-X
death	B-X
is	B-X
prevented	B-X
by	B-X
specific	B-X
cytokines	B-X
,	B-X
namely	B-X
,	B-X
by	B-X
IL-2	B-X
in	B-X
Th1	B-X
cells	B-X
and	B-X
by	B-X
IL-4	B-X
in	B-X
Th2	B-X
cells	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
this	B-X
differential	B-X
rescue	B-X
by	B-X
specific	B-X
cytokines	B-X
in	B-X
Th	B-X
cells	B-X
correlates	B-X
with	B-X
the	B-X
level	B-X
of	B-X
IkappaBalpha	B-X
that	B-X
is	B-X
regulated	B-X
by	B-X
DEX	B-X
and	B-X
cytokines	B-X
.	B-X
In	B-X
both	B-X
cell	B-X
types	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
IkappaBalpha	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
evaluated	B-X
by	B-X
DEX	B-X
treatment	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
DEX-mediated	B-X
IkappaBalpha	B-X
induction	B-X
was	B-X
completely	B-X
inhibited	B-X
by	B-X
IL-2	B-X
,	B-X
but	B-X
not	B-X
IL-4	B-X
,	B-X
in	B-X
Th1	B-X
cells	B-X
,	B-X
while	B-X
the	B-X
reverse	B-X
profile	B-X
was	B-X
seen	B-X
in	B-X
Th2	B-X
cells	B-X
.	B-X
In	B-X
both	B-X
cell	B-X
types	B-X
,	B-X
the	B-X
cytokine	B-X
that	B-X
inhibits	B-X
the	B-X
induction	B-X
of	B-X
IkappaBalpha	B-X
by	B-X
DEX	B-X
,	B-X
also	B-X
rescues	B-X
these	B-X
cells	B-X
from	B-X
DEX-induced	B-X
apoptosis	B-X
,	B-X
although	B-X
the	B-X
rescue	B-X
cytokine	B-X
is	B-X
different	B-X
in	B-X
Th1	B-X
and	B-X
Th2	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
imply	B-X
that	B-X
T	B-X
cells	B-X
need	B-X
to	B-X
maintain	B-X
a	B-X
certain	B-X
level	B-X
of	B-X
NF-kappaB	B-X
transcriptional	B-X
activity	B-X
in	B-X
order	B-X
to	B-X
survive	B-X
;	B-X
up-	B-X
or	B-X
down-regulation	B-X
of	B-X
nuclear	B-X
NF	B-X
kappaB	B-X
through	B-X
modulation	B-X
of	B-X
IkappaBalpha	B-X
expression	B-X
by	B-X
cytokines	B-X
or	B-X
DEX	B-X
may	B-X
lead	B-X
to	B-X
cell	B-X
survival	B-X
or	B-X
cell	B-X
death	B-X
,	B-X
respectively	B-X
.	B-X

Interestingly	O
,	O
the	O
DEX	O
-	O
mediated	O
IkappaBalpha	B-Protein
induction	O
was	O
completely	O
inhibited	O
by	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
in	O
Th1	O
cells	O
,	O
while	O
the	O
reverse	O
profile	O
was	O
seen	O
in	O
Th2	O
cells	O
.	O

In	O
both	O
cell	O
types	O
,	O
the	O
cytokine	O
that	O
inhibits	O
the	O
induction	O
of	O
IkappaBalpha	B-Protein
by	O
DEX	O
,	O
also	O
rescues	O
these	O
cells	O
from	O
DEX	O
-	O
induced	O
apoptosis	O
,	O
although	O
the	O
rescue	O
cytokine	O
is	O
different	O
in	O
Th1	O
and	O
Th2	O
cells	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
reported	B-X
that	B-X
dexamethasone	B-X
(	B-X
DEX	B-X
)	B-X
,	B-X
a	B-X
synthetic	B-X
glucocorticoid	B-X
,	B-X
causes	B-X
apoptosis	B-X
in	B-X
mature	B-X
Th	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
that	B-X
this	B-X
induction	B-X
of	B-X
cell	B-X
death	B-X
is	B-X
prevented	B-X
by	B-X
specific	B-X
cytokines	B-X
,	B-X
namely	B-X
,	B-X
by	B-X
IL-2	B-X
in	B-X
Th1	B-X
cells	B-X
and	B-X
by	B-X
IL-4	B-X
in	B-X
Th2	B-X
cells	B-X
.	B-X
We	B-X
now	B-X
show	B-X
that	B-X
this	B-X
differential	B-X
rescue	B-X
by	B-X
specific	B-X
cytokines	B-X
in	B-X
Th	B-X
cells	B-X
correlates	B-X
with	B-X
the	B-X
level	B-X
of	B-X
IkappaBalpha	B-X
that	B-X
is	B-X
regulated	B-X
by	B-X
DEX	B-X
and	B-X
cytokines	B-X
.	B-X
In	B-X
both	B-X
cell	B-X
types	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
IkappaBalpha	B-X
mRNA	B-X
and	B-X
protein	B-X
were	B-X
evaluated	B-X
by	B-X
DEX	B-X
treatment	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
DEX-mediated	B-X
IkappaBalpha	B-X
induction	B-X
was	B-X
completely	B-X
inhibited	B-X
by	B-X
IL-2	B-X
,	B-X
but	B-X
not	B-X
IL-4	B-X
,	B-X
in	B-X
Th1	B-X
cells	B-X
,	B-X
while	B-X
the	B-X
reverse	B-X
profile	B-X
was	B-X
seen	B-X
in	B-X
Th2	B-X
cells	B-X
.	B-X
In	B-X
both	B-X
cell	B-X
types	B-X
,	B-X
the	B-X
cytokine	B-X
that	B-X
inhibits	B-X
the	B-X
induction	B-X
of	B-X
IkappaBalpha	B-X
by	B-X
DEX	B-X
,	B-X
also	B-X
rescues	B-X
these	B-X
cells	B-X
from	B-X
DEX-induced	B-X
apoptosis	B-X
,	B-X
although	B-X
the	B-X
rescue	B-X
cytokine	B-X
is	B-X
different	B-X
in	B-X
Th1	B-X
and	B-X
Th2	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
imply	B-X
that	B-X
T	B-X
cells	B-X
need	B-X
to	B-X
maintain	B-X
a	B-X
certain	B-X
level	B-X
of	B-X
NF-kappaB	B-X
transcriptional	B-X
activity	B-X
in	B-X
order	B-X
to	B-X
survive	B-X
;	B-X
up-	B-X
or	B-X
down-regulation	B-X
of	B-X
nuclear	B-X
NF	B-X
kappaB	B-X
through	B-X
modulation	B-X
of	B-X
IkappaBalpha	B-X
expression	B-X
by	B-X
cytokines	B-X
or	B-X
DEX	B-X
may	B-X
lead	B-X
to	B-X
cell	B-X
survival	B-X
or	B-X
cell	B-X
death	B-X
,	B-X
respectively	B-X
.	B-X

Our	O
results	O
imply	O
that	O
T	O
cells	O
need	O
to	O
maintain	O
a	O
certain	O
level	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
order	O
to	O
survive	O
;	O
up	O
-	O
or	O
down	O
-	O
regulation	O
of	O
nuclear	O
NF	O
kappaB	O
through	O
modulation	O
of	O
IkappaBalpha	B-Protein
expression	O
by	O
cytokines	O
or	O
DEX	O
may	O
lead	O
to	O
cell	O
survival	O
or	O
cell	O
death	O
,	O
respectively	O
.	O

Xenogeneic	O
human	O
serum	O
promotes	O
leukocyte	O
adhesion	O
to	O
porcine	O
endothelium	O
under	O
flow	O
conditions	O
,	O
possibly	O
through	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
activation	B-X
and	B-X
leukocyte	B-X
infiltration	B-X
are	B-X
a	B-X
consistent	B-X
feature	B-X
of	B-X
discordant	B-X
xenograft	B-X
rejection	B-X
.	B-X
Here	B-X
we	B-X
evaluated	B-X
whether	B-X
xenogeneic	B-X
serum	B-X
,	B-X
as	B-X
a	B-X
source	B-X
of	B-X
xenoreactive	B-X
natural	B-X
antibodies	B-X
and	B-X
complement	B-X
,	B-X
induced	B-X
endothelial	B-X
cell	B-X
activation	B-X
with	B-X
consequent	B-X
leukocyte	B-X
adhesion	B-X
under	B-X
flow	B-X
conditions	B-X
.	B-X
Porcine	B-X
aortic	B-X
endothelial	B-X
cells	B-X
(	B-X
PAEC	B-X
)	B-X
were	B-X
incubated	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
or	B-X
5	B-X
hr	B-X
with	B-X
10	B-X
%	B-X
homologous	B-X
porcine	B-X
serum	B-X
(	B-X
control	B-X
)	B-X
or	B-X
10	B-X
%	B-X
xenogeneic	B-X
human	B-X
serum	B-X
and	B-X
then	B-X
perfused	B-X
with	B-X
total	B-X
human	B-X
leukocytes	B-X
in	B-X
a	B-X
parallel	B-X
plate	B-X
flow	B-X
chamber	B-X
under	B-X
laminar	B-X
flow	B-X
(	B-X
1.5	B-X
dynes/cm2	B-X
)	B-X
.	B-X
Xenogeneic	B-X
human	B-X
serum	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
as	B-X
compared	B-X
with	B-X
porcine	B-X
serum	B-X
.	B-X
A	B-X
similar	B-X
adhesive	B-X
response	B-X
was	B-X
elicited	B-X
by	B-X
TNF	B-X
alpha	B-X
(	B-X
100	B-X
U/ml	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
inducers	B-X
of	B-X
endothelial	B-X
cell	B-X
adhesive	B-X
properties	B-X
,	B-X
here	B-X
used	B-X
as	B-X
positive	B-X
control	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
possible	B-X
mechanisms	B-X
underlying	B-X
endothelial	B-X
cell	B-X
activation	B-X
by	B-X
xenogeneic	B-X
serum	B-X
,	B-X
we	B-X
focussed	B-X
on	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
a	B-X
central	B-X
regulator	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
different	B-X
genes	B-X
,	B-X
including	B-X
adhesive	B-X
molecules	B-X
and	B-X
chemoattractants	B-X
.	B-X
By	B-X
confocal	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
positive	B-X
staining	B-X
for	B-X
NF-kappa	B-X
B	B-X
(	B-X
p65	B-X
subunit	B-X
)	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
PAEC	B-X
exposed	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
to	B-X
human	B-X
serum	B-X
,	B-X
which	B-X
indicated	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
this	B-X
setting	B-X
.	B-X
At	B-X
variance	B-X
,	B-X
in	B-X
PAEC	B-X
incubated	B-X
with	B-X
the	B-X
homologous	B-X
serum	B-X
,	B-X
NF-kappa	B-X
B	B-X
was	B-X
strictly	B-X
localized	B-X
in	B-X
the	B-X
cell	B-X
cytoplasm	B-X
.	B-X
Treatment	B-X
of	B-X
PAEC	B-X
exposed	B-X
to	B-X
xenogeneic	B-X
serum	B-X
with	B-X
the	B-X
NF-kappa	B-X
B	B-X
inhibitors	B-X
pyrrolidinedithiocarbamate	B-X
(	B-X
PDTC	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
and	B-X
tosyl-phechloromethylketone	B-X
(	B-X
TPCK	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
reduced	B-X
leukocyte	B-X
adhesion	B-X
in	B-X
respect	B-X
to	B-X
PAEC	B-X
treated	B-X
with	B-X
human	B-X
serum	B-X
alone	B-X
.	B-X
Findings	B-X
that	B-X
xenogeneic	B-X
serum	B-X
promotes	B-X
leukocyte-endothelium	B-X
interaction	B-X
possibly	B-X
through	B-X
NF-kappa	B-X
B	B-X
activation	B-X
might	B-X
be	B-X
relevant	B-X
for	B-X
designing	B-X
future	B-X
therapeutic	B-X
strategies	B-X
aimed	B-X
at	B-X
prolonging	B-X
xenograft	B-X
survival	B-X
.	B-X

Endothelial	O
cell	O
activation	O
and	O
leukocyte	O
infiltration	O
are	O
a	O
consistent	O
feature	O
of	O
discordant	O
xenograft	O
rejection	O
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
is	B-X
a	B-X
consistent	B-X
feature	B-X
of	B-X
discordant	B-X
xenograft	B-X
rejection	B-X
.	B-X
Treatment	B-X
of	B-X
xenograft	B-X
recipients	B-X
with	B-X
complement	B-X
inhibitors	B-X
and	B-X
xenoreactive	B-X
natural	B-X
antibody	B-X
depletion	B-X
leads	B-X
to	B-X
delayed	B-X
xenograft	B-X
rejection	B-X
associated	B-X
with	B-X
a	B-X
cellular	B-X
infiltrate	B-X
comprising	B-X
up	B-X
to	B-X
20	B-X
%	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
importance	B-X
of	B-X
NK	B-X
cells	B-X
in	B-X
xenograft	B-X
rejection	B-X
,	B-X
we	B-X
studied	B-X
EC	B-X
activation	B-X
and	B-X
cytotoxicity	B-X
in	B-X
co-cultures	B-X
containing	B-X
human	B-X
NK	B-X
cells	B-X
and	B-X
porcine	B-X
EC	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
freshly	B-X
isolated	B-X
NK	B-X
cells	B-X
to	B-X
porcine	B-X
EC	B-X
resulted	B-X
in	B-X
EC	B-X
cell	B-X
activation	B-X
,	B-X
characterized	B-X
by	B-X
the	B-X
induction	B-X
of	B-X
mRNA	B-X
and	B-X
protein	B-X
for	B-X
the	B-X
adhesion	B-X
molecule	B-X
E-selectin	B-X
and	B-X
the	B-X
chemotactic	B-X
cytokine	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-8	B-X
.	B-X
The	B-X
induction	B-X
of	B-X
E-selectin	B-X
and	B-X
IL-8	B-X
occurred	B-X
with	B-X
three	B-X
separate	B-X
sources	B-X
of	B-X
NK	B-X
cells	B-X
:	B-X
purified	B-X
CD56+ve	B-X
cells	B-X
,	B-X
the	B-X
NK	B-X
cell	B-X
clone	B-X
B22	B-X
,	B-X
and	B-X
the	B-X
Fc	B-X
receptor-deficient	B-X
NK	B-X
cell	B-X
line	B-X
NK92	B-X
.	B-X
These	B-X
effects	B-X
could	B-X
not	B-X
be	B-X
inhibited	B-X
with	B-X
human	B-X
recombinant	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
receptor	B-X
,	B-X
and	B-X
the	B-X
transfer	B-X
of	B-X
supernatants	B-X
or	B-X
cell	B-X
lysates	B-X
from	B-X
activated	B-X
EC	B-X
to	B-X
secondary	B-X
cultures	B-X
did	B-X
not	B-X
result	B-X
in	B-X
EC	B-X
activation	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
human	B-X
IgG	B-X
enhanced	B-X
the	B-X
level	B-X
of	B-X
E-selectin	B-X
expression	B-X
and	B-X
cellular	B-X
cytotoxicity	B-X
,	B-X
and	B-X
resulted	B-X
in	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
and	B-X
interferon-gamma	B-X
secretion	B-X
.	B-X
Thus	B-X
,	B-X
human	B-X
NK	B-X
cells	B-X
can	B-X
lyse	B-X
or	B-X
activate	B-X
EC	B-X
by	B-X
direct	B-X
cell	B-X
contact	B-X
and	B-X
the	B-X
addition	B-X
of	B-X
IgG	B-X
enhances	B-X
EC	B-X
activation	B-X
and	B-X
NK	B-X
cell	B-X
cytokine	B-X
secretion	B-X
.	B-X
These	B-X
findings	B-X
implicate	B-X
NK	B-X
cells	B-X
in	B-X
EC	B-X
activation	B-X
and	B-X
cell-mediated	B-X
xenograft	B-X
rejection	B-X
.	B-X

Here	O
we	O
evaluated	O
whether	O
xenogeneic	O
serum	O
,	O
as	O
a	O
source	O
of	O
xenoreactive	O
natural	O
antibodies	O
and	O
complement	O
,	O
induced	O
endothelial	O
cell	O
activation	O
with	O
consequent	O
leukocyte	O
adhesion	O
under	O
flow	O
conditions	O
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
activation	B-X
and	B-X
leukocyte	B-X
infiltration	B-X
are	B-X
a	B-X
consistent	B-X
feature	B-X
of	B-X
discordant	B-X
xenograft	B-X
rejection	B-X
.	B-X
Here	B-X
we	B-X
evaluated	B-X
whether	B-X
xenogeneic	B-X
serum	B-X
,	B-X
as	B-X
a	B-X
source	B-X
of	B-X
xenoreactive	B-X
natural	B-X
antibodies	B-X
and	B-X
complement	B-X
,	B-X
induced	B-X
endothelial	B-X
cell	B-X
activation	B-X
with	B-X
consequent	B-X
leukocyte	B-X
adhesion	B-X
under	B-X
flow	B-X
conditions	B-X
.	B-X
Porcine	B-X
aortic	B-X
endothelial	B-X
cells	B-X
(	B-X
PAEC	B-X
)	B-X
were	B-X
incubated	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
or	B-X
5	B-X
hr	B-X
with	B-X
10	B-X
%	B-X
homologous	B-X
porcine	B-X
serum	B-X
(	B-X
control	B-X
)	B-X
or	B-X
10	B-X
%	B-X
xenogeneic	B-X
human	B-X
serum	B-X
and	B-X
then	B-X
perfused	B-X
with	B-X
total	B-X
human	B-X
leukocytes	B-X
in	B-X
a	B-X
parallel	B-X
plate	B-X
flow	B-X
chamber	B-X
under	B-X
laminar	B-X
flow	B-X
(	B-X
1.5	B-X
dynes/cm2	B-X
)	B-X
.	B-X
Adherent	B-X
cells	B-X
were	B-X
counted	B-X
by	B-X
digital	B-X
image	B-X
analysis	B-X
.	B-X
Xenogeneic	B-X
human	B-X
serum	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
as	B-X
compared	B-X
with	B-X
porcine	B-X
serum	B-X
.	B-X
A	B-X
similar	B-X
adhesive	B-X
response	B-X
was	B-X
elicited	B-X
by	B-X
TNF	B-X
alpha	B-X
(	B-X
100	B-X
U/ml	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
inducers	B-X
of	B-X
endothelial	B-X
cell	B-X
adhesive	B-X
properties	B-X
,	B-X
here	B-X
used	B-X
as	B-X
positive	B-X
control	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
possible	B-X
mechanisms	B-X
underlying	B-X
endothelial	B-X
cell	B-X
activation	B-X
by	B-X
xenogeneic	B-X
serum	B-X
,	B-X
we	B-X
focussed	B-X
on	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
a	B-X
central	B-X
regulator	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
different	B-X
genes	B-X
,	B-X
including	B-X
adhesive	B-X
molecules	B-X
and	B-X
chemoattractants	B-X
.	B-X
By	B-X
confocal	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
positive	B-X
staining	B-X
for	B-X
NF-kappa	B-X
B	B-X
(	B-X
p65	B-X
subunit	B-X
)	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
PAEC	B-X
exposed	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
to	B-X
human	B-X
serum	B-X
,	B-X
which	B-X
indicated	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
this	B-X
setting	B-X
.	B-X
At	B-X
variance	B-X
,	B-X
in	B-X
PAEC	B-X
incubated	B-X
with	B-X
the	B-X
homologous	B-X
serum	B-X
,	B-X
NF-kappa	B-X
B	B-X
was	B-X
strictly	B-X
localized	B-X
in	B-X
the	B-X
cell	B-X
cytoplasm	B-X
.	B-X
Treatment	B-X
of	B-X
PAEC	B-X
exposed	B-X
to	B-X
xenogeneic	B-X
serum	B-X
with	B-X
the	B-X
NF-kappa	B-X
B	B-X
inhibitors	B-X
pyrrolidinedithiocarbamate	B-X
(	B-X
PDTC	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
and	B-X
tosyl-phechloromethylketone	B-X
(	B-X
TPCK	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
reduced	B-X
leukocyte	B-X
adhesion	B-X
in	B-X
respect	B-X
to	B-X
PAEC	B-X
treated	B-X
with	B-X
human	B-X
serum	B-X
alone	B-X
.	B-X
Findings	B-X
that	B-X
xenogeneic	B-X
serum	B-X
promotes	B-X
leukocyte-endothelium	B-X
interaction	B-X
possibly	B-X
through	B-X
NF-kappa	B-X
B	B-X
activation	B-X
might	B-X
be	B-X
relevant	B-X
for	B-X
designing	B-X
future	B-X
therapeutic	B-X
strategies	B-X
aimed	B-X
at	B-X
prolonging	B-X
xenograft	B-X
survival	B-X
.	B-X

Porcine	O
aortic	O
endothelial	O
cells	O
(	O
PAEC	O
)	O
were	O
incubated	O
for	O
1	O
hr	O
30	O
min	O
or	O
5	O
hr	O
with	O
10	O
%	O
homologous	O
porcine	O
serum	O
(	O
control	O
)	O
or	O
10	O
%	O
xenogeneic	O
human	O
serum	O
and	O
then	O
perfused	O
with	O
total	O
human	O
leukocytes	O
in	O
a	O
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
1	O
.	O
5	O
dynes	O
/	O
cm2	O
)	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
evaluated	B-X
whether	B-X
xenogeneic	B-X
serum	B-X
,	B-X
as	B-X
a	B-X
source	B-X
of	B-X
xenoreactive	B-X
natural	B-X
antibodies	B-X
and	B-X
complement	B-X
,	B-X
induced	B-X
endothelial	B-X
cell	B-X
activation	B-X
with	B-X
consequent	B-X
leukocyte	B-X
adhesion	B-X
under	B-X
flow	B-X
conditions	B-X
.	B-X
Porcine	B-X
aortic	B-X
endothelial	B-X
cells	B-X
(	B-X
PAEC	B-X
)	B-X
were	B-X
incubated	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
or	B-X
5	B-X
hr	B-X
with	B-X
10	B-X
%	B-X
homologous	B-X
porcine	B-X
serum	B-X
(	B-X
control	B-X
)	B-X
or	B-X
10	B-X
%	B-X
xenogeneic	B-X
human	B-X
serum	B-X
and	B-X
then	B-X
perfused	B-X
with	B-X
total	B-X
human	B-X
leukocytes	B-X
in	B-X
a	B-X
parallel	B-X
plate	B-X
flow	B-X
chamber	B-X
under	B-X
laminar	B-X
flow	B-X
(	B-X
1.5	B-X
dynes/cm2	B-X
)	B-X
.	B-X
Adherent	B-X
cells	B-X
were	B-X
counted	B-X
by	B-X
digital	B-X
image	B-X
analysis	B-X
.	B-X
Xenogeneic	B-X
human	B-X
serum	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
as	B-X
compared	B-X
with	B-X
porcine	B-X
serum	B-X
.	B-X
A	B-X
similar	B-X
adhesive	B-X
response	B-X
was	B-X
elicited	B-X
by	B-X
TNF	B-X
alpha	B-X
(	B-X
100	B-X
U/ml	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
inducers	B-X
of	B-X
endothelial	B-X
cell	B-X
adhesive	B-X
properties	B-X
,	B-X
here	B-X
used	B-X
as	B-X
positive	B-X
control	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
possible	B-X
mechanisms	B-X
underlying	B-X
endothelial	B-X
cell	B-X
activation	B-X
by	B-X
xenogeneic	B-X
serum	B-X
,	B-X
we	B-X
focussed	B-X
on	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
a	B-X
central	B-X
regulator	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
different	B-X
genes	B-X
,	B-X
including	B-X
adhesive	B-X
molecules	B-X
and	B-X
chemoattractants	B-X
.	B-X
By	B-X
confocal	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
positive	B-X
staining	B-X
for	B-X
NF-kappa	B-X
B	B-X
(	B-X
p65	B-X
subunit	B-X
)	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
PAEC	B-X
exposed	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
to	B-X
human	B-X
serum	B-X
,	B-X
which	B-X
indicated	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
this	B-X
setting	B-X
.	B-X
At	B-X
variance	B-X
,	B-X
in	B-X
PAEC	B-X
incubated	B-X
with	B-X
the	B-X
homologous	B-X
serum	B-X
,	B-X
NF-kappa	B-X
B	B-X
was	B-X
strictly	B-X
localized	B-X
in	B-X
the	B-X
cell	B-X
cytoplasm	B-X
.	B-X
Treatment	B-X
of	B-X
PAEC	B-X
exposed	B-X
to	B-X
xenogeneic	B-X
serum	B-X
with	B-X
the	B-X
NF-kappa	B-X
B	B-X
inhibitors	B-X
pyrrolidinedithiocarbamate	B-X
(	B-X
PDTC	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
and	B-X
tosyl-phechloromethylketone	B-X
(	B-X
TPCK	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
reduced	B-X
leukocyte	B-X
adhesion	B-X
in	B-X
respect	B-X
to	B-X
PAEC	B-X
treated	B-X
with	B-X
human	B-X
serum	B-X
alone	B-X
.	B-X
Findings	B-X
that	B-X
xenogeneic	B-X
serum	B-X
promotes	B-X
leukocyte-endothelium	B-X
interaction	B-X
possibly	B-X
through	B-X
NF-kappa	B-X
B	B-X
activation	B-X
might	B-X
be	B-X
relevant	B-X
for	B-X
designing	B-X
future	B-X
therapeutic	B-X
strategies	B-X
aimed	B-X
at	B-X
prolonging	B-X
xenograft	B-X
survival	B-X
.	B-X

Adherent	O
cells	O
were	O
counted	O
by	O
digital	O
image	O
analysis	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
use	B-X
a	B-X
technique	B-X
that	B-X
utilizes	B-X
digital	B-X
holography	B-X
,	B-X
allowing	B-X
label-free	B-X
and	B-X
completely	B-X
non-invasive	B-X
cell	B-X
counting	B-X
directly	B-X
in	B-X
cell	B-X
culture	B-X
vessels	B-X
with	B-X
adherent	B-X
viable	B-X
cells	B-X
.	B-X
The	B-X
images	B-X
produced	B-X
can	B-X
provide	B-X
both	B-X
quantitative	B-X
and	B-X
qualitative	B-X
phase	B-X
information	B-X
from	B-X
a	B-X
single	B-X
hologram	B-X
.	B-X
The	B-X
recently	B-X
constructed	B-X
microscope	B-X
Holomonitor	B-X
(	B-X
Phase	B-X
Holographic	B-X
Imaging	B-X
AB	B-X
,	B-X
Lund	B-X
,	B-X
Sweden	B-X
)	B-X
combines	B-X
the	B-X
commonly	B-X
used	B-X
phase	B-X
contrast	B-X
microscope	B-X
with	B-X
digital	B-X
holography	B-X
,	B-X
the	B-X
latter	B-X
giving	B-X
us	B-X
the	B-X
possibility	B-X
of	B-X
achieving	B-X
quantitative	B-X
information	B-X
on	B-X
cellular	B-X
shape	B-X
,	B-X
area	B-X
,	B-X
confluence	B-X
and	B-X
optical	B-X
thickness	B-X
.	B-X
This	B-X
project	B-X
aimed	B-X
at	B-X
determining	B-X
the	B-X
accuracy	B-X
and	B-X
repeatability	B-X
of	B-X
cell	B-X
counting	B-X
measurements	B-X
using	B-X
digital	B-X
holography	B-X
compared	B-X
to	B-X
the	B-X
conventional	B-X
manual	B-X
cell	B-X
counting	B-X
method	B-X
using	B-X
a	B-X
haemocytometer	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
digital	B-X
holography	B-X
can	B-X
be	B-X
used	B-X
for	B-X
non-invasive	B-X
automatic	B-X
cell	B-X
counting	B-X
as	B-X
precisely	B-X
as	B-X
conventional	B-X
manual	B-X
cell	B-X
counting	B-X
.	B-X

Xenogeneic	O
human	O
serum	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
increased	O
the	O
number	O
of	O
adherent	O
leukocytes	O
as	O
compared	O
with	O
porcine	O
serum	O
.	O

A	O
similar	O
adhesive	O
response	O
was	O
elicited	O
by	O
TNF	O
alpha	O
(	O
100	O
U	O
/	O
ml	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
inducers	O
of	O
endothelial	O
cell	O
adhesive	O
properties	O
,	O
here	O
used	O
as	O
positive	O
control	O
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
activation	B-X
and	B-X
leukocyte	B-X
infiltration	B-X
are	B-X
a	B-X
consistent	B-X
feature	B-X
of	B-X
discordant	B-X
xenograft	B-X
rejection	B-X
.	B-X
Here	B-X
we	B-X
evaluated	B-X
whether	B-X
xenogeneic	B-X
serum	B-X
,	B-X
as	B-X
a	B-X
source	B-X
of	B-X
xenoreactive	B-X
natural	B-X
antibodies	B-X
and	B-X
complement	B-X
,	B-X
induced	B-X
endothelial	B-X
cell	B-X
activation	B-X
with	B-X
consequent	B-X
leukocyte	B-X
adhesion	B-X
under	B-X
flow	B-X
conditions	B-X
.	B-X
Porcine	B-X
aortic	B-X
endothelial	B-X
cells	B-X
(	B-X
PAEC	B-X
)	B-X
were	B-X
incubated	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
or	B-X
5	B-X
hr	B-X
with	B-X
10	B-X
%	B-X
homologous	B-X
porcine	B-X
serum	B-X
(	B-X
control	B-X
)	B-X
or	B-X
10	B-X
%	B-X
xenogeneic	B-X
human	B-X
serum	B-X
and	B-X
then	B-X
perfused	B-X
with	B-X
total	B-X
human	B-X
leukocytes	B-X
in	B-X
a	B-X
parallel	B-X
plate	B-X
flow	B-X
chamber	B-X
under	B-X
laminar	B-X
flow	B-X
(	B-X
1.5	B-X
dynes/cm2	B-X
)	B-X
.	B-X
Adherent	B-X
cells	B-X
were	B-X
counted	B-X
by	B-X
digital	B-X
image	B-X
analysis	B-X
.	B-X
A	B-X
similar	B-X
adhesive	B-X
response	B-X
was	B-X
elicited	B-X
by	B-X
TNF	B-X
alpha	B-X
(	B-X
100	B-X
U/ml	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
inducers	B-X
of	B-X
endothelial	B-X
cell	B-X
adhesive	B-X
properties	B-X
,	B-X
here	B-X
used	B-X
as	B-X
positive	B-X
control	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
possible	B-X
mechanisms	B-X
underlying	B-X
endothelial	B-X
cell	B-X
activation	B-X
by	B-X
xenogeneic	B-X
serum	B-X
,	B-X
we	B-X
focussed	B-X
on	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
a	B-X
central	B-X
regulator	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
different	B-X
genes	B-X
,	B-X
including	B-X
adhesive	B-X
molecules	B-X
and	B-X
chemoattractants	B-X
.	B-X
By	B-X
confocal	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
positive	B-X
staining	B-X
for	B-X
NF-kappa	B-X
B	B-X
(	B-X
p65	B-X
subunit	B-X
)	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
PAEC	B-X
exposed	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
to	B-X
human	B-X
serum	B-X
,	B-X
which	B-X
indicated	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
this	B-X
setting	B-X
.	B-X
At	B-X
variance	B-X
,	B-X
in	B-X
PAEC	B-X
incubated	B-X
with	B-X
the	B-X
homologous	B-X
serum	B-X
,	B-X
NF-kappa	B-X
B	B-X
was	B-X
strictly	B-X
localized	B-X
in	B-X
the	B-X
cell	B-X
cytoplasm	B-X
.	B-X
Treatment	B-X
of	B-X
PAEC	B-X
exposed	B-X
to	B-X
xenogeneic	B-X
serum	B-X
with	B-X
the	B-X
NF-kappa	B-X
B	B-X
inhibitors	B-X
pyrrolidinedithiocarbamate	B-X
(	B-X
PDTC	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
and	B-X
tosyl-phechloromethylketone	B-X
(	B-X
TPCK	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
reduced	B-X
leukocyte	B-X
adhesion	B-X
in	B-X
respect	B-X
to	B-X
PAEC	B-X
treated	B-X
with	B-X
human	B-X
serum	B-X
alone	B-X
.	B-X

In	O
order	O
to	O
elucidate	O
possible	O
mechanisms	O
underlying	O
endothelial	O
cell	O
activation	O
by	O
xenogeneic	O
serum	O
,	O
we	O
focussed	O
on	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
a	O
central	O
regulator	O
for	O
the	O
induction	O
of	O
different	O
genes	O
,	O
including	O
adhesive	O
molecules	O
and	O
chemoattractants	O
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
activation	B-X
and	B-X
leukocyte	B-X
infiltration	B-X
are	B-X
a	B-X
consistent	B-X
feature	B-X
of	B-X
discordant	B-X
xenograft	B-X
rejection	B-X
.	B-X
Here	B-X
we	B-X
evaluated	B-X
whether	B-X
xenogeneic	B-X
serum	B-X
,	B-X
as	B-X
a	B-X
source	B-X
of	B-X
xenoreactive	B-X
natural	B-X
antibodies	B-X
and	B-X
complement	B-X
,	B-X
induced	B-X
endothelial	B-X
cell	B-X
activation	B-X
with	B-X
consequent	B-X
leukocyte	B-X
adhesion	B-X
under	B-X
flow	B-X
conditions	B-X
.	B-X
Porcine	B-X
aortic	B-X
endothelial	B-X
cells	B-X
(	B-X
PAEC	B-X
)	B-X
were	B-X
incubated	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
or	B-X
5	B-X
hr	B-X
with	B-X
10	B-X
%	B-X
homologous	B-X
porcine	B-X
serum	B-X
(	B-X
control	B-X
)	B-X
or	B-X
10	B-X
%	B-X
xenogeneic	B-X
human	B-X
serum	B-X
and	B-X
then	B-X
perfused	B-X
with	B-X
total	B-X
human	B-X
leukocytes	B-X
in	B-X
a	B-X
parallel	B-X
plate	B-X
flow	B-X
chamber	B-X
under	B-X
laminar	B-X
flow	B-X
(	B-X
1.5	B-X
dynes/cm2	B-X
)	B-X
.	B-X
Adherent	B-X
cells	B-X
were	B-X
counted	B-X
by	B-X
digital	B-X
image	B-X
analysis	B-X
.	B-X
Xenogeneic	B-X
human	B-X
serum	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
as	B-X
compared	B-X
with	B-X
porcine	B-X
serum	B-X
.	B-X
A	B-X
similar	B-X
adhesive	B-X
response	B-X
was	B-X
elicited	B-X
by	B-X
TNF	B-X
alpha	B-X
(	B-X
100	B-X
U/ml	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
inducers	B-X
of	B-X
endothelial	B-X
cell	B-X
adhesive	B-X
properties	B-X
,	B-X
here	B-X
used	B-X
as	B-X
positive	B-X
control	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
possible	B-X
mechanisms	B-X
underlying	B-X
endothelial	B-X
cell	B-X
activation	B-X
by	B-X
xenogeneic	B-X
serum	B-X
,	B-X
we	B-X
focussed	B-X
on	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
a	B-X
central	B-X
regulator	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
different	B-X
genes	B-X
,	B-X
including	B-X
adhesive	B-X
molecules	B-X
and	B-X
chemoattractants	B-X
.	B-X
By	B-X
confocal	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
positive	B-X
staining	B-X
for	B-X
NF-kappa	B-X
B	B-X
(	B-X
p65	B-X
subunit	B-X
)	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
PAEC	B-X
exposed	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
to	B-X
human	B-X
serum	B-X
,	B-X
which	B-X
indicated	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
this	B-X
setting	B-X
.	B-X
At	B-X
variance	B-X
,	B-X
in	B-X
PAEC	B-X
incubated	B-X
with	B-X
the	B-X
homologous	B-X
serum	B-X
,	B-X
NF-kappa	B-X
B	B-X
was	B-X
strictly	B-X
localized	B-X
in	B-X
the	B-X
cell	B-X
cytoplasm	B-X
.	B-X
Treatment	B-X
of	B-X
PAEC	B-X
exposed	B-X
to	B-X
xenogeneic	B-X
serum	B-X
with	B-X
the	B-X
NF-kappa	B-X
B	B-X
inhibitors	B-X
pyrrolidinedithiocarbamate	B-X
(	B-X
PDTC	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
and	B-X
tosyl-phechloromethylketone	B-X
(	B-X
TPCK	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
reduced	B-X
leukocyte	B-X
adhesion	B-X
in	B-X
respect	B-X
to	B-X
PAEC	B-X
treated	B-X
with	B-X
human	B-X
serum	B-X
alone	B-X
.	B-X
Findings	B-X
that	B-X
xenogeneic	B-X
serum	B-X
promotes	B-X
leukocyte-endothelium	B-X
interaction	B-X
possibly	B-X
through	B-X
NF-kappa	B-X
B	B-X
activation	B-X
might	B-X
be	B-X
relevant	B-X
for	B-X
designing	B-X
future	B-X
therapeutic	B-X
strategies	B-X
aimed	B-X
at	B-X
prolonging	B-X
xenograft	B-X
survival	B-X
.	B-X

By	O
confocal	O
fluorescence	O
microscopy	O
,	O
we	O
observed	O
a	O
positive	O
staining	O
for	O
NF	O
-	O
kappa	O
B	O
(	O
p65	B-Protein
subunit	O
)	O
in	O
the	O
nuclei	O
of	O
PAEC	O
exposed	O
for	O
1	O
hr	O
30	O
min	O
to	O
human	O
serum	O
,	O
which	O
indicated	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
this	O
setting	O
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
activation	B-X
and	B-X
leukocyte	B-X
infiltration	B-X
are	B-X
a	B-X
consistent	B-X
feature	B-X
of	B-X
discordant	B-X
xenograft	B-X
rejection	B-X
.	B-X
Here	B-X
we	B-X
evaluated	B-X
whether	B-X
xenogeneic	B-X
serum	B-X
,	B-X
as	B-X
a	B-X
source	B-X
of	B-X
xenoreactive	B-X
natural	B-X
antibodies	B-X
and	B-X
complement	B-X
,	B-X
induced	B-X
endothelial	B-X
cell	B-X
activation	B-X
with	B-X
consequent	B-X
leukocyte	B-X
adhesion	B-X
under	B-X
flow	B-X
conditions	B-X
.	B-X
Porcine	B-X
aortic	B-X
endothelial	B-X
cells	B-X
(	B-X
PAEC	B-X
)	B-X
were	B-X
incubated	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
or	B-X
5	B-X
hr	B-X
with	B-X
10	B-X
%	B-X
homologous	B-X
porcine	B-X
serum	B-X
(	B-X
control	B-X
)	B-X
or	B-X
10	B-X
%	B-X
xenogeneic	B-X
human	B-X
serum	B-X
and	B-X
then	B-X
perfused	B-X
with	B-X
total	B-X
human	B-X
leukocytes	B-X
in	B-X
a	B-X
parallel	B-X
plate	B-X
flow	B-X
chamber	B-X
under	B-X
laminar	B-X
flow	B-X
(	B-X
1.5	B-X
dynes/cm2	B-X
)	B-X
.	B-X
Xenogeneic	B-X
human	B-X
serum	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
as	B-X
compared	B-X
with	B-X
porcine	B-X
serum	B-X
.	B-X
A	B-X
similar	B-X
adhesive	B-X
response	B-X
was	B-X
elicited	B-X
by	B-X
TNF	B-X
alpha	B-X
(	B-X
100	B-X
U/ml	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
inducers	B-X
of	B-X
endothelial	B-X
cell	B-X
adhesive	B-X
properties	B-X
,	B-X
here	B-X
used	B-X
as	B-X
positive	B-X
control	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
possible	B-X
mechanisms	B-X
underlying	B-X
endothelial	B-X
cell	B-X
activation	B-X
by	B-X
xenogeneic	B-X
serum	B-X
,	B-X
we	B-X
focussed	B-X
on	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
a	B-X
central	B-X
regulator	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
different	B-X
genes	B-X
,	B-X
including	B-X
adhesive	B-X
molecules	B-X
and	B-X
chemoattractants	B-X
.	B-X
By	B-X
confocal	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
positive	B-X
staining	B-X
for	B-X
NF-kappa	B-X
B	B-X
(	B-X
p65	B-X
subunit	B-X
)	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
PAEC	B-X
exposed	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
to	B-X
human	B-X
serum	B-X
,	B-X
which	B-X
indicated	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
this	B-X
setting	B-X
.	B-X
At	B-X
variance	B-X
,	B-X
in	B-X
PAEC	B-X
incubated	B-X
with	B-X
the	B-X
homologous	B-X
serum	B-X
,	B-X
NF-kappa	B-X
B	B-X
was	B-X
strictly	B-X
localized	B-X
in	B-X
the	B-X
cell	B-X
cytoplasm	B-X
.	B-X
Treatment	B-X
of	B-X
PAEC	B-X
exposed	B-X
to	B-X
xenogeneic	B-X
serum	B-X
with	B-X
the	B-X
NF-kappa	B-X
B	B-X
inhibitors	B-X
pyrrolidinedithiocarbamate	B-X
(	B-X
PDTC	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
and	B-X
tosyl-phechloromethylketone	B-X
(	B-X
TPCK	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
reduced	B-X
leukocyte	B-X
adhesion	B-X
in	B-X
respect	B-X
to	B-X
PAEC	B-X
treated	B-X
with	B-X
human	B-X
serum	B-X
alone	B-X
.	B-X
Findings	B-X
that	B-X
xenogeneic	B-X
serum	B-X
promotes	B-X
leukocyte-endothelium	B-X
interaction	B-X
possibly	B-X
through	B-X
NF-kappa	B-X
B	B-X
activation	B-X
might	B-X
be	B-X
relevant	B-X
for	B-X
designing	B-X
future	B-X
therapeutic	B-X
strategies	B-X
aimed	B-X
at	B-X
prolonging	B-X
xenograft	B-X
survival	B-X
.	B-X

At	O
variance	O
,	O
in	O
PAEC	O
incubated	O
with	O
the	O
homologous	O
serum	O
,	O
NF	O
-	O
kappa	O
B	O
was	O
strictly	O
localized	O
in	O
the	O
cell	O
cytoplasm	O
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
activation	B-X
and	B-X
leukocyte	B-X
infiltration	B-X
are	B-X
a	B-X
consistent	B-X
feature	B-X
of	B-X
discordant	B-X
xenograft	B-X
rejection	B-X
.	B-X
Here	B-X
we	B-X
evaluated	B-X
whether	B-X
xenogeneic	B-X
serum	B-X
,	B-X
as	B-X
a	B-X
source	B-X
of	B-X
xenoreactive	B-X
natural	B-X
antibodies	B-X
and	B-X
complement	B-X
,	B-X
induced	B-X
endothelial	B-X
cell	B-X
activation	B-X
with	B-X
consequent	B-X
leukocyte	B-X
adhesion	B-X
under	B-X
flow	B-X
conditions	B-X
.	B-X
Porcine	B-X
aortic	B-X
endothelial	B-X
cells	B-X
(	B-X
PAEC	B-X
)	B-X
were	B-X
incubated	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
or	B-X
5	B-X
hr	B-X
with	B-X
10	B-X
%	B-X
homologous	B-X
porcine	B-X
serum	B-X
(	B-X
control	B-X
)	B-X
or	B-X
10	B-X
%	B-X
xenogeneic	B-X
human	B-X
serum	B-X
and	B-X
then	B-X
perfused	B-X
with	B-X
total	B-X
human	B-X
leukocytes	B-X
in	B-X
a	B-X
parallel	B-X
plate	B-X
flow	B-X
chamber	B-X
under	B-X
laminar	B-X
flow	B-X
(	B-X
1.5	B-X
dynes/cm2	B-X
)	B-X
.	B-X
Adherent	B-X
cells	B-X
were	B-X
counted	B-X
by	B-X
digital	B-X
image	B-X
analysis	B-X
.	B-X
Xenogeneic	B-X
human	B-X
serum	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
as	B-X
compared	B-X
with	B-X
porcine	B-X
serum	B-X
.	B-X
A	B-X
similar	B-X
adhesive	B-X
response	B-X
was	B-X
elicited	B-X
by	B-X
TNF	B-X
alpha	B-X
(	B-X
100	B-X
U/ml	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
inducers	B-X
of	B-X
endothelial	B-X
cell	B-X
adhesive	B-X
properties	B-X
,	B-X
here	B-X
used	B-X
as	B-X
positive	B-X
control	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
possible	B-X
mechanisms	B-X
underlying	B-X
endothelial	B-X
cell	B-X
activation	B-X
by	B-X
xenogeneic	B-X
serum	B-X
,	B-X
we	B-X
focussed	B-X
on	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
a	B-X
central	B-X
regulator	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
different	B-X
genes	B-X
,	B-X
including	B-X
adhesive	B-X
molecules	B-X
and	B-X
chemoattractants	B-X
.	B-X
By	B-X
confocal	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
positive	B-X
staining	B-X
for	B-X
NF-kappa	B-X
B	B-X
(	B-X
p65	B-X
subunit	B-X
)	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
PAEC	B-X
exposed	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
to	B-X
human	B-X
serum	B-X
,	B-X
which	B-X
indicated	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
this	B-X
setting	B-X
.	B-X
At	B-X
variance	B-X
,	B-X
in	B-X
PAEC	B-X
incubated	B-X
with	B-X
the	B-X
homologous	B-X
serum	B-X
,	B-X
NF-kappa	B-X
B	B-X
was	B-X
strictly	B-X
localized	B-X
in	B-X
the	B-X
cell	B-X
cytoplasm	B-X
.	B-X
Treatment	B-X
of	B-X
PAEC	B-X
exposed	B-X
to	B-X
xenogeneic	B-X
serum	B-X
with	B-X
the	B-X
NF-kappa	B-X
B	B-X
inhibitors	B-X
pyrrolidinedithiocarbamate	B-X
(	B-X
PDTC	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
and	B-X
tosyl-phechloromethylketone	B-X
(	B-X
TPCK	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
reduced	B-X
leukocyte	B-X
adhesion	B-X
in	B-X
respect	B-X
to	B-X
PAEC	B-X
treated	B-X
with	B-X
human	B-X
serum	B-X
alone	B-X
.	B-X
Findings	B-X
that	B-X
xenogeneic	B-X
serum	B-X
promotes	B-X
leukocyte-endothelium	B-X
interaction	B-X
possibly	B-X
through	B-X
NF-kappa	B-X
B	B-X
activation	B-X
might	B-X
be	B-X
relevant	B-X
for	B-X
designing	B-X
future	B-X
therapeutic	B-X
strategies	B-X
aimed	B-X
at	B-X
prolonging	B-X
xenograft	B-X
survival	B-X
.	B-X

Treatment	O
of	O
PAEC	O
exposed	O
to	O
xenogeneic	O
serum	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitors	O
pyrrolidinedithiocarbamate	O
(	O
PDTC	O
,	O
25	O
microM	O
)	O
and	O
tosyl	O
-	O
phechloromethylketone	O
(	O
TPCK	O
,	O
25	O
microM	O
)	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
reduced	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
PAEC	O
treated	O
with	O
human	O
serum	O
alone	O
.	O

Findings	O
that	O
xenogeneic	O
serum	O
promotes	O
leukocyte	O
-	O
endothelium	O
interaction	O
possibly	O
through	O
NF	O
-	O
kappa	O
B	O
activation	O
might	O
be	O
relevant	O
for	O
designing	O
future	O
therapeutic	O
strategies	O
aimed	O
at	O
prolonging	O
xenograft	O
survival	O
.	O
<EOS>	B-X
Endothelial	B-X
cell	B-X
activation	B-X
and	B-X
leukocyte	B-X
infiltration	B-X
are	B-X
a	B-X
consistent	B-X
feature	B-X
of	B-X
discordant	B-X
xenograft	B-X
rejection	B-X
.	B-X
Here	B-X
we	B-X
evaluated	B-X
whether	B-X
xenogeneic	B-X
serum	B-X
,	B-X
as	B-X
a	B-X
source	B-X
of	B-X
xenoreactive	B-X
natural	B-X
antibodies	B-X
and	B-X
complement	B-X
,	B-X
induced	B-X
endothelial	B-X
cell	B-X
activation	B-X
with	B-X
consequent	B-X
leukocyte	B-X
adhesion	B-X
under	B-X
flow	B-X
conditions	B-X
.	B-X
Porcine	B-X
aortic	B-X
endothelial	B-X
cells	B-X
(	B-X
PAEC	B-X
)	B-X
were	B-X
incubated	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
or	B-X
5	B-X
hr	B-X
with	B-X
10	B-X
%	B-X
homologous	B-X
porcine	B-X
serum	B-X
(	B-X
control	B-X
)	B-X
or	B-X
10	B-X
%	B-X
xenogeneic	B-X
human	B-X
serum	B-X
and	B-X
then	B-X
perfused	B-X
with	B-X
total	B-X
human	B-X
leukocytes	B-X
in	B-X
a	B-X
parallel	B-X
plate	B-X
flow	B-X
chamber	B-X
under	B-X
laminar	B-X
flow	B-X
(	B-X
1.5	B-X
dynes/cm2	B-X
)	B-X
.	B-X
Xenogeneic	B-X
human	B-X
serum	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
adherent	B-X
leukocytes	B-X
as	B-X
compared	B-X
with	B-X
porcine	B-X
serum	B-X
.	B-X
A	B-X
similar	B-X
adhesive	B-X
response	B-X
was	B-X
elicited	B-X
by	B-X
TNF	B-X
alpha	B-X
(	B-X
100	B-X
U/ml	B-X
)	B-X
,	B-X
one	B-X
of	B-X
the	B-X
most	B-X
potent	B-X
inducers	B-X
of	B-X
endothelial	B-X
cell	B-X
adhesive	B-X
properties	B-X
,	B-X
here	B-X
used	B-X
as	B-X
positive	B-X
control	B-X
.	B-X
In	B-X
order	B-X
to	B-X
elucidate	B-X
possible	B-X
mechanisms	B-X
underlying	B-X
endothelial	B-X
cell	B-X
activation	B-X
by	B-X
xenogeneic	B-X
serum	B-X
,	B-X
we	B-X
focussed	B-X
on	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
a	B-X
central	B-X
regulator	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
different	B-X
genes	B-X
,	B-X
including	B-X
adhesive	B-X
molecules	B-X
and	B-X
chemoattractants	B-X
.	B-X
By	B-X
confocal	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
we	B-X
observed	B-X
a	B-X
positive	B-X
staining	B-X
for	B-X
NF-kappa	B-X
B	B-X
(	B-X
p65	B-X
subunit	B-X
)	B-X
in	B-X
the	B-X
nuclei	B-X
of	B-X
PAEC	B-X
exposed	B-X
for	B-X
1	B-X
hr	B-X
30	B-X
min	B-X
to	B-X
human	B-X
serum	B-X
,	B-X
which	B-X
indicated	B-X
NF-kappa	B-X
B	B-X
activation	B-X
in	B-X
this	B-X
setting	B-X
.	B-X
At	B-X
variance	B-X
,	B-X
in	B-X
PAEC	B-X
incubated	B-X
with	B-X
the	B-X
homologous	B-X
serum	B-X
,	B-X
NF-kappa	B-X
B	B-X
was	B-X
strictly	B-X
localized	B-X
in	B-X
the	B-X
cell	B-X
cytoplasm	B-X
.	B-X
Treatment	B-X
of	B-X
PAEC	B-X
exposed	B-X
to	B-X
xenogeneic	B-X
serum	B-X
with	B-X
the	B-X
NF-kappa	B-X
B	B-X
inhibitors	B-X
pyrrolidinedithiocarbamate	B-X
(	B-X
PDTC	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
and	B-X
tosyl-phechloromethylketone	B-X
(	B-X
TPCK	B-X
,	B-X
25	B-X
microM	B-X
)	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.01	B-X
)	B-X
reduced	B-X
leukocyte	B-X
adhesion	B-X
in	B-X
respect	B-X
to	B-X
PAEC	B-X
treated	B-X
with	B-X
human	B-X
serum	B-X
alone	B-X
.	B-X
Findings	B-X
that	B-X
xenogeneic	B-X
serum	B-X
promotes	B-X
leukocyte-endothelium	B-X
interaction	B-X
possibly	B-X
through	B-X
NF-kappa	B-X
B	B-X
activation	B-X
might	B-X
be	B-X
relevant	B-X
for	B-X
designing	B-X
future	B-X
therapeutic	B-X
strategies	B-X
aimed	B-X
at	B-X
prolonging	B-X
xenograft	B-X
survival	B-X
.	B-X

IL	B-Protein
-	I-Protein
2	I-Protein
-	O
induced	O
growth	O
of	O
CD8	O
+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
cells	O
mediated	O
by	O
NF	O
-	O
kappaB	O
induction	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
alpha	I-Protein
expression	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
of	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
to	B-X
its	B-X
receptor	B-X
on	B-X
normal	B-X
T	B-X
cells	B-X
induces	B-X
nuclear	B-X
expression	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
receptor	B-X
(	B-X
IL-2R	B-X
)	B-X
alpha	B-X
chain	B-X
gene	B-X
,	B-X
and	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IL-2R	B-X
signaling	B-X
in	B-X
the	B-X
growth	B-X
of	B-X
CD8+	B-X
T	B-X
cell	B-X
prolymphocytic	B-X
leukemia	B-X
(	B-X
T-PLL	B-X
)	B-X
cells	B-X
has	B-X
been	B-X
investigated	B-X
.	B-X
Flow	B-X
cytometry	B-X
revealed	B-X
that	B-X
primary	B-X
leukemia	B-X
cells	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
CD8+	B-X
T-PLL	B-X
expressed	B-X
IL-2Ralpha	B-X
and	B-X
beta	B-X
chains	B-X
,	B-X
and	B-X
the	B-X
cells	B-X
showed	B-X
a	B-X
proliferative	B-X
response	B-X
and	B-X
an	B-X
increase	B-X
in	B-X
IL-2Ralpha	B-X
expression	B-X
on	B-X
culture	B-X
with	B-X
exogeneous	B-X
IL-2	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
failed	B-X
to	B-X
detect	B-X
IL-2	B-X
mRNA	B-X
,	B-X
suggesting	B-X
that	B-X
IL-2	B-X
may	B-X
act	B-X
in	B-X
a	B-X
paracrine	B-X
manner	B-X
in	B-X
vivo	B-X
.	B-X
Electrophoretic	B-X
mobility-shift	B-X
assays	B-X
revealed	B-X
that	B-X
recombinant	B-X
IL-2	B-X
increased	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
the	B-X
leukemia	B-X
cells	B-X
,	B-X
and	B-X
Northern	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
IL-2	B-X
increased	B-X
the	B-X
abundance	B-X
of	B-X
mRNAs	B-X
encoding	B-X
the	B-X
NF-kappaB	B-X
components	B-X
c-Rel	B-X
and	B-X
KBF1	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
IL-2	B-X
binding	B-X
analysis	B-X
demonstrated	B-X
that	B-X
IL-2	B-X
markedly	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
low	B-X
affinity	B-X
IL-2Rs	B-X
on	B-X
the	B-X
leukemia	B-X
cells	B-X
,	B-X
without	B-X
an	B-X
effect	B-X
on	B-X
the	B-X
number	B-X
of	B-X
high-affinity	B-X
IL-2Rs	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
IL-2	B-X
is	B-X
capable	B-X
of	B-X
inducing	B-X
the	B-X
nuclear	B-X
expression	B-X
of	B-X
NF-kappaB	B-X
in	B-X
primary	B-X
CD8+	B-X
T-PLL	B-X
cells	B-X
,	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
at	B-X
a	B-X
pretranslational	B-X
level	B-X
.	B-X

The	O
binding	O
of	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
to	O
its	O
receptor	O
on	O
normal	O
T	O
cells	O
induces	O
nuclear	O
expression	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
activation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
receptor	I-Protein
(	I-Protein
IL	I-Protein
-	I-Protein
2R	I-Protein
)	I-Protein
alpha	I-Protein
chain	I-Protein
gene	O
,	O
and	O
cell	O
proliferation	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
of	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
to	B-X
its	B-X
receptor	B-X
on	B-X
normal	B-X
T	B-X
cells	B-X
induces	B-X
nuclear	B-X
expression	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
receptor	B-X
(	B-X
IL-2R	B-X
)	B-X
alpha	B-X
chain	B-X
gene	B-X
,	B-X
and	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IL-2R	B-X
signaling	B-X
in	B-X
the	B-X
growth	B-X
of	B-X
CD8+	B-X
T	B-X
cell	B-X
prolymphocytic	B-X
leukemia	B-X
(	B-X
T-PLL	B-X
)	B-X
cells	B-X
has	B-X
been	B-X
investigated	B-X
.	B-X
Flow	B-X
cytometry	B-X
revealed	B-X
that	B-X
primary	B-X
leukemia	B-X
cells	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
CD8+	B-X
T-PLL	B-X
expressed	B-X
IL-2Ralpha	B-X
and	B-X
beta	B-X
chains	B-X
,	B-X
and	B-X
the	B-X
cells	B-X
showed	B-X
a	B-X
proliferative	B-X
response	B-X
and	B-X
an	B-X
increase	B-X
in	B-X
IL-2Ralpha	B-X
expression	B-X
on	B-X
culture	B-X
with	B-X
exogeneous	B-X
IL-2	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
failed	B-X
to	B-X
detect	B-X
IL-2	B-X
mRNA	B-X
,	B-X
suggesting	B-X
that	B-X
IL-2	B-X
may	B-X
act	B-X
in	B-X
a	B-X
paracrine	B-X
manner	B-X
in	B-X
vivo	B-X
.	B-X
Electrophoretic	B-X
mobility-shift	B-X
assays	B-X
revealed	B-X
that	B-X
recombinant	B-X
IL-2	B-X
increased	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
the	B-X
leukemia	B-X
cells	B-X
,	B-X
and	B-X
Northern	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
IL-2	B-X
increased	B-X
the	B-X
abundance	B-X
of	B-X
mRNAs	B-X
encoding	B-X
the	B-X
NF-kappaB	B-X
components	B-X
c-Rel	B-X
and	B-X
KBF1	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
IL-2	B-X
binding	B-X
analysis	B-X
demonstrated	B-X
that	B-X
IL-2	B-X
markedly	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
low	B-X
affinity	B-X
IL-2Rs	B-X
on	B-X
the	B-X
leukemia	B-X
cells	B-X
,	B-X
without	B-X
an	B-X
effect	B-X
on	B-X
the	B-X
number	B-X
of	B-X
high-affinity	B-X
IL-2Rs	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
IL-2	B-X
is	B-X
capable	B-X
of	B-X
inducing	B-X
the	B-X
nuclear	B-X
expression	B-X
of	B-X
NF-kappaB	B-X
in	B-X
primary	B-X
CD8+	B-X
T-PLL	B-X
cells	B-X
,	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
at	B-X
a	B-X
pretranslational	B-X
level	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
IL	O
-	O
2R	O
signaling	O
in	O
the	O
growth	O
of	O
CD8	O
+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
(	O
T	O
-	O
PLL	O
)	O
cells	O
has	O
been	O
investigated	O
.	O

Flow	O
cytometry	O
revealed	O
that	O
primary	O
leukemia	O
cells	O
from	O
a	O
patient	O
with	O
CD8	O
+	O
T	O
-	O
PLL	O
expressed	O
IL	B-Protein
-	I-Protein
2Ralpha	I-Protein
and	O
beta	B-Protein
chains	O
,	O
and	O
the	O
cells	O
showed	O
a	O
proliferative	O
response	O
and	O
an	O
increase	O
in	O
IL	B-Protein
-	I-Protein
2Ralpha	I-Protein
expression	O
on	O
culture	O
with	O
exogeneous	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Northern	O
blot	O
analysis	O
failed	O
to	O
detect	O
IL	B-Protein
-	I-Protein
2	I-Protein
mRNA	O
,	O
suggesting	O
that	O
IL	B-Protein
-	I-Protein
2	I-Protein
may	O
act	O
in	O
a	O
paracrine	O
manner	O
in	O
vivo	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
revealed	O
that	O
recombinant	O
IL	B-Protein
-	I-Protein
2	I-Protein
increased	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
of	O
the	O
leukemia	O
cells	O
,	O
and	O
Northern	O
blot	O
analysis	O
showed	O
that	O
IL	B-Protein
-	I-Protein
2	I-Protein
increased	O
the	O
abundance	O
of	O
mRNAs	O
encoding	O
the	O
NF	O
-	O
kappaB	O
components	O
c	B-Protein
-	I-Protein
Rel	I-Protein
and	O
KBF1	B-Protein
in	O
these	O
cells	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
of	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
to	B-X
its	B-X
receptor	B-X
on	B-X
normal	B-X
T	B-X
cells	B-X
induces	B-X
nuclear	B-X
expression	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
receptor	B-X
(	B-X
IL-2R	B-X
)	B-X
alpha	B-X
chain	B-X
gene	B-X
,	B-X
and	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IL-2R	B-X
signaling	B-X
in	B-X
the	B-X
growth	B-X
of	B-X
CD8+	B-X
T	B-X
cell	B-X
prolymphocytic	B-X
leukemia	B-X
(	B-X
T-PLL	B-X
)	B-X
cells	B-X
has	B-X
been	B-X
investigated	B-X
.	B-X
Flow	B-X
cytometry	B-X
revealed	B-X
that	B-X
primary	B-X
leukemia	B-X
cells	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
CD8+	B-X
T-PLL	B-X
expressed	B-X
IL-2Ralpha	B-X
and	B-X
beta	B-X
chains	B-X
,	B-X
and	B-X
the	B-X
cells	B-X
showed	B-X
a	B-X
proliferative	B-X
response	B-X
and	B-X
an	B-X
increase	B-X
in	B-X
IL-2Ralpha	B-X
expression	B-X
on	B-X
culture	B-X
with	B-X
exogeneous	B-X
IL-2	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
failed	B-X
to	B-X
detect	B-X
IL-2	B-X
mRNA	B-X
,	B-X
suggesting	B-X
that	B-X
IL-2	B-X
may	B-X
act	B-X
in	B-X
a	B-X
paracrine	B-X
manner	B-X
in	B-X
vivo	B-X
.	B-X
Electrophoretic	B-X
mobility-shift	B-X
assays	B-X
revealed	B-X
that	B-X
recombinant	B-X
IL-2	B-X
increased	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
the	B-X
leukemia	B-X
cells	B-X
,	B-X
and	B-X
Northern	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
IL-2	B-X
increased	B-X
the	B-X
abundance	B-X
of	B-X
mRNAs	B-X
encoding	B-X
the	B-X
NF-kappaB	B-X
components	B-X
c-Rel	B-X
and	B-X
KBF1	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
IL-2	B-X
binding	B-X
analysis	B-X
demonstrated	B-X
that	B-X
IL-2	B-X
markedly	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
low	B-X
affinity	B-X
IL-2Rs	B-X
on	B-X
the	B-X
leukemia	B-X
cells	B-X
,	B-X
without	B-X
an	B-X
effect	B-X
on	B-X
the	B-X
number	B-X
of	B-X
high-affinity	B-X
IL-2Rs	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
IL-2	B-X
is	B-X
capable	B-X
of	B-X
inducing	B-X
the	B-X
nuclear	B-X
expression	B-X
of	B-X
NF-kappaB	B-X
in	B-X
primary	B-X
CD8+	B-X
T-PLL	B-X
cells	B-X
,	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
at	B-X
a	B-X
pretranslational	B-X
level	B-X
.	B-X

IL	B-Protein
-	I-Protein
2	I-Protein
binding	O
analysis	O
demonstrated	O
that	O
IL	B-Protein
-	I-Protein
2	I-Protein
markedly	O
increased	O
the	O
number	O
of	O
low	O
affinity	O
IL	O
-	O
2Rs	O
on	O
the	O
leukemia	O
cells	O
,	O
without	O
an	O
effect	O
on	O
the	O
number	O
of	O
high	O
-	O
affinity	O
IL	O
-	O
2Rs	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
of	B-X
interleukin-2	B-X
(	B-X
IL-2	B-X
)	B-X
to	B-X
its	B-X
receptor	B-X
on	B-X
normal	B-X
T	B-X
cells	B-X
induces	B-X
nuclear	B-X
expression	B-X
of	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
,	B-X
activation	B-X
of	B-X
the	B-X
IL-2	B-X
receptor	B-X
(	B-X
IL-2R	B-X
)	B-X
alpha	B-X
chain	B-X
gene	B-X
,	B-X
and	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
role	B-X
of	B-X
IL-2R	B-X
signaling	B-X
in	B-X
the	B-X
growth	B-X
of	B-X
CD8+	B-X
T	B-X
cell	B-X
prolymphocytic	B-X
leukemia	B-X
(	B-X
T-PLL	B-X
)	B-X
cells	B-X
has	B-X
been	B-X
investigated	B-X
.	B-X
Flow	B-X
cytometry	B-X
revealed	B-X
that	B-X
primary	B-X
leukemia	B-X
cells	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
CD8+	B-X
T-PLL	B-X
expressed	B-X
IL-2Ralpha	B-X
and	B-X
beta	B-X
chains	B-X
,	B-X
and	B-X
the	B-X
cells	B-X
showed	B-X
a	B-X
proliferative	B-X
response	B-X
and	B-X
an	B-X
increase	B-X
in	B-X
IL-2Ralpha	B-X
expression	B-X
on	B-X
culture	B-X
with	B-X
exogeneous	B-X
IL-2	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
failed	B-X
to	B-X
detect	B-X
IL-2	B-X
mRNA	B-X
,	B-X
suggesting	B-X
that	B-X
IL-2	B-X
may	B-X
act	B-X
in	B-X
a	B-X
paracrine	B-X
manner	B-X
in	B-X
vivo	B-X
.	B-X
Electrophoretic	B-X
mobility-shift	B-X
assays	B-X
revealed	B-X
that	B-X
recombinant	B-X
IL-2	B-X
increased	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
the	B-X
leukemia	B-X
cells	B-X
,	B-X
and	B-X
Northern	B-X
blot	B-X
analysis	B-X
showed	B-X
that	B-X
IL-2	B-X
increased	B-X
the	B-X
abundance	B-X
of	B-X
mRNAs	B-X
encoding	B-X
the	B-X
NF-kappaB	B-X
components	B-X
c-Rel	B-X
and	B-X
KBF1	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
IL-2	B-X
binding	B-X
analysis	B-X
demonstrated	B-X
that	B-X
IL-2	B-X
markedly	B-X
increased	B-X
the	B-X
number	B-X
of	B-X
low	B-X
affinity	B-X
IL-2Rs	B-X
on	B-X
the	B-X
leukemia	B-X
cells	B-X
,	B-X
without	B-X
an	B-X
effect	B-X
on	B-X
the	B-X
number	B-X
of	B-X
high-affinity	B-X
IL-2Rs	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
IL-2	B-X
is	B-X
capable	B-X
of	B-X
inducing	B-X
the	B-X
nuclear	B-X
expression	B-X
of	B-X
NF-kappaB	B-X
in	B-X
primary	B-X
CD8+	B-X
T-PLL	B-X
cells	B-X
,	B-X
and	B-X
that	B-X
this	B-X
effect	B-X
is	B-X
mediated	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
at	B-X
a	B-X
pretranslational	B-X
level	B-X
.	B-X

These	O
results	O
show	O
that	O
IL	B-Protein
-	I-Protein
2	I-Protein
is	O
capable	O
of	O
inducing	O
the	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
CD8	O
+	O
T	O
-	O
PLL	O
cells	O
,	O
and	O
that	O
this	O
effect	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
at	O
a	O
pretranslational	O
level	O
.	O

Molecular	O
and	O
cellular	O
analysis	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
induced	O
apoptosis	O
in	O
lymphoblastoid	O
T	O
-	O
cell	O
-	O
line	O
-	O
expressing	O
wild	O
-	O
type	O
and	O
mutated	O
CD4	B-Protein
receptors	I-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
CD4	B-X
cytoplasmic	B-X
tail	B-X
is	B-X
critical	B-X
for	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
-induced	B-X
apoptosis	B-X
(	B-X
J.	B-X
Corbeil	B-X
,	B-X
M.	B-X
Tremblay	B-X
,	B-X
and	B-X
D.	B-X
D.	B-X
Richman	B-X
,	B-X
J.	B-X
Exp	B-X
.	B-X
We	B-X
have	B-X
pursued	B-X
our	B-X
investigation	B-X
of	B-X
the	B-X
role	B-X
of	B-X
the	B-X
CD4	B-X
transduction	B-X
pathway	B-X
in	B-X
HIV-induced	B-X
apoptosis	B-X
.	B-X
To	B-X
do	B-X
this	B-X
,	B-X
wild-type	B-X
and	B-X
mutant	B-X
forms	B-X
of	B-X
the	B-X
CD4	B-X
cytoplasmic	B-X
tail	B-X
were	B-X
stably	B-X
expressed	B-X
in	B-X
the	B-X
lymphoblastoid	B-X
T-cell	B-X
line	B-X
A2.01	B-X
.	B-X
Apoptosis	B-X
was	B-X
prevented	B-X
when	B-X
CD4	B-X
truncated	B-X
at	B-X
residue	B-X
402	B-X
was	B-X
expressed	B-X
;	B-X
however	B-X
,	B-X
cells	B-X
expressing	B-X
mutated	B-X
receptors	B-X
that	B-X
do	B-X
not	B-X
associate	B-X
with	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
(	B-X
mutated	B-X
at	B-X
the	B-X
dicysteine	B-X
motif	B-X
and	B-X
truncated	B-X
at	B-X
residue	B-X
418	B-X
)	B-X
but	B-X
which	B-X
conserved	B-X
proximal	B-X
domains	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
underwent	B-X
apoptosis	B-X
like	B-X
wild-type	B-X
CD4	B-X
.	B-X
The	B-X
differences	B-X
between	B-X
wild-type	B-X
and	B-X
mutated	B-X
receptors	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
were	B-X
not	B-X
related	B-X
to	B-X
levels	B-X
of	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
or	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Initial	B-X
signaling	B-X
through	B-X
the	B-X
CD4	B-X
receptor	B-X
played	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
sensitization	B-X
of	B-X
HIV-infected	B-X
T	B-X
cells	B-X
to	B-X
undergo	B-X
apoptosis	B-X
.	B-X
Incubation	B-X
of	B-X
HIV-infected	B-X
cells	B-X
with	B-X
monoclonal	B-X
antibody	B-X
(	B-X
MAb	B-X
)	B-X
13B8-2	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
CD4	B-X
in	B-X
a	B-X
region	B-X
critical	B-X
for	B-X
dimerization	B-X
of	B-X
the	B-X
receptor	B-X
,	B-X
prevented	B-X
apoptosis	B-X
without	B-X
inhibiting	B-X
HIV	B-X
replication	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
apoptotic	B-X
process	B-X
was	B-X
not	B-X
related	B-X
to	B-X
Fas-Fas	B-X
ligand	B-X
interaction	B-X
;	B-X
however	B-X
,	B-X
an	B-X
antagonistic	B-X
anti-Fas	B-X
MAb	B-X
(	B-X
ZB-4	B-X
)	B-X
enhanced	B-X
apoptosis	B-X
in	B-X
HIV-infected	B-X
cells	B-X
without	B-X
inducing	B-X
apoptosis	B-X
in	B-X
uninfected	B-X
cells	B-X
.	B-X
These	B-X
observations	B-X
demonstrate	B-X
that	B-X
CD4	B-X
signaling	B-X
mediates	B-X
HIV-induced	B-X
apoptosis	B-X
by	B-X
a	B-X
mechanism	B-X
independent	B-X
of	B-X
Fas-Fas	B-X
ligand	B-X
interaction	B-X
,	B-X
does	B-X
not	B-X
require	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
signaling	B-X
,	B-X
and	B-X
may	B-X
involve	B-X
a	B-X
critical	B-X
region	B-X
for	B-X
CD4	B-X
dimerization	B-X
.	B-X

We	O
have	O
previously	O
shown	O
that	O
the	O
presence	O
of	O
the	O
CD4	B-Protein
cytoplasmic	O
tail	O
is	O
critical	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
induced	O
apoptosis	O
(	O
J	O
.	O
Corbeil	O
,	O
M	O
.	O
Tremblay	O
,	O
and	O
D	O
.	O
D	O
.	O
Richman	O
,	O
J	O
.	O
Exp	O
.	O
Med	O
.	O
183	O
:	O
39	O
-	O
48	O
,	O
1996	O
)	O
.	O

We	O
have	O
pursued	O
our	O
investigation	O
of	O
the	O
role	O
of	O
the	O
CD4	B-Protein
transduction	O
pathway	O
in	O
HIV	O
-	O
induced	O
apoptosis	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
CD4	B-X
cytoplasmic	B-X
tail	B-X
is	B-X
critical	B-X
for	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
-induced	B-X
apoptosis	B-X
(	B-X
J.	B-X
Corbeil	B-X
,	B-X
M.	B-X
Tremblay	B-X
,	B-X
and	B-X
D.	B-X
D.	B-X
Richman	B-X
,	B-X
J.	B-X
Exp	B-X
.	B-X
We	B-X
have	B-X
pursued	B-X
our	B-X
investigation	B-X
of	B-X
the	B-X
role	B-X
of	B-X
the	B-X
CD4	B-X
transduction	B-X
pathway	B-X
in	B-X
HIV-induced	B-X
apoptosis	B-X
.	B-X
To	B-X
do	B-X
this	B-X
,	B-X
wild-type	B-X
and	B-X
mutant	B-X
forms	B-X
of	B-X
the	B-X
CD4	B-X
cytoplasmic	B-X
tail	B-X
were	B-X
stably	B-X
expressed	B-X
in	B-X
the	B-X
lymphoblastoid	B-X
T-cell	B-X
line	B-X
A2.01	B-X
.	B-X
Apoptosis	B-X
was	B-X
prevented	B-X
when	B-X
CD4	B-X
truncated	B-X
at	B-X
residue	B-X
402	B-X
was	B-X
expressed	B-X
;	B-X
however	B-X
,	B-X
cells	B-X
expressing	B-X
mutated	B-X
receptors	B-X
that	B-X
do	B-X
not	B-X
associate	B-X
with	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
(	B-X
mutated	B-X
at	B-X
the	B-X
dicysteine	B-X
motif	B-X
and	B-X
truncated	B-X
at	B-X
residue	B-X
418	B-X
)	B-X
but	B-X
which	B-X
conserved	B-X
proximal	B-X
domains	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
underwent	B-X
apoptosis	B-X
like	B-X
wild-type	B-X
CD4	B-X
.	B-X
The	B-X
differences	B-X
between	B-X
wild-type	B-X
and	B-X
mutated	B-X
receptors	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
were	B-X
not	B-X
related	B-X
to	B-X
levels	B-X
of	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
or	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Initial	B-X
signaling	B-X
through	B-X
the	B-X
CD4	B-X
receptor	B-X
played	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
sensitization	B-X
of	B-X
HIV-infected	B-X
T	B-X
cells	B-X
to	B-X
undergo	B-X
apoptosis	B-X
.	B-X
Incubation	B-X
of	B-X
HIV-infected	B-X
cells	B-X
with	B-X
monoclonal	B-X
antibody	B-X
(	B-X
MAb	B-X
)	B-X
13B8-2	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
CD4	B-X
in	B-X
a	B-X
region	B-X
critical	B-X
for	B-X
dimerization	B-X
of	B-X
the	B-X
receptor	B-X
,	B-X
prevented	B-X
apoptosis	B-X
without	B-X
inhibiting	B-X
HIV	B-X
replication	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
apoptotic	B-X
process	B-X
was	B-X
not	B-X
related	B-X
to	B-X
Fas-Fas	B-X
ligand	B-X
interaction	B-X
;	B-X
however	B-X
,	B-X
an	B-X
antagonistic	B-X
anti-Fas	B-X
MAb	B-X
(	B-X
ZB-4	B-X
)	B-X
enhanced	B-X
apoptosis	B-X
in	B-X
HIV-infected	B-X
cells	B-X
without	B-X
inducing	B-X
apoptosis	B-X
in	B-X
uninfected	B-X
cells	B-X
.	B-X
These	B-X
observations	B-X
demonstrate	B-X
that	B-X
CD4	B-X
signaling	B-X
mediates	B-X
HIV-induced	B-X
apoptosis	B-X
by	B-X
a	B-X
mechanism	B-X
independent	B-X
of	B-X
Fas-Fas	B-X
ligand	B-X
interaction	B-X
,	B-X
does	B-X
not	B-X
require	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
signaling	B-X
,	B-X
and	B-X
may	B-X
involve	B-X
a	B-X
critical	B-X
region	B-X
for	B-X
CD4	B-X
dimerization	B-X
.	B-X

To	O
do	O
this	O
,	O
wild	O
-	O
type	O
and	O
mutant	O
forms	O
of	O
the	O
CD4	B-Protein
cytoplasmic	O
tail	O
were	O
stably	O
expressed	O
in	O
the	O
lymphoblastoid	O
T	O
-	O
cell	O
line	O
A2	O
.	O
01	O
.	O

Apoptosis	O
was	O
prevented	O
when	O
CD4	B-Protein
truncated	O
at	O
residue	O
402	O
was	O
expressed	O
;	O
however	O
,	O
cells	O
expressing	O
mutated	O
receptors	O
that	O
do	O
not	O
associate	O
with	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
(	O
mutated	O
at	O
the	O
dicysteine	O
motif	O
and	O
truncated	O
at	O
residue	O
418	O
)	O
but	O
which	O
conserved	O
proximal	O
domains	O
of	O
the	O
cytoplasmic	O
tail	O
underwent	O
apoptosis	O
like	O
wild	O
-	O
type	O
CD4	B-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
CD4	B-X
cytoplasmic	B-X
tail	B-X
is	B-X
critical	B-X
for	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
-induced	B-X
apoptosis	B-X
(	B-X
J.	B-X
Corbeil	B-X
,	B-X
M.	B-X
Tremblay	B-X
,	B-X
and	B-X
D.	B-X
D.	B-X
Richman	B-X
,	B-X
J.	B-X
Exp	B-X
.	B-X
We	B-X
have	B-X
pursued	B-X
our	B-X
investigation	B-X
of	B-X
the	B-X
role	B-X
of	B-X
the	B-X
CD4	B-X
transduction	B-X
pathway	B-X
in	B-X
HIV-induced	B-X
apoptosis	B-X
.	B-X
To	B-X
do	B-X
this	B-X
,	B-X
wild-type	B-X
and	B-X
mutant	B-X
forms	B-X
of	B-X
the	B-X
CD4	B-X
cytoplasmic	B-X
tail	B-X
were	B-X
stably	B-X
expressed	B-X
in	B-X
the	B-X
lymphoblastoid	B-X
T-cell	B-X
line	B-X
A2.01	B-X
.	B-X
Apoptosis	B-X
was	B-X
prevented	B-X
when	B-X
CD4	B-X
truncated	B-X
at	B-X
residue	B-X
402	B-X
was	B-X
expressed	B-X
;	B-X
however	B-X
,	B-X
cells	B-X
expressing	B-X
mutated	B-X
receptors	B-X
that	B-X
do	B-X
not	B-X
associate	B-X
with	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
(	B-X
mutated	B-X
at	B-X
the	B-X
dicysteine	B-X
motif	B-X
and	B-X
truncated	B-X
at	B-X
residue	B-X
418	B-X
)	B-X
but	B-X
which	B-X
conserved	B-X
proximal	B-X
domains	B-X
of	B-X
the	B-X
cytoplasmic	B-X
tail	B-X
underwent	B-X
apoptosis	B-X
like	B-X
wild-type	B-X
CD4	B-X
.	B-X
The	B-X
differences	B-X
between	B-X
wild-type	B-X
and	B-X
mutated	B-X
receptors	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
were	B-X
not	B-X
related	B-X
to	B-X
levels	B-X
of	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
or	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Initial	B-X
signaling	B-X
through	B-X
the	B-X
CD4	B-X
receptor	B-X
played	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
sensitization	B-X
of	B-X
HIV-infected	B-X
T	B-X
cells	B-X
to	B-X
undergo	B-X
apoptosis	B-X
.	B-X
Incubation	B-X
of	B-X
HIV-infected	B-X
cells	B-X
with	B-X
monoclonal	B-X
antibody	B-X
(	B-X
MAb	B-X
)	B-X
13B8-2	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
CD4	B-X
in	B-X
a	B-X
region	B-X
critical	B-X
for	B-X
dimerization	B-X
of	B-X
the	B-X
receptor	B-X
,	B-X
prevented	B-X
apoptosis	B-X
without	B-X
inhibiting	B-X
HIV	B-X
replication	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
apoptotic	B-X
process	B-X
was	B-X
not	B-X
related	B-X
to	B-X
Fas-Fas	B-X
ligand	B-X
interaction	B-X
;	B-X
however	B-X
,	B-X
an	B-X
antagonistic	B-X
anti-Fas	B-X
MAb	B-X
(	B-X
ZB-4	B-X
)	B-X
enhanced	B-X
apoptosis	B-X
in	B-X
HIV-infected	B-X
cells	B-X
without	B-X
inducing	B-X
apoptosis	B-X
in	B-X
uninfected	B-X
cells	B-X
.	B-X
These	B-X
observations	B-X
demonstrate	B-X
that	B-X
CD4	B-X
signaling	B-X
mediates	B-X
HIV-induced	B-X
apoptosis	B-X
by	B-X
a	B-X
mechanism	B-X
independent	B-X
of	B-X
Fas-Fas	B-X
ligand	B-X
interaction	B-X
,	B-X
does	B-X
not	B-X
require	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
signaling	B-X
,	B-X
and	B-X
may	B-X
involve	B-X
a	B-X
critical	B-X
region	B-X
for	B-X
CD4	B-X
dimerization	B-X
.	B-X

The	O
differences	O
between	O
wild	O
-	O
type	O
and	O
mutated	O
receptors	O
in	O
the	O
induction	O
of	O
apoptosis	O
were	O
not	O
related	O
to	O
levels	O
of	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
or	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
factor-κB	B-X
(	B-X
NF-κB	B-X
)	B-X
transcription	B-X
factor	B-X
family	B-X
has	B-X
been	B-X
considered	B-X
the	B-X
central	B-X
mediator	B-X
of	B-X
the	B-X
inflammatory	B-X
process	B-X
and	B-X
a	B-X
key	B-X
participant	B-X
in	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
responses	B-X
.	B-X
Coincident	B-X
with	B-X
the	B-X
molecular	B-X
cloning	B-X
of	B-X
NF-κB/RelA	B-X
and	B-X
identification	B-X
of	B-X
its	B-X
kinship	B-X
to	B-X
the	B-X
v-Rel	B-X
oncogene	B-X
,	B-X
it	B-X
was	B-X
anticipated	B-X
that	B-X
NF-κB	B-X
itself	B-X
would	B-X
be	B-X
involved	B-X
in	B-X
cancer	B-X
development	B-X
.	B-X
Oncogenic	B-X
activating	B-X
mutations	B-X
in	B-X
NF-κB	B-X
genes	B-X
are	B-X
rare	B-X
and	B-X
have	B-X
been	B-X
identified	B-X
only	B-X
in	B-X
some	B-X
lymphoid	B-X
malignancies	B-X
,	B-X
while	B-X
most	B-X
NF-κB	B-X
activating	B-X
mutations	B-X
in	B-X
lymphoid	B-X
malignancies	B-X
occur	B-X
in	B-X
upstream	B-X
signaling	B-X
components	B-X
that	B-X
feed	B-X
into	B-X
NF-κB	B-X
.	B-X
NF-κB	B-X
activation	B-X
is	B-X
also	B-X
prevalent	B-X
in	B-X
carcinomas	B-X
,	B-X
in	B-X
which	B-X
NF-κB	B-X
activation	B-X
is	B-X
mainly	B-X
driven	B-X
by	B-X
inflammatory	B-X
cytokines	B-X
within	B-X
the	B-X
tumor	B-X
microenvironment	B-X
.	B-X
Importantly	B-X
,	B-X
however	B-X
,	B-X
in	B-X
all	B-X
malignancies	B-X
,	B-X
NF-κB	B-X
acts	B-X
in	B-X
a	B-X
cell	B-X
type-specific	B-X
manner	B-X
:	B-X
activating	B-X
survival	B-X
genes	B-X
within	B-X
cancer	B-X
cells	B-X
and	B-X
inflammation-promoting	B-X
genes	B-X
in	B-X
components	B-X
of	B-X
the	B-X
tumor	B-X
microenvironment	B-X
.	B-X
Yet	B-X
,	B-X
the	B-X
complex	B-X
biological	B-X
functions	B-X
of	B-X
NF-κB	B-X
have	B-X
made	B-X
its	B-X
therapeutic	B-X
targeting	B-X
a	B-X
challenge	B-X
.	B-X

Initial	O
signaling	O
through	O
the	O
CD4	B-Protein
receptor	I-Protein
played	O
a	O
major	O
role	O
in	O
the	O
sensitization	O
of	O
HIV	O
-	O
infected	O
T	O
cells	O
to	O
undergo	O
apoptosis	O
.	O

Incubation	O
of	O
HIV	O
-	O
infected	O
cells	O
with	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
13B8	O
-	O
2	O
,	O
which	O
binds	O
to	O
CD4	B-Protein
in	O
a	O
region	O
critical	O
for	O
dimerization	O
of	O
the	O
receptor	O
,	O
prevented	O
apoptosis	O
without	O
inhibiting	O
HIV	O
replication	O
.	O

Moreover	O
,	O
the	O
apoptotic	O
process	O
was	O
not	O
related	O
to	O
Fas	B-Protein
-	O
Fas	B-Protein
ligand	I-Protein
interaction	O
;	O
however	O
,	O
an	O
antagonistic	O
anti	O
-	O
Fas	B-Protein
MAb	O
(	O
ZB	O
-	O
4	O
)	O
enhanced	O
apoptosis	O
in	O
HIV	O
-	O
infected	O
cells	O
without	O
inducing	O
apoptosis	O
in	O
uninfected	O
cells	O
.	O
<EOS>	B-X
Autophagy	B-X
is	B-X
a	B-X
complex	B-X
,	B-X
physiological	B-X
process	B-X
devoted	B-X
to	B-X
degrade	B-X
and	B-X
recycle	B-X
cellular	B-X
components	B-X
.	B-X
Moreover	B-X
,	B-X
autophagy	B-X
holds	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
physiopathology	B-X
of	B-X
several	B-X
diseases	B-X
.	B-X
In	B-X
cancer	B-X
,	B-X
excellent	B-X
works	B-X
demonstrated	B-X
the	B-X
dual	B-X
functions	B-X
of	B-X
autophagy	B-X
in	B-X
tumour	B-X
biology	B-X
:	B-X
autophagy	B-X
activation	B-X
can	B-X
promote	B-X
cancer	B-X
cells	B-X
survival	B-X
(	B-X
protective	B-X
autophagy	B-X
)	B-X
,	B-X
or	B-X
contribute	B-X
to	B-X
cancer	B-X
cell	B-X
death	B-X
(	B-X
cytotoxic/nonprotective	B-X
autophagy	B-X
)	B-X
.	B-X
Vascular	B-X
endothelial	B-X
cells	B-X
(	B-X
VECs	B-X
)	B-X
,	B-X
which	B-X
are	B-X
lined	B-X
up	B-X
in	B-X
the	B-X
inner	B-X
surface	B-X
of	B-X
blood	B-X
vessels	B-X
,	B-X
are	B-X
in	B-X
direct	B-X
contact	B-X
with	B-X
the	B-X
metabolite-related	B-X
endogenous	B-X
danger	B-X
signals	B-X
in	B-X
the	B-X
circulatory	B-X
system	B-X
.	B-X
Moreover	B-X
,	B-X
VECs	B-X
death	B-X
impairs	B-X
vasodilation	B-X
and	B-X
increases	B-X
endothelium-dependent	B-X
permeability	B-X
,	B-X
which	B-X
is	B-X
strongly	B-X
correlated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
atherosclerosis	B-X
(	B-X
AS	B-X
)	B-X
.	B-X
Among	B-X
several	B-X
forms	B-X
of	B-X
cell	B-X
death	B-X
,	B-X
regulatory	B-X
death	B-X
of	B-X
endothelial	B-X
cells	B-X
frequently	B-X
occurs	B-X
in	B-X
AS	B-X
,	B-X
mainly	B-X
including	B-X
ferroptosis	B-X
,	B-X
pyroptosis	B-X
,	B-X
apoptosis	B-X
and	B-X
autophagy	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
regulatory	B-X
factors	B-X
and	B-X
signaling	B-X
mechanisms	B-X
of	B-X
regulatory	B-X
death	B-X
in	B-X
endothelial	B-X
cells	B-X
,	B-X
discussing	B-X
their	B-X
effects	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
atherosclerotic	B-X
procession	B-X
.	B-X

These	O
observations	O
demonstrate	O
that	O
CD4	B-Protein
signaling	O
mediates	O
HIV	O
-	O
induced	O
apoptosis	O
by	O
a	O
mechanism	O
independent	O
of	O
Fas	B-Protein
-	O
Fas	B-Protein
ligand	I-Protein
interaction	O
,	O
does	O
not	O
require	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
signaling	O
,	O
and	O
may	O
involve	O
a	O
critical	O
region	O
for	O
CD4	B-Protein
dimerization	O
.	O

NF	O
-	O
kappaB	O
only	O
partially	O
mediates	O
Epstein	O
-	O
Barr	O
virus	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
activation	O
of	O
B	O
cells	O
.	O
<EOS>	B-X
The	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
required	B-X
for	B-X
EBV-induced	B-X
immortalization	B-X
of	B-X
human	B-X
B	B-X
cells	B-X
and	B-X
causes	B-X
tumorigenic	B-X
transformation	B-X
of	B-X
cell	B-X
lines	B-X
.	B-X
LMP1	B-X
expression	B-X
induces	B-X
phenotypic	B-X
changes	B-X
resembling	B-X
B	B-X
cell	B-X
activation	B-X
,	B-X
such	B-X
as	B-X
cell	B-X
size	B-X
increase	B-X
and	B-X
up-regulation	B-X
of	B-X
cell	B-X
surface	B-X
activation	B-X
markers	B-X
.	B-X
LMP1	B-X
contains	B-X
two	B-X
domains	B-X
that	B-X
activate	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
one	B-X
through	B-X
interactions	B-X
with	B-X
TRAF	B-X
proteins	B-X
and	B-X
the	B-X
other	B-X
with	B-X
the	B-X
TRADD	B-X
protein	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
importance	B-X
of	B-X
NF-kappaB	B-X
induction	B-X
in	B-X
the	B-X
up-regulation	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
activation	B-X
markers	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
by	B-X
LMP1	B-X
.	B-X
This	B-X
study	B-X
shows	B-X
that	B-X
expression	B-X
of	B-X
LMP1	B-X
activates	B-X
transcription	B-X
from	B-X
p50/p65-	B-X
and	B-X
c-Rel-responsive	B-X
promoters	B-X
,	B-X
and	B-X
that	B-X
this	B-X
activity	B-X
can	B-X
be	B-X
completely	B-X
inhibited	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
inhibitory	B-X
IkappaB	B-X
mutant	B-X
.	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
are	B-X
nevertheless	B-X
up-regulated	B-X
by	B-X
LMP1	B-X
in	B-X
primary	B-X
B	B-X
cells	B-X
and	B-X
cell	B-X
lines	B-X
expressing	B-X
the	B-X
dominant	B-X
IkappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
LMP1-induced	B-X
cell	B-X
size	B-X
increase	B-X
of	B-X
primary	B-X
B	B-X
cells	B-X
was	B-X
unaffected	B-X
by	B-X
IkappaB	B-X
expression	B-X
.	B-X
It	B-X
was	B-X
concluded	B-X
that	B-X
even	B-X
when	B-X
LMP1	B-X
is	B-X
unable	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
,	B-X
it	B-X
is	B-X
still	B-X
capable	B-X
of	B-X
inducing	B-X
certain	B-X
characteristics	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
,	B-X
strongly	B-X
suggesting	B-X
that	B-X
LMP1	B-X
can	B-X
also	B-X
activate	B-X
cells	B-X
independently	B-X
of	B-X
NF-kappaB	B-X
.	B-X

The	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
(	O
LMP1	B-Protein
)	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
required	O
for	O
EBV	O
-	O
induced	O
immortalization	O
of	O
human	O
B	O
cells	O
and	O
causes	O
tumorigenic	O
transformation	O
of	O
cell	O
lines	O
.	O

LMP1	B-Protein
expression	O
induces	O
phenotypic	O
changes	O
resembling	O
B	O
cell	O
activation	O
,	O
such	O
as	O
cell	O
size	O
increase	O
and	O
up	O
-	O
regulation	O
of	O
cell	O
surface	O
activation	O
markers	O
.	O
<EOS>	B-X
The	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
required	B-X
for	B-X
EBV-induced	B-X
immortalization	B-X
of	B-X
human	B-X
B	B-X
cells	B-X
and	B-X
causes	B-X
tumorigenic	B-X
transformation	B-X
of	B-X
cell	B-X
lines	B-X
.	B-X
LMP1	B-X
expression	B-X
induces	B-X
phenotypic	B-X
changes	B-X
resembling	B-X
B	B-X
cell	B-X
activation	B-X
,	B-X
such	B-X
as	B-X
cell	B-X
size	B-X
increase	B-X
and	B-X
up-regulation	B-X
of	B-X
cell	B-X
surface	B-X
activation	B-X
markers	B-X
.	B-X
LMP1	B-X
contains	B-X
two	B-X
domains	B-X
that	B-X
activate	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
one	B-X
through	B-X
interactions	B-X
with	B-X
TRAF	B-X
proteins	B-X
and	B-X
the	B-X
other	B-X
with	B-X
the	B-X
TRADD	B-X
protein	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
importance	B-X
of	B-X
NF-kappaB	B-X
induction	B-X
in	B-X
the	B-X
up-regulation	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
activation	B-X
markers	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
by	B-X
LMP1	B-X
.	B-X
This	B-X
study	B-X
shows	B-X
that	B-X
expression	B-X
of	B-X
LMP1	B-X
activates	B-X
transcription	B-X
from	B-X
p50/p65-	B-X
and	B-X
c-Rel-responsive	B-X
promoters	B-X
,	B-X
and	B-X
that	B-X
this	B-X
activity	B-X
can	B-X
be	B-X
completely	B-X
inhibited	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
inhibitory	B-X
IkappaB	B-X
mutant	B-X
.	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
are	B-X
nevertheless	B-X
up-regulated	B-X
by	B-X
LMP1	B-X
in	B-X
primary	B-X
B	B-X
cells	B-X
and	B-X
cell	B-X
lines	B-X
expressing	B-X
the	B-X
dominant	B-X
IkappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
LMP1-induced	B-X
cell	B-X
size	B-X
increase	B-X
of	B-X
primary	B-X
B	B-X
cells	B-X
was	B-X
unaffected	B-X
by	B-X
IkappaB	B-X
expression	B-X
.	B-X
It	B-X
was	B-X
concluded	B-X
that	B-X
even	B-X
when	B-X
LMP1	B-X
is	B-X
unable	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
,	B-X
it	B-X
is	B-X
still	B-X
capable	B-X
of	B-X
inducing	B-X
certain	B-X
characteristics	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
,	B-X
strongly	B-X
suggesting	B-X
that	B-X
LMP1	B-X
can	B-X
also	B-X
activate	B-X
cells	B-X
independently	B-X
of	B-X
NF-kappaB	B-X
.	B-X

LMP1	B-Protein
contains	O
two	O
domains	O
that	O
activate	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
one	O
through	O
interactions	O
with	O
TRAF	O
proteins	O
and	O
the	O
other	O
with	O
the	O
TRADD	O
protein	O
.	O
<EOS>	B-X
The	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
required	B-X
for	B-X
EBV-induced	B-X
immortalization	B-X
of	B-X
human	B-X
B	B-X
cells	B-X
and	B-X
causes	B-X
tumorigenic	B-X
transformation	B-X
of	B-X
cell	B-X
lines	B-X
.	B-X
LMP1	B-X
expression	B-X
induces	B-X
phenotypic	B-X
changes	B-X
resembling	B-X
B	B-X
cell	B-X
activation	B-X
,	B-X
such	B-X
as	B-X
cell	B-X
size	B-X
increase	B-X
and	B-X
up-regulation	B-X
of	B-X
cell	B-X
surface	B-X
activation	B-X
markers	B-X
.	B-X
LMP1	B-X
contains	B-X
two	B-X
domains	B-X
that	B-X
activate	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
one	B-X
through	B-X
interactions	B-X
with	B-X
TRAF	B-X
proteins	B-X
and	B-X
the	B-X
other	B-X
with	B-X
the	B-X
TRADD	B-X
protein	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
importance	B-X
of	B-X
NF-kappaB	B-X
induction	B-X
in	B-X
the	B-X
up-regulation	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
activation	B-X
markers	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
by	B-X
LMP1	B-X
.	B-X
This	B-X
study	B-X
shows	B-X
that	B-X
expression	B-X
of	B-X
LMP1	B-X
activates	B-X
transcription	B-X
from	B-X
p50/p65-	B-X
and	B-X
c-Rel-responsive	B-X
promoters	B-X
,	B-X
and	B-X
that	B-X
this	B-X
activity	B-X
can	B-X
be	B-X
completely	B-X
inhibited	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
inhibitory	B-X
IkappaB	B-X
mutant	B-X
.	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
are	B-X
nevertheless	B-X
up-regulated	B-X
by	B-X
LMP1	B-X
in	B-X
primary	B-X
B	B-X
cells	B-X
and	B-X
cell	B-X
lines	B-X
expressing	B-X
the	B-X
dominant	B-X
IkappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
LMP1-induced	B-X
cell	B-X
size	B-X
increase	B-X
of	B-X
primary	B-X
B	B-X
cells	B-X
was	B-X
unaffected	B-X
by	B-X
IkappaB	B-X
expression	B-X
.	B-X
It	B-X
was	B-X
concluded	B-X
that	B-X
even	B-X
when	B-X
LMP1	B-X
is	B-X
unable	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
,	B-X
it	B-X
is	B-X
still	B-X
capable	B-X
of	B-X
inducing	B-X
certain	B-X
characteristics	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
,	B-X
strongly	B-X
suggesting	B-X
that	B-X
LMP1	B-X
can	B-X
also	B-X
activate	B-X
cells	B-X
independently	B-X
of	B-X
NF-kappaB	B-X
.	B-X

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
importance	O
of	O
NF	O
-	O
kappaB	O
induction	O
in	O
the	O
up	O
-	O
regulation	O
of	O
the	O
B	O
cell	O
activation	O
markers	O
ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
CD71	B-Protein
by	O
LMP1	B-Protein
.	O

This	O
study	O
shows	O
that	O
expression	O
of	O
LMP1	B-Protein
activates	O
transcription	O
from	O
p50	B-Protein
/	O
p65	B-Protein
-	O
and	O
c	B-Protein
-	I-Protein
Rel	I-Protein
-	O
responsive	O
promoters	O
,	O
and	O
that	O
this	O
activity	O
can	O
be	O
completely	O
inhibited	O
by	O
expression	O
of	O
a	O
dominant	O
inhibitory	O
IkappaB	O
mutant	O
.	O

ICAM	B-Protein
-	I-Protein
1	I-Protein
and	O
CD71	B-Protein
are	O
nevertheless	O
up	O
-	O
regulated	O
by	O
LMP1	B-Protein
in	O
primary	O
B	O
cells	O
and	O
cell	O
lines	O
expressing	O
the	O
dominant	O
IkappaB	O
.	O
<EOS>	B-X
The	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
required	B-X
for	B-X
EBV-induced	B-X
immortalization	B-X
of	B-X
human	B-X
B	B-X
cells	B-X
and	B-X
causes	B-X
tumorigenic	B-X
transformation	B-X
of	B-X
cell	B-X
lines	B-X
.	B-X
LMP1	B-X
expression	B-X
induces	B-X
phenotypic	B-X
changes	B-X
resembling	B-X
B	B-X
cell	B-X
activation	B-X
,	B-X
such	B-X
as	B-X
cell	B-X
size	B-X
increase	B-X
and	B-X
up-regulation	B-X
of	B-X
cell	B-X
surface	B-X
activation	B-X
markers	B-X
.	B-X
LMP1	B-X
contains	B-X
two	B-X
domains	B-X
that	B-X
activate	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
one	B-X
through	B-X
interactions	B-X
with	B-X
TRAF	B-X
proteins	B-X
and	B-X
the	B-X
other	B-X
with	B-X
the	B-X
TRADD	B-X
protein	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
importance	B-X
of	B-X
NF-kappaB	B-X
induction	B-X
in	B-X
the	B-X
up-regulation	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
activation	B-X
markers	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
by	B-X
LMP1	B-X
.	B-X
This	B-X
study	B-X
shows	B-X
that	B-X
expression	B-X
of	B-X
LMP1	B-X
activates	B-X
transcription	B-X
from	B-X
p50/p65-	B-X
and	B-X
c-Rel-responsive	B-X
promoters	B-X
,	B-X
and	B-X
that	B-X
this	B-X
activity	B-X
can	B-X
be	B-X
completely	B-X
inhibited	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
inhibitory	B-X
IkappaB	B-X
mutant	B-X
.	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
are	B-X
nevertheless	B-X
up-regulated	B-X
by	B-X
LMP1	B-X
in	B-X
primary	B-X
B	B-X
cells	B-X
and	B-X
cell	B-X
lines	B-X
expressing	B-X
the	B-X
dominant	B-X
IkappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
LMP1-induced	B-X
cell	B-X
size	B-X
increase	B-X
of	B-X
primary	B-X
B	B-X
cells	B-X
was	B-X
unaffected	B-X
by	B-X
IkappaB	B-X
expression	B-X
.	B-X
It	B-X
was	B-X
concluded	B-X
that	B-X
even	B-X
when	B-X
LMP1	B-X
is	B-X
unable	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
,	B-X
it	B-X
is	B-X
still	B-X
capable	B-X
of	B-X
inducing	B-X
certain	B-X
characteristics	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
,	B-X
strongly	B-X
suggesting	B-X
that	B-X
LMP1	B-X
can	B-X
also	B-X
activate	B-X
cells	B-X
independently	B-X
of	B-X
NF-kappaB	B-X
.	B-X

Furthermore	O
,	O
LMP1	B-Protein
-	O
induced	O
cell	O
size	O
increase	O
of	O
primary	O
B	O
cells	O
was	O
unaffected	O
by	O
IkappaB	O
expression	O
.	O
<EOS>	B-X
The	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
required	B-X
for	B-X
EBV-induced	B-X
immortalization	B-X
of	B-X
human	B-X
B	B-X
cells	B-X
and	B-X
causes	B-X
tumorigenic	B-X
transformation	B-X
of	B-X
cell	B-X
lines	B-X
.	B-X
LMP1	B-X
expression	B-X
induces	B-X
phenotypic	B-X
changes	B-X
resembling	B-X
B	B-X
cell	B-X
activation	B-X
,	B-X
such	B-X
as	B-X
cell	B-X
size	B-X
increase	B-X
and	B-X
up-regulation	B-X
of	B-X
cell	B-X
surface	B-X
activation	B-X
markers	B-X
.	B-X
LMP1	B-X
contains	B-X
two	B-X
domains	B-X
that	B-X
activate	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
one	B-X
through	B-X
interactions	B-X
with	B-X
TRAF	B-X
proteins	B-X
and	B-X
the	B-X
other	B-X
with	B-X
the	B-X
TRADD	B-X
protein	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
importance	B-X
of	B-X
NF-kappaB	B-X
induction	B-X
in	B-X
the	B-X
up-regulation	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
activation	B-X
markers	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
by	B-X
LMP1	B-X
.	B-X
This	B-X
study	B-X
shows	B-X
that	B-X
expression	B-X
of	B-X
LMP1	B-X
activates	B-X
transcription	B-X
from	B-X
p50/p65-	B-X
and	B-X
c-Rel-responsive	B-X
promoters	B-X
,	B-X
and	B-X
that	B-X
this	B-X
activity	B-X
can	B-X
be	B-X
completely	B-X
inhibited	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
inhibitory	B-X
IkappaB	B-X
mutant	B-X
.	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
are	B-X
nevertheless	B-X
up-regulated	B-X
by	B-X
LMP1	B-X
in	B-X
primary	B-X
B	B-X
cells	B-X
and	B-X
cell	B-X
lines	B-X
expressing	B-X
the	B-X
dominant	B-X
IkappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
LMP1-induced	B-X
cell	B-X
size	B-X
increase	B-X
of	B-X
primary	B-X
B	B-X
cells	B-X
was	B-X
unaffected	B-X
by	B-X
IkappaB	B-X
expression	B-X
.	B-X
It	B-X
was	B-X
concluded	B-X
that	B-X
even	B-X
when	B-X
LMP1	B-X
is	B-X
unable	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
,	B-X
it	B-X
is	B-X
still	B-X
capable	B-X
of	B-X
inducing	B-X
certain	B-X
characteristics	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
,	B-X
strongly	B-X
suggesting	B-X
that	B-X
LMP1	B-X
can	B-X
also	B-X
activate	B-X
cells	B-X
independently	B-X
of	B-X
NF-kappaB	B-X
.	B-X

It	O
was	O
concluded	O
that	O
even	O
when	O
LMP1	B-Protein
is	O
unable	O
to	O
activate	O
NF	O
-	O
kappaB	O
,	O
it	O
is	O
still	O
capable	O
of	O
inducing	O
certain	O
characteristics	O
of	O
activated	O
B	O
cells	O
,	O
strongly	O
suggesting	O
that	O
LMP1	B-Protein
can	O
also	O
activate	O
cells	O
independently	O
of	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
The	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
is	B-X
required	B-X
for	B-X
EBV-induced	B-X
immortalization	B-X
of	B-X
human	B-X
B	B-X
cells	B-X
and	B-X
causes	B-X
tumorigenic	B-X
transformation	B-X
of	B-X
cell	B-X
lines	B-X
.	B-X
LMP1	B-X
expression	B-X
induces	B-X
phenotypic	B-X
changes	B-X
resembling	B-X
B	B-X
cell	B-X
activation	B-X
,	B-X
such	B-X
as	B-X
cell	B-X
size	B-X
increase	B-X
and	B-X
up-regulation	B-X
of	B-X
cell	B-X
surface	B-X
activation	B-X
markers	B-X
.	B-X
LMP1	B-X
contains	B-X
two	B-X
domains	B-X
that	B-X
activate	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
one	B-X
through	B-X
interactions	B-X
with	B-X
TRAF	B-X
proteins	B-X
and	B-X
the	B-X
other	B-X
with	B-X
the	B-X
TRADD	B-X
protein	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
importance	B-X
of	B-X
NF-kappaB	B-X
induction	B-X
in	B-X
the	B-X
up-regulation	B-X
of	B-X
the	B-X
B	B-X
cell	B-X
activation	B-X
markers	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
by	B-X
LMP1	B-X
.	B-X
This	B-X
study	B-X
shows	B-X
that	B-X
expression	B-X
of	B-X
LMP1	B-X
activates	B-X
transcription	B-X
from	B-X
p50/p65-	B-X
and	B-X
c-Rel-responsive	B-X
promoters	B-X
,	B-X
and	B-X
that	B-X
this	B-X
activity	B-X
can	B-X
be	B-X
completely	B-X
inhibited	B-X
by	B-X
expression	B-X
of	B-X
a	B-X
dominant	B-X
inhibitory	B-X
IkappaB	B-X
mutant	B-X
.	B-X
ICAM-1	B-X
and	B-X
CD71	B-X
are	B-X
nevertheless	B-X
up-regulated	B-X
by	B-X
LMP1	B-X
in	B-X
primary	B-X
B	B-X
cells	B-X
and	B-X
cell	B-X
lines	B-X
expressing	B-X
the	B-X
dominant	B-X
IkappaB	B-X
.	B-X
Furthermore	B-X
,	B-X
LMP1-induced	B-X
cell	B-X
size	B-X
increase	B-X
of	B-X
primary	B-X
B	B-X
cells	B-X
was	B-X
unaffected	B-X
by	B-X
IkappaB	B-X
expression	B-X
.	B-X
It	B-X
was	B-X
concluded	B-X
that	B-X
even	B-X
when	B-X
LMP1	B-X
is	B-X
unable	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
,	B-X
it	B-X
is	B-X
still	B-X
capable	B-X
of	B-X
inducing	B-X
certain	B-X
characteristics	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
,	B-X
strongly	B-X
suggesting	B-X
that	B-X
LMP1	B-X
can	B-X
also	B-X
activate	B-X
cells	B-X
independently	B-X
of	B-X
NF-kappaB	B-X
.	B-X

Relationship	O
between	O
IkappaBalpha	B-Protein
constitutive	O
expression	O
,	O
TNFalpha	B-Protein
synthesis	O
,	O
and	O
apoptosis	O
in	O
EBV	O
-	O
infected	O
lymphoblastoid	O
cells	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
transformation	B-X
we	B-X
have	B-X
established	B-X
stably	B-X
transfected	B-X
IkappaBalpha	B-X
into	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X
Two	B-X
clones	B-X
were	B-X
obtained	B-X
in	B-X
which	B-X
the	B-X
loss	B-X
of	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
correlated	B-X
with	B-X
the	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
transgenic	B-X
IkappaBalpha	B-X
.	B-X
Protein	B-X
latency	B-X
expression	B-X
was	B-X
determined	B-X
by	B-X
immunocytochemistry	B-X
.	B-X
Percentage	B-X
of	B-X
apoptotic	B-X
cells	B-X
was	B-X
determined	B-X
by	B-X
in-situ	B-X
labelling	B-X
of	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
No	B-X
significative	B-X
changes	B-X
in	B-X
EBV	B-X
latency	B-X
nor	B-X
in	B-X
cell	B-X
surface	B-X
marker	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
intracytoplasmic	B-X
TNFalpha	B-X
levels	B-X
were	B-X
strongly	B-X
reduced	B-X
in	B-X
transfected	B-X
clones	B-X
.	B-X
Furthermore	B-X
,	B-X
30	B-X
%	B-X
of	B-X
IkappaBalpha	B-X
transfected	B-X
cells	B-X
were	B-X
apoptotic	B-X
after	B-X
8	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
This	B-X
correlated	B-X
with	B-X
a	B-X
strong	B-X
reduction	B-X
of	B-X
BrdU	B-X
incorporation	B-X
after	B-X
24	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
No	B-X
effect	B-X
was	B-X
seen	B-X
with	B-X
non	B-X
transfected	B-X
cells	B-X
or	B-X
with	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
control	B-X
plasmid	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
TNFalpha	B-X
gene	B-X
could	B-X
be	B-X
one	B-X
of	B-X
the	B-X
targets	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
infected	B-X
cells	B-X
and	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
EBV-infected	B-X
cells	B-X
from	B-X
apoptosis	B-X
induced	B-X
by	B-X
TNFalpha	B-X
,	B-X
which	B-X
may	B-X
favour	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
this	B-X
cytokine	B-X
.	B-X

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
EBV	O
transformation	O
we	O
have	O
established	O
stably	O
transfected	O
IkappaBalpha	B-Protein
into	O
lymphoblastoid	O
cells	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
transformation	B-X
we	B-X
have	B-X
established	B-X
stably	B-X
transfected	B-X
IkappaBalpha	B-X
into	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X
Two	B-X
clones	B-X
were	B-X
obtained	B-X
in	B-X
which	B-X
the	B-X
loss	B-X
of	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
correlated	B-X
with	B-X
the	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
transgenic	B-X
IkappaBalpha	B-X
.	B-X
Percentage	B-X
of	B-X
apoptotic	B-X
cells	B-X
was	B-X
determined	B-X
by	B-X
in-situ	B-X
labelling	B-X
of	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
No	B-X
significative	B-X
changes	B-X
in	B-X
EBV	B-X
latency	B-X
nor	B-X
in	B-X
cell	B-X
surface	B-X
marker	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
intracytoplasmic	B-X
TNFalpha	B-X
levels	B-X
were	B-X
strongly	B-X
reduced	B-X
in	B-X
transfected	B-X
clones	B-X
.	B-X
Furthermore	B-X
,	B-X
30	B-X
%	B-X
of	B-X
IkappaBalpha	B-X
transfected	B-X
cells	B-X
were	B-X
apoptotic	B-X
after	B-X
8	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
This	B-X
correlated	B-X
with	B-X
a	B-X
strong	B-X
reduction	B-X
of	B-X
BrdU	B-X
incorporation	B-X
after	B-X
24	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
No	B-X
effect	B-X
was	B-X
seen	B-X
with	B-X
non	B-X
transfected	B-X
cells	B-X
or	B-X
with	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
control	B-X
plasmid	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
TNFalpha	B-X
gene	B-X
could	B-X
be	B-X
one	B-X
of	B-X
the	B-X
targets	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
infected	B-X
cells	B-X
and	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
EBV-infected	B-X
cells	B-X
from	B-X
apoptosis	B-X
induced	B-X
by	B-X
TNFalpha	B-X
,	B-X
which	B-X
may	B-X
favour	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
this	B-X
cytokine	B-X
.	B-X

Two	O
clones	O
were	O
obtained	O
in	O
which	O
the	O
loss	O
of	O
NF	O
-	O
kappaB	O
binding	O
activity	O
correlated	O
with	O
the	O
constitutive	O
expression	O
of	O
the	O
transgenic	O
IkappaBalpha	B-Protein
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
transformation	B-X
we	B-X
have	B-X
established	B-X
stably	B-X
transfected	B-X
IkappaBalpha	B-X
into	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X
Two	B-X
clones	B-X
were	B-X
obtained	B-X
in	B-X
which	B-X
the	B-X
loss	B-X
of	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
correlated	B-X
with	B-X
the	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
transgenic	B-X
IkappaBalpha	B-X
.	B-X
Protein	B-X
latency	B-X
expression	B-X
was	B-X
determined	B-X
by	B-X
immunocytochemistry	B-X
.	B-X
No	B-X
significative	B-X
changes	B-X
in	B-X
EBV	B-X
latency	B-X
nor	B-X
in	B-X
cell	B-X
surface	B-X
marker	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
intracytoplasmic	B-X
TNFalpha	B-X
levels	B-X
were	B-X
strongly	B-X
reduced	B-X
in	B-X
transfected	B-X
clones	B-X
.	B-X
Furthermore	B-X
,	B-X
30	B-X
%	B-X
of	B-X
IkappaBalpha	B-X
transfected	B-X
cells	B-X
were	B-X
apoptotic	B-X
after	B-X
8	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
This	B-X
correlated	B-X
with	B-X
a	B-X
strong	B-X
reduction	B-X
of	B-X
BrdU	B-X
incorporation	B-X
after	B-X
24	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
TNFalpha	B-X
gene	B-X
could	B-X
be	B-X
one	B-X
of	B-X
the	B-X
targets	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
infected	B-X
cells	B-X
and	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
EBV-infected	B-X
cells	B-X
from	B-X
apoptosis	B-X
induced	B-X
by	B-X
TNFalpha	B-X
,	B-X
which	B-X
may	B-X
favour	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
this	B-X
cytokine	B-X
.	B-X

Protein	O
latency	O
expression	O
was	O
determined	O
by	O
immunocytochemistry	O
.	O
<EOS>	B-X
PRG-1	B-X
relieves	B-X
pain	B-X
and	B-X
depressive-like	B-X
behaviors	B-X
in	B-X
rats	B-X
of	B-X
bone	B-X
cancer	B-X
pain	B-X
by	B-X
regulation	B-X
of	B-X
dendritic	B-X
spine	B-X
in	B-X
hippocampus	B-X
.	B-X
In	B-X
cultured	B-X
NIH3T3	B-X
cells	B-X
,	B-X
P311	B-X
binds	B-X
to	B-X
the	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
(	B-X
TGF-β	B-X
)	B-X
-1	B-X
latency-associated	B-X
protein	B-X
(	B-X
LAP	B-X
)	B-X
and	B-X
induces	B-X
the	B-X
myofibroblast	B-X
phenotype	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
levels	B-X
of	B-X
P311	B-X
and	B-X
TGF-β1	B-X
proteins	B-X
in	B-X
tubulointerstitial	B-X
tissue	B-X
of	B-X
patients	B-X
with	B-X
different	B-X
severities	B-X
of	B-X
immunoglobulin-A	B-X
nephropathy	B-X
(	B-X
IgAN	B-X
)	B-X
,	B-X
and	B-X
analyzed	B-X
the	B-X
relationships	B-X
between	B-X
P311	B-X
protein	B-X
expression	B-X
and	B-X
clinical	B-X
data	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
association	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
protease	B-X
activated	B-X
receptor	B-X
2	B-X
(	B-X
PAR2	B-X
)	B-X
,	B-X
TMEM16A	B-X
and	B-X
neuropathic	B-X
pain	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
PAR2	B-X
and	B-X
TMEM16A	B-X
proteins	B-X
in	B-X
the	B-X
DRG	B-X
neurons	B-X
of	B-X
rats	B-X
following	B-X
CCI	B-X
of	B-X
the	B-X
sciatic	B-X
nerve	B-X
was	B-X
investigated	B-X
.	B-X
Following	B-X
the	B-X
creation	B-X
of	B-X
the	B-X
CCI	B-X
model	B-X
,	B-X
the	B-X
thermal	B-X
withdrawal	B-X
latency	B-X
(	B-X
TWL	B-X
)	B-X
was	B-X
examined	B-X
by	B-X
a	B-X
hot	B-X
plate	B-X
test	B-X
.	B-X
An	B-X
immunofluorescence	B-X
assay	B-X
and	B-X
western	B-X
blot	B-X
assay	B-X
were	B-X
performed	B-X
to	B-X
determine	B-X
the	B-X
expression	B-X
of	B-X
PAR2	B-X
and	B-X
TMEM16A	B-X
proteins	B-X
in	B-X
the	B-X
ipsilateral	B-X
L4‑6	B-X
DRG	B-X
neurons	B-X
.	B-X
The	B-X
concentration	B-X
of	B-X
inositol	B-X
1,4,5‑triphosphate	B-X
(	B-X
IP3	B-X
)	B-X
in	B-X
the	B-X
L4‑6	B-X
DRG	B-X
was	B-X
determined	B-X
by	B-X
ELISA	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
PAR2	B-X
and	B-X
TMEM16A	B-X
proteins	B-X
in	B-X
the	B-X
CCI‑D7	B-X
and	B-X
CCI‑D14	B-X
groups	B-X
were	B-X
significantly	B-X
upregulated	B-X
compared	B-X
with	B-X
the	B-X
sham	B-X
operated	B-X
group	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
;	B-X
n=12	B-X
)	B-X
.	B-X
These	B-X
ﬁndings	B-X
suggest	B-X
that	B-X
the	B-X
upregulation	B-X
of	B-X
PAR2	B-X
and	B-X
TMEM16A	B-X
in	B-X
DRG	B-X
neurons	B-X
,	B-X
the	B-X
co‑expression	B-X
of	B-X
the	B-X
two	B-X
proteins	B-X
and	B-X
increasing	B-X
IP3	B-X
are	B-X
critical	B-X
to	B-X
the	B-X
development	B-X
of	B-X
neuropathic	B-X
pain	B-X
.	B-X

Expression	O
of	O
surface	O
markers	O
,	O
intracytoplasmic	O
content	O
of	O
cytokines	O
cell	O
cycle	O
analysis	O
after	O
BrdU	O
incorporation	O
and	O
DNA	O
staining	O
with	O
propidium	O
iodide	O
were	O
studied	O
by	O
flow	O
cytometry	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
transformation	B-X
we	B-X
have	B-X
established	B-X
stably	B-X
transfected	B-X
IkappaBalpha	B-X
into	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X
Expression	B-X
of	B-X
surface	B-X
markers	B-X
,	B-X
intracytoplasmic	B-X
content	B-X
of	B-X
cytokines	B-X
cell	B-X
cycle	B-X
analysis	B-X
after	B-X
BrdU	B-X
incorporation	B-X
and	B-X
DNA	B-X
staining	B-X
with	B-X
propidium	B-X
iodide	B-X
were	B-X
studied	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
Percentage	B-X
of	B-X
apoptotic	B-X
cells	B-X
was	B-X
determined	B-X
by	B-X
in-situ	B-X
labelling	B-X
of	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
No	B-X
significative	B-X
changes	B-X
in	B-X
EBV	B-X
latency	B-X
nor	B-X
in	B-X
cell	B-X
surface	B-X
marker	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
intracytoplasmic	B-X
TNFalpha	B-X
levels	B-X
were	B-X
strongly	B-X
reduced	B-X
in	B-X
transfected	B-X
clones	B-X
.	B-X
Furthermore	B-X
,	B-X
30	B-X
%	B-X
of	B-X
IkappaBalpha	B-X
transfected	B-X
cells	B-X
were	B-X
apoptotic	B-X
after	B-X
8	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
This	B-X
correlated	B-X
with	B-X
a	B-X
strong	B-X
reduction	B-X
of	B-X
BrdU	B-X
incorporation	B-X
after	B-X
24	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
No	B-X
effect	B-X
was	B-X
seen	B-X
with	B-X
non	B-X
transfected	B-X
cells	B-X
or	B-X
with	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
control	B-X
plasmid	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
TNFalpha	B-X
gene	B-X
could	B-X
be	B-X
one	B-X
of	B-X
the	B-X
targets	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
infected	B-X
cells	B-X
and	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
EBV-infected	B-X
cells	B-X
from	B-X
apoptosis	B-X
induced	B-X
by	B-X
TNFalpha	B-X
,	B-X
which	B-X
may	B-X
favour	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
this	B-X
cytokine	B-X
.	B-X

Percentage	O
of	O
apoptotic	O
cells	O
was	O
determined	O
by	O
in	O
-	O
situ	O
labelling	O
of	O
DNA	O
strand	O
breaks	O
.	O
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
sperm	B-X
cells	B-X
characterized	B-X
by	B-X
increased	B-X
sensitivity	B-X
of	B-X
DNA	B-X
in	B-X
situ	B-X
to	B-X
denaturation	B-X
and	B-X
by	B-X
abnormal	B-X
morphology	B-X
(	B-X
shape	B-X
)	B-X
in	B-X
semen	B-X
is	B-X
associated	B-X
with	B-X
low	B-X
fertility	B-X
.	B-X
Such	B-X
cells	B-X
often	B-X
appear	B-X
in	B-X
increasing	B-X
numbers	B-X
following	B-X
exposure	B-X
to	B-X
toxic	B-X
or	B-X
mutagenic	B-X
agents	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
sensitivity	B-X
of	B-X
DNA	B-X
in	B-X
situ	B-X
to	B-X
acid-induced	B-X
denaturation	B-X
was	B-X
assayed	B-X
in	B-X
sperm	B-X
cells	B-X
of	B-X
25	B-X
patients	B-X
attending	B-X
a	B-X
human	B-X
fertility	B-X
center	B-X
.	B-X
The	B-X
same	B-X
samples	B-X
were	B-X
also	B-X
subjected	B-X
to	B-X
analysis	B-X
of	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
A	B-X
new	B-X
method	B-X
for	B-X
detecting	B-X
DNA	B-X
strand	B-X
breaks	B-X
in	B-X
situ	B-X
by	B-X
labeling	B-X
3'-OH	B-X
termini	B-X
with	B-X
biotinylated	B-X
dUTP	B-X
in	B-X
a	B-X
reaction	B-X
employing	B-X
exogenous	B-X
terminal	B-X
deoxynucleotidyl	B-X
transferase	B-X
has	B-X
been	B-X
applied	B-X
.	B-X
A	B-X
good	B-X
correlation	B-X
was	B-X
observed	B-X
in	B-X
all	B-X
samples	B-X
between	B-X
the	B-X
percentage	B-X
of	B-X
sperm	B-X
cells	B-X
with	B-X
DNA	B-X
strand	B-X
breaks	B-X
and	B-X
the	B-X
percentage	B-X
of	B-X
cells	B-X
characterized	B-X
by	B-X
an	B-X
increased	B-X
sensitivity	B-X
of	B-X
DNA	B-X
to	B-X
denaturation	B-X
(	B-X
r	B-X
=	B-X
0.87	B-X
;	B-X
P	B-X
<	B-X
=	B-X
0.05	B-X
)	B-X
.	B-X
It	B-X
is	B-X
likely	B-X
,	B-X
thus	B-X
,	B-X
that	B-X
the	B-X
sperm	B-X
cells	B-X
characterized	B-X
by	B-X
increased	B-X
DNA	B-X
sensitivity	B-X
to	B-X
denaturation	B-X
have	B-X
extensive	B-X
DNA	B-X
strand	B-X
breakage	B-X
.	B-X
The	B-X
above	B-X
properties	B-X
of	B-X
abnormal	B-X
sperm	B-X
cells	B-X
,	B-X
which	B-X
in	B-X
all	B-X
probability	B-X
are	B-X
dead	B-X
in	B-X
terms	B-X
of	B-X
their	B-X
reproductive	B-X
capacity	B-X
,	B-X
resemble	B-X
properties	B-X
of	B-X
apoptotic	B-X
somatic	B-X
cells	B-X
.	B-X
Activation	B-X
of	B-X
the	B-X
endogenous	B-X
endonuclease	B-X
which	B-X
causes	B-X
extensive	B-X
DNA	B-X
breakage	B-X
,	B-X
thus	B-X
,	B-X
is	B-X
characteristic	B-X
to	B-X
both	B-X
the	B-X
programmed	B-X
death	B-X
of	B-X
somatic	B-X
cells	B-X
(	B-X
apoptosis	B-X
)	B-X
and	B-X
functional	B-X
elimination	B-X
(	B-X
of	B-X
possibly	B-X
defective	B-X
)	B-X
germ	B-X
cells	B-X
from	B-X
the	B-X
reproductive	B-X
pool	B-X
.	B-X

No	O
significative	O
changes	O
in	O
EBV	O
latency	O
nor	O
in	O
cell	O
surface	O
marker	O
expression	O
was	O
found	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
transformation	B-X
we	B-X
have	B-X
established	B-X
stably	B-X
transfected	B-X
IkappaBalpha	B-X
into	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X
Two	B-X
clones	B-X
were	B-X
obtained	B-X
in	B-X
which	B-X
the	B-X
loss	B-X
of	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
correlated	B-X
with	B-X
the	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
transgenic	B-X
IkappaBalpha	B-X
.	B-X
Protein	B-X
latency	B-X
expression	B-X
was	B-X
determined	B-X
by	B-X
immunocytochemistry	B-X
.	B-X
Expression	B-X
of	B-X
surface	B-X
markers	B-X
,	B-X
intracytoplasmic	B-X
content	B-X
of	B-X
cytokines	B-X
cell	B-X
cycle	B-X
analysis	B-X
after	B-X
BrdU	B-X
incorporation	B-X
and	B-X
DNA	B-X
staining	B-X
with	B-X
propidium	B-X
iodide	B-X
were	B-X
studied	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
Percentage	B-X
of	B-X
apoptotic	B-X
cells	B-X
was	B-X
determined	B-X
by	B-X
in-situ	B-X
labelling	B-X
of	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
No	B-X
significative	B-X
changes	B-X
in	B-X
EBV	B-X
latency	B-X
nor	B-X
in	B-X
cell	B-X
surface	B-X
marker	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
Furthermore	B-X
,	B-X
30	B-X
%	B-X
of	B-X
IkappaBalpha	B-X
transfected	B-X
cells	B-X
were	B-X
apoptotic	B-X
after	B-X
8	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
No	B-X
effect	B-X
was	B-X
seen	B-X
with	B-X
non	B-X
transfected	B-X
cells	B-X
or	B-X
with	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
control	B-X
plasmid	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
TNFalpha	B-X
gene	B-X
could	B-X
be	B-X
one	B-X
of	B-X
the	B-X
targets	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
infected	B-X
cells	B-X
and	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
EBV-infected	B-X
cells	B-X
from	B-X
apoptosis	B-X
induced	B-X
by	B-X
TNFalpha	B-X
,	B-X
which	B-X
may	B-X
favour	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
this	B-X
cytokine	B-X
.	B-X

In	O
contrast	O
,	O
intracytoplasmic	O
TNFalpha	B-Protein
levels	O
were	O
strongly	O
reduced	O
in	O
transfected	O
clones	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
transformation	B-X
we	B-X
have	B-X
established	B-X
stably	B-X
transfected	B-X
IkappaBalpha	B-X
into	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X
Two	B-X
clones	B-X
were	B-X
obtained	B-X
in	B-X
which	B-X
the	B-X
loss	B-X
of	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
correlated	B-X
with	B-X
the	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
transgenic	B-X
IkappaBalpha	B-X
.	B-X
Expression	B-X
of	B-X
surface	B-X
markers	B-X
,	B-X
intracytoplasmic	B-X
content	B-X
of	B-X
cytokines	B-X
cell	B-X
cycle	B-X
analysis	B-X
after	B-X
BrdU	B-X
incorporation	B-X
and	B-X
DNA	B-X
staining	B-X
with	B-X
propidium	B-X
iodide	B-X
were	B-X
studied	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
intracytoplasmic	B-X
TNFalpha	B-X
levels	B-X
were	B-X
strongly	B-X
reduced	B-X
in	B-X
transfected	B-X
clones	B-X
.	B-X
Furthermore	B-X
,	B-X
30	B-X
%	B-X
of	B-X
IkappaBalpha	B-X
transfected	B-X
cells	B-X
were	B-X
apoptotic	B-X
after	B-X
8	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
This	B-X
correlated	B-X
with	B-X
a	B-X
strong	B-X
reduction	B-X
of	B-X
BrdU	B-X
incorporation	B-X
after	B-X
24	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
No	B-X
effect	B-X
was	B-X
seen	B-X
with	B-X
non	B-X
transfected	B-X
cells	B-X
or	B-X
with	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
control	B-X
plasmid	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
TNFalpha	B-X
gene	B-X
could	B-X
be	B-X
one	B-X
of	B-X
the	B-X
targets	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
infected	B-X
cells	B-X
and	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
EBV-infected	B-X
cells	B-X
from	B-X
apoptosis	B-X
induced	B-X
by	B-X
TNFalpha	B-X
,	B-X
which	B-X
may	B-X
favour	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
this	B-X
cytokine	B-X
.	B-X

Furthermore	O
,	O
30	O
%	O
of	O
IkappaBalpha	B-Protein
transfected	O
cells	O
were	O
apoptotic	O
after	O
8	O
h	O
of	O
TNFalpha	B-Protein
treatment	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
transformation	B-X
we	B-X
have	B-X
established	B-X
stably	B-X
transfected	B-X
IkappaBalpha	B-X
into	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X
Two	B-X
clones	B-X
were	B-X
obtained	B-X
in	B-X
which	B-X
the	B-X
loss	B-X
of	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
correlated	B-X
with	B-X
the	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
transgenic	B-X
IkappaBalpha	B-X
.	B-X
Protein	B-X
latency	B-X
expression	B-X
was	B-X
determined	B-X
by	B-X
immunocytochemistry	B-X
.	B-X
Expression	B-X
of	B-X
surface	B-X
markers	B-X
,	B-X
intracytoplasmic	B-X
content	B-X
of	B-X
cytokines	B-X
cell	B-X
cycle	B-X
analysis	B-X
after	B-X
BrdU	B-X
incorporation	B-X
and	B-X
DNA	B-X
staining	B-X
with	B-X
propidium	B-X
iodide	B-X
were	B-X
studied	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
Percentage	B-X
of	B-X
apoptotic	B-X
cells	B-X
was	B-X
determined	B-X
by	B-X
in-situ	B-X
labelling	B-X
of	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
No	B-X
significative	B-X
changes	B-X
in	B-X
EBV	B-X
latency	B-X
nor	B-X
in	B-X
cell	B-X
surface	B-X
marker	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
intracytoplasmic	B-X
TNFalpha	B-X
levels	B-X
were	B-X
strongly	B-X
reduced	B-X
in	B-X
transfected	B-X
clones	B-X
.	B-X
Furthermore	B-X
,	B-X
30	B-X
%	B-X
of	B-X
IkappaBalpha	B-X
transfected	B-X
cells	B-X
were	B-X
apoptotic	B-X
after	B-X
8	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
This	B-X
correlated	B-X
with	B-X
a	B-X
strong	B-X
reduction	B-X
of	B-X
BrdU	B-X
incorporation	B-X
after	B-X
24	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
No	B-X
effect	B-X
was	B-X
seen	B-X
with	B-X
non	B-X
transfected	B-X
cells	B-X
or	B-X
with	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
control	B-X
plasmid	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
TNFalpha	B-X
gene	B-X
could	B-X
be	B-X
one	B-X
of	B-X
the	B-X
targets	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
infected	B-X
cells	B-X
and	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
EBV-infected	B-X
cells	B-X
from	B-X
apoptosis	B-X
induced	B-X
by	B-X
TNFalpha	B-X
,	B-X
which	B-X
may	B-X
favour	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
this	B-X
cytokine	B-X
.	B-X

This	O
correlated	O
with	O
a	O
strong	O
reduction	O
of	O
BrdU	O
incorporation	O
after	O
24	O
h	O
of	O
TNFalpha	B-Protein
treatment	O
.	O

No	O
effect	O
was	O
seen	O
with	O
non	O
transfected	O
cells	O
or	O
with	O
cells	O
transfected	O
with	O
a	O
control	O
plasmid	O
.	O
<EOS>	B-X
To	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
Bmi-1	B-X
gene	B-X
in	B-X
the	B-X
proliferation	B-X
of	B-X
squamous	B-X
carcinoma	B-X
cells	B-X
and	B-X
whether	B-X
the	B-X
silencing	B-X
Bmi-1	B-X
can	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
cells	B-X
.	B-X
The	B-X
hepatocellular	B-X
carcinoma	B-X
cell	B-X
lines	B-X
PRL/PRF/5	B-X
and	B-X
Hep3B	B-X
,	B-X
and	B-X
the	B-X
pancreatic	B-X
carcinoma	B-X
Panc-1	B-X
cells	B-X
were	B-X
transfected	B-X
with	B-X
lipofectin	B-X
or	B-X
irradiated	B-X
with	B-X
a	B-X
linear	B-X
probe	B-X
with	B-X
a	B-X
frequency	B-X
of	B-X
8	B-X
MHz	B-X
at	B-X
a	B-X
mechanical	B-X
index	B-X
of	B-X
0.4	B-X
through	B-X
the	B-X
bottom	B-X
of	B-X
the	B-X
plates	B-X
for	B-X
5	B-X
min	B-X
using	B-X
diagnostic	B-X
ultrasound	B-X
(	B-X
US	B-X
)	B-X
with	B-X
pEGFP-N1	B-X
[	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
expression	B-X
plasmid	B-X
]	B-X
,	B-X
and	B-X
observed	B-X
under	B-X
fluorescence	B-X
microscopy	B-X
48	B-X
h	B-X
later	B-X
.	B-X
The	B-X
cell	B-X
lines	B-X
were	B-X
transfected	B-X
or	B-X
irradiated	B-X
with	B-X
US	B-X
with	B-X
pGL3	B-X
control	B-X
(	B-X
luciferase	B-X
reporter	B-X
plasmid	B-X
)	B-X
,	B-X
and	B-X
a	B-X
luciferase	B-X
assay	B-X
(	B-X
48	B-X
h	B-X
later	B-X
)	B-X
or	B-X
an	B-X
MTS	B-X
assay	B-X
(	B-X
72	B-X
h	B-X
later	B-X
)	B-X
were	B-X
performed	B-X
.	B-X
Although	B-X
signals	B-X
of	B-X
GFP	B-X
were	B-X
observed	B-X
in	B-X
cells	B-X
with	B-X
US	B-X
,	B-X
the	B-X
transfection	B-X
efficiencies	B-X
of	B-X
US	B-X
were	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
transfection	B-X
.	B-X
Luciferase	B-X
activities	B-X
of	B-X
cells	B-X
with	B-X
US	B-X
were	B-X
higher	B-X
than	B-X
those	B-X
of	B-X
non-irradiated	B-X
or	B-X
transfected	B-X
cells	B-X
,	B-X
but	B-X
lower	B-X
than	B-X
those	B-X
of	B-X
transfection	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
the	O
TNFalpha	B-Protein
gene	O
could	O
be	O
one	O
of	O
the	O
targets	O
of	O
NF	O
-	O
kappaB	O
in	O
EBV	O
infected	O
cells	O
and	O
that	O
NF	O
-	O
kappaB	O
protects	O
EBV	O
-	O
infected	O
cells	O
from	O
apoptosis	O
induced	O
by	O
TNFalpha	B-Protein
,	O
which	O
may	O
favour	O
the	O
proliferative	O
effect	O
of	O
this	O
cytokine	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
transformation	B-X
we	B-X
have	B-X
established	B-X
stably	B-X
transfected	B-X
IkappaBalpha	B-X
into	B-X
lymphoblastoid	B-X
cells	B-X
.	B-X
Two	B-X
clones	B-X
were	B-X
obtained	B-X
in	B-X
which	B-X
the	B-X
loss	B-X
of	B-X
NF-kappaB	B-X
binding	B-X
activity	B-X
correlated	B-X
with	B-X
the	B-X
constitutive	B-X
expression	B-X
of	B-X
the	B-X
transgenic	B-X
IkappaBalpha	B-X
.	B-X
Expression	B-X
of	B-X
surface	B-X
markers	B-X
,	B-X
intracytoplasmic	B-X
content	B-X
of	B-X
cytokines	B-X
cell	B-X
cycle	B-X
analysis	B-X
after	B-X
BrdU	B-X
incorporation	B-X
and	B-X
DNA	B-X
staining	B-X
with	B-X
propidium	B-X
iodide	B-X
were	B-X
studied	B-X
by	B-X
flow	B-X
cytometry	B-X
.	B-X
Percentage	B-X
of	B-X
apoptotic	B-X
cells	B-X
was	B-X
determined	B-X
by	B-X
in-situ	B-X
labelling	B-X
of	B-X
DNA	B-X
strand	B-X
breaks	B-X
.	B-X
No	B-X
significative	B-X
changes	B-X
in	B-X
EBV	B-X
latency	B-X
nor	B-X
in	B-X
cell	B-X
surface	B-X
marker	B-X
expression	B-X
was	B-X
found	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
intracytoplasmic	B-X
TNFalpha	B-X
levels	B-X
were	B-X
strongly	B-X
reduced	B-X
in	B-X
transfected	B-X
clones	B-X
.	B-X
Furthermore	B-X
,	B-X
30	B-X
%	B-X
of	B-X
IkappaBalpha	B-X
transfected	B-X
cells	B-X
were	B-X
apoptotic	B-X
after	B-X
8	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
This	B-X
correlated	B-X
with	B-X
a	B-X
strong	B-X
reduction	B-X
of	B-X
BrdU	B-X
incorporation	B-X
after	B-X
24	B-X
h	B-X
of	B-X
TNFalpha	B-X
treatment	B-X
.	B-X
No	B-X
effect	B-X
was	B-X
seen	B-X
with	B-X
non	B-X
transfected	B-X
cells	B-X
or	B-X
with	B-X
cells	B-X
transfected	B-X
with	B-X
a	B-X
control	B-X
plasmid	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
TNFalpha	B-X
gene	B-X
could	B-X
be	B-X
one	B-X
of	B-X
the	B-X
targets	B-X
of	B-X
NF-kappaB	B-X
in	B-X
EBV	B-X
infected	B-X
cells	B-X
and	B-X
that	B-X
NF-kappaB	B-X
protects	B-X
EBV-infected	B-X
cells	B-X
from	B-X
apoptosis	B-X
induced	B-X
by	B-X
TNFalpha	B-X
,	B-X
which	B-X
may	B-X
favour	B-X
the	B-X
proliferative	B-X
effect	B-X
of	B-X
this	B-X
cytokine	B-X
.	B-X

Uncoupling	O
activation	O
-	O
dependent	O
HS1	B-Protein
phosphorylation	O
from	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
transcriptional	O
activation	O
in	O
Jurkat	O
T	O
cells	O
:	O
differential	O
signaling	O
through	O
CD3	O
and	O
the	O
costimulatory	O
receptors	O
CD2	B-Protein
and	O
CD28	B-Protein
.	O

CD3	O
,	O
CD2	B-Protein
,	O
and	O
CD28	B-Protein
are	O
functionally	O
distinct	O
receptors	O
on	O
T	O
lymphocytes	O
.	O

Engagement	O
of	O
any	O
of	O
these	O
receptors	O
induces	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
a	O
shared	O
group	O
of	O
intracellular	O
signaling	O
proteins	O
,	O
including	O
Vav	B-Protein
,	O
Cbl	B-Protein
,	O
p85	O
phosphoinositide	O
3	O
-	O
kinase	O
,	O
and	O
the	O
Src	B-Protein
family	O
kinases	O
Lck	B-Protein
and	O
Fyn	B-Protein
.	O
<EOS>	B-X
CD3	B-X
,	B-X
CD2	B-X
,	B-X
and	B-X
CD28	B-X
are	B-X
functionally	B-X
distinct	B-X
receptors	B-X
on	B-X
T	B-X
lymphocytes	B-X
.	B-X
Engagement	B-X
of	B-X
any	B-X
of	B-X
these	B-X
receptors	B-X
induces	B-X
the	B-X
rapid	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
a	B-X
shared	B-X
group	B-X
of	B-X
intracellular	B-X
signaling	B-X
proteins	B-X
,	B-X
including	B-X
Vav	B-X
,	B-X
Cbl	B-X
,	B-X
p85	B-X
phosphoinositide	B-X
3-kinase	B-X
,	B-X
and	B-X
the	B-X
Src	B-X
family	B-X
kinases	B-X
Lck	B-X
and	B-X
Fyn	B-X
.	B-X
Ligation	B-X
of	B-X
CD3	B-X
also	B-X
induces	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
,	B-X
a	B-X
75-kDa	B-X
hematopoietic	B-X
cell-specific	B-X
intracellular	B-X
signaling	B-X
protein	B-X
of	B-X
unknown	B-X
function	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
changes	B-X
in	B-X
HS1	B-X
phosphorylation	B-X
after	B-X
differential	B-X
stimulation	B-X
of	B-X
CD3	B-X
,	B-X
CD2	B-X
,	B-X
and	B-X
CD28	B-X
to	B-X
elucidate	B-X
its	B-X
role	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
to	B-X
further	B-X
delineate	B-X
the	B-X
signaling	B-X
pathways	B-X
recruited	B-X
by	B-X
these	B-X
receptors	B-X
.	B-X
Unlike	B-X
ligation	B-X
of	B-X
CD3	B-X
,	B-X
stimulation	B-X
with	B-X
anti-CD28	B-X
mAb	B-X
or	B-X
CHO	B-X
cells	B-X
expressing	B-X
the	B-X
CD28	B-X
ligands	B-X
CD80	B-X
or	B-X
CD86	B-X
did	B-X
not	B-X
lead	B-X
to	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
Additionally	B-X
,	B-X
no	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
was	B-X
induced	B-X
by	B-X
mitogenic	B-X
pairs	B-X
of	B-X
anti-CD2	B-X
mAbs	B-X
capable	B-X
of	B-X
activating	B-X
the	B-X
transcription	B-X
factor	B-X
NFAT	B-X
(	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
)	B-X
.	B-X
Costimulation	B-X
through	B-X
CD28	B-X
and/or	B-X
CD2	B-X
did	B-X
not	B-X
modulate	B-X
the	B-X
CD3-dependent	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
.	B-X
In	B-X
vivo	B-X
studies	B-X
indicated	B-X
that	B-X
CD3-induced	B-X
HSI	B-X
phosphorylation	B-X
was	B-X
dependent	B-X
upon	B-X
both	B-X
the	B-X
Src	B-X
family	B-X
tyrosine	B-X
kinase	B-X
Lck	B-X
and	B-X
the	B-X
tyrosine	B-X
phosphatase	B-X
CD45	B-X
,	B-X
did	B-X
not	B-X
require	B-X
MEK1	B-X
kinase	B-X
activity	B-X
,	B-X
and	B-X
was	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
C	B-X
activation	B-X
.	B-X
Thus	B-X
,	B-X
although	B-X
CD3	B-X
,	B-X
CD28	B-X
,	B-X
and	B-X
CD2	B-X
activate	B-X
many	B-X
of	B-X
the	B-X
same	B-X
signaling	B-X
molecules	B-X
,	B-X
they	B-X
differed	B-X
in	B-X
their	B-X
capacity	B-X
to	B-X
induce	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HSI	B-X
.	B-X
Furthermore	B-X
,	B-X
activation-dependent	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
was	B-X
not	B-X
required	B-X
for	B-X
NFAT	B-X
transcriptional	B-X
activation	B-X
.	B-X

Ligation	O
of	O
CD3	O
also	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-Protein
,	O
a	O
75	O
-	O
kDa	O
hematopoietic	O
cell	O
-	O
specific	O
intracellular	O
signaling	O
protein	O
of	O
unknown	O
function	O
.	O
<EOS>	B-X
CD3	B-X
,	B-X
CD2	B-X
,	B-X
and	B-X
CD28	B-X
are	B-X
functionally	B-X
distinct	B-X
receptors	B-X
on	B-X
T	B-X
lymphocytes	B-X
.	B-X
Engagement	B-X
of	B-X
any	B-X
of	B-X
these	B-X
receptors	B-X
induces	B-X
the	B-X
rapid	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
a	B-X
shared	B-X
group	B-X
of	B-X
intracellular	B-X
signaling	B-X
proteins	B-X
,	B-X
including	B-X
Vav	B-X
,	B-X
Cbl	B-X
,	B-X
p85	B-X
phosphoinositide	B-X
3-kinase	B-X
,	B-X
and	B-X
the	B-X
Src	B-X
family	B-X
kinases	B-X
Lck	B-X
and	B-X
Fyn	B-X
.	B-X
Ligation	B-X
of	B-X
CD3	B-X
also	B-X
induces	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
,	B-X
a	B-X
75-kDa	B-X
hematopoietic	B-X
cell-specific	B-X
intracellular	B-X
signaling	B-X
protein	B-X
of	B-X
unknown	B-X
function	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
changes	B-X
in	B-X
HS1	B-X
phosphorylation	B-X
after	B-X
differential	B-X
stimulation	B-X
of	B-X
CD3	B-X
,	B-X
CD2	B-X
,	B-X
and	B-X
CD28	B-X
to	B-X
elucidate	B-X
its	B-X
role	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
to	B-X
further	B-X
delineate	B-X
the	B-X
signaling	B-X
pathways	B-X
recruited	B-X
by	B-X
these	B-X
receptors	B-X
.	B-X
Unlike	B-X
ligation	B-X
of	B-X
CD3	B-X
,	B-X
stimulation	B-X
with	B-X
anti-CD28	B-X
mAb	B-X
or	B-X
CHO	B-X
cells	B-X
expressing	B-X
the	B-X
CD28	B-X
ligands	B-X
CD80	B-X
or	B-X
CD86	B-X
did	B-X
not	B-X
lead	B-X
to	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
Additionally	B-X
,	B-X
no	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
was	B-X
induced	B-X
by	B-X
mitogenic	B-X
pairs	B-X
of	B-X
anti-CD2	B-X
mAbs	B-X
capable	B-X
of	B-X
activating	B-X
the	B-X
transcription	B-X
factor	B-X
NFAT	B-X
(	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
)	B-X
.	B-X
Costimulation	B-X
through	B-X
CD28	B-X
and/or	B-X
CD2	B-X
did	B-X
not	B-X
modulate	B-X
the	B-X
CD3-dependent	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
.	B-X
In	B-X
vivo	B-X
studies	B-X
indicated	B-X
that	B-X
CD3-induced	B-X
HSI	B-X
phosphorylation	B-X
was	B-X
dependent	B-X
upon	B-X
both	B-X
the	B-X
Src	B-X
family	B-X
tyrosine	B-X
kinase	B-X
Lck	B-X
and	B-X
the	B-X
tyrosine	B-X
phosphatase	B-X
CD45	B-X
,	B-X
did	B-X
not	B-X
require	B-X
MEK1	B-X
kinase	B-X
activity	B-X
,	B-X
and	B-X
was	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
C	B-X
activation	B-X
.	B-X
Thus	B-X
,	B-X
although	B-X
CD3	B-X
,	B-X
CD28	B-X
,	B-X
and	B-X
CD2	B-X
activate	B-X
many	B-X
of	B-X
the	B-X
same	B-X
signaling	B-X
molecules	B-X
,	B-X
they	B-X
differed	B-X
in	B-X
their	B-X
capacity	B-X
to	B-X
induce	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HSI	B-X
.	B-X
Furthermore	B-X
,	B-X
activation-dependent	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
was	B-X
not	B-X
required	B-X
for	B-X
NFAT	B-X
transcriptional	B-X
activation	B-X
.	B-X

We	O
have	O
examined	O
changes	O
in	O
HS1	B-Protein
phosphorylation	O
after	O
differential	O
stimulation	O
of	O
CD3	O
,	O
CD2	B-Protein
,	O
and	O
CD28	B-Protein
to	O
elucidate	O
its	O
role	O
in	O
T	O
cells	O
and	O
to	O
further	O
delineate	O
the	O
signaling	O
pathways	O
recruited	O
by	O
these	O
receptors	O
.	O

Unlike	O
ligation	O
of	O
CD3	O
,	O
stimulation	O
with	O
anti	O
-	O
CD28	B-Protein
mAb	O
or	O
CHO	O
cells	O
expressing	O
the	O
CD28	B-Protein
ligands	O
CD80	B-Protein
or	O
CD86	B-Protein
did	O
not	O
lead	O
to	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-Protein
in	O
Jurkat	O
T	O
cells	O
.	O
<EOS>	B-X
Cytotoxic	B-X
T-lymphocyte-associated	B-X
protein	B-X
4	B-X
(	B-X
CTLA-4	B-X
)	B-X
is	B-X
an	B-X
inhibitory	B-X
receptor	B-X
belonging	B-X
to	B-X
the	B-X
CD28	B-X
immunoglobulin	B-X
subfamily	B-X
,	B-X
expressed	B-X
primarily	B-X
by	B-X
T-cells	B-X
.	B-X
Its	B-X
ligands	B-X
,	B-X
CD80	B-X
and	B-X
CD86	B-X
,	B-X
are	B-X
typically	B-X
found	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
antigen-presenting	B-X
cells	B-X
and	B-X
can	B-X
either	B-X
bind	B-X
CD28	B-X
or	B-X
CTLA-4	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
costimulatory	B-X
or	B-X
a	B-X
co-inhibitory	B-X
response	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
mechanisms	B-X
by	B-X
which	B-X
CTLA-4	B-X
exerts	B-X
its	B-X
inhibitory	B-X
function	B-X
can	B-X
be	B-X
categorized	B-X
as	B-X
either	B-X
cell-intrinsic	B-X
(	B-X
affects	B-X
the	B-X
CTLA-4	B-X
expressing	B-X
T-cell	B-X
)	B-X
or	B-X
cell-extrinsic	B-X
(	B-X
affects	B-X
secondary	B-X
cells	B-X
)	B-X
.	B-X
Research	B-X
from	B-X
the	B-X
last	B-X
decade	B-X
has	B-X
shown	B-X
that	B-X
CTLA-4	B-X
mainly	B-X
acts	B-X
in	B-X
a	B-X
cell-extrinsic	B-X
manner	B-X
via	B-X
its	B-X
competition	B-X
with	B-X
CD28	B-X
,	B-X
CTLA-4-mediated	B-X
trans-endocytosis	B-X
of	B-X
CD80	B-X
and	B-X
CD86	B-X
,	B-X
and	B-X
its	B-X
direct	B-X
tolerogenic	B-X
effects	B-X
on	B-X
the	B-X
interacting	B-X
cell	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
role	B-X
of	B-X
costimulation	B-X
in	B-X
immune	B-X
response	B-X
induction	B-X
as	B-X
well	B-X
as	B-X
the	B-X
main	B-X
mechanisms	B-X
by	B-X
which	B-X
CTLA-4	B-X
can	B-X
inhibit	B-X
this	B-X
process	B-X
.	B-X

Additionally	O
,	O
no	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-Protein
was	O
induced	O
by	O
mitogenic	O
pairs	O
of	O
anti	O
-	O
CD2	B-Protein
mAbs	O
capable	O
of	O
activating	O
the	O
transcription	O
factor	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
.	O
<EOS>	B-X
CD3	B-X
,	B-X
CD2	B-X
,	B-X
and	B-X
CD28	B-X
are	B-X
functionally	B-X
distinct	B-X
receptors	B-X
on	B-X
T	B-X
lymphocytes	B-X
.	B-X
Engagement	B-X
of	B-X
any	B-X
of	B-X
these	B-X
receptors	B-X
induces	B-X
the	B-X
rapid	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
a	B-X
shared	B-X
group	B-X
of	B-X
intracellular	B-X
signaling	B-X
proteins	B-X
,	B-X
including	B-X
Vav	B-X
,	B-X
Cbl	B-X
,	B-X
p85	B-X
phosphoinositide	B-X
3-kinase	B-X
,	B-X
and	B-X
the	B-X
Src	B-X
family	B-X
kinases	B-X
Lck	B-X
and	B-X
Fyn	B-X
.	B-X
Ligation	B-X
of	B-X
CD3	B-X
also	B-X
induces	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
,	B-X
a	B-X
75-kDa	B-X
hematopoietic	B-X
cell-specific	B-X
intracellular	B-X
signaling	B-X
protein	B-X
of	B-X
unknown	B-X
function	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
changes	B-X
in	B-X
HS1	B-X
phosphorylation	B-X
after	B-X
differential	B-X
stimulation	B-X
of	B-X
CD3	B-X
,	B-X
CD2	B-X
,	B-X
and	B-X
CD28	B-X
to	B-X
elucidate	B-X
its	B-X
role	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
to	B-X
further	B-X
delineate	B-X
the	B-X
signaling	B-X
pathways	B-X
recruited	B-X
by	B-X
these	B-X
receptors	B-X
.	B-X
Unlike	B-X
ligation	B-X
of	B-X
CD3	B-X
,	B-X
stimulation	B-X
with	B-X
anti-CD28	B-X
mAb	B-X
or	B-X
CHO	B-X
cells	B-X
expressing	B-X
the	B-X
CD28	B-X
ligands	B-X
CD80	B-X
or	B-X
CD86	B-X
did	B-X
not	B-X
lead	B-X
to	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
Additionally	B-X
,	B-X
no	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
was	B-X
induced	B-X
by	B-X
mitogenic	B-X
pairs	B-X
of	B-X
anti-CD2	B-X
mAbs	B-X
capable	B-X
of	B-X
activating	B-X
the	B-X
transcription	B-X
factor	B-X
NFAT	B-X
(	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
)	B-X
.	B-X
Costimulation	B-X
through	B-X
CD28	B-X
and/or	B-X
CD2	B-X
did	B-X
not	B-X
modulate	B-X
the	B-X
CD3-dependent	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
.	B-X
In	B-X
vivo	B-X
studies	B-X
indicated	B-X
that	B-X
CD3-induced	B-X
HSI	B-X
phosphorylation	B-X
was	B-X
dependent	B-X
upon	B-X
both	B-X
the	B-X
Src	B-X
family	B-X
tyrosine	B-X
kinase	B-X
Lck	B-X
and	B-X
the	B-X
tyrosine	B-X
phosphatase	B-X
CD45	B-X
,	B-X
did	B-X
not	B-X
require	B-X
MEK1	B-X
kinase	B-X
activity	B-X
,	B-X
and	B-X
was	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
C	B-X
activation	B-X
.	B-X
Thus	B-X
,	B-X
although	B-X
CD3	B-X
,	B-X
CD28	B-X
,	B-X
and	B-X
CD2	B-X
activate	B-X
many	B-X
of	B-X
the	B-X
same	B-X
signaling	B-X
molecules	B-X
,	B-X
they	B-X
differed	B-X
in	B-X
their	B-X
capacity	B-X
to	B-X
induce	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HSI	B-X
.	B-X
Furthermore	B-X
,	B-X
activation-dependent	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
was	B-X
not	B-X
required	B-X
for	B-X
NFAT	B-X
transcriptional	B-X
activation	B-X
.	B-X

Costimulation	O
through	O
CD28	B-Protein
and	O
/	O
or	O
CD2	B-Protein
did	O
not	O
modulate	O
the	O
CD3	O
-	O
dependent	O
phosphorylation	O
of	O
HS1	B-Protein
.	O
<EOS>	B-X
We	B-X
show	B-X
that	B-X
tonic	B-X
CAR	B-X
CD3-ζ	B-X
phosphorylation	B-X
,	B-X
triggered	B-X
by	B-X
antigen-independent	B-X
clustering	B-X
of	B-X
CAR	B-X
single-chain	B-X
variable	B-X
fragments	B-X
,	B-X
can	B-X
induce	B-X
early	B-X
exhaustion	B-X
of	B-X
CAR	B-X
T	B-X
cells	B-X
that	B-X
limits	B-X
antitumor	B-X
efficacy	B-X
.	B-X
We	B-X
further	B-X
determine	B-X
that	B-X
CD28	B-X
costimulation	B-X
augments	B-X
,	B-X
whereas	B-X
4-1BB	B-X
costimulation	B-X
reduces	B-X
,	B-X
exhaustion	B-X
induced	B-X
by	B-X
persistent	B-X
CAR	B-X
signaling	B-X
.	B-X
Our	B-X
results	B-X
provide	B-X
biological	B-X
explanations	B-X
for	B-X
the	B-X
antitumor	B-X
effects	B-X
of	B-X
CD19	B-X
CARs	B-X
and	B-X
for	B-X
the	B-X
observations	B-X
that	B-X
CD19	B-X
CAR	B-X
T	B-X
cells	B-X
incorporating	B-X
the	B-X
4-1BB	B-X
costimulatory	B-X
domain	B-X
are	B-X
more	B-X
persistent	B-X
than	B-X
those	B-X
incorporating	B-X
CD28	B-X
in	B-X
clinical	B-X
trials	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
peripheral	B-X
blood	B-X
mononucleated	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
with	B-X
anti-CD3/CD28-coated	B-X
magnetic	B-X
beads	B-X
promotes	B-X
intrinsic	B-X
resistance	B-X
to	B-X
HIV	B-X
as	B-X
well	B-X
as	B-X
cell	B-X
expansion	B-X
.	B-X

In	O
vivo	O
studies	O
indicated	O
that	O
CD3	O
-	O
induced	O
HSI	B-Protein
phosphorylation	O
was	O
dependent	O
upon	O
both	O
the	O
Src	B-Protein
family	O
tyrosine	O
kinase	O
Lck	B-Protein
and	O
the	O
tyrosine	O
phosphatase	O
CD45	B-Protein
,	O
did	O
not	O
require	O
MEK1	B-Protein
kinase	O
activity	O
,	O
and	O
was	O
regulated	O
by	O
protein	O
kinase	O
C	O
activation	O
.	O

Thus	O
,	O
although	O
CD3	O
,	O
CD28	B-Protein
,	O
and	O
CD2	B-Protein
activate	O
many	O
of	O
the	O
same	O
signaling	O
molecules	O
,	O
they	O
differed	O
in	O
their	O
capacity	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
HSI	B-Protein
.	O
<EOS>	B-X
CD3	B-X
,	B-X
CD2	B-X
,	B-X
and	B-X
CD28	B-X
are	B-X
functionally	B-X
distinct	B-X
receptors	B-X
on	B-X
T	B-X
lymphocytes	B-X
.	B-X
Engagement	B-X
of	B-X
any	B-X
of	B-X
these	B-X
receptors	B-X
induces	B-X
the	B-X
rapid	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
a	B-X
shared	B-X
group	B-X
of	B-X
intracellular	B-X
signaling	B-X
proteins	B-X
,	B-X
including	B-X
Vav	B-X
,	B-X
Cbl	B-X
,	B-X
p85	B-X
phosphoinositide	B-X
3-kinase	B-X
,	B-X
and	B-X
the	B-X
Src	B-X
family	B-X
kinases	B-X
Lck	B-X
and	B-X
Fyn	B-X
.	B-X
Ligation	B-X
of	B-X
CD3	B-X
also	B-X
induces	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
,	B-X
a	B-X
75-kDa	B-X
hematopoietic	B-X
cell-specific	B-X
intracellular	B-X
signaling	B-X
protein	B-X
of	B-X
unknown	B-X
function	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
changes	B-X
in	B-X
HS1	B-X
phosphorylation	B-X
after	B-X
differential	B-X
stimulation	B-X
of	B-X
CD3	B-X
,	B-X
CD2	B-X
,	B-X
and	B-X
CD28	B-X
to	B-X
elucidate	B-X
its	B-X
role	B-X
in	B-X
T	B-X
cells	B-X
and	B-X
to	B-X
further	B-X
delineate	B-X
the	B-X
signaling	B-X
pathways	B-X
recruited	B-X
by	B-X
these	B-X
receptors	B-X
.	B-X
Unlike	B-X
ligation	B-X
of	B-X
CD3	B-X
,	B-X
stimulation	B-X
with	B-X
anti-CD28	B-X
mAb	B-X
or	B-X
CHO	B-X
cells	B-X
expressing	B-X
the	B-X
CD28	B-X
ligands	B-X
CD80	B-X
or	B-X
CD86	B-X
did	B-X
not	B-X
lead	B-X
to	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
in	B-X
Jurkat	B-X
T	B-X
cells	B-X
.	B-X
Additionally	B-X
,	B-X
no	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
was	B-X
induced	B-X
by	B-X
mitogenic	B-X
pairs	B-X
of	B-X
anti-CD2	B-X
mAbs	B-X
capable	B-X
of	B-X
activating	B-X
the	B-X
transcription	B-X
factor	B-X
NFAT	B-X
(	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
)	B-X
.	B-X
Costimulation	B-X
through	B-X
CD28	B-X
and/or	B-X
CD2	B-X
did	B-X
not	B-X
modulate	B-X
the	B-X
CD3-dependent	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
.	B-X
In	B-X
vivo	B-X
studies	B-X
indicated	B-X
that	B-X
CD3-induced	B-X
HSI	B-X
phosphorylation	B-X
was	B-X
dependent	B-X
upon	B-X
both	B-X
the	B-X
Src	B-X
family	B-X
tyrosine	B-X
kinase	B-X
Lck	B-X
and	B-X
the	B-X
tyrosine	B-X
phosphatase	B-X
CD45	B-X
,	B-X
did	B-X
not	B-X
require	B-X
MEK1	B-X
kinase	B-X
activity	B-X
,	B-X
and	B-X
was	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
C	B-X
activation	B-X
.	B-X
Thus	B-X
,	B-X
although	B-X
CD3	B-X
,	B-X
CD28	B-X
,	B-X
and	B-X
CD2	B-X
activate	B-X
many	B-X
of	B-X
the	B-X
same	B-X
signaling	B-X
molecules	B-X
,	B-X
they	B-X
differed	B-X
in	B-X
their	B-X
capacity	B-X
to	B-X
induce	B-X
the	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HSI	B-X
.	B-X
Furthermore	B-X
,	B-X
activation-dependent	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
HS1	B-X
was	B-X
not	B-X
required	B-X
for	B-X
NFAT	B-X
transcriptional	B-X
activation	B-X
.	B-X

Furthermore	O
,	O
activation	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
HS1	B-Protein
was	O
not	O
required	O
for	O
NFAT	O
transcriptional	O
activation	O
.	O
<EOS>	B-X
Hematopoietic	B-X
progenitor	B-X
kinase-1	B-X
(	B-X
HPK1	B-X
)	B-X
,	B-X
which	B-X
is	B-X
expressed	B-X
predominantly	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
mammalian	B-X
Ste20	B-X
homologue	B-X
that	B-X
,	B-X
upon	B-X
transfection	B-X
,	B-X
leads	B-X
to	B-X
activation	B-X
of	B-X
JNK/SAPK	B-X
in	B-X
nonhematopoietic	B-X
cells	B-X
.	B-X
We	B-X
therefore	B-X
examined	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
HPK1	B-X
in	B-X
erythropoietin	B-X
(	B-X
Epo	B-X
)	B-X
and	B-X
environmental	B-X
stress-induced	B-X
JNK/SAPK	B-X
activation	B-X
in	B-X
the	B-X
Epo-dependent	B-X
FD-EPO	B-X
cells	B-X
and	B-X
Epo-responsive	B-X
SKT6	B-X
cells	B-X
.	B-X
We	B-X
found	B-X
that	B-X
Epo	B-X
,	B-X
but	B-X
not	B-X
environmental	B-X
stresses	B-X
,	B-X
induced	B-X
rapid	B-X
and	B-X
transient	B-X
activation	B-X
of	B-X
HPK1	B-X
,	B-X
whereas	B-X
both	B-X
induced	B-X
activation	B-X
of	B-X
JNK/SAPK	B-X
.	B-X
A	B-X
screen	B-X
for	B-X
HPK1	B-X
binding	B-X
proteins	B-X
identified	B-X
the	B-X
hematopoietic	B-X
cell-specific	B-X
protein	B-X
1	B-X
(	B-X
HS1	B-X
)	B-X
as	B-X
a	B-X
potential	B-X
HPK1	B-X
interaction	B-X
partner	B-X
.	B-X
We	B-X
found	B-X
HPK1	B-X
constitutively	B-X
associated	B-X
with	B-X
HS1	B-X
and	B-X
that	B-X
HS1	B-X
was	B-X
tyrosine-phosphorylated	B-X
in	B-X
response	B-X
to	B-X
cellular	B-X
stresses	B-X
as	B-X
well	B-X
as	B-X
Epo	B-X
stimulation	B-X
.	B-X
Furthermore	B-X
,	B-X
antisense	B-X
oligonucleotides	B-X
to	B-X
HPK1	B-X
suppressed	B-X
Epo-dependent	B-X
cell	B-X
growth	B-X
and	B-X
Epo-induced	B-X
erythroid	B-X
differentiation	B-X
.	B-X
We	B-X
therefore	B-X
conclude	B-X
that	B-X
Epo	B-X
induces	B-X
activation	B-X
of	B-X
both	B-X
HPK1	B-X
and	B-X
HS1	B-X
,	B-X
whereas	B-X
cellular	B-X
stresses	B-X
activate	B-X
only	B-X
HS1	B-X
,	B-X
and	B-X
that	B-X
the	B-X
HPK1-JNK/SAPK	B-X
pathway	B-X
is	B-X
involved	B-X
in	B-X
Epo-induced	B-X
growth	B-X
and	B-X
differentiation	B-X
signals	B-X
.	B-X

IL	B-Protein
-	I-Protein
7	I-Protein
reconstitutes	O
multiple	O
aspects	O
of	O
v	B-Protein
-	I-Protein
Abl	I-Protein
-	O
mediated	O
signaling	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
early	B-X
lymphoid	B-X
cells	B-X
are	B-X
selectively	B-X
transformed	B-X
by	B-X
v-Abl	B-X
is	B-X
currently	B-X
unknown	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
constitutive	B-X
activation	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
activation	B-X
of	B-X
Janus	B-X
protein	B-X
kinase	B-X
(	B-X
JAK	B-X
)	B-X
1	B-X
,	B-X
JAK3	B-X
,	B-X
STAT5	B-X
,	B-X
and	B-X
STAT6	B-X
,	B-X
in	B-X
pre-B	B-X
cells	B-X
transformed	B-X
by	B-X
v-Abl	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
activation	B-X
of	B-X
these	B-X
cytokine	B-X
signaling	B-X
pathways	B-X
by	B-X
v-Abl	B-X
is	B-X
important	B-X
in	B-X
the	B-X
cellular	B-X
events	B-X
induced	B-X
by	B-X
the	B-X
Abelson	B-X
murine	B-X
leukemia	B-X
virus	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
on	B-X
pre-B	B-X
cells	B-X
transformed	B-X
with	B-X
a	B-X
temperature-sensitive	B-X
v-Abl	B-X
mutant	B-X
were	B-X
examined	B-X
.	B-X
Whereas	B-X
IL-4	B-X
had	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
,	B-X
IL-7	B-X
delayed	B-X
both	B-X
the	B-X
apoptosis	B-X
and	B-X
cell	B-X
cycle	B-X
arrest	B-X
that	B-X
occur	B-X
upon	B-X
v-Abl	B-X
kinase	B-X
inactivation	B-X
.	B-X
IL-7	B-X
also	B-X
delayed	B-X
the	B-X
decreases	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
c-Myc	B-X
,	B-X
Bcl-2	B-X
,	B-X
and	B-X
Bcl-xL	B-X
that	B-X
occur	B-X
upon	B-X
loss	B-X
of	B-X
v-Abl	B-X
kinase	B-X
activity	B-X
.	B-X
IL-7	B-X
did	B-X
not	B-X
maintain	B-X
v-Abl-mediated	B-X
differentiation	B-X
arrest	B-X
of	B-X
the	B-X
pre-B	B-X
cells	B-X
,	B-X
as	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
RAG	B-X
gene	B-X
transcription	B-X
was	B-X
unaffected	B-X
by	B-X
IL-7	B-X
.	B-X
These	B-X
results	B-X
identify	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
in	B-X
transformation	B-X
by	B-X
v-Abl	B-X
while	B-X
demonstrating	B-X
that	B-X
a	B-X
combination	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
can	B-X
not	B-X
substitute	B-X
for	B-X
an	B-X
active	B-X
v-Abl	B-X
kinase	B-X
in	B-X
transformed	B-X
pre-B	B-X
cells	B-X
.	B-X

The	O
mechanism	O
by	O
which	O
early	O
lymphoid	O
cells	O
are	O
selectively	O
transformed	O
by	O
v	B-Protein
-	I-Protein
Abl	I-Protein
is	O
currently	O
unknown	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
early	B-X
lymphoid	B-X
cells	B-X
are	B-X
selectively	B-X
transformed	B-X
by	B-X
v-Abl	B-X
is	B-X
currently	B-X
unknown	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
constitutive	B-X
activation	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
activation	B-X
of	B-X
Janus	B-X
protein	B-X
kinase	B-X
(	B-X
JAK	B-X
)	B-X
1	B-X
,	B-X
JAK3	B-X
,	B-X
STAT5	B-X
,	B-X
and	B-X
STAT6	B-X
,	B-X
in	B-X
pre-B	B-X
cells	B-X
transformed	B-X
by	B-X
v-Abl	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
activation	B-X
of	B-X
these	B-X
cytokine	B-X
signaling	B-X
pathways	B-X
by	B-X
v-Abl	B-X
is	B-X
important	B-X
in	B-X
the	B-X
cellular	B-X
events	B-X
induced	B-X
by	B-X
the	B-X
Abelson	B-X
murine	B-X
leukemia	B-X
virus	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
on	B-X
pre-B	B-X
cells	B-X
transformed	B-X
with	B-X
a	B-X
temperature-sensitive	B-X
v-Abl	B-X
mutant	B-X
were	B-X
examined	B-X
.	B-X
Whereas	B-X
IL-4	B-X
had	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
,	B-X
IL-7	B-X
delayed	B-X
both	B-X
the	B-X
apoptosis	B-X
and	B-X
cell	B-X
cycle	B-X
arrest	B-X
that	B-X
occur	B-X
upon	B-X
v-Abl	B-X
kinase	B-X
inactivation	B-X
.	B-X
IL-7	B-X
also	B-X
delayed	B-X
the	B-X
decreases	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
c-Myc	B-X
,	B-X
Bcl-2	B-X
,	B-X
and	B-X
Bcl-xL	B-X
that	B-X
occur	B-X
upon	B-X
loss	B-X
of	B-X
v-Abl	B-X
kinase	B-X
activity	B-X
.	B-X
IL-7	B-X
did	B-X
not	B-X
maintain	B-X
v-Abl-mediated	B-X
differentiation	B-X
arrest	B-X
of	B-X
the	B-X
pre-B	B-X
cells	B-X
,	B-X
as	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
RAG	B-X
gene	B-X
transcription	B-X
was	B-X
unaffected	B-X
by	B-X
IL-7	B-X
.	B-X
These	B-X
results	B-X
identify	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
in	B-X
transformation	B-X
by	B-X
v-Abl	B-X
while	B-X
demonstrating	B-X
that	B-X
a	B-X
combination	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
can	B-X
not	B-X
substitute	B-X
for	B-X
an	B-X
active	B-X
v-Abl	B-X
kinase	B-X
in	B-X
transformed	B-X
pre-B	B-X
cells	B-X
.	B-X

Previous	O
studies	O
have	O
shown	O
constitutive	O
activation	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
7	I-Protein
signaling	O
pathways	O
,	O
as	O
measured	O
by	O
activation	O
of	O
Janus	B-Protein
protein	I-Protein
kinase	I-Protein
(	I-Protein
JAK	I-Protein
)	I-Protein
1	I-Protein
,	O
JAK3	B-Protein
,	O
STAT5	O
,	O
and	O
STAT6	B-Protein
,	O
in	O
pre	O
-	O
B	O
cells	O
transformed	O
by	O
v	B-Protein
-	I-Protein
Abl	I-Protein
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
early	B-X
lymphoid	B-X
cells	B-X
are	B-X
selectively	B-X
transformed	B-X
by	B-X
v-Abl	B-X
is	B-X
currently	B-X
unknown	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
constitutive	B-X
activation	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
activation	B-X
of	B-X
Janus	B-X
protein	B-X
kinase	B-X
(	B-X
JAK	B-X
)	B-X
1	B-X
,	B-X
JAK3	B-X
,	B-X
STAT5	B-X
,	B-X
and	B-X
STAT6	B-X
,	B-X
in	B-X
pre-B	B-X
cells	B-X
transformed	B-X
by	B-X
v-Abl	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
activation	B-X
of	B-X
these	B-X
cytokine	B-X
signaling	B-X
pathways	B-X
by	B-X
v-Abl	B-X
is	B-X
important	B-X
in	B-X
the	B-X
cellular	B-X
events	B-X
induced	B-X
by	B-X
the	B-X
Abelson	B-X
murine	B-X
leukemia	B-X
virus	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
on	B-X
pre-B	B-X
cells	B-X
transformed	B-X
with	B-X
a	B-X
temperature-sensitive	B-X
v-Abl	B-X
mutant	B-X
were	B-X
examined	B-X
.	B-X
Whereas	B-X
IL-4	B-X
had	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
,	B-X
IL-7	B-X
delayed	B-X
both	B-X
the	B-X
apoptosis	B-X
and	B-X
cell	B-X
cycle	B-X
arrest	B-X
that	B-X
occur	B-X
upon	B-X
v-Abl	B-X
kinase	B-X
inactivation	B-X
.	B-X
IL-7	B-X
also	B-X
delayed	B-X
the	B-X
decreases	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
c-Myc	B-X
,	B-X
Bcl-2	B-X
,	B-X
and	B-X
Bcl-xL	B-X
that	B-X
occur	B-X
upon	B-X
loss	B-X
of	B-X
v-Abl	B-X
kinase	B-X
activity	B-X
.	B-X
IL-7	B-X
did	B-X
not	B-X
maintain	B-X
v-Abl-mediated	B-X
differentiation	B-X
arrest	B-X
of	B-X
the	B-X
pre-B	B-X
cells	B-X
,	B-X
as	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
RAG	B-X
gene	B-X
transcription	B-X
was	B-X
unaffected	B-X
by	B-X
IL-7	B-X
.	B-X
These	B-X
results	B-X
identify	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
in	B-X
transformation	B-X
by	B-X
v-Abl	B-X
while	B-X
demonstrating	B-X
that	B-X
a	B-X
combination	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
can	B-X
not	B-X
substitute	B-X
for	B-X
an	B-X
active	B-X
v-Abl	B-X
kinase	B-X
in	B-X
transformed	B-X
pre-B	B-X
cells	B-X
.	B-X

To	O
determine	O
whether	O
activation	O
of	O
these	O
cytokine	O
signaling	O
pathways	O
by	O
v	B-Protein
-	I-Protein
Abl	I-Protein
is	O
important	O
in	O
the	O
cellular	O
events	O
induced	O
by	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
,	O
the	O
effects	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
7	I-Protein
on	O
pre	O
-	O
B	O
cells	O
transformed	O
with	O
a	O
temperature	O
-	O
sensitive	O
v	B-Protein
-	I-Protein
Abl	I-Protein
mutant	O
were	O
examined	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
early	B-X
lymphoid	B-X
cells	B-X
are	B-X
selectively	B-X
transformed	B-X
by	B-X
v-Abl	B-X
is	B-X
currently	B-X
unknown	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
constitutive	B-X
activation	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
activation	B-X
of	B-X
Janus	B-X
protein	B-X
kinase	B-X
(	B-X
JAK	B-X
)	B-X
1	B-X
,	B-X
JAK3	B-X
,	B-X
STAT5	B-X
,	B-X
and	B-X
STAT6	B-X
,	B-X
in	B-X
pre-B	B-X
cells	B-X
transformed	B-X
by	B-X
v-Abl	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
activation	B-X
of	B-X
these	B-X
cytokine	B-X
signaling	B-X
pathways	B-X
by	B-X
v-Abl	B-X
is	B-X
important	B-X
in	B-X
the	B-X
cellular	B-X
events	B-X
induced	B-X
by	B-X
the	B-X
Abelson	B-X
murine	B-X
leukemia	B-X
virus	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
on	B-X
pre-B	B-X
cells	B-X
transformed	B-X
with	B-X
a	B-X
temperature-sensitive	B-X
v-Abl	B-X
mutant	B-X
were	B-X
examined	B-X
.	B-X
Whereas	B-X
IL-4	B-X
had	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
,	B-X
IL-7	B-X
delayed	B-X
both	B-X
the	B-X
apoptosis	B-X
and	B-X
cell	B-X
cycle	B-X
arrest	B-X
that	B-X
occur	B-X
upon	B-X
v-Abl	B-X
kinase	B-X
inactivation	B-X
.	B-X
IL-7	B-X
also	B-X
delayed	B-X
the	B-X
decreases	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
c-Myc	B-X
,	B-X
Bcl-2	B-X
,	B-X
and	B-X
Bcl-xL	B-X
that	B-X
occur	B-X
upon	B-X
loss	B-X
of	B-X
v-Abl	B-X
kinase	B-X
activity	B-X
.	B-X
IL-7	B-X
did	B-X
not	B-X
maintain	B-X
v-Abl-mediated	B-X
differentiation	B-X
arrest	B-X
of	B-X
the	B-X
pre-B	B-X
cells	B-X
,	B-X
as	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
RAG	B-X
gene	B-X
transcription	B-X
was	B-X
unaffected	B-X
by	B-X
IL-7	B-X
.	B-X
These	B-X
results	B-X
identify	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
in	B-X
transformation	B-X
by	B-X
v-Abl	B-X
while	B-X
demonstrating	B-X
that	B-X
a	B-X
combination	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
can	B-X
not	B-X
substitute	B-X
for	B-X
an	B-X
active	B-X
v-Abl	B-X
kinase	B-X
in	B-X
transformed	B-X
pre-B	B-X
cells	B-X
.	B-X

Whereas	O
IL	B-Protein
-	I-Protein
4	I-Protein
had	O
little	O
or	O
no	O
effect	O
,	O
IL	B-Protein
-	I-Protein
7	I-Protein
delayed	O
both	O
the	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
that	O
occur	O
upon	O
v	O
-	O
Abl	O
kinase	O
inactivation	O
.	O
<EOS>	B-X
The	B-X
oral	B-X
mucosa	B-X
is	B-X
the	B-X
initial	B-X
interface	B-X
between	B-X
food	B-X
antigens	B-X
,	B-X
microbiota	B-X
,	B-X
and	B-X
mucosal	B-X
immunity	B-X
,	B-X
yet	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
oral	B-X
host-environment	B-X
dynamics	B-X
in	B-X
food	B-X
allergy	B-X
.	B-X
Cytokines	B-X
represent	B-X
the	B-X
major	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
communication	B-X
between	B-X
T	B-X
cells	B-X
,	B-X
macrophages	B-X
and	B-X
other	B-X
immune	B-X
cells	B-X
in	B-X
the	B-X
course	B-X
of	B-X
an	B-X
immune	B-X
response	B-X
to	B-X
antigens	B-X
and	B-X
infectious	B-X
agents	B-X
.	B-X
A	B-X
number	B-X
of	B-X
studies	B-X
on	B-X
mouse	B-X
and	B-X
human	B-X
T	B-X
helper	B-X
(	B-X
Th	B-X
)	B-X
clones	B-X
have	B-X
recently	B-X
provided	B-X
extensive	B-X
evidence	B-X
for	B-X
the	B-X
existence	B-X
of	B-X
different	B-X
activities	B-X
exhibited	B-X
by	B-X
Th	B-X
cells	B-X
(	B-X
called	B-X
Th1	B-X
and	B-X
Th2	B-X
)	B-X
,	B-X
which	B-X
was	B-X
apparently	B-X
inferred	B-X
from	B-X
the	B-X
profile	B-X
of	B-X
cytokine	B-X
secretion	B-X
.	B-X
The	B-X
Th1-type	B-X
immune	B-X
response	B-X
is	B-X
generally	B-X
associated	B-X
with	B-X
IgG2a	B-X
production	B-X
and	B-X
the	B-X
development	B-X
of	B-X
cellular	B-X
immunity	B-X
,	B-X
the	B-X
Th2-type	B-X
response	B-X
with	B-X
IgE	B-X
production	B-X
,	B-X
eosinophils	B-X
and	B-X
mast	B-X
cell	B-X
production	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
role	B-X
of	B-X
different	B-X
cytokines	B-X
produced	B-X
by	B-X
macrophages	B-X
(	B-X
especially	B-X
interferons	B-X
(	B-X
IFNs	B-X
)	B-X
,	B-X
TNF-alpha	B-X
,	B-X
IL-10	B-X
and	B-X
IL-12	B-X
)	B-X
or	B-X
T	B-X
cells	B-X
(	B-X
IFNs	B-X
,	B-X
IL-2	B-X
,	B-X
IL-4	B-X
,	B-X
IL-10	B-X
,	B-X
IL-13	B-X
and	B-X
TGF-beta	B-X
)	B-X
in	B-X
macrophage-T	B-X
cell	B-X
interactions	B-X
and	B-X
the	B-X
cytokine	B-X
relevance	B-X
in	B-X
the	B-X
differentiation	B-X
of	B-X
Th	B-X
cells	B-X
towards	B-X
the	B-X
Th1	B-X
or	B-X
Th2	B-X
type	B-X
of	B-X
immune	B-X
response	B-X
.	B-X
Th1-derived	B-X
cytokines	B-X
(	B-X
IFN-gamma	B-X
,	B-X
IL-2	B-X
,	B-X
TNF-alpha	B-X
)	B-X
favor	B-X
macrophage	B-X
activation	B-X
,	B-X
whereas	B-X
the	B-X
Th2	B-X
cytokines	B-X
(	B-X
IL-4	B-X
,	B-X
IL-10	B-X
,	B-X
IL-13	B-X
)	B-X
exhibit	B-X
suppressive	B-X
activities	B-X
on	B-X
macrophage	B-X
functions	B-X
.	B-X
A	B-X
key	B-X
role	B-X
in	B-X
the	B-X
differentiation	B-X
towards	B-X
the	B-X
Th1-type	B-X
response	B-X
is	B-X
now	B-X
attributed	B-X
to	B-X
IL-12	B-X
,	B-X
a	B-X
recently	B-X
described	B-X
cytokine	B-X
produced	B-X
mainly	B-X
by	B-X
macrophages	B-X
.	B-X
Its	B-X
production	B-X
can	B-X
be	B-X
upregulated	B-X
by	B-X
IFN-gamma	B-X
and	B-X
is	B-X
inhibited	B-X
by	B-X
IL-10	B-X
and	B-X
IL-4	B-X
.	B-X
This	B-X
article	B-X
also	B-X
aims	B-X
to	B-X
review	B-X
recent	B-X
data	B-X
concerning	B-X
the	B-X
roles	B-X
of	B-X
IFNs	B-X
alpha/beta	B-X
(	B-X
type	B-X
I	B-X
)	B-X
and	B-X
IFN-gamma	B-X
(	B-X
type	B-X
II	B-X
)	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
.	B-X
While	B-X
there	B-X
is	B-X
much	B-X
information	B-X
on	B-X
the	B-X
regulatory	B-X
effects	B-X
of	B-X
IFN-gamma	B-X
(	B-X
also	B-X
called	B-X
``	B-X
immune	B-X
IFN	B-X
''	B-X
)	B-X
on	B-X
the	B-X
immune	B-X
response	B-X
,	B-X
little	B-X
is	B-X
so	B-X
far	B-X
known	B-X
of	B-X
the	B-X
role	B-X
of	B-X
type	B-X
I	B-X
IFNs	B-X
.	B-X
These	B-X
cytokines	B-X
,	B-X
originally	B-X
described	B-X
as	B-X
simple	B-X
antiviral	B-X
substances	B-X
,	B-X
are	B-X
now	B-X
taken	B-X
to	B-X
be	B-X
important	B-X
regulators	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
.	B-X
The	B-X
stimulatory	B-X
effects	B-X
of	B-X
IFN-alpha	B-X
on	B-X
the	B-X
generation	B-X
of	B-X
the	B-X
Th1-type	B-X
response	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
its	B-X
therapeutic	B-X
effects	B-X
in	B-X
some	B-X
human	B-X
diseases	B-X
,	B-X
including	B-X
early	B-X
AIDS	B-X
,	B-X
hypereosinophilia	B-X
and	B-X
certain	B-X
tumors	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
400	B-X
WORDS	B-X
)	B-X

IL	B-Protein
-	I-Protein
7	I-Protein
also	O
delayed	O
the	O
decreases	O
in	O
the	O
levels	O
of	O
c	B-Protein
-	I-Protein
Myc	I-Protein
,	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
Bcl	B-Protein
-	I-Protein
xL	I-Protein
that	O
occur	O
upon	O
loss	O
of	O
v	O
-	O
Abl	O
kinase	O
activity	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
early	B-X
lymphoid	B-X
cells	B-X
are	B-X
selectively	B-X
transformed	B-X
by	B-X
v-Abl	B-X
is	B-X
currently	B-X
unknown	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
constitutive	B-X
activation	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
activation	B-X
of	B-X
Janus	B-X
protein	B-X
kinase	B-X
(	B-X
JAK	B-X
)	B-X
1	B-X
,	B-X
JAK3	B-X
,	B-X
STAT5	B-X
,	B-X
and	B-X
STAT6	B-X
,	B-X
in	B-X
pre-B	B-X
cells	B-X
transformed	B-X
by	B-X
v-Abl	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
activation	B-X
of	B-X
these	B-X
cytokine	B-X
signaling	B-X
pathways	B-X
by	B-X
v-Abl	B-X
is	B-X
important	B-X
in	B-X
the	B-X
cellular	B-X
events	B-X
induced	B-X
by	B-X
the	B-X
Abelson	B-X
murine	B-X
leukemia	B-X
virus	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
on	B-X
pre-B	B-X
cells	B-X
transformed	B-X
with	B-X
a	B-X
temperature-sensitive	B-X
v-Abl	B-X
mutant	B-X
were	B-X
examined	B-X
.	B-X
Whereas	B-X
IL-4	B-X
had	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
,	B-X
IL-7	B-X
delayed	B-X
both	B-X
the	B-X
apoptosis	B-X
and	B-X
cell	B-X
cycle	B-X
arrest	B-X
that	B-X
occur	B-X
upon	B-X
v-Abl	B-X
kinase	B-X
inactivation	B-X
.	B-X
IL-7	B-X
also	B-X
delayed	B-X
the	B-X
decreases	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
c-Myc	B-X
,	B-X
Bcl-2	B-X
,	B-X
and	B-X
Bcl-xL	B-X
that	B-X
occur	B-X
upon	B-X
loss	B-X
of	B-X
v-Abl	B-X
kinase	B-X
activity	B-X
.	B-X
IL-7	B-X
did	B-X
not	B-X
maintain	B-X
v-Abl-mediated	B-X
differentiation	B-X
arrest	B-X
of	B-X
the	B-X
pre-B	B-X
cells	B-X
,	B-X
as	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
RAG	B-X
gene	B-X
transcription	B-X
was	B-X
unaffected	B-X
by	B-X
IL-7	B-X
.	B-X
These	B-X
results	B-X
identify	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
in	B-X
transformation	B-X
by	B-X
v-Abl	B-X
while	B-X
demonstrating	B-X
that	B-X
a	B-X
combination	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
can	B-X
not	B-X
substitute	B-X
for	B-X
an	B-X
active	B-X
v-Abl	B-X
kinase	B-X
in	B-X
transformed	B-X
pre-B	B-X
cells	B-X
.	B-X

IL	B-Protein
-	I-Protein
7	I-Protein
did	O
not	O
maintain	O
v	B-Protein
-	I-Protein
Abl	I-Protein
-	O
mediated	O
differentiation	O
arrest	O
of	O
the	O
pre	O
-	O
B	O
cells	O
,	O
as	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
RAG	O
gene	O
transcription	O
was	O
unaffected	O
by	O
IL	B-Protein
-	I-Protein
7	I-Protein
.	O
<EOS>	B-X
The	B-X
cytokine	B-X
IL-7	B-X
and	B-X
its	B-X
receptor	B-X
,	B-X
IL-7R	B-X
,	B-X
are	B-X
critical	B-X
for	B-X
T	B-X
cell	B-X
and	B-X
,	B-X
in	B-X
the	B-X
mouse	B-X
,	B-X
B	B-X
cell	B-X
development	B-X
,	B-X
as	B-X
well	B-X
as	B-X
differentiation	B-X
and	B-X
survival	B-X
of	B-X
naive	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
memory	B-X
T	B-X
cells	B-X
.	B-X
They	B-X
are	B-X
also	B-X
required	B-X
for	B-X
innate	B-X
lymphoid	B-X
cell	B-X
(	B-X
ILC	B-X
)	B-X
development	B-X
and	B-X
maintenance	B-X
,	B-X
and	B-X
consequently	B-X
for	B-X
generation	B-X
of	B-X
lymphoid	B-X
structures	B-X
and	B-X
barrier	B-X
defense	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
the	B-X
central	B-X
role	B-X
of	B-X
IL-7	B-X
and	B-X
IL-7R	B-X
in	B-X
the	B-X
lymphoid	B-X
system	B-X
and	B-X
highlight	B-X
the	B-X
impact	B-X
of	B-X
their	B-X
deregulation	B-X
,	B-X
placing	B-X
a	B-X
particular	B-X
emphasis	B-X
on	B-X
their	B-X
'dark	B-X
side	B-X
'	B-X
as	B-X
promoters	B-X
of	B-X
cancer	B-X
development	B-X
.	B-X
We	B-X
also	B-X
explore	B-X
therapeutic	B-X
implications	B-X
and	B-X
opportunities	B-X
associated	B-X
with	B-X
either	B-X
positive	B-X
or	B-X
negative	B-X
modulation	B-X
of	B-X
the	B-X
IL-7-IL-7R	B-X
signaling	B-X
axis	B-X
.	B-X

These	O
results	O
identify	O
a	O
potential	O
role	O
for	O
IL	B-Protein
-	I-Protein
7	I-Protein
signaling	O
pathways	O
in	O
transformation	O
by	O
v	B-Protein
-	I-Protein
Abl	I-Protein
while	O
demonstrating	O
that	O
a	O
combination	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
7	I-Protein
signaling	O
cannot	O
substitute	O
for	O
an	O
active	O
v	B-Protein
-	I-Protein
Abl	I-Protein
kinase	O
in	O
transformed	O
pre	O
-	O
B	O
cells	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
early	B-X
lymphoid	B-X
cells	B-X
are	B-X
selectively	B-X
transformed	B-X
by	B-X
v-Abl	B-X
is	B-X
currently	B-X
unknown	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
shown	B-X
constitutive	B-X
activation	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
activation	B-X
of	B-X
Janus	B-X
protein	B-X
kinase	B-X
(	B-X
JAK	B-X
)	B-X
1	B-X
,	B-X
JAK3	B-X
,	B-X
STAT5	B-X
,	B-X
and	B-X
STAT6	B-X
,	B-X
in	B-X
pre-B	B-X
cells	B-X
transformed	B-X
by	B-X
v-Abl	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
activation	B-X
of	B-X
these	B-X
cytokine	B-X
signaling	B-X
pathways	B-X
by	B-X
v-Abl	B-X
is	B-X
important	B-X
in	B-X
the	B-X
cellular	B-X
events	B-X
induced	B-X
by	B-X
the	B-X
Abelson	B-X
murine	B-X
leukemia	B-X
virus	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
on	B-X
pre-B	B-X
cells	B-X
transformed	B-X
with	B-X
a	B-X
temperature-sensitive	B-X
v-Abl	B-X
mutant	B-X
were	B-X
examined	B-X
.	B-X
Whereas	B-X
IL-4	B-X
had	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
,	B-X
IL-7	B-X
delayed	B-X
both	B-X
the	B-X
apoptosis	B-X
and	B-X
cell	B-X
cycle	B-X
arrest	B-X
that	B-X
occur	B-X
upon	B-X
v-Abl	B-X
kinase	B-X
inactivation	B-X
.	B-X
IL-7	B-X
also	B-X
delayed	B-X
the	B-X
decreases	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
c-Myc	B-X
,	B-X
Bcl-2	B-X
,	B-X
and	B-X
Bcl-xL	B-X
that	B-X
occur	B-X
upon	B-X
loss	B-X
of	B-X
v-Abl	B-X
kinase	B-X
activity	B-X
.	B-X
IL-7	B-X
did	B-X
not	B-X
maintain	B-X
v-Abl-mediated	B-X
differentiation	B-X
arrest	B-X
of	B-X
the	B-X
pre-B	B-X
cells	B-X
,	B-X
as	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
RAG	B-X
gene	B-X
transcription	B-X
was	B-X
unaffected	B-X
by	B-X
IL-7	B-X
.	B-X
These	B-X
results	B-X
identify	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
IL-7	B-X
signaling	B-X
pathways	B-X
in	B-X
transformation	B-X
by	B-X
v-Abl	B-X
while	B-X
demonstrating	B-X
that	B-X
a	B-X
combination	B-X
of	B-X
IL-4	B-X
and	B-X
IL-7	B-X
signaling	B-X
can	B-X
not	B-X
substitute	B-X
for	B-X
an	B-X
active	B-X
v-Abl	B-X
kinase	B-X
in	B-X
transformed	B-X
pre-B	B-X
cells	B-X
.	B-X

p21ras	B-Protein
initiates	O
Rac	B-Protein
-	I-Protein
1	I-Protein
but	O
not	O
phosphatidyl	O
inositol	O
3	O
kinase	O
/	O
PKB	B-Protein
,	O
mediated	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O
<EOS>	B-X
p21ras	B-X
is	B-X
activated	B-X
by	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
then	B-X
co-ordinates	B-X
important	B-X
signaling	B-X
pathways	B-X
for	B-X
T	B-X
lymphocyte	B-X
activation	B-X
.	B-X
Effector	B-X
pathways	B-X
for	B-X
this	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
protein	B-X
in	B-X
T	B-X
cells	B-X
are	B-X
mediated	B-X
by	B-X
the	B-X
serine/threonine	B-X
kinase	B-X
Raf-1	B-X
and	B-X
the	B-X
Ras-related	B-X
GTPase	B-X
Rac-1	B-X
.	B-X
In	B-X
fibroblasts	B-X
,	B-X
an	B-X
important	B-X
effector	B-X
for	B-X
the	B-X
Ras	B-X
oncogene	B-X
is	B-X
Phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PtdIns	B-X
3-kinase	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
this	B-X
lipid	B-X
kinase	B-X
is	B-X
able	B-X
to	B-X
induce	B-X
critical	B-X
Rac-1	B-X
signaling	B-X
pathways	B-X
and	B-X
can	B-X
couple	B-X
p21ras	B-X
to	B-X
cell	B-X
survival	B-X
mechanisms	B-X
via	B-X
the	B-X
serine/threonine	B-X
kinase	B-X
Akt/PKB	B-X
.	B-X
The	B-X
role	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
in	B-X
Ras	B-X
signaling	B-X
in	B-X
T	B-X
cells	B-X
has	B-X
not	B-X
been	B-X
explored	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
to	B-X
initiate	B-X
the	B-X
Rac-1	B-X
signaling	B-X
pathways	B-X
important	B-X
for	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
possibility	B-X
that	B-X
Akt/PKB	B-X
is	B-X
regulated	B-X
by	B-X
Ras	B-X
signaling	B-X
pathways	B-X
in	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Ras	B-X
can	B-X
initiate	B-X
a	B-X
Rac-1	B-X
mediated	B-X
pathway	B-X
that	B-X
regulates	B-X
the	B-X
transcriptional	B-X
function	B-X
of	B-X
AP-1	B-X
complexes	B-X
.	B-X
PtdIns	B-X
3-kinase	B-X
signals	B-X
can	B-X
not	B-X
mimic	B-X
p21ras	B-X
and	B-X
induce	B-X
the	B-X
Rac	B-X
mediated	B-X
responses	B-X
of	B-X
AP-1	B-X
transcriptional	B-X
activation	B-X
.	B-X
Moreover	B-X
,	B-X
neither	B-X
TCR	B-X
or	B-X
Ras	B-X
activation	B-X
of	B-X
AP-1	B-X
is	B-X
dependent	B-X
on	B-X
PtdIns	B-X
3-kinase	B-X
.	B-X
PKB	B-X
is	B-X
activated	B-X
in	B-X
response	B-X
to	B-X
triggering	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
;	B-X
PtdIns	B-X
3-kinase	B-X
activity	B-X
is	B-X
both	B-X
required	B-X
and	B-X
sufficient	B-X
for	B-X
this	B-X
TCR	B-X
response	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
p21ras	B-X
signals	B-X
are	B-X
unable	B-X
to	B-X
induce	B-X
Akt/PKB	B-X
activity	B-X
in	B-X
T	B-X
cell	B-X
nor	B-X
is	B-X
Ras	B-X
function	B-X
required	B-X
for	B-X
Akt/PKB	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
the	B-X
TCR	B-X
.	B-X
The	B-X
present	B-X
data	B-X
thus	B-X
highlight	B-X
that	B-X
PtdIns	B-X
3-kinase	B-X
and	B-X
Akt/PKB	B-X
are	B-X
not	B-X
universal	B-X
Ras	B-X
effector	B-X
molecules	B-X
.	B-X
Ras	B-X
can	B-X
initiate	B-X
Rac-1	B-X
regulated	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
context	B-X
of	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
function	B-X
independently	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
activity	B-X
.	B-X

p21ras	B-Protein
is	O
activated	O
by	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
and	O
then	O
co	O
-	O
ordinates	O
important	O
signaling	O
pathways	O
for	O
T	O
lymphocyte	O
activation	O
.	O

Effector	O
pathways	O
for	O
this	O
guanine	O
nucleotide	O
binding	O
protein	O
in	O
T	O
cells	O
are	O
mediated	O
by	O
the	O
serine	O
/	O
threonine	O
kinase	O
Raf	B-Protein
-	I-Protein
1	I-Protein
and	O
the	O
Ras	O
-	O
related	O
GTPase	O
Rac	B-Protein
-	I-Protein
1	I-Protein
.	O

In	O
fibroblasts	O
,	O
an	O
important	O
effector	O
for	O
the	O
Ras	O
oncogene	O
is	O
Phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PtdIns	O
3	O
-	O
kinase	O
)	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
phosphatidylinositol	B-X
3-kinase	B-X
alpha	B-X
(	B-X
PI	B-X
3-Kalpha	B-X
)	B-X
(	B-X
p85alpha-p110alpha	B-X
)	B-X
is	B-X
required	B-X
for	B-X
DNA	B-X
synthesis	B-X
induced	B-X
by	B-X
various	B-X
growth	B-X
factors	B-X
(	B-X
S.	B-X
Roche	B-X
,	B-X
M.	B-X
Koegl	B-X
,	B-X
and	B-X
S.	B-X
A.	B-X
Courtneidge	B-X
,	B-X
Proc	B-X
.	B-X
USA	B-X
91:9185-9189	B-X
,	B-X
1994	B-X
)	B-X
in	B-X
fibroblasts	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
the	B-X
function	B-X
of	B-X
PI	B-X
3-Kbeta	B-X
(	B-X
p85alpha-p110beta	B-X
)	B-X
during	B-X
mitogenesis	B-X
.	B-X
By	B-X
using	B-X
antibodies	B-X
specific	B-X
to	B-X
p110beta	B-X
we	B-X
showed	B-X
that	B-X
PI	B-X
3-Kbeta	B-X
is	B-X
expressed	B-X
in	B-X
NIH	B-X
3T3	B-X
cells	B-X
.	B-X
PI	B-X
3-Kbeta	B-X
and	B-X
PI	B-X
3-Kalpha	B-X
have	B-X
common	B-X
features	B-X
:	B-X
PI	B-X
3-Kbeta	B-X
is	B-X
tightly	B-X
associated	B-X
with	B-X
a	B-X
protein	B-X
serine	B-X
kinase	B-X
that	B-X
phosphorylates	B-X
p85alpha	B-X
,	B-X
it	B-X
interacts	B-X
with	B-X
the	B-X
Src-middle	B-X
T	B-X
antigen	B-X
complex	B-X
and	B-X
the	B-X
activated	B-X
platelet-derived	B-X
growth	B-X
factor	B-X
(	B-X
PDGF	B-X
)	B-X
receptor	B-X
in	B-X
fibroblasts	B-X
in	B-X
vivo	B-X
,	B-X
and	B-X
it	B-X
becomes	B-X
tyrosine	B-X
phosphorylated	B-X
after	B-X
PDGF	B-X
stimulation	B-X
.	B-X
PI	B-X
3-Kbeta	B-X
was	B-X
also	B-X
activated	B-X
in	B-X
Swiss	B-X
3T3	B-X
and	B-X
Cos7	B-X
cells	B-X
stimulated	B-X
with	B-X
lysophosphatidic	B-X
acid	B-X
(	B-X
LPA	B-X
)	B-X
,	B-X
a	B-X
mitogen	B-X
that	B-X
interacts	B-X
with	B-X
a	B-X
heterotrimeric	B-X
G	B-X
protein-coupled	B-X
receptor	B-X
.	B-X
In	B-X
contrast	B-X
PI	B-X
3-Kalpha	B-X
was	B-X
activated	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Microinjection	B-X
of	B-X
neutralizing	B-X
antibodies	B-X
specific	B-X
for	B-X
p110beta	B-X
into	B-X
quiescent	B-X
fibroblasts	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
induced	B-X
by	B-X
both	B-X
insulin	B-X
and	B-X
LPA	B-X
but	B-X
poorly	B-X
affected	B-X
PDGF	B-X
receptor	B-X
signaling	B-X
.	B-X
Therefore	B-X
,	B-X
PI	B-X
3-Kbeta	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
transmitting	B-X
the	B-X
mitogenic	B-X
response	B-X
induced	B-X
by	B-X
some	B-X
,	B-X
but	B-X
not	B-X
all	B-X
,	B-X
growth	B-X
factors	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
while	B-X
oncogenic	B-X
V12Ras	B-X
interacts	B-X
with	B-X
type	B-X
I	B-X
PI	B-X
3-Ks	B-X
,	B-X
it	B-X
could	B-X
induce	B-X
DNA	B-X
synthesis	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
active	B-X
PI	B-X
3-Kalpha	B-X
and	B-X
PI	B-X
3-Kbeta	B-X
,	B-X
suggesting	B-X
that	B-X
Ras	B-X
uses	B-X
other	B-X
effectors	B-X
for	B-X
DNA	B-X
synthesis	B-X
.	B-X

Activation	O
of	O
this	O
lipid	O
kinase	O
is	O
able	O
to	O
induce	O
critical	O
Rac	B-Protein
-	I-Protein
1	I-Protein
signaling	O
pathways	O
and	O
can	O
couple	O
p21ras	B-Protein
to	O
cell	O
survival	O
mechanisms	O
via	O
the	O
serine	O
/	O
threonine	O
kinase	O
Akt	B-Protein
/	O
PKB	B-Protein
.	O
<EOS>	B-X
p21ras	B-X
is	B-X
activated	B-X
by	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
then	B-X
co-ordinates	B-X
important	B-X
signaling	B-X
pathways	B-X
for	B-X
T	B-X
lymphocyte	B-X
activation	B-X
.	B-X
Effector	B-X
pathways	B-X
for	B-X
this	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
protein	B-X
in	B-X
T	B-X
cells	B-X
are	B-X
mediated	B-X
by	B-X
the	B-X
serine/threonine	B-X
kinase	B-X
Raf-1	B-X
and	B-X
the	B-X
Ras-related	B-X
GTPase	B-X
Rac-1	B-X
.	B-X
In	B-X
fibroblasts	B-X
,	B-X
an	B-X
important	B-X
effector	B-X
for	B-X
the	B-X
Ras	B-X
oncogene	B-X
is	B-X
Phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PtdIns	B-X
3-kinase	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
this	B-X
lipid	B-X
kinase	B-X
is	B-X
able	B-X
to	B-X
induce	B-X
critical	B-X
Rac-1	B-X
signaling	B-X
pathways	B-X
and	B-X
can	B-X
couple	B-X
p21ras	B-X
to	B-X
cell	B-X
survival	B-X
mechanisms	B-X
via	B-X
the	B-X
serine/threonine	B-X
kinase	B-X
Akt/PKB	B-X
.	B-X
The	B-X
role	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
in	B-X
Ras	B-X
signaling	B-X
in	B-X
T	B-X
cells	B-X
has	B-X
not	B-X
been	B-X
explored	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
to	B-X
initiate	B-X
the	B-X
Rac-1	B-X
signaling	B-X
pathways	B-X
important	B-X
for	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
possibility	B-X
that	B-X
Akt/PKB	B-X
is	B-X
regulated	B-X
by	B-X
Ras	B-X
signaling	B-X
pathways	B-X
in	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Ras	B-X
can	B-X
initiate	B-X
a	B-X
Rac-1	B-X
mediated	B-X
pathway	B-X
that	B-X
regulates	B-X
the	B-X
transcriptional	B-X
function	B-X
of	B-X
AP-1	B-X
complexes	B-X
.	B-X
PtdIns	B-X
3-kinase	B-X
signals	B-X
can	B-X
not	B-X
mimic	B-X
p21ras	B-X
and	B-X
induce	B-X
the	B-X
Rac	B-X
mediated	B-X
responses	B-X
of	B-X
AP-1	B-X
transcriptional	B-X
activation	B-X
.	B-X
Moreover	B-X
,	B-X
neither	B-X
TCR	B-X
or	B-X
Ras	B-X
activation	B-X
of	B-X
AP-1	B-X
is	B-X
dependent	B-X
on	B-X
PtdIns	B-X
3-kinase	B-X
.	B-X
PKB	B-X
is	B-X
activated	B-X
in	B-X
response	B-X
to	B-X
triggering	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
;	B-X
PtdIns	B-X
3-kinase	B-X
activity	B-X
is	B-X
both	B-X
required	B-X
and	B-X
sufficient	B-X
for	B-X
this	B-X
TCR	B-X
response	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
p21ras	B-X
signals	B-X
are	B-X
unable	B-X
to	B-X
induce	B-X
Akt/PKB	B-X
activity	B-X
in	B-X
T	B-X
cell	B-X
nor	B-X
is	B-X
Ras	B-X
function	B-X
required	B-X
for	B-X
Akt/PKB	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
the	B-X
TCR	B-X
.	B-X
The	B-X
present	B-X
data	B-X
thus	B-X
highlight	B-X
that	B-X
PtdIns	B-X
3-kinase	B-X
and	B-X
Akt/PKB	B-X
are	B-X
not	B-X
universal	B-X
Ras	B-X
effector	B-X
molecules	B-X
.	B-X
Ras	B-X
can	B-X
initiate	B-X
Rac-1	B-X
regulated	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
context	B-X
of	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
function	B-X
independently	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
activity	B-X
.	B-X

The	O
role	O
of	O
PtdIns	O
3	O
-	O
kinase	O
in	O
Ras	O
signaling	O
in	O
T	O
cells	O
has	O
not	O
been	O
explored	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
ability	O
of	O
PtdIns	O
3	O
-	O
kinase	O
to	O
initiate	O
the	O
Rac	B-Protein
-	I-Protein
1	I-Protein
signaling	O
pathways	O
important	O
for	O
T	O
cell	O
activation	O
.	O

We	O
also	O
examined	O
the	O
possibility	O
that	O
Akt	B-Protein
/	O
PKB	B-Protein
is	O
regulated	O
by	O
Ras	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

The	O
results	O
show	O
that	O
Ras	O
can	O
initiate	O
a	O
Rac	B-Protein
-	I-Protein
1	I-Protein
mediated	O
pathway	O
that	O
regulates	O
the	O
transcriptional	O
function	O
of	O
AP	O
-	O
1	O
complexes	O
.	O
<EOS>	B-X
p21ras	B-X
is	B-X
activated	B-X
by	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
then	B-X
co-ordinates	B-X
important	B-X
signaling	B-X
pathways	B-X
for	B-X
T	B-X
lymphocyte	B-X
activation	B-X
.	B-X
Effector	B-X
pathways	B-X
for	B-X
this	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
protein	B-X
in	B-X
T	B-X
cells	B-X
are	B-X
mediated	B-X
by	B-X
the	B-X
serine/threonine	B-X
kinase	B-X
Raf-1	B-X
and	B-X
the	B-X
Ras-related	B-X
GTPase	B-X
Rac-1	B-X
.	B-X
In	B-X
fibroblasts	B-X
,	B-X
an	B-X
important	B-X
effector	B-X
for	B-X
the	B-X
Ras	B-X
oncogene	B-X
is	B-X
Phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PtdIns	B-X
3-kinase	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
this	B-X
lipid	B-X
kinase	B-X
is	B-X
able	B-X
to	B-X
induce	B-X
critical	B-X
Rac-1	B-X
signaling	B-X
pathways	B-X
and	B-X
can	B-X
couple	B-X
p21ras	B-X
to	B-X
cell	B-X
survival	B-X
mechanisms	B-X
via	B-X
the	B-X
serine/threonine	B-X
kinase	B-X
Akt/PKB	B-X
.	B-X
The	B-X
role	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
in	B-X
Ras	B-X
signaling	B-X
in	B-X
T	B-X
cells	B-X
has	B-X
not	B-X
been	B-X
explored	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
to	B-X
initiate	B-X
the	B-X
Rac-1	B-X
signaling	B-X
pathways	B-X
important	B-X
for	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
possibility	B-X
that	B-X
Akt/PKB	B-X
is	B-X
regulated	B-X
by	B-X
Ras	B-X
signaling	B-X
pathways	B-X
in	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Ras	B-X
can	B-X
initiate	B-X
a	B-X
Rac-1	B-X
mediated	B-X
pathway	B-X
that	B-X
regulates	B-X
the	B-X
transcriptional	B-X
function	B-X
of	B-X
AP-1	B-X
complexes	B-X
.	B-X
PtdIns	B-X
3-kinase	B-X
signals	B-X
can	B-X
not	B-X
mimic	B-X
p21ras	B-X
and	B-X
induce	B-X
the	B-X
Rac	B-X
mediated	B-X
responses	B-X
of	B-X
AP-1	B-X
transcriptional	B-X
activation	B-X
.	B-X
Moreover	B-X
,	B-X
neither	B-X
TCR	B-X
or	B-X
Ras	B-X
activation	B-X
of	B-X
AP-1	B-X
is	B-X
dependent	B-X
on	B-X
PtdIns	B-X
3-kinase	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
p21ras	B-X
signals	B-X
are	B-X
unable	B-X
to	B-X
induce	B-X
Akt/PKB	B-X
activity	B-X
in	B-X
T	B-X
cell	B-X
nor	B-X
is	B-X
Ras	B-X
function	B-X
required	B-X
for	B-X
Akt/PKB	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
the	B-X
TCR	B-X
.	B-X
The	B-X
present	B-X
data	B-X
thus	B-X
highlight	B-X
that	B-X
PtdIns	B-X
3-kinase	B-X
and	B-X
Akt/PKB	B-X
are	B-X
not	B-X
universal	B-X
Ras	B-X
effector	B-X
molecules	B-X
.	B-X
Ras	B-X
can	B-X
initiate	B-X
Rac-1	B-X
regulated	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
context	B-X
of	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
function	B-X
independently	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
activity	B-X
.	B-X

PtdIns	O
3	O
-	O
kinase	O
signals	O
cannot	O
mimic	O
p21ras	B-Protein
and	O
induce	O
the	O
Rac	O
mediated	O
responses	O
of	O
AP	O
-	O
1	O
transcriptional	O
activation	O
.	O
<EOS>	B-X
p21ras	B-X
is	B-X
activated	B-X
by	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
then	B-X
co-ordinates	B-X
important	B-X
signaling	B-X
pathways	B-X
for	B-X
T	B-X
lymphocyte	B-X
activation	B-X
.	B-X
Effector	B-X
pathways	B-X
for	B-X
this	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
protein	B-X
in	B-X
T	B-X
cells	B-X
are	B-X
mediated	B-X
by	B-X
the	B-X
serine/threonine	B-X
kinase	B-X
Raf-1	B-X
and	B-X
the	B-X
Ras-related	B-X
GTPase	B-X
Rac-1	B-X
.	B-X
In	B-X
fibroblasts	B-X
,	B-X
an	B-X
important	B-X
effector	B-X
for	B-X
the	B-X
Ras	B-X
oncogene	B-X
is	B-X
Phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PtdIns	B-X
3-kinase	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
this	B-X
lipid	B-X
kinase	B-X
is	B-X
able	B-X
to	B-X
induce	B-X
critical	B-X
Rac-1	B-X
signaling	B-X
pathways	B-X
and	B-X
can	B-X
couple	B-X
p21ras	B-X
to	B-X
cell	B-X
survival	B-X
mechanisms	B-X
via	B-X
the	B-X
serine/threonine	B-X
kinase	B-X
Akt/PKB	B-X
.	B-X
The	B-X
role	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
in	B-X
Ras	B-X
signaling	B-X
in	B-X
T	B-X
cells	B-X
has	B-X
not	B-X
been	B-X
explored	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
to	B-X
initiate	B-X
the	B-X
Rac-1	B-X
signaling	B-X
pathways	B-X
important	B-X
for	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Ras	B-X
can	B-X
initiate	B-X
a	B-X
Rac-1	B-X
mediated	B-X
pathway	B-X
that	B-X
regulates	B-X
the	B-X
transcriptional	B-X
function	B-X
of	B-X
AP-1	B-X
complexes	B-X
.	B-X
PtdIns	B-X
3-kinase	B-X
signals	B-X
can	B-X
not	B-X
mimic	B-X
p21ras	B-X
and	B-X
induce	B-X
the	B-X
Rac	B-X
mediated	B-X
responses	B-X
of	B-X
AP-1	B-X
transcriptional	B-X
activation	B-X
.	B-X
Moreover	B-X
,	B-X
neither	B-X
TCR	B-X
or	B-X
Ras	B-X
activation	B-X
of	B-X
AP-1	B-X
is	B-X
dependent	B-X
on	B-X
PtdIns	B-X
3-kinase	B-X
.	B-X
PKB	B-X
is	B-X
activated	B-X
in	B-X
response	B-X
to	B-X
triggering	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
;	B-X
PtdIns	B-X
3-kinase	B-X
activity	B-X
is	B-X
both	B-X
required	B-X
and	B-X
sufficient	B-X
for	B-X
this	B-X
TCR	B-X
response	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
p21ras	B-X
signals	B-X
are	B-X
unable	B-X
to	B-X
induce	B-X
Akt/PKB	B-X
activity	B-X
in	B-X
T	B-X
cell	B-X
nor	B-X
is	B-X
Ras	B-X
function	B-X
required	B-X
for	B-X
Akt/PKB	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
the	B-X
TCR	B-X
.	B-X
The	B-X
present	B-X
data	B-X
thus	B-X
highlight	B-X
that	B-X
PtdIns	B-X
3-kinase	B-X
and	B-X
Akt/PKB	B-X
are	B-X
not	B-X
universal	B-X
Ras	B-X
effector	B-X
molecules	B-X
.	B-X
Ras	B-X
can	B-X
initiate	B-X
Rac-1	B-X
regulated	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
context	B-X
of	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
function	B-X
independently	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
activity	B-X
.	B-X

Moreover	O
,	O
neither	O
TCR	O
or	O
Ras	O
activation	O
of	O
AP	O
-	O
1	O
is	O
dependent	O
on	O
PtdIns	O
3	O
-	O
kinase	O
.	O
<EOS>	B-X
Immunotherapy	B-X
of	B-X
cancer	B-X
has	B-X
made	B-X
tremendous	B-X
progress	B-X
in	B-X
recent	B-X
years	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
the	B-X
remarkable	B-X
clinical	B-X
responses	B-X
obtained	B-X
from	B-X
adoptive	B-X
cell	B-X
transfer	B-X
(	B-X
ACT	B-X
)	B-X
of	B-X
patient-derived	B-X
tumor	B-X
infiltrating	B-X
lymphocytes	B-X
,	B-X
chimeric	B-X
antigen	B-X
receptor	B-X
(	B-X
CAR	B-X
)	B-X
-modified	B-X
T	B-X
cells	B-X
(	B-X
CAR-T	B-X
)	B-X
and	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
-engineered	B-X
T	B-X
cells	B-X
(	B-X
TCR-T	B-X
)	B-X
.	B-X
TCR-T	B-X
uses	B-X
specific	B-X
TCRS	B-X
optimized	B-X
for	B-X
tumor	B-X
engagement	B-X
and	B-X
can	B-X
recognize	B-X
epitopes	B-X
derived	B-X
from	B-X
both	B-X
cell-surface	B-X
and	B-X
intracellular	B-X
targets	B-X
,	B-X
including	B-X
tumor-associated	B-X
antigens	B-X
,	B-X
cancer	B-X
germline	B-X
antigens	B-X
,	B-X
viral	B-X
oncoproteins	B-X
,	B-X
and	B-X
tumor-specific	B-X
neoantigens	B-X
(	B-X
neoAgs	B-X
)	B-X
that	B-X
are	B-X
largely	B-X
sequestered	B-X
in	B-X
the	B-X
cytoplasm	B-X
and	B-X
nucleus	B-X
of	B-X
tumor	B-X
cells	B-X
.	B-X
Moreover	B-X
,	B-X
as	B-X
TCRS	B-X
are	B-X
naturally	B-X
developed	B-X
for	B-X
sensitive	B-X
antigen	B-X
detection	B-X
,	B-X
they	B-X
are	B-X
able	B-X
to	B-X
recognize	B-X
epitopes	B-X
at	B-X
far	B-X
lower	B-X
concentrations	B-X
than	B-X
required	B-X
for	B-X
CAR-T	B-X
activation	B-X
.	B-X
Therefore	B-X
,	B-X
TCR-T	B-X
holds	B-X
great	B-X
promise	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
human	B-X
cancers	B-X
.	B-X
In	B-X
this	B-X
focused	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
basic	B-X
,	B-X
translational	B-X
,	B-X
and	B-X
clinical	B-X
insights	B-X
into	B-X
the	B-X
challenges	B-X
and	B-X
opportunities	B-X
of	B-X
TCR-T.	B-X
We	B-X
review	B-X
emerging	B-X
strategies	B-X
used	B-X
in	B-X
current	B-X
ACT	B-X
,	B-X
point	B-X
out	B-X
limitations	B-X
,	B-X
and	B-X
propose	B-X
possible	B-X
solutions	B-X
.	B-X
We	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
targeting	B-X
tumor-specific	B-X
neoAgs	B-X
and	B-X
outline	B-X
a	B-X
strategy	B-X
of	B-X
combining	B-X
neoAg	B-X
vaccines	B-X
,	B-X
checkpoint	B-X
blockade	B-X
therapy	B-X
,	B-X
and	B-X
adoptive	B-X
transfer	B-X
of	B-X
neoAg-specific	B-X
TCR-T	B-X
to	B-X
produce	B-X
a	B-X
truly	B-X
tumor-specific	B-X
therapy	B-X
,	B-X
which	B-X
is	B-X
able	B-X
to	B-X
penetrate	B-X
into	B-X
solid	B-X
tumors	B-X
and	B-X
resist	B-X
the	B-X
immunosuppressive	B-X
tumor	B-X
microenvironment	B-X
.	B-X

PKB	B-Protein
is	O
activated	O
in	O
response	O
to	O
triggering	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
;	O
PtdIns	O
3	O
-	O
kinase	O
activity	O
is	O
both	O
required	O
and	O
sufficient	O
for	O
this	O
TCR	O
response	O
.	O

In	O
contrast	O
,	O
p21ras	B-Protein
signals	O
are	O
unable	O
to	O
induce	O
Akt	B-Protein
/	O
PKB	B-Protein
activity	O
in	O
T	O
cell	O
nor	O
is	O
Ras	O
function	O
required	O
for	O
Akt	B-Protein
/	O
PKB	B-Protein
activation	O
in	O
response	O
to	O
the	O
TCR	O
.	O

The	O
present	O
data	O
thus	O
highlight	O
that	O
PtdIns	O
3	O
-	O
kinase	O
and	O
Akt	B-Protein
/	O
PKB	B-Protein
are	O
not	O
universal	O
Ras	O
effector	O
molecules	O
.	O
<EOS>	B-X
Data	B-X
suggest	B-X
that	B-X
the	B-X
phosphoinositide-3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/protein	B-X
kinase	B-X
B	B-X
(	B-X
AKT	B-X
)	B-X
pathway	B-X
regulates	B-X
PTEC	B-X
protein	B-X
reabsorption	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
worked	B-X
on	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
physiologic	B-X
albumin	B-X
concentration	B-X
and	B-X
PI3K/AKT	B-X
pathway	B-X
form	B-X
a	B-X
positive	B-X
feedback	B-X
loop	B-X
to	B-X
expand	B-X
endocytic	B-X
capacity	B-X
.	B-X
Using	B-X
LLC-PK1	B-X
cells	B-X
,	B-X
a	B-X
model	B-X
of	B-X
PTECs	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
the	B-X
PI3K/AKT	B-X
pathway	B-X
is	B-X
required	B-X
for	B-X
megalin	B-X
recycling	B-X
and	B-X
surface	B-X
expression	B-X
,	B-X
affecting	B-X
albumin	B-X
uptake	B-X
.	B-X

Ras	O
can	O
initiate	O
Rac	B-Protein
-	I-Protein
1	I-Protein
regulated	O
signaling	O
pathways	O
in	O
the	O
context	O
of	O
T	O
cell	O
antigen	O
receptor	O
function	O
independently	O
of	O
PtdIns	O
3	O
-	O
kinase	O
activity	O
.	O
<EOS>	B-X
p21ras	B-X
is	B-X
activated	B-X
by	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
then	B-X
co-ordinates	B-X
important	B-X
signaling	B-X
pathways	B-X
for	B-X
T	B-X
lymphocyte	B-X
activation	B-X
.	B-X
Effector	B-X
pathways	B-X
for	B-X
this	B-X
guanine	B-X
nucleotide	B-X
binding	B-X
protein	B-X
in	B-X
T	B-X
cells	B-X
are	B-X
mediated	B-X
by	B-X
the	B-X
serine/threonine	B-X
kinase	B-X
Raf-1	B-X
and	B-X
the	B-X
Ras-related	B-X
GTPase	B-X
Rac-1	B-X
.	B-X
In	B-X
fibroblasts	B-X
,	B-X
an	B-X
important	B-X
effector	B-X
for	B-X
the	B-X
Ras	B-X
oncogene	B-X
is	B-X
Phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PtdIns	B-X
3-kinase	B-X
)	B-X
.	B-X
Activation	B-X
of	B-X
this	B-X
lipid	B-X
kinase	B-X
is	B-X
able	B-X
to	B-X
induce	B-X
critical	B-X
Rac-1	B-X
signaling	B-X
pathways	B-X
and	B-X
can	B-X
couple	B-X
p21ras	B-X
to	B-X
cell	B-X
survival	B-X
mechanisms	B-X
via	B-X
the	B-X
serine/threonine	B-X
kinase	B-X
Akt/PKB	B-X
.	B-X
The	B-X
role	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
in	B-X
Ras	B-X
signaling	B-X
in	B-X
T	B-X
cells	B-X
has	B-X
not	B-X
been	B-X
explored	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
to	B-X
initiate	B-X
the	B-X
Rac-1	B-X
signaling	B-X
pathways	B-X
important	B-X
for	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
possibility	B-X
that	B-X
Akt/PKB	B-X
is	B-X
regulated	B-X
by	B-X
Ras	B-X
signaling	B-X
pathways	B-X
in	B-X
T	B-X
lymphocytes	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
Ras	B-X
can	B-X
initiate	B-X
a	B-X
Rac-1	B-X
mediated	B-X
pathway	B-X
that	B-X
regulates	B-X
the	B-X
transcriptional	B-X
function	B-X
of	B-X
AP-1	B-X
complexes	B-X
.	B-X
PtdIns	B-X
3-kinase	B-X
signals	B-X
can	B-X
not	B-X
mimic	B-X
p21ras	B-X
and	B-X
induce	B-X
the	B-X
Rac	B-X
mediated	B-X
responses	B-X
of	B-X
AP-1	B-X
transcriptional	B-X
activation	B-X
.	B-X
Moreover	B-X
,	B-X
neither	B-X
TCR	B-X
or	B-X
Ras	B-X
activation	B-X
of	B-X
AP-1	B-X
is	B-X
dependent	B-X
on	B-X
PtdIns	B-X
3-kinase	B-X
.	B-X
PKB	B-X
is	B-X
activated	B-X
in	B-X
response	B-X
to	B-X
triggering	B-X
of	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
;	B-X
PtdIns	B-X
3-kinase	B-X
activity	B-X
is	B-X
both	B-X
required	B-X
and	B-X
sufficient	B-X
for	B-X
this	B-X
TCR	B-X
response	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
p21ras	B-X
signals	B-X
are	B-X
unable	B-X
to	B-X
induce	B-X
Akt/PKB	B-X
activity	B-X
in	B-X
T	B-X
cell	B-X
nor	B-X
is	B-X
Ras	B-X
function	B-X
required	B-X
for	B-X
Akt/PKB	B-X
activation	B-X
in	B-X
response	B-X
to	B-X
the	B-X
TCR	B-X
.	B-X
The	B-X
present	B-X
data	B-X
thus	B-X
highlight	B-X
that	B-X
PtdIns	B-X
3-kinase	B-X
and	B-X
Akt/PKB	B-X
are	B-X
not	B-X
universal	B-X
Ras	B-X
effector	B-X
molecules	B-X
.	B-X
Ras	B-X
can	B-X
initiate	B-X
Rac-1	B-X
regulated	B-X
signaling	B-X
pathways	B-X
in	B-X
the	B-X
context	B-X
of	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
function	B-X
independently	B-X
of	B-X
PtdIns	B-X
3-kinase	B-X
activity	B-X
.	B-X

Signal	O
transduction	O
abnormalities	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
advanced	O
renal	O
carcinoma	O
:	O
clinical	O
relevance	O
and	O
effects	O
of	O
cytokine	O
therapy	O
.	O

Studies	O
have	O
demonstrated	O
abnormalities	O
of	O
the	O
CD3	O
/	O
T	O
-	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
and	O
pathways	O
of	O
signal	O
transduction	O
in	O
T	O
lymphocytes	O
from	O
animals	O
and	O
patients	O
with	O
advanced	O
malignancy	O
.	O

Diminished	O
expression	O
of	O
TCRzeta	B-Protein
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
that	O
are	O
associated	O
with	O
the	O
TCR	O
and	O
reduced	O
nuclear	O
localization	O
of	O
RelA	B-Protein
containing	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
complexes	O
have	O
been	O
noted	O
.	O
<EOS>	B-X
Studies	B-X
have	B-X
demonstrated	B-X
abnormalities	B-X
of	B-X
the	B-X
CD3/T-cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
pathways	B-X
of	B-X
signal	B-X
transduction	B-X
in	B-X
T	B-X
lymphocytes	B-X
from	B-X
animals	B-X
and	B-X
patients	B-X
with	B-X
advanced	B-X
malignancy	B-X
.	B-X
Diminished	B-X
expression	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
TCR	B-X
and	B-X
reduced	B-X
nuclear	B-X
localization	B-X
of	B-X
RelA	B-X
containing	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NFkappaB	B-X
)	B-X
complexes	B-X
have	B-X
been	B-X
noted	B-X
.	B-X
To	B-X
further	B-X
characterize	B-X
altered	B-X
expression	B-X
of	B-X
TCRzeta	B-X
,	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
,	B-X
T	B-X
lymphocytes	B-X
were	B-X
obtained	B-X
from	B-X
65	B-X
patients	B-X
with	B-X
RCC	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
whom	B-X
were	B-X
receiving	B-X
combination	B-X
cytokine	B-X
therapy	B-X
[	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
,	B-X
IFN	B-X
alpha-containing	B-X
regimens	B-X
]	B-X
and	B-X
37	B-X
control	B-X
individuals	B-X
.	B-X
In	B-X
29	B-X
of	B-X
these	B-X
patients	B-X
,	B-X
levels	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
determined	B-X
by	B-X
Western	B-X
blots	B-X
of	B-X
T-cell	B-X
lysates	B-X
and	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
.	B-X
In	B-X
another	B-X
group	B-X
of	B-X
28	B-X
patients	B-X
(	B-X
three	B-X
individuals	B-X
from	B-X
the	B-X
first	B-X
group	B-X
)	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
abnormal	B-X
NFkappaB	B-X
activation	B-X
was	B-X
studied	B-X
using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
after	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
.	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
in	B-X
27	B-X
of	B-X
29	B-X
patients	B-X
,	B-X
and	B-X
overall	B-X
,	B-X
reduced	B-X
levels	B-X
were	B-X
noted	B-X
visually	B-X
in	B-X
12	B-X
of	B-X
29	B-X
(	B-X
41	B-X
%	B-X
)	B-X
and	B-X
13	B-X
of	B-X
29	B-X
(	B-X
45	B-X
%	B-X
)	B-X
individuals	B-X
,	B-X
respectively	B-X
.	B-X
When	B-X
levels	B-X
were	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
,	B-X
significant	B-X
decreases	B-X
of	B-X
TCRzeta	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
but	B-X
not	B-X
CD3epsilon	B-X
(	B-X
P	B-X
=	B-X
0.131	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
control	B-X
levels	B-X
,	B-X
were	B-X
found	B-X
.	B-X
In	B-X
patients	B-X
treated	B-X
with	B-X
IL-2/IFN	B-X
alpha-based	B-X
therapy	B-X
,	B-X
relative	B-X
levels	B-X
of	B-X
TCRzeta	B-X
increased	B-X
significantly	B-X
(	B-X
P	B-X
=	B-X
0.002	B-X
)	B-X
on	B-X
day	B-X
15	B-X
of	B-X
cycle	B-X
one	B-X
compared	B-X
with	B-X
the	B-X
baseline	B-X
.	B-X
Correlations	B-X
of	B-X
TCRzeta	B-X
or	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
levels	B-X
with	B-X
response	B-X
or	B-X
disease	B-X
variables	B-X
,	B-X
except	B-X
for	B-X
lower	B-X
TCRzeta	B-X
levels	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
bone	B-X
metastases	B-X
,	B-X
were	B-X
not	B-X
found	B-X
.	B-X
Abnormal	B-X
NFkappaB	B-X
activation	B-X
after	B-X
stimulation	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
and/or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
was	B-X
found	B-X
in	B-X
59	B-X
%	B-X
of	B-X
patients	B-X
(	B-X
17	B-X
of	B-X
28	B-X
)	B-X
and	B-X
was	B-X
not	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
advanced	B-X
age	B-X
of	B-X
the	B-X
study	B-X
cohort	B-X
.	B-X
Activation	B-X
of	B-X
NFkappaB	B-X
in	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
was	B-X
inducible	B-X
during	B-X
cytokine	B-X
therapy	B-X
in	B-X
four	B-X
of	B-X
six	B-X
individuals	B-X
who	B-X
displayed	B-X
impaired	B-X
NFkappaB	B-X
activity	B-X
prior	B-X
to	B-X
therapy	B-X
.	B-X
Moreover	B-X
,	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
does	B-X
not	B-X
appear	B-X
linked	B-X
to	B-X
a	B-X
reduction	B-X
of	B-X
TCRzeta	B-X
expression	B-X
,	B-X
because	B-X
in	B-X
five	B-X
patients	B-X
,	B-X
normal	B-X
TCRzeta	B-X
levels	B-X
were	B-X
present	B-X
although	B-X
kappaB	B-X
binding	B-X
was	B-X
not	B-X
inducible	B-X
.	B-X
In	B-X
the	B-X
majority	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
RCC	B-X
,	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
express	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
in	B-X
a	B-X
subset	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
these	B-X
TCRzeta	B-X
associated	B-X
molecules	B-X
are	B-X
seen	B-X
that	B-X
may	B-X
increase	B-X
during	B-X
cytokine-based	B-X
therapy	B-X
.	B-X
Abnormal	B-X
activation	B-X
of	B-X
NFkappaB	B-X
is	B-X
also	B-X
present	B-X
in	B-X
>	B-X
50	B-X
%	B-X
of	B-X
patients	B-X
and	B-X
may	B-X
also	B-X
revert	B-X
to	B-X
normal	B-X
during	B-X
IL-2/IFN	B-X
alpha-based	B-X
treatment	B-X
.	B-X
This	B-X
alteration	B-X
in	B-X
NFkappaB	B-X
activation	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
normal	B-X
expression	B-X
of	B-X
TCRzeta-associated	B-X
signaling	B-X
elements	B-X
.	B-X

These	O
defects	O
have	O
been	O
described	O
in	O
T	O
cells	O
from	O
patients	O
with	O
malignant	O
melanoma	O
,	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
,	O
ovarian	O
cancer	O
,	O
and	O
colorectal	O
cancer	O
.	O

Preliminary	O
observations	O
also	O
indicate	O
possible	O
correlation	O
with	O
clinical	O
variables	O
such	O
as	O
stage	O
in	O
selected	O
instances	O
.	O
<EOS>	B-X
Preliminary	B-X
observations	B-X
also	B-X
indicate	B-X
possible	B-X
correlation	B-X
with	B-X
clinical	B-X
variables	B-X
such	B-X
as	B-X
stage	B-X
in	B-X
selected	B-X
instances	B-X
.	B-X
Relative	B-X
levels	B-X
were	B-X
then	B-X
correlated	B-X
with	B-X
a	B-X
series	B-X
of	B-X
clinical	B-X
variables	B-X
including	B-X
response	B-X
to	B-X
therapy	B-X
,	B-X
performance	B-X
status	B-X
,	B-X
survival	B-X
,	B-X
disease	B-X
sites	B-X
,	B-X
age	B-X
,	B-X
and	B-X
others	B-X
.	B-X
Changes	B-X
in	B-X
these	B-X
signaling	B-X
molecules	B-X
during	B-X
cytokine	B-X
treatment	B-X
were	B-X
also	B-X
investigated	B-X
.	B-X
Correlations	B-X
of	B-X
TCRzeta	B-X
or	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
levels	B-X
with	B-X
response	B-X
or	B-X
disease	B-X
variables	B-X
,	B-X
except	B-X
for	B-X
lower	B-X
TCRzeta	B-X
levels	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
bone	B-X
metastases	B-X
,	B-X
were	B-X
not	B-X
found	B-X
.	B-X
Abnormal	B-X
activation	B-X
of	B-X
NFkappaB	B-X
is	B-X
also	B-X
present	B-X
in	B-X
>	B-X
50	B-X
%	B-X
of	B-X
patients	B-X
and	B-X
may	B-X
also	B-X
revert	B-X
to	B-X
normal	B-X
during	B-X
IL-2/IFN	B-X
alpha-based	B-X
treatment	B-X
.	B-X
The	B-X
clinical	B-X
significance	B-X
of	B-X
these	B-X
findings	B-X
remains	B-X
unclear	B-X
.	B-X

To	O
further	O
characterize	O
altered	O
expression	O
of	O
TCRzeta	B-Protein
,	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
,	O
and	O
impaired	O
activation	O
of	O
NFkappaB	O
,	O
T	O
lymphocytes	O
were	O
obtained	O
from	O
65	O
patients	O
with	O
RCC	O
,	O
the	O
majority	O
of	O
whom	O
were	O
receiving	O
combination	O
cytokine	O
therapy	O
[	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
2	I-Protein
,	O
IFN	B-Protein
alpha	I-Protein
-	O
containing	O
regimens	O
]	O
and	O
37	O
control	O
individuals	O
.	O
<EOS>	B-X
Studies	B-X
have	B-X
demonstrated	B-X
abnormalities	B-X
of	B-X
the	B-X
CD3/T-cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
pathways	B-X
of	B-X
signal	B-X
transduction	B-X
in	B-X
T	B-X
lymphocytes	B-X
from	B-X
animals	B-X
and	B-X
patients	B-X
with	B-X
advanced	B-X
malignancy	B-X
.	B-X
Diminished	B-X
expression	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
TCR	B-X
and	B-X
reduced	B-X
nuclear	B-X
localization	B-X
of	B-X
RelA	B-X
containing	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NFkappaB	B-X
)	B-X
complexes	B-X
have	B-X
been	B-X
noted	B-X
.	B-X
These	B-X
defects	B-X
have	B-X
been	B-X
described	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
malignant	B-X
melanoma	B-X
,	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
,	B-X
ovarian	B-X
cancer	B-X
,	B-X
and	B-X
colorectal	B-X
cancer	B-X
.	B-X
To	B-X
further	B-X
characterize	B-X
altered	B-X
expression	B-X
of	B-X
TCRzeta	B-X
,	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
,	B-X
T	B-X
lymphocytes	B-X
were	B-X
obtained	B-X
from	B-X
65	B-X
patients	B-X
with	B-X
RCC	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
whom	B-X
were	B-X
receiving	B-X
combination	B-X
cytokine	B-X
therapy	B-X
[	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
,	B-X
IFN	B-X
alpha-containing	B-X
regimens	B-X
]	B-X
and	B-X
37	B-X
control	B-X
individuals	B-X
.	B-X
In	B-X
29	B-X
of	B-X
these	B-X
patients	B-X
,	B-X
levels	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
determined	B-X
by	B-X
Western	B-X
blots	B-X
of	B-X
T-cell	B-X
lysates	B-X
and	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
.	B-X
Relative	B-X
levels	B-X
were	B-X
then	B-X
correlated	B-X
with	B-X
a	B-X
series	B-X
of	B-X
clinical	B-X
variables	B-X
including	B-X
response	B-X
to	B-X
therapy	B-X
,	B-X
performance	B-X
status	B-X
,	B-X
survival	B-X
,	B-X
disease	B-X
sites	B-X
,	B-X
age	B-X
,	B-X
and	B-X
others	B-X
.	B-X
In	B-X
another	B-X
group	B-X
of	B-X
28	B-X
patients	B-X
(	B-X
three	B-X
individuals	B-X
from	B-X
the	B-X
first	B-X
group	B-X
)	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
abnormal	B-X
NFkappaB	B-X
activation	B-X
was	B-X
studied	B-X
using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
after	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
.	B-X
Changes	B-X
in	B-X
these	B-X
signaling	B-X
molecules	B-X
during	B-X
cytokine	B-X
treatment	B-X
were	B-X
also	B-X
investigated	B-X
.	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
in	B-X
27	B-X
of	B-X
29	B-X
patients	B-X
,	B-X
and	B-X
overall	B-X
,	B-X
reduced	B-X
levels	B-X
were	B-X
noted	B-X
visually	B-X
in	B-X
12	B-X
of	B-X
29	B-X
(	B-X
41	B-X
%	B-X
)	B-X
and	B-X
13	B-X
of	B-X
29	B-X
(	B-X
45	B-X
%	B-X
)	B-X
individuals	B-X
,	B-X
respectively	B-X
.	B-X
When	B-X
levels	B-X
were	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
,	B-X
significant	B-X
decreases	B-X
of	B-X
TCRzeta	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
but	B-X
not	B-X
CD3epsilon	B-X
(	B-X
P	B-X
=	B-X
0.131	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
control	B-X
levels	B-X
,	B-X
were	B-X
found	B-X
.	B-X
In	B-X
patients	B-X
treated	B-X
with	B-X
IL-2/IFN	B-X
alpha-based	B-X
therapy	B-X
,	B-X
relative	B-X
levels	B-X
of	B-X
TCRzeta	B-X
increased	B-X
significantly	B-X
(	B-X
P	B-X
=	B-X
0.002	B-X
)	B-X
on	B-X
day	B-X
15	B-X
of	B-X
cycle	B-X
one	B-X
compared	B-X
with	B-X
the	B-X
baseline	B-X
.	B-X
Correlations	B-X
of	B-X
TCRzeta	B-X
or	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
levels	B-X
with	B-X
response	B-X
or	B-X
disease	B-X
variables	B-X
,	B-X
except	B-X
for	B-X
lower	B-X
TCRzeta	B-X
levels	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
bone	B-X
metastases	B-X
,	B-X
were	B-X
not	B-X
found	B-X
.	B-X
Abnormal	B-X
NFkappaB	B-X
activation	B-X
after	B-X
stimulation	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
and/or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
was	B-X
found	B-X
in	B-X
59	B-X
%	B-X
of	B-X
patients	B-X
(	B-X
17	B-X
of	B-X
28	B-X
)	B-X
and	B-X
was	B-X
not	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
advanced	B-X
age	B-X
of	B-X
the	B-X
study	B-X
cohort	B-X
.	B-X
Activation	B-X
of	B-X
NFkappaB	B-X
in	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
was	B-X
inducible	B-X
during	B-X
cytokine	B-X
therapy	B-X
in	B-X
four	B-X
of	B-X
six	B-X
individuals	B-X
who	B-X
displayed	B-X
impaired	B-X
NFkappaB	B-X
activity	B-X
prior	B-X
to	B-X
therapy	B-X
.	B-X
Moreover	B-X
,	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
does	B-X
not	B-X
appear	B-X
linked	B-X
to	B-X
a	B-X
reduction	B-X
of	B-X
TCRzeta	B-X
expression	B-X
,	B-X
because	B-X
in	B-X
five	B-X
patients	B-X
,	B-X
normal	B-X
TCRzeta	B-X
levels	B-X
were	B-X
present	B-X
although	B-X
kappaB	B-X
binding	B-X
was	B-X
not	B-X
inducible	B-X
.	B-X
In	B-X
the	B-X
majority	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
RCC	B-X
,	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
express	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
in	B-X
a	B-X
subset	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
these	B-X
TCRzeta	B-X
associated	B-X
molecules	B-X
are	B-X
seen	B-X
that	B-X
may	B-X
increase	B-X
during	B-X
cytokine-based	B-X
therapy	B-X
.	B-X
Abnormal	B-X
activation	B-X
of	B-X
NFkappaB	B-X
is	B-X
also	B-X
present	B-X
in	B-X
>	B-X
50	B-X
%	B-X
of	B-X
patients	B-X
and	B-X
may	B-X
also	B-X
revert	B-X
to	B-X
normal	B-X
during	B-X
IL-2/IFN	B-X
alpha-based	B-X
treatment	B-X
.	B-X
This	B-X
alteration	B-X
in	B-X
NFkappaB	B-X
activation	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
normal	B-X
expression	B-X
of	B-X
TCRzeta-associated	B-X
signaling	B-X
elements	B-X
.	B-X

In	O
29	O
of	O
these	O
patients	O
,	O
levels	O
of	O
TCRzeta	B-Protein
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
were	O
determined	O
by	O
Western	O
blots	O
of	O
T	O
-	O
cell	O
lysates	O
and	O
semiquantitated	O
using	O
densitometry	O
.	O
<EOS>	B-X
Studies	B-X
have	B-X
demonstrated	B-X
abnormalities	B-X
of	B-X
the	B-X
CD3/T-cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
pathways	B-X
of	B-X
signal	B-X
transduction	B-X
in	B-X
T	B-X
lymphocytes	B-X
from	B-X
animals	B-X
and	B-X
patients	B-X
with	B-X
advanced	B-X
malignancy	B-X
.	B-X
Diminished	B-X
expression	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
TCR	B-X
and	B-X
reduced	B-X
nuclear	B-X
localization	B-X
of	B-X
RelA	B-X
containing	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NFkappaB	B-X
)	B-X
complexes	B-X
have	B-X
been	B-X
noted	B-X
.	B-X
These	B-X
defects	B-X
have	B-X
been	B-X
described	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
malignant	B-X
melanoma	B-X
,	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
,	B-X
ovarian	B-X
cancer	B-X
,	B-X
and	B-X
colorectal	B-X
cancer	B-X
.	B-X
To	B-X
further	B-X
characterize	B-X
altered	B-X
expression	B-X
of	B-X
TCRzeta	B-X
,	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
,	B-X
T	B-X
lymphocytes	B-X
were	B-X
obtained	B-X
from	B-X
65	B-X
patients	B-X
with	B-X
RCC	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
whom	B-X
were	B-X
receiving	B-X
combination	B-X
cytokine	B-X
therapy	B-X
[	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
,	B-X
IFN	B-X
alpha-containing	B-X
regimens	B-X
]	B-X
and	B-X
37	B-X
control	B-X
individuals	B-X
.	B-X
In	B-X
29	B-X
of	B-X
these	B-X
patients	B-X
,	B-X
levels	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
determined	B-X
by	B-X
Western	B-X
blots	B-X
of	B-X
T-cell	B-X
lysates	B-X
and	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
.	B-X
Relative	B-X
levels	B-X
were	B-X
then	B-X
correlated	B-X
with	B-X
a	B-X
series	B-X
of	B-X
clinical	B-X
variables	B-X
including	B-X
response	B-X
to	B-X
therapy	B-X
,	B-X
performance	B-X
status	B-X
,	B-X
survival	B-X
,	B-X
disease	B-X
sites	B-X
,	B-X
age	B-X
,	B-X
and	B-X
others	B-X
.	B-X
In	B-X
another	B-X
group	B-X
of	B-X
28	B-X
patients	B-X
(	B-X
three	B-X
individuals	B-X
from	B-X
the	B-X
first	B-X
group	B-X
)	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
abnormal	B-X
NFkappaB	B-X
activation	B-X
was	B-X
studied	B-X
using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
after	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
.	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
in	B-X
27	B-X
of	B-X
29	B-X
patients	B-X
,	B-X
and	B-X
overall	B-X
,	B-X
reduced	B-X
levels	B-X
were	B-X
noted	B-X
visually	B-X
in	B-X
12	B-X
of	B-X
29	B-X
(	B-X
41	B-X
%	B-X
)	B-X
and	B-X
13	B-X
of	B-X
29	B-X
(	B-X
45	B-X
%	B-X
)	B-X
individuals	B-X
,	B-X
respectively	B-X
.	B-X
When	B-X
levels	B-X
were	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
,	B-X
significant	B-X
decreases	B-X
of	B-X
TCRzeta	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
but	B-X
not	B-X
CD3epsilon	B-X
(	B-X
P	B-X
=	B-X
0.131	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
control	B-X
levels	B-X
,	B-X
were	B-X
found	B-X
.	B-X
In	B-X
patients	B-X
treated	B-X
with	B-X
IL-2/IFN	B-X
alpha-based	B-X
therapy	B-X
,	B-X
relative	B-X
levels	B-X
of	B-X
TCRzeta	B-X
increased	B-X
significantly	B-X
(	B-X
P	B-X
=	B-X
0.002	B-X
)	B-X
on	B-X
day	B-X
15	B-X
of	B-X
cycle	B-X
one	B-X
compared	B-X
with	B-X
the	B-X
baseline	B-X
.	B-X
Correlations	B-X
of	B-X
TCRzeta	B-X
or	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
levels	B-X
with	B-X
response	B-X
or	B-X
disease	B-X
variables	B-X
,	B-X
except	B-X
for	B-X
lower	B-X
TCRzeta	B-X
levels	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
bone	B-X
metastases	B-X
,	B-X
were	B-X
not	B-X
found	B-X
.	B-X
Abnormal	B-X
NFkappaB	B-X
activation	B-X
after	B-X
stimulation	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
and/or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
was	B-X
found	B-X
in	B-X
59	B-X
%	B-X
of	B-X
patients	B-X
(	B-X
17	B-X
of	B-X
28	B-X
)	B-X
and	B-X
was	B-X
not	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
advanced	B-X
age	B-X
of	B-X
the	B-X
study	B-X
cohort	B-X
.	B-X
Activation	B-X
of	B-X
NFkappaB	B-X
in	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
was	B-X
inducible	B-X
during	B-X
cytokine	B-X
therapy	B-X
in	B-X
four	B-X
of	B-X
six	B-X
individuals	B-X
who	B-X
displayed	B-X
impaired	B-X
NFkappaB	B-X
activity	B-X
prior	B-X
to	B-X
therapy	B-X
.	B-X
Moreover	B-X
,	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
does	B-X
not	B-X
appear	B-X
linked	B-X
to	B-X
a	B-X
reduction	B-X
of	B-X
TCRzeta	B-X
expression	B-X
,	B-X
because	B-X
in	B-X
five	B-X
patients	B-X
,	B-X
normal	B-X
TCRzeta	B-X
levels	B-X
were	B-X
present	B-X
although	B-X
kappaB	B-X
binding	B-X
was	B-X
not	B-X
inducible	B-X
.	B-X
In	B-X
the	B-X
majority	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
RCC	B-X
,	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
express	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
in	B-X
a	B-X
subset	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
these	B-X
TCRzeta	B-X
associated	B-X
molecules	B-X
are	B-X
seen	B-X
that	B-X
may	B-X
increase	B-X
during	B-X
cytokine-based	B-X
therapy	B-X
.	B-X
Abnormal	B-X
activation	B-X
of	B-X
NFkappaB	B-X
is	B-X
also	B-X
present	B-X
in	B-X
>	B-X
50	B-X
%	B-X
of	B-X
patients	B-X
and	B-X
may	B-X
also	B-X
revert	B-X
to	B-X
normal	B-X
during	B-X
IL-2/IFN	B-X
alpha-based	B-X
treatment	B-X
.	B-X
This	B-X
alteration	B-X
in	B-X
NFkappaB	B-X
activation	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
normal	B-X
expression	B-X
of	B-X
TCRzeta-associated	B-X
signaling	B-X
elements	B-X
.	B-X

Relative	O
levels	O
were	O
then	O
correlated	O
with	O
a	O
series	O
of	O
clinical	O
variables	O
including	O
response	O
to	O
therapy	O
,	O
performance	O
status	O
,	O
survival	O
,	O
disease	O
sites	O
,	O
age	O
,	O
and	O
others	O
.	O
<EOS>	B-X
Description	B-X
of	B-X
the	B-X
condition	B-X
Malaria	B-X
,	B-X
an	B-X
infectious	B-X
disease	B-X
transmitted	B-X
by	B-X
the	B-X
bite	B-X
of	B-X
female	B-X
mosquitoes	B-X
from	B-X
several	B-X
Anopheles	B-X
species	B-X
,	B-X
occurs	B-X
in	B-X
87	B-X
countries	B-X
with	B-X
ongoing	B-X
transmission	B-X
(	B-X
WHO	B-X
2020	B-X
)	B-X
.	B-X
Of	B-X
these	B-X
malaria	B-X
cases	B-X
,	B-X
an	B-X
estimated	B-X
409,000	B-X
deaths	B-X
occurred	B-X
globally	B-X
,	B-X
with	B-X
67	B-X
%	B-X
occurring	B-X
in	B-X
children	B-X
under	B-X
five	B-X
years	B-X
of	B-X
age	B-X
(	B-X
WHO	B-X
2020	B-X
)	B-X
.	B-X
In	B-X
2015	B-X
,	B-X
the	B-X
WHO	B-X
added	B-X
the	B-X
dosage	B-X
of	B-X
0.4	B-X
mg	B-X
of	B-X
folic	B-X
acid	B-X
to	B-X
the	B-X
essential	B-X
drug	B-X
list	B-X
(	B-X
WHO	B-X
2015c	B-X
)	B-X
.	B-X
How	B-X
the	B-X
intervention	B-X
might	B-X
work	B-X
Potential	B-X
interactions	B-X
between	B-X
folate	B-X
status	B-X
and	B-X
malaria	B-X
infection	B-X
The	B-X
malaria	B-X
parasite	B-X
requires	B-X
folate	B-X
for	B-X
survival	B-X
and	B-X
growth	B-X
;	B-X
this	B-X
has	B-X
led	B-X
to	B-X
the	B-X
hypothesis	B-X
that	B-X
folate	B-X
status	B-X
may	B-X
influence	B-X
malaria	B-X
risk	B-X
and	B-X
severity	B-X
.	B-X
Further	B-X
,	B-X
folate	B-X
status	B-X
measured	B-X
via	B-X
RBC	B-X
folate	B-X
is	B-X
not	B-X
an	B-X
appropriate	B-X
biomarker	B-X
of	B-X
folate	B-X
status	B-X
in	B-X
malaria-infected	B-X
individuals	B-X
since	B-X
RBC	B-X
folate	B-X
values	B-X
in	B-X
these	B-X
individuals	B-X
are	B-X
indicative	B-X
of	B-X
both	B-X
the	B-X
person	B-X
's	B-X
stores	B-X
and	B-X
the	B-X
parasite	B-X
's	B-X
folate	B-X
synthesis	B-X
.	B-X
A	B-X
study	B-X
in	B-X
Nigeria	B-X
found	B-X
that	B-X
children	B-X
with	B-X
malaria	B-X
infection	B-X
had	B-X
significantly	B-X
higher	B-X
RBC	B-X
folate	B-X
concentrations	B-X
compared	B-X
to	B-X
children	B-X
without	B-X
malaria	B-X
infection	B-X
,	B-X
but	B-X
plasma	B-X
folate	B-X
levels	B-X
were	B-X
similar	B-X
(	B-X
Bradley-Moore	B-X
1985	B-X
)	B-X
.	B-X
Why	B-X
it	B-X
is	B-X
important	B-X
to	B-X
do	B-X
this	B-X
review	B-X
The	B-X
malaria	B-X
parasite	B-X
needs	B-X
folate	B-X
for	B-X
survival	B-X
and	B-X
growth	B-X
in	B-X
humans	B-X
.	B-X
For	B-X
individuals	B-X
,	B-X
adequate	B-X
folate	B-X
levels	B-X
are	B-X
critical	B-X
for	B-X
health	B-X
and	B-X
well-being	B-X
,	B-X
and	B-X
for	B-X
the	B-X
prevention	B-X
of	B-X
anaemia	B-X
and	B-X
neural	B-X
tube	B-X
defects	B-X
.	B-X
Many	B-X
countries	B-X
rely	B-X
on	B-X
folic	B-X
acid	B-X
supplementation	B-X
to	B-X
ensure	B-X
adequate	B-X
folate	B-X
status	B-X
in	B-X
at-risk	B-X
populations	B-X
.	B-X
Different	B-X
formulations	B-X
for	B-X
folic	B-X
acid	B-X
supplements	B-X
are	B-X
available	B-X
in	B-X
many	B-X
international	B-X
settings	B-X
,	B-X
with	B-X
dosages	B-X
ranging	B-X
from	B-X
400	B-X
µg	B-X
to	B-X
5	B-X
mg	B-X
.	B-X
Evaluating	B-X
folic	B-X
acid	B-X
dosage	B-X
levels	B-X
used	B-X
in	B-X
supplementation	B-X
efforts	B-X
may	B-X
increase	B-X
public	B-X
health	B-X
understanding	B-X
of	B-X
its	B-X
potential	B-X
impacts	B-X
on	B-X
malaria	B-X
risk	B-X
and	B-X
severity	B-X
and	B-X
on	B-X
treatment	B-X
failures	B-X
.	B-X
Examining	B-X
folic	B-X
acid	B-X
interactions	B-X
with	B-X
antifolate	B-X
antimalarial	B-X
medications	B-X
and	B-X
with	B-X
malaria	B-X
disease	B-X
progression	B-X
may	B-X
help	B-X
countries	B-X
in	B-X
malaria-endemic	B-X
areas	B-X
determine	B-X
what	B-X
are	B-X
the	B-X
most	B-X
appropriate	B-X
lower	B-X
dose	B-X
folic	B-X
acid	B-X
formulations	B-X
for	B-X
at-risk	B-X
populations	B-X
.	B-X
The	B-X
WHO	B-X
has	B-X
highlighted	B-X
the	B-X
limited	B-X
evidence	B-X
available	B-X
and	B-X
has	B-X
indicated	B-X
the	B-X
need	B-X
for	B-X
further	B-X
research	B-X
on	B-X
biomarkers	B-X
of	B-X
folate	B-X
status	B-X
,	B-X
particularly	B-X
interactions	B-X
between	B-X
RBC	B-X
folate	B-X
concentrations	B-X
and	B-X
tuberculosis	B-X
,	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
,	B-X
and	B-X
antifolate	B-X
antimalarial	B-X
drugs	B-X
(	B-X
WHO	B-X
2015b	B-X
)	B-X
.	B-X
An	B-X
earlier	B-X
Cochrane	B-X
Review	B-X
assessed	B-X
the	B-X
effects	B-X
and	B-X
safety	B-X
of	B-X
iron	B-X
supplementation	B-X
,	B-X
with	B-X
or	B-X
without	B-X
folic	B-X
acid	B-X
,	B-X
in	B-X
children	B-X
living	B-X
in	B-X
hyperendemic	B-X
or	B-X
holoendemic	B-X
malaria	B-X
areas	B-X
;	B-X
it	B-X
demonstrated	B-X
that	B-X
iron	B-X
supplementation	B-X
did	B-X
not	B-X
increase	B-X
the	B-X
risk	B-X
of	B-X
malaria	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
fever	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
parasites	B-X
in	B-X
the	B-X
blood	B-X
(	B-X
Neuberger	B-X
2016	B-X
)	B-X
.	B-X
Additionally	B-X
,	B-X
it	B-X
will	B-X
contribute	B-X
to	B-X
achieving	B-X
both	B-X
the	B-X
WHO	B-X
Global	B-X
Technical	B-X
Strategy	B-X
for	B-X
Malaria	B-X
2016-2030	B-X
(	B-X
WHO	B-X
2015d	B-X
)	B-X
,	B-X
and	B-X
United	B-X
Nations	B-X
Sustainable	B-X
Development	B-X
Goal	B-X
3	B-X
(	B-X
to	B-X
ensure	B-X
healthy	B-X
lives	B-X
and	B-X
to	B-X
promote	B-X
well-being	B-X
for	B-X
all	B-X
of	B-X
all	B-X
ages	B-X
)	B-X
(	B-X
United	B-X
Nations	B-X
2021	B-X
)	B-X
,	B-X
and	B-X
evaluating	B-X
whether	B-X
the	B-X
potential	B-X
effects	B-X
of	B-X
folic	B-X
acid	B-X
supplementation	B-X
,	B-X
at	B-X
different	B-X
doses	B-X
(	B-X
e.g	B-X
.	B-X

In	O
another	O
group	O
of	O
28	O
patients	O
(	O
three	O
individuals	O
from	O
the	O
first	O
group	O
)	O
,	O
the	O
frequency	O
of	O
abnormal	O
NFkappaB	O
activation	O
was	O
studied	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
after	O
activation	O
of	O
T	O
cells	O
with	O
phorbol	O
myristate	O
acetate	O
/	O
ionomycin	O
or	O
anti	O
-	O
CD3	O
monoclonal	O
antibody	O
.	O
<EOS>	B-X
Findings	B-X
of	B-X
small	B-X
studies	B-X
have	B-X
suggested	B-X
that	B-X
short	B-X
treatments	B-X
with	B-X
anti-CD3	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
are	B-X
mutated	B-X
to	B-X
reduce	B-X
Fc	B-X
receptor	B-X
binding	B-X
preserve	B-X
β-cell	B-X
function	B-X
and	B-X
decrease	B-X
insulin	B-X
needs	B-X
in	B-X
patients	B-X
with	B-X
recent-onset	B-X
type	B-X
1	B-X
diabetes	B-X
.	B-X
In	B-X
this	B-X
phase	B-X
3	B-X
trial	B-X
,	B-X
we	B-X
assessed	B-X
the	B-X
safety	B-X
and	B-X
efficacy	B-X
of	B-X
one	B-X
such	B-X
antibody	B-X
,	B-X
teplizumab	B-X
.	B-X
In	B-X
the	B-X
past	B-X
decade	B-X
,	B-X
there	B-X
has	B-X
been	B-X
a	B-X
growing	B-X
trend	B-X
towards	B-X
the	B-X
use	B-X
of	B-X
specialized	B-X
agents	B-X
such	B-X
as	B-X
antibody	B-X
therapies	B-X
for	B-X
induction	B-X
.	B-X
Azathioprine	B-X
and	B-X
steroids	B-X
were	B-X
among	B-X
the	B-X
first	B-X
drugs	B-X
available	B-X
for	B-X
pharmacologic	B-X
immunosuppression	B-X
allowed	B-X
for	B-X
the	B-X
first	B-X
long-term	B-X
successes	B-X
in	B-X
kidney	B-X
and	B-X
liver	B-X
transplantation	B-X
,	B-X
though	B-X
survivors	B-X
experienced	B-X
significant	B-X
adverse	B-X
effects	B-X
of	B-X
the	B-X
immunosuppression	B-X
.	B-X
Azathioprine	B-X
is	B-X
an	B-X
antimetabolite	B-X
which	B-X
inhibits	B-X
the	B-X
de	B-X
novo	B-X
and	B-X
salvage	B-X
pathways	B-X
of	B-X
purine	B-X
synthesis	B-X
.	B-X
Mycophenolate	B-X
mofetil	B-X
(	B-X
MMF	B-X
)	B-X
,	B-X
another	B-X
antimetabolite	B-X
drug	B-X
,	B-X
inhibits	B-X
only	B-X
the	B-X
de	B-X
novo	B-X
purine	B-X
synthesis	B-X
pathway	B-X
.	B-X
The	B-X
use	B-X
of	B-X
antibody	B-X
to	B-X
produce	B-X
immunosuppression	B-X
began	B-X
with	B-X
polyclonal	B-X
sera	B-X
developed	B-X
in	B-X
animals	B-X
such	B-X
as	B-X
horses	B-X
or	B-X
goats	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
monoclonal	B-X
antibody	B-X
OKT3	B-X
is	B-X
specific	B-X
for	B-X
the	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
/CD3	B-X
complex	B-X
,	B-X
thus	B-X
preventing	B-X
activation	B-X
of	B-X
T-lymphocutes	B-X
.	B-X
Most	B-X
recently	B-X
,	B-X
human	B-X
and	B-X
chimeric	B-X
murine	B-X
monoclonal	B-X
antibodies	B-X
daclizumab	B-X
and	B-X
basiliximab	B-X
have	B-X
provided	B-X
effective	B-X
induction	B-X
therapy	B-X
with	B-X
virtually	B-X
no	B-X
adverse	B-X
effects	B-X
.	B-X

Changes	O
in	O
these	O
signaling	O
molecules	O
during	O
cytokine	O
treatment	O
were	O
also	O
investigated	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
role	B-X
of	B-X
neuroinflammation	B-X
in	B-X
MMD	B-X
has	B-X
been	B-X
studied	B-X
,	B-X
the	B-X
mechanistic	B-X
interplay	B-X
between	B-X
antidepressants	B-X
,	B-X
neuroinflammation	B-X
,	B-X
and	B-X
autophagy	B-X
is	B-X
yet	B-X
to	B-X
be	B-X
investigated	B-X
.	B-X
The	B-X
present	B-X
study	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
melatonin	B-X
on	B-X
LPS-induced	B-X
neuroinflammation	B-X
,	B-X
depression	B-X
,	B-X
and	B-X
autophagy	B-X
impairment	B-X
.	B-X
Our	B-X
results	B-X
showed	B-X
that	B-X
in	B-X
mice	B-X
,	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
treatment	B-X
induced	B-X
depressive-like	B-X
behaviors	B-X
and	B-X
caused	B-X
autophagy	B-X
impairment	B-X
by	B-X
dysregulating	B-X
ATG	B-X
genes	B-X
.	B-X
Moreover	B-X
,	B-X
LPS	B-X
treatment	B-X
significantly	B-X
increased	B-X
the	B-X
levels	B-X
of	B-X
cytokines	B-X
(	B-X
TNFα	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
)	B-X
,	B-X
enhanced	B-X
NF-ᴋB	B-X
phosphorylation	B-X
,	B-X
caused	B-X
glial	B-X
(	B-X
astrocytes	B-X
and	B-X
microglia	B-X
)	B-X
cell	B-X
activation	B-X
,	B-X
dysregulated	B-X
FOXO3a	B-X
expression	B-X
,	B-X
increased	B-X
the	B-X
levels	B-X
of	B-X
redox	B-X
signaling	B-X
molecules	B-X
such	B-X
as	B-X
ROS/TBARs	B-X
,	B-X
and	B-X
altered	B-X
expression	B-X
of	B-X
Nrf2	B-X
,	B-X
SOD2	B-X
,	B-X
and	B-X
HO-1	B-X
.	B-X
Melatonin	B-X
treatment	B-X
significantly	B-X
abolished	B-X
the	B-X
effects	B-X
of	B-X
LPS	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
improved	B-X
depressive-like	B-X
behaviors	B-X
,	B-X
normalized	B-X
autophagy-related	B-X
gene	B-X
expression	B-X
,	B-X
and	B-X
reduced	B-X
levels	B-X
of	B-X
cytokines	B-X
.	B-X
Further	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
autophagy	B-X
in	B-X
LPS-induced	B-X
depressive-like	B-X
behavior	B-X
and	B-X
neuroinflammation	B-X
using	B-X
autophagy	B-X
inhibitors	B-X
3-MA	B-X
and	B-X
Ly294002	B-X
.	B-X
Interestingly	B-X
,	B-X
inhibitor	B-X
treatment	B-X
significantly	B-X
abolished	B-X
and	B-X
reversed	B-X
the	B-X
anti-depressive	B-X
,	B-X
pro-autophagy	B-X
,	B-X
and	B-X
anti-inflammatory	B-X
effects	B-X
of	B-X
melatonin	B-X
.	B-X
The	B-X
present	B-X
study	B-X
concludes	B-X
that	B-X
the	B-X
anti-depressive	B-X
effects	B-X
of	B-X
melatonin	B-X
in	B-X
LPS-induced	B-X
depression	B-X
might	B-X
be	B-X
mediated	B-X
via	B-X
autophagy	B-X
modulation	B-X
through	B-X
FOXO3a	B-X
signaling	B-X
.	B-X

TCRzeta	B-Protein
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
were	O
detected	O
in	O
the	O
peripheral	O
blood	O
T	O
cells	O
in	O
27	O
of	O
29	O
patients	O
,	O
and	O
overall	O
,	O
reduced	O
levels	O
were	O
noted	O
visually	O
in	O
12	O
of	O
29	O
(	O
41	O
%	O
)	O
and	O
13	O
of	O
29	O
(	O
45	O
%	O
)	O
individuals	O
,	O
respectively	O
.	O

When	O
levels	O
were	O
semiquantitated	O
using	O
densitometry	O
,	O
significant	O
decreases	O
of	O
TCRzeta	B-Protein
(	O
P	O
=	O
0	O
.	O
029	O
)	O
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
(	O
P	O
=	O
0	O
.	O
029	O
)	O
but	O
not	O
CD3epsilon	B-Protein
(	O
P	O
=	O
0	O
.	O
131	O
)	O
,	O
compared	O
with	O
control	O
levels	O
,	O
were	O
found	O
.	O

In	O
patients	O
treated	O
with	O
IL	B-Protein
-	I-Protein
2	I-Protein
/	O
IFN	B-Protein
alpha	I-Protein
-	O
based	O
therapy	O
,	O
relative	O
levels	O
of	O
TCRzeta	B-Protein
increased	O
significantly	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
on	O
day	O
15	O
of	O
cycle	O
one	O
compared	O
with	O
the	O
baseline	O
.	O

Correlations	O
of	O
TCRzeta	B-Protein
or	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
levels	O
with	O
response	O
or	O
disease	O
variables	O
,	O
except	O
for	O
lower	O
TCRzeta	B-Protein
levels	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
presence	O
of	O
bone	O
metastases	O
,	O
were	O
not	O
found	O
.	O

Abnormal	O
NFkappaB	O
activation	O
after	O
stimulation	O
with	O
phorbol	O
myristate	O
acetate	O
/	O
ionomycin	O
and	O
/	O
or	O
anti	O
-	O
CD3	O
monoclonal	O
antibody	O
was	O
found	O
in	O
59	O
%	O
of	O
patients	O
(	O
17	O
of	O
28	O
)	O
and	O
was	O
not	O
accounted	O
for	O
by	O
the	O
advanced	O
age	O
of	O
the	O
study	O
cohort	O
.	O
<EOS>	B-X
To	B-X
quantify	B-X
the	B-X
T-helper	B-X
type	B-X
(	B-X
Th	B-X
)	B-X
1	B-X
cytokine	B-X
interferon	B-X
gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
-positive	B-X
and	B-X
the	B-X
Th2	B-X
cytokine	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4-positive	B-X
cells	B-X
in	B-X
synovial	B-X
fluid	B-X
(	B-X
SF	B-X
)	B-X
and	B-X
synovial	B-X
membrane	B-X
(	B-X
SM	B-X
)	B-X
at	B-X
the	B-X
single-cell	B-X
level	B-X
in	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
in	B-X
comparison	B-X
to	B-X
reactive	B-X
arthritis	B-X
(	B-X
ReA	B-X
)	B-X
,	B-X
and	B-X
to	B-X
manipulate	B-X
the	B-X
cytokine	B-X
pattern	B-X
of	B-X
RA	B-X
patients	B-X
in	B-X
vitro	B-X
.	B-X
Studies	B-X
have	B-X
demonstrated	B-X
abnormalities	B-X
of	B-X
the	B-X
CD3/T-cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
pathways	B-X
of	B-X
signal	B-X
transduction	B-X
in	B-X
T	B-X
lymphocytes	B-X
from	B-X
animals	B-X
and	B-X
patients	B-X
with	B-X
advanced	B-X
malignancy	B-X
.	B-X
Diminished	B-X
expression	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
TCR	B-X
and	B-X
reduced	B-X
nuclear	B-X
localization	B-X
of	B-X
RelA	B-X
containing	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NFkappaB	B-X
)	B-X
complexes	B-X
have	B-X
been	B-X
noted	B-X
.	B-X
These	B-X
defects	B-X
have	B-X
been	B-X
described	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
malignant	B-X
melanoma	B-X
,	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
,	B-X
ovarian	B-X
cancer	B-X
,	B-X
and	B-X
colorectal	B-X
cancer	B-X
.	B-X
Preliminary	B-X
observations	B-X
also	B-X
indicate	B-X
possible	B-X
correlation	B-X
with	B-X
clinical	B-X
variables	B-X
such	B-X
as	B-X
stage	B-X
in	B-X
selected	B-X
instances	B-X
.	B-X
To	B-X
further	B-X
characterize	B-X
altered	B-X
expression	B-X
of	B-X
TCRzeta	B-X
,	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
,	B-X
T	B-X
lymphocytes	B-X
were	B-X
obtained	B-X
from	B-X
65	B-X
patients	B-X
with	B-X
RCC	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
whom	B-X
were	B-X
receiving	B-X
combination	B-X
cytokine	B-X
therapy	B-X
[	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
,	B-X
IFN	B-X
alpha-containing	B-X
regimens	B-X
]	B-X
and	B-X
37	B-X
control	B-X
individuals	B-X
.	B-X
In	B-X
29	B-X
of	B-X
these	B-X
patients	B-X
,	B-X
levels	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
determined	B-X
by	B-X
Western	B-X
blots	B-X
of	B-X
T-cell	B-X
lysates	B-X
and	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
.	B-X
Relative	B-X
levels	B-X
were	B-X
then	B-X
correlated	B-X
with	B-X
a	B-X
series	B-X
of	B-X
clinical	B-X
variables	B-X
including	B-X
response	B-X
to	B-X
therapy	B-X
,	B-X
performance	B-X
status	B-X
,	B-X
survival	B-X
,	B-X
disease	B-X
sites	B-X
,	B-X
age	B-X
,	B-X
and	B-X
others	B-X
.	B-X
In	B-X
another	B-X
group	B-X
of	B-X
28	B-X
patients	B-X
(	B-X
three	B-X
individuals	B-X
from	B-X
the	B-X
first	B-X
group	B-X
)	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
abnormal	B-X
NFkappaB	B-X
activation	B-X
was	B-X
studied	B-X
using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
after	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
.	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
in	B-X
27	B-X
of	B-X
29	B-X
patients	B-X
,	B-X
and	B-X
overall	B-X
,	B-X
reduced	B-X
levels	B-X
were	B-X
noted	B-X
visually	B-X
in	B-X
12	B-X
of	B-X
29	B-X
(	B-X
41	B-X
%	B-X
)	B-X
and	B-X
13	B-X
of	B-X
29	B-X
(	B-X
45	B-X
%	B-X
)	B-X
individuals	B-X
,	B-X
respectively	B-X
.	B-X
When	B-X
levels	B-X
were	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
,	B-X
significant	B-X
decreases	B-X
of	B-X
TCRzeta	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
but	B-X
not	B-X
CD3epsilon	B-X
(	B-X
P	B-X
=	B-X
0.131	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
control	B-X
levels	B-X
,	B-X
were	B-X
found	B-X
.	B-X
In	B-X
patients	B-X
treated	B-X
with	B-X
IL-2/IFN	B-X
alpha-based	B-X
therapy	B-X
,	B-X
relative	B-X
levels	B-X
of	B-X
TCRzeta	B-X
increased	B-X
significantly	B-X
(	B-X
P	B-X
=	B-X
0.002	B-X
)	B-X
on	B-X
day	B-X
15	B-X
of	B-X
cycle	B-X
one	B-X
compared	B-X
with	B-X
the	B-X
baseline	B-X
.	B-X
Correlations	B-X
of	B-X
TCRzeta	B-X
or	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
levels	B-X
with	B-X
response	B-X
or	B-X
disease	B-X
variables	B-X
,	B-X
except	B-X
for	B-X
lower	B-X
TCRzeta	B-X
levels	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
bone	B-X
metastases	B-X
,	B-X
were	B-X
not	B-X
found	B-X
.	B-X
Abnormal	B-X
NFkappaB	B-X
activation	B-X
after	B-X
stimulation	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
and/or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
was	B-X
found	B-X
in	B-X
59	B-X
%	B-X
of	B-X
patients	B-X
(	B-X
17	B-X
of	B-X
28	B-X
)	B-X
and	B-X
was	B-X
not	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
advanced	B-X
age	B-X
of	B-X
the	B-X
study	B-X
cohort	B-X
.	B-X
Activation	B-X
of	B-X
NFkappaB	B-X
in	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
was	B-X
inducible	B-X
during	B-X
cytokine	B-X
therapy	B-X
in	B-X
four	B-X
of	B-X
six	B-X
individuals	B-X
who	B-X
displayed	B-X
impaired	B-X
NFkappaB	B-X
activity	B-X
prior	B-X
to	B-X
therapy	B-X
.	B-X
Moreover	B-X
,	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
does	B-X
not	B-X
appear	B-X
linked	B-X
to	B-X
a	B-X
reduction	B-X
of	B-X
TCRzeta	B-X
expression	B-X
,	B-X
because	B-X
in	B-X
five	B-X
patients	B-X
,	B-X
normal	B-X
TCRzeta	B-X
levels	B-X
were	B-X
present	B-X
although	B-X
kappaB	B-X
binding	B-X
was	B-X
not	B-X
inducible	B-X
.	B-X
In	B-X
the	B-X
majority	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
RCC	B-X
,	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
express	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
in	B-X
a	B-X
subset	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
these	B-X
TCRzeta	B-X
associated	B-X
molecules	B-X
are	B-X
seen	B-X
that	B-X
may	B-X
increase	B-X
during	B-X
cytokine-based	B-X
therapy	B-X
.	B-X
Abnormal	B-X
activation	B-X
of	B-X
NFkappaB	B-X
is	B-X
also	B-X
present	B-X
in	B-X
>	B-X
50	B-X
%	B-X
of	B-X
patients	B-X
and	B-X
may	B-X
also	B-X
revert	B-X
to	B-X
normal	B-X
during	B-X
IL-2/IFN	B-X
alpha-based	B-X
treatment	B-X
.	B-X
This	B-X
alteration	B-X
in	B-X
NFkappaB	B-X
activation	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
normal	B-X
expression	B-X
of	B-X
TCRzeta-associated	B-X
signaling	B-X
elements	B-X
.	B-X

Activation	O
of	O
NFkappaB	O
in	O
peripheral	O
blood	O
T	O
cells	O
was	O
inducible	O
during	O
cytokine	O
therapy	O
in	O
four	O
of	O
six	O
individuals	O
who	O
displayed	O
impaired	O
NFkappaB	O
activity	O
prior	O
to	O
therapy	O
.	O

Moreover	O
,	O
impaired	O
activation	O
of	O
NFkappaB	O
does	O
not	O
appear	O
linked	O
to	O
a	O
reduction	O
of	O
TCRzeta	B-Protein
expression	O
,	O
because	O
in	O
five	O
patients	O
,	O
normal	O
TCRzeta	B-Protein
levels	O
were	O
present	O
although	O
kappaB	O
binding	O
was	O
not	O
inducible	O
.	O
<EOS>	B-X
Although	B-X
many	B-X
plant-based	B-X
compounds	B-X
appear	B-X
to	B-X
exert	B-X
an	B-X
anti-aging	B-X
effect	B-X
,	B-X
the	B-X
most	B-X
effective	B-X
resulted	B-X
in	B-X
being	B-X
flavonoids	B-X
,	B-X
terpenoids	B-X
,	B-X
saponins	B-X
,	B-X
and	B-X
polysaccharides	B-X
,	B-X
which	B-X
include	B-X
astragaloside	B-X
,	B-X
ginkgolide	B-X
,	B-X
ginsenoside	B-X
,	B-X
and	B-X
gypenoside	B-X
specifically	B-X
covered	B-X
in	B-X
this	B-X
review	B-X
.	B-X
Telomere	B-X
and	B-X
telomerase	B-X
,	B-X
PPAR-α	B-X
,	B-X
GLUTs	B-X
,	B-X
FOXO1	B-X
,	B-X
caspase-3	B-X
,	B-X
bcl-2	B-X
,	B-X
along	B-X
with	B-X
SIRT1/AMPK	B-X
,	B-X
PI3K/Akt	B-X
,	B-X
NF-κB	B-X
,	B-X
and	B-X
insulin/insulin-like	B-X
growth	B-X
factor-1	B-X
pathways	B-X
appear	B-X
to	B-X
be	B-X
their	B-X
preferential	B-X
targets	B-X
.	B-X
Moreover	B-X
,	B-X
their	B-X
ability	B-X
to	B-X
work	B-X
as	B-X
antioxidants	B-X
and	B-X
to	B-X
improve	B-X
the	B-X
resistance	B-X
to	B-X
DNA	B-X
damage	B-X
is	B-X
also	B-X
discussed	B-X
.	B-X
The	B-X
major	B-X
molecules	B-X
involved	B-X
in	B-X
impaired	B-X
insulin	B-X
signaling	B-X
include	B-X
IRS	B-X
,	B-X
PI3K	B-X
,	B-X
Akt	B-X
,	B-X
and	B-X
GSK-3β	B-X
.	B-X
Activation	B-X
or	B-X
inactivation	B-X
of	B-X
these	B-X
major	B-X
molecules	B-X
through	B-X
increased	B-X
or	B-X
decreased	B-X
phosphorylation	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
insulin	B-X
signaling	B-X
abnormalities	B-X
or	B-X
insulin	B-X
resistance	B-X
.	B-X
Moreover	B-X
,	B-X
caspases	B-X
,	B-X
Nrf2	B-X
,	B-X
and	B-X
NF-κB	B-X
influence	B-X
this	B-X
pathway	B-X
in	B-X
an	B-X
indirect	B-X
way	B-X
.	B-X
Moreover	B-X
,	B-X
studies	B-X
also	B-X
depict	B-X
a	B-X
strong	B-X
correlation	B-X
of	B-X
other	B-X
neurodegenerative	B-X
diseases	B-X
such	B-X
as	B-X
Parkinson	B-X
's	B-X
disease	B-X
and	B-X
Huntington	B-X
's	B-X
disease	B-X
with	B-X
insulin	B-X
resistance	B-X
.	B-X

In	O
the	O
majority	O
of	O
patients	O
with	O
advanced	O
RCC	O
,	O
peripheral	O
blood	O
T	O
cells	O
express	O
TCRzeta	B-Protein
and	O
p56	B-Protein
(	I-Protein
lck	I-Protein
)	I-Protein
,	O
and	O
in	O
a	O
subset	O
,	O
reduced	O
levels	O
of	O
these	O
TCRzeta	B-Protein
associated	O
molecules	O
are	O
seen	O
that	O
may	O
increase	O
during	O
cytokine	O
-	O
based	O
therapy	O
.	O

Abnormal	O
activation	O
of	O
NFkappaB	O
is	O
also	O
present	O
in	O
>	O
50	O
%	O
of	O
patients	O
and	O
may	O
also	O
revert	O
to	O
normal	O
during	O
IL	B-Protein
-	I-Protein
2	I-Protein
/	O
IFN	B-Protein
alpha	I-Protein
-	O
based	O
treatment	O
.	O
<EOS>	B-X
Studies	B-X
have	B-X
demonstrated	B-X
abnormalities	B-X
of	B-X
the	B-X
CD3/T-cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
pathways	B-X
of	B-X
signal	B-X
transduction	B-X
in	B-X
T	B-X
lymphocytes	B-X
from	B-X
animals	B-X
and	B-X
patients	B-X
with	B-X
advanced	B-X
malignancy	B-X
.	B-X
Diminished	B-X
expression	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
TCR	B-X
and	B-X
reduced	B-X
nuclear	B-X
localization	B-X
of	B-X
RelA	B-X
containing	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NFkappaB	B-X
)	B-X
complexes	B-X
have	B-X
been	B-X
noted	B-X
.	B-X
These	B-X
defects	B-X
have	B-X
been	B-X
described	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
patients	B-X
with	B-X
malignant	B-X
melanoma	B-X
,	B-X
renal	B-X
cell	B-X
carcinoma	B-X
(	B-X
RCC	B-X
)	B-X
,	B-X
ovarian	B-X
cancer	B-X
,	B-X
and	B-X
colorectal	B-X
cancer	B-X
.	B-X
Preliminary	B-X
observations	B-X
also	B-X
indicate	B-X
possible	B-X
correlation	B-X
with	B-X
clinical	B-X
variables	B-X
such	B-X
as	B-X
stage	B-X
in	B-X
selected	B-X
instances	B-X
.	B-X
To	B-X
further	B-X
characterize	B-X
altered	B-X
expression	B-X
of	B-X
TCRzeta	B-X
,	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
,	B-X
T	B-X
lymphocytes	B-X
were	B-X
obtained	B-X
from	B-X
65	B-X
patients	B-X
with	B-X
RCC	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
whom	B-X
were	B-X
receiving	B-X
combination	B-X
cytokine	B-X
therapy	B-X
[	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
,	B-X
IFN	B-X
alpha-containing	B-X
regimens	B-X
]	B-X
and	B-X
37	B-X
control	B-X
individuals	B-X
.	B-X
In	B-X
29	B-X
of	B-X
these	B-X
patients	B-X
,	B-X
levels	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
determined	B-X
by	B-X
Western	B-X
blots	B-X
of	B-X
T-cell	B-X
lysates	B-X
and	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
.	B-X
In	B-X
another	B-X
group	B-X
of	B-X
28	B-X
patients	B-X
(	B-X
three	B-X
individuals	B-X
from	B-X
the	B-X
first	B-X
group	B-X
)	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
abnormal	B-X
NFkappaB	B-X
activation	B-X
was	B-X
studied	B-X
using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
after	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
.	B-X
Changes	B-X
in	B-X
these	B-X
signaling	B-X
molecules	B-X
during	B-X
cytokine	B-X
treatment	B-X
were	B-X
also	B-X
investigated	B-X
.	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
in	B-X
27	B-X
of	B-X
29	B-X
patients	B-X
,	B-X
and	B-X
overall	B-X
,	B-X
reduced	B-X
levels	B-X
were	B-X
noted	B-X
visually	B-X
in	B-X
12	B-X
of	B-X
29	B-X
(	B-X
41	B-X
%	B-X
)	B-X
and	B-X
13	B-X
of	B-X
29	B-X
(	B-X
45	B-X
%	B-X
)	B-X
individuals	B-X
,	B-X
respectively	B-X
.	B-X
When	B-X
levels	B-X
were	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
,	B-X
significant	B-X
decreases	B-X
of	B-X
TCRzeta	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
but	B-X
not	B-X
CD3epsilon	B-X
(	B-X
P	B-X
=	B-X
0.131	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
control	B-X
levels	B-X
,	B-X
were	B-X
found	B-X
.	B-X
In	B-X
patients	B-X
treated	B-X
with	B-X
IL-2/IFN	B-X
alpha-based	B-X
therapy	B-X
,	B-X
relative	B-X
levels	B-X
of	B-X
TCRzeta	B-X
increased	B-X
significantly	B-X
(	B-X
P	B-X
=	B-X
0.002	B-X
)	B-X
on	B-X
day	B-X
15	B-X
of	B-X
cycle	B-X
one	B-X
compared	B-X
with	B-X
the	B-X
baseline	B-X
.	B-X
Abnormal	B-X
NFkappaB	B-X
activation	B-X
after	B-X
stimulation	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
and/or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
was	B-X
found	B-X
in	B-X
59	B-X
%	B-X
of	B-X
patients	B-X
(	B-X
17	B-X
of	B-X
28	B-X
)	B-X
and	B-X
was	B-X
not	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
advanced	B-X
age	B-X
of	B-X
the	B-X
study	B-X
cohort	B-X
.	B-X
Activation	B-X
of	B-X
NFkappaB	B-X
in	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
was	B-X
inducible	B-X
during	B-X
cytokine	B-X
therapy	B-X
in	B-X
four	B-X
of	B-X
six	B-X
individuals	B-X
who	B-X
displayed	B-X
impaired	B-X
NFkappaB	B-X
activity	B-X
prior	B-X
to	B-X
therapy	B-X
.	B-X
Moreover	B-X
,	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
does	B-X
not	B-X
appear	B-X
linked	B-X
to	B-X
a	B-X
reduction	B-X
of	B-X
TCRzeta	B-X
expression	B-X
,	B-X
because	B-X
in	B-X
five	B-X
patients	B-X
,	B-X
normal	B-X
TCRzeta	B-X
levels	B-X
were	B-X
present	B-X
although	B-X
kappaB	B-X
binding	B-X
was	B-X
not	B-X
inducible	B-X
.	B-X
In	B-X
the	B-X
majority	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
RCC	B-X
,	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
express	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
in	B-X
a	B-X
subset	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
these	B-X
TCRzeta	B-X
associated	B-X
molecules	B-X
are	B-X
seen	B-X
that	B-X
may	B-X
increase	B-X
during	B-X
cytokine-based	B-X
therapy	B-X
.	B-X
Abnormal	B-X
activation	B-X
of	B-X
NFkappaB	B-X
is	B-X
also	B-X
present	B-X
in	B-X
>	B-X
50	B-X
%	B-X
of	B-X
patients	B-X
and	B-X
may	B-X
also	B-X
revert	B-X
to	B-X
normal	B-X
during	B-X
IL-2/IFN	B-X
alpha-based	B-X
treatment	B-X
.	B-X
This	B-X
alteration	B-X
in	B-X
NFkappaB	B-X
activation	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
normal	B-X
expression	B-X
of	B-X
TCRzeta-associated	B-X
signaling	B-X
elements	B-X
.	B-X

This	O
alteration	O
in	O
NFkappaB	O
activation	O
occurred	O
in	O
the	O
presence	O
of	O
normal	O
expression	O
of	O
TCRzeta	B-Protein
-	O
associated	O
signaling	O
elements	O
.	O
<EOS>	B-X
Studies	B-X
have	B-X
demonstrated	B-X
abnormalities	B-X
of	B-X
the	B-X
CD3/T-cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
and	B-X
pathways	B-X
of	B-X
signal	B-X
transduction	B-X
in	B-X
T	B-X
lymphocytes	B-X
from	B-X
animals	B-X
and	B-X
patients	B-X
with	B-X
advanced	B-X
malignancy	B-X
.	B-X
Diminished	B-X
expression	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
TCR	B-X
and	B-X
reduced	B-X
nuclear	B-X
localization	B-X
of	B-X
RelA	B-X
containing	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NFkappaB	B-X
)	B-X
complexes	B-X
have	B-X
been	B-X
noted	B-X
.	B-X
To	B-X
further	B-X
characterize	B-X
altered	B-X
expression	B-X
of	B-X
TCRzeta	B-X
,	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
,	B-X
T	B-X
lymphocytes	B-X
were	B-X
obtained	B-X
from	B-X
65	B-X
patients	B-X
with	B-X
RCC	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
whom	B-X
were	B-X
receiving	B-X
combination	B-X
cytokine	B-X
therapy	B-X
[	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-2	B-X
,	B-X
IFN	B-X
alpha-containing	B-X
regimens	B-X
]	B-X
and	B-X
37	B-X
control	B-X
individuals	B-X
.	B-X
In	B-X
29	B-X
of	B-X
these	B-X
patients	B-X
,	B-X
levels	B-X
of	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
determined	B-X
by	B-X
Western	B-X
blots	B-X
of	B-X
T-cell	B-X
lysates	B-X
and	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
.	B-X
In	B-X
another	B-X
group	B-X
of	B-X
28	B-X
patients	B-X
(	B-X
three	B-X
individuals	B-X
from	B-X
the	B-X
first	B-X
group	B-X
)	B-X
,	B-X
the	B-X
frequency	B-X
of	B-X
abnormal	B-X
NFkappaB	B-X
activation	B-X
was	B-X
studied	B-X
using	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
after	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
.	B-X
Changes	B-X
in	B-X
these	B-X
signaling	B-X
molecules	B-X
during	B-X
cytokine	B-X
treatment	B-X
were	B-X
also	B-X
investigated	B-X
.	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
in	B-X
27	B-X
of	B-X
29	B-X
patients	B-X
,	B-X
and	B-X
overall	B-X
,	B-X
reduced	B-X
levels	B-X
were	B-X
noted	B-X
visually	B-X
in	B-X
12	B-X
of	B-X
29	B-X
(	B-X
41	B-X
%	B-X
)	B-X
and	B-X
13	B-X
of	B-X
29	B-X
(	B-X
45	B-X
%	B-X
)	B-X
individuals	B-X
,	B-X
respectively	B-X
.	B-X
When	B-X
levels	B-X
were	B-X
semiquantitated	B-X
using	B-X
densitometry	B-X
,	B-X
significant	B-X
decreases	B-X
of	B-X
TCRzeta	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
but	B-X
not	B-X
CD3epsilon	B-X
(	B-X
P	B-X
=	B-X
0.131	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
control	B-X
levels	B-X
,	B-X
were	B-X
found	B-X
.	B-X
In	B-X
patients	B-X
treated	B-X
with	B-X
IL-2/IFN	B-X
alpha-based	B-X
therapy	B-X
,	B-X
relative	B-X
levels	B-X
of	B-X
TCRzeta	B-X
increased	B-X
significantly	B-X
(	B-X
P	B-X
=	B-X
0.002	B-X
)	B-X
on	B-X
day	B-X
15	B-X
of	B-X
cycle	B-X
one	B-X
compared	B-X
with	B-X
the	B-X
baseline	B-X
.	B-X
Correlations	B-X
of	B-X
TCRzeta	B-X
or	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
levels	B-X
with	B-X
response	B-X
or	B-X
disease	B-X
variables	B-X
,	B-X
except	B-X
for	B-X
lower	B-X
TCRzeta	B-X
levels	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
bone	B-X
metastases	B-X
,	B-X
were	B-X
not	B-X
found	B-X
.	B-X
Abnormal	B-X
NFkappaB	B-X
activation	B-X
after	B-X
stimulation	B-X
with	B-X
phorbol	B-X
myristate	B-X
acetate/ionomycin	B-X
and/or	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
was	B-X
found	B-X
in	B-X
59	B-X
%	B-X
of	B-X
patients	B-X
(	B-X
17	B-X
of	B-X
28	B-X
)	B-X
and	B-X
was	B-X
not	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
advanced	B-X
age	B-X
of	B-X
the	B-X
study	B-X
cohort	B-X
.	B-X
Activation	B-X
of	B-X
NFkappaB	B-X
in	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
was	B-X
inducible	B-X
during	B-X
cytokine	B-X
therapy	B-X
in	B-X
four	B-X
of	B-X
six	B-X
individuals	B-X
who	B-X
displayed	B-X
impaired	B-X
NFkappaB	B-X
activity	B-X
prior	B-X
to	B-X
therapy	B-X
.	B-X
Moreover	B-X
,	B-X
impaired	B-X
activation	B-X
of	B-X
NFkappaB	B-X
does	B-X
not	B-X
appear	B-X
linked	B-X
to	B-X
a	B-X
reduction	B-X
of	B-X
TCRzeta	B-X
expression	B-X
,	B-X
because	B-X
in	B-X
five	B-X
patients	B-X
,	B-X
normal	B-X
TCRzeta	B-X
levels	B-X
were	B-X
present	B-X
although	B-X
kappaB	B-X
binding	B-X
was	B-X
not	B-X
inducible	B-X
.	B-X
In	B-X
the	B-X
majority	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
RCC	B-X
,	B-X
peripheral	B-X
blood	B-X
T	B-X
cells	B-X
express	B-X
TCRzeta	B-X
and	B-X
p56	B-X
(	B-X
lck	B-X
)	B-X
,	B-X
and	B-X
in	B-X
a	B-X
subset	B-X
,	B-X
reduced	B-X
levels	B-X
of	B-X
these	B-X
TCRzeta	B-X
associated	B-X
molecules	B-X
are	B-X
seen	B-X
that	B-X
may	B-X
increase	B-X
during	B-X
cytokine-based	B-X
therapy	B-X
.	B-X
Abnormal	B-X
activation	B-X
of	B-X
NFkappaB	B-X
is	B-X
also	B-X
present	B-X
in	B-X
>	B-X
50	B-X
%	B-X
of	B-X
patients	B-X
and	B-X
may	B-X
also	B-X
revert	B-X
to	B-X
normal	B-X
during	B-X
IL-2/IFN	B-X
alpha-based	B-X
treatment	B-X
.	B-X
This	B-X
alteration	B-X
in	B-X
NFkappaB	B-X
activation	B-X
occurred	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
normal	B-X
expression	B-X
of	B-X
TCRzeta-associated	B-X
signaling	B-X
elements	B-X
.	B-X

The	O
clinical	O
significance	O
of	O
these	O
findings	O
remains	O
unclear	O
.	O
<EOS>	B-X
The	B-X
clinical	B-X
presentation	B-X
of	B-X
brucellosis	B-X
in	B-X
humans	B-X
is	B-X
variable	B-X
and	B-X
unspecific	B-X
,	B-X
and	B-X
thus	B-X
,	B-X
laboratory	B-X
corroboration	B-X
of	B-X
the	B-X
diagnosis	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
patient	B-X
's	B-X
proper	B-X
treatment	B-X
.	B-X
Modern	B-X
automated	B-X
blood	B-X
culture	B-X
systems	B-X
enable	B-X
detection	B-X
of	B-X
acute	B-X
cases	B-X
of	B-X
brucellosis	B-X
within	B-X
the	B-X
routine	B-X
5-	B-X
to	B-X
7-day	B-X
incubation	B-X
protocol	B-X
employed	B-X
in	B-X
clinical	B-X
microbiology	B-X
laboratories	B-X
,	B-X
although	B-X
a	B-X
longer	B-X
incubation	B-X
and	B-X
performance	B-X
of	B-X
blind	B-X
subcultures	B-X
may	B-X
be	B-X
needed	B-X
for	B-X
protracted	B-X
cases	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
altered	B-X
neural	B-X
processing	B-X
,	B-X
defined	B-X
as	B-X
altering	B-X
neural	B-X
networks	B-X
responsible	B-X
for	B-X
perceptions	B-X
of	B-X
pain	B-X
and	B-X
function	B-X
,	B-X
on	B-X
chronic	B-X
pain	B-X
remains	B-X
unclear	B-X
.	B-X
Although	B-X
both	B-X
biomechanical	B-X
and	B-X
neurophysiological	B-X
phenomena	B-X
have	B-X
been	B-X
thought	B-X
to	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
observed	B-X
clinical	B-X
effects	B-X
of	B-X
spinal	B-X
manipulation	B-X
,	B-X
a	B-X
growing	B-X
number	B-X
of	B-X
recent	B-X
studies	B-X
have	B-X
indicated	B-X
peripheral	B-X
,	B-X
spinal	B-X
and	B-X
supraspinal	B-X
mechanisms	B-X
of	B-X
manipulation	B-X
and	B-X
suggested	B-X
that	B-X
the	B-X
improved	B-X
clinical	B-X
outcomes	B-X
are	B-X
largely	B-X
of	B-X
neurophysiological	B-X
origin	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
reviewed	B-X
the	B-X
relevance	B-X
of	B-X
various	B-X
neurophysiological	B-X
theories	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
findings	B-X
of	B-X
mechanistic	B-X
studies	B-X
that	B-X
demonstrated	B-X
neural	B-X
responses	B-X
following	B-X
spinal	B-X
manipulation	B-X
.	B-X
However	B-X
,	B-X
the	B-X
clinical	B-X
relevance	B-X
of	B-X
these	B-X
changes	B-X
in	B-X
relation	B-X
to	B-X
the	B-X
mechanisms	B-X
that	B-X
underlie	B-X
the	B-X
effectiveness	B-X
of	B-X
spinal	B-X
manipulation	B-X
is	B-X
still	B-X
unclear	B-X
.	B-X
Future	B-X
mechanistic	B-X
studies	B-X
should	B-X
have	B-X
an	B-X
appropriate	B-X
study	B-X
design	B-X
and	B-X
methodology	B-X
and	B-X
should	B-X
plan	B-X
for	B-X
a	B-X
long-term	B-X
follow-up	B-X
in	B-X
order	B-X
to	B-X
determine	B-X
the	B-X
clinical	B-X
significance	B-X
of	B-X
the	B-X
neural	B-X
responses	B-X
evoked	B-X
following	B-X
spinal	B-X
manipulation	B-X
.	B-X

Transcriptional	O
regulation	O
of	O
lysosomal	B-Protein
acid	I-Protein
lipase	I-Protein
in	O
differentiating	O
monocytes	O
is	O
mediated	O
by	O
transcription	O
factors	O
Sp1	B-Protein
and	O
AP	O
-	O
2	O
.	O
<EOS>	B-X
Human	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
is	B-X
a	B-X
hydrolase	B-X
required	B-X
for	B-X
the	B-X
cleavage	B-X
of	B-X
cholesteryl	B-X
esters	B-X
and	B-X
triglycerides	B-X
derived	B-X
from	B-X
plasma	B-X
lipoproteins	B-X
.	B-X
The	B-X
cell	B-X
type-specific	B-X
increase	B-X
in	B-X
LAL	B-X
expression	B-X
is	B-X
further	B-X
investigated	B-X
in	B-X
the	B-X
THP-1	B-X
cell	B-X
line	B-X
with	B-X
respect	B-X
to	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
order	B-X
to	B-X
determine	B-X
the	B-X
cis-acting	B-X
elements	B-X
necessary	B-X
for	B-X
both	B-X
basal	B-X
and	B-X
phorbol	B-X
12-myristate-13	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
-enhanced	B-X
promoter	B-X
activity	B-X
,	B-X
we	B-X
performed	B-X
deletion	B-X
analysis	B-X
and	B-X
reporter	B-X
gene	B-X
assays	B-X
.	B-X
A	B-X
PMA	B-X
responsive	B-X
element	B-X
has	B-X
been	B-X
identified	B-X
between	B-X
-182	B-X
bp	B-X
and	B-X
-107	B-X
bp	B-X
upstream	B-X
of	B-X
the	B-X
major	B-X
transcription	B-X
start	B-X
site	B-X
.	B-X
Gel	B-X
mobility	B-X
shift	B-X
assays	B-X
demonstrated	B-X
that	B-X
binding	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
to	B-X
the	B-X
LAL	B-X
promoter	B-X
is	B-X
increased	B-X
by	B-X
PMA	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Co-transfections	B-X
with	B-X
expression	B-X
plasmids	B-X
for	B-X
Sp1	B-X
and	B-X
AP-2	B-X
further	B-X
emphasized	B-X
the	B-X
important	B-X
role	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
PMA-enhanced	B-X
LAL	B-X
expression	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
differentiation	B-X
dependent	B-X
increase	B-X
of	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
expression	B-X
in	B-X
THP-1	B-X
cells	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
concerted	B-X
action	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
.	B-X

Human	O
lysosomal	B-Protein
acid	I-Protein
lipase	I-Protein
(	O
LAL	B-Protein
)	O
is	O
a	O
hydrolase	O
required	O
for	O
the	O
cleavage	O
of	O
cholesteryl	O
esters	O
and	O
triglycerides	O
derived	O
from	O
plasma	O
lipoproteins	O
.	O
<EOS>	B-X
Human	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
is	B-X
a	B-X
hydrolase	B-X
required	B-X
for	B-X
the	B-X
cleavage	B-X
of	B-X
cholesteryl	B-X
esters	B-X
and	B-X
triglycerides	B-X
derived	B-X
from	B-X
plasma	B-X
lipoproteins	B-X
.	B-X
It	B-X
is	B-X
shown	B-X
here	B-X
that	B-X
during	B-X
monocyte	B-X
to	B-X
macrophage	B-X
differentiation	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
LAL-mRNA	B-X
is	B-X
induced	B-X
.	B-X
The	B-X
cell	B-X
type-specific	B-X
increase	B-X
in	B-X
LAL	B-X
expression	B-X
is	B-X
further	B-X
investigated	B-X
in	B-X
the	B-X
THP-1	B-X
cell	B-X
line	B-X
with	B-X
respect	B-X
to	B-X
transcriptional	B-X
regulation	B-X
.	B-X
The	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cell	B-X
line	B-X
THP-1	B-X
differentiates	B-X
into	B-X
macrophage-like	B-X
cells	B-X
when	B-X
treated	B-X
with	B-X
phorbol	B-X
esters	B-X
.	B-X
Gel	B-X
mobility	B-X
shift	B-X
assays	B-X
demonstrated	B-X
that	B-X
binding	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
to	B-X
the	B-X
LAL	B-X
promoter	B-X
is	B-X
increased	B-X
by	B-X
PMA	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Co-transfections	B-X
with	B-X
expression	B-X
plasmids	B-X
for	B-X
Sp1	B-X
and	B-X
AP-2	B-X
further	B-X
emphasized	B-X
the	B-X
important	B-X
role	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
PMA-enhanced	B-X
LAL	B-X
expression	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
differentiation	B-X
dependent	B-X
increase	B-X
of	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
expression	B-X
in	B-X
THP-1	B-X
cells	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
concerted	B-X
action	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
.	B-X

It	O
is	O
shown	O
here	O
that	O
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
,	O
the	O
expression	O
of	O
LAL	B-Protein
-	O
mRNA	O
is	O
induced	O
.	O
<EOS>	B-X
Human	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
is	B-X
a	B-X
hydrolase	B-X
required	B-X
for	B-X
the	B-X
cleavage	B-X
of	B-X
cholesteryl	B-X
esters	B-X
and	B-X
triglycerides	B-X
derived	B-X
from	B-X
plasma	B-X
lipoproteins	B-X
.	B-X
It	B-X
is	B-X
shown	B-X
here	B-X
that	B-X
during	B-X
monocyte	B-X
to	B-X
macrophage	B-X
differentiation	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
LAL-mRNA	B-X
is	B-X
induced	B-X
.	B-X
The	B-X
cell	B-X
type-specific	B-X
increase	B-X
in	B-X
LAL	B-X
expression	B-X
is	B-X
further	B-X
investigated	B-X
in	B-X
the	B-X
THP-1	B-X
cell	B-X
line	B-X
with	B-X
respect	B-X
to	B-X
transcriptional	B-X
regulation	B-X
.	B-X
The	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cell	B-X
line	B-X
THP-1	B-X
differentiates	B-X
into	B-X
macrophage-like	B-X
cells	B-X
when	B-X
treated	B-X
with	B-X
phorbol	B-X
esters	B-X
.	B-X
Gel	B-X
mobility	B-X
shift	B-X
assays	B-X
demonstrated	B-X
that	B-X
binding	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
to	B-X
the	B-X
LAL	B-X
promoter	B-X
is	B-X
increased	B-X
by	B-X
PMA	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Co-transfections	B-X
with	B-X
expression	B-X
plasmids	B-X
for	B-X
Sp1	B-X
and	B-X
AP-2	B-X
further	B-X
emphasized	B-X
the	B-X
important	B-X
role	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
PMA-enhanced	B-X
LAL	B-X
expression	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
differentiation	B-X
dependent	B-X
increase	B-X
of	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
expression	B-X
in	B-X
THP-1	B-X
cells	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
concerted	B-X
action	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
.	B-X

This	O
induction	O
is	O
dependent	O
on	O
protein	O
kinase	O
C	O
activity	O
and	O
protein	O
synthesis	O
.	O
<EOS>	B-X
Under	B-X
some	B-X
circumstances	B-X
5-HT-dependent	B-X
facilitation	B-X
requires	B-X
the	B-X
activity	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
One	B-X
critical	B-X
site	B-X
of	B-X
PKC	B-X
's	B-X
contribution	B-X
to	B-X
5-HT-dependent	B-X
synaptic	B-X
facilitation	B-X
is	B-X
the	B-X
presynaptic	B-X
sensory	B-X
neuron	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
postsynaptic	B-X
PKC	B-X
also	B-X
contributes	B-X
to	B-X
synaptic	B-X
facilitation	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
contribution	B-X
of	B-X
PKC	B-X
to	B-X
enhancement	B-X
of	B-X
the	B-X
glutamate-evoked	B-X
potential	B-X
(	B-X
Glu-EP	B-X
)	B-X
in	B-X
isolated	B-X
siphon	B-X
motor	B-X
neurons	B-X
in	B-X
cell	B-X
culture	B-X
.	B-X
A	B-X
10	B-X
min	B-X
application	B-X
of	B-X
either	B-X
5-HT	B-X
or	B-X
phorbol	B-X
ester	B-X
,	B-X
which	B-X
activates	B-X
PKC	B-X
,	B-X
produced	B-X
persistent	B-X
(	B-X
>	B-X
50	B-X
min	B-X
)	B-X
enhancement	B-X
of	B-X
the	B-X
Glu-EP	B-X
.	B-X
Chelerythrine	B-X
and	B-X
bisindolylmaleimide-1	B-X
(	B-X
Bis	B-X
)	B-X
,	B-X
two	B-X
inhibitors	B-X
of	B-X
PKC	B-X
,	B-X
both	B-X
blocked	B-X
the	B-X
induction	B-X
of	B-X
5-HT-dependent	B-X
enhancement	B-X
.	B-X
An	B-X
inhibitor	B-X
of	B-X
calpain	B-X
,	B-X
a	B-X
calcium-dependent	B-X
protease	B-X
,	B-X
also	B-X
blocked	B-X
5-HT	B-X
's	B-X
effect	B-X
.	B-X
Because	B-X
Bis	B-X
has	B-X
greater	B-X
selectivity	B-X
for	B-X
conventional	B-X
and	B-X
novel	B-X
isoforms	B-X
of	B-X
PKC	B-X
than	B-X
for	B-X
atypical	B-X
isoforms	B-X
,	B-X
this	B-X
result	B-X
implicates	B-X
an	B-X
atypical	B-X
isoform	B-X
in	B-X
the	B-X
maintenance	B-X
of	B-X
5-HT	B-X
's	B-X
effect	B-X
.	B-X
Although	B-X
induction	B-X
of	B-X
enhancement	B-X
of	B-X
the	B-X
Glu-EP	B-X
requires	B-X
protein	B-X
synthesis	B-X
(	B-X
Villareal	B-X
et	B-X
al.	B-X
,	B-X
2007	B-X
)	B-X
,	B-X
we	B-X
found	B-X
that	B-X
maintenance	B-X
of	B-X
the	B-X
enhancement	B-X
does	B-X
not	B-X
.	B-X
Maintenance	B-X
of	B-X
5-HT-dependent	B-X
enhancement	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
a	B-X
PKM-type	B-X
fragment	B-X
generated	B-X
by	B-X
calpain-dependent	B-X
proteolysis	B-X
of	B-X
atypical	B-X
PKC	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
5-HT	B-X
treatment	B-X
triggers	B-X
two	B-X
phases	B-X
of	B-X
PKC	B-X
activity	B-X
within	B-X
the	B-X
motor	B-X
neuron	B-X
,	B-X
an	B-X
early	B-X
phase	B-X
that	B-X
may	B-X
involve	B-X
conventional	B-X
,	B-X
novel	B-X
or	B-X
atypical	B-X
isoforms	B-X
of	B-X
PKC	B-X
,	B-X
and	B-X
a	B-X
later	B-X
phase	B-X
that	B-X
selectively	B-X
involves	B-X
an	B-X
atypical	B-X
isoform	B-X
.	B-X

The	O
cell	O
type	O
-	O
specific	O
increase	O
in	O
LAL	B-Protein
expression	O
is	O
further	O
investigated	O
in	O
the	O
THP	O
-	O
1	O
cell	O
line	O
with	O
respect	O
to	O
transcriptional	O
regulation	O
.	O
<EOS>	B-X
Human	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
is	B-X
a	B-X
hydrolase	B-X
required	B-X
for	B-X
the	B-X
cleavage	B-X
of	B-X
cholesteryl	B-X
esters	B-X
and	B-X
triglycerides	B-X
derived	B-X
from	B-X
plasma	B-X
lipoproteins	B-X
.	B-X
It	B-X
is	B-X
shown	B-X
here	B-X
that	B-X
during	B-X
monocyte	B-X
to	B-X
macrophage	B-X
differentiation	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
LAL-mRNA	B-X
is	B-X
induced	B-X
.	B-X
The	B-X
cell	B-X
type-specific	B-X
increase	B-X
in	B-X
LAL	B-X
expression	B-X
is	B-X
further	B-X
investigated	B-X
in	B-X
the	B-X
THP-1	B-X
cell	B-X
line	B-X
with	B-X
respect	B-X
to	B-X
transcriptional	B-X
regulation	B-X
.	B-X
The	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cell	B-X
line	B-X
THP-1	B-X
differentiates	B-X
into	B-X
macrophage-like	B-X
cells	B-X
when	B-X
treated	B-X
with	B-X
phorbol	B-X
esters	B-X
.	B-X
In	B-X
order	B-X
to	B-X
determine	B-X
the	B-X
cis-acting	B-X
elements	B-X
necessary	B-X
for	B-X
both	B-X
basal	B-X
and	B-X
phorbol	B-X
12-myristate-13	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
-enhanced	B-X
promoter	B-X
activity	B-X
,	B-X
we	B-X
performed	B-X
deletion	B-X
analysis	B-X
and	B-X
reporter	B-X
gene	B-X
assays	B-X
.	B-X
A	B-X
PMA	B-X
responsive	B-X
element	B-X
has	B-X
been	B-X
identified	B-X
between	B-X
-182	B-X
bp	B-X
and	B-X
-107	B-X
bp	B-X
upstream	B-X
of	B-X
the	B-X
major	B-X
transcription	B-X
start	B-X
site	B-X
.	B-X
Gel	B-X
mobility	B-X
shift	B-X
assays	B-X
demonstrated	B-X
that	B-X
binding	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
to	B-X
the	B-X
LAL	B-X
promoter	B-X
is	B-X
increased	B-X
by	B-X
PMA	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Co-transfections	B-X
with	B-X
expression	B-X
plasmids	B-X
for	B-X
Sp1	B-X
and	B-X
AP-2	B-X
further	B-X
emphasized	B-X
the	B-X
important	B-X
role	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
PMA-enhanced	B-X
LAL	B-X
expression	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
differentiation	B-X
dependent	B-X
increase	B-X
of	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
expression	B-X
in	B-X
THP-1	B-X
cells	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
concerted	B-X
action	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
.	B-X

The	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
differentiates	O
into	O
macrophage	O
-	O
like	O
cells	O
when	O
treated	O
with	O
phorbol	O
esters	O
.	O
<EOS>	B-X
In	B-X
different	B-X
microenvironments	B-X
,	B-X
macrophages	B-X
can	B-X
polarize	B-X
into	B-X
two	B-X
types	B-X
:	B-X
classically	B-X
activated	B-X
macrophages	B-X
(	B-X
M1	B-X
)	B-X
or	B-X
alternatively	B-X
activated	B-X
macrophages	B-X
(	B-X
M2	B-X
)	B-X
.	B-X
M1	B-X
macrophages	B-X
are	B-X
a	B-X
well-known	B-X
bacteriostatic	B-X
macrophage	B-X
,	B-X
and	B-X
conversely	B-X
,	B-X
M2	B-X
macrophages	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
tumor	B-X
growth	B-X
and	B-X
tissue	B-X
remodeling	B-X
.	B-X
M1	B-X
macrophages	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
have	B-X
high	B-X
intracellular	B-X
iron	B-X
stores	B-X
,	B-X
while	B-X
M2	B-X
macrophages	B-X
contain	B-X
lower	B-X
intracellular	B-X
iron	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
investigate	B-X
if	B-X
chronic	B-X
iron	B-X
overload	B-X
is	B-X
capable	B-X
of	B-X
polarizing	B-X
macrophages	B-X
.	B-X
Human	B-X
monocytic	B-X
leukemia	B-X
THP-1	B-X
cells	B-X
were	B-X
maintained	B-X
in	B-X
culture	B-X
medium	B-X
that	B-X
contained	B-X
100	B-X
μM	B-X
ferrous	B-X
sulfate	B-X
heptahydrate	B-X
(	B-X
FeSO	B-X

In	O
order	O
to	O
determine	O
the	O
cis	O
-	O
acting	O
elements	O
necessary	O
for	O
both	O
basal	O
and	O
phorbol	O
12	O
-	O
myristate	O
-	O
13	O
acetate	O
(	O
PMA	O
)	O
-	O
enhanced	O
promoter	O
activity	O
,	O
we	O
performed	O
deletion	O
analysis	O
and	O
reporter	O
gene	O
assays	O
.	O
<EOS>	B-X
This	B-X
induction	B-X
is	B-X
dependent	B-X
on	B-X
protein	B-X
kinase	B-X
C	B-X
activity	B-X
and	B-X
protein	B-X
synthesis	B-X
.	B-X
The	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cell	B-X
line	B-X
THP-1	B-X
differentiates	B-X
into	B-X
macrophage-like	B-X
cells	B-X
when	B-X
treated	B-X
with	B-X
phorbol	B-X
esters	B-X
.	B-X
In	B-X
order	B-X
to	B-X
determine	B-X
the	B-X
cis-acting	B-X
elements	B-X
necessary	B-X
for	B-X
both	B-X
basal	B-X
and	B-X
phorbol	B-X
12-myristate-13	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
-enhanced	B-X
promoter	B-X
activity	B-X
,	B-X
we	B-X
performed	B-X
deletion	B-X
analysis	B-X
and	B-X
reporter	B-X
gene	B-X
assays	B-X
.	B-X
A	B-X
PMA	B-X
responsive	B-X
element	B-X
has	B-X
been	B-X
identified	B-X
between	B-X
-182	B-X
bp	B-X
and	B-X
-107	B-X
bp	B-X
upstream	B-X
of	B-X
the	B-X
major	B-X
transcription	B-X
start	B-X
site	B-X
.	B-X
Gel	B-X
mobility	B-X
shift	B-X
assays	B-X
demonstrated	B-X
that	B-X
binding	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
to	B-X
the	B-X
LAL	B-X
promoter	B-X
is	B-X
increased	B-X
by	B-X
PMA	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Co-transfections	B-X
with	B-X
expression	B-X
plasmids	B-X
for	B-X
Sp1	B-X
and	B-X
AP-2	B-X
further	B-X
emphasized	B-X
the	B-X
important	B-X
role	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
PMA-enhanced	B-X
LAL	B-X
expression	B-X
.	B-X

A	O
PMA	O
responsive	O
element	O
has	O
been	O
identified	O
between	O
-	O
182	O
bp	O
and	O
-	O
107	O
bp	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
.	O
<EOS>	B-X
The	B-X
cell	B-X
type-specific	B-X
increase	B-X
in	B-X
LAL	B-X
expression	B-X
is	B-X
further	B-X
investigated	B-X
in	B-X
the	B-X
THP-1	B-X
cell	B-X
line	B-X
with	B-X
respect	B-X
to	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
order	B-X
to	B-X
determine	B-X
the	B-X
cis-acting	B-X
elements	B-X
necessary	B-X
for	B-X
both	B-X
basal	B-X
and	B-X
phorbol	B-X
12-myristate-13	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
-enhanced	B-X
promoter	B-X
activity	B-X
,	B-X
we	B-X
performed	B-X
deletion	B-X
analysis	B-X
and	B-X
reporter	B-X
gene	B-X
assays	B-X
.	B-X
A	B-X
PMA	B-X
responsive	B-X
element	B-X
has	B-X
been	B-X
identified	B-X
between	B-X
-182	B-X
bp	B-X
and	B-X
-107	B-X
bp	B-X
upstream	B-X
of	B-X
the	B-X
major	B-X
transcription	B-X
start	B-X
site	B-X
.	B-X
Gel	B-X
mobility	B-X
shift	B-X
assays	B-X
demonstrated	B-X
that	B-X
binding	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
to	B-X
the	B-X
LAL	B-X
promoter	B-X
is	B-X
increased	B-X
by	B-X
PMA	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Co-transfections	B-X
with	B-X
expression	B-X
plasmids	B-X
for	B-X
Sp1	B-X
and	B-X
AP-2	B-X
further	B-X
emphasized	B-X
the	B-X
important	B-X
role	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
PMA-enhanced	B-X
LAL	B-X
expression	B-X
.	B-X

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
binding	O
of	O
Sp1	B-Protein
and	O
AP	O
-	O
2	O
to	O
the	O
LAL	B-Protein
promoter	O
is	O
increased	O
by	O
PMA	O
in	O
THP	O
-	O
1	O
cells	O
.	O

Co	O
-	O
transfections	O
with	O
expression	O
plasmids	O
for	O
Sp1	B-Protein
and	O
AP	O
-	O
2	O
further	O
emphasized	O
the	O
important	O
role	O
of	O
these	O
transcription	O
factors	O
in	O
both	O
basal	O
and	O
PMA	O
-	O
enhanced	O
LAL	B-Protein
expression	O
.	O
<EOS>	B-X
Human	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
is	B-X
a	B-X
hydrolase	B-X
required	B-X
for	B-X
the	B-X
cleavage	B-X
of	B-X
cholesteryl	B-X
esters	B-X
and	B-X
triglycerides	B-X
derived	B-X
from	B-X
plasma	B-X
lipoproteins	B-X
.	B-X
It	B-X
is	B-X
shown	B-X
here	B-X
that	B-X
during	B-X
monocyte	B-X
to	B-X
macrophage	B-X
differentiation	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
LAL-mRNA	B-X
is	B-X
induced	B-X
.	B-X
The	B-X
cell	B-X
type-specific	B-X
increase	B-X
in	B-X
LAL	B-X
expression	B-X
is	B-X
further	B-X
investigated	B-X
in	B-X
the	B-X
THP-1	B-X
cell	B-X
line	B-X
with	B-X
respect	B-X
to	B-X
transcriptional	B-X
regulation	B-X
.	B-X
In	B-X
order	B-X
to	B-X
determine	B-X
the	B-X
cis-acting	B-X
elements	B-X
necessary	B-X
for	B-X
both	B-X
basal	B-X
and	B-X
phorbol	B-X
12-myristate-13	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
-enhanced	B-X
promoter	B-X
activity	B-X
,	B-X
we	B-X
performed	B-X
deletion	B-X
analysis	B-X
and	B-X
reporter	B-X
gene	B-X
assays	B-X
.	B-X
A	B-X
PMA	B-X
responsive	B-X
element	B-X
has	B-X
been	B-X
identified	B-X
between	B-X
-182	B-X
bp	B-X
and	B-X
-107	B-X
bp	B-X
upstream	B-X
of	B-X
the	B-X
major	B-X
transcription	B-X
start	B-X
site	B-X
.	B-X
Gel	B-X
mobility	B-X
shift	B-X
assays	B-X
demonstrated	B-X
that	B-X
binding	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
to	B-X
the	B-X
LAL	B-X
promoter	B-X
is	B-X
increased	B-X
by	B-X
PMA	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Co-transfections	B-X
with	B-X
expression	B-X
plasmids	B-X
for	B-X
Sp1	B-X
and	B-X
AP-2	B-X
further	B-X
emphasized	B-X
the	B-X
important	B-X
role	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
PMA-enhanced	B-X
LAL	B-X
expression	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
differentiation	B-X
dependent	B-X
increase	B-X
of	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
expression	B-X
in	B-X
THP-1	B-X
cells	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
concerted	B-X
action	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
.	B-X

Our	O
data	O
suggest	O
that	O
differentiation	O
dependent	O
increase	O
of	O
lysosomal	B-Protein
acid	I-Protein
lipase	I-Protein
(	O
LAL	B-Protein
)	O
expression	O
in	O
THP	O
-	O
1	O
cells	O
is	O
mediated	O
by	O
a	O
concerted	O
action	O
of	O
Sp1	B-Protein
and	O
AP	O
-	O
2	O
.	O
<EOS>	B-X
Human	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
is	B-X
a	B-X
hydrolase	B-X
required	B-X
for	B-X
the	B-X
cleavage	B-X
of	B-X
cholesteryl	B-X
esters	B-X
and	B-X
triglycerides	B-X
derived	B-X
from	B-X
plasma	B-X
lipoproteins	B-X
.	B-X
It	B-X
is	B-X
shown	B-X
here	B-X
that	B-X
during	B-X
monocyte	B-X
to	B-X
macrophage	B-X
differentiation	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
LAL-mRNA	B-X
is	B-X
induced	B-X
.	B-X
This	B-X
induction	B-X
is	B-X
dependent	B-X
on	B-X
protein	B-X
kinase	B-X
C	B-X
activity	B-X
and	B-X
protein	B-X
synthesis	B-X
.	B-X
The	B-X
cell	B-X
type-specific	B-X
increase	B-X
in	B-X
LAL	B-X
expression	B-X
is	B-X
further	B-X
investigated	B-X
in	B-X
the	B-X
THP-1	B-X
cell	B-X
line	B-X
with	B-X
respect	B-X
to	B-X
transcriptional	B-X
regulation	B-X
.	B-X
The	B-X
human	B-X
monocytic	B-X
leukemia	B-X
cell	B-X
line	B-X
THP-1	B-X
differentiates	B-X
into	B-X
macrophage-like	B-X
cells	B-X
when	B-X
treated	B-X
with	B-X
phorbol	B-X
esters	B-X
.	B-X
In	B-X
order	B-X
to	B-X
determine	B-X
the	B-X
cis-acting	B-X
elements	B-X
necessary	B-X
for	B-X
both	B-X
basal	B-X
and	B-X
phorbol	B-X
12-myristate-13	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
-enhanced	B-X
promoter	B-X
activity	B-X
,	B-X
we	B-X
performed	B-X
deletion	B-X
analysis	B-X
and	B-X
reporter	B-X
gene	B-X
assays	B-X
.	B-X
A	B-X
PMA	B-X
responsive	B-X
element	B-X
has	B-X
been	B-X
identified	B-X
between	B-X
-182	B-X
bp	B-X
and	B-X
-107	B-X
bp	B-X
upstream	B-X
of	B-X
the	B-X
major	B-X
transcription	B-X
start	B-X
site	B-X
.	B-X
Gel	B-X
mobility	B-X
shift	B-X
assays	B-X
demonstrated	B-X
that	B-X
binding	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
to	B-X
the	B-X
LAL	B-X
promoter	B-X
is	B-X
increased	B-X
by	B-X
PMA	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
Co-transfections	B-X
with	B-X
expression	B-X
plasmids	B-X
for	B-X
Sp1	B-X
and	B-X
AP-2	B-X
further	B-X
emphasized	B-X
the	B-X
important	B-X
role	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
in	B-X
both	B-X
basal	B-X
and	B-X
PMA-enhanced	B-X
LAL	B-X
expression	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
differentiation	B-X
dependent	B-X
increase	B-X
of	B-X
lysosomal	B-X
acid	B-X
lipase	B-X
(	B-X
LAL	B-X
)	B-X
expression	B-X
in	B-X
THP-1	B-X
cells	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
concerted	B-X
action	B-X
of	B-X
Sp1	B-X
and	B-X
AP-2	B-X
.	B-X

A	O
nongenomic	O
mechanism	O
for	O
progesterone	O
-	O
mediated	O
immunosuppression	O
:	O
inhibition	O
of	O
K	O
+	O
channels	O
,	O
Ca2	O
+	O
signaling	O
,	O
and	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
.	O

The	O
mechanism	O
by	O
which	O
progesterone	O
causes	O
localized	O
suppression	O
of	O
the	O
immune	O
response	O
during	O
pregnancy	O
has	O
remained	O
elusive	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
progesterone	B-X
causes	B-X
localized	B-X
suppression	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
during	B-X
pregnancy	B-X
has	B-X
remained	B-X
elusive	B-X
.	B-X
Using	B-X
human	B-X
T	B-X
lymphocytes	B-X
and	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
we	B-X
show	B-X
that	B-X
progesterone	B-X
,	B-X
at	B-X
concentrations	B-X
found	B-X
in	B-X
the	B-X
placenta	B-X
,	B-X
rapidly	B-X
and	B-X
reversibly	B-X
blocks	B-X
voltage-gated	B-X
and	B-X
calcium-activated	B-X
K+	B-X
channels	B-X
(	B-X
KV	B-X
and	B-X
KCa	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
resulting	B-X
in	B-X
depolarization	B-X
of	B-X
the	B-X
membrane	B-X
potential	B-X
.	B-X
K+	B-X
channel	B-X
blockade	B-X
by	B-X
progesterone	B-X
is	B-X
specific	B-X
;	B-X
other	B-X
steroid	B-X
hormones	B-X
had	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
,	B-X
although	B-X
the	B-X
progesterone	B-X
antagonist	B-X
RU	B-X
486	B-X
also	B-X
blocked	B-X
KV	B-X
and	B-X
KCa	B-X
channels	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
direct	B-X
inhibition	B-X
of	B-X
K+	B-X
channels	B-X
in	B-X
T	B-X
cells	B-X
by	B-X
progesterone	B-X
contributes	B-X
to	B-X
progesterone-induced	B-X
immunosuppression	B-X
.	B-X

Using	O
human	O
T	O
lymphocytes	O
and	O
T	O
cell	O
lines	O
,	O
we	O
show	O
that	O
progesterone	O
,	O
at	O
concentrations	O
found	O
in	O
the	O
placenta	O
,	O
rapidly	O
and	O
reversibly	O
blocks	O
voltage	O
-	O
gated	O
and	O
calcium	O
-	O
activated	O
K	O
+	O
channels	O
(	O
KV	O
and	O
KCa	O
,	O
respectively	O
)	O
,	O
resulting	O
in	O
depolarization	O
of	O
the	O
membrane	O
potential	O
.	O

As	O
a	O
result	O
,	O
Ca2	O
+	O
signaling	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
-	O
driven	O
gene	O
expression	O
are	O
inhibited	O
.	O
<EOS>	B-X
Using	B-X
human	B-X
T	B-X
lymphocytes	B-X
and	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
we	B-X
show	B-X
that	B-X
progesterone	B-X
,	B-X
at	B-X
concentrations	B-X
found	B-X
in	B-X
the	B-X
placenta	B-X
,	B-X
rapidly	B-X
and	B-X
reversibly	B-X
blocks	B-X
voltage-gated	B-X
and	B-X
calcium-activated	B-X
K+	B-X
channels	B-X
(	B-X
KV	B-X
and	B-X
KCa	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
resulting	B-X
in	B-X
depolarization	B-X
of	B-X
the	B-X
membrane	B-X
potential	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
Ca2+	B-X
signaling	B-X
and	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NF-AT	B-X
)	B-X
-driven	B-X
gene	B-X
expression	B-X
are	B-X
inhibited	B-X
.	B-X
Progesterone	B-X
acts	B-X
distally	B-X
to	B-X
the	B-X
initial	B-X
steps	B-X
of	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
-mediated	B-X
signal	B-X
transduction	B-X
,	B-X
since	B-X
it	B-X
blocks	B-X
sustained	B-X
Ca2+	B-X
signals	B-X
after	B-X
thapsigargin	B-X
stimulation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
oscillatory	B-X
Ca2+	B-X
signals	B-X
,	B-X
but	B-X
not	B-X
the	B-X
Ca2+	B-X
transient	B-X
after	B-X
TCR	B-X
stimulation	B-X
.	B-X
Progesterone	B-X
effectively	B-X
blocked	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
K+	B-X
channels	B-X
,	B-X
reducing	B-X
both	B-X
Kv1.3	B-X
and	B-X
charybdotoxin-resistant	B-X
components	B-X
of	B-X
KV	B-X
current	B-X
and	B-X
KCa	B-X
current	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
blocking	B-X
several	B-X
cloned	B-X
KV	B-X
channels	B-X
expressed	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
Progesterone	B-X
had	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
on	B-X
a	B-X
cloned	B-X
voltage-gated	B-X
Na+	B-X
channel	B-X
,	B-X
an	B-X
inward	B-X
rectifier	B-X
K+	B-X
channel	B-X
,	B-X
or	B-X
on	B-X
lymphocyte	B-X
Ca2+	B-X
and	B-X
Cl-	B-X
channels	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
direct	B-X
inhibition	B-X
of	B-X
K+	B-X
channels	B-X
in	B-X
T	B-X
cells	B-X
by	B-X
progesterone	B-X
contributes	B-X
to	B-X
progesterone-induced	B-X
immunosuppression	B-X
.	B-X

Progesterone	O
acts	O
distally	O
to	O
the	O
initial	O
steps	O
of	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
mediated	O
signal	O
transduction	O
,	O
since	O
it	O
blocks	O
sustained	O
Ca2	O
+	O
signals	O
after	O
thapsigargin	O
stimulation	O
,	O
as	O
well	O
as	O
oscillatory	O
Ca2	O
+	O
signals	O
,	O
but	O
not	O
the	O
Ca2	O
+	O
transient	O
after	O
TCR	O
stimulation	O
.	O

K	O
+	O
channel	O
blockade	O
by	O
progesterone	O
is	O
specific	O
;	O
other	O
steroid	O
hormones	O
had	O
little	O
or	O
no	O
effect	O
,	O
although	O
the	O
progesterone	O
antagonist	O
RU	O
486	O
also	O
blocked	O
KV	O
and	O
KCa	O
channels	O
.	O
<EOS>	B-X
The	B-X
Slo3	B-X
potassium	B-X
(	B-X
K	B-X
The	B-X
mechanism	B-X
by	B-X
which	B-X
progesterone	B-X
causes	B-X
localized	B-X
suppression	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
during	B-X
pregnancy	B-X
has	B-X
remained	B-X
elusive	B-X
.	B-X
Using	B-X
human	B-X
T	B-X
lymphocytes	B-X
and	B-X
T	B-X
cell	B-X
lines	B-X
,	B-X
we	B-X
show	B-X
that	B-X
progesterone	B-X
,	B-X
at	B-X
concentrations	B-X
found	B-X
in	B-X
the	B-X
placenta	B-X
,	B-X
rapidly	B-X
and	B-X
reversibly	B-X
blocks	B-X
voltage-gated	B-X
and	B-X
calcium-activated	B-X
K+	B-X
channels	B-X
(	B-X
KV	B-X
and	B-X
KCa	B-X
,	B-X
respectively	B-X
)	B-X
,	B-X
resulting	B-X
in	B-X
depolarization	B-X
of	B-X
the	B-X
membrane	B-X
potential	B-X
.	B-X
K+	B-X
channel	B-X
blockade	B-X
by	B-X
progesterone	B-X
is	B-X
specific	B-X
;	B-X
other	B-X
steroid	B-X
hormones	B-X
had	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
,	B-X
although	B-X
the	B-X
progesterone	B-X
antagonist	B-X
RU	B-X
486	B-X
also	B-X
blocked	B-X
KV	B-X
and	B-X
KCa	B-X
channels	B-X
.	B-X
Progesterone	B-X
effectively	B-X
blocked	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
K+	B-X
channels	B-X
,	B-X
reducing	B-X
both	B-X
Kv1.3	B-X
and	B-X
charybdotoxin-resistant	B-X
components	B-X
of	B-X
KV	B-X
current	B-X
and	B-X
KCa	B-X
current	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
blocking	B-X
several	B-X
cloned	B-X
KV	B-X
channels	B-X
expressed	B-X
in	B-X
cell	B-X
lines	B-X
.	B-X
Progesterone	B-X
had	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
on	B-X
a	B-X
cloned	B-X
voltage-gated	B-X
Na+	B-X
channel	B-X
,	B-X
an	B-X
inward	B-X
rectifier	B-X
K+	B-X
channel	B-X
,	B-X
or	B-X
on	B-X
lymphocyte	B-X
Ca2+	B-X
and	B-X
Cl-	B-X
channels	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
direct	B-X
inhibition	B-X
of	B-X
K+	B-X
channels	B-X
in	B-X
T	B-X
cells	B-X
by	B-X
progesterone	B-X
contributes	B-X
to	B-X
progesterone-induced	B-X
immunosuppression	B-X
.	B-X

Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K	O
+	O
channels	O
,	O
reducing	O
both	O
Kv1	B-Protein
.	I-Protein
3	I-Protein
and	O
charybdotoxin	O
-	O
resistant	O
components	O
of	O
KV	O
current	O
and	O
KCa	O
current	O
in	O
T	O
cells	O
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	O
KV	O
channels	O
expressed	O
in	O
cell	O
lines	O
.	O

Progesterone	O
had	O
little	O
or	O
no	O
effect	O
on	O
a	O
cloned	O
voltage	O
-	O
gated	O
Na	O
+	O
channel	O
,	O
an	O
inward	O
rectifier	O
K	O
+	O
channel	O
,	O
or	O
on	O
lymphocyte	O
Ca2	O
+	O
and	O
Cl	O
-	O
channels	O
.	O
<EOS>	B-X
Progesterone	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
maintaining	B-X
a	B-X
pregnancy	B-X
,	B-X
and	B-X
supplementation	B-X
with	B-X
different	B-X
progestogens	B-X
in	B-X
early	B-X
pregnancy	B-X
has	B-X
been	B-X
attempted	B-X
to	B-X
rescue	B-X
a	B-X
pregnancy	B-X
in	B-X
women	B-X
with	B-X
early	B-X
pregnancy	B-X
bleeding	B-X
(	B-X
threatened	B-X
miscarriage	B-X
)	B-X
,	B-X
and	B-X
to	B-X
prevent	B-X
miscarriages	B-X
in	B-X
asymptomatic	B-X
women	B-X
who	B-X
have	B-X
a	B-X
history	B-X
of	B-X
three	B-X
or	B-X
more	B-X
previous	B-X
miscarriages	B-X
(	B-X
recurrent	B-X
miscarriage	B-X
)	B-X
.	B-X
Despite	B-X
this	B-X
,	B-X
the	B-X
role	B-X
of	B-X
uterine	B-X
glands	B-X
in	B-X
first	B-X
trimester	B-X
human	B-X
pregnancy	B-X
is	B-X
little	B-X
understood	B-X
.	B-X
Real-time	B-X
qPCR	B-X
and	B-X
bulk	B-X
RNA-sequencing	B-X
analysis	B-X
revealed	B-X
effects	B-X
of	B-X
hormone	B-X
treatment	B-X
on	B-X
gene	B-X
expression	B-X
that	B-X
recapitulated	B-X
changes	B-X
in	B-X
proliferative	B-X
and	B-X
secretory	B-X
phase	B-X
endometrium	B-X
.	B-X
Hormone	B-X
replacement	B-X
therapy	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
effective	B-X
in	B-X
alleviating	B-X
menopausal	B-X
symptoms	B-X
.	B-X
Bioidentical	B-X
hormone	B-X
therapy	B-X
has	B-X
also	B-X
been	B-X
used	B-X
by	B-X
dermatologists	B-X
for	B-X
its	B-X
anti-aging	B-X
effects	B-X
on	B-X
the	B-X
skin	B-X
,	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
efficacy	B-X
and	B-X
side	B-X
effects	B-X
of	B-X
bioidentical	B-X
hormones	B-X
in	B-X
this	B-X
field	B-X
.	B-X
This	B-X
review	B-X
illustrates	B-X
the	B-X
main	B-X
purpose	B-X
of	B-X
bioidentical	B-X
hormone	B-X
therapy	B-X
for	B-X
dermatological	B-X
uses	B-X
and	B-X
its	B-X
potential	B-X
side	B-X
effects	B-X
,	B-X
serving	B-X
as	B-X
a	B-X
tool	B-X
for	B-X
dermatologists	B-X
when	B-X
facing	B-X
these	B-X
patients	B-X
.	B-X

We	O
propose	O
that	O
direct	O
inhibition	O
of	O
K	O
+	O
channels	O
in	O
T	O
cells	O
by	O
progesterone	O
contributes	O
to	O
progesterone	O
-	O
induced	O
immunosuppression	O
.	O

Role	O
of	O
IKK1	B-Protein
and	O
IKK2	B-Protein
in	O
lipopolysaccharide	O
signaling	O
in	O
human	O
monocytic	O
cells	O
.	O
<EOS>	B-X
Bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induces	B-X
monocytes	B-X
to	B-X
express	B-X
a	B-X
variety	B-X
of	B-X
genes	B-X
by	B-X
activating	B-X
the	B-X
NF-kappaB/Rel	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
interleukin	B-X
1	B-X
signaling	B-X
pathways	B-X
activate	B-X
two	B-X
kinases	B-X
,	B-X
IKK1	B-X
and	B-X
IKK2	B-X
.	B-X
At	B-X
present	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
IKKs	B-X
in	B-X
LPS	B-X
signaling	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
LPS	B-X
induces	B-X
IKK	B-X
activity	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
.	B-X
The	B-X
kinetics	B-X
of	B-X
activation	B-X
of	B-X
kinase	B-X
activity	B-X
in	B-X
monocytic	B-X
cells	B-X
are	B-X
relatively	B-X
slow	B-X
with	B-X
maximal	B-X
activity	B-X
observed	B-X
at	B-X
60	B-X
min	B-X
,	B-X
which	B-X
coincides	B-X
with	B-X
the	B-X
degradation	B-X
of	B-X
IkappaBs	B-X
and	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappaB	B-X
.	B-X
In	B-X
transfection	B-X
experiments	B-X
,	B-X
overexpression	B-X
of	B-X
wild	B-X
type	B-X
IKK1	B-X
,	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
IKK1	B-X
(	B-X
K44M	B-X
)	B-X
,	B-X
or	B-X
wild	B-X
type	B-X
IKK2	B-X
did	B-X
not	B-X
affect	B-X
LPS-induced	B-X
kappaB-dependent	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
IKK2	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
kappaB-dependent	B-X
transcription	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
LPS	B-X
induction	B-X
of	B-X
kappaB-dependent	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
requires	B-X
activation	B-X
of	B-X
IKK2	B-X
.	B-X

Mononuclear	O
phagocytes	O
play	O
a	O
major	O
role	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
monocytes	O
to	O
express	O
a	O
variety	O
of	O
genes	O
by	O
activating	O
the	O
NF	O
-	O
kappaB	O
/	O
Rel	O
transcription	O
factor	O
family	O
.	O
<EOS>	B-X
Binding	B-X
of	B-X
plasma	B-X
Factor	B-X
VII/VIIa	B-X
to	B-X
the	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
receptor	B-X
initiates	B-X
the	B-X
coagulation	B-X
protease	B-X
cascades	B-X
.	B-X
TF	B-X
expression	B-X
by	B-X
circulating	B-X
monocytes	B-X
is	B-X
associated	B-X
with	B-X
thrombotic	B-X
and	B-X
inflammatory	B-X
complications	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
diseases	B-X
.	B-X
Transcriptional	B-X
activation	B-X
of	B-X
the	B-X
human	B-X
TF	B-X
gene	B-X
in	B-X
monocytic	B-X
cells	B-X
exposed	B-X
to	B-X
bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
is	B-X
mediated	B-X
by	B-X
binding	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
to	B-X
a	B-X
kappa	B-X
B	B-X
site	B-X
in	B-X
the	B-X
TF	B-X
promoter	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
family	B-X
of	B-X
anti-inflammatory	B-X
agents	B-X
,	B-X
known	B-X
as	B-X
the	B-X
salicylates	B-X
,	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
activity	B-X
and	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
at	B-X
clinically	B-X
relevant	B-X
doses	B-X
.	B-X
Furthermore	B-X
,	B-X
sodium	B-X
salicylate	B-X
blocked	B-X
the	B-X
LPS-induced	B-X
proteolytic	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
which	B-X
prevented	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
two	B-X
other	B-X
nonsteroidal	B-X
anti-inflammatory	B-X
drugs	B-X
,	B-X
ibuprofen	B-X
and	B-X
indomethacin	B-X
,	B-X
did	B-X
not	B-X
inhibit	B-X
LPS	B-X
induction	B-X
of	B-X
the	B-X
TF	B-X
gene	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
salicylates	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
TF	B-X
gene	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
by	B-X
preventing	B-X
nuclear	B-X
translocation	B-X
of	B-X
c-Rel/p65	B-X
heterodimers	B-X
.	B-X
The	B-X
clinical	B-X
benefits	B-X
of	B-X
salicylates	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
several	B-X
diseases	B-X
,	B-X
including	B-X
atherosclerosis	B-X
and	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
may	B-X
be	B-X
related	B-X
to	B-X
their	B-X
ability	B-X
to	B-X
reduce	B-X
monocyte	B-X
gene	B-X
expression	B-X
.	B-X

Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
tumor	O
necrosis	O
factor	O
and	O
interleukin	O
1	O
signaling	O
pathways	O
activate	O
two	O
kinases	O
,	O
IKK1	B-Protein
and	O
IKK2	B-Protein
.	O
<EOS>	B-X
Bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induces	B-X
monocytes	B-X
to	B-X
express	B-X
a	B-X
variety	B-X
of	B-X
genes	B-X
by	B-X
activating	B-X
the	B-X
NF-kappaB/Rel	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
interleukin	B-X
1	B-X
signaling	B-X
pathways	B-X
activate	B-X
two	B-X
kinases	B-X
,	B-X
IKK1	B-X
and	B-X
IKK2	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
IkappaB	B-X
cytoplasmic	B-X
inhibitors	B-X
,	B-X
IkappaBalpha	B-X
,	B-X
IkappaBbeta	B-X
,	B-X
and	B-X
IkappaBepsilon	B-X
,	B-X
by	B-X
these	B-X
kinases	B-X
triggers	B-X
proteolytic	B-X
degradation	B-X
and	B-X
the	B-X
release	B-X
of	B-X
NF-kappaB/Rel	B-X
proteins	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
At	B-X
present	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
IKKs	B-X
in	B-X
LPS	B-X
signaling	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
LPS	B-X
induces	B-X
IKK	B-X
activity	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
.	B-X
In	B-X
transfection	B-X
experiments	B-X
,	B-X
overexpression	B-X
of	B-X
wild	B-X
type	B-X
IKK1	B-X
,	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
IKK1	B-X
(	B-X
K44M	B-X
)	B-X
,	B-X
or	B-X
wild	B-X
type	B-X
IKK2	B-X
did	B-X
not	B-X
affect	B-X
LPS-induced	B-X
kappaB-dependent	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
IKK2	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
kappaB-dependent	B-X
transcription	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
LPS	B-X
induction	B-X
of	B-X
kappaB-dependent	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
requires	B-X
activation	B-X
of	B-X
IKK2	B-X
.	B-X

Phosphorylation	O
of	O
the	O
IkappaB	O
cytoplasmic	O
inhibitors	O
,	O
IkappaBalpha	B-Protein
,	O
IkappaBbeta	B-Protein
,	O
and	O
IkappaBepsilon	B-Protein
,	O
by	O
these	O
kinases	O
triggers	O
proteolytic	O
degradation	O
and	O
the	O
release	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
proteins	O
into	O
the	O
nucleus	O
.	O
<EOS>	B-X
Bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induces	B-X
monocytes	B-X
to	B-X
express	B-X
a	B-X
variety	B-X
of	B-X
genes	B-X
by	B-X
activating	B-X
the	B-X
NF-kappaB/Rel	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
interleukin	B-X
1	B-X
signaling	B-X
pathways	B-X
activate	B-X
two	B-X
kinases	B-X
,	B-X
IKK1	B-X
and	B-X
IKK2	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
IkappaB	B-X
cytoplasmic	B-X
inhibitors	B-X
,	B-X
IkappaBalpha	B-X
,	B-X
IkappaBbeta	B-X
,	B-X
and	B-X
IkappaBepsilon	B-X
,	B-X
by	B-X
these	B-X
kinases	B-X
triggers	B-X
proteolytic	B-X
degradation	B-X
and	B-X
the	B-X
release	B-X
of	B-X
NF-kappaB/Rel	B-X
proteins	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
The	B-X
kinetics	B-X
of	B-X
activation	B-X
of	B-X
kinase	B-X
activity	B-X
in	B-X
monocytic	B-X
cells	B-X
are	B-X
relatively	B-X
slow	B-X
with	B-X
maximal	B-X
activity	B-X
observed	B-X
at	B-X
60	B-X
min	B-X
,	B-X
which	B-X
coincides	B-X
with	B-X
the	B-X
degradation	B-X
of	B-X
IkappaBs	B-X
and	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappaB	B-X
.	B-X
In	B-X
transfection	B-X
experiments	B-X
,	B-X
overexpression	B-X
of	B-X
wild	B-X
type	B-X
IKK1	B-X
,	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
IKK1	B-X
(	B-X
K44M	B-X
)	B-X
,	B-X
or	B-X
wild	B-X
type	B-X
IKK2	B-X
did	B-X
not	B-X
affect	B-X
LPS-induced	B-X
kappaB-dependent	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
IKK2	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
kappaB-dependent	B-X
transcription	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
LPS	B-X
induction	B-X
of	B-X
kappaB-dependent	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
requires	B-X
activation	B-X
of	B-X
IKK2	B-X
.	B-X

At	O
present	O
,	O
the	O
role	O
of	O
the	O
IKKs	O
in	O
LPS	O
signaling	O
has	O
not	O
been	O
investigated	O
.	O

Here	O
,	O
we	O
report	O
that	O
LPS	O
induces	O
IKK	O
activity	O
in	O
human	O
monocytes	O
and	O
THP	O
-	O
1	O
monocytic	O
cells	O
.	O
<EOS>	B-X
It	B-X
has	B-X
also	B-X
been	B-X
reported	B-X
that	B-X
minocycline	B-X
can	B-X
induce	B-X
autophagy	B-X
,	B-X
suggesting	B-X
that	B-X
autophagy	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
process	B-X
of	B-X
minocycline	B-X
regulating	B-X
inflammation	B-X
and	B-X
immune	B-X
response	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
used	B-X
enzyme-linked	B-X
immunosorbent	B-X
assays	B-X
(	B-X
ELISA	B-X
)	B-X
to	B-X
measure	B-X
the	B-X
production	B-X
of	B-X
cytokines	B-X
following	B-X
minocycline	B-X
treatment	B-X
of	B-X
lipopolysaccharide-	B-X
(	B-X
LPS-	B-X
)	B-X
stimulated	B-X
THP-1	B-X
cells	B-X
.	B-X
Cell	B-X
proliferation	B-X
was	B-X
measured	B-X
by	B-X
WST-1	B-X
cell	B-X
proliferation	B-X
assay	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
LPS	B-X
induced	B-X
autophagy	B-X
in	B-X
a	B-X
tumor	B-X
necrosis	B-X
factor-	B-X
(	B-X
TNF-	B-X
)	B-X

The	O
kinetics	O
of	O
activation	O
of	O
kinase	O
activity	O
in	O
monocytic	O
cells	O
are	O
relatively	O
slow	O
with	O
maximal	O
activity	O
observed	O
at	O
60	O
min	O
,	O
which	O
coincides	O
with	O
the	O
degradation	O
of	O
IkappaBs	O
and	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
Mononuclear	B-X
phagocytes	B-X
play	B-X
a	B-X
major	B-X
role	B-X
in	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
.	B-X
Bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induces	B-X
monocytes	B-X
to	B-X
express	B-X
a	B-X
variety	B-X
of	B-X
genes	B-X
by	B-X
activating	B-X
the	B-X
NF-kappaB/Rel	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
interleukin	B-X
1	B-X
signaling	B-X
pathways	B-X
activate	B-X
two	B-X
kinases	B-X
,	B-X
IKK1	B-X
and	B-X
IKK2	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
IkappaB	B-X
cytoplasmic	B-X
inhibitors	B-X
,	B-X
IkappaBalpha	B-X
,	B-X
IkappaBbeta	B-X
,	B-X
and	B-X
IkappaBepsilon	B-X
,	B-X
by	B-X
these	B-X
kinases	B-X
triggers	B-X
proteolytic	B-X
degradation	B-X
and	B-X
the	B-X
release	B-X
of	B-X
NF-kappaB/Rel	B-X
proteins	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
LPS	B-X
induces	B-X
IKK	B-X
activity	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
.	B-X
The	B-X
kinetics	B-X
of	B-X
activation	B-X
of	B-X
kinase	B-X
activity	B-X
in	B-X
monocytic	B-X
cells	B-X
are	B-X
relatively	B-X
slow	B-X
with	B-X
maximal	B-X
activity	B-X
observed	B-X
at	B-X
60	B-X
min	B-X
,	B-X
which	B-X
coincides	B-X
with	B-X
the	B-X
degradation	B-X
of	B-X
IkappaBs	B-X
and	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappaB	B-X
.	B-X
In	B-X
transfection	B-X
experiments	B-X
,	B-X
overexpression	B-X
of	B-X
wild	B-X
type	B-X
IKK1	B-X
,	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
IKK1	B-X
(	B-X
K44M	B-X
)	B-X
,	B-X
or	B-X
wild	B-X
type	B-X
IKK2	B-X
did	B-X
not	B-X
affect	B-X
LPS-induced	B-X
kappaB-dependent	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
IKK2	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
kappaB-dependent	B-X
transcription	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
LPS	B-X
induction	B-X
of	B-X
kappaB-dependent	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
requires	B-X
activation	B-X
of	B-X
IKK2	B-X
.	B-X

In	O
transfection	O
experiments	O
,	O
overexpression	O
of	O
wild	O
type	O
IKK1	B-Protein
,	O
a	O
dominant	O
negative	O
mutant	O
IKK1	B-Protein
(	O
K44M	O
)	O
,	O
or	O
wild	O
type	O
IKK2	B-Protein
did	O
not	O
affect	O
LPS	O
-	O
induced	O
kappaB	O
-	O
dependent	O
transcription	O
in	O
monocytic	O
cells	O
.	O
<EOS>	B-X
On	B-X
TNF	B-X
binding	B-X
,	B-X
receptor-interacting	B-X
protein	B-X
kinase	B-X
1	B-X
(	B-X
RIPK1	B-X
)	B-X
is	B-X
recruited	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
TNFR1	B-X
,	B-X
at	B-X
which	B-X
it	B-X
becomes	B-X
ubiquitylated	B-X
and	B-X
serves	B-X
as	B-X
a	B-X
platform	B-X
for	B-X
recruitment	B-X
and	B-X
activation	B-X
of	B-X
NEMO/IKK1/IKK2	B-X
and	B-X
TAK1/TAB2	B-X
.	B-X
RIPK1	B-X
is	B-X
commonly	B-X
thought	B-X
to	B-X
be	B-X
required	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
canonical	B-X
NF-kappaB	B-X
and	B-X
for	B-X
inhibition	B-X
TNFR1-induced	B-X
apoptosis	B-X
.	B-X
RIPK1	B-X
has	B-X
,	B-X
however	B-X
,	B-X
also	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
TNFR1-induced	B-X
apoptosis	B-X
when	B-X
cIAPs	B-X
are	B-X
depleted	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
RIPK1	B-X
in	B-X
TNF/IAP	B-X
antagonist-induced	B-X
death	B-X
,	B-X
we	B-X
compared	B-X
wild	B-X
type	B-X
(	B-X
WT	B-X
)	B-X
and	B-X
RIPK1	B-X
(	B-X
-/-	B-X
)	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
(	B-X
MEFs	B-X
)	B-X
treated	B-X
with	B-X
these	B-X
compounds	B-X
.	B-X
Surprisingly	B-X
,	B-X
however	B-X
,	B-X
on	B-X
being	B-X
treated	B-X
with	B-X
TNF	B-X
alone	B-X
,	B-X
RIPK1	B-X
(	B-X
-/-	B-X
)	B-X
MEFs	B-X
activated	B-X
canonical	B-X
NF-kappaB	B-X
and	B-X
did	B-X
not	B-X
die	B-X
.	B-X
Furthermore	B-X
,	B-X
several	B-X
cell	B-X
types	B-X
from	B-X
E18	B-X
RIPK1	B-X
(	B-X
-/-	B-X
)	B-X
embryos	B-X
seem	B-X
to	B-X
activate	B-X
NF-kappaB	B-X
in	B-X
response	B-X
to	B-X
TNF	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
models	B-X
proposing	B-X
that	B-X
RIPK1	B-X
is	B-X
essential	B-X
for	B-X
TNFR1	B-X
to	B-X
activate	B-X
canonical	B-X
NF-kappaB	B-X
are	B-X
incorrect	B-X
.	B-X

In	O
contrast	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
IKK2	B-Protein
inhibited	O
LPS	O
induction	O
of	O
kappaB	O
-	O
dependent	O
transcription	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
indicate	O
that	O
LPS	O
induction	O
of	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
requires	O
activation	O
of	O
IKK2	B-Protein
.	O
<EOS>	B-X
Bacterial	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induces	B-X
monocytes	B-X
to	B-X
express	B-X
a	B-X
variety	B-X
of	B-X
genes	B-X
by	B-X
activating	B-X
the	B-X
NF-kappaB/Rel	B-X
transcription	B-X
factor	B-X
family	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
reported	B-X
that	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
and	B-X
interleukin	B-X
1	B-X
signaling	B-X
pathways	B-X
activate	B-X
two	B-X
kinases	B-X
,	B-X
IKK1	B-X
and	B-X
IKK2	B-X
.	B-X
Phosphorylation	B-X
of	B-X
the	B-X
IkappaB	B-X
cytoplasmic	B-X
inhibitors	B-X
,	B-X
IkappaBalpha	B-X
,	B-X
IkappaBbeta	B-X
,	B-X
and	B-X
IkappaBepsilon	B-X
,	B-X
by	B-X
these	B-X
kinases	B-X
triggers	B-X
proteolytic	B-X
degradation	B-X
and	B-X
the	B-X
release	B-X
of	B-X
NF-kappaB/Rel	B-X
proteins	B-X
into	B-X
the	B-X
nucleus	B-X
.	B-X
At	B-X
present	B-X
,	B-X
the	B-X
role	B-X
of	B-X
the	B-X
IKKs	B-X
in	B-X
LPS	B-X
signaling	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
LPS	B-X
induces	B-X
IKK	B-X
activity	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
THP-1	B-X
monocytic	B-X
cells	B-X
.	B-X
The	B-X
kinetics	B-X
of	B-X
activation	B-X
of	B-X
kinase	B-X
activity	B-X
in	B-X
monocytic	B-X
cells	B-X
are	B-X
relatively	B-X
slow	B-X
with	B-X
maximal	B-X
activity	B-X
observed	B-X
at	B-X
60	B-X
min	B-X
,	B-X
which	B-X
coincides	B-X
with	B-X
the	B-X
degradation	B-X
of	B-X
IkappaBs	B-X
and	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappaB	B-X
.	B-X
In	B-X
transfection	B-X
experiments	B-X
,	B-X
overexpression	B-X
of	B-X
wild	B-X
type	B-X
IKK1	B-X
,	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
IKK1	B-X
(	B-X
K44M	B-X
)	B-X
,	B-X
or	B-X
wild	B-X
type	B-X
IKK2	B-X
did	B-X
not	B-X
affect	B-X
LPS-induced	B-X
kappaB-dependent	B-X
transcription	B-X
in	B-X
monocytic	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
IKK2	B-X
inhibited	B-X
LPS	B-X
induction	B-X
of	B-X
kappaB-dependent	B-X
transcription	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
LPS	B-X
induction	B-X
of	B-X
kappaB-dependent	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
monocytic	B-X
cells	B-X
requires	B-X
activation	B-X
of	B-X
IKK2	B-X
.	B-X

Effects	O
of	O
overexpression	O
of	O
IL	O
-	O
1	O
receptor	O
-	O
associated	O
kinase	O
on	O
NFkappaB	O
activation	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
and	O
stress	O
-	O
activated	O
protein	O
kinases	O
in	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
.	O
<EOS>	B-X
The	B-X
association	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
IL-1	B-X
receptor-associated	B-X
protein	B-X
kinase	B-X
(	B-X
IRAK	B-X
)	B-X
to	B-X
the	B-X
IL-1	B-X
receptor	B-X
complex	B-X
is	B-X
one	B-X
of	B-X
the	B-X
earliest	B-X
events	B-X
detectable	B-X
in	B-X
IL-1	B-X
signal	B-X
transduction	B-X
.	B-X
We	B-X
generated	B-X
permanent	B-X
clones	B-X
of	B-X
the	B-X
murine	B-X
T	B-X
cell	B-X
line	B-X
EL4	B-X
6.1	B-X
overexpressing	B-X
human	B-X
(	B-X
h	B-X
)	B-X
IRAK	B-X
to	B-X
evaluate	B-X
the	B-X
role	B-X
of	B-X
this	B-X
kinase	B-X
in	B-X
IL-1	B-X
signaling	B-X
.	B-X
Overexpression	B-X
of	B-X
hIRAK	B-X
enhanced	B-X
IL-1-stimulated	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NFkappaB	B-X
,	B-X
whereas	B-X
a	B-X
truncated	B-X
form	B-X
(	B-X
N-IRAK	B-X
)	B-X
specifically	B-X
inhibited	B-X
IL-1-dependent	B-X
NFkappaB	B-X
activity	B-X
.	B-X
In	B-X
clones	B-X
stably	B-X
overexpressing	B-X
hIRAK	B-X
a	B-X
weak	B-X
constitutive	B-X
activation	B-X
of	B-X
NFkappaB	B-X
correlated	B-X
with	B-X
a	B-X
low	B-X
basal	B-X
IL-2	B-X
production	B-X
which	B-X
was	B-X
enhanced	B-X
in	B-X
an	B-X
IL-1-dependent	B-X
manner	B-X
.	B-X
Compared	B-X
to	B-X
the	B-X
parental	B-X
cell	B-X
line	B-X
the	B-X
dose-response	B-X
curve	B-X
of	B-X
IL-1-induced	B-X
IL-2	B-X
production	B-X
was	B-X
shifted	B-X
in	B-X
both	B-X
potency	B-X
and	B-X
efficacy	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
IRAK	B-X
directly	B-X
triggers	B-X
NFkappaB-mediated	B-X
gene	B-X
expression	B-X
in	B-X
EL4	B-X
cells	B-X
.	B-X
Qualitatively	B-X
different	B-X
effects	B-X
were	B-X
observed	B-X
for	B-X
the	B-X
IL-1-induced	B-X
activation	B-X
of	B-X
stress-activated	B-X
protein	B-X
(	B-X
SAP	B-X
)	B-X
kinases	B-X
:	B-X
permanent	B-X
overexpression	B-X
of	B-X
IRAK	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
dose	B-X
dependence	B-X
but	B-X
prolonged	B-X
the	B-X
kinetics	B-X
of	B-X
IL-1-induced	B-X
activation	B-X
of	B-X
SAP	B-X
kinases	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
signaling	B-X
branch	B-X
may	B-X
be	B-X
regulated	B-X
by	B-X
distinct	B-X
mechanisms	B-X
.	B-X

The	O
association	O
and	O
activation	O
of	O
the	O
IL	O
-	O
1	O
receptor	O
-	O
associated	O
protein	O
kinase	O
(	O
IRAK	O
)	O
to	O
the	O
IL	O
-	O
1	O
receptor	O
complex	O
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
in	O
IL	O
-	O
1	O
signal	O
transduction	O
.	O

We	O
generated	O
permanent	O
clones	O
of	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
6	O
.	O
1	O
overexpressing	O
human	O
(	O
h	O
)	O
IRAK	O
to	O
evaluate	O
the	O
role	O
of	O
this	O
kinase	O
in	O
IL	O
-	O
1	O
signaling	O
.	O

Overexpression	O
of	O
hIRAK	O
enhanced	O
IL	O
-	O
1	O
-	O
stimulated	O
activation	O
of	O
the	O
transcription	O
factor	O
NFkappaB	O
,	O
whereas	O
a	O
truncated	O
form	O
(	O
N	O
-	O
IRAK	O
)	O
specifically	O
inhibited	O
IL	O
-	O
1	O
-	O
dependent	O
NFkappaB	O
activity	O
.	O

In	O
clones	O
stably	O
overexpressing	O
hIRAK	O
a	O
weak	O
constitutive	O
activation	O
of	O
NFkappaB	O
correlated	O
with	O
a	O
low	O
basal	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
which	O
was	O
enhanced	O
in	O
an	O
IL	O
-	O
1	O
-	O
dependent	O
manner	O
.	O

Compared	O
to	O
the	O
parental	O
cell	O
line	O
the	O
dose	O
-	O
response	O
curve	O
of	O
IL	O
-	O
1	O
-	O
induced	O
IL	B-Protein
-	I-Protein
2	I-Protein
production	O
was	O
shifted	O
in	O
both	O
potency	O
and	O
efficacy	O
.	O

These	O
results	O
demonstrate	O
that	O
IRAK	O
directly	O
triggers	O
NFkappaB	O
-	O
mediated	O
gene	O
expression	O
in	O
EL4	O
cells	O
.	O
<EOS>	B-X
The	B-X
association	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
IL-1	B-X
receptor-associated	B-X
protein	B-X
kinase	B-X
(	B-X
IRAK	B-X
)	B-X
to	B-X
the	B-X
IL-1	B-X
receptor	B-X
complex	B-X
is	B-X
one	B-X
of	B-X
the	B-X
earliest	B-X
events	B-X
detectable	B-X
in	B-X
IL-1	B-X
signal	B-X
transduction	B-X
.	B-X
We	B-X
generated	B-X
permanent	B-X
clones	B-X
of	B-X
the	B-X
murine	B-X
T	B-X
cell	B-X
line	B-X
EL4	B-X
6.1	B-X
overexpressing	B-X
human	B-X
(	B-X
h	B-X
)	B-X
IRAK	B-X
to	B-X
evaluate	B-X
the	B-X
role	B-X
of	B-X
this	B-X
kinase	B-X
in	B-X
IL-1	B-X
signaling	B-X
.	B-X
Overexpression	B-X
of	B-X
hIRAK	B-X
enhanced	B-X
IL-1-stimulated	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NFkappaB	B-X
,	B-X
whereas	B-X
a	B-X
truncated	B-X
form	B-X
(	B-X
N-IRAK	B-X
)	B-X
specifically	B-X
inhibited	B-X
IL-1-dependent	B-X
NFkappaB	B-X
activity	B-X
.	B-X
In	B-X
clones	B-X
stably	B-X
overexpressing	B-X
hIRAK	B-X
a	B-X
weak	B-X
constitutive	B-X
activation	B-X
of	B-X
NFkappaB	B-X
correlated	B-X
with	B-X
a	B-X
low	B-X
basal	B-X
IL-2	B-X
production	B-X
which	B-X
was	B-X
enhanced	B-X
in	B-X
an	B-X
IL-1-dependent	B-X
manner	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
IRAK	B-X
directly	B-X
triggers	B-X
NFkappaB-mediated	B-X
gene	B-X
expression	B-X
in	B-X
EL4	B-X
cells	B-X
.	B-X
Qualitatively	B-X
different	B-X
effects	B-X
were	B-X
observed	B-X
for	B-X
the	B-X
IL-1-induced	B-X
activation	B-X
of	B-X
stress-activated	B-X
protein	B-X
(	B-X
SAP	B-X
)	B-X
kinases	B-X
:	B-X
permanent	B-X
overexpression	B-X
of	B-X
IRAK	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
dose	B-X
dependence	B-X
but	B-X
prolonged	B-X
the	B-X
kinetics	B-X
of	B-X
IL-1-induced	B-X
activation	B-X
of	B-X
SAP	B-X
kinases	B-X
,	B-X
suggesting	B-X
that	B-X
this	B-X
signaling	B-X
branch	B-X
may	B-X
be	B-X
regulated	B-X
by	B-X
distinct	B-X
mechanisms	B-X
.	B-X

Qualitatively	O
different	O
effects	O
were	O
observed	O
for	O
the	O
IL	O
-	O
1	O
-	O
induced	O
activation	O
of	O
stress	O
-	O
activated	O
protein	O
(	O
SAP	O
)	O
kinases	O
:	O
permanent	O
overexpression	O
of	O
IRAK	O
did	O
not	O
affect	O
the	O
dose	O
dependence	O
but	O
prolonged	O
the	O
kinetics	O
of	O
IL	O
-	O
1	O
-	O
induced	O
activation	O
of	O
SAP	O
kinases	O
,	O
suggesting	O
that	O
this	O
signaling	O
branch	O
may	O
be	O
regulated	O
by	O
distinct	O
mechanisms	O
.	O

Decreased	O
IL	O
-	O
12	O
production	O
and	O
Th1	O
cell	O
development	O
by	O
acetyl	O
salicylic	O
acid	O
-	O
mediated	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
IL-12	B-X
is	B-X
a	B-X
75-kDa	B-X
heterodimeric	B-X
cytokine	B-X
composed	B-X
of	B-X
two	B-X
covalently	B-X
linked	B-X
p35	B-X
and	B-X
p40	B-X
chains	B-X
.	B-X
This	B-X
pro-inflammatory	B-X
cytokine	B-X
plays	B-X
a	B-X
prominent	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
Th1	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
.	B-X
Th1	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
chronic	B-X
inflammatory	B-X
autoimmune	B-X
diseases	B-X
.	B-X
Thus	B-X
,	B-X
IL-12	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
chronic	B-X
inflammatory	B-X
conditions	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
a	B-X
commonly	B-X
prescribed	B-X
anti-inflammatory	B-X
drug	B-X
,	B-X
acetyl	B-X
salicylic	B-X
acid	B-X
(	B-X
ASA	B-X
)	B-X
,	B-X
on	B-X
IL-12	B-X
production	B-X
and	B-X
Th1	B-X
cell	B-X
development	B-X
.	B-X
ASA	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
secretion	B-X
of	B-X
the	B-X
IL-12	B-X
heterodimer	B-X
as	B-X
well	B-X
as	B-X
p40	B-X
monomer	B-X
by	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
This	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
down-regulation	B-X
of	B-X
IL-12p40	B-X
mRNA	B-X
expression	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p40	B-X
gene	B-X
promoter	B-X
revealed	B-X
that	B-X
ASA	B-X
inhibited	B-X
NF-kappaB	B-X
activation	B-X
and	B-X
binding	B-X
to	B-X
the	B-X
p40-kappaB	B-X
site	B-X
in	B-X
the	B-X
p40	B-X
promoter	B-X
,	B-X
leading	B-X
to	B-X
transcriptional	B-X
repression	B-X
of	B-X
the	B-X
p40	B-X
gene	B-X
.	B-X
Addition	B-X
of	B-X
ASA	B-X
to	B-X
an	B-X
in	B-X
vitro	B-X
T	B-X
helper	B-X
cell	B-X
differentiation	B-X
system	B-X
,	B-X
at	B-X
concentrations	B-X
compatible	B-X
with	B-X
plasma	B-X
levels	B-X
reached	B-X
during	B-X
anti-inflammatory	B-X
therapy	B-X
,	B-X
resulted	B-X
in	B-X
reduced	B-X
development	B-X
of	B-X
Th1	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
ASA	B-X
leads	B-X
to	B-X
down-regulation	B-X
of	B-X
IL-12	B-X
production	B-X
and	B-X
inhibition	B-X
of	B-X
Th1	B-X
cell	B-X
development	B-X
.	B-X

IL	O
-	O
12	O
is	O
a	O
75	O
-	O
kDa	O
heterodimeric	O
cytokine	O
composed	O
of	O
two	O
covalently	O
linked	O
p35	B-Protein
and	O
p40	B-Protein
chains	O
.	O
<EOS>	B-X
IL-12	B-X
is	B-X
a	B-X
75-kDa	B-X
heterodimeric	B-X
cytokine	B-X
composed	B-X
of	B-X
two	B-X
covalently	B-X
linked	B-X
p35	B-X
and	B-X
p40	B-X
chains	B-X
.	B-X
This	B-X
pro-inflammatory	B-X
cytokine	B-X
plays	B-X
a	B-X
prominent	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
Th1	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
.	B-X
Thus	B-X
,	B-X
IL-12	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
chronic	B-X
inflammatory	B-X
conditions	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
a	B-X
commonly	B-X
prescribed	B-X
anti-inflammatory	B-X
drug	B-X
,	B-X
acetyl	B-X
salicylic	B-X
acid	B-X
(	B-X
ASA	B-X
)	B-X
,	B-X
on	B-X
IL-12	B-X
production	B-X
and	B-X
Th1	B-X
cell	B-X
development	B-X
.	B-X
ASA	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
secretion	B-X
of	B-X
the	B-X
IL-12	B-X
heterodimer	B-X
as	B-X
well	B-X
as	B-X
p40	B-X
monomer	B-X
by	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
This	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
down-regulation	B-X
of	B-X
IL-12p40	B-X
mRNA	B-X
expression	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p40	B-X
gene	B-X
promoter	B-X
revealed	B-X
that	B-X
ASA	B-X
inhibited	B-X
NF-kappaB	B-X
activation	B-X
and	B-X
binding	B-X
to	B-X
the	B-X
p40-kappaB	B-X
site	B-X
in	B-X
the	B-X
p40	B-X
promoter	B-X
,	B-X
leading	B-X
to	B-X
transcriptional	B-X
repression	B-X
of	B-X
the	B-X
p40	B-X
gene	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
ASA	B-X
leads	B-X
to	B-X
down-regulation	B-X
of	B-X
IL-12	B-X
production	B-X
and	B-X
inhibition	B-X
of	B-X
Th1	B-X
cell	B-X
development	B-X
.	B-X

This	O
pro	O
-	O
inflammatory	O
cytokine	O
plays	O
a	O
prominent	O
role	O
in	O
the	O
development	O
of	O
Th1	O
cell	O
-	O
mediated	O
immune	O
responses	O
.	O

Th1	O
cell	O
-	O
mediated	O
immune	O
responses	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
inflammatory	O
autoimmune	O
diseases	O
.	O
<EOS>	B-X
T	B-X
helper	B-X
17	B-X
(	B-X
Th17	B-X
)	B-X
cells	B-X
are	B-X
important	B-X
mediators	B-X
of	B-X
immune	B-X
responses	B-X
against	B-X
extracellular	B-X
bacteria	B-X
and	B-X
fungi	B-X
,	B-X
and	B-X
as	B-X
such	B-X
play	B-X
critical	B-X
regulatory	B-X
roles	B-X
in	B-X
maintaining	B-X
mucosal	B-X
homeostasis	B-X
.	B-X
Conversely	B-X
,	B-X
Th17	B-X
cells	B-X
and	B-X
their	B-X
effector	B-X
molecules	B-X
interleukin	B-X
17A	B-X
(	B-X
IL-17A	B-X
)	B-X
,	B-X
IL-17F	B-X
,	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
γ	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
α	B-X
,	B-X
and	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
are	B-X
implicated	B-X
in	B-X
the	B-X
pathology	B-X
of	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Interactions	B-X
between	B-X
Th17	B-X
cells	B-X
and	B-X
other	B-X
immune	B-X
cells	B-X
or	B-X
stromal	B-X
cells	B-X
that	B-X
are	B-X
present	B-X
in	B-X
the	B-X
synovial	B-X
tissue	B-X
during	B-X
the	B-X
earliest	B-X
phases	B-X
of	B-X
the	B-X
disease	B-X
,	B-X
may	B-X
eventually	B-X
lead	B-X
to	B-X
chronic	B-X
inflammation	B-X
,	B-X
irreversible	B-X
cartilage	B-X
degradation	B-X
and	B-X
bone	B-X
erosions	B-X
.	B-X
Recent	B-X
evidence	B-X
points	B-X
towards	B-X
Th17	B-X
cell	B-X
plasticity	B-X
as	B-X
an	B-X
essential	B-X
contributing	B-X
process	B-X
in	B-X
RA	B-X
pathology	B-X
,	B-X
since	B-X
Th17	B-X
cells	B-X
are	B-X
able	B-X
to	B-X
adopt	B-X
a	B-X
pathogenic	B-X
phenotype	B-X
under	B-X
the	B-X
influence	B-X
of	B-X
environmental	B-X
,	B-X
inflammatory	B-X
and	B-X
genetic	B-X
factors	B-X
.	B-X
A	B-X
remarkable	B-X
feature	B-X
of	B-X
this	B-X
pathogenic	B-X
Th17	B-X
cell	B-X
phenotype	B-X
is	B-X
the	B-X
high	B-X
production	B-X
of	B-X
GM-CSF	B-X
and	B-X
TNFα	B-X
and	B-X
the	B-X
co-appearance	B-X
of	B-X
Th1	B-X
cell	B-X
characteristics	B-X
,	B-X
such	B-X
as	B-X
transcription	B-X
factor	B-X
T-box	B-X
21	B-X
(	B-X
T-bet	B-X
)	B-X
and	B-X
IFNγ	B-X
expression	B-X
.	B-X
Recently	B-X
,	B-X
much	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
in	B-X
unravelling	B-X
the	B-X
mechanisms	B-X
underlying	B-X
Th17	B-X
cell	B-X
plasticity	B-X
and	B-X
pathogenicity	B-X
.	B-X
Of	B-X
interest	B-X
,	B-X
many	B-X
of	B-X
the	B-X
environmental	B-X
and	B-X
inflammatory	B-X
factors	B-X
associated	B-X
with	B-X
RA	B-X
pathology	B-X
,	B-X
such	B-X
as	B-X
pro-inflammatory	B-X
mediators	B-X
and	B-X
cytokines	B-X
,	B-X
microbiome	B-X
dysbiosis	B-X
,	B-X
metabolism	B-X
and	B-X
diet	B-X
,	B-X
obesity	B-X
,	B-X
vitamins	B-X
,	B-X
steroids	B-X
and	B-X
hormones	B-X
are	B-X
linked	B-X
to	B-X
the	B-X
development	B-X
of	B-X
pathogenic	B-X
Th17	B-X
cells	B-X
.	B-X
Moreover	B-X
proteins	B-X
encoded	B-X
by	B-X
established	B-X
genetic	B-X
risk	B-X
factors	B-X
for	B-X
RA	B-X
including	B-X
CCR6	B-X
,	B-X
CD226	B-X
,	B-X
CSF2	B-X
,	B-X
EOMES	B-X
,	B-X
ETS1	B-X
,	B-X
GATA3	B-X
,	B-X
IL2	B-X
,	B-X
IL6R	B-X
,	B-X
IL23R	B-X
,	B-X
IKZF3	B-X
,	B-X
IRAK1	B-X
,	B-X
IRF4	B-X
,	B-X
IRF8	B-X
,	B-X
PRKCQ	B-X
,	B-X
PRDM1	B-X
,	B-X
RBPJ	B-X
,	B-X
RUNX1	B-X
and	B-X
TAGAP	B-X
are	B-X
directly	B-X
involved	B-X
in	B-X
Th17	B-X
cell	B-X
differentiation	B-X
and/or	B-X
function	B-X
.	B-X
This	B-X
review	B-X
provides	B-X
a	B-X
detailed	B-X
overview	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
heterogeneity	B-X
and	B-X
pathogenicity	B-X
of	B-X
Th17	B-X
cells	B-X
in	B-X
the	B-X
context	B-X
of	B-X
autoimmune	B-X
diseases	B-X
,	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
RA	B-X
.	B-X

Thus	O
,	O
IL	O
-	O
12	O
appears	O
to	O
be	O
a	O
critical	O
factor	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
chronic	O
inflammatory	O
conditions	O
.	O
<EOS>	B-X
IL-12	B-X
is	B-X
a	B-X
75-kDa	B-X
heterodimeric	B-X
cytokine	B-X
composed	B-X
of	B-X
two	B-X
covalently	B-X
linked	B-X
p35	B-X
and	B-X
p40	B-X
chains	B-X
.	B-X
This	B-X
pro-inflammatory	B-X
cytokine	B-X
plays	B-X
a	B-X
prominent	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
Th1	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
.	B-X
Th1	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
chronic	B-X
inflammatory	B-X
autoimmune	B-X
diseases	B-X
.	B-X
Thus	B-X
,	B-X
IL-12	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
chronic	B-X
inflammatory	B-X
conditions	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
a	B-X
commonly	B-X
prescribed	B-X
anti-inflammatory	B-X
drug	B-X
,	B-X
acetyl	B-X
salicylic	B-X
acid	B-X
(	B-X
ASA	B-X
)	B-X
,	B-X
on	B-X
IL-12	B-X
production	B-X
and	B-X
Th1	B-X
cell	B-X
development	B-X
.	B-X
ASA	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
secretion	B-X
of	B-X
the	B-X
IL-12	B-X
heterodimer	B-X
as	B-X
well	B-X
as	B-X
p40	B-X
monomer	B-X
by	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
This	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
down-regulation	B-X
of	B-X
IL-12p40	B-X
mRNA	B-X
expression	B-X
.	B-X
Addition	B-X
of	B-X
ASA	B-X
to	B-X
an	B-X
in	B-X
vitro	B-X
T	B-X
helper	B-X
cell	B-X
differentiation	B-X
system	B-X
,	B-X
at	B-X
concentrations	B-X
compatible	B-X
with	B-X
plasma	B-X
levels	B-X
reached	B-X
during	B-X
anti-inflammatory	B-X
therapy	B-X
,	B-X
resulted	B-X
in	B-X
reduced	B-X
development	B-X
of	B-X
Th1	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
ASA	B-X
leads	B-X
to	B-X
down-regulation	B-X
of	B-X
IL-12	B-X
production	B-X
and	B-X
inhibition	B-X
of	B-X
Th1	B-X
cell	B-X
development	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
commonly	O
prescribed	O
anti	O
-	O
inflammatory	O
drug	O
,	O
acetyl	O
salicylic	O
acid	O
(	O
ASA	O
)	O
,	O
on	O
IL	O
-	O
12	O
production	O
and	O
Th1	O
cell	O
development	O
.	O
<EOS>	B-X
IL-12	B-X
is	B-X
a	B-X
75-kDa	B-X
heterodimeric	B-X
cytokine	B-X
composed	B-X
of	B-X
two	B-X
covalently	B-X
linked	B-X
p35	B-X
and	B-X
p40	B-X
chains	B-X
.	B-X
This	B-X
pro-inflammatory	B-X
cytokine	B-X
plays	B-X
a	B-X
prominent	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
Th1	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
.	B-X
Th1	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
chronic	B-X
inflammatory	B-X
autoimmune	B-X
diseases	B-X
.	B-X
Thus	B-X
,	B-X
IL-12	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
chronic	B-X
inflammatory	B-X
conditions	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
a	B-X
commonly	B-X
prescribed	B-X
anti-inflammatory	B-X
drug	B-X
,	B-X
acetyl	B-X
salicylic	B-X
acid	B-X
(	B-X
ASA	B-X
)	B-X
,	B-X
on	B-X
IL-12	B-X
production	B-X
and	B-X
Th1	B-X
cell	B-X
development	B-X
.	B-X
ASA	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
secretion	B-X
of	B-X
the	B-X
IL-12	B-X
heterodimer	B-X
as	B-X
well	B-X
as	B-X
p40	B-X
monomer	B-X
by	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
This	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
down-regulation	B-X
of	B-X
IL-12p40	B-X
mRNA	B-X
expression	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p40	B-X
gene	B-X
promoter	B-X
revealed	B-X
that	B-X
ASA	B-X
inhibited	B-X
NF-kappaB	B-X
activation	B-X
and	B-X
binding	B-X
to	B-X
the	B-X
p40-kappaB	B-X
site	B-X
in	B-X
the	B-X
p40	B-X
promoter	B-X
,	B-X
leading	B-X
to	B-X
transcriptional	B-X
repression	B-X
of	B-X
the	B-X
p40	B-X
gene	B-X
.	B-X
Addition	B-X
of	B-X
ASA	B-X
to	B-X
an	B-X
in	B-X
vitro	B-X
T	B-X
helper	B-X
cell	B-X
differentiation	B-X
system	B-X
,	B-X
at	B-X
concentrations	B-X
compatible	B-X
with	B-X
plasma	B-X
levels	B-X
reached	B-X
during	B-X
anti-inflammatory	B-X
therapy	B-X
,	B-X
resulted	B-X
in	B-X
reduced	B-X
development	B-X
of	B-X
Th1	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
ASA	B-X
leads	B-X
to	B-X
down-regulation	B-X
of	B-X
IL-12	B-X
production	B-X
and	B-X
inhibition	B-X
of	B-X
Th1	B-X
cell	B-X
development	B-X
.	B-X

ASA	O
was	O
found	O
to	O
inhibit	O
secretion	O
of	O
the	O
IL	O
-	O
12	O
heterodimer	O
as	O
well	O
as	O
p40	B-Protein
monomer	O
by	O
human	O
monocytic	O
cells	O
.	O
<EOS>	B-X
IL-12	B-X
is	B-X
a	B-X
75-kDa	B-X
heterodimeric	B-X
cytokine	B-X
composed	B-X
of	B-X
two	B-X
covalently	B-X
linked	B-X
p35	B-X
and	B-X
p40	B-X
chains	B-X
.	B-X
Thus	B-X
,	B-X
IL-12	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
factor	B-X
in	B-X
the	B-X
generation	B-X
and	B-X
maintenance	B-X
of	B-X
chronic	B-X
inflammatory	B-X
conditions	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effects	B-X
of	B-X
a	B-X
commonly	B-X
prescribed	B-X
anti-inflammatory	B-X
drug	B-X
,	B-X
acetyl	B-X
salicylic	B-X
acid	B-X
(	B-X
ASA	B-X
)	B-X
,	B-X
on	B-X
IL-12	B-X
production	B-X
and	B-X
Th1	B-X
cell	B-X
development	B-X
.	B-X
ASA	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
secretion	B-X
of	B-X
the	B-X
IL-12	B-X
heterodimer	B-X
as	B-X
well	B-X
as	B-X
p40	B-X
monomer	B-X
by	B-X
human	B-X
monocytic	B-X
cells	B-X
.	B-X
This	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
down-regulation	B-X
of	B-X
IL-12p40	B-X
mRNA	B-X
expression	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
p40	B-X
gene	B-X
promoter	B-X
revealed	B-X
that	B-X
ASA	B-X
inhibited	B-X
NF-kappaB	B-X
activation	B-X
and	B-X
binding	B-X
to	B-X
the	B-X
p40-kappaB	B-X
site	B-X
in	B-X
the	B-X
p40	B-X
promoter	B-X
,	B-X
leading	B-X
to	B-X
transcriptional	B-X
repression	B-X
of	B-X
the	B-X
p40	B-X
gene	B-X
.	B-X
Addition	B-X
of	B-X
ASA	B-X
to	B-X
an	B-X
in	B-X
vitro	B-X
T	B-X
helper	B-X
cell	B-X
differentiation	B-X
system	B-X
,	B-X
at	B-X
concentrations	B-X
compatible	B-X
with	B-X
plasma	B-X
levels	B-X
reached	B-X
during	B-X
anti-inflammatory	B-X
therapy	B-X
,	B-X
resulted	B-X
in	B-X
reduced	B-X
development	B-X
of	B-X
Th1	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
inhibition	B-X
of	B-X
NF-kappaB	B-X
activation	B-X
by	B-X
ASA	B-X
leads	B-X
to	B-X
down-regulation	B-X
of	B-X
IL-12	B-X
production	B-X
and	B-X
inhibition	B-X
of	B-X
Th1	B-X
cell	B-X
development	B-X
.	B-X

This	O
was	O
associated	O
with	O
the	O
down	O
-	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
12p40	I-Protein
mRNA	O
expression	O
.	O
<EOS>	B-X
Down-regulation	B-X
of	B-X
dltA	B-X
and	B-X
icaAB	B-X
expression	B-X
,	B-X
along	B-X
with	B-X
the	B-X
reduction	B-X
in	B-X
membrane	B-X
potential	B-X
with	B-X
a	B-X
sub-MIC	B-X
dose	B-X
of	B-X
vitexin	B-X
,	B-X
explains	B-X
reduced	B-X
S.	B-X
aureus	B-X
surface	B-X
hydrophobicity	B-X
.	B-X
Vitexin	B-X
was	B-X
found	B-X
to	B-X
interfere	B-X
with	B-X
S.	B-X
aureus	B-X
biofilm-associated	B-X
protein	B-X
biomass	B-X
,	B-X
EPS	B-X
production	B-X
,	B-X
and	B-X
swarming	B-X
movement	B-X
.	B-X
Subsequently	B-X
,	B-X
the	B-X
suppression	B-X
of	B-X
proteases	B-X
production	B-X
and	B-X
down-regulation	B-X
of	B-X
icaAB	B-X
and	B-X
agrAC	B-X
gene	B-X
expression	B-X
with	B-X
a	B-X
sub-MIC	B-X
dose	B-X
of	B-X
vitexin	B-X
explained	B-X
the	B-X
inhibition	B-X
of	B-X
S.	B-X
aureus	B-X
virulence	B-X
in	B-X
vitro	B-X
.	B-X
Treatment	B-X
with	B-X
vitexin	B-X
exhibits	B-X
a	B-X
protective	B-X
response	B-X
in	B-X
S.	B-X
aureus	B-X
infected	B-X
macrophages	B-X
through	B-X
modulation	B-X
of	B-X
expression	B-X
of	B-X
cytokines	B-X
like	B-X
IL-10	B-X
and	B-X
IL-12p40	B-X
at	B-X
protein	B-X
and	B-X
mRNA	B-X
levels	B-X
.	B-X
Furthermore	B-X
,	B-X
CFU	B-X
count	B-X
and	B-X
histological	B-X
examination	B-X
of	B-X
infected	B-X
mouse	B-X
tissue	B-X
(	B-X
liver	B-X
and	B-X
spleen	B-X
)	B-X
justify	B-X
the	B-X
in	B-X
vivo	B-X
protective	B-X
effect	B-X
of	B-X
vitexin	B-X
from	B-X
S.	B-X
aureus	B-X
biofilm-associated	B-X
infection	B-X
.	B-X

Analysis	O
of	O
the	O
regulation	O
of	O
the	O
p40	B-Protein
gene	O
promoter	O
revealed	O
that	O
ASA	O
inhibited	O
NF	O
-	O
kappaB	O
activation	O
and	O
binding	O
to	O
the	O
p40	B-Protein
-	O
kappaB	O
site	O
in	O
the	O
p40	B-Protein
promoter	O
,	O
leading	O
to	O
transcriptional	O
repression	O
of	O
the	O
p40	B-Protein
gene	O
.	O

Addition	O
of	O
ASA	O
to	O
an	O
in	O
vitro	O
T	O
helper	O
cell	O
differentiation	O
system	O
,	O
at	O
concentrations	O
compatible	O
with	O
plasma	O
levels	O
reached	O
during	O
anti	O
-	O
inflammatory	O
therapy	O
,	O
resulted	O
in	O
reduced	O
development	O
of	O
Th1	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
ASA	O
leads	O
to	O
down	O
-	O
regulation	O
of	O
IL	O
-	O
12	O
production	O
and	O
inhibition	O
of	O
Th1	O
cell	O
development	O
.	O

Membrane	O
-	O
associated	O
lymphotoxin	O
on	O
natural	O
killer	O
cells	O
activates	O
endothelial	O
cells	O
via	O
an	O
NF	O
-	O
kappaB	O
-	O
dependent	O
pathway	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X

BACKGROUND	O
:	O
Inhibition	O
of	O
complement	O
in	O
small	O
animal	O
models	O
of	O
xenotransplantation	O
has	O
demonstrated	O
graft	O
infiltration	O
with	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
monocytes	O
associated	O
with	O
endothelial	O
cell	O
(	O
EC	O
)	O
activation	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
the	B-X
NK	B-X
cell	B-X
line	B-X
NK92	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
basis	B-X
of	B-X
NK	B-X
cell-mediated	B-X
EC	B-X
activation	B-X
.	B-X

We	O
have	O
previously	O
demonstrated	O
that	O
human	O
NK	O
cells	O
activate	O
porcine	O
EC	O
in	O
vitro	O
,	O
which	O
results	O
in	O
adhesion	O
molecule	O
expression	O
and	O
cytokine	O
secretion	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
the	B-X
NK	B-X
cell	B-X
line	B-X
NK92	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
basis	B-X
of	B-X
NK	B-X
cell-mediated	B-X
EC	B-X
activation	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
used	O
the	O
NK	O
cell	O
line	O
NK92	O
to	O
define	O
the	O
molecular	O
and	O
cellular	O
basis	O
of	O
NK	O
cell	O
-	O
mediated	O
EC	O
activation	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
the	B-X
NK	B-X
cell	B-X
line	B-X
NK92	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
basis	B-X
of	B-X
NK	B-X
cell-mediated	B-X
EC	B-X
activation	B-X
.	B-X

METHODS	O
:	O
EC	O
were	O
transfected	O
with	O
either	O
reporter	O
constructs	O
containing	O
the	O
luciferase	O
gene	O
driven	O
either	O
by	O
E	B-Protein
-	I-Protein
selectin	I-Protein
or	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
8	I-Protein
promoters	O
or	O
a	O
synthetic	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoter	O
.	O
<EOS>	B-X
Interactions	B-X
between	B-X
the	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
family	B-X
of	B-X
proteins	B-X
(	B-X
RelA	B-X
,	B-X
RelB	B-X
,	B-X
c-Rel	B-X
,	B-X
p50	B-X
and	B-X
p52	B-X
)	B-X
and	B-X
DNA	B-X
are	B-X
vital	B-X
for	B-X
cells	B-X
to	B-X
function	B-X
normally	B-X
;	B-X
for	B-X
example	B-X
,	B-X
in	B-X
the	B-X
human	B-X
myometrium	B-X
,	B-X
NF-kappaB-regulated	B-X
pro-inflammatory	B-X
mediators	B-X
,	B-X
including	B-X
TNFalpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
IL-8	B-X
and	B-X
COX-2	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
onset	B-X
of	B-X
labour	B-X
.	B-X
NF-kappaB	B-X
,	B-X
however	B-X
,	B-X
regulates	B-X
the	B-X
expression	B-X
of	B-X
over	B-X
400	B-X
genes	B-X
,	B-X
although	B-X
it	B-X
is	B-X
unlikely	B-X
these	B-X
would	B-X
all	B-X
be	B-X
activated	B-X
in	B-X
concert	B-X
by	B-X
a	B-X
single	B-X
inducer	B-X
.	B-X
At	B-X
present	B-X
,	B-X
defining	B-X
the	B-X
role	B-X
of	B-X
the	B-X
NF-kappaB	B-X
RelA	B-X
:	B-X
p50	B-X
dimer	B-X
,	B-X
which	B-X
governs	B-X
a	B-X
number	B-X
of	B-X
inflammatory	B-X
promoters	B-X
,	B-X
is	B-X
at	B-X
the	B-X
forefront	B-X
of	B-X
the	B-X
parturition	B-X
research	B-X
field	B-X
.	B-X
Consequently	B-X
this	B-X
review	B-X
highlights	B-X
other	B-X
mechanisms	B-X
by	B-X
which	B-X
the	B-X
NF-kappaB	B-X
family	B-X
of	B-X
regulators	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
function	B-X
in	B-X
other	B-X
systems	B-X
and	B-X
how	B-X
they	B-X
may	B-X
readily	B-X
translate	B-X
to	B-X
understanding	B-X
the	B-X
regulation	B-X
underpinning	B-X
human	B-X
parturition	B-X
.	B-X

In	O
addition	O
,	O
a	O
dominant	O
-	O
negative	O
mutant	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
I	I-Protein
(	O
TNFRI	B-Protein
)	O
expression	O
vector	O
was	O
co	O
-	O
transfected	O
in	O
inhibition	O
studies	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
EC	O
were	O
stimulated	O
with	O
NK	O
cells	O
or	O
NK	O
cell	O
membrane	O
extracts	O
for	O
7	O
hr	O
and	O
activation	O
was	O
measured	O
by	O
a	O
luciferase	O
assay	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
the	B-X
NK	B-X
cell	B-X
line	B-X
NK92	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
basis	B-X
of	B-X
NK	B-X
cell-mediated	B-X
EC	B-X
activation	B-X
.	B-X

RESULTS	O
:	O
Co	O
-	O
culture	O
of	O
NK	O
cells	O
with	O
transfected	O
EC	O
enhanced	O
E	B-Protein
-	I-Protein
selectin	I-Protein
,	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoter	O
activity	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
the	B-X
NK	B-X
cell	B-X
line	B-X
NK92	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
basis	B-X
of	B-X
NK	B-X
cell-mediated	B-X
EC	B-X
activation	B-X
.	B-X

NK	O
cell	O
membrane	O
extracts	O
retained	O
the	O
capacity	O
to	O
activate	O
EC	O
and	O
induced	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
(	O
p50	B-Protein
and	O
p65	B-Protein
)	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
the	B-X
NK	B-X
cell	B-X
line	B-X
NK92	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
basis	B-X
of	B-X
NK	B-X
cell-mediated	B-X
EC	B-X
activation	B-X
.	B-X

Western	O
blotting	O
of	O
NK	O
cell	O
and	O
membrane	O
extracts	O
detected	O
the	O
presence	O
of	O
Lymphotoxin	B-Protein
-	I-Protein
alpha	I-Protein
(	O
LTalpha	B-Protein
)	O
but	O
not	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
.	O

Furthermore	O
,	O
LTalpha	B-Protein
was	O
secreted	O
in	O
NK	O
:	O
EC	O
co	O
-	O
cultures	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
the	B-X
NK	B-X
cell	B-X
line	B-X
NK92	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
basis	B-X
of	B-X
NK	B-X
cell-mediated	B-X
EC	B-X
activation	B-X
.	B-X

Co	O
-	O
transfection	O
with	O
dominant	O
-	O
negative	O
mutant	O
TNFRI	B-Protein
inhibited	O
EC	O
activation	O
by	O
NK	O
cell	O
membrane	O
extracts	O
and	O
by	O
NK	O
cells	O
by	O
80	O
%	O
and	O
47	O
%	O
,	O
respectively	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
the	B-X
NK	B-X
cell	B-X
line	B-X
NK92	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
basis	B-X
of	B-X
NK	B-X
cell-mediated	B-X
EC	B-X
activation	B-X
.	B-X

The	O
same	O
pattern	O
of	O
inhibition	O
was	O
observed	O
using	O
anti	O
-	O
human	O
LT	O
sera	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X

CONCLUSIONS	O
:	O
Human	O
NK	O
cell	O
membrane	O
-	O
bound	O
LT	O
signals	O
across	O
species	O
via	O
TNFRI	B-Protein
,	O
leading	O
to	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
transcription	O
of	O
E	B-Protein
-	I-Protein
selectin	I-Protein
and	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
which	O
results	O
in	O
EC	O
activation	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
the	B-X
NK	B-X
cell	B-X
line	B-X
NK92	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
basis	B-X
of	B-X
NK	B-X
cell-mediated	B-X
EC	B-X
activation	B-X
.	B-X

The	O
discrepancy	O
in	O
the	O
degree	O
of	O
inhibition	O
by	O
membrane	O
extracts	O
and	O
NK	O
cells	O
with	O
mutant	O
TNFRI	B-Protein
suggests	O
that	O
additional	O
pathways	O
are	O
utilized	O
by	O
NK	O
cells	O
to	O
activate	O
EC	O
.	O
<EOS>	B-X
Inhibition	B-X
of	B-X
complement	B-X
in	B-X
small	B-X
animal	B-X
models	B-X
of	B-X
xenotransplantation	B-X
has	B-X
demonstrated	B-X
graft	B-X
infiltration	B-X
with	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
monocytes	B-X
associated	B-X
with	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
activation	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
demonstrated	B-X
that	B-X
human	B-X
NK	B-X
cells	B-X
activate	B-X
porcine	B-X
EC	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
results	B-X
in	B-X
adhesion	B-X
molecule	B-X
expression	B-X
and	B-X
cytokine	B-X
secretion	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
the	B-X
NK	B-X
cell	B-X
line	B-X
NK92	B-X
to	B-X
define	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
basis	B-X
of	B-X
NK	B-X
cell-mediated	B-X
EC	B-X
activation	B-X
.	B-X

The	O
involvement	O
of	O
multiple	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
-	O
associated	O
factors	O
in	O
the	O
signaling	O
mechanisms	O
of	O
receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
,	O
a	O
member	O
of	O
the	O
TNFR	O
superfamily	O
.	O
<EOS>	B-X
Receptor	B-X
activator	B-X
of	B-X
NF-kappaB	B-X
(	B-X
RANK	B-X
)	B-X
is	B-X
a	B-X
recently	B-X
identified	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
superfamily	B-X
and	B-X
is	B-X
expressed	B-X
on	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
dendritic	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
the	B-X
interaction	B-X
of	B-X
RANK	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factors	B-X
(	B-X
TRAFs	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
6	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
cells	B-X
.	B-X
Mapping	B-X
of	B-X
the	B-X
structural	B-X
requirements	B-X
for	B-X
TRAF/RANK	B-X
interaction	B-X
revealed	B-X
multiple	B-X
TRAF	B-X
binding	B-X
sites	B-X
clustered	B-X
in	B-X
two	B-X
distinct	B-X
domains	B-X
in	B-X
the	B-X
RANK	B-X
cytoplasmic	B-X
tail	B-X
.	B-X
These	B-X
TRAF	B-X
binding	B-X
domains	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
RANK-dependent	B-X
induction	B-X
of	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activities	B-X
.	B-X
When	B-X
this	B-X
membrane-proximal	B-X
TRAF6	B-X
interaction	B-X
domain	B-X
was	B-X
deleted	B-X
,	B-X
RANK-mediated	B-X
NF-kappaB	B-X
signaling	B-X
was	B-X
completely	B-X
inhibited	B-X
while	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activation	B-X
was	B-X
partially	B-X
inhibited	B-X
.	B-X
An	B-X
NH2-terminal	B-X
truncation	B-X
mutant	B-X
of	B-X
TRAF6	B-X
inhibited	B-X
RANKL-mediated	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
constitutive	B-X
signaling	B-X
induced	B-X
by	B-X
receptor	B-X
overexpression	B-X
,	B-X
revealing	B-X
a	B-X
selective	B-X
role	B-X
for	B-X
TRAF6	B-X
in	B-X
ligand-induced	B-X
activation	B-X
events	B-X
.	B-X

Receptor	B-Protein
activator	I-Protein
of	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
(	O
RANK	B-Protein
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
and	O
is	O
expressed	O
on	O
activated	O
T	O
cells	O
and	O
dendritic	O
cells	O
.	O
<EOS>	B-X
TNF	B-X
and	B-X
TNFR	B-X
family	B-X
proteins	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
the	B-X
control	B-X
of	B-X
cell	B-X
death	B-X
,	B-X
proliferation	B-X
,	B-X
autoimmunity	B-X
,	B-X
the	B-X
function	B-X
of	B-X
immune	B-X
cells	B-X
,	B-X
or	B-X
the	B-X
organogenesis	B-X
of	B-X
lymphoid	B-X
organs	B-X
.	B-X
Recently	B-X
,	B-X
novel	B-X
members	B-X
of	B-X
this	B-X
large	B-X
family	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
have	B-X
critical	B-X
functions	B-X
in	B-X
immunity	B-X
and	B-X
that	B-X
couple	B-X
lymphoid	B-X
cells	B-X
with	B-X
other	B-X
organ	B-X
systems	B-X
such	B-X
as	B-X
bone	B-X
morphogenesis	B-X
and	B-X
mammary	B-X
gland	B-X
formation	B-X
in	B-X
pregnancy	B-X
.	B-X
The	B-X
TNF-family	B-X
molecule	B-X
RANK-L	B-X
(	B-X
RANK-L	B-X
,	B-X
TRANCE	B-X
,	B-X
ODF	B-X
)	B-X
and	B-X
its	B-X
receptor	B-X
RANK	B-X
are	B-X
key	B-X
regulators	B-X
of	B-X
bone	B-X
remodeling	B-X
,	B-X
and	B-X
they	B-X
are	B-X
essential	B-X
for	B-X
the	B-X
development	B-X
and	B-X
activation	B-X
of	B-X
osteoclasts	B-X
.	B-X
Intriguingly	B-X
,	B-X
RANK-L/RANK	B-X
interactions	B-X
also	B-X
regulate	B-X
T	B-X
cell/dendritic	B-X
cell	B-X
communications	B-X
,	B-X
dendritic	B-X
cell	B-X
survival	B-X
,	B-X
and	B-X
lymph	B-X
node	B-X
formation	B-X
;	B-X
T	B-X
cell-derived	B-X
RANK-L	B-X
can	B-X
mediate	B-X
bone	B-X
loss	B-X
in	B-X
arthritis	B-X
and	B-X
periodontal	B-X
disease	B-X
.	B-X
Moreover	B-X
,	B-X
RANK-L	B-X
and	B-X
RANK	B-X
are	B-X
expressed	B-X
in	B-X
mammary	B-X
gland	B-X
epithelial	B-X
cells	B-X
,	B-X
and	B-X
they	B-X
control	B-X
the	B-X
development	B-X
of	B-X
a	B-X
lactating	B-X
mammary	B-X
gland	B-X
during	B-X
pregnancy	B-X
and	B-X
the	B-X
propagation	B-X
of	B-X
mammalian	B-X
species	B-X
.	B-X

Its	O
cognate	O
ligand	O
(	O
RANKL	B-Protein
)	O
plays	O
significant	O
roles	O
in	O
the	O
activation	O
of	O
dendritic	O
cell	O
function	O
and	O
osteoclast	O
differentiation	O
.	O
<EOS>	B-X
Receptor	B-X
activator	B-X
of	B-X
NF-kappaB	B-X
(	B-X
RANK	B-X
)	B-X
is	B-X
a	B-X
recently	B-X
identified	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
superfamily	B-X
and	B-X
is	B-X
expressed	B-X
on	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
dendritic	B-X
cells	B-X
.	B-X
Its	B-X
cognate	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
plays	B-X
significant	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
dendritic	B-X
cell	B-X
function	B-X
and	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
the	B-X
interaction	B-X
of	B-X
RANK	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factors	B-X
(	B-X
TRAFs	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
6	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
cells	B-X
.	B-X
These	B-X
TRAF	B-X
binding	B-X
domains	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
RANK-dependent	B-X
induction	B-X
of	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activities	B-X
.	B-X
When	B-X
this	B-X
membrane-proximal	B-X
TRAF6	B-X
interaction	B-X
domain	B-X
was	B-X
deleted	B-X
,	B-X
RANK-mediated	B-X
NF-kappaB	B-X
signaling	B-X
was	B-X
completely	B-X
inhibited	B-X
while	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activation	B-X
was	B-X
partially	B-X
inhibited	B-X
.	B-X
An	B-X
NH2-terminal	B-X
truncation	B-X
mutant	B-X
of	B-X
TRAF6	B-X
inhibited	B-X
RANKL-mediated	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
constitutive	B-X
signaling	B-X
induced	B-X
by	B-X
receptor	B-X
overexpression	B-X
,	B-X
revealing	B-X
a	B-X
selective	B-X
role	B-X
for	B-X
TRAF6	B-X
in	B-X
ligand-induced	B-X
activation	B-X
events	B-X
.	B-X

We	O
demonstrate	O
here	O
the	O
interaction	O
of	O
RANK	B-Protein
with	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
factors	I-Protein
(	I-Protein
TRAFs	I-Protein
)	I-Protein
1	I-Protein
,	O
2	B-Protein
,	O
3	B-Protein
,	O
5	B-Protein
,	O
and	O
6	B-Protein
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O
<EOS>	B-X
Receptor	B-X
activator	B-X
of	B-X
NF-kappaB	B-X
(	B-X
RANK	B-X
)	B-X
is	B-X
a	B-X
recently	B-X
identified	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
superfamily	B-X
and	B-X
is	B-X
expressed	B-X
on	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
dendritic	B-X
cells	B-X
.	B-X
Its	B-X
cognate	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
plays	B-X
significant	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
dendritic	B-X
cell	B-X
function	B-X
and	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
the	B-X
interaction	B-X
of	B-X
RANK	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factors	B-X
(	B-X
TRAFs	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
6	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
cells	B-X
.	B-X
Mapping	B-X
of	B-X
the	B-X
structural	B-X
requirements	B-X
for	B-X
TRAF/RANK	B-X
interaction	B-X
revealed	B-X
multiple	B-X
TRAF	B-X
binding	B-X
sites	B-X
clustered	B-X
in	B-X
two	B-X
distinct	B-X
domains	B-X
in	B-X
the	B-X
RANK	B-X
cytoplasmic	B-X
tail	B-X
.	B-X
These	B-X
TRAF	B-X
binding	B-X
domains	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
RANK-dependent	B-X
induction	B-X
of	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activities	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
demonstrated	B-X
that	B-X
these	B-X
TRAF	B-X
binding	B-X
sites	B-X
exhibited	B-X
selective	B-X
binding	B-X
for	B-X
different	B-X
TRAF	B-X
proteins	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
TRAF6	B-X
interacted	B-X
with	B-X
membrane-proximal	B-X
determinants	B-X
distinct	B-X
from	B-X
those	B-X
binding	B-X
TRAFs	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
and	B-X
5	B-X
.	B-X
When	B-X
this	B-X
membrane-proximal	B-X
TRAF6	B-X
interaction	B-X
domain	B-X
was	B-X
deleted	B-X
,	B-X
RANK-mediated	B-X
NF-kappaB	B-X
signaling	B-X
was	B-X
completely	B-X
inhibited	B-X
while	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activation	B-X
was	B-X
partially	B-X
inhibited	B-X
.	B-X
An	B-X
NH2-terminal	B-X
truncation	B-X
mutant	B-X
of	B-X
TRAF6	B-X
inhibited	B-X
RANKL-mediated	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
constitutive	B-X
signaling	B-X
induced	B-X
by	B-X
receptor	B-X
overexpression	B-X
,	B-X
revealing	B-X
a	B-X
selective	B-X
role	B-X
for	B-X
TRAF6	B-X
in	B-X
ligand-induced	B-X
activation	B-X
events	B-X
.	B-X

Mapping	O
of	O
the	O
structural	O
requirements	O
for	O
TRAF	O
/	O
RANK	B-Protein
interaction	O
revealed	O
multiple	O
TRAF	O
binding	O
sites	O
clustered	O
in	O
two	O
distinct	O
domains	O
in	O
the	O
RANK	B-Protein
cytoplasmic	O
tail	O
.	O
<EOS>	B-X
Receptor	B-X
activator	B-X
of	B-X
NF-kappaB	B-X
(	B-X
RANK	B-X
)	B-X
is	B-X
a	B-X
recently	B-X
identified	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
superfamily	B-X
and	B-X
is	B-X
expressed	B-X
on	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
dendritic	B-X
cells	B-X
.	B-X
Its	B-X
cognate	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
plays	B-X
significant	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
dendritic	B-X
cell	B-X
function	B-X
and	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
the	B-X
interaction	B-X
of	B-X
RANK	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factors	B-X
(	B-X
TRAFs	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
6	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
cells	B-X
.	B-X
Mapping	B-X
of	B-X
the	B-X
structural	B-X
requirements	B-X
for	B-X
TRAF/RANK	B-X
interaction	B-X
revealed	B-X
multiple	B-X
TRAF	B-X
binding	B-X
sites	B-X
clustered	B-X
in	B-X
two	B-X
distinct	B-X
domains	B-X
in	B-X
the	B-X
RANK	B-X
cytoplasmic	B-X
tail	B-X
.	B-X
These	B-X
TRAF	B-X
binding	B-X
domains	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
RANK-dependent	B-X
induction	B-X
of	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activities	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
demonstrated	B-X
that	B-X
these	B-X
TRAF	B-X
binding	B-X
sites	B-X
exhibited	B-X
selective	B-X
binding	B-X
for	B-X
different	B-X
TRAF	B-X
proteins	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
TRAF6	B-X
interacted	B-X
with	B-X
membrane-proximal	B-X
determinants	B-X
distinct	B-X
from	B-X
those	B-X
binding	B-X
TRAFs	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
and	B-X
5	B-X
.	B-X
When	B-X
this	B-X
membrane-proximal	B-X
TRAF6	B-X
interaction	B-X
domain	B-X
was	B-X
deleted	B-X
,	B-X
RANK-mediated	B-X
NF-kappaB	B-X
signaling	B-X
was	B-X
completely	B-X
inhibited	B-X
while	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activation	B-X
was	B-X
partially	B-X
inhibited	B-X
.	B-X
An	B-X
NH2-terminal	B-X
truncation	B-X
mutant	B-X
of	B-X
TRAF6	B-X
inhibited	B-X
RANKL-mediated	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
constitutive	B-X
signaling	B-X
induced	B-X
by	B-X
receptor	B-X
overexpression	B-X
,	B-X
revealing	B-X
a	B-X
selective	B-X
role	B-X
for	B-X
TRAF6	B-X
in	B-X
ligand-induced	B-X
activation	B-X
events	B-X
.	B-X

These	O
TRAF	O
binding	O
domains	O
were	O
shown	O
to	O
be	O
functionally	O
important	O
for	O
the	O
RANK	B-Protein
-	O
dependent	O
induction	O
of	O
NF	O
-	O
kappaB	O
and	O
c	B-Protein
-	I-Protein
Jun	I-Protein
NH2	O
-	O
terminal	O
kinase	O
activities	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
these	O
TRAF	O
binding	O
sites	O
exhibited	O
selective	O
binding	O
for	O
different	O
TRAF	O
proteins	O
.	O
<EOS>	B-X
Its	B-X
cognate	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
plays	B-X
significant	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
dendritic	B-X
cell	B-X
function	B-X
and	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
the	B-X
interaction	B-X
of	B-X
RANK	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factors	B-X
(	B-X
TRAFs	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
6	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
cells	B-X
.	B-X
Mapping	B-X
of	B-X
the	B-X
structural	B-X
requirements	B-X
for	B-X
TRAF/RANK	B-X
interaction	B-X
revealed	B-X
multiple	B-X
TRAF	B-X
binding	B-X
sites	B-X
clustered	B-X
in	B-X
two	B-X
distinct	B-X
domains	B-X
in	B-X
the	B-X
RANK	B-X
cytoplasmic	B-X
tail	B-X
.	B-X
These	B-X
TRAF	B-X
binding	B-X
domains	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
RANK-dependent	B-X
induction	B-X
of	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activities	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
demonstrated	B-X
that	B-X
these	B-X
TRAF	B-X
binding	B-X
sites	B-X
exhibited	B-X
selective	B-X
binding	B-X
for	B-X
different	B-X
TRAF	B-X
proteins	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
TRAF6	B-X
interacted	B-X
with	B-X
membrane-proximal	B-X
determinants	B-X
distinct	B-X
from	B-X
those	B-X
binding	B-X
TRAFs	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
and	B-X
5	B-X
.	B-X
When	B-X
this	B-X
membrane-proximal	B-X
TRAF6	B-X
interaction	B-X
domain	B-X
was	B-X
deleted	B-X
,	B-X
RANK-mediated	B-X
NF-kappaB	B-X
signaling	B-X
was	B-X
completely	B-X
inhibited	B-X
while	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activation	B-X
was	B-X
partially	B-X
inhibited	B-X
.	B-X
An	B-X
NH2-terminal	B-X
truncation	B-X
mutant	B-X
of	B-X
TRAF6	B-X
inhibited	B-X
RANKL-mediated	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
constitutive	B-X
signaling	B-X
induced	B-X
by	B-X
receptor	B-X
overexpression	B-X
,	B-X
revealing	B-X
a	B-X
selective	B-X
role	B-X
for	B-X
TRAF6	B-X
in	B-X
ligand-induced	B-X
activation	B-X
events	B-X
.	B-X

In	O
particular	O
,	O
TRAF6	B-Protein
interacted	O
with	O
membrane	O
-	O
proximal	O
determinants	O
distinct	O
from	O
those	O
binding	O
TRAFs	B-Protein
1	I-Protein
,	O
2	B-Protein
,	O
3	B-Protein
,	O
and	O
5	B-Protein
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
here	B-X
the	B-X
interaction	B-X
of	B-X
RANK	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factors	B-X
(	B-X
TRAFs	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
6	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
cells	B-X
.	B-X
Mapping	B-X
of	B-X
the	B-X
structural	B-X
requirements	B-X
for	B-X
TRAF/RANK	B-X
interaction	B-X
revealed	B-X
multiple	B-X
TRAF	B-X
binding	B-X
sites	B-X
clustered	B-X
in	B-X
two	B-X
distinct	B-X
domains	B-X
in	B-X
the	B-X
RANK	B-X
cytoplasmic	B-X
tail	B-X
.	B-X
These	B-X
TRAF	B-X
binding	B-X
domains	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
RANK-dependent	B-X
induction	B-X
of	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activities	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
demonstrated	B-X
that	B-X
these	B-X
TRAF	B-X
binding	B-X
sites	B-X
exhibited	B-X
selective	B-X
binding	B-X
for	B-X
different	B-X
TRAF	B-X
proteins	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
TRAF6	B-X
interacted	B-X
with	B-X
membrane-proximal	B-X
determinants	B-X
distinct	B-X
from	B-X
those	B-X
binding	B-X
TRAFs	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
and	B-X
5	B-X
.	B-X
When	B-X
this	B-X
membrane-proximal	B-X
TRAF6	B-X
interaction	B-X
domain	B-X
was	B-X
deleted	B-X
,	B-X
RANK-mediated	B-X
NF-kappaB	B-X
signaling	B-X
was	B-X
completely	B-X
inhibited	B-X
while	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activation	B-X
was	B-X
partially	B-X
inhibited	B-X
.	B-X
An	B-X
NH2-terminal	B-X
truncation	B-X
mutant	B-X
of	B-X
TRAF6	B-X
inhibited	B-X
RANKL-mediated	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
constitutive	B-X
signaling	B-X
induced	B-X
by	B-X
receptor	B-X
overexpression	B-X
,	B-X
revealing	B-X
a	B-X
selective	B-X
role	B-X
for	B-X
TRAF6	B-X
in	B-X
ligand-induced	B-X
activation	B-X
events	B-X
.	B-X

When	O
this	O
membrane	O
-	O
proximal	O
TRAF6	B-Protein
interaction	O
domain	O
was	O
deleted	O
,	O
RANK	B-Protein
-	O
mediated	O
NF	O
-	O
kappaB	O
signaling	O
was	O
completely	O
inhibited	O
while	O
c	B-Protein
-	I-Protein
Jun	I-Protein
NH2	O
-	O
terminal	O
kinase	O
activation	O
was	O
partially	O
inhibited	O
.	O

An	O
NH2	O
-	O
terminal	O
truncation	O
mutant	O
of	O
TRAF6	B-Protein
inhibited	O
RANKL	B-Protein
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
,	O
but	O
failed	O
to	O
affect	O
constitutive	O
signaling	O
induced	O
by	O
receptor	O
overexpression	O
,	O
revealing	O
a	O
selective	O
role	O
for	O
TRAF6	B-Protein
in	O
ligand	O
-	O
induced	O
activation	O
events	O
.	O
<EOS>	B-X
Receptor	B-X
activator	B-X
of	B-X
NF-kappaB	B-X
(	B-X
RANK	B-X
)	B-X
is	B-X
a	B-X
recently	B-X
identified	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
superfamily	B-X
and	B-X
is	B-X
expressed	B-X
on	B-X
activated	B-X
T	B-X
cells	B-X
and	B-X
dendritic	B-X
cells	B-X
.	B-X
Its	B-X
cognate	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
plays	B-X
significant	B-X
roles	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
dendritic	B-X
cell	B-X
function	B-X
and	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
We	B-X
demonstrate	B-X
here	B-X
the	B-X
interaction	B-X
of	B-X
RANK	B-X
with	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor-associated	B-X
factors	B-X
(	B-X
TRAFs	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
6	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
cells	B-X
.	B-X
These	B-X
TRAF	B-X
binding	B-X
domains	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
functionally	B-X
important	B-X
for	B-X
the	B-X
RANK-dependent	B-X
induction	B-X
of	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activities	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
demonstrated	B-X
that	B-X
these	B-X
TRAF	B-X
binding	B-X
sites	B-X
exhibited	B-X
selective	B-X
binding	B-X
for	B-X
different	B-X
TRAF	B-X
proteins	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
TRAF6	B-X
interacted	B-X
with	B-X
membrane-proximal	B-X
determinants	B-X
distinct	B-X
from	B-X
those	B-X
binding	B-X
TRAFs	B-X
1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
and	B-X
5	B-X
.	B-X
When	B-X
this	B-X
membrane-proximal	B-X
TRAF6	B-X
interaction	B-X
domain	B-X
was	B-X
deleted	B-X
,	B-X
RANK-mediated	B-X
NF-kappaB	B-X
signaling	B-X
was	B-X
completely	B-X
inhibited	B-X
while	B-X
c-Jun	B-X
NH2-terminal	B-X
kinase	B-X
activation	B-X
was	B-X
partially	B-X
inhibited	B-X
.	B-X
An	B-X
NH2-terminal	B-X
truncation	B-X
mutant	B-X
of	B-X
TRAF6	B-X
inhibited	B-X
RANKL-mediated	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
but	B-X
failed	B-X
to	B-X
affect	B-X
constitutive	B-X
signaling	B-X
induced	B-X
by	B-X
receptor	B-X
overexpression	B-X
,	B-X
revealing	B-X
a	B-X
selective	B-X
role	B-X
for	B-X
TRAF6	B-X
in	B-X
ligand-induced	B-X
activation	B-X
events	B-X
.	B-X

Regulation	O
of	O
interleukin	B-Protein
-	I-Protein
1beta	I-Protein
transcription	O
by	O
Epstein	O
-	O
Barr	O
virus	O
involves	O
a	O
number	O
of	O
latent	O
proteins	O
via	O
their	O
interaction	O
with	O
RBP	O
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
infects	B-X
B	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
outgrowth	B-X
of	B-X
immortalised	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
(	B-X
LCLs	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
through	B-X
the	B-X
use	B-X
of	B-X
intracellular	B-X
staining	B-X
that	B-X
interleukin-1beta	B-X
(	B-X
IL-1beta	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
LCLs	B-X
and	B-X
investigate	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
individual	B-X
latent	B-X
proteins	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
IL-1beta	B-X
.	B-X
Using	B-X
RT-PCR	B-X
,	B-X
IL-1beta	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
EBV-transformed	B-X
LCLs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
group	B-X
III	B-X
Burkitt	B-X
's	B-X
lymphoma	B-X
(	B-X
BL	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
compared	B-X
with	B-X
group	B-X
I	B-X
BL	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
IL-1beta	B-X
message	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
the	B-X
latent	B-X
membrane	B-X
protein-1	B-X
,	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
2	B-X
,	B-X
3	B-X
,	B-X
4	B-X
,	B-X
and	B-X
6	B-X
genes	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
demonstrated	B-X
that	B-X
the	B-X
-300	B-X
region	B-X
of	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
binding	B-X
site	B-X
,	B-X
contained	B-X
a	B-X
functional	B-X
RBP	B-X
binding	B-X
site	B-X
.	B-X
Binding	B-X
of	B-X
RBP	B-X
to	B-X
this	B-X
site	B-X
could	B-X
be	B-X
inhibited	B-X
by	B-X
addition	B-X
of	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
3	B-X
and	B-X
6	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
displace	B-X
RBP	B-X
from	B-X
its	B-X
recognition	B-X
sequence	B-X
,	B-X
removing	B-X
transcriptional	B-X
repression	B-X
and	B-X
allowing	B-X
gene	B-X
transcription	B-X
to	B-X
occur	B-X
.	B-X
In	B-X
group	B-X
I	B-X
BL	B-X
cells	B-X
,	B-X
containing	B-X
low	B-X
levels	B-X
of	B-X
NF-kappaB	B-X
,	B-X
only	B-X
RBP	B-X
binding	B-X
was	B-X
observed	B-X
in	B-X
EMSAs	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
binding	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
EBV-transformed	B-X
B	B-X
cell	B-X
lines	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
NF-kappaB	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
latent	B-X
membrane	B-X
protein-1	B-X
led	B-X
to	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
that	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
.	B-X
The	B-X
study	B-X
demonstrates	B-X
that	B-X
EBV	B-X
can	B-X
up-regulate	B-X
IL-1beta	B-X
expression	B-X
,	B-X
possibly	B-X
by	B-X
using	B-X
RBP	B-X
,	B-X
NF-kappaB	B-X
,	B-X
or	B-X
both	B-X
.	B-X

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infects	O
B	O
cells	O
,	O
resulting	O
in	O
the	O
outgrowth	O
of	O
immortalised	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
infects	B-X
B	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
outgrowth	B-X
of	B-X
immortalised	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
(	B-X
LCLs	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
through	B-X
the	B-X
use	B-X
of	B-X
intracellular	B-X
staining	B-X
that	B-X
interleukin-1beta	B-X
(	B-X
IL-1beta	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
LCLs	B-X
and	B-X
investigate	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
individual	B-X
latent	B-X
proteins	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
IL-1beta	B-X
.	B-X
Using	B-X
RT-PCR	B-X
,	B-X
IL-1beta	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
EBV-transformed	B-X
LCLs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
group	B-X
III	B-X
Burkitt	B-X
's	B-X
lymphoma	B-X
(	B-X
BL	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
compared	B-X
with	B-X
group	B-X
I	B-X
BL	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
IL-1beta	B-X
message	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
the	B-X
latent	B-X
membrane	B-X
protein-1	B-X
,	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
2	B-X
,	B-X
3	B-X
,	B-X
4	B-X
,	B-X
and	B-X
6	B-X
genes	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
demonstrated	B-X
that	B-X
the	B-X
-300	B-X
region	B-X
of	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
binding	B-X
site	B-X
,	B-X
contained	B-X
a	B-X
functional	B-X
RBP	B-X
binding	B-X
site	B-X
.	B-X
Binding	B-X
of	B-X
RBP	B-X
to	B-X
this	B-X
site	B-X
could	B-X
be	B-X
inhibited	B-X
by	B-X
addition	B-X
of	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
3	B-X
and	B-X
6	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
displace	B-X
RBP	B-X
from	B-X
its	B-X
recognition	B-X
sequence	B-X
,	B-X
removing	B-X
transcriptional	B-X
repression	B-X
and	B-X
allowing	B-X
gene	B-X
transcription	B-X
to	B-X
occur	B-X
.	B-X
In	B-X
group	B-X
I	B-X
BL	B-X
cells	B-X
,	B-X
containing	B-X
low	B-X
levels	B-X
of	B-X
NF-kappaB	B-X
,	B-X
only	B-X
RBP	B-X
binding	B-X
was	B-X
observed	B-X
in	B-X
EMSAs	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
binding	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
EBV-transformed	B-X
B	B-X
cell	B-X
lines	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
NF-kappaB	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
latent	B-X
membrane	B-X
protein-1	B-X
led	B-X
to	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
that	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
.	B-X
The	B-X
study	B-X
demonstrates	B-X
that	B-X
EBV	B-X
can	B-X
up-regulate	B-X
IL-1beta	B-X
expression	B-X
,	B-X
possibly	B-X
by	B-X
using	B-X
RBP	B-X
,	B-X
NF-kappaB	B-X
,	B-X
or	B-X
both	B-X
.	B-X

Here	O
,	O
we	O
demonstrate	O
through	O
the	O
use	O
of	O
intracellular	O
staining	O
that	O
interleukin	B-Protein
-	I-Protein
1beta	I-Protein
(	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
)	O
is	O
expressed	O
in	O
LCLs	O
and	O
investigate	O
the	O
influence	O
of	O
the	O
individual	O
latent	O
proteins	O
on	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
infects	B-X
B	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
outgrowth	B-X
of	B-X
immortalised	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
(	B-X
LCLs	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
through	B-X
the	B-X
use	B-X
of	B-X
intracellular	B-X
staining	B-X
that	B-X
interleukin-1beta	B-X
(	B-X
IL-1beta	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
LCLs	B-X
and	B-X
investigate	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
individual	B-X
latent	B-X
proteins	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
IL-1beta	B-X
.	B-X
Using	B-X
RT-PCR	B-X
,	B-X
IL-1beta	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
EBV-transformed	B-X
LCLs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
group	B-X
III	B-X
Burkitt	B-X
's	B-X
lymphoma	B-X
(	B-X
BL	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
compared	B-X
with	B-X
group	B-X
I	B-X
BL	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
IL-1beta	B-X
message	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
the	B-X
latent	B-X
membrane	B-X
protein-1	B-X
,	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
2	B-X
,	B-X
3	B-X
,	B-X
4	B-X
,	B-X
and	B-X
6	B-X
genes	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
demonstrated	B-X
that	B-X
the	B-X
-300	B-X
region	B-X
of	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
binding	B-X
site	B-X
,	B-X
contained	B-X
a	B-X
functional	B-X
RBP	B-X
binding	B-X
site	B-X
.	B-X
Binding	B-X
of	B-X
RBP	B-X
to	B-X
this	B-X
site	B-X
could	B-X
be	B-X
inhibited	B-X
by	B-X
addition	B-X
of	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
3	B-X
and	B-X
6	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
displace	B-X
RBP	B-X
from	B-X
its	B-X
recognition	B-X
sequence	B-X
,	B-X
removing	B-X
transcriptional	B-X
repression	B-X
and	B-X
allowing	B-X
gene	B-X
transcription	B-X
to	B-X
occur	B-X
.	B-X
In	B-X
group	B-X
I	B-X
BL	B-X
cells	B-X
,	B-X
containing	B-X
low	B-X
levels	B-X
of	B-X
NF-kappaB	B-X
,	B-X
only	B-X
RBP	B-X
binding	B-X
was	B-X
observed	B-X
in	B-X
EMSAs	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
binding	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
EBV-transformed	B-X
B	B-X
cell	B-X
lines	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
NF-kappaB	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
latent	B-X
membrane	B-X
protein-1	B-X
led	B-X
to	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
that	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
.	B-X
The	B-X
study	B-X
demonstrates	B-X
that	B-X
EBV	B-X
can	B-X
up-regulate	B-X
IL-1beta	B-X
expression	B-X
,	B-X
possibly	B-X
by	B-X
using	B-X
RBP	B-X
,	B-X
NF-kappaB	B-X
,	B-X
or	B-X
both	B-X
.	B-X

Using	O
RT	O
-	O
PCR	O
,	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
was	O
shown	O
to	O
be	O
up	O
-	O
regulated	O
in	O
EBV	O
-	O
transformed	O
LCLs	O
as	O
well	O
as	O
in	O
group	O
III	O
Burkitt	O
'	O
s	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
compared	O
with	O
group	O
I	O
BL	O
cell	O
lines	O
.	O

The	O
up	O
-	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
message	O
could	O
be	O
mediated	O
by	O
the	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
,	O
EBV	B-Protein
nuclear	I-Protein
proteins	I-Protein
2	I-Protein
,	O
3	B-Protein
,	O
4	B-Protein
,	O
and	O
6	B-Protein
genes	I-Protein
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
infects	B-X
B	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
outgrowth	B-X
of	B-X
immortalised	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
(	B-X
LCLs	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
through	B-X
the	B-X
use	B-X
of	B-X
intracellular	B-X
staining	B-X
that	B-X
interleukin-1beta	B-X
(	B-X
IL-1beta	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
LCLs	B-X
and	B-X
investigate	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
individual	B-X
latent	B-X
proteins	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
IL-1beta	B-X
.	B-X
Using	B-X
RT-PCR	B-X
,	B-X
IL-1beta	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
EBV-transformed	B-X
LCLs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
group	B-X
III	B-X
Burkitt	B-X
's	B-X
lymphoma	B-X
(	B-X
BL	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
compared	B-X
with	B-X
group	B-X
I	B-X
BL	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
IL-1beta	B-X
message	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
the	B-X
latent	B-X
membrane	B-X
protein-1	B-X
,	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
2	B-X
,	B-X
3	B-X
,	B-X
4	B-X
,	B-X
and	B-X
6	B-X
genes	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
demonstrated	B-X
that	B-X
the	B-X
-300	B-X
region	B-X
of	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
binding	B-X
site	B-X
,	B-X
contained	B-X
a	B-X
functional	B-X
RBP	B-X
binding	B-X
site	B-X
.	B-X
Binding	B-X
of	B-X
RBP	B-X
to	B-X
this	B-X
site	B-X
could	B-X
be	B-X
inhibited	B-X
by	B-X
addition	B-X
of	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
3	B-X
and	B-X
6	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
displace	B-X
RBP	B-X
from	B-X
its	B-X
recognition	B-X
sequence	B-X
,	B-X
removing	B-X
transcriptional	B-X
repression	B-X
and	B-X
allowing	B-X
gene	B-X
transcription	B-X
to	B-X
occur	B-X
.	B-X
In	B-X
group	B-X
I	B-X
BL	B-X
cells	B-X
,	B-X
containing	B-X
low	B-X
levels	B-X
of	B-X
NF-kappaB	B-X
,	B-X
only	B-X
RBP	B-X
binding	B-X
was	B-X
observed	B-X
in	B-X
EMSAs	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
binding	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
EBV-transformed	B-X
B	B-X
cell	B-X
lines	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
NF-kappaB	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
latent	B-X
membrane	B-X
protein-1	B-X
led	B-X
to	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
that	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
.	B-X
The	B-X
study	B-X
demonstrates	B-X
that	B-X
EBV	B-X
can	B-X
up-regulate	B-X
IL-1beta	B-X
expression	B-X
,	B-X
possibly	B-X
by	B-X
using	B-X
RBP	B-X
,	B-X
NF-kappaB	B-X
,	B-X
or	B-X
both	B-X
.	B-X

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
the	O
-	O
300	O
region	O
of	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
promoter	O
,	O
which	O
contains	O
a	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
binding	O
site	O
,	O
contained	O
a	O
functional	O
RBP	O
binding	O
site	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
through	B-X
the	B-X
use	B-X
of	B-X
intracellular	B-X
staining	B-X
that	B-X
interleukin-1beta	B-X
(	B-X
IL-1beta	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
LCLs	B-X
and	B-X
investigate	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
individual	B-X
latent	B-X
proteins	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
IL-1beta	B-X
.	B-X
Using	B-X
RT-PCR	B-X
,	B-X
IL-1beta	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
EBV-transformed	B-X
LCLs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
group	B-X
III	B-X
Burkitt	B-X
's	B-X
lymphoma	B-X
(	B-X
BL	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
compared	B-X
with	B-X
group	B-X
I	B-X
BL	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
IL-1beta	B-X
message	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
the	B-X
latent	B-X
membrane	B-X
protein-1	B-X
,	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
2	B-X
,	B-X
3	B-X
,	B-X
4	B-X
,	B-X
and	B-X
6	B-X
genes	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
demonstrated	B-X
that	B-X
the	B-X
-300	B-X
region	B-X
of	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
binding	B-X
site	B-X
,	B-X
contained	B-X
a	B-X
functional	B-X
RBP	B-X
binding	B-X
site	B-X
.	B-X
Binding	B-X
of	B-X
RBP	B-X
to	B-X
this	B-X
site	B-X
could	B-X
be	B-X
inhibited	B-X
by	B-X
addition	B-X
of	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
3	B-X
and	B-X
6	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
displace	B-X
RBP	B-X
from	B-X
its	B-X
recognition	B-X
sequence	B-X
,	B-X
removing	B-X
transcriptional	B-X
repression	B-X
and	B-X
allowing	B-X
gene	B-X
transcription	B-X
to	B-X
occur	B-X
.	B-X
In	B-X
group	B-X
I	B-X
BL	B-X
cells	B-X
,	B-X
containing	B-X
low	B-X
levels	B-X
of	B-X
NF-kappaB	B-X
,	B-X
only	B-X
RBP	B-X
binding	B-X
was	B-X
observed	B-X
in	B-X
EMSAs	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
binding	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
EBV-transformed	B-X
B	B-X
cell	B-X
lines	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
NF-kappaB	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
latent	B-X
membrane	B-X
protein-1	B-X
led	B-X
to	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
that	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
.	B-X
The	B-X
study	B-X
demonstrates	B-X
that	B-X
EBV	B-X
can	B-X
up-regulate	B-X
IL-1beta	B-X
expression	B-X
,	B-X
possibly	B-X
by	B-X
using	B-X
RBP	B-X
,	B-X
NF-kappaB	B-X
,	B-X
or	B-X
both	B-X
.	B-X

Binding	O
of	O
RBP	O
to	O
this	O
site	O
could	O
be	O
inhibited	O
by	O
addition	O
of	O
EBV	B-Protein
nuclear	I-Protein
proteins	I-Protein
3	I-Protein
and	O
6	B-Protein
,	O
suggesting	O
that	O
these	O
proteins	O
displace	O
RBP	O
from	O
its	O
recognition	O
sequence	O
,	O
removing	O
transcriptional	O
repression	O
and	O
allowing	O
gene	O
transcription	O
to	O
occur	O
.	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
infects	B-X
B	B-X
cells	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
outgrowth	B-X
of	B-X
immortalised	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
(	B-X
LCLs	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
through	B-X
the	B-X
use	B-X
of	B-X
intracellular	B-X
staining	B-X
that	B-X
interleukin-1beta	B-X
(	B-X
IL-1beta	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
LCLs	B-X
and	B-X
investigate	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
individual	B-X
latent	B-X
proteins	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
IL-1beta	B-X
.	B-X
Using	B-X
RT-PCR	B-X
,	B-X
IL-1beta	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
EBV-transformed	B-X
LCLs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
group	B-X
III	B-X
Burkitt	B-X
's	B-X
lymphoma	B-X
(	B-X
BL	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
compared	B-X
with	B-X
group	B-X
I	B-X
BL	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
IL-1beta	B-X
message	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
the	B-X
latent	B-X
membrane	B-X
protein-1	B-X
,	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
2	B-X
,	B-X
3	B-X
,	B-X
4	B-X
,	B-X
and	B-X
6	B-X
genes	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
demonstrated	B-X
that	B-X
the	B-X
-300	B-X
region	B-X
of	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
binding	B-X
site	B-X
,	B-X
contained	B-X
a	B-X
functional	B-X
RBP	B-X
binding	B-X
site	B-X
.	B-X
Binding	B-X
of	B-X
RBP	B-X
to	B-X
this	B-X
site	B-X
could	B-X
be	B-X
inhibited	B-X
by	B-X
addition	B-X
of	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
3	B-X
and	B-X
6	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
displace	B-X
RBP	B-X
from	B-X
its	B-X
recognition	B-X
sequence	B-X
,	B-X
removing	B-X
transcriptional	B-X
repression	B-X
and	B-X
allowing	B-X
gene	B-X
transcription	B-X
to	B-X
occur	B-X
.	B-X
In	B-X
group	B-X
I	B-X
BL	B-X
cells	B-X
,	B-X
containing	B-X
low	B-X
levels	B-X
of	B-X
NF-kappaB	B-X
,	B-X
only	B-X
RBP	B-X
binding	B-X
was	B-X
observed	B-X
in	B-X
EMSAs	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
binding	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
EBV-transformed	B-X
B	B-X
cell	B-X
lines	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
NF-kappaB	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
latent	B-X
membrane	B-X
protein-1	B-X
led	B-X
to	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
that	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
.	B-X
The	B-X
study	B-X
demonstrates	B-X
that	B-X
EBV	B-X
can	B-X
up-regulate	B-X
IL-1beta	B-X
expression	B-X
,	B-X
possibly	B-X
by	B-X
using	B-X
RBP	B-X
,	B-X
NF-kappaB	B-X
,	B-X
or	B-X
both	B-X
.	B-X

In	O
group	O
I	O
BL	O
cells	O
,	O
containing	O
low	O
levels	O
of	O
NF	O
-	O
kappaB	O
,	O
only	O
RBP	O
binding	O
was	O
observed	O
in	O
EMSAs	O
,	O
whereas	O
NF	O
-	O
kappaB	O
binding	O
could	O
be	O
demonstrated	O
in	O
EBV	O
-	O
transformed	O
B	O
cell	O
lines	O
containing	O
high	O
levels	O
of	O
activated	O
NF	O
-	O
kappaB	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
latent	B-Protein
membrane	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
led	O
to	O
activation	O
of	O
NF	O
-	O
kappaB	O
that	O
was	O
capable	O
of	O
binding	O
the	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
promoter	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
through	B-X
the	B-X
use	B-X
of	B-X
intracellular	B-X
staining	B-X
that	B-X
interleukin-1beta	B-X
(	B-X
IL-1beta	B-X
)	B-X
is	B-X
expressed	B-X
in	B-X
LCLs	B-X
and	B-X
investigate	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
individual	B-X
latent	B-X
proteins	B-X
on	B-X
the	B-X
expression	B-X
of	B-X
IL-1beta	B-X
.	B-X
Using	B-X
RT-PCR	B-X
,	B-X
IL-1beta	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
up-regulated	B-X
in	B-X
EBV-transformed	B-X
LCLs	B-X
as	B-X
well	B-X
as	B-X
in	B-X
group	B-X
III	B-X
Burkitt	B-X
's	B-X
lymphoma	B-X
(	B-X
BL	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
compared	B-X
with	B-X
group	B-X
I	B-X
BL	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
up-regulation	B-X
of	B-X
IL-1beta	B-X
message	B-X
could	B-X
be	B-X
mediated	B-X
by	B-X
the	B-X
latent	B-X
membrane	B-X
protein-1	B-X
,	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
2	B-X
,	B-X
3	B-X
,	B-X
4	B-X
,	B-X
and	B-X
6	B-X
genes	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
demonstrated	B-X
that	B-X
the	B-X
-300	B-X
region	B-X
of	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
binding	B-X
site	B-X
,	B-X
contained	B-X
a	B-X
functional	B-X
RBP	B-X
binding	B-X
site	B-X
.	B-X
Binding	B-X
of	B-X
RBP	B-X
to	B-X
this	B-X
site	B-X
could	B-X
be	B-X
inhibited	B-X
by	B-X
addition	B-X
of	B-X
EBV	B-X
nuclear	B-X
proteins	B-X
3	B-X
and	B-X
6	B-X
,	B-X
suggesting	B-X
that	B-X
these	B-X
proteins	B-X
displace	B-X
RBP	B-X
from	B-X
its	B-X
recognition	B-X
sequence	B-X
,	B-X
removing	B-X
transcriptional	B-X
repression	B-X
and	B-X
allowing	B-X
gene	B-X
transcription	B-X
to	B-X
occur	B-X
.	B-X
In	B-X
group	B-X
I	B-X
BL	B-X
cells	B-X
,	B-X
containing	B-X
low	B-X
levels	B-X
of	B-X
NF-kappaB	B-X
,	B-X
only	B-X
RBP	B-X
binding	B-X
was	B-X
observed	B-X
in	B-X
EMSAs	B-X
,	B-X
whereas	B-X
NF-kappaB	B-X
binding	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
EBV-transformed	B-X
B	B-X
cell	B-X
lines	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
activated	B-X
NF-kappaB	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
latent	B-X
membrane	B-X
protein-1	B-X
led	B-X
to	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
that	B-X
was	B-X
capable	B-X
of	B-X
binding	B-X
the	B-X
IL-1beta	B-X
promoter	B-X
.	B-X
The	B-X
study	B-X
demonstrates	B-X
that	B-X
EBV	B-X
can	B-X
up-regulate	B-X
IL-1beta	B-X
expression	B-X
,	B-X
possibly	B-X
by	B-X
using	B-X
RBP	B-X
,	B-X
NF-kappaB	B-X
,	B-X
or	B-X
both	B-X
.	B-X

The	O
study	O
demonstrates	O
that	O
EBV	O
can	O
up	O
-	O
regulate	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
expression	O
,	O
possibly	O
by	O
using	O
RBP	O
,	O
NF	O
-	O
kappaB	O
,	O
or	O
both	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O
<EOS>	B-X
Copyright	B-X
1998	B-X
Academic	B-X
Press	B-X
Limited	B-X
Copyright	B-X
1998	B-X
Academic	B-X
Press	B-X
Limited	B-X
Copyright	B-X
1998	B-X
Academic	B-X
Press	B-X
.	B-X
Copyright	B-X
1998	B-X
Academic	B-X
Press	B-X
.	B-X

Characterization	O
of	O
the	O
human	O
elk	B-Protein
-	I-Protein
1	I-Protein
promoter	O
.	O
<EOS>	B-X
To	B-X
characterize	B-X
the	B-X
human	B-X
elk-1	B-X
promoter	B-X
,	B-X
we	B-X
mapped	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
and	B-X
isolated	B-X
elk-1-specific	B-X
genomic	B-X
phage	B-X
clones	B-X
that	B-X
contained	B-X
extensive	B-X
upstream	B-X
and	B-X
downstream	B-X
sequences	B-X
.	B-X
Functional	B-X
analyses	B-X
of	B-X
DNA	B-X
fragments	B-X
containing	B-X
the	B-X
TATA	B-X
element	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
DNase	B-X
I-hypersensitive	B-X
chromatin	B-X
site	B-X
(	B-X
HS	B-X
1	B-X
)	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
TATA	B-X
box	B-X
suggest	B-X
that	B-X
the	B-X
identified	B-X
TATA	B-X
motif	B-X
is	B-X
important	B-X
for	B-X
elk-1	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
Sequences	B-X
upstream	B-X
and	B-X
downstream	B-X
from	B-X
the	B-X
TATA	B-X
box	B-X
were	B-X
found	B-X
to	B-X
contribute	B-X
to	B-X
elk-1	B-X
promoter	B-X
activity	B-X
.	B-X
A	B-X
second	B-X
hypersensitive	B-X
site	B-X
(	B-X
HS	B-X
2	B-X
)	B-X
was	B-X
identified	B-X
within	B-X
the	B-X
first	B-X
intron	B-X
in	B-X
pre-monocytic	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
Elk-1	B-X
only	B-X
when	B-X
differentiating	B-X
to	B-X
monocytes	B-X
.	B-X
In	B-X
a	B-X
variety	B-X
of	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
which	B-X
display	B-X
a	B-X
constitutive	B-X
Elk-1	B-X
expression	B-X
,	B-X
HS	B-X
2	B-X
did	B-X
not	B-X
exist	B-X
,	B-X
suggesting	B-X
that	B-X
inducibility	B-X
of	B-X
elk-1	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
HS	B-X
2	B-X
.	B-X
Egr-1	B-X
and	B-X
the	B-X
serum	B-X
response	B-X
factor	B-X
were	B-X
found	B-X
to	B-X
interact	B-X
specifically	B-X
with	B-X
the	B-X
intronic	B-X
sequence	B-X
at	B-X
+265	B-X
and	B-X
+448	B-X
,	B-X
respectively	B-X
.	B-X
Because	B-X
Egr-1	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
to	B-X
increase	B-X
significantly	B-X
before	B-X
induction	B-X
of	B-X
elk-1	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Egr-1	B-X
is	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
elk-1	B-X
transcription	B-X
in	B-X
differentiating	B-X
monocytes	B-X
.	B-X

Potential	O
role	O
of	O
a	O
downstream	O
intronic	O
sequence	O
for	O
elk	B-Protein
-	I-Protein
1	I-Protein
gene	O
expression	O
in	O
monocytes	O
.	O
<EOS>	B-X
To	B-X
characterize	B-X
the	B-X
human	B-X
elk-1	B-X
promoter	B-X
,	B-X
we	B-X
mapped	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
and	B-X
isolated	B-X
elk-1-specific	B-X
genomic	B-X
phage	B-X
clones	B-X
that	B-X
contained	B-X
extensive	B-X
upstream	B-X
and	B-X
downstream	B-X
sequences	B-X
.	B-X
Functional	B-X
analyses	B-X
of	B-X
DNA	B-X
fragments	B-X
containing	B-X
the	B-X
TATA	B-X
element	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
DNase	B-X
I-hypersensitive	B-X
chromatin	B-X
site	B-X
(	B-X
HS	B-X
1	B-X
)	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
TATA	B-X
box	B-X
suggest	B-X
that	B-X
the	B-X
identified	B-X
TATA	B-X
motif	B-X
is	B-X
important	B-X
for	B-X
elk-1	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
Sequences	B-X
upstream	B-X
and	B-X
downstream	B-X
from	B-X
the	B-X
TATA	B-X
box	B-X
were	B-X
found	B-X
to	B-X
contribute	B-X
to	B-X
elk-1	B-X
promoter	B-X
activity	B-X
.	B-X
A	B-X
second	B-X
hypersensitive	B-X
site	B-X
(	B-X
HS	B-X
2	B-X
)	B-X
was	B-X
identified	B-X
within	B-X
the	B-X
first	B-X
intron	B-X
in	B-X
pre-monocytic	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
Elk-1	B-X
only	B-X
when	B-X
differentiating	B-X
to	B-X
monocytes	B-X
.	B-X
In	B-X
a	B-X
variety	B-X
of	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
which	B-X
display	B-X
a	B-X
constitutive	B-X
Elk-1	B-X
expression	B-X
,	B-X
HS	B-X
2	B-X
did	B-X
not	B-X
exist	B-X
,	B-X
suggesting	B-X
that	B-X
inducibility	B-X
of	B-X
elk-1	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
HS	B-X
2	B-X
.	B-X
Egr-1	B-X
and	B-X
the	B-X
serum	B-X
response	B-X
factor	B-X
were	B-X
found	B-X
to	B-X
interact	B-X
specifically	B-X
with	B-X
the	B-X
intronic	B-X
sequence	B-X
at	B-X
+265	B-X
and	B-X
+448	B-X
,	B-X
respectively	B-X
.	B-X
Because	B-X
Egr-1	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
to	B-X
increase	B-X
significantly	B-X
before	B-X
induction	B-X
of	B-X
elk-1	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Egr-1	B-X
is	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
elk-1	B-X
transcription	B-X
in	B-X
differentiating	B-X
monocytes	B-X
.	B-X

To	O
characterize	O
the	O
human	O
elk	B-Protein
-	I-Protein
1	I-Protein
promoter	O
,	O
we	O
mapped	O
the	O
transcriptional	O
start	O
site	O
and	O
isolated	O
elk	B-Protein
-	I-Protein
1	I-Protein
-	O
specific	O
genomic	O
phage	O
clones	O
that	O
contained	O
extensive	O
upstream	O
and	O
downstream	O
sequences	O
.	O
<EOS>	B-X
To	B-X
characterize	B-X
the	B-X
human	B-X
elk-1	B-X
promoter	B-X
,	B-X
we	B-X
mapped	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
and	B-X
isolated	B-X
elk-1-specific	B-X
genomic	B-X
phage	B-X
clones	B-X
that	B-X
contained	B-X
extensive	B-X
upstream	B-X
and	B-X
downstream	B-X
sequences	B-X
.	B-X
A	B-X
TATA-like	B-X
motif	B-X
was	B-X
identified	B-X
immediately	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Functional	B-X
analyses	B-X
of	B-X
DNA	B-X
fragments	B-X
containing	B-X
the	B-X
TATA	B-X
element	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
DNase	B-X
I-hypersensitive	B-X
chromatin	B-X
site	B-X
(	B-X
HS	B-X
1	B-X
)	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
TATA	B-X
box	B-X
suggest	B-X
that	B-X
the	B-X
identified	B-X
TATA	B-X
motif	B-X
is	B-X
important	B-X
for	B-X
elk-1	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
Sequences	B-X
upstream	B-X
and	B-X
downstream	B-X
from	B-X
the	B-X
TATA	B-X
box	B-X
were	B-X
found	B-X
to	B-X
contribute	B-X
to	B-X
elk-1	B-X
promoter	B-X
activity	B-X
.	B-X
A	B-X
second	B-X
hypersensitive	B-X
site	B-X
(	B-X
HS	B-X
2	B-X
)	B-X
was	B-X
identified	B-X
within	B-X
the	B-X
first	B-X
intron	B-X
in	B-X
pre-monocytic	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
Elk-1	B-X
only	B-X
when	B-X
differentiating	B-X
to	B-X
monocytes	B-X
.	B-X
In	B-X
a	B-X
variety	B-X
of	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
which	B-X
display	B-X
a	B-X
constitutive	B-X
Elk-1	B-X
expression	B-X
,	B-X
HS	B-X
2	B-X
did	B-X
not	B-X
exist	B-X
,	B-X
suggesting	B-X
that	B-X
inducibility	B-X
of	B-X
elk-1	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
HS	B-X
2	B-X
.	B-X
Egr-1	B-X
and	B-X
the	B-X
serum	B-X
response	B-X
factor	B-X
were	B-X
found	B-X
to	B-X
interact	B-X
specifically	B-X
with	B-X
the	B-X
intronic	B-X
sequence	B-X
at	B-X
+265	B-X
and	B-X
+448	B-X
,	B-X
respectively	B-X
.	B-X
Because	B-X
Egr-1	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
to	B-X
increase	B-X
significantly	B-X
before	B-X
induction	B-X
of	B-X
elk-1	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Egr-1	B-X
is	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
elk-1	B-X
transcription	B-X
in	B-X
differentiating	B-X
monocytes	B-X
.	B-X

A	O
TATA	O
-	O
like	O
motif	O
was	O
identified	O
immediately	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O
<EOS>	B-X
We	B-X
used	B-X
structure-function	B-X
analysis	B-X
of	B-X
the	B-X
core	B-X
promoter	B-X
region	B-X
to	B-X
elucidate	B-X
the	B-X
transcriptional	B-X
features	B-X
of	B-X
the	B-X
mouse	B-X
alpha	B-X
1	B-X
(	B-X
V	B-X
)	B-X
collagen	B-X
gene	B-X
(	B-X
Col5a1	B-X
)	B-X
.	B-X
The	B-X
core	B-X
promoter	B-X
,	B-X
which	B-X
lacks	B-X
a	B-X
typical	B-X
TATA	B-X
motif	B-X
and	B-X
has	B-X
a	B-X
high	B-X
GC	B-X
content	B-X
,	B-X
was	B-X
defined	B-X
within	B-X
the	B-X
231	B-X
bp	B-X
immediately	B-X
upstream	B-X
from	B-X
the	B-X
major	B-X
transcription	B-X
start	B-X
site	B-X
by	B-X
transient	B-X
transfection	B-X
experiments	B-X
.	B-X
In	B-X
this	B-X
region	B-X
,	B-X
we	B-X
identified	B-X
three	B-X
nuclear-factor	B-X
binding	B-X
sites	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
:	B-X
BS1	B-X
(	B-X
-195	B-X
to	B-X
-167	B-X
)	B-X
,	B-X
BS2	B-X
(	B-X
-134	B-X
to	B-X
-106	B-X
)	B-X
,	B-X
and	B-X
BS3	B-X
(	B-X
-110	B-X
to	B-X
-80	B-X
)	B-X
.	B-X
The	B-X
CCAAT-like	B-X
motif	B-X
,	B-X
CAAAT	B-X
,	B-X
and	B-X
flanking	B-X
sequences	B-X
are	B-X
conserved	B-X
between	B-X
the	B-X
mouse	B-X
and	B-X
human	B-X
gene	B-X
.	B-X
CBF	B-X
,	B-X
which	B-X
recognizes	B-X
this	B-X
motif	B-X
,	B-X
activated	B-X
the	B-X
Col5a1	B-X
promoter	B-X
,	B-X
as	B-X
previously	B-X
reported	B-X
for	B-X
Col1a1	B-X
and	B-X
Col1a2	B-X
.	B-X

Functional	O
analyses	O
of	O
DNA	O
fragments	O
containing	O
the	O
TATA	O
element	O
and	O
the	O
identification	O
of	O
a	O
DNase	O
I	O
-	O
hypersensitive	O
chromatin	O
site	O
(	O
HS	O
1	O
)	O
in	O
close	O
proximity	O
to	O
the	O
TATA	O
box	O
suggest	O
that	O
the	O
identified	O
TATA	O
motif	O
is	O
important	O
for	O
elk	B-Protein
-	I-Protein
1	I-Protein
transcription	O
in	O
vivo	O
.	O

Sequences	O
upstream	O
and	O
downstream	O
from	O
the	O
TATA	O
box	O
were	O
found	O
to	O
contribute	O
to	O
elk	B-Protein
-	I-Protein
1	I-Protein
promoter	O
activity	O
.	O
<EOS>	B-X
To	B-X
characterize	B-X
the	B-X
human	B-X
elk-1	B-X
promoter	B-X
,	B-X
we	B-X
mapped	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
and	B-X
isolated	B-X
elk-1-specific	B-X
genomic	B-X
phage	B-X
clones	B-X
that	B-X
contained	B-X
extensive	B-X
upstream	B-X
and	B-X
downstream	B-X
sequences	B-X
.	B-X
A	B-X
TATA-like	B-X
motif	B-X
was	B-X
identified	B-X
immediately	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Functional	B-X
analyses	B-X
of	B-X
DNA	B-X
fragments	B-X
containing	B-X
the	B-X
TATA	B-X
element	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
DNase	B-X
I-hypersensitive	B-X
chromatin	B-X
site	B-X
(	B-X
HS	B-X
1	B-X
)	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
TATA	B-X
box	B-X
suggest	B-X
that	B-X
the	B-X
identified	B-X
TATA	B-X
motif	B-X
is	B-X
important	B-X
for	B-X
elk-1	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
Sequences	B-X
upstream	B-X
and	B-X
downstream	B-X
from	B-X
the	B-X
TATA	B-X
box	B-X
were	B-X
found	B-X
to	B-X
contribute	B-X
to	B-X
elk-1	B-X
promoter	B-X
activity	B-X
.	B-X
A	B-X
second	B-X
hypersensitive	B-X
site	B-X
(	B-X
HS	B-X
2	B-X
)	B-X
was	B-X
identified	B-X
within	B-X
the	B-X
first	B-X
intron	B-X
in	B-X
pre-monocytic	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
Elk-1	B-X
only	B-X
when	B-X
differentiating	B-X
to	B-X
monocytes	B-X
.	B-X
In	B-X
a	B-X
variety	B-X
of	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
which	B-X
display	B-X
a	B-X
constitutive	B-X
Elk-1	B-X
expression	B-X
,	B-X
HS	B-X
2	B-X
did	B-X
not	B-X
exist	B-X
,	B-X
suggesting	B-X
that	B-X
inducibility	B-X
of	B-X
elk-1	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
HS	B-X
2	B-X
.	B-X
Egr-1	B-X
and	B-X
the	B-X
serum	B-X
response	B-X
factor	B-X
were	B-X
found	B-X
to	B-X
interact	B-X
specifically	B-X
with	B-X
the	B-X
intronic	B-X
sequence	B-X
at	B-X
+265	B-X
and	B-X
+448	B-X
,	B-X
respectively	B-X
.	B-X
Because	B-X
Egr-1	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
to	B-X
increase	B-X
significantly	B-X
before	B-X
induction	B-X
of	B-X
elk-1	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Egr-1	B-X
is	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
elk-1	B-X
transcription	B-X
in	B-X
differentiating	B-X
monocytes	B-X
.	B-X

A	O
second	O
hypersensitive	O
site	O
(	O
HS	O
2	O
)	O
was	O
identified	O
within	O
the	O
first	O
intron	O
in	O
pre	O
-	O
monocytic	O
cells	O
,	O
which	O
express	O
Elk	B-Protein
-	I-Protein
1	I-Protein
only	O
when	O
differentiating	O
to	O
monocytes	O
.	O
<EOS>	B-X
To	B-X
characterize	B-X
the	B-X
human	B-X
elk-1	B-X
promoter	B-X
,	B-X
we	B-X
mapped	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
and	B-X
isolated	B-X
elk-1-specific	B-X
genomic	B-X
phage	B-X
clones	B-X
that	B-X
contained	B-X
extensive	B-X
upstream	B-X
and	B-X
downstream	B-X
sequences	B-X
.	B-X
A	B-X
TATA-like	B-X
motif	B-X
was	B-X
identified	B-X
immediately	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Functional	B-X
analyses	B-X
of	B-X
DNA	B-X
fragments	B-X
containing	B-X
the	B-X
TATA	B-X
element	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
DNase	B-X
I-hypersensitive	B-X
chromatin	B-X
site	B-X
(	B-X
HS	B-X
1	B-X
)	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
TATA	B-X
box	B-X
suggest	B-X
that	B-X
the	B-X
identified	B-X
TATA	B-X
motif	B-X
is	B-X
important	B-X
for	B-X
elk-1	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
Sequences	B-X
upstream	B-X
and	B-X
downstream	B-X
from	B-X
the	B-X
TATA	B-X
box	B-X
were	B-X
found	B-X
to	B-X
contribute	B-X
to	B-X
elk-1	B-X
promoter	B-X
activity	B-X
.	B-X
A	B-X
second	B-X
hypersensitive	B-X
site	B-X
(	B-X
HS	B-X
2	B-X
)	B-X
was	B-X
identified	B-X
within	B-X
the	B-X
first	B-X
intron	B-X
in	B-X
pre-monocytic	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
Elk-1	B-X
only	B-X
when	B-X
differentiating	B-X
to	B-X
monocytes	B-X
.	B-X
In	B-X
a	B-X
variety	B-X
of	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
which	B-X
display	B-X
a	B-X
constitutive	B-X
Elk-1	B-X
expression	B-X
,	B-X
HS	B-X
2	B-X
did	B-X
not	B-X
exist	B-X
,	B-X
suggesting	B-X
that	B-X
inducibility	B-X
of	B-X
elk-1	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
HS	B-X
2	B-X
.	B-X
Egr-1	B-X
and	B-X
the	B-X
serum	B-X
response	B-X
factor	B-X
were	B-X
found	B-X
to	B-X
interact	B-X
specifically	B-X
with	B-X
the	B-X
intronic	B-X
sequence	B-X
at	B-X
+265	B-X
and	B-X
+448	B-X
,	B-X
respectively	B-X
.	B-X
Because	B-X
Egr-1	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
to	B-X
increase	B-X
significantly	B-X
before	B-X
induction	B-X
of	B-X
elk-1	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Egr-1	B-X
is	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
elk-1	B-X
transcription	B-X
in	B-X
differentiating	B-X
monocytes	B-X
.	B-X

In	O
a	O
variety	O
of	O
other	O
cell	O
types	O
,	O
which	O
display	O
a	O
constitutive	O
Elk	B-Protein
-	I-Protein
1	I-Protein
expression	O
,	O
HS	O
2	O
did	O
not	O
exist	O
,	O
suggesting	O
that	O
inducibility	O
of	O
elk	B-Protein
-	I-Protein
1	I-Protein
expression	O
is	O
associated	O
with	O
the	O
presence	O
of	O
HS	O
2	O
.	O

Egr	B-Protein
-	I-Protein
1	I-Protein
and	O
the	O
serum	B-Protein
response	I-Protein
factor	I-Protein
were	O
found	O
to	O
interact	O
specifically	O
with	O
the	O
intronic	O
sequence	O
at	O
+	O
265	O
and	O
+	O
448	O
,	O
respectively	O
.	O
<EOS>	B-X
To	B-X
characterize	B-X
the	B-X
human	B-X
elk-1	B-X
promoter	B-X
,	B-X
we	B-X
mapped	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
and	B-X
isolated	B-X
elk-1-specific	B-X
genomic	B-X
phage	B-X
clones	B-X
that	B-X
contained	B-X
extensive	B-X
upstream	B-X
and	B-X
downstream	B-X
sequences	B-X
.	B-X
Functional	B-X
analyses	B-X
of	B-X
DNA	B-X
fragments	B-X
containing	B-X
the	B-X
TATA	B-X
element	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
DNase	B-X
I-hypersensitive	B-X
chromatin	B-X
site	B-X
(	B-X
HS	B-X
1	B-X
)	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
TATA	B-X
box	B-X
suggest	B-X
that	B-X
the	B-X
identified	B-X
TATA	B-X
motif	B-X
is	B-X
important	B-X
for	B-X
elk-1	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
Sequences	B-X
upstream	B-X
and	B-X
downstream	B-X
from	B-X
the	B-X
TATA	B-X
box	B-X
were	B-X
found	B-X
to	B-X
contribute	B-X
to	B-X
elk-1	B-X
promoter	B-X
activity	B-X
.	B-X
A	B-X
second	B-X
hypersensitive	B-X
site	B-X
(	B-X
HS	B-X
2	B-X
)	B-X
was	B-X
identified	B-X
within	B-X
the	B-X
first	B-X
intron	B-X
in	B-X
pre-monocytic	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
Elk-1	B-X
only	B-X
when	B-X
differentiating	B-X
to	B-X
monocytes	B-X
.	B-X
In	B-X
a	B-X
variety	B-X
of	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
which	B-X
display	B-X
a	B-X
constitutive	B-X
Elk-1	B-X
expression	B-X
,	B-X
HS	B-X
2	B-X
did	B-X
not	B-X
exist	B-X
,	B-X
suggesting	B-X
that	B-X
inducibility	B-X
of	B-X
elk-1	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
HS	B-X
2	B-X
.	B-X
Egr-1	B-X
and	B-X
the	B-X
serum	B-X
response	B-X
factor	B-X
were	B-X
found	B-X
to	B-X
interact	B-X
specifically	B-X
with	B-X
the	B-X
intronic	B-X
sequence	B-X
at	B-X
+265	B-X
and	B-X
+448	B-X
,	B-X
respectively	B-X
.	B-X
Because	B-X
Egr-1	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
to	B-X
increase	B-X
significantly	B-X
before	B-X
induction	B-X
of	B-X
elk-1	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Egr-1	B-X
is	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
elk-1	B-X
transcription	B-X
in	B-X
differentiating	B-X
monocytes	B-X
.	B-X

Because	O
Egr	B-Protein
-	I-Protein
1	I-Protein
mRNA	O
and	O
protein	O
levels	O
were	O
observed	O
to	O
increase	O
significantly	O
before	O
induction	O
of	O
elk	B-Protein
-	I-Protein
1	I-Protein
expression	O
,	O
we	O
propose	O
that	O
Egr	B-Protein
-	I-Protein
1	I-Protein
is	O
important	O
for	O
the	O
regulation	O
of	O
elk	B-Protein
-	I-Protein
1	I-Protein
transcription	O
in	O
differentiating	O
monocytes	O
.	O
<EOS>	B-X
To	B-X
characterize	B-X
the	B-X
human	B-X
elk-1	B-X
promoter	B-X
,	B-X
we	B-X
mapped	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
and	B-X
isolated	B-X
elk-1-specific	B-X
genomic	B-X
phage	B-X
clones	B-X
that	B-X
contained	B-X
extensive	B-X
upstream	B-X
and	B-X
downstream	B-X
sequences	B-X
.	B-X
A	B-X
TATA-like	B-X
motif	B-X
was	B-X
identified	B-X
immediately	B-X
upstream	B-X
of	B-X
the	B-X
transcriptional	B-X
start	B-X
site	B-X
.	B-X
Functional	B-X
analyses	B-X
of	B-X
DNA	B-X
fragments	B-X
containing	B-X
the	B-X
TATA	B-X
element	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
DNase	B-X
I-hypersensitive	B-X
chromatin	B-X
site	B-X
(	B-X
HS	B-X
1	B-X
)	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
TATA	B-X
box	B-X
suggest	B-X
that	B-X
the	B-X
identified	B-X
TATA	B-X
motif	B-X
is	B-X
important	B-X
for	B-X
elk-1	B-X
transcription	B-X
in	B-X
vivo	B-X
.	B-X
Sequences	B-X
upstream	B-X
and	B-X
downstream	B-X
from	B-X
the	B-X
TATA	B-X
box	B-X
were	B-X
found	B-X
to	B-X
contribute	B-X
to	B-X
elk-1	B-X
promoter	B-X
activity	B-X
.	B-X
A	B-X
second	B-X
hypersensitive	B-X
site	B-X
(	B-X
HS	B-X
2	B-X
)	B-X
was	B-X
identified	B-X
within	B-X
the	B-X
first	B-X
intron	B-X
in	B-X
pre-monocytic	B-X
cells	B-X
,	B-X
which	B-X
express	B-X
Elk-1	B-X
only	B-X
when	B-X
differentiating	B-X
to	B-X
monocytes	B-X
.	B-X
In	B-X
a	B-X
variety	B-X
of	B-X
other	B-X
cell	B-X
types	B-X
,	B-X
which	B-X
display	B-X
a	B-X
constitutive	B-X
Elk-1	B-X
expression	B-X
,	B-X
HS	B-X
2	B-X
did	B-X
not	B-X
exist	B-X
,	B-X
suggesting	B-X
that	B-X
inducibility	B-X
of	B-X
elk-1	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
HS	B-X
2	B-X
.	B-X
Egr-1	B-X
and	B-X
the	B-X
serum	B-X
response	B-X
factor	B-X
were	B-X
found	B-X
to	B-X
interact	B-X
specifically	B-X
with	B-X
the	B-X
intronic	B-X
sequence	B-X
at	B-X
+265	B-X
and	B-X
+448	B-X
,	B-X
respectively	B-X
.	B-X
Because	B-X
Egr-1	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
were	B-X
observed	B-X
to	B-X
increase	B-X
significantly	B-X
before	B-X
induction	B-X
of	B-X
elk-1	B-X
expression	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
Egr-1	B-X
is	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
elk-1	B-X
transcription	B-X
in	B-X
differentiating	B-X
monocytes	B-X
.	B-X

Functional	O
association	O
of	O
Nmi	B-Protein
with	O
Stat5	O
and	O
Stat1	B-Protein
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
and	O
IFNgamma	B-Protein
-	O
mediated	O
signaling	O
.	O
<EOS>	B-X
Using	B-X
the	B-X
coiled-coil	B-X
region	B-X
of	B-X
Stat5b	B-X
as	B-X
the	B-X
bait	B-X
in	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
,	B-X
we	B-X
identified	B-X
the	B-X
association	B-X
of	B-X
Nmi	B-X
,	B-X
a	B-X
protein	B-X
of	B-X
unknown	B-X
function	B-X
previously	B-X
reported	B-X
as	B-X
an	B-X
N-Myc	B-X
interactor	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
Nmi	B-X
interacts	B-X
with	B-X
all	B-X
STATs	B-X
except	B-X
Stat2	B-X
.	B-X
We	B-X
evaluated	B-X
two	B-X
cytokine	B-X
systems	B-X
,	B-X
IL-2	B-X
and	B-X
IFNgamma	B-X
,	B-X
and	B-X
demonstrate	B-X
that	B-X
Nmi	B-X
augments	B-X
STAT-mediated	B-X
transcription	B-X
in	B-X
response	B-X
to	B-X
these	B-X
cytokines	B-X
.	B-X
Interestingly	B-X
,	B-X
Nmi	B-X
lacks	B-X
an	B-X
intrinsic	B-X
transcriptional	B-X
activation	B-X
domain	B-X
;	B-X
instead	B-X
,	B-X
Nmi	B-X
enhances	B-X
the	B-X
association	B-X
of	B-X
CBP/p300	B-X
coactivator	B-X
proteins	B-X
with	B-X
Stat1	B-X
and	B-X
Stat5	B-X
,	B-X
and	B-X
together	B-X
with	B-X
CBP/p300	B-X
can	B-X
augment	B-X
IL-2-	B-X
and	B-X
IFNgamma-dependent	B-X
transcription	B-X
.	B-X
Therefore	B-X
,	B-X
our	B-X
data	B-X
not	B-X
only	B-X
reveal	B-X
that	B-X
Nmi	B-X
can	B-X
potentiate	B-X
STAT-dependent	B-X
transcription	B-X
,	B-X
but	B-X
also	B-X
suggest	B-X
that	B-X
it	B-X
can	B-X
augment	B-X
coactivator	B-X
protein	B-X
recruitment	B-X
to	B-X
at	B-X
least	B-X
some	B-X
members	B-X
of	B-X
a	B-X
group	B-X
of	B-X
sequence-specific	B-X
transcription	B-X
factors	B-X
.	B-X

Using	O
the	O
coiled	O
-	O
coil	O
region	O
of	O
Stat5b	B-Protein
as	O
the	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
we	O
identified	O
the	O
association	O
of	O
Nmi	B-Protein
,	O
a	O
protein	O
of	O
unknown	O
function	O
previously	O
reported	O
as	O
an	O
N	B-Protein
-	I-Protein
Myc	I-Protein
interactor	I-Protein
.	O

We	O
further	O
show	O
that	O
Nmi	B-Protein
interacts	O
with	O
all	O
STATs	O
except	O
Stat2	B-Protein
.	O
<EOS>	B-X
Using	B-X
the	B-X
coiled-coil	B-X
region	B-X
of	B-X
Stat5b	B-X
as	B-X
the	B-X
bait	B-X
in	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
,	B-X
we	B-X
identified	B-X
the	B-X
association	B-X
of	B-X
Nmi	B-X
,	B-X
a	B-X
protein	B-X
of	B-X
unknown	B-X
function	B-X
previously	B-X
reported	B-X
as	B-X
an	B-X
N-Myc	B-X
interactor	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
Nmi	B-X
interacts	B-X
with	B-X
all	B-X
STATs	B-X
except	B-X
Stat2	B-X
.	B-X
We	B-X
evaluated	B-X
two	B-X
cytokine	B-X
systems	B-X
,	B-X
IL-2	B-X
and	B-X
IFNgamma	B-X
,	B-X
and	B-X
demonstrate	B-X
that	B-X
Nmi	B-X
augments	B-X
STAT-mediated	B-X
transcription	B-X
in	B-X
response	B-X
to	B-X
these	B-X
cytokines	B-X
.	B-X
Interestingly	B-X
,	B-X
Nmi	B-X
lacks	B-X
an	B-X
intrinsic	B-X
transcriptional	B-X
activation	B-X
domain	B-X
;	B-X
instead	B-X
,	B-X
Nmi	B-X
enhances	B-X
the	B-X
association	B-X
of	B-X
CBP/p300	B-X
coactivator	B-X
proteins	B-X
with	B-X
Stat1	B-X
and	B-X
Stat5	B-X
,	B-X
and	B-X
together	B-X
with	B-X
CBP/p300	B-X
can	B-X
augment	B-X
IL-2-	B-X
and	B-X
IFNgamma-dependent	B-X
transcription	B-X
.	B-X
Therefore	B-X
,	B-X
our	B-X
data	B-X
not	B-X
only	B-X
reveal	B-X
that	B-X
Nmi	B-X
can	B-X
potentiate	B-X
STAT-dependent	B-X
transcription	B-X
,	B-X
but	B-X
also	B-X
suggest	B-X
that	B-X
it	B-X
can	B-X
augment	B-X
coactivator	B-X
protein	B-X
recruitment	B-X
to	B-X
at	B-X
least	B-X
some	B-X
members	B-X
of	B-X
a	B-X
group	B-X
of	B-X
sequence-specific	B-X
transcription	B-X
factors	B-X
.	B-X

We	O
evaluated	O
two	O
cytokine	O
systems	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IFNgamma	B-Protein
,	O
and	O
demonstrate	O
that	O
Nmi	B-Protein
augments	O
STAT	O
-	O
mediated	O
transcription	O
in	O
response	O
to	O
these	O
cytokines	O
.	O
<EOS>	B-X
Using	B-X
the	B-X
coiled-coil	B-X
region	B-X
of	B-X
Stat5b	B-X
as	B-X
the	B-X
bait	B-X
in	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
,	B-X
we	B-X
identified	B-X
the	B-X
association	B-X
of	B-X
Nmi	B-X
,	B-X
a	B-X
protein	B-X
of	B-X
unknown	B-X
function	B-X
previously	B-X
reported	B-X
as	B-X
an	B-X
N-Myc	B-X
interactor	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
Nmi	B-X
interacts	B-X
with	B-X
all	B-X
STATs	B-X
except	B-X
Stat2	B-X
.	B-X
We	B-X
evaluated	B-X
two	B-X
cytokine	B-X
systems	B-X
,	B-X
IL-2	B-X
and	B-X
IFNgamma	B-X
,	B-X
and	B-X
demonstrate	B-X
that	B-X
Nmi	B-X
augments	B-X
STAT-mediated	B-X
transcription	B-X
in	B-X
response	B-X
to	B-X
these	B-X
cytokines	B-X
.	B-X
Interestingly	B-X
,	B-X
Nmi	B-X
lacks	B-X
an	B-X
intrinsic	B-X
transcriptional	B-X
activation	B-X
domain	B-X
;	B-X
instead	B-X
,	B-X
Nmi	B-X
enhances	B-X
the	B-X
association	B-X
of	B-X
CBP/p300	B-X
coactivator	B-X
proteins	B-X
with	B-X
Stat1	B-X
and	B-X
Stat5	B-X
,	B-X
and	B-X
together	B-X
with	B-X
CBP/p300	B-X
can	B-X
augment	B-X
IL-2-	B-X
and	B-X
IFNgamma-dependent	B-X
transcription	B-X
.	B-X
Therefore	B-X
,	B-X
our	B-X
data	B-X
not	B-X
only	B-X
reveal	B-X
that	B-X
Nmi	B-X
can	B-X
potentiate	B-X
STAT-dependent	B-X
transcription	B-X
,	B-X
but	B-X
also	B-X
suggest	B-X
that	B-X
it	B-X
can	B-X
augment	B-X
coactivator	B-X
protein	B-X
recruitment	B-X
to	B-X
at	B-X
least	B-X
some	B-X
members	B-X
of	B-X
a	B-X
group	B-X
of	B-X
sequence-specific	B-X
transcription	B-X
factors	B-X
.	B-X

Interestingly	O
,	O
Nmi	B-Protein
lacks	O
an	O
intrinsic	O
transcriptional	O
activation	O
domain	O
;	O
instead	O
,	O
Nmi	B-Protein
enhances	O
the	O
association	O
of	O
CBP	O
/	O
p300	O
coactivator	O
proteins	O
with	O
Stat1	B-Protein
and	O
Stat5	O
,	O
and	O
together	O
with	O
CBP	O
/	O
p300	O
can	O
augment	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
and	O
IFNgamma	B-Protein
-	O
dependent	O
transcription	O
.	O
<EOS>	B-X
Using	B-X
the	B-X
coiled-coil	B-X
region	B-X
of	B-X
Stat5b	B-X
as	B-X
the	B-X
bait	B-X
in	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
screen	B-X
,	B-X
we	B-X
identified	B-X
the	B-X
association	B-X
of	B-X
Nmi	B-X
,	B-X
a	B-X
protein	B-X
of	B-X
unknown	B-X
function	B-X
previously	B-X
reported	B-X
as	B-X
an	B-X
N-Myc	B-X
interactor	B-X
.	B-X
We	B-X
further	B-X
show	B-X
that	B-X
Nmi	B-X
interacts	B-X
with	B-X
all	B-X
STATs	B-X
except	B-X
Stat2	B-X
.	B-X
We	B-X
evaluated	B-X
two	B-X
cytokine	B-X
systems	B-X
,	B-X
IL-2	B-X
and	B-X
IFNgamma	B-X
,	B-X
and	B-X
demonstrate	B-X
that	B-X
Nmi	B-X
augments	B-X
STAT-mediated	B-X
transcription	B-X
in	B-X
response	B-X
to	B-X
these	B-X
cytokines	B-X
.	B-X
Interestingly	B-X
,	B-X
Nmi	B-X
lacks	B-X
an	B-X
intrinsic	B-X
transcriptional	B-X
activation	B-X
domain	B-X
;	B-X
instead	B-X
,	B-X
Nmi	B-X
enhances	B-X
the	B-X
association	B-X
of	B-X
CBP/p300	B-X
coactivator	B-X
proteins	B-X
with	B-X
Stat1	B-X
and	B-X
Stat5	B-X
,	B-X
and	B-X
together	B-X
with	B-X
CBP/p300	B-X
can	B-X
augment	B-X
IL-2-	B-X
and	B-X
IFNgamma-dependent	B-X
transcription	B-X
.	B-X
Therefore	B-X
,	B-X
our	B-X
data	B-X
not	B-X
only	B-X
reveal	B-X
that	B-X
Nmi	B-X
can	B-X
potentiate	B-X
STAT-dependent	B-X
transcription	B-X
,	B-X
but	B-X
also	B-X
suggest	B-X
that	B-X
it	B-X
can	B-X
augment	B-X
coactivator	B-X
protein	B-X
recruitment	B-X
to	B-X
at	B-X
least	B-X
some	B-X
members	B-X
of	B-X
a	B-X
group	B-X
of	B-X
sequence-specific	B-X
transcription	B-X
factors	B-X
.	B-X

Therefore	O
,	O
our	O
data	O
not	O
only	O
reveal	O
that	O
Nmi	B-Protein
can	O
potentiate	O
STAT	O
-	O
dependent	O
transcription	O
,	O
but	O
also	O
suggest	O
that	O
it	O
can	O
augment	O
coactivator	O
protein	O
recruitment	O
to	O
at	O
least	O
some	O
members	O
of	O
a	O
group	O
of	O
sequence	O
-	O
specific	O
transcription	O
factors	O
.	O
<EOS>	B-X
Designing	B-X
,	B-X
conducting	B-X
,	B-X
analyzing	B-X
,	B-X
reporting	B-X
,	B-X
and	B-X
interpreting	B-X
the	B-X
findings	B-X
of	B-X
a	B-X
research	B-X
study	B-X
require	B-X
an	B-X
understanding	B-X
of	B-X
the	B-X
types	B-X
and	B-X
characteristics	B-X
of	B-X
data	B-X
and	B-X
variables	B-X
.	B-X
Descriptive	B-X
statistics	B-X
are	B-X
typically	B-X
used	B-X
simply	B-X
to	B-X
calculate	B-X
,	B-X
describe	B-X
,	B-X
and	B-X
summarize	B-X
the	B-X
collected	B-X
research	B-X
data	B-X
in	B-X
a	B-X
logical	B-X
,	B-X
meaningful	B-X
,	B-X
and	B-X
efficient	B-X
way	B-X
.	B-X
Inferential	B-X
statistics	B-X
allow	B-X
researchers	B-X
to	B-X
make	B-X
a	B-X
valid	B-X
estimate	B-X
of	B-X
the	B-X
association	B-X
between	B-X
an	B-X
intervention	B-X
and	B-X
the	B-X
treatment	B-X
effect	B-X
in	B-X
a	B-X
specific	B-X
population	B-X
,	B-X
based	B-X
upon	B-X
their	B-X
randomly	B-X
collected	B-X
,	B-X
representative	B-X
sample	B-X
data	B-X
.	B-X
Categorical	B-X
data	B-X
can	B-X
be	B-X
either	B-X
dichotomous	B-X
or	B-X
polytomous	B-X
.	B-X
Dichotomous	B-X
data	B-X
have	B-X
only	B-X
2	B-X
categories	B-X
,	B-X
and	B-X
thus	B-X
are	B-X
considered	B-X
binary	B-X
.	B-X
Polytomous	B-X
data	B-X
have	B-X
more	B-X
than	B-X
2	B-X
categories	B-X
.	B-X
Unlike	B-X
dichotomous	B-X
and	B-X
polytomous	B-X
data	B-X
,	B-X
ordinal	B-X
data	B-X
are	B-X
rank	B-X
ordered	B-X
,	B-X
typically	B-X
based	B-X
on	B-X
a	B-X
numerical	B-X
scale	B-X
that	B-X
is	B-X
comprised	B-X
of	B-X
a	B-X
small	B-X
set	B-X
of	B-X
discrete	B-X
classes	B-X
or	B-X
integers	B-X
.	B-X
Continuous	B-X
data	B-X
are	B-X
measured	B-X
on	B-X
a	B-X
continuum	B-X
and	B-X
can	B-X
have	B-X
any	B-X
numeric	B-X
value	B-X
over	B-X
this	B-X
continuous	B-X
range	B-X
.	B-X
Continuous	B-X
data	B-X
can	B-X
be	B-X
meaningfully	B-X
divided	B-X
into	B-X
smaller	B-X
and	B-X
smaller	B-X
or	B-X
finer	B-X
and	B-X
finer	B-X
increments	B-X
,	B-X
depending	B-X
upon	B-X
the	B-X
precision	B-X
of	B-X
the	B-X
measurement	B-X
instrument	B-X
.	B-X
Interval	B-X
data	B-X
are	B-X
a	B-X
form	B-X
of	B-X
continuous	B-X
data	B-X
in	B-X
which	B-X
equal	B-X
intervals	B-X
represent	B-X
equal	B-X
differences	B-X
in	B-X
the	B-X
property	B-X
being	B-X
measured	B-X
.	B-X
Ratio	B-X
data	B-X
are	B-X
another	B-X
form	B-X
of	B-X
continuous	B-X
data	B-X
,	B-X
which	B-X
have	B-X
the	B-X
same	B-X
properties	B-X
as	B-X
interval	B-X
data	B-X
,	B-X
plus	B-X
a	B-X
true	B-X
definition	B-X
of	B-X
an	B-X
absolute	B-X
zero	B-X
point	B-X
,	B-X
and	B-X
the	B-X
ratios	B-X
of	B-X
the	B-X
values	B-X
on	B-X
the	B-X
measurement	B-X
scale	B-X
make	B-X
sense	B-X
.	B-X
Many	B-X
applied	B-X
inferential	B-X
statistical	B-X
tests	B-X
are	B-X
predicated	B-X
on	B-X
the	B-X
assumption	B-X
that	B-X
the	B-X
analyzed	B-X
data	B-X
follow	B-X
a	B-X
normal	B-X
distribution	B-X
.	B-X
The	B-X
histogram	B-X
and	B-X
the	B-X
Q-Q	B-X
plot	B-X
are	B-X
2	B-X
graphical	B-X
methods	B-X
to	B-X
assess	B-X
if	B-X
a	B-X
set	B-X
of	B-X
data	B-X
have	B-X
a	B-X
normal	B-X
distribution	B-X
(	B-X
display	B-X
``	B-X
normality	B-X
''	B-X
)	B-X
.	B-X
The	B-X
Shapiro-Wilk	B-X
test	B-X
and	B-X
the	B-X
Kolmogorov-Smirnov	B-X
test	B-X
are	B-X
2	B-X
well-known	B-X
and	B-X
historically	B-X
widely	B-X
applied	B-X
quantitative	B-X
methods	B-X
to	B-X
assess	B-X
for	B-X
data	B-X
normality	B-X
.	B-X
If	B-X
the	B-X
normality	B-X
test	B-X
concludes	B-X
that	B-X
the	B-X
study	B-X
data	B-X
deviate	B-X
significantly	B-X
from	B-X
a	B-X
Gaussian	B-X
distribution	B-X
,	B-X
rather	B-X
than	B-X
applying	B-X
a	B-X
less	B-X
robust	B-X
nonparametric	B-X
test	B-X
,	B-X
the	B-X
problem	B-X
can	B-X
potentially	B-X
be	B-X
remedied	B-X
by	B-X
judiciously	B-X
and	B-X
openly	B-X
:	B-X
(	B-X
1	B-X
)	B-X
performing	B-X
a	B-X
data	B-X
transformation	B-X
of	B-X
all	B-X
the	B-X
data	B-X
values	B-X
;	B-X
or	B-X
(	B-X
2	B-X
)	B-X
eliminating	B-X
any	B-X
obvious	B-X
data	B-X
outlier	B-X
(	B-X
s	B-X
)	B-X
.	B-X

